

New response evaluation criteria in solid tumours: Revi

European Journal of Cancer

45, 228-247

DOI: 10.1016/j.ejca.2008.10.026

Citation Report

#	ARTICLE	IF	CITATIONS
1	Optimizing Sedative Dose in Preterm Infants. , 0, , 277-292.		0
2	Systemic Therapy in Gynaecological Cancers. , 0, , 52-61.		0
5	ecancermedalscience. Ecancermedalscience, 2014, 8, 452.	1.1	1
6	Preoperative Serum Tumor Marker Levels in Gastric Cancer. Pakistan Journal of Medical Sciences, 1969, 30, 145-9.	0.6	16
7	A Low Noise CMOS Integrated Signal Processor for Multi-Element Particle Detectors. , 1988, , .		12
9	Role of everolimus in the treatment of renal cell carcinoma. Therapeutics and Clinical Risk Management, 2009, 5, 699.	2.0	6
10	Nodal staging. Cancer Imaging, 2009, 9, 104-11.	2.8	94
12	Targeted molecular therapies in thyroid carcinoma. Arquivos Brasileiros De Endocrinologia E Metabologia, 2009, 53, 1061-1073.	1.3	11
13	Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. Thyroid, 2009, 19, 1393-1400.	4.5	80
14	Portal Vein Tumor Thrombosis Revascularization During Sorafenib Treatment for Hepatocellular Carcinoma. American Journal of Gastroenterology, 2009, 104, 1852-1854.	0.4	25
15	New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2009, 9, 1159-1167.	2.4	16
16	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009, 15, 7412-7420.	7.0	2,857
17	Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature. Oncologist, 2009, 14, 816-827.	3.7	47
18	Distinguishing Between Anti-Neutrophil Cytoplasmic Antibody Patterns in Inflammatory Bowel Disease: Is the "Atypical Pattern" Adding More Information?. American Journal of Gastroenterology, 2009, 104, 1854-1855.	0.4	8
19	Standards for PET Image Acquisition and Quantitative Data Analysis. Journal of Nuclear Medicine, 2009, 50, 11S-20S.	5.0	720
20	Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology, 2009, 27, 5109-5114.	1.6	50
21	Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [¹⁸ F]-labeled isatin sulfonamide. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16375-16380.	7.1	157
22	Novel Designs and End Points for Phase II Clinical Trials. Clinical Cancer Research, 2009, 15, 1866-1872.	7.0	65

#	ARTICLE	IF	CITATIONS
23	Measuring Response with FDGâ€PET: Methodological Aspects. <i>Oncologist</i> , 2009, 14, 369-377.	3.7	63
24	Diffusion-Weighted MRI of Advanced Hepatocellular Carcinoma During Sorafenib Treatment: Initial Results. <i>American Journal of Roentgenology</i> , 2009, 193, W301-W307.	2.2	91
26	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. <i>Future Oncology</i> , 2009, 5, 871-888.	2.4	6
27	Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1760-1769.	5.0	65
28	Commentary: Troublesome Words, Linguistic Precision, and Medical Oncology. <i>Oncologist</i> , 2009, 14, 445-447.	3.7	3
29	Has Quantitative Multimodal Imaging of Treatment Response Arrived?. <i>Clinical Cancer Research</i> , 2009, 15, 6473-6475.	7.0	2
30	Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma. <i>Oncologist</i> , 2009, 14, 30-40.	3.7	51
31	Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. <i>Journal of Clinical Oncology</i> , 2009, 27, 5650-5659.	1.6	115
33	Alternate Endpoints for Screening Phase II Studies. <i>Clinical Cancer Research</i> , 2009, 15, 1873-1882.	7.0	78
34	Production of hyperpolarized [1,4- ¹³ C ₂]malate from [1,4- ¹³ C ₂]fumarate is a marker of cell necrosis and treatment response in tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19801-19806.	7.1	328
35	Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1493-1499.	3.6	101
36	Incidental PET/CT findings in the cancer patient: How should they be managed?. <i>Surgery</i> , 2009, 146, 274-281.	1.9	75
37	Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. <i>BMC Cancer</i> , 2009, 9, 208.	2.6	71
38	Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment. <i>Seminars in Oncology</i> , 2009, 36, 302-311.	2.2	41
39	Molecular imaging of breast cancer. <i>Breast</i> , 2009, 18, S66-S73.	2.2	88
42	Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC). <i>Clinical and Translational Oncology</i> , 2009, 11, 773-774.	2.4	0
43	Evolving end points for clinical trials in advanced colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 135-139.	0.5	1
44	Targeted therapies in thyroid cancer. <i>Targeted Oncology</i> , 2009, 4, 275-285.	3.6	2

#	ARTICLE	IF	CITATIONS
45	Combined Cetuximab and Reirradiation for Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 775-781.	2.0	43
46	Monitoring cancer therapy with PET: probably effective, but more research is needed. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1520-1525.	6.4	8
47	A statistical model for the dependence between progression-free survival and overall survival. <i>Statistics in Medicine</i> , 2009, 28, 2669-2686.	1.6	55
48	Imaging metastatic bone disease from carcinoma of the prostate. <i>British Journal of Cancer</i> , 2009, 101, 1225-1232.	6.4	106
49	Role of Imaging in Prostate Cancer: A Review. <i>Imaging Decisions</i> (Berlin, Germany), 2009, 13, 68-87.	0.2	2
50	Imaging response to systemic therapy for bone metastases. <i>European Radiology</i> , 2009, 19, 2495-2507.	4.5	75
51	Assessing Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1S-10S.	5.0	226
52	Cancer clinical trial outcomes: Any progress in tumour-size assessment?. <i>European Journal of Cancer</i> , 2009, 45, 225-227.	2.8	33
53	Individual patient data analysis to assess modifications to the RECIST criteria. <i>European Journal of Cancer</i> , 2009, 45, 248-260.	2.8	176
54	Evaluation of lymph nodes with RECIST 1.1. <i>European Journal of Cancer</i> , 2009, 45, 261-267.	2.8	233
55	Validation of novel imaging methodologies for use as cancer clinical trial end-points. <i>European Journal of Cancer</i> , 2009, 45, 290-299.	2.8	110
56	A simulation study to evaluate the impact of the number of lesions measured on response assessment. <i>European Journal of Cancer</i> , 2009, 45, 300-310.	2.8	51
57	Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?. <i>European Journal of Cancer</i> , 2009, 45, 2249-2252.	2.8	37
58	Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. <i>European Journal of Cancer</i> , 2009, 45, 2930-2934.	2.8	113
59	Recommendations for the assessment of progression in randomised cancer treatment trials. <i>European Journal of Cancer</i> , 2009, 45, 281-289.	2.8	107
60	Biomarkers in oncology drug development. <i>Molecular Oncology</i> , 2009, 3, 24-32.	4.6	28
61	From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 122S-150S.	5.0	3,047
62	Quantitative Imaging to Assess Tumor Response to Therapy: Common Themes of Measurement, Truth Data, and Error Sources. <i>Translational Oncology</i> , 2009, 2, 198-210.	3.7	49

#	ARTICLE	IF	CITATIONS
63	Computed Tomography in Metastatic Renal Cell Carcinoma. Seminars in Ultrasound, CT and MRI, 2009, 30, 359-366.	1.5	9
64	Radiology reporting templates in oncology: A time for change. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 511-513.	1.8	13
65	Standardised tumour, node and metastasis reporting of oncology CT scans. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 345-352.	1.8	4
66	Appréciation de la réponse : Évolution des concepts. Revue De Pneumologie Clinique, 2009, 65, S84-S87.	0.0	0
68	L'évaluation en oncologie: comment je fais en imagerie?. Feuilles De Radiologie, 2009, 49, 392-406.	0.0	0
70	Stable Disease Is a Valid End Point in Clinical Trials. Cancer Journal (Sudbury, Mass), 2009, 15, 374-378.	2.0	16
71	Overall Survival: Still the Gold Standard. Cancer Journal (Sudbury, Mass), 2009, 15, 401-405.	2.0	126
72	Other Paradigms: Better Treatments Are Identified by Better Trials. Cancer Journal (Sudbury, Mass), 2009, 15, 426-430.	2.0	10
73	Other Paradigms. Cancer Journal (Sudbury, Mass), 2009, 15, 431-434.	2.0	8
74	Response Rates. Cancer Journal (Sudbury, Mass), 2009, 15, 361-365.	2.0	7
75	Successful Treatment of Lung Cancer with Gefitinib and EGFR Mutation Status Determination Using EBUS-TBNA Samples in an Extremely Old Patient. Internal Medicine, 2009, 48, 1905-1907.	0.7	8
77	Tumor Shrinkage and Objective Response Rates. Cancer Journal (Sudbury, Mass), 2009, 15, 354-360.	2.0	14
78	Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials. Cancer Journal (Sudbury, Mass), 2009, 15, 421-425.	2.0	38
79	Palliative photodynamic therapy for biliary tract carcinoma may improve survival and has a similar outcome to attempted curative surgery with positive resection margins. , 2009, , .		0
80	Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study. Clinical Cancer Research, 2010, 16, 3215-3225.	7.0	46
81	Prediction of Lymph Node Manifestations in Malignant Lymphoma. Journal of Computer Assisted Tomography, 2010, 34, 564-569.	0.9	21
82	Second-Line Therapy for Elderly Patients with Non-small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients. Journal of Thoracic Oncology, 2010, 5, 376-379.	1.1	21
83	Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology, 2010, 5, 1551-1558.	1.1	117

#	ARTICLE	IF	CITATIONS
84	Prediction and Monitoring of Therapeutic Response by Molecular Imaging. <i>Current Medical Imaging</i> , 2010, 6, 29-32.	0.8	0
86	Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, S286-S290.	1.1	80
87	Tumor Response Evaluation in Oncology. <i>Journal of Computer Assisted Tomography</i> , 2010, 34, 479-484.	0.9	44
88	Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors. <i>Journal of Immunotherapy</i> , 2010, 33, 557-569.	2.4	34
89	Surgical and radiologic staging of cervical cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010, 22, 15-20.	2.0	15
90	Intra- and Interobserver Variability of Linear and Volumetric Measurements of Brain Metastases Using Contrast-Enhanced Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2010, 45, 49-56.	6.2	60
91	Dose Reduction for Semi-Automated Volumetry of Hepatic Metastasis in MDCT Studies. <i>Investigative Radiology</i> , 2010, 45, 77-81.	6.2	8
92	Angiogenesis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2010, 25, 142-150.	1.5	23
94	Semiautomatic Lymph Node Segmentation in Multislice Computed Tomography. <i>Investigative Radiology</i> , 2010, 45, 82-88.	6.2	13
95	Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy. <i>Current Drug Targets</i> , 2010, 11, 1121-1132.	2.1	20
96	Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. <i>Anti-Cancer Drugs</i> , 2010, 21, 553-558.	1.4	15
98	QA procedures for multimodality preclinical tumor drug response testing. <i>Medical Physics</i> , 2010, 37, 4806-4816.	3.0	3
99	Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms. <i>Medical Physics</i> , 2010, 37, 2541-2552.	3.0	21
100	Preliminary trial of adjuvant surgery for advanced gastric cancer. <i>Oncology Letters</i> , 2010, 1, 743-747.	1.8	36
101	Standard Outcome Measures for Thymic Malignancies. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2017-2023.	1.1	146
102	Restaging by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in Patients with Inoperable Advanced Lung Cancer. <i>Internal Medicine</i> , 2010, 49, 787-790.	0.7	10
103	Quantitative Analysis of mRNA for 10 Different Drug Resistance Factors in Dogs with Lymphoma. <i>Journal of Veterinary Medical Science</i> , 2010, 72, 1165-1172.	0.9	30
104	Evaluating the extent of cell death in 3D high frequency ultrasound by registration with	3.0	10

#	ARTICLE	IF	CITATIONS
105	When and how often should PET scans be performed in the management of cervical cancer?. Expert Review of Anticancer Therapy, 2010, 10, 983-986.	2.4	2
106	Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. Journal of Thoracic Oncology, 2010, 5, 491-496.	1.1	51
107	Volume assessment accuracy in computed tomography: a phantom study. Journal of Applied Clinical Medical Physics, 2010, 11, 168-180.	1.9	45
109	Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need. Therapie, 2010, 65, 373-377.	1.0	3
110	FDA phantom CT database: a resource for the assessment of lung nodule size estimation methodologies and software development. Proceedings of SPIE, 2010, , .	0.8	5
111	COMBINED EFFECTS OF SELECTIVE PHOTOTHERMAL THERAPY AND IMMUNOADJUVANT AGAINST STAGE IV BREAST CANCER. Journal of Innovative Optical Health Sciences, 2010, 03, 279-284.	1.0	5
112	Ovarian Cancer: The Role of Functional Imaging as an End Point in Clinical Trials. International Journal of Gynecological Cancer, 2010, 20, 971-978.	2.5	6
113	Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 979-984.	2.5	44
114	Imaging ovarian cancer and peritoneal metastasesâ€”current and emerging techniques. Nature Reviews Clinical Oncology, 2010, 7, 381-393.	27.6	108
115	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. European Radiology, 2010, 20, 1456-1467.	4.5	168
116	Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. European Radiology, 2010, 20, 2890-2898.	4.5	87
117	ESUR guidelines: ovarian cancer staging and follow-up. European Radiology, 2010, 20, 2773-2780.	4.5	157
118	Is conflict of interest in our best interest?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1063-1068.	6.4	4
119	Tumor Shrinkage Assessed by Volumetric MRI in the Long-Term Follow-Up after Stereotactic Radiotherapy of Meningiomas. Strahlentherapie Und Onkologie, 2010, 186, 423-429.	2.0	36
121	Registration and functional analysis of CT dynamic image sequences for the follow-up of patients with hepatic tumors undergoing antiangiogenic therapy. Irbm, 2010, 31, 263-270.	5.6	6
122	Head and neck sarcoma: report of a case treated by intensity-modulated radiation therapy. International Journal of Clinical Oncology, 2010, 15, 305-309.	2.2	1
123	Nouveaux d�veloppements en IRM en oncologie. Oncologie, 2010, 12, 187-196.	0.7	3
124	Biomarqueurs en imagerie pour lâ€™�valuation des nouvelles th�rapies anticanc�reuses. Oncologie, 2010, 12, 178-186.	0.7	0

#	ARTICLE	IF	CITATIONS
125	PART 1 – p53 adapted preoperative radiotherapy for T2 and T3 rectal cancer. A study of the p53 research group. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 18-23.	0.7	1
126	Response, disease-free survival, and overall survival: What matters for whom?. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 5-7.	0.7	1
128	Qualitative and quantitative assessment of endpoints in clinical trials. Memo - Magazine of European Medical Oncology, 2010, 3, 33-36.	0.5	1
129	Castration-refractory prostate cancer: New drugs in the pipeline. Advances in Therapy, 2010, 27, 285-296.	2.9	22
130	White paper on imaging biomarkers. Insights Into Imaging, 2010, 1, 42-45.	3.4	61
131	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumor Biology, 2010, 31, 351-357.	1.8	46
132	Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Targeted Oncology, 2010, 5, 39-52.	3.6	95
133	Targeted therapies in renal cell cancer: recent developments in imaging. Targeted Oncology, 2010, 5, 95-112.	3.6	47
134	Multi-modality morphological correlation of axillary lymph nodes. International Journal of Computer Assisted Radiology and Surgery, 2010, 5, 343-350.	2.8	3
135	Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature. Endocrine, 2010, 37, 6-10.	2.3	9
136	The role of magnetic resonance imaging in oncology. Clinical and Translational Oncology, 2010, 12, 606-613.	2.4	27
137	Response Assessment Challenges in Clinical Trials of Gliomas. Current Oncology Reports, 2010, 12, 68-75.	4.0	36
138	Targeting activated integrin $\alpha_3\beta_1$ with patient-derived antibodies impacts late-stage multiorgan metastasis. Clinical and Experimental Metastasis, 2010, 27, 217-231.	3.3	12
141	Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theory. BMC Genomics, 2010, 11, S15.	2.8	6
142	Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer. Clinical Breast Cancer, 2010, 10, 483-488.	2.4	20
143	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer, 2010, 10, 368.	2.6	152
144	Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer, 2010, 10, 480.	2.6	26
145	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. European Urology, 2010, 58, 906-911.	1.9	55

#	ARTICLE	IF	CITATIONS
146	Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study. <i>Clinical Imaging</i> , 2010, 34, 196-202.	1.5	2
147	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. <i>Drug Discovery Today</i> , 2010, 15, 102-114.	6.4	45
148	Targeted therapy of thyroid cancer. <i>Biochemical Pharmacology</i> , 2010, 80, 592-601.	4.4	70
149	“Clinical benefit rate” in phase 2 gynecologic cancer trials: Implying more than the data support?. <i>Gynecologic Oncology</i> , 2010, 117, 348-349.	1.4	0
150	Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. <i>Gynecologic Oncology</i> , 2010, 117, 467-472.	1.4	14
151	Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. <i>Cancer</i> , 2010, 116, 2332-2342.	4.1	51
152	Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. <i>Hepatology</i> , 2010, 52, 1741-1749.	7.3	385
153	Gastrointestinal stromal tumors: Current management. <i>Journal of Surgical Oncology</i> , 2010, 102, 530-538.	1.7	42
154	Optimizing resection for “nonresponding” hepatic metastases after neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2010, 102, 1002-1008.	1.7	7
155	Usefulness of ¹⁸ F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. <i>Liver Transplantation</i> , 2010, 16, 767-772.	2.4	48
156	Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer. <i>Clinical Oncology</i> , 2010, 22, 448-455.	1.4	21
157	Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients. <i>Clinical Oncology</i> , 2010, 22, 818-827.	1.4	50
158	Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: Current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 202-212.	4.4	64
159	Gamma Knife Radiosurgery as a Therapeutic Strategy for Intracranial Sarcomatous Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 513-519.	0.8	63
160	Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 696-702.	0.8	39
161	Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. <i>Pediatric Blood and Cancer</i> , 2010, 54, 1035-1037.	1.5	27
162	Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). <i>Pediatric Blood and Cancer</i> , 2010, 55, 369-373.	1.5	63
163	Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document. <i>Veterinary and Comparative Oncology</i> , 2010, 8, 28-37.	1.8	210

#	ARTICLE	IF	CITATIONS
164	PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. <i>Veterinary and Comparative Oncology</i> , 2010, 8, no-no.	1.8	32
165	Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. <i>Hpb</i> , 2010, 12, 418-426.	0.3	23
166	Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. <i>Cancer Science</i> , 2010, 101, 882-888.	3.9	23
167	Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. <i>British Journal of Cancer</i> , 2010, 103, 196-200.	6.4	93
168	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. <i>British Journal of Cancer</i> , 2010, 103, 597-606.	6.4	25
169	Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. <i>British Journal of Cancer</i> , 2010, 103, 1400-1406.	6.4	124
170	Translating cancer research into targeted therapeutics. <i>Nature</i> , 2010, 467, 543-549.	27.8	310
171	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 760-774.	28.4	943
172	Perfusion CT and US of Colorectal Cancer Liver Metastases: A Correlative Study of Two Dynamic Imaging Modalities. <i>Ultrasound in Medicine and Biology</i> , 2010, 36, 1626-1636.	1.5	18
173	Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. <i>Ecological Management and Restoration</i> , 2010, 23, 641-645.	0.4	38
174	Positron emission tomography: current status and future challenges. <i>Internal Medicine Journal</i> , 2010, 40, 19-29.	0.8	20
175	Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. <i>World Journal of Gastroenterology</i> , 2010, 16, 5766.	3.3	14
176	Response Evaluation Criteria in Cancer of the Liver (RECICL). <i>Acta Hepatologica Japonica</i> , 2010, 51, 261-266.	0.1	20
177	Pedagogical immigration to 3D virtual worlds: A critical review of underlying themes and their concepts. , 2010, , .		6
178	Perfusion magnetic resonance imaging of the liver. <i>World Journal of Gastroenterology</i> , 2010, 16, 1598.	3.3	103
179	Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis. <i>Marine Drugs</i> , 2010, 8, 2647-2658.	4.6	13
180	Antivascular Therapy for Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-16.	1.3	7
181	Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls. <i>Journal of Oncology</i> , 2010, 2010, 1-17.	1.3	55

#	ARTICLE	IF	CITATIONS
182	Current and Future Trends in Magnetic Resonance Imaging Assessments of the Response of Breast Tumors to Neoadjuvant Chemotherapy. <i>Journal of Oncology</i> , 2010, 2010, 1-17.	1.3	32
183	Imaging in clinical trials. <i>Cancer Imaging</i> , 2010, 10, S74-S82.	2.8	25
184	Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?. <i>Cancer Imaging</i> , 2010, 10, S68-S72.	2.8	9
185	Paclitaxel as Neoadjuvant Therapy for High Grade Angiosarcoma of the Spleen: A Brief Report and Literature Review. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S5329.	1.3	20
186	Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice. <i>PLoS ONE</i> , 2010, 5, e12965.	2.5	36
187	Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. <i>Journal of Gynecologic Oncology</i> , 2010, 21, 3.	2.2	25
188	Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine. <i>Hepatic Medicine: Evidence and Research</i> , 2010, 2, 111.	2.5	2
189	Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria. <i>Korean Journal of Radiology</i> , 2010, 11, 618.	3.4	23
190	Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?. <i>Cancer Imaging</i> , 2010, 10, S179-S188.	2.8	60
191	Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 4493-4495.	7.0	11
192	Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2243-2254.	4.1	48
193	Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab. <i>Clinical Cancer Research</i> , 2010, 16, 4236-4245.	7.0	52
194	Clinical Trials Data Collection: When Less Is More. <i>Journal of Clinical Oncology</i> , 2010, 28, 5019-5021.	1.6	11
195	Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2010, 28, 3994-4005.	1.6	358
196	Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. <i>Annals of Oncology</i> , 2010, 21, 936-941.	1.2	83
197	Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 2195-2200.	1.2	8
198	Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction?. <i>Clinical Cancer Research</i> , 2010, 16, 5956-5962.	7.0	38
199	Principles of Cancer Treatment. , 2010, , 1-9.		0

#	ARTICLE	IF	CITATIONS
200	Finding the Right Dose for Cancer Therapeuticsâ€”Can We Do Better?. Clinical Cancer Research, 2010, 16, 1085-1087.	7.0	3
201	Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 1322-1328.	1.6	58
202	Multiparametric Imaging of Tumor Response to Therapy. Radiology, 2010, 256, 348-364.	7.3	201
203	¹¹¹ In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. Journal of Nuclear Medicine, 2010, 51, 1707-1715.	5.0	47
204	Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging. Molecular Cancer Therapeutics, 2010, 9, 673-681.	4.1	27
205	Detection of Tumor Response to a Vascular Disrupting Agent by Hyperpolarized ¹³ C Magnetic Resonance Spectroscopy. Molecular Cancer Therapeutics, 2010, 9, 3278-3288.	4.1	66
206	Metastatic Disease Response to Treatment: How Many Lesions to Measure?. Journal of Clinical Oncology, 2010, 28, e81-e81.	1.6	2
207	Bar the Windows but Open the Door to Randomization. Journal of Clinical Oncology, 2010, 28, 3104-3106.	1.6	18
208	Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy. Japanese Journal of Clinical Oncology, 2010, 40, 855-862.	1.3	20
209	Living With Imperfection. Journal of Clinical Oncology, 2010, 28, 191-192.	1.6	32
210	Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. Cancer Biomarkers, 2010, 6, 21-32.	1.7	24
211	Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. JAMA - Journal of the American Medical Association, 2010, 303, 1062.	7.4	170
212	A phantom study of nodule size evaluation with chest tomosynthesis and computed tomography. Radiation Protection Dosimetry, 2010, 139, 140-143.	0.8	14
213	Assessing oncologic benefit in clinical trials of immunotherapy agents. Annals of Oncology, 2010, 21, 1944-1951.	1.2	51
214	Optimal Lesion Number for Evaluation of Tumor Response in Response Evaluation Criteria in Solid Tumors. Journal of Clinical Oncology, 2010, 28, e159-e160.	1.6	7
215	The integration of quantitative multi-modality imaging data into mathematical models of tumors. Physics in Medicine and Biology, 2010, 55, 2429-2449.	3.0	39
216	A novel approach to the assessment of response to chemotherapy in sarcoma imaged with PET-FDG. , 2010, , .		1
217	Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma. Molecular Therapy, 2010, 18, 651-659.	8.2	48

#	ARTICLE	IF	CITATIONS
218	Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3131-3137.	1.6	136
219	[18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. <i>Postgraduate Medical Journal</i> , 2010, 86, 174-182.	1.8	36
220	Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. <i>Annals of Oncology</i> , 2010, 21, 2324-2332.	1.2	106
221	Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression. <i>Oncologist</i> , 2010, 15, 969-975.	3.7	131
222	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198.	1.2	41
223	Repeatability of Metabolically Active Volume Measurements with ¹⁸ F-FDG and ¹⁸ F-FLT PET in Non-“Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1870-1877.	5.0	98
224	Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. <i>Annals of Oncology</i> , 2010, 21, 19-26.	1.2	42
225	Imaging in drug development: will it deliver on the promise of personalised medicine?. <i>British Journal of Radiology</i> , 2010, 83, 453-455.	2.2	1
226	Functional imaging of renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010, 7, 258-266.	3.8	36
227	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v15-v19.	1.2	95
228	Use of modified RECIST criteria to improve response assessment in targeted therapies: Challenges and opportunities. <i>Cancer Biology and Therapy</i> , 2010, 9, 20-22.	3.4	19
229	Partial volume correction for volume estimation of liver metastases and lymph nodes in CT scans using spatial subdivision. <i>Proceedings of SPIE</i> , 2010, , .	0.8	1
230	Targeted Radionuclide Therapy for Neuroendocrine Tumours: Principles and Application. <i>Neuroendocrinology</i> , 2010, 91, 1-15.	2.5	25
231	18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY AS A TOOL FOR RESPONSE PREDICTION IN SOLID TUMOURS. <i>Acta Clinica Belgica</i> , 2010, 65, 291-299.	1.2	11
232	Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. <i>American Journal of Roentgenology</i> , 2010, 195, 281-289.	2.2	329
233	Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT. <i>Radiology</i> , 2010, 256, 511-518.	7.3	124
234	Modeling Opportunities in Comparative Oncology for Drug Development. <i>ILAR Journal</i> , 2010, 51, 214-220.	1.8	42
235	Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2010, 30, 052-060.	3.6	3,250

#	ARTICLE	IF	CITATIONS
236	Measurement Accuracy and Reproducibility of Semiautomated Metric and Volumetric Lymph Node Analysis in MDCT. American Journal of Roentgenology, 2010, 195, 979-985.	2.2	27
237	Radioembolization for colorectal liver metastases. Nature Reviews Clinical Oncology, 2010, 7, 1-1.	27.6	1
238	Does primary tumour volumetry performed early in the course of definitive concomitant chemoradiotherapy for head and neck squamous cell carcinoma improve prediction of primary site outcome?. British Journal of Radiology, 2010, 83, 964-970.	2.2	16
239	Quantitative Imaging in Oncology Patients: Part 1, Radiology Practice Patterns at Major U.S. Cancer Centers. American Journal of Roentgenology, 2010, 195, 101-106.	2.2	39
240	High Efficacy of Concomitant Treatment of Undifferentiated (Anaplastic) Thyroid Cancer with Radiation and Docetaxel. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E54-E57.	3.6	70
241	Quantitative Imaging in Oncology Patients: Part 2, Oncologists' Opinions and Expectations at Major U.S. Cancer Centers. American Journal of Roentgenology, 2010, 195, W19-W30.	2.2	27
242	New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Nonâ€“Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. American Journal of Roentgenology, 2010, 195, W221-W228.	2.2	182
243	Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. Molecular Therapy, 2010, 18, 1874-1884.	8.2	201
244	Suitability of Semi-Automated Tumor Response Assessment of Liver Metastases using a Dedicated Software Package. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2010, 182, 581-588.	1.3	18
245	Semiautomated Segmentation for Volumetric Analysis of Intratumoral Ethiodol Uptake and Subsequent Tumor Necrosis After Chemoembolization. American Journal of Roentgenology, 2010, 195, 1220-1230.	2.2	53
246	Does Multidetector CT Attenuation Change in Colon Cancer Liver Metastases Treated with90Y Help Predict Metabolic Activity at FDG PET?. Radiology, 2010, 255, 164-172.	7.3	31
247	<i>nab</i>-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opinion on Drug Safety, 2010, 9, 515-523.	2.4	13
248	Dendritic Cell Vaccines for Brain Tumors. Neurosurgery Clinics of North America, 2010, 21, 139-157.	1.7	44
250	Hepatic Perfusion Imaging: Concepts and Application. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 465-475.	1.1	13
251	Assessment of Acute Antivascular Effects of Vandetanib with High-Resolution Dynamic Contrast-Enhanced Computed Tomographic Imaging in a Human Colon Tumor Xenograft Model in the Nude Rat. Neoplasia, 2010, 12, 697-707.	5.3	20
252	Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear (23Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer. Academic Radiology, 2010, 17, 1477-1485.	2.5	49
253	Assessment of Response to Therapy for Bone Metastases: Is it Still a Challenge in Oncology?. PET Clinics, 2010, 5, 311-326.	3.0	3
254	Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias. , 2010, , 15-62.		3

#	ARTICLE	IF	CITATIONS
255	Imaging tumour cell metabolism using hyperpolarized ¹³ C magnetic resonance spectroscopy. Biochemical Society Transactions, 2010, 38, 1220-1224.	3.4	40
256	Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nature Reviews Urology, 2010, 7, 311-325.	3.8	49
257	Imaging the life and death of tumors in living subjects: Preclinical PET imaging of proliferation and apoptosis. Integrative Biology (United Kingdom), 2010, 2, 483.	1.3	22
258	Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2010, 69, 105-109.	2.0	21
259	Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer, 2010, 67, 127-135.	2.0	30
260	Involved field radiotherapy for locally advanced non-small cell lung cancer: Isolated mediastinal nodal relapse. Lung Cancer, 2010, 70, 218-220.	2.0	6
261	TGFBI expression is associated with a better response to chemotherapy in NSCLC. Molecular Cancer, 2010, 9, 130.	19.2	61
262	Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case. World Journal of Surgical Oncology, 2010, 8, 109.	1.9	9
263	Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World Journal of Surgical Oncology, 2010, 8, 40.	1.9	19
264	DNA polymerase β protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. Journal of Translational Medicine, 2010, 8, 126.	4.4	53
265	First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. Journal of Translational Medicine, 2010, 8, 71.	4.4	209
266	Human Immunodeficiency Virus-Associated Primary Lung Cancer in the Era of Highly Active Antiretroviral Therapy: A Multi-Institutional Collaboration. Clinical Lung Cancer, 2010, 11, 396-404.	2.6	67
267	Functional imaging of tumors. Part 2. Radiologia, 2010, 52, 208-220.	0.5	5
268	Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Annals of Oncology, 2010, 21, 1751-1755.	1.2	81
269	Myeloma Bone Disease. , 2010, , .		3
270	Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Annals of Oncology, 2010, 21, 2278-2283.	1.2	53
271	Bone Metastases from Prostate Cancer: Assessing Treatment Response by Using Diffusion-weighted Imaging and Functional Diffusion Maps-Initial Observations. Radiology, 2010, 257, 523-531.	7.3	127
272	RECIST versus volume measurement in medical CT using ellipsoids of known size. Optics Express, 2010, 18, 8151.	3.4	20

#	ARTICLE	IF	CITATIONS
273	A resource for the assessment of lung nodule size estimation methods: database of thoracic CT scans of an anthropomorphic phantom. Optics Express, 2010, 18, 15244.	3.4	56
274	An open-source toolkit for the volumetric measurement of CT lung lesions. Optics Express, 2010, 18, 15256.	3.4	30
275	Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. Optics Express, 2010, 18, 15267.	3.4	15
276	Apport de la TEP/TDM au 18FDG dans la stadification initiale et lâ€™évaluation précoce de la réponse thérapeutique des rhabdomyosarcomes pédiatriques. Medecine Nucleaire, 2010, 34, 655-663.	0.2	2
277	FDG PET/CT in oncology: â€œraising the barâ€. Clinical Radiology, 2010, 65, 522-535.	1.1	35
278	Imaging in gastrointestinal stromal tumours: current status and future directions. Clinical Radiology, 2010, 65, 584-592.	1.1	22
279	An introduction to functional and molecular imaging with MRI. Clinical Radiology, 2010, 65, 557-566.	1.1	54
280	Molecular biology of breast cancer stem cells: Potential clinical applications. Cancer Treatment Reviews, 2010, 36, 485-491.	7.7	61
281	Multikinase inhibitors in thyroid cancer. European Journal of Cancer, 2010, 46, 1012-1018.	2.8	14
282	Two decades at the cross-roads of biology, physics and epidemiology: Lessons learned in [18F]FDG positron emission tomography in oncology. European Journal of Cancer, 2010, 46, 2150-2158.	2.8	1
284	Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. Hepatology Research, 2010, 40, 1195-1203.	3.4	21
286	Positron Emission Tomography-Computed Tomography Reporting in Radiation Therapy Planning and Response Assessment. Seminars in Ultrasound, CT and MRI, 2010, 31, 516-529.	1.5	7
287	Patient and Image Data Management in Positron Emission Tomography-Computed Tomography for Radiation Therapy and Therapy Response Assessment. Seminars in Ultrasound, CT and MRI, 2010, 31, 480-489.	1.5	4
288	Therapy Response Evaluation with Positron Emission Tomography-Computed Tomography. Seminars in Ultrasound, CT and MRI, 2010, 31, 490-495.	1.5	4
289	Targeting breast cancer stem cells. Molecular Oncology, 2010, 4, 404-419.	4.6	170
290	Potential pitfalls in the design and reporting of clinical trials. Lancet Oncology, The, 2010, 11, 694-700.	10.7	7
291	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncology, The, 2010, 11, 992-1000.	10.7	91
292	The Use of Volumetric CT as an Imaging Biomarker in Lung Cancer. Academic Radiology, 2010, 17, 100-106.	2.5	43

#	ARTICLE	IF	CITATIONS
293	Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology, 2010, 28, 2641-2647.	1.6	78
295	Diffusion-Weighted MR Imaging. Medical Radiology, 2010, , .	0.1	16
296	Imaging Tumors of the Lung and Pleura. , 2010, , 1-40.		2
297	Measuring the "Unmeasurable". Academic Radiology, 2010, 17, 1175-1185.	2.5	5
298	Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental and Clinical Cancer Research, 2010, 29, 70.	8.6	86
299	Longitudinal assessment of cyst-like lesions of the knee and their relation to radiographic osteoarthritis and MRI-detected effusion and synovitis in patients with knee pain. Arthritis Research and Therapy, 2010, 12, R172.	3.5	42
300	Improved Endpoints for Cancer Immunotherapy Trials. Journal of the National Cancer Institute, 2010, 102, 1388-1397.	6.3	495
301	A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer. Cancer Investigation, 2010, 28, 865-871.	1.3	8
302	Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta OncolÃ³gica, 2010, 49, 509-514.	1.8	82
303	Modeling tumor growth and treatment response based on quantitative imaging data. Integrative Biology (United Kingdom), 2010, 2, 338.	1.3	12
304	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
305	Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 119-128.	1.4	83
306	Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut, 2010, 59, 838-858.	12.1	45
307	Potential of imaging biomarkers for characterization of renal masses. Expert Review of Anticancer Therapy, 2010, 10, 781-786.	2.4	3
308	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Review of Anticancer Therapy, 2010, 10, 825-835.	2.4	17
309	Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines, 2011, 10, 853-873.	4.4	27
310	Treating rheumatic patients with a malignancy. Arthritis Research and Therapy, 2011, 13, 223.	3.5	30
311	Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta OncolÃ³gica, 2011, 50, 1191-1198.	1.8	19

#	ARTICLE	IF	CITATIONS
312	Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent. <i>Radiation Research</i> , 2011, 175, 10-20.	1.5	14
313	Advanced aggressive fibromatosis: Effective palliation with chemotherapy. <i>Acta Oncol</i> 3gica, 2011, 50, 455-461.	1.8	55
314	Treatment of Borrmann Type IV Gastric Cancer with a Neoadjuvant Chemotherapy Combination of Docetaxel, Cisplatin and 5-Fluorouracil/Leucovorin. <i>Journal of International Medical Research</i> , 2011, 39, 2096-2102.	1.0	19
315	Outcome predictors of Gamma Knife surgery for melanoma brain metastases. <i>Journal of Neurosurgery</i> , 2011, 114, 769-779.	1.6	150
316	Multiplexed PET Probes for Imaging Breast Cancer Early Response to VEGF₁₂₁/rGel Treatment. <i>Molecular Pharmaceutics</i> , 2011, 8, 621-628.	4.6	24
317	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes. <i>Journal of Clinical Oncology</i> , 2011, 29, 3114-3119.	1.6	136
318	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 241-253.	0.0	3
320	Research Reporting Standards for Radioembolization of Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 265-278.	0.5	185
321	Other PET Tracers and Prospects for the Future. <i>PET Clinics</i> , 2011, 6, 91-97.	3.0	0
322	3D Assessment of Lymph Nodes vs. RECIST 1.1. <i>Academic Radiology</i> , 2011, 18, 391-394.	2.5	10
323	The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. <i>Imaging in Medicine</i> , 2011, 3, 333-343.	0.0	2
324	The Value of Cyto-reductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. <i>Journal of Urology</i> , 2011, 185, 54-59.	0.4	65
326	Invited Commentary. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1362-1363.	0.5	1
327	Consolidation of Hepatic Arterial Inflow by Embolization of Variant Hepatic Arteries in Preparation for Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1364-1371.e1.	0.5	34
329	Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. <i>Translational Oncology</i> , 2011, 4, 328-335.	3.7	24
330	A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. <i>PET Clinics</i> , 2011, 6, 299-311.	3.0	4
331	Conventional versus Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1545-1552.	0.5	203
333	Diffusion MR Imaging for Monitoring of Treatment Response. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2011, 19, 181-209.	1.1	123

#	ARTICLE	IF	CITATIONS
335	Comparison of Semiautomated and Manual Measurements for Simulated Hypo- and Hyper-attenuating Hepatic Tumors on MDCT. Academic Radiology, 2011, 18, 626-633.	2.5	3
336	New Imaging Techniques for 90Y Microsphere Radioembolization. Journal of Nuclear Medicine & Radiation Therapy, 2011, 01, .	0.2	11
337	Imaging in Renal Cell Carcinoma. Hematology/Oncology Clinics of North America, 2011, 25, 687-715.	2.2	21
338	Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy, 2011, 11, 997-1009.	3.1	20
339	Methodological and practical challenges for personalized cancer therapies. Nature Reviews Clinical Oncology, 2011, 8, 135-141.	27.6	159
340	Opportunities and pitfalls of cancer imaging in clinical trials. Nature Reviews Clinical Oncology, 2011, 8, 517-527.	27.6	31
341	Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances. Urologia Internationalis, 2011, 86, 125-139.	1.3	27
342	New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer, 2011, 73, 63-69.	2.0	55
343	The role of positron emission tomography in management of small cell lung cancer. Lung Cancer, 2011, 73, 121-126.	2.0	39
344	Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer. Drugs, 2011, 71, 1397-1412.	10.9	132
345	Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study. Annals of Surgical Oncology, 2011, 18, 192-198.	1.5	176
346	Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Annals of Surgical Oncology, 2011, 18, 3657-3665.	1.5	151
347	Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. Journal of Experimental and Clinical Cancer Research, 2011, 30, 30.	8.6	77
348	Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib. Academic Radiology, 2011, 18, 89-96.	2.5	25
349	Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3217-3225.	3.6	100
350	Principles of Anticancer Drug Development. , 2011, , .		0
351	Radiotherapy for Hodgkin Lymphoma. , 2011, , .		3
352	Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response. Urologia Internationalis, 2011, 86, 256-260.	1.3	8

#	ARTICLE	IF	CITATIONS
354	Neuroendocrine Tumors. , 2011, , .		7
355	Colorectal cancer vaccines in clinical trials. Expert Review of Vaccines, 2011, 10, 899-921.	4.4	23
356	Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clinical Radiology, 2011, 66, 224-236.	1.1	66
357	A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treatment Reviews, 2011, 37, 373-384.	7.7	49
358	Parental consanguineous marriages and clinical response to chemotherapy in locally advanced breast cancer patients. Cancer Letters, 2011, 302, 109-112.	7.2	5
359	Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2011, 15, 54-63.	1.4	32
360	Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resistance Updates, 2011, 14, 224-235.	14.4	10
361	Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. European Journal of Cancer, 2011, 47, 983-989.	2.8	20
362	Recommendations for capture, validation and summarisation of data from studies using RECIST. European Journal of Cancer, 2011, 47, 697-701.	2.8	5
363	Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. European Journal of Cancer, 2011, 47, 1763-1771.	2.8	43
364	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. European Journal of Cancer, 2011, 47, 1955-1961.	2.8	111
365	Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?. European Journal of Cancer, 2011, 47, 1759-1762.	2.8	10
366	Tumour growth rates and RECIST criteria in early drug development. European Journal of Cancer, 2011, 47, 2512-2516.	2.8	73
367	Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. European Journal of Cancer, 2011, 47, 2603-2606.	2.8	104
368	Semi-automated volumetric analysis of artificial lymph nodes in a phantom study. European Journal of Radiology, 2011, 80, e451-e457.	2.6	9
369	Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. European Journal of Surgical Oncology, 2011, 37, 245-251.	1.0	17
370	A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer. European Journal of Surgical Oncology, 2011, 37, 583-588.	1.0	7
371	Novel Oncologic Drugs: What They Do and How They Affect Images. Radiographics, 2011, 31, 2059-2091.	3.3	71

#	ARTICLE	IF	CITATIONS
372	Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. <i>Gut</i> , 2011, 60, 1009-1021.	12.1	74
375	Évaluation de la réponse thérapeutique par tomographie par Émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. <i>Medecine Nucleaire</i> , 2011, 35, 600-607.	0.2	5
376	Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: A phase II study. <i>Journal of Geriatric Oncology</i> , 2011, 2, 31-35.	1.0	2
377	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation. <i>Journal of Hepatology</i> , 2011, 54, 695-704.	3.7	140
378	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. <i>Journal of Hepatology</i> , 2011, 55, 1309-1316.	3.7	286
379	Cancer immunotherapy “revisited”. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 591-600.	46.4	346
380	Molecular imaging of the small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 589-592.	1.6	4
381	Imaging of Lung Cancer in the Era of Molecular Medicine. <i>Academic Radiology</i> , 2011, 18, 424-436.	2.5	37
382	End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 3695-3704.	1.6	202
383	GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. <i>Pharmacogenomics</i> , 2011, 12, 1061-1073.	1.3	37
384	Imaging characteristics following ⁹⁰ yttrium microsphere treatment for unresectable liver cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011, 55, 111-118.	1.8	36
385	Embolization of Parasitized Extrahepatic Arteries to Reestablish Intrahepatic Arterial Supply to Tumors before Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1355-1362.	0.5	38
386	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, R67.	5.0	188
387	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <i>Lung Cancer</i> , 2011, 72, 333-339.	2.0	45
388	Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: Comparison with a contemporaneous cohort with pathologically proven disease. <i>Radiotherapy and Oncology</i> , 2011, 101, 250-254.	0.6	128
389	BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2000-2007.	4.1	85
390	Intra-arterial brachytherapy of hepatic malignancies: watch the flow. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 115-120.	27.6	24
391	Targeted Systemic Radiotherapy of Pheochromocytoma and Medullary Thyroid Cancer. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 369-373.	4.6	13

#	ARTICLE	IF	CITATIONS
392	Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors. <i>Radiotherapy and Oncology</i> , 2011, 99, 18-22.	0.6	35
393	Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. <i>Radiotherapy and Oncology</i> , 2011, 99, 166-171.	0.6	66
394	Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 284-290.	0.6	30
395	Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 452-459.	0.8	10
396	Retrospective Study of Palliative Radiotherapy in Newly Diagnosed Head and Neck Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 958-963.	0.8	48
397	Low-Dose Radiotherapy in Indolent Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e1-e6.	0.8	24
398	Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans: Evaluation of the hemodynamic features and correlation with the chemotherapy response. <i>European Journal of Radiology</i> , 2011, 80, e278-e283.	2.6	17
399	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2011, 377, 1846-1854.	13.7	370
400	Practical Management of Imatinib in Gastrointestinal Stromal Tumors. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 533-545.	0.6	6
401	Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2011, 15, 206.	1.0	4
402	Pilot study of a pediatric metronomic 4-drug regimen. <i>Oncotarget</i> , 2011, 2, 960-965.	1.8	61
403	Trans-arterial 90Yttrium radioembolization for patients with unresectable tumors originating from the biliary tree. <i>Annals of Hepatology</i> , 2011, 10, 349-354.	1.5	9
404	From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy. <i>Tumori</i> , 2011, 97, 160-165.	1.1	10
405	BIOMARKERS AND PUBLICâ€“PRIVATE PARTNERSHIPS. , 0, , 193-194.		0
406	Discovery and Development of Drugs Targeting Tumor Invasion and Metastasis. , 0, , 600-611.		2
407	New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 429.	2.0	11
408	Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2011, 71, 15.	1.8	4
409	Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. <i>Current Oncology</i> , 2011, 18, .	2.2	9

#	ARTICLE	IF	CITATIONS
410	Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. <i>Cancer Imaging</i> , 2011, 11, 259-265.	2.8	37
411	Imaging follow-up of RF ablation of lung tumours. <i>Cancer Imaging</i> , 2011, 11, S123-S128.	2.8	12
412	Contrast-enhanced ultrasound in oncology. <i>Cancer Imaging</i> , 2011, 11, S167-S173.	2.8	21
413	Can CD44+/CD24- Tumor Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy?. <i>Journal of Breast Cancer</i> , 2011, 14, 175.	1.9	3
416	IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES. , 0, , 222-264.		1
417	Clinical Features, Treatment, and Outcome in 102 Adult and Pediatric Patients with Localized High-Grade Synovial Sarcoma. <i>Sarcoma</i> , 2011, 2011, 1-7.	1.3	46
418	Grand Challenges for Cancer Imaging and Diagnosis. <i>Frontiers in Oncology</i> , 2011, 1, 15.	2.8	1
419	Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?. <i>Journal of Gynecologic Oncology</i> , 2011, 22, 183.	2.2	11
420	Gavecelt Consensus Statement on the Correct use of Totally Implantable Venous Access Devices for Diagnostic Radiology Procedures. <i>Journal of Vascular Access</i> , 2011, 12, 292-305.	0.9	17
421	Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study. <i>International Journal of Biological Markers</i> , 2011, 26, 94-101.	1.8	38
422	Computer-Aided Evaluation of Breast MRI for the Residual Tumor Extent and Response Monitoring in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Korean Journal of Radiology</i> , 2011, 12, 34.	3.4	21
423	FDG PET/CT in cancer therapy monitoring. <i>Nuklearmedizin - Nuclear Medicine</i> , 2011, 50, 83-92.	0.7	2
424	A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors. <i>PLoS ONE</i> , 2011, 6, e16031.	2.5	48
425	Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction. <i>PLoS ONE</i> , 2011, 6, e23303.	2.5	50
426	The Effect of Neoadjuvant Chemotherapy on Hormone Receptor Status, HER2/neu and Prolactin in Breast Cancer. <i>Tumori</i> , 2011, 97, 704-710.	1.1	6
427	Role of Immunotherapy for Renal Cell Cancer in 2011. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1011-1018.	4.9	22
428	PET/CT with ^3H -deoxy- ^3H -[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. <i>Nuclear Medicine Communications</i> , 2011, 32, 348-355.	1.1	18
429	Contemporary management of metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2011, 21, 241-247.	1.8	12

#	ARTICLE	IF	CITATIONS
430	The Usefulness of Tc-99m-Tetrofosmin SPECT/CT in the Detection of Residual Tumors and Axillary Lymph Node Metastases in Breast Cancer Patients Following Neoadjuvant Therapy. Clinical Nuclear Medicine, 2011, 36, 997-1002.	1.3	8
431	Temsirolimus in advanced leiomyosarcomas. Anti-Cancer Drugs, 2011, 22, 463-467.	1.4	26
432	Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro. Journal of Immunotherapy, 2011, 34, 45-57.	2.4	35
433	The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature. Mini-Reviews in Medicinal Chemistry, 2011, 11, 746-752.	2.4	4
434	The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nuclear Medicine Communications, 2011, 32, 106-112.	1.1	51
435	Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging. , 2011, , .		4
436	CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. American Journal of Roentgenology, 2011, 197, W1060-W1066.	2.2	32
437	Recurrent thyroid cancer: a molecular-based therapeutic breakthrough. Current Opinion in Oncology, 2011, 23, 235-240.	2.4	9
438	Liver Metastases From Colorectal Cancer Treated With Conventional and Antiangiogenetic Chemotherapy. Journal of Computer Assisted Tomography, 2011, 35, 690-696.	0.9	56
439	PET/CT Allows Stratification of Responders to Neoadjuvant Chemotherapy for High-Grade Sarcoma. Clinical Nuclear Medicine, 2011, 36, 526-532.	1.3	36
440	Current and Future Trends in Imaging Informatics for Oncology. Cancer Journal (Sudbury, Mass), 2011, 17, 203-210.	2.0	15
441	Metabolic Response of Rectal Cancer Assessed by 18-FDG PET Following Chemoradiotherapy is Prognostic for Patient Outcome. Diseases of the Colon and Rectum, 2011, 54, 518-525.	1.3	27
442	Dual Energy CT for Monitoring Targeted Therapies in Patients with Advanced Gastrointestinal Stromal Tumor: Initial Results. Current Pharmaceutical Biotechnology, 2011, 12, 547-557.	1.6	21
443	Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. The Cochrane Library, 2011, , CD004787.	2.8	173
444	Early Response of Hepatic Malignancies to Locoregional Therapy-Value of Diffusion-Weighted Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy. Journal of Computer Assisted Tomography, 2011, 35, 167-173.	0.9	21
445	Laser immunotherapy for the treatment of human breast cancer: one-year follow up results. , 2011, , .		0
446	Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiology and Oncology, 2011, 45, 285-91.	1.7	13
447	Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial. Journal of Thoracic Oncology, 2011, 6, 1915-1922.	1.1	9

#	ARTICLE	IF	CITATIONS
448	Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. Yearbook of Diagnostic Radiology, 2011, 2011, 190-191.	0.0	0
449	Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2011, 21, 1573-1578.	2.5	25
450	Multigene Mutation Analysis of Metastatic Lymph Nodes in Non-small Cell Lung Cancer Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Chest, 2011, 140, 1319-1324.	0.8	115
451	Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1267-1273.	1.1	16
452	Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clinical Investigation, 2011, 1, 33-44.	0.0	2
453	Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Oncology Reports, 2011, 25, 1047-52.	2.6	17
455	Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Española Multidisciplinar en Cancer Digestivo (GEMCAD). Reviews on Recent Clinical Trials, 2011, 6, 158-170.	0.8	2
456	Transesophageal Ultrasound-Guided Fine-Needle Aspiration for the Mediastinal Restaging of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1510-1515.	1.1	36
457	Cisplatin and TRAIL enhance breast cancer stem cell death. International Journal of Oncology, 2011, 39, 891-8.	3.3	27
458	Standard Outcome Measures for Thymic Malignancies. Journal of Thoracic Oncology, 2011, 6, S1691-S1697.	1.1	128
459	FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. International Journal of Oncology, 2011, 39, 91-100.	3.3	3
460	Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Experimental and Therapeutic Medicine, 2011, 2, 1177-1181.	1.8	17
461	A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria. Journal of Thoracic Oncology, 2011, 6, 598-601.	1.1	39
462	Tumor volume measurement errors of RECIST studied with ellipsoids. Medical Physics, 2011, 38, 2552-2557.	3.0	9
463	Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 1930-1937.	1.1	79
464	Automated 3-dimensional segmentation of pelvic lymph nodes in magnetic resonance images. Medical Physics, 2011, 38, 6178-6187.	3.0	17
465	Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clinical Transplantation, 2011, 25, E541-51.	1.6	20
466	Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Disease, 2011, 13, e388-e395.	1.4	54

#	ARTICLE	IF	CITATIONS
467	Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1201-1206.	2.8	12
468	Clinical features and natural history of hepatocellular adenomas: the impact of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 664-674.	3.7	85
469	Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1193-1201.	3.7	102
470	Tumour heterogeneity of mucosal melanomas during treatment with imatinib. <i>British Journal of Dermatology</i> , 2011, 165, 419-424.	1.5	7
471	New therapeutic options for metastatic malignant insulinomas. <i>Clinical Endocrinology</i> , 2011, 75, 277-284.	2.4	54
472	Diffusion-weighted Imaging in Evaluating the Response to Neoadjuvant Breast Cancer Treatment. <i>Breast Journal</i> , 2011, 17, 610-619.	1.0	58
473	An Audit Strategy for Progression-Free Survival. <i>Biometrics</i> , 2011, 67, 1092-1099.	1.4	25
474	Therapeutic cancer vaccines: are we there yet?. <i>Immunological Reviews</i> , 2011, 239, 27-44.	6.0	249
475	Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 817-825.	4.7	47
476	Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration. <i>Journal of Controlled Release</i> , 2011, 154, 20-26.	9.9	30
477	A complex adaptive system using statistical learning theory as an inline preprocess for clinical survival analysis. <i>Procedia Computer Science</i> , 2011, 6, 279-284.	2.0	3
478	The Role of Magnetic Resonance Imaging Biomarkers in Clinical Trials of Treatment Response in Cancer. <i>Seminars in Oncology</i> , 2011, 38, 16-25.	2.2	34
479	Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. <i>Gynecologic Oncology</i> , 2011, 122, 107-110.	1.4	28
480	Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. <i>Gynecologic Oncology</i> , 2011, 123, 553-556.	1.4	68
481	miRNA signature associated with outcome of gastric cancer patients following chemotherapy. <i>BMC Medical Genomics</i> , 2011, 4, 79.	1.5	123
482	Clinical trials in the era of personalized oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 365-381.	329.8	56
483	Hepatic Arterial Infusion of Doxorubicin-Loaded Microsphere for Treatment of Hepatocellular Cancer: A Multi-Institutional Registry. <i>Journal of the American College of Surgeons</i> , 2011, 213, 493-500.	0.5	18
484	Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non-Small-Cell Lung Cancer With Pleural Effusion. <i>Clinical Lung Cancer</i> , 2011, 12, 307-312.	2.6	21

#	ARTICLE	IF	CITATIONS
485	Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 40-53.	4.4	63
486	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 10-15.	1.9	98
488	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011, 20, 34-38.	2.2	8
489	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <i>Breast</i> , 2011, 20, 319-323.	2.2	38
490	Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. <i>Clinical Immunology</i> , 2011, 138, 23-32.	3.2	18
491	Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1399-1405.	1.9	44
492	Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. <i>Frontiers of Medicine</i> , 2011, 5, 323-332.	3.4	16
493	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 235-241.	0.1	0
494	The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. <i>European Radiology</i> , 2011, 21, 281-290.	4.5	126
495	Semi-automated volumetric analysis of lymph node metastases during follow-up—initial results. <i>European Radiology</i> , 2011, 21, 683-692.	4.5	16
496	Comparison of semi-automated and manual methods to measure the volume of liver tumours on MDCT images. <i>European Radiology</i> , 2011, 21, 996-1003.	4.5	8
497	Neoadjuvant chemotherapy in breast cancer—response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. <i>European Radiology</i> , 2011, 21, 1188-1199.	4.5	133
498	Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. <i>European Radiology</i> , 2011, 21, 2169-2177.	4.5	90
499	Precision Hepatic Arterial Irinotecan Therapy in the Treatment of Unresectable Intrahepatic Cholangiocellular Carcinoma: Optimal Tolerance and Prolonged Overall Survival. <i>Annals of Surgical Oncology</i> , 2011, 18, 431-438.	1.5	46
500	Disease-Related Mortality within the First Year after Subtotal Esophagectomy for Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1139-1144.	1.5	5
501	Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 932-938.	1.5	42
502	Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases. <i>Annals of Surgical Oncology</i> , 2011, 18, 1081-1087.	1.5	194
503	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. <i>Annals of Surgical Oncology</i> , 2011, 18, 2192-2199.	1.5	76

#	ARTICLE	IF	CITATIONS
504	Radiologic Assessment of Response to Therapy: Comparison of RECIST Versions 1.1 and 1.0. Radiographics, 2011, 31, 2093-2105.	3.3	73
505	Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Research and Treatment, 2011, 128, 119-126.	2.5	69
506	Linear accelerator-based stereotactic radiosurgery for brainstem metastases: the Dana-Farber/Brigham and Women's Cancer Center experience. Journal of Neuro-Oncology, 2011, 104, 553-557.	2.9	40
507	Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma. Molecular Imaging and Biology, 2011, 13, 368-377.	2.6	32
508	Adjuvant surgical therapy for patients with initially unresectable pancreatic cancer with long-term favorable responses to chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 712-716.	2.6	35
509	The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 21-29.	2.8	34
510	Observed magnetic resonance imaging changes in pediatric patients treated with stereotactic radiosurgery for intracranial tumors. Child's Nervous System, 2011, 27, 399-406.	1.1	9
511	Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer, 2011, 14, 101-112.	5.3	3,039
512	Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study. International Journal of Clinical Oncology, 2011, 16, 613-616.	2.2	6
514	Tubulocystic renal carcinoma: a clinical perspective. World Journal of Urology, 2011, 29, 349-354.	2.2	25
515	Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World Journal of Urology, 2011, 29, 355-360.	2.2	9
517	Molecular imaging in cancer treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 358-377.	6.4	77
518	Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 302-311.	6.4	186
519	18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1059-1063.	6.4	16
520	FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1029-1036.	6.4	51
521	18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1037-1045.	6.4	79
522	Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1669-1674.	6.4	89
523	Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1854-1861.	6.4	41

#	ARTICLE	IF	CITATIONS
524	Assessment of the treatment response of HCC. Abdominal Imaging, 2011, 36, 300-314.	2.0	52
525	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdominal Imaging, 2011, 36, 677-683.	2.0	22
526	Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunology, Immunotherapy, 2011, 60, 1097-1107.	4.2	48
527	Treatment Planning and Volumetric Response Assessment for Yttrium-90 Radioembolization: Semiautomated Determination of Liver Volume and Volume of Tumor Necrosis in Patients with Hepatic Malignancy. CardioVascular and Interventional Radiology, 2011, 34, 306-318.	2.0	27
528	Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemotherapy and Pharmacology, 2011, 67, 847-853.	2.3	26
529	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 539-545.	2.3	29
530	Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1081-1087.	2.3	8
531	Contrast-enhanced sonography in pediatrics. Pediatric Radiology, 2011, 41, 238-242.	2.0	39
532	Pediatric oncology and the future of oncological imaging. Pediatric Radiology, 2011, 41, 172-185.	2.0	13
533	Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine, 2011, 40, 181-186.	2.3	13
534	Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Medical Oncology, 2011, 28, 115-120.	2.5	7
535	Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy. Clinical and Translational Oncology, 2011, 13, 18-24.	2.4	24
536	A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. Clinical and Translational Oncology, 2011, 13, 686-691.	2.4	3
537	FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma. Hormones and Cancer, 2011, 2, 354-362.	4.9	51
538	Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Into Imaging, 2011, 2, 621-630.	3.4	41
539	Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumor Biology, 2011, 32, 647-652.	1.8	12
540	BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells. Tumor Biology, 2011, 32, 985-995.	1.8	22
541	Liver tumors segmentation from CTA images using voxels classification and affinity constraint propagation. International Journal of Computer Assisted Radiology and Surgery, 2011, 6, 247-255.	2.8	36

#	ARTICLE	IF	CITATIONS
542	Response Assessment in Neuro-Oncology. Current Oncology Reports, 2011, 13, 50-56.	4.0	96
543	Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. BMC Medical Research Methodology, 2011, 11, 164.	3.1	2
544	Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer, 2011, 11, 295.	2.6	54
545	A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. BMC Cancer, 2011, 11, 510.	2.6	12
546	Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial. BMC Cancer, 2011, 11, 67.	2.6	37
547	Evaluation of early imaging response criteria in glioblastoma multiforme. Radiation Oncology, 2011, 6, 121.	2.7	20
548	Preclinical multimodality phantom design for quality assurance of tumor size measurement. BMC Medical Physics, 2011, 11, 1.	2.4	17
549	Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatric Blood and Cancer, 2011, 56, 733-737.	1.5	125
550	Preliminary study of the specific endothelin A receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate, 2011, 71, 1264-1275.	2.3	18
551	Time-to-event analysis with treatment arm selection at interim. Statistics in Medicine, 2011, 30, 3067-3081.	1.6	20
552	How is retrospective independent review influenced by investigator-introduced informative censoring: A quantitative approach. Statistics in Medicine, 2011, 30, 3373-3386.	1.6	5
553	An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics, 2011, 10, 347-356.	1.3	156
554	Prognostic significance of expression of vegf and cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. Journal of Surgical Oncology, 2011, 103, 46-52.	1.7	30
555	The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. Journal of Surgical Oncology, 2011, 104, 661-666.	1.7	14
556	Monitoring neoadjuvant chemotherapy in breast cancer patients: Improved MR assessment at 3 T?. Journal of Magnetic Resonance Imaging, 2011, 34, 547-556.	3.4	15
557	Tumor imaging using hyperpolarized ¹³ C magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 2011, 66, 505-519.	3.0	229
558	The role of ¹⁸ F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. American Journal of Hematology, 2011, 86, 567-572.	4.1	42
559	Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI. NMR in Biomedicine, 2011, 24, 750-763.	2.8	24

#	ARTICLE	IF	CITATIONS
560	Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. <i>Hepatology</i> , 2011, 54, 2238-2244.	7.3	101
561	Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer. <i>Cancer</i> , 2011, 117, 1262-1271.	4.1	99
562	Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. <i>Cancer</i> , 2011, 117, 1377-1385.	4.1	43
563	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.	4.1	74
564	The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. <i>Cancer</i> , 2011, 117, 3963-3971.	4.1	35
565	Response assessment in gastrointestinal stromal tumor. <i>International Journal of Cancer</i> , 2011, 128, 1251-1258.	5.1	14
566	Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors. <i>International Journal of Cancer</i> , 2011, 129, 2533-2542.	5.1	55
567	Cohort study of patients with adrenal lesions discovered incidentally. <i>British Journal of Surgery</i> , 2011, 98, 1383-1391.	0.3	45
568	Positron emission tomography and colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 30-47.	4.4	21
569	Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. <i>Journal of Proteomics</i> , 2011, 74, 698-703.	2.4	11
570	Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. <i>Clinical Investigation</i> , 2011, 1, 1545-1554.	0.0	4
571	Quantitative effects of using compressed sensing in dynamic contrast enhanced MRI. <i>Physics in Medicine and Biology</i> , 2011, 56, 4933-4946.	3.0	48
572	MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 5812-5821.	7.0	147
573	¹⁷⁷ Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1041-1047.	5.0	144
574	Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy. <i>American Journal of Roentgenology</i> , 2011, 197, W992-W1000.	2.2	231
575	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. <i>Annals of Pharmacotherapy</i> , 2011, 45, 263-275.	1.9	0
576	Response to Treatment Series: Part 2, Tumor Response Assessment—Using New and Conventional Criteria. <i>American Journal of Roentgenology</i> , 2011, 197, 18-27.	2.2	66
577	A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 6840-6846.	7.0	47

#	ARTICLE	IF	CITATIONS
578	Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 549-559.	1.4	40
579	Radiologic Aspects of Immune-Related Tumor Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Ipilimumab Therapy. American Journal of Roentgenology, 2011, 197, W241-W246.	2.2	62
580	Whole-Tumor Perfusion CT in Patients with Advanced Lung Adenocarcinoma Treated with Conventional and Antiangiogenetic Chemotherapy: Initial Experience. Radiology, 2011, 259, 574-582.	7.3	81
581	Oncologic Imaging: A Guiding Hand of Personalized Cancer Care. Radiology, 2011, 259, 633-640.	7.3	49
582	Targeted therapies for thyroid tumors. Modern Pathology, 2011, 24, S44-S52.	5.5	75
583	Renal Cell Carcinoma: What the Surgeon and Treating Physician Need to Know. American Journal of Roentgenology, 2011, 196, 1255-1262.	2.2	13
584	Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer Biology and Therapy, 2011, 12, 865-871.	3.4	43
585	Liver Lesion Segmentation in MSCT: Effect of Slice Thickness on Segmentation Quality, Measurement Precision and Interobserver Variability. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2011, 183, 372-380.	1.3	8
586	Lung Cancer in Never Smokers. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 010-021.	2.1	31
588	Tumor Markers in Fine-Needle Aspiration Washout for Cervical Lymphadenopathy in Patients With Known Malignancy: Preliminary Study. American Journal of Roentgenology, 2011, 197, W730-W736.	2.2	7
589	Arterially Directed Therapies for Hepatocellular Carcinoma. American Journal of Roentgenology, 2011, 197, W590-W602.	2.2	21
590	MR Evaluation of Retroperitoneal Fibrosis. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2011, 183, 721-726.	1.3	23
593	Investigation on the use of deformable registrations in lymph node tracking over time. , 2011, 2011, 8037-40.		0
594	Toward quantitative X-ray CT phantoms of metastatic tumors using rapid prototyping technology. , 2011, , .		13
595	Random walk-based automated segmentation for the prognosis of malignant pleural mesothelioma. , 2011, , .		7
596	Analysis of variability in manual liver tumor delineation in CT scans. , 2011, , .		4
597	Repeated Chemoembolization Followed by Laser-Induced Thermotherapy for Liver Metastasis of Breast Cancer. American Journal of Roentgenology, 2011, 196, W66-W72.	2.2	32
598	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy" An Aide et Recherche en Cancérologie Digestive Group Study. Journal of Clinical Oncology, 2011, 29, 4199-4204.	1.6	51

#	ARTICLE	IF	CITATIONS
599	A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 6313-6321.	7.0	57
600	Enhancement characteristics of lymphomatous lymph nodes of the mediastinum. <i>Acta Radiologica</i> , 2011, 52, 1113-1118.	1.1	2
601	Volume-of-Interest Assessment of Oncologic Response Using 18F-FDG PET/CT: A Phantom Study. <i>Journal of Nuclear Medicine Technology</i> , 2011, 39, 14-18.	0.8	2
602	[18F]-3â€²Deoxy-3â€²-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel. <i>Clinical Cancer Research</i> , 2011, 17, 7664-7672.	7.0	81
603	Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 4504-4512.	7.0	83
604	Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus. <i>Oncology</i> , 2011, 80, 307-313.	1.9	95
605	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi25-vi30.	1.2	266
606	Nanotechnology Development and Utilization: A Primer for Diagnostic and Interventional Radiologists. <i>Radiographics</i> , 2011, 31, 1449-1462.	3.3	14
607	Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. <i>Annals of Oncology</i> , 2011, 22, 288-294.	1.2	129
608	Different gene expression profiles in metastasizing midgut carcinoid tumors. <i>Endocrine-Related Cancer</i> , 2011, 18, 479-489.	3.1	24
609	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , 2011, 13, 1364-1369.	1.2	309
610	Combination of Gemcitabine and Paclitaxel is a Favorable Option for Patients with Advanced or Metastatic Urothelial Carcinoma Previously Treated with Cisplatin-based Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1214-1220.	1.3	19
611	Liver Metastasis: Biology and Clinical Management. <i>Cancer Metastasis - Biology and Treatment</i> , 2011, , .	0.1	6
612	The CT flare response of metastatic bone disease in prostate cancer. <i>Acta Radiologica</i> , 2011, 52, 557-561.	1.1	55
613	EGFR Protein Expression in Nonâ€“Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitorâ€“A Novel Antibody for Immunohistochemistry or AQUA Technology. <i>Clinical Cancer Research</i> , 2011, 17, 7796-7807.	7.0	37
614	Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2011, 17, 4814-4824.	7.0	19
615	Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues. <i>Oncologist</i> , 2011, 16, 783-787.	3.7	62
616	Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [⁹⁰ Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2416-2423.	1.6	571

#	ARTICLE	IF	CITATIONS
617	18F-Fluoromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 437-444.	5.0	31
618	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. <i>Oncologist</i> , 2011, 16, 859-867.	3.7	16
619	Developing imaging strategies for castration resistant prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 39-48.	1.8	48
620	Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Chemotherapy</i> , 2011, 57, 147-155.	1.6	14
621	Apparent Diffusion Coefficient Values Measured by Diffusion-Weighted Imaging Predict Chemoradiotherapeutic Effect for Advanced Esophageal Cancer. <i>Digestive Surgery</i> , 2011, 28, 252-257.	1.2	76
622	Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: Correlation of apparent diffusion coefficients with epithelial and stromal densities on histology. <i>Cancer Biomarkers</i> , 2011, 7, 201-210.	1.7	14
623	Hyponatremia of non-small cell lung cancer: Indian experience. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2011, 32, 139-142.	0.2	9
624	Treatment of Advanced Hepatocellular Carcinoma: Sorafenib and Beyond. <i>Clinical Medicine Reviews in Oncology</i> , 2011, 3, 39-47.	0.0	0
625	Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?. <i>Digestive Surgery</i> , 2011, 28, 114-120.	1.2	49
626	Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2011, 22, 145-148.	1.2	52
627	Optimal assessment of response in ovarian cancer. <i>Annals of Oncology</i> , 2011, 22, viii49-viii51.	1.2	18
628	Randomized Phase II Trials: A Long-term Investment With Promising Returns. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1093-1100.	6.3	82
629	A Time to Keep and a Time to Cast Away Categories of Tumor Response. <i>Journal of Clinical Oncology</i> , 2011, 29, 3109-3111.	1.6	13
630	Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer. <i>Oncologist</i> , 2011, 16, 1458-1468.	3.7	43
631	Multicentre Phase II Study of XELOX with Bevacizumab in Late-stage Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer: An ASCA Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 134-138.	1.3	1
632	Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. <i>Journal of Chemotherapy</i> , 2011, 23, 300-305.	1.5	14
633	Conventional MRI evaluation of gliomas. <i>British Journal of Radiology</i> , 2011, 84, S107-S111.	2.2	179
634	Follow-Up of Known Carcinoid Liver Metastases: Is Respiratory-Gated T ₂ *-Fast Spin-Echo Enough?. <i>Neuroendocrinology</i> , 2011, 93, 241-248.	2.5	7

#	ARTICLE	IF	CITATIONS
635	Des-Î ³ -Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2011, 29, 321-325.	1.9	49
636	Early Decrease in Î±-Fetoprotein, but Not Des-Î ³ -Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 251-258.	1.9	78
637	Liver Volume Variations as a Parameter to Assess Therapy Response in Advanced Metastatic Liver Disease. <i>Onkologie</i> , 2011, 34, 30-34.	0.8	5
638	Targeted “Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?”. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 259-265.	0.8	18
639	Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 419-423.	2.5	500
640	Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker. <i>Radiology</i> , 2011, 261, 165-171.	7.3	328
641	Response to Treatment Series: Part 1 and Introduction, Measuring Tumor Response—Challenges in the Era of Molecular Medicine. <i>American Journal of Roentgenology</i> , 2011, 197, 15-17.	2.2	28
642	Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1895-1901.	1.1	117
643	Metastatic Ovarian and Primary Peritoneal Cancer: Assessing Chemotherapy Response with Diffusion-weighted MR Imaging—Value of Histogram Analysis of Apparent Diffusion Coefficients. <i>Radiology</i> , 2011, 261, 182-192.	7.3	211
644	Clinical End Points and Response Criteria in Mycosis Fungoides and S��zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	1.6	550
645	Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. <i>Journal of Clinical Pathology</i> , 2011, 64, 947-952.	2.0	68
646	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1727-1732.	5.0	46
647	Beyond chemotherapy: new agents for targeted treatment of lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 85-96.	27.6	73
648	Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements. <i>Acta Radiologica</i> , 2011, 52, 241-246.	1.1	3
649	Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology. <i>Veterinary Pathology</i> , 2011, 48, 7-18.	1.7	71
650	Imaging assessment of tumor response: past, present and future. <i>Future Oncology</i> , 2011, 7, 669-677.	2.4	14
651	Automated temporal tracking and segmentation of lymphoma on serial CT examinations. <i>Medical Physics</i> , 2011, 38, 5879-5886.	3.0	15
652	Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). <i>Annals of Oncology</i> , 2011, 22, 2466-2470.	1.2	210

#	ARTICLE	IF	CITATIONS
653	PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. British Journal of Cancer, 2011, 105, 1850-1855.	6.4	68
654	Objective assessment of tumour response to therapy based on tumour growth kinetics. British Journal of Cancer, 2011, 105, 682-686.	6.4	24
655	EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. British Journal of Cancer, 2011, 105, 255-262.	6.4	41
656	Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocrine-Related Cancer, 2011, 18, 159-169.	3.1	138
657	The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. Expert Opinion on Investigational Drugs, 2011, 20, 305-307.	4.1	7
658	Computational approaches to assist in the evaluation of cancer treatment response. Imaging in Medicine, 2011, 3, 233-246.	0.0	3
659	Do we need novel radiologic response criteria for brain tumor immunotherapy?. Expert Review of Neurotherapeutics, 2011, 11, 619-622.	2.8	22
660	X-Ray Computed Tomography: Semiautomated Volumetric Analysis of Late-Stage Lung Tumors as a Basis for Response Assessments. International Journal of Biomedical Imaging, 2011, 2011, 1-11.	3.9	16
661	Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?. European Journal of Cardio-thoracic Surgery, 2011, 40, e29-e33.	1.4	38
662	The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: A phase II study. International Journal of Hyperthermia, 2011, 27, 27-32.	2.5	27
663	Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Annals of Oncology, 2011, 22, 1346-1352.	1.2	170
664	FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer. Oncologist, 2011, 16, 1111-1119.	3.7	73
665	Quantifying sclerotic bone metastases with 2D ultra short TE MRI: A feasibility study. Cancer Biomarkers, 2011, 7, 211-218.	1.7	9
666	Hepatocellular Carcinoma: Response to TACE Assessed with Semiautomated Volumetric and Functional Analysis of Diffusion-weighted and Contrast-enhanced MR Imaging Data. Radiology, 2011, 260, 752-761.	7.3	99
667	A Novel Chemo-radiotherapy with Low-dose Daily Cisplatin, 5-Fluorouracil and Doxorubicin for Anaplastic Thyroid Carcinoma: A Preliminary Report. Japanese Journal of Clinical Oncology, 2011, 41, 1074-1078.	1.3	10
668	Usefulness of semi-automatic volumetry compared to established linear measurements in predicting lymph node metastases in MSCT. Acta Radiologica, 2011, 52, 540-546.	1.1	8
669	It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. Journal of Clinical Oncology, 2011, 29, 3211-3213.	1.6	21
670	Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology, 2011, 13, 353-361.	1.2	105

#	ARTICLE	IF	CITATIONS
671	New Agents and New End Points for Recurrent Gliomas. <i>Journal of Clinical Oncology</i> , 2011, 29, e245-e246.	1.6	6
672	Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 836-852.	0.8	22
673	Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. <i>Journal of Radiation Research</i> , 2012, 53, 704-709.	1.6	4
674	Observer variability in a phase II trial â€œ assessing consistency in RECIST application. <i>Acta OncolÃ³gica</i> , 2012, 51, 774-780.	1.8	17
675	Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2012, 18, 1073-1081.	7.0	24
676	Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy. <i>British Journal of Radiology</i> , 2012, 85, 1243-1249.	2.2	5
677	Targeted Therapy and Molecular Genetics. , 2012, , 539-560.e6.		1
678	Reduction in growth threshold for pulmonary metastases: an opportunity for volumetry and its impact on treatment decisions. <i>British Journal of Radiology</i> , 2012, 85, 959-964.	2.2	6
679	Watching tumours gasp and die with MRI: the promise of hyperpolarised ¹³ C MR spectroscopic imaging. <i>British Journal of Radiology</i> , 2012, 85, 697-708.	2.2	31
680	The ARCAD advanced colorectal cancer databaseâ€œopen for business. <i>Annals of Oncology</i> , 2012, 23, 281-282.	1.2	13
681	Adrenal lesions in patients with extra-adrenal malignancy â€œ benign or malignant?. <i>Acta OncolÃ³gica</i> , 2012, 51, 215-221.	1.8	18
682	Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation. <i>British Journal of Radiology</i> , 2012, 85, 813-818.	2.2	25
683	Stereotactic Reirradiation of Recurrent Nasopharyngeal Carcinoma Using CyberKnife System: Preliminary Results. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 23-30.	0.1	0
684	Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. <i>Frontiers in Oncology</i> , 2012, 2, 167.	2.8	13
685	Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma. <i>Sarcoma</i> , 2012, 2012, 1-4.	1.3	5
686	Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study. <i>Case Reports in Oncology</i> , 2012, 5, 657-666.	0.7	1
687	The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. <i>OncoTargets and Therapy</i> , 2012, 5, 349.	2.0	12
688	Clinical Safety and Efficacy of Kanglaite®(Coix Seed Oil) Injection Combined with Chemotherapy in Treating Patients with Gastric Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 5319-5321.	1.2	75

#	ARTICLE	IF	CITATIONS
689	Alveolar Soft Part Sarcoma: A Single-Center 26-Patient Case Series and Review of the Literature. <i>Sarcoma</i> , 2012, 2012, 1-6.	1.3	65
690	Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1359-1366.	5.0	20
691	Can Response to Induction Chemotherapy Be a Predictive Marker for Ultimate Outcome in Hypopharyngeal Cancer?. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 146, 74-80.	1.9	6
692	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2012, 17, 260-266.	3.7	170
693	Sorafenib in metastatic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, 209-216.	3.1	96
694	[131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 914-922.	3.6	70
695	The Impact of Acquisition Time on Image Quality in Whole-Body 18F-FDG PET/CT for Cancer Staging. <i>Journal of Nuclear Medicine Technology</i> , 2012, 40, 255-258.	0.8	17
696	Radioembolization for the Treatment of Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 91-99.	1.3	118
697	Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2731-2738.	1.6	82
698	Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 105-109.	1.3	10
699	Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 160-175.	2.0	176
700	Molecular imaging of prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 320-327.	1.8	56
701	Clinical Outcomes and Dosimetric Considerations Using Stereotactic Body Radiotherapy for Abdominopelvic Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 537-542.	1.3	38
702	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii56-vii64.	1.2	647
703	Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 281-286.	5.0	15
704	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii11-vii19.	1.2	400
705	Response Evaluation in Patients With Colorectal Liver Metastases: RECIST Version 1.1 Versus Modified CT Criteria. <i>American Journal of Roentgenology</i> , 2012, 199, 809-815.	2.2	77
706	A DNA Repair Pathwayâ€“Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2012, 104, 670-681.	6.3	161

#	ARTICLE	IF	CITATIONS
707	Assessing response of myeloma bone disease with diffusion-weighted MRI. British Journal of Radiology, 2012, 85, e1198-e1203.	2.2	128
708	Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study. Journal of Nuclear Medicine, 2012, 53, 191-198.	5.0	19
709	Epithelialâ€Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2012, 11, 2526-2534.	4.1	194
710	A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. Oncology, 2012, 82, 333-340.	1.9	29
711	Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints. Clinical Cancer Research, 2012, 18, 2309-2315.	7.0	28
712	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1386-1394.	7.0	589
713	¹⁸ F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast Cancer. Journal of Nuclear Medicine, 2012, 53, 371-377.	5.0	103
714	Imaging of Tumor Viability in Lung Cancer: Initial Results Using ²³ Na-MRI. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2012, 184, 340-344.	1.3	22
715	Genitourinary Imaging: Part 2, Role of Imaging in Medical Management of Advanced Renal Cell Carcinoma. American Journal of Roentgenology, 2012, 199, W554-W564.	2.2	11
716	Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older. Women's Health, 2012, 8, 455-471.	1.5	24
718	An EFSUMB Introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for Quantification of Tumour Perfusion. Ultraschall in Der Medizin, 2012, 33, 344-351.	1.5	305
719	External Beam Radiation Therapy (EBRT) for Patients with Malignant Pheochromocytoma and Non-Head and -Neck Paraganglioma: Combination with ¹³¹ I-MIBG. Hormone and Metabolic Research, 2012, 44, 405-410.	1.5	64
720	MSCT Follow-Up in Malignant Lymphoma: Comparison of Manual Linear Measurements with Semi-Automated Lymph Node Analysis for Therapy Response Classification. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2012, 184, 795-804.	1.3	10
721	Lung, Liver and Lymph Node Metastases in Follow-Up MSCT: Comprehensive Volumetric Assessment of Lesion Size Changes. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2012, 184, 820-828.	1.3	14
722	The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applications. Ultraschall in Der Medizin, 2012, 33, 33-59.	1.5	922
723	Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel. Cancer Biology and Therapy, 2012, 13, 156-163.	3.4	14
724	Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models. Radiology, 2012, 262, 708-718.	7.3	239
726	A Spotlight from Prostate Cancer. Cancer Discovery, 2012, 2, 301-303.	9.4	0

#	ARTICLE	IF	CITATIONS
727	US FDA draft Guidance Standard for Clinical Trial Imaging Endpoints: more than just imaging?. Biomarkers in Medicine, 2012, 6, 839-847.	1.4	7
728	Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine. Future Oncology, 2012, 8, 1215-1218.	2.4	13
729	Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. Future Oncology, 2012, 8, 1605-1612.	2.4	13
730	Colorectal Liver Metastasis After ⁹⁰ Y Radioembolization Therapy: Pilot Study of Change in MDCT Attenuation as a Surrogate Marker for Future FDG PET Response. American Journal of Roentgenology, 2012, 198, 1093-1099.	2.2	18
731	Hepatic Tumors: Region-of-Interest versus Volumetric Analysis for Quantification of Attenuation at CT. Radiology, 2012, 262, 853-861.	7.3	31
732	Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). Hormone and Metabolic Research, 2012, 44, 411-414.	1.5	71
733	Treatment of Hepatocellular Carcinoma with Sorafenib - Focus on Special Populations and Adverse Event Management. Zeitschrift Fur Gastroenterologie, 2012, 50, 1018-1027.	0.5	10
734	EFSUMB Guidelines 2011: Comment on Emergent Indications and Visions. Ultraschall in Der Medizin, 2012, 33, S39-S47.	1.5	35
735	Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4040-4050.	3.6	185
736	Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer. Molecular Therapy, 2012, 20, 221-229.	8.2	33
737	Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. Expert Review of Anticancer Therapy, 2012, 12, 1217-1228.	2.4	12
738	Reporting of preclinical tumor-graft cancer therapeutic studies. Cancer Biology and Therapy, 2012, 13, 1262-1268.	3.4	14
739	Plasmid IL-12 electroporation in melanoma. Human Vaccines and Immunotherapeutics, 2012, 8, 1734-1738.	3.3	35
740	Pulmonary Nodule Size Evaluation with Chest Tomosynthesis. Radiology, 2012, 265, 273-282.	7.3	33
741	Repeat Biopsy for Mutational Analysis of Non-Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications. Radiology, 2012, 265, 939-948.	7.3	98
742	A cross-platform and distributive database system for cumulative tumor measurement. , 2012, 2012, 1266-9.		2
743	Informatics in Radiology: Improving Clinical Work Flow through an AIM Database: A Sample Web-based Lesion Tracking Application. Radiographics, 2012, 32, 1543-1552.	3.3	17
744	Implementation of a controlled injection system for dynamic contrast-enhanced ultrasonography. , 2012, , .		2

#	ARTICLE	IF	CITATIONS
745	CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer, 2012, 106, 633-637.	6.4	36
746	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research, 2012, 18, 6373-6383.	7.0	458
747	Intratumoral Molecular Heterogeneity in a <i>BRAF</i> -Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 2012, 11, 2704-2708.	4.1	78
748	Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. British Journal of Cancer, 2012, 106, 1274-1279.	6.4	24
749	Islet Cell Liver Metastases: Assessment of Volumetric Early Response with Functional MR Imaging after Transarterial Chemoembolization. Radiology, 2012, 264, 97-109.	7.3	40
750	Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. British Journal of Cancer, 2012, 106, 854-857.	6.4	45
751	Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. British Journal of Cancer, 2012, 106, 1926-1933.	6.4	105
752	A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. British Journal of Cancer, 2012, 107, 604-611.	6.4	16
753	Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?. Leukemia, 2012, 26, 1148-1149.	7.2	10
754	Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram. Oncologist, 2012, 17, 1508-1514.	3.7	83
755	Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging—Prospective Assessment. Radiology, 2012, 263, 53-63.	7.3	113
756	The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Annals of Oncology, 2012, 23, 948-954.	1.2	92
757	Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro-Oncology, 2012, 14, 667-673.	1.2	94
758	Assessment of Response to Therapy. Medical Radiology, 2012, , 279-322.	0.1	2
759	Surgical treatment of early stage small cell lung cancer. Asian Cardiovascular and Thoracic Annals, 2012, 20, 694-698.	0.5	11
760	Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies. Journal of Clinical Oncology, 2012, 30, 2684-2690.	1.6	86
761	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1120-1128.	7.0	57
762	Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma. Chemotherapy, 2012, 58, 468-474.	1.6	38

#	ARTICLE	IF	CITATIONS
763	2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2012, 1, 5-14.	2.4	137
764	Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. <i>European Respiratory Journal</i> , 2012, 39, 9-28.	6.7	38
765	Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009. <i>Clinical Cancer Research</i> , 2012, 18, 6356-6363.	7.0	21
766	Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. <i>Neuro-Oncology</i> , 2012, 14, 491-495.	1.2	83
767	Cardiac Tumors in a Tertiary Care Cancer Hospital: Clinical Features, Echocardiographic Findings, Treatment and Outcomes. <i>Heart International</i> , 2012, 7, hi.2012.e4.	1.4	69
768	18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244,ARRY-142886) in patients with solid tumors. <i>World Journal of Nuclear Medicine</i> , 2012, 11, 65-69.	0.5	7
769	Three-Dimensional Segmented Volumetric Analysis of Sporadic Vestibular Schwannomas. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 737-743.	1.9	45
770	Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2012, 19, L1-L4.	3.1	52
771	Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. <i>Breast Cancer: Targets and Therapy</i> , 2012, 2012, 139.	1.8	20
772	Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 395.	3.2	14
773	PET/CT in renal and bladder cancers. <i>Archive of Oncology</i> , 2012, 20, 97-102.	0.2	0
774	Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series. <i>Archive of Oncology</i> , 2012, 20, 143-148.	0.2	0
775	Repeatability of ¹⁸ F-FDG Uptake Measurements in Tumors: A Metaanalysis. <i>Journal of Nuclear Medicine</i> , 2012, 53, 701-708.	5.0	149
776	New Insight into the Treatment of Advanced Differentiated Thyroid Cancer. <i>Journal of Thyroid Research</i> , 2012, 2012, 1-8.	1.3	9
777	BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 791-797.	9.4	194
778	Hepatocellular carcinoma: natural history, current management, and emerging tools. <i>Biologics: Targets and Therapy</i> , 2012, 6, 207.	3.2	54
779	Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1221-1225.	4.1	70
780	Progression-Free Survival: Meaningful or Simply Measurable?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1030-1033.	1.6	278

#	ARTICLE	IF	CITATIONS
781	Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3345-3352.	1.6	81
782	Persistent neck disease after chemoradiation for head and neck squamous cell carcinoma. <i>Journal of Laryngology and Otology</i> , 2012, 126, 1121-1126.	0.8	3
783	A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 860-866.	1.2	43
784	Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 1687-1693.	1.2	70
785	PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 182-190.	5.0	136
786	Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1385-1388.	4.1	16
787	[18F]Fluorodeoxyglucose Positron Emission Tomography-Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case. <i>Journal of Clinical Oncology</i> , 2012, 30, e246-e249.	1.6	5
788	Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1. <i>American Journal of Hypertension</i> , 2012, 25, 1118-1123.	2.0	39
789	Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 979-986.	2.5	78
790	Efficacy of Trabectedin in Patients with Advanced or Metastatic Alveolar Soft-Part Sarcoma. <i>Onkologie</i> , 2012, 35, 249-252.	0.8	14
791	Evaluation of the mRECIST and α -Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib. <i>Oncology</i> , 2012, 83, 192-200.	1.9	66
792	Surgical Results after Downstaging of Initially Marginal or Non-Resectable Liver Metastases. <i>Digestive Diseases</i> , 2012, 30, 143-149.	1.9	4
793	Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead. <i>Neuroendocrinology</i> , 2012, 96, 261-271.	2.5	51
794	Chemotherapy Combined with Radionuclide Therapy. <i>Medical Radiology</i> , 2012, , 901-908.	0.1	0
795	Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. <i>Radiology</i> , 2012, 263, 149-159.	7.3	89
796	Independent Radiologic Review in Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. <i>Radiology</i> , 2012, 263, 86-95.	7.3	4
797	Bexarotene via CBP/p300 Induces Suppression of NF- κ B-Dependent Cell Growth and Invasion in Thyroid Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 442-453.	7.0	28
798	MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer. <i>British Journal of Radiology</i> , 2012, 85, e995-e1103.	2.2	5

#	ARTICLE	IF	CITATIONS
799	The ARCAD Clinical Trials Program: An Update and Invitation. <i>Oncologist</i> , 2012, 17, 188-191.	3.7	9
800	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. <i>American Journal of Roentgenology</i> , 2012, 198, 737-745.	2.2	169
801	Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 996-1001.	1.4	42
803	Primary Liver Cancer. <i>Medical Radiology</i> , 2012, , 163-182.	0.1	1
804	Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 151-157.	1.8	35
805	Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 403-412.	4.9	22
806	Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. <i>Radiology and Oncology</i> , 2012, 46, 8-18.	1.7	42
807	Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 571-583.	1.6	18
808	Optimisation of reconstruction for the registration of CT liver perfusion sequences. <i>Proceedings of SPIE</i> , 2012, , .	0.8	1
809	Diagnostic Ability of Fluid-Attenuated Inversion Recovery MR Imaging to Detect Remnant or Recurrent Meningiomas after Resection. <i>Neuroradiology Journal</i> , 2012, 25, 163-171.	1.2	3
810	Diffusion-Weighted Imaging in Abdominal Oncology. <i>Current Medical Imaging</i> , 2012, 8, 82-91.	0.8	1
811	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72.	2.4	111
812	[18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy. <i>Nuclear Medicine Communications</i> , 2012, 33, 889-894.	1.1	22
814	Monitoring Molecular, Functional and Morphologic Aspects of Bone Metastases Using Non-Invasive Imaging. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 584-594.	1.6	8
816	Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. <i>Oncology Letters</i> , 2012, 3, 662-666.	1.8	8
817	Electrochemotherapy for the Treatment of Recurrent Head and Neck Cancers: Preliminary Results. <i>Tumori</i> , 2012, 98, 308-313.	1.1	42
818	Interpretation of PET Scans: Do Not Take SUVs at Face Value. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1744-1746.	1.1	13
819	Approaches Used in Immunotherapy for Prostate Cancer. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 238-244.	0.3	0

#	ARTICLE	IF	CITATIONS
820	Monitoring Response to Antiangiogenic Treatment and Predicting Outcomes in Advanced Hepatocellular Carcinoma Using Image Biomarkers, CT Perfusion, Tumor Density, and Tumor Size (RECIST). <i>Investigative Radiology</i> , 2012, 47, 11-17.	6.2	141
821	PNET Spine. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e164-e169.	0.6	5
822	The role of positron emission tomography following radiosurgical treatment of malignant lung lesions. <i>Nuclear Medicine Communications</i> , 2012, 33, 607-612.	1.1	4
823	Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 1107-1111.	1.4	10
824	Clinical trials in drug development. <i>Current Opinion in Oncology</i> , 2012, 24, 332-337.	2.4	3
825	Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1006-1012.	2.5	39
826	Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced, Recurrent, or Metastatic Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 865-868.	2.5	33
827	Preoperative Chemotherapy With Doxorubicin in Wilms Tumor. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e106-e109.	0.6	4
828	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. <i>Neurosurgery</i> , 2012, 70, 234-244.	1.1	204
829	Improving T-cell Immunotherapy for Melanoma Through a Mathematically Motivated Strategy. <i>Journal of Immunotherapy</i> , 2012, 35, 116-124.	2.4	21
830	Dynamic Contrast-Enhanced Computed Tomography Imaging Biomarkers Correlated With Immunohistochemistry for Monitoring the Effects of Sorafenib on Experimental Prostate Carcinomas. <i>Investigative Radiology</i> , 2012, 47, 49-57.	6.2	38
831	Models for Disease Progression: New Approaches and Uses. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 125-131.	4.7	55
832	Targeting Cancer Stem Cells with Natural Products. <i>Current Drug Targets</i> , 2012, 13, 1054-1064.	2.1	29
833	Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer. <i>Oncology Letters</i> , 2012, 4, 131-134.	1.8	1
834	BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis. <i>Oncology Letters</i> , 2012, 4, 141-145.	1.8	3
836	Complete Response of a Patient with Advanced Primary Splenic Histiocytic Sarcoma by Treatment with Chemotherapeutic Drugs Selected Using the Collagen Gel Droplet-embedded Culture Drug Sensitivity Test. <i>Internal Medicine</i> , 2012, 51, 2893-2897.	0.7	6
837	Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. <i>Oncology Letters</i> , 2012, 3, 1064-1068.	1.8	4
838	Computer-aided lymph node segmentation in volumetric CT data. <i>Medical Physics</i> , 2012, 39, 5419-5428.	3.0	10

#	ARTICLE	IF	CITATIONS
839	Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. International Journal of Oncology, 2012, 41, 1593-1600.	3.3	36
840	Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Experimental and Therapeutic Medicine, 2012, 4, 1010-1016.	1.8	12
841	Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study. Oncology Letters, 2012, 3, 761-766.	1.8	5
842	Use of Aromatase Inhibitors as First-and Second-Line Medical Therapy in Patients With Endometrial Adenocarcinoma: A Retrospective Study. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 664-672.	0.7	14
843	Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 512-519.	1.1	166
845	Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Experimental and Therapeutic Medicine, 2012, 3, 898-902.	1.8	11
846	Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 993-1000.	1.1	32
848	Maintenance Therapy and Advanced Non-Small-Cell Lung Cancer: A Skeptic's View. Journal of Thoracic Oncology, 2012, 7, 1331-1336.	1.1	24
849	EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. Journal of Thoracic Oncology, 2012, 7, 98-104.	1.1	99
850	Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy. Oncology Letters, 2012, 4, 905-909.	1.8	15
851	Structural and Molecular Imaging in Cancer Therapy Clinical Trials. , 2012, , 387-412.		0
853	Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component. Endocrine Journal, 2012, 59, 839-844.	1.6	11
854	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, The, 2012, 379, 1893-1901.	13.7	856
855	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2012, 380, 358-365.	13.7	2,691
856	TFAP2E and DKK4 and Chemoresistance in Colorectal Cancer. New England Journal of Medicine, 2012, 366, 44-53.	27.0	165
857	Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Annals of Oncology, 2012, 23, 2937-2942.	1.2	191
858	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine, 2012, 367, 1187-1197.	27.0	3,847
859	Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 329-339.	4.1	92

#	ARTICLE	IF	CITATIONS
860	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. <i>Tumor Biology</i> , 2012, 33, 2061-2068.	1.8	30
861	Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features. <i>Lung Cancer</i> , 2012, 77, 64-69.	2.0	97
862	Computed Tomography-Based Anatomic Assessment Overestimates Local Tumor Recurrence in Patients With Mass-like Consolidation After Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1071-1077.	0.8	70
863	Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity. <i>Clinical Cancer Research</i> , 2012, 18, 5796-5805.	7.0	77
864	Imaging in oncology—over a century of advances. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 728-737.	27.6	25
865	Mechanistic understanding in clinical practice: complementing evidence-based medicine with personalized medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 1000-1005.	1.8	10
866	Different approaches to volume assessment of lymph nodes in computer tomography scans of head and neck squamous cell carcinoma in comparison with a real gold standard. <i>ANZ Journal of Surgery</i> , 2012, 82, 737-741.	0.7	5
867	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012, 110, E661-6.	2.5	76
868	The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus. <i>Oncologist</i> , 2012, 17, 1225-1239.	3.7	453
869	Clinical Trial Design in the Age of Molecular Profiling. <i>Methods in Molecular Biology</i> , 2012, 823, 19-34.	0.9	2
870	A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3440-3451.	7.0	51
871	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. <i>Targeted Oncology</i> , 2012, 7, 253-265.	3.6	57
872	Survival in BRAF V600E-Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	27.0	1,955
873	Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients: A Feasibility Study. <i>Oncology</i> , 2012, 82, 3-10.	1.9	104
874	Imaging in Drug Development. , 2012, , 327-341.		0
875	Multicenter Prospective Trial of Hypofractionated Radiation Treatment, Toceranib, and Prednisone for Measurable Canine Mast Cell Tumors. <i>Journal of Veterinary Internal Medicine</i> , 2012, 26, 135-141.	1.6	49
876	Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. <i>Investigational New Drugs</i> , 2012, 30, 2377-2383.	2.6	104
877	The developing cancer stem-cell model: clinical challenges and opportunities. <i>Lancet Oncology</i> , The, 2012, 13, e83-e89.	10.7	327

#	ARTICLE	IF	CITATIONS
879	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to the Paris classification. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1850-1857.	2.8	45
880	Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Research, 2012, 14, 206.	5.0	32
881	The Stoichiometric Production of IL-2 and IFN- γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans. Science Translational Medicine, 2012, 4, 149ra120.	12.4	51
882	Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. European Radiology, 2012, 22, 2533-2539.	4.5	53
883	Workflow-centred evaluation of an automatic lesion tracking software for chemotherapy monitoring by CT. European Radiology, 2012, 22, 2759-2767.	4.5	13
884	Intelligent image retrieval based on radiology reports. European Radiology, 2012, 22, 2750-2758.	4.5	27
885	Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer. European Archives of Oto-Rhino-Laryngology, 2012, 269, 2391-2399.	1.6	3
886	Intracranial meningeal hemangiopericytoma: 10 years experience of a tertiary care Institute. Acta Neurochirurgica, 2012, 154, 1647-1651.	1.7	35
887	Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?. International Journal of Clinical Oncology, 2012, 17, 610-615.	2.2	22
888	A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy. International Journal of Clinical Oncology, 2012, 17, 522-527.	2.2	20
889	Weekly low-dose Semustine in a patient with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) coupled with subcutaneous involvement and positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. Chinese-German Journal of Clinical Oncology, 2012, 11, 544-547.	0.1	0
890	Observe the efficacy of the air wave pressure therapeutic equipment in treatment of oxaliplatin nerve toxicity. Chinese-German Journal of Clinical Oncology, 2012, 11, 602-604.	0.1	1
891	Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 136, 789-794.	2.5	52
892	Epigenetics as a Therapeutic Target in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 191-204.	2.7	105
893	New Frontiers in the Design and Synthesis of Imaging Probes for PET Oncology: Current Challenges and Future Directions. Molecular Imaging and Biology, 2012, 14, 653-666.	2.6	35
895	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Experimental Hematology, 2012, 40, 882-891.e1.	0.4	43
896	A Phase II Comparative Study of Gross Tumor Volume Definition With or Without PET/CT Fusion in Dosimetric Planning for Non-Small-Cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515. International Journal of Radiation Oncology Biology Physics, 2012, 82, 435-441.e1.	0.8	99
897	Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 889-897.	0.8	221

#	ARTICLE	IF	CITATIONS
898	Tumor Shrinkage Assessed by Volumetric MRI in Long-Term Follow-Up After Fractionated Stereotactic Radiotherapy of Nonfunctioning Pituitary Adenoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1262-1267.	0.8	23
899	Tumor Volume Reduction Rate After Preoperative Chemoradiotherapy as a Prognostic Factor in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e193-e199.	0.8	52
900	Early Changes in Apparent Diffusion Coefficient From Diffusion-Weighted MR Imaging During Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 749-755.	0.8	42
901	Evaluation of an Automatic Registration-Based Algorithm for Direct Measurement of Volume Change in Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1038-1046.	0.8	10
902	Reirradiation With Cetuximab in Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck: Feasibility and First Efficacy Results. International Journal of Radiation Oncology Biology Physics, 2012, 83, e377-e383.	0.8	31
903	Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control. International Journal of Radiation Oncology Biology Physics, 2012, 83, e551-e555.	0.8	72
904	Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer. Journal of Urology, 2012, 188, 103-109.	0.4	43
905	Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and Oncology, 2012, 102, 45-50.	0.6	39
906	Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. Radiotherapy and Oncology, 2012, 102, 377-382.	0.6	21
907	Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiotherapy and Oncology, 2012, 102, 335-342.	0.6	209
908	The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: A comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 257-260.	0.0	9
909	Rentabilidad diagn�stica de los estudios PET/TC basal y de seguimiento en la terapia ablativa del c�ncer de pulm�n de c�lulas no peque�as. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 301-307.	0.0	3
910	Potential Application Value of Contrast-Enhanced Ultrasound In Neoadjuvant Chemotherapy of Breast Cancer. Ultrasound in Medicine and Biology, 2012, 38, 2065-2071.	1.5	41
911	Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 695-703.	1.6	20
912	Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer. Gynecologic Oncology, 2012, 127, 217-222.	1.4	17
913	Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecologic Oncology, 2012, 127, 511-515.	1.4	45
914	Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic Oncology, 2012, 127, 451-455.	1.4	52
915	Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. Tumor Biology, 2012, 33, 1151-1158.	1.8	19

#	ARTICLE	IF	CITATIONS
916	Exacerbation of diabetic nephropathy mimicking thrombotic microangiopathy during sunitinib treatment for metastatic renal cell carcinoma. International Cancer Conference Journal, 2012, 1, 183-189.	0.5	1
918	Temporary Balloon Occlusion of the Common Hepatic Artery for Administration of Yttrium-90 Resin Microspheres in a Patient with Patent Hepatoenteric Collaterals. Journal of Vascular and Interventional Radiology, 2012, 23, 277-280.	0.5	26
919	Clinical Utility of Des-Î ³ -Carboxy Prothrombin Kinetics as a Complement to Radiologic Response in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2012, 23, 927-936.	0.5	21
920	Explorative Study on the Predictive and Prognostic Value of Early Complete Metabolic Response By FDG-PETâ€“CT During Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer. Clinical Ovarian and Other Gynecologic Cancer, 2012, 5, 2-9.	0.1	2
921	Anti-ovarian antibodies in sera of patients with ovarian tumors. Immunology Letters, 2012, 148, 133-137.	2.5	6
922	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. Clinical Colorectal Cancer, 2012, 11, 297-303.	2.3	6
923	MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy. Academic Radiology, 2012, 19, 48-54.	2.5	29
924	Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: An exploratory study. Radiotherapy and Oncology, 2012, 105, 41-48.	0.6	18
925	Combined In Vivo Molecular and Anatomic Imaging for Detection of Ovarian Carcinoma-Associated Protease Activity and Integrin Expression in Mice. Neoplasia, 2012, 14, 451-IN2.	5.3	24
926	Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 301-307.	0.2	3
927	Research Imaging in an Academic Medical Center. Academic Radiology, 2012, 19, 762-771.	2.5	6
928	The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: A comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 257-260.	0.2	0
929	Measurement of Tumor Volumes Improves RECIST-Based Response Assessments in Advanced Lung Cancer. Translational Oncology, 2012, 5, 19-25.	3.7	96
930	Using the Semantic Web and Web Apps to Connect Radiologists and Oncologists. , 2012, , .		3
931	Phase I-II Study of Radiopeptide¹⁷⁷Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 561-569.	1.0	144
932	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Annals of Oncology, 2012, 23, 618-624.	1.2	239
933	Multiple Inguinal and Pelvic Lymph Node Metastases of Malignant Melanoma of the Heel Identified by Common Iliac Lymphadenopathy. Lymphatic Research and Biology, 2012, 10, 118-121.	1.1	2
934	Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: A retrospective study. International Journal of Hyperthermia, 2012, 28, 554-561.	2.5	14

#	ARTICLE	IF	CITATIONS
935	Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports. <i>Cancer Investigation</i> , 2012, 30, 712-720.	1.3	10
936	On the comparability of medical image measurements in cancer clinical trials. , 2012, , .		0
937	Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 541-554.	2.4	42
938	Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. <i>International Journal of Hyperthermia</i> , 2012, 28, 597-604.	2.5	40
939	Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. <i>Future Oncology</i> , 2012, 8, 1193-1197.	2.4	4
940	A software prototype for the assessment of tumor treatment response using diffusion and perfusion MR imaging. , 2012, 2012, 388-91.		1
941	Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, S217-S224.	3.1	22
942	Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 3-9.	5.9	7
943	Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). <i>Annals of Oncology</i> , 2012, 23, 182-186.	1.2	130
944	Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptorâ€“positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3002-3011.	1.5	44
945	Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2401-2407.	1.6	232
946	Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. <i>Acta OncolÃ³gica</i> , 2012, 51, 575-583.	1.8	102
947	Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2012, 53, 872-880.	5.0	89
948	ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2012, 166, 5-11.	3.7	104
949	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	7.0	345
950	Prognostic utility of tumor thickness at the tumor-normal interface in chemotherapy-treated hepatic colorectal metastasis. <i>Pathology Research and Practice</i> , 2012, 208, 235-239.	2.3	8
951	Cancer biomarkers: selecting the right drug for the right patient. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 201-214.	46.4	225
952	Unusual Short-Term Complete Response to Two Regimens of Cytotoxic Chemotherapy in a Patient with Poorly Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3046-3050.	3.6	18

#	ARTICLE	IF	CITATIONS
953	Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. <i>Veterinary and Comparative Oncology</i> , 2012, 10, 184-193.	1.8	35
954	Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. <i>Hpb</i> , 2012, 14, 162-170.	0.3	11
955	Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. <i>Hpb</i> , 2012, 14, 260-268.	0.3	19
956	Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. <i>Hpb</i> , 2012, 14, 298-309.	0.3	30
957	Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. <i>Hpb</i> , 2012, 14, 341-350.	0.3	23
958	Outcomes in patients with indeterminate pulmonary nodules undergoing resection for colorectal liver metastases. <i>Hpb</i> , 2012, 14, 448-454.	0.3	13
959	The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1165-1171.	3.9	19
960	Why RECIST Works and Why It Should Stay—Counterpoint. <i>Cancer Research</i> , 2012, 72, 5151-5157.	0.9	28
961	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point. <i>Cancer Research</i> , 2012, 72, 5145-5149.	0.9	77
962	When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1534-1541.	6.3	118
963	Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 406-411.	3.7	35
964	A novel biliary stent loaded with 125I seeds in patients with malignant biliary obstruction: Preliminary results versus a conventional biliary stent. <i>Journal of Hepatology</i> , 2012, 56, 1104-1111.	3.7	81
965	Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 1324-1329.	3.7	16
966	Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 1336-1342.	3.7	148
967	Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Pancreas. <i>Journal of Surgical Research</i> , 2012, 174, 319-325.	1.6	101
968	Intérêt de la TEP dans le bilan d'extension et l'évaluation de la maladie résiduelle des tumeurs testiculaires: Étude rétrospective. <i>Medecine Nucleaire</i> , 2012, 36, 268-277.	0.2	0
969	Clinical response to chemotherapy in locally advanced breast cancer was not associated with several polymorphisms in detoxification enzymes and DNA repair genes. <i>Biochemical and Biophysical Research Communications</i> , 2012, 419, 117-119.	2.1	6
970	Digital tomosynthesis of the chest: Utility for detection of lung metastasis in patients with colorectal cancer. <i>Clinical Radiology</i> , 2012, 67, 232-238.	1.1	42

#	ARTICLE	IF	CITATIONS
971	MRI features of the complete histopathological response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy. <i>Clinical Radiology</i> , 2012, 67, 546-552.	1.1	22
972	Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 63-67.	7.7	28
973	The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 202-208.	2.8	170
974	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. <i>European Journal of Cancer</i> , 2012, 48, 1495-1502.	2.8	17
975	[18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment. <i>European Journal of Cancer</i> , 2012, 48, 416-424.	2.8	78
976	Radiomics: Extracting more information from medical images using advanced feature analysis. <i>European Journal of Cancer</i> , 2012, 48, 441-446.	2.8	3,846
977	Qualification of imaging biomarkers for oncology drug development. <i>European Journal of Cancer</i> , 2012, 48, 409-415.	2.8	66
978	Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. <i>European Journal of Cancer</i> , 2012, 48, 1332-1340.	2.8	18
979	Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study. <i>European Journal of Cancer</i> , 2012, 48, 1512-1518.	2.8	31
980	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1031-1037.	2.8	49
981	Circulating Tumour Cells in locally advanced head and neck cancer: Preliminary report about their possible role in predicting response to non-surgical treatment and survival. <i>European Journal of Cancer</i> , 2012, 48, 3019-3026.	2.8	92
982	Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. <i>European Journal of Cancer</i> , 2012, 48, 3027-3035.	2.8	104
983	Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 2293-2299.	2.8	21
984	Perfusion Computed Tomography (PCT) adopting different perfusion metrics: Recurrence of brain metastasis or radiation necrosis?. <i>European Journal of Radiology</i> , 2012, 81, 1246-1252.	2.6	11
985	Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. <i>European Journal of Radiology</i> , 2012, 81, 1173-1178.	2.6	92
986	Assessment of colorectal hepatic metastases by quantitative T2 relaxation time. <i>European Journal of Radiology</i> , 2012, 81, e536-e540.	2.6	8
987	The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. <i>European Journal of Surgical Oncology</i> , 2012, 38, 64-71.	1.0	65
988	The current status of S-100B as a biomarker in melanoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 281-285.	1.0	43

#	ARTICLE	IF	CITATIONS
989	Application of a stochastic model to response assessments in a study of squamous cell carcinoma of the head and neck. <i>Pharmaceutical Statistics</i> , 2012, 11, 462-467.	1.3	0
990	Estimation of secondary endpoints in two-stage phase II oncology trials. <i>Statistics in Medicine</i> , 2012, 31, 4352-4368.	1.6	2
991	Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2012, 12, 127.	2.0	9
992	A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. <i>BMC Cancer</i> , 2012, 12, 108.	2.6	5
993	A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). <i>BMC Cancer</i> , 2012, 12, 307.	2.6	12
994	Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. <i>BMC Cancer</i> , 2012, 12, 356.	2.6	23
995	Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 361.	2.6	43
996	Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). <i>BMC Cancer</i> , 2012, 12, 483.	2.6	11
997	Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. <i>BMC Cancer</i> , 2012, 12, 530.	2.6	24
998	Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. <i>BMC Cancer</i> , 2012, 12, 609.	2.6	11
999	Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. <i>World Journal of Surgical Oncology</i> , 2012, 10, 41.	1.9	33
1000	The immuno-oncology framework. <i>OncoImmunology</i> , 2012, 1, 334-339.	4.6	40
1001	Nanoprobes for hybrid SPECT/MR molecular imaging. <i>Nanomedicine</i> , 2012, 7, 719-733.	3.3	21
1002	Neuroblastoma: The impact of biology and cooperation leading to personalized treatments. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 85-115.	6.1	35
1003	Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy. <i>Oncology</i> , 2012, 82, 298-304.	1.9	20
1004	Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. <i>Oncology Letters</i> , 2012, 3, 363-368.	1.8	5
1005	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213.	1.2	40
1006	PET for Measuring Therapy Response After Radionuclide Therapy. <i>Medical Radiology</i> , 2012, , 917-929.	0.1	0

#	ARTICLE	IF	CITATIONS
1007	Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis. <i>Clinical Genetics</i> , 2012, 82, 552-557.	2.0	24
1008	Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2010-2016.	3.6	29
1009	A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2342-2349.	3.6	21
1010	Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. <i>Thoracic Cancer</i> , 2012, 3, 341-347.	1.9	25
1011	Crizotinib. <i>Drugs</i> , 2012, 72, 99-107.	10.9	38
1012	Pharmacotherapy Options for Advanced Thyroid Cancer. <i>Drugs</i> , 2012, 72, 67-85.	10.9	5
1013	Management of Metastatic Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2012, 72, 1011-1028.	10.9	31
1014	Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2012, 11, 195-199.	2.3	26
1015	Tumor Burden Analysis on Computed Tomography by Automated Liver and Tumor Segmentation. <i>IEEE Transactions on Medical Imaging</i> , 2012, 31, 1965-1976.	8.9	102
1016	Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era. <i>Expert Review of Vaccines</i> , 2012, 11, 287-302.	4.4	7
1017	Radiotherapy for solitary plasmacytoma of bone and soft tissue. <i>Annals of Hematology</i> , 2012, 91, 1785-1793.	1.8	62
1018	Immunotherapy for Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 465-481.	1.8	11
1019	RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. <i>European Respiratory Journal</i> , 2012, 39, 677-684.	6.7	45
1020	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 723-743.	5.0	26
1021	Introduction to Regulated Clinical Trials. , 2012, , 17-50.		1
1022	EORTC Imaging Group. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 82-87.	2.2	2
1023	Measuring the response to selective internal radiation therapy. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 57-58.	2.2	0
1024	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 810-816.	10.7	130

#	ARTICLE	IF	CITATIONS
1025	Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2012, 13, 1025-1034.	10.7	150
1026	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	10.7	841
1027	Improving outcomes for elderly patients with AML. <i>Lancet Oncology</i> , The, 2012, 13, 1065-1066.	10.7	4
1028	The limitations of imaging response criteria. <i>Lancet Oncology</i> , The, 2012, 13, 1064-1065.	10.7	2
1029	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology</i> , The, 2012, 13, 1133-1140.	10.7	490
1030	Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. <i>International Immunopharmacology</i> , 2012, 14, 546-549.	3.8	15
1031	Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2012, 204, 580-585.	1.8	33
1032	Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI. <i>Breast</i> , 2012, 21, 669-677.	2.2	165
1033	Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAB) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 500-504.	2.6	85
1034	Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: A review of existing evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 208-215.	4.4	12
1035	Integration of cell biology, pharmacological modeling and statistical analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 153-169.	4.4	1
1036	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 194-207.	4.4	61
1037	Comprehensive treatment of malignant mesothelioma patients after the failure of systemic chemotherapy. <i>Cryobiology</i> , 2012, 65, 284-288.	0.7	7
1038	Percutaneous ultrasonography and computed tomography guided pancreatic cryoablation: Feasibility and safety assessment. <i>Cryobiology</i> , 2012, 65, 301-307.	0.7	22
1039	Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 662-672.	7.7	18
1040	The role of imaging in staging and monitoring testicular cancer. <i>Diagnostic and Interventional Imaging</i> , 2012, 93, 310-318.	3.2	30
1041	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. <i>Digestive and Liver Disease</i> , 2012, 44, 432-437.	0.9	54
1042	Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01. <i>European Journal of Cancer</i> , 2012, 48, 3240-3248.	2.8	81

#	ARTICLE	IF	CITATIONS
1043	CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. <i>European Journal of Radiology</i> , 2012, 81, 2717-2725.	2.6	32
1044	Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. <i>European Journal of Radiology</i> , 2012, 81, 2627-2631.	2.6	18
1045	Semi-automatic software increases CT measurement accuracy but not response classification of colorectal liver metastases after chemotherapy. <i>European Journal of Radiology</i> , 2012, 81, 2543-2549.	2.6	13
1046	Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: Preliminary results of a prospective study. <i>European Journal of Radiology</i> , 2012, 81, 3542-3550.	2.6	21
1047	Clinical lymph node staging—Influence of slice thickness and reconstruction kernel on volumetry and RECIST measurements. <i>European Journal of Radiology</i> , 2012, 81, 3124-3130.	2.6	8
1048	Dalteparin Low Molecular Weight Heparin (LMWH) in ovarian cancer: A phase II randomized study. <i>Thrombosis Research</i> , 2012, 130, 894-900.	1.7	17
1049	The value of tumor diameter in predicting prognosis of oropharynx cancer treated with chemoradiation. <i>Oral Oncology</i> , 2012, 48, 876-880.	1.5	2
1050	Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. <i>Oral Oncology</i> , 2012, 48, 787-793.	1.5	40
1051	Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. <i>Photodiagnosis and Photodynamic Therapy</i> , 2012, 9, 287-292.	2.6	22
1052	Role of imaging techniques in the TNM classification of non-small cell bronchogenic carcinoma. <i>Radiologia</i> , 2012, 54, 306-320.	0.5	0
1053	Carboplatin Based Induction Chemotherapy for Nonorgan Confined Bladder Cancer—A Reasonable Alternative for Cisplatin Unfit Patients?. <i>Journal of Urology</i> , 2012, 188, 1108-1114.	0.4	41
1054	Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. <i>Lung Cancer</i> , 2012, 75, 213-216.	2.0	9
1055	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 439-444.	2.0	28
1056	Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study. <i>Lung Cancer</i> , 2012, 77, 121-127.	2.0	73
1057	Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. <i>Lung Cancer</i> , 2012, 77, 146-150.	2.0	34
1058	Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients. <i>Lung Cancer</i> , 2012, 77, 427-432.	2.0	10
1059	EGFR mutations as a predictive marker of cytotoxic chemotherapy. <i>Lung Cancer</i> , 2012, 77, 433-437.	2.0	25
1060	Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. <i>Lung Cancer</i> , 2012, 78, 76-80.	2.0	51

#	ARTICLE	IF	CITATIONS
1061	PET-MRI in oncology. <i>Medecine Nucleaire</i> , 2012, 36, 459-461.	0.2	0
1062	Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design. <i>Molecular Oncology</i> , 2012, 6, 196-203.	4.6	23
1063	Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1059-1067.	1.8	2
1064	3D Slicer as an image computing platform for the Quantitative Imaging Network. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1323-1341.	1.8	5,126
1065	Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1268-1278.	1.8	32
1066	Simultaneous PET&M;MRI in oncology: a solution looking for a problem?. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1342-1356.	1.8	66
1067	Promise and pitfalls of quantitative imaging in oncology clinical trials. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1301-1312.	1.8	83
1068	The clinical evaluation of novel imaging methods for cancer management. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 738-744.	27.6	20
1069	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1137-1147.	2.4	54
1070	MRI in ovarian cancer. <i>Imaging in Medicine</i> , 2012, 4, 59-75.	0.0	10
1071	Response to Treatment: The Role of Imaging. , 2012, , 15-37.		5
1073	Ovarian Carcinomatosis: How the Radiologist Can Help Plan the Surgical Approach. <i>Radiographics</i> , 2012, 32, 1775-1800.	3.3	111
1074	Radiology: Criteria for Determining Response to Treatment and Recurrence of High-Grade Gliomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 269-276.	1.7	3
1075	GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. <i>Medical Oncology</i> , 2012, 29, 1421-1428.	2.5	35
1076	Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor. <i>Medical Oncology</i> , 2012, 29, 2633-2639.	2.5	9
1077	A phase II trial of temsirolimus in second-line metastatic urothelial cancer. <i>Medical Oncology</i> , 2012, 29, 2870-2876.	2.5	42
1078	Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. <i>Medical Oncology</i> , 2012, 29, 3291-3297.	2.5	40
1079	Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. <i>Medical Oncology</i> , 2012, 29, 3101-3107.	2.5	23

#	ARTICLE	IF	CITATIONS
1080	Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. <i>Medical Oncology</i> , 2012, 29, 3029-3034.	2.5	19
1081	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. <i>Clinical and Translational Oncology</i> , 2012, 14, 835-841.	2.4	6
1082	Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1629-1637.	0.5	93
1083	Radioiodine Treatment of Metastatic Thyroid Cancer: Relative Efficacy and Side Effect Profile of Preparation by Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin. <i>Thyroid</i> , 2012, 22, 310-317.	4.5	80
1084	Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2012, 106, 1790-1797.	6.4	54
1085	Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: Clinical outcomes and dose-volume histogram analysis. <i>Brachytherapy</i> , 2012, 11, 181-191.	0.5	31
1086	A Multidisciplinary Approach to Cancer. , 2012, , 1-6.		0
1087	Whole-Body Diffusion-Weighted MRI: Tips, Tricks, and Pitfalls. <i>American Journal of Roentgenology</i> , 2012, 199, 252-262.	2.2	158
1088	Radiological Imaging in Metastatic Bone Disease and Myeloma: Current Status and Limitations. , 2012, , 173-194.		0
1089	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1858-1867.	6.4	24
1090	The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1391-1399.	6.4	83
1091	Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1441-1448.	6.4	22
1092	Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer. <i>Abdominal Imaging</i> , 2012, 37, 1021-1031.	2.0	15
1093	Prospective Evaluation of Transcatheter Arterial Chemoembolization (TACE) with Multiple Anti-Cancer Drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) Compared with TACE with Epirubicin for Treatment of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1363-1371.	2.0	55
1094	Irreversible Electroporation for Focal Ablation at the Porta Hepatis. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1531-1534.	2.0	23
1095	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 539-546.	2.3	4
1096	A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 583-590.	2.3	6
1097	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 399-405.	2.3	257

#	ARTICLE	IF	CITATIONS
1098	Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2012, 70, 451-459.	2.3	8
1099	Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. European Radiology, 2012, 23, 632-9.	4.5	29
1100	Bone Metastases. , 2012, , 591-609.		2
1101	Assessing Response to Therapy. , 2012, , 25-33.		0
1104	Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. Archives of Orthopaedic and Trauma Surgery, 2012, 132, 1379-1386.	2.4	38
1105	Management of Non-Small Cell Lung in Cancer Patients with Stable Disease. Drugs, 2012, 72, 20-27.	10.9	6
1106	Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Medical Oncology, 2012, 29, 3298-3305.	2.5	23
1107	Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach “ present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314.	1.5	53
1109	Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. Immunotherapy, 2012, 4, 995-1009.	2.0	7
1110	Follow-up CT and MR findings of osteoblastic spinal metastatic lesions after stereotactic radiotherapy. Japanese Journal of Radiology, 2012, 30, 492-498.	2.4	3
1111	An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. EJNMMI Research, 2012, 2, 62.	2.5	12
1112	Her2-enriched breast cancer brain metastases exhibit resistance to Gamma Knife radiosurgery: findings from a single institutional series review. Journal of Radiation Oncology, 2012, 1, 283-290.	0.7	1
1113	Imaging in Clinical Trials. , 2012, , 597-617.		1
1114	What inference for two-stage phase II trials?. BMC Medical Research Methodology, 2012, 12, 117.	3.1	15
1115	Semi-automatic analysis of standard uptake values in serial PET/CT studies in patients with lung cancer and lymphoma. BMC Medical Imaging, 2012, 12, 6.	2.7	1
1117	Systematic Pelvic and Aortic Lymphadenectomy in Advanced Ovarian Cancer Patients at the Time of Interval Debulking Surgery: A Double-Institution Case“Control Study. Annals of Surgical Oncology, 2012, 19, 3522-3527.	1.5	36
1118	Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2012, 6, 391.	4.3	102
1119	Design Considerations for using PET as a Response Measure in Single Site and Multicenter Clinical Trials. Academic Radiology, 2012, 19, 184-190.	2.5	30

#	ARTICLE	IF	CITATIONS
1120	EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiation Oncology, 2012, 7, 181.	2.7	61
1121	Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors. Radiation Oncology, 2012, 7, 148.	2.7	14
1122	Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiation Oncology, 2012, 7, 67.	2.7	99
1123	Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer. PLoS ONE, 2012, 7, e41380.	2.5	42
1124	Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLoS ONE, 2012, 7, e29794.	2.5	213
1125	Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Management and Research, 2012, 4, 341.	1.9	21
1126	Vinorelbine-Based Chemo-Radiotherapy in Non-Small Cell Lung Cancer. Tumori, 2012, 98, 464-470.	1.1	5
1127	Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. International Journal of Oncology, 2012, 41, 611-620.	3.3	16
1128	Response to Concurrent Chemoradiotherapy as a Prognostic Marker in Elderly Patients with Locally Advanced Esophageal Cancer. Tumori, 2012, 98, 225-232.	1.1	6
1129	Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging, 2012, 12, 126-135.	2.8	64
1130	Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts. Korean Journal of Radiology, 2012, 13, 371.	3.4	72
1131	Lessons on Tumour Response: Imaging during Therapy with ¹⁷⁷ Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics, 2012, 2, 459-471.	10.0	24
1132	Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours. Cancer Imaging, 2012, 12, 497-505.	2.8	24
1133	Stereotactic Body Radiation Therapy for Liver Metastases from Colorectal Cancer: Analysis of Safety, Feasibility, and Early Outcomes. Frontiers in Oncology, 2012, 2, 8.	2.8	34
1134	A gist of gastrointestinal stromal tumors: A review. World Journal of Gastrointestinal Oncology, 2012, 5, 102.	2.0	130
1136	In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes. Current Molecular Imaging, 2012, 1, 55-62.	0.7	3
1137	Assessment of Quantitative Perfusion Parameters by Dynamic Contrast-Enhanced Sonography Using a Deconvolution Method. Journal of Ultrasound in Medicine, 2012, 31, 595-608.	1.7	31
1138	Resection for Colorectal Liver Metastases. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
1139	New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma. , 0, , .		0
1140	Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Reports, 2012, 2012, bcr1220115374-bcr1220115374.	0.5	34
1141	Oral vinorelbine: a Better Choice for Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. Journal of Solid Tumors, 2012, 2, .	0.1	2
1142	The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Nonâ€“Small Cell Lung Cancer. Medicina (Lithuania), 2012, 48, 25.	2.0	2
1143	ADDENBROOKE'S HOSPITAL. , 0, , 148-153.		1
1144	Imaging paradigms in assessment of rectal carcinoma: loco-regional and distant staging. Cancer Imaging, 2012, 12, 290-303.	2.8	14
1145	Single nucleotide polymorphisms in NOS2A and NOS3 genes are not associated with treatment response of non-small cell lung cancer patients following the definitive radiochemotherapy. Neoplasma, 2012, 59, 631-640.	1.6	1
1146	Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. Neoplasma, 2012, 60, 83-91.	1.6	4
1148	Hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	1.6	14
1149	High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2012, 53, 1120.	2.2	16
1150	Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?. Korean Journal of Radiology, 2012, 13, 702.	3.4	57
1151	Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience. Yonsei Medical Journal, 2012, 53, 352.	2.2	60
1152	Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. Experimental and Therapeutic Medicine, 2012, 3, 66-71.	1.8	13
1153	Evaluation of therapeutic effect of tumor-targeted therapy. OncoTargets and Therapy, 2012, 5, 191.	2.0	1
1154	Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. Cancer Imaging, 2012, 12, 212-224.	2.8	9
1155	New ways of assessing ovarian cancer response: metabolic imaging and beyond. Cancer Imaging, 2012, 12, 310-314.	2.8	14
1156	Multiparametric PET/CT in oncology. Cancer Imaging, 2012, 12, 336-344.	2.8	28
1157	RECIST rules. Cancer Imaging, 2012, 12, 345-346.	2.8	28

#	ARTICLE	IF	CITATIONS
1158	Imaging beyond RECIST: CT and MRI in molecular therapies. <i>Cancer Imaging</i> , 2012, 12, 347-350.	2.8	12
1159	Cetuximab in Refractory Skin Cancer Treatment. <i>Journal of Cancer</i> , 2012, 3, 257-261.	2.5	43
1160	Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 38.	0.8	11
1161	Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. <i>Clinical Sarcoma Research</i> , 2012, 2, 2.	2.3	48
1162	Attenuation of treatment effect due to measurement variability in assessment of progression-free survival. <i>Pharmaceutical Statistics</i> , 2012, 11, 394-402.	1.3	10
1163	Overcoming resistance of cancer stem cells. <i>Lancet Oncology</i> , The, 2012, 13, e187-e188.	10.7	24
1164	High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway. <i>Clinical Cancer Research</i> , 2012, 18, 1374-1385.	7.0	165
1165	Recurrence Following Hepatectomy for Metastatic Colorectal Cancer: Development of a Model that Predicts Patterns of Recurrence and Survival. <i>Annals of Surgical Oncology</i> , 2012, 19, 139-144.	1.5	35
1166	Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. <i>British Journal of Cancer</i> , 2012, 106, 1722-1727.	6.4	222
1167	β -tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2012, 107, 823-830.	6.4	33
1168	Tumor response assessments with diffusion and perfusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 745-763.	3.4	150
1169	Optimizing the functional diffusion map using Monte Carlo simulations. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 1002-1009.	3.4	2
1170	Perioperative chemotherapy for resectable colorectal liver metastasis: Does timing of systemic therapy matter?. <i>Journal of Surgical Oncology</i> , 2012, 105, 511-519.	1.7	25
1171	A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 577-585.	1.7	17
1172	Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer. <i>Head and Neck</i> , 2012, 34, 1634-1639.	2.0	2
1174	Early diagnosis of hepatocellular carcinoma: It's not a matter of opinion. <i>Hepatology</i> , 2012, 56, 787-787.	7.3	0
1175	Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 56, 788-789.	7.3	27
1176	Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. <i>Science Translational Medicine</i> , 2012, 4, 128ra39.	12.4	978

#	ARTICLE	IF	CITATIONS
1177	Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. <i>Oncologist</i> , 2012, 17, 321-e329.	3.7	100
1178	Distal Pancreatectomy with En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Adenocarcinoma Following Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1152-1159.	1.7	78
1179	KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2012, 107, 626-631.	6.4	24
1180	Mechanisms of resistance to vascular endothelial growth factor blockade. <i>Cancer</i> , 2012, 118, 3455-3467.	4.1	67
1181	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012, 118, 3330-3336.	4.1	118
1182	^{18}F -fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma. <i>Cancer</i> , 2012, 118, 3135-3144.	4.1	40
1183	Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. <i>Cancer</i> , 2012, 118, 5358-5365.	4.1	16
1184	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	4.1	85
1185	Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. <i>Cancer</i> , 2012, 118, 5749-5756.	4.1	457
1186	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	27.0	1,976
1187	Immunohistochemical Detection of Breast Cancer Stem Cells in Hormone Receptor-Positive Breast Cancer and Their Role in Response to Endocrine Therapy and Clinical Outcome. <i>Oncology</i> , 2012, 82, 168-174.	1.9	16
1188	Neo Adjuvant Treatment with Targeted Molecules for Renal Cell Cancer in Current Clinical Practise. <i>Indian Journal of Surgical Oncology</i> , 2012, 3, 114-119.	0.7	3
1189	Stereotactic body radiotherapy for adrenal metastases from lung cancer. <i>Journal of Radiation Oncology</i> , 2012, 1, 155-163.	0.7	30
1190	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 401-410.	2.5	81
1191	Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. <i>Investigational New Drugs</i> , 2012, 30, 1628-1640.	2.6	81
1192	Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. <i>Targeted Oncology</i> , 2012, 7, 127-133.	3.6	45
1193	Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1531-1538.	1.7	75
1194	Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. <i>Annals of Nuclear Medicine</i> , 2012, 26, 426-435.	2.2	22

#	ARTICLE	IF	CITATIONS
1195	Assessment of pituitary adenoma volumetric change using longitudinal MR image registration. <i>Neuroradiology</i> , 2012, 54, 435-443.	2.2	9
1196	Functional imaging techniques in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1070-1079.	6.4	16
1197	Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1107-1116.	6.4	35
1198	Colorectal cancer: prognostic role of 18F-FDG-PET/CT. <i>Abdominal Imaging</i> , 2012, 37, 575-579.	2.0	23
1199	Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 725-732.	4.2	32
1200	Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1181-1188.	2.3	11
1201	Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1529-1536.	2.3	6
1202	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1641-1645.	2.3	78
1203	The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 715-720.	2.2	49
1204	An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2012, 269, 1985-1991.	1.6	3
1205	Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 33-39.	2.8	21
1206	Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 687-693.	2.5	22
1207	Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 2288-2298.	2.4	16
1208	Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. <i>Gastric Cancer</i> , 2012, 15, 154-161.	5.3	123
1209	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	1.6	33
1210	Quantified Visual Scoring of Metastatic Melanoma Patient Treatment Response Using Computed Tomography: Improving on the Current Standard. <i>Journal of Digital Imaging</i> , 2012, 25, 258-265.	2.9	1
1211	The clinical research of elemene emulsion combined with FOLFOX4 regimen in the treatment of advanced gastric carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 336-339.	0.1	2
1212	First clinical trial of cancer vaccine therapy with artificially synthesized helper/â€škiller-hybrid epitope long peptide of MAGE-A4 cancer antigen. <i>Cancer Science</i> , 2012, 103, 150-153.	3.9	53

#	ARTICLE	IF	CITATIONS
1213	Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 151-156.	2.4	7
1214	Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. <i>Clinical Imaging</i> , 2012, 36, 98-103.	1.5	34
1215	Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?. <i>Clinical Imaging</i> , 2012, 36, 360-364.	1.5	10
1216	The Prognostic Significance of Lymphovascular Invasion on Biopsy Specimens in Lung Cancer Treated With Definitive Chemoradiotherapy. <i>Clinical Lung Cancer</i> , 2012, 13, 59-67.	2.6	2
1217	Randomized phase III clinical trial of a combined treatment with carnitine+â€”celecoxib+â€”megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. <i>Clinical Nutrition</i> , 2012, 31, 176-182.	5.0	108
1218	Automating the tracking of lymph nodes in follow-up studies of thoracic CT images. <i>Computer Methods and Programs in Biomedicine</i> , 2012, 106, 150-159.	4.7	4
1219	The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2012, 61, 639-647.	1.9	28
1220	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. <i>European Urology</i> , 2012, 61, 307-316.	1.9	52
1221	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2012, 61, 1132-1138.	1.9	120
1222	Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?. <i>European Urology</i> , 2012, 62, 68-75.	1.9	257
1223	Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system. <i>Biomaterials</i> , 2012, 33, 2701-2709.	11.4	30
1224	Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. <i>Breast</i> , 2012, 21, 40-45.	2.2	14
1225	Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. <i>Breast</i> , 2012, 21, 556-561.	2.2	15
1226	Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer. <i>Seminars in Oncology</i> , 2012, 39, 348-357.	2.2	36
1227	Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC). <i>Journal of Internal Medicine</i> , 2012, 271, 366-378.	6.0	46
1228	COMPARISON OF ABDOMINAL COMPUTED TOMOGRAPHY AND ABDOMINAL ULTRASOUND IN SEDATED DOGS. <i>Veterinary Radiology and Ultrasound</i> , 2012, 53, 513-517.	0.9	42
1229	Asian Oceanian Congress of Radiology 2012 and The Royal Australian and New Zealand College of Radiologists 63rd Annual Scientific Meeting. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 78-162.	1.8	0
1230	Anti-â€”angiogenic Therapy: Concept to Clinic. <i>Microcirculation</i> , 2012, 19, 115-125.	1.8	30

#	ARTICLE	IF	CITATIONS
1231	Response to gemcitabine+platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. Thoracic Cancer, 2012, 3, 19-26.	1.9	2
1232	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- γ for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatology Research, 2012, 42, 442-453.	3.4	27
1233	Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatology Research, 2012, 42, 879-886.	3.4	86
1234	A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal) Tj ETQq1 1 0.784314 rgBT /Overl Internal Medicine, 2012, 26, 598-607.	1.6	38
1235	Cancer Stem Cells as a Predictive Factor in Radiotherapy. Seminars in Radiation Oncology, 2012, 22, 151-174.	2.2	83
1236	Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 2012, 75, 1276-1283.	2.4	28
1237	Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. Journal of Proteomics, 2012, 75, 1577-1589.	2.4	19
1238	Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 2012, 75, 2745-2752.	2.4	36
1239	Mediastinal atlas creation from 3-D chest computed tomography images: Application to automated detection and station mapping of lymph nodes. Medical Image Analysis, 2012, 16, 63-74.	11.6	40
1240	Prognostic studies of canine and feline mammary tumours: The need for standardized procedures. Veterinary Journal, 2012, 193, 24-31.	1.7	68
1241	In vitro evaluation of the impact of ultrasound scanner settings and contrast bolus volume on time-intensity curves. Ultrasonics, 2012, 52, 12-19.	3.9	21
1242	A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecologic Oncology, 2012, 125, 367-371.	1.4	90
1243	Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology, 2012, 125, 661-666.	1.4	166
1244	FDG PET/CT in staging of advanced epithelial ovarian cancer: Frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecologic Oncology, 2012, 126, 64-68.	1.4	81
1245	Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer. Cancer Science, 2012, 103, 1065-1070.	3.9	16
1246	The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. British Journal of Clinical Pharmacology, 2012, 73, 846-854.	2.4	37
1247	Malignancy-associated chylothorax: a 20-year study of 18 patients from a single institution. European Journal of Cancer Care, 2012, 21, 599-605.	1.5	29
1248	Tumor-Cut: Segmentation of Brain Tumors on Contrast Enhanced MR Images for Radiosurgery Applications. IEEE Transactions on Medical Imaging, 2012, 31, 790-804.	8.9	216

#	ARTICLE	IF	CITATIONS
1249	Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. <i>Clinical Transplantation</i> , 2012, 26, 764-774.	1.6	34
1250	Clinical features and outcomes of primary hepatic neuroendocrine carcinomas. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1306-1311.	2.8	72
1251	Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy. <i>Ecological Management and Restoration</i> , 2012, 25, 750-756.	0.4	30
1252	Sorafenib rechallenge in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2012, 110, E228-34.	2.5	32
1253	Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. <i>BJU International</i> , 2012, 110, 1289-1300.	2.5	12
1254	The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E575-82.	2.5	28
1255	Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E628-34.	2.5	72
1256	Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers. <i>BMC Cancer</i> , 2012, 12, 59.	2.6	8
1257	Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. <i>Clinical Sarcoma Research</i> , 2012, 2, 5.	2.3	26
1258	Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. <i>Breast Cancer Research</i> , 2012, 14, R29.	5.0	72
1259	Reirradiation and hyperthermia for radiation-associated sarcoma. <i>Cancer</i> , 2012, 118, 180-187.	4.1	44
1260	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 147-156.	4.1	250
1261	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	4.1	88
1262	The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 206-211.	1.7	24
1263	Oncologic applications of diffusion-weighted MRI in the body. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 257-279.	3.4	108
1264	Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging. <i>Current Urology Reports</i> , 2012, 13, 70-81.	2.2	12
1265	Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. <i>Japanese Journal of Radiology</i> , 2012, 30, 62-68.	2.4	16
1266	Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. <i>Endocrine</i> , 2012, 41, 40-52.	2.3	58

#	ARTICLE	IF	CITATIONS
1267	Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor. <i>Medical Oncology</i> , 2012, 29, 185-192.	2.5	7
1268	Retrocrural Lymph Node Metastasis Disclosed by 18F-FDG PET/CT: A Predictor of Supra-diaphragmatic Spread in Ovarian Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 41-47.	1.0	7
1269	Image-guided drug delivery in lung cancer. <i>Drug Delivery and Translational Research</i> , 2012, 2, 31-44.	5.8	2
1270	Neoadjuvant Treatment of Duodenal Adenocarcinoma: A Rescue Strategy. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 320-324.	1.7	41
1271	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or Tj ETQq0 0 0 rg213/Overlook 10 Tf 50	2.3	5
1272	Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 351-356.	2.3	8
1273	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 415-424.	2.3	39
1274	A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 743-751.	2.3	40
1275	Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 235-242.	2.5	31
1276	Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 51-62.	3.3	30
1277	Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. <i>Investigational New Drugs</i> , 2012, 30, 758-764.	2.6	19
1278	Progression of the lung cancer primary correlates with the identification of new brain metastases after initial radiosurgery. <i>Journal of Neuro-Oncology</i> , 2012, 106, 161-167.	2.9	4
1279	Phase I trial of dose escalation of capecitabine combined with fixed docetaxel in previously treated patients with non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 6-10.	0.1	3
1280	Frequent <i>EGFR</i> mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. <i>European Respiratory Journal</i> , 2013, 41, 417-424.	6.7	41
1281	Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. <i>Magnetic Resonance in Medicine</i> , 2013, 69, 1721-1734.	3.0	25
1282	Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography. <i>NMR in Biomedicine</i> , 2013, 26, 185-192.	2.8	28
1283	External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. <i>Prostate</i> , 2013, 73, 211-218.	2.3	51
1284	Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors. <i>World Journal of Surgical Oncology</i> , 2013, 11, 166.	1.9	25

#	ARTICLE	IF	CITATIONS
1285	Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2013, 11, 112.	1.9	60
1286	Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. World Journal of Surgical Oncology, 2013, 11, 90.	1.9	22
1287	High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. Journal of Translational Medicine, 2013, 11, 41.	4.4	38
1288	Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy. Radiation Oncology, 2013, 8, 167.	2.7	14
1289	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiation Oncology, 2013, 8, 148.	2.7	91
1290	Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiation Oncology, 2013, 8, 44.	2.7	104
1291	CA-125â€‘indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. Journal of Ovarian Research, 2013, 6, 14.	3.0	22
1292	A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. Trials, 2013, 14, 228.	1.6	34
1293	Plasma RANTES, IL-10, and IL-8 levels in nonâ€‘small-cell lung cancer patients treated with EGFR-TKIs. BMC Research Notes, 2013, 6, 139.	1.4	22
1294	ESR statement on the stepwise development of imaging biomarkers. Insights Into Imaging, 2013, 4, 147-152.	3.4	42
1295	Interleukin-2 and Lanreotide in the Treatment of Medullary Thyroid Cancer: In Vitro and In Vivo Studies. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1567-E1574.	3.6	14
1297	Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Research, 2013, 3, 45.	2.5	92
1298	The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clinical Sarcoma Research, 2013, 3, 7.	2.3	96
1299	Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer. Journal of Gastrointestinal Cancer, 2013, 44, 285-292.	1.3	54
1300	Volumetric tumor growth in advanced nonâ€‘small cell lung cancer patients with <i>EGFR</i> mutations during EGFRâ€‘tyrosine kinase inhibitor therapy. Cancer, 2013, 119, 3761-3768.	4.1	40
1301	Characterization and therapy monitoring of head and neck carcinomas using diffusion-imaging-based intravoxel incoherent motion parametersâ€‘preliminary results. Neuroradiology, 2013, 55, 527-536.	2.2	77
1302	Management of Lung Cancer in Older People. , 2013, , .		1
1303	Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology, 2013, 201, 80-96.	2.2	73

#	ARTICLE	IF	CITATIONS
1305	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	7.3	217
1306	Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1834-1841.	2.8	18
1307	A Radiologist's Guide to Treatment Response Criteria in Oncologic Imaging: Anatomic Imaging Biomarkers. <i>American Journal of Roentgenology</i> , 2013, 201, 237-245.	2.2	16
1308	A Radiologist's Guide to Treatment Response Criteria in Oncologic Imaging: Functional, Molecular, and Disease-Specific Imaging Biomarkers. <i>American Journal of Roentgenology</i> , 2013, 201, 246-256.	2.2	17
1309	The shifting landscape of metastatic breast cancer to the CNS. <i>Neurosurgical Review</i> , 2013, 36, 377-382.	2.4	42
1310	Imaging Tumor Angiogenesis: The Road to Clinical Utility. <i>American Journal of Roentgenology</i> , 2013, 201, W183-W191.	2.2	55
1311	Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. <i>Radiologia Medica</i> , 2013, 118, 949-961.	7.7	57
1312	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	10.7	487
1313	Imaging tumor response following liver-directed intra-arterial therapy. <i>Abdominal Imaging</i> , 2013, 38, 1286-1299.	2.0	28
1314	Cell mates: paracrine and stromal targets for prostate cancer therapy. <i>Nature Reviews Urology</i> , 2013, 10, 441-451.	3.8	32
1315	Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumours. <i>Cancer Treatment Reviews</i> , 2013, 39, 862-871.	7.7	60
1316	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial. <i>BMC Cancer</i> , 2013, 13, 279.	2.6	237
1317	Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study. <i>BMC Cancer</i> , 2013, 13, 254.	2.6	53
1318	Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. <i>BMC Cancer</i> , 2013, 13, 239.	2.6	16
1319	Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. <i>BMC Cancer</i> , 2013, 13, 232.	2.6	13
1320	Evaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴ Cu-ATSM positron emission tomography/computed tomography. <i>BMC Cancer</i> , 2013, 13, 218.	2.6	18
1321	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. <i>BMC Cancer</i> , 2013, 13, 190.	2.6	11
1322	[¹⁸ F]FDG and [¹⁸ F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. <i>BMC Cancer</i> , 2013, 13, 168.	2.6	22

#	ARTICLE	IF	CITATIONS
1323	Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2013, 13, 78.	2.6	95
1324	A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. <i>BMC Cancer</i> , 2013, 13, 67.	2.6	41
1325	Image-Guided Radiation Therapy (IGRT): TomoTherapy. , 2013, , 355-364.		0
1326	Intra-arterial radioembolization of breast cancer liver metastases: A structured review. <i>European Journal of Pharmacology</i> , 2013, 709, 37-42.	3.5	20
1327	Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 668-676.	6.4	31
1328	Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. <i>European Radiology</i> , 2013, 23, 739-747.	4.5	48
1329	Laparoscopic Versus Open Radical Hysterectomy for Stage IB2â€“IIB Cervical Cancer in the Setting of Neoadjuvant Chemotherapy: A Multi-institutional Cohort Study. <i>Annals of Surgical Oncology</i> , 2013, 20, 2007-2015.	1.5	38
1330	Special session on validating new procedures. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2013, 8, 209-212.	2.8	0
1331	Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 1219-1224.	1.7	14
1332	Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?. <i>Current Oncology Reports</i> , 2013, 15, 162-169.	4.0	11
1333	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2013, , CD009256.	2.8	70
1334	Survival and failure outcomes in locally advanced esthesioneuroblastoma: a single centre experience of 15 patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 1897-1901.	1.6	13
1335	Can a Less Radical Surgery Using Photodynamic Therapy With Acridine Orange Be Equal to a Wide-margin Resection?. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 792-802.	1.5	17
1336	Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 313-317.	1.3	9
1337	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 703-713.	4.2	7
1338	Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases. <i>Clinical and Translational Oncology</i> , 2013, 15, 484-491.	2.4	11
1339	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 547-556.	2.8	18
1340	Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 981-986.	2.5	6

#	ARTICLE	IF	CITATIONS
1341	A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 367-378.	2.5	27
1342	WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 457-463.	2.5	35
1343	Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2249-2249.	2.4	10
1344	Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 191-197.	0.5	10
1345	Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 198-202.	0.5	18
1346	Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 347.	4.2	110
1347	Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. <i>Annals of Nuclear Medicine</i> , 2013, 27, 839-846.	2.2	26
1348	Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. <i>Annals of Nuclear Medicine</i> , 2013, 27, 802-807.	2.2	45
1349	Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. <i>Annals of Nuclear Medicine</i> , 2013, 27, 748-755.	2.2	20
1350	Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates. <i>AAPS Journal</i> , 2013, 15, 832-839.	4.4	7
1351	Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 402-410.	2.2	41
1353	Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 1047-1062.	3.3	52
1354	Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. <i>Annals of Surgical Oncology</i> , 2013, 20, 2518-2525.	1.5	76
1355	Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. <i>Gastric Cancer</i> , 2013, 16, 324-328.	5.3	15
1356	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	2.6	50
1357	Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 959-966.	2.6	28
1358	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 974-985.	2.6	28
1359	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022.	2.6	41

#	ARTICLE	IF	CITATIONS
1360	Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 317-323.	4.6	30
1361	Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. <i>British Journal of Cancer</i> , 2013, 109, 926-933.	6.4	251
1363	Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 832-841.	6.4	11
1364	Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 80-90.	6.4	44
1365	Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1499-1509.	4.2	236
1366	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 471-479.	4.2	146
1367	Role of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer. <i>World Journal of Surgery</i> , 2013, 37, 169-178.	1.6	68
1368	Radiofrequency Ablation of Liver Tumors in Combination with Local OK-432 Injection Prolongs Survival and Suppresses Distant Tumor Growth in the Rabbit Model with Intra- and Extrahepatic VX2 Tumors. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 1383-1392.	2.0	13
1369	Transcatheter Arterial Embolization With Spherical Embolic Agent for Pulmonary Metastases From Renal Cell Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 1527-1535.	2.0	22
1370	Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 231-240.	2.3	17
1371	A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 263-267.	2.3	10
1372	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1493-1498.	2.3	12
1373	Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1183-1190.	2.3	35
1374	Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 937-943.	2.3	9
1375	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 705-711.	2.3	6
1376	Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 399-404.	2.3	6
1377	Erlotinib in patients with advanced lung squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 203-208.	2.3	7
1378	Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy. <i>European Radiology</i> , 2013, 23, 3450-3455.	4.5	107

#	ARTICLE	IF	CITATIONS
1379	Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation. <i>European Radiology</i> , 2013, 23, 805-815.	4.5	10
1380	Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression. <i>European Radiology</i> , 2013, 23, 879-886.	4.5	39
1381	Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature. <i>International Urology and Nephrology</i> , 2013, 45, 1017-1021.	1.4	13
1383	Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. <i>International Journal of Colorectal Disease</i> , 2013, 28, 527-535.	2.2	37
1384	PET/CT in Oncology: Current Status and Perspectives. <i>Current Radiology Reports</i> , 2013, 1, 177-190.	1.4	77
1385	Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. <i>Clinical Pharmacokinetics</i> , 2013, 52, 593-609.	3.5	77
1386	Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. <i>Future Oncology</i> , 2013, 9, 419-426.	2.4	9
1387	[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer Therapy. <i>Medical Principles and Practice</i> , 2013, 22, 427-437.	2.4	31
1388	Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. <i>British Journal of Cancer</i> , 2013, 109, 1230-1242.	6.4	42
1389	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€™Part I. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1157-1164.	0.5	28
1390	Drug rechallenge and treatment beyond progressionâ€™implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 571-587.	27.6	219
1391	A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. <i>Surgery Today</i> , 2013, 43, 556-561.	1.5	21
1392	CyberKnife robotic image-guided stereotactic radiotherapy for oligometastatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 448-455.	2.0	26
1393	Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. <i>Amino Acids</i> , 2013, 44, 543-553.	2.7	24
1394	Whole-body PET/MRI in oncology: current status and clinical applications. <i>Clinical and Translational Imaging</i> , 2013, 1, 31-44.	2.1	41
1395	Imaging in Oncology. , 2013, , 364-373.		0
1398	Combination percutaneous cryotherapy and iodine-125 seed implantation for unresectable malignant thymoma: Experience in 19 patients. <i>Cryobiology</i> , 2013, 67, 170-174.	0.7	8
1399	Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 1175-1182.	10.7	159

#	ARTICLE	IF	CITATIONS
1400	Semiautomatic Volumetric Tumor Segmentation for Hepatocellular Carcinoma. Academic Radiology, 2013, 20, 446-452.	2.5	51
1402	Minimum Detectable Change in Lung Nodule Volume in a Phantom CT Study. Academic Radiology, 2013, 20, 1364-1370.	2.5	17
1403	Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: Comparison of RECIST, Choi and volumetric criteria. European Journal of Radiology, 2013, 82, 951-958.	2.6	33
1404	Diffusion weighted <scp>MRI</scp>; overview and implications for rectal cancer management. Colorectal Disease, 2013, 15, 655-661.	1.4	23
1405	Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria. Radiographics, 2013, 33, 1323-1341.	3.3	251
1406	Reduction in radiation and contrast medium dose via optimization of low-kilovoltage CT protocols using a hybrid iterative reconstruction algorithm at 256-slice body CT: Phantom study and clinical correlation. Clinical Radiology, 2013, 68, e128-e135.	1.1	40
1407	CT-based response assessment of advanced gastrointestinal stromal tumor: Dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria. European Journal of Radiology, 2013, 82, 923-928.	2.6	65
1408	Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: Case report and review of the literature. European Journal of Cancer, 2013, 49, 3850-3855.	2.8	16
1409	Activity endpoints reported in soft tissue sarcoma phase II trials: Quality of reported endpoints and correlation with overall survival. Critical Reviews in Oncology/Hematology, 2013, 88, 309-317.	4.4	8
1410	Survivorship—Competing Mortalities, Morbidities, and Second Malignancies. Otolaryngologic Clinics of North America, 2013, 46, 681-710.	1.1	12
1411	A clinical experience of single agent bevacizumab in relapsing ovarian cancer. Gynecologic Oncology, 2013, 129, 459-462.	1.4	20
1412	The predictive and prognostic significance of pre- and post-treatment topoisomerase II α in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. European Journal of Surgical Oncology, 2013, 39, 619-626.	1.0	12
1413	An Update on Criteria for Assessing Tumor Response to Treatment. Current Problems in Diagnostic Radiology, 2013, 42, 209-219.	1.4	1
1414	Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. European Journal of Surgical Oncology, 2013, 39, 1377-1383.	1.0	61
1416	Liver PET/CT and Molecular Imaging. , 2013, , 943-954.		0
1417	Liver Intervention: Angiography. , 2013, , 969-982.		0
1418	Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Annals of Oncology, 2013, 24, 655-661.	1.2	51
1419	Advanced chondrosarcomas: role of chemotherapy and survival. Annals of Oncology, 2013, 24, 2916-2922.	1.2	184

#	ARTICLE	IF	CITATIONS
1420	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i>-Amplified Well-Differentiated or Dedifferentiated Liposarcoma. Journal of Clinical Oncology, 2013, 31, 2024-2028.	1.6	370
1421	A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. International Journal of Cancer, 2013, 132, 2705-2713.	5.1	27
1422	Quantitative Ultrasound in Soft Tissues. , 2013, , .		137
1423	Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia. Photodiagnosis and Photodynamic Therapy, 2013, 10, 229-235.	2.6	37
1424	“Rapid Learning health care in oncology” “ An approach towards decision support systems enabling customised radiotherapy”. Radiotherapy and Oncology, 2013, 109, 159-164.	0.6	175
1425	Biopsy Specimens Obtained 7 Days After Starting Chemoradiotherapy (CRT) Provide Reliable Predictors of Response to CRT for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1232-1238.	0.8	24
1426	Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Human Pathology, 2013, 44, 1638-1647.	2.0	36
1427	Evaluation and management of pulmonary nodules: state-of-the-art and future perspectives. Expert Opinion on Medical Diagnostics, 2013, 7, 629-644.	1.6	11
1428	Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. British Journal of Surgery, 2013, 100, 1777-1783.	0.3	89
1429	Emerging antiangiogenics for renal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 495-511.	2.4	15
1430	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology, 2013, 31, 4453-4461.	1.6	147
1431	Volumetric response classification in metastatic solid tumors on MSCT: Initial results in a whole-body setting. European Journal of Radiology, 2013, 82, e567-e573.	2.6	18
1432	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. Science Translational Medicine, 2013, 5, 208ra147.	12.4	198
1433	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 α Inhibitors in <i>PIK3CA</i>-Mutant Breast Cancer. Science Translational Medicine, 2013, 5, 196ra99.	12.4	251
1434	Lung Cancer Imaging. , 2013, , .		2
1435	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2047-2056.	2.5	28
1436	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncology, The, 2013, 14, e396-e406.	10.7	116
1437	CA125-related Measures of Tumor Kinetics and Outcome of Patients with Recurrent Ovarian Cancer Receiving Chemotherapy: A Retrospective Evaluation. Japanese Journal of Clinical Oncology, 2013, 43, 1203-1209.	1.3	5

#	ARTICLE	IF	CITATIONS
1438	Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health and Quality of Life Outcomes, 2013, 11, 163.	2.4	9
1439	Statistics of Survival Prediction and Nomogram Development. Medical Radiology, 2013, , 7-28.	0.1	0
1440	Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study. Investigational New Drugs, 2013, 31, 1573-1579.	2.6	68
1441	Statistical issues and challenges in immuno-oncology. , 2013, 1, 18.		133
1442	A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiation Oncology, 2013, 8, 239.	2.7	28
1443	A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Translational Medicine, 2013, 11, 259.	4.4	102
1444	Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. Radiation Oncology, 2013, 8, 238.	2.7	16
1445	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Journal of Translational Medicine, 2013, 11, 246.	4.4	94
1446	Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis. Gastric Cancer, 2013, 16, 543-548.	5.3	7
1447	Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Veterinary Research, 2013, 9, 190.	1.9	75
1448	Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC Cancer, 2013, 13, 419.	2.6	22
1449	Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. Journal of Radiation Oncology, 2013, 2, 315-321.	0.7	52
1450	Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 61.	8.6	12
1451	Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	2.7	23
1452	Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: Tj ETQq0 0 0 rgBT /Overlock 10 T	2.7	23
1453	Complete response of esophageal small cell carcinoma amrubicin treatment. Journal of Infection and Chemotherapy, 2013, 19, 770-775.	1.7	6
1454	Which is the Optimal Response Criteria for Evaluating Preoperative Treatment in Esophageal Cancer: RECIST or Histology?. Annals of Surgical Oncology, 2013, 20, 3009-3014.	1.5	28
1455	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer and Metastasis Reviews, 2013, 32, 179-188.	5.9	218

#	ARTICLE	IF	CITATIONS
1456	Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 135-143.	2.5	16
1457	Common toxicities and objective response rate in metastatic colorectal cancer patients treated with irinotecan based regimens. <i>Chinese-German Journal of Clinical Oncology</i> , 2013, 12, 109-112.	0.1	0
1458	Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. <i>Respiratory Research</i> , 2013, 14, 139.	3.6	18
1459	Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer. <i>Rare Cancers and Therapy</i> , 2013, 1, 3-19.	0.2	2
1460	Radiofrequency induction on sodium/iodide symporter expression of thyroid cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2013, 12, 516-520.	0.1	1
1461	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. <i>BMC Cancer</i> , 2013, 13, 583.	2.6	6
1462	Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 549-558.	2.5	32
1463	Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. <i>Targeted Oncology</i> , 2013, 8, 295-300.	3.6	13
1464	The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma. <i>Journal of Radiation Oncology</i> , 2013, 2, 341-352.	0.7	7
1465	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. <i>Journal of Radiation Oncology</i> , 2013, 2, 413-425.	0.7	74
1466	Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. <i>Medical Oncology</i> , 2013, 30, 746.	2.5	9
1467	Sunitinib treatment enabling resection of massive liver metastasis: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 234.	0.8	1
1470	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). <i>Gynecologic Oncology</i> , 2013, 130, 269-274.	1.4	91
1471	Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity. <i>Molecular Therapy</i> , 2013, 21, 904-912.	8.2	578
1472	Metastatic Disease to the Lungs and Pleura: An Overview. <i>Seminars in Roentgenology</i> , 2013, 48, 335-343.	0.6	5
1473	Predictive value of apparent diffusion coefficient in evaluation of colorectal carcinoma hepatic metastases' response to radiofrequency ablation. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1027-1032.	3.4	11
1474	A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 357-361.	1.4	43
1475	High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 283-289.e1.	1.9	6

#	ARTICLE	IF	CITATIONS
1476	Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 141-148.	1.9	41
1477	Results of Gamma Knife surgery for Cushing's disease. <i>Journal of Neurosurgery</i> , 2013, 119, 1486-1492.	1.6	82
1478	Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1-7.	4.1	13
1479	Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. <i>British Journal of Cancer</i> , 2013, 108, 1440-1448.	6.4	66
1480	Sequencing Therapy in Metastatic Renal Cell Cancer. <i>Seminars in Oncology</i> , 2013, 40, 465-471.	2.2	10
1481	Blinded independent central reviews: The FDA weighs in. <i>Clinical Research and Regulatory Affairs</i> , 2013, 30, 33-37.	2.1	0
1482	Effects of <scp>BRAF</scp> inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 499-508.	3.3	37
1483	Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial. <i>Cancer Science</i> , 2013, 104, 718-724.	3.9	50
1484	Can C-Arm Cone-Beam CT Detect a Micro-Embolic Effect After TheraSphere Radioembolization of Neuroendocrine and Carcinoid Liver Metastasis?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 459-465.	1.0	18
1485	Response to a costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 470-471.	1.5	0
1486	Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. <i>International Journal of Hyperthermia</i> , 2013, 29, 8-16.	2.5	43
1487	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.	1.6	2,854
1488	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. <i>Expert Review of Vaccines</i> , 2013, 12, 1219-1234.	4.4	8
1489	Texture analysis in assessment and prediction of chemotherapy response in breast cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 89-101.	3.4	170
1490	The effect of XELOX plus bevacizumab on rectal hepatoid adenocarcinoma. <i>International Cancer Conference Journal</i> , 2013, 2, 22-26.	0.5	1
1491	Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. <i>Investigational New Drugs</i> , 2013, 31, 167-174.	2.6	3
1492	Cancer pharmacogenomics: strategies and challenges. <i>Nature Reviews Genetics</i> , 2013, 14, 23-34.	16.3	192
1493	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 55-63.	10.7	522

#	ARTICLE	IF	CITATIONS
1494	Computed Tomography and Magnetic Resonance Imaging. Recent Results in Cancer Research, 2013, 187, 3-63.	1.8	6
1495	Selection for hepatic resection of colorectal liver metastases: expert consensus statement. Hpb, 2013, 15, 91-103.	0.3	268
1496	Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: A quantitative analysis of CT density changes. Acta Oncol ³ gica, 2013, 52, 910-918.	1.8	54
1497	Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Strahlentherapie Und Onkologie, 2013, 189, 33-40.	2.0	26
1498	FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunology, Immunotherapy, 2013, 62, 17-25.	4.2	12
1499	Sensitivity and accuracy of volumetry of pulmonary nodules on low-dose 16- and 64-row multi-detector CT: an anthropomorphic phantom study. European Radiology, 2013, 23, 139-147.	4.5	55
1500	Non-invasive visualisation and volume estimation of maggot masses using computed tomography scanning. International Journal of Legal Medicine, 2013, 127, 185-194.	2.2	8
1501	Quantitative Imaging Biomarkers: The Application of Advanced Image Processing and Analysis to Clinical and Preclinical Decision Making. Journal of Digital Imaging, 2013, 26, 97-108.	2.9	65
1502	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 137, 503-510.	2.5	118
1503	Assessment of Chemotherapy Response in Colorectal Liver Metastases in Patients Undergoing Hepatic Resection and the Correlation to Pathologic Residual Viable Tumor. Journal of the American College of Surgeons, 2013, 216, 845-856.	0.5	39
1504	Transarterial Chemoembolization with Irinotecan Beads in the Treatment of Colorectal Liver Metastases: Systematic Review. Journal of Vascular and Interventional Radiology, 2013, 24, 1209-1217.	0.5	86
1505	Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast, 2013, 22, 1101-1107.	2.2	16
1506	Pre-hysterectomy cone biopsy is able to predict response in locally advanced cervical cancer patients submitted to neo-adjuvant chemoradiation. European Journal of Surgical Oncology, 2013, 39, 1025-1029.	1.0	5
1507	Safety and Efficacy of Drug-eluting Bead Chemoembolization for Hepatocellular Carcinoma: Comparison of Small-versus Medium-size Particles. Journal of Vascular and Interventional Radiology, 2013, 24, 301-306.	0.5	84
1508	Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. Clinical Lung Cancer, 2013, 14, 383-389.	2.6	63
1509	Novel Dedifferentiated Liposarcoma Xenograft Models Reveal PTEN Down-Regulation as a Malignant Signature and Response to PI3K Pathway Inhibition. American Journal of Pathology, 2013, 182, 1400-1411.	3.8	31
1510	Challenges in research related to perioperative cancer care and cancer outcomes. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2013, 27, 457-464.	4.0	5
1511	Improving methodology to go beyond histology in rare cancers. Lancet Oncology, The, 2013, 14, 276-277.	10.7	3

#	ARTICLE	IF	CITATIONS
1512	Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Journal of Hepatology</i> , 2013, 58, 1181-1187.	3.7	109
1513	Percutaneous cryoablation for stage IV lung cancer: A retrospective analysis. <i>Cryobiology</i> , 2013, 67, 151-155.	0.7	30
1514	Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. <i>European Journal of Cancer</i> , 2013, 49, 2486-2493.	2.8	38
1515	Monitoring of extra-axial brain tumor response to radiotherapy using pseudo-continuous arterial spin labeling images: Preliminary results. <i>Magnetic Resonance Imaging</i> , 2013, 31, 1271-1277.	1.8	8
1516	Pancreatic ductal adenocarcinomas with multiple large cystic structures: A clinicopathologic and immunohistochemical study of seven cases. <i>Pancreatology</i> , 2013, 13, 401-408.	1.1	9
1517	The effect of Radachlorin® PDT in advanced NSCLC: A pilot study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2013, 10, 120-126.	2.6	35
1518	Assessment of Standardised Uptake Values in PET Imaging Using Different Software Packages. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2013, 44, 188-196.	0.3	3
1519	Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRIA®) for colorectal liver metastases does not predict tumour destruction or long-term outcome. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1122-1128.	1.0	21
1520	Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 636-643.	2.6	25
1521	Improving Accuracy in Reporting CT Scans of Oncology Patients. <i>Academic Radiology</i> , 2013, 20, 351-357.	2.5	10
1522	Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. <i>European Urology</i> , 2013, 64, 994-1002.	1.9	30
1523	Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 58, 169-177.	3.7	61
1524	Effect of Xiaoaiping injection on advanced hepatocellular carcinoma in patients. <i>Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</i> , 2013, 33, 34-38.	0.4	47
1525	A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2013, 49, 999-1008.	2.8	19
1526	Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 602-606.	1.3	15
1527	Microwave Ablation of Pancreatic Head Cancer: Safety and Efficacy. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1513-1520.	0.5	78
1528	Comparison of Semi-automatic Volumetric VX2 Hepatic Tumor Segmentation from Cone Beam CT and Multi-detector CT with Histology in Rabbit Models. <i>Academic Radiology</i> , 2013, 20, 115-121.	2.5	37
1530	Diffusion-weighted imaging in rectal carcinoma patients without and after chemoradiotherapy: A comparative study with histology. <i>European Journal of Radiology</i> , 2013, 82, 444-452.	2.6	48

#	ARTICLE	IF	CITATIONS
1531	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€”MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	2.2	77
1532	Diagnosis and treatment of coagulopathy following percutaneous cryoablation of liver tumors: Experience in 372 patients. <i>Cryobiology</i> , 2013, 67, 146-150.	0.7	4
1533	Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation. <i>Urology</i> , 2013, 81, 111-115.	1.0	21
1534	Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab. <i>Clinical Colorectal Cancer</i> , 2013, 12, 45-53.	2.3	13
1535	A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. <i>Annals of Oncology</i> , 2013, 24, 2686-2693.	1.2	158
1536	An Update of Laparoscopy in Cervical Cancer Staging: Is It a Useful Procedure?. <i>Oncology</i> , 2013, 85, 160-165.	1.9	15
1537	Stereotactic Body Radiation Therapy: Lung Cancer. , 2013, , .		0
1538	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. <i>Academic Radiology</i> , 2013, 20, 423-429.	2.5	6
1539	High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 51-57.	0.6	124
1540	Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. <i>Cryobiology</i> , 2013, 67, 235-240.	0.7	48
1541	A Phase II Trial of Tamsirrolimus in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	1.9	52
1542	Progress in emerging therapies for advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 275-289.	7.7	60
1543	Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study. <i>Lung Cancer</i> , 2013, 80, 197-202.	2.0	22
1544	Size determination and response assessment of liver metastases with computed tomographyâ€”Comparison of RECIST and volumetric algorithms. <i>European Journal of Radiology</i> , 2013, 82, 1831-1839.	2.6	39
1545	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. <i>Journal of Hepatology</i> , 2013, 59, 59-66.	3.7	128
1546	Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer. <i>Cryobiology</i> , 2013, 66, 76-80.	0.7	20
1547	Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 689-693.	1.4	54
1548	Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, 55-60.	0.4	7

#	ARTICLE	IF	CITATIONS
1549	Dynamic volume perfusion CT in patients with lung cancer: Baseline perfusion characteristics of different histological subtypes. <i>European Journal of Radiology</i> , 2013, 82, e894-e900.	2.6	29
1550	Low toxicity for lung tumors near the mediastinum treated with stereotactic body radiation therapy. <i>Practical Radiation Oncology</i> , 2013, 3, 130-137.	2.1	12
1551	A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. <i>European Journal of Cancer</i> , 2013, 49, 2077-2085.	2.8	72
1552	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2013, 79, 283-288.	2.0	68
1553	The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 231-235.	2.0	16
1554	Management of uterine adenocarcinomas with and without sarcomatous overgrowth. <i>Gynecologic Oncology</i> , 2013, 129, 140-144.	1.4	83
1555	Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. <i>Lung Cancer</i> , 2013, 82, 330-339.	2.0	38
1556	Clinical and prognostic significance of coagulation assays in lung cancer. <i>Respiratory Medicine</i> , 2013, 107, 451-457.	2.9	71
1557	Percutaneous comprehensive cryoablation for metastatic esophageal cancer after failure of radical surgery. <i>Cryobiology</i> , 2013, 67, 363-368.	0.7	1
1558	Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: Comparison with early stage disease. <i>European Journal of Surgical Oncology</i> , 2013, 39, 87-93.	1.0	21
1559	Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer. <i>Urology</i> , 2013, 82, 1090-1093.	1.0	22
1561	A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2013, 79, 270-275.	2.0	17
1562	Influence of pathologic complete response to neoadjuvant chemotherapy on long-term survival of patients with advanced head and neck squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 115, 218-223.	0.4	7
1563	Fractionated Stereotactic Radiotherapy for Acoustic Neuromas: Long-term Outcomes. <i>Clinical Oncology</i> , 2013, 25, 734-738.	1.4	28
1564	Benefit of Overlapping Reconstruction for Improving the Quantitative Assessment of CT Lung Nodule Volume. <i>Academic Radiology</i> , 2013, 20, 173-180.	2.5	29
1565	CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. <i>Cancer Letters</i> , 2013, 337, 285-292.	7.2	37
1566	Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients. <i>Cryobiology</i> , 2013, 67, 225-229.	0.7	12
1567	Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. <i>Breast</i> , 2013, 22, 525-531.	2.2	102

#	ARTICLE	IF	CITATIONS
1568	Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. <i>Lung Cancer</i> , 2013, 79, 167-172.	2.0	31
1569	mTHPC mediated photodynamic therapy (PDT) of squamous cell carcinoma in the head and neck: A systematic review. <i>Oral Oncology</i> , 2013, 49, 192-210.	1.5	49
1570	Interventional oncology in the elderly: Complications and early response in liver and kidney malignancies. <i>Journal of Geriatric Oncology</i> , 2013, 4, 58-63.	1.0	3
1571	Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 947-956.	0.5	37
1572	Place actuelle du scanner et de l'IRM corps entier dans le myélome multiple. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 175-189.	0.0	0
1573	The size of the metastatic lymph node is an independent prognostic factor for the patients with cervical cancer treated by definitive radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 108, 168-173.	0.6	36
1574	Perioperative chemotherapy for resectable gastroesophageal cancer: A single-center experience. <i>European Journal of Surgical Oncology</i> , 2013, 39, 814-822.	1.0	11
1575	Inter-observer reproducibility of semi-automatic tumor diameter measurement and volumetric analysis in patients with lung cancer. <i>Lung Cancer</i> , 2013, 82, 76-82.	2.0	38
1576	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	2.8	71
1577	Automated Registration, Segmentation, and Measurement of Metastatic Melanoma Tumors in Serial CT Scans. <i>Academic Radiology</i> , 2013, 20, 604-613.	2.5	16
1578	Targeted therapy-induced radiation recall. <i>European Journal of Cancer</i> , 2013, 49, 1662-1668.	2.8	55
1579	Snake model-based lymphoma segmentation for sequential CT images. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 111, 366-375.	4.7	12
1580	Managing Incidental Findings on Abdominal and Pelvic CT and MRI, Part 3: White Paper of the ACR Incidental Findings Committee II on Splenic and Nodal Findings. <i>Journal of the American College of Radiology</i> , 2013, 10, 833-839.	1.8	101
1581	Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. <i>European Journal of Radiology</i> , 2013, 82, 959-968.	2.6	76
1582	Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. <i>Cryobiology</i> , 2013, 67, 17-22.	0.7	26
1583	Imaging in pleural mesothelioma: A review of the 11th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2013, 82, 190-196.	2.0	37
1584	Advanced Hepatocellular Carcinoma: Early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. <i>European Journal of Radiology</i> , 2013, 82, e205-e211.	2.6	88
1585	Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. <i>European Journal of Radiology</i> , 2013, 82, e212-e218.	2.6	78

#	ARTICLE	IF	CITATIONS
1586	Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. <i>Medical Oncology</i> , 2013, 30, 415.	2.5	7
1587	Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases. <i>Clinical and Translational Oncology</i> , 2013, 15, 72-78.	2.4	11
1588	Predictive value of 3β -deoxy- 3β -[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma. <i>Annals of Nuclear Medicine</i> , 2013, 27, 1-10.	2.2	23
1589	Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases. <i>Journal of Surgical Research</i> , 2013, 182, 257-263.	1.6	12
1590	Magnetic Resonance Imaging of Rectal Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2013, 21, 385-408.	1.1	30
1591	Editors' pick 2012. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1-6.	2.4	0
1592	Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. <i>Cancer Science</i> , 2013, 104, 98-104.	3.9	14
1593	Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 336-340.	1.3	10
1594	Expression of angiogenic chemokines in ovarian clear cell carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 297-304.	1.3	4
1595	Breast cancer stem cells: Obstacles to therapy. <i>Cancer Letters</i> , 2013, 338, 57-62.	7.2	61
1596	Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1199-1209.	27.0	1,884
1597	Use of Etoposide B (Patupilone) in Refractory Lymphoma and Advanced Solid Tumors in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2013, 27, 120-125.	1.6	3
1598	Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcome (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. <i>BMC Cancer</i> , 2013, 13, 84.	2.6	113
1599	Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study. <i>Urology</i> , 2013, 81, 805-812.	1.0	37
1600	Editorial Comment. <i>Urology</i> , 2013, 81, 812.	1.0	0
1601	Translating metastasis-related biomarkers to the clinic—progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 169-179.	27.6	40
1602	Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. <i>Lung Cancer</i> , 2013, 81, 102-108.	2.0	39
1603	Translating TRAIL-receptor targeting agents to the clinic. <i>Cancer Letters</i> , 2013, 332, 194-201.	7.2	67

#	ARTICLE	IF	CITATIONS
1604	Neoadjuvant Targeted Therapy and Consolidative Surgery. , 2013, , 219-228.		0
1605	BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 2013, 49, 1073-1079.	2.8	105
1606	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. Molecular Therapy, 2013, 21, 1212-1223.	8.2	146
1607	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. European Journal of Cancer, 2013, 49, 1027-1031.	2.8	69
1608	Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria. Wiener Medizinische Wochenschrift, 2013, 163, 137-152.	1.1	9
1609	Performance of FDG PET/CT in the Clinical Management of Breast Cancer. Radiology, 2013, 266, 388-405.	7.3	224
1610	Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review. Fertility and Sterility, 2013, 99, 2017-2024.	1.0	69
1612	Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2013, 62, 1293-1301.	4.2	76
1613	Safety and Tumor Responses with Lambrolizumab (Anti-“PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
1614	Patient Tailored Resection Planning in Patients Undergoing Liver Surgery for Colorectal Liver Metastases; How and Why Should You Do It?. Journal of Gastrointestinal Surgery, 2013, 17, 1836-1849.	1.7	2
1615	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cellular Oncology (Dordrecht), 2013, 36, 277-288.	4.4	80
1616	Design of oncology clinical trials: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 144-153.	4.4	21
1617	The intriguing patterns of tumor response to trabectedin. Expert Review of Anticancer Therapy, 2013, 13, 21-24.	2.4	6
1618	KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics. Journal of Molecular Diagnostics, 2013, 15, 299-311.	2.8	27
1619	A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. British Journal of Cancer, 2013, 108, 1838-1845.	6.4	120
1620	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients with Cytologically Proven Node-positive Breast Cancer at Diagnosis. Annals of Surgical Oncology, 2013, 20, 2858-2865.	1.5	56
1621	Response Evaluation Criteria in Solid Tumors Response of the Primary Lesion in Metastatic Renal Cell Carcinomas Treated With Sunitinib: Does the Primary Lesion Have to Be Regarded as a Target Lesion?. Clinical Genitourinary Cancer, 2013, 11, 276-282.	1.9	2
1622	Tivantinib: a new promising mesenchymal-“epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncology, 2013, 9, 153-165.	2.4	17

#	ARTICLE	IF	CITATIONS
1623	Stereotactic Body Radiation Therapy for Curative Treatment of Adrenal Metastases. Technology in Cancer Research and Treatment, 2013, 12, 217-224.	1.9	58
1624	Treatment With Metformin Is Associated With Higher Remission Rate in Diabetic Patients With Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3269-3279.	3.6	94
1625	MRI characteristics of nodular fasciitis of the musculoskeletal system. Skeletal Radiology, 2013, 42, 975-982.	2.0	56
1626	Vemurafenib in melanoma. Expert Review of Anticancer Therapy, 2013, 13, 513-522.	2.4	9
1627	Regression and local control rates after radiotherapy for jugulotympanic paragangliomas: Systematic review and meta-analysis. Radiotherapy and Oncology, 2013, 106, 161-168.	0.6	41
1628	Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase <scp>III</scp> trial. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 349-356.	1.1	14
1629	Crizotinib versus Chemotherapy in Advanced <i>ALK</i>-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	27.0	3,181
1630	Designing exploratory cancer trials using change in tumour size as primary endpoint. Statistics in Medicine, 2013, 32, 2544-2554.	1.6	14
1631	Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Medical Oncology, 2013, 30, 556.	2.5	47
1632	The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival. Clinical Cancer Research, 2013, 19, 2621-2628.	7.0	20
1633	Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Targeted Oncology, 2013, 8, 237-242.	3.6	25
1634	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences, 2013, 1291, 1-13.	3.8	270
1635	Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients. Wiener Medizinische Wochenschrift, 2013, 163, 372-375.	1.1	11
1636	Imaging after Local Tumor Therapies: Kidney and Liver. Seminars in Roentgenology, 2013, 48, 273-284.	0.6	2
1637	Clinical Trials and Developmental Therapeutics. , 2013, , 293-304.		1
1638	Cancer Immunotherapy. , 2013, , 198-214.		2
1639	Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1214-1222.	6.4	24
1640	A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. British Journal of Cancer, 2013, 108, 1061-1070.	6.4	151

#	ARTICLE	IF	CITATIONS
1641	A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance. Journal of Urology, 2013, 189, 1930-1938.	0.4	61
1642	Predictive Value of Intratumoral ^{99m} Tc-Macroaggregated Albumin Uptake in Patients with Colorectal Liver Metastases Scheduled for Radioembolization with ⁹⁰ Y-Microspheres. Journal of Nuclear Medicine, 2013, 54, 516-522.	5.0	81
1643	Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Medical Oncology, 2013, 30, 572.	2.5	21
1644	Current role of CT and whole body MRI in multiple myeloma. Diagnostic and Interventional Imaging, 2013, 94, 169-183.	3.2	15
1645	Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology, 2013, 717, 2-11.	3.5	14
1646	Optimal Management of Metastatic Renal Cell Carcinoma: Current Status. Drugs, 2013, 73, 427-438.	10.9	95
1647	Quantitative therapy response assessment by volumetric iodine-uptake measurement: Initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Radiology, 2013, 82, 327-334.	2.6	71
1648	Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal, 2013, 61, 25-31.	0.9	61
1649	Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer, 2013, 13, 513.	2.6	16
1650	High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Radiation Oncology, 2013, 8, 198.	2.7	17
1651	Aldehyde Dehydrogenase 1 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2013, 20, 209-217.	1.5	22
1652	The Impact of Preoperative Lymph Node Size on Long-Term Outcome Following Curative Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 1598-1603.	1.5	24
1653	Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Annals of Surgical Oncology, 2013, 20, 4397-4404.	1.5	34
1654	The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers. International Journal of Clinical Oncology, 2013, 18, 321-328.	2.2	2
1656	117 cases of advanced malignancies treated with recombinant human endostatin plus chemotherapy. Chinese-German Journal of Clinical Oncology, 2013, 12, 61-64.	0.1	3
1657	A micro-imaging study linking bone cancer pain with tumor growth and bone resorption in a rat model. Clinical and Experimental Metastasis, 2013, 30, 225-236.	3.3	13
1658	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncology, 2013, 9, 1653-1664.	2.4	10
1659	A Pilot Phase II Study of the Efficacy and Biosafety of Doxorubicin Chemotherapy in Tumor-Bearing Equidae. Journal of Veterinary Internal Medicine, 2013, 27, 1581-1588.	1.6	11

#	ARTICLE	IF	CITATIONS
1660	Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour. European Journal of Cancer, 2013, 49, 2449-2452.	2.8	0
1661	Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors. Japanese Journal of Clinical Oncology, 2013, 43, 1073-1079.	1.3	29
1662	Invited Editorial: Response to therapy assessment of colorectal liver metastasis. European Journal of Radiology, 2013, 82, 903-904.	2.6	1
1663	Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2013, 86, 336-342.	0.8	168
1664	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. European Journal of Cancer, 2013, 49, 3609-3615.	2.8	76
1665	Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 2013, 15, 1563-1570.	0.7	386
1666	Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. Journal of Surgical Oncology, 2013, 107, 544-549.	1.7	289
1667	Computer-assisted solid lung nodule 3D volumetry on CT: influence of scan mode and iterative reconstruction: a CT phantom study. Japanese Journal of Radiology, 2013, 31, 677-684.	2.4	11
1668	Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transplantation, 2013, 19, 1343-1353.	2.4	135
1669	Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: A clinical case study. Medical Physics, 2013, 40, 072902.	3.0	178
1670	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1691-1700.	2.5	29
1671	Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy. International Journal of Clinical Oncology, 2013, 18, 864-868.	2.2	1
1672	Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency. International Journal of Clinical Oncology, 2013, 18, 910-915.	2.2	3
1673	Percutaneous CT-Guided Radiofrequency Ablation as Supplemental Therapy After Systemic Chemotherapy for Selected Advanced Non-Small Cell Lung Cancers. American Journal of Roentgenology, 2013, 201, 1362-1367.	2.2	39
1674	Randomized Two-Stage Phase II Clinical Trial Designs Based on Barnard's Exact Test. Journal of Biopharmaceutical Statistics, 2013, 23, 1081-1090.	0.8	31
1675	Metastatic Renal Cell Carcinoma: Radiologic Findings and Assessment of Response to Targeted Antiangiogenic Therapy by Using Multidetector CT. Radiographics, 2013, 33, 1691-1716.	3.3	111
1676	What Radiologists Need to Know about Diagnosis and Treatment of Inflammatory Breast Cancer: A Multidisciplinary Approach. Radiographics, 2013, 33, 2003-2017.	3.3	295
1677	The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (<sc>GEP</sc>-NET</sc>). Clinical Endocrinology, 2013, 78, 950-956.	2.4	3

#	ARTICLE	IF	CITATIONS
1678	Evaluation of therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer using diffusion-weighted MR imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 187-193.	3.4	68
1679	A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916). <i>Pediatric Blood and Cancer</i> , 2013, 60, 390-395.	1.5	75
1680	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 760-768.	2.6	297
1681	Performance characteristics of a conformal ultra-wideband multilayer applicator (CUMLA) for hyperthermia in veterinary patients: a pilot evaluation of its use in the adjuvant treatment of non-resectable tumours. <i>Veterinary and Comparative Oncology</i> , 2013, 11, 14-29.	1.8	5
1682	Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. <i>Veterinary and Comparative Oncology</i> , 2013, 11, 296-305.	1.8	24
1683	PKPD Modeling of VEGF, sVEGFR α 2, sVEGFR α 3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.	2.5	53
1684	Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin. <i>Neuroendocrinology</i> , 2013, 98, 137-143.	2.5	44
1685	CT image feature analysis in distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a preliminary study. <i>Proceedings of SPIE</i> , 2013, , .	0.8	2
1686	Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis. <i>Molecular and Clinical Oncology</i> , 2013, 1, 175-179.	1.0	12
1687	Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. <i>Molecular and Clinical Oncology</i> , 2013, 1, 241-248.	1.0	15
1688	Investigation of the clinicopathological features of fallopian tube malignancy. <i>Oncology Reports</i> , 2013, 30, 79-84.	2.6	4
1689	The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. <i>Clinical Cancer Research</i> , 2013, 19, 2629-2636.	7.0	110
1690	Electrochemotherapy as a new therapeutic strategy in advanced Merkel cell carcinoma of head and neck region. <i>Radiology and Oncology</i> , 2013, 47, 366-369.	1.7	21
1691	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 181-191.	3.6	132
1692	Correlation Between Standardized Uptake Value and Apparent Diffusion Coefficient of Neoplastic Lesions Evaluated With Whole-Body Simultaneous Hybrid PET/MRI. <i>American Journal of Roentgenology</i> , 2013, 201, 1115-1119.	2.2	65
1693	RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0. <i>American Journal of Roentgenology</i> , 2013, 201, W64-W71.	2.2	39
1694	Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 705-712.	1.7	23
1695	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4006-4012.	3.6	102

#	ARTICLE	IF	CITATIONS
1696	Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy. <i>Neuroendocrinology</i> , 2013, 97, 74-85.	2.5	58
1697	Intra- and Interobserver Variability in CT Measurements in Oncology. <i>Radiology</i> , 2013, 269, 451-459.	7.3	83
1698	Tumor Response on CT Following Hypofractionated Stereotactic Ablative Body Radiotherapy for Small Hypervascular Hepatocellular Carcinoma With Cirrhosis. <i>American Journal of Roentgenology</i> , 2013, 201, W812-W820.	2.2	36
1699	Comparison of Multiplanar Reformatted CT Lung Tumor Measurements to Axial Tumor Measurement Alone: Impact on Maximal Tumor Dimension and T Stage. <i>American Journal of Roentgenology</i> , 2013, 201, 959-963.	2.2	22
1700	Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part II. Response Stratification Using Volumetric Functional Criteria after Intraarterial Therapy. <i>Radiology</i> , 2013, 268, 431-439.	7.3	49
1701	Surgery after Preoperative Chemotherapy for Patients with Unresectable Advanced Gastric Cancer. <i>Oncology</i> , 2013, 85, 241-247.	1.9	12
1702	Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. <i>Annals of Oncology</i> , 2013, 24, 2813-2818.	1.2	33
1703	Response Assessment in Pediatric Rhabdomyosarcoma: Can Response Evaluation Criteria in Solid Tumors Replace Three-dimensional Volume Assessments?. <i>Radiology</i> , 2013, 269, 870-878.	7.3	34
1704	Adaptive 4D Volume Perfusion CT of Lung Cancer: Effects of Computerized Motion Correction and the Range of Volume Coverage on Measurement Reproducibility. <i>American Journal of Roentgenology</i> , 2013, 200, W603-W609.	2.2	16
1705	Early Response to Anti-Tumoral Treatment in Hepatocellular Carcinoma - Can Quantitative Contrast-Enhanced Ultrasound Predict Outcome?. <i>Ultraschall in Der Medizin</i> , 2013, 34, 38-46.	1.5	30
1706	Liver Metastases in the Era of Molecular Targeted Therapy: New Faces of Treatment Response. <i>American Journal of Roentgenology</i> , 2013, 201, W15-W28.	2.2	32
1707	Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantifica. <i>Radiology and Oncology</i> , 2013, 47, 219-223.	1.7	29
1709	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 874-889.	1.8	38
1710	MRI for Response Assessment In Oncologic Bone Marrow Lesions. <i>Medical Radiology</i> , 2013, , 121-143.	0.1	1
1711	Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. <i>Future Oncology</i> , 2013, 9, 1841-1848.	2.4	6
1712	Retreatment after Secondary Resistance or Mixed Response: A Pilot Study. <i>Oncology</i> , 2013, 85, 350-355.	1.9	4
1713	Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain. <i>Journal of Neurosurgery</i> , 2013, 118, 1250-1257.	1.6	38
1714	Editorial: Asymptomatic meningiomas. <i>Journal of Neurosurgery</i> , 2013, 119, 482-486.	1.6	3

#	ARTICLE	IF	CITATIONS
1715	Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional Response Criteria. <i>Radiology</i> , 2013, 268, 420-430.	7.3	41
1716	An economic model to value companion diagnostics in non-small-cell lung cancer. <i>Personalized Medicine</i> , 2013, 10, 139-147.	1.5	10
1717	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. <i>British Journal of Cancer</i> , 2013, 108, 924-931.	6.4	55
1718	Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. <i>Radiographics</i> , 2013, 33, 1781-1800.	3.3	85
1719	Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4532-4540.	7.0	307
1720	Radiographic Parameters in Predicting Outcome of Patients with Hepatocellular Carcinoma Treated with Yttrium-90 Microsphere Radioembolization. <i>ISRN Oncology</i> , 2013, 2013, 1-8.	2.1	8
1721	Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. <i>Annals of Oncology</i> , 2013, 24, 1972-1979.	1.2	120
1722	99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies. <i>Cancers</i> , 2013, 5, 550-568.	3.7	17
1723	What is the best treatment option in postmenopausal, hormone responsive breast cancer patients with isolated bone metastases?. <i>Indian Journal of Cancer</i> , 2013, 50, 52.	0.2	2
1724	Single institutional experience of the treatment of angiosarcoma of the face and scalp. <i>British Journal of Radiology</i> , 2013, 86, 20130439.	2.2	30
1725	Ablation of a Site of Progression With Stereotactic Body Radiation Therapy Extends Sunitinib Treatment From 14 to 22 Months. <i>Journal of Clinical Oncology</i> , 2013, 31, e401-e403.	1.6	29
1726	Recommendations for imaging tumor response in neurofibromatosis clinical trials. <i>Neurology</i> , 2013, 81, S33-40.	1.1	107
1727	Multicentre phase II trial of bevacizumab combined with docetaxel+carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). <i>Annals of Oncology</i> , 2013, 24, 1485-1490.	1.2	31
1728	Optimal Dose Levels in Screening Chest CT for Unimpaired Detection and Volumetry of Lung Nodules, with and without Computer Assisted Detection at Minimal Patient Radiation. <i>PLoS ONE</i> , 2013, 8, e82919.	2.5	21
1729	Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2013, 6, 1089-1095.	1.8	2
1730	mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). <i>Annals of Oncology</i> , 2013, 24, 965-973.	1.2	109
1731	Role of Diffusion MRI and Dynamic Contrast-enhanced MRI in Assessment of Hepatocellular Carcinoma after Trans-arterial Chemoembolization. <i>The Egyptian Journal of Hospital Medicine</i> , 2013, 53, 935-946.	0.1	0
1732	Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement. <i>Journal of Visualized Experiments</i> , 2013, , .	0.3	0

#	ARTICLE	IF	CITATIONS
1733	Radiotherapy for Metastatic Fibrolamellar Hepatocellular Carcinoma. <i>Rare Tumors</i> , 2013, 5, 101-102.	0.6	11
1734	Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. <i>Acta Oncologica</i> , 2013, 52, 1231-1233.	1.8	43
1735	Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. <i>British Journal of Radiology</i> , 2013, 86, 20130147.	2.2	37
1736	Adrenal lesions: variability in attenuation over time, between scanners, and between observers. <i>Acta Radiologica</i> , 2013, 54, 817-826.	1.1	16
1737	Achieving consensus for clinical trials. <i>Neurology</i> , 2013, 81, S1-5.	1.1	59
1738	Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. <i>Annals of Oncology</i> , 2013, 24, 1900-1907.	1.2	49
1739	Validation of Nomogram-based Prediction of Survival Probability after Salvage Re-irradiation of Head and Neck Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 154-160.	1.3	12
1740	Functional imaging to monitor vascular and metabolic response in canine head and neck tumors during fractionated radiotherapy. <i>Acta Oncologica</i> , 2013, 52, 1293-1299.	1.8	8
1741	Immune Toxicities and Long Remission Duration after Ipilimumab Therapy for Metastatic Melanoma: Two Illustrative Cases. <i>Current Oncology</i> , 2013, 20, 165-169.	2.2	33
1742	DCE-CT in the follow-up of targeted therapy in GISTs. <i>Acta Radiologica</i> , 2013, 54, 709-710.	1.1	0
1743	Genitourinary Small-Cell Carcinoma: A Single-Institution Experience. <i>Current Oncology</i> , 2013, 20, 258-264.	2.2	14
1744	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. <i>Annals of Oncology</i> , 2013, 24, 2681-2685.	1.2	19
1745	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. <i>Annals of Oncology</i> , 2013, 24, 1924-1930.	1.2	43
1746	Inter- and intrascanner variability of pulmonary nodule volumetry on low-dose 64-row CT: an anthropomorphic phantom study. <i>British Journal of Radiology</i> , 2013, 86, 20130160.	2.2	15
1747	What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?. <i>Asian Cardiovascular and Thoracic Annals</i> , 2013, 21, 432-436.	0.5	2
1748	Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Oncologist</i> , 2013, 18, 1214-1220.	3.7	119
1749	The use of biomarkers in neuroendocrine tumours. <i>Frontline Gastroenterology</i> , 2013, 4, 175-181.	1.8	7
1750	Phase II study on lapatinib in advanced EGFR-positive chordoma. <i>Annals of Oncology</i> , 2013, 24, 1931-1936.	1.2	122

#	ARTICLE	IF	CITATIONS
1751	Assessment of treatment response in hepatocellular carcinoma: a review of the literature. <i>Future Oncology</i> , 2013, 9, 845-854.	2.4	8
1752	Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101. <i>Clinical Cancer Research</i> , 2013, 19, 2518-2527.	7.0	13
1753	Advanced Imaging (Positron Emission Tomography and Magnetic Resonance Imaging) and Image-Guided Biopsy in Initial Staging and Monitoring of Therapy of Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 208-216.	2.0	19
1754	Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 468-473.	1.2	28
1755	Stereotactic Body Radiotherapy in the Treatment of Adrenal Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 509-513.	1.3	55
1756	Pilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection. <i>Oncologist</i> , 2013, 18, 1180-1188.	3.7	22
1757	S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. <i>Melanoma Research</i> , 2013, 23, 396-401.	1.2	22
1758	Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 388-391.	1.3	5
1759	ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 597-604.	1.5	35
1760	The Influence of Primary Site on Outcomes in Leiomyosarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 368-374.	1.3	35
1761	Response to Cabozantinib in Patients with <i>RET</i> Fusion-Positive Lung Adenocarcinomas. <i>Cancer Discovery</i> , 2013, 3, 630-635.	9.4	438
1762	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases. <i>Investigative Radiology</i> , 2013, 48, 787-794.	6.2	42
1763	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	1.6	439
1764	^{99m} Tc-Sestamibi Using a Direct Conversion Molecular Breast Imaging System to Assess Tumor Response to Neoadjuvant Chemotherapy in Women With Locally Advanced Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 949-956.	1.3	25
1765	Role of Radiotherapy in Adrenocortical Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 288-294.	2.0	36
1766	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. <i>Anti-Cancer Drugs</i> , 2013, 24, 980-985.	1.4	19
1767	Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2013, 42, 1143-1149.	1.1	72
1768	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. <i>Onc Immunology</i> , 2013, 2, e26615.	4.6	97

#	ARTICLE	IF	CITATIONS
1769	In Vivo Dosimetry Based on SPECT and MR Imaging of ¹⁶⁶ Ho-Microspheres for Treatment of Liver Malignancies. Journal of Nuclear Medicine, 2013, 54, 2093-2100.	5.0	65
1770	A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112). Clinical Cancer Research, 2013, 19, 6578-6584.	7.0	60
1771	Response Phenotype As a Predictive Biomarker to Guide Treatment With Targeted Therapies. Journal of Clinical Oncology, 2013, 31, 3739-3741.	1.6	5
1772	Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision Making. Clinical Cancer Research, 2013, 19, 314-319.	7.0	13
1773	Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases. Journal of Clinical Oncology, 2013, 31, 1931-1938.	1.6	362
1774	Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2013, 31, 2110-2114.	1.6	119
1775	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 2013, 12, 1332-1342.	4.1	71
1776	GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Annals of Oncology, 2013, 24, 2922-2926.	1.2	74
1777	Reporting Guidance for Oncologic ¹⁸ F-FDG PET/CT Imaging. Journal of Nuclear Medicine, 2013, 54, 756-761.	5.0	32
1778	Identification of $\alpha 1$ -antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis. Journal of International Medical Research, 2013, 41, 573-583.	1.0	12
1779	Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression. Cancer Research, 2013, 73, 2976-2986.	0.9	62
1780	Efficacy vs. effectiveness: Erlotinib in previously treated non-small-cell lung cancer. Journal of Oncology Pharmacy Practice, 2013, 19, 228-236.	0.9	6
1781	Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [¹¹ C]docetaxel and Positron Emission Tomography. Clinical Cancer Research, 2013, 19, 4163-4173.	7.0	58
1782	Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical Trial. Journal of Clinical Oncology, 2013, 31, 2004-2009.	1.6	38
1783	Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results. Journal of Clinical Oncology, 2013, 31, 886-894.	1.6	173
1784	Enhancement Characteristics of Retroperitoneal Lymphomatous LYMPH Nodes. Acta Radiologica, 2013, 54, 333-339.	1.1	1
1785	New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials. Journal of Comparative Effectiveness Research, 2013, 2, 469-481.	1.4	2
1786	When Inoperable Becomes Operable?. Journal of Clinical Oncology, 2013, 31, 4474-4474.	1.6	1

#	ARTICLE	IF	CITATIONS
1787	Nonâ€“Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT. Radiology, 2013, 266, 326-336.	7.3	384
1788	High quality machineâ€“robust image features: Identification in nonsmall cell lung cancer computed tomography images. Medical Physics, 2013, 40, 121916.	3.0	96
1789	Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma. Oncology Research and Treatment, 2013, 36, 763-765.	1.2	11
1790	Short Hydration in Chemotherapy Containing Cisplatin (>=75 mg/m2) for Patients with Lung Cancer: A Prospective Study. Japanese Journal of Clinical Oncology, 2013, 43, 1105-1109.	1.3	50
1791	A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Annals of Oncology, 2013, 24, 3089-3094.	1.2	120
1792	Typology of the Primary Outcome Construction in Dermatology: A Systematic Review of Published Randomized Controlled Trials. Journal of Investigative Dermatology, 2013, 133, 371-376.	0.7	9
1793	Impact of slice thickness on semi-automated measurements for volume and whole-tumor attenuation of colorectal hepatic metastases in multislice computed tomography. Acta Radiologica, 2013, 54, 863-868.	1.1	3
1794	Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: How should we evaluate treatment effects?. Hepatology Research, 2013, 43, 717-727.	3.4	28
1795	Methodological assessment of HCC literature. Annals of Oncology, 2013, 24, 6-14.	1.2	1
1796	An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology. Clinical Trials, 2013, 10, 754-760.	1.6	2
1797	Prognostic Factors for Metastatic Urothelial Carcinoma Undergoing Cisplatin-based Salvage Chemotherapy. Japanese Journal of Clinical Oncology, 2013, 43, 923-928.	1.3	28
1798	Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer. Chemotherapy, 2013, 59, 402-406.	1.6	41
1799	A Genetic Polymorphism in pre-miR-27a Confers Clinical Outcome of Non-Small Cell Lung Cancer in a Chinese Population. PLoS ONE, 2013, 8, e79135.	2.5	21
1800	Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2013, 12, 491-498.	4.1	55
1801	Phase II study of the HSP90-inhibitor BIB021 in gastrointestinal stromal tumors. Annals of Oncology, 2013, 24, 252-257.	1.2	97
1802	Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer. Scandinavian Journal of Gastroenterology, 2013, 49, 84-91.	1.5	17
1803	Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned. Oncologist, 2013, 18, 525-532.	3.7	41
1804	Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology, 2013, 31, 1732-1739.	1.6	78

#	ARTICLE	IF	CITATIONS
1805	Reply to U.R. Mansmann et al and M.-W. An et al. Journal of Clinical Oncology, 2013, 31, 4374-4375.	1.6	3
1806	Validation of Several SUV-Based Parameters Derived from ¹⁸ F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer. Journal of Nuclear Medicine, 2013, 54, 1202-1208.	5.0	78
1807	¹⁸ F-ICMT-11, a Caspase-3-Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry. Journal of Nuclear Medicine, 2013, 54, 1551-1556.	5.0	83
1808	Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials. Clinical Cancer Research, 2013, 19, 2613-2620.	7.0	34
1809	Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. Clinical Cancer Research, 2013, 19, 3936-3943.	7.0	438
1810	DNA Damage-Inducible Gene, Reprimo Functions as a Tumor Suppressor and Is Suppressed by Promoter Methylation in Gastric Cancer. Molecular Cancer Research, 2013, 11, 1362-1374.	3.4	40
1811	Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting the Early Response to Chemoradiotherapy of Advanced Esophageal Squamous Cell Carcinoma. Digestive Surgery, 2013, 30, 240-248.	1.2	48
1812	Hepatic Arterial Infusion of Gemcitabine plus Oxaliplatin as Second-Line Treatment for Locally Advanced Intrahepatic Cholangiocarcinoma: Preliminary Experience. Chemotherapy, 2013, 59, 354-360.	1.6	28
1813	First-Line Combination Chemotherapy with Cisplatin, Etoposide and Ifosfamide for the Treatment of Disseminated Germ Cell Cancer: Re-Evaluation in the Granulocyte Colony-Stimulating Factor Era. Chemotherapy, 2013, 59, 441-446.	1.6	2
1814	A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer. Journal of Radiation Research, 2013, 54, 126-134.	1.6	10
1815	Salvage-Targeted Kidney Cancer Therapy in Patients Progressing on High-Dose Interleukin-2 Immunotherapy. Cancer Journal (Sudbury, Mass), 2013, 19, 189-196.	2.0	9
1816	Overview of Positron Emission Tomography, Hybrid Positron Emission Tomography Instrumentation, and Positron Emission Tomography Quantification. Journal of Thoracic Imaging, 2013, 28, 4-10.	1.5	21
1817	Advances in Thymoma Imaging. Journal of Thoracic Imaging, 2013, 28, 69-83.	1.5	94
1818	Outcome of endoscopic therapy for cancer bleeding in patients with unresectable gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1489-1495.	2.8	52
1819	Clinical experience with radio-, chemo- and hyperthermotherapy combined trimodality on locally advanced esophageal cancer. Molecular and Clinical Oncology, 2013, 1, 1009-1012.	1.0	7
1820	A prospective clinical trial of tumor hypoxia imaging with ¹⁸ F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. Journal of Radiation Research, 2013, 54, 1078-1084.	1.6	57
1821	Thymoma: Clinical experience from a tertiary care institute from North India. Journal of Cancer Research and Therapeutics, 2013, 9, 235.	0.9	8
1822	Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma. BioMed Research International, 2013, 2013, 1-6.	1.9	52

#	ARTICLE	IF	CITATIONS
1823	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. <i>Molecular and Clinical Oncology</i> , 2013, 1, 949-952.	1.0	6
1824	Computed tomography fluoroscopy-guided percutaneous 125I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1019-1024.	1.0	19
1825	A Retrospective Study of Chemotherapy with Cisplatin Plus Gemcitabine After the Failure of Gemcitabine Monotherapy for Biliary Tract Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 636-640.	1.3	10
1826	Contrast enhanced ultrasonography (CEUS) in the characterization of tumor microcirculation. Validation of the procedure in the animal experimental model. <i>Medical Ultrasonography</i> , 2013, 15, 85-94.	0.8	14
1827	Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1483-92.	2.3	19
1828	Immunogene Zelltodmarker HMGB1 und sRAGE als neue prädiktive und prognostische Serum Biomarker bei Tumorerkrankungen/Immunogenic cell death markers HMGB1 and sRAGE as new predictive and prognostic serum biomarkers in cancer disease. <i>Laboratoriums Medizin</i> , 2013, 37, .	0.6	1
1829	Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. <i>Upsala Journal of Medical Sciences</i> , 2013, 118, 16-22.	0.9	58
1830	Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma. <i>Upsala Journal of Medical Sciences</i> , 2013, 118, 91-97.	0.9	16
1831	Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?. <i>ISRN Oncology</i> , 2013, 2013, 1-6.	2.1	16
1832	Survival and Failure Outcomes in Primary Thyroid Lymphomas: A Single Centre Experience of Combined Modality Approach. <i>Journal of Thyroid Research</i> , 2013, 2013, 1-5.	1.3	21
1833	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-6.	1.3	54
1834	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens. <i>Cancer Biology and Therapy</i> , 2013, 14, 1098-1103.	3.4	27
1835	Salvage Therapy beyond Targeted Therapy in Lung Adenocarcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 837-844.	2.1	5
1836	Small cell carcinoma of the head and neck: report of three cases. <i>Journal of Laryngology and Otology</i> , 2013, 127, 942-946.	0.8	6
1837	Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and ¹⁸F-FLT PET imaging. <i>Contrast Media and Molecular Imaging</i> , 2013, 8, 274-280.	0.8	8
1838	<sc>EGFR</sc> and <sc>KRAS</sc> mutation analyses from specimens obtained by bronchoscopy and <sc>EBUS-EBNA</sc>. <i>Thoracic Cancer</i> , 2013, 4, 264-272.	1.9	8
1839	FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. <i>Oncologist</i> , 2013, 18, 543-548.	3.7	265
1840	[¹⁸F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer. <i>Human Gene Therapy</i> , 2013, 24, 1029-1041.	2.7	23

#	ARTICLE	IF	CITATIONS
1841	Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 80-88.	3.4	32
1842	Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. <i>Cancer</i> , 2013, 119, 4223-4230.	4.1	44
1843	Tumor size increase following preoperative radiation of soft tissue sarcomas does not affect prognosis. <i>Journal of Surgical Oncology</i> , 2013, 107, 723-727.	1.7	10
1844	Advanced MR techniques in multicenter clinical trials. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 761-769.	3.4	12
1845	Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and ¹⁸F-FDG PET. <i>Clinical Endocrinology</i> , 2013, 78, 760-767.	2.4	77
1846	Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. <i>Cancer Science</i> , 2013, 104, 1039-1044.	3.9	9
1847	Recent advances and developments in the antitumor effect of the HIV envelope vector on malignant melanoma: from the bench to clinical application. <i>Cancer Gene Therapy</i> , 2013, 20, 599-605.	4.6	18
1848	A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 878-883.	2.0	10
1849	A costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 467-470.	1.5	3
1850	Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. <i>Journal of Surgical Oncology</i> , 2013, 107, 511-516.	1.7	39
1851	Ipilimumab and radiation therapy for melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 899-906.	2.8	256
1852	Using continuous data on tumour measurements to improve inference in phase II cancer studies. <i>Statistics in Medicine</i> , 2013, 32, 4639-4650.	1.6	19
1853	Electrochemotherapy Under Tumescant Local Anesthesia for the Treatment of Cutaneous Metastases. <i>Dermatologic Surgery</i> , 2013, 39, 1023-1032.	0.8	14
1854	Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, 555-561.	1.6	46
1855	Liver resection for colorectal liver metastases with perioperative chemotherapy: oncological results of R1 resections. <i>Hpb</i> , 2013, 15, 359-364.	0.3	32
1856	Multicentre results of stereotactic body radiotherapy for secondary liver tumours. <i>Hpb</i> , 2013, 15, 851-857.	0.3	28
1857	Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma: a whole-body MRI and diffusion-weighted imaging study. <i>NMR in Biomedicine</i> , 2013, 26, 1186-1194.	2.8	24
1858	Clinical Impact of PET/MR Imaging in Patients with Cancer Undergoing Same-Day PET/CT: Initial Experience in 134 Patients: A Hypothesis-generating Exploratory Study. <i>Radiology</i> , 2013, 269, 857-869.	7.3	153

#	ARTICLE	IF	CITATIONS
1859	Circulating endothelial cells and tumor blood volume as predictors in lung cancer. <i>Cancer Science</i> , 2013, 104, 445-452.	3.9	21
1860	A pragmatic dose-finding approach using short-term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials. <i>Pharmaceutical Statistics</i> , 2013, 12, 315-327.	1.3	6
1861	Phase I Clinical Trial of Vinorelbine in Tumor-Bearing Cats. <i>Journal of Veterinary Internal Medicine</i> , 2013, 27, 943-948.	1.6	3
1862	Classification and regression tree analysis of patients with non-small-cell lung cancer treated with gefitinib after chemotherapy. <i>Thoracic Cancer</i> , 2013, 4, 280-286.	1.9	2
1863	Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 70-77.	1.5	43
1864	Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 108-114.	1.9	31
1866	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9845-9850.	7.1	176
1867	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 1894-1901.	7.0	93
1868	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	7.0	38
1869	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. <i>Cancer Biology and Therapy</i> , 2013, 14, 340-346.	3.4	13
1870	Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients. <i>Clinical Cancer Research</i> , 2013, 19, 3059-3067.	7.0	33
1871	A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3068-3077.	7.0	212
1872	Reevaluating the Accelerated Approval Process for Oncology Drugs. <i>Clinical Cancer Research</i> , 2013, 19, 2804-2809.	7.0	18
1873	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 889-897.	2.4	38
1874	Tremelimumab: a review of development to date in solid tumors. <i>Immunotherapy</i> , 2013, 5, 215-229.	2.0	55
1875	Regorafenib. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1685-1696.	1.9	45
1876	Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT. <i>Acta Radiologica</i> , 2013, 54, 837-842.	1.1	20
1877	MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). <i>British Journal of Ophthalmology</i> , 2013, 97, 52-58.	3.9	11

#	ARTICLE	IF	CITATIONS
1878	Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). <i>British Journal of Cancer</i> , 2013, 109, 2998-3004.	6.4	22
1879	miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. <i>British Journal of Cancer</i> , 2013, 109, 92-99.	6.4	69
1880	Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. <i>British Journal of Cancer</i> , 2013, 108, 1021-1026.	6.4	118
1881	Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. <i>Oncogenesis</i> , 2013, 2, e40-e40.	4.9	101
1882	Baseline tumour measurements predict survival in advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2013, 109, 1476-1481.	6.4	30
1883	Effect of stereotactic radiosurgery before bilateral adrenalectomy for Cushing's disease on the incidence of Nelson's syndrome. <i>Journal of Neurosurgery</i> , 2013, 119, 1493-1497.	1.6	37
1884	Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. <i>British Journal of Cancer</i> , 2013, 109, 934-942.	6.4	71
1885	Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. <i>British Journal of Cancer</i> , 2013, 109, 1537-1542.	6.4	50
1886	Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2013, 109, 1528-1536.	6.4	83
1887	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2013, 109, 1085-1092.	6.4	54
1888	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	6.4	18
1889	Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 2072-2078.	6.4	30
1890	Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 1587-1592.	6.4	59
1891	Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 365-372.	1.6	148
1892	Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1631-1639.	1.6	672
1893	¹⁸ F-FDG PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1528-1534.	5.0	104
1894	Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013, 16, 166-172.	1.1	46
1895	Vismodegib for the treatment of basal cell skin cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1033-1038.	1.0	17

#	ARTICLE	IF	CITATIONS
1896	A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan. <i>Oncology</i> , 2013, 84, 210-213.	1.9	11
1897	A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 2601-2606.	1.2	128
1898	Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation. <i>Radiology</i> , 2013, 268, 662-672.	7.3	47
1899	Measuring tumour response: RECIST 1.1 and beyond. <i>Imaging</i> , 2013, 22, 20110083.	0.0	1
1900	Cutaneous versus Non-Cutaneous Angiosarcoma: Clinicopathologic Features and Treatment Outcomes in 60 Patients at a Single Asian Cancer Centre. <i>Oncology</i> , 2013, 85, 182-190.	1.9	14
1901	Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. <i>Journal of Thoracic Oncology</i> , 2013, 8, 179-184.	1.1	269
1902	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1069-1074.	1.1	110
1903	Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1434-1437.	1.1	51
1905	Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. <i>Prostate International</i> , 2013, 1, 125-132.	2.3	7
1906	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1059-1068.	1.1	48
1907	Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1095-1101.	1.1	27
1908	Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib. <i>JAMA Dermatology</i> , 2013, 149, 322.	4.1	32
1909	Improving Imaging Diagnosis of Persistent Nodal Metastases after Definitive Therapy for Oropharyngeal Carcinoma: Specific Signs for CT and Best Performance of Combined Criteria. <i>American Journal of Neuroradiology</i> , 2013, 34, 1637-1642.	2.4	8
1910	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-1-S-50.	4.9	245
1912	Development of [11C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status. <i>Clinical Cancer Research</i> , 2013, 19, 183-193.	7.0	117
1913	Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. <i>Anti-Cancer Drugs</i> , 2013, 24, 422-425.	1.4	29
1914	Volume-Based Parameters of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Improve Outcome Prediction in Early-Stage Non-Small Cell Lung Cancer After Surgical Resection. <i>Annals of Surgery</i> , 2013, 257, 364-370.	4.2	105
1916	Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small-Cell Lung Cancer Treated with Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2013, 8, 19-30.	1.1	79

#	ARTICLE	IF	CITATIONS
1917	Chemotherapy for thymic carcinoma and advanced thymoma in adults. The Cochrane Library, 2022, CD008588.	2.8	19
1918	Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed. Journal of Thoracic Oncology, 2013, 8, 96-101.	1.1	56
1920	Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer. Experimental and Therapeutic Medicine, 2013, 6, 355-360.	1.8	18
1921	The PARAMOUNT trial: implications for maintenance therapy in lung cancer patients. Lung Cancer Management, 2013, 2, 243-246.	1.5	0
1922	Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. European Journal of Gastroenterology and Hepatology, 2013, 25, 232-238.	1.6	62
1923	EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. European Journal of Gastroenterology and Hepatology, 2013, 25, 620-627.	1.6	10
1924	MRI-Monitored Transcatheter Intra-Arterial Delivery of SPIO-Labeled Natural Killer Cells to Hepatocellular Carcinoma. Investigative Radiology, 2013, 48, 492-499.	6.2	39
1925	Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anti-Cancer Drugs, 2013, 24, 212-218.	1.4	32
1926	Early increase in α -fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2013, 25, 683-689.	1.6	73
1927	Detection of Local Tumor Progression by 18F-FDG PET/CT Following Lung Radiofrequency Ablation. Clinical Nuclear Medicine, 2013, 38, e166-e170.	1.3	13
1928	Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer. Annals of Surgery, 2013, 258, 1040-1050.	4.2	128
1929	Magnetic Resonance Imaging Enhancement Features Before and After Neoadjuvant Chemotherapy in Patients With Breast Cancer. Journal of Computer Assisted Tomography, 2013, 37, 432-439.	0.9	3
1930	Dynamic Computed Tomography of Locally Advanced Pancreatic Cancer. Journal of Computer Assisted Tomography, 2013, 37, 790-796.	0.9	13
1931	Imaging in childhood cancer: A society for pediatric radiology and children's oncology group joint task force report. Pediatric Blood and Cancer, 2013, 60, 1253-1260.	1.5	42
1932	Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Anti-Cancer Drugs, 2013, 24, 415-421.	1.4	15
1933	The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3' untranslated region. Pharmacogenetics and Genomics, 2013, 23, 142-147.	1.5	51
1934	Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatric Blood and Cancer, 2013, 60, 1128-1134.	1.5	92
1935	Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 355-360.	2.5	14

#	ARTICLE	IF	CITATIONS
1936	Primary Gliosarcoma of the Brain: Radiologic and Histopathologic Features. <i>Neuroradiology Journal</i> , 2013, 26, 639-648.	1.2	18
1938	Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie. <i>Haematologica</i> , 2013, 98, 264-268.	3.5	36
1939	MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery. <i>Diagnostic and Interventional Radiology</i> , 2013, 19, 463-70.	1.5	12
1940	Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1179.	4.3	70
1941	Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1574-1577.	1.1	165
1942	Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. <i>Oncology Letters</i> , 2013, 6, 648-654.	1.8	40
1943	Evaluation of the Response by Multimodality Imaging. <i>Medical Radiology</i> , 2013, , 91-103.	0.1	0
1944	RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma. <i>Oncology Letters</i> , 2013, 6, 480-486.	1.8	13
1945	Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 345-351.	4.7	11
1946	MR perfusion imaging in oncology: applications outside the brain. , 0, , 238-254.		0
1947	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-“Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1084-1090.	1.1	111
1948	A quantification strategy for missing bone mass in case of osteolytic bone lesions. <i>Medical Physics</i> , 2013, 40, 123501.	3.0	3
1949	Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. <i>Oncology Letters</i> , 2013, 5, 637-640.	1.8	10
1950	Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report. <i>Oncology Letters</i> , 2013, 5, 1877-1880.	1.8	4
1952	Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. <i>Cancer Imaging</i> , 2013, 13, 306-313.	2.8	35
1953	Potential of compressed sensing in quantitative MR imaging of cancer. <i>Cancer Imaging</i> , 2013, 13, 633-644.	2.8	16
1954	Functional imaging biomarkers for assessing response to treatment in liver and lung metastases. <i>Cancer Imaging</i> , 2013, 13, 482-494.	2.8	3
1955	Metastatic renal cell cancer. <i>Cancer Imaging</i> , 2013, 13, 374-380.	2.8	27

#	ARTICLE	IF	CITATIONS
1956	Drugs for solid cancer the productivity crisis prompts a rethink. <i>OncoTargets and Therapy</i> , 2013, 6, 767.	2.0	9
1957	Diffusion-weighted imaging of the liver: an update. <i>Cancer Imaging</i> , 2013, 13, 171-185.	2.8	31
1958	Erlotinib Induced Trichomegaly of the Eyelashes. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 74, 37.	1.8	6
1959	Colorectal cancer: Current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. <i>World Journal of Gastroenterology</i> , 2013, 19, 8502.	3.3	134
1960	Establishment of a stable T lymphoma cell line transduced with HLA-A*02:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring. <i>Biomedical Research</i> , 2013, 34, 41-50.	0.9	4
1961	Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 1178.	2.2	27
1962	Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 1527.	2.0	20
1963	Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. <i>OncoTargets and Therapy</i> , 2013, 6, 371.	2.0	26
1964	A Simulation Study to Evaluate Accuracy and Precision of Blinded Independent Central Reviews of Progression-free Survival in Cancer Clinical Trials. <i>Journal of Clinical Trials</i> , 2013, 03, .	0.1	1
1965	Usefulness of Carcinoembryonic Antigen for Monitoring Tumor Progression during Palliative Chemotherapy in Metastatic Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2013, 54, 116.	2.2	18
1966	Clinical study on gefitinib combined with ¹³⁷ I-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085). <i>Molecular and Clinical Oncology</i> , 2013, 1, 711-715.	1.0	7
1967	New strategy for monitoring targeted therapy: molecular imaging. <i>International Journal of Nanomedicine</i> , 2013, 8, 3703.	6.7	30
1968	Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. <i>Oncology Letters</i> , 2013, 6, 605-611.	1.8	14
1969	Expression of ABCG2 Associated with Tumor Response in Metastatic Colorectal Cancer Patients Receiving First-line FOLFOX Therapy – Preliminary Evidence. <i>International Journal of Biological Markers</i> , 2013, 28, 182-186.	1.8	10
1970	Comparison of the Diagnostic Performance of Response Evaluation Criteria in Solid Tumor 1.0 with Response Evaluation Criteria in Solid Tumor 1.1 on MRI in Advanced Breast Cancer Response Evaluation to Neoadjuvant Chemotherapy. <i>Korean Journal of Radiology</i> , 2013, 14, 13.	3.4	8
1971	Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 485.	2.0	5
1972	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. <i>Lung Cancer: Targets and Therapy</i> , 2013, 4, 9.	2.7	8
1973	Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature. <i>Tumori</i> , 2013, 99, e172-e176.	1.1	6

#	ARTICLE	IF	CITATIONS
1974	Potential Use of Recombinant Human Thyrotropin in the Treatment of Distant Metastases in Patients with Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2013, 19, 139-148.	2.1	27
1975	mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. <i>Diagnostic and Interventional Radiology</i> , 2013, 20, 136-42.	1.5	15
1976	Predicting tumour response. <i>Cancer Imaging</i> , 2013, 13, 381-390.	2.8	7
1977	Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer. <i>Oncology Letters</i> , 2013, 5, 840-844.	1.8	21
1978	18F-FDG PET/CT findings in patients with Kikuchi disease. <i>Nuklearmedizin - Nuclear Medicine</i> , 2013, 52, 101-106.	0.7	14
1980	Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric. <i>PLoS ONE</i> , 2013, 8, e51951.	2.5	79
1981	The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study. <i>PLoS ONE</i> , 2013, 8, e62543.	2.5	32
1982	Characterizing Venous Vasculatures of Hepatocellular Carcinoma Using a Multi-Breath-Hold Two-Dimensional Susceptibility Weighted Imaging. <i>PLoS ONE</i> , 2013, 8, e65895.	2.5	12
1983	Clinical and Laboratory Toxicity after Intra-Arterial Radioembolization with 90Y-Microspheres for Unresectable Liver Metastases. <i>PLoS ONE</i> , 2013, 8, e69448.	2.5	16
1984	SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e77223.	2.5	24
1985	Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single Institution. <i>PLoS ONE</i> , 2013, 8, e78977.	2.5	34
1986	Magnetic Resonance Metabolic Profiling of Breast Cancer Tissue Obtained with Core Needle Biopsy for Predicting Pathologic Response to Neoadjuvant Chemotherapy. <i>PLoS ONE</i> , 2013, 8, e83866.	2.5	40
1987	Expression of DNA Translesion Synthesis Polymerase η in Head and Neck Squamous Cell Cancer Predicts Resistance to Gemcitabine and Cisplatin-Based Chemotherapy. <i>PLoS ONE</i> , 2013, 8, e83978.	2.5	54
1988	Imaging of Treatment Response to the Combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumors in Mice Using FDG and FLT PET. <i>PLoS ONE</i> , 2013, 8, e85126.	2.5	19
1989	Neuromuscular Electrical Stimulation of the Quadriceps in Patients with Non-Small Cell Lung Cancer Receiving Palliative Chemotherapy: A Randomized Phase II Study. <i>PLoS ONE</i> , 2013, 8, e86059.	2.5	38
1990	Post-Therapeutic Follow-Up and Early Detection of Recurrence in Hepatocellular Carcinoma. , 0, , .		1
1991	Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. <i>OncoTargets and Therapy</i> , 2013, 6, 1589.	2.0	40
1992	Pancreatic ductal adenocarcinoma staging. <i>Cancer Imaging</i> , 2013, 13, 360-364.	2.8	6

#	ARTICLE	IF	CITATIONS
1993	Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. Tumori, 2013, 99, 611-616.	1.1	15
1994	Is SUV_{max} a Useful Indicator of Survival in Patients with Advanced Nonsmall-Cell Lung Cancer?. Scientific World Journal, The, 2013, 2013, 1-4.	2.1	1
1995	Selective Arterial Embolization of Liver Metastases from Gastrinomas: A Single-Centre Experience. ISRN Hepatology, 2013, 2013, 1-8.	0.9	0
1996	Quantification of Plasma Cell-Free DNA ¹ in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma. Disease Markers, 2013, 34, 105-111.	1.3	36
1997	Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 85, 7.	1.1	5
1998	Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature. OncoTargets and Therapy, 2013, 6, 1559.	2.0	6
1999	Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging, 2013, 13, 73-80.	2.8	45
2000	Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment. Diagnostic and Interventional Radiology, 2013, 19, 447-56.	1.5	8
2001	Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate. , 0, , .		1
2002	Radiological Detection and Assessment of Tumor Response. Medical Radiology, 2013, , 77-89.	0.1	0
2003	Imagen Thecniques in Renal-Cell Carcinoma. , 2013, , .		0
2004	Curative Radiotherapy using Different Radiation Techniques for Isolated Lung Metastasis from Colorectal Cancer. Tumori, 2013, 99, 68-75.	1.1	2
2005	PET â€œ Assessment of Oncologic Treatment Response. , 0, , .		0
2006	Value of apparent diffusion coefficient (ADC) in evaluating response of carcinoma of the cervix treated with chemoradiotherapy. South African Journal of Radiology, 2013, 17, 11-15.	0.3	1
2007	Evaluating patterns of failure and salvage therapy for patients treated with primary stereotactic body radiation therapy for early stage non-small cell lung cancer. Journal of Solid Tumors, 2014, 4, .	0.1	3
2008	Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach. Journal of Gastric Cancer, 2014, 14, 87.	2.5	163
2010	Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemo-naïve patients with EGFR-mutant lung adenocarcinoma. OncoTargets and Therapy, 2014, 7, 799.	2.0	14
2011	Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Management and Research, 2014, 6, 93.	1.9	18

#	ARTICLE	IF	CITATIONS
2012	Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer, 2014, 17, 40.	1.9	90
2013	Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. OncoTargets and Therapy, 2014, 7, 1185.	2.0	18
2014	Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer. Journal of Cancer, 2014, 5, 58-68.	2.5	89
2015	Detection of Time-Varying Structures by Large Deformation Diffeomorphic Metric Mapping to Aid Reading of High-Resolution CT Images of the Lung. PLoS ONE, 2014, 9, e85580.	2.5	14
2016	Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?. Nuklearmedizin - NuclearMedicine, 2014, 53, 54-59.	0.7	31
2017	Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PLoS ONE, 2014, 9, e85004.	2.5	67
2018	Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution. PLoS ONE, 2014, 9, e86697.	2.5	36
2019	Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer. PLoS ONE, 2014, 9, e90141.	2.5	34
2020	18F-FDG and 18F-FLT-PET Imaging for Monitoring Everolimus Effect on Tumor-Growth in Neuroendocrine Tumors: Studies in Human Tumor Xenografts in Mice. PLoS ONE, 2014, 9, e91387.	2.5	26
2021	The Association of Transporter Genes Polymorphisms and Lung Cancer Chemotherapy Response. PLoS ONE, 2014, 9, e91967.	2.5	31
2022	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. PLoS ONE, 2014, 9, e92147.	2.5	18
2023	Insulin-Like-Growth-Factor-Binding-Protein-3 (IGFBP-3) Contrasts Melanoma Progression In Vitro and In Vivo. PLoS ONE, 2014, 9, e98641.	2.5	17
2024	Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients. PLoS ONE, 2014, 9, e98715.	2.5	20
2025	Heterogeneous EGFR Gene Copy Number Increase Is Common in Colorectal Cancer and Defines Response to Anti-EGFR Therapy. PLoS ONE, 2014, 9, e99590.	2.5	14
2026	Early Treatment Response in Non-Small Cell Lung Cancer Patients Using Diffusion-Weighted Imaging and Functional Diffusion Maps – A Feasibility Study. PLoS ONE, 2014, 9, e108052.	2.5	17
2027	³ Deoxy- ³ -[18F]-Fluorothymidine PET Imaging Reflects PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in Colorectal Cancer. PLoS ONE, 2014, 9, e108193.	2.5	12
2028	miR-375 Mediated Acquired Chemo-Resistance in Cervical Cancer by Facilitating EMT. PLoS ONE, 2014, 9, e109299.	2.5	50
2029	Feasibility Study of Pelvic Helical IMRT for Elderly Patients with Endometrial Cancer. PLoS ONE, 2014, 9, e113279.	2.5	3

#	ARTICLE	IF	CITATIONS
2031	What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials. Bulletin Du Cancer, 2014, 101, E19-E24.	1.6	2
2032	Early detection of disease progression after palliative chemotherapy in NSCLC patients by 18F-FDG-PET. Nuklearmedizin - NuclearMedicine, 2014, 53, 197-204.	0.7	7
2033	Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center. Scientific World Journal, The, 2014, 2014, 1-10.	2.1	12
2034	Prediction of Early Response to Chemotherapy in Lung Cancer by Using Diffusion-Weighted MR Imaging. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	11
2035	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). Current Signal Transduction Therapy, 2014, 8, 219-228.	0.5	67
2036	Salvage Stereotactic Re-irradiation with CyberKnife for Locally Recurrent Head and Neck Cancer: A Single Center Experience. Tumori, 2014, 100, 278-283.	1.1	8
2037	Terminology and Reporting Criteria for Radiofrequency Ablation of Tumors in the Scientific Literature: Systematic Review of Compliance with Reporting Standards. Korean Journal of Radiology, 2014, 15, 95.	3.4	11
2038	Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Frontiers in Cellular and Infection Microbiology, 2014, 4, 51.	3.9	112
2039	CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. International Journal of Molecular Sciences, 2014, 15, 15767-15777.	4.1	20
2040	How Using Dedicated Software Can Improve RECIST Readings. Informatics, 2014, 1, 160-173.	3.9	3
2041	A Phase II Trial of Neoadjuvant Chemotherapy with Genexol- α (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer. Journal of Breast Cancer, 2014, 17, 344.	1.9	4
2042	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget, 2014, 5, 3012-3022.	1.8	82
2043	Human papillomavirus 18 as a poor prognostic factor in stage I-IIA cervical cancer following primary surgical treatment. Obstetrics and Gynecology Science, 2014, 57, 492.	1.6	17
2044	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. OncoTargets and Therapy, 2014, 7, 1349.	2.0	37
2045	Indicadores (Outcomes) Primários e Secundários em Ensaios Clínicos Oncológicos: Definição e Usos. Acta Medica Portuguesa, 2014, 27, 498.	0.4	2
2046	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine, 2014, 9, 1443.	6.7	19
2047	Imaging of the mediastinum. , 0, , 4-24.		0
2048	Treatment with Octreotide in Patients with Well-Differentiated Neuroendocrine Tumors of the Ileum: Prognostic Stratification with Ga-68-DOTA-TATE Positron Emission Tomography. Molecular Imaging, 2014, 13, 7290.2014.00009.	1.4	26

#	ARTICLE	IF	CITATIONS
2049	EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1595.	4.3	36
2050	Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model. <i>OncoTargets and Therapy</i> , 2014, 7, 1945.	2.0	23
2051	Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases. <i>Molecular and Clinical Oncology</i> , 2014, 2, 695-700.	1.0	11
2052	Cervical carcinoma following myelodysplastic syndrome: A case report. <i>Oncology Letters</i> , 2014, 8, 82-84.	1.8	2
2053	Response to sorafenib treatment in advanced metastatic thyroid cancer. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 37-41.	1.3	12
2054	Efficacy of Egfr Tyrosine Kinase Inhibitors (Egfr Tkis) in Patients with Egfr-Mutated Non-Small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L858R: a Retrospective Analysis in Korea. <i>Annals of Oncology</i> , 2014, 25, iv448.	1.2	0
2055	Association between time to disease progression end points and overall survival in patients with neuroendocrine tumors. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2014, , 103.	5.5	4
2056	Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 835-841.	1.5	3
2057	Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?. <i>Chemotherapy</i> , 2014, 03, .	0.0	0
2058	Cost Evaluation of Metastatic Colorectal Cancer Treatment in the Brazilian Public Healthcare System. <i>Journal of Integrative Oncology</i> , 2014, 04, .	0.3	0
2059	Clinical Analysis of Osteosarcoma Patients Treated with High-Dose Methotrexate-Free Neoadjuvant Chemotherapy. <i>Current Oncology</i> , 2014, 21, 678-684.	2.2	23
2060	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. <i>Oncology Reports</i> , 2014, 32, 808-814.	2.6	6
2061	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Neoplasia</i> , 2014, 61, 233-240.	1.6	27
2062	Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution. <i>Tuberculosis and Respiratory Diseases</i> , 2014, 77, 13.	1.8	0
2063	The Predictive Value of Pretreatment 18-F-FDG-PET-CT in Locally Advanced Nasopharyngeal Cancer Patients Treated Definitively with Induction Chemotherapy Followed by Concurrent Chemo-Radiotherapy. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2014, 05, .	0.2	2
2064	Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?. <i>Cancer Research and Treatment</i> , 2014, 46, 374-382.	3.0	21
2065	Density of Tumor-Infiltrating FOXP3+ T Cells as a Response Marker for Induction Chemoradiotherapy and a Potential Prognostic Factor in Patients Treated with Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2014, 20, 980-986.	0.8	9
2066	Pazopanib-the Latest First-Line Standard of Care Targeted Kinase Inhibitor for the Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Medicine Insights Therapeutics</i> , 2014, 6, CMT.S9280.	0.4	0

#	ARTICLE	IF	CITATIONS
2067	Survival after ¹³¹ I-labeled lipiodol therapy for hepatocellular carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2014, 53, 46-53.	0.7	7
2068	Activity of T-Dm1 in Her2-Positive Breast Cancer Brain Metastases. <i>Annals of Oncology</i> , 2014, 25, iv122.	1.2	0
2069	Erfolge und Grenzen zielgerichteter Therapien beim Nierenzellkarzinom. <i>Karger Kompass Onkologie</i> , 2014, 1, 66-74.	0.0	0
2070	The Lack of Antitumor Effects of o,p'-DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment. <i>Hormones and Cancer</i> , 2014, 5, 312-323.	4.9	19
2071	Optimal management of primary retroperitoneal sarcoma: an update. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 565-579.	2.4	31
2072	New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer. <i>Translational Oncology</i> , 2014, 7, 694-701.	3.7	6
2074	Avances en imágenes para la estadificación y seguimiento de pacientes con carcinoma de células renales. <i>Urología Colombiana</i> , 2014, 23, 194-204.	0.0	1
2075	Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer. <i>Acta Radiologica</i> , 2014, 55, 131-139.	1.1	4
2076	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. <i>Tumor Biology</i> , 2014, 35, 8451-8459.	1.8	25
2077	Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 519-528.	1.1	12
2078	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. <i>Cancer Discovery</i> , 2014, 4, 1036-1045.	9.4	348
2079	Vaccines versus immunotherapy: Overview of approaches in deciding between options. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3369-3374.	3.3	11
2080	Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. <i>British Journal of Cancer</i> , 2014, 111, 1703-1709.	6.4	41
2081	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. <i>Pharmacogenomics</i> , 2014, 15, 1985-1999.	1.3	16
2082	Wait-and-See Policy as a First-Line Management for Extra-Abdominal Desmoid Tumors. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, 631-638.	3.0	80
2083	Randomized Study of Antiinflammatory and Immune-Modulatory Effects of Enteral Immunonutrition During Concurrent Chemoradiotherapy for Esophageal Cancer. <i>Nutrition and Cancer</i> , 2014, 66, 1-5.	2.0	47
2084	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 939-946.	2.3	10
2085	Effects of zoledronic acid and the association between its efficacy and T cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. <i>Journal of Translational Medicine</i> , 2014, 12, 310.	4.4	5

#	ARTICLE	IF	CITATIONS
2086	Calcifications on Mammogram Do Not Correlate with Tumor Size After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3310-3316.	1.5	49
2087	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
2088	Quality assessment of clinical research on liver cancer treated by intra-arterial infusion of Chinese medicine. <i>Chinese Journal of Integrative Medicine</i> , 2014, 20, 870-875.	1.6	3
2089	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 799-808.	2.3	7
2090	A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1207-1215.	2.3	29
2091	Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). <i>BMC Cancer</i> , 2014, 14, 865.	2.6	19
2092	Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1099-1108.	3.3	3
2093	Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2090-2092.	6.4	14
2094	Challenges in the Management of <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2014, 87, 83-94.	1.9	4
2095	The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see foreverâ€¦. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2189-2193.	6.4	8
2096	The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer â€” a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). <i>BMC Cancer</i> , 2014, 14, 741.	2.6	86
2097	Impact of imaging measurements on response assessment in glioblastoma clinical trials. <i>Neuro-Oncology</i> , 2014, 16, vii24-vii35.	1.2	32
2098	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	1.2	41
2099	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	5.0	94
2100	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 1246-1257.	2.6	95
2101	Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 535-540.	2.5	1
2102	Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2014, 14, 671.	2.6	106
2103	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 312-324.	0.5	69

#	ARTICLE	IF	CITATIONS
2104	High-spatial and high-temporal resolution dynamic contrast-enhanced perfusion imaging of the liver with time-resolved three-dimensional radial MRI. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 934-941.	3.0	29
2105	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , 2014, 110, 1917-1922.	6.4	64
2106	First-line bevacizumab and capecitabine+oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. <i>British Journal of Cancer</i> , 2014, 111, 241-248.	6.4	29
2107	Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. <i>British Journal of Cancer</i> , 2014, 110, 1433-1437.	6.4	18
2108	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	6.4	16
2109	Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis. <i>Modern Pathology</i> , 2014, 27, 1394-1404.	5.5	27
2110	Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma. <i>Progress in Tumor Research</i> , 2014, 41, 98-112.	0.1	8
2112	Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. <i>British Journal of Cancer</i> , 2014, 110, 1517-1524.	6.4	22
2113	Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 325-331.	3.9	31
2114	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. <i>Modern Pathology</i> , 2014, 27, 1193-1202.	5.5	18
2115	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. <i>British Journal of Cancer</i> , 2014, 111, 25-32.	6.4	41
2116	Whole-Body PET/CT Studies with Lowered 18F-FDG Doses: The Influence of Body Mass Index in Dose Reduction. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 62-67.	0.8	18
2117	Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2014, 100, 35-44.	2.5	76
2118	First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. <i>European Respiratory Review</i> , 2014, 23, 92-105.	7.1	43
2119	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. <i>British Journal of Cancer</i> , 2014, 110, 55-62.	6.4	351
2120	Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. <i>British Journal of Cancer</i> , 2014, 110, 888-893.	6.4	18
2121	Quantitative multimodality imaging in cancer research and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 670-680.	27.6	105
2122	Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1897-1904.	2.8	12

#	ARTICLE	IF	CITATIONS
2123	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Expert Review of Anticancer Therapy, 2014, 14, 523-542.	2.4	11
2124	Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. CNS Oncology, 2014, 3, 407-419.	3.0	30
2125	Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. OncoImmunology, 2014, 3, e28131.	4.6	160
2126	A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. British Journal of Cancer, 2014, 111, 660-666.	6.4	80
2127	A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.1	93
2128	Renal cell carcinoma metastasis to the thyroid: How long is long enough?. Acta OncolÃ³gica, 2014, 53, 1277-1278.	1.8	5
2129	Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Experimental and Therapeutic Medicine, 2014, 7, 1083-1088.	1.8	34
2130	ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. Canadian Urological Association Journal, 2014, 8, 353.	0.6	2
2131	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Hepatocellular Carcinoma Treated With Sorafenib. Oncologist, 2014, 19, 394-402.	3.7	134
2132	Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report. OncoTargets and Therapy, 2014, 7, 165.	2.0	7
2133	Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmacogenomics and Personalized Medicine, 2014, 7, 31.	0.7	20
2134	Positron Emission Tomography (PET) in Oncology. Cancers, 2014, 6, 1821-1889.	3.7	231
2135	Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer. International Journal of Molecular Sciences, 2014, 15, 9546-9565.	4.1	50
2136	Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report. Oncology Letters, 2014, 8, 2093-2095.	1.8	2
2137	Update of cetuximab for non-melanoma skin cancer. Expert Opinion on Biological Therapy, 2014, 14, 271-276.	3.1	27
2138	Clinical management of aggressive fibromatosis/desmoid tumour. Expert Opinion on Orphan Drugs, 2014, 2, 1027-1036.	0.8	0
2139	Axillary reverse mapping: Is it feasible in locally advanced breast cancer patients?. Breast Disease, 2014, 34, 151-155.	0.8	14
2140	Abdominal lymphadenopathy detection using random forest. Proceedings of SPIE, 2014, , .	0.8	12

#	ARTICLE	IF	CITATIONS
2141	Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. <i>British Journal of Cancer</i> , 2014, 110, 384-391.	6.4	46
2142	Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. <i>BMJ Open</i> , 2014, 4, e005762.	1.9	22
2143	Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?. <i>Oncology</i> , 2014, 86, 191-198.	1.9	18
2144	Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	31
2145	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 583.	0.6	7
2146	Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease. <i>Acta Oncol</i> , 2014, 53, 702-706.	1.8	13
2147	Clinical outcome of thymic lymphoepithelioma-like carcinoma: Case report of a 14-year-old male. <i>Oncology Letters</i> , 2014, 8, 2183-2186.	1.8	17
2148	Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients. <i>Oncology Letters</i> , 2014, 8, 2485-2488.	1.8	8
2149	FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. <i>Experimental and Therapeutic Medicine</i> , 2014, 7, 461-467.	1.8	16
2150	Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients. <i>Cancer Biomarkers</i> , 2014, 14, 215-223.	1.7	13
2151	¹¹ C-Hydroxyephedrine Positron Emission Tomography in the Postoperative Management of Pheochromocytoma and Paraganglioma. <i>Neuroendocrinology</i> , 2014, 100, 60-70.	2.5	2
2152	Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients. <i>Acta Dermato-Venereologica</i> , 2014, 94, 45-49.	1.3	41
2153	Palliative self-expandable metal stents for acute malignant colorectal obstruction: clinical outcomes and risk factors for complications. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 967-973.	1.5	8
2154	Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. <i>Acta Oncol</i> , 2014, 53, 143-148.	1.8	11
2155	Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer. <i>Acta Oncol</i> , 2014, 53, 1275-1277.	1.8	7
2156	Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report. <i>Oncology Letters</i> , 2014, 8, 2624-2626.	1.8	2
2157	Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma and the Evaluation of Response to Treatment. <i>Seminars in Liver Disease</i> , 2014, 34, 398-414.	3.6	11
2158	Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. <i>Gastroenterology Report</i> , 2014, 2, 201-206.	1.3	10

#	ARTICLE	IF	CITATIONS
2159	Renal Toxicity Associated with Weekly Cisplatin and Gemcitabine Combination Therapy for Treatment of Advanced Biliary Tract Cancer. <i>Oncology</i> , 2014, 87, 30-39.	1.9	12
2160	Investigation of Using Diffusion-Weighted Magnetic Resonance Imaging to Evaluate the Therapeutic Effect of Esophageal Carcinoma Treatment. <i>Oncology Research and Treatment</i> , 2014, 37, 112-116.	1.2	22
2161	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
2162	Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. <i>Immunopharmacology and Immunotoxicology</i> , 2014, 36, 182-186.	2.4	2
2163	Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients. <i>Molecular and Clinical Oncology</i> , 2014, 2, 454-460.	1.0	2
2164	Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung. <i>Oncology Letters</i> , 2014, 7, 2180-2184.	1.8	15
2165	Use and Misuse of Waterfall Plots. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	19
2166	New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment. <i>Oncology Research and Treatment</i> , 2014, 37, 351-353.	1.2	78
2167	Impact of the Enhanced Permeability and Retention (EPR) Effect and Cathepsins Levels on the Activity of Polymer-Drug Conjugates. <i>Polymers</i> , 2014, 6, 2186-2220.	4.5	34
2168	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 191.	4.8	71
2169	Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 525-529.	1.9	5
2170	Automated segmentation of murine lung tumors in x-ray micro-CT images. <i>Proceedings of SPIE</i> , 2014, , .	0.8	0
2171	The Clinical Impact of the Sum of the Maximum Standardized Uptake Value on the Pretreatment with 18F-FDG-PET/CT in Small-Cell Lung Cancer. <i>Oncology</i> , 2014, 86, 1-9.	1.9	14
2172	TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon. <i>Oncology</i> , 2014, 86, 289-294.	1.9	10
2173	Quantitative ultrasound monitoring of breast tumor response to chemotherapy by analysis of frequency-dependent attenuation and backscattered power. <i>Proceedings of SPIE</i> , 2014, , .	0.8	0
2174	Automatic detection and segmentation of liver metastatic lesions on serial CT examinations. <i>Proceedings of SPIE</i> , 2014, , .	0.8	3
2175	Survival analysis of cancer patients with multiple endpoints using global score test methodology. , 2014, , .		2
2176	Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital. <i>Future Oncology</i> , 2014, 10, 233-239.	2.4	19

#	ARTICLE	IF	CITATIONS
2178	Radiological Monitoring of the Treatment of Solid Tumors in Practice. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2014, 186, 466-473.	1.3	10
2179	Radiological Evaluation of the Therapeutic Response of Malignant Diseases: Status Quo, Innovative Developments and Requirements for Radiology. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2014, 186, 927-936.	1.3	5
2180	Effect of Kernels Used for the Reconstruction of MDCT Datasets on the Semi-Automated Segmentation and Volumetry of Liver Lesions. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2014, 186, 780-784.	1.3	2
2181	Therapy Response Evaluation of Malignant Lymphoma in a Multicenter Study: Comparison of Manual and Semiautomatic Measurements in CT. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2014, 186, 768-779.	1.3	1
2182	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 6277-6283.	7.0	39
2183	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Investigational New Drugs, 2014, 32, 1269-1277.	2.6	45
2184	Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumor Biology, 2014, 35, 12389-12395.	1.8	47
2185	Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab. Radiology, 2014, 270, 425-434.	7.3	25
2186	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology, 2014, 25, 2244-2251.	1.2	153
2187	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 2014, 5, 5694.	12.8	295
2188	Developing an objective marker to optimize patient selection and predict survival benefit in early phase cancer trials. Cancer, 2014, 120, 262-270.	4.1	14
2189	Can a treatment be licenced on the basis of post-treatment predictive biomarkers?. Pharmaceutical Statistics, 2014, 13, 214-221.	1.3	1
2190	Personalized oncology: genomic screening in phase 1. Apmis, 2014, 122, 723-733.	2.0	18
2191	Combination chemotherapy for metastatic extramammary Paget disease. British Journal of Dermatology, 2014, 170, 1354-1357.	1.5	55
2192	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1578-1584.	1.2	10
2193	Prognostic Factors Affecting Disease-Specific Survival in Patients with Recurrent and/or Metastatic Differentiated Thyroid Carcinoma Detected by Positron Emission Tomography/Computed Tomography. Thyroid, 2014, 24, 287-295.	4.5	13
2194	A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Annals of Oncology, 2014, 25, 1416-1421.	1.2	68
2195	A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 44-48.	1.4	16

#	ARTICLE	IF	CITATIONS
2196	Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. <i>NMR in Biomedicine</i> , 2014, 27, 1333-1345.	2.8	21
2197	Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. <i>Histopathology</i> , 2014, 64, 484-493.	2.9	14
2198	Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy. <i>Tumor Biology</i> , 2014, 35, 10121-10127.	1.8	17
2199	Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2014, 109, 740-745.	1.7	75
2200	Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. <i>British Journal of Surgery</i> , 2014, 101, 1712-1720.	0.3	28
2201	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOC 2010-01). <i>Annals of Oncology</i> , 2014, 25, 998-1004.	1.2	33
2202	¹³¹ I-MIBG therapy for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2014, 80, 487-501.	2.4	150
2203	Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. <i>Cancer</i> , 2014, 120, 530-536.	4.1	39
2204	Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations. <i>Radiology</i> , 2014, 273, 859-869.	7.3	78
2205	Revised Choi Imaging Criteria Correlate with Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. <i>Radiology</i> , 2014, 273, 452-461.	7.3	33
2206	Fluorine 18 Fluorodeoxyglucose PET/CT Volume-based Indices in Locally Advanced Non-Small Cell Lung Cancer: Prediction of Residual Viable Tumor after Induction Chemotherapy. <i>Radiology</i> , 2014, 272, 875-884.	7.3	20
2207	ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization. <i>Radiology</i> , 2014, 272, 568-576.	7.3	140
2208	Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. <i>Medical Oncology</i> , 2014, 31, 323.	2.5	39
2209	Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. <i>Oncology</i> , 2014, 86, 24-32.	1.9	45
2210	First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2167-2177.	27.0	2,808
2211	ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1449-1458.	2.5	93
2212	Cryoprotective therapy for huge hepatocellular carcinoma: A study of 14 patients with a single lesion. <i>Cryobiology</i> , 2014, 69, 457-461.	0.7	4
2213	Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , 2014, 15, 1493-1502.	10.7	109

#	ARTICLE	IF	CITATIONS
2214	Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 337-342.	1.9	6
2215	Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2014, 81, 642-651.	2.4	151
2216	Impact of long-acting octreotide in patients with early-stage <sc>MEN</sc>-related duodenopancreatic neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2014, 80, 850-855.	2.4	42
2217	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 1046-1061.	9.4	1,655
2218	FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer. <i>Oncology</i> , 2014, 87, 148-158.	1.9	15
2219	<i>SDHB</i> mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. <i>International Journal of Cancer</i> , 2014, 135, 2711-2720.	5.1	155
2220	Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 632.e1-632.e8.	1.3	60
2221	Population pharmacokinetics and pharmacodynamics of <sc>BYL</sc>719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 543-555.	2.4	27
2222	Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection according to the intention-to-treat principle. <i>Clinical Transplantation</i> , 2014, 28, 37-46.	1.6	9
2223	Japanese phase I study of <sc>GC</sc>33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. <i>Cancer Science</i> , 2014, 105, 455-462.	3.9	60
2224	Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 305-312.	3.9	28
2225	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562.	27.8	2,109
2226	Quantification of gross tumour volume changes between simulation and first day of radiotherapy for patients with locally advanced malignancies of the lung and head/neck. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 618-624.	1.8	9
2227	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	27.8	4,342
2228	A phase I/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. <i>Cancer</i> , 2014, 120, 1194-1202.	4.1	26
2229	Pregnancy complicated by a <sc>K</sc>rukenberg tumor with an undetermined origin and its management. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 2076-2080.	1.3	4
2230	Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in hepatic metastasis: A preliminary investigation of reproducibility and diagnostic value. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 448-456.	3.4	25
2231	Comparison of latino and non-Latino patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 233-237.	1.5	8

#	ARTICLE	IF	CITATIONS
2232	Electrochemotherapy as a novel treatment for primary cutaneous marginal zone B-cell lymphomas. <i>Dermatologic Therapy</i> , 2014, 27, 244-247.	1.7	11
2233	Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer. <i>Digestive Endoscopy</i> , 2014, 26, 77-86.	2.3	35
2234	Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat and With Which Drug? Those Are the Questions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4390-4396.	3.6	49
2236	A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 441-445.	1.4	69
2237	The Effects of Applying Breast Compression in Dynamic Contrast Material-enhanced MR Imaging. <i>Radiology</i> , 2014, 272, 79-90.	7.3	15
2238	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii27-iii39.	1.2	600
2239	Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria. <i>Cancer</i> , 2014, 120, 711-721.	4.1	40
2240	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19 IL2 Results in Sustained Clinical and Systemic Immunologic Responses. <i>Cancer Immunology Research</i> , 2014, 2, 668-678.	3.4	81
2241	Relationship Between Serum VEGF Level and Radiosensitivity of Patients with Nonsmall Cell Lung Cancer Among Asians: A Meta-Analysis. <i>DNA and Cell Biology</i> , 2014, 33, 426-437.	1.9	14
2242	Joint modeling tumor burden and time to event data in oncology trials. <i>Pharmaceutical Statistics</i> , 2014, 13, 286-293.	1.3	7
2243	Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas. <i>Liver International</i> , 2014, 34, e136-43.	3.9	25
2244	Concordance of <i>Kit</i> Mutational Status in Matched Primary and Metastatic Cutaneous Canine Mast Cell Tumors at Baseline. <i>Journal of Veterinary Internal Medicine</i> , 2014, 28, 547-553.	1.6	22
2245	Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. <i>EMBO Molecular Medicine</i> , 2014, 6, 539-550.	6.9	21
2246	Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. <i>NMR in Biomedicine</i> , 2014, 27, 887-896.	2.8	110
2247	Effects of MTHFR Genetic Polymorphisms on Toxicity and Clinical Response of Irinotecan-Based Chemotherapy in Patients with Colorectal Cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 313-322.	0.7	7
2248	Functional imaging in lung cancer. <i>Clinical Physiology and Functional Imaging</i> , 2014, 34, 340-355.	1.2	14
2249	Radiographic progression by Prostate Cancer Working Group (PCWG) criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2014, 114, E25-E31.	2.5	39
2250	Early Response Monitoring of Receptor Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma Using [F-18]Fluorothymidine-Positron Emission Tomography-Magnetic Resonance. <i>Seminars in Roentgenology</i> , 2014, 49, 238-241.	0.6	4

#	ARTICLE	IF	CITATIONS
2251	Benefit of palliative chemotherapy and hospice enrollment in late-stage ovarian cancer patients. Journal of Obstetrics and Gynaecology Research, 2014, 40, 1399-1406.	1.3	6
2252	Efficacy of crizotinib treatment in patients with stage III / b / IV non-small cell lung cancer. Thoracic Cancer, 2014, 5, 243-249.	1.9	7
2253	Prognosis according to histochemical analysis of liver metastases removed at liver resection. British Journal of Surgery, 2014, 101, 1681-1691.	0.3	55
2254	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. PLoS ONE, 2014, 9, e112025.	2.5	15
2255	Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86, 86-93.	1.9	19
2256	PET/CT in therapy evaluation of patients with lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 595-620.	2.4	8
2257	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. , 2014, , 29-42.		1
2258	Systemic Therapy: Current Strategies and New Directions. Medical Radiology, 2014, , 275-281.	0.1	0
2259	Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. Acta Radiologica, 2014, 55, 399-408.	1.1	15
2261	Addition of Local Hepatic Therapy to Sorafenib in Patients with Advanced Hepatocellular Carcinoma (Stage BCLC C). Digestion, 2014, 90, 219-228.	2.3	9
2262	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 1227-1234.	2.3	11
2263	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research, 2014, 20, 5392-5402.	7.0	83
2264	Treating medullary thyroid cancer in the age of targeted therapy. International Journal of Endocrine Oncology, 2014, 1, 203-216.	0.4	12
2265	High-dose Versus Standard-dose Radiotherapy with Concurrent Chemotherapy in Stages II-III Esophageal Cancer. Japanese Journal of Clinical Oncology, 2014, 44, 534-540.	1.3	61
2266	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 911-915.	2.3	7
2268	Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 1236-1245.	2.6	11
2269	Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma. Radiologia Medica, 2014, 119, 878-883.	7.7	12
2270	Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Medical Oncology, 2014, 31, 311.	2.5	18

#	ARTICLE	IF	CITATIONS
2271	Knowledge-Based Extraction of Measurement-Entity Relations from German Radiology Reports. , 2014, ,		2
2272	Response assessment in daily practice: RECIST and its modifications. Cancer Imaging, 2014, 14, .	2.8	1
2273	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer, 2014, 14, 619.	2.6	86
2274	Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer, 2014, 14, 976.	2.6	63
2275	Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma. BMC Cancer, 2014, 14, 981.	2.6	30
2276	Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study. BMC Cancer, 2014, 14, 989.	2.6	8
2277	Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2014, 12, 397.	1.9	86
2278	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
2279	Stereotactic radiosurgery for intraventricular brain metastases. Journal of Neurosurgery, 2014, 121, 26-34.	1.6	9
2280	Current Status of Imaging and Emerging Techniques to Evaluate Liver Metastases From Colorectal Carcinoma. Annals of Surgery, 2014, 259, 861-872.	4.2	57
2281	Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. Clinical Nuclear Medicine, 2014, 39, 951-959.	1.3	10
2282	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy, 2014, 10, 1415-1425.	9.1	149
2283	Protein kinase inhibitors in renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2014, 15, 337-351.	1.8	8
2284	Methylated DNA for monitoring tumor growth and regression: How do we get there?. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 149-159.	6.1	5
2285	Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma: A Retrospective Cohort Study. International Journal of Gynecological Cancer, 2014, 24, 1256-1261.	2.5	12
2286	Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology, 2014, 9, 1345-1353.	1.1	416
2287	Using Serum CA125 to Assess the Activity of Potential Cytostatic Agents in Ovarian Cancer. International Journal of Gynecological Cancer, 2014, 24, 676-681.	2.5	5
2288	Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research, 2014, 24, 468-474.	1.2	42

#	ARTICLE	IF	CITATIONS
2289	Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1704-1708.	1.1	29
2290	Target Lesion Selection. <i>Investigative Radiology</i> , 2014, 49, 509-517.	6.2	27
2291	Efficacy of cetuximab in the treatment of squamous cell carcinoma. <i>Journal of Dermatological Treatment</i> , 2014, 25, 424-427.	2.2	54
2292	Phase 2 Trial of Paclitaxel, 13-cis Retinoic Acid, and Interferon Alfa-2b in the Treatment of Advanced Stage or Recurrent Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1636-1641.	2.5	7
2293	Can MRI replace serial biopsies in men on active surveillance for prostate cancer?. <i>Current Opinion in Urology</i> , 2014, 24, 280-287.	1.8	29
2294	Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1162-1170.	1.1	61
2295	Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. <i>Clinical Cancer Research</i> , 2014, 20, 4218-4227.	7.0	29
2296	Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 386-393.	4.7	56
2297	Vemurafenib in the French temporary authorization for use metastatic melanoma cohort. <i>Melanoma Research</i> , 2014, 24, 75-82.	1.2	20
2298	Effectiveness of Chemotherapy in Measurable Granulosa Cell Tumors: A Retrospective Study and Review of Literature. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 496-505.	2.5	33
2299	Dynamic Contrast-Enhanced Computed Tomography as a Potential Biomarker in Patients With Metastatic Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2014, 49, 601-607.	6.2	21
2300	A Practical Guide from the International Thymic Malignancy Interest Group (ITMIC) Regarding the Radiographic Assessment of Treatment Response of Thymic Epithelial Tumors Using Modified RECIST Criteria. <i>Journal of Thoracic Oncology</i> , 2014, 9, S119-S124.	1.1	45
2301	Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors. <i>Investigative Radiology</i> , 2014, 49, 794-800.	6.2	121
2302	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. <i>Journal of Thoracic Oncology</i> , 2014, 9, 141-143.	1.1	23
2303	Diagnostic Accuracy of 18F Choline PET/CT using Time-of-Flight Reconstruction Algorithm in Prostate Cancer Patients With Biochemical Recurrence. <i>Clinical Nuclear Medicine</i> , 2014, 39, e197-e201.	1.3	13
2304	A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1031-1035.	1.1	44
2305	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 504-508.	1.2	70
2306	Image-guided Radiation Therapy for Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 561-567.	1.3	6

#	ARTICLE	IF	CITATIONS
2307	Linac-based Stereotactic Body Radiotherapy for Oligometastatic Patients With Single Abdominal Lymph Node Recurrent Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 227-233.	1.3	71
2308	Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases. <i>Melanoma Research</i> , 2014, 24, 349-353.	1.2	34
2309	Patterns of Failure in Colorectal Patients With Liver Metastases After Yttrium-90 Radioembolization. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 234-240.	1.3	7
2310	Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. <i>Nuclear Medicine Communications</i> , 2014, 35, 1119-1126.	1.1	27
2311	Vaccination With NY-ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY-ESO-1 Antigen. <i>Journal of Immunotherapy</i> , 2014, 37, 84-92.	2.4	31
2312	Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. <i>Journal of Radiation Research</i> , 2014, 55, 113-120.	1.6	23
2313	Open-label uncontrolled pilot study to evaluate complementary therapy with <i>Ruta graveolens</i> 9c in patients with advanced cancer. <i>Homeopathy</i> , 2014, 103, 232-238.	1.0	8
2314	Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 6336-6345.	7.0	70
2315	Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 846-851.	1.3	18
2316	Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma—Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 270-277.	1.3	83
2317	Mediastinal lymph node detection on thoracic CT scans using spatial prior from multi-atlas label fusion. <i>Proceedings of SPIE</i> , 2014, , .	0.8	7
2318	Circulating IGF system and treatment outcome in epithelial ovarian cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 217-229.	3.1	34
2319	EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. <i>Frontiers in Oncology</i> , 2014, 4, 350.	2.8	12
2320	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	7.0	38
2321	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. <i>Clinical Cancer Research</i> , 2014, 20, 5956-5963.	7.0	10
2322	Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test-Retest Measurements for Tumor FDG Uptake, Diameter, and Volume. <i>Clinical Cancer Research</i> , 2014, 20, 2751-2760.	7.0	38
2323	Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K/Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 4047-4058.	7.0	34
2324	A Pharmacodynamic/Pharmacokinetic Study of Ficluzumab in Patients with Advanced Solid Tumors and Liver Metastases. <i>Clinical Cancer Research</i> , 2014, 20, 2793-2804.	7.0	31

#	ARTICLE	IF	CITATIONS
2325	Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status. <i>Gastroenterology Report</i> , 2014, 2, 295-299.	1.3	2
2326	Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm. <i>Clinical Cancer Research</i> , 2014, 20, 3560-3568.	7.0	16
2327	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2397.	7.4	359
2328	Quality of reporting of phase II trials: a focus on highly ranked oncology journals. <i>Annals of Oncology</i> , 2014, 25, 536-541.	1.2	16
2329	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. <i>Seminars in Liver Disease</i> , 2014, 34, 444-455.	3.6	112
2330	<i>HER2</i> Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2014, 142, 755-766.	0.7	109
2331	Feasibility and Safety of Intraoperative Electrochemotherapy in Locally Advanced Pancreatic Tumor: A Preliminary Experience. <i>European Journal of Inflammation</i> , 2014, 12, 467-477.	0.5	12
2332	New Applications of Magnetic Resonance Imaging for Thoracic Oncology. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 027-040.	2.1	29
2333	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 197-209.	2.5	6
2334	Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. <i>The Cochrane Library</i> , 2019, 2019, CD010401.	2.8	43
2335	Omics Approaches in Breast Cancer. , 2014, , .		10
2336	Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. <i>Endocrine-Related Cancer</i> , 2014, 21, R105-R120.	3.1	59
2337	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. <i>Clinical Sarcoma Research</i> , 2014, 4, 17.	2.3	16
2338	10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study. <i>Oncologist</i> , 2014, 19, 507-514.	3.7	44
2339	Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles. <i>Science Translational Medicine</i> , 2014, 6, 229ra43.	12.4	298
2340	Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. <i>Annals of Oncology</i> , 2014, 25, 663-668.	1.2	71
2341	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2014, 20, 246-252.	7.0	144
2342	Male Pelvic Squamous Cell Carcinoma of Unknown Primary Origin. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-5.	0.3	5

#	ARTICLE	IF	CITATIONS
2343	Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. <i>Cancer Biomarkers</i> , 2014, 14, 207-214.	1.7	18
2344	Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 166-170.	1.0	3
2345	Efficacy of neoadjuvant cisplatin and 5-fluorouracil prior to surgery in FIGO stage IB2/IIA2 cervical cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 240-244.	1.0	9
2346	Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases. <i>Molecular and Clinical Oncology</i> , 2014, 2, 449-453.	1.0	3
2347	Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. <i>Molecular and Clinical Oncology</i> , 2014, 2, 991-996.	1.0	8
2348	Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 953-959.	1.0	9
2349	Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1023-1027.	1.0	7
2350	Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. <i>Molecular and Clinical Oncology</i> , 2014, 2, 997-1002.	1.0	4
2351	Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series. <i>ISRN Oncology</i> , 2014, 2014, 1-7.	2.1	7
2352	Sarcoma Immunotherapy: Past Approaches and Future Directions. <i>Sarcoma</i> , 2014, 2014, 1-13.	1.3	43
2353	The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 239.	0.9	14
2354	Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma. <i>Case Reports in Medicine</i> , 2014, 2014, 1-5.	0.7	7
2355	Response assessment in metronomic chemotherapy: RECIST or PERCIST?. <i>Indian Journal of Nuclear Medicine</i> , 2014, 29, 74.	0.3	12
2356	Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective. <i>Frontiers in Oncology</i> , 2014, 4, 210.	2.8	139
2357	Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries. <i>Molecular and Clinical Oncology</i> , 2014, 2, 269-274.	1.0	2
2358	Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. <i>Hepatology Research</i> , 2014, 44, 1179-1185.	3.4	40
2359	Positron Emission Tomography/Computed Tomography and Biomarkers for Early Treatment Response Evaluation in Metastatic Colon Cancer. <i>Oncologist</i> , 2014, 19, 164-172.	3.7	13
2360	Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. <i>Radiation Oncology</i> , 2014, 9, 213.	2.7	15

#	ARTICLE	IF	CITATIONS
2361	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 13.	2.3	28
2362	MAP Kinase Pathway Alterations in <i>BRAF</i> -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition. <i>Cancer Discovery</i> , 2014, 4, 61-68.	9.4	419
2363	Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy. <i>Urologia Internationalis</i> , 2014, 93, 49-54.	1.3	6
2364	Prediction of Survival by Tumor Area on Endosonography after Definitive Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of the Esophagus. <i>Digestion</i> , 2014, 90, 98-107.	2.3	7
2365	Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma. <i>Chemotherapy</i> , 2014, 60, 201-210.	1.6	4
2366	ATL. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 488-495.	2.5	27
2367	Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21. <i>Journal of Thoracic Oncology</i> , 2014, 9, 506-511.	1.1	44
2368	A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. <i>Journal of Thoracic Oncology</i> , 2014, 9, 769-774.	1.1	40
2369	Comparative Outcomes Between Initially Unresectable and Recurrent Cases of Advanced Pancreatic Cancer Following Palliative Chemotherapy. <i>Pancreas</i> , 2014, 43, 411-416.	1.1	17
2370	Molecular Analysis of the KIT Gene in Gastrointestinal Stromal Tumors With Novel Mutations. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 37-45.	1.2	7
2371	A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2014, 25, 1794-1799.	1.2	11
2372	Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma. <i>International Journal of Urology</i> , 2014, 21, 1114-1119.	1.0	10
2373	Peripancreatic tuberculous lymphadenopathy masquerading as pancreatic malignancy: A single-center experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 409-416.	2.8	33
2374	Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. <i>Science Translational Medicine</i> , 2014, 6, 232ra51.	12.4	315
2375	Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. <i>Pharmacogenomics Journal</i> , 2014, 14, 256-262.	2.0	16
2376	Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules. <i>Journal of Urology</i> , 2014, 191, 611-618.	0.4	122
2377	Hormone therapy in ovarian granulosa cell tumors: A systematic review. <i>Gynecologic Oncology</i> , 2014, 134, 196-205.	1.4	82
2378	Systemic and Targeted Therapy for Biliary Tract Tumors and Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 369-381.	1.5	10

#	ARTICLE	IF	CITATIONS
2379	The current role and limitations of surrogate endpoints in advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 28.e1-28.e9.	1.6	14
2380	Diffusion-weighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinoma. Magnetic Resonance Imaging, 2014, 32, 630-637.	1.8	71
2381	Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiotherapy and Oncology, 2014, 110, 126-131.	0.6	40
2382	Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, e1-e6.	2.6	1
2383	Experiencia inicial con acetato de abiraterona en pacientes con c�ncer de pr�stata resistente a la castraci�n. Actas Urol�gicas Espa�olas, 2014, 38, 339-345.	0.7	2
2384	The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. European Urology, 2014, 66, 646-652.	1.9	126
2385	Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. European Journal of Cancer, 2014, 50, 563-569.	2.8	20
2386	The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. European Journal of Cancer, 2014, 50, 972-980.	2.8	20
2387	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 539-546.	0.8	70
2388	PET-CT and diagnostic CT: The synergy of metabolic and morphological data in onco-haematology. Diagnostic and Interventional Imaging, 2014, 95, 55-62.	3.2	8
2389	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 689-699.	10.7	595
2391	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. European Journal of Cancer, 2014, 50, 260-266.	2.8	34
2392	Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecologic Oncology, 2014, 133, 460-466.	1.4	21
2393	Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. European Urology, 2014, 65, 766-777.	1.9	32
2394	Tumor Growth Kinetics Versus RECIST to Assess Response to Locoregional Therapy in Breast Cancer Liver Metastases. Academic Radiology, 2014, 21, 950-957.	2.5	11
2395	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Translational Oncology, 2014, 7, 55-64.	3.7	16
2396	Image Registration for Quantitative Parametric Response Mapping of Cancer Treatment Response. Translational Oncology, 2014, 7, 101-110.	3.7	22
2397	A phase II evaluation of AMG 102 (rilutumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 2014, 132, 526-530.	1.4	40

#	ARTICLE	IF	CITATIONS
2398	Early Treatment Response Evaluation after Yttrium-90 Radioembolization of Liver Malignancy with CT Perfusion. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 747-759.	0.5	26
2399	Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 359-365.	1.9	3
2400	Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 339-345.	0.2	1
2401	Abiraterone—What Is Wrong With the Adrenal Glands?. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e133-e137.	1.9	3
2402	Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. <i>Vaccine</i> , 2014, 32, 2241-2250.	3.8	43
2403	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	1.9	15
2404	Liver resection with concomitant inferior vena cava resection: experiences without veno-venous bypass. <i>Surgery Today</i> , 2014, 44, 1063-1071.	1.5	10
2405	Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case. <i>Surgery Today</i> , 2014, 44, 373-377.	1.5	16
2406	MRI volume measurements compared with the RECIST 1.1 for evaluating the response to neoadjuvant chemotherapy for mass-type lesions. <i>Breast Cancer</i> , 2014, 21, 316-324.	2.9	8
2407	The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 662-666.	2.2	5
2408	Outcome of patients treated with palliative weekly Paclitaxel plus Cetuximab in recurrent head and neck cancer after failure of platinum-based therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 373-378.	1.6	29
2409	Efficacy of Nimotuzumab Combined with Docetaxel—Cisplatin—Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma. <i>Cell Biochemistry and Biophysics</i> , 2014, 68, 181-184.	1.8	9
2410	Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 330-335.	2.4	74
2411	Safety and Effectiveness of Chemoembolization with Drug-Eluting Beads for Advanced-Stage Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 381-387.	2.0	61
2412	Transcatheter Arterial Chemoembolization (TACE) of Colorectal Cancer Liver Metastases by Irinotecan-Eluting Microspheres in a Salvage Patient Population. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 154-164.	2.0	49
2413	The role of functional imaging in the era of targeted therapy of renal cell carcinoma. <i>World Journal of Urology</i> , 2014, 32, 47-58.	2.2	18
2414	Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?. <i>World Journal of Urology</i> , 2014, 32, 39-45.	2.2	9
2415	Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumors. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 204-209.	2.0	4

#	ARTICLE	IF	CITATIONS
2417	A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Targeted Oncology, 2014, 9, 331-338.	3.6	13
2418	Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer, 2014, 17, 703-710.	5.3	100
2420	Treatment of liver tumours with yttrium radioembolisation. Clinical and Translational Imaging, 2014, 2, 165-182.	2.1	2
2421	Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. European Radiology, 2014, 24, 267-276.	4.5	26
2422	Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Annals of Hematology, 2014, 93, 249-253.	1.8	39
2423	Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need?. Current Urology Reports, 2014, 15, 375.	2.2	11
2424	Diffusion-weighted magnetic resonance imaging in the prediction and assessment of chemotherapy outcome in liver metastases. Radiologia Medica, 2014, 119, 625-633.	7.7	21
2425	Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. Medical Oncology, 2014, 31, 810.	2.5	20
2426	Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Investigational New Drugs, 2014, 32, 510-517.	2.6	64
2427	A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemotherapy and Pharmacology, 2014, 73, 181-189.	2.3	83
2428	Lymph Node Counts and Ratio in Axillary Dissections Following Neoadjuvant Chemotherapy for Breast Cancer: A Better Alternative to Traditional pN Staging. Annals of Surgical Oncology, 2014, 21, 42-50.	1.5	12
2429	Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases. Annals of Surgical Oncology, 2014, 21, 263-268.	1.5	58
2430	A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Investigational New Drugs, 2014, 32, 355-361.	2.6	104
2431	Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Clinical and Translational Oncology, 2014, 16, 739-745.	2.4	18
2432	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	5.9	27
2433	Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiologia Medica, 2014, 119, 215-221.	7.7	24
2434	Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 50-58.	6.4	116
2435	PNist: interactive volumetric measurements of plexiform neurofibromas in MRI scans. International Journal of Computer Assisted Radiology and Surgery, 2014, 9, 683-693.	2.8	7

#	ARTICLE	IF	CITATIONS
2436	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. <i>European Journal of Cancer</i> , 2014, 50, 78-84.	2.8	178
2437	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Cut</i> , 2014, 63, 844-855.	12.1	1,180
2439	Reprogramming antitumor immunity. <i>Trends in Immunology</i> , 2014, 35, 178-185.	6.8	39
2440	Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. <i>International Urology and Nephrology</i> , 2014, 46, 1531-1535.	1.4	21
2441	Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 874-880.	1.9	131
2442	Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis. <i>Clinical Lung Cancer</i> , 2014, 15, 110-118.	2.6	49
2443	Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug. <i>Clinical Lung Cancer</i> , 2014, 15, 145-151.	2.6	19
2444	The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 665-674.	7.7	52
2445	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	10.7	1,740
2446	Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1575-1582.	1.5	11
2447	Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 591-595.	1.5	21
2448	Recent developments of dual-energy CT in oncology. <i>European Radiology</i> , 2014, 24, 930-939.	4.5	84
2449	ERCC1 in Advanced Biliary Tract Cancer Patients Treated with Chemotherapy: Prognostic and Predictive Roles. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 80-86.	1.3	4
2450	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. <i>Targeted Oncology</i> , 2014, 9, 339-347.	3.6	28
2451	Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 857-867.	2.3	5
2452	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β^2 (TGF β^2) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	2.6	50
2453	A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. <i>Investigational New Drugs</i> , 2014, 32, 549-554.	2.6	5
2454	A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 485-493.	2.3	14

#	ARTICLE	IF	CITATIONS
2455	Fractal Analysis of Contrast-Enhanced CT Images to Predict Survival of Patients with Hepatocellular Carcinoma Treated with Sunitinib. Digestive Diseases and Sciences, 2014, 59, 1996-2003.	2.3	25
2456	Relationship of serum levels of VEGF and TGF- β 21 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer. Tumor Biology, 2014, 35, 4785-4789.	1.8	5
2457	Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 670-676.	1.5	57
2458	Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. Annals of Surgical Oncology, 2014, 21, 466-472.	1.5	41
2459	FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer. Open Medicine (Poland), 2014, 9, 306-312.	1.3	0
2460	Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer. Annals of Nuclear Medicine, 2014, 28, 81-87.	2.2	4
2461	Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. International Journal of Clinical Oncology, 2014, 19, 63-67.	2.2	16
2462	Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiation Oncology, 2014, 9, 41.	2.7	40
2463	Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. Clinical and Translational Oncology, 2014, 16, 234-242.	2.4	12
2464	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 2014, 63, 175-183.	4.2	80
2465	Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdominal Imaging, 2014, 39, 518-525.	2.0	11
2466	Imaging as a pharmacodynamic and response biomarker in cancer. Clinical and Translational Imaging, 2014, 2, 13-31.	2.1	5
2467	Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 682-693.	6.4	39
2468	A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 87-93.	2.6	9
2469	A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Investigational New Drugs, 2014, 32, 171-177.	2.6	11
2470	Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 2014, 63, 381-394.	4.2	84
2471	Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?. BMC Cancer, 2014, 14, 23.	2.6	19
2472	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1 α), in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 343-348.	2.3	129

#	ARTICLE	IF	CITATIONS
2473	Use of liposomal doxorubicin+cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. <i>Journal of Neuro-Oncology</i> , 2014, 117, 253-259.	2.9	21
2474	Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. <i>Annals of Surgical Oncology</i> , 2014, 21, 1530-1537.	1.5	127
2475	Staging, surveillance, and evaluation of response to therapy in renal cell carcinoma: role of MDCT. <i>Abdominal Imaging</i> , 2014, 39, 66-85.	2.0	3
2476	Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCcer trial): a multicenter randomised controlled study. <i>BMC Cancer</i> , 2014, 14, 22.	2.6	37
2477	Does "Conversion Chemotherapy" Really Improve Survival in Metastatic Colorectal Cancer Patients with Liver-Limited Disease?. <i>World Journal of Surgery</i> , 2014, 38, 936-946.	1.6	21
2478	A Phase 2 Study of 16Î±-[18F]-fluoro-17Î²-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). <i>Molecular Imaging and Biology</i> , 2014, 16, 431-440.	2.6	80
2479	Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. <i>International Journal of Clinical Oncology</i> , 2014, 19, 516-522.	2.2	15
2480	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014, 32, 243-249.	2.6	70
2481	Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. <i>European Journal of Cancer</i> , 2014, 50, 706-712.	2.8	88
2482	Prognostic significance of the treatment-free interval in patients with recurrent endometrial cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 92-96.	1.1	7
2483	Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 105-110.	1.4	23
2484	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977.	7.0	447
2485	A pRb-responsive, RGD-modified, and Hyaluronidase-armed Canine Oncolytic Adenovirus for Application in Veterinary Oncology. <i>Molecular Therapy</i> , 2014, 22, 986-998.	8.2	40
2486	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 569-579.	10.7	384
2487	Modelling of overall survival by an association between progression-free and post-progression survival using a conditional distribution. <i>Statistical Modelling</i> , 2014, 14, 77-98.	1.1	3
2488	Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial. <i>Clinical Oncology</i> , 2014, 26, 81-89.	1.4	26
2489	CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases. <i>European Radiology</i> , 2014, 24, 1251-1256.	4.5	9
2490	Medical Imaging in Clinical Trials. , 2014, , .		19

#	ARTICLE	IF	CITATIONS
2491	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71
2492	Modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver Criteria Using Delayed-Phase Imaging at an Early Time Point Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma following Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 256-265.	0.5	86
2493	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju033.	6.3	59
2494	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	2.4	91
2495	Radionuclide Imaging of Cancer Therapy. , 2014, , 45-54.		0
2496	Ultrasound Imaging of Cancer Therapy. , 2014, , 127-137.		3
2497	Serum human epidermal growth factor receptor 2 levels as a real-time marker for tumor burden in breast cancer patients. <i>Journal of Surgical Oncology</i> , 2014, 109, 421-425.	1.7	5
2498	A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients. <i>AAPS Journal</i> , 2014, 16, 609-619.	4.4	26
2500	Synopsis of Pathophysiology in Nuclear Medicine. , 2014, , .		8
2501	Assessment of response to therapy in hepatocellular carcinoma. <i>Annals of Medicine</i> , 2014, 46, 130-137.	3.8	8
2502	Imaging techniques for the evaluation of ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2014, 28, 697-720.	2.8	55
2503	A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2633-2643.	5.1	55
2504	Perspectives in Molecular Imaging Through Translational Research, Human Medicine, and Veterinary Medicine. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 66-75.	4.6	3
2505	Neuroendocrine tumours: the role of imaging for diagnosis and therapy. <i>Nature Reviews Endocrinology</i> , 2014, 10, 102-114.	9.6	120
2506	Malignant Skin and Subcutaneous Neoplasms in Adults: Multimodality Imaging With CT, MRI, and ¹⁸ F-FDG PET/CT. <i>American Journal of Roentgenology</i> , 2014, 202, W422-W438.	2.2	49
2507	Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. <i>Targeted Oncology</i> , 2014, 9, 9-24.	3.6	5
2508	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 406-410.	2.8	26
2509	Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOC0507-A). <i>Gastric Cancer</i> , 2014, 17, 514-521.	5.3	64

#	ARTICLE	IF	CITATIONS
2510	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Nonâ€“Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. <i>Clinical Lung Cancer</i> , 2014, 15, 86-92.	2.6	40
2511	Nanotechnologies for Noninvasive Measurement of Drug Release. <i>Molecular Pharmaceutics</i> , 2014, 11, 24-39.	4.6	43
2512	The value of diffusion-weighted MRI to evaluate the response to radiochemotherapy for cervical cancer. <i>Magnetic Resonance Imaging</i> , 2014, 32, 342-349.	1.8	59
2513	p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2014, 50, 128-134.	1.5	31
2514	Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). <i>Lung Cancer</i> , 2014, 83, 182-188.	2.0	15
2515	Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values. <i>Skeletal Radiology</i> , 2014, 43, 205-208.	2.0	20
2516	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. <i>Clinica Chimica Acta</i> , 2014, 429, 168-174.	1.1	20
2517	Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , .	0.1	5
2518	Differences in CT features of peritoneal carcinomatosis, sarcomatosis, and lymphomatosis: Retrospective analysis of 122 cases at a tertiary cancer institution. <i>Clinical Radiology</i> , 2014, 69, 1219-1227.	1.1	23
2519	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3619-3625.	1.6	94
2520	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. <i>Journal of Immunology</i> , 2014, 192, 2505-2513.	0.8	69
2522	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	1.6	173
2523	Effect of treatment with branchedâ€“chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 302-312.	3.4	25
2524	The evaluation of efficacy and safety of sunitinib on <i>EGFR</i> ^{TKI} pretreated advanced nonâ€“small cell lung cancer patients in <i>China</i> . <i>Clinical Respiratory Journal</i> , 2014, 8, 206-212.	1.6	6
2525	Efficacy of traditional and alternative sunitinib treatment schedules in <i>Japanese</i> patients with metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2014, 21, 1065-1068.	1.0	13
2526	Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy. <i>Cancer Medicine</i> , 2014, 3, 1368-1376.	2.8	49
2527	Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 296-301.	3.4	23
2529	Non-target progression â€“ The fine line between objectivity and subjectivity. <i>European Journal of Cancer</i> , 2014, 50, 3271-3272.	2.8	1

#	ARTICLE	IF	CITATIONS
2530	Selective activity over a constitutively active RET variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BOO2 phase I trial. <i>Molecular Oncology</i> , 2014, 8, 1719-1728.	4.6	3
2531	Carcinome bronchique non À petites cellules : quelle chimiothérapie de rattrapage ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 442-452.	0.0	0
2532	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. <i>Clinical Breast Cancer</i> , 2014, 14, 468-474.	2.4	29
2533	Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria A 10-Year Update. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1691-1705.e4.	0.5	365
2534	Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. <i>Surgery</i> , 2014, 156, 1369-1377.	1.9	105
2535	Clinical observation on the efficacy of CyberKnife for primary or metastatic retroperitoneal tumours. <i>European Journal of Cancer Care</i> , 2014, 23, 76-81.	1.5	2
2536	Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. <i>Medical Physics</i> , 2014, 41, 033502.	3.0	95
2537	Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. <i>International Journal of Cancer</i> , 2014, 135, 1961-1969.	5.1	233
2538	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. <i>International Journal of Cancer</i> , 2014, 135, 720-730.	5.1	36
2539	Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. <i>Prostate</i> , 2014, 74, 433-440.	2.3	13
2540	A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. <i>Cancer Medicine</i> , 2014, 3, 988-997.	2.8	22
2541	The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. <i>Annals of Surgical Oncology</i> , 2014, 21, 4211-4217.	1.5	40
2542	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	27.0	1,824
2543	Cardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer. <i>Breast Care</i> , 2014, 9, 3-3.	1.4	5
2544	A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2014, 111, 1932-1944.	6.4	71
2545	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 3136-3144.	2.8	17
2546	Selection of Therapeutic Treatment with Alternating Chemoradiotherapy for Larynx Preservation in Laryngeal Carcinoma Patients. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1063-1069.	1.3	5
2547	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. <i>Future Oncology</i> , 2014, 10, 533-540.	2.4	6

#	ARTICLE	IF	CITATIONS
2548	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	10.7	119
2549	Validation of optimal DCE-MRI perfusion threshold to classify at-risk tumor imaging voxels in heterogeneous cervical cancer for outcome prediction. <i>Magnetic Resonance Imaging</i> , 2014, 32, 1198-1205.	1.8	12
2550	Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. <i>European Journal of Cancer</i> , 2014, 50, 2897-2904.	2.8	40
2551	A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. <i>Molecular BioSystems</i> , 2014, 10, 2126-2133.	2.9	40
2552	Current Perspectives on Immunotherapy. <i>Seminars in Oncology</i> , 2014, 41, S14-S29.	2.2	28
2553	A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. <i>Lung Cancer</i> , 2014, 86, 288-290.	2.0	23
2554	Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases. <i>Lung Cancer</i> , 2014, 86, 225-230.	2.0	10
2555	A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). <i>Lung Cancer</i> , 2014, 86, 195-200.	2.0	8
2556	Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 385-389.	2.0	12
2557	A Prospective Observational Study to Examine the Relationship between Quality of Life and Adverse Events of First-line Chemotherapy Plus Cetuximab in Patients with KRAS Wild-type Unresectable Metastatic Colorectal Cancer: QUACK Trial. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 383-387.	1.3	7
2558	Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme. <i>American Journal of Neuroradiology</i> , 2014, 35, 498-503.	2.4	60
2559	Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer. <i>Nutrition Research</i> , 2014, 34, 585-594.	2.9	34
2560	The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1291-1297.	3.6	89
2561	Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. <i>Cancer Science</i> , 2014, 105, 996-1001.	3.9	41
2562	Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance. <i>Journal of Nuclear Medicine</i> , 2014, 55, 772-779.	5.0	15
2563	A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 1226-1235.	2.6	9
2564	A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. <i>Lung Cancer</i> , 2014, 86, 59-66.	2.0	50
2565	Segmentation of heterogeneous or small FDG PET positive tissue based on a 3D-locally adaptive random walk algorithm. <i>Computerized Medical Imaging and Graphics</i> , 2014, 38, 753-763.	5.8	28

#	ARTICLE	IF	CITATIONS
2566	Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Translational Oncology, 2014, 7, 447-455.	3.7	41
2567	Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Oncologist, 2014, 19, 51-60.	3.7	57
2568	Exploring the role of endothelium in the tumour response to anti-angiogenic therapy. Biochemical Society Transactions, 2014, 42, 1569-1575.	3.4	6
2569	Quantitative Radiology. Advances in Cancer Research, 2014, 124, 1-30.	5.0	1
2570	The evolving role of neurological imaging in neuro-oncology. Journal of Neuro-Oncology, 2014, 119, 491-502.	2.9	2
2571	Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression. Cancer Research, 2014, 74, 4762-4771.	0.9	34
2572	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British Journal of Cancer, 2014, 111, 2248-2253.	6.4	52
2573	Phase II Study of Concurrent Chemoradiotherapy with S-1 in Patients with Stage II (T2N0M0) Squamous Cell Carcinoma of the Pharynx or Larynx. Japanese Journal of Clinical Oncology, 2014, 44, 1158-1163.	1.3	9
2574	Outcome Reporting in Neoadjuvant Surgical Trials: A Systematic Review of the Literature and Proposals for New Standards. Journal of the National Cancer Institute, 2014, 106, dju217-dju217.	6.3	9
2575	Adaptive radiotherapy in lung cancer: dosimetric benefits and clinical outcome. British Journal of Radiology, 2014, 87, 20130643.	2.2	34
2576	Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Using Non-Contrast-Enhanced Computed Tomography. Academic Radiology, 2014, 21, 1434-1440.	2.5	0
2577	Initially Localized Synovial Sarcoma in Adults: A Retrospective Single-Center Analysis of 26 Patients Registered at the Department of Oncology, University of Vienna between 2004 and 2013. Oncology, 2014, 87, 48-57.	1.9	2
2578	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1224-1235.	10.7	1,932
2579	Quantitative Volumetric CT-Histogram Analysis in N-Staging of ¹⁸ F-FDG-“Equivocal” Patients with Lung Cancer. Journal of Nuclear Medicine, 2014, 55, 559-564.	5.0	31
2580	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
2581	Systemic treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 921-935.	2.4	9
2582	MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer. Lung Cancer, 2014, 85, 442-448.	2.0	22
2583	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncology, The, 2014, 15, 1119-1128.	10.7	631

#	ARTICLE	IF	CITATIONS
2584	Everolimus Reduces ⁸⁹ Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1087-1092.	5.0	56
2585	The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 814-821.	0.8	23
2586	Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. <i>European Journal of Cancer</i> , 2014, 50, 2519-2531.	2.8	134
2587	Predicting success in regulatory approval from Phase I results. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1099-1103.	2.3	9
2588	Assessment of Vocal Quality Following Treatment of Advanced Pharyngo-laryngeal Carcinoma With a Protocol of Organ Preservation. <i>Acta Otorrinolaringologica (English Edition)</i> , 2014, 65, 283-288.	0.2	2
2589	Tracking Cellular and Immune Therapies in Cancer. <i>Advances in Cancer Research</i> , 2014, 124, 257-296.	5.0	25
2590	A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. <i>European Journal of Cancer</i> , 2014, 50, 2408-2416.	2.8	21
2591	Impact of response evaluation for resectable esophageal adenocarcinoma – A retrospective cohort study. <i>International Journal of Surgery</i> , 2014, 12, 1025-1030.	2.7	5
2593	Commercial Laboratory Testing of Excision Repair Cross-Complementation Group 1 Expression in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2014, 19, 459-465.	3.7	9
2594	Semiautomatic segmentation and follow-up of multicomponent low-grade tumors in longitudinal brain MRI studies. <i>Medical Physics</i> , 2014, 41, 052303.	3.0	23
2595	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
2596	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. <i>Annals of Oncology</i> , 2014, 25, 1948-1953.	1.2	31
2597	Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer. <i>Journal of Surgical Oncology</i> , 2014, 109, 659-664.	1.7	15
2598	Management of Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , .	0.0	2
2599	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 799-808.	10.7	279
2600	Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). <i>British Journal of Cancer</i> , 2014, 110, 1163-1168.	6.4	114
2601	P0072 Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. <i>European Journal of Cancer</i> , 2014, 50, e29.	2.8	0
2602	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	2.8	32

#	ARTICLE	IF	CITATIONS
2603	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients â€“ A phase II trial. <i>European Journal of Cancer</i> , 2014, 50, 2190-2200.	2.8	67
2605	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 525-535.	27.6	377
2606	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.	1.2	27
2607	Evolutionary assembled neural networks for making medical decisions with minimal regret: Application for predicting advanced bladder cancer outcome. <i>Expert Systems With Applications</i> , 2014, 41, 8092-8100.	7.6	13
2608	Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 558-563.	2.8	53
2609	Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). <i>Bone</i> , 2014, 68, 32-40.	2.9	18
2610	Evolving Approaches in Managing Radioactive Iodine-Refractory Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2014, 20, 263-275.	2.1	21
2611	Magnetic Resonance Imaging of the Liver After Loco-Regional and Systemic Therapy. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2014, 22, 353-372.	1.1	10
2613	The Utility of an Extensive Postchemotherapy Staging Evaluation in Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer. <i>Urology</i> , 2014, 84, 358-364.	1.0	14
2614	Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging. <i>Magnetic Resonance Imaging</i> , 2014, 32, 993-1000.	1.8	75
2615	Tumor Response to Treatment: Prediction and Assessment. <i>Current Radiology Reports</i> , 2014, 2, 1.	1.4	7
2616	Contrast Evaluation of Liver Masses. <i>Ultrasound Clinics</i> , 2014, 9, 605-623.	0.2	0
2617	Assessing Treatment Response of Osteolytic Lesions by Manual Volumetry, Automatic Segmentation, and RECIST in Experimental Bone Metastases. <i>Academic Radiology</i> , 2014, 21, 1177-1184.	2.5	8
2618	The role of CT analyses of the sternal end of the clavicle and the first costal cartilage in age estimation. <i>International Journal of Legal Medicine</i> , 2014, 128, 825-839.	2.2	29
2619	Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2066-2073.	6.4	42
2620	CT Perfusion of the Liver: Principles and Applications in Oncology. <i>Radiology</i> , 2014, 272, 322-344.	7.3	154
2621	Accuracy of lung nodule volumetry in low-dose CT with iterative reconstruction: an anthropomorphic thoracic phantom study. <i>British Journal of Radiology</i> , 2014, 87, 20130644.	2.2	39
2622	Segmentation-Based Partial Volume Correction for Volume Estimation of Solid Lesions in CT. <i>IEEE Transactions on Medical Imaging</i> , 2014, 33, 462-480.	8.9	32

#	ARTICLE	IF	CITATIONS
2623	Clinical Translation of Molecular Imaging Agents Used in PET Studies of Cancer. <i>Advances in Cancer Research</i> , 2014, 124, 329-374.	5.0	6
2624	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , 2014, 15, 1147-1156.	10.7	181
2625	The nature and management of metastatic melanoma after progression on <scp>BRAF</scp> inhibitors: Effects of extended <scp>BRAF</scp> inhibition. <i>Cancer</i> , 2014, 120, 3142-3153.	4.1	65
2626	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. <i>Clinical Cancer Research</i> , 2014, 20, 4827-4836.	7.0	186
2627	Systematic review of minimally invasive ablation treatment for locally advanced pancreatic cancer. <i>Radiologia Medica</i> , 2014, 119, 483-498.	7.7	37
2628	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , 2014, 31, 88.	2.5	15
2629	Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. <i>Medical Oncology</i> , 2014, 31, 228.	2.5	23
2630	Volumetric FDG-PET predicts overall and progression-free survival after 14Âdays of targeted therapy in metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2014, 14, 408.	2.6	29
2631	FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 497.	2.6	76
2632	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. <i>BMC Cancer</i> , 2014, 14, 512.	2.6	65
2633	A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. <i>BMC Cancer</i> , 2014, 14, 622.	2.6	18
2634	Serum TFF3 may be a pharmacodynamic marker of responses to chemotherapy in gastrointestinal cancers. <i>BMC Clinical Pathology</i> , 2014, 14, 26.	1.8	19
2635	An innovative system for 3D clinical photography in the resource-limited settings. <i>Journal of Translational Medicine</i> , 2014, 12, 169.	4.4	3
2636	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 317.	1.6	33
2637	An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 234.	0.8	2
2638	Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. <i>Journal of Ovarian Research</i> , 2014, 7, 62.	3.0	45
2639	Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. <i>Clinical Sarcoma Research</i> , 2014, 4, 5.	2.3	28
2640	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. , 2014, 2, 17.		77

#	ARTICLE	IF	CITATIONS
2641	Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. <i>Journal of Translational Medicine</i> , 2014, 12, 215.	4.4	8
2642	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFR β /c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. <i>Journal of Hematology and Oncology</i> , 2014, 7, 52.	17.0	33
2643	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. , 2014, 2, 30.		27
2644	Chest-abdomen-pelvis CT for staging in cancer patients: dose effectiveness and image quality using automated attenuation-based tube potential selection. <i>Cancer Imaging</i> , 2014, 14, 28.	2.8	11
2645	Multimodal Magnetic Resonance Imaging Evaluation of Primary Brain Tumors. <i>Seminars in Oncology</i> , 2014, 41, 478-495.	2.2	10
2646	Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8249-8267.	6.4	454
2647	Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1560-1568.	2.3	36
2648	Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Cancer Letters</i> , 2014, 353, 160-166.	7.2	76
2649	Molecular Imaging Biomarkers for Oncology Clinical Trials. <i>Journal of Nuclear Medicine</i> , 2014, 55, 525-528.	5.0	63
2650	Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 457-463.	2.3	15
2651	Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 503-509.	2.3	5
2652	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	2.5	59
2653	Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity-time curves adequate?. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 335-343.	2.5	28
2654	Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. <i>British Journal of Cancer</i> , 2014, 111, 17-24.	6.4	70
2656	Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1216-1221.	1.0	23
2657	Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 806-814.	2.0	75
2659	Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study. <i>Abdominal Imaging</i> , 2014, 39, 488-96.	2.0	9
2660	Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 939-946.	4.2	67

#	ARTICLE	IF	CITATIONS
2661	A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1155-1161.	2.3	61
2662	Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 45-54.	2.3	7
2663	Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 333-340.	2.3	12
2664	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 447-455.	2.3	4
2665	Blood oxygenation level-dependent MR imaging as a predictor of therapeutic response to concurrent chemoradiotherapy in cervical cancer: a preliminary experience. <i>European Radiology</i> , 2014, 24, 1514-1520.	4.5	37
2666	Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. <i>European Radiology</i> , 2014, 24, 1455-1465.	4.5	27
2667	Dual-energy computed tomography for the assessment of early treatment effects of regorafenib in a preclinical tumor model: comparison with dynamic contrast-enhanced CT and conventional contrast-enhanced single-energy CT. <i>European Radiology</i> , 2014, 24, 1896-1905.	4.5	16
2668	Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm. <i>European Radiology</i> , 2014, 24, 1521-1528.	4.5	5
2669	Comparison of Once and Twice Daily Radiotherapy for Limited Stage Small-Cell Lung Cancer. <i>Lung</i> , 2014, 192, 151-158.	3.3	19
2670	Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 773-781.	1.9	4
2671	Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1159-1170.	2.5	59
2672	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1615-1624.	2.5	84
2673	The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1751-1758.	2.5	8
2674	A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1957-1963.	2.5	16
2676	Local control and prognostic significance of transarterial treatment for limited recurrence of ovarian cancer as third-line and beyond therapy. <i>International Journal of Clinical Oncology</i> , 2014, 19, 1065-1073.	2.2	3
2677	Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 1112-1117.	2.2	5
2678	Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 153-162.	2.5	43
2679	Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 340-346.	2.6	24

#	ARTICLE	IF	CITATIONS
2680	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2014, 32, 465-472.	2.6	31
2681	A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2014, 32, 739-745.	2.6	96
2682	A phase I/II trial of capecitabine combined with peginterferon α -2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 762-768.	2.6	5
2683	A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 937-945.	2.6	57
2684	A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 976-984.	2.6	44
2685	Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. <i>Investigational New Drugs</i> , 2014, 32, 1181-1187.	2.6	34
2686	Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. , 2014, 2, 13.		82
2687	Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy. <i>SpringerPlus</i> , 2014, 3, 243.	1.2	31
2688	Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. <i>Genome Biology</i> , 2014, 15, R47.	9.6	645
2689	Metabolic Response to Preoperative Chemotherapy Predicts Prognosis for Patients Undergoing Surgical Resection of Colorectal Cancer Metastatic to the Liver. <i>Annals of Surgical Oncology</i> , 2014, 21, 2420-2428.	1.5	28
2690	A Contemporary Large Single-Institution Evaluation of Resected Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2150-2158.	1.5	65
2691	The Usefulness of Neoadjuvant Chemoradiation Therapy for Locally Advanced Esophageal Cancer with Multiple Lymph-Node Metastases. <i>Annals of Surgical Oncology</i> , 2014, 21, 2845-2849.	1.5	7
2692	Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. <i>Annals of Surgical Oncology</i> , 2014, 21, 610-618.	1.5	15
2693	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2831-2837.	1.5	27
2694	Standardization and Quantification in FDG-PET/CT Imaging for Staging and Restaging of Malignant Disease. <i>PET Clinics</i> , 2014, 9, 117-127.	3.0	16
2695	Assessing Response to Treatment in Non-Small-Cell Lung Cancer: Role of Tumor Volume Evaluated By Computed Tomography. <i>Clinical Lung Cancer</i> , 2014, 15, 103-109.	2.6	11
2696	INVITED REVIEW "NEUROIMAGING RESPONSE ASSESSMENT CRITERIA FOR BRAIN TUMORS IN VETERINARY PATIENTS. <i>Veterinary Radiology and Ultrasound</i> , 2014, 55, 115-132.	0.9	26
2697	Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. <i>European Journal of Endocrinology</i> , 2014, 170, 575-582.	3.7	95

#	ARTICLE	IF	CITATIONS
2698	Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. European Journal of Cancer, 2014, 50, 981-986.	2.8	29
2699	Tumor Response Assessment Using Volumetric Doubling Time. Academic Radiology, 2014, 21, 947-949.	2.5	1
2700	Pseudo-progression after stereotactic radiotherapy of brain metastases: lesion analysis using MRI cine-loops. Journal of Neuro-Oncology, 2014, 119, 437-443.	2.9	14
2701	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> "RAF" Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	7.0	60
2702	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Annals of Oncology, 2014, 25, 1729-1735.	1.2	308
2703	Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. International Urology and Nephrology, 2014, 46, 1081-1087.	1.4	19
2704	Scoring system for prediction of lymph node metastasis in radical cystectomy cohort. International Urology and Nephrology, 2014, 46, 1317-1323.	1.4	1
2705	Molecular Targeted Therapy in Hepatocellular Carcinoma: From Biology to Clinical Practice and Future. Current Treatment Options in Oncology, 2014, 15, 380-394.	3.0	21
2706	Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites: an Interim Analysis. Journal of Gastrointestinal Cancer, 2014, 45, 307-311.	1.3	18
2707	Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. Medical Oncology, 2014, 31, 58.	2.5	8
2708	Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Medical Oncology, 2014, 31, 949.	2.5	27
2709	Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Medical Oncology, 2014, 31, 976.	2.5	4
2710	Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatology International, 2014, 8, 395-404.	4.2	41
2711	Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clinical and Translational Oncology, 2014, 16, 1012-1017.	2.4	4
2712	The Role of 18F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy. Nuclear Medicine and Molecular Imaging, 2014, 48, 130-136.	1.0	34
2713	XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumor Biology, 2014, 35, 5637-5645.	1.8	10
2714	Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?. Tumor Biology, 2014, 35, 7009-7015.	1.8	42
2715	Valutazione economica in base allo studio NAVOTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. Pharmacoeconomics Italian Research Articles, 2014, 16, 1.	0.2	2

#	ARTICLE	IF	CITATIONS
2716	RECIST measurements in cancer treatment: is there a role for physician assistants? - A pilot study. Cancer Imaging, 2014, 14, 12.	2.8	1
2717	Clinical evaluation of semi-automatic landmark-based lesion tracking software for CT-scans. Cancer Imaging, 2014, 14, 6.	2.8	2
2718	Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterology, 2014, 14, 84.	2.0	97
2719	Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer, 2014, 14, 268.	2.6	51
2720	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 2014, 14, 423.	2.6	48
2721	Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma. BMC Urology, 2014, 14, 26.	1.4	5
2722	Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World Journal of Surgical Oncology, 2014, 12, 127.	1.9	34
2723	Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials, 2014, 15, 68.	1.6	11
2724	Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report. Journal of Medical Case Reports, 2014, 8, 122.	0.8	3
2725	The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report. Journal of Medical Case Reports, 2014, 8, 95.	0.8	11
2726	A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. International Journal of Cancer, 2014, 134, 1214-1224.	5.1	27
2727	Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. British Journal of Cancer, 2014, 110, 2201-2208.	6.4	19
2728	Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. Clinical Pharmacology and Therapeutics, 2014, 96, 214-223.	4.7	73
2729	Limited-Stage Hodgkin Lymphoma: Managing Uncertainty. Journal of Clinical Oncology, 2014, 32, 1180-1182.	1.6	9
2730	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discovery, 2014, 4, 546-553.	9.4	266
2731	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, 2014, 32, 5901-5907.	3.8	54
2732	A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 839-846.	2.3	16
2733	Pilot Phase I/II Personalized Therapy Trial for Metastatic Colorectal Cancer: Evaluating the Feasibility of Protein Pathway Activation Mapping for Stratifying Patients to Therapy with Imatinib and Panitumumab. Journal of Proteome Research, 2014, 13, 2846-2855.	3.7	35

#	ARTICLE	IF	CITATIONS
2734	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1202-1209.	1.6	159
2735	State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine. <i>Radiology</i> , 2014, 271, 6-27.	7.3	114
2736	Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study. <i>European Radiology</i> , 2014, 24, 2709-2718.	4.5	7
2737	The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas. <i>Cancer Letters</i> , 2014, 353, 104-114.	7.2	22
2738	Referrals to phase I clinical trials in a gynecologic oncology unit. <i>Gynecologic Oncology</i> , 2014, 132, 231-235.	1.4	1
2739	Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1259-1268.	2.8	95
2740	Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: A phase II, multi-institutional clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 36-46.e1.	0.8	102
2741	Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2086-2094.	3.6	87
2742	Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI. <i>Journal of Bone Oncology</i> , 2014, 3, 5-9.	2.4	6
2743	Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. <i>European Journal of Cancer</i> , 2014, 50, 1581-1589.	2.8	119
2744	Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation. , 2014, 142, 351-361.		32
2745	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	2.8	80
2746	Immunotherapy in the treatment of non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 101-109.	2.0	106
2747	High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience. <i>Urology</i> , 2014, 83, 1129-1134.	1.0	24
2748	Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. <i>Cytotherapy</i> , 2014, 16, 234-244.	0.7	35
2749	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	1.9	24
2750	Automated Tracking of Quantitative Assessments of Tumor Burden in Clinical Trials. <i>Translational Oncology</i> , 2014, 7, 23-35.	3.7	48
2751	Advanced hepatocellular carcinoma treated by a combination of sorafenib and radiotherapy. <i>Advances in Digestive Medicine</i> , 2014, 1, 25-29.	0.2	1

#	ARTICLE	IF	CITATIONS
2752	Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-“Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01). <i>Clinical Lung Cancer</i> , 2014, 15, 258-265.	2.6	19
2753	TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 752-757.	1.4	32
2754	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 679-689.	2.8	40
2755	Percutaneous cryotherapy for metastatic bladder cancer: Experience with 23 patients. <i>Cryobiology</i> , 2014, 68, 79-83.	0.7	15
2756	Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. <i>European Urology</i> , 2014, 66, 459-465.	1.9	128
2757	Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-“targeted therapy. <i>Human Pathology</i> , 2014, 45, 1437-1444.	2.0	22
2758	Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells. <i>Cancer Letters</i> , 2014, 349, 144-151.	7.2	8
2760	Reproducible Surveillance Breast Ultrasound Using an Image Fusion Technique in a Short-Interval Follow-up for BI-RADS 3 Lesions: A Pilot Study. <i>Ultrasound in Medicine and Biology</i> , 2014, 40, 1049-1057.	1.5	8
2762	Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A monoinstitutional experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 42.e1-42.e5.	1.6	1
2763	Prospective screening for ALK: Clinical features and outcome according to ALK status. <i>European Journal of Cancer</i> , 2014, 50, 1239-1246.	2.8	46
2764	The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. <i>European Journal of Cancer</i> , 2014, 50, 1847-1853.	2.8	32
2765	Superselective Yttrium-90 Radioembolization for Hepatocellular Carcinoma Yields High Response Rates with Minimal Toxicity. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1067-1073.	0.5	70
2766	Histological analysis suggests an invasion-independent metastatic mechanism in alveolar soft part sarcoma. <i>Human Pathology</i> , 2014, 45, 137-142.	2.0	12
2767	Monitoring of Tumor Response to Cisplatin Using Optical Spectroscopy. <i>Translational Oncology</i> , 2014, 7, 230-239.	3.7	17
2768	Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): A retrospective cohort study at the National Center for Tumor Diseases Heidelberg. <i>Pancreatology</i> , 2014, 14, 211-215.	1.1	25
2769	Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1041-1047.	0.8	118
2770	Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy. <i>Medical Hypotheses</i> , 2014, 82, 295-299.	1.5	11
2771	Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney Cancer. <i>European Urology</i> , 2014, 66, 275-281.	1.9	10

#	ARTICLE	IF	CITATIONS
2772	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 601-611.	10.7	371
2773	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 63-69.e1.	1.9	27
2774	Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. <i>European Journal of Radiology</i> , 2014, 83, 1169-1176.	2.6	109
2775	Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. <i>Lung Cancer</i> , 2014, 85, 19-24.	2.0	185
2776	Comparison of 1D, 2D, and 3D Nodule Sizing Methods by Radiologists for Spherical and Complex Nodules on Thoracic CT Phantom Images. <i>Academic Radiology</i> , 2014, 21, 30-40.	2.5	39
2777	Theranostics with Ga-68 Somatostatin Receptor PET/CT. <i>PET Clinics</i> , 2014, 9, 91-97.	3.0	24
2778	Factors Predicting Recurrence and Postrecurrence Survival in Completely Resected Thymic Carcinoma. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1169-1175.	1.3	15
2779	Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, 167-173.	2.1	22
2780	Évaluation radiologique de la réponse au traitement: application aux cancers du rein métastatiques sous traitement anti-angiogénique. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 527-540.	0.0	1
2781	Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. <i>Medical Oncology</i> , 2014, 31, 35.	2.5	15
2782	Whole-Body Diffusion-weighted MR Imaging for Assessment of Treatment Response in Myeloma. <i>Radiology</i> , 2014, 271, 785-794.	7.3	178
2783	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. <i>Cancer</i> , 2014, 120, 1932-1938.	4.1	35
2784	FDG PET/CT of Primary Bone Tumors. <i>American Journal of Roentgenology</i> , 2014, 202, W521-W531.	2.2	92
2785	Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer. <i>Abdominal Imaging</i> , 2014, 39, 1261-1266.	2.0	6
2786	Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 428-432.	1.9	33
2787	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , 2014, 50, 2050-2056.	2.8	63
2788	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. <i>European Journal of Cancer</i> , 2014, 50, 2072-2081.	2.8	283
2789	Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2014, 111, 412-417.	0.6	177

#	ARTICLE	IF	CITATIONS
2790	Role of expert centres in the management of sarcomas – A UK perspective. <i>European Journal of Cancer</i> , 2014, 50, 1951-1956.	2.8	21
2791	Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 689-703.	3.2	52
2792	Antiangiogenic therapy in metastatic renal cell carcinoma: More promises and more challenges for imaging. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 525-526.	3.2	1
2793	Radiological evaluation of response to treatment: Application to metastatic renal cancers receiving anti-angiogenic treatment. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 527-539.	3.2	26
2794	Percutaneous Irreversible Electroporation for the Treatment of Colorectal Cancer Liver Metastases with a Proposal for a New Response Evaluation System. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1233-1239.e2.	0.5	51
2795	An (only) partially established paradigm of drug development of targeted therapies. <i>European Journal of Cancer</i> , 2014, 50, 2037-2039.	2.8	7
2796	Cryoprotective therapy for hepatocellular carcinoma: Study of 51 patients with a single lesion. <i>Cryobiology</i> , 2014, 69, 61-67.	0.7	8
2798	Assessment of Folate Receptor- β and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2014, 15, 320-330.e3.	2.6	14
2800	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014, 61, 318-324.	3.7	203
2801	Peptide receptor radionuclide therapy of neuroendocrine tumors with ^{90}Y -DOTATOC: Is treatment response predictable by pre-therapeutic uptake of ^{68}Ga -DOTATOC?. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 289-300.	3.2	85
2802	Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions. <i>Respiratory Investigation</i> , 2014, 52, 184-189.	1.8	8
2803	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	1.9	71
2804	Valoración de la calidad vocal tras el tratamiento del carcinoma faringolaríngeo avanzado en un protocolo de preservación de laringo. <i>Acta Otorrinolaringológica Española</i> , 2014, 65, 283-288.	0.4	3
2805	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	10.7	239
2806	Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience. <i>Journal of Dermatological Treatment</i> , 2014, 25, 419-423.	2.2	17
2807	Ideal number of target lesions per organ to measure in metastatic colorectal cancer. <i>Oncology Letters</i> , 2014, 8, 1896-1900.	1.8	6
2809	Future Directions for Monitoring Treatment Response in Colorectal Cancer. <i>Journal of Cancer</i> , 2014, 5, 44-57.	2.5	40
2810	Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer. <i>Journal of Cancer</i> , 2014, 5, 3-24.	2.5	78

#	ARTICLE	IF	CITATIONS
2812	Capecitabine for ER-positive versus ER-negative breast cancer. The Cochrane Library, 2014, , .	2.8	1
2813	Interobserver Variability of Radiographic Pulmonary Nodule Diameter Measurements in Dogs and Cats. Journal of the American Animal Hospital Association, 2014, 50, 83-88.	1.1	2
2814	Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal Cancer. Oncology, 2014, 86, 117-121.	1.9	18
2815	â€Deepness of Response' Is Associated with Overall Survival in Standard Systemic Chemotherapy for Metastatic Colorectal Cancer. Chemotherapy, 2014, 60, 360-367.	1.6	4
2817	Monitoring in Metastatic Breast Cancer: Is Imaging Outdated in the Era of Circulating Tumor Cells?. Breast Care, 2014, 9, 16-21.	1.4	25
2818	Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 194-203.	4.9	4
2819	Peripheral T-cell lymphoma complicated by immunoglobulin A pemphigus: A case report and literature review. Oncology Letters, 2014, 8, 62-66.	1.8	6
2820	Novel application of stereotactic ablative radiotherapy using CyberKnife® for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences. Oncology Letters, 2014, 8, 355-360.	1.8	26
2821	Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer. Oncology Letters, 2014, 8, 351-354.	1.8	12
2822	Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss Case Series. Dermatology, 2014, 229, 97-101.	2.1	18
2823	Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation. Oncology, 2014, 87, 215-223.	1.9	15
2824	Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer. International Journal of Oncology, 2014, 45, 1017-1026.	3.3	14
2825	Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2014, 9, 1398-1405.	1.1	55
2826	Metastatic brain cancer: prediction of response to whole-brain helical tomotherapy with simultaneous intralesional boost for metastatic disease using quantitative MR imaging features. , 2014, , .		0
2827	Parametric contrast-enhanced ultrasound as an early predictor of radiation-based therapeutic response for lymph node metastases of nasopharyngeal carcinoma. Molecular and Clinical Oncology, 2014, 2, 666-672.	1.0	7
2828	Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment. Journal of Thoracic Oncology, 2014, 9, e31-e33.	1.1	12
2829	A semi-parametric Bayesian model of inter- and intra-examiner agreement for periodontal probing depth. Annals of Applied Statistics, 2014, 8, 331-351.	1.1	7
2830	Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: A retrospective study. Oncology Reports, 2014, 32, 2619-2627.	2.6	30

#	ARTICLE	IF	CITATIONS
2831	A Review of Mixed-effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-10.	2.5	137
2832	XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer. Oncology Letters, 2014, 8, 1864-1872.	1.8	4
2833	Controversial (Unresolved) Issues in Noninferiority Trials. , 2014, , 133-150.		0
2834	Quantitative Insight in Utilizing Circulating Angiogenic Factors as Biomarkers for Antiangiogenic Therapy: Systems Pharmacology Approach. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-10.	2.5	6
2835	Posterior Cervical lymph Node Metastasis as the Valuable Prognostic Factor for Stage IVA/IVB Nasopharyngeal Carcinoma Treated with Induction Chemotherapy Followed by Concurrent Chemo-Radiotherapy. International Journal of Biological Markers, 2014, 29, 387-0394.	1.8	3
2836	Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. Molecular and Clinical Oncology, 2014, 2, 586-590.	1.0	3
2838	Outcomes of Adjuvant Endocrine Therapy and Hormone Receptor Status Change following Neoadjuvant Chemotherapy in Breast Cancer Patients. International Journal of Biological Markers, 2014, 29, 380-386.	1.8	1
2839	Long-Term Follow-Up and Prognostic Factors for Advanced Thymic Carcinoma. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock 14	1.0	14
2840	Comparison of RECIST, mRECIST, and Choi Criteria for Early Response Evaluation of Hepatocellular Carcinoma After Transarterial Chemoembolization Using Drug-Eluting Beads. Journal of Computer Assisted Tomography, 2014, 38, 391-397.	0.9	16
2841	Development of a Multi-Centre Clinical Trial Data Archiving and Analysis Platform for Functional Imaging. Journal of Physics: Conference Series, 2014, 489, 012089.	0.4	0
2842	Early prediction of lung cancer recurrence after stereotactic radiotherapy using second order texture statistics. , 2014, , .		1
2843	Efficacy of Capecitabine and Temozolomide Combination in Well-Differentiated Neuroendocrine Tumors. Pancreas, 2014, 43, 1303-1305.	1.1	31
2844	Functional Volumetric MRI in Assessing Treatment Response to Intra-Arterial Therapy of Primary and Secondary Liver Tumors. Journal of Computer Assisted Tomography, 2014, 38, 513-517.	0.9	6
2845	Evaluation of correlation between CT image features and ERCC1 protein expression in assessing lung cancer prognosis. , 2014, , .		0
2846	Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival. Clinical Pharmacology and Therapeutics, 2014, 96, 135-137.	4.7	11
2847	Robotic radical hysterectomy following neoadjuvant chemotherapy in FIGO stage IIIB cervical cancer: a case report. International Journal of Medical Robotics and Computer Assisted Surgery, 2014, 10, 98-102.	2.3	1
2848	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Molecular and Clinical Oncology, 2014, 2, 731-736.	1.0	20
2849	Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas. Nanomedicine, 2014, 9, 421-434.	3.3	28

#	ARTICLE	IF	CITATIONS
2850	Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm. <i>Medicine (United States)</i> , 2014, 93, e247.	1.0	50
2851	Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting. <i>Translational Oncology</i> , 2015, 8, 474-479.	3.7	24
2852	Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer. <i>Medicine (United States)</i> , 2015, 94, e1720.	1.0	48
2853	The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 903-909.	1.1	36
2854	Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 3131-3139.	1.5	4
2855	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.5	2
2856	Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1129-1134.	1.0	9
2857	Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1259-1265.	2.3	5
2858	Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , 2015, 90, 561-567.	2.0	8
2859	The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2015, 147, 157-164.	0.8	250
2860	Automatic brain tumor detection and segmentation from multi-modal MRI images based on region growing and level set evolution. , 2015, , .		22
2861	Results of surgical resection after induction chemoradiation for Pancoast tumours. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 805-812.	1.1	19
2862	Quantitative ultrasound spectroscopy and a kernel-based metric in clinical cancer response monitoring. , 2015, , .		3
2864	Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases. <i>British Journal of Surgery</i> , 2015, 102, 1240-1249.	0.3	50
2865	Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2015, 4, 1161-1170.	2.8	59
2866	Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2015, 4, 1505-1513.	2.8	12
2867	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. <i>Cancer Medicine</i> , 2015, 4, 1836-1843.	2.8	54
2868	A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. <i>Cancer</i> , 2015, 121, 3481-3490.	4.1	68

#	ARTICLE	IF	CITATIONS
2869	Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced nonâ€‘small cell lung cancer. <i>Cancer</i> , 2015, 121, 3146-3156.	4.1	11
2870	Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. <i>International Journal of Cancer</i> , 2015, 136, 2730-2737.	5.1	31
2871	Prediction of Response to Temozolomide in Lowâ€‘Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 728-737.	2.5	18
2872	<scp>DNA</scp> repair gene <scp>ERCC1 C118T</scp> polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a <scp>C</scp>hinese population. <i>Thoracic Cancer</i> , 2015, 6, 741-748.	1.9	21
2873	Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. <i>Cancer Science</i> , 2015, 106, 611-617.	3.9	21
2874	Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecularâ€‘targeted therapy. <i>Cancer Science</i> , 2015, 106, 618-626.	3.9	24
2875	Electroporation Enhances Bleomycin Efficacy in Cats with Periocular Carcinoma and Advanced Squamous Cell Carcinoma of the Head. <i>Journal of Veterinary Internal Medicine</i> , 2015, 29, 1368-1375.	1.6	35
2876	Subsequent treatment of epidermal growth factor receptorâ€‘tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2015, 6, 678-686.	1.9	3
2877	Evolution of induction chemotherapy for nonâ€‘small cell lung cancer over the last 30 years: A surgical appraisal. <i>Thoracic Cancer</i> , 2015, 6, 731-740.	1.9	3
2878	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the <scp>I</scp>alian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	2.5	17
2880	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1648-1652.	1.1	52
2881	Clinical significance of serum claudin-1 and claudin-7 levels in patients with colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1255-1267.	1.0	14
2882	Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-<i>kit</i> mutation. <i>Journal of Veterinary Medical Science</i> , 2015, 77, 1535-1539.	0.9	22
2883	FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Nonâ€‘Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 897-902.	1.1	32
2884	Mean platelet volume predicts chemotherapy response and prognosis in patients with unresectable gastric cancer. <i>Oncology Letters</i> , 2015, 10, 3419-3424.	1.8	21
2885	Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. <i>Oncology Letters</i> , 2015, 10, 1423-1429.	1.8	11
2886	Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. <i>Thoracic Cancer</i> , 2015, 6, 629-635.	1.9	12
2887	Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1160-1164.	1.0	8

#	ARTICLE	IF	CITATIONS
2888	Borderline Resectable Adenocarcinoma of the Pancreas. , 2015, , 415-450.		0
2889	Personalized medicine: challenges in biomarker-related clinical trial design. Clinical Investigation, 2015, 5, 175-188.	0.0	0
2890	Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis. Molecular and Clinical Oncology, 2015, 3, 403-407.	1.0	9
2891	Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Molecular and Clinical Oncology, 2015, 3, 334-340.	1.0	6
2892	Efficacy of 3D conformal thoracic radiotherapy for extensive-stage small-cell lung cancer: A retrospective study. Experimental and Therapeutic Medicine, 2015, 10, 671-678.	1.8	16
2893	Prognostic value of parotid lymph node metastasis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Scientific Reports, 2015, 5, 13919.	3.3	10
2894	Maintenance therapy for advanced non-small cell lung cancer (NSCLC). The Cochrane Library, 0, , .	2.8	0
2895	Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report. Oncology Letters, 2015, 10, 492-496.	1.8	3
2896	Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies. International Journal of Oncology, 2015, 46, 989-998.	3.3	3
2897	Molecular Magnetic Resonance Imaging of Tumor Response to Therapy. Scientific Reports, 2015, 5, 14759.	3.3	43
2898	Investigation of the potential role of preoperative chemotherapy in treatment for gastric cancer with outlet obstruction. Molecular and Clinical Oncology, 2015, 3, 1177-1183.	1.0	5
2899	Breast cancer resistance protein (BCRP)-containing circulating microvesicles contribute to chemoresistance in breast cancer. Oncology Letters, 2015, 10, 3742-3748.	1.8	36
2900	Metastatic Embryonal Carcinoma Mimicking Locally Advanced Non-small Cell Lung Cancer. Internal Medicine, 2015, 54, 59-61.	0.7	1
2901	Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters, 2015, 10, 2598-2602.	1.8	11
2902	Effectiveness of Positron Emission Tomography-Computed Tomography in Evaluation of Superselective Intra-arterial Chemoradiotherapy in Patients with Advanced Maxillary and Upper Gingival Carcinomas. Practica Otologica, Supplement, 2015, 144, 74-75.	0.0	0
2903	A prospective clinical trial of radiofrequency ablation for pulmonary metastases. Molecular and Clinical Oncology, 2015, 3, 559-562.	1.0	5
2904	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. Journal of Thoracic Oncology, 2015, 10, 1189-1194.	1.1	26
2905	Computer-aided breast MR image feature analysis for prediction of tumor response to chemotherapy. Medical Physics, 2015, 42, 6520-6528.	3.0	44

#	ARTICLE	IF	CITATIONS
2906	Statistical analysis of lung nodule volume measurements with CT in a large-scale phantom study. <i>Medical Physics</i> , 2015, 42, 3932-3947.	3.0	27
2907	Predictors of long-term survival following postoperative radiochemotherapy for pathologically confirmed suprasellar germ cell tumors. <i>Molecular and Clinical Oncology</i> , 2015, 3, 430-434.	1.0	11
2908	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. <i>Scientific Reports</i> , 2015, 5, 9289.	3.3	43
2909	Sodium glycididazole enhances the efficacy of combined iodine-125 seed implantation and chemotherapy in patients with non small-cell lung cancer. <i>Oncology Letters</i> , 2015, 9, 2335-2340.	1.8	8
2910	Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. <i>Oncology Letters</i> , 2015, 9, 2577-2582.	1.8	3
2911	Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e37-e48.	4.9	16
2912	Modified one-day etoposide and cisplatin combination for previously untreated extensive-disease small-cell lung cancer: A retrospective evaluation of 36 cases. <i>Molecular and Clinical Oncology</i> , 2015, 3, 914-918.	1.0	3
2913	Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1208-1212.	1.0	12
2914	Obesity Correlation with Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S32812.	1.3	70
2915	Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 109-117.	4.9	25
2916	Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification. <i>Pathology</i> , 2015, 47, 320-328.	0.6	18
2917	Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. <i>Oncology Letters</i> , 2015, 10, 3535-3541.	1.8	6
2918	Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study. <i>Oncology Letters</i> , 2015, 9, 2680-2686.	1.8	27
2919	Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. <i>Scientific Reports</i> , 2015, 5, 12077.	3.3	2
2920	Simultaneous Parenchyma-Preserving Liver Resection, Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stage IV Colorectal Cancer. <i>Acta Chirurgica Belgica</i> , 2015, 115, 261-267.	0.4	8
2921	Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 607-612.	0.9	45
2922	Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. <i>Updates in Surgery</i> , 2015, 67, 389-400.	2.0	23
2923	Breast conservation after neoadjuvant therapy for tumors ≥ 5 cm: A prospective cohort study. <i>International Journal of Surgery Open</i> , 2015, 1, 10-13.	0.7	1

#	ARTICLE	IF	CITATIONS
2924	Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1051-1061.	2.3	18
2926	The relevance of positron emission tomography response in non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 119-129.	0.5	1
2927	Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients. <i>BMC Cancer</i> , 2015, 15, 739.	2.6	10
2928	Semantic representation of reported measurements in radiology. <i>BMC Medical Informatics and Decision Making</i> , 2015, 16, 5.	3.0	8
2929	Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 10.	3.6	11
2930	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring <i>KIT</i> Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015, 20, 1312-1319.	3.7	70
2931	Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer. <i>Acta Radiologica Open</i> , 2015, 4, 205846011558810.	0.6	4
2932	Translating imaging biomarkers into clinical practice. <i>Cancer Imaging</i> , 2015, 15, O9.	2.8	0
2933	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. <i>Cancer Imaging</i> , 2015, 15, 15.	2.8	35
2934	Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, e58-e60.	1.1	14
2936	Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. <i>BMC Cancer</i> , 2015, 15, 662.	2.6	106
2937	Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. <i>BMC Cancer</i> , 2015, 15, 695.	2.6	22
2938	Colorectal liver metastatic disease: efficacy of irreversible electroporation—a single-arm phase II clinical trial (COLD FIRE-2 trial). <i>BMC Cancer</i> , 2015, 15, 772.	2.6	36
2939	Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 328.	1.9	29
2940	Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study. <i>Radiation Oncology</i> , 2015, 10, 185.	2.7	29
2941	Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1111-1121.	7.3	51
2942	Diffusion kurtosis imaging predicts neoadjuvant chemotherapy responses within 4 days in advanced nasopharyngeal carcinoma patients. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1354-1361.	3.4	50
2943	Intralesional bevacizumab in patients with Human immunodeficiency virus-associated Kaposi's sarcoma in the upper airway. <i>Laryngoscope</i> , 2015, 125, E132-7.	2.0	11

#	ARTICLE	IF	CITATIONS
2944	Microvasculature alters the dispersion properties of shear waves - a multi-frequency MR elastography study. <i>NMR in Biomedicine</i> , 2015, 28, 1763-1771.	2.8	20
2945	Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. <i>Pediatric Blood and Cancer</i> , 2015, 62, 616-621.	1.5	17
2946	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	2.3	24
2947	Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1135-1138.	1.0	12
2948	Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 851-855.	1.3	53
2949	Lung Cancer Screening. <i>Journal of Thoracic Imaging</i> , 2015, 30, 283-289.	1.5	18
2950	Transcript Profiling Distinguishes Complete Treatment Responders With Locally Advanced Cervical Cancer. <i>Translational Oncology</i> , 2015, 8, 77-84.	3.7	11
2951	Quantification of Ultrasonic Scattering Properties of In Vivo Tumor Cell Death in Mouse Models of Breast Cancer. <i>Translational Oncology</i> , 2015, 8, 463-473.	3.7	26
2952	Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. <i>Journal of Laryngology and Otology</i> , 2015, 129, 1046-1052.	0.8	6
2953	The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected. <i>Statistical Methods in Medical Research</i> , 2015, 24, 909-919.	1.5	6
2954	Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival. <i>SpringerPlus</i> , 2015, 4, 9.	1.2	8
2955	OLIGOPELVIS "GETUG P07": a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. <i>BMC Cancer</i> , 2015, 15, 646.	2.6	44
2956	Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. <i>BMC Cancer</i> , 2015, 15, 643.	2.6	23
2957	Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. <i>BMC Cancer</i> , 2015, 15, 659.	2.6	30
2958	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. <i>BMC Cancer</i> , 2015, 15, 700.	2.6	37
2959	Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP). <i>BMC Cancer</i> , 2015, 15, 812.	2.6	7
2960	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 989.	2.6	31
2961	Permanent interstitial 125I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment. <i>World Journal of Surgical Oncology</i> , 2015, 13, 335.	1.9	12

#	ARTICLE	IF	CITATIONS
2962	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 351.	4.4	56
2963	Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using 18F-FDG positron emission tomography: a retrospective cohort study. <i>Radiation Oncology</i> , 2015, 10, 259.	2.7	4
2964	Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 127.	17.0	45
2965	Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 454.	1.6	17
2966	Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. <i>BMC Research Notes</i> , 2015, 8, 609.	1.4	30
2967	Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. <i>BMC Research Notes</i> , 2015, 8, 800.	1.4	38
2968	Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. <i>SpringerPlus</i> , 2015, 4, 376.	1.2	6
2969	The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. , 2015, 3, 57.		17
2970	Changes of lung tumour volume on CT - prediction of the reliability of assessments. <i>Cancer Imaging</i> , 2015, 15, 17.	2.8	7
2971	Large artery stiffness and hypertension after antiangiogenic drugs. <i>Journal of Hypertension</i> , 2015, 33, 1310-1317.	0.5	27
2972	Prognostic Similarities and Differences in Optimally Resected Liver Metastases and Peritoneal Metastases From Colorectal Cancers. <i>Annals of Surgery</i> , 2015, 261, 157-163.	4.2	68
2973	Palliative electrochemotherapy in elderly patients with vulvar cancer: A phase II trial. <i>Journal of Surgical Oncology</i> , 2015, 112, 529-532.	1.7	25
2974	The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. <i>American Journal of Transplantation</i> , 2015, 15, 2665-2673.	4.7	137
2975	Frequency of C¹ and C² HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival. <i>Clinical Respiratory Journal</i> , 2015, 9, 297-304.	1.6	12
2976	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. <i>NMR in Biomedicine</i> , 2015, 28, 1645-1654.	2.8	51
2977	What Tumor Dynamics Modeling Can Teach us about Exploiting the Stem-Cell View for Better Cancer Treatment. <i>Cancer Informatics</i> , 2015, 14s2, CIN.S17294.	1.9	1
2978	Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. <i>Breast Care</i> , 2015, 10, 179-183.	1.4	3
2979	Panitumumab after Progression on Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients: a Single Institution Experience. <i>Tumori</i> , 2015, 101, 524-528.	1.1	6

#	ARTICLE	IF	CITATIONS
2980	Efficacy of Capecitabine Monotherapy as the First-line Treatment of Metastatic HER2-negative Breast Cancer. <i>Tumori</i> , 2015, 101, 418-423.	1.1	9
2981	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e259-e264.	1.3	16
2982	Medical interventions for high-grade vulval intraepithelial neoplasia. <i>The Cochrane Library</i> , 2016, 2016, CD007924.	2.8	10
2983	Selective internal radiation therapy for liver malignancies. <i>British Journal of Surgery</i> , 2015, 102, 1533-1540.	0.3	11
2984	Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of secondâ€line chemotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1935-1941.	1.5	37
2985	mTHPC mediated, systemic photodynamic therapy (PDT) for nonmelanoma skin cancers: Case and literature review. <i>Lasers in Surgery and Medicine</i> , 2015, 47, 779-787.	2.1	21
2986	A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extraâ€cranial solid tumors: A Children's Oncology Group Phase I Consortium report. <i>Pediatric Blood and Cancer</i> , 2015, 62, 751-758.	1.5	47
2987	Model free audit methodology for bias evaluation of tumour progression in oncology. <i>Pharmaceutical Statistics</i> , 2015, 14, 455-463.	1.3	3
2988	Follicular dendritic cell sarcoma of mediastinum: a key role of radiotherapy in a multidisciplinary approach. <i>Future Oncology</i> , 2015, 11, 57-61.	2.4	5
2989	Will the attributes of multiparametric MRI permit the creation of a new approach to therapy?. <i>Current Opinion in Urology</i> , 2015, 25, 518-521.	1.8	2
2990	Liver metastases from esophageal carcinoma: is there a role for surgical resection?. <i>Ecological Management and Restoration</i> , 2015, 28, 483-487.	0.4	44
2991	MRI of pleural diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 399-406.	2.6	9
2992	Value added. <i>Current Opinion in Oncology</i> , 2015, 27, 323-331.	2.4	27
2993	Phase I and Pharmacokinetic Study of Erlotinib Administered in Combination With Amrubicin in Patients With Previously Treated, Advanced Nonâ€small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 405-410.	1.3	3
2994	Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1461-1467.	2.5	18
2995	Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1645-1651.	2.5	28
2996	Prognostic Value of Altered N-Glycosylation of Circulating Glycoproteins in Patients With Unresectable Pancreatic Cancer Treated With Gemcitabine. <i>Pancreas</i> , 2015, 44, 551-556.	1.1	7
2997	Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels. <i>Pancreas</i> , 2015, 44, 756-763.	1.1	67

#	ARTICLE	IF	CITATIONS
2998	Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents. Cancer Journal (Sudbury, Mass), 2015, 21, 357-364.	2.0	25
2999	Combined dynamic contrast-enhanced liver MRI and MRA using interleaved variable density sampling. Magnetic Resonance in Medicine, 2015, 73, 973-983.	3.0	7
3000	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatric Blood and Cancer, 2015, 62, 1717-1724.	1.5	103
3001	Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs, 2015, 26, 785-792.	1.4	2
3002	Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. Anti-Cancer Drugs, 2015, 26, 1043-1053.	1.4	27
3003	Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation. Colorectal Disease, 2015, 17, 491-498.	1.4	19
3004	Estimating the Additive Benefit of Surgical Excision to Stereotactic Radiosurgery in the Management of Metastatic Brain Disease. Neurosurgery, 2015, 76, 707-713.	1.1	20
3005	The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Medicine (United States), 2015, 94, e2222.	1.0	8
3006	Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial. Head and Neck, 2015, 37, 722-726.	2.0	34
3007	Comparison of hepatic arterial infusion chemotherapy <i>versus</i> sorafenib monotherapy in patients with advanced hepatocellular carcinoma. Journal of Digestive Diseases, 2015, 16, 505-512.	1.5	40
3008	Influence of different imageâ€guided tracking methods upon the local efficacy of <sc>C</sc>yber<sc>K</sc>nife treatment in lung tumors. Thoracic Cancer, 2015, 6, 255-259.	1.9	11
3009	Elektrochemotherapie bei fortgeschrittenen Hauttumoren und Hautmetastasen â€ eine retrospektive multizentrische Auswertung. JDDG - Journal of the German Society of Dermatology, 2015, 13, 308-316.	0.8	3
3010	Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. International Journal of Gynecological Cancer, 2015, 25, 977-984.	2.5	14
3011	Imaging of the Posttherapeutic Brain. Topics in Magnetic Resonance Imaging, 2015, 24, 147-154.	1.2	9
3012	Randomized controlled trial of irinotecan drugâ€eluting beads with simultaneous <sc>FOLFOX</sc> and bevacizumab for patients with unresectable colorectal liverâ€limited metastasis. Cancer, 2015, 121, 3649-3658.	4.1	128
3013	Clinicopathologic features associated with efficacy and longâ€term survival in metastatic melanoma patients treated with <sc>BRAF</sc> or combined <sc>BRAF</sc> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	4.1	40
3014	Towards new response criteria in neuroendocrine tumors: Which changes in MRI parameters are associated with longer progressionâ€free survival after radioembolization of liver metastases?. Journal of Magnetic Resonance Imaging, 2015, 41, 361-368.	3.4	11
3015	Convergent Science Physical Oncology. Convergent Science Physical Oncology, 2015, 1, 010201.	2.6	0

#	ARTICLE	IF	CITATIONS
3016	Response of Relapsed Pancreatoblastoma to a Combination of Vinorelbine and Oral Cyclophosphamide. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e378-e380.	0.6	6
3017	Three-Dimensional Ultrasound Molecular Imaging of Angiogenesis in Colon Cancer Using a Clinical Matrix Array Ultrasound Transducer. <i>Investigative Radiology</i> , 2015, 50, 322-329.	6.2	43
3018	Indeterminate Pulmonary Nodules in Colorectal Cancer. <i>Annals of Surgery</i> , 2015, 261, 1145-1152.	4.2	24
3019	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 440-444.	1.5	94
3020	Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1855-1861.	5.0	21
3021	Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive. <i>Cancer</i> , 2015, 121, 4190-4196.	4.1	64
3022	Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1407-1420.	3.4	20
3023	MiR-95p influences cellular growth and is associated with poor survival in colorectal cancer patients. <i>Molecular Carcinogenesis</i> , 2015, 54, 1442-1450.	2.7	81
3024	Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 1269-1275.	2.8	34
3025	Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. <i>Veterinary and Comparative Oncology</i> , 2015, 13, 176-183.	1.8	309
3026	Metastatic liver tumour segmentation from discriminant Grassmannian manifolds. <i>Physics in Medicine and Biology</i> , 2015, 60, 6459-6478.	3.0	22
3027	Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 529-534.	0.8	2
3028	Three-dimensional conformal radiation therapy for inoperable massive hepatocellular carcinoma in six dogs. <i>Journal of Small Animal Practice</i> , 2015, 56, 441-445.	1.2	14
3029	Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 1083-1088.	1.4	10
3030	Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 605-609.	1.3	5
3031	Cell Cycle Kinetic Analysis of Colorectal Neoplasms Using a New Automated Immunohistochemistry-Based Cell Cycle Detection Method. <i>Medicine (United States)</i> , 2015, 94, e501.	1.0	5
3032	Intravoxel Incoherent Motion-Magnetic Resonance Imaging as an Early Predictor of Treatment Response to Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e973.	1.0	46
3033	Feasibility and Timing of Cyto-reduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib. <i>Medicine (United States)</i> , 2015, 94, e1014.	1.0	10

#	ARTICLE	IF	CITATIONS
3034	Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1121.	1.0	11
3035	Behind and Beyond the Masaoka Staging. <i>Medicine (United States)</i> , 2015, 94, e2278.	1.0	8
3036	How Imaging Can Impact Clinical Trial Design. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 218-224.	2.0	19
3037	Diagnostic Accuracy of Diffusion-Weighted Magnetic Resonance Imaging Versus Positron Emission Tomography/Computed Tomography for Early Response Assessment of Liver Metastases to Y90-Radioembolization. <i>Investigative Radiology</i> , 2015, 50, 409-415.	6.2	35
3038	Quantitative Computed Tomography Imaging Biomarkers in the Diagnosis and Management of Lung Cancer. <i>Investigative Radiology</i> , 2015, 50, 571-583.	6.2	41
3039	Semiautomatic Analysis on Computed Tomography in Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2015, 30, 290-299.	1.5	2
3040	Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy. <i>Journal of Thoracic Imaging</i> , 2015, 30, 300-307.	1.5	12
3041	Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 83.	2.7	0
3042	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. <i>Oncotarget</i> , 2015, 6, 28716-28730.	1.8	14
3043	2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2015, 16, 465.	3.4	168
3044	Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer. <i>Diagnostic and Interventional Radiology</i> , 2015, 22, 35-39.	1.5	6
3045	Do Diametric Measurements Provide Sufficient and Reliable Tumor Assessment? An Evaluation of Diametric, Areametric, and Volumetric Variability of Lung Lesion Measurements on Computerized Tomography Scans. <i>Journal of Oncology</i> , 2015, 2015, 1-6.	1.3	14
3046	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	1.8	278
3047	Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2015, 18, 365.	1.9	14
3048	Image-guided high-dose rate brachytherapy: preliminary outcomes and toxicity of a joint interventional radiology and radiation oncology technique for achieving local control in challenging cases. <i>Journal of Contemporary Brachytherapy</i> , 2015, 5, 327-335.	0.9	7
3049	The Assessment of Tumor Response by Measuring the Single Largest Lesion per Organ in Metastatic Tumors: A Pooled Analysis of Previously Reported Data. <i>Journal of Cancer</i> , 2015, 6, 169-176.	2.5	7
3050	Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. <i>Journal of Cancer</i> , 2015, 6, 387-393.	2.5	14
3051	Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. <i>Ecancermedicalscience</i> , 2015, 9, 582.	1.1	7

#	ARTICLE	IF	CITATIONS
3052	Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib. <i>OncoTargets and Therapy</i> , 2015, 8, 2081.	2.0	8
3053	Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. <i>OncoTargets and Therapy</i> , 2015, 8, 3193.	2.0	1
3054	Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF. <i>Breast Disease</i> , 2015, 35, 253-261.	0.8	3
3055	Predictors of the patency of self-expandable metallic stents in malignant gastroduodenal obstruction. <i>World Journal of Gastroenterology</i> , 2015, 21, 9134.	3.3	7
3056	Hepatic Surgery for Colorectal Cancer Metastasis – Possibilities and Prerequisites. , 0, , .		1
3057	The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment. <i>Korean Journal of Urology</i> , 2015, 56, 689.	1.2	2
3058	Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 1321.	2.0	17
3059	ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. <i>Wspolczesna Onkologia</i> , 2015, 3, 207-213.	1.4	12
3060	Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. <i>Wspolczesna Onkologia</i> , 2015, 5, 385-390.	1.4	2
3061	Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5215.	4.3	19
3062	Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1295-1300.	1.0	38
3063	Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma. <i>Genetics and Molecular Research</i> , 2015, 14, 12967-12972.	0.2	13
3064	Early α -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 39.	3.7	24
3065	Readjustment of abdominal computed tomography protocols in a university hospital: impact on radiation dose. <i>Radiologia Brasileira</i> , 2015, 48, 292-297.	0.7	5
3066	Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 13101.	3.3	15
3067	Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5785.	4.3	30
3068	Prognostic Value of CYFRA 21-1 and Carcinoembryonic Antigen in Non-Small Cell Lung Cancer. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	1
3069	Monitoring Reader Metrics in Blinded Independent Central Review of Oncology Studies. <i>Journal of Clinical Trials</i> , 2015, 05, .	0.1	0

#	ARTICLE	IF	CITATIONS
3070	Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. <i>Molecular and Clinical Oncology</i> , 2015, 3, 829-832.	1.0	6
3071	Evaluating agreement between solid tumor measurements used to assess response. <i>Journal of Biomedical Graphics and Computing</i> , 2015, 5, .	0.2	0
3072	P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane. <i>Oncoscience</i> , 2015, 2, 294-308.	2.2	26
3073	Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. <i>Patient Preference and Adherence</i> , 2015, 9, 1561.	1.8	11
3074	Successful treatment of quintuple primary cancer, including esophageal cancer: A case report. <i>Oncology Letters</i> , 2015, 9, 2583-2585.	1.8	3
3075	Volumetric assessment of lymph node metastases in patients with non-seminomatous germ cell tumors treated with chemotherapy. <i>Canadian Urological Association Journal</i> , 2015, 9, 247.	0.6	2
3076	Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. <i>Oncology Letters</i> , 2015, 10, 1135-1140.	1.8	6
3077	Function of and Need for a Pharmaceutical Outpatient Clinic Run by Oncology Pharmacy Specialists. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2015, 41, 254-265.	0.1	7
3078	Inferior Mesenteric Artery Chemoembolization and Chemotherapy for Advanced Rectal Cancer: Report of a Clinical Case. <i>Tumori</i> , 2015, 101, e82-e84.	1.1	1
3079	Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation (18F-FDG, 64Cu-ATSM and) Tj ETQq1 1 0.784314 rgBT /Overl Monitoring. <i>Diagnostics</i> , 2015, 5, 372-382.	2.6	2
3080	Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 68-77.	2.5	4
3081	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. <i>Frontiers in Medicine</i> , 2015, 2, 84.	2.6	29
3082	Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1387-1391.	1.0	2
3083	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. <i>The Cochrane Library</i> , 2015, , .	2.8	1
3084	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15048.	4.1	7
3085	Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. <i>Journal of Cancer</i> , 2015, 6, 652-657.	2.5	10
3086	Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. <i>Clinics</i> , 2015, 70, 781-789.	1.5	2
3087	Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT. <i>Journal of Korean Medical Science</i> , 2015, 30, 808.	2.5	29

#	ARTICLE	IF	CITATIONS
3088	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLoS ONE, 2015, 10, e0118564.	2.5	197
3089	A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study. PLoS ONE, 2015, 10, e0118569.	2.5	5
3090	High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase III Clinical Trial. PLoS ONE, 2015, 10, e0120228.	2.5	83
3091	Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan. PLoS ONE, 2015, 10, e0120852.	2.5	88
3092	Advantages of the Phosphatidylserine-Recognizing Peptide PSP1 for Molecular Imaging of Tumor Apoptosis Compared with Annexin V. PLoS ONE, 2015, 10, e0121171.	2.5	17
3093	Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. PLoS ONE, 2015, 10, e0122151.	2.5	55
3094	Perioperative Chemotherapy in Gastroesophageal Cancer. A Retrospective Monocenter Evaluation of 42 Cases. PLoS ONE, 2015, 10, e0122974.	2.5	0
3095	Integrated Multimodal Imaging of Dynamic Bone-Tumor Alterations Associated with Metastatic Prostate Cancer. PLoS ONE, 2015, 10, e0123877.	2.5	9
3096	A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy. PLoS ONE, 2015, 10, e0126649.	2.5	21
3097	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. PLoS ONE, 2015, 10, e0133371.	2.5	7
3098	Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities. PLoS ONE, 2015, 10, e0129679.	2.5	20
3099	Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma. PLoS ONE, 2015, 10, e0129954.	2.5	47
3100	Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer. PLoS ONE, 2015, 10, e0132901.	2.5	58
3101	Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS ONE, 2015, 10, e0133133.	2.5	7
3102	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS ONE, 2015, 10, e0134102.	2.5	25
3103	Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review. PLoS ONE, 2015, 10, e0137235.	2.5	13
3104	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0138341.	2.5	16
3105	Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS ONE, 2015, 10, e0139940.	2.5	43

#	ARTICLE	IF	CITATIONS
3106	Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. PLoS ONE, 2015, 10, e0142876.	2.5	84
3107	Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2015, 10, e0145442.	2.5	23
3108	Response Evaluation Criteria in Cancer of the Liver (RECICL 2015 revised version). Acta Hepatologica Japonica, 2015, 56, 116-121.	0.1	11
3109	Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Molecular and Clinical Oncology, 2015, 3, 929-935.	1.0	12
3110	Evaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with ¹⁸ F-FDG-PET/CT. Radiology and Oncology, 2015, 49, 115-120.	1.7	5
3111	Is there a subset of patients with recurrent cancer in the vagina who are not candidates for interstitial brachytherapy that can be treated with multichannel vaginal brachytherapy using graphic optimization?. Journal of Contemporary Brachytherapy, 2015, 2, 135-141.	0.9	2
3112	Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC. OncoTargets and Therapy, 2015, 8, 3227.	2.0	13
3113	Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. Cancer Biomarkers, 2015, 15, 843-850.	1.7	9
3114	A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Management and Research, 2015, 7, 153.	1.9	7
3115	The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Management and Research, 2015, 7, 265.	1.9	33
3116	Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	42
3117	The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma. BioMed Research International, 2015, 2015, 1-8.	1.9	0
3118	Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review. Sarcoma, 2015, 2015, 1-6.	1.3	31
3119	Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncology Letters, 2015, 9, 2567-2571.	1.8	6
3120	Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review. Gastroenterology Research and Practice, 2015, 2015, 1-7.	1.5	14
3121	CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterology Research and Practice, 2015, 2015, 1-10.	1.5	20
3122	Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer. BioMed Research International, 2015, 2015, 1-6.	1.9	7
3123	Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm ² to Predict Response to Induction Chemotherapy. Magnetic Resonance in Medical Sciences, 2015, 14, 337-345.	2.0	18

#	ARTICLE	IF	CITATIONS
3124	Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer. <i>Tumori</i> , 2015, 101, 506-510.	1.1	9
3125	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	1.8	25
3126	Preliminary Results of Proton-Beam Therapy for Stage iii Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2015, 22, 370-375.	2.2	8
3127	Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. <i>Sarcoma</i> , 2015, 2015, 1-7.	1.3	49
3128	Chemotherapy and Chemoprevention by Thiazolidinediones. <i>BioMed Research International</i> , 2015, 2015, 1-14.	1.9	74
3129	Prolonged Response of Meningeal Carcinomatosis from Non-small Cell Lung Cancer to Salvage Intrathecal Etoposide Subsequent to Failure of First-Line Methotrexate: A Case Report and Literature Review. <i>American Journal of Case Reports</i> , 2015, 16, 224-227.	0.8	4
3130	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. , 0, , .		4
3131	Neoadjuvant chemotherapy followed by surgery in gastric cancer patients with extensive lymph node metastasis. <i>World Journal of Clinical Oncology</i> , 2015, 6, 291.	2.3	9
3133	Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report. <i>Oncology Letters</i> , 2015, 10, 3519-3522.	1.8	10
3134	Induction Chemotherapy with Cisplatin and 5-Fluorouracil in Advanced Head and Neck Cancers: A Short Term Response Evaluation. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, XC08-XC12.	0.8	2
3135	Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients. <i>Neoplasma</i> , 2015, 62, 239-249.	1.6	13
3136	Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma. <i>Plastic Surgery</i> , 2015, 23, 25-30.	1.0	5
3137	WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results. <i>Ecancermedalscience</i> , 2015, 9, 604.	1.1	11
3138	Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for management. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211218.	0.5	6
3139	Clinical Trials in Glioblastoma â€” Designs and Challenges. , 2015, , .		4
3140	Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 642-649.	1.3	15
3141	Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist. <i>Journal of Thoracic Oncology</i> , 2015, 10, 412-419.	1.1	53
3142	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. <i>Pharmacogenomics Journal</i> , 2015, 15, 521-529.	2.0	13

#	ARTICLE	IF	CITATIONS
3143	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	27.0	7,261
3144	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	30.7	809
3145	Patient-reported outcomes as end points and outcome indicators in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 358-370.	27.6	55
3146	Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?. <i>Annals of Oncology</i> , 2015, 26, 1045-1047.	1.2	2
3147	PET Response Criteria in Solid Tumors Predicts Progression-Free Survival and Time to Local or Distant Progression After Chemotherapy with Regional Hyperthermia for Soft-Tissue Sarcoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 530-537.	5.0	31
3148	¹⁸ F-fluorodeoxyglucose positron emission tomography for predicting tumor response to radiochemotherapy in nasopharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 642-648.	2.0	4
3149	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 999-1009.	4.2	138
3150	Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. <i>Gastric Cancer</i> , 2015, 18, 627-634.	5.3	14
3151	Electrochemotherapy in combination with chemoradiotherapy in the treatment of oral carcinomas in advanced stages of disease: efficacy, safety, and clinical outcomes in a small number of selected cases. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1185.	4.3	13
3152	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology</i> , 2015, 16, 312-319.	10.7	78
3153	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 619-629.	10.7	574
3154	Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. <i>Lung Cancer</i> , 2015, 88, 187-194.	2.0	68
3155	Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. <i>Annals of Pharmacotherapy</i> , 2015, 49, 907-937.	1.9	155
3156	Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1445-1454.	3.3	36
3157	Liver metastases and SBRT: A new paradigm?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 464-471.	0.6	31
3158	Monitoring tumor state from thermal images in animal and human models. <i>Medical Physics</i> , 2015, 42, 1297-1306.	3.0	12
3159	Response Assessment in Locally Advanced Head and Neck Cancer Based on RECIST and Volume Measurements Using Cone Beam CT Images. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 19-27.	1.9	15
3160	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	7.1	552

#	ARTICLE	IF	CITATIONS
3161	Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials. <i>Pediatric Radiology</i> , 2015, 45, 1600-1615.	2.0	4
3162	Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 18-23.	1.4	64
3163	Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 686-694.	10.7	77
3164	The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 259-262.	1.4	35
3165	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
3166	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	27.0	1,239
3167	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015, 121, 1898-1905.	4.1	12
3168	Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2015, 37, 182-187.	2.0	76
3169	Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2015, 137, 1397-1405.	5.1	52
3170	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. <i>Cancer Discovery</i> , 2015, 5, 598-609.	9.4	72
3171	Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1047-1056.	4.2	48
3172	Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 21-27.	2.3	19
3173	Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 69-74.	2.3	37
3174	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1301-1309.	2.5	135
3175	Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1211-1217.	2.2	18
3176	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015, 33, 679-690.	2.6	43
3177	Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 691-699.	2.6	8
3178	A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. <i>Investigational New Drugs</i> , 2015, 33, 969-976.	2.6	50

#	ARTICLE	IF	CITATIONS
3179	Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. <i>Targeted Oncology</i> , 2015, 10, 287-295.	3.6	10
3180	Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations. <i>Clinical and Translational Oncology</i> , 2015, 17, 702-709.	2.4	12
3181	Pitfalls in RECIST Data Extraction for Clinical Trials. <i>Academic Radiology</i> , 2015, 22, 779-786.	2.5	31
3182	Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 62, 1076-1084.	3.7	21
3183	Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. <i>Lung Cancer</i> , 2015, 88, 139-146.	2.0	31
3185	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€” An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 137, 386-391.	1.4	224
3186	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	13.7	1,175
3187	Nivolumab for advanced squamous cell lung cancer: what are the next steps?. <i>Lancet Oncology, The</i> , 2015, 16, 234-235.	10.7	16
3188	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 716-728.	10.7	325
3189	Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 158.	4.4	20
3190	Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. <i>Cancer Cell International</i> , 2015, 15, 43.	4.1	22
3191	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 335-348.	3.0	51
3192	Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study. <i>Journal of International Medical Research</i> , 2015, 43, 573-582.	1.0	36
3193	Improved Efficiency in Clinical Workflow of Reporting Measured Oncology Lesions Via PACS-Integrated Lesion Tracking Tool. <i>American Journal of Roentgenology</i> , 2015, 204, 576-583.	2.2	14
3194	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. <i>Future Oncology</i> , 2015, 11, 591-606.	2.4	16
3195	Immunotherapy for non-small-cell lung cancer: the past 10 years. <i>Future Oncology</i> , 2015, 11, 2681-2695.	2.4	6
3196	Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. <i>Acta OncolÃ³gica</i> , 2015, 54, 1105-1112.	1.8	14
3197	Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. <i>BMC Cancer</i> , 2015, 15, 236.	2.6	16

#	ARTICLE	IF	CITATIONS
3198	The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 347.	2.6	50
3199	Feasibility of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan. <i>BMC Urology</i> , 2015, 15, 32.	1.4	7
3200	Pretreatment levels of the serum biomarkers CEA, CYFRA 211, SCC and the soluble EGFR and its ligands EGF, TGF- α , HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. <i>SpringerPlus</i> , 2015, 4, 171.	1.2	30
3201	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	7.0	39
3202	Efficacy of RetroNectin-Activated Cytokine-Induced Killer Cell Therapy in Metastatic Brain Tumor Patients. <i>Oncology Research and Treatment</i> , 2015, 38, 160-165.	1.2	10
3203	Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer. <i>Chemotherapy</i> , 2015, 60, 267-273.	1.6	2
3204	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , 2015, 16, e270-e278.	10.7	711
3205	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology</i> , 2015, 16, 729-736.	10.7	198
3206	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 986-991.	3.4	21
3207	Treatment outcomes using CyberKnife for brain metastases from lung cancer. <i>Journal of Radiation Research</i> , 2015, 56, 151-158.	1.6	26
3208	Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. <i>Cancer Letters</i> , 2015, 365, 23-29.	7.2	84
3209	Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors. <i>Annals of Internal Medicine</i> , 2015, 162, 682-689.	3.9	36
3210	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	2.5	22
3211	Metrics for Radiologists in the Era of Value-based Health Care Delivery. <i>Radiographics</i> , 2015, 35, 866-876.	3.3	84
3212	Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. <i>European Journal of Cancer</i> , 2015, 51, 1212-1220.	2.8	43
3213	Improved pulmonary nodule classification utilizing lung parenchyma texture features. <i>Proceedings of SPIE</i> , 2015, , .	0.8	5
3214	Texture analysis of automatic graph cuts segmentations for detection of lung cancer recurrence after stereotactic radiotherapy. , 2015, , .		2
3215	Nuclear imaging of renal tumours: a step towards improved risk stratification. <i>Nature Reviews Urology</i> , 2015, 12, 445-450.	3.8	13

#	ARTICLE	IF	CITATIONS
3216	The 2â€‰%+â€‰%1 paradigm: an efficient algorithm for central reading of Mayo endoscopic subscores in global multicenter phase 3 ulcerative colitis clinical trials. <i>Gastroenterology Report</i> , 2016, 4, gov024.	1.3	8
3217	Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment. <i>Medicine (United States)</i> , 2015, 94, e2016.	1.0	20
3218	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015, 15, 713.	2.6	43
3219	Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Medicine (United States)</i> , 2015, 94, e2239.	1.0	8
3220	Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 660-668.	2.5	17
3221	Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience. <i>Radiology and Oncology</i> , 2015, 49, 271-278.	1.7	5
3222	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced nonâ€‰small cell lung cancer harboring activating <i><scp>EGFR</scp></i> mutations: Subgroup analysis of <scp>LUX</scp>â€‰Lung 3. <i>Cancer Science</i> , 2015, 106, 1202-1211.	3.9	99
3223	The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. <i>BMC Cancer</i> , 2015, 15, 513.	2.6	18
3224	Making Progress on Progression in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1322-1324.	1.6	3
3225	Pseudoprogression and Immune-Related Response in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3541-3543.	1.6	720
3226	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1730-1734.	6.4	65
3227	PI3K/MEK pathway-targeted therapy in non-small cell lung carcinoma. <i>Cogent Medicine</i> , 2015, 2, 1114709.	0.7	0
3228	Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). <i>Annals of Oncology</i> , 2015, 26, 2097-2101.	1.2	41
3229	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv239.	6.3	18
3230	Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT. <i>Journal of Radiation Research</i> , 2015, 56, 553-560.	1.6	10
3231	A phase I study of volasertib combined with afatinib, in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 843-851.	2.3	19
3232	What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. <i>Cancer Epidemiology</i> , 2015, 39, 848-853.	1.9	8
3233	Gamma knife stereotactic radiosurgery in the treatment of brainstem metastases: The MD Anderson experience. <i>Neuro-Oncology Practice</i> , 2015, 2, 40-47.	1.6	9

#	ARTICLE	IF	CITATIONS
3234	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 823-842.	5.9	39
3235	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791.	2.8	53
3236	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5235-5244.	7.0	25
3237	RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancerâ€”Response. <i>Clinical Cancer Research</i> , 2015, 21, 2188-2188.	7.0	3
3238	A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. <i>Acta Radiologica Open</i> , 2015, 4, 204798161557041.	0.6	15
3239	Improved pulmonary nodule classification utilizing quantitative lung parenchyma features. <i>Journal of Medical Imaging</i> , 2015, 2, 041004.	1.5	44
3240	Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 739-750.	2.3	14
3241	Response to chemotherapy in patients with recurrent rectal cancer in previously irradiated area. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1075-1080.	2.2	11
3242	Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO). <i>Investigational New Drugs</i> , 2015, 33, 1115-1122.	2.6	4
3243	Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. <i>Urology</i> , 2015, 86, 1206-1211.	1.0	34
3244	Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy. <i>Medicine (United States)</i> , 2015, 94, e1593.	1.0	14
3245	Automated detection of breast tumor in MRI and comparison of kinetic features for assessing tumor response to chemotherapy. <i>Proceedings of SPIE</i> , 2015, , .	0.8	1
3246	Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatin Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer. <i>Medicine (United States)</i> , 2015, 94, e2303.	1.0	5
3247	Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1221-1228.	1.1	25
3249	Automatic Liver Tumor Segmentation in Follow-Up CT Scans: Preliminary Method and Results. <i>Lecture Notes in Computer Science</i> , 2015, , 54-61.	1.3	28
3250	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. <i>Current Anesthesiology Reports</i> , 2015, 5, 257-267.	2.0	0
3251	Evaluation of chemotherapy response in ovarian cancer treatment using quantitative CT image biomarkers: a preliminary study. <i>Proceedings of SPIE</i> , 2015, , .	0.8	0
3252	Analysis of the Vancouver lung nodule malignancy model with respect to manual and automated segmentation. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
3253	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. <i>Chronobiology International</i> , 2015, 32, 1359-1366.	2.0	1
3254	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4387-4395.	3.6	12
3255	A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1063-1072.	2.3	25
3256	Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2015, 13, 296.	1.9	7
3257	3D Markup of Radiological Images in ePAD, a Web-Based Image Annotation Tool. , 2015, , .		6
3258	Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities. <i>Hpb</i> , 2015, 17, 983-987.	0.3	22
3259	Induction chemotherapy with cetuximab, vinorelbine+cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine+cisplatin in patients with unresectable stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 249-254.	2.0	8
3260	Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial. <i>Clinical Investigation</i> , 2015, 5, 665-675.	0.0	1
3261	SEOM clinical guidelines in metastatic breast cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 946-955.	2.4	25
3262	Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy. <i>Journal of Medical Imaging</i> , 2015, 2, 041010.	1.5	29
3263	Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 10, 263-267.	1.8	8
3264	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.8	269
3265	Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1041-1049.	2.3	31
3266	Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2015, 27, 181-187.	1.5	5
3267	Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Oncology Letters</i> , 2015, 10, 1123-1130.	1.8	2
3268	Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. <i>Oncology Letters</i> , 2015, 10, 3411-3418.	1.8	53
3269	Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients before and after Cytotoxic Chemotherapy or Targeted Therapy. <i>Canadian Association of Radiologists Journal</i> , 2015, 66, 356-362.	2.0	4
3270	A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. <i>Gynecologic Oncology</i> , 2015, 138, 513-518.	1.4	38

#	ARTICLE	IF	CITATIONS
3271	Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET. <i>Abdominal Imaging</i> , 2015, 40, 3043-3051.	2.0	10
3272	Outcomes of Neoadjuvant Chemotherapy without Radiation for Rectal Cancer. <i>Digestive Surgery</i> , 2015, 32, 275-283.	1.2	14
3273	A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1375-1380.	1.0	14
3274	Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report. <i>Oncology Letters</i> , 2015, 10, 2981-2985.	1.8	7
3275	Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging. <i>Oncology Letters</i> , 2015, 10, 3607-3612.	1.8	26
3276	A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. <i>Cancer Investigation</i> , 2015, 33, 477-482.	1.3	15
3277	First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma. <i>JAMA Oncology</i> , 2015, 1, 1272.	7.1	86
3278	A risk management approach for imaging biomarker-driven clinical trials in oncology. <i>Lancet Oncology, The</i> , 2015, 16, e622-e628.	10.7	10
3279	Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data. <i>Physics in Medicine and Biology</i> , 2015, 60, 8491-8503.	3.0	10
3280	The combination of radiation therapy and immunotherapy for genitourinary cancer treatment: rationale, current evidence, and prospects. <i>Journal of Radiation Oncology</i> , 2015, 4, 355-363.	0.7	0
3281	Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. <i>Oncology</i> , 2015, 89, 53-59.	1.9	13
3282	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2015, 23, 1699-1708.	2.2	129
3283	Quantification of ultrasonic texture intra-heterogeneity via volumetric stochastic modeling for tissue characterization. <i>Medical Image Analysis</i> , 2015, 21, 59-71.	11.6	27
3284	Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?. <i>Abdominal Imaging</i> , 2015, 40, 1471-1480.	2.0	20
3285	Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. <i>European Journal of Cancer</i> , 2015, 51, 137-145.	2.8	9
3287	Repair mechanisms help glioblastoma resist treatment. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 14-20.	1.5	48
3288	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology, The</i> , 2015, 16, e43-e52.	10.7	72
3289	Volume-based Response Evaluation with Consensual Lesion Selection. <i>Academic Radiology</i> , 2015, 22, 217-225.	2.5	11

#	ARTICLE	IF	CITATIONS
3290	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2015, 16, 98-107.	10.7	270
3291	Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 36-41.	1.6	15
3292	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. <i>Lancet Oncology</i> , The, 2015, 16, e32-e42.	10.7	152
3293	Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 2640-2648.	1.5	59
3294	Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience. <i>Gynecologic and Obstetric Investigation</i> , 2015, 80, 10-14.	1.6	7
3295	Bone Marrow Minimal Residual Disease Was an Early Response Marker and a Consistent Independent Predictor of Survival After Anti-GD2 Immunotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 755-763.	1.6	40
3296	Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response. <i>Clinical Lung Cancer</i> , 2015, 16, 298-304.e2.	2.6	24
3297	Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. <i>Gynecologic Oncology</i> , 2015, 136, 121-129.	1.4	12
3298	Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis. <i>European Journal of Cancer</i> , 2015, 51, 202-209.	2.8	25
3299	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	1.9	17
3300	Surgically treated rectal cancer patientsâ€™ Outcomes at a tertiary care cancer hospital in Pakistan. <i>Asian Journal of Surgery</i> , 2015, 38, 13-20.	0.4	2
3301	The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). <i>IEEE Transactions on Medical Imaging</i> , 2015, 34, 1993-2024.	8.9	3,589
3302	Developing biomarker-specific end points in lung cancer clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 135-146.	27.6	43
3303	Circulating tumor cell enumeration by the CellSearch system: The clinicianâ€™s guide to breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 144-150.	7.7	62
3304	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2015, 112, 103-111.	6.4	98
3305	Accuracy of multidetector-row CT in diagnosing lymph node metastasis in patients with gastric cancer. <i>European Radiology</i> , 2015, 25, 368-374.	4.5	74
3306	BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 80-85.	2.4	48
3307	Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. <i>Acta Radiologica</i> , 2015, 56, 790-797.	1.1	10

#	ARTICLE	IF	CITATIONS
3308	Image-guided stereotactic ablative radiotherapy for the liver: A safe and effective treatment. <i>European Journal of Surgical Oncology</i> , 2015, 41, 249-256.	1.0	20
3309	Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study. <i>Clinical Lung Cancer</i> , 2015, 16, 121-127.	2.6	12
3310	Evaluation of an Interactive Science Publishing Tool. <i>Academic Radiology</i> , 2015, 22, 380-386.	2.5	0
3311	Robust semi-automatic segmentation of pulmonary subsolid nodules in chest computed tomography scans. <i>Physics in Medicine and Biology</i> , 2015, 60, 1307-1323.	3.0	61
3312	Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 213-220.	1.7	146
3313	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
3314	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 621-630.	27.0	1,526
3315	Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. <i>Tumor Biology</i> , 2015, 36, 5451-5457.	1.8	22
3316	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Hepatology Research</i> , 2015, 45, 949-959.	3.4	40
3317	Chemoradiation in elderly patients with head and neck cancers: a single institution experience. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2015, 36, 117-121.	1.3	15
3318	The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 43-47.	1.3	4
3319	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 185-192.	1.9	2
3320	Induction chemotherapy followed by surgery for advanced oesophageal cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 323-332.	1.0	5
3322	Single Fraction Radiosurgery for the Treatment of Renal Tumors. <i>Journal of Urology</i> , 2015, 193, 771-775.	0.4	84
3323	Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel. <i>Tumor Biology</i> , 2015, 36, 5529-5535.	1.8	8
3324	Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases. <i>Clinical Oncology</i> , 2015, 27, 353-361.	1.4	33
3325	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. <i>Current Urology Reports</i> , 2015, 16, 3.	2.2	12
3326	Immediate post- α -doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 981-989.	3.4	20

#	ARTICLE	IF	CITATIONS
3327	THERAPY OF ENDOCRINE DISEASE: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2015, 172, R215-R225.	3.7	60
3328	Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2157-2166.	7.0	227
3329	Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy. <i>Cancer Treatment Reviews</i> , 2015, 41, 136-143.	7.7	76
3330	Risk Stratification of Metastatic Neck Nodes by CT and PET in Patients with Head and Neck Cancer Receiving Definitive Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 183-189.	5.0	17
3331	¹⁸ F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2015, 56, 222-228.	5.0	86
3332	Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 1881-1888.	1.6	555
3333	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. <i>Cancer</i> , 2015, 121, 1654-1661.	4.1	39
3334	HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. <i>Gastric Cancer</i> , 2015, 18, 698-710.	5.3	58
3335	Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 111-124.	3.3	17
3336	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. <i>Annals of Oncology</i> , 2015, 26, 415-421.	1.2	78
3337	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
3338	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	1.6	127
3339	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	1.9	36
3340	Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 37-54.	4.7	82
3341	Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. <i>Nuclear Medicine and Biology</i> , 2015, 42, 349-354.	0.6	40
3342	The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: An exploratory study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 484-492.	1.0	20
3343	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <i>BRCA</i> -Mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1574-1582.	7.0	124
3344	Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial. <i>Medical Oncology</i> , 2015, 32, 334.	2.5	2

#	ARTICLE	IF	CITATIONS
3345	Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 624-629.	6.4	100
3346	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2015, 26, 58-64.	1.2	111
3347	The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 169-175.	2.0	81
3348	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. <i>Clinical Cancer Research</i> , 2015, 21, 68-76.	7.0	65
3349	Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer in the Era of Personalized Medicine. <i>Journal of Clinical Oncology</i> , 2015, 33, 524-524.	1.6	13
3350	A phase II trial of secondâ€“line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. <i>Cancer</i> , 2015, 121, 1620-1627.	4.1	47
3351	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. <i>Lung Cancer</i> , 2015, 87, 148-154.	2.0	81
3352	Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2015, 87, 155-161.	2.0	8
3353	A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 762-768.	1.2	75
3354	Liver stiffnessâ€“based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	3.9	34
3355	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
3356	Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response. <i>International Journal of Colorectal Disease</i> , 2015, 30, 367-373.	2.2	12
3357	CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression. <i>American Journal of Roentgenology</i> , 2015, 204, W11-W18.	2.2	23
3358	Is there an antiandrogen withdrawal syndrome with enzalutamide?. <i>BJU International</i> , 2015, 115, 373-380.	2.5	34
3359	Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer. <i>Oncologist</i> , 2015, 20, 94-104.	3.7	53
3360	A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 187-193.	2.6	35
3361	A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. <i>Oral Oncology</i> , 2015, 51, 383-388.	1.5	74
3362	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. <i>Clinical Cancer Research</i> , 2015, 21, 544-552.	7.0	56

#	ARTICLE	IF	CITATIONS
3363	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	27.8	2,132
3364	A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 422-426.	1.3	9
3365	Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2015, 56, 177-182.	5.0	179
3366	Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 720-728.	2.6	105
3367	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2520-2529.	7.0	59
3368	Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. <i>Gynecologic Oncology</i> , 2015, 137, 223-228.	1.4	127
3369	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	3.4	145
3370	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
3371	Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. <i>Endocrine</i> , 2015, 49, 854-858.	2.3	10
3372	Safety of high-dose-rate stereotactic body radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 27.	2.7	16
3373	Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 147-154.	2.3	22
3374	Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). <i>Gastric Cancer</i> , 2015, 18, 597-604.	5.3	29
3375	Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 160-164.	1.0	26
3376	Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan. <i>International Journal of Clinical Oncology</i> , 2015, 20, 561-565.	2.2	6
3377	Trans-arterial p53-Gene-Embolization with Gelatin Sponge Microparticles for Hepatocellular Carcinoma with BCLC Stage B: Single-Center Experience. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 99-104.	1.8	11
3378	Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 482-488.	1.5	36
3379	³ Deoxy- ³ -18F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 831-840.	6.4	24
3380	Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. <i>Clinical Sarcoma Research</i> , 2015, 5, 5.	2.3	69

#	ARTICLE	IF	CITATIONS
3381	The Role of Neoadjuvant Therapy in Characterizing Indeterminate Lung Lesions in Patients with Resectable Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 2201-2208.	1.5	3
3382	Radiation exposure from diagnostic imaging in young patients with testicular cancer. <i>European Radiology</i> , 2015, 25, 1005-1013.	4.5	12
3383	Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer. <i>Medical Oncology</i> , 2015, 32, 55.	2.5	18
3384	A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 293-300.	2.3	47
3385	Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer. <i>Medical Oncology</i> , 2015, 32, 421.	2.5	9
3386	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 851-859.	2.3	53
3387	Favourable outcomes of ¹⁷⁷ Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 176-185.	6.4	91
3388	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Annals of Oncology</i> , 2015, 26, 1012-1018.	1.2	56
3389	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 257-265.	10.7	1,269
3390	A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomasâ€”NCIC-CTG IND 200. <i>Annals of Oncology</i> , 2015, 26, 973-981.	1.2	37
3391	Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1457-1464.	2.5	22
3392	Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer. <i>Esophagus</i> , 2015, 12, 352-359.	1.9	13
3393	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. <i>Clinical Lung Cancer</i> , 2015, 16, e83-e89.	2.6	40
3394	Volume estimation of low-contrast lesions with CT: a comparison of performances from a phantom study, simulations and theoretical analysis. <i>Physics in Medicine and Biology</i> , 2015, 60, 671-688.	3.0	15
3395	Estrategia en oncologÃa. EMC - Tratado De Medicina, 2015, 19, 1-6.	0.0	0
3396	Carbon-ion radiotherapy for locally advanced primary or postoperative recurrent epithelial carcinoma of the lacrimal gland. <i>Radiotherapy and Oncology</i> , 2015, 114, 373-377.	0.6	20
3397	Region-based snake with edge constraint for segmentation of lymph nodes on CT images. <i>Computers in Biology and Medicine</i> , 2015, 60, 86-91.	7.0	7
3398	Clinical and Pathological Response to Neoadjuvant Chemotherapy Based on Primary Tumor Reduction is Correlated to Survival in Hormone Receptor-Positive but not Hormone Receptor-Negative Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 32-39.	1.5	21

#	ARTICLE	IF	CITATIONS
3399	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 129-144.	5.9	11
3400	Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. <i>Medical Oncology</i> , 2015, 32, 52.	2.5	19
3401	Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. <i>Journal of Gastroenterology</i> , 2015, 50, 769-775.	5.1	32
3402	Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1005-1011.	2.2	5
3403	Why measure tumours?. <i>Pediatric Radiology</i> , 2015, 45, 35-41.	2.0	6
3404	Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 17-23.	2.3	25
3405	Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel+prednisone in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2015, 33, 397-408.	2.6	15
3406	Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice. <i>International Journal of Clinical Oncology</i> , 2015, 20, 480-489.	2.2	10
3407	Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. <i>Targeted Oncology</i> , 2015, 10, 247-253.	3.6	54
3408	Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis. <i>European Radiology</i> , 2015, 25, 1801-1813.	4.5	3
3409	Esophageal cancer associated with bilateral hilar lymphadenopathy caused by sarcoid-like reactions: a report of two cases. <i>Esophagus</i> , 2015, 12, 322-326.	1.9	4
3410	Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 821-827.	2.3	19
3411	Expression of caspase-3 predicts prognosis in advanced noncardia gastric cancer. <i>Medical Oncology</i> , 2015, 32, 416.	2.5	13
3412	<scpi>ibex</scpi>: An open infrastructure software platform to facilitate collaborative work in radiomics. <i>Medical Physics</i> , 2015, 42, 1341-1353.	3.0	274
3413	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. <i>International Journal of Clinical Oncology</i> , 2015, 20, 668-673.	2.2	13
3414	Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2015, 22, 153-157.	1.0	10
3415	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2015, 26, 894-901.	1.2	275
3416	A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. <i>Medical Oncology</i> , 2015, 32, 325.	2.5	47

#	ARTICLE	IF	CITATIONS
3418	Oesophageal cancer: assessment of tumour response to chemoradiotherapy with tridimensional CT. <i>Radiologia Medica</i> , 2015, 120, 430-439.	7.7	11
3419	CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer. <i>Abdominal Imaging</i> , 2015, 40, 1170-1176.	2.0	3
3420	Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 353-359.	2.5	19
3421	Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2015, 13, 11.	1.9	30
3422	Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 2729-2737.	1.5	37
3423	Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. <i>Targeted Oncology</i> , 2015, 10, 429-437.	3.6	27
3424	A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 309-318.	2.3	4
3425	Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 281-288.	2.4	9
3426	A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 354-362.	1.2	132
3427	Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. <i>Cancer Science</i> , 2015, 106, 397-406.	3.9	65
3428	Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 805-812.	2.3	1
3429	Multiple liver metastases of pancreatic solid pseudopapillary tumor treated with resection following chemotherapy and transcatheter arterial embolization: A case report. <i>Oncology Letters</i> , 2015, 9, 1733-1738.	1.8	17
3430	Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 837-842.	0.8	82
3431	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo) Tj ETQq1 1 0,784314 rgBT /Overlo 262-273.	2.6	54
3432	A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. <i>Annals of Oncology</i> , 2015, 26, 556-561.	1.2	79
3433	The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience. <i>Oncologist</i> , 2015, 20, 508-515.	3.7	36
3434	MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 876-883.	2.4	34
3435	DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study. <i>Oncology Letters</i> , 2015, 9, 491-497.	1.8	7

#	ARTICLE	IF	CITATIONS
3436	PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 268-281.	4.6	29
3437	Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria. <i>Indian Journal of Nuclear Medicine</i> , 2015, 30, 21.	0.3	12
3438	Heterogeneity Underlies the Emergence of <i>EGFR</i> Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	9.4	429
3439	A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy. <i>Oncology Letters</i> , 2015, 9, 67-74.	1.8	23
3440	Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. <i>Seminars in Oncology</i> , 2015, 42, 626-639.	2.2	76
3441	Current Status of Imaging to Evaluate Liver Metastases From Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 168-177.	0.5	0
3442	Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). <i>European Journal of Cancer</i> , 2015, 51, 1927-1936.	2.8	150
3443	Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2015, 41, 868-874.	1.0	20
3444	Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This “Early Metabolic Look” Strategy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2591-2593.	1.6	6
3445	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 251-256.	2.3	11
3446	Whole-body diffusion-weighted MRI and 18F-FDG PET/CT can discriminate between different lymphoma subtypes. <i>Clinical Radiology</i> , 2015, 70, 1229-1236.	1.1	29
3447	RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 21-23.	2.1	32
3448	2015 update on the diagnosis and management of neoplastic pericardial disease. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 377-389.	1.5	21
3449	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 366, 112-122.	7.2	21
3450	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1946-1952.	2.8	63
3451	Chemoembolization follow-up of hepatocellular carcinoma with diffusion-weighted MR imaging. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2015, 46, 871-878.	0.6	0
3452	Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. <i>Cytotherapy</i> , 2015, 17, 1130-1138.	0.7	20
3453	Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. <i>Practical Radiation Oncology</i> , 2015, 5, e355-e363.	2.1	18

#	ARTICLE	IF	CITATIONS
3454	Effect of Neoadjuvant Chemotherapy Treatment on Prognosis of Patients with Advanced Gastric Cancer: a Retrospective Study. Chinese Medical Sciences Journal, 2015, 30, 84-89.	0.4	6
3455	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2015, 13, e79-e85.	1.9	78
3456	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. European Journal of Cancer, 2015, 51, 1694-1703.	2.8	25
3457	An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. European Journal of Cancer, 2015, 51, 1588-1595.	2.8	42
3458	Robotic nerve-sparing radical hysterectomy for locally advanced cervical cancer after neoadjuvant chemotherapy. International Journal of Gynecology and Obstetrics, 2015, 131, 152-155.	2.3	6
3459	Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3184-3190.	1.5	36
3460	Use of Imaging in the Management of Metastatic Spine Disease With Percutaneous Ablation and Vertebral Augmentation. American Journal of Roentgenology, 2015, 205, 434-441.	2.2	54
3461	The Evolution of Active Surveillance for Prostate Cancer. European Urology, 2015, 68, 822-823.	1.9	4
3462	Olfactory Groove Meningioma: Report of 99 Cases Surgically Treated at the Catholic University School of Medicine, Rome. World Neurosurgery, 2015, 83, 219-231.e3.	1.3	60
3463	Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1341-1352.	6.4	43
3464	Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?. Clinical Oncology, 2015, 27, 411-419.	1.4	30
3465	Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study. Oncology, 2015, 89, 103-110.	1.9	28
3466	Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients. Oncologist, 2015, 20, 758-766.	3.7	9
3467	ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. SpringerPlus, 2015, 4, 327.	1.2	10
3468	Magnetic resonance imaging biomarkers of chronic obstructive pulmonary disease prior to radiation therapy for non-small cell lung cancer. European Journal of Radiology Open, 2015, 2, 81-89.	1.6	4
3469	Proposal for Standardized Tabular Reporting of Observational Surgical Studies Illustrated in a Study on Primary Repair of Bile Duct Injuries. Journal of the American College of Surgeons, 2015, 221, 678-688.	0.5	21
3470	Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecologic Oncology, 2015, 136, 498-504.	1.4	42
3471	CT-guided permanent 125I seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy. Brachytherapy, 2015, 14, 662-669.	0.5	21

#	ARTICLE	IF	CITATIONS
3472	Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 203.e1-203.e9.	1.6	11
3473	Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 268.e9-268.e15.	1.6	36
3474	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , 2015, 112, 1326-1331.	6.4	30
3475	Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC. <i>British Journal of Radiology</i> , 2015, 88, 20140728.	2.2	11
3476	Threatened with death but growing: changes in and determinants of posttraumatic growth over the dying process for Taiwanese terminally ill cancer patients. <i>Psycho-Oncology</i> , 2015, 24, 147-154.	2.3	24
3477	Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. <i>Lung Cancer</i> , 2015, 89, 255-261.	2.0	108
3478	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2472-2480.	1.6	94
3479	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2450-2456.	1.6	61
3480	A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3896-3905.	7.0	48
3481	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2890-2898.	3.6	30
3482	Pembrolizumab for the treatment of melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 515-527.	3.1	2
3483	Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhus Gastric Cancer. <i>Oncology</i> , 2015, 88, 281-288.	1.9	3
3484	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 272-281.	4.4	15
3485	Gastric metastasis from sphenoid sinus melanoma: A case report. <i>Oncology Letters</i> , 2015, 9, 609-613.	1.8	5
3486	Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer. <i>Oncology Letters</i> , 2015, 9, 1822-1826.	1.8	13
3487	Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 139, 413-418.	1.4	18
3488	Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of MEK162 as a single agent in patients with refractory solid tumors. <i>Cancer</i> , 2015, 121, 1056-1063.	4.1	24
3489	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015, 26, 300-306.	1.2	77

#	ARTICLE	IF	CITATIONS
3490	A phase II study of sorafenib, oxaliplatin, and 2Âdays of high-dose capecitabine in advanced pancreas cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 317-323.	2.3	9
3491	Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 447-451.	1.4	45
3492	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. <i>Scientific Reports</i> , 2015, 5, 11198.	3.3	150
3493	Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3409-3415.	1.6	261
3494	Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 747-757.	4.1	28
3495	Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries. <i>Frontiers in Oncology</i> , 2014, 4, 362.	2.8	2
3496	Scalp metastasis from gastric cancer: A case report and literature review. <i>Oncology Letters</i> , 2015, 9, 641-644.	1.8	5
3497	TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer. <i>Oncology Letters</i> , 2015, 9, 1059-1064.	1.8	0
3498	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015, 88, 319-324.	2.0	5
3499	Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2015, 1, 836.	7.1	92
3500	Role of the Apparent Diffusion Coefficient in theÂPrediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 370-380.	2.4	47
3501	Single-Lesion Measurement per Organ for Assessing Tumor Response in Advanced Gastric Cancer. <i>Oncology</i> , 2015, 88, 69-75.	1.9	7
3502	Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. <i>Endocrine-Related Cancer</i> , 2015, 22, 289-298.	3.1	119
3503	Role of imaging for patients with colorectal hepatic metastases: what the radiologist needs to know. <i>Abdominal Imaging</i> , 2015, 40, 3029-3042.	2.0	8
3504	TFAP2E Methylation Status and Prognosis of Patients with Radically Resected Colorectal Cancer. <i>Oncology</i> , 2015, 88, 122-132.	1.9	17
3505	Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. <i>Lung Cancer</i> , 2015, 90, 65-70.	2.0	42
3506	Lobulated Enhancement Evaluation in the Follow-Up of Liver Metastases Treated by Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 292-298.	0.8	12
3507	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 5222-5234.	7.0	4

#	ARTICLE	IF	CITATIONS
3508	Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2015, 51, 1865-1873.	2.8	60
3509	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1027-1035.	3.4	27
3510	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	10.7	353
3511	Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-“Rearranged Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e84-e87.	1.6	108
3512	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2667-2674.	1.6	237
3514	Single-“cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis?. <i>Cancer</i> , 2015, 121, 1214-1222.	4.1	27
3515	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3512-3521.	1.5	135
3516	Imaging in Hepatocellular Carcinoma: Radiologic Assessment. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 33-44.	0.6	1
3518	PET response-adapted clinical trials in Hodgkin lymphoma: a comprehensive review. <i>Clinical and Translational Imaging</i> , 2015, 3, 283-294.	2.1	0
3519	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. <i>Journal of Hepatology</i> , 2015, 63, 896-904.	3.7	44
3520	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. <i>Trends in Molecular Medicine</i> , 2015, 21, 482-491.	6.7	146
3521	Urocor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 259-272.	0.6	16
3522	Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. <i>Annals of Oncology</i> , 2015, 26, 1385-1389.	1.2	32
3523	Exploring new quantitative CT image features to improve assessment of lung cancer prognosis. <i>Proceedings of SPIE</i> , 2015, , .	0.8	1
3524	Quantification of tumor changes during neoadjuvant chemotherapy with longitudinal breast DCE-MRI registration. , 2015, , .		1
3525	Tumor Bed Radiosurgery Following Resection and Prior Stereotactic Radiosurgery for Locally Persistent Brain Metastasis. <i>Frontiers in Oncology</i> , 2015, 5, 84.	2.8	25
3526	Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen. <i>Tumor Biology</i> , 2015, 36, 9465-9473.	1.8	14
3527	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1140-1147.	3.4	12

#	ARTICLE	IF	CITATIONS
3528	Pulmonary Nodules With Ground-Glass Opacity Can Be Reliably Measured With Low-Dose Techniques Regardless of Iterative Reconstruction: Results of a Phantom Study. American Journal of Roentgenology, 2015, 204, 1242-1247.	2.2	24
3529	Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treatment Reviews, 2015, 41, 729-741.	7.7	430
3530	Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma. Oncology Letters, 2015, 9, 257-261.	1.8	0
3531	Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 1128-1137.	4.1	447
3532	Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy, 2015, 17, 979-988.	0.7	47
3533	Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. Japanese Journal of Clinical Oncology, 2015, 45, 449-455.	1.3	13
3534	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event) Tj ETQq0 0 0 rgBT /Owlock 140Tf 50 492	0.7	3
3535	Relationship of Pathologic Factors to Efficacy of Sorafenib Treatment in Patients With Metastatic Clear Cell Renal Cell Carcinoma. American Journal of Clinical Pathology, 2015, 143, 492-499.	0.7	3
3536	First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters, 2015, 9, 987-993.	1.8	7
3537	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs, 2015, 33, 710-719.	2.6	24
3538	Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. Targeted Oncology, 2015, 10, 557-563.	3.6	9
3539	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2015, 16, 561-568.	10.7	141
3540	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European Journal of Cancer, 2015, 51, 482-488.	2.8	103
3541	Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer, 2015, 51, 507-513.	2.8	12
3542	[18F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Annals of Nuclear Medicine, 2015, 29, 535-542.	2.2	8
3543	Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials. Contemporary Clinical Trials, 2015, 42, 9-17.	1.8	10
3544	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology, 2015, 137, 216-222.	1.4	65
3545	Low percentage of CD24hiCD27+CD19+ B cells decelerates gastric cancer progression in XELOX-treated patients. International Immunopharmacology, 2015, 26, 322-327.	3.8	7

#	ARTICLE	IF	CITATIONS
3546	Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial. <i>Cancer Letters</i> , 2015, 360, 213-218.	7.2	45
3547	Comparison of Volumetric and Linear Serial CT Assessments of Lung Metastases in Renal Cell Carcinoma Patients in a Clinical Phase IIB Study. <i>Academic Radiology</i> , 2015, 22, 619-625.	2.5	8
3548	Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis. <i>Human Pathology</i> , 2015, 46, 739-745.	2.0	21
3549	Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. <i>Radiotherapy and Oncology</i> , 2015, 115, 246-252.	0.6	53
3550	Lung Cancer Assessment Using MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2015, 23, 231-244.	1.1	15
3551	A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer. <i>Journal of Chemotherapy</i> , 2015, 27, 52-56.	1.5	3
3552	Clinically meaningful end points in the evolving treatment paradigm for radioactive iodine-refractory differentiated thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 337-344.	2.4	0
3553	Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. <i>Acta Oncologica</i> , 2015, 54, 340-348.	1.8	170
3554	Pazopanib and Liposomal Doxorubicin in the Treatment of Patients with Relapsed/Refractory Epithelial Ovarian Cancer: A Phase Ib Study of the Sarah Cannon Research Institute. <i>Cancer Investigation</i> , 2015, 33, 47-52.	1.3	6
3555	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. <i>Thoracic Cancer</i> , 2015, 6, 224-226.	1.9	1
3556	MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer. <i>British Journal of Radiology</i> , 2015, 88, 20150097.	2.2	24
3557	Equivocal ALK fluorescence in situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. <i>Histopathology</i> , 2015, 67, 654-663.	2.9	15
3558	Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2015, 16, 228-236.	2.6	23
3559	Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. <i>Clinical Imaging</i> , 2015, 39, 454-462.	1.5	3
3561	Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. <i>Bulletin Du Cancer</i> , 2015, 102, 324-331.	1.6	47
3562	Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. <i>Oral Oncology</i> , 2015, 51, 508-513.	1.5	20
3563	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	2.8	47
3564	Goblet cell appendiceal tumors – Management dilemmas and long-term outcomes. <i>Surgical Oncology</i> , 2015, 24, 47-53.	1.6	41

3566	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 499-508.	10.7	753
3567	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 509-521.	10.7	174
3568	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1551-1556.	1.6	110
3569	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	27.0	5,183
3570	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 386-396.	6.4	130
3571	18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 367-369.	6.4	4
3572	Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1223-1230.	6.4	59
3573	Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing) Tj ETQq0 0 0 rgBT /Overlock 1	4.28	26
3574	Small Versus Large-Sized Drug-Eluting Beads (DEBIRI) for the Treatment of Hepatic Colorectal Metastases: A Propensity Score Matching Analysis. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 361-371.	2.0	37
3575	Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 301-308.	2.3	5
3576	Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 365-371.	2.3	22
3577	Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 475-483.	2.3	62
3578	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 521-526.	2.3	62
3579	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 791-803.	2.3	46
3580	Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. <i>European Radiology</i> , 2015, 25, 380-390.	4.5	24
3581	Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome. <i>International Journal of Colorectal Disease</i> , 2015, 30, 315-321.	2.2	11
3582	Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1103-1108.	2.5	15

#	ARTICLE	IF	CITATIONS
3583	Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1026-1034.	2.2	37
3584	A Mathematical Simulation to Assess Variability in Lung Nodule Size Measurement Associated With Nodule-Slice Position. <i>Journal of Digital Imaging</i> , 2015, 28, 373-379.	2.9	1
3585	A multicenter phase 1 study of \hat{I}^3 -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 169-176.	2.6	32
3586	A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 225-232.	2.6	40
3587	A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 463-471.	2.6	75
3588	Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. <i>Investigational New Drugs</i> , 2015, 33, 611-620.	2.6	20
3589	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 621-631.	2.6	63
3590	Sorafenib treatment in Childâ€Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. <i>Investigational New Drugs</i> , 2015, 33, 729-739.	2.6	75
3591	LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. <i>Journal of Neuro-Oncology</i> , 2015, 122, 121-126.	2.9	62
3592	Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. <i>Targeted Oncology</i> , 2015, 10, 453-465.	3.6	18
3593	Lymph Node Staging in Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 30.	2.2	45
3594	Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 1653-1661.	1.8	8
3595	Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice. <i>Endocrine</i> , 2015, 48, 582-588.	2.3	16
3596	Radiation sensitization with sodium nitrite in patients with brain metastases: a pilot randomized controlled trial. <i>Medical Oncology</i> , 2015, 32, 46.	2.5	6
3597	Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population. <i>Clinical and Translational Oncology</i> , 2015, 17, 564-569.	2.4	22
3598	Single fraction volumetric modulated arc radiosurgery of brain metastases. <i>Clinical and Translational Oncology</i> , 2015, 17, 596-603.	2.4	10
3599	Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. <i>Annals of Nuclear Medicine</i> , 2015, 29, 426-430.	2.2	9
3600	Diagnostic Performance of ^{68}Ga -DOTATATE PET/CT, ^{18}F -FDG PET/CT and ^{131}I -MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 143-151.	1.0	61

#	ARTICLE	IF	CITATIONS
3601	Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. <i>Tumor Biology</i> , 2015, 36, 861-869.	1.8	8
3602	Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy. <i>Tumor Biology</i> , 2015, 36, 3941-3947.	1.8	14
3603	Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer. <i>Tumor Biology</i> , 2015, 36, 5925-5929.	1.8	9
3604	A new system of microwave ablation at 2450ÂMHz: preliminary experience. <i>Updates in Surgery</i> , 2015, 67, 39-45.	2.0	56
3605	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
3606	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	27.0	2,489
3607	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. <i>BMC Cancer</i> , 2015, 15, 61.	2.6	25
3608	Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. <i>BMC Cancer</i> , 2015, 15, 58.	2.6	14
3609	Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial. <i>BMC Cancer</i> , 2015, 15, 40.	2.6	17
3610	GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. <i>BMC Cancer</i> , 2015, 15, 47.	2.6	29
3611	The effect of individualized NUTritional counseling on muscle mass and treatment outcome in patients with metastatic COLOrectal cancer undergoing chemotherapy: a randomized controlled trial protocol. <i>BMC Cancer</i> , 2015, 15, 98.	2.6	14
3612	Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. <i>BMC Cancer</i> , 2015, 15, 180.	2.6	57
3613	Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. <i>BMC Cancer</i> , 2015, 15, 237.	2.6	83
3614	Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. <i>Trials</i> , 2015, 16, 110.	1.6	57
3615	Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal 18F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC). <i>EJNMMI Research</i> , 2015, 5, 15.	2.5	7
3616	Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital. <i>Clinical Sarcoma Research</i> , 2015, 5, 8.	2.3	28
3617	Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospitalâ€™s experience. <i>SpringerPlus</i> , 2015, 4, 118.	1.2	4
3618	Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. <i>Cancer & Metabolism</i> , 2015, 3, 3.	5.0	110

#	ARTICLE	IF	CITATIONS
3619	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 2.	2.4	33
3620	Hypertrophic adenoids in patients with nasopharyngeal carcinoma: appearance at magnetic resonance imaging before and after treatment. <i>Chinese Journal of Cancer</i> , 2015, 34, 130-6.	4.9	6
3621	CEA Change After Neoadjuvant Chemotherapy Including Bevacizumab and Clinical Outcome in Patients Undergoing Liver Resection for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 1315-1323.	1.5	15
3622	Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2599-2607.	1.5	19
3623	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 583-594.	10.7	358
3624	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e145-e152.	1.9	16
3625	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. <i>Clinical Lung Cancer</i> , 2015, 16, 358-365.	2.6	14
3626	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	3.7	57
3627	Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. <i>International Journal of Surgery</i> , 2015, 18, 230-236.	2.7	79
3628	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. <i>Clinical Cancer Research</i> , 2015, 21, 642-651.	7.0	98
3629	A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 13-20.	2.3	30
3630	Hyperthermia and reirradiation for locoregional recurrences in preirradiated breast cancers: a single institutional experience. <i>Swiss Medical Weekly</i> , 2015, 145, w14133.	1.6	10
3631	Intra-arterial chemoradiation therapy with weekly low-dose cisplatin for squamous cell carcinoma of the maxillary sinus. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2015, 44, 697-704.	1.5	15
3632	Liver MRI. , 2015, , .		1
3633	Whole-Body 3D T1-weighted MR Imaging in Patients with Prostate Cancer: Feasibility and Evaluation in Screening for Metastatic Disease. <i>Radiology</i> , 2015, 275, 155-166.	7.3	71
3634	Liquid biopsies to evaluate early therapeutic response in colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1525-1527.	1.2	19
3635	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. <i>BMC Cancer</i> , 2015, 15, 403.	2.6	70
3636	Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET. <i>Molecular Imaging and Biology</i> , 2015, 17, 865-873.	2.6	5

#	ARTICLE	IF	CITATIONS
3637	Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 881-889.	2.6	46
3638	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	27.0	1,027
3639	Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. <i>Croatian Medical Journal</i> , 2015, 56, 128-138.	0.7	4
3640	Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. <i>American Journal of Ophthalmology</i> , 2015, 160, 220-227.e2.	3.3	50
3643	Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 338-348.	10.7	106
3644	The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 459-465.	4.2	34
3645	Computerized PET/CT image analysis in the evaluation of tumour response to therapy. <i>British Journal of Radiology</i> , 2015, 88, 20140625.	2.2	16
3646	Anti-VEGF Molecular Targeted Therapies in Common Solid Malignancies: Comprehensive Update for Radiologists. <i>Radiographics</i> , 2015, 35, 455-474.	3.3	34
3647	Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. <i>British Journal of Radiology</i> , 2015, 88, 20140712.	2.2	26
3648	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2015, 16, e25-e35.	2.6	100
3649	A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 587-594.	2.3	8
3650	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	27.8	1,955
3651	Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 336-342.	1.3	12
3652	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	10.7	2,353
3653	MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. <i>British Journal of Cancer</i> , 2015, 112, 504-513.	6.4	25
3654	EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1118-1123.	1.2	11
3655	The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 2352-2358.	1.5	147
3656	Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases. <i>Hpb</i> , 2015, 17, 529-535.	0.3	16

#	ARTICLE	IF	CITATIONS
3657	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. <i>Annals of Oncology</i> , 2015, 26, 1728-1733.	1.2	8
3658	2014 KLCSC-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2015, 9, 267-317.	2.9	167
3659	Preliminary results of CyberKnife stereotactic radiotherapy (SBRT) boost for primary head and neck cancers: is it the future direction?. <i>Journal of Radiotherapy in Practice</i> , 2015, 14, 187-193.	0.5	3
3660	A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 154-161.	2.3	27
3661	New <i>RAS</i> -Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e52-e56.	1.6	28
3662	Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. <i>Journal of Surgical Oncology</i> , 2015, 111, 840-847.	1.7	15
3663	Nutritional Risk Screening Predicts Tumor Response in Lung Cancer Patients. <i>Journal of the American College of Nutrition</i> , 2015, 34, 425-429.	1.8	20
3664	Measuring Tumor Metabolism by ¹⁸ F-FDG PET Predicts Outcome in a Multicenter Study: A Step Off in the Right Direction. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1-2.	5.0	12
3665	Translational value of mouse models in oncology drug development. <i>Nature Medicine</i> , 2015, 21, 431-439.	30.7	242
3666	Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology. <i>Cancer Research</i> , 2015, 75, 2416-2425.	0.9	9
3667	Safety of pembrolizumab for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 957-964.	2.4	27
3668	<i>PIK3CA</i> Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2530-2537.	7.0	48
3670	Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD). <i>Colorectal Cancer</i> , 2015, 4, 97-112.	0.8	0
3671	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015, 21, 560-562.	30.7	1,280
3672	Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. <i>Annals of Oncology</i> , 2015, 26, 179-185.	1.2	66
3673	PET in the management of locally advanced and metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 395-407.	27.6	75
3674	Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. <i>Acta Radiologica</i> , 2015, 56, 1437-1445.	1.1	6
3675	EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1609-1619.	1.6	148

#	ARTICLE	IF	CITATIONS
3676	Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. <i>Clinical Cancer Research</i> , 2015, 21, 3204-3215.	7.0	59
3677	Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 1851-1858.	7.0	72
3678	Stereotactic Radiosurgery for Facial Nerve Schwannomas. <i>Otology and Neurotology</i> , 2015, 36, 393-398.	1.3	22
3679	KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 33-40.	1.3	39
3680	Assessing the Multimodal Management of Advanced Solitary Fibrous Tumors of the Pleura in a Routine Practice Setting. <i>Journal of Thoracic Oncology</i> , 2015, 10, 309-315.	1.1	23
3681	Response criteria for malignant lymphoma. <i>Nuclear Medicine Communications</i> , 2015, 36, 398-405.	1.1	1
3682	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Measurements in Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2015, 50, 57-66.	6.2	29
3683	Dynamic Contrast-Enhanced Ultrasound Parametric Maps to Evaluate Intratumoral Vascularization. <i>Investigative Radiology</i> , 2015, 50, 212-217.	6.2	44
3684	Dynamic Volume Perfusion Computed Tomography Parameters versus RECIST for the Prediction of Outcome in Lung Cancer Patients Treated with Conventional Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 164-171.	1.1	19
3685	Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 307-313.	2.5	60
3686	Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 395-405.	10.7	205
3687	Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 131-153.	4.5	29
3688	Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 61-67.	1.3	36
3689	Nab-paclitaxel for the management of triple-negative metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 117-122.	1.4	8
3690	Functional Magnetic Resonance Imaging Response of Targeted Tumor Burden and Its Impact on Survival in Patients With Hepatocellular Carcinoma. <i>Investigative Radiology</i> , 2015, 50, 283-289.	6.2	16
3691	Multimodal Treatment With Doxorubicin, Cisplatin, and Ifosfamide for the Treatment of Advanced or Metastatic Uterine Leiomyosarcoma: A Unicentric Experience. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 296-302.	2.5	6
3692	Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?. <i>Clinical Nuclear Medicine</i> , 2015, 40, 123-127.	1.3	43
3693	Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1180-1185.	1.6	107

#	ARTICLE	IF	CITATIONS
3694	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	12.4	205
3695	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 848-857.	6.4	25
3696	Assessment of Bronchial and Pulmonary Blood Supply in Non-Small Cell Lung Cancer Subtypes Using Computed Tomography Perfusion. <i>Investigative Radiology</i> , 2015, 50, 179-186.	6.2	39
3697	Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 603-610.	1.1	64
3698	Metabolic Phenotype of Stage IV Lung Adenocarcinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e190-e195.	1.3	28
3699	Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer. <i>Investigative Radiology</i> , 2015, 50, 195-204.	6.2	126
3700	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 426-435.	10.7	272
3701	Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. <i>Gynecologic Oncology</i> , 2015, 137, 392-400.	1.4	14
3702	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015, 26, 1188-1194.	1.2	153
3703	Platelet VEGF and serum TGF- β 1 levels predict chemotherapy response in non-small cell lung cancer patients. <i>Tumor Biology</i> , 2015, 36, 6477-6483.	1.8	16
3704	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. <i>European Journal of Radiology</i> , 2015, 84, 1259-1268.	2.6	105
3705	Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 406-416.	10.7	191
3706	Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). <i>Insights Into Imaging</i> , 2015, 6, 141-155.	3.4	107
3707	Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2015, 45, 1089-1097.	6.7	26
3708	Combining Regulatory and Exploratory Trials. , 2015, , 239-242.		0
3709	Measuring Treatment Response to Systemic Therapy and Predicting Outcome in Biliary Tract Cancer: Comparing Tumor Size, Volume, Density, and Metabolism. <i>American Journal of Roentgenology</i> , 2015, 204, 776-781.	2.2	8
3710	A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4217-4223.	1.5	20
3711	Design, synthesis and initial characterisation of a radiolabelled [¹⁸ F]pyrimidoindolone probe for detecting activated caspase-3/7. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 5418-5423.	2.8	8

#	ARTICLE	IF	CITATIONS
3712	Electrochemotherapy in advanced skin tumors and cutaneous metastases – a retrospective multicenter analysis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 308-315.	0.8	27
3713	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. Future Oncology, 2015, 11, 107-119.	2.4	16
3714	Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of <scp>R</scp>esponse <scp>E</scp>valuation <scp>C</scp>riteria in <scp>S</scp>olid <scp>T</scp>umors and tumor markers. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 726-732.	2.8	18
3715	When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer. Annals of Surgical Oncology, 2015, 22, 944-951.	1.5	13
3716	Ovarian Cancer from Anatomy to Functional Imaging. Current Radiology Reports, 2015, 3, 1.	1.4	1
3717	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	27.0	7,973
3718	PET/Computed Tomography and Thermoablation (Radiofrequency, Microwave, Cryotherapy, Laser) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.0	5
3719	Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. European Journal of Radiology, 2015, 84, 1708-1714.	2.6	9
3720	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research, 2015, 21, 4327-4336.	7.0	187
3721	Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2). BMC Cancer, 2015, 15, 475.	2.6	11
3722	Rationale for combining immunotherapy with chemotherapy. Immunotherapy, 2015, 7, 309-316.	2.0	41
3723	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 2797-2802.	1.6	153
3724	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist, 2015, 20, 648-652.	3.7	38
3725	First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. Current Treatment Options in Oncology, 2015, 16, 52.	3.0	66
3726	BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. Oncoimmunology, 2015, 4, e1014246.	4.6	50
3727	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	27.0	1,004
3728	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813.	27.0	4,889
3729	Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. Annals of Oncology, 2015, 26, 1048-1057.	1.2	58

#	ARTICLE	IF	CITATIONS
3730	Phase III trial of chemoradiotherapy with Sâ€ plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). Cancer Science, 2015, 106, 726-733.	3.9	17
3731	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. Journal of Clinical Oncology, 2015, 33, 4048-4057.	1.6	6
3732	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment, 2015, 154, 287-297.	2.5	26
3733	Long-term outcomes of 131Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 2002-2012.	6.4	6
3734	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
3735	Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4417-4424.	3.6	79
3736	A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 1058-1067.	2.6	13
3737	Reduced Dose Intensity of Chemotherapy may not Lead to Inferior Palliation in Locally Advanced Carcinoma of the Gall Bladder: An Experience from a Regional Cancer Centre in Eastern India. Journal of Gastrointestinal Cancer, 2015, 46, 297-300.	1.3	8
3738	Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 350-358.	1.9	63
3739	Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. Annals of Surgical Oncology, 2015, 22, 952-958.	1.5	51
3740	Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. Annals of Surgical Oncology, 2015, 22, 442-450.	1.5	58
3741	Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. European Respiratory Journal, 2015, 46, 1773-1780.	6.7	114
3742	Proton beam therapy for metastatic liver tumors. Radiotherapy and Oncology, 2015, 117, 322-327.	0.6	30
3743	Automated method for detection and segmentation of liver metastatic lesions in follow-up CT examinations. Journal of Medical Imaging, 2015, 2, 034502.	1.5	12
3744	An overview of imaging techniques for liver metastases management. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1561-1576.	3.0	10
3745	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist, 2015, 20, 1261-1265.	3.7	42
3746	Medullary Thyroid Carcinoma: Imaging. Recent Results in Cancer Research, 2015, 204, 91-116.	1.8	16
3747	Treatment of isolated mediastinal and hilar recurrence of lung cancer with bronchoscopic endobronchial ultrasound guided intratumoral injection of chemotherapy with cisplatin. Lung Cancer, 2015, 90, 542-547.	2.0	35

#	ARTICLE	IF	CITATIONS
3748	Practical Approaches to Immunotherapy in the Clinic. <i>Seminars in Oncology</i> , 2015, 42, S20-S27.	2.2	10
3749	Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. <i>Journal of Neuro-Oncology</i> , 2015, 125, 411-418.	2.9	14
3750	Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. <i>BMC Cancer</i> , 2015, 15, 392.	2.6	61
3751	Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 835-844.	2.0	10
3752	Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 925-932.	2.3	40
3753	Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients. <i>Tumor Biology</i> , 2015, 36, 9031-9037.	1.8	13
3754	Percutaneous management of pulmonary metastases arising from colorectal cancer; a systematic review. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1447-1455.	1.0	42
3755	Medullary Thyroid Carcinoma. <i>Recent Results in Cancer Research</i> , 2015, , .	1.8	4
3756	Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, hvv149.	1.3	14
3757	Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)? <i>Cancer Investigation</i> , 2015, 33, 347-353.	1.3	1
3758	Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters. <i>Radiotherapy and Oncology</i> , 2015, 117, 223-228.	0.6	60
3759	A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1421-1426.	6.4	62
3760	Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. <i>BMC Cancer</i> , 2015, 15, 327.	2.6	13
3761	Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients. <i>BMC Cancer</i> , 2015, 15, 458.	2.6	19
3762	STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 496.	2.6	20
3763	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4569-4575.	7.0	12
3764	Tumor Response After Stereotactic Body Radiation Therapy to Nonspine Bone Metastases: An Evaluation of Response Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 879-881.	0.8	17
3765	The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 862-869.	0.8	110

#	ARTICLE	IF	CITATIONS
3766	Relationships between the Effect of Sunitinib and Immature Blood Vessels in Metastatic Renal Cell Cancer. <i>Urologia Internationalis</i> , 2015, 94, 137-143.	1.3	2
3767	Safety and Feasibility of Irreversible Electroporation (IRE) in Patients with Locally Advanced Pancreatic Cancer: Results of a Prospective Study. <i>Digestive Surgery</i> , 2015, 32, 90-97.	1.2	114
3768	First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 761-769.	2.3	21
3769	Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 432-439.	2.4	8
3770	COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 37-46.	0.8	75
3771	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	10.1	307
3772	A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 109-114.	1.8	22
3773	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 190-200.	3.4	73
3774	Impact of early tumor shrinkage on clinical outcome in wild-type <i>KRAS</i> colorectal liver metastases treated with cetuximab. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 674-679.	2.8	13
3775	Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First-Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2015, 29, 261-267.	1.6	52
3776	Early Tumor Response to Intraarterial or Intravenous Administration of Carboplatin to Treat Naturally Occurring Lower Urinary Tract Carcinoma in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2015, 29, 900-907.	1.6	17
3777	Detailed imaging and genetic analysis reveal a secondary <i>BRAF</i> ^{L505H} resistance mutation and extensive inpatient heterogeneity in metastatic <i>BRAF</i> mutant melanoma patients treated with vemurafenib. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 318-323.	3.3	20
3778	Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2015, 124, 507-514.	2.9	33
3779	Multimodal imaging of bone metastases: From preclinical to clinical applications. <i>Journal of Orthopaedic Translation</i> , 2015, 3, 166-177.	3.9	15
3780	Detection of <i>KRAS</i> mutations in circulating tumor cells from patients with metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1289-1295.	3.4	49
3781	Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75 years with impaired performance status. <i>Journal of Geriatric Oncology</i> , 2015, 6, 380-386.	1.0	7
3782	Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹ In-Pentetreotide Quantitative SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 985-988.	5.0	7
3783	A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 757-764.	0.8	317

#	ARTICLE	IF	CITATIONS
3784	Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer. <i>BMC Cancer</i> , 2015, 15, 493.	2.6	20
3785	Tivantinib for hepatocellular carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 343-351.	0.8	0
3786	Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. <i>British Journal of Cancer</i> , 2015, 113, 1298-1304.	6.4	15
3787	A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. <i>Annals of Oncology</i> , 2015, 26, 2280-2286.	1.2	28
3788	Quantitative imaging as cancer biomarker. , 2015, , .		0
3789	A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 615-620.	2.3	8
3790	Pharmacologic Management of Advanced Cervical Cancer: Antiangiogenesis Therapy and Immunotherapeutic Considerations. <i>Drugs</i> , 2015, 75, 1853-1865.	10.9	11
3791	RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy. <i>American Journal of Roentgenology</i> , 2015, 204, W282-W288.	2.2	21
3792	A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2569-2575.	4.1	98
3793	Grundlagen der gastrointestinalen Tumorerkrankungen. , 2015, , 397-459.		0
3794	Response evaluation in mesothelioma: Beyond RECIST. <i>Lung Cancer</i> , 2015, 90, 433-441.	2.0	25
3795	A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. <i>British Journal of Cancer</i> , 2015, 113, 1140-1147.	6.4	30
3796	A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer. <i>BMC Research Notes</i> , 2015, 8, 220.	1.4	6
3797	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	2.4	12
3798	Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Urology</i> , 2015, 194, 990-990.	0.4	2
3799	The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2015, 20, 1253-1260.	3.7	40
3800	Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1674-1681.	6.4	48
3801	Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 375-382.	2.3	32

#	ARTICLE	IF	CITATIONS
3802	99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2083-2097.	6.4	37
3803	Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 441-446.	1.9	7
3804	Dual-energy snap-shot perfusion CT in suspect pulmonary nodules and masses and for lung cancer staging. <i>European Journal of Radiology</i> , 2015, 84, 2393-2400.	2.6	27
3805	Patient-centric trials for therapeutic development in precision oncology. <i>Nature</i> , 2015, 526, 361-370.	27.8	251
3807	Update and current status of diffusion-weighted MRI in anorectal malignancy. <i>Colorectal Cancer</i> , 2015, 4, 141-152.	0.8	0
3808	Dose-Finding Quantitative ¹⁸ F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1828-1835.	5.0	24
3809	Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer. <i>Journal of International Medical Research</i> , 2015, 43, 727-737.	1.0	4
3810	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	2.6	58
3811	Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 1212-1220.	1.5	77
3812	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015, 90, 255-260.	2.0	43
3813	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. <i>Bioconjugate Chemistry</i> , 2015, 26, 2062-2069.	3.6	139
3814	Automating the generation of lexical patterns for processing free text in clinical documents. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 980-986.	4.4	8
3815	Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 89-97.	2.5	22
3816	Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer. <i>Medical Oncology</i> , 2015, 32, 235.	2.5	9
3817	Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. <i>Annals of Oncology</i> , 2015, 26, 1465-1470.	1.2	15
3819	Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 267-272.	3.8	7
3820	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	1.9	9
3821	Imatinib in advanced chordoma: A retrospective case series analysis. <i>European Journal of Cancer</i> , 2015, 51, 2609-2614.	2.8	78

#	ARTICLE	IF	CITATIONS
3822	Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 279-285.	2.3	4
3823	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	27.0	1,483
3824	Nuclear Medicine Imaging of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , 2015, 44, 73-87.	1.0	13
3825	Assessing Imaging Response to Therapy. <i>Radiologic Clinics of North America</i> , 2015, 53, 1077-1088.	1.8	17
3826	Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. <i>PET Clinics</i> , 2015, 10, 461-476.	3.0	21
3827	Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. <i>Translational Oncology</i> , 2015, 8, 126-135.	3.7	14
3828	Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2609-2616.	1.6	31
3829	Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. <i>Medical Hypotheses</i> , 2015, 85, 480-484.	1.5	29
3830	Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1554-1561.	5.0	152
3831	Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 1078-1085.	2.6	2
3832	Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis. <i>American Journal of Roentgenology</i> , 2015, 205, W283-W293.	2.2	51
3833	Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas. <i>Oncology</i> , 2015, 89, 294-303.	1.9	29
3834	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. <i>Journal of Clinical Oncology</i> , 2015, 33, 4039-4047.	1.6	230
3835	The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. <i>British Journal of Radiology</i> , 2015, 88, 20150111.	2.2	15
3836	Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer ¹⁸ F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1415-1421.	5.0	47
3837	Differentiation of lipid-poor adrenal adenomas from non-adenomas with magnetic resonance imaging: Utility of dynamic, contrast enhancement and single-shot T2-weighted sequences. <i>European Journal of Radiology</i> , 2015, 84, 2045-2051.	2.6	17
3838	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	12.6	2,275
3839	Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 244-249.	1.9	10

#	ARTICLE	IF	CITATIONS
3841	A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 382-390.	0.8	5
3842	<i>EGFR</i> Kinase Domain Duplication (<i>EGFR</i> -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery, 2015, 5, 1155-1163.	9.4	94
3843	Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins. Langenbeck's Archives of Surgery, 2015, 400, 683-691.	1.9	7
3844	MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy. European Journal of Radiology, 2015, 84, 2438-2443.	2.6	32
3845	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung Cancer, 2015, 90, 261-266.	2.0	4
3846	Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes. Journal of Gastrointestinal Surgery, 2015, 19, 1653-1661.	1.7	29
3847	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 1324-1334.	10.7	897
3848	The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. European Journal of Surgical Oncology, 2015, 41, 859-867.	1.0	67
3849	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Letters, 2015, 369, 97-102.	7.2	82
3850	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Annals of Oncology, 2015, 26, 1470-1475.	1.2	46
3851	Whole body MRI, including diffusion-weighted imaging in follow-up of patients with testicular cancer. Acta Oncologica, 2015, 54, 1763-1769.	1.8	22
3852	Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. Methods in Molecular Biology, 2015, 1317, 365-382.	0.9	32
3853	Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunology, Immunotherapy, 2015, 64, 977-987.	4.2	44
3854	Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clinical and Experimental Metastasis, 2015, 32, 729-737.	3.3	103
3855	Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients. Cellular Oncology (Dordrecht), 2015, 38, 387-395.	4.4	14
3856	Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study. Medical Oncology, 2015, 32, 227.	2.5	11
3857	Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. European Journal of Cancer, 2015, 51, 2800-2807.	2.8	58
3858	Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncology, The, 2015, 16, e595-e603.	10.7	170

#	ARTICLE	IF	CITATIONS
3859	Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, , .	0.8	0
3860	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. <i>British Journal of Cancer</i> , 2015, 113, 1565-1570.	6.4	83
3861	Diffusion-weighted MRI Before and After Robotic Radiosurgery (Cyberknife®) in Primary and Secondary Liver Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 191-199.	1.9	9
3862	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	1.9	10
3863	Classification and Reporting of Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Proposing a New System. <i>Clinical Lung Cancer</i> , 2015, 16, e245-e251.	2.6	6
3864	The power of phase II end-points for different possible mechanisms of action of an experimental treatment. <i>European Journal of Cancer</i> , 2015, 51, 984-992.	2.8	4
3865	Improved inter-observer agreement of an expert review panel in an oncology treatment trial “ Insights from a structured interventional process. <i>European Journal of Cancer</i> , 2015, 51, 2525-2533.	2.8	24
3866	Dynamic contrast enhanced ultrasound for therapy monitoring. <i>European Journal of Radiology</i> , 2015, 84, 1650-1657.	2.6	65
3867	Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1630-1638.	0.5	9
3868	Management of High Hepatopulmonary Shunting in Patients Undergoing Hepatic Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1751-1760.	0.5	24
3869	Determining the Variability of Lesion Size Measurements from CT Patient Data Sets Acquired under “No Change” Conditions. <i>Translational Oncology</i> , 2015, 8, 55-64.	3.7	26
3870	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. <i>Annals of Oncology</i> , 2015, 26, 2341-2346.	1.2	30
3871	Evaluation of Accuracy and Precision of Manual Size Measurements in Chest Tomosynthesis using Simulated Pulmonary Nodules. <i>Academic Radiology</i> , 2015, 22, 496-504.	2.5	14
3872	Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e285-e295.	1.9	21
3873	Irreversible Electroporation of Hepatic and Pancreatic Malignancies: Radiologic-Pathologic Correlation. <i>Techniques in Vascular and Interventional Radiology</i> , 2015, 18, 176-182.	1.0	14
3874	Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 563-571.	2.5	124
3875	Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 591-608.	2.5	37
3876	RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. <i>Lung Cancer</i> , 2015, 90, 477-483.	2.0	43

#	ARTICLE	IF	CITATIONS
3877	Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1285-1295.	2.3	17
3878	Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial â€” the PRODIGE 22 - ECKINOXE trial. <i>BMC Cancer</i> , 2015, 15, 511.	2.6	43
3879	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	2.6	27
3880	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1086-1092.	2.6	33
3881	A retrospective analysis of lung metastasis in 64 patients with alveolar soft part sarcoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 803-809.	2.4	11
3882	Response assessment to neoadjuvant therapy in soft tissue sarcomas: using CT texture analysis in comparison to tumor size, density, and perfusion. <i>Abdominal Imaging</i> , 2015, 40, 1705-1712.	2.0	41
3883	A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. <i>Pediatric Blood and Cancer</i> , 2015, 62, 158-159.	1.5	6
3884	Circulating endothelial progenitor cell: a promising biomarker in clinical oncology. <i>Medical Oncology</i> , 2015, 32, 332.	2.5	19
3885	Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 264-271.	2.0	11
3886	Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study. <i>Annals of Oncology</i> , 2015, 26, 598-607.	1.2	48
3887	Can we improve the morbidity and mortality associated with the associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) procedure in the management of colorectal liver metastases?. <i>Surgery</i> , 2015, 157, 194-201.	1.9	136
3888	A phase <sc>I</sc> study of <sc>TRC</sc>105 antiâ€œendoglin (<sc>CD</sc>105) antibody in metastatic castrationâ€resistant prostate cancer. <i>BJU International</i> , 2015, 116, 546-555.	2.5	55
3889	Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 46-50.	2.6	26
3890	Retrospective cohort study of portacaval lymphadenopathy identified on multidetector CT and implications for follow-up. <i>Abdominal Imaging</i> , 2015, 40, 1481-1486.	2.0	0
3891	Monitoring gastric cancer progression with circulating tumour DNA. <i>British Journal of Cancer</i> , 2015, 112, 352-356.	6.4	90
3892	Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment. <i>Clinical Lung Cancer</i> , 2015, 16, 60-66.	2.6	13
3893	Interdisciplinary counseling service for renal malignancies: A patient-centered approach to raise guideline adherence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e1-23.e7.	1.6	11
3894	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	3.7	50

#	ARTICLE	IF	CITATIONS
3895	PI3K ² -Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in <i>BRAF</i> -Mutated Melanoma. <i>Cancer Discovery</i> , 2015, 5, 143-153.	9.4	51
3896	Clinical trials of interventional oncologyâ€”moving from efficacy to outcomes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 93-104.	27.6	18
3897	Immunotherapy in prostate cancer: review of the current evidence. <i>Clinical and Translational Oncology</i> , 2015, 17, 339-357.	2.4	25
3898	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
3899	Methods and Challenges in Quantitative Imaging Biomarker Development. <i>Academic Radiology</i> , 2015, 22, 25-32.	2.5	80
3900	Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 11-23.	2.4	8
3901	Translation in solid cancer: are size-based response criteria an anachronism?. <i>Clinical and Translational Oncology</i> , 2015, 17, 1-10.	2.4	12
3902	Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. <i>Translational Research</i> , 2015, 165, 558-577.	5.0	40
3903	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	27.0	2,240
3904	A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy. <i>Frontiers of Medicine</i> , 2015, 9, 112-116.	3.4	15
3905	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippelâ€”Lindau (VHL) disease: clinical outcome and patterns of radiological response. <i>Familial Cancer</i> , 2015, 14, 309-316.	1.9	21
3906	Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 36-42.	13.7	441
3907	Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series. <i>Head and Neck</i> , 2015, 37, 1403-1409.	2.0	44
3908	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	1.9	35
3909	An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. <i>Targeted Oncology</i> , 2015, 10, 55-63.	3.6	17
3910	Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. <i>Acta Radiologica</i> , 2015, 56, 70-77.	1.1	17
3911	Evaluation of serum HER2-ECD levels in patients with gastric cancer. <i>Journal of Gastroenterology</i> , 2015, 50, 41-45.	5.1	29
3912	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.	1.9	32

#	ARTICLE	IF	CITATIONS
3913	Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 71-79.	1.9	10
3914	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 124-129.	1.9	14
3915	Neoadjuvant Taxane-Based Combination Chemotherapy in Patients With Advanced Penile Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 44-49.	1.9	50
3916	Monitoring treatment response in patients undergoing chemoradiotherapy for locally advanced uterine cervical cancer by additional diffusion-weighted imaging: A systematic review. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 572-594.	3.4	56
3917	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e19-e26.	1.9	18
3918	Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 119-127.	2.6	13
3920	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. <i>Clinical Chemistry</i> , 2015, 61, 297-304.	3.2	221
3921	Armed antibodies for cancer treatment: a promising tool in a changing era. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 113-121.	4.2	28
3922	Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials. <i>Cancer</i> , 2015, 121, 1737-1746.	4.1	59
3923	Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2015, 5, 72-81.	9.4	168
3924	Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E77-E81.	3.6	109
3925	Contrast-enhanced magnetic resonance imaging of pulmonary lesions: Description of a technique aiming clinical practice. <i>European Journal of Radiology</i> , 2015, 84, 185-192.	2.6	12
3926	Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?. <i>Cancer</i> , 2015, 121, 1728-1730.	4.1	0
3927	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	1.9	27
3928	Bone Marrow MRI. , 2015, , .		16
3929	Prognostic value of biomarkers in metastatic colorectal cancer patients. <i>Journal of Surgical Research</i> , 2015, 194, 343-350.	1.6	5
3930	Role of ^{3&Dil} conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 607-617.	3.4	40
3931	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , 2015, 68, 317-324.	1.9	96

#	ARTICLE	IF	CITATIONS
3932	Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib failure. Targeted Oncology, 2015, 10, 135-140.	3.6	29
3933	Preoperative chemoradiotherapy with docetaxel, doxorubicin, and low-dose cisplatin for stage II/III squamous cell carcinoma of the esophagus. Esophagus, 2015, 12, 191-198.	1.9	0
3934	Diffuse intrinsic pontine glioma: is MRI surveillance improved by region of interest volumetry?. Pediatric Radiology, 2015, 45, 203-210.	2.0	6
3935	Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. British Journal of Clinical Pharmacology, 2015, 79, 56-71.	2.4	82
3936	RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 834-842.	1.5	90
3937	Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 843-849.	2.3	38
3938	Correlation Between E-cadherin Immunoreactivity and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer. Pathology and Oncology Research, 2015, 21, 347-356.	1.9	12
3939	Assessment of Treatment Response Using PET. PET Clinics, 2015, 10, 9-26.	3.0	17
3940	Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clinical Radiology, 2015, 70, 81-95.	1.1	57
3941	Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?. Scientific Reports, 2014, 4, 5996.	3.3	9
3942	Carlumab, an anti-CCL2 chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Targeted Oncology, 2015, 10, 111-123.	3.6	158
3943	Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Targeted Oncology, 2015, 10, 125-133.	3.6	18
3944	Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 543-553.	2.5	145
3945	Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. Pathology and Oncology Research, 2015, 21, 423-431.	1.9	2
3946	Irinotecan and Temozolamide Treatment for Relapsed Ewing Sarcoma: A Single-Center Experience and Review of the Literature. Pediatric Hematology and Oncology, 2015, 32, 50-59.	0.8	30
3947	Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. World Journal of Urology, 2015, 33, 111-118.	2.2	13
3948	External validation of existing nomograms predicting lymph node metastases in cystectomized patients. International Journal of Clinical Oncology, 2015, 20, 164-170.	2.2	4
3949	Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: a phase I dose-finding study. Veterinary and Comparative Oncology, 2016, 14, 202-209.	1.8	29

#	ARTICLE	IF	CITATIONS
3950	COX-2 expression correlation with invasion in human breast carcinomas and in cell line MDA-MB-231 in vitro. Bangladesh Journal of Pharmacology, 0, 11, S43-S54.	0.4	1
3951	Role of Neck Dissection in Locoregionally Advanced Head and Neck Cancer Treated with Primary Chemoradiotherapy. Otolaryngology (Sunnyvale, Calif), 2016, 06, .	0.0	0
3952	Assessing the Early Response of Advanced Cervical Cancer to Neoadjuvant Chemotherapy Using Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging. Chinese Medical Journal, 2016, 129, 665-671.	2.3	22
3953	A Single-institution Experience with Open Irreversible Electroporation for Locally Advanced Pancreatic Carcinoma. Chinese Medical Journal, 2016, 129, 2920-2925.	2.3	46
3954	Lactate Dehydrogenase-5 (Ldh-5) Immunohistochemical Expression as Predictor of Efficacy of First-Line Therapy in Patients with Advanced Colorectal Cancer Treated with Chemotherapy and Bevacizumab. , 2016, 06, .		0
3955	Sipuleucel-T for metastatic castration-resistant prostate cancer. The Cochrane Library, 0, , .	2.8	0
3956	Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy. Molecular and Clinical Oncology, 2016, 4, 303-309.	1.0	14
3957	Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome. Molecular and Clinical Oncology, 2016, 4, 655-659.	1.0	8
3958	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	1.8	6
3959	Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer. Lung Cancer: Targets and Therapy, 2016, 7, 35.	2.7	12
3960	BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2016, 29, 173-179.	0.5	7
3961	The effects of miR-1207-5p expression in peripheral blood on cisplatin-based chemosensitivity of primary gallbladder carcinoma. OncoTargets and Therapy, 2016, 9, 3633.	2.0	6
3962	Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis. Oncotarget, 2016, 7, 55741-55756.	1.8	14
3963	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget, 2016, 7, 10547-10556.	1.8	52
3964	New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. Therapeutics and Clinical Risk Management, 2016, 12, 735.	2.0	13
3965	Association Between HIF-1 Alpha Gene Polymorphisms and Response in Patients Undergoing Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer. Medical Science Monitor, 2016, 22, 3140-3146.	1.1	5
3966	Dual oxidase 1: A predictive tool for the prognosis of hepatocellular carcinoma patients. Oncology Reports, 2016, 35, 3198-3208.	2.6	19
3967	Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma1. Bladder Cancer, 2016, 2, 395-403.	0.4	13

#	ARTICLE	IF	CITATIONS
3968	Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3443.	2.0	13
3969	Bilateral breast adenocarcinomas with EML4—ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?. <i>OncoTargets and Therapy</i> , 2016, 9, 3589.	2.0	3
3970	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4681-4686.	2.0	9
3971	A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4879-4886.	2.0	27
3972	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 929.	2.0	13
3973	Challenges in translating end points from trials to observational cohort studies in oncology. <i>Clinical Epidemiology</i> , 2016, 8, 195.	3.0	12
3974	Comparison of cisplatin/paclitaxel with cisplatin/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2129-2136.	4.3	9
3975	Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1520.	4.1	8
3976	The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4089-4098.	2.0	10
3977	Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study. <i>Current Oncology</i> , 2016, 23, 589-597.	2.2	18
3978	Circulating tumor cells predict survival benefit from chemotherapy in patients with lung cancer. <i>Oncotarget</i> , 2016, 7, 67586-67596.	1.8	16
3979	Early responses of <i>EGFR</i> circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment. <i>Oncotarget</i> , 2016, 7, 71782-71789.	1.8	16
3980	The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6479-6484.	2.0	3
3981	Association of PTP1B with Outcomes of Breast Cancer Patients who Underwent Neoadjuvant Chemotherapy. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S40934.	1.1	4
3982	Natural Killer Cell Lymphoma: A Case with Classification Dilemma. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, ED07-8.	0.8	2
3983	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7275-7283.	2.0	49
3984	Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. <i>Nuclear Medicine Communications</i> , 2016, 37, 9-15.	1.1	47
3985	Mutations of <i>KRAS/NRAS/BRAF</i> predict cetuximab resistance in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2016, 7, 22257-22270.	1.8	109

#	ARTICLE	IF	CITATIONS
3986	Imaging in interventional oncology: Role of image guidance. , 0, , 65-76.		0
3987	Osteoblastic Changes During Non-Small Cell Lung Cancer (NSCLC) Treatment: How to Distinguish between Objective Response and Progressive Disease. Journal of Nuclear Medicine & Radiation Therapy, 2016, 7, .	0.2	0
3988	Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma. OncoTargets and Therapy, 2016, 9, 2855.	2.0	2
3989	Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. OncoTargets and Therapy, 2016, Volume 9, 3985-3992.	2.0	19
3990	Pragmatic medicine in solid cancer: a translational alternative to precision medicine. OncoTargets and Therapy, 2016, 9, 1839.	2.0	6
3991	Clinical observation of gene expression-guided chemoradiation therapy for nonsurgical esophageal squamous cell carcinoma patients: a retrospective analysis of 36 cases. OncoTargets and Therapy, 2016, Volume 9, 4561-4568.	2.0	0
3992	Risk factors and patterns of lymph node involvement in primary gastric large B-cell lymphoma: implications for target definition. OncoTargets and Therapy, 2016, Volume 9, 4757-4762.	2.0	2
3993	A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. OncoTargets and Therapy, 2016, Volume 9, 7527-7535.	2.0	15
3994	Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience. OncoTargets and Therapy, 2016, Volume 9, 6305-6314.	2.0	8
3995	Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. OncoTargets and Therapy, 2016, Volume 9, 7503-7513.	2.0	31
3996	Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. OncoTargets and Therapy, 2016, 9, 2911.	2.0	18
3997	Bladder Cancer Segmentation in CT for Treatment Response Assessment: Application of Deep-Learning Convolution Neural Network”A Pilot Study. Tomography, 2016, 2, 421-429.	1.8	64
3998	New targeted treatments for non-small-cell lung cancer – role of nivolumab. Biologics: Targets and Therapy, 2016, Volume 10, 103-117.	3.2	23
3999	Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation. Molecular and Clinical Oncology, 2016, 5, 265-268.	1.0	12
4000	Selective use of sorafenib in the treatment of thyroid cancer. Drug Design, Development and Therapy, 2016, 10, 1119.	4.3	54
4001	Sequential measurements of serum matrix metalloproteinase 9 to monitor chemotherapy responses in patients with advanced non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 3299.	2.0	4
4002	Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1. OncoTargets and Therapy, 2016, Volume 9, 5287-5295.	2.0	2
4003	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. OncoTargets and Therapy, 2016, 9, 3671.	2.0	3

#	ARTICLE	IF	CITATIONS
4004	Clinical efficacy of photodynamic therapy. <i>Obstetrics and Gynecology Science</i> , 2016, 59, 479.	1.6	37
4005	Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5123-5131.	2.0	4
4006	Effects of CYP3A5 genetic polymorphism and smoking on the prognosis of non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 1461.	2.0	7
4007	Impact of Systemic Therapy and Recurrence Pattern on Survival Outcome after Radiofrequency Ablation for Colorectal Liver Metastases. <i>Journal of Cancer</i> , 2016, 7, 1939-1949.	2.5	7
4008	Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis. <i>Case Reports in Gastroenterology</i> , 2016, 10, 17-23.	0.6	6
4009	PET/CT with Fluorodeoxyglucose During Neoadjuvant. <i>Ecancermedicalscience</i> , 2016, 10, 629.	1.1	7
4010	CT-guided 125I seed implantation for inoperable retroperitoneal sarcoma: A technique for delivery of local tumor brachytherapy. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 3843-3850.	1.8	12
4011	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e247-e257.	3.8	9
4012	Survival analyses in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3457-3463.	1.4	5
4013	Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women. <i>Journal of Thoracic Disease</i> , 2016, 8, 2519-2529.	1.4	6
4014	Reproducibility: Principles, Problems, Practices, and Prospects. , 2016, , .		57
4015	Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT. <i>Journal of Thoracic Disease</i> , 2016, 8, 862-871.	1.4	12
4016	Diagnosis and treatment pattern among rural and urban breast cancer patients in Southwest China from 2005 to 2009. <i>Oncotarget</i> , 2016, 7, 78168-78179.	1.8	15
4017	Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. <i>Oncotarget</i> , 2016, 7, 27848-27854.	1.8	50
4018	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4345-4353.	1.6	68
4019	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e558-e564.	3.8	8
4020	BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 556-561.	1.4	20
4021	Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 1019-1029.	1.4	11

#	ARTICLE	IF	CITATIONS
4022	Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. Journal of Thoracic Disease, 2016, 8, 2530-2537.	1.4	21
4023	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Journal of Thoracic Disease, 2016, 8, 3175-3186.	1.4	4
4024	Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy. Oncotarget, 2016, 7, 19762-19780.	1.8	11
4025	Is early response by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 365-372.	1.4	2
4026	Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases. Translational Lung Cancer Research, 2016, 5, 637-646.	2.8	6
4027	Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget, 2016, 7, 58007-58021.	1.8	63
4028	Rate of elimination of radioiodineavid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. Nuklearmedizin - NuclearMedicine, 2016, 55, 221-227.	0.7	4
4029	Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Hepatitis Monthly, 2016, 16, e37584.	0.2	9
4030	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. Translational and Clinical Pharmacology, 2016, 24, 7.	0.9	3
4031	Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer. Yonsei Medical Journal, 2016, 57, 1070.	2.2	9
4032	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget, 2016, 7, 66020-66031.	1.8	75
4033	Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget, 2016, 7, 77404-77415.	1.8	139
4034	Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncology Letters, 2016, 12, 3127-3134.	1.8	2
4035	Imaging and Adenoviral Gene Therapy. , 2016, , 767-802.		2
4036	Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy. Disease Markers, 2016, 2016, 1-9.	1.3	16
4037	Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid Colon Cancer following 156 Courses of FOLFIRI Regimen. Case Reports in Surgery, 2016, 2016, 1-5.	0.4	4
4038	Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. BioMed Research International, 2016, 2016, 1-9.	1.9	6
4039	CT-Guided ¹²⁵ I Seed Interstitial Brachytherapy as a Salvage Treatment for Recurrent Spinal Metastases after External Beam Radiotherapy. BioMed Research International, 2016, 2016, 1-10.	1.9	21

#	ARTICLE	IF	CITATIONS
4040	Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterology Research and Practice, 2016, 2016, 1-13.	1.5	27
4041	Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation. International Journal of Molecular Imaging, 2016, 2016, 1-12.	1.3	18
4042	Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. Canadian Respiratory Journal, 2016, 2016, 1-8.	1.6	12
4043	Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients. BioMed Research International, 2016, 2016, 1-6.	1.9	12
4044	Addition and Subtraction Theory of TCM Using Xiao-Chaihu-Decoction and Naturopathy in Predicting Survival Outcomes of Primary Liver Cancer Patients: A Prospective Cohort Study. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-9.	1.2	5
4045	Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes. OncoTargets and Therapy, 2016, 9, 1735.	2.0	13
4046	New utility of an old marker: serum low-density lipoprotein predicts histopathological response of neoadjuvant chemotherapy in locally advanced gastric cancer. OncoTargets and Therapy, 2016, Volume 9, 5041-5047.	2.0	5
4047	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 2016, 8, 81.	3.7	61
4048	Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis. Oncology Letters, 2016, 12, 1293-1300.	1.8	19
4049	2 Response assessmentsNeuro-oncologic response assessmentsResponse Assessment in Neuro-oncology. , 2016, , .		0
4050	[¹⁷⁷ Lu-DOTA] ⁰ -D-Phe ¹ -Tyr ³ -Octreotide (¹⁷⁷ Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics, 2016, 6, 501-510.	10.0	86
4051	EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP) Tj ETQq1 1,0,784314 rgBT /Ove	1.9	15
4052	Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. OncoTargets and Therapy, 2016, Volume 9, 5671-5678.	2.0	20
4053	Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma. Current Oncology, 2016, 23, 472-480.	2.2	13
4054	Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration. Radiation Oncology Journal, 2016, 34, 209-215.	1.5	10
4055	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. Korean Journal of Internal Medicine, 2016, 31, 570-578.	1.7	38
4056	Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Frontiers in Immunology, 2016, 7, 345.	4.8	59
4057	Quantitative Evaluation of Therapeutic Response by FDG-PETâ€“CT in Metastatic Breast Cancer. Frontiers in Medicine, 2016, 3, 19.	2.6	9

#	ARTICLE	IF	CITATIONS
4058	Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. <i>Frontiers in Oncology</i> , 2016, 6, 44.	2.8	49
4059	Potential Clinical Roles for Metabolic Imaging with Hyperpolarized [1-13C]Pyruvate. <i>Frontiers in Oncology</i> , 2016, 6, 59.	2.8	49
4060	BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery. <i>Frontiers in Oncology</i> , 2016, 6, 107.	2.8	15
4061	Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. <i>Frontiers in Oncology</i> , 2016, 6, 152.	2.8	24
4062	The Necrosis-Avid Small Molecule HQ4-DTPA as a Multimodal Imaging Agent for Monitoring Radiation Therapy-Induced Tumor Cell Death. <i>Frontiers in Oncology</i> , 2016, 6, 221.	2.8	11
4063	Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. <i>Frontiers in Oncology</i> , 2016, 6, 252.	2.8	5
4064	Neoplastic diseases in avian species. , 2016, , 107-141.		18
4065	Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT. <i>Diagnostics</i> , 2016, 6, 28.	2.6	6
4066	Bone Density as a Marker of Response to Radiotherapy in Bone Metastatic Lesions: A Review of the Published Data. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1391.	4.1	7
4067	EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2132.	4.1	48
4068	Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases. <i>Medical Sciences (Basel, Switzerland)</i> , 2016, 4, 8.	2.9	7
4069	A Novel Optical Bioimaging Method for Direct Assessment of Ovarian Cancer Chemotherapy Response at Laparoscopy. <i>Cancer Informatics</i> , 2016, 15, CIN.S40660.	1.9	3
4070	Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab [®] -Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma. <i>BMC Cancer</i> , 2016, 16, 464.	2.6	12
4071	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 338.	2.6	12
4072	Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. <i>BMC Cancer</i> , 2016, 16, 638.	2.6	47
4073	Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST. <i>BMC Cancer</i> , 2016, 16, 672.	2.6	14
4074	Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. <i>PLoS ONE</i> , 2016, 11, e0151832.	2.5	64
4075	Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition. <i>PLoS ONE</i> , 2016, 11, e0149955.	2.5	11

#	ARTICLE	IF	CITATIONS
4076	Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors. PLoS ONE, 2016, 11, e0154679.	2.5	12
4077	Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status. PLoS ONE, 2016, 11, e0158307.	2.5	16
4078	A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS ONE, 2016, 11, e0164244.	2.5	43
4079	The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation. PLoS ONE, 2016, 11, e0167720.	2.5	9
4080	A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. International Journal of Biological Sciences, 2016, 12, 1022-1031.	6.4	158
4081	Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. OncoTargets and Therapy, 2016, 9, 1579.	2.0	22
4082	Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". Frontiers in Pharmacology, 2016, 7, 287.	3.5	10
4083	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. Frontiers in Pharmacology, 2016, 7, 331.	3.5	13
4084	Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Molecular and Clinical Oncology, 2016, 5, 458-462.	1.0	23
4085	FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma. OncoTargets and Therapy, 2016, Volume 9, 6857-6863.	2.0	6
4086	Total Lesion Glycolysis Using ¹⁸ F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer. Journal of Korean Medical Science, 2016, 31, 39.	2.5	35
4087	ROI for outlining an entire tumor is a reliable approach for quantification of lung cancer tumor vascular parameters using CT perfusion. OncoTargets and Therapy, 2016, 9, 2377.	2.0	9
4088	Linee guida Carcinoma della Prostata - AIRO, 2016. Tumori, 2016, 102, S1-S79.	1.1	4
4089	Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis. OncoTargets and Therapy, 2016, 9, 1135.	2.0	17
4090	Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population. Genetics and Molecular Research, 2016, 15, .	0.2	6
4091	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. OncoTargets and Therapy, 2016, 9, 1571.	2.0	7
4092	Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 5761-5770.	2.0	30
4094	Adjudication Rates between Readers in Blinded Independent Central Review of Oncology Studies. Journal of Clinical Trials, 2016, 06, .	0.1	7

#	ARTICLE	IF	CITATIONS
4095	TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer. <i>Oncotarget</i> , 2016, 7, 29620-29634.	1.8	32
4096	Circulating tumor cells as an early predictive marker of disease progression in metastatic breast cancer patients. <i>Annals of Oncology</i> , 2016, 27, vi71.	1.2	1
4097	Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer. <i>Medicine (United States)</i> , 2016, 95, e2598.	1.0	14
4098	Pretreatment Intra-Voxel Incoherent Motion Diffusion-Weighted Imaging (IVIM-DWI) in Predicting Induction Chemotherapy Response in Locally Advanced Hypopharyngeal Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e3698.	1.0	18
4099	Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients. <i>Medicine (United States)</i> , 2016, 95, e3698.	1.0	18
4100	C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 110-116.	1.1	37
4101	Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline. <i>Anti-Cancer Drugs</i> , 2016, 27, 264-267.	1.4	9
4102	High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer: A Phase 2 Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 640-647.	2.5	3
4103	Oncologic Outcomes of Stage IVB or Persistent or Recurrent Cervical Carcinoma Patients Treated With Chemotherapy at Siriraj Hospital: Thailand's Largest Tertiary Referral Center. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1154-1161.	2.5	4
4104	MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 625-633.	3.1	78
4105	Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes. <i>Oncology Letters</i> , 2016, 12, 663-669.	1.8	4
4106	Outcomes Following Hypofractionated Stereotactic Radiotherapy in the Management of Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 379-383.	1.3	12
4107	Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2015). <i>Journal of Veterinary Internal Medicine</i> , 2016, 50, 115-121.	1.2	14
4108	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 281-288.	2.3	51
4109	Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 116-125.	1.5	11
4110	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031.	4.1	72
4111	Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group. <i>Journal of Surgical Oncology</i> , 2016, 114, 495-500.	1.7	22
4112	Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1012-1019.	2.5	6

#	ARTICLE	IF	CITATIONS
4113	Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases. <i>Medicine (United States)</i> , 2016, 95, e3722.	1.0	18
4114	Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. <i>Pancreas</i> , 2016, 45, 761-771.	1.1	28
4115	Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare. <i>BJU International</i> , 2016, 118, 880-884.	2.5	10
4116	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	2.0	31
4117	Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives. <i>Future Oncology</i> , 2016, 12, 2603-2613.	2.4	13
4118	Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma. <i>British Journal of Surgery</i> , 2016, 103, 1200-1208.	0.3	21
4119	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	3.4	20
4120	Usefulness of Pseudocontinuous Arterial Spin-Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period. <i>American Journal of Neuroradiology</i> , 2016, 37, 342-348.	2.4	29
4121	Temporal variations in stump pressure and assessment of images obtained from cone-beam computed tomography during balloon-occluded transarterial chemoembolization. <i>Hepatology Research</i> , 2016, 46, 468-476.	3.4	8
4122	Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. <i>Hepatology Research</i> , 2016, 46, 1088-1098.	3.4	35
4123	Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 189-195.	1.3	53
4124	Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers. <i>Clinical Nuclear Medicine</i> , 2016, 41, e44-e50.	1.3	30
4125	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 596-603.	2.6	43
4126	Prognostic impact of pathological response to neoadjuvant chemotherapy followed by definitive surgery in sinonasal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1305-11.	2.0	30
4127	Comparison of intravoxel incoherent motion diffusion-weighted MR imaging with dynamic contrast-enhanced MRI for differentiating lung cancer from benign solitary pulmonary lesions. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 669-679.	3.4	53
4128	Intravoxel incoherent motion MRI for predicting early response to induction chemotherapy and chemoradiotherapy in patients with nasopharyngeal carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 1179-1190.	3.4	62
4129	Pilot study on the detection of antiandrogen resistance using serial diffusion-weighted imaging of bone metastases in prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 1407-1416.	3.4	7
4130	Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis. <i>Journal of Surgical Oncology</i> , 2016, 113, 144-151.	1.7	26

#	ARTICLE	IF	CITATIONS
4131	Tumor histopathology predicts outcomes after resection of colorectal cancer liver metastases treated with and without pre-operative chemotherapy. <i>Journal of Surgical Oncology</i> , 2016, 113, 456-462.	1.7	8
4132	Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration. <i>Laryngoscope</i> , 2016, 126, 2358-2362.	2.0	15
4133	Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. <i>Pediatric Blood and Cancer</i> , 2016, 63, 997-1005.	1.5	64
4134	An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. <i>Statistics in Medicine</i> , 2016, 35, 4093-4109.	1.6	21
4135	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1533-1539.	1.0	104
4136	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1018-1019.	1.6	0
4137	Intratumoral expression levels of <i>PD-L1</i> , <i>GZMA</i> , and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. <i>Oncot Immunology</i> , 2016, 5, e1204507.	4.6	107
4138	Liver Malignancies Treated With Intra-Arterial Therapy. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 206-211.	0.9	0
4139	Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2016, 264, 1091-1097.	4.2	53
4140	Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000-05 Trial. <i>Biometrics</i> , 2016, 72, 907-916.	1.4	28
4141	Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>European Journal of Cancer Care</i> , 2016, 25, 466-477.	1.5	5
4142	Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. <i>Hepatology Research</i> , 2016, 46, 1402-1408.	3.4	9
4143	Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. <i>International Journal of Urology</i> , 2016, 23, 404-411.	1.0	26
4144	Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. <i>Cancer</i> , 2016, 122, 758-765.	4.1	138
4145	MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 890-898.	5.1	45
4146	Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2016, 105, 946-951.	1.5	10
4147	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 2004-2012.	2.8	5
4148	Raster-scanned intensity-controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. <i>Head and Neck</i> , 2016, 38, E1445-51.	2.0	13

#	ARTICLE	IF	CITATIONS
4149	Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. <i>Annals of Oncology</i> , 2016, 27, 1794-1799.	1.2	91
4150	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	1.6	397
4151	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	1.6	444
4152	Reining in the Excessive Use of Medical Tests: What Are the Next Steps?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2807-2809.	1.6	0
4153	Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 811-20.	2.4	61
4154	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2016, 175, G1-G34.	3.7	1,173
4155	Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. <i>Oncology Letters</i> , 2016, 11, 3975-3981.	1.8	35
4156	Imaging Procedures for Colorectal Cancer. <i>Visceral Medicine</i> , 2016, 32, 166-171.	1.3	10
4157	Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study. <i>Journal of Surgical Oncology</i> , 2016, 114, 246-253.	1.7	30
4158	Practical experiences with eribulin in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 112-117.	1.4	6
4159	Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2016, 27, 689-694.	1.4	17
4160	Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 275-283.	1.1	8
4161	How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?. <i>Leukemia</i> , 2016, 30, 1453-1455.	7.2	1
4162	Ensemble lymph node detection from CT volumes combining local intensity structure analysis approach and appearance learning approach. <i>Proceedings of SPIE</i> , 2016, , .	0.8	2
4163	Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with RAS -activated tumors. <i>Cancer</i> , 2016, 122, 875-883.	4.1	55
4164	Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. <i>Cancer</i> , 2016, 122, 1434-1443.	4.1	31
4165	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	4.1	16
4166	Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair. <i>International Journal of Cancer</i> , 2016, 139, 467-479.	5.1	14

#	ARTICLE	IF	CITATIONS
4167	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. The Cochrane Library, 2016, 2, CD011313.	2.8	27
4168	Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study. Oncology Research, 2016, 23, 291-302.	1.5	21
4169	Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases. Hemodialysis International, 2016, 20, E1-5.	0.9	9
4170	Prognostic value of CA 19â€9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 493-500.	2.8	19
4171	Early decrement of serum carbohydrate antigen 19â€9 predicts favorable outcome in advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 506-512.	2.8	15
4172	Bone recurrence rarely seen in endometrial cancer and review of the literature. Journal of Obstetrics and Gynaecology Research, 2016, 42, 602-611.	1.3	6
4173	FEASIBILITY FOR USING HYPOFRACTIONATED STEREOTACTIC VOLUMETRIC MODULATED ARC RADIOTHERAPY (VMAT) WITH ADAPTIVE PLANNING FOR TREATMENT OF THYMOMA IN RABBITS: 15 CASES. Veterinary Radiology and Ultrasound, 2016, 57, 313-320.	0.9	18
4174	Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer. Molecular and Clinical Oncology, 2016, 4, 873-877.	1.0	7
4175	Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy. EJNMMI Research, 2016, 6, 71.	2.5	20
4176	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Childâ€Pugh B cirrhosis. Cancer Science, 2016, 107, 1263-1269.	3.9	22
4177	Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients. Biomedical Reports, 2016, 4, 489-492.	2.0	3
4178	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open, 2016, 6, e009558.	1.9	9
4179	First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice. Lung Cancer Management, 2016, 5, 123-130.	1.5	3
4180	Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study. Oncology, 2016, 91, 127-134.	1.9	1
4181	A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. BMC Cancer, 2016, 16, 775.	2.6	2
4182	Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Research, 2016, 18, 118.	5.0	65
4183	SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clinical and Translational Oncology, 2016, 18, 1243-1253.	2.4	34
4184	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Translational Oncology, 2016, 9, 557-564.	3.7	16

#	ARTICLE	IF	CITATIONS
4185	Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?. Radiation Oncology, 2016, 11, 90.	2.7	23
4186	Role of miR-196 and its target gene HoxB8 in the development and proliferation of human colorectal cancer and the impact of neoadjuvant chemotherapy with FOLFOX4 on their expression. Oncology Letters, 2016, 12, 4041-4047.	1.8	22
4187	Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease. Internal Medicine, 2016, 55, 629-634.	0.7	9
4188	Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. , 2016, 4, 58.		35
4189	A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC Cancer, 2016, 16, 577.	2.6	4
4190	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer, 2016, 16, 850.	2.6	22
4191	Single-source chest-abdomen-pelvis cancer staging on a third generation dual-source CT system: comparison of automated tube potential selection to second generation dual-source CT. Cancer Imaging, 2016, 16, 33.	2.8	8
4192	Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 755-761.	3.7	21
4194	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq0 0 0 4 BT /Over 10 T	4.8	21
4195	Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Science, 2016, 107, 1492-1498.	3.9	5
4196	Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. BMC Cancer, 2016, 16, 945.	2.6	20
4197	Utility of photodynamic therapy for the management of oral potentially malignant disorders and oral cancer. Translational Research in Oral Oncology, 2016, 1, 2057178X1666916.	3.3	4
4198	Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 916-922.	1.0	6
4199	Prognostic significance of platelet-lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. SpringerPlus, 2016, 5, 1889.	1.2	23
4200	Computed tomography evaluation of morphological changes, clinical response and survival in colorectal cancer liver metastasis treated by regorafenib: A case report. Molecular and Clinical Oncology, 2016, 5, 807-810.	1.0	2
4201	Neuroradiology of gliomas. , 0, , 121-145.		0
4202	Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients. BMC Cancer, 2016, 16, 619.	2.6	15
4203	The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients. Scientific Reports, 2016, 6, 24582.	3.3	15

#	ARTICLE	IF	CITATIONS
4204	Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. <i>BMC Cancer</i> , 2016, 16, 417.	2.6	17
4205	Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. <i>BMC Cancer</i> , 2016, 16, 686.	2.6	17
4207	A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. <i>Cancer Biomarkers</i> , 2016, 16, 19-29.	1.7	6
4208	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 13665.	12.8	170
4209	Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study. <i>Medical Physics</i> , 2016, 43, 6608-6620.	3.0	8
4210	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
4211	Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. <i>BMC Cancer</i> , 2016, 16, 473.	2.6	5
4212	Efficacy of repeat hepatectomy for recurrence following curative hepatectomy for colorectal liver metastases: A Retrospective Cohort Study of 128 patients. <i>International Journal of Surgery</i> , 2016, 36, 96-103.	2.7	12
4213	Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population. <i>Scientific Reports</i> , 2016, 6, 21677.	3.3	26
4214	Improving lung cancer prognosis assessment by incorporating synthetic minority oversampling technique and score fusion method. <i>Medical Physics</i> , 2016, 43, 2694-2703.	3.0	23
4215	Mediastinal lymph node detection and station mapping on chest CT using spatial priors and random forest. <i>Medical Physics</i> , 2016, 43, 4362-4374.	3.0	42
4216	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. <i>Value in Health</i> , 2016, 19, 1009-1015.	0.3	24
4217	Percutaneous Ablation in Painful Bone Tumors. <i>Seminars in Musculoskeletal Radiology</i> , 2016, 20, 472-485.	0.7	7
4218	Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. <i>EJNMMI Research</i> , 2016, 6, 81.	2.5	2
4219	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016, 5, 3437-3444.	2.8	20
4220	Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma. <i>Oncology Letters</i> , 2016, 11, 3369-3376.	1.8	8
4222	Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. <i>Lung Cancer</i> , 2016, 102, 9-14.	2.0	13
4223	The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. <i>Cancer Biomarkers</i> , 2016, 17, 49-54.	1.7	11

#	ARTICLE	IF	CITATIONS
4224	Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO) Tj ETQq0 0 0 r g BT /Overback 10 Tf 5		
4225	Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Scientific Reports, 2016, 6, 18999.	3.3	32
4226	Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. Lung Cancer, 2016, 102, 1-8.	2.0	18
4227	Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer. Scientific Reports, 2016, 6, 22112.	3.3	42
4228	Computer aided prognosis for cell death categorization and prediction <i>in vivo</i> using quantitative ultrasound and machine learning techniques. Medical Physics, 2016, 43, 6439-6454.	3.0	8
4230	Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. Journal of Biotechnology, 2016, 239, 115-125.	3.8	43
4231	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Investigational New Drugs, 2016, 34, 575-583.	2.6	9
4232	A novel approach to assess the treatment response using Gaussian random field in PET. Medical Physics, 2016, 43, 833-842.	3.0	2
4233	Phase I trial of <scp>GBS</scp>â€œ01 for advanced pancreatic cancer refractory to gemcitabine. Cancer Science, 2016, 107, 1818-1824.	3.9	46
4234	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Scientific Reports, 2016, 6, 25952.	3.3	36
4235	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Biomedical Science, 2016, 23, 86.	7.0	41
4236	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted Oncology, 2016, 11, 807-814.	3.6	4
4237	Outcome of Neoadjuvant Intra-Arterial Chemotherapy and Radical Hysterectomy for Treatment of Bulky Stage IB to Stage IIB Uterine Cervical Cancer: Can Postoperative Irradiation Be Avoided?. International Journal of Gynecological Cancer, 2016, 26, 1258-1263.	2.5	9
4238	PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation. Clinical Nuclear Medicine, 2016, 41, 677-682.	1.3	13
4239	Phase I, multicenter, openâ€œlabel, doseâ€œescalation study of sonidegib in Asian patients with advanced solid tumors. Cancer Science, 2016, 107, 1477-1483.	3.9	16
4240	Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging. Journal of Algorithms and Computational Technology, 2016, 10, 290-301.	0.7	15
4241	CT guided cryoablation for locally recurrent or metastatic bone and soft tissue tumor: initial experience. BMC Cancer, 2016, 16, 798.	2.6	27
4242	Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors â€œ assessment of intra-tumour heterogeneity. BMC Medicine, 2016, 14, 201.	5.5	3

#	ARTICLE	IF	CITATIONS
4243	Prognostic value of computed tomography characteristics for overall survival in patients with maxillary cancer. BMC Cancer, 2016, 16, 783.	2.6	0
4244	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
4245	Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Research, 2016, 18, 126.	5.0	58
4246	Noadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib) Tj ETQq1 1 0.784314 rgBT /Over 0.1		
4247	Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy. Clinical and Translational Radiation Oncology, 2016, 1, 27-32.	1.7	2
4249	Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol. JAAD Case Reports, 2016, 2, 497-499.	0.8	22
4250	Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer, 2016, 102, 82-88.	2.0	46
4251	Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Translational Oncology, 2016, 9, 600-605.	3.7	11
4252	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Translational Oncology, 2016, 9, 505-511.	3.7	13
4254	Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer, 2016, 2, 16037.	5.2	26
4255	Firstâ€line epidermal growth factor receptor (EGFR)â€tyrosine kinase inhibitor alone or with wholeâ€brain radiotherapy for brain metastases in patients with EGFR â€mutated lung adenocarcinoma. Cancer Science, 2016, 107, 1800-1805.	3.9	53
4256	Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment â€ initial experience. Scientific Reports, 2016, 6, 28081.	3.3	16
4257	Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study. Journal of Laryngology and Otology, 2016, 130, 833-842.	0.8	6
4258	Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. International Journal of Oncology, 2016, 48, 2693-2703.	3.3	20
4259	Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncology Letters, 2016, 12, 4635-4642.	1.8	16
4260	Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. Oncology Letters, 2016, 12, 4829-4837.	1.8	17
4261	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer, 2016, 16, 312.	2.6	21
4262	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multiâ€institution observational study in Taiwan. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 396-402.	1.1	12

#	ARTICLE	IF	CITATIONS
4263	Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer. The Cochrane Library, 0, , .	2.8	0
4264	Tumor Shrinkage Assessed by Volumetric MRI in the Long Term Follow-up After Fractionated Stereotactic Radiotherapy of Non-Functioning Pituitary Adenoma. IFMBE Proceedings, 2016, , 287-291.	0.3	0
4265	Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study. European Radiology, 2016, 26, 3500-3509.	4.5	3
4266	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87.	2.0	19
4268	Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2016, 42, 1303-1311.	1.5	17
4269	High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. Japanese Journal of Clinical Oncology, 2016, 46, 357-362.	1.3	34
4270	Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma. Radiology, 2016, 280, 805-814.	7.3	35
4271	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncology, The, 2016, 17, 632-641.	10.7	98
4272	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clinical Breast Cancer, 2016, 16, 256-261.	2.4	19
4273	Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study. Lung Cancer, 2016, 96, 113-119.	2.0	32
4274	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i>-Positive Nonâ€“Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology, 2016, 34, 2858-2865.	1.6	216
4275	Multi-technique imaging of bone metastases: spotlight on PET-CT. Clinical Radiology, 2016, 71, 620-631.	1.1	22
4276	Response monitoring using quantitative ultrasound methods and supervised dictionary learning in locally advanced breast cancer. Proceedings of SPIE, 2016, , .	0.8	0
4277	Radiomics versus physician assessment for the early prediction of local cancer recurrence after stereotactic radiotherapy for lung cancer. Proceedings of SPIE, 2016, , .	0.8	0
4278	Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clinical Imaging, 2016, 40, 880-884.	1.5	9
4279	RESPECT: Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone â€“ a Whole Body MRI Study. Clinical Oncology, 2016, 28, e5.	1.4	0
4280	RECIST 1.1â€“Update and clarification: From the RECIST committee. European Journal of Cancer, 2016, 62, 132-137.	2.8	1,143
4281	Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study. Gynecologic Oncology, 2016, 142, 231-236.	1.4	16

#	ARTICLE	IF	CITATIONS
4282	CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). <i>Annals of Oncology</i> , 2016, 27, 1565-1572.	1.2	26
4283	Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 1953-1956.	1.6	59
4284	Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 97-104.	0.5	5
4285	A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles. <i>Molecular Medicine Reports</i> , 2016, 13, 4643-4653.	2.4	19
4286	Patients With Advanced Non-Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, 292-300.	2.6	10
4287	A phase II study of nintedanib in patients with relapsed small cell lung cancer. <i>Lung Cancer</i> , 2016, 96, 108-112.	2.0	30
4288	Treatment of cerebral radiation necrosis with nerve growth factor: A prospective, randomized, controlled phase II study. <i>Radiotherapy and Oncology</i> , 2016, 120, 69-75.	0.6	17
4289	Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. <i>Gynecologic Oncology</i> , 2016, 142, 89-94.	1.4	54
4290	Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries. <i>Current Medical Research and Opinion</i> , 2016, 32, 1577-1584.	1.9	4
4291	Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1945-1953.	6.4	58
4292	Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. <i>Clinical Breast Cancer</i> , 2016, 16, 364-371.	2.4	5
4293	Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e575-e583.	1.9	10
4294	Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan. <i>Radiotherapy and Oncology</i> , 2016, 119, 229-235.	0.6	29
4295	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 312-318.	0.6	51
4296	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. <i>Spine Journal</i> , 2016, 16, 291-298.	1.3	32
4297	A germline predictive signature of response to platinum chemotherapy in esophageal cancer. <i>Translational Research</i> , 2016, 171, 29-37.e1.	5.0	16
4298	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	7.0	977
4299	Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. <i>Future Oncology</i> , 2016, 12, 2095-2105.	2.4	21

#	ARTICLE	IF	CITATIONS
4300	Distal Pancreatectomy with <i>En Bloc</i> Resection of the Celiac Axis with Preservation or Reconstruction of the Left Gastric Artery in Patients with Pancreatic Body Cancer. <i>World Journal of Surgery</i> , 2016, 40, 2245-2253.	1.6	47
4301	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016, 34, 96-103.	2.6	2
4302	The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies. <i>Annals of Oncology</i> , 2016, 27, 1638-1643.	1.2	17
4303	Functional imaging of interstitial brachytherapy in pancreatic carcinoma xenografts using spectral CT: how does iodine concentration correlate with standardized uptake value of ¹⁸ F-FDG-PET-CT?. <i>British Journal of Radiology</i> , 2016, 89, 20150573.	2.2	4
4304	A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naïve patients with unresectable pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 640-645.	1.1	35
4305	ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients. <i>Pharmacological Research</i> , 2016, 108, 111-118.	7.1	12
4306	Rociletinib: has the TIGER lost a few of its stripes?. <i>Annals of Oncology</i> , 2016, 27, 1161-1164.	1.2	19
4307	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. <i>Cancer Discovery</i> , 2016, 6, 740-753.	9.4	565
4308	Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2279-2286.	1.6	63
4309	Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. <i>Endocrine-Related Cancer</i> , 2016, 23, R185-R205.	3.1	154
4310	PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy. <i>Tumor Biology</i> , 2016, 37, 7785-7796.	1.8	6
4311	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , 2016, 17, 245-252.e1.	2.6	20
4312	Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in METastatic RCC (RESUME) Study. <i>European Journal of Cancer</i> , 2016, 62, 28-35.	2.8	31
4313	Global curriculum in surgical oncology. <i>European Journal of Surgical Oncology</i> , 2016, 42, 754-766.	1.0	18
4314	Feasibility of intensity-modulated radiotherapy for esophageal cancer in definite chemoradiotherapy. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 375-381.	1.4	11
4315	Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1101-1111.	1.1	49
4316	Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 225-230.	1.4	27
4317	Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France. <i>Journal of Thoracic Oncology</i> , 2016, 11, 391-399.	1.1	11

#	ARTICLE	IF	CITATIONS
4318	Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells™ Subpopulations in the Peripheral Blood of Patients with Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1263-1272.	1.1	81
4319	S768I Mutation in EGFR in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1798-1801.	1.1	50
4320	Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 201, 161-165.	1.1	15
4321	Biochemical remission by chemoradiotherapy in male mediastinal choriocarcinoma with diffuse lung metastasis: A case report. <i>Oncology Letters</i> , 2016, 11, 2615-2618.	1.8	6
4322	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2016, 76, 969-978.	10.9	34
4323	Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Nonâ€Small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1574-1585.	1.1	22
4324	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	7.0	480
4325	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	7.1	154
4326	Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1209-1215.	2.3	21
4327	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	1.9	12
4328	Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e449-e452.	1.9	22
4329	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 261-264.e4.	1.9	22
4330	Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer. <i>Clinical Oncology</i> , 2016, 28, e155-e164.	1.4	9
4331	Altretamine in advanced pretreated epithelial ovarian carcinoma patients: Experience from a center in north India. <i>Current Medicine Research and Practice</i> , 2016, 6, 109-112.	0.1	5
4332	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. <i>European Journal of Cancer</i> , 2016, 56, 1-9.	2.8	76
4333	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. <i>Gynecologic Oncology Reports</i> , 2016, 16, 42-46.	0.6	40
4334	Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies. <i>Abdominal Radiology</i> , 2016, 41, 1086-1099.	2.1	9
4335	Local salvage therapy for late (â‰¥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 238.e9-238.e17.	1.6	7

#	ARTICLE	IF	CITATIONS
4336	Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 338.e1-338.e9.	1.6	9
4337	The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 705-715.	2.4	8
4338	Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. <i>Annals of Oncology</i> , 2016, 27, 1594-1600.	1.2	48
4339	Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin+folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. <i>BMC Cancer</i> , 2016, 16, 318.	2.6	34
4340	Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2820-2826.	1.6	28
4341	A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. <i>Medicine (United States)</i> , 2016, 95, e2565.	1.0	0
4342	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography. <i>Endocrine</i> , 2016, 53, 791-800.	2.3	8
4343	Progression-Free and Overall Survival of Patients With ALK Rearrangement+Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. <i>Clinical Lung Cancer</i> , 2016, 17, 528-534.	2.6	39
4344	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	1.6	149
4345	Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study. <i>British Journal of Radiology</i> , 2016, 89, 20150966.	2.2	10
4346	Functional imaging of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 137-153.	4.2	1
4347	Heterogeneous Tissue Characterization Using Ultrasound: A Comparison of Fractal Analysis Backscatter Models on Liver Tumors. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 1612-1626.	1.5	17
4348	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	12.6	3,421
4349	PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 855-864.	2.0	58
4350	Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area. <i>Radiologia Medica</i> , 2016, 121, 122-131.	7.7	46
4351	Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 320-325.	0.7	21
4352	Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. <i>Clinical Colorectal Cancer</i> , 2016, 15, e109-e115.	2.3	20
4353	Les anticorps monoclonaux dirigés contre les checkpoints immunologiques: de nouvelles approches d'immunothérapie en onco-hématologie. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2016, 4, 5-12.	0.1	4

#	ARTICLE	IF	CITATIONS
4354	Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 939-947.	2.3	38
4355	Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate- to high-risk non-muscle-invasive bladder cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 374-380.	2.5	53
4356	Measurement of pancreatic cystic lesions on magnetic resonance imaging: efficacy of standards in reducing inter-observer variability. <i>Abdominal Radiology</i> , 2016, 41, 500-507.	2.1	25
4357	The tandem duplicator phenotype as a distinct genomic configuration in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2373-82.	7.1	103
4358	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2016, 15, 337-344.e2.	2.3	33
4359	A phase I dose-escalation study of apatersen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. <i>Annals of Oncology</i> , 2016, 27, 1116-1122.	1.2	74
4360	EASL Clinical Practice Guidelines on the management of benign liver tumours. <i>Journal of Hepatology</i> , 2016, 65, 386-398.	3.7	372
4361	Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes. <i>Chemotherapy</i> , 2016, 61, 171-178.	1.6	6
4362	Current Role of Dacomitinib in Head and Neck Cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 735-742.	4.1	5
4363	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 989-1004.	3.1	10
4364	Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, e99-e101.	1.1	5
4365	New systemic therapies for locally advanced and metastatic thyroid cancer. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 143-159.	0.4	1
4366	PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1753-1764.	6.4	59
4367	Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1184-1190.	0.8	36
4368	Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 715-725.	4.2	58
4369	First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. <i>American Journal of Surgery</i> , 2016, 212, 221-229.	1.8	35
4370	Radiomic phenotype features predict pathological response in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 480-486.	0.6	266
4371	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1286-1291.	1.2	92

#	ARTICLE	IF	CITATIONS
4372	Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. <i>Medicine (United States)</i> , 2016, 95, e3338.	1.0	8
4373	A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 4574-4584.	7.0	13
4374	Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 927-938.	2.3	10
4375	NF- κ B-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2526-35.	7.1	71
4376	Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 839-851.	6.4	120
4377	What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). <i>Annals of Oncology</i> , 2016, 27, 920-926.	1.2	261
4378	Long-term results of percutaneous radiofrequency ablation of pulmonary metastases: a single institution experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 57-64.	1.1	16
4379	Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2016, 23, R173-R183.	3.1	28
4380	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	7.4	857
4381	A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. <i>European Journal of Cancer</i> , 2016, 55, 81-97.	2.8	98
4382	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	27.0	1,048
4383	Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer. <i>Journal of Chemotherapy</i> , 2016, 28, 129-134.	1.5	7
4384	A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma. <i>Journal of Chemotherapy</i> , 2016, 28, 116-122.	1.5	0
4385	Evaluation of a Simplified Intravoxel Incoherent Motion (IVIM) Analysis of Diffusion-Weighted Imaging for Prediction of Tumor Size Changes and Imaging Response in Breast Cancer Liver Metastases Undergoing Radioembolization. <i>Medicine (United States)</i> , 2016, 95, e3275.	1.0	23
4386	Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients. <i>Oncology</i> , 2016, 90, 232-238.	1.9	16
4387	Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2016, 152, 816.	4.1	95
4388	A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 4567-4573.	7.0	21
4389	Progress in Fully Automated Abdominal CT Interpretation. <i>American Journal of Roentgenology</i> , 2016, 207, 67-79.	2.2	71

#	ARTICLE	IF	CITATIONS
4390	Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 432-437.	1.9	14
4391	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 2016, 34, 439-449.	2.6	86
4392	Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1399-1404.	0.8	127
4393	Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)â€“tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1304-1311.	1.2	66
4394	Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. <i>Lung Cancer</i> , 2016, 97, 43-47.	2.0	42
4395	Primary hepatic neuroendocrine tumors: clinical characteristics and imaging features on contrast-enhanced ultrasound and computed tomography. <i>Abdominal Radiology</i> , 2016, 41, 1767-1775.	2.1	19
4396	Response Assessment Criteria and Their Applications in Lymphoma: Part 1. <i>Journal of Nuclear Medicine</i> , 2016, 57, 928-935.	5.0	21
4397	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 109-116.	2.5	38
4398	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the <i>KRAS</i> G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
4399	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitorâ€“Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
4400	Personalized Clinical Decision Making in Gastrointestinal Malignancies. <i>PET Clinics</i> , 2016, 11, 273-283.	3.0	7
4401	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With<i>CDK4</i>Inhibitor Palbociclib. <i>JAMA Oncology</i> , 2016, 2, 937.	7.1	241
4402	Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 853-861.	2.2	14
4403	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Nonâ€“Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016, 17, e77-e94.	2.6	27
4404	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2016, 114, 1084-1089.	6.4	113
4405	Digestive neuroendocrine neoplasms: A 2016 overview. <i>Digestive and Liver Disease</i> , 2016, 48, 829-835.	0.9	14
4406	Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1245-1252.	2.3	48
4407	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1291-1298.	1.2	129

#	ARTICLE	IF	CITATIONS
4408	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , 2016, 94, 81-87.	2.0	34
4409	Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. <i>Genes and Development</i> , 2016, 30, 1002-1019.	5.9	579
4410	Global Curriculum in Surgical Oncology. <i>Annals of Surgical Oncology</i> , 2016, 23, 1782-1795.	1.5	33
4411	Repeatability of Quantitative Whole-Body ¹⁸ F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1343-1349.	5.0	53
4412	Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. <i>World Journal of Urology</i> , 2016, 34, 1139-1145.	2.2	19
4413	The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. <i>Developmental Cell</i> , 2016, 37, 114-125.	7.0	96
4414	Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. <i>Acta Oto-Laryngologica</i> , 2016, 136, 948-951.	0.9	54
4415	Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. <i>Clinical Cancer Research</i> , 2016, 22, 1553-1558.	7.0	235
4416	Usefulness of 18 F-FDG PET/CT in thyroid carcinoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 186-192.	0.2	1
4417	Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 1109-1116.	6.4	37
4418	Toward Observation as First-line Management in Abdominal Desmoid Tumors. <i>Annals of Surgical Oncology</i> , 2016, 23, 2212-2219.	1.5	58
4419	Fluorescence imaging for photodynamic therapy of non-melanoma skin malignancies – A retrospective clinical study. <i>Photonics & Lasers in Medicine</i> , 2016, 5, 101-111.	0.2	9
4420	Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 781-796.	4.1	12
4421	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 601-611.	9.4	97
4422	Stent placement above the sphincter of Oddi permits implementation of neoadjuvant chemotherapy in patients with initially unresectable Klatskin tumor. <i>Endoscopy International Open</i> , 2016, 04, E427-E433.	1.8	24
4424	Canine transitional cell carcinoma: a review of current paradigms. <i>Companion Animal</i> , 2016, 21, 21-28.	0.2	1
4425	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2016, , 535-573.		0
4426	Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). <i>Annals of Oncology</i> , 2016, 27, 1006-1013.	1.2	7

#	ARTICLE	IF	CITATIONS
4427	The â€˜nivolutionâ€™™ in renal cell carcinoma: behind the scenes of clinical trials. <i>Future Oncology</i> , 2016, 12, 2061-2063.	2.4	2
4428	Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation. <i>Pathology and Oncology Research</i> , 2016, 22, 763-768.	1.9	25
4429	A Novel Scoring System Based on Fibrinogen and the Neutrophil-Lymphocyte Ratio as a Predictor of Chemotherapy Response and Prognosis in Patients with Advanced Gastric Cancer. <i>Oncology</i> , 2016, 90, 186-192.	1.9	33
4430	Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. <i>Acta Radiologica</i> , 2016, 57, 1149-1155.	1.1	23
4431	Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 111.	8.6	37
4432	The Therapeutic Benefit of Radical Resection for T4b Oral Cavity Squamous Cell Carcinoma with Partial or Complete Response After Radical Chemo-Intensity-Modulated Radiotherapy (IMRT). <i>Annals of Surgical Oncology</i> , 2016, 23, 866-873.	1.5	7
4433	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R469-R484.	3.1	12
4434	Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1940-1953.	1.1	23
4435	Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Prediction of Early Arterial Blood Flow Stasis in Radioembolization of Breast Cancer Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1320-1328.	0.5	10
4436	Biology and treatment of Wilmsâ€™™ tumours in childhood. <i>Revue D'Oncologie HÃ©matologie PÃ©diatrique</i> , 2016, 4, 170-181.	0.1	3
4437	Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 375-382.	3.2	39
4438	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. <i>Future Oncology</i> , 2016, 12, 2683-2688.	2.4	17
4439	Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result. <i>Oncology Letters</i> , 2016, 12, 579-584.	1.8	16
4440	Minimising the impact of errors in the interpretation of CT images for surveillance and evaluation of therapy in cancer. <i>Clinical Radiology</i> , 2016, 71, 1083-1094.	1.1	9
4441	Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. <i>Annals of Oncology</i> , 2016, 27, 1922-1928.	1.2	27
4442	Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5â€™fluorouracil or carboplatin/paclitaxel for firstâ€™line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3803-3811.	4.1	34
4443	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	10.7	1,034
4444	A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study). <i>Clinical Colorectal Cancer</i> , 2016, 15, 329-336.	2.3	16

#	ARTICLE	IF	CITATIONS
4445	Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced <scp>NSCLC</scp>. Thoracic Cancer, 2016, 7, 422-427.	1.9	6
4446	Statistical controversies in clinical research: should schedules of tumor size assessments be changed?. Annals of Oncology, 2016, 27, 1981-1987.	1.2	2
4447	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2016, 17, 1923-1936.	1.8	15
4448	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853.	1.6	69
4449	Assessment of glioma response to radiotherapy using 3D pulsed-continuous arterial spin labeling and 3D segmented volume. European Journal of Radiology, 2016, 85, 1987-1992.	2.6	13
4450	Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy. Radiology, 2016, 281, 484-498.	7.3	22
4451	Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience. European Journal of Cancer, 2016, 66, 9-16.	2.8	19
4452	Epithelial-mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy. Cancer Medicine, 2016, 5, 1989-1999.	2.8	27
4453	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 107, 44-53.	4.4	25
4454	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Annals of Oncology, 2016, 27, 1940-1946.	1.2	94
4455	Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. Biomedical Journal, 2016, 39, 121-129.	3.1	3
4456	Phase I trials in melanoma: A framework to translate preclinical findings to the clinic. European Journal of Cancer, 2016, 67, 213-222.	2.8	32
4457	Portal Vein Stent Placement in Five Patients with Chronic Portal Vein Thrombosis Prior to Pancreatic Surgery. Journal of Vascular and Interventional Radiology, 2016, 27, 889-894.	0.5	2
4458	Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 234-256.	1.3	41
4459	Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: A case report. Molecular and Clinical Oncology, 2016, 5, 337-341.	1.0	1
4460	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1590-1598.	10.7	594
4461	Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. European Journal of Radiology, 2016, 85, 1867-1874.	2.6	99
4463	Tumor volume measurement error using computed tomography imaging in a phase II clinical trial in lung cancer. Journal of Medical Imaging, 2016, 3, 035505.	1.5	18

#	ARTICLE	IF	CITATIONS
4464	A Randomized Phase 2 Study Comparing the Combination of Ficlatusumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1736-1744.	1.1	46
4465	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research, 2016, 4, 959-967.	3.4	428
4466	Quantitative diagnosis of <sc>HER</sc>2 protein expressing breast cancer by singleâ€particle quantum dot imaging. Cancer Medicine, 2016, 5, 2813-2824.	2.8	26
4467	Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Research and Treatment, 2016, 160, 101-109.	2.5	12
4468	Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1509-1520.	10.7	704
4469	Evidence of good prognosis of hepatocellular adenoma in post-menopausal women. Journal of Hepatology, 2016, 65, 1163-1170.	3.7	23
4470	The Management of Thyroid and Parathyroid Cancer. , 2016, , 673-692.		0
4471	Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 921-927.	2.3	1
4472	Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?. Respiratory Medicine Case Reports, 2016, 19, 118-120.	0.4	10
4473	Quantification of epidermal growth factor receptor (<sc>EGFR</sc>) mutation may be a predictor of <sc>EGFR</sc>â€tyrosine kinase inhibitor treatment response. Thoracic Cancer, 2016, 7, 639-647.	1.9	6
4474	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 2016, 68, 1-10.	2.8	9
4475	TEP-TDM au FDG pour le nodule solitaire et le cancer bronchopulmonaireÂ: analyse de la litt��rature. Diagnostic and Interventional Imaging, 2016, 97, 425-440.	0.0	0
4476	Management of para-aortic lymph node metastasis in colorectal patients: A systemic review. Surgical Oncology, 2016, 25, 411-418.	1.6	47
4477	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncology, The, 2016, 17, 1497-1508.	10.7	1,279
4478	Evaluation of lung tumor response to therapy: Current and emerging techniques. Diagnostic and Interventional Imaging, 2016, 97, 1053-1065.	3.2	24
4479	Association of circulating miR-125b and survival in patients with osteosarcomaâ€A single center experience. Journal of Bone Oncology, 2016, 5, 167-172.	2.4	10
4480	A Kindler syndrome-associated squamous cell carcinoma treated with radiotherapy. Reports of Practical Oncology and Radiotherapy, 2016, 21, 532-536.	0.6	3
4481	Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 378-385.	1.3	21

#	ARTICLE	IF	CITATIONS
4482	Radiation Therapy for Stage I Nonoperable or Medically Inoperable Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 716-726.	2.1	6
4483	Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 158.	0.8	9
4484	Modeling Tumor Growth in Animals and Humans: An Evolutionary Approach. , 2016, , 209-235.		1
4485	Bowel strangulation caused by massive intraperitoneal adhesion due to effective chemotherapy for multiple peritoneal metastases originating from descending colon cancer. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 306-311.	0.8	2
4486	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	6.4	50
4487	Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment. , 2016, 4, 30.		44
4488	Gelatin sponge microparticles for the treatment of the spontaneous rupture of hepatocellular carcinoma hemorrhage. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 2201-2207.	1.8	9
4489	Foamed bleomycin sclerosis of airway venous malformations: The role of interspecialty collaboration. <i>Laryngoscope</i> , 2016, 126, 2726-2732.	2.0	16
4490	A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. <i>European Journal of Cancer</i> , 2016, 63, 55-63.	2.8	57
4491	RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases “results and lessons learnt. <i>British Journal of Cancer</i> , 2016, 115, 1193-1200.	6.4	13
4492	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. <i>Clinical Oncology</i> , 2016, 28, 726-731.	1.4	10
4493	Pembrolizumab versus Chemotherapy for PD-L1“Positive Non“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	27.0	7,847
4494	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	27.0	1,390
4495	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164.	27.0	1,860
4496	Electrochemotherapy of mucosal head and neck tumors: a systematic review. <i>Acta OncolÃ³gica</i> , 2016, 55, 1266-1272.	1.8	13
4497	ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan. <i>Oncology Letters</i> , 2016, 12, 2752-2760.	1.8	30
4498	Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. <i>Translational Oncology</i> , 2016, 9, 377-383.	3.7	10
4499	Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 841-849.	1.5	10

#	ARTICLE	IF	CITATIONS
4500	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
4501	Programmed Death-Ligand 1 Expression and Response to the Anti-“Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	1.6	528
4502	Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9. <i>Cancer Investigation</i> , 2016, 34, 385-392.	1.3	13
4503	Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the <i>EGFR</i> T790M mutation: a retrospective observational study of 141 patients in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1135-1142.	1.3	3
4504	Detecting tumor progression in glioma: current standards and new techniques. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1177-1188.	2.4	18
4505	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. <i>Journal of Biological Chemistry</i> , 2016, 291, 23756-23768.	3.4	48
4506	Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1851-1857.	5.0	29
4507	Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2016, 98, 99-105.	2.0	13
4508	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260.	10.7	832
4509	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5480-5486.	7.0	84
4510	Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2016, 5, 2294-2301.	2.8	203
4511	Testosterone Therapy Among Prostate Cancer Survivors. <i>Sexual Medicine Reviews</i> , 2016, 4, 376-388.	2.9	16
4512	A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. <i>Molecular and Clinical Oncology</i> , 2016, 5, 395-399.	1.0	5
4513	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	2.6	30
4514	RANO Criteria. , 2016, , 409-418.		4
4515	The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study. <i>Thyroid</i> , 2016, 26, 1293-1299.	4.5	43
4516	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX+Bevacizumab Drug Treatment Regimen. <i>Cancer Research</i> , 2016, 76, 5241-5252.	0.9	203
4517	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3258-3266.	1.6	153

#	ARTICLE	IF	CITATIONS
4518	Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 922-930.	3.7	10
4519	Prognostic significance of Livin expression in nasopharyngeal carcinoma after radiotherapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 384-390.	1.4	3
4520	Laparoscopic nerve-sparing radical hysterectomy for bulky cervical cancer (â‰¥6Âcm) after neoadjuvant chemotherapy: A multicenter prospective cohort study. <i>International Journal of Surgery</i> , 2016, 34, 35-40.	2.7	11
4521	Longitudinal analysis of bone metabolism using SPECT/CT and 99mTc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis. <i>EJNMMI Research</i> , 2016, 6, 60.	2.5	60
4522	Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). <i>European Journal of Radiology</i> , 2016, 85, 1445-1452.	2.6	23
4523	Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?. <i>Annals of Oncology</i> , 2016, 27, 1365-1366.	1.2	7
4524	Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. <i>Pharmacological Research</i> , 2016, 111, 877-884.	7.1	29
4525	Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastasesâ€”A Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1305-1315.	0.5	42
4526	Implementation of AMNOG: An industry perspective. <i>Biometrical Journal</i> , 2016, 58, 76-88.	1.0	13
4527	Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2016, 5, 415-425.	2.8	27
4528	<sc>PEPCOL</sc>: a <sc>GERCOR</sc> randomized phase <sc>II</sc> study of nanoliposomal irinotecan <sc>PEP</sc>02 (<sc>MM</sc>â€”98) or irinotecan with leucovorin/5â€”fluorouracil as secondâ€”line therapy in metastatic colorectal cancer. <i>Cancer Medicine</i> , 2016, 5, 676-683.	2.8	44
4529	Comparison of prognoses according to nonâ€”positive and positive spectrin Î± II expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.. <i>Cancer Medicine</i> , 2016, 5, 1081-1092.	2.8	2
4530	Retrospective analysis of bevacizumabâ€”induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. <i>Cancer Medicine</i> , 2016, 5, 1381-1387.	2.8	32
4531	Impact of <sc><i>KRAS</i></sc> , <sc><i>BRAF</i></sc> , <sc><i>PIK3CA</i></sc> , <sc><i>TP5</i> 3 </sc> status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	5.1	79
4532	The Effect of a Highâ€”Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1288-1295.	2.0	34
4533	Infantile Fibrosarcoma With <i>NTRK3â€”ETV6</i> Fusion Successfully Treated With the Tropomyosinâ€”Related Kinase Inhibitor LOXOâ€”401. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1468-1470.	1.5	97
4534	Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1400-1406.	1.5	6
4535	PKâ€”PD modeling of individual lesion FDGâ€”PET response to predict overall survival in patients with sunitinibâ€”treated gastrointestinal stromal tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 173-181.	2.5	16

#	ARTICLE	IF	CITATIONS
4536	A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 577-584.	2.3	12
4537	Liver recurrence in endometrial cancer: a multi-institutional analysis of factors predictive of postrecurrence survival. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 707-715.	3.3	6
4538	Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 452-458.	1.9	8
4539	Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 61-69.	1.1	37
4540	Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. <i>Cancer Science</i> , 2016, 107, 590-600.	3.9	12
4541	Clinical features and treatment of patients with esophageal cancer and a history of gastrectomy: a multicenter, questionnaire survey in Kyushu, Japan. <i>Ecological Management and Restoration</i> , 2016, 29, 1135-1143.	0.4	2
4542	INVITED REVIEW "IMAGE REGISTRATION IN VETERINARY RADIATION ONCOLOGY: INDICATIONS, IMPLICATIONS, AND FUTURE ADVANCES. <i>Veterinary Radiology and Ultrasound</i> , 2016, 57, 113-123.	0.9	8
4543	Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 182-189.	1.9	9
4544	Hypofractionated radiotherapy for medically inoperable stage <sc>I</sc> non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 296-303.	1.9	5
4545	Neoadjuvant intra-arterial chemotherapy in advanced laryngeal and hypopharyngeal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e97-104.	1.1	2
4546	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 3-18.	1.1	8
4547	Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 326-327.	2.5	17
4548	Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. <i>Clinical and Translational Science</i> , 2016, 9, 43-50.	3.1	10
4549	Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes. <i>International Journal of Urology</i> , 2016, 23, 153-158.	1.0	25
4550	Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. <i>Molecular Imaging and Biology</i> , 2016, 18, 446-453.	2.6	40
4551	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	1.8	37
4552	Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3166-3174.	1.6	133
4553	Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes. <i>Molecular and Clinical Oncology</i> , 2016, 4, 947-953.	1.0	5

#	ARTICLE	IF	CITATIONS
4554	Systematic Review of Genetic Variation in Chromosome 5p15.33 and Telomere Length as Predictive and Prognostic Biomarkers for Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1537-1549.	2.5	17
4555	Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study). <i>International Journal of Clinical Oncology</i> , 2016, 21, 1142-1149.	2.2	0
4556	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1426-1434.	10.7	336
4557	Validation of clinical risk scores for laparoscopic liver resections of colorectal liver metastases: A 10-year observed follow-up study. <i>Journal of Surgical Oncology</i> , 2016, 114, 757-763.	1.7	11
4558	Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 809-814.	2.3	28
4559	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , 2016, 34, 771-776.	2.6	4
4560	Imaging oligometastatic cancer before local treatment. <i>Lancet Oncology</i> , The, 2016, 17, e406-e414.	10.7	22
4561	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. <i>Clinical and Translational Imaging</i> , 2016, 4, 439-447.	2.1	56
4562	Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. <i>Internal Medicine Journal</i> , 2016, 46, 1392-1398.	0.8	5
4563	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 3680-3685.	1.6	17
4564	Interobserver reproducibility of cervical lymph node measurements at CT in patients with head and neck squamous cell carcinoma. <i>Clinical Radiology</i> , 2016, 71, 1226-1232.	1.1	7
4565	Birth of a standard: MET-RADS-P for metastatic prostate cancer. <i>Nature Reviews Urology</i> , 2016, 13, 568-570.	3.8	4
4566	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 323-330.	3.2	13
4567	Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). <i>European Journal of Cancer</i> , 2016, 64, 74-82.	2.8	28
4568	Two-stage laparoscopic curative resection for synchronous multiple colorectal cancers: A case report. <i>Asian Journal of Endoscopic Surgery</i> , 2016, 9, 300-302.	0.9	0
4569	Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. <i>Cancer Research</i> , 2016, 76, 6331-6339.	0.9	59
4570	Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 895-919.	2.3	13
4571	Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. <i>Drugs and Aging</i> , 2016, 33, 655-663.	2.7	15

#	ARTICLE	IF	CITATIONS
4572	Standardized uptake value on 18 F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Lung Cancer, 2016, 100, 14-19.	2.0	20
4573	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transplantation, 2016, 22, 1491-1500.	2.4	31
4574	Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer. European Journal of Cancer, 2016, 66, 95-103.	2.8	16
4575	A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 578-588.	0.8	190
4576	Clinical value of imaging for lymph nodes evaluation with particular emphasis on ultrasonography. Zeitschrift Fur Gastroenterologie, 2016, 54, 774-790.	0.5	15
4577	Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell and Melanoma Research, 2016, 29, 679-687.	3.3	8
4578	Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer, 2016, 65, 11-20.	2.8	19
4579	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1255-1261.	3.3	12
4580	Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). Clinical Radiology, 2016, 71, 854-862.	1.1	57
4581	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Molecular Cancer Therapeutics, 2016, 15, 2814-2821.	4.1	9
4582	The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer, 2016, 16, 564.	2.6	63
4583	Applications for Drug Development. Imaging in Medical Diagnosis and Therapy, 2016, , 463-486.	0.0	0
4584	Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiology, 2016, 45, 1365-1373.	2.0	46
4585	Improving Spleen Volume Estimation Via Computer-assisted Segmentation on Clinically Acquired CT Scans. Academic Radiology, 2016, 23, 1214-1220.	2.5	9
4586	FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review. Diagnostic and Interventional Imaging, 2016, 97, 1003-1017.	3.2	103
4587	From Mice to Men: Translation from Bench to Bedside. , 2016, , 291-314.		1
4588	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Investigational New Drugs, 2016, 34, 760-770.	2.6	29
4589	Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 2016, 27, 1895-1902.	1.2	70

#	ARTICLE	IF	CITATIONS
4590	Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 759-767.	3.1	131
4591	Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: An investigation of distant metastasis. <i>Molecular and Clinical Oncology</i> , 2016, 5, 246-252.	1.0	39
4592	Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatoryÂmyofibroblastic tumor with crizotinib. <i>Journal of AAPOS</i> , 2016, 20, 260-263.	0.3	16
4593	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 14-24.	4.4	10
4594	PARAGON II â€“ A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1866-1872.	1.0	35
4595	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 314-336.	6.6	11
4596	CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience. <i>Medical Oncology</i> , 2016, 33, 103.	2.5	1
4597	Quantification of Rac1 and Rac1b in serum of non small cell lung cancer by label free real time assay. <i>Clinica Chimica Acta</i> , 2016, 460, 231-235.	1.1	16
4598	High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck. <i>Oral Oncology</i> , 2016, 60, 74-80.	1.5	11
4599	Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment. <i>Clinical Lung Cancer</i> , 2016, 17, 573-580.e1.	2.6	5
4600	Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 525-527.	1.2	6
4601	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	4.1	288
4602	Histogram analysis of apparent diffusion coefficients after neoadjuvant chemotherapy in breast cancer. <i>Japanese Journal of Radiology</i> , 2016, 34, 657-666.	2.4	15
4603	SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 183-198.	6.1	23
4604	Interval Laparoscopic En-Bloc Resection of the Pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: Description of the technique and surgical outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 477-483.	1.4	13
4605	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	2.6	11
4606	Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer. <i>Cancer Biomarkers</i> , 2016, 16, 145-152.	1.7	5
4607	Significance of different response evaluation criteria in predicting progressionâ€free survival of lung cancer with certain imaging characteristics. <i>Thoracic Cancer</i> , 2016, 7, 535-542.	1.9	11

#	ARTICLE	IF	CITATIONS
4608	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. , 2016, 4, 72.		156
4609	A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. BMC Veterinary Research, 2016, 12, 257.	1.9	23
4610	A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study. SpringerPlus, 2016, 5, 1800.	1.2	3
4611	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2525.	3.6	55
4612	Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. Oncologist, 2016, 21, 1212-1217.	3.7	17
4613	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. British Journal of Cancer, 2016, 115, 1504-1512.	6.4	55
4614	4D subharmonic aided pressure estimation for monitoring neoadjuvant chemotherapy response of breast cancer. , 2016, , .		0
4615	Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs. Lung Cancer, 2016, 102, 101-107.	2.0	35
4616	Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open, 2016, 1, e000037.	4.5	63
4617	Postâ€chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study. Journal of Surgical Oncology, 2016, 114, 992-996.	1.7	13
4620	Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. Medical Oncology, 2016, 33, 116.	2.5	30
4621	Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Pancreatology, 2016, 16, 1085-1091.	1.1	21
4622	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 2016, 5, e1214788.	4.6	123
4623	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Journal of Clinical Oncology, 2016, 34, 3898-3905.	1.6	151
4624	A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 949-958.	2.3	3
4625	Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. Breast Cancer Research and Treatment, 2016, 160, 41-49.	2.5	9
4626	Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. Journal of Gastrointestinal Surgery, 2016, 20, 1830-1835.	1.7	70
4627	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 705-718.	1.1	25

#	ARTICLE	IF	CITATIONS
4628	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. <i>Endocrine Connections</i> , 2016, 5, 174-187.	1.9	83
4629	A phase 2 study of dalantercept, an activin receptor-like kinase ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3641-3649.	4.1	32
4630	Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1591-1596.	1.0	8
4631	Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. <i>Oncolmunology</i> , 2016, 5, e1231292.	4.6	89
4632	Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence. <i>Neuroendocrinology</i> , 2016, 103, 500-517.	2.5	41
4633	Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-Three Cases Evaluated according to the WHO 2010 Classification. <i>Neuroendocrinology</i> , 2016, 103, 567-577.	2.5	11
4634	Imaging biomarkers in the clinic. <i>Biomarkers in Medicine</i> , 2016, 10, 1073-1079.	1.4	0
4635	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016, 50, 129-141.	7.7	81
4636	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	1.4	81
4637	Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1088-1094.	1.3	7
4638	Conservative management of desmoid tumors is safe and effective. <i>Journal of Surgical Research</i> , 2016, 205, 115-120.	1.6	24
4639	Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. <i>Annals of Oncology</i> , 2016, 27, 2288-2294.	1.2	117
4640	Pediatric/Wildtype gastrointestinal stromal tumors. <i>Seminars in Pediatric Surgery</i> , 2016, 25, 305-310.	1.1	15
4641	Computed tomography imaging assessment of postexternal beam radiation changes of the liver. <i>Future Oncology</i> , 2016, 12, 2729-2739.	2.4	9
4642	Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1767-1774.	2.2	11
4643	ANG1005 for breast cancer brain metastases: correlation between 18F-FLT PET after first cycle and MRI in response assessment. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 51-59.	2.5	27
4644	First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2016, 5, 375-379.	1.0	6
4645	Correlation between histological grade and positron emission tomography parameters in cervical carcinoma. <i>Oncology Letters</i> , 2016, 12, 1408-1414.	1.8	2

#	ARTICLE	IF	CITATIONS
4646	Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. <i>British Journal of Surgery</i> , 2016, 103, 845-854.	0.3	88
4647	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	3.7	183
4648	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 744-754.	3.4	131
4649	Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Journal of Urology</i> , 2016, 196, 1363-1370.	0.4	42
4650	A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies. <i>Investigational New Drugs</i> , 2016, 34, 584-595.	2.6	12
4651	A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. <i>Cancer Investigation</i> , 2016, 34, 265-270.	1.3	34
4652	Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification. <i>British Journal of Radiology</i> , 2016, 89, 20150945.	2.2	7
4653	Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. <i>British Journal of Radiology</i> , 2016, 89, 20160383.	2.2	10
4654	RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do. <i>Current Radiology Reports</i> , 2016, 4, 1.	1.4	9
4655	Prognostic factors analysis in EGFR mutation-positive non-small cell lung cancer with brain metastases treated with whole brain-radiotherapy and EGFR-tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2016, 11, 2249-2254.	1.8	9
4656	Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 297-304.	2.5	9
4657	Is diffusion-weighted MRI sufficient for follow-up of neuroendocrine tumour liver metastases?. <i>Clinical Radiology</i> , 2016, 71, 863-868.	1.1	11
4658	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2016, 375, 819-829.	27.0	2,430
4659	Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. <i>American Journal of Roentgenology</i> , 2016, 207, 661-670.	2.2	29
4660	Robotic Surgery in Patients With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 521-527.	2.5	8
4661	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016, 76, 1218-1226.	2.3	63
4662	Nanomedicine and tumor heterogeneity: Concept and complex reality. <i>Nano Today</i> , 2016, 11, 402-414.	11.9	59
4663	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. <i>Cancer Investigation</i> , 2016, 34, 348-354.	1.3	16

#	ARTICLE	IF	CITATIONS
4664	Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma. <i>Medicine (United States)</i> , 2016, 95, e2611.	1.0	4
4665	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	1.6	202
4666	Evolutionary magnetic resonance appearance of renal cell carcinoma after percutaneous cryoablation. <i>British Journal of Radiology</i> , 2016, 89, 20160151.	2.2	23
4667	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	9.4	919
4668	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	1.5	56
4669	Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1037-1041.	1.0	21
4670	Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. <i>Molecular and Clinical Oncology</i> , 2016, 5, 74-78.	1.0	13
4671	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	5.1	69
4672	Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group. <i>Clinical Lung Cancer</i> , 2016, 17, 543-549.	2.6	10
4673	Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 465-470.	1.4	16
4674	A microRNA expression signature for clinical response in locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2016, 142, 557-565.	1.4	49
4675	Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients. <i>Thyroid</i> , 2016, 26, 1085-1092.	4.5	9
4676	124: Detection of Local Cancer Recurrence after Stereotactic Ablative Radiotherapy (SABR) for Lung Cancer: Physician Performance Versus Radiomic Assessment. <i>Radiotherapy and Oncology</i> , 2016, 120, S46-S47.	0.6	1
4677	A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1206-1214.	6.4	47
4678	A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2016, 27, 2268-2274.	1.2	108
4679	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	1.2	90
4680	Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1-year experience. <i>SpringerPlus</i> , 2016, 5, 1675.	1.2	1
4681	Can quantitative contrast-enhanced ultrasonography predict cervical tumor response to neoadjuvant chemotherapy?. <i>European Journal of Radiology</i> , 2016, 85, 2111-2118.	2.6	16

#	ARTICLE	IF	CITATIONS
4682	The Pursuit of Noninvasive Diagnosis of Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 670-680.	2.1	13
4683	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	10.7	200
4684	Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. <i>Cancer Science</i> , 2016, 107, 1465-1470.	3.9	30
4685	Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 895-901.	1.1	30
4686	Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy. <i>Radiologia Medica</i> , 2016, 121, 950-957.	7.7	3
4687	Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?. <i>European Journal of Cancer</i> , 2016, 69, 142-150.	2.8	59
4688	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	27.0	1,943
4689	Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. <i>Molecular Cancer</i> , 2016, 15, 73.	19.2	47
4690	Reliability of MRI in measuring the response to neoadjuvant chemotherapy in breast cancer patients and its therapeutic implications. <i>Breast Cancer Management</i> , 2016, 5, 107-118.	0.2	2
4691	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 238.	1.9	25
4692	18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1245-1252.	2.3	4
4693	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. <i>BMC Cancer</i> , 2016, 16, 864.	2.6	41
4694	Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2016, 121, 239-245.	0.6	17
4695	The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 121, 246-251.	0.6	43
4696	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>World Journal of Surgical Oncology</i> , 2016, 14, 253.	1.9	91
4697	Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. <i>Scientific Reports</i> , 2016, 6, 30091.	3.3	18
4698	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. <i>Scientific Reports</i> , 2016, 6, 35249.	3.3	33
4699	Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. <i>BMC Cancer</i> , 2016, 16, 599.	2.6	23

#	ARTICLE	IF	CITATIONS
4700	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1672-1682.	10.7	865
4701	DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC. <i>Scientific Reports</i> , 2016, 6, 35569.	3.3	34
4702	The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 899-901.	2.4	10
4703	Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. <i>EJNMMI Research</i> , 2016, 6, 76.	2.5	104
4704	Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging. <i>Oncology Letters</i> , 2016, 12, 1711-1716.	1.8	2
4705	GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1163-1173.	2.3	11
4706	Personalized Medicine. <i>Europeanization and Globalization</i> , 2016, , .	0.1	5
4708	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1661-1671.	10.7	115
4709	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660.	10.7	365
4710	Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. <i>British Journal of Cancer</i> , 2016, 115, 1321-1327.	6.4	24
4711	Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. <i>Scientific Reports</i> , 2016, 6, 36458.	3.3	75
4712	Local Efficacy and Survival after Microwave Ablation of Lung Tumors: A Retrospective Study in 183 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1806-1814.	0.5	33
4713	Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 295-305.	2.5	35
4714	A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 740-749.	2.6	67
4715	Report of two cases of pseudoprogression in patients with nonâ€“small cell lung cancer treated with nivolumabâ€“including histological analysis of one case after tumor regression. <i>Lung Cancer</i> , 2016, 102, 44-48.	2.0	72
4716	Telotristat ethyl: a new option for the management of carcinoid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2487-2498.	1.8	27
4717	Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. <i>Thoracic Cancer</i> , 2016, 7, 543-548.	1.9	10
4718	Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration. <i>BMC Cancer</i> , 2016, 16, 808.	2.6	14

#	ARTICLE	IF	CITATIONS
4719	Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer. <i>International Journal of Oncology</i> , 2016, 48, 1297-1304.	3.3	4
4720	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1683-1696.	10.7	298
4721	Paradox CA 15â€³ increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series. <i>Biomarkers in Medicine</i> , 2016, 10, 1191-1195.	1.4	5
4722	Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2016, 101, 48-58.	2.0	38
4723	Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. <i>Scientific Reports</i> , 2016, 6, 29093.	3.3	16
4724	Clinical impact of postâ€³progression survival on overall survival in elderly patients with extensive disease smallâ€³cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 655-662.	1.9	13
4725	Assessment of Chemotherapy Response in Ewing Sarcoma. <i>Radiology</i> , 2016, 281, 647-649.	7.3	2
4726	Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. <i>Journal of Translational Medicine</i> , 2016, 14, 296.	4.4	42
4727	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520
4728	Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study. <i>Gynecologic Oncology</i> , 2016, 143, 516-520.	1.4	35
4729	MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment. <i>Scientific Reports</i> , 2016, 6, 28929.	3.3	39
4730	Apparent diffusion coefficient histogram shape analysis for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy. <i>Radiation Oncology</i> , 2016, 11, 141.	2.7	15
4731	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. <i>Neoplasia</i> , 2016, 18, 647-653.	5.3	44
4732	Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. <i>Nature Communications</i> , 2016, 7, 11702.	12.8	155
4733	Multidimensional Texture Analysis for Improved Prediction of Ultrasound Liver Tumor Response to Chemotherapy Treatment. <i>Lecture Notes in Computer Science</i> , 2016, , 619-626.	1.3	1
4734	Management of Patients with Castration-Resistant Prostate Cancer (CRPC): Results of an Italian Survey Using the Delphi Method. <i>Tumori</i> , 2016, 102, 514-520.	1.1	2
4735	A multicenter retrospective observational study on the safety and efficacy of cetuximab for patients with oral cancerâ€³Original Articleâ€³. <i>Journal of Japanese Society of Oral Oncology</i> , 2016, 28, 169-179.	0.1	9
4736	Imaging Biomarkers in Immunotherapy. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31805.	3.6	31

#	ARTICLE	IF	CITATIONS
4737	Low expression of PKC δ and high expression of KRAS predict poor prognosis in patients with colorectal cancer. <i>Oncology Letters</i> , 2016, 12, 1655-1660.	1.8	18
4738	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 319-326.	0.6	3
4740	Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report. <i>Oncology Letters</i> , 2016, 11, 2297-2299.	1.8	17
4741	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v1-v27.	1.2	1,351
4742	A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S32783.	1.1	140
4743	Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity. <i>Radiation Oncology</i> , 2016, 11, 133.	2.7	13
4744	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
4745	Integrating cancer genomic data into electronic health records. <i>Genome Medicine</i> , 2016, 8, 113.	8.2	57
4746	Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
4747	Correlation Between Aspirin Intake and Reduced Growth of Human Vestibular Schwannoma. <i>Otology and Neurotology</i> , 2016, 37, 1428-1434.	1.3	46
4748	Minimax and admissible adaptive two-stage designs in phase II clinical trials. <i>BMC Medical Research Methodology</i> , 2016, 16, 90.	3.1	16
4749	Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation. <i>BMC Cancer</i> , 2016, 16, 556.	2.6	27
4750	With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study. <i>BMC Cancer</i> , 2016, 16, 774.	2.6	17
4751	Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafenib in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. <i>BMC Cancer</i> , 2016, 16, 856.	2.6	20
4752	Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2016, 16, 868.	2.6	15
4753	Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial. <i>BMC Cancer</i> , 2016, 16, 932.	2.6	33
4754	Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?. <i>BMC Cancer</i> , 2016, 16, 905.	2.6	25
4755	Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 520.	1.6	14

#	ARTICLE	IF	CITATIONS
4756	Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. , 2016, 4, 34.		34
4757	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Scientific Reports, 2016, 6, 25.	3.3	32
4758	Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (United States), 2016, 95, e4183.	1.0	11
4759	Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 1253-1261.	2.3	11
4762	Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats. Journal of Visualized Experiments, 2016, , .	0.3	20
4763	Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anti-Cancer Drugs, 2016, 27, 891-898.	1.4	3
4764	Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma. Medicine (United States), 2016, 95, e4450.	1.0	11
4765	Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution. Anti-Cancer Drugs, 2016, 27, 1038-1043.	1.4	9
4766	Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. Medicine (United States), 2016, 95, e3518.	1.0	27
4767	Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT. Medicine (United States), 2016, 95, e4308.	1.0	4
4768	Low-grade Nonrhabdomyosarcoma Soft Tissue Sarcoma: What is Peculiar for Childhood. Journal of Pediatric Hematology/Oncology, 2016, 38, 615-621.	0.6	1
4769	DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases. Medicine (United States), 2016, 95, e3236.	1.0	10
4770	The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations. Medicine (United States), 2016, 95, e3991.	1.0	4
4771	Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. Medicine (United States), 2016, 95, e5460.	1.0	3
4772	Future Directions in the Treatment of Gastrointestinal and Pancreatic Neuroendocrine Tumors. Pancreas, 2016, 45, 786-788.	1.1	1
4773	Assessment of Early Therapeutic Changes to Concurrent Chemoradiotherapy in Uterine Cervical Cancer Using Blood Oxygenation Levelâ€Dependent Magnetic Resonance Imaging. Journal of Computer Assisted Tomography, 2016, 40, 730-734.	0.9	5
4774	Treatment of Gastric Cancer With Paraaortic Lymph Node Metastasis. International Surgery, 2016, 101, 583-589.	0.1	0
4775	Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S38335.	1.3	19

#	ARTICLE	IF	CITATIONS
4776	Testing of evaluation bias for progression free survival endpoint in oncology clinical trials. <i>Statistics in Medicine</i> , 2016, 35, 3923-3932.	1.6	0
4777	Utility-based designs for randomized comparative trials with categorical outcomes. <i>Statistics in Medicine</i> , 2016, 35, 4285-4305.	1.6	19
4778	Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. <i>The Cochrane Library</i> , 2016, 2016, CD011837.	2.8	29
4779	Pharmacodynamic markers and clinical results from the phase 2 study of the <scp>SMAC</scp> mimetic birinapant in women with relapsed platinum-resistant or refractory epithelial ovarian cancer. <i>Cancer</i> , 2016, 122, 588-597.	4.1	77
4780	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
4781	Contrast-enhanced susceptibility weighted imaging with ultrasmall superparamagnetic iron oxide improves the detection of tumor vascularity in a hepatocellular carcinoma nude mouse model. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 288-295.	3.4	8
4782	Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 521-540.	3.4	146
4783	Applying a new quantitative global breast MRI feature analysis scheme to assess tumor response to chemotherapy. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1099-1106.	3.4	55
4784	Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. <i>British Journal of Surgery</i> , 2016, 103, 267-275.	0.3	68
4785	Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. <i>Melanoma Research</i> , 2016, 26, 382-386.	1.2	31
4786	Case Report of Contrast-Enhanced Ultrasound Features of Primary Hepatic Neuroendocrine Tumor. <i>Medicine (United States)</i> , 2016, 95, e3450.	1.0	16
4787	Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. <i>British Journal of Dermatology</i> , 2016, 175, 1382-1386.	1.5	112
4788	Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. <i>BJU International</i> , 2016, 118, 927-934.	2.5	7
4789	Current evidence for the diagnostic value of gadoxetic acid-enhanced magnetic resonance imaging for liver metastasis. <i>Hepatology Research</i> , 2016, 46, 853-861.	3.4	34
4790	Reintervention for occluded metal stent in malignant bile duct obstruction: A prospective randomized trial comparing covered and uncovered metal stent. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1901-1907.	2.8	20
4791	TOLERABILITY AND TUMOR RESPONSE OF A NOVEL LOW-DOSE PALLIATIVE RADIATION THERAPY PROTOCOL IN DOGS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER AND URETHRA. <i>Veterinary Radiology and Ultrasound</i> , 2016, 57, 341-351.	0.9	24
4792	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2016, 151, e161137.	4.3	365
4793	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 113-125.e5.	1.2	133

#	ARTICLE	IF	CITATIONS
4794	Clinical significance of serum laminin levels in patients with lung cancer. Biomedical Reports, 2016, 4, 485-488.	2.0	3
4795	Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?. Journal of Digital Imaging, 2016, 29, 357-364.	2.9	11
4796	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCT019041). Investigational New Drugs, 2016, 34, 104-111.	2.6	17
4797	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet, The, 2016, 388, 488-497.	13.7	512
4798	Clinical Outcomes and Prognostic Factors of High-Dose Proton Beam Therapy for Peripheral Stage I Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 427-432.	2.6	15
4799	El reto de la adecuada detección de metástasis en el paciente con cáncer de próstata resistente a la castración. Revista Mexicana De Urología, 2016, 76, 129-130.	0.0	1
4800	Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. BMC Cancer, 2016, 16, 30.	2.6	14
4801	Accelerated hypofractionated three-dimensional conformal radiation therapy (3Â Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial. BMC Cancer, 2016, 16, 288.	2.6	17
4802	ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. World Journal of Surgical Oncology, 2016, 14, 139.	1.9	7
4803	Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. Journal of Translational Medicine, 2016, 14, 10.	4.4	10
4804	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. Nutrition and Cancer, 2016, 68, 750-755.	2.0	0
4805	Single-dose intra-arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB-IB cervical cancer. Molecular and Clinical Oncology, 2016, 4, 1068-1072.	1.0	2
4806	Can diffusion-weighted magnetic resonance imaging predict tumor recurrence of uterine cervical cancer after concurrent chemoradiotherapy?. Abdominal Radiology, 2016, 41, 1604-1610.	2.1	15
4807	Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. European Radiology, 2016, 26, 2009-2018.	4.5	66
4808	Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. European Radiology, 2016, 26, 2771-2778.	4.5	31
4809	Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R and D, 2016, 16, 45-52.	2.2	10
4810	Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurology, 2016, 73, 928.	9.0	238
4811	Assessment of Brain Tumor Response: RANO and Its Offspring. Current Treatment Options in Oncology, 2016, 17, 35.	3.0	65

#	ARTICLE	IF	CITATIONS
4812	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	10.7	789
4813	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 289-295.	3.7	89
4814	Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. <i>BMC Palliative Care</i> , 2016, 15, 25.	1.8	7
4815	Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling. <i>British Journal of Cancer</i> , 2016, 114, 897-904.	6.4	13
4816	The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 568-574.	1.3	8
4817	A B-spline image registration based CAD scheme to evaluate drug treatment response of ovarian cancer patients. , 2016, , .		0
4818	A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial. <i>Molecular and Clinical Oncology</i> , 2016, 4, 510-514.	1.0	9
4819	Molecular Radio-Oncology. <i>Recent Results in Cancer Research</i> , 2016, , .	1.8	1
4820	Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. <i>Journal of Neuro-Oncology</i> , 2016, 129, 355-361.	2.9	25
4821	Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. <i>Oncologist</i> , 2016, 21, 50-58.	3.7	46
4822	Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2016, 207, W26-W32.	2.2	36
4823	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3119-3125.	1.6	755
4824	Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2105-2113.	6.4	42
4825	High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 333-339.	2.3	64
4826	A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1585-1590.	1.8	14
4827	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	2.6	15
4828	Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy. <i>Oncology Letters</i> , 2016, 11, 723-730.	1.8	15
4829	A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 23-30.	2.0	57

#	ARTICLE	IF	CITATIONS
4830	Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2016, 5, 213-215.	1.0	14
4831	Early Evaluation of Relative Changes in Tumor Stiffness by Shear Wave Elastography Predicts the Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 1619-1627.	1.7	53
4832	Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. <i>Investigational New Drugs</i> , 2016, 34, 636-642.	2.6	28
4833	Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 325-332.	2.3	18
4834	Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 688-697.	1.5	25
4835	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. <i>British Journal of Cancer</i> , 2016, 115, 297-302.	6.4	58
4836	FDG and Beyond. <i>Recent Results in Cancer Research</i> , 2016, 198, 163-173.	1.8	6
4837	Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. <i>British Journal of Radiology</i> , 2016, 89, 20160086.	2.2	2
4838	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 1805-1822.	2.4	6
4839	The clinical utility of molecular genetic cancer profiling. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 827-838.	3.1	6
4840	Algorithm Variability in the Estimation of Lung Nodule Volume From Phantom CT Scans: Results of the QIBA 3A Public Challenge. <i>Academic Radiology</i> , 2016, 23, 940-952.	2.5	18
4841	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 426-431.	1.9	9
4842	Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 420-425.	1.9	19
4843	Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. <i>European Journal of Cancer</i> , 2016, 60, 117-124.	2.8	22
4844	Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A "real world" experience. <i>Prostate International</i> , 2016, 4, 15-19.	2.3	11
4845	Biopsia del ganglio centinela y quimioterapia neoadyuvante en pacientes con cáncer de mama: nuestra experiencia. <i>Revista De Senología Y Patología Mamaria</i> , 2016, 29, 4-12.	0.1	2
4846	Update to Rociletinib Data with the RECIST Confirmed Response Rate. <i>New England Journal of Medicine</i> , 2016, 374, 2296-2297.	27.0	72
4847	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1005-1009.	2.3	14

#	ARTICLE	IF	CITATIONS
4848	Assessing size of pituitary adenomas: a comparison of qualitative and quantitative methods on MR. <i>Acta Neurochirurgica</i> , 2016, 158, 677-683.	1.7	35
4849	CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1331-1342.	1.7	44
4850	Presentation and Outcome of Castleman's Disease in Immunocompetent Hosts. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 468-474.	0.6	4
4852	The prognostic value of pretreatment FDG-PET parameters in HPV-associated oropharynx cancer. <i>Journal of Radiation Oncology</i> , 2016, 5, 161-167.	0.7	1
4853	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	10.7	846
4854	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	10.7	1,091
4855	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	10.7	293
4856	The Attenuation Distribution Across the Long Axis (ADLA). <i>Academic Radiology</i> , 2016, 23, 718-723.	2.5	3
4857	A multicenter phase II study of concurrent chemoradiotherapy with cisplatin and oral S-1, followed by surgery for locally advanced non-small-cell lung cancer. <i>Cancer Treatment Communications</i> , 2016, 7, 11-16.	0.4	1
4858	Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. <i>European Urology Focus</i> , 2016, 2, 547-552.	3.1	13
4859	Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. <i>Hpb</i> , 2016, 18, 549-556.	0.3	42
4860	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. <i>British Journal of Radiology</i> , 2016, 89, 20160146.	2.2	15
4861	ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. <i>European Journal of Endocrinology</i> , 2016, 175, R185-R202.	3.7	42
4862	Do Elderly Patients Complete their Planned Adjuvant Breast Cancer Chemotherapy? A Comparison of Patients Aged 60-64, 65-69 Years and Over 70 Years. <i>Clinical Oncology</i> , 2016, 28, e4-e5.	1.4	0
4863	Febrile Neutropenia Rates According to BMI and Dose-capping: a Retrospective Analysis in a Tertiary Referral Centre. <i>Clinical Oncology</i> , 2016, 28, e5.	1.4	0
4864	Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience. <i>Clinical Oncology</i> , 2016, 28, e109-e114.	1.4	44
4865	Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 134-141.	0.8	37
4866	Granulocyte-colony stimulating factor-producing gallbladder carcinoma-include analysis all case reports: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 21, 87-90.	0.6	5

#	ARTICLE	IF	CITATIONS
4867	Leiomyosarcoma de pr ³ stata en paciente de 25 a [±] os. Revista Argentina De Radiologia, 2016, 80, 204-206.	0.0	0
4868	Quantitative Evaluation of Local Control and Wound Healing Following Surgery and Stereotactic Spine Radiosurgery for Spine Tumors. World Neurosurgery, 2016, 87, 48-54.	1.3	20
4869	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 176-187.	3.2	25
4870	A phase II study of axitinib in advanced neuroendocrine tumors. Endocrine-Related Cancer, 2016, 23, 411-418.	3.1	38
4871	Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. Clinical Breast Cancer, 2016, 16, 349-355.	2.4	29
4872	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. Clinical Lung Cancer, 2016, 17, 391-397.	2.6	75
4873	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusionâ€“Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology, 2016, 11, 1140-1152.	1.1	64
4874	Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study. Translational Oncology, 2016, 9, 155-162.	3.7	94
4875	Unconditional tests for comparing two ordered multinomials. Statistical Methods in Medical Research, 2016, 25, 241-254.	1.5	33
4876	Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surgical Oncology, 2016, 25, 190-199.	1.6	12
4877	Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Annals of Surgical Oncology, 2016, 23, 2330-2335.	1.5	49
4878	Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2016, 15, 815-820.	1.9	6
4879	Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. Clinical Trials, 2016, 13, 545-554.	1.6	2
4880	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. BMC Cancer, 2016, 16, 116.	2.6	31
4881	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer, 2016, 16, 153.	2.6	62
4882	Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. BMC Cancer, 2016, 16, 147.	2.6	12
4883	The efficacy of iodine-125 permanent brachytherapy versus intensity-modulated radiation for inoperable salivary gland malignancies: study protocol of a randomised controlled trial. BMC Cancer, 2016, 16, 193.	2.6	9
4884	Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer, 2016, 16, 214.	2.6	35

#	ARTICLE	IF	CITATIONS
4885	Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases. <i>World Journal of Surgical Oncology</i> , 2016, 14, 56.	1.9	7
4886	The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. <i>World Journal of Surgical Oncology</i> , 2016, 14, 60.	1.9	18
4887	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	4.4	117
4888	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	4.4	36
4889	A mathematical model of tumor growth and its response to single irradiation. <i>Theoretical Biology and Medical Modelling</i> , 2016, 13, 6.	2.1	65
4890	Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. <i>Radiation Oncology</i> , 2016, 11, 60.	2.7	18
4891	The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. <i>BMC Research Notes</i> , 2016, 9, 79.	1.4	15
4892	An exploratory study of volumetric analysis for assessing tumor response with 18F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC). <i>EJNMMI Research</i> , 2016, 6, 33.	2.5	11
4893	A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer. <i>SpringerPlus</i> , 2016, 5, 164.	1.2	17
4894	Induction of potentially lethal hypermagnesemia, ischemic colitis, and toxic megacolon by a preoperative mechanical bowel preparation: report of a case. <i>Surgical Case Reports</i> , 2016, 2, 18.	0.6	8
4895	Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. <i>Chinese Journal of Cancer</i> , 2016, 35, 2.	4.9	62
4896	Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. <i>Chinese Journal of Cancer</i> , 2016, 35, 30.	4.9	42
4897	T-Cell Therapy Using Interleukin-21â€œPrimed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016, 34, 3787-3795.	1.6	98
4898	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2636-2643.	1.6	77
4899	Pulmonary imaging after stereotactic radiotherapyâ€œdoes RECIST still apply?. <i>British Journal of Radiology</i> , 2016, 89, 20160113.	2.2	29
4900	TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2155-2165.	6.4	25
4901	Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: safety and short-term oncologic results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 4265-4271.	2.4	35
4902	Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. , 2016, , 667-680.		0

#	ARTICLE	IF	CITATIONS
4903	Pseudoprogression in Neuro-Oncology. , 2016, , 681-695.		1
4904	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. Journal of Clinical Oncology, 2016, 34, 3511-3517.	1.6	64
4905	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2016, 65, 951-959.	4.2	62
4906	The Role of Intravoxel Incoherent Motion MRI in Predicting Early Treatment Response to Chemoradiation for Metastatic Lymph Nodes in Nasopharyngeal Carcinoma. Advances in Therapy, 2016, 33, 1158-1168.	2.9	12
4907	Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. European Journal of Endocrinology, 2016, 175, 173-180.	3.7	18
4908	Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patientsâ€™ survival: PEACH study. Cancer Chemistry and Pharmacology, 2016, 77, 121-126.	2.3	2
4909	Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. International Journal of Clinical Oncology, 2016, 21, 1071-1078.	2.2	22
4910	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Investigational New Drugs, 2016, 34, 184-192.	2.6	46
4911	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Targeted Oncology, 2016, 11, 317-327.	3.6	10
4912	Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs. International Cancer Conference Journal, 2016, 5, 163-167.	0.5	1
4913	Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics, 2016, 32, 2891-2895.	4.1	113
4914	Modified breast cancer model for preclinical immunotherapy studies. Journal of Surgical Research, 2016, 204, 467-474.	1.6	22
4916	Imaging and therapeutic applications of zinc(II)-dipicolylamine molecular probes for anionic biomembranes. Chemical Communications, 2016, 52, 8787-8801.	4.1	60
4917	Efficacy of the nanoparticleâ€“drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase IIa clinical trial. Annals of Oncology, 2016, 27, 1579-1585.	1.2	41
4918	Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy. International Journal of Cancer, 2016, 138, 481-488.	5.1	36
4919	MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine, 2016, 29, 732-743.	2.8	19
4920	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 2016, 76, 125-139.	2.3	17
4921	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptorâ€“directed therapies. Prostate, 2016, 76, 512-520.	2.3	19

#	ARTICLE	IF	CITATIONS
4922	Differential Crizotinib Response Duration Among <i>ALK</i> Fusion Variants in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3383-3389.	1.6	236
4923	Rare Genitourinary Tumors. , 2016, , .		0
4924	Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 839-844.	1.3	3
4925	Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 385-392.	3.8	8
4926	Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 397-403.	2.3	9
4927	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. <i>Investigational New Drugs</i> , 2016, 34, 625-635.	2.6	52
4928	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.	1.5	236
4929	¹⁸ F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. <i>Oncology Letters</i> , 2016, 11, 316-322.	1.8	21
4930	Cognitive and Affective Symptoms Experienced by Cancer Patients Receiving High-Dose Intravenous Interleukin 2 Therapy. <i>Cancer Nursing</i> , 2016, 39, 349-357.	1.5	5
4931	Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. <i>BJU International</i> , 2016, 117, 118-125.	2.5	57
4932	Outcomes treating stage <i>III</i> non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. <i>Clinical Respiratory Journal</i> , 2016, 10, 428-434.	1.6	3
4933	A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 424-431.	6.3	41
4934	A case report of three patients with metastatic gastric cancer on hemodialysis who were treated with cisplatin-fluorouracil regimen. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 345-349.	0.9	3
4935	mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response. <i>European Radiology</i> , 2016, 26, 278-285.	4.5	13
4936	Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 122-129.	1.9	21
4937	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	6.4	256
4938	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 215-224.	3.4	128
4939	Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 42-49.	1.4	10

#	ARTICLE	IF	CITATIONS
4940	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600E-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	1.6	266
4941	Is hyperthermia combined with radiotherapy adequate in elderly patients with muscle-invasive bladder cancers? Thermo-radiobiological implications from an audit of initial results. <i>International Journal of Hyperthermia</i> , 2016, 32, 390-397.	2.5	8
4942	ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 549-558.	2.3	15
4943	A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 539-548.	2.3	10
4944	A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016, 140, 204-209.	1.4	40
4945	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 460-464.	0.6	11
4946	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 378-388.	10.7	327
4947	Retrospective comparison of laparoscopic versus open radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 132, 29-33.	2.3	12
4948	Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. <i>British Journal of Cancer</i> , 2016, 114, 138-145.	6.4	81
4949	Quantitative Imaging in Cancer Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 284-290.	7.0	106
4950	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	2.4	8
4951	Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1121-1128.	0.8	123
4952	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , 2016, 17, 400-406.	3.4	67
4953	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2098-2106.	1.6	264
4954	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. <i>Medical Oncology</i> , 2016, 33, 4.	2.5	1
4955	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. <i>Molecular Oncology</i> , 2016, 10, 635-643.	4.6	131
4956	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 153-163.	10.7	210
4957	High CYP2C19 phenotypic variability in gastrointestinal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 195-204.	2.3	6

#	ARTICLE	IF	CITATIONS
4958	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. <i>Medical Oncology</i> , 2016, 33, 13.	2.5	12
4959	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	7.0	103
4960	11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 84-91.	6.4	77
4961	A Patch-Based Approach for the Segmentation of Pathologies: Application to Glioma Labelling. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 1066-1076.	8.9	41
4962	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. <i>Investigational New Drugs</i> , 2016, 34, 255-260.	2.6	40
4963	EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. <i>Cancer Biology and Therapy</i> , 2016, 17, 320-327.	3.4	30
4964	A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy. , 2016, , 355-363.		0
4965	Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. <i>Carcinogenesis</i> , 2016, 37, 461-470.	2.8	122
4966	PD-1 Blockade Expands Intratumoral Memory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 194-203.	3.4	321
4967	Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, NP47-NP60.	1.9	12
4968	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 693-699.	1.2	73
4969	Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 141-150.	4.2	24
4970	3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. <i>European Radiology</i> , 2016, 26, 3243-3252.	4.5	24
4971	Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. <i>European Radiology</i> , 2016, 26, 3447-3455.	4.5	14
4972	Epigenetic Regulation of the Homeobox Gene <i>MSX1</i> Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3097-3104.	7.0	45
4973	Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. <i>Molecular Oncology</i> , 2016, 10, 475-480.	4.6	52
4974	Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2016, 152, 452.	4.1	82
4975	Tumor/normal esophagus ratio in 18F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. <i>Journal of Gastroenterology</i> , 2016, 51, 788-795.	5.1	18

#	ARTICLE	IF	CITATIONS
4976	Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. International Journal of Radiation Oncology Biology Physics, 2016, 94, 155-162.	0.8	8
4977	Electrochemotherapy as palliative treatment in patients with thyroid papillary carcinoma. Brazilian Journal of Otorhinolaryngology, 2016, 82, 285-288.	1.0	5
4978	Approach to the Solitary Liver Lesion: Imaging and When to Biopsy. Canadian Association of Radiologists Journal, 2016, 67, 130-148.	2.0	11
4979	Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. Targeted Oncology, 2016, 11, 167-174.	3.6	16
4980	Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients. Clinical and Translational Oncology, 2016, 18, 310-316.	2.4	37
4981	Systemic treatment in breast cancer: a primer for radiologists. Insights Into Imaging, 2016, 7, 131-144.	3.4	12
4982	Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute, 2016, 108, .	6.3	70
4983	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	13.7	5,456
4984	A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 77, 99-108.	2.3	12
4985	Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer, 2016, 53, 42-50.	2.8	76
4986	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. Molecular Diagnosis and Therapy, 2016, 20, 55-63.	3.8	22
4987	Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells. Clinical Cancer Research, 2016, 22, 2197-2206.	7.0	135
4988	Treatment of Large Brain Metastases With Stereotactic Radiosurgery. Technology in Cancer Research and Treatment, 2016, 15, 186-195.	1.9	20
4989	Computer Aided Theragnosis Using Quantitative Ultrasound Spectroscopy and Maximum Mean Discrepancy in Locally Advanced Breast Cancer. IEEE Transactions on Medical Imaging, 2016, 35, 778-790.	8.9	30
4991	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	7.1	534
4992	Quantitative Features of Liver Lesions, Lung Nodules, and Renal Stones at Multi-Phase Detector Row CT Examinations: Dependency on Radiation Dose and Reconstruction Algorithm. Radiology, 2016, 279, 185-194.	7.3	93
4993	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 66-74.	2.6	15
4994	Infrared spectra of primary melanomas can predict response to chemotherapy: The example of dacarbazine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 174-181.	3.8	19

#	ARTICLE	IF	CITATIONS
4995	Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. <i>Radiology</i> , 2016, 279, 44-55.	7.3	186
4996	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody—Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652.	7.0	74
4997	Alectinib in Crizotinib-Refractory <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 661-668.	1.6	548
4998	Population pharmacokinetics and exposure—response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 807-817.	2.3	43
4999	Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience. <i>Clinical Colorectal Cancer</i> , 2016, 15, e17-e22.	2.3	16
5000	Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. <i>Clinical Cancer Research</i> , 2016, 22, 1341-1347.	7.0	5
5001	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. <i>International Journal of Hyperthermia</i> , 2016, 32, 331-338.	2.5	6
5002	Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2016, 18, 1019-1025.	2.4	42
5003	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	1.3	1,644
5004	Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 271-275.	1.4	47
5005	The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 89S-95S.	5.0	27
5006	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.	2.6	116
5007	Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy. <i>Molecular and Clinical Oncology</i> , 2016, 4, 801-806.	1.0	14
5008	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 96S-104S.	5.0	8
5009	Liver-Directed Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 67-80.	0.5	0
5010	Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. <i>Clinical Oncology</i> , 2016, 28, 13-20.	1.4	47
5011	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 462-467.	1.3	54
5012	Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2367-2372.	1.5	5

#	ARTICLE	IF	CITATIONS
5013	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. <i>Investigational New Drugs</i> , 2016, 34, 355-363.	2.6	58
5014	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. <i>Science China Life Sciences</i> , 2016, 59, 468-479.	4.9	222
5015	Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. <i>Biomedical Reports</i> , 2016, 4, 609-614.	2.0	21
5016	Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 59, 65-78.	2.8	26
5017	Functional Outcomes of Salvage Surgery for Vestibular Schwannomas after Failed Gamma Knife Radiosurgery. <i>World Neurosurgery</i> , 2016, 90, 385-390.	1.3	14
5018	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 537-544.	1.1	42
5019	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 141, 2-9.	1.4	40
5020	Imaging of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , 2016, 45, 142-151.	1.0	18
5021	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 909-919.	2.4	4
5022	Transarterial embolization of hypervascular tumors using trisacryl gelatin microspheres (Embosphere): a prospective multicenter clinical trial in Japan. <i>Japanese Journal of Radiology</i> , 2016, 34, 366-375.	2.4	11
5023	In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. <i>Breast Cancer Research</i> , 2016, 18, 30.	5.0	129
5024	Predictive value of radiological response rate for pathological response to neoadjuvant chemotherapy and post-cystectomy survival of bladder urothelial cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 560-567.	1.3	9
5025	Cardiophrenic angle lymph node is an indicator of metastatic spread but not specifically peritoneal carcinomatosis in colorectal cancer patients. <i>European Journal of Surgical Oncology</i> , 2016, 42, 861-868.	1.0	3
5026	A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1288-1297.	0.5	6
5027	Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 303-309.	1.3	40
5028	Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 61-65.	1.9	7
5029	Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. <i>Cancer Science</i> , 2016, 107, 353-358.	3.9	28
5030	Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy. <i>European Journal of Radiology</i> , 2016, 85, 176-186.	2.6	29

#	ARTICLE	IF	CITATIONS
5031	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016, 7, 211-218.	4.9	16
5032	NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer. <i>Journal of Chemotherapy</i> , 2016, 28, 225-229.	1.5	6
5033	A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 571-578.	2.4	31
5034	Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. <i>Journal of Nuclear Medicine</i> , 2016, 57, 27S-33S.	5.0	84
5035	Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy. <i>Abdominal Radiology</i> , 2016, 41, 231-238.	2.1	17
5036	Observer variability in RECIST-based tumour burden measurements: a meta-analysis. <i>European Journal of Cancer</i> , 2016, 53, 5-15.	2.8	59
5037	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. <i>Lung Cancer</i> , 2016, 96, 87-92.	2.0	81
5038	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 877-885.	7.0	59
5039	Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. <i>European Journal of Surgical Oncology</i> , 2016, 42, 523-530.	1.0	47
5040	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). <i>Annals of Oncology</i> , 2016, 27, 856-861.	1.2	107
5041	Comparison of CT volumetric measurement with RECIST response in patients with lung cancer. <i>European Journal of Radiology</i> , 2016, 85, 524-533.	2.6	51
5042	Volumetric Radiosurgery for 1 to 10 Brain Metastases: A Multicenter, Single-Arm, Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 312-321.	0.8	37
5043	Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 5-7.	6.4	6
5044	Rapid development of image analysis research tools: Bridging the gap between researcher and clinician with pyOsiriX. <i>Computers in Biology and Medicine</i> , 2016, 69, 203-212.	7.0	34
5045	Evaluation of the Efficacy of Targeted Imaging Agents. <i>Journal of Nuclear Medicine</i> , 2016, 57, 653-659.	5.0	6
5046	Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. <i>Complementary Therapies in Medicine</i> , 2016, 24, 81-89.	2.7	45
5047	Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw005.	6.3	56
5048	Early Prediction of Tumor Response to Treatment: Preclinical Validation of ^{99m} Tc-Duramycin. <i>Journal of Nuclear Medicine</i> , 2016, 57, 805-811.	5.0	30

#	ARTICLE	IF	CITATIONS
5049	The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). International Journal of Oncology, 2016, 48, 900-907.	3.3	17
5050	Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 673-679.	0.8	102
5051	Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2016, 42, 763-768.	1.5	13
5052	Personalized chemotherapy of lung cancer: What the radiologist should know. Diagnostic and Interventional Imaging, 2016, 97, 287-296.	3.2	9
5053	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	3.6	34
5054	The Utility of Molecular Imaging in Prostate Cancer. Current Urology Reports, 2016, 17, 26.	2.2	15
5055	Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 169-176.	2.6	18
5056	A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Annals of Oncology, 2016, 27, 526-532.	1.2	69
5057	An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. Cancer Research, 2016, 76, 1214-1224.	0.9	16
5058	Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 713-722.	2.3	20
5059	Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer: biweekly versus standard triweekly XELOX (The ORION) Trial. Journal of Clinical Oncology, 2016, 34, 1723-1731.	1.6	289
5060	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Annals of Oncology, 2016, 27, 648-653.	1.2	36
5061	The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clinical Cancer Research, 2016, 22, 2323-2328.	7.0	28
5062	Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage. Journal of Cellular Immunotherapy, 2016, 2, 36-43.	0.6	2
5063	Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiotherapy and Oncology, 2016, 118, 442-446.	0.6	59
5064	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. OncoImmunology, 2016, 5, e1143997.	4.6	74
5065	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2016, 34, 1723-1731.	1.6	289
5066	Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Nutrition and Cancer, 2016, 68, 234-240.	2.0	12

#	ARTICLE	IF	CITATIONS
5067	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv437.	6.3	20
5068	What are we expecting from PET/MRI?. <i>Medecine Nucleaire</i> , 2016, 40, 31-40.	0.2	1
5069	Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. <i>Oral Oncology</i> , 2016, 54, 7-14.	1.5	92
5070	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3016-3024.	7.0	39
5071	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3157-3163.	7.0	207
5072	Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. <i>Japanese Journal of Radiology</i> , 2016, 34, 35-42.	2.4	3
5073	¹⁸ F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 34S-39S.	5.0	91
5074	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	13.7	610
5075	Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 637-645.	2.4	56
5076	Molecular Imaging of Biomarkers in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 53S-59S.	5.0	56
5077	Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 254.e7-254.e13.	1.6	12
5078	Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 111-121.	3.9	58
5079	The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis. <i>Journal of Chemotherapy</i> , 2016, 28, 235-241.	1.5	6
5080	Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients. <i>European Journal of Oncology Nursing</i> , 2016, 20, 133-139.	2.1	2
5081	Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1394-1400.	1.0	60
5082	Clinical efficacy and safety of laparoscopic nerve-sparing radical hysterectomy for locally advanced cervical cancer. <i>International Journal of Surgery</i> , 2016, 25, 54-58.	2.7	11
5083	Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 457-473.	0.5	98
5084	The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2016, 93, 47-54.	2.0	16

#	ARTICLE	IF	CITATIONS
5085	Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2897-2907.	7.0	48
5086	Serial ¹⁸ F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , 2016, 12, 333-342.	2.4	31
5087	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2016, 127, 569-579.	2.9	40
5088	Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 193-201.	1.0	75
5089	¹⁷⁷ Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1006-1013.	5.0	432
5090	Association of sentinel lymph node diameter with melanoma metastasis. <i>American Journal of Surgery</i> , 2016, 212, 315-320.	1.8	5
5091	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2016, 17, 299-308.	10.7	556
5092	Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NF- κ B-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. <i>Cancer Research</i> , 2016, 76, 2000-2012.	0.9	98
5093	The expanding landscape of diffusion-weighted MRI in prostate cancer. <i>Abdominal Radiology</i> , 2016, 41, 854-861.	2.1	8
5094	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 439-447.	4.1	85
5095	Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). <i>Journal of Chemotherapy</i> , 2016, 28, 50-58.	1.5	9
5096	Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 862-867.	1.2	137
5097	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	1.6	148
5098	Long-Term Survival Benefit and Potential for Cure after R1 Resection for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1897-1905.	1.5	33
5099	Molecular response assessed by ⁶⁸ Ga-DOTANOC and survival after ⁹⁰ Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 432-440.	6.4	40
5100	Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. <i>World Journal of Surgery</i> , 2016, 40, 1178-1190.	1.6	38
5101	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. <i>Cancer Treatment Reviews</i> , 2016, 44, 26-41.	7.7	45
5102	Unidimensional Measurement May Evaluate Target Lymph Nodal Response After Induction Chemotherapy for Nasopharyngeal Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e2667.	1.0	4

#	ARTICLE	IF	CITATIONS
5103	Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: A retrospective study. <i>International Journal of Hyperthermia</i> , 2016, 32, 316-323.	2.5	36
5104	Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 819-827.	2.3	14
5105	Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. <i>American Journal of Roentgenology</i> , 2016, 206, 645-654.	2.2	20
5106	Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. <i>Tumor Biology</i> , 2016, 37, 8901-8907.	1.8	15
5107	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 738-748.	27.0	303
5108	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 279-286.	2.2	16
5109	Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 772.	7.1	34
5110	Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1071-1083.	1.0	66
5111	A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 407-414.	1.3	15
5112	Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network. <i>Annals of Surgical Oncology</i> , 2016, 23, 1279-1286.	1.5	18
5113	Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. <i>Oncologist</i> , 2016, 21, 220-232.	3.7	35
5114	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	27.6	909
5115	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 380-390.	1.1	300
5116	Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. <i>Radiology</i> , 2016, 280, 576-584.	7.3	311
5117	Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. <i>American Journal of Roentgenology</i> , 2016, 206, 544-553.	2.2	41
5118	Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1585-1592.	6.4	74
5119	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1500-1509.	1.6	72
5120	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	1.9	133

#	ARTICLE	IF	CITATIONS
5121	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1062-1067.	1.2	35
5122	Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. <i>Radiation Oncology</i> , 2016, 11, 31.	2.7	28
5123	First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4142-4150.	1.6	187
5124	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	13.7	3,077
5125	Utilidad de la 18F-FDG PET/TC en el c�ncer de tiroides. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 186-192.	0.0	3
5126	Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. <i>Radiology and Oncology</i> , 2016, 50, 1-13.	1.7	101
5127	A Population-Based Gaussian Mixture Model Incorporating ¹⁸ F-FDG PET and Diffusion-Weighted MRI Quantifies Tumor Tissue Classes. <i>Journal of Nuclear Medicine</i> , 2016, 57, 473-479.	5.0	29
5128	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma â The SHELTER study. <i>Journal of Hepatology</i> , 2016, 65, 280-288.	3.7	98
5129	Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. <i>Clinical Cancer Research</i> , 2016, 22, 3831-3840.	7.0	99
5130	Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response. <i>Oncology Letters</i> , 2016, 11, 1294-1298.	1.8	14
5131	Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. <i>Radiology</i> , 2016, 280, 630-639.	7.3	66
5132	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	1.6	627
5133	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1325-1330.	2.5	20
5134	A Comparison of Lung Nodule Segmentation Algorithms: Methods and Results from a Multi-institutional Study. <i>Journal of Digital Imaging</i> , 2016, 29, 476-487.	2.9	68
5135	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 122-136.	4.4	24
5136	Randomised controlled trial of temoporfin photodynamic therapy plus chemotherapy in nonresectable biliary carcinomaâPCS Nordic study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 330-333.	2.6	22
5137	Prognostic Factors for Post-Recurrence Survival in Patients with Thoracic Esophageal Squamous Cell Carcinoma after Curative Resection. <i>Digestive Surgery</i> , 2016, 33, 136-145.	1.2	7
5138	Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668.	1.6	99

#	ARTICLE	IF	CITATIONS
5139	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. European Radiology, 2016, 26, 4303-4312.	4.5	63
5140	Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. International Urology and Nephrology, 2016, 48, 985-992.	1.4	10
5141	Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clinical Breast Cancer, 2016, 16, 180-187.	2.4	15
5142	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. Journal of Nuclear Medicine, 2016, 57, 355-360.	5.0	22
5143	Impact of the scout view orientation on the radiation exposure and image quality in thoracic and abdominal CT. European Radiology, 2016, 26, 4072-4079.	4.5	13
5144	Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 827-837.	1.1	94
5145	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Investigational New Drugs, 2016, 34, 236-242.	2.6	21
5146	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 724-731.	1.9	59
5147	Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. Radiographics, 2016, 36, 481-496.	3.3	80
5148	Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. European Journal of Surgical Oncology, 2016, 42, 829-835.	1.0	37
5149	Profiling of rectal cancers MRI in pathological complete remission states after neoadjuvant concurrent chemoradiation therapy. Clinical Radiology, 2016, 71, 250-257.	1.1	5
5150	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation—Positive Non-Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 305.	7.1	201
5151	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 873-883.	2.5	17
5152	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 309-314.	2.6	13
5153	A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational New Drugs, 2016, 34, 168-175.	2.6	40
5154	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 339-347.	2.3	4
5155	Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs, 2016, 34, 119-128.	2.6	30
5156	Measurements of Hepatic Metastasis on MR Imaging. Academic Radiology, 2016, 23, 132-143.	2.5	9

#	ARTICLE	IF	CITATIONS
5157	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 158-169.	4.4	10
5158	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1603-1610.	7.0	37
5159	Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 706-713.	1.6	60
5160	Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 740-746.	1.6	37
5161	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	1.6	517
5162	Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. <i>Endocrine-Related Cancer</i> , 2016, 23, R71-R84.	3.1	43
5163	Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2016, 21, 658-667.	2.2	18
5164	Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. <i>Tumor Biology</i> , 2016, 37, 5285-5293.	1.8	40
5165	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2351-2358.	7.0	141
5166	Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 38-43.	1.5	50
5167	Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. <i>Urology</i> , 2016, 89, 10-11.	1.0	2
5168	Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 82-88.	1.3	15
5169	A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). <i>European Journal of Cancer</i> , 2016, 53, 144-154.	2.8	29
5170	A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 316-325.	8.9	22
5171	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 477-484.	2.3	13
5172	Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. <i>International Journal of Clinical Oncology</i> , 2016, 21, 531-538.	2.2	3
5173	Patterns of Recurrence in Electively Irradiated Lymph Node Regions After Definitive Accelerated Intensity Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 766-774.	0.8	31
5174	Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. <i>Annals of Oncology</i> , 2016, 27, 487-493.	1.2	51

#	ARTICLE	IF	CITATIONS
5175	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American) T J ETQq0 2.4 rgBT / Overlock 10	2.4	10
5176	Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery?. International Journal of Surgery, 2016, 25, 98-105.	2.7	26
5177	Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Annals of Oncology, 2016, 27, 434-441.	1.2	213
5178	Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. Thyroid, 2016, 26, 414-419.	4.5	38
5179	Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. International Journal of Clinical Oncology, 2016, 21, 676-683.	2.2	4
5180	Intraprocedural blood volume measurement using C-arm CT as a predictor for treatment response of malignant liver tumours undergoing repetitive transarterial chemoembolization (TACE). European Radiology, 2016, 26, 755-763.	4.5	18
5181	Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery, 2016, 159, 302-310.	1.9	83
5182	“End of life”™ conversations, appreciation sequences, and the interaction order in cancer clinics. Patient Education and Counseling, 2016, 99, 92-100.	2.2	25
5184	An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clinical Cancer Research, 2016, 22, 54-60.	7.0	44
5185	Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer, 2016, 23, 771-779.	2.9	18
5186	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. Molecular Diagnosis and Therapy, 2016, 20, 65-74.	3.8	7
5187	Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 163-177.	2.2	20
5188	MR Imaging Biomarkers in Oncology Clinical Trials. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 11-29.	1.1	33
5189	Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 187-204.	1.1	11
5190	Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Supportive Care in Cancer, 2016, 24, 2075-2084.	2.2	99
5191	Phase II study of everolimus in refractory testicular germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 122.e17-122.e22.	1.6	39
5192	First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. Cancer Biology and Therapy, 2016, 17, 14-19.	3.4	4
5193	S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 99-108.	10.7	63

#	ARTICLE	IF	CITATIONS
5194	Multiparametric MR Imaging in Abdominal Malignancies. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 157-186.	1.1	26
5195	Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2016, 23, 1104-1110.	1.5	116
5196	Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trialâ€NCT02324595): a feasibility study. American Journal of Obstetrics and Gynecology, 2016, 214, 503.e1-503.e6.	1.3	66
5198	Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment. European Radiology, 2016, 26, 2828-2836.	4.5	66
5199	Body Diffusion-weighted MR Imaging in Oncology. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 31-44.	1.1	17
5200	An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clinical Cancer Research, 2016, 22, 1325-1329.	7.0	115
5201	Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma. Cellular Oncology (Dordrecht), 2016, 39, 15-21.	4.4	2
5202	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of Oncology, 2016, 27, 619-624.	1.2	269
5203	Upfront Genotyping of <i>DPYD</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology, 2016, 34, 227-234.	1.6	279
5204	Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival. World Journal of Urology, 2016, 34, 569-576.	2.2	21
5205	CT texture analysis can help differentiate between malignant and benign lymph nodes in the mediastinum in patients suspected for lung cancer. Acta Radiologica, 2016, 57, 669-676.	1.1	82
5206	Treatment of cancer patients in their last month of life: aimless chemotherapy. Supportive Care in Cancer, 2016, 24, 1603-1608.	2.2	22
5207	Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. Journal of Oncology Pharmacy Practice, 2016, 22, 599-604.	0.9	31
5208	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clinical Genitourinary Cancer, 2016, 14, 48-55.	1.9	14
5209	Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors. Tumor Biology, 2016, 37, 2863-2869.	1.8	12
5210	[18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 212-220.	6.4	39
5211	Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy. Radiologia Medica, 2016, 121, 229-237.	7.7	7
5212	Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 249-258.	6.4	49

#	ARTICLE	IF	CITATIONS
5213	High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab. <i>Clinical and Translational Oncology</i> , 2016, 18, 405-412.	2.4	1
5214	Cancer Imaging for Therapy Assessment. <i>Biosystems and Biorobotics</i> , 2016, , 387-405.	0.3	0
5215	Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 141-149.	0.8	15
5216	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	7.0	78
5217	Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. <i>European Radiology</i> , 2016, 26, 1590-1596.	4.5	61
5218	Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients. <i>IEEE Transactions on Biomedical Engineering</i> , 2016, 63, 1034-1043.	4.2	100
5219	Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival. <i>Radiologia Medica</i> , 2016, 121, 54-59.	7.7	30
5220	Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 102-109.	2.2	12
5221	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 277-282.	0.4	54
5222	18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 29-35.	1.4	44
5223	Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. <i>Journal of Neuro-Oncology</i> , 2016, 126, 483-491.	2.9	15
5224	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. <i>European Urology</i> , 2016, 69, 980-983.	1.9	12
5225	The best of both worlds “ managing the cancer, saving the bone. <i>Nature Reviews Endocrinology</i> , 2016, 12, 29-42.	9.6	35
5226	Management of advanced medullary thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 64-71.	11.4	100
5227	Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1078057.	4.6	29
5228	Do circulating long non-coding RNAs (lncRNAs) (lncRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?. <i>Tumor Biology</i> , 2016, 37, 3969-3978.	1.8	61
5229	Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors. <i>World Journal of Urology</i> , 2016, 34, 501-508.	2.2	8
5230	Influence of allelic variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2193-2199.	1.6	3

#	ARTICLE	IF	CITATIONS
5231	CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy?. United European Gastroenterology Journal, 2016, 4, 257-263.	3.8	99
5232	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatology, 2016, 152, 45.	4.1	539
5233	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. Clinical Genitourinary Cancer, 2016, 14, 231-236.	1.9	38
5234	ReCAP: Serum Tumor Marker Use in Patients With Advanced Solid Tumors. Journal of Oncology Practice, 2016, 12, 65-66.	2.5	16
5235	The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer. Tumor Biology, 2016, 37, 2219-2223.	1.8	9
5236	Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases. Clinical and Translational Oncology, 2016, 18, 342-351.	2.4	9
5237	Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. Tumor Biology, 2016, 37, 2145-2152.	1.8	12
5238	Augmented Reality Guidance for the Resection of Missing Colorectal Liver Metastases: An Initial Experience. World Journal of Surgery, 2016, 40, 419-426.	1.6	72
5239	Clinical outcome and predictors of treatment response in foam sodium tetradecyl sulfate sclerotherapy of venous malformations. European Radiology, 2016, 26, 1301-1310.	4.5	35
5240	Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology, 2016, 278, 275-284.	7.3	85
5241	Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan. Targeted Oncology, 2016, 11, 175-182.	3.6	20
5242	Circulating DNA in solid organ cancersâ€”analysis and clinical application. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 223-227.	0.5	15
5243	Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Clinical Lung Cancer, 2016, 17, 223-231.	2.6	57
5245	Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?. Annals of Surgical Oncology, 2016, 23, 789-795.	1.5	84
5246	Effectiveness and toxicity of hypofractionated high-dose intensity-modulated radiotherapy versus 2â€• and 3â€•dimensional radiotherapy in incurable head and neck cancer. Head and Neck, 2016, 38, E1264-70.	2.0	10
5247	Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). Hepatology Research, 2016, 46, 3-9.	3.4	51
5248	Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs^{â€•}. Veterinary and Comparative Oncology, 2016, 14, e171-e183.	1.8	18
5249	Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. European Radiology, 2016, 26, 286-295.	4.5	24

#	ARTICLE	IF	CITATIONS
5250	Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?. <i>Breast Cancer</i> , 2016, 23, 789-796.	2.9	5
5251	Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 118.	7.1	53
5252	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 1-133.	4.5	10,674
5253	EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. <i>Clinical Lung Cancer</i> , 2016, 17, 56-61.	2.6	26
5254	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. <i>Gastric Cancer</i> , 2016, 19, 3-14.	5.3	339
5255	Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 400-408.	2.0	27
5257	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 149-156.	3.6	1
5258	Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. <i>Neuroendocrinology</i> , 2016, 103, 345-353.	2.5	79
5259	Tankyrase Inhibition Blocks Wnt/ β -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 644-656.	7.0	143
5260	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 79-85.	7.0	65
5261	Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination ^{177}Lu -Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. <i>Neuroendocrinology</i> , 2016, 103, 432-439.	2.5	87
5262	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430.	5.3	11
5263	A review of statistical designs for improving the efficiency of phase II studies in oncology. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1010-1021.	1.5	8
5264	High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 272-280.	0.6	77
5265	A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial. <i>Acta Oncologica</i> , 2016, 55, 140-148.	1.8	17
5266	Uterine cervical cancer volumetry using T2- and diffusion-weighted MR images in patients treated by primary surgery and neoadjuvant chemotherapy. <i>Acta Radiologica</i> , 2016, 57, 378-383.	1.1	5
5267	A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 218-224.	1.5	61
5268	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606.	5.3	31

#	ARTICLE	IF	CITATIONS
5269	Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model. <i>Mathematical Medicine and Biology</i> , 2016, 33, 159-188.	1.2	28
5270	Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. <i>Acta Radiologica</i> , 2016, 57, 260-270.	1.1	29
5271	Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. <i>Pharmacogenomics Journal</i> , 2016, 16, 47-53.	2.0	24
5272	Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour. <i>European Radiology</i> , 2016, 26, 206-215.	4.5	24
5273	Two-stage phase II oncology designs using short-term endpoints for early stopping. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1671-1683.	1.5	15
5274	Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 126-135.	5.3	111
5275	Intravenous 100% 3 Fatty Acids Plus Gemcitabine. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 398-403.	2.6	18
5276	Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer. <i>Clinical Respiratory Journal</i> , 2017, 11, 632-639.	1.6	3
5277	Feasibility of Imaging and Treatment Monitoring of Breast Lesions with Three-Dimensional Shear Wave Elastography. <i>Ultraschall in Der Medizin</i> , 2017, 38, 51-59.	1.5	26
5278	Gene Expression Profiling of Tumors From Heavily Pretreated Patients With Metastatic Cancer for the Selection of Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 140-145.	1.3	10
5279	Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. <i>Molecular Carcinogenesis</i> , 2017, 56, 106-117.	2.7	19
5280	Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 53-59.	1.9	1
5281	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017, 71, 204-209.	1.9	65
5282	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 81-92.	1.9	230
5283	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	1.9	80
5284	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	1.9	40
5285	Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e189-e194.	1.1	47
5286	Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study. <i>Acta Radiologica</i> , 2017, 58, 249-255.	1.1	2

#	ARTICLE	IF	CITATIONS
5287	Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET. Lung Cancer, 2017, 107, 1-13.	2.0	30
5288	Prediction of the treatment outcome using intravoxel incoherent motion and diffusional kurtosis imaging in nasal or sinonasal squamous cell carcinoma patients. European Radiology, 2017, 27, 956-965.	4.5	48
5289	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. Gastric Cancer, 2017, 20, 358-367.	5.3	4
5290	Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. European Radiology, 2017, 27, 966-975.	4.5	25
5291	Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World Journal of Urology, 2017, 35, 45-49.	2.2	61
5292	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. Cancer Letters, 2017, 387, 25-31.	7.2	24
5293	Preceding bronchial cutting for exposure of the pulmonary artery buried in scar tissue after chemoradiotherapy. General Thoracic and Cardiovascular Surgery, 2017, 65, 67-70.	0.9	0
5294	Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer. Breast Cancer, 2017, 24, 137-146.	2.9	7
5295	Metastatic liver tumour segmentation with a neural network-guided 3D deformable model. Medical and Biological Engineering and Computing, 2017, 55, 127-139.	2.8	20
5296	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer, 2017, 20, 254-262.	5.3	51
5297	The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of <i>EGFR</i> Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment. Integrative Cancer Therapies, 2017, 16, 126-131.	2.0	16
5298	Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort. Journal of Neurosurgery, 2017, 126, 708-725.	1.6	29
5299	Toxicity and response in cats with neoplasia treated with toceranib phosphate. Journal of Feline Medicine and Surgery, 2017, 19, 619-623.	1.6	22
5300	SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer. Clinical and Translational Oncology, 2017, 19, 135-148.	2.4	3
5301	Clinical outcome, <i>PDGFRβ</i> and <i>KIT</i> expression in feline histiocytic disorders: a multicentre study. Veterinary and Comparative Oncology, 2017, 15, 65-77.	1.8	14
5302	Computational particle-haemodynamics analysis of liver radioembolization pretreatment as an actual treatment surrogate. International Journal for Numerical Methods in Biomedical Engineering, 2017, 33, e02791.	2.1	19
5304	Principles of Kinase Inhibitor Therapy for Solid Tumors. Annals of Surgery, 2017, 265, 311-319.	4.2	10
5305	Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma. Hepatology Research, 2017, 47, 387-397.	3.4	6

#	ARTICLE	IF	CITATIONS
5306	Single-institution Experience of SBRT for Lung Metastases in Sarcoma Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 83-85.	1.3	27
5307	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 60-65.	1.3	4
5308	Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 294-299.	1.3	6
5309	Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 288-293.	1.3	28
5310	Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 439-443.	1.3	21
5311	Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 27-34.	1.3	43
5312	Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 241-249.	1.3	5
5313	Outcome in dogs with advanced (stage 3b) anal sac gland carcinoma treated with surgery or hypofractionated radiation therapy. Veterinary and Comparative Oncology, 2017, 15, 1073-1086.	1.8	34
5314	Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 260-265.	1.3	3
5315	Diffusion MRI in early cancer therapeutic response assessment. NMR in Biomedicine, 2017, 30, e3458.	2.8	70
5316	Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 152-157.	1.3	59
5317	Safety, tolerability and pharmacokinetic properties of the novel triazene ^{TrIN} 2755 in tumour bearing dogs—A phase I study. Veterinary and Comparative Oncology, 2017, 15, 94-104.	1.8	1
5318	The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. Veterinary and Comparative Oncology, 2017, 15, 632-640.	1.8	24
5319	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine, 2017, 9, .	12.4	263
5320	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates in Surgery, 2017, 69, 67-73.	2.0	15
5321	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	7.0	53
5322	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. British Journal of Cancer, 2017, 116, 568-574.	6.4	155
5323	Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology Research and Treatment, 2017, 40, 21-26.	1.2	5

#	ARTICLE	IF	CITATIONS
5324	Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. <i>Oncology Letters</i> , 2017, 13, 811-818.	1.8	2
5325	Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?. <i>Journal of Surgical Oncology</i> , 2017, 115, 376-383.	1.7	32
5326	Radiotherapy in desmoid tumors. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 269-275.	2.0	30
5327	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017, 144, 486-490.	1.4	47
5328	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , 2017, 104, 119-125.	2.0	41
5329	A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. <i>Lung Cancer</i> , 2017, 104, 65-69.	2.0	19
5330	Point of care assessment of melanoma tumor signaling and metastatic burden from ¹²⁵ I-NMR analysis of tumor fine needle aspirates and peripheral blood. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 821-828.	3.3	9
5331	Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. <i>Radiotherapy and Oncology</i> , 2017, 122, 122-129.	0.6	37
5332	Evaluation of response after SBRT for liver tumors. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 170-175.	0.6	17
5333	Proton beam therapy for liver metastases from gastric cancer. <i>Journal of Radiation Research</i> , 2017, 58, 357-362.	1.6	20
5334	Intra-arterial therapies for liver cancer: assessing tumor response. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 119-127.	2.4	11
5335	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	1.6	327
5336	Cáncer de próstata resistente a la castración. Recomendaciones de consenso de la Asociación Española de Urología. <i>Actas Urológicas Españolas</i> , 2017, 41, 141-145.	0.7	6
5337	First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e609-e614.	1.9	42
5338	Prognostic value of post-Yttrium 90 radioembolization therapy 18F-fluorodeoxyglucose positron emission tomography in patients with liver tumors. <i>Clinical Imaging</i> , 2017, 42, 43-49.	1.5	2
5339	RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. <i>Clinical Lung Cancer</i> , 2017, 18, e223-e232.	2.6	24
5340	Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 234-240.e2.	2.6	6
5341	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. <i>European Journal of Radiology</i> , 2017, 88, 15-20.	2.6	15

#	ARTICLE	IF	CITATIONS
5342	Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIA study (BOOG2006-04). <i>European Journal of Surgical Oncology</i> , 2017, 43, 619-624.	1.0	1
5343	A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 751-759.	2.0	3
5344	Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial. <i>Breast Cancer</i> , 2017, 24, 615-623.	2.9	14
5345	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e345-e355.	1.9	6
5346	Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 931-938.	0.8	41
5347	Pseudoprogression of a spinal metastasis after stereotactic ablative body radiation therapy and immune checkpoint therapy. <i>Practical Radiation Oncology</i> , 2017, 7, 109-112.	2.1	3
5348	Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017, 125, 267-269.	1.2	30
5349	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 226-232.	1.3	8
5350	Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 361-369.	0.6	1
5351	Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 735-742.	1.0	33
5352	G4C14A4T14 polymorphism is associated with survival in advanced non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2017, 8, 63-72.	1.9	2
5353	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , 2017, 144, 621-630.	1.4	26
5354	Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. <i>Gynecologic Oncology</i> , 2017, 145, 37-40.	1.4	51
5355	Glycolysis inhibition improves photodynamic therapy response rates for equine sarcoids. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1543-1552.	1.8	13
5356	Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 939-946.	0.8	94
5357	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. <i>Future Oncology</i> , 2017, 13, 415-423.	2.4	18
5358	Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. <i>Abdominal Radiology</i> , 2017, 42, 1424-1433.	2.1	33
5359	ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2017, 35, 599-607.	2.6	41

#	ARTICLE	IF	CITATIONS
5360	First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 324-333.	2.6	81
5361	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 357-368.	2.4	11
5362	Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 901-911.	1.7	35
5363	Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. <i>Investigational New Drugs</i> , 2017, 35, 217-226.	2.6	12
5364	Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. <i>Leukemia Research</i> , 2017, 55, 58-64.	0.8	5
5365	Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report. <i>Medical Oncology</i> , 2017, 34, 18.	2.5	14
5366	FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 3479-3483.	7.0	63
5367	Paper-Based MicroRNA Expression Profiling from Plasma and Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2017, 63, 731-741.	3.2	16
5368	En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery. <i>Gynecologic Oncology</i> , 2017, 144, 564-570.	1.4	18
5369	Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. <i>British Journal of Cancer</i> , 2017, 116, 561-567.	6.4	48
5370	Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae. <i>Chinese Journal of Cancer</i> , 2017, 36, 8.	4.9	18
5371	ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases. <i>Journal of Digital Imaging</i> , 2017, 30, 275-286.	2.9	6
5373	U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 3484-3488.	7.0	106
5374	ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. <i>Experimental and Molecular Pathology</i> , 2017, 102, 78-85.	2.1	14
5375	Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials. <i>American Journal of Roentgenology</i> , 2017, 208, W31-W37.	2.2	10
5376	Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2017, 13, 704-714.	1.8	8
5377	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 312-322.	10.7	1,388
5378	Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 378-380.	3.3	23

#	ARTICLE	IF	CITATIONS
5379	Methylated free-circulating <i>HPP1</i> DNA is an early response marker in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 2134-2144.	5.1	55
5380	Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study. <i>Investigational New Drugs</i> , 2017, 35, 269-276.	2.6	15
5381	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 221-227.	3.9	70
5382	Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. <i>Immunotherapy</i> , 2017, 9, 197-206.	2.0	1
5383	Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2017, 22, 61-69.	3.7	40
5385	Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 865-873.	2.4	20
5386	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , 2017, 75, 24-32.	2.8	162
5387	Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial. <i>BMC Health Services Research</i> , 2017, 17, 133.	2.2	16
5388	Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I. <i>Journal of Nuclear Medicine</i> , 2017, 58, 881-887.	5.0	24
5389	Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1075-1082.	2.5	22
5390	Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1050-1055.	1.0	66
5391	A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017, 116, 884-892.	6.4	69
5392	Three-dimensional power Doppler ultrasound in the early assessment of response to concurrent chemo-radiotherapy for advanced cervical cancer. <i>Acta Radiologica</i> , 2017, 58, 1147-1154.	1.1	3
5393	Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769118.	1.8	13
5394	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	1.6	89
5395	The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts. <i>Scientific Reports</i> , 2017, 7, 42905.	3.3	16
5396	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	28.4	724
5397	Long-term follow-up of Dupuytren disease after injection of triamcinolone acetonide in Chinese patients in Taiwan. <i>Journal of Hand Surgery: European Volume</i> , 2017, 42, 678-682.	1.0	14

#	ARTICLE	IF	CITATIONS
5398	Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. <i>Oncolmmunology</i> , 2017, 6, e1283461.	4.6	75
5399	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 439-445.	2.5	10
5400	The American College of Radiology Incidental Findings Committee Recommendations for Management of Incidental Lymph Nodes. <i>Academic Radiology</i> , 2017, 24, 603-608.	2.5	2
5401	Sporadic desmoid tumors in the pediatric population: A single center experience and review of the literature. <i>Journal of Pediatric Surgery</i> , 2017, 52, 1637-1641.	1.6	11
5402	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. <i>Journal of Thoracic Oncology</i> , 2017, 12, 547-555.	1.1	16
5403	A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. <i>Oncologist</i> , 2017, 22, 129-e8.	3.7	18
5404	Skeletal muscle loss and prognosis of breast cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 2221-2227.	2.2	27
5405	Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: Tj ETQq1 1 0284314 rgt /Overdo	2.8	14
5406	Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. <i>Radiotherapy and Oncology</i> , 2017, 123, 234-239.	0.6	20
5407	Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 42743.	3.3	13
5408	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	27.0	2,677
5409	First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 315-323.	2.6	33
5410	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	10.7	322
5411	Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. <i>Journal of the American College of Surgeons</i> , 2017, 224, 906-916.	0.5	56
5412	A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2017, 43, 763-771.	1.0	38
5413	NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. <i>Neuroendocrinology</i> , 2017, 104, 170-182.	2.5	87
5414	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. <i>BMC Cancer</i> , 2017, 17, 137.	2.6	47
5415	Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 93-101.	2.5	14

#	ARTICLE	IF	CITATIONS
5416	Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study. <i>Breast Cancer</i> , 2017, 24, 635-641.	2.9	5
5417	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55.	2.8	145
5418	External beam radiotherapy for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011314.	2.8	14
5419	Custirsén in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2017, 18, 473-485.	10.7	67
5420	Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. <i>British Journal of Cancer</i> , 2017, 116, 994-1001.	6.4	40
5421	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2164-2178.	3.3	4
5422	Volumetric analysis of intravoxel incoherent motion imaging for assessment of solitary pulmonary lesions. <i>Acta Radiologica</i> , 2017, 58, 1448-1456.	1.1	14
5423	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 435-445.	10.7	399
5424	The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma. <i>International Immunopharmacology</i> , 2017, 46, 75-79.	3.8	39
5425	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	3.7	26
5426	Histogram analysis of apparent diffusion coefficient for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy. <i>Acta Radiologica</i> , 2017, 58, 1400-1408.	1.1	15
5427	A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 875-879.	5.6	16
5428	Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2017, 19, 762-771.	2.6	6
5429	Dynamic Evaluation of Liver Volume and Function in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 967-974.	1.7	50
5430	Is there a different dose—effect relation between the primary tumor and involved lymph nodes in locally advanced non-small-cell lung cancer? A hypothesis-generating study. <i>Acta Oncologica</i> , 2017, 56, 541-547.	1.8	4
5431	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	2.3	13
5432	Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. <i>Current Problems in Cancer</i> , 2017, 41, 182-193.	2.0	75
5433	Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 1-6.	2.0	21

#	ARTICLE	IF	CITATIONS
5434	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	1.4	55
5435	<i>PIK3CA</i> -mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 353-367.	3.3	9
5436	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 486-499.	10.7	60
5437	Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. <i>European Journal of Cancer</i> , 2017, 75, 259-267.	2.8	39
5438	DWI as an Imaging Biomarker for Bladder Cancer. <i>American Journal of Roentgenology</i> , 2017, 208, 1218-1228.	2.2	48
5439	Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. <i>Statistics in Medicine</i> , 2017, 36, 1172-1200.	1.6	5
5440	Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 103-110.	2.5	29
5441	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2017, 19, 14.	4.0	46
5442	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	10.7	1,612
5443	The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases. <i>International Journal of Hyperthermia</i> , 2017, 33, 483-488.	2.5	9
5444	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 152.e13-152.e22.	1.6	2
5445	Using Flow Characteristics in Three-Dimensional Power Doppler Ultrasound Imaging to Predict Complete Responses in Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 887-900.	1.7	7
5446	The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. <i>Medical Oncology</i> , 2017, 34, 11.	2.5	14
5447	Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas. <i>Hormones and Cancer</i> , 2017, 8, 108-118.	4.9	39
5448	Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. <i>Gut</i> , 2017, 66, 1449-1462.	12.1	131
5449	Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. <i>Radiation Research</i> , 2017, 187, 79-88.	1.5	15
5450	Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer. <i>Oncology Reports</i> , 2017, 37, 1059-1065.	2.6	29
5451	Treatment of peritoneal metastases from small bowel adenocarcinoma. <i>International Journal of Hyperthermia</i> , 2017, 33, 571-578.	2.5	20

#	ARTICLE	IF	CITATIONS
5452	Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists?. British Journal of Radiology, 2017, 90, 20160627.	2.2	25
5453	Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer, 2017, 123, 2303-2311.	4.1	32
5454	Association of Time-Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis. Clinical Pharmacology and Therapeutics, 2017, 101, 657-666.	4.7	142
5455	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 371-383.	10.7	43
5456	Statistical tools for the temporal analysis and classification of lung lesions. Computer Methods and Programs in Biomedicine, 2017, 142, 55-72.	4.7	5
5457	Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?. BMC Cancer, 2017, 17, 154.	2.6	30
5458	Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database. Prostate Cancer and Prostatic Diseases, 2017, 20, 289-293.	3.9	43
5459	Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab. JAMA Dermatology, 2017, 153, 291.	4.1	29
5460	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Molecular Imaging and Biology, 2017, 19, 903-914.	2.6	91
5461	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncology, The, 2017, 18, 464-472.	10.7	139
5462	Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clinical Genitourinary Cancer, 2017, 15, e583-e589.	1.9	8
5463	Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell Renal-Cell-Carcinoma: Proof-of-Concept Study. Scientific Reports, 2017, 7, 43356.	3.3	58
5464	Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours. British Journal of Radiology, 2017, 90, 20160853.	2.2	4
5465	Indeterminate Pulmonary Nodules in Resected Liver Metastases from Colorectal Cancer: A Comparison of Patient Outcomes. World Journal of Surgery, 2017, 41, 1834-1839.	1.6	6
5466	Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?. Clinical Genitourinary Cancer, 2017, 15, 502-508.	1.9	8
5467	Pre-treatment MDCT-based texture analysis for therapy response prediction in gastric cancer: Comparison with tumour regression grade at final histology. European Journal of Radiology, 2017, 90, 129-137.	2.6	55
5468	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology, 2017, 72, 962-971.	1.9	199
5469	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 142-148.	1.6	16

#	ARTICLE	IF	CITATIONS
5470	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2017, 75, 268-279.	2.8	62
5471	CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. <i>Clinical Cancer Research</i> , 2017, 23, 3684-3691.	7.0	20
5472	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
5473	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 21.	4.4	21
5474	Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. <i>Oncology Letters</i> , 2017, 13, 281-288.	1.8	33
5475	Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4251-4258.	7.0	62
5476	Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. <i>Investigational New Drugs</i> , 2017, 35, 235-241.	2.6	16
5477	Improving patient selection for selective internal radiation therapy of intrahepatic cholangiocarcinoma: A meta-regression study. <i>Liver International</i> , 2017, 37, 1056-1064.	3.9	35
5478	Radiological biomarkers for assessing response to locoregional therapies in hepatocellular carcinoma: From morphological to functional imaging. <i>Oncology Reports</i> , 2017, 37, 1337-1346.	2.6	3
5479	Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. <i>Nature Communications</i> , 2017, 8, 14262.	12.8	260
5480	Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. <i>BJU International</i> , 2017, 120, 623-630.	2.5	85
5481	Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non-Small Cell Lung Cancer. <i>Clinical Therapeutics</i> , 2017, 39, 610-619.	2.5	2
5482	Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 432-437.	1.6	8
5483	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. <i>Seminars in Oncology</i> , 2017, 44, 3-7.	2.2	83
5484	Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 797-810.	5.0	25
5485	LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 131-138.	2.3	8
5486	A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 804-813.	1.1	46
5487	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 82.	17.0	105

#	ARTICLE	IF	CITATIONS
5488	Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study. <i>International Journal of Endocrine Oncology</i> , 2017, 4, 9-22.	0.4	0
5489	Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence. <i>Clinical Colorectal Cancer</i> , 2017, 16, 349-357.e1.	2.3	14
5490	Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. <i>European Journal of Cancer</i> , 2017, 77, 117-126.	2.8	80
5491	Integration of PET/MR Hybrid Imaging into Radiation Therapy Treatment. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2017, 25, 377-430.	1.1	8
5492	Using circulating cell-free DNA to monitor personalized cancer therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 205-218.	6.1	107
5493	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	3.4	40
5494	Bone metastasis from lung cancer identified by genetic profiling. <i>Oncology Letters</i> , 2017, 13, 847-850.	1.8	4
5495	Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis. <i>Journal of Surgical Research</i> , 2017, 215, 114-124.	1.6	7
5496	CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. <i>Annals of Oncology</i> , 2017, 28, 1495-1507.	1.2	91
5497	Impact of target area selection in 125 Iodine seed brachytherapy on locoregional recurrence in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2017, 8, 147-152.	1.9	5
5499	Increasing circulating exosomes carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients. <i>Cancer Science</i> , 2017, 108, 448-454.	3.9	69
5500	A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. <i>Seminars in Oncology</i> , 2017, 44, 24-33.	2.2	12
5501	Resection after preoperative chemotherapy versus synchronous liver resection of colorectal cancer liver metastases. <i>Medicine (United States)</i> , 2017, 96, e6174.	1.0	10
5502	Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Renal Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e177-e182.	1.3	17
5503	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. <i>Future Oncology</i> , 2017, 13, 1181-1193.	2.4	25
5504	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 773-781.	2.6	4
5505	Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. <i>Immunology Letters</i> , 2017, 186, 20-27.	2.5	31
5506	A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound. <i>Scientific Reports</i> , 2017, 7, 45733.	3.3	49

#	ARTICLE	IF	CITATIONS
5507	irRECIST and iRECIST: the devil is in the details. <i>Annals of Oncology</i> , 2017, 28, 1676-1678.	1.2	27
5508	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. <i>Chemotherapy</i> , 2017, 62, 205-213.	1.6	10
5509	Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. <i>Journal of Surgical Oncology</i> , 2017, 116, 227-235.	1.7	19
5510	Management of Patients with Bilateral Multifocal Colorectal Liver Metastases: ALPPS. , 2017, , 57-71.		0
5511	Reduced dose CT with model-based iterative reconstruction compared to standard dose CT of the chest, abdomen, and pelvis in oncology patients: intra-individual comparison study on image quality and lesion conspicuity. <i>Abdominal Radiology</i> , 2017, 42, 2279-2288.	2.1	23
5512	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	13.7	3,224
5513	YWHAЕ -rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. <i>Gynecologic Oncology</i> , 2017, 145, 531-535.	1.4	32
5514	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 639-646.	1.3	51
5515	Gastric cancer with pituitary metastasis presenting as symptomatic secondary adrenal insufficiency: A case report. <i>Journal of Digestive Diseases</i> , 2017, 18, 369-372.	1.5	3
5516	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. <i>British Journal of Cancer</i> , 2017, 116, 1279-1286.	6.4	37
5517	ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. <i>Future Oncology</i> , 2017, 13, 1517-1525.	2.4	4
5518	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 690-697.	2.2	20
5519	Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 1247-1252.	2.4	22
5520	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2017, 18, 803-811.	10.7	261
5521	A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. <i>Cancer Investigation</i> , 2017, 35, 386-392.	1.3	8
5522	Pneumotoxicity associated with immune checkpoint inhibitor therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 305-316.	2.6	18
5523	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4617-4624.	7.0	399
5524	Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer. <i>Abdominal Radiology</i> , 2017, 42, 2513-2520.	2.1	14

#	ARTICLE	IF	CITATIONS
5525	Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1077-1085.	2.3	6
5526	The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma. <i>Human Pathology</i> , 2017, 64, 98-105.	2.0	6
5527	Simulation-based adjustment after exploratory biomarker subgroup selection in phase II. <i>Statistics in Medicine</i> , 2017, 36, 2378-2390.	1.6	3
5528	Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1383-1391.	2.0	9
5529	Automated detection and quantification of residual brain tumor using an interactive computer-aided detection scheme. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0
5530	The effects of iterative reconstruction in CT on low-contrast liver lesion volumetry: a phantom study. <i>Proceedings of SPIE</i> , 2017, , .	0.8	1
5531	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 1658-1666.	1.2	26
5532	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. <i>Annals of Oncology</i> , 2017, 28, 1532-1539.	1.2	239
5533	The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 696-702.	2.5	16
5534	First report of stereotactic body radiotherapy for large-volume spinal tumors. <i>International Cancer Conference Journal</i> , 2017, 6, 149-153.	0.5	3
5535	Risk factors for relapse of resectable pathologic N2 non small lung cancer and prediction model for time-to-progression. <i>Biomedical Journal</i> , 2017, 40, 55-61.	3.1	5
5536	Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China. <i>Cancer Gene Therapy</i> , 2017, 24, 215-220.	4.6	18
5537	Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST). <i>World Journal of Surgical Oncology</i> , 2017, 15, 79.	1.9	13
5538	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	1.9	209
5539	Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 388-395.	0.8	68
5540	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	3.4	400
5541	Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. <i>British Journal of Surgery</i> , 2017, 104, 669-678.	0.3	140
5542	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 298-306.	2.6	26

#	ARTICLE	IF	CITATIONS
5543	Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>Oncology Research and Treatment</i> , 2017, 40, 7-13.	1.2	9
5544	Management of desmoid tumours: A large national database of familial adenomatous patients shows a link to colectomy modalities and low efficacy of medical treatments. <i>United European Gastroenterology Journal</i> , 2017, 5, 735-741.	3.8	17
5545	Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. <i>Journal of Nuclear Medicine</i> , 2017, 58, 689-696.	5.0	15
5546	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 902-909.	2.8	37
5547	Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 2045-2052.	1.6	16
5548	Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial. <i>Molecular and Clinical Oncology</i> , 2017, 6, 622-626.	1.0	1
5549	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1319-1327.	6.4	15
5550	Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis. <i>British Journal of Cancer</i> , 2017, 116, 1329-1339.	6.4	35
5551	<i>PIK3CA</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4602-4616.	7.0	72
5552	Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1717-1726.	4.1	47
5553	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. <i>Melanoma Research</i> , 2017, 27, 243-250.	1.2	12
5554	Genome-wide DNA Methylation Analysis Reveals <i>GABBR2</i> as a Novel Epigenetic Target for <i>EGFR</i> 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 5003-5014.	7.0	16
5555	Prognostic value of incidental hypervascular micronodules detected on cone-beam computed tomography angiography of patients with liver metastasis. <i>European Radiology</i> , 2017, 27, 4837-4845.	4.5	2
5556	Prognostic value of tumor volume for patients with advanced lung cancer treated with chemotherapy. <i>Computer Methods and Programs in Biomedicine</i> , 2017, 144, 165-177.	4.7	10
5557	Role of contrast enhanced spectral mammography in predicting pathological response of locally advanced breast cancer post neo-adjuvant chemotherapy. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 519-527.	0.6	31
5558	Darolutamide (ODM-201) for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 945-952.	1.8	52
5559	Contrast-enhanced Ultrasound Classification of Previously Indeterminate Renal Lesions. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 1819-1827.	1.7	33
5560	A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. <i>Oncology Letters</i> , 2017, 13, 3285-3290.	1.8	2

#	ARTICLE	IF	CITATIONS
5561	Immunotherapy for metastatic renal cell carcinoma. The Cochrane Library, 2017, 2017, CD011673.	2.8	31
5562	Innovations in Clinical Trial Design in the Era of Molecular Profiling. Methods in Molecular Biology, 2017, 1606, 19-36.	0.9	5
5563	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncology, The, 2017, 18, 743-754.	10.7	372
5564	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. European Journal of Cancer, 2017, 79, 185-192.	2.8	24
5565	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
5566	Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. Lung Cancer, 2017, 109, 89-91.	2.0	16
5567	Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary Experience. Radiology, 2017, 285, 53-62.	7.3	39
5568	Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1428-1437.	6.4	74
5569	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1486-1494.	3.6	27
5570	Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2017, 48, 103-109.	1.3	19
5571	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncology, The, 2017, 18, 770-778.	10.7	167
5572	350-560 µm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma. Medicine (United States), 2017, 96, e6629.	1.0	7
5573	A Dose-Volume Response Model for Brain Metastases Treated With Frameless Single-Fraction Robotic Radiosurgery: Seeking to Better Predict Response to Treatment. Technology in Cancer Research and Treatment, 2017, 16, 344-351.	1.9	6
5574	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	10.7	370
5575	Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncology Letters, 2017, 13, 1165-1174.	1.8	52
5576	Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy. International Journal of Cancer, 2017, 141, 621-635.	5.1	40
5577	Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clinical Lung Cancer, 2017, 18, 698-705.e2.	2.6	29
5578	Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecologic Oncology, 2017, 146, 52-57.	1.4	12

#	ARTICLE	IF	CITATIONS
5579	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1765-1767.	3.3	3
5580	Paclitaxel: What has been done and the challenges remain ahead. <i>International Journal of Pharmaceutics</i> , 2017, 526, 474-495.	5.2	286
5581	Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevacizumab: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 403-408.	1.0	8
5582	MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. <i>Oncology Letters</i> , 2017, 13, 1451-1455.	1.8	14
5583	Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 1647-1654.	1.8	5
5584	Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 1719-1724.	1.8	4
5585	Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy. <i>Oncology Letters</i> , 2017, 13, 2549-2556.	1.8	11
5586	A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. <i>Oncology Letters</i> , 2017, 13, 2957-2964.	1.8	19
5587	Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 534-542.	2.0	16
5588	Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 335-347.	4.7	38
5589	Small-cell lung cancer in never smokers: The clinicopathological features including the prognosis. <i>Cancer Treatment and Research Communications</i> , 2017, 12, 1-5.	1.7	0
5590	RECISTing the Temptation to Prematurely Stop Nivolumab. <i>European Urology</i> , 2017, 72, 377-378.	1.9	0
5591	Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011). <i>Lung Cancer</i> , 2017, 108, 232-237.	2.0	7
5592	Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 169-175.	1.8	13
5593	Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, 1280-1287.	1.2	42
5594	Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors. <i>Oncology</i> , 2017, 92, 353-359.	1.9	11
5595	Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1169-1177.	2.3	37
5596	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 146, 64-68.	1.4	35

#	ARTICLE	IF	CITATIONS
5597	Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics. <i>Oncology Letters</i> , 2017, 13, 1974-1982.	1.8	4
5598	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	2.2	18
5599	Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. <i>Clinical and Translational Imaging</i> , 2017, 5, 183-197.	2.1	59
5600	Neoadjuvant endocrine therapy in breast cancer patients. <i>Porto Biomedical Journal</i> , 2017, 2, 170-173.	1.0	1
5601	Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer—effect of renal insufficiency. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 407-412.	1.3	0
5602	Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 588.	3.3	254
5603	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1605-1611.	1.2	474
5604	Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST?. <i>Annals of Oncology</i> , 2017, 28, 1409-1411.	1.2	6
5605	Efficacy and safety of osimertinib in a Japanese compassionate use program. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 625-629.	1.3	12
5606	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. <i>Pancreatology</i> , 2017, 17, 629-634.	1.1	16
5607	PET/CT of Osteosarcoma and Ewing Sarcoma. <i>Seminars in Roentgenology</i> , 2017, 52, 255-268.	0.6	14
5608	Phase 1 dose-escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor β -targeting antibody-drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.	4.1	94
5609	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	4.1	170
5610	Mid-term outcomes after percutaneous cryoablation of symptomatic abdominal wall endometriosis: comparison with surgery alone in a single institution. <i>European Radiology</i> , 2017, 27, 4298-4306.	4.5	31
5611	Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors. <i>Cancer Treatment Reviews</i> , 2017, 56, 8-15.	7.7	33
5612	Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value. <i>Oral Oncology</i> , 2017, 68, 81-91.	1.5	55
5613	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1402-1407.	6.4	54
5614	Review article: delivering precision oncology in intermediate-stage liver cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1514-1523.	3.7	30

#	ARTICLE	IF	CITATIONS
5615	Agreement assessment in size measurement of hepatic metastases. Proceedings of SPIE, 2017, , .	0.8	0
5616	Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0. International Journal of Colorectal Disease, 2017, 32, 1077-1084.	2.2	30
5617	Beyond Correlations, Sensitivities, and Specificities. Academic Radiology, 2017, 24, 1027-1035.	2.5	6
5618	Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study. European Journal of Radiology Open, 2017, 4, 45-49.	1.6	2
5619	A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatric Blood and Cancer, 2017, 64, e26565.	1.5	11
5620	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	9.4	341
5621	Beyond Correlations, Sensitivities, and Specificities. Academic Radiology, 2017, 24, 1036-1049.	2.5	9
5622	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open, 2017, 2, e000168.	4.5	48
5623	Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 29-39.	2.5	66
5624	CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. European Radiology, 2017, 27, 3104-3116.	4.5	123
5625	Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. Annals of Surgical Oncology, 2017, 24, 914-922.	1.5	78
5626	Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. Acta Oncologica, 2017, 56, 101-103.	1.8	39
5627	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 357-364.	4.1	65
5628	Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Molecular Cancer Therapeutics, 2017, 16, 376-387.	4.1	23
5629	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 37.	7.4	129
5630	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncology, The, 2017, 18, 31-41.	10.7	845
5631	Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e187-e196.	2.6	11
5632	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. European Journal of Cancer, 2017, 70, 111-121.	2.8	70

#	ARTICLE	IF	CITATIONS
5633	Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 906-913.	1.5	32
5634	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509.	7.1	154
5635	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	10.7	975
5636	Perioperative blood transfusion: does it influence survival and cancer progression in metastatic spine tumor surgery?. <i>Transfusion</i> , 2017, 57, 440-450.	1.6	21
5638	Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. <i>Annals of Oncology</i> , 2017, 28, 1898-1902.	1.2	53
5639	Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. <i>Cancer Science</i> , 2017, 108, 1520-1529.	3.9	16
5640	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5339-5348.	7.0	142
5641	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials. <i>JAMA Oncology</i> , 2017, 3, e171029.	7.1	70
5642	Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. <i>International Cancer Conference Journal</i> , 2017, 6, 175-179.	0.5	6
5643	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	1.9	39
5644	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 31-35.	2.4	85
5645	Histological evaluations of primary lesions are independently associated with prognosis in patients with gastric cancer who receive neoadjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 13, 4892-4896.	1.8	4
5646	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 319-334.	4.7	26
5647	The Predictive Value of Tumor Size, Volume, and Markers During Radiation Therapy in Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 123-130.	2.5	14
5648	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. <i>Pharmacoeconomics</i> , 2017, 35, 831-844.	3.3	115
5649	Wide versus narrow margins after partial hepatectomy for hepatocellular carcinoma: Balancing recurrence risk and liver function. <i>American Journal of Surgery</i> , 2017, 214, 273-277.	1.8	20
5650	Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 282-285.	1.3	5
5651	Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. <i>Gynecologic Oncology</i> , 2017, 146, 491-497.	1.4	53

#	ARTICLE	IF	CITATIONS
5652	Simultaneous overactivation of Wnt/ β -catenin and TGF β signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. <i>Nature Communications</i> , 2017, 8, 15870.	12.8	159
5653	The efficacy and toxicities of intensive induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with N3 disease. <i>Scientific Reports</i> , 2017, 7, 3668.	3.3	11
5654	Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. <i>Immunologic Research</i> , 2017, 65, 880-887.	2.9	55
5655	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	2.8	76
5656	Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 515-529.	1.5	16
5657	Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. <i>British Journal of Cancer</i> , 2017, 117, 8-14.	6.4	31
5658	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017, 22, 1075-1083.	3.7	31
5659	Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). <i>Clinical and Experimental Metastasis</i> , 2017, 34, 309-314.	3.3	55
5660	Statistical controversies in clinical research: futility analyses in oncology—lessons on potential pitfalls from a randomized controlled trial. <i>Annals of Oncology</i> , 2017, 28, 1419-1426.	1.2	12
5661	Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. <i>Journal of Translational Medicine</i> , 2017, 15, 82.	4.4	35
5662	Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1962-1968.	5.0	120
5663	Systematic review of transarterial embolization for hepatocellular adenomas. <i>British Journal of Surgery</i> , 2017, 104, 823-835.	0.3	34
5664	Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up. <i>Endocrine</i> , 2017, 57, 35-45.	2.3	7
5665	A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer. <i>Breast Cancer</i> , 2017, 24, 783-789.	2.9	8
5666	MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer. <i>Cancer Biomarkers</i> , 2017, 18, 451-458.	1.7	14
5667	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. <i>Investigational New Drugs</i> , 2017, 35, 634-641.	2.6	25
5668	Review of phase I and II trials for Wilms' tumour — Can we optimise the search for novel agents?. <i>European Journal of Cancer</i> , 2017, 79, 205-213.	2.8	25
5669	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	2.8	29

#	ARTICLE	IF	CITATIONS
5670	CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies. Lung Cancer, 2017, 108, 168-172.	2.0	14
5671	Does pregnancy influence melanoma prognosis? A meta-analysis. Melanoma Research, 2017, 27, 289-299.	1.2	32
5672	Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes. Oncology, 2017, 93, 127-135.	1.9	9
5673	Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemotherapy and Pharmacology, 2017, 80, 29-36.	2.3	24
5674	A case of advanced gastric cancer achieved a pathological complete response by chemotherapy. Surgical Case Reports, 2017, 3, 68.	0.6	5
5675	Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies. Oncologist, 2017, 22, 979-988.	3.7	19
5676	Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series. CardioVascular and Interventional Radiology, 2017, 40, 1631-1640.	2.0	10
5677	Irinotecan+temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957.	10.7	205
5678	Dynamic Liver Magnetic Resonance Imaging in Free-Breathing. Investigative Radiology, 2017, 52, 708-714.	6.2	24
5679	Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. Tumor Biology, 2017, 39, 101042831770163.	1.8	8
5680	First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). European Journal of Cancer, 2017, 81, 191-202.	2.8	68
5681	Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nature Reviews Urology, 2017, 14, 549-563.	3.8	88
5682	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2415-2426.	27.0	2,145
5683	Information for Clinicians: Approach to the Patient with Progressive Radioiodine-Refractory Thyroid Cancer—When to Use Systemic Therapy. Thyroid, 2017, 27, 987-993.	4.5	12
5684	A Phase 1 study evaluating AMG 337 in Asian patients with advanced solid tumors. Japanese Journal of Clinical Oncology, 2017, 47, 772-776.	1.3	4
5685	The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine (United States), 2017, 96, e5946.	1.0	12
5686	The role of radiotherapy in bone metastases: A critical review of current literature. European Journal of Cancer Care, 2017, 26, e12724.	1.5	25
5687	High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology, 2017, 285, 472-481.	7.3	46

#	ARTICLE	IF	CITATIONS
5688	Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831771057.	1.8	3
5689	Immunotherapy: The Wave of the Future in Bladder Cancer?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, S3-S17.	1.9	8
5690	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 565-575.	8.1	362
5691	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , 2017, 82, 56-65.	2.8	162
5692	Liver transplantation for hepatocellular carcinoma. <i>Current Opinion in Organ Transplantation</i> , 2017, 22, 128-134.	1.6	11
5693	Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study. <i>BMC Cancer</i> , 2017, 17, 294.	2.6	14
5694	Head-to-Head Comparison of Chest X-Ray/Head and Neck MRI, Chest CT/Head and Neck MRI, and ¹⁸ F-FDG PET/CT for Detection of Distant Metastases and Synchronous Cancer in Oral, Pharyngeal, and Laryngeal Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1919-1924.	5.0	72
5695	BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. <i>Statistics in Medicine</i> , 2017, 36, 3302-3314.	1.6	62
5696	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 463-474.	3.6	64
5697	Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. <i>Academic Radiology</i> , 2017, 24, 1233-1239.	2.5	41
5698	Management of advanced ovarian cancer in South West Wales â a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort. <i>Cancer Epidemiology</i> , 2017, 49, 85-91.	1.9	2
5699	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 635-641.	1.9	5
5700	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. <i>European Journal of Cancer</i> , 2017, 81, 17-25.	2.8	64
5701	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2017, 81, 9-16.	2.8	13
5702	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , 2017, 81, 36-44.	2.8	76
5703	Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1932-1938.	1.0	6
5704	Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 109, 28-35.	2.0	10
5705	A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). <i>British Journal of Cancer</i> , 2017, 117, 33-40.	6.4	104

#	ARTICLE	IF	CITATIONS
5707	Preoperative Predictive Factors for Complete Cyto-reduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy. International Journal of Gynecological Cancer, 2017, 27, 420-429.	2.5	12
5708	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clinical Cancer Research, 2017, 23, 4671-4679.	7.0	110
5709	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18Fâ€“Fluorodeoxyglucose (18Fâ€“FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer, 2017, 17, 392.	2.6	14
5710	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. Future Oncology, 2017, 13, 1677-1683.	2.4	5
5711	The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer. Molecular and Clinical Oncology, 2017, 6, 856-860.	1.0	7
5712	Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. Molecular and Clinical Oncology, 2017, 6, 963-967.	1.0	21
5713	MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. Oncology Letters, 2017, 14, 743-750.	1.8	26
5714	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 534-539.	1.9	3
5715	Role of Imaging in Response Assessment and Individualised Treatment for Sarcomas. Clinical Oncology, 2017, 29, 481-488.	1.4	19
5716	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Cancer Journal (Sudbury, Mass), 2017, 23, 86-91.	2.0	71
5717	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â€“ Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	7.0	492
5718	Comparison of FDG PET metabolic tumour volume <i>versus</i> ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer. British Journal of Radiology, 2017, 90, 20170035.	2.2	22
5719	Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Molecular and Clinical Oncology, 2017, 6, 753-757.	1.0	7
5720	Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. British Journal of Cancer, 2017, 117, 25-32.	6.4	74
5721	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3KÎ± Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2017, 23, 5015-5023.	7.0	65
5722	CTâ€“Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.5	30
5723	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research, 2017, 27, 358-368.	1.2	20
5724	Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Research, 2017, 27, 457-462.	1.2	15

#	ARTICLE	IF	CITATIONS
5725	Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells. <i>Melanoma Research</i> , 2017, 27, 411-416.	1.2	3
5726	Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. <i>Nuclear Medicine Communications</i> , 2017, 38, 593-600.	1.1	15
5727	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	4.1	24
5728	Liver Metastasis Is Facilitated by the Adherence of Circulating Tumor Cells to Vascular Fibronectin Deposits. <i>Cancer Research</i> , 2017, 77, 3431-3441.	0.9	60
5729	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	7.0	50
5730	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	2.8	11
5731	The prognostic utility of the "Tumor Burden Score" based on preoperative radiographic features of colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2017, 116, 515-523.	1.7	45
5732	Racial differences in colorectal cancer survival at a safety net hospital. <i>Cancer Epidemiology</i> , 2017, 49, 30-37.	1.9	11
5733	Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using ⁶⁸ Ga-PSMA PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1632-1637.	5.0	33
5734	Melanoma patient imaging in the era of effective systemic therapies. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1517-1527.	1.0	14
5735	Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. <i>Vaccine</i> , 2017, 35, 3582-3590.	3.8	30
5736	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. <i>Scientific Reports</i> , 2017, 7, 2388.	3.3	18
5737	Dinitrophenyl hapten with laser immunotherapy for advanced malignant melanoma: A clinical study. <i>Oncology Letters</i> , 2017, 13, 1425-1431.	1.8	9
5738	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 563-573.	4.9	272
5739	Sacituzumab govitecan (IMMU-132), an anti-CTRP2/CSN38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. <i>Cancer</i> , 2017, 123, 3843-3854.	4.1	145
5740	Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. <i>NMR in Biomedicine</i> , 2017, 30, e3748.	2.8	23
5741	Therapy assessment in prostate cancer using choline and PSMA PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 78-83.	6.4	31
5742	The impact of image reconstruction settings on 18F-FDG PET radiomic features: multi-scanner phantom and patient studies. <i>European Radiology</i> , 2017, 27, 4498-4509.	4.5	148

#	ARTICLE	IF	CITATIONS
5743	Utility of the maximum standardized uptake value on positron emission tomography for predicting therapeutic effect in recurrent gynecological malignancies: A preliminary study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1335-1341.	1.3	1
5744	Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2734-2743.	1.5	70
5745	CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma. <i>American Journal of Roentgenology</i> , 2017, 209, W85-W92.	2.2	10
5746	Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 427-432.	4.9	8
5747	Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety. <i>International Journal of Clinical Oncology</i> , 2017, 22, 880-886.	2.2	6
5748	Percutaneous radiofrequency ablation of lung metastases from colorectal carcinoma under C-arm cone beam CT guidance. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 793-799.	3.2	7
5749	Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I-II Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1256-1260.	2.5	14
5750	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3278-3287.	3.6	125
5751	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	7.0	29
5752	TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 261-273.	2.3	37
5753	Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 161-168.	1.0	17
5754	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. <i>BMJ Open</i> , 2017, 7, e014961.	1.9	69
5755	Extra-hepatic sarcoma metastasis surveillance in the liver: is arterial phase imaging necessary?. <i>Abdominal Radiology</i> , 2017, 42, 1679-1684.	2.1	1
5756	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1345-1357.	4.2	22
5757	Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2017, 15, 24-26.	4.4	14
5758	Evolution of lymphoma staging and response evaluation: current limitations and future directions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 631-645.	27.6	26
5759	Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma. <i>Biomedical Reports</i> , 2017, 7, 79-84.	2.0	24
5760	Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26650.	1.5	1

#	ARTICLE	IF	CITATIONS
5761	Prognostic Impact of Change in the Fibrinogen and Albumin Score During Preoperative Treatment in Esophageal Cancer Patients. <i>World Journal of Surgery</i> , 2017, 41, 2788-2795.	1.6	21
5762	A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. <i>Current Treatment Options in Oncology</i> , 2017, 18, 42.	3.0	7
5763	Reirradiation of the spine with stereotactic radiosurgery: Efficacy and toxicity. <i>Practical Radiation Oncology</i> , 2017, 7, e409-e417.	2.1	21
5764	Importance of recombinant human thyrotropin as an adjuvant in the radioiodine treatment of thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 261-267.	2.4	2
5765	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017, 28, 1346-1351.	1.2	34
5766	Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. <i>Future Oncology</i> , 2017, 13, 1699-1710.	2.4	98
5767	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 329-341.	2.5	40
5768	Radiographic predictors of response to endoluminal brachytherapy for the treatment of rectal cancer. <i>Journal of Radiation Oncology</i> , 2017, 6, 287-294.	0.7	0
5769	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 599-610.	10.7	257
5770	Accuracy of contemporary oesophageal cancer lymph node staging with radiological-pathological correlation. <i>Clinical Radiology</i> , 2017, 72, 693.e1-693.e7.	1.1	38
5771	The Arg803Lys genetic polymorphism is associated with susceptibility to and chemoradiotherapy efficacy in cervical carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 187-194.	1.9	4
5772	Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. <i>Surgery Today</i> , 2017, 47, 1249-1258.	1.5	24
5773	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. <i>Annals of Oncology</i> , 2017, 28, 1130-1136.	1.2	253
5774	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1294-1301.	1.2	150
5775	Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). <i>Oncology Letters</i> , 2017, 13, 747-753.	1.8	13
5776	Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017, 123, 2955-2964.	4.1	70
5777	A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 234-239.	1.6	2
5778	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	27.6	945

#	ARTICLE	IF	CITATIONS
5779	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , 2017, 28, 1302-1308.	1.2	32
5780	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 826-830.	1.6	24
5781	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after <i>ivolumab</i> treatment. <i>Thoracic Cancer</i> , 2017, 8, 275-277.	1.9	17
5782	Clinical Impact of Preoperative Chemotherapy on Microscopic Cancer Spread Surrounding Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 2326-2333.	1.5	19
5783	The significance of multi-line chemotherapy for advanced gastric cancer: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 606-612.	1.0	1
5784	Use of image registration and fusion algorithms and techniques in radiotherapy: Report of the AAPM Radiation Therapy Committee Task Group No. 132. <i>Medical Physics</i> , 2017, 44, e43-e76.	3.0	536
5785	A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 373-382.	2.5	15
5786	Magnetic resonance imaging guided reirradiation of recurrent and second primary head and neck cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 167-175.	1.2	28
5787	Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 8-20.	1.2	9
5788	Volumetric Versus Unidimensional Measures of Metastatic Colorectal Cancer in Assessing Disease Response. <i>Clinical Colorectal Cancer</i> , 2017, 16, 324-333.e1.	2.3	8
5789	Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e455-e462.	1.9	19
5790	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564.	2.6	12
5791	An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 480-488.	2.6	17
5792	Efficacy and safety of ethanol injection for endobronchial tumor debulking (a feasibility study). <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2017, 66, 471-476.	0.2	1
5793	Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation. <i>Journal of Surgical Research</i> , 2017, 213, 147-157.	1.6	5
5794	Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. <i>World Neurosurgery</i> , 2017, 100, 632-640.e4.	1.3	48
5795	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 704-715.	9.4	127
5796	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 141-153.	1.6	11

#	ARTICLE	IF	CITATIONS
5797	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544.	2.5	16
5798	Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma. <i>Academic Radiology</i> , 2017, 24, 1094-1100.	2.5	6
5799	Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. <i>European Journal of Cancer</i> , 2017, 76, 125-133.	2.8	38
5800	What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2017, 30, 397-405.	2.0	6
5801	Critères d'interprétation en imagerie cancérologique solide: RECIST, PERCIST. <i>Medecine Nucleaire</i> , 2017, 41, 241-248.	0.2	2
5802	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 236-242.	1.4	17
5803	Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. <i>Scientific Reports</i> , 2017, 7, 45193.	3.3	37
5804	Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2017, 37, 649-654.	0.9	17
5805	Efficacy and safety of eribulin in taxane-refractory patients in the "real world". <i>Future Oncology</i> , 2017, 13, 971-978.	2.4	13
5806	Utility of PET/CT After Cryoablation for Early Identification of Local Tumor Progression in Osseous Metastatic Disease. <i>American Journal of Roentgenology</i> , 2017, 208, 1342-1351.	2.2	8
5807	Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate. The impact of fibrosarcomatous transformation. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1134-1141.	1.0	55
5808	Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?. <i>Lung Cancer</i> , 2017, 108, 90-95.	2.0	10
5809	Photoacoustic signal characterization of cancer treatment response: Correlation with changes in tumor oxygenation. <i>Photoacoustics</i> , 2017, 5, 25-35.	7.8	44
5810	Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 1149-1158.	2.4	10
5811	Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 681-688.	2.3	4
5812	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 713-719.	10.9	33
5813	Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2017, 35, 271-276.	1.3	3
5814	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	1.2	249

#	ARTICLE	IF	CITATIONS
5815	â€˜Turban-likeâ€™ skull metastasis from pulmonary adenocarcinoma. <i>Thorax</i> , 2017, 72, 767-768.	5.6	2
5816	Computer-aided classification of mammographic masses using visually sensitive image features. <i>Journal of X-Ray Science and Technology</i> , 2017, 25, 171-186.	1.0	27
5817	Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors. <i>JAMA Oncology</i> , 2017, 3, 1222.	7.1	47
5818	Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinibâ€Treated Patients With Gastrointestinal Stromal Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 449-457.	2.5	11
5819	Evaluation of the efficacy of cisplatinâ€etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. <i>ERJ Open Research</i> , 2017, 3, 00128-2016.	2.6	20
5820	Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). <i>AAPS Journal</i> , 2017, 19, 1054-1070.	4.4	31
5821	iRECIST: A clarification of tumour response assessment in the immunotherapy era. <i>European Journal of Cancer</i> , 2017, 77, 165-167.	2.8	19
5822	Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 477-487.	1.3	15
5823	Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases. <i>Oncology</i> , 2017, 92, 135-141.	1.9	5
5824	Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naïve prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 891-901.	4.2	71
5825	Spatiotemporal diversification of inpatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. <i>Drug Discovery Today</i> , 2017, 22, 1148-1164.	6.4	30
5826	The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 77, 109-116.	2.8	35
5827	Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 4-10.	1.1	27
5828	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
5829	The Predictive Value of Early In-Treatment ¹⁸ F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Nonâ€Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1243-1248.	5.0	13
5830	Using a novel NQO1 bioactivatable drug, betaâ€lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 83-88.	1.7	24
5831	Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response. <i>Oncolimmunology</i> , 2017, 6, e1273311.	4.6	41
5832	Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. <i>American Journal of Roentgenology</i> , 2017, 209, 67-76.	2.2	27

#	ARTICLE	IF	CITATIONS
5833	18F-FDG-PET Suv as a Prognostic Marker of Increasing Size in Thyroid Cancer Tumors. Endocrine Practice, 2017, 23, 182-189.	2.1	3
5834	Combined fibrinogen and neutrophilâ€”lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Science, 2017, 108, 193-199.	3.9	68
5835	A Phase Iâ€”II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research, 2017, 23, 4095-4106.	7.0	213
5836	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncology, 2017, 3, e170231.	7.1	9
5837	Radiotherapy for adrenal gland metastases from hepatocellular carcinoma. Clinical and Translational Oncology, 2017, 19, 1154-1160.	2.4	9
5838	Clinical endpoints in trials of chemoradiation for patients with anal cancer. Lancet Oncology, The, 2017, 18, e218-e227.	10.7	22
5839	O 2 â€” and H 2 O 2 -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell, 2017, 31, 487-500.e8.	16.8	316
5840	LEP rs7799039, LEPR rs1137101, and ADIPOQ rs2241766 and 1501299 Polymorphisms Are Associated With Obesity and Chemotherapy Response in Mexican Women With Breast Cancer. Clinical Breast Cancer, 2017, 17, 453-462.	2.4	26
5841	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology, 2017, 105, 212-244.	2.5	325
5842	Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptorâ€”tyrosine kinase inhibitors. Tumor Biology, 2017, 39, 101042831769593.	1.8	4
5843	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Journal of Nuclear Medicine, 2017, 58, 1421-1428.	5.0	209
5844	Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer. Molecular and Clinical Oncology, 2017, 6, 163-166.	1.0	24
5845	Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Investigational New Drugs, 2017, 35, 491-498.	2.6	7
5846	A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Targeted Oncology, 2017, 12, 323-332.	3.6	84
5847	Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy. Molecular and Clinical Oncology, 2017, 6, 235-242.	1.0	29
5848	Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 55-66.	6.4	117
5849	Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. Neoplasia, 2017, 19, 255-260.	5.3	35
5850	Comparing available criteria for measuring brain metastasis response to immunotherapy. Journal of Neuro-Oncology, 2017, 132, 479-485.	2.9	39

#	ARTICLE	IF	CITATIONS
5851	Dynamic nuclear polarisation: The future of imaging in oncology?. Porto Biomedical Journal, 2017, 2, 71-75.	1.0	5
5852	Apply radiomics approach for early stage prognostic evaluation of ovarian cancer patients: a preliminary study. Proceedings of SPIE, 2017, , .	0.8	1
5853	Neoadjuvant chemotherapy response evaluation in breast cancer based on mammogram registration and tumor segmentation. Pattern Recognition and Image Analysis, 2017, 27, 122-130.	1.0	0
5854	Preclinical Antitumor Efficacy of BAY 1129980â€”a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibodyâ€”Drug Conjugate for the Treatment of Nonâ€”Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 893-904.	4.1	37
5855	New concepts in embolotherapy of HCC. Medical Oncology, 2017, 34, 58.	2.5	53
5856	The Role of High Dose Interleukin-2 in the Era of Targeted Therapy. Journal of Urology, 2017, 198, 538-545.	0.4	3
5857	Analysis of the RENAL and mRENAL Scores and the Relative Importance of Their Components in the Prediction of Complications and Local Progression after Percutaneous Renal Cryoablation. Journal of Vascular and Interventional Radiology, 2017, 28, 860-867.	0.5	27
5858	Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. Journal of Proteome Research, 2017, 16, 1868-1879.	3.7	17
5859	Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy. Journal of Dermatology, 2017, 44, 959-962.	1.2	4
5860	mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)â€”Study Design andÂ”Rationale. Clinical Colorectal Cancer, 2017, 16, 154-157.e1.	2.3	4
5861	Investigation of patterns of nodal metastases in BRAF mutant lung cancer. Lung Cancer, 2017, 108, 62-65.	2.0	8
5862	Measures to Prevent Air Embolism in Transthoracic Biopsy of the Lung. American Journal of Roentgenology, 2017, 208, W184-W191.	2.2	28
5863	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	4.4	22
5864	Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunology Letters, 2017, 184, 98-104.	2.5	29
5865	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology, 2017, 67, 173-183.	3.7	165
5866	Repeated diffusion MRI reveals earliest time point for stratification of radiotherapy response in brain metastases. Physics in Medicine and Biology, 2017, 62, 2990-3002.	3.0	36
5867	Tumor Cellâ€”Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clinical Cancer Research, 2017, 23, 5074-5081.	7.0	120
5869	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613. Clinical Lung Cancer, 2017, 18, 583-588.	2.6	84

#	ARTICLE	IF	CITATIONS
5870	Targeted Therapy in Thyroid Cancer: State of the Art. <i>Clinical Oncology</i> , 2017, 29, 316-324.	1.4	110
5871	Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study. <i>Lung Cancer</i> , 2017, 108, 66-71.	2.0	10
5872	Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. <i>Oncolimmunology</i> , 2017, 6, e1305535.	4.6	56
5873	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
5874	Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. <i>Oncologist</i> , 2017, 22, 394-401.	3.7	21
5875	Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 766-772.	2.6	25
5877	A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. <i>European Journal of Cancer</i> , 2017, 76, 144-151.	2.8	92
5878	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 501.	7.1	23
5879	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced "Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 556-566.	1.1	40
5880	Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26265.	1.5	14
5881	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588.	2.0	8
5882	Desmoid tumours of the head and neck in children: Review of management. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2017, 134, 155-160.	0.7	12
5883	Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. <i>Annals of Oncology</i> , 2017, 28, 590-596.	1.2	58
5884	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	3.6	22
5885	A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). <i>Annals of Oncology</i> , 2017, 28, 505-511.	1.2	57
5886	Clinical and therapeutic implications of <i>BRAF</i> mutation heterogeneity in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 233-242.	3.3	16
5887	Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review. <i>Liver Transplantation</i> , 2017, 23, 375-385.	2.4	16
5888	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185.	6.4	76

#	ARTICLE	IF	CITATIONS
5889	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, 354-361.	1.2	50
5890	Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. <i>Pharmacogenomics Journal</i> , 2017, 17, 441-451.	2.0	21
5891	Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. <i>Acta Oncol</i> , 2017, 56, 7-16.	1.8	33
5892	Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies. <i>Oncology Reports</i> , 2017, 37, 57-65.	2.6	15
5893	A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 290-297.	2.6	20
5894	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	1.4	7
5895	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3557-3565.	7.0	19
5896	Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAB) in the Second- and Third-Line Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2017, 19, 527-533.	4.4	10
5897	Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 396-402.	1.9	7
5898	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 2972-2980.	7.0	106
5899	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). <i>Clinical Lung Cancer</i> , 2017, 18, 333-339.	2.6	47
5900	Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. <i>Oncologist</i> , 2017, 22, 33-40.	3.7	29
5901	Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study. <i>Supportive Care in Cancer</i> , 2017, 25, 1257-1261.	2.2	11
5902	Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data. <i>Medical Physics</i> , 2017, 44, 479-496.	3.0	22
5903	Gastrointestinal Stromal Tumors. , 2017, , .		70
5904	Imaging and Response Evaluation of Gastrointestinal Stromal Tumors. , 2017, , 73-89.		1
5905	Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 358-364.	1.3	7
5906	Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT. <i>European Journal of Radiology</i> , 2017, 86, 83-91.	2.6	24

#	ARTICLE	IF	CITATIONS
5907	Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study. Lung Cancer, 2017, 104, 58-64.	2.0	22
5908	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Annals of Oncology, 2017, 28, 791-797.	1.2	178
5909	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 324-332.e1.	2.6	33
5910	A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Annals of Oncology, 2017, 28, 804-808.	1.2	31
5911	Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. Apmis, 2017, 125, 79-84.	2.0	30
5912	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clinical Cancer Research, 2017, 23, 3520-3528.	7.0	19
5913	Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. Neurosurgical Focus, 2017, 42, E5.	2.3	19
5914	Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image. Journal of Magnetic Resonance Imaging, 2017, 46, 281-289.	3.4	22
5915	Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast, 2017, 32, 66-72.	2.2	29
5916	Feasibility of the administration of chemotherapy using cisplatin plus etoposide for non-small cell lung cancer patients with interstitial lung disease on chest computed tomography. Cancer Treatment and Research Communications, 2017, 10, 6-11.	1.7	3
5917	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Annals of the Rheumatic Diseases, 2017, 76, 43-50.	0.9	317
5918	Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor- β (PDGF- β), and PDGF- β receptor expression in papillary renal cell carcinoma. Human Pathology, 2017, 61, 78-89.	2.0	5
5919	RECIST – learning from the past to build the future. Nature Reviews Clinical Oncology, 2017, 14, 187-192.	27.6	78
5920	Multiplex KRAS G12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Annals of Oncology, 2017, 28, 642-650.	1.2	41
5921	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research, 2017, 23, 2691-2701.	7.0	106
5922	Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clinical Cancer Research, 2017, 23, 3097-3108.	7.0	223
5923	Reply. American Journal of Neuroradiology, 2017, 38, E20-E20.	2.4	0
5924	Intravoxel incoherent motion diffusion-weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma. Journal of Magnetic Resonance Imaging, 2017, 45, 1013-1023.	3.4	50

#	ARTICLE	IF	CITATIONS
5925	Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26375.	1.5	12
5926	Magnetic Resonance Imaging for Axillary Breast Cancer Metastasis in the Neoadjuvant Setting: A Prospective Study. <i>Clinical Breast Cancer</i> , 2017, 17, 180-187.	2.4	16
5927	Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 502-512.	0.5	34
5928	Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. <i>British Journal of Radiology</i> , 2017, 90, 20160665.	2.2	270
5929	Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. <i>Molecular Biology Reports</i> , 2017, 44, 149-158.	2.3	7
5930	Radiologic Response Assessment in Pediatric Soft Tissue Sarcoma: Computed-Assisted Volume Evaluation. <i>Journal of Pediatrics</i> , 2017, 182, 327-334.e2.	1.8	7
5931	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	1.4	11
5932	Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 425-433.	1.7	37
5933	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , 2017, 57, 539-543.	2.3	10
5934	Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2017, 40, 707-710.	1.2	7
5935	Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy. <i>American Journal of Roentgenology</i> , 2017, 209, 1278-1284.	2.2	5
5936	Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1189-1196.	2.3	7
5937	Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 59-65.	4.4	35
5938	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.6	16
5939	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	2.0	11
5940	Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 331-337.	0.6	26
5941	Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01. <i>Gynecologic Oncology</i> , 2017, 147, 577-584.	1.4	25
5942	Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients. <i>Immunotherapy</i> , 2017, 9, 1165-1174.	2.0	3

#	ARTICLE	IF	CITATIONS
5943	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1798-1805.	1.1	311
5944	Transarterial Chemoembolization of Renal Cell Carcinoma: A Prospective Controlled Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1664-1672.	0.5	18
5946	Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. <i>Head and Neck</i> , 2017, 39, 2406-2415.	2.0	25
5947	High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer. <i>Radiology and Oncology</i> , 2017, 51, 324-330.	1.7	11
5948	Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review. <i>Oncology Letters</i> , 2017, 14, 4085-4091.	1.8	14
5949	Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. <i>Cancer Science</i> , 2017, 108, 2213-2220.	3.9	22
5950	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. <i>ESMO Open</i> , 2017, 2, e000236.	4.5	30
5951	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. <i>JAMA Neurology</i> , 2017, 74, 1352.	9.0	12
5952	Liver transarterial embolizations in metastatic neuroendocrine tumors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 459-471.	5.7	38
5953	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1197-1207.	2.3	27
5954	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 995-1004.	2.0	14
5955	Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report. <i>Oncology Letters</i> , 2017, 14, 7099-7106.	1.8	7
5956	Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. <i>Clinical and Translational Radiation Oncology</i> , 2017, 6, 25-30.	1.7	5
5957	Assessment of radiological pulmonary shadows in patients with extra pulmonary neoplasm. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2017, 66, 681-686.	0.2	1
5958	Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach. <i>Cancer Science</i> , 2017, 108, 2030-2038.	3.9	18
5959	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2017, 390, 2461-2471.	13.7	1,749
5960	11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. <i>Cancer Investigation</i> , 2017, 35, 586-593.	1.3	14
5961	Whole-Body MRI: Current Applications in Oncology. <i>American Journal of Roentgenology</i> , 2017, 209, W336-W349.	2.2	89

#	ARTICLE	IF	CITATIONS
5962	Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Review of Anticancer Therapy, 2017, 17, 1093-1098.	2.4	23
5963	Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Oncology, 2017, 93, 367-376.	1.9	43
5964	High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. Molecular Medicine Reports, 2017, 16, 7185-7190.	2.4	3
5965	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. Clinical Skin Cancer, 2017, 2, 24-31.	0.1	2
5966	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncology, The, 2017, 18, 1532-1542.	10.7	65
5967	Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open, 2017, 2, e000214.	4.5	30
5968	Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. Annals of Surgical Oncology, 2017, 24, 3842-3849.	1.5	32
5969	Manual of Cardio-oncology. , 2017, , .		1
5970	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncology, The, 2017, 18, 1512-1522.	10.7	317
5971	Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. Surgical Oncology, 2017, 26, 460-472.	1.6	21
5972	Ultra-early apparent diffusion coefficient change indicates irradiation and predicts radiotherapy outcome in brain metastases. Acta Oncologica, 2017, 56, 1651-1653.	1.8	8
5973	Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer. Cancer Biomarkers, 2017, 20, 333-343.	1.7	7
5974	Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 784-786.	0.8	2
5975	Interim 18 F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review. Radiotherapy and Oncology, 2017, 125, 200-212.	0.6	30
5976	The best platinum regimens for chemo-naïve incurable non-small cell lung cancer: network meta-analysis. Scientific Reports, 2017, 7, 13185.	3.3	15
5977	Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 3803-3810.	1.5	45
5978	Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. European Journal of Radiology, 2017, 95, 96-101.	2.6	7
5979	Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology, 2017, 285, 358-375.	7.3	159

#	ARTICLE	IF	CITATIONS
5980	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 13-21.	4.4	56
5981	Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice. <i>Chemotherapy</i> , 2017, 62, 374-380.	1.6	10
5982	Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy. <i>Japanese Journal of Radiology</i> , 2017, 35, 740-747.	2.4	7
5984	A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2754-2760.	1.2	51
5985	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	10.7	535
5986	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017, 86, 257-265.	2.8	31
5987	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2017, 28, 2786-2792.	1.2	87
5988	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. <i>Annals of Oncology</i> , 2017, 28, 3044-3050.	1.2	198
5989	Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients. <i>Journal of Surgical Oncology</i> , 2017, 115, 760-767.	1.7	18
5990	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571.	1.4	9
5991	Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2017, 5, e1424.	0.6	36
5992	Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis. <i>Acta Oncol</i> , 2017, 56, 1621-1625.	1.8	21
5993	Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases. <i>American Journal of Roentgenology</i> , 2017, 209, 1039-1045.	2.2	15
5995	Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 807-813.	2.3	11
5996	Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2017, 38, 858-867.	1.1	13
5997	Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1858-1863.	3.9	18
5998	Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e437-e442.	0.6	4
5999	Optimizing tumor immune response through combination of radiation and immunotherapy. <i>Medical Oncology</i> , 2017, 34, 165.	2.5	14

#	ARTICLE	IF	CITATIONS
6000	Long non-coding <scp>RNA CRLA</scp> is associated with poor response to chemotherapy in primary breast cancer. Thoracic Cancer, 2017, 8, 582-591.	1.9	16
6001	Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. Oncologist, 2017, 22, 1265-1270.	3.7	24
6002	Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies. Molecular and Clinical Oncology, 2017, 7, 205-210.	1.0	3
6003	Characterization of folate receptor alpha (FR α) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR α -targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecologic Oncology, 2017, 147, 402-407.	1.4	73
6004	Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma. Seminars in Liver Disease, 2017, 37, 259-274.	3.6	0
6005	TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response. Molecular Cancer Therapeutics, 2017, 16, 2913-2926.	4.1	13
6006	Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. Statistics in Medicine, 2017, 36, 4616-4626.	1.6	13
6007	A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 707-713.	2.3	14
6008	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 849-861.	27.0	578
6009	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Annals of Oncology, 2017, 28, 2595-2605.	1.2	229
6010	MR imaging characteristics of breast cancer diagnosed during lactation. British Journal of Radiology, 2017, 90, 20170203.	2.2	17
6011	First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study. Molecular and Clinical Oncology, 2017, 7, 347-350.	1.0	5
6012	Adaptive phase <scp>I</scp>/<scp>II</scp> clinical trials for drug combination assessment in oncology using the outcomes of each cycle. Pharmaceutical Statistics, 2017, 16, 433-444.	1.3	0
6013	Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review. Cancer Chemotherapy and Pharmacology, 2017, 80, 729-735.	2.3	15
6014	Automatic detection of new tumors and tumor burden evaluation in longitudinal liver CT scan studies. International Journal of Computer Assisted Radiology and Surgery, 2017, 12, 1945-1957.	2.8	61
6015	Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma. Medicine (United States), 2017, 96, e7920.	1.0	17
6016	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. Journal of the American College of Surgeons, 2017, 225, 740-746.	0.5	77
6017	Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer. Thoracic Cancer, 2017, 8, 620-629.	1.9	16

#	ARTICLE	IF	CITATIONS
6018	<i>In Silico</i> Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer. Cancer Research, 2017, 77, 6442-6452.	0.9	90
6019	Crohn Disease. Clinical Nuclear Medicine, 2017, 42, 837-841.	1.3	8
6020	Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107. Cancer Chemotherapy and Pharmacology, 2017, 80, 939-943.	2.3	1
6021	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	12.8	109
6022	Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology, 2017, 26, 411-422.	1.6	10
6023	Electrochemotherapy of Locally Advanced Pancreatic Cancer. , 2017, , 1871-1886.		0
6024	Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Scientific Reports, 2017, 7, 9255.	3.3	23
6025	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology, 2017, 147, 267-275.	1.4	222
6026	Analyzing breast tumor heterogeneity to predict the response to chemotherapy using 3D MR images registration. , 2017, , .		8
6027	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	13.7	1,261
6028	Long-term Observation of CT-guided Radiofrequency Ablation of Lung Neoplasm in 476 Consecutive Patients by a Thoracic Surgical Service. Academic Radiology, 2017, 24, 1517-1525.	2.5	3
6029	Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer. Medicine (United States), 2017, 96, e7823.	1.0	12
6030	Efficacy of Peptide Receptor Radionuclide Therapy in a United Statesâ€‘Based Cohort of Metastatic Neuroendocrine Tumor Patients. Pancreas, 2017, 46, 1121-1126.	1.1	22
6031	Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases. Pancreas, 2017, 46, 1219-1224.	1.1	26
6032	Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Science Translational Medicine, 2017, 9, .	12.4	174
6033	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	9.4	701
6034	DCEâ€‘and DWâ€‘MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer. NMR in Biomedicine, 2017, 30, e3799.	2.8	17
6035	A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anti-Cancer Drugs, 2017, 28, 1157-1165.	1.4	29

#	ARTICLE	IF	CITATIONS
6036	Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. <i>Neoplasia</i> , 2017, 19, 848-855.	5.3	475
6037	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Scientific Reports</i> , 2017, 7, 11836.	3.3	57
6038	Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer. <i>Oncology Letters</i> , 2017, 14, 3319-3326.	1.8	1
6039	Diagnostic imaging using positron emission tomography for gynecological malignancy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1687-1699.	1.3	17
6040	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. <i>Oncology</i> , 2017, 93, 279-286.	1.9	9
6041	Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal Cancer Resection. <i>Scientific Reports</i> , 2017, 7, 10816.	3.3	31
6042	The TRIANGLE operation “radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. <i>Hpb</i> , 2017, 19, 1001-1007.	0.3	124
6043	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. <i>Lung Cancer</i> , 2017, 113, 51-58.	2.0	16
6044	Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e7884.	1.0	16
6045	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	7.0	115
6046	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6771-6780.	7.0	114
6047	Retrospective study on timing of resection of hepatocellular adenoma. <i>British Journal of Surgery</i> , 2017, 104, 1695-1703.	0.3	30
6048	Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2527-2533.	2.5	14
6049	Volume fractions of DCE-MRI parameter as early predictor of histologic response in soft tissue sarcoma: A feasibility study. <i>European Journal of Radiology</i> , 2017, 95, 228-235.	2.6	15
6050	Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. <i>Investigational New Drugs</i> , 2017, 35, 800-812.	2.6	23
6051	Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1397-1410.	10.7	352
6052	Response Evaluation of Malignant Liver Lesions After TACE/SIRT: Comparison of Manual and Semi-Automatic Measurement of Different Response Criteria in Multislice CT. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2017, 189, 1067-1075.	1.3	2
6053	Collagen gel droplet-embedded culture drug sensitivity testing in hard palate cancer-predicted antitumor efficacy of cetuximab: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 637-641.	1.0	4

#	ARTICLE	IF	CITATIONS
6054	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. <i>Scientific Reports</i> , 2017, 7, 9519.	3.3	15
6055	Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2607-2618.	2.5	43
6056	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. <i>Pharmacoeconomics</i> , 2017, 35, 1257-1270.	3.3	49
6057	Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. <i>European Journal of Radiology Open</i> , 2017, 4, 101-107.	1.6	32
6058	PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. <i>Annals of Surgery</i> , 2017, 266, 91-98.	4.2	22
6059	Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer. <i>Chemotherapy</i> , 2017, 62, 361-366.	1.6	8
6060	Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. <i>Medical Oncology</i> , 2017, 34, 174.	2.5	22
6061	Quantitative analysis and clonal characterization of T-cell receptor $\hat{\Gamma}^2$ repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine. <i>Oncology Letters</i> , 2017, 14, 283-292.	1.8	6
6062	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	10.7	356
6063	Transcatheter Arterial Chemoembolization with Spherical Embolic Agent in Patients with Pulmonary or Mediastinal Metastases from Breast Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1386-1394.	0.5	21
6065	Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 785-791.	1.3	25
6066	Pelvic lymphangioliomyomatosis treated successfully with everolimus. <i>Medicine (United States)</i> , 2017, 96, e4562.	1.0	11
6067	Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine. <i>Radiology</i> , 2017, 284, 333-351.	7.3	46
6068	Stochastic Partial Differential Equations for Computer Vision with Uncertain Data. <i>Synthesis Lectures on Visual Computing</i> , 2017, 9, 1-160.	1.0	1
6069	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	10.7	2,058
6070	Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 707-716.	10.7	159
6071	Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. <i>Cancer Letters</i> , 2017, 406, 22-26.	7.2	47
6072	Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 636-643.	1.4	15

#	ARTICLE	IF	CITATIONS
6073	Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. <i>Annals of Oncology</i> , 2017, 28, 2559-2566.	1.2	80
6074	Therapy Modalities, Prognostic Factors, and Outcome of the Primary Cervical Carcinosarcoma: Meta-analysis of Extremely Rare Tumor of Cervix. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1957-1969.	2.5	23
6075	Lung adenocarcinoma patients of young age have lower <i>EGFR</i> mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. <i>ERJ Open Research</i> , 2017, 3, 00092-2016.	2.6	33
6076	Ultrasound Imaging of Apoptosis: Spectroscopic Detection of DNA-Damage Effects In Vivo. <i>Methods in Molecular Biology</i> , 2017, 1644, 41-60.	0.9	0
6077	The Natural History of Petroclival Meningiomas: A Volumetric Study. <i>Otology and Neurotology</i> , 2017, 38, 123-128.	1.3	18
6078	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	2.8	25
6079	Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 603.e7-603.e14.	1.6	0
6080	Population pharmacokinetics and exposureâ€“response of trastuzumab emtansine in advanced breast cancer previously treated with â€“HER2â€“targeted regimens. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2767-2777.	2.4	18
6081	⁸⁹ Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6128-6137.	7.0	51
6082	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWSâ€“FLI1 fusion transcript. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 645-652.	2.3	54
6083	Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status. <i>Investigational New Drugs</i> , 2017, 35, 682-690.	2.6	27
6084	Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	8
6085	A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 554-559.	1.4	15
6086	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. <i>Annals of Oncology</i> , 2017, 28, 2481-2488.	1.2	24
6087	Complete remission of refractory hepatoblastoma after liver transplantation in a child with sorafenib monotherapy: A new hope?. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26701.	1.5	7
6088	Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials. <i>Contemporary Clinical Trials Communications</i> , 2017, 7, 73-80.	1.1	1
6089	Accelerated Radiation Therapy Using Weekend Boost with Concurrent Cisplatin in Head and Neck Squamous Cell Cancers: An Indian Institutional Experience. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2017, 48, 307-315.	0.3	1
6090	Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 111, 43-50.	2.0	2

#	ARTICLE	IF	CITATIONS
6091	Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy. <i>Convergent Science Physical Oncology</i> , 2017, 3, 034001.	2.6	8
6092	Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1038-1046.	1.3	10
6093	Cancer Measurement at Ultrasound. <i>Ultrasound Quarterly</i> , 2017, 33, 116-124.	0.8	1
6094	Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase <scp>II</scp> study. <i>Cancer Science</i> , 2017, 108, 1223-1230.	3.9	66
6095	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
6096	Chimiothérapies personnalisées du cancer bronchique: ce que le radiologue doit connaître. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 146-156.	0.0	0
6097	Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. <i>Surgery</i> , 2017, 162, 836-845.	1.9	25
6098	Tumeurs desmoïdes cervico-faciales de l'enfant: mise au point sur la prise en charge. <i>Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2017, 134, 150-155.	0.0	0
6099	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 46-53.	7.7	2
6100	The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. <i>Urology</i> , 2017, 108, 114-121.	1.0	11
6101	Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2017, 146, 560-565.	1.4	33
6102	FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-associated Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7165-7170.	7.0	133
6103	An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 812-822.	2.0	14
6104	Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 151-158.	2.4	23
6105	Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 1843-1849.	3.9	40
6106	Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. <i>Lung Cancer</i> , 2017, 111, 176-181.	2.0	631
6107	Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma. <i>Melanoma Research</i> , 2017, 27, 463-468.	1.2	19
6108	Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PlvOTAL study. <i>European Journal of Cancer Care</i> , 2017, 26, e12734.	1.5	39

#	ARTICLE	IF	CITATIONS
6109	No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2017, 34, 141.	2.5	9
6110	Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis. <i>Scientific Reports</i> , 2017, 7, 5593.	3.3	28
6111	Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases. <i>Scientific Reports</i> , 2017, 7, 5809.	3.3	9
6112	Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2017, 96, e7223.	1.0	13
6114	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 615-622.	2.3	13
6115	Agreement Between Magnetic Resonance Imaging and Pathologic Findings in the Tumor Size Evaluation Before and After Neoadjuvant Chemotherapy Treatment: A Prospective Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1472-1479.	2.5	3
6116	Resisting RECISTâ€™ Uniformity Versus Clinical Validity. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1619-1627.	2.5	1
6117	Treatment outcome of diffuse large B-cell lymphoma involving the head and neck. <i>Medicine (United States)</i> , 2017, 96, e7223.	1.0	11
6118	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 6411-6420.	7.0	43
6119	Next generation sequencing of progressive colorectal liver metastases after portal vein embolization. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 351-361.	3.3	4
6120	First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). <i>Cancer Investigation</i> , 2017, 35, 541-546.	1.3	5
6121	The Role of ¹⁸ F-fluorodeoxyglucose Positron Emission Tomographyâ€Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors. <i>World Journal of Surgery</i> , 2017, 41, 1828-1833.	1.6	7
6122	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 41-46.	1.4	17
6123	Phase 1 doseâ€escalation study of singleâ€agent veliparib in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2017, 108, 1834-1842.	3.9	23
6124	Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 473-480.	2.5	32
6125	Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 403-408.	2.5	38
6126	Veliparib Monotherapy to Patients With <i>BRCA</i> Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1842-1849.	2.5	33
6127	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 63-67.	2.0	8

#	ARTICLE	IF	CITATIONS
6128	Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2017, 31, 89-95.	2.2	14
6129	Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 230-236.	1.4	12
6130	MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study. <i>Melanoma Research</i> , 2017, 27, 439-447.	1.2	24
6131	Dynamic Contrast-Enhanced Computed Tomographyâ€Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2017, 52, 103-110.	6.2	15
6132	Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy. <i>Clinical Nuclear Medicine</i> , 2017, 42, 655-662.	1.3	15
6133	Imaging-Based Preoperative Planning. , 2017, , 53-64.		0
6134	Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1979-1986.	2.3	10
6135	Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum. <i>Oncology Letters</i> , 2017, 14, 1628-1636.	1.8	11
6136	Immunotherapy in Nonâ€Small Cell Lung Cancer Treatment. <i>Journal of Thoracic Imaging</i> , 2017, 32, 300-312.	1.5	47
6137	Lung cancer requires multidisciplinary treatment to improve patient survival: A case report. <i>Oncology Letters</i> , 2017, 14, 3035-3038.	1.8	26
6138	Screening circular RNA related to chemotherapeutic resistance in breast cancer. <i>Epigenomics</i> , 2017, 9, 1175-1188.	2.1	136
6139	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 283-290.	1.4	37
6140	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e136139.	4.6	60
6141	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. <i>Oncology</i> , 2017, 93, 249-258.	1.9	19
6142	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	6.4	46
6143	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. <i>JAMA Oncology</i> , 2017, 3, e172411.	7.1	750
6145	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. <i>Head and Neck</i> , 2017, 39, 2329-2349.	2.0	26
6146	Lenalidomide as secondâ€line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 722-730.	3.7	12

#	ARTICLE	IF	CITATIONS
6147	Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. <i>Endocrine Connections</i> , 2017, 6, 549-556.	1.9	11
6148	Optimizing Lenvatinib Therapy in Patients with Metastatic Radioactive Iodine-resistant Differentiated Thyroid Cancers. <i>Endocrine Practice</i> , 2017, 23, 1254-1261.	2.1	22
6149	Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study. <i>Urology</i> , 2017, 108, 135-141.	1.0	10
6150	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. <i>European Respiratory Journal</i> , 2017, 50, 1700050.	6.7	301
6151	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	3.7	13
6152	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 90-95.	2.0	188
6153	Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534). <i>Annals of Surgery</i> , 2017, 266, 470-478.	4.2	99
6154	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 316-324.	4.9	3
6155	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. <i>Targeted Oncology</i> , 2017, 12, 655-661.	3.6	14
6156	Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites. <i>Oncology Letters</i> , 2017, 14, 1691-1696.	1.8	8
6157	Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1063-1072.	2.3	26
6158	EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. <i>European Respiratory Journal</i> , 2017, 50, 1700514.	6.7	20
6159	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	3.7	20
6160	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017, 17, 461-467.	2.2	5
6161	4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers. <i>Radiotherapy and Oncology</i> , 2017, 125, 147-153.	0.6	61
6162	Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. <i>Pancreatology</i> , 2017, 17, 833-838.	1.1	10
6163	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 757-766.	6.4	24
6164	Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. <i>Scientific Reports</i> , 2017, 7, 6595.	3.3	29

#	ARTICLE	IF	CITATIONS
6165	Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up. <i>Seminars in Ultrasound, CT and MRI</i> , 2017, 38, 559-570.	1.5	10
6166	Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 2707-2714.	1.2	70
6167	Unexpected side effect in mCRC. <i>Medicine (United States)</i> , 2017, 96, e6522.	1.0	5
6168	⁸⁹ Zr-anti- γ H2AX-TAT but not ¹⁸ F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 6498-6504.	7.0	20
6169	VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. <i>Medicine (United States)</i> , 2017, 96, e5942.	1.0	4
6170	Treatment of metastatic refractory colorectal cancer following regorafenib failure. <i>Molecular and Clinical Oncology</i> , 2017, 7, 308-312.	1.0	6
6171	Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 454-460.	1.0	0
6172	Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 2491-2498.	1.8	4
6173	A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy. <i>Medicine (United States)</i> , 2017, 96, e8534.	1.0	9
6175	European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. <i>European Journal of Cancer</i> , 2017, 87, 172-181.	2.8	72
6176	Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 803-807.	1.0	7
6177	High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. <i>Scientific Reports</i> , 2017, 7, 17188.	3.3	94
6178	Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses. <i>Clinical Medicine Insights: Case Reports</i> , 2017, 10, CCRP.S39851.	0.7	10
6179	Alternate Fractionation for Hepatic Tumors. <i>Medical Radiology</i> , 2017, , 173-201.	0.1	0
6180	Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. <i>Medical Oncology</i> , 2017, 34, 200.	2.5	7
6181	Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 14, 6525-6532.	1.8	32
6182	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	3.3	21
6184	Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2017, 75, 120-126.	1.5	12

#	ARTICLE	IF	CITATIONS
6185	Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 236-249.	7.7	24
6186	Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors. <i>Heliyon</i> , 2017, 3, e00438.	3.2	9
6187	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. <i>European Journal of Cancer</i> , 2017, 87, 65-74.	2.8	19
6188	Treatment and prognostic factors of patients with thymic epithelial tumors at first recurrence or progression. <i>Future Oncology</i> , 2017, 13, 2429-2439.	2.4	8
6189	Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study. <i>Drugs in R and D</i> , 2017, 17, 585-596.	2.2	16
6190	Combination of platelet count and neutrophil-lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival in metastatic advanced gastric cancer. <i>Biomarkers in Medicine</i> , 2017, 11, 835-845.	1.4	4
6191	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 86, 349-357.	2.8	82
6192	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.	2.8	23
6193	LesionTracker: Extensible Open-Source Zero-Footprint Web Viewer for Cancer Imaging Research and Clinical Trials. <i>Cancer Research</i> , 2017, 77, e119-e122.	0.9	26
6194	Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?. <i>Oral Oncology</i> , 2017, 74, 142-147.	1.5	22
6195	Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2017, 14, 7589-7596.	1.8	25
6196	Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report. <i>Oncology Letters</i> , 2017, 14, 7545-7548.	1.8	4
6197	A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 551-557.	0.8	9
6198	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1600-1609.	10.7	282
6199	MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. <i>Journal of Surgical Research</i> , 2017, 220, 391-401.	1.6	17
6200	Tumor-Volume-Doubling Time of Pulmonary Metastases in Follicular-Cell-Derived Thyroid Carcinoma May Allow More Appropriate Selection of Patients for Multikinase Inhibitor Therapy. <i>Clinical Thyroidology</i> , 2017, 29, 378-381.	0.1	1
6201	Breast cancer response post neoadjuvant chemotherapy using MRI measurements. , 2017, , .		1
6202	One-Step Systemic Staging for Patients with Breast Cancer. , 2017, , 265-276.		0

#	ARTICLE	IF	CITATIONS
6203	Weekly cabazitaxel plus prednisone is effective and less toxic for \sim unfit TM metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. <i>European Journal of Cancer</i> , 2017, 87, 30-37.	2.8	17
6204	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	7.0	107
6205	Platinum-containing regimens for metastatic breast cancer. <i>The Cochrane Library</i> , 2017, 2017, CD003374.	2.8	40
6206	Efficacy and safety of recombinant human lymphotoxin α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. <i>Cancer</i> , 2017, 123, 3986-3994.	4.1	6
6207	<i>NUT</i> carcinoma in children and adults: A multicenter retrospective study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26693.	1.5	65
6208	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
6209	Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. <i>Lung Cancer</i> , 2017, 110, 56-62.	2.0	82
6210	Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review. <i>Dermatologic Surgery</i> , 2017, 43, 40-49.	0.8	60
6211	Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2131-2141.	2.5	13
6212	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1089-1103.	10.7	214
6213	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. <i>European Urology</i> , 2017, 72, 411-423.	1.9	89
6214	Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases – results of a prospective, non-randomized, single-centre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2030-2037.	2.4	20
6215	Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. <i>International Journal of Surgery</i> , 2017, 44, 152-159.	2.7	16
6216	Randomized Phase II Study of Preoperative Chemoradiotherapy \pm Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1413-1420.	1.1	22
6217	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. <i>The Cochrane Library</i> , 2017, 6, CD007047.	2.8	60
6219	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 497-505.	2.3	16
6220	Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 333-342.	2.3	23
6221	Unsupervised detection of density changes through principal component analysis for lung lesion classification. <i>Multimedia Tools and Applications</i> , 2017, 76, 18929-18954.	3.9	5

#	ARTICLE	IF	CITATIONS
6222	Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck. <i>Molecular and Clinical Oncology</i> , 2017, 7, 151-157.	1.0	22
6223	Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC. <i>Oncology Letters</i> , 2017, 14, 2573-2579.	1.8	20
6224	Targeted therapies for renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2017, 13, 496-511.	9.6	185
6225	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 654-659.	1.4	2
6226	Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel+carboplatin combination therapy in patients with epithelial ovarian cancer?. <i>Anti-Cancer Drugs</i> , 2017, 28, 922-927.	1.4	5
6227	Melanoma treatment guided by a panel of microRNA biomarkers. <i>Melanoma Management</i> , 2017, 4, 75-77.	0.5	1
6228	Complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 93-97.	1.0	1
6229	Interobserver reproducibility of maximal axial diameter and tumour volume measurements from CT of patients with head and neck squamous cell carcinoma. <i>Clinical Radiology</i> , 2017, 72, 993.e7-993.e13.	1.1	1
6230	Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. <i>Molecular and Clinical Oncology</i> , 2017, 7, 56-60.	1.0	16
6232	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. <i>European Journal of Cancer</i> , 2017, 82, 27-33.	2.8	25
6233	Response to Somatostatin Analog Therapy in a Patient With von Hippel-Lindau Disease and Multiple Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, e57-e57.	1.1	5
6234	The Prognostic Impact of Determining Resection Margin Status for Multiple Colorectal Metastases According to the Margin of the Largest Lesion. <i>Annals of Surgical Oncology</i> , 2017, 24, 2438-2446.	1.5	19
6235	Factors favouring long-term survival following recurrence in ovarian cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 42-46.	1.0	6
6236	Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. <i>Oncology Letters</i> , 2017, 14, 306-312.	1.8	11
6237	Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status. <i>Oncology Letters</i> , 2017, 14, 885-890.	1.8	15
6238	Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer. <i>Oncology Letters</i> , 2017, 14, 579-586.	1.8	6
6239	SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. <i>Medical Oncology</i> , 2017, 34, 136.	2.5	7
6240	Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. <i>Medical Oncology</i> , 2017, 34, 139.	2.5	11

#	ARTICLE	IF	CITATIONS
6241	Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2017, 7, 5082.	3.3	28
6243	Kikuchi-Fujimoto disease in the regional lymph nodes with node metastasis in a patient with tongue cancer: A case report and literature review. <i>Oncology Letters</i> , 2017, 14, 257-263.	1.8	8
6244	Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 507-516.	2.3	12
6245	Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. <i>World Journal of Urology</i> , 2017, 35, 1807-1816.	2.2	8
6246	Strain elastography imaging for early detection and prediction of tumor response to concurrent chemo-radiotherapy in locally advanced cervical cancer: feasibility study. <i>BMC Cancer</i> , 2017, 17, 427.	2.6	7
6247	The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. <i>Clinical Biochemistry</i> , 2017, 50, 982-987.	1.9	17
6248	Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1040-1048.	10.7	537
6249	Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1047-e1053.	1.9	7
6250	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. <i>Translational Oncology</i> , 2017, 10, 679-685.	3.7	9
6251	A pilot study of cabergoline for the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 585-592.	2.5	13
6252	Are we reproducible in measurement of NET liver metastasis?. <i>Digestive and Liver Disease</i> , 2017, 49, 1121-1127.	0.9	5
6253	Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer. <i>Oncology Letters</i> , 2017, 13, 4947-4952.	1.8	4
6254	First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 81, 142-150.	2.8	24
6255	Safety and feasibility of electrochemotherapy in patients with unresectable colorectal liver metastases: A pilot study. <i>International Journal of Surgery</i> , 2017, 44, 26-32.	2.7	35
6256	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase- α -inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. <i>Clinical Cancer Research</i> , 2017, 23, 5711-5719.	7.0	107
6257	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	7.0	69
6258	Percutaneous Image-Guided Thermal Ablation for Multifocal Renal Cell Carcinoma: 10-Year Experience at a Single Center. <i>American Journal of Roentgenology</i> , 2017, 209, 733-739.	2.2	15
6259	A systematic review and meta-analysis of traditional insect Chinese medicines combined chemotherapy for non-surgical hepatocellular carcinoma therapy. <i>Scientific Reports</i> , 2017, 7, 4355.	3.3	32

#	ARTICLE	IF	CITATIONS
6260	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). <i>European Journal of Endocrinology</i> , 2017, 177, 309-317.	3.7	30
6261	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1711-1717.	1.0	28
6262	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 27-31.	1.0	15
6263	A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 131-134.	1.0	13
6264	Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 733-741.	2.5	27
6265	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	2.5	25
6267	Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer. <i>Neoplasia</i> , 2017, 19, 617-627.	5.3	40
6268	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 655-668.	27.6	787
6269	Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. <i>Npj Systems Biology and Applications</i> , 2017, 3, 14.	3.0	45
6270	Assessing treatment efficacy in the subset of responders in a randomized clinical trial. <i>Annals of Oncology</i> , 2017, 28, 1640-1647.	1.2	7
6271	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	1.2	274
6273	First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. <i>Breast</i> , 2017, 35, 78-84.	2.2	23
6274	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 150.	4.4	26
6275	Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. <i>Radiation Oncology</i> , 2017, 12, 105.	2.7	34
6276	Trends in radiology and experimental research. <i>European Radiology Experimental</i> , 2017, 1, 1.	3.4	41
6277	Checkpoint inhibition for advanced mucosal melanoma. <i>European Journal of Dermatology</i> , 2017, 27, 160-165.	0.6	17
6278	Opening the Regulatory Black Box of Clinical Cancer Research: Transnational Expertise Networks and "Disruptive" Technologies. <i>Minerva</i> , 2017, 55, 161-185.	2.4	16
6279	Metronomic oral cyclophosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. <i>Medicine (United States)</i> , 2017, 96, e6518.	1.0	5

#	ARTICLE	IF	CITATIONS
6280	Longitudinal Computed Tomography Monitoring of Pelvic Bones in Patients With Breast Cancer Using Automated Bone Subtraction Software. <i>Investigative Radiology</i> , 2017, 52, 288-294.	6.2	5
6281	First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5703-5710.	7.0	160
6282	The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2017, 17, 39.	2.6	24
6283	Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. <i>BMC Cancer</i> , 2017, 17, 70.	2.6	10
6284	Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. <i>BMC Cancer</i> , 2017, 17, 322.	2.6	4
6285	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	2.6	28
6286	Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. <i>BMC Cancer</i> , 2017, 17, 390.	2.6	36
6287	Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. <i>BMC Cancer</i> , 2017, 17, 437.	2.6	21
6288	Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells. <i>Respiratory Research</i> , 2017, 18, 56.	3.6	6
6289	Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis. <i>World Journal of Surgical Oncology</i> , 2017, 15, 112.	1.9	3
6290	Molecular imaging biomarkers for cell-based immunotherapies. <i>Journal of Translational Medicine</i> , 2017, 15, 140.	4.4	11
6291	High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. <i>Radiation Oncology</i> , 2017, 12, 92.	2.7	9
6292	PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 174.	1.6	3
6293	Nuclear protein in testis carcinoma of the mediastinum: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 152.	0.8	5
6294	A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC. <i>EJNMMI Research</i> , 2017, 7, 8.	2.5	16
6295	Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer. <i>Biomarker Research</i> , 2017, 5, 19.	6.8	29
6296	Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
6297	Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone. , 2017, 5, 34.		6

#	ARTICLE	IF	CITATIONS
6298	Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. , 2017, 5, 52.		42
6299	Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. Cancer Imaging, 2017, 17, 10.	2.8	7
6300	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. JAMA Oncology, 2017, 3, 1511.	7.1	131
6301	Treatment Beyond Progression With Immune Checkpoint Inhibitorsâ€”Known Unknowns. JAMA Oncology, 2017, 3, 1473.	7.1	26
6302	Progressive hypofractionated carbonâ€”ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer, 2017, 123, 3955-3965.	4.1	66
6303	The treatment results of definitive radiotherapy for cervical esophageal cancer: a single-institution experience. Esophagus, 2017, 14, 254-261.	1.9	2
6304	A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. Journal of Neuro-Oncology, 2017, 133, 435-442.	2.9	9
6305	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. Current Oncology Reports, 2017, 19, 50.	4.0	17
6306	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2017, 28, 1210-1223.e3.	0.5	103
6307	A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Investigation, 2017, 35, 463-472.	1.3	23
6308	Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Thyroid, 2017, 27, 1135-1141.	4.5	37
6309	Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. Topics in Magnetic Resonance Imaging, 2017, 26, 43-53.	1.2	32
6310	Segmentation of Skeleton and Organs in Whole-Body CT Images via Iterative Trilateration. IEEE Transactions on Medical Imaging, 2017, 36, 2276-2286.	8.9	12
6311	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. American Journal of Roentgenology, 2017, 209, 567-575.	2.2	26
6312	Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma. Medicine (United States), 2017, 96, e5913.	1.0	28
6313	Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2017, 40, 1373-1380.	3.3	13
6314	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clinical Cancer Research, 2017, 23, 5416-5425.	7.0	189
6315	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Targeted Oncology, 2017, 12, 525-533.	3.6	15

#	ARTICLE	IF	CITATIONS
6316	Imaging for Oncologic Response Assessment in Lymphoma. American Journal of Roentgenology, 2017, 208, 18-31.	2.2	22
6317	Parametric Net Influx Rate Images of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast. Journal of Nuclear Medicine, 2017, 58, 744-749.	5.0	23
6318	The intensity of 18F-FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 638-646.	6.4	16
6319	The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology. Trends in Pharmacological Sciences, 2017, 38, 41-54.	8.7	21
6320	Cone-beam computed tomography for lung cancer validation with CT and monitoring tumour response during chemoradiation therapy. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 263-270.	1.8	6
6321	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research, 2017, 23, 1920-1928.	7.0	960
6322	Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin. Gastric Cancer, 2017, 20, 640-645.	5.3	3
6323	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational New Drugs, 2017, 35, 87-94.	2.6	9
6324	Intra-individual comparison of CAIPIRINHA VIBE technique with conventional VIBE sequences in contrast-enhanced MRI of focal liver lesions. European Journal of Radiology, 2017, 86, 20-25.	2.6	5
6325	Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer. Annals of Surgical Oncology, 2017, 24, 1057-1063.	1.5	8
6326	Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?. Radiology, 2017, 283, 883-894.	7.3	38
6327	Evaluation of sorafenib for advanced hepatocellular carcinoma with low α -fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. Journal of Medical Ultrasonics (2001), 2017, 44, 101-107.	1.3	13
6328	Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. Oncogene, 2017, 36, 1965-1977.	5.9	107
6329	Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE. Molecular Imaging and Biology, 2017, 19, 437-445.	2.6	28
6330	Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology, 2017, 52, 512-519.	5.1	275
6331	Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 11-20.	2.5	88
6332	RETROSPECTIVE COMPARISON OF THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY VS. PREDNISOLONE ALONE IN 30 CASES OF CANINE INFRATENTORIAL BRAIN TUMORS. Veterinary Radiology and Ultrasound, 2017, 58, 106-116.	0.9	18
6333	Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma. Radiology, 2017, 283, 580-589.	7.3	36

#	ARTICLE	IF	CITATIONS
6334	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	4.1	45
6335	Survival of de novo stage IV breast cancer patients over three decades. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 509-519.	2.5	30
6336	Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 69-80.	2.0	81
6337	Factors predicting outcomes of microwave ablation of small hepatocellular carcinoma. <i>Radiologia Medica</i> , 2017, 122, 81-87.	7.7	11
6338	First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2017, 23, 908-917.	7.0	149
6339	Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung. <i>Thyroid</i> , 2017, 27, 49-58.	4.5	14
6340	Diagnostic accuracy of computed tomography urography and visual assessment during ureterorenoscopy in upper tract urothelial carcinoma. <i>BJU International</i> , 2017, 119, 289-297.	2.5	26
6341	¹²⁵ Iodine brachytherapy via a trans-superior vena cava approach in patients with metastases in middle mediastinal lymph nodes: a novel approach. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 219-225.	1.1	3
6342	Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2017, 39, 456-463.	2.0	41
6343	Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 83-94.	2.5	156
6344	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , 2017, 71, 970-978.	1.9	12
6345	Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 666-676.	7.0	140
6346	Doxorubicin-Loaded 70-150 µm Microspheres for Liver-Dominant Metastatic Breast Cancer: Results and Outcomes of a Pilot Study. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 81-89.	2.0	19
6347	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , 2017, 28, 90-95.	1.2	24
6348	Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 13-20.	1.1	25
6349	Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo. <i>Endocrine-Related Cancer</i> , 2017, 24, 1-15.	3.1	14
6350	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. <i>Future Oncology</i> , 2017, 13, 615-624.	2.4	32
6351	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. <i>International Journal of Cancer</i> , 2017, 140, 948-958.	5.1	42

#	ARTICLE	IF	CITATIONS
6352	<i>EGFR</i> gene copy number predicts response to anti- <i>EGFR</i> treatment in <i>RAS</i> wild type and <i>RAS</i> / <i>BRAF</i> / <i>PIK3CA</i> wild type metastatic colorectal cancer. International Journal of Cancer, 2017, 140, 922-929.	5.1	25
6353	Imaging Biomarkers. , 2017, , .		7
6354	A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Annals of Oncology, 2017, 28, 121-127.	1.2	24
6355	The challenges of tumor genetic diversity. Cancer, 2017, 123, 917-927.	4.1	67
6356	PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer, 2017, 20, 416-427.	5.3	29
6357	Single and multidimensional measurements underestimate neuroblastoma response to therapy. Pediatric Blood and Cancer, 2017, 64, 18-24.	1.5	9
6358	Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e57-e70.	2.6	45
6359	The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy. Clinical Nutrition, 2017, 36, 1022-1028.	5.0	8
6360	Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients. Molecular Imaging and Biology, 2017, 19, 315-322.	2.6	30
6361	The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. International Journal of Clinical Oncology, 2017, 22, 159-165.	2.2	15
6362	Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. Journal of Dermatology, 2017, 44, 117-122.	1.2	170
6363	Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e217-e222.	1.9	14
6364	Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report. Nephrology, 2017, 22, 1017-1022.	1.6	6
6365	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clinical and Translational Oncology, 2017, 19, 364-372.	2.4	11
6366	Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. Journal of Medical Economics, 2017, 20, 140-150.	2.1	44
6367	Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 30.e1-30.e8.	1.6	42
6368	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. Future Oncology, 2017, 13, 31-49.	2.4	19
6369	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 2017, 71, 630-642.	1.9	1,215

#	ARTICLE	IF	CITATIONS
6370	Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. <i>Radiology</i> , 2017, 282, 585-597.	7.3	111
6371	Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017, 140, 208-215.	5.1	7
6372	Biocompatible astaxanthin as novel contrast agent for biomedical imaging. <i>Journal of Biophotonics</i> , 2017, 10, 1053-1061.	2.3	16
6373	[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 8-16.	6.4	20
6374	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. <i>Journal of Neuro-Oncology</i> , 2017, 131, 105-115.	2.9	61
6375	Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional Experience. <i>Journal of Obstetrics and Gynecology of India</i> , 2017, 67, 126-132.	0.9	6
6376	A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 47-58.	2.6	34
6377	Correlation Between SUV _{max} and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 282-287.	5.0	44
6378	Investigating the prediction value of multiparametric magnetic resonance imaging at 3T in response to neoadjuvant chemotherapy in breast cancer. <i>European Radiology</i> , 2017, 27, 1901-1911.	4.5	59
6379	MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. <i>European Radiology</i> , 2017, 27, 2521-2531.	4.5	38
6380	A novel approach for semi-quantitative assessment of reliability of blood flow values in DCE-CT perfusion. <i>Biomedical Signal Processing and Control</i> , 2017, 31, 257-264.	5.7	10
6381	Early responses assessment of neoadjuvant chemotherapy in nasopharyngeal carcinoma by serial dynamic contrast-enhanced MR imaging. <i>Magnetic Resonance Imaging</i> , 2017, 35, 125-131.	1.8	27
6382	Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 223-239.	3.1	62
6383	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 347-353.	1.1	50
6384	Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. <i>European Radiology</i> , 2017, 27, 2532-2537.	4.5	48
6385	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 476-489.	6.4	42
6386	Radiologic Response to Neoadjuvant Treatment Predicts Histologic Response in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 354-367.	1.1	14
6387	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 1955-1966.	7.0	27

#	ARTICLE	IF	CITATIONS
6388	Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 176-180.	1.3	20
6389	Cancer heterogeneity and imaging. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 48-57.	5.0	39
6390	A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. <i>Cancer</i> , 2017, 123, 420-425.	4.1	12
6391	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e275-e280.	1.9	19
6392	Phase 2 Study of Erlotinib in Combination With Afatinib (OSI-906) or Placebo in Chemotherapy-Naïve Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2.	2.6	29
6393	First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey. <i>Journal of Chemotherapy</i> , 2017, 29, 38-41.	1.5	2
6394	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 368-376.	1.2	641
6395	Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 1110-1120.	3.0	45
6396	A Randomized Feasibility Study of ¹⁸ F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40
6397	Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases: preliminary study. <i>Clinical Imaging</i> , 2017, 41, 1-6.	1.5	8
6398	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
6399	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. <i>Clinical Lung Cancer</i> , 2017, 18, 68-76.e2.	2.6	59
6400	The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges. <i>American Journal of Roentgenology</i> , 2017, 208, 131-139.	2.2	66
6401	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 310-315.	1.9	32
6402	Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. <i>Journal of Medical Economics</i> , 2017, 20, 1-7.	2.1	32
6403	Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. <i>Clinical Colorectal Cancer</i> , 2017, 16, 58-64.	2.3	59
6404	Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 313-319.	1.9	33
6405	Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 34-40.	2.4	5

#	ARTICLE	IF	CITATIONS
6406	Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, 16-22.	2.3	17
6407	Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECURSE trial. <i>Clinical and Translational Oncology</i> , 2017, 19, 227-235.	2.4	24
6408	Choosing a Prescription Isodose in Stereotactic Radiosurgery for Brain Metastases: Implications for Local Control. <i>World Neurosurgery</i> , 2017, 98, 761-767.e1.	1.3	11
6409	Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. <i>Journal of Nuclear Medicine</i> , 2017, 58, 899-904.	5.0	20
6410	Reporting standards for the imaging-based diagnosis of renal masses on CT and MRI: a national survey of academic abdominal radiologists and urologists. <i>Abdominal Radiology</i> , 2017, 42, 1229-1240.	2.1	27
6411	Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 299-308.	4.2	11
6412	Frameless stereotactic volumetric modulated arc radiotherapy of brachial plexus tumours in dogs: 10 cases. <i>British Journal of Radiology</i> , 2017, 90, 20160617.	2.2	15
6413	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764.	6.4	27
6414	Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response Criteria. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 61-68.	2.0	4
6415	Ultrasonographic findings can identify "pseudoprogression" under nivolumab therapy. <i>British Journal of Dermatology</i> , 2017, 177, 1726-1731.	1.5	11
6416	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1937-1944.	7.0	67
6417	Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 147-157.	3.2	17
6418	Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 259-267.	2.5	30
6419	Evaluation of pseudoprogression in patients with glioblastoma. <i>Neuro-Oncology Practice</i> , 2017, 4, 120-134.	1.6	12
6420	Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 208, 41-45.	1.1	12
6421	Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response. <i>Radiology</i> , 2017, 283, 663-672.	7.3	55
6422	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , 2017, 283, 168-177.	7.3	81
6423	Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2017, 92, 39-47.	1.9	24

#	ARTICLE	IF	CITATIONS
6424	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	1.6	584
6425	Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. <i>Gastric Cancer</i> , 2017, 20, 655-662.	5.3	34
6426	Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 37-46.	2.6	26
6427	Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial. <i>Annals of Nuclear Medicine</i> , 2017, 31, 153-162.	2.2	2
6428	A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 285-291.	1.2	12
6429	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1910-1919.	7.0	66
6430	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. <i>Prostate</i> , 2017, 77, 385-395.	2.3	6
6431	A Lesion-Based Response Prediction Model Using Pretherapy PET/CT Image Features for Y90 Radioembolization to Hepatic Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 620-629.	1.9	13
6432	Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. <i>International Journal of Clinical Oncology</i> , 2017, 22, 126-135.	2.2	5
6433	Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. <i>Annals of Surgical Oncology</i> , 2017, 24, 202-210.	1.5	49
6434	Prospective Evaluation of Reduced Dose Computed Tomography for the Detection of Low-Contrast Liver Lesions: Direct Comparison with Concurrent Standard Dose Imaging. <i>European Radiology</i> , 2017, 27, 2055-2066.	4.5	38
6435	An overview of PET/MR, focused on clinical applications. <i>Abdominal Radiology</i> , 2017, 42, 631-644.	2.1	21
6436	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 155-163.	1.7	34
6437	Image guided SBRT for multiple liver metastases with ExacTrac® Adaptive Gating. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 150-157.	0.6	11
6438	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <i>Cancer</i> , 2017, 123, 253-262.	4.1	42
6439	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 135-141.	1.5	24
6440	EGFR Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 585-590.	1.1	52
6441	Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 188-192.	1.0	19

#	ARTICLE	IF	CITATIONS
6442	Texture-based treatment prediction by automatic liver tumor segmentation on computed tomography. , 2017, , .		22
6443	Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis. Medicine (United States), 2017, 96, e8985.	1.0	11
6444	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. Medicine (United) Tj ETQq0 0 0 rgBT/Overlook 10 Tf 50		
6446	The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Oncology, 2017, 93, 75-82.	1.9	11
6447	A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. British Journal of Cancer, 2017, 117, 1592-1599.	6.4	77
6448	Efficacy of secondâ€‘line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with nonâ€‘small cell lung cancer without epidermal growth factor receptor mutations. Oncology Letters, 2017, 15, 600-609.	1.8	2
6449	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. British Journal of Cancer, 2017, 117, 1450-1458.	6.4	52
6450	Oxaliplatin and infliximab synergize to induce regression of colon cancer. Oncology Letters, 2018, 15, 1517-1522.	1.8	7
6451	P3.01-018 Mutation Abundance Affects the Therapeutic Efficacy of EGFR-TKI in Patients with Advanced Lung Adenocarcinoma: A Retrospective Analysis. Journal of Thoracic Oncology, 2017, 12, S2206-S2207.	1.1	0
6452	SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatric Blood and Cancer, 2017, 64, e26737.	1.5	21
6453	Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncology Letters, 2017, 15, 315-323.	1.8	22
6454	Longer recurrenceâ€‘free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus. Clinical Case Reports (discontinued), 2017, 5, 1950-1953.	0.5	2
6455	Clinical effects and safety of intraâ€‘arterial infusion therapy of cisplatin suspension in lipiodol combined with 5â€‘fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extraâ€‘hepatic spread: A prospective cohort study. Molecular and Clinical Oncology, 2017, 7, 1013-1020.	1.0	27
6456	Neurofibromatosis Type 1â€‘Associated MPNST State of the Science: Outlining a Research Agenda for the Future. Journal of the National Cancer Institute, 2017, 109, .	6.3	80
6457	Phase <sc>II</sc> study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02). Annals of Gastroenterological Surgery, 2017, 1, 219-225.	2.4	1
6458	Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Annals of Oncology, 2017, 28, 3037-3043.	1.2	14
6459	Ultrasonography, a useful tool for detecting tumour â€‘pseudoprogressionâ€™™. British Journal of Dermatology, 2017, 177, 1483-1484.	1.5	0
6460	Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Current Medical Science, 2017, 37, 864-872.	1.8	4

#	ARTICLE	IF	CITATIONS
6461	Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. <i>Annals of Oncology</i> , 2017, 28, 702-710.	1.2	46
6462	Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer in a Korean population: A single-center cohort study. <i>Seminars in Oncology</i> , 2017, 44, 420-427.	2.2	16
6463	Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study. <i>BMJ Open</i> , 2017, 7, e016816.	1.9	13
6464	Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy. <i>Oncology Letters</i> , 2017, 14, 6059-6065.	1.8	14
6465	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2017, 3, 147-148.	0.4	2
6466	Detection of circulating tumor cells in pulmonary venous blood for resectable non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 15, 1103-1112.	1.8	10
6467	Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer. <i>BMC Cancer</i> , 2017, 17, 604.	2.6	15
6468	Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. <i>BMC Gastroenterology</i> , 2017, 17, 143.	2.0	17
6469	Heterogeneity of advanced prostate cancer: clinical implications of genomics. <i>Trends in Urology & Men's Health</i> , 2017, 8, 24-27.	0.4	0
6470	Thyroid Cancer Treated with Tyrosine Kinase Inhibitor at Osaka University. <i>Journal of Otolaryngology of Japan</i> , 2017, 120, 1231-1238.	0.1	0
6471	A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma. <i>Journal of Rural Medicine: JRM</i> , 2017, 12, 105-111.	0.5	3
6472	Long-term Results of Therapy with Sunitinib in Metastatic Alveolar Soft Part Sarcoma. <i>Tumori</i> , 2017, 103, 231-235.	1.1	30
6473	Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 153.	17.0	70
6474	Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1021-1026.	1.0	4
6475	Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. <i>ESMO Open</i> , 2017, 2, e000272.	4.5	2
6476	Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. <i>BMC Cancer</i> , 2017, 17, 888.	2.6	46
6477	CONSORT 2010 statement: extension checklist for reporting within person randomised trials. <i>BMJ: British Medical Journal</i> , 2017, 357, j2835.	2.3	149
6478	Fractals for Biomedical Texture Analysis. , 2017, , 131-161.		5

#	ARTICLE	IF	CITATIONS
6479	Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC. <i>Oncology Letters</i> , 2017, 15, 1089-1096.	1.8	8
6480	Malignant pleural mesothelioma segmentation from thoracic CT scans. , 2017, , .		2
6481	Targeted therapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 0, , .	2.8	12
6482	Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 88835-88844.	1.8	44
6483	Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. <i>Gut and Liver</i> , 2017, 11, 298-305.	2.9	10
6484	A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. <i>Oncotarget</i> , 2017, 8, 44121-44130.	1.8	53
6485	CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease. <i>Oncotarget</i> , 2017, 8, 100421-100432.	1.8	19
6486	The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. <i>Annals of Research Hospitals</i> , 2017, 1, 1-1.	0.0	1
6487	Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90430-90443.	1.8	63
6488	Modern Imaging in Neurooncology. <i>Neurology International Open</i> , 2017, 01, E160-E170.	0.4	0
6489	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>MET</i>-amplified gastric cancer. <i>Oncotarget</i> , 2017, 8, 79546-79555.	1.8	21
6490	Treatment of succinate dehydrogenase B-associated renal cancer. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219626.	0.5	0
6491	Comparison of One-Dimensional and Volumetric Computed Tomography Measurements of Injected-Water Phantoms. <i>Journal of Research of the National Institute of Standards and Technology</i> , 2017, 122, 1-9.	1.2	3
6492	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 325-339.	1.8	52
6493	Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?. <i>Investigative and Clinical Urology</i> , 2017, 58, 324.	2.0	3
6494	Immune Checkpoint in Glioblastoma: Promising and Challenging. <i>Frontiers in Pharmacology</i> , 2017, 8, 242.	3.5	133
6495	The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2335-2340.	2.0	21
6496	CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy. <i>Diagnostic and Interventional Radiology</i> , 2017, 23, 257-262.	1.5	7

#	ARTICLE	IF	CITATIONS
6497	Cross-Platform Comparison of Four Leading Technologies for Detecting <i>EGFR</i> Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma. <i>Theranostics</i> , 2017, 7, 1437-1446.	10.0	75
6498	Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3329-3336.	2.0	17
6499	Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4239-4250.	2.0	36
6500	Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours. <i>Current Oncology</i> , 2017, 24, 285-289.	2.2	0
6501	Long-term Patterns of Regional Failure for Nasopharyngeal Carcinoma following Intensity-Modulated Radiation Therapy. <i>Journal of Cancer</i> , 2017, 8, 993-999.	2.5	18
6502	Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 184-194.	0.9	49
6503	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. <i>Korean Journal of Radiology</i> , 2017, 18, 42.	3.4	33
6504	Immunotherapy Clinical Trials in Neuro-Oncology. , 2017, , 181-210.		0
6505	Cancer immunology and melanoma immunotherapy. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 830-835.	1.1	8
6506	Systemic immune–inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. <i>Cancer Management and Research</i> , 2017, Volume 9, 849-867.	1.9	63
6507	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
6508	Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. <i>Archives of Endocrinology and Metabolism</i> , 2017, 61, 81-89.	0.6	65
6509	Clinical staging of malignant pleural mesothelioma: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 127-139.	2.7	16
6510	Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer. <i>Journal of Breast Cancer</i> , 2017, 20, 378.	1.9	18
6511	Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2569-2580.	2.0	15
6512	Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1212-1218.	1.3	29
6513	Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. <i>Marine Drugs</i> , 2017, 15, 122.	4.6	96
6514	The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 1865-1871.	2.5	8

#	ARTICLE	IF	CITATIONS
6515	Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review. International Journal of Molecular Sciences, 2017, 18, 1926.	4.1	39
6516	Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. International Journal of Molecular Sciences, 2017, 18, 1937.	4.1	15
6517	Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?. International Journal of Molecular Sciences, 2017, 18, 2382.	4.1	8
6518	Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. Metabolites, 2017, 7, 20.	2.9	19
6519	Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach. Metabolites, 2017, 7, 60.	2.9	16
6520	The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. Obstetrics and Gynecology Science, 2017, 60, 433.	1.6	1
6521	Imaging Tools in Clinical Research. , 2017, , 157-179.		2
6522	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 18, 419-449.	1.2	4
6523	Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics, 2017, 7, 10.	2.6	38
6524	Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy. Diagnostics, 2017, 7, 35.	2.6	10
6525	The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. International Journal of Molecular Sciences, 2017, 18, 380.	4.1	29
6526	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences, 2017, 18, 1035.	4.1	39
6527	Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study. International Journal of Molecular Sciences, 2017, 18, 1265.	4.1	11
6528	Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. International Journal of Molecular Sciences, 2017, 18, 1458.	4.1	14
6529	Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. Frontiers in Endocrinology, 2017, 8, 312.	3.5	46
6530	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology, 2017, 8, 1617.	4.8	43
6531	One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review. Frontiers in Oncology, 2017, 7, 272.	2.8	12
6532	Usefulness of chemoradiotherapy for inoperable gastric cancer. Annals of the Royal College of Surgeons of England, 2017, 99, 332-336.	0.6	7

#	ARTICLE	IF	CITATIONS
6533	Treatment of Recurrent or Metastatic Uterine Adenosarcoma. <i>Sarcoma</i> , 2017, 2017, 1-9.	1.3	12
6534	Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. <i>Sarcoma</i> , 2017, 2017, 1-10.	1.3	84
6535	Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy. <i>Oncology Letters</i> , 2017, 14, 8051-8059.	1.8	13
6536	Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. <i>Prostate Cancer</i> , 2017, 2017, 1-8.	0.6	15
6537	Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. <i>Sarcoma</i> , 2017, 2017, 1-6.	1.3	3
6538	Exploration of Superior Modality: Safety and Efficacy of Hypofractionated Image-Guided Intensity Modulated Radiation Therapy in Patients with Unresectable but Confined Intrahepatic Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.	1.9	7
6539	Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. <i>International Journal of Surgical Oncology</i> , 2017, 2017, 1-14.	0.6	8
6540	Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors. <i>Sarcoma</i> , 2017, 2017, 1-6.	1.3	7
6541	A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma. <i>Journal of Skin Cancer</i> , 2017, 2017, 1-7.	1.2	22
6542	Liver Metastases in Pancreatic Acinar Cell Carcinoma Treated with Selective Internal Radiation Therapy with Y-90 Resin Microspheres. <i>Case Reports in Hepatology</i> , 2017, 2017, 1-7.	0.7	3
6543	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. <i>The Cochrane Library</i> , 2017, , .	2.8	1
6544	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017, 17, 132.	2.5	54
6545	A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. <i>Canadian Urological Association Journal</i> , 2017, 11, 350-5.	0.6	16
6546	Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4347-4354.	2.0	3
6547	A practical guide to the handling and administration of talimogene laherparepvec in Europe. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3867-3880.	2.0	33
6548	The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. <i>Wspolczesna Onkologia</i> , 2017, 21, 285-289.	1.4	10
6549	Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 231-240.	2.7	19
6550	<div>Emerging treatment options for ovarian cancer: focus on rucaparib</div>. <i>International Journal of Women's Health</i> , 2017, Volume 9, 913-924.	2.6	19

#	ARTICLE	IF	CITATIONS
6551	Response Evaluation of Chemotherapy for Lung Cancer. Tuberculosis and Respiratory Diseases, 2017, 80, 136.	1.8	16
6552	Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. Journal of Gynecologic Oncology, 2017, 28, e38.	2.2	10
6553	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics, 2017, 7, 1149-1158.	10.0	201
6554	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502.	2.0	12
6555	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. OncoTargets and Therapy, 2017, Volume 10, 3697-3708.	2.0	6
6556	Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS ONE, 2017, 12, e0170634.	2.5	69
6557	Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy. PLoS ONE, 2017, 12, e0173663.	2.5	7
6558	Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PLoS ONE, 2017, 12, e0176972.	2.5	13
6559	A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. PLoS ONE, 2017, 12, e0178325.	2.5	10
6560	Role of post-chemotherapy radiation in the management of children and adolescents with primary advanced malignant mediastinal germ cell tumors. PLoS ONE, 2017, 12, e0183219.	2.5	5
6561	Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS ONE, 2017, 12, e0183331.	2.5	24
6562	The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. PLoS ONE, 2017, 12, e0187500.	2.5	27
6563	Clinical Significance of Circulating Tumor Cells in Patients with Small-cell Lung Cancer. Tumori, 2017, 103, 242-248.	1.1	6
6564	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 129-137.	4.2	16
6565	Application of MRI to Study the Role of Nitric Oxide in Cancer Therapy. , 2017, , 197-210.		0
6566	Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma. Endocrine Journal, 2017, 64, 819-826.	1.6	28
6567	Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC. PLoS ONE, 2017, 12, e0174268.	2.5	7
6568	Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS ONE, 2017, 12, e0184597.	2.5	92

#	ARTICLE	IF	CITATIONS
6569	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer, 2017, 17, 505.	2.6	166
6570	Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study. BMC Cancer, 2017, 17, 475.	2.6	11
6571	Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE). BMC Cancer, 2017, 17, 483.	2.6	10
6572	Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer, 2017, 17, 547.	2.6	5
6573	The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer, 2017, 17, 645.	2.6	41
6574	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646.	2.6	24
6575	Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. BMC Cancer, 2017, 17, 755.	2.6	11
6576	Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer, 2017, 17, 781.	2.6	39
6577	Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. BMC Cancer, 2017, 17, 819.	2.6	11
6578	Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies. BMC Pulmonary Medicine, 2017, 17, 175.	2.0	14
6579	Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MElanoma In hoSpital) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 5	2.2	4
6580	Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health and Quality of Life Outcomes, 2017, 15, 247.	2.4	14
6581	Safety and efficacy of intralesional steroid injection for aggressive fibromatosis. World Journal of Surgical Oncology, 2017, 15, 195.	1.9	5
6582	Novel three-dimensional bone â€œmappingâ€™ software can help assess progression of osseous metastases from routine CT. Radiation Oncology, 2017, 12, 143.	2.7	1
6583	Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiation Oncology, 2017, 12, 157.	2.7	28
6584	â€œHEATPACâ€™- a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. Radiation Oncology, 2017, 12, 183.	2.7	20
6586	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19, 89.	5.0	45
6587	Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. BMC Research Notes, 2017, 10, 320.	1.4	7

#	ARTICLE	IF	CITATIONS
6588	Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 227.	0.8	8
6589	FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. <i>EJNMMI Research</i> , 2017, 7, 56.	2.5	6
6590	Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol. <i>Systematic Reviews</i> , 2017, 6, 244.	5.3	2
6591	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. <i>Biomarker Research</i> , 2017, 5, 32.	6.8	33
6592	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.		37
6593	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
6595	A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 16.	3.6	4
6596	Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. <i>Breast Cancer Research</i> , 2017, 19, 106.	5.0	103
6597	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. <i>BMC Cancer</i> , 2017, 17, 880.	2.6	10
6598	Gemcitabine-induced Thrombocytosis as a Potential Predictive Factor in Non-small Cell Lung Cancer: Analysis of 318 Patients. <i>Tumori</i> , 2017, 103, 143-147.	1.1	5
6599	Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. <i>Chinese Journal of Cancer</i> , 2017, 36, 78.	4.9	11
6600	Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy. <i>Chinese Journal of Cancer</i> , 2017, 36, 76.	4.9	11
6601	An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	3
6602	Precision of manual two-dimensional segmentations of lung and liver metastases and its impact on tumour response assessment using RECIST 1.1. <i>European Radiology Experimental</i> , 2017, 1, 16.	3.4	11
6603	Breast MRI radiomics: comparison of computer- and human-extracted imaging phenotypes. <i>European Radiology Experimental</i> , 2017, 1, 22.	3.4	29
6604	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 842-847.	2.6	13
6605	Evaluation of hepatocellular carcinoma transarterial chemoembolization using 3D contrast enhanced ultrasound time-intensity curve analysis. , 2017, , .		0
6606	Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 534.	3.7	31

#	ARTICLE	IF	CITATIONS
6608	Organ-preserving surgery for locally advanced duodenal gastrointestinal stromal tumor after neoadjuvant treatment. <i>BioScience Trends</i> , 2017, 11, 483-489.	3.4	13
6609	Evaluation of hepatocellular carcinoma transarterial chemoembolization using 3D contrast enhanced ultrasound time-intensity curve analysis. , 2017, , .		0
6611	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. <i>Oncotarget</i> , 2017, 8, 66293-66304.	1.8	11
6612	Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. <i>Oncotarget</i> , 2017, 8, 7039-7049.	1.8	54
6613	Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. <i>Journal of Cancer Science & Therapy</i> , 2017, 9, .	1.7	5
6614	Central Image Archiving and Management System for Multicenter Clinical Studies: Lessons from Low-dose CT for Appendicitis Trial. <i>Journal of the Korean Society of Radiology</i> , 2017, 76, 165.	0.2	1
6615	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017, 1, 41-47.	0.4	13
6616	Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 137-144.	1.3	49
6617	Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1018-1025.	1.4	42
6618	Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-7.	0.3	7
6619	Apatinib is effective for treatment of advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 105596-105605.	1.8	45
6620	Multifunctional nanosized emulsions for theragnosis of life threatening diseases. , 2017, , 579-617.		3
6621	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. <i>Oncotarget</i> , 2017, 8, 111795-111806.	1.8	6
6622	Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer. <i>International Journal of Medical Sciences</i> , 2017, 14, 1410-1417.	2.5	5
6623	Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature. <i>Archives of Endocrinology and Metabolism</i> , 2017, 61, 90-97.	0.6	15
6624	Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2017, 17, 74.	2.5	102
6625	Response Assessment in Neuro-Oncology Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2439-2449.	1.6	306
6626	Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 803-810.	2.0	3

#	ARTICLE	IF	CITATIONS
6627	Accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2971-2981.	2.0	2
6628	Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4687-4690.	2.0	2
6629	Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement. <i>Polish Journal of Radiology</i> , 2017, 82, 593-597.	0.9	14
6630	The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?. <i>Journal of Cancer</i> , 2017, 8, 1179-1186.	2.5	17
6631	Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4007-4016.	2.0	30
6632	NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4625-4633.	2.0	20
6633	Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. <i>Annals of Surgical Treatment and Research</i> , 2017, 93, 186.	1.0	28
6634	A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology. <i>Yonsei Medical Journal</i> , 2017, 58, 1.	2.2	13
6635	The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1112-1118.	1.0	6
6636	Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. <i>Kidney Cancer</i> , 2017, 1, 107-114.	0.4	8
6637	Gastrointestinal Involvement of Recurrent Renal Cell Carcinoma: CT Findings and Clinicopathologic Features. <i>Korean Journal of Radiology</i> , 2017, 18, 452.	3.4	19
6638	Detection of Treatment Success after Photodynamic Therapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <i>Theranostics</i> , 2017, 7, 4643-4657.	10.0	9
6639	Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1955-1967.	2.0	7
6640	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2017, 7, 23.	2.6	13
6641	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4129-4146.	6.7	52
6642	Chemoresistance of colorectal cancer to 5-fluorouracil is associated with silencing of the BNIP3 gene through aberrant methylation. <i>Journal of Cancer</i> , 2017, 8, 1187-1196.	2.5	51
6643	Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression. <i>Journal of Cancer</i> , 2017, 8, 3682-3688.	2.5	3
6644	Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 249-257.	2.7	25

#	ARTICLE	IF	CITATIONS
6645	Association between Tumor Response and Change in EQ5D-3L Quality of Life among Cancer Patients. Archives in Cancer Research, 2017, 05, .	0.3	0
6646	Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 553-560.	2.2	13
6647	Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. Journal of Gastrointestinal Oncology, 2017, 8, E32-E38.	1.4	25
6648	Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 455-462.	2.2	13
6649	CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Cancer Research and Treatment, 2017, 49, 807-815.	3.0	6
6650	Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). Oncotarget, 2017, 8, 94450-94461.	1.8	15
6651	Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma. Molecular and Clinical Oncology, 2017, 8, 204-208.	1.0	3
6652	Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?. Bladder Cancer, 2017, 3, 237-244.	0.4	30
6653	Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2017, 35, 1304-1311.	1.6	82
6654	Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2017, 1, 49-56.	0.4	36
6655	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World Journal of Clinical Oncology, 2017, 8, 37.	2.3	64
6656	Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. Journal of Gastrointestinal Oncology, 2017, 8, E4-E9.	1.4	0
6657	Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology, 2017, 3, 035002.	2.6	5
6658	Accuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients. Oncotarget, 2017, 8, 36696-36706.	1.8	8
6659	Clinical Activity of the β -Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive) Tj ETQq0 0 0 rgBT /Overclock 10	1.6	145
6660	Comparison of Symptom Score and Bronchoscopy-Based Assessment With Conventional Computed Tomography-Based Assessment of Response to Chemotherapy in Lung Cancer. Journal of Global Oncology, 2017, 3, 370-379.	0.5	3
6661	Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer. JCO Precision Oncology, 2017, 1, 1-3.	3.0	11
6662	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. Journal of Clinical Oncology, 2017, 35, 3760-3773.	1.6	91

#	ARTICLE	IF	CITATIONS
6663	Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1395-1402.	1.6	283
6664	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3105-3112.	1.6	168
6665	Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2692-2699.	1.6	144
6666	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trialâ€“FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	1.6	251
6667	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m ²) and the Currently Approved Dose (25 mg/m ²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancerâ€“PROSELICA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3198-3206.	1.6	218
6668	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	1.6	384
6669	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	1.6	364
6670	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2017, 35, 2580-2587.	1.6	219
6671	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2028-2036.	1.6	111
6672	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2149-2156.	1.6	371
6673	Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis. <i>Oncotarget</i> , 2017, 8, 86886-86896.	1.8	9
6674	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2490-2498.	1.6	506
6675	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2â€“ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	1.6	1,105
6676	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 4027-4034.	1.6	141
6677	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq0 0 QrgBT /Overclock 10 T	1.6	2,220
6678	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2993-3001.	1.6	145
6679	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	1.6	1,099
6680	Therapy of Advanced Nonâ€“Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. <i>Journal of Clinical Oncology</i> , 2017, 35, 2790-2797.	1.6	119

#	ARTICLE	IF	CITATIONS
6681	Prognostic Role of Serum Vitamin B ₁₂ in Solid Tumor Patients. Korean Journal of Health Promotion, 2017, 17, 282.	0.2	0
6682	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget, 2017, 8, 75675-75686.	1.8	42
6683	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Na ⁺ ve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	1.6	73
6684	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precision Oncology, 2017, 2017, 1-18.	3.0	107
6685	Targeting RET in Patients With <i>RET</i> -Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	1.6	277
6686	Avelumab, an Anti [®] “Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	1.6	538
6687	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 3338-3346.	1.6	69
6688	Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response Evaluation. JCO Clinical Cancer Informatics, 2017, 1, 1-16.	2.1	3
6689	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 1, 1-11.	3.0	13
6690	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha [®] “Targeting Antibody [®] “Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of Clinical Oncology, 2017, 35, 1112-1118.	1.6	158
6691	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA [®] “Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology, 2017, 1, 1-15.	3.0	31
6692	Promise of Wearable Physical Activity Monitors in Oncology Practice. Journal of Oncology Practice, 2017, 13, 82-89.	2.5	77
6693	Review: Oncolytic virotherapy, updates and future directions. Oncotarget, 2017, 8, 102617-102639.	1.8	111
6694	Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Annals of Gastroenterology, 2017, 31, 65-70.	0.6	10
6695	Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer. Oncotarget, 2017, 8, 94417-94430.	1.8	28
6696	Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials. Neoplasma, 2017, 64, 253-261.	1.6	2
6697	S-1 Salvage Chemotherapy for Esophageal Squamous Cell Carcinoma Refractory to the Standard Chemotherapy. Journal of Cancer Science & Therapy, 2017, 09, .	1.7	1
6698	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	5.0	26

#	ARTICLE	IF	CITATIONS
6699	Treatment of advanced Gall bladder cancer in the real worldâ€”can continuation chemotherapy improve outcomes?. Journal of Gastrointestinal Oncology, 2017, 8, 368-376.	1.4	9
6700	Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study. Journal of Thoracic Disease, 2017, 9, 3911-3918.	1.4	6
6701	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. Journal of Thoracic Disease, 2017, 9, S1364-S1372.	1.4	13
6702	Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization. Translational Lung Cancer Research, 2017, 6, 670-688.	2.8	18
6704	Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget, 2017, 8, 36354-36367.	1.8	40
6705	Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. Journal of Gastrointestinal Oncology, 2017, 8, 799-807.	1.4	23
6706	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal of Gastrointestinal Oncology, 2017, 8, 925-935.	1.4	0
6707	Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extractsâ€”a case report. Journal of Thoracic Disease, 2017, 9, E1064-E1070.	1.4	23
6708	Quantitative assessment of nonsolid pulmonary nodule volume with computed tomography in a phantom study. Quantitative Imaging in Medicine and Surgery, 2017, 7, 623-635.	2.0	6
6709	Variations within 3â€™-UTR of <i>MDM4</i> gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy. Oncotarget, 2017, 8, 16313-16324.	1.8	14
6710	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875507.	3.2	13
6711	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. Prostate, 2018, 78, 336-342.	2.3	41
6712	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 696-713.	9.4	107
6713	Survival-associated factors of first-line <i>EGFR</i> -tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common <i>EGFR</i> mutations. Molecular and Clinical Oncology, 2018, 8, 421-428.	1.0	5
6714	Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. British Journal of Surgery, 2018, 105, 535-543.	0.3	19
6715	A phase I and pharmacokinetic study of taladegib, a Smoothed inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 647-656.	2.6	17
6716	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 60-69.	3.7	153
6717	Efficacy of Larotrectinib in <i>TRK</i> -Fusion-Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036

#	ARTICLE	IF	CITATIONS
6718	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. <i>Oncolmunology</i> , 2018, 7, e1440168.	4.6	31
6719	Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. <i>Radiologia Medica</i> , 2018, 123, 406-414.	7.7	17
6720	Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. <i>Breast Cancer</i> , 2018, 25, 479-488.	2.9	40
6721	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2018, 20, 280-288.	5.3	23
6722	A randomized phase II trial of interleukin-2 and interferon- γ plus bevacizumab versus interleukin-2 and interferon- γ in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. <i>Acta Oncologica</i> , 2018, 57, 589-594.	1.8	19
6723	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 44-49.	2.0	14
6724	Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. <i>Oncolmunology</i> , 2018, 7, e1442166.	4.6	57
6725	Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e9704.	1.0	35
6726	Tyrosine kinase inhibitor therapies for gastrointestinal stromal tumours. <i>The Cochrane Library</i> , 0, , .	2.8	1
6727	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 458-467.	2.6	61
6728	Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients. <i>Cancer Letters</i> , 2018, 423, 1-8.	7.2	39
6729	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). <i>Ultraschall in Der Medizin</i> , 2018, 39, e2-e44.	1.5	627
6730	CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. <i>Oncolmunology</i> , 2018, 7, e1440169.	4.6	219
6731	Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1125-1131.	1.3	16
6732	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	7.1	46
6733	A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 829-838.	2.3	4
6734	Pathology and images of radiation-induced hepatitis: a review article. <i>Japanese Journal of Radiology</i> , 2018, 36, 241-256.	2.4	34
6735	Risk factors in securing successful surgical resection of oral squamous cell carcinoma. <i>Oral Science International</i> , 2018, 15, 56-60.	0.7	4

#	ARTICLE	IF	CITATIONS
6736	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2018, 39, 14-18.	2.2	14
6737	Role of WNT/ β -Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 257-265.	1.9	12
6738	Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT â€“ RECIST 1.1 vs. PERCIST 1.0. <i>European Journal of Radiology</i> , 2018, 101, 65-71.	2.6	28
6739	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018, 7, 690-697.	2.8	90
6740	18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1224-1232.	6.4	38
6741	Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. <i>Abdominal Radiology</i> , 2018, 43, 2329-2339.	2.1	36
6742	Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. <i>Hpb</i> , 2018, 20, 605-611.	0.3	69
6743	Patient reported outcomes in prospective cohort study of Electrochemotherapy. <i>International Journal of Surgery</i> , 2018, 52, 110-119.	2.7	10
6744	Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unresectable lung cancer: A retrospective study. <i>Oncology Letters</i> , 2018, 15, 4017-4025.	1.8	5
6745	Does docetaxel prolong survival of patients with nonâ€metastatic castrationâ€resistant prostate cancer?. <i>Prostate</i> , 2018, 78, 498-505.	2.3	8
6746	Comparison between low-dose chemotherapy and surgery for the treatment of extremity-associated solitary bone lesions in children with Langerhans cell histiocytosis in South China: A case-control study. <i>Journal of Bone Oncology</i> , 2018, 12, 1-6.	2.4	2
6747	HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. <i>Tumor Biology</i> , 2018, 40, 101042831875710.	1.8	36
6748	Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT. <i>Abdominal Radiology</i> , 2018, 43, 445-456.	2.1	19
6749	Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomy. <i>European Radiology</i> , 2018, 28, 3505-3512.	4.5	20
6750	Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. <i>European Journal of Radiology</i> , 2018, 101, 118-123.	2.6	17
6751	Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. <i>Cancer Science</i> , 2018, 109, 785-793.	3.9	16
6752	Palbociclib in combination with letrozole as firstâ€line treatment for advanced breast cancer: A Japanese phase <sc>II</sc> study. <i>Cancer Science</i> , 2018, 109, 803-813.	3.9	29
6753	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. <i>ESMO Open</i> , 2018, 3, e000303.	4.5	12

#	ARTICLE	IF	CITATIONS
6754	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. <i>Tumor Biology</i> , 2018, 40, 101042831876042.	1.8	22
6755	Management of acquired resistance to EGFR TKIâ€“targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38.	19.2	489
6756	A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , 2018, 36, 451-457.	2.6	24
6757	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , 2018, 64, 830-842.	3.2	50
6758	Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 893-897.	6.4	25
6759	Stereotactic radiosurgery for multiple myeloma of the spine. <i>Journal of Radiation Oncology</i> , 2018, 7, 37-44.	0.7	1
6760	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). <i>Oncology</i> , 2018, 94, 289-296.	1.9	5
6761	The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. <i>Medical Oncology</i> , 2018, 35, 45.	2.5	3
6762	Immunotherapy in Lung Cancer and the Role of Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2018, 39, 314-321.	1.5	4
6763	Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. <i>ESMO Open</i> , 2018, 3, e000288.	4.5	10
6764	Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials. <i>Veterinary Radiology and Ultrasound</i> , 2018, 59, 261-271.	0.9	26
6765	Surgical Treatment following Chemo-Targeted Therapy with Bevacizumab for Lung Metastasis from Colorectal Carcinoma: Analysis of Safety and Histological Therapeutic Effects in Patients Treated at a Single Institution. <i>Case Reports in Oncology</i> , 2018, 11, 98-108.	0.7	3
6766	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1289-1296.	6.4	90
6767	Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2082-2091.	7.0	51
6768	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 825-834.	4.2	91
6769	Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1676-1685.	1.5	35
6770	Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-Î±, TRAIL, and interleukin-12. <i>Drug Delivery</i> , 2018, 25, 679-689.	5.7	31
6771	Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 970-988.	6.4	179

#	ARTICLE	IF	CITATIONS
6772	Combined chemoembolization and thermal ablation for the treatment of metastases to the liver. <i>Abdominal Radiology</i> , 2018, 43, 2859-2867.	2.1	7
6773	Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 83-92.	2.5	15
6774	CT texture analysis in colorectal liver metastases and the surrounding liver parenchyma and its potential as an imaging biomarker of disease aggressiveness, response and survival. <i>European Journal of Radiology</i> , 2018, 102, 15-21.	2.6	51
6775	A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. <i>Clinical Cancer Research</i> , 2018, 24, 2285-2293.	7.0	49
6776	Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 815-821.	2.3	21
6777	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. <i>Current Problems in Cancer</i> , 2018, 42, 8-11.	2.0	0
6778	Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases—A pilot study. <i>European Journal of Radiology</i> , 2018, 101, 184-190.	2.6	23
6779	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 133-141.	0.5	56
6780	Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC-MS metabolomics approach. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 154, 95-101.	2.8	16
6781	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. <i>Lung Cancer</i> , 2018, 119, 14-20.	2.0	115
6783	Treatment of solid tumors in dogs using veterinary high-intensity focused ultrasound: A retrospective clinical study. <i>Veterinary Journal</i> , 2018, 234, 126-129.	1.7	11
6784	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e1-240.e11.	1.6	20
6785	A Prospective Observational Study Evaluating the Correlation of <i>c-MET</i> Expression and <i>EGFR</i> Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2018, 94, 373-382.	1.9	4
6786	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	2.4	11
6787	Impact of Right-sided Primary Tumor Location Among Patients With Oligometastatic Colorectal Cancer Treated With Stereotactic Body Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1172-1175.	1.3	0
6788	Clinical impact of boost irradiation to pelvic lymph node in uterine cervical cancer treated with definitive chemoradiotherapy. <i>Medicine (United States)</i> , 2018, 97, e0517.	1.0	22
6789	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3263-3272.	7.0	61
6790	Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. <i>Cancer</i> , 2018, 124, 2841-2849.	4.1	7

#	ARTICLE	IF	CITATIONS
6791	Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. <i>European Radiology</i> , 2018, 28, 4265-4273.	4.5	34
6792	Pitfalls in the radiological response—assessment of immunotherapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 138-143.	0.5	59
6793	Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer. <i>Translational Oncology</i> , 2018, 11, 732-742.	3.7	32
6794	Improvement of radiology reporting in a clinical cancer network: impact of an optimised multidisciplinary workflow. <i>European Radiology</i> , 2018, 28, 4274-4280.	4.5	13
6795	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-“small cell lung cancer (<i>ALK</i>+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282.	1.1	6
6796	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 547-557.	2.5	32
6797	Update on Cancer Treatment in Exotics. <i>Veterinary Clinics of North America - Exotic Animal Practice</i> , 2018, 21, 465-509.	0.7	15
6798	Characteristics and Predictive Value of PD-L1 Status in Real-World Non-“Small Cell Lung Cancer Patients. <i>Journal of Immunotherapy</i> , 2018, 41, 292-299.	2.4	30
6799	Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. <i>Pancreas</i> , 2018, 47, 631-636.	1.1	15
6800	A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 1294-1301.	1.3	7
6801	Correlation between circulating cell-free <i>PIK</i>3<i>CA</i> tumor <i>DNA</i> levels and treatment response in patients with <i>PIK</i>3<i>CA</i>-mutated metastatic breast cancer. <i>Molecular Oncology</i> , 2018, 12, 925-935.	4.6	57
6802	Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. <i>Cancer Medicine</i> , 2018, 7, 2567-2580.	2.8	26
6803	mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1389-1399.	3.3	16
6804	The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 1595-1605.	1.6	33
6805	MRI Detection of Intratumoral Fat in Colorectal Liver Metastases After Preoperative Chemotherapy. <i>American Journal of Roentgenology</i> , 2018, 210, W196-W204.	2.2	3
6806	Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1373-1383.	2.0	6
6807	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 1099-1106.	3.3	27
6808	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 86.	4.4	33

#	ARTICLE	IF	CITATIONS
6809	Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival â€œearly onâ€œin neoadjuvant treatment of breast cancer. <i>Cancer Imaging</i> , 2018, 18, 12.	2.8	51
6811	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	27.0	1,495
6812	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€œSmall-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
6813	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	27.0	2,469
6814	Functional and Hybrid Imaging of Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 961-972.	2.8	18
6815	Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. <i>Gastric Cancer</i> , 2018, 21, 1050-1057.	5.3	16
6816	Potential role of MicroRNA 200c gene expression in assessment of colorectal cancer. <i>Archives of Biochemistry and Biophysics</i> , 2018, 647, 41-46.	3.0	8
6817	Nivolumab vs investigatorâ€™s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
6818	The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 5837.	3.3	13
6819	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876823.	3.2	78
6820	Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines. <i>Journal of Ethnopharmacology</i> , 2018, 221, 137-150.	4.1	51
6821	Selective RET kinase inhibition for patients with RET-altered cancers. <i>Annals of Oncology</i> , 2018, 29, 1869-1876.	1.2	304
6822	On Quality Metrics and Quantitative Imaging. <i>Radiology</i> , 2018, 287, 367-372.	7.3	1
6823	Immunotherapy and the role of imaging. <i>Cancer</i> , 2018, 124, 2906-2922.	4.1	63
6824	Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death. <i>Statistics in Medicine</i> , 2018, 37, 2148-2161.	1.6	7
6825	How We Manage Patients with Plasmacytomas. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 227-235.	2.3	10
6826	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. <i>Future Oncology</i> , 2018, 14, 2115-2129.	2.4	47
6827	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€œ3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 413-423.	8.1	180

#	ARTICLE	IF	CITATIONS
6828	Imaging Biomarkers for Precision Medicine in Locally Advanced Breast Cancer. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2018, 49, 342-351.	0.3	9
6829	Update of MR Imaging for Evaluation of Lung Cancer. <i>Radiologic Clinics of North America</i> , 2018, 56, 437-469.	1.8	28
6830	Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 614-622.	0.9	17
6831	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3299-3308.	7.0	37
6832	Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?. <i>Journal of Surgical Oncology</i> , 2018, 117, 858-863.	1.7	20
6833	A predictive probability interim design for phase II clinical trials with continuous endpoints. <i>Statistics in Medicine</i> , 2018, 37, 1960-1972.	1.6	3
6834	Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy. <i>Abdominal Radiology</i> , 2018, 43, 2991-3000.	2.1	7
6835	Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. <i>Cancer Science</i> , 2018, 109, 1592-1601.	3.9	24
6836	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. <i>Cancer</i> , 2018, 124, 2169-2173.	4.1	86
6837	To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer. <i>Molecular Imaging and Biology</i> , 2018, 20, 1061-1067.	2.6	10
6838	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	1.0	70
6839	Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 695-705.	3.4	106
6840	The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer. <i>Medicine (United States)</i> , 2018, 97, e0340.	1.0	22
6841	A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases. <i>Chemotherapy</i> , 2018, 63, 90-94.	1.6	11
6842	Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?. <i>Cancer Biomarkers</i> , 2018, 22, 143-149.	1.7	7
6843	Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. <i>Thoracic Cancer</i> , 2018, 9, 656-661.	1.9	5
6844	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	3.6	14
6845	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1686-1695.	3.6	105

#	ARTICLE	IF	CITATIONS
6846	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2018, 19, 649-659.	10.7	450
6847	Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. <i>Thoracic Cancer</i> , 2018, 9, 613-620.	1.9	0
6848	Quantitative image analysis for evaluation of tumor response in clinical oncology. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 18-28.	1.2	16
6849	A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, 231-239.e7.	2.3	42
6850	Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus. <i>Anti-Cancer Drugs</i> , 2018, 29, 565-571.	1.4	10
6851	Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1185-1195.	2.5	9
6852	The Prognostic Value of Varying Definitions of Positive Resection Margin in Patients with Colorectal Cancer Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1350-1357.	1.7	15
6853	Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. <i>Annals of Oncology</i> , 2018, 29, 1445-1453.	1.2	103
6854	Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (<scp>CORMAC</scp>). <i>Colorectal Disease</i> , 2018, 20, 371-382.	1.4	20
6855	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3253-3262.	7.0	71
6856	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	7.1	63
6857	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	16.8	827
6858	Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, e451-e456.	2.3	12
6859	Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. <i>Cancer</i> , 2018, 124, 2355-2364.	4.1	11
6860	A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1035-1041.	2.3	3
6861	Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 650-660.	0.8	65
6862	Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results. <i>Cancer</i> , 2018, 124, 2427-2437.	4.1	69
6863	Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2018, 139, 205-213.	2.9	25

#	ARTICLE	IF	CITATIONS
6864	Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature. <i>Future Science OA</i> , 2018, 4, FSO264.	1.9	9
6865	Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 1073-1083.	1.7	19
6866	Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis. <i>Scientific Reports</i> , 2018, 8, 2974.	3.3	4
6867	Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. <i>Cancer</i> , 2018, 124, 1982-1991.	4.1	12
6868	Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2018, 92, 69-76.	2.8	11
6869	Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY). <i>Breast Cancer</i> , 2018, 25, 438-446.	2.9	10
6871	Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 228-236.	2.5	13
6872	Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 131-135.	0.4	2
6873	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 347-355.	10.7	290
6874	Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. <i>Lung Cancer</i> , 2018, 117, 38-43.	2.0	3
6875	Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 2047.	3.3	22
6876	Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?. <i>Acta Oncologica</i> , 2018, 57, 750-758.	1.8	7
6877	Rethinking neoadjuvant chemotherapy for breast cancer. <i>BMJ: British Medical Journal</i> , 2018, 360, j5913.	2.3	73
6878	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Oncology</i> , 2018, 29, 959-965.	1.2	388
6879	Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , 2018, 23, 518-523.	3.7	40
6880	Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 549-554.	2.3	20
6881	The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. <i>European Radiology</i> , 2018, 28, 2281-2290.	4.5	28
6882	First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 469-479.	2.5	39

#	ARTICLE	IF	CITATIONS
6883	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. <i>Lung Cancer</i> , 2018, 118, 1-5.	2.0	63
6884	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. <i>European Urology</i> , 2018, 74, 218-225.	1.9	140
6885	Response evaluation of giant-cell tumor of bone treated by denosumab: Histogram and texture analysis of CT images. <i>Journal of Orthopaedic Science</i> , 2018, 23, 570-577.	1.1	17
6886	Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review. <i>Journal of Thoracic Oncology</i> , 2018, 13, 624-635.	1.1	35
6887	Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 114-120.	0.4	32
6888	Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants. <i>Lung Cancer</i> , 2018, 118, 128-133.	2.0	50
6889	Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival. <i>Pathology Research and Practice</i> , 2018, 214, 335-342.	2.3	11
6890	A sequence polymorphism on 8q24 is associated with survival in hepatocellular carcinoma patients who received radiation therapy. <i>Scientific Reports</i> , 2018, 8, 2264.	3.3	3
6891	Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data. <i>BMJ Open</i> , 2018, 8, e019409.	1.9	8
6892	Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 698-709.	4.1	9
6893	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	1.9	33
6894	Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. <i>Future Oncology</i> , 2018, 14, 2905-2913.	2.4	10
6895	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	7.1	87
6896	Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. <i>European Radiology</i> , 2018, 28, 2969-2978.	4.5	18
6897	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	3.6	31
6898	Ultrasonic histogram assessment of early response to concurrent chemo-radiotherapy in patients with locally advanced cervical cancer: a feasibility study. <i>Clinical Imaging</i> , 2018, 49, 144-149.	1.5	9
6899	A phase I trial of the β -secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018, 118, 793-801.	6.4	90
6900	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degradar AZD9496 for ER+/HER2- Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3510-3518.	7.0	80

#	ARTICLE	IF	CITATIONS
6901	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709.	4.1	35
6902	Characteristics and management of ganglioneuroma and ganglioneuroblastoma intermixed in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26964.	1.5	35
6903	Retrospective analysis to determine outcomes of patients with bilateral Wilms tumor undergoing nephron sparing surgery: 15-year tertiary single-institution experience. <i>Pediatric Surgery International</i> , 2018, 34, 427-433.	1.4	8
6904	A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 725-734.	2.5	17
6905	Gynecological Lymphoma: A Case Series and Review of the Literature. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 435-440.	0.9	10
6906	Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26940.	1.5	10
6907	Treatment of refractory thyroid cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R209-R223.	3.1	63
6908	Development and Validation of Segmentation Method for Lung Cancer Volumetry on Chest CT. <i>Journal of Digital Imaging</i> , 2018, 31, 505-512.	2.9	7
6909	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018, 118, 648-653.	6.4	31
6910	Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 153-158.	1.1	19
6911	Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774581.	3.2	16
6912	Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 539-548.	2.3	13
6913	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1423172.	4.6	25
6914	Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1101-1105.	1.3	55
6915	Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 3726-3734.	1.8	6
6916	Phase 1 trial of ontuxizumab (MORAb004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). <i>Pediatric Blood and Cancer</i> , 2018, 65, e26944.	1.5	19
6917	The Application of Sigmoid Sinus Tunnel-packing or Push-packing of the Inferior Petrous Sinus in the Microsurgical Management of Jugular Paragangliomas. <i>Otology and Neurotology</i> , 2018, 39, e166-e172.	1.3	4
6918	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. <i>Lancet Oncology</i> , The, 2018, 19, 229-239.	10.7	111

#	ARTICLE	IF	CITATIONS
6919	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193.	10.7	233
6920	Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). <i>Cancer Medicine</i> , 2018, 7, 351-359.	2.8	25
6921	Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 532-542.	1.6	17
6922	Revisiting RECIST: the case of treatment beyond progression. <i>Lancet Oncology</i> , The, 2018, 19, 157-159.	10.7	2
6923	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). <i>Annals of Oncology</i> , 2018, 29, 1004-1009.	1.2	68
6924	Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series. <i>Oncology Research and Treatment</i> , 2018, 41, 8-13.	1.2	1
6925	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti- PD-1 Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	7.1	229
6926	Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1408-1418.	27.0	947
6927	Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status. <i>Oncology</i> , 2018, 94, 207-214.	1.9	3
6928	Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1432-1439.	1.5	28
6929	Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. <i>Scientific Reports</i> , 2018, 8, 2238.	3.3	13
6930	Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. <i>Annals of Oncology</i> , 2018, 29, 1220-1226.	1.2	36
6931	Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2018, 138, 209-216.	2.9	2
6932	Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 48-53.	1.8	2
6933	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 263-270.	8.1	121
6934	PD-L1 expression in large cell neuroendocrine carcinoma of the lung. <i>Lung Cancer</i> , 2018, 118, 76-82.	2.0	26
6935	Clinical features, treatment, and outcomes of cutaneous and oral squamous cell carcinoma in avian species. <i>Journal of the American Veterinary Medical Association</i> , 2018, 252, 309-315.	0.5	16
6936	Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 749-756.	1.7	3

#	ARTICLE	IF	CITATIONS
6937	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. <i>Future Oncology</i> , 2018, 14, 1023-1034.	2.4	1
6938	The decreased expression of Stat3 and p-Stat3 in preeclampsia-like rat placenta. <i>Journal of Molecular Histology</i> , 2018, 49, 175-183.	2.2	15
6939	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Scientific Reports</i> , 2018, 8, 1005.	3.3	22
6940	Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). <i>Annals of Oncology</i> , 2018, 29, 985-991.	1.2	36
6941	18F-FDG PET/CT in Local Ablative Therapies: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2018, 59, 551-556.	5.0	16
6942	First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. <i>Gastric Cancer</i> , 2018, 21, 792-801.	5.3	11
6943	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 848-859.	2.6	55
6944	CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 242.e15-242.e21.	1.6	2
6945	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018, 24, 1805-1815.	7.0	45
6946	Mechanically Coupled Reaction-Diffusion Model to Predict Glioma Growth: Methodological Details. <i>Methods in Molecular Biology</i> , 2018, 1711, 225-241.	0.9	27
6947	Genotype and risk of tumour rupture in gastrointestinal stromal tumour. <i>British Journal of Surgery</i> , 2018, 105, e169-e175.	0.3	25
6948	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. <i>Nature Chemical Biology</i> , 2018, 14, 291-298.	8.0	56
6949	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. <i>Melanoma Research</i> , 2018, 28, 111-119.	1.2	51
6950	Lung Nodule Detection Using PET/MRI. , 2018, , 249-260.		0
6951	Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1.	2.5	7
6952	Use of helical tomotherapy in locally advanced and/or metastatic breast cancer for locoregional treatment. <i>British Journal of Radiology</i> , 2018, 91, 20170822.	2.2	6
6953	<i>EML4-ALK</i> fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in <i>ALK</i> non-small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 142, 2589-2598.	5.1	93
6954	Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 744-752.	2.0	34

#	ARTICLE	IF	CITATIONS
6955	Prognostic significance of interim ¹⁸ F-fluorodeoxyglucose positron emission tomography-CT computed tomography volumetric parameters in metastatic or recurrent gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e302-e309.	1.1	4
6956	No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2018, 23, 576-583.	2.2	4
6957	Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine, 2018, 59, 395-401.	2.3	20
6958	Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients. Clinical Lung Cancer, 2018, 19, e323-e333.	2.6	71
6959	The effect of photodynamic therapy with talaporfin sodium, a second-generation photosensitizer, on oral squamous cell carcinoma: A series of eight cases. Photodiagnosis and Photodynamic Therapy, 2018, 21, 176-180.	2.6	17
6960	MRI evaluation of sacral chordoma treated with carbon ion radiotherapy alone. Radiotherapy and Oncology, 2018, 128, 203-208.	0.6	11
6961	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncology, 2018, 14, 255-266.	2.4	22
6962	Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 647-651.	0.8	11
6963	Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, 97-105.	1.1	180
6965	How to use neoadjuvant medical treatment to maximize surgery in melanoma. Expert Review of Anticancer Therapy, 2018, 18, 121-130.	2.4	7
6966	Tumor Boost Using External Beam Radiation in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy. International Journal of Gynecological Cancer, 2018, 28, 371-378.	2.5	8
6967	Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. Annals of Surgical Oncology, 2018, 25, 885-893.	1.5	7
6968	Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist, 2018, 23, 277-e26.	3.7	34
6969	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clinical Lung Cancer, 2018, 19, 280-288.e4.	2.6	45
6970	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine, 2018, 7, 95-104.	2.8	16
6971	Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Clinical Genitourinary Cancer, 2018, 16, 219-225.	1.9	17
6972	Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer. Magnetic Resonance Imaging, 2018, 48, 27-33.	1.8	35
6973	Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience. Clinical Genitourinary Cancer, 2018, 16, e577-e586.	1.9	15

#	ARTICLE	IF	CITATIONS
6974	Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e637-e644.	1.9	6
6975	Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other Indices. <i>Clinical Lung Cancer</i> , 2018, 19, 340-345.	2.6	16
6976	Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 7-12.	1.7	19
6977	Advanced imaging to predict response to chemotherapy in colorectal liver metastases â€” a systematic review. <i>Hpb</i> , 2018, 20, 120-127.	0.3	28
6978	Phase 1 Dose Escalation Trial of Ipilimumab andÂStereotactic Body Radiation Therapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 906-915.	0.8	30
6979	Local Control and Toxicity of External Beam Reirradiation With a Pulsed Low-dose-rate Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 959-964.	0.8	7
6980	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	3.7	100
6981	Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2233-2242.e2.	0.8	4
6982	PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Nonâ€”Small Cell Lung Cancer Patients with Malignant Pleural Effusion. <i>Journal of Thoracic Oncology</i> , 2018, 13, 447-453.	1.1	38
6983	Predictive Performance of Four Programmed CellÂDeath Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Nonâ€”Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 377-386.	1.1	50
6984	Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 244-253.e2.	0.5	18
6985	High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. <i>Lung Cancer</i> , 2018, 115, 42-48.	2.0	7
6986	Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. <i>Practical Radiation Oncology</i> , 2018, 8, e71-e78.	2.1	32
6987	Prostate-specific membrane antigen theranostics. <i>Current Opinion in Urology</i> , 2018, 28, 197-204.	1.8	39
6988	Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical Studies. <i>Clinical Cancer Research</i> , 2018, 24, 2262-2267.	7.0	4
6989	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. <i>Journal of Surgical Oncology</i> , 2018, 117, 1170-1178.	1.7	65
6990	Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC. <i>Annals of Surgical Oncology</i> , 2018, 25, 702-708.	1.5	33
6991	Androgen deprivation therapy for androgen receptorâ€”positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. <i>Head and Neck</i> , 2018, 40, 605-613.	2.0	94

#	ARTICLE	IF	CITATIONS
6992	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	10.7	87
6993	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2018, 163, 761-767.	1.9	65
6994	Irreversible Electroporation of Tumors Within the Pelvic Cavity. , 2018, , 223-238.		0
6995	Evaluation of two-dimensional ultrasonography and computed tomography in the mapping and measuring of canine urinary bladder tumors. <i>Veterinary Journal</i> , 2018, 232, 23-26.	1.7	12
6996	Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. <i>Acta Oncol</i> ³gica, 2018, 57, 807-812.	1.8	24
6997	A randomized phase 2 study of a HSP27 targeting antisense, apatonsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 278-287.	2.6	37
6998	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. <i>Oncologist</i> , 2018, 23, 360-366.	3.7	36
6999	Locally Advanced Breast Cancer. , 2018, , 567-578.		0
7000	Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26896.	1.5	44
7001	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 496-508.	6.4	152
7002	Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis. <i>Cancer Biology and Therapy</i> , 2018, 19, 169-174.	3.4	14
7003	Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care. <i>Current Opinion in Oncology</i> , 2018, 30, 77-83.	2.4	13
7004	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. <i>Oncologist</i> , 2018, 23, 316-323.	3.7	34
7005	Advances in ovarian cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 17-38.	2.3	393
7006	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018, 73, 751-759.	1.9	99
7007	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , 2018, 126, 217-223.	2.0	89
7008	Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. <i>Modern Rheumatology</i> , 2018, 28, 838-844.	1.8	24
7009	Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study. <i>Cancer Biology and Therapy</i> , 2018, 19, 198-204.	3.4	42

#	ARTICLE	IF	CITATIONS
7010	The importance of the initial response to cancer treatment in predicting longer overall survival. Expert Review of Clinical Pharmacology, 2018, 11, 109-111.	3.1	0
7011	Tailoring the colorectal cancer disease assessment to the treatment strategy. Gut, 2018, 67, 996-997.	12.1	0
7012	Reirradiation+ hyperthermia for recurrent breast cancer en cuirasse. Strahlentherapie Und Onkologie, 2018, 194, 206-214.	2.0	23
7013	The use of breast imaging for predicting response to+neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results+from Neo-ALTO. European Journal of Cancer, 2018, 89, 42-48.	2.8	13
7014	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	47.7	64
7015	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. Clinical Cancer Research, 2018, 24, 2268-2275.	7.0	116
7016	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research, 2018, 24, 1872-1880.	7.0	319
7017	The role of albumin+ bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2018, 194, 403-413.	2.0	20
7018	Measurement variability of liver metastases from neuroendocrine tumors on different magnetic resonance imaging sequences. Diagnostic and Interventional Imaging, 2018, 99, 73-81.	3.2	12
7019	Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. International Journal of Gynecological Cancer, 2018, 28, 657-665.	2.5	7
7020	Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. CardioVascular and Interventional Radiology, 2018, 41, 734-743.	2.0	35
7021	eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells. Cancer Letters, 2018, 418, 64-74.	7.2	8
7022	Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non+Small Cell Lung Cancer. Thoracic and Cardiovascular Surgeon, 2018, 66, 129-134.	1.0	0
7023	Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. European Journal of Cancer, 2018, 91, 38-46.	2.8	17
7024	Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to 177Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. Translational Oncology, 2018, 11, 193-204.	3.7	9
7025	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. Clinical Colorectal Cancer, 2018, 17, e233-e255.	2.3	26
7026	Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints. Journal of Biopharmaceutical Statistics, 2018, 28, 824-839.	0.8	0
7027	Phase II trial of ipilimumab in melanoma patients with preexisting humoral immune response to NY-ESO-1. European Journal of Cancer, 2018, 90, 122-129.	2.8	17

#	ARTICLE	IF	CITATIONS
7028	Recombinant Adenovirus-p53 Gene Therapy for Advanced Unresectable Soft-Tissue Sarcomas. Human Gene Therapy, 2018, 29, 699-707.	2.7	8
7029	Fast elastic registration of soft tissues under large deformations. Medical Image Analysis, 2018, 45, 24-40.	11.6	41
7030	Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study. Japanese Journal of Clinical Oncology, 2018, 48, 144-152.	1.3	4
7031	Intratumoral injection of radioactive holmium-166 microspheres in recurrent head and neck squamous cell carcinoma. Nuclear Medicine Communications, 2018, 39, 213-221.	1.1	23
7032	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Academic Radiology, 2018, 25, 144-152.	2.5	17
7033	Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDfP) for Stage I-II esophageal carcinoma. Ecological Management and Restoration, 2018, 31, .	0.4	6
7034	Clinical outcomes and prognostic factors of chemoradiotherapy for postoperative lymph node recurrence of esophageal cancer. Japanese Journal of Clinical Oncology, 2018, 48, 259-264.	1.3	18
7035	OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Annals of Oncology, 2018, 29, 431-438.	1.2	54
7036	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	12.6	898
7037	Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Endocrine-Related Cancer, 2018, 25, 217-231.	3.1	50
7038	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91.	2.2	27
7039	Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews, 2018, 64, 1-10.	7.7	63
7040	Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back. Journal of Minimally Invasive Gynecology, 2018, 25, 816-822.	0.6	45
7041	Impact of minimum point dose on local control and toxicity in T3-4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy. Japanese Journal of Clinical Oncology, 2018, 48, 265-271.	1.3	7
7042	Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer. Current Opinion in Oncology, 2018, 30, 98-104.	2.4	3
7043	Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open, 2018, 3, e000291.	4.5	37
7044	A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomarkers, 2018, 22, 333-344.	1.7	3
7045	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 963.	7.1	426

#	ARTICLE	IF	CITATIONS
7046	Radical Gastrectomy After Chemotherapy May Prolong Survival in Stage IV Gastric Cancer: A Korean Multi-institutional Analysis. <i>World Journal of Surgery</i> , 2018, 42, 3286-3293.	1.6	9
7047	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	16.8	725
7048	Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial. <i>Trials</i> , 2018, 19, 221.	1.6	8
7049	Esophageal pulmonary fistula “a rare complication of radiation therapy: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 116.	0.8	8
7050	Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study. <i>Applied Cancer Research</i> , 2018, 38, .	1.0	2
7051	UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 87-98.	2.3	12
7052	Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. <i>European Journal of Radiology</i> , 2018, 104, 49-57.	2.6	22
7053	Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1382-1391.	0.8	8
7054	Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1212-1221.	0.8	89
7055	Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion“Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1222-1226.	1.1	59
7056	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1128-1137.	1.1	160
7057	Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. <i>Radiotherapy and Oncology</i> , 2018, 127, 493-500.	0.6	28
7058	Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer. <i>BMC Cancer</i> , 2018, 18, 207.	2.6	53
7059	Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. <i>Journal of Translational Medicine</i> , 2018, 16, 54.	4.4	12
7060	Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. <i>Journal of Translational Medicine</i> , 2018, 16, 87.	4.4	35
7061	Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy. <i>European Radiology</i> , 2018, 28, 4296-4305.	4.5	11
7062	Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications. <i>Hpb</i> , 2018, 20, 841-847.	0.3	50
7063	Herbal medicine for hand“foot syndrome induced by fluoropyrimidines: A systematic review and meta-analysis. <i>Phytotherapy Research</i> , 2018, 32, 1211-1228.	5.8	10

#	ARTICLE	IF	CITATIONS
7064	Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. <i>Scientific Reports</i> , 2018, 8, 6223.	3.3	12
7065	A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2018, 94, 329-339.	1.9	36
7066	68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1862-1872.	6.4	91
7067	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	2.8	2
7068	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. <i>The Cochrane Library</i> , 2018, 2018, CD011746.	2.8	51
7069	Bone Metastases in Prostate Cancer. , 2018, , 323-343.		0
7070	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2018, 35, 78.	2.5	15
7071	Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. <i>Acta Oncol</i> , 2018, 57, 1373-1380.	1.8	19
7072	Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience. <i>Breast</i> , 2018, 40, 60-66.	2.2	5
7073	The emerging roles of functional imaging in ovarian cancer with peritoneal carcinomatosis. <i>Clinical Radiology</i> , 2018, 73, 597-609.	1.1	7
7074	Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy. <i>JAAD Case Reports</i> , 2018, 4, 379-381.	0.8	2
7075	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018, 118, 1419-1424.	6.4	7
7076	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	1.3	54
7077	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	4.4	10
7078	Predicting pathological response to neoadjuvant chemotherapy in breast cancer patients based on imbalanced clinical data. <i>Personal and Ubiquitous Computing</i> , 2018, 22, 1039-1047.	2.8	8
7079	<scp>CD8</scp> lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. <i>Cancer Reports</i> , 2018, 1, e1002.	1.4	8
7080	HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer</i> , 2018, 25, 605-613.	2.9	41
7081	Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. <i>Annals of Oncology</i> , 2018, 29, 1541-1547.	1.2	526

#	ARTICLE	IF	CITATIONS
7082	Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, 791-797.	3.7	13
7083	Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. <i>Clinical Cancer Research</i> , 2018, 24, 3829-3837.	7.0	69
7084	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. <i>Tumori</i> , 2018, 104, 88-95.	1.1	17
7085	Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study. <i>Open Medicine (Poland)</i> , 2018, 13, 142-147.	1.3	7
7086	Early brain metastasis of advanced gastric cancer with a pathological complete response to neoadjuvant chemotherapy followed by surgery: A case report and literature review. <i>Cancer Biology and Therapy</i> , 2018, 19, 875-878.	3.4	4
7087	Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002089.	1.2	4
7088	A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 923-933.	2.3	7
7089	Neuroimaging classification of progression patterns in glioblastoma: a systematic review. <i>Journal of Neuro-Oncology</i> , 2018, 139, 77-88.	2.9	15
7090	Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. <i>Medical Oncology</i> , 2018, 35, 59.	2.5	5
7091	Criterios específicos de respuesta tumoral. <i>Radiologia</i> , 2018, 60, 64-81.	0.5	3
7092	Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1437-1444.	1.2	615
7093	TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer. <i>Oncology Letters</i> , 2018, 15, 8165-8171.	1.8	4
7094	Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1240-1250.	4.1	40
7095	A viscous modified Gompertz model for the analysis of the kinetics of tumors under electrochemical therapy. <i>Mathematics and Computers in Simulation</i> , 2018, 151, 96-110.	4.4	10
7096	Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-term Results of a Randomized Clinical Trial. <i>World Journal of Surgery</i> , 2018, 42, 506-513.	1.6	23
7097	Is there a role for Yttrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma?. <i>American Journal of Surgery</i> , 2018, 215, 467-470.	1.8	22
7098	Yttrium-90 Radioembolization of the Right Inferior Phrenic Artery in 20 Patients with Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 556-563.	0.5	19
7099	Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. <i>Lung Cancer</i> , 2018, 119, 48-55.	2.0	21

#	ARTICLE	IF	CITATIONS
7100	Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging ¹⁸ F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer. <i>Radiology</i> , 2018, 287, 983-992.	7.3	88
7101	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. <i>Clinical Cancer Research</i> , 2018, 24, 2653-2664.	7.0	109
7102	Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?. <i>Future Oncology</i> , 2018, 14, 919-926.	2.4	29
7103	Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. <i>JAMA Oncology</i> , 2018, 4, 661.	7.1	311
7104	Curva de aprendizaje en el manejo de los inhibidores de tirosina quinasa como primera línea de tratamiento en pacientes con cáncer renal metastásico. <i>Actas Urológicas Españolas</i> , 2018, 42, 389-395.	0.7	0
7105	Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation ⁺ Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). <i>Journal of Thoracic Oncology</i> , 2018, 13, 682-688.	1.1	182
7106	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , 2018, 57, 958-964.	1.8	41
7107	Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial. <i>Tumor Biology</i> , 2018, 40, 101042831876400.	1.8	14
7108	Clinical and imaging features of Kaposiform Hemangioendothelioma. <i>British Journal of Radiology</i> , 2018, 91, 20170798.	2.2	23
7109	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. <i>Oncologist</i> , 2018, 23, 1210-1217.	3.7	19
7110	A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation. <i>Clinical Lung Cancer</i> , 2018, 19, e567-e574.	2.6	16
7111	Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 911-921.	2.3	8
7112	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	10.7	732
7113	Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, 387-394.e2.	2.6	44
7114	Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial. <i>OncolImmunology</i> , 2018, 7, e1419113.	4.6	29
7115	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018, 13, 227-234.	3.6	33
7116	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	2.4	37
7117	Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. <i>European Journal of Cancer</i> , 2018, 94, 187-198.	2.8	6

#	ARTICLE	IF	CITATIONS
7118	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 2517-2529.	7.0	26
7119	Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. <i>Experimental Hematology and Oncology</i> , 2018, 7, 6.	5.0	32
7120	Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2018, 19, 705-714.	10.7	419
7121	The liver-first approach for synchronous colorectal liver metastases: more than a decade of experience in a single centre. <i>Hpb</i> , 2018, 20, 631-640.	0.3	15
7122	Diseases of the Abdomen and Pelvis 2018-2021. <i>IDKD Springer Series</i> , 2018, , .	0.8	22
7123	Preoperative Chemotherapy May Not Influence the Remnant Liver Regenerations and Outcomes After Hepatectomy for Colorectal Liver Metastasis. <i>World Journal of Surgery</i> , 2018, 42, 3316-3330.	1.6	13
7124	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. <i>World Journal of Urology</i> , 2018, 36, 1703-1709.	2.2	71
7125	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	2.8	280
7126	European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. <i>Clinical Oncology</i> , 2018, 30, 448-454.	1.4	29
7127	Long-term results of CT-guided percutaneous radiofrequency ablation of inoperable patients with stage Ia non-small cell lung cancer: A retrospective cohort study. <i>International Journal of Surgery</i> , 2018, 53, 143-150.	2.7	27
7128	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334
7129	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	7.0	141
7130	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	10.7	751
7131	Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation. <i>International Journal of Clinical Oncology</i> , 2018, 23, 608-614.	2.2	6
7132	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2018, 391, 1163-1173.	13.7	3,542
7133	Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 206-214.	2.3	14
7134	Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. <i>Cancer Biology and Therapy</i> , 2018, 19, 687-694.	3.4	19
7135	Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2428-2433.	1.5	16

#	ARTICLE	IF	CITATIONS
7136	A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 667-673.	2.6	2
7137	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. <i>Endocrine</i> , 2018, 62, 46-56.	2.3	16
7138	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	10.7	81
7139	Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1069-1077.	1.0	16
7140	Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. <i>Annals of Oncology</i> , 2018, 29, 1304-1311.	1.2	51
7141	65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. <i>Endocrine-Related Cancer</i> , 2018, 25, T159-T169.	3.1	18
7142	A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. <i>Oncologist</i> , 2018, 23, 658-e72.	3.7	47
7143	Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Oncologist</i> , 2018, 23, 764-e86.	3.7	6
7144	Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. <i>Metabolic Brain Disease</i> , 2018, 33, 969-976.	2.9	18
7145	Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results. <i>Clinical Imaging</i> , 2018, 49, 163-168.	1.5	29
7146	Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 850-857.e1.	0.5	124
7147	Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. <i>Radiologia Medica</i> , 2018, 123, 489-497.	7.7	7
7148	Patient-specific and global convolutional neural networks for robust automatic liver tumor delineation in follow-up CT studies. <i>Medical and Biological Engineering and Computing</i> , 2018, 56, 1699-1713.	2.8	35
7149	Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. <i>Medical Oncology</i> , 2018, 35, 48.	2.5	6
7150	Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 81-89.	0.7	5
7151	The use of stereotactic radiosurgery for benign spinal tumors: single institution experience. <i>Journal of Radiation Oncology</i> , 2018, 7, 157-165.	0.7	0
7152	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	10.7	486
7153	Immune-modified response criteria — an iterative learning process?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 267-268.	27.6	5

#	ARTICLE	IF	CITATIONS
7154	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	6.4	17
7155	Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. <i>Scientific Reports</i> , 2018, 8, 4352.	3.3	22
7156	Role of circulating tumor DNA in the management of early-stage lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 509-515.	1.9	25
7157	EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 385-390.	1.3	38
7158	Metabolic response evaluation for colorectal liver metastases and correlation to pathologic response and tumour markers. <i>ANZ Journal of Surgery</i> , 2018, 88, E108-E113.	0.7	1
7159	Changes in serum α -fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 153-163.	1.7	21
7160	The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI. <i>Acta Radiologica</i> , 2018, 59, 41-49.	1.1	7
7161	Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 45-52.	2.6	1
7162	Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 23-31.	1.1	43
7163	Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and L-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 132-137.	1.3	7
7164	Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. <i>Journal of Feline Medicine and Surgery</i> , 2018, 20, 95-102.	1.6	17
7165	Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. <i>Journal of Neurosurgery</i> , 2018, 128, 23-31.	1.6	49
7166	Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	2.1	34
7167	Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 116-123.	1.3	22
7168	The use of low-dose metronomic chemotherapy in dogs—insight into a modern cancer field. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 2-11.	1.8	24
7169	Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small cell lung cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	2.1	39
7170	Estimating breast tumor blood flow during neoadjuvant chemotherapy using interleaved high temporal and high spatial resolution MRI. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 317-326.	3.0	17
7171	Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 568-575.	1.3	27

#	ARTICLE	IF	CITATIONS
7172	MRI-guided radiotherapy for head and neck cancer: initial clinical experience. <i>Clinical and Translational Oncology</i> , 2018, 20, 160-168.	2.4	35
7173	The long-term survival of stage IV gastric cancer patients with conversion therapy. <i>Gastric Cancer</i> , 2018, 21, 315-323.	5.3	111
7174	Robotic radiosurgery of head and neck paragangliomas: a single institution experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e3-e7.	1.1	7
7175	Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy. <i>Breast Cancer</i> , 2018, 25, 43-49.	2.9	16
7176	Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, E87-E97.	3.4	12
7177	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 53-61.	2.6	15
7178	Extraskelatal Osteosarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 832-837.	1.3	20
7179	Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up. <i>Surgery Today</i> , 2018, 48, 87-94.	1.5	3
7180	The Tumor Burden Score. <i>Annals of Surgery</i> , 2018, 267, 132-141.	4.2	264
7181	Safety and Outcome Measures of First-in-Human Intraperitoneal \pm Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 716-721.	1.3	70
7182	Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 90-101.	1.8	35
7183	Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. <i>Clinical and Translational Oncology</i> , 2018, 20, 140-149.	2.4	3
7184	Targeted Therapy and Molecular Genetics. , 2018, , 470-492.e10.		3
7185	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. <i>Hepatology</i> , 2018, 67, 575-585.	7.3	57
7186	Malignant pleural mesothelioma segmentation for photodynamic therapy planning. <i>Computerized Medical Imaging and Graphics</i> , 2018, 65, 79-92.	5.8	5
7187	Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e39-e40.	2.4	13
7188	Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report. <i>Integrative Cancer Therapies</i> , 2018, 17, 558-561.	2.0	7
7189	Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, E98-E106.	3.4	7

#	ARTICLE	IF	CITATIONS
7190	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-“Small-Cell Lung Cancer”(NSCLC). <i>Clinical Lung Cancer</i> , 2018, 19, e19-e28.	2.6	17
7191	Increased Incidence of Post-transplant Lymphoproliferative Disorder in Autoimmune Liver Disease: An Irish National Experience. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 42-49.	0.9	6
7192	<i>HSD3B1</i> and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 554.	7.1	48
7193	Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-“small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 967-971.	1.3	0
7194	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	7.0	127
7195	Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 78-87.	0.8	42
7196	Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. <i>Annals of Oncology</i> , 2018, 29, 209-214.	1.2	137
7197	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 659-669.	2.5	64
7198	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 416-423.	2.6	17
7199	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	1.2	304
7200	Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 97-108.	6.3	199
7201	Targeting Hypoxia to Improve Non-“Small Cell Lung Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2018, 110, 14-30.	6.3	177
7202	Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience. <i>Clinical and Translational Oncology</i> , 2018, 20, 658-665.	2.4	3
7203	Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma. <i>Cytotherapy</i> , 2018, 20, 134-148.	0.7	43
7204	Multimodality Management of Recurrent Skull Base Chordomas: Factors Impacting Tumor Control and Disease-Specific Survival. <i>Operative Neurosurgery</i> , 2018, 15, 131-143.	0.8	13
7205	Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-“A report from the SIOP Renal Tumor Study Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26849.	1.5	11
7206	Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 35-41.	1.8	12
7207	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 321-335.	2.5	27

#	ARTICLE	IF	CITATIONS
7208	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. Targeted Oncology, 2018, 13, 107-112.	3.6	8
7209	Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	12.6	3,689
7210	Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. American Journal of Roentgenology, 2018, 210, 175-182.	2.2	21
7211	Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus–positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer, 2018, 124, 521-529.	4.1	21
7212	Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors. Hormones and Cancer, 2018, 9, 62-69.	4.9	18
7213	Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report. Advances in Radiation Oncology, 2018, 3, 57-61.	1.2	12
7214	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, e143-e149.	2.4	15
7215	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer, 2018, 16, e483-e490.	1.9	12
7216	The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e205-e209.	2.6	3
7217	The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival. American Journal of Roentgenology, 2018, 210, W1-W7.	2.2	4
7218	Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clinical Cancer Research, 2018, 24, 407-419.	7.0	203
7219	Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer—Predictive Factors and Prognosis. Clinical Colorectal Cancer, 2018, 17, e91-e97.	2.3	18
7220	Using Imaging to Predict Treatment Response in Genitourinary Malignancies. European Urology Focus, 2018, 4, 804-817.	3.1	3
7221	MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. International Journal of Clinical Oncology, 2018, 23, 281-286.	2.2	1
7222	Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 12.e1-12.e6.	1.6	11
7223	Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus–associated oropharyngeal squamous cell cancer. Head and Neck, 2018, 40, 233-241.	2.0	33
7224	Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer. JAMA Oncology, 2018, 4, e173501.	7.1	755
7225	Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. Clinical Endocrinology, 2018, 88, 318-326.	2.4	23

#	ARTICLE	IF	CITATIONS
7226	First-in-class human trial of the PI3K β -selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	4.1	29
7227	A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 485-493.	2.5	71
7228	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 7-12.	1.7	16
7229	Predictive Value of 18 F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 756-761.	5.0	26
7230	The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival. <i>Digestive Surgery</i> , 2018, 35, 303-310.	1.2	22
7231	Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. <i>Oncologist</i> , 2018, 23, 171-178.	3.7	31
7232	Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes. <i>Clinical Colorectal Cancer</i> , 2018, 17, e77-e81.	2.3	8
7233	Cerenkov luminescence imaging on evaluation of early response to chemotherapy of drug-resistant gastric cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 205-213.	3.3	30
7234	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. <i>International Journal of Hyperthermia</i> , 2018, 34, 840-852.	2.5	24
7235	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 5-21.	5.0	7
7236	Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results. <i>Investigational New Drugs</i> , 2018, 36, 442-450.	2.6	16
7237	Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 209-217.	0.9	8
7238	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 175-182.	4.2	90
7239	Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e289-e295.	1.9	10
7240	First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. <i>Investigational New Drugs</i> , 2018, 36, 230-239.	2.6	32
7241	The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma. <i>Annals of Pharmacotherapy</i> , 2018, 52, 60-68.	1.9	5
7242	Promoting Collaborations Between Radiologists and Scientists. <i>Academic Radiology</i> , 2018, 25, 9-17.	2.5	4
7243	Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 372-381.	2.4	144

#	ARTICLE	IF	CITATIONS
7244	Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. <i>Radiotherapy and Oncology</i> , 2018, 126, 37-42.	0.6	72
7245	Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. <i>British Journal of Surgery</i> , 2018, 105, 839-847.	0.3	176
7246	Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. <i>Abdominal Radiology</i> , 2018, 43, 3-12.	2.1	47
7247	Immune Modulation Therapy and Imaging: Workshop Report. <i>Journal of Nuclear Medicine</i> , 2018, 59, 410-417.	5.0	23
7248	Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study. <i>Journal of Neurosurgery</i> , 2018, 129, 71-83.	1.6	25
7249	Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. <i>Abdominal Radiology</i> , 2018, 43, 218-230.	2.1	86
7250	Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy. <i>Acta Oncologica</i> , 2018, 57, 311-319.	1.8	85
7251	¹⁸ F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 95-101.	6.4	46
7252	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	2.5	70
7253	Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≤ 2 cm. <i>Journal of Neurosurgery</i> , 2018, 129, 366-382.	1.6	83
7254	Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26768.	1.5	12
7255	HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 79-87.	4.2	7
7256	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e135-e142.	2.4	17
7257	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. <i>Investigative Radiology</i> , 2018, 53, 96-102.	6.2	36
7258	Efficacy of Radioembolization with ¹⁶⁶ Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 582-588.	5.0	77
7259	Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 61-68.	1.1	8
7260	Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e1-e2.	1.1	4
7261	An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018, 21, 413-420.	5.3	18

#	ARTICLE	IF	CITATIONS
7262	Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 195-207.	6.7	28
7263	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 262-277.	6.4	97
7264	Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 39-45.	4.2	45
7265	Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 470-475.	1.3	12
7266	Transvaginal Ultrasoundâ€¢Guided Core Needle Biopsy of Pelvic Masses. <i>Journal of Ultrasound in Medicine</i> , 2018, 37, 453-461.	1.7	16
7267	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	7.3	55
7268	The promise of signal transduction in genetically driven sarcomas of the nerve. <i>Experimental Neurology</i> , 2018, 299, 317-325.	4.1	15
7269	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. <i>Journal of Investigative Dermatology</i> , 2018, 138, 58-67.	0.7	47
7270	Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Nonâ€¢Small Cell Lung Cancer. <i>Value in Health</i> , 2018, 21, 9-17.	0.3	20
7271	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, 128-139.	1.3	417
7272	Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. <i>Oncology</i> , 2018, 94, 19-24.	1.9	25
7273	Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 433-442.	2.0	19
7274	Metastasectomy following incomplete response to highâ€¢dose interleukinâ€¢2. <i>Journal of Surgical Oncology</i> , 2018, 117, 572-578.	1.7	3
7275	Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2018, 28, 79-87.	4.5	91
7276	Biomarkers and Imaging of Breast Cancer. <i>American Journal of Roentgenology</i> , 2018, 210, 271-278.	2.2	54
7277	Growth of Focal Nodular Hyperplasia is Not a Reason for Surgical Intervention, but Patients Should be Referred to a Tertiary Referral Centre. <i>World Journal of Surgery</i> , 2018, 42, 1506-1513.	1.6	13
7278	Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). <i>Acta OncolÃ³gica</i> , 2018, 57, 31-37.	1.8	13
7279	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2â€¢ advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 127-134.	2.5	90

#	ARTICLE	IF	CITATIONS
7280	Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma. <i>European Journal of Radiology</i> , 2018, 98, 100-106.	2.6	106
7281	Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2018, 20, 785-793.	2.4	3
7282	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	7.0	225
7283	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	2.5	27
7284	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. <i>Targeted Oncology</i> , 2018, 13, 81-87.	3.6	8
7285	Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. <i>European Journal of Cancer</i> , 2018, 88, 1-9.	2.8	133
7286	Immune-related tumour response assessment criteria: a comprehensive review. <i>British Journal of Radiology</i> , 2018, 91, 20170457.	2.2	58
7287	Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer. <i>Future Oncology</i> , 2018, 14, 537-544.	2.4	14
7288	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018, 88, 38-47.	2.8	248
7289	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018, 118, 181-188.	6.4	23
7290	Real life experience with nivolumab for the treatment of non-small cell lung carcinoma. <i>Lung Cancer</i> , 2018, 126, 210-216.	2.0	36
7291	Predicting Treatment Response of Breast Cancer to Neoadjuvant Chemotherapy Using Ultrasound-Guided Diffuse Optical Tomography. <i>Translational Oncology</i> , 2018, 11, 56-64.	3.7	12
7292	Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 81-89.	2.4	29
7293	Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 602-612.	6.4	107
7294	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. <i>Targeted Oncology</i> , 2018, 13, 89-98.	3.6	63
7295	Volumetric measurement of hepatic tumors: Accuracy of manual contouring using CT with volumetric pathology as the reference method. <i>Diagnostic and Interventional Imaging</i> , 2018, 99, 83-89.	3.2	9
7296	Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 333-337.	2.3	8
7297	Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. <i>Clinical and Translational Oncology</i> , 2018, 20, 939-953.	2.4	63

#	ARTICLE	IF	CITATIONS
7298	Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates. <i>Pancreatology</i> , 2018, 18, 94-99.	1.1	20
7299	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	2.6	16
7300	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. <i>European Journal of Cancer</i> , 2018, 89, 56-63.	2.8	60
7301	Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. <i>Molecular and Cellular Biochemistry</i> , 2018, 444, 197-206.	3.1	16
7302	Platinum sensitivity in metastatic prostate cancer: does histology matter?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 92-99.	3.9	17
7303	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 751-762.	4.1	22
7305	Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 325-332.	2.3	11
7306	Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. <i>Cancer Science</i> , 2018, 109, 215-224.	3.9	39
7307	Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 196.	7.1	60
7308	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	10.7	149
7309	Reviewing RECIST in the Era of Prolonged and Targeted Therapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 154-164.	1.1	22
7310	Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. <i>Annals of Nuclear Medicine</i> , 2018, 32, 105-113.	2.2	54
7311	Cardiophrenic lymph node resection in advanced ovarian cancer: surgical outcomes, pre- and postoperative imaging. <i>Acta Oncologica</i> , 2018, 57, 820-824.	1.8	12
7312	Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. <i>Future Oncology</i> , 2018, 14, 515-525.	2.4	23
7313	Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 692-698.	1.7	16
7314	Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 689-698.	6.4	14
7315	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 88, 67-76.	2.8	15
7316	Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 163-169.	1.0	60

#	ARTICLE	IF	CITATIONS
7317	Apparent transverse relaxation (T2) on <scp>MRI</scp> as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 224-231.	1.8	5
7318	Imaging in retroperitoneal soft tissue sarcoma. Journal of Surgical Oncology, 2018, 117, 25-32.	1.7	35
7319	Optimizing Primary Tumor Management in Stage IV Rectal Cancer. , 2018, , 257-268.		0
7320	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunology, Immunotherapy, 2018, 67, 459-470.	4.2	132
7321	eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 149-154.	1.9	26
7322	Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocrine Connections, 2018, 7, 169-178.	1.9	26
7323	Prognostic impact of circulating tumor cells in patients with ampullary cancer. Journal of Cellular Physiology, 2018, 233, 5014-5022.	4.1	9
7324	Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. Oncoimmunology, 2018, 7, e1377872.	4.6	39
7325	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clinical Cancer Research, 2018, 24, 1785-1794.	7.0	42
7326	Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literatureâ€based metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 163-169.	1.5	15
7327	Some statistical considerations in the clinical development of cancer immunotherapies. Pharmaceutical Statistics, 2018, 17, 49-60.	1.3	22
7328	Heterogeneity analysis of diffusion-weighted MRI for prediction and assessment of microstructural changes early after one cycle of induction chemotherapy in nasopharyngeal cancer patients. Radiologia Medica, 2018, 123, 36-43.	7.7	5
7329	Sequential CT Findings in Patients With Nonâ€small-cell Lung Cancer Receiving Nivolumab. Clinical Lung Cancer, 2018, 19, 175-180.	2.6	1
7330	Added Value of a Single Fast 20-second Deep-Inspiration Breath-hold Acquisition in FDG PET/CT in the Assessment of Lung Nodules. Radiology, 2018, 286, 260-270.	7.3	11
7331	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 316-325.	7.0	17
7332	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment, 2018, 167, 671-686.	2.5	564
7333	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329.	1.2	30
7334	Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery, 2018, 163, 218-225.	1.9	98

#	ARTICLE	IF	CITATIONS
7335	With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage IIâ€“III squamous cell carcinoma of the esophagus: A propensity score-matched analysis. Radiotherapy and Oncology, 2018, 129, 154-160.	0.6	16
7336	Percutaneous Thermal Ablation of Spinal Metastases: Recent Advances and Review. American Journal of Roentgenology, 2018, 210, 142-152.	2.2	44
7338	Radiographic Evaluation of Immunotherapy. Current Cancer Research, 2018, , 115-131.	0.2	0
7339	A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib. Lung Cancer, 2018, 116, 96-98.	2.0	1
7340	Phase I Study of Chimeric Antigen Receptorâ€“Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clinical Cancer Research, 2018, 24, 1277-1286.	7.0	159
7341	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirusâ€“Related Cervical Carcinoma. JAMA Oncology, 2018, 4, e173776.	7.1	116
7342	Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 288-294.	1.7	6
7343	Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 2018, 191, 133-148.	2.6	57
7344	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerâ€“clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Annals of the Rheumatic Diseases, 2018, 77, 393-398.	0.9	230
7345	NeXt for neuroâ€“radiosurgery: A fully automatic approach for necrosis extraction in brain tumor MRI using an unsupervised machine learning technique. International Journal of Imaging Systems and Technology, 2018, 28, 21-37.	4.1	41
7346	Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectable pancreatic cancer. Immunologic Research, 2018, 66, 172-178.	2.9	2
7347	Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis. Annals of Surgical Oncology, 2018, 25, 122-130.	1.5	33
7348	Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e1-81.e7.	1.6	2
7349	State of the Art Treatment and Surveillance Imaging of Glioblastomas. Seminars in Roentgenology, 2018, 53, 23-36.	0.6	7
7350	Response Assessment in Treated Brain Tumors: The Fundamentals. Seminars in Roentgenology, 2018, 53, 37-44.	0.6	0
7351	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	2.6	149
7352	Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Nonâ€“Small-cell Lung Cancer: A Phase I Study. Clinical Lung Cancer, 2018, 19, e277-e285.	2.6	19
7353	Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. Annals of Surgical Oncology, 2018, 25, 107-116.	1.5	15

#	ARTICLE	IF	CITATIONS
7354	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed mTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
7355	Imaging the multiple facets of immuno-oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 121-122.	6.4	0
7356	Comprehensive study of three novel cases of <i>TFEB</i> -amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 99-113.	2.8	23
7357	Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2018, 36, 96-102.	2.6	150
7358	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. <i>Investigational New Drugs</i> , 2018, 36, 103-113.	2.6	19
7359	Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies. <i>Annals of Surgical Oncology</i> , 2018, 25, 83-90.	1.5	50
7360	IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 150-160.	4.1	20
7361	Efficiency of electrochemotherapy with reduced bleomycin dose in the treatment of nonmelanoma head and neck skin cancer: Preliminary results. <i>Head and Neck</i> , 2018, 40, 120-125.	2.0	33
7362	Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2018, 36, 156-162.	2.6	19
7363	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
7364	Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 91-97.	2.0	21
7365	Brain volume reduction after whole-brain radiotherapy: quantification and prognostic relevance. <i>Neuro-Oncology</i> , 2018, 20, 268-278.	1.2	14
7366	Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. <i>Hepatology</i> , 2018, 67, 873-883.	7.3	41
7367	A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 114-121.	2.0	5
7368	Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 201-208.	1.4	14
7369	Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 851-860.	1.3	6
7370	Feasibility of monitoring advanced melanoma patients using cell-free <i>scp</i> DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	3.3	25
7371	GTVcut for neuro-radiosurgery treatment planning: an MRI brain cancer seeded image segmentation method based on a cellular automata model. <i>Natural Computing</i> , 2018, 17, 521-536.	3.0	32

#	ARTICLE	IF	CITATIONS
7372	Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage. <i>JAMA Oncology</i> , 2018, 4, 40.	7.1	140
7373	Predictive Value of FDG PET/CT to Detect Lymph Node Metastases in Cervical Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 793-801.	1.3	20
7374	Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. <i>Medicine (United States)</i> , 2018, 97, e12750.	1.0	7
7375	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.0	3
7376	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	17
7377	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. <i>Oncotarget</i> , 2018, 9, 31066-31076.	1.8	18
7378	Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2018, 6, 150-155.	0.8	3
7379	Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1130-1137.	2.5	16
7380	Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e48.	2.2	12
7381	Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 1008-1018.	3.8	52
7382	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2Î± Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 867-874.	1.6	290
7383	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	1.6	43
7384	Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e13214.	1.0	5
7385	Cancer Care Treatment Outcome Ontology: A Novel Computable Ontology for Profiling Treatment Outcomes in Patients With Solid Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	2.1	7
7386	The Value of Diffusion-Weighted Magnetic Resonance Imaging in Predicting the Efficacy of Radiation and Chemotherapy in Cervical Cancer. <i>Open Life Sciences</i> , 2018, 13, 305-311.	1.4	1
7387	Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma. <i>Oncotarget</i> , 2018, 9, 37042-37053.	1.8	12
7388	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4152-4163.	3.3	134
7389	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	1.6	43

#	ARTICLE	IF	CITATIONS
7390	Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 1019-1029.	3.8	55
7391	Power Analysis of Collapsed Ordered Categories with Application to Cancer Data. Calcutta Statistical Association Bulletin, 2018, 70, 87-95.	0.3	1
7392	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	1.6	207
7393	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 3298-3306.	1.6	88
7394	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	1.6	247
7395	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	98
7396	US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. Journal of Clinical Oncology, 2018, 36, 1225-1231.	1.6	15
7397	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 3007-3014.	1.6	184
7398	What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?. Journal of Oncology Practice, 2018, 14, e722-e728.	2.5	31
7399	Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. Korean Journal of Internal Medicine, 2018, 33, 737-744.	1.7	21
7400	Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience". International Journal of Gynecological Cancer, 2018, 28, 1569-1575.	2.5	6
7401	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	1.6	431
7402	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology, 2018, 36, 765-772.	1.6	117
7403	SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. Journal of Clinical Oncology, 2018, 36, 1913-1921.	1.6	467
7404	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1389-1395.	1.6	137
7405	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 2018, 36, 2465-2472.	1.6	704
7406	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1343-1373.	1.6	324
7407	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. Journal of Clinical Oncology, 2018, 36, 350-358.	1.6	160

#	ARTICLE	IF	CITATIONS
7408	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	1.6	362
7409	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2â€“Positive and Hormone Receptorâ€“Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2826-2835.	1.6	152
7410	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	1.6	134
7411	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repairâ€“Deficient/Microsatellite Instabilityâ€“High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	1.6	1,525
7412	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2693-2701.	1.6	124
7413	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858.	1.6	288
7414	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	1.6	267
7415	Patterns of Response and Progression to Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 169-178.	3.8	196
7416	Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1922-1929.	1.6	245
7417	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2836-2844.	1.6	459
7418	Phase II Study of BCI398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	1.6	524
7419	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	1.6	276
7420	Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes. <i>Translational Lung Cancer Research</i> , 2018, 8, 32-47.	2.8	17
7421	Neoadjuvant chemotherapy with or without neoadjuvant radiotherapy compared with neoadjuvant chemoradiotherapy for esophageal cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 4715-4723.	1.4	5
7422	Palliative therapy in pancreatic cancerâ€“interventional treatment with radiofrequency ablation/irreversible electroporation. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 80-80.	3.0	37
7423	Atlas of PET-CT. , 2018, , .		0
7424	Percutaneous microwave thermosphere ablation of pancreatic tumours. <i>Gland Surgery</i> , 2018, 7, 59-66.	1.1	32
7425	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 135-139.	1.4	11

#	ARTICLE	IF	CITATIONS
7426	Do immune checkpoint inhibitors need new studies methodology?. Journal of Thoracic Disease, 2018, 10, S1564-S1580.	1.4	58
7427	Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. Journal of Thoracic Disease, 2018, 10, 1386-1393.	1.4	4
7428	Pathologic complete response after induction therapy—the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 2795-2803.	1.4	16
7429	A new era of treating advanced lung cancer is upon us. Translational Lung Cancer Research, 2018, 7, S202-S205.	2.8	2
7430	A lower level of forced expiratory volume in one second predicts the poor prognosis of small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 2179-2185.	1.4	15
7431	Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. Journal of Thoracic Disease, 2018, 10, 3329-3340.	1.4	12
7432	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 2948-2959.	1.4	2
7433	Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy. Journal of Thoracic Disease, 2018, 10, 6863-6872.	1.4	6
7434	The preoperative modified Glasgow prognostic score for the prediction of survival after pancreatic cancer resection following non-surgical treatment of an initially unresectable disease. Współczesna Onkologia, 2018, 22, 229-235.	1.4	5
7435	Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer. Radiation Oncology Journal, 2018, 36, 192-199.	1.5	4
7436	What information could the main actors of liquid biopsy provide? A representative case of non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2018, 10, E570-E576.	1.4	9
7437	Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib. Medicine (United States), 2018, 97, e11646.	1.0	9
7438	The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs. Medicine (United States), 2018, 97, e11648.	1.0	28
7439	Clinical application of plasma mitochondrial DNA content in patients with lung cancer. Oncology Letters, 2018, 16, 7074-7081.	1.8	17
7440	Changing paradigms of non-small cell lung cancer treatment. Journal of Thoracic Disease, 2018, 10, S4170-S4172.	1.4	2
7441	Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy. Oncology Letters, 2018, 17, 921-926.	1.8	4
7442	EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2018, 50, 908-916.	3.0	32
7443	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0

#	ARTICLE	IF	CITATIONS
7444	Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1592-1599.	2.5	9
7445	Enhancement of Photodynamic Therapy for Bowen's Disease Using Plum-Blossom Needling to Augment Drug Delivery. <i>Dermatologic Surgery</i> , 2018, 44, 1516-1524.	0.8	17
7446	Impact of the occurrence of new lesions on the survival of patients who undergo chemotherapy for metastatic colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2019, 10, 285-292.	1.0	2
7447	Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection. <i>Cancer Imaging</i> , 2018, 18, 50.	2.8	20
7448	Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study. <i>Molecular and Clinical Oncology</i> , 2018, 10, 125-131.	1.0	3
7449	Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 113-117.	1.0	0
7450	AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. <i>Oncology Letters</i> , 2018, 17, 773-780.	1.8	9
7451	Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. <i>Oncology Letters</i> , 2019, 17, 1349-1356.	1.8	27
7452	A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. <i>Oncology Letters</i> , 2018, 17, 1980-1985.	1.8	3
7453	Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. <i>Acta Oto-Laryngologica</i> , 2018, 138, 1146-1153.	0.9	2
7454	Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 17, 594-602.	1.8	9
7455	Change in standardized uptake values in delayed 18F-FDG positron emission tomography images in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e12817.	1.0	4
7456	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. <i>BMC Cancer</i> , 2018, 18, 1030.	2.6	50
7457	Therapeutic effect of combined hyperbaric oxygen and radiation therapy for single brain metastasis and its influence on osteopontin and MMP-9. <i>Experimental and Therapeutic Medicine</i> , 2018, 17, 465-471.	1.8	2
7458	Optimal Phase of Dynamic Computed Tomography for Reliable Size Measurement of Metastatic Neuroendocrine Tumors of the Liver: Comparison between Pre- and Post-Contrast Phases. <i>Korean Journal of Radiology</i> , 2018, 19, 1066.	3.4	4
7459	Changes in renal function following nedaplatin-containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin. <i>Oncology Letters</i> , 2019, 17, 2551-2556.	1.8	1
7460	Clinical analysis of neoadjuvant chemotherapy in patients with advanced vulvar cancer. <i>Medicine (United States)</i> , 2018, 97, e11786.	1.0	8
7461	Prognostic evaluation of patients with resectable lung cancer using systemic inflammatory response parameters. <i>Oncology Letters</i> , 2018, 17, 2244-2256.	1.8	8

#	ARTICLE	IF	CITATIONS
7462	Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden. <i>Medicine (United States)</i> , 2018, 97, e13517.	1.0	19
7463	TumorEncode - Deep Convolutional Autoencoder for Computed Tomography Tumor Treatment Assessment. , 2018, , .		0
7464	Concurrent Administration of Trastuzumab and Anthracycline for Breast Cancer Treatment: An Unassailable Contraindication?. , 2018, , .		1
7465	The impacts of chemotherapeutic response for clinical stage II and III breast cancer patients after neoadjuvant chemotherapy. <i>Therapeutic Radiology and Oncology</i> , 0, 2, 13-13.	0.2	0
7466	Panitumumab in combination with modified docetaxel/ cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. <i>Annals of Gastroenterology</i> , 2018, 31, 698-704.	0.6	3
7467	Taxanes for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0
7468	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	8
7469	Concomitant driver mutations in advanced <i>EGFR</i>-mutated non-small-cell lung cancer and their impact on erlotinib treatment. <i>Oncotarget</i> , 2018, 9, 26195-26208.	1.8	35
7470	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 365-369.	1.7	36
7471	Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 421-430.	2.0	25
7472	Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	3.0	2
7473	<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to Entrectinib. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	3.0	16
7474	S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report. <i>Surgical Case Reports</i> , 2018, 4, 52.	0.6	0
7475	Can 18F-fluorodeoxyglucose positron emission tomography predict the response to radioactive iodine therapy in metastatic differentiated thyroid carcinoma?. <i>European Journal of Hybrid Imaging</i> , 2018, 2, .	1.5	2
7476	Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	3.0	3
7478	Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-16.	3.0	12
7479	Pathological complete response of locally advanced colon cancer after preoperative radiotherapy: a case report and narrative review of the literature. <i>Surgical Case Reports</i> , 2018, 4, 58.	0.6	4
7480	Placement of a self-expandable metallic stent as a bridge to surgery for large bowel obstruction induced by effective neoadjuvant therapy: report of three cases. <i>Surgical Case Reports</i> , 2018, 4, 100.	0.6	0

#	ARTICLE	IF	CITATIONS
7481	<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2018, 2, 1-14.	3.0	19
7482	Treatment outcomes of locally advanced hypopharyngeal squamous cell carcinoma. Therapeutic Radiology and Oncology, 2018, 2, 17-17.	0.2	1
7483	Pregnancy and Delivery After PRRT Without Sequelae. Clinical Nuclear Medicine, 2018, 43, 842-845.	1.3	2
7484	Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. Journal of Hematology and Oncology, 2018, 11, 129.	17.0	27
7485	Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases. Anticancer Research, 2018, 38, 6501-6506.	1.1	2
7486	Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only. Oncology Letters, 2018, 15, 5662-5670.	1.8	5
7487	Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Journal of Translational Medicine, 2018, 16, 300.	4.4	78
7488	Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha. Anticancer Research, 2018, 38, 6393-6397.	1.1	3
7489	Rheumatic immune-related adverse events secondary to anti-“programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	2.8	53
7490	Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. PLoS ONE, 2018, 13, e0207362.	2.5	31
7491	Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal of Visualized Experiments, 2018, , .	0.3	10
7492	Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. European Journal of Cancer, 2018, 105, 114-126.	2.8	52
7493	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer, 2018, 18, 1116.	2.6	51
7494	Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer. BMC Cancer, 2018, 18, 1120.	2.6	23
7495	Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer. In Vivo, 2018, 32, 1581-1586.	1.3	2
7496	Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study. Oncology Letters, 2018, 16, 7271-7277.	1.8	34
7497	ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Clinical Nuclear Medicine, 2018, 43, 899-908.	1.3	29
7498	⁸⁹ Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858.	30.7	468

#	ARTICLE	IF	CITATIONS
7499	Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway. <i>International Journal of Biological Sciences</i> , 2018, 14, 1859-1872.	6.4	8
7500	Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. <i>Journal of Cancer</i> , 2018, 9, 4099-4107.	2.5	7
7501	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , 2018, 18, 1171.	2.6	22
7502	Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2018, 10, 466.	3.7	23
7503	Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2018, 18, 1146.	2.6	36
7504	Fractionated Stereotactic Radiosurgery for Brain Metastases Using the Novalis Tx [®] System. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 525-529.	1.2	4
7505	Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 226-233.	1.9	1
7506	Systematic review of the applications of three-dimensional printing in colorectal surgery. <i>Colorectal Disease</i> , 2019, 21, 261-269.	1.4	19
7507	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7513-7519.	2.0	6
7508	Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 5283-5290.	1.9	5
7509	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133
7510	Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 318.	4.4	5
7511	Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?. <i>Frontiers in Immunology</i> , 2018, 9, 2804.	4.8	94
7512	Persistent Head and Neck Cancer Following First-Line Treatment. <i>Cancers</i> , 2018, 10, 421.	3.7	14
7513	Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. <i>International Journal of Hyperthermia</i> , 2018, 35, 398-418.	2.5	62
7514	Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. <i>BMC Cancer</i> , 2018, 18, 1137.	2.6	69
7515	Salvage Carbon-ion Radiotherapy for Isolated Lymph Node Recurrence Following Curative Resection of Esophageal Cancer. <i>Anticancer Research</i> , 2018, 38, 6453-6458.	1.1	16
7516	Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy. <i>Cancers</i> , 2018, 10, 454.	3.7	9

#	ARTICLE	IF	CITATIONS
7517	MRI assessment of surrounding tissues in soft-tissue sarcoma during neoadjuvant chemotherapy can help predicting response and prognosis. <i>European Journal of Radiology</i> , 2018, 109, 178-187.	2.6	14
7518	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxalisib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1471-1476.	6.4	74
7519	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	2.6	12
7520	Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 307.	4.4	16
7521	The Role of Energy Balance on Colorectal Cancer Survival. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 266-273.	0.5	1
7522	Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer. <i>In Vivo</i> , 2018, 32, 1643-1646.	1.3	1
7524	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
7525	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. <i>European Journal of Radiology</i> , 2018, 109, 68-76.	2.6	8
7526	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664.	12.8	331
7527	Natural History of Small Pancreatic Lesions Suspected to Be Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2018, 47, 1357-1363.	1.1	11
7528	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. <i>PLoS ONE</i> , 2018, 13, e0206942.	2.5	35
7529	Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients. <i>Anticancer Research</i> , 2018, 38, 6543-6550.	1.1	3
7530	Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 6565-6569.	1.1	3
7531	Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype. <i>Oncology Letters</i> , 2018, 16, 2539-2548.	1.8	2
7532	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
7533	Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. <i>Heliyon</i> , 2018, 4, e01031.	3.2	13
7534	Prognostic significance of pretreatment ¹⁸ F-fluorodeoxyglucose positron emission tomography evaluation using metabolic tumor volume of the primary tumor and lymph nodes in advanced hypopharyngeal cancer. <i>Head and Neck</i> , 2019, 41, 739-747.	2.0	3
7535	Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 340.	4.4	4

#	ARTICLE	IF	CITATIONS
7536	Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 359-368.	1.9	8
7537	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 11, 29-42.	1.8	6
7538	Radiomics – the value of the numbers in present and future radiology. <i>Polish Journal of Radiology</i> , 2018, 83, 171-174.	0.9	10
7539	Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma. <i>Cancer Science</i> , 2018, 109, 3962-3970.	3.9	7
7540	Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880733.	3.2	27
7541	Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3963.	4.1	37
7542	Resonancia magnética en el cáncer de mama tratado con neoadyuvancia: correlación radiopatológica de la respuesta. <i>Revista De Senología Y Patología Mamaria</i> , 2018, 31, 141-151.	0.1	0
7543	Deep Lesion Graphs in the Wild: Relationship Learning and Organization of Significant Radiology Image Findings in a Diverse Large-Scale Lesion Database. , 2018, , .		78
7544	Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. <i>Journal of Oncology</i> , 2018, 2018, 1-9.	1.3	53
7545	Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 128.	1.1	22
7546	Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8623-8632.	2.0	13
7547	Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): a population based outcome study. <i>Radiation Oncology</i> , 2018, 13, 247.	2.7	2
7548	Normalized Serum EGF Levels as a Potential Biomarker in Non-Small Cell Lung Cancer: The Role of Platelets. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2018, 09, .	0.4	3
7549	Sorafenib for Advanced and Refractory Desmoid Tumors. <i>New England Journal of Medicine</i> , 2018, 379, 2417-2428.	27.0	287
7550	MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. <i>Oncotarget</i> , 2018, 9, 7501-7512.	1.8	58
7551	Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study. <i>Oncotarget</i> , 2018, 9, 24537-24547.	1.8	11
7552	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	2.6	31
7553	Evaluación postratamiento locorregional y sistémico del carcinoma hepatocelular. <i>Radiología</i> , 2018, 60, 424-436.	0.5	0

#	ARTICLE	IF	CITATIONS
7554	Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Pancreatic Cancer</i> , 2018, 4, 64-71.	0.9	5
7555	Gastrointestinal stromal tumors: A multidisciplinary challenge. <i>World Journal of Gastroenterology</i> , 2018, 24, 1925-1941.	3.3	54
7556	Nodal volume as a prognostic factor in locally advanced head and neck cancer: Identifying candidates for elective neck dissection after chemoradiation with IGRT from a single institutional prospective series from the Indian subcontinent. <i>Oral Oncology</i> , 2018, 87, 179-185.	1.5	5
7557	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 1267.	2.6	12
7558	Novel imaging techniques in staging oesophageal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 17-25.	2.4	29
7559	Measurable Krukenberg tumor is preferably characterized as a non-target lesion in the clinical evaluation of ^{125}I gastric cancer therapeutics: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 622-628.	1.0	0
7560	High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study. <i>Head and Neck</i> , 2019, 41, 146-153.	2.0	15
7561	Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8945-8950.	2.0	4
7562	Safely Chemotherapy Administration in Patient with Small-cell Lung Cancer and End-stage Renal Disease Undergoing Haemodialysis. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2018, 09, .	0.3	0
7563	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , 2018, 4, 41.	5.2	41
7564	Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI). <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	50
7565	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. <i>BMC Cancer</i> , 2018, 18, 1231.	2.6	10
7566	Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. <i>Oncotarget</i> , 2018, 9, 15418-15434.	1.8	21
7567	Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series. <i>Ecancermedicalscience</i> , 2018, 12, 875.	1.1	1
7568	Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer. <i>Radiation Oncology Journal</i> , 2018, 36, 35-44.	1.5	4
7569	Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1442-1450.	4.9	6
7570	The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer. <i>Head and Neck</i> , 2019, 41, 329-339.	2.0	16
7571	Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 415-421.	0.8	3

#	ARTICLE	IF	CITATIONS
7572	Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer. <i>Journal of Cancer</i> , 2018, 9, 4172-4178.	2.5	3
7573	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
7574	Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma. <i>Case Reports in Oncology</i> , 2018, 11, 735-741.	0.7	12
7575	microRNA expression pattern as an ancillary prognostic signature for radiotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 341.	4.4	12
7576	Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy. <i>BMC Clinical Pathology</i> , 2018, 18, 12.	1.8	24
7577	Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7345-7352.	2.0	11
7578	Preliminary report of a singleâ€channel applicator in high dose rate afterloading brachytherapy for cervical cancer. <i>Cancer Science</i> , 2018, 109, 3953-3961.	3.9	6
7579	Use of apparent diffusion coefficient images to predict response to induction chemotherapy in sinonasal cancer. , 2018, 2018, 782-785.		1
7580	Unusual metastatic localization to the kidney of basaloid squamous cell carcinoma of the oropharynx. <i>Urologia</i> , 2018, 85, 182-185.	0.7	0
7581	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5â€years of follow-up. <i>Radiation Oncology</i> , 2018, 13, 234.	2.7	73
7582	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
7583	The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI. <i>International Journal of General Medicine</i> , 2018, Volume 11, 423-430.	1.8	26
7584	Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 6771-6782.	1.1	33
7585	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. <i>Cancer Management and Research</i> , 2018, Volume 10, 5537-5544.	1.9	1
7586	A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6911-6917.	1.1	13
7587	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. <i>Nutrients</i> , 2018, 10, 1854.	4.1	61
7588	Statins improve survival in patients previously treated with nivolumab for advanced nonâ€small cell lung cancer: An observational study. <i>Molecular and Clinical Oncology</i> , 2018, 10, 137-143.	1.0	39
7589	Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2018, 22, 386.	0.1	17

#	ARTICLE	IF	CITATIONS
7590	Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapy. <i>Molecular and Clinical Oncology</i> , 2018, 9, 545-552.	1.0	2
7591	Phase 1 study of EGFR antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlates. <i>Cancer</i> , 2018, 124, 3881-3889.	4.1	8
7592	Imaging Criteria for Tumor Treatment Response Evaluation. , 2018, , 11-23.		0
7593	TRK Inhibition: A New Tumor-Agnostic Treatment Strategy. <i>Targeted Oncology</i> , 2018, 13, 545-556.	3.6	71
7595	Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. <i>Thoracic Cancer</i> , 2018, 9, 1699-1706.	1.9	3
7596	Evaluation of the Laser-Induced Thermoablation Treatment Effect of Breast Cancer Based on Tissue Viscoelastic Properties. <i>Journal of Engineering and Science in Medical Diagnostics and Therapy</i> , 2018, 1, .	0.5	0
7597	Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 5859-5866.	1.1	42
7598	Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors. <i>Anticancer Research</i> , 2018, 38, 5963-5968.	1.1	14
7599	Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial. <i>Anticancer Research</i> , 2018, 38, 5975-5981.	1.1	12
7600	Metastatic medullary thyroid cancer to the brain: a case report and review of the literature. <i>International Journal of Endocrine Oncology</i> , 2018, 5, IJE11.	0.4	2
7601	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
7602	A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 6015-6021.	1.1	4
7603	Clinical Implications of Soft Tissue Sarcomas. , 2018, , 111-119.		0
7604	Breast Cancer: PET/CT Imaging. , 2018, , 293-297.		0
7605	A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1021-1029.	2.3	32
7606	Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review. <i>Lung</i> , 2018, 196, 633-642.	3.3	18
7607	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. <i>Oncimmunology</i> , 2018, 7, e1502905.	4.6	80
7608	A Phase Ib study of ruxolitinib + gemcitabine & plusmn nab-paclitaxel in patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2399-2407.	2.0	11

#	ARTICLE	IF	CITATIONS
7609	Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 420-429.	1.0	30
7610	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	21.4	145
7611	Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. <i>Breast Cancer Research</i> , 2018, 20, 48.	5.0	80
7612	¹⁸ F-FDG PET/CT for the early prediction of the response rate and survival of patients with recurrent or metastatic breast cancer. <i>Oncology Letters</i> , 2018, 16, 4151-4158.	1.8	6
7613	Prospective memory impairment following whole brain radiotherapy in patients with metastatic brain cancer. <i>Cancer Medicine</i> , 2018, 7, 5315-5321.	2.8	18
7614	Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1648-1655.	1.9	3
7615	Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2285-2299.	6.4	35
7616	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2018, 13, 611-619.	3.6	3
7617	Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer. <i>Nutrition and Cancer</i> , 2018, 70, 1322-1329.	2.0	13
7618	The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. <i>Cancer Management and Research</i> , 2018, Volume 10, 3305-3315.	1.9	14
7619	Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 125, 150-156.	2.0	152
7620	Checkpoint molecule PD-1-assisted CD8 ⁺ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 3419-3431.	1.9	47
7621	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. <i>Immunotherapy</i> , 2018, 10, 1123-1132.	2.0	9
7622	Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 383-393.	2.4	5
7623	Radioiodine Refractory Thyroid Cancer. , 2018, , 201-212.		0
7624	Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2457-2463.	2.5	8
7625	Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. <i>European Journal of Cancer</i> , 2018, 103, 165-175.	2.8	40
7626	Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab. <i>Case Reports in Gastroenterology</i> , 2018, 12, 532-539.	0.6	1

#	ARTICLE	IF	CITATIONS
7627	Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 971-978.	2.3	19
7628	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1468-1479.	10.7	370
7629	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 845-855.	8.1	32
7630	Quantitative Whole-Body Diffusion-Weighted MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 479-494.	1.1	19
7631	Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 1623-1630.	1.9	38
7632	Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer. <i>Oncology Letters</i> , 2018, 16, 6589-6597.	1.8	13
7633	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. <i>JAMA Oncology</i> , 2018, 4, 1610.	7.1	27
7634	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. <i>Journal of Surgical Oncology</i> , 2018, 118, 1021-1026.	1.7	20
7635	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	3.6	22
7636	Percutaneous Minimally Invasive Thermal Ablation of Musculoskeletal Lesions. <i>PET Clinics</i> , 2018, 13, 579-585.	3.0	4
7637	Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. <i>Scientific Reports</i> , 2018, 8, 14036.	3.3	139
7639	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , The, 2018, 19, e534-e545.	10.7	98
7640	Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?. <i>Cancer Communications</i> , 2018, 38, 1-10.	9.2	22
7641	Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. <i>PLoS ONE</i> , 2018, 13, e0204729.	2.5	83
7642	Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-9.	1.4	24
7643	Percutaneous radiofrequency ablation in the treatment of pulmonary malignancies: efficacy, safety and predictive factors. <i>Oncotarget</i> , 2018, 9, 11722-11733.	1.8	6
7644	Imaging Biomarker Ontology (IBO): A Biomedical Ontology to Annotate and Share Imaging Biomarker Data. <i>Journal on Data Semantics</i> , 2018, 7, 223-236.	2.0	1
7645	Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment. <i>British Journal of Cancer</i> , 2018, 119, 572-579.	6.4	12

#	ARTICLE	IF	CITATIONS
7646	Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. <i>Cancer Science</i> , 2018, 109, 3554-3563.	3.9	24
7647	Adverse effects and radiological manifestations of new immunotherapy agents. <i>British Journal of Radiology</i> , 2019, 92, 20180164.	2.2	14
7648	Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 3669-3677.	1.9	2
7649	Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3085-3093.	4.3	6
7650	Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a "no-fly zone"? <i>Acta Oncologica</i> , 2018, 57, 1532-1539.	1.8	7
7651	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	1.2	1,571
7652	The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. <i>BMC Cancer</i> , 2018, 18, 938.	2.6	94
7653	Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. <i>World Journal of Surgical Oncology</i> , 2018, 16, 191.	1.9	39
7654	Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond. <i>Journal of the Endocrine Society</i> , 2018, 2, 1109-1130.	0.2	26
7655	Interpretation of Results from Under-Enrolling Studies. <i>Oncologist</i> , 2018, 23, 755-756.	3.7	0
7656	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
7657	SUV _{max} -based Parameters of FDG-PET/CT Reliably Predict Pathologic Complete Response After Preoperative Hyperthermo-chemoradiotherapy in Rectal Cancer. <i>Anticancer Research</i> , 2018, 38, 5909-5916.	1.1	8
7658	Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 909.	2.6	25
7659	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 352.	1.6	4
7660	Early tumor response prediction for lung cancer patients using novel longitudinal pattern features from sequential PET/CT image scans. <i>Physica Medica</i> , 2018, 54, 21-29.	0.7	38
7661	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	27.0	691
7662	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2040-2051.	27.0	2,676
7663	Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2018, 3, e000305.	4.5	34

#	ARTICLE	IF	CITATIONS
7664	FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA. <i>Cancer Letters</i> , 2018, 439, 78-90.	7.2	44
7665	Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China. <i>Thoracic Cancer</i> , 2018, 9, 1565-1572.	1.9	5
7666	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126.	7.1	180
7667	Whole-Body Magnetic Resonance Imaging in Oncology. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 495-507.	1.1	32
7668	Metastasis Reporting and Data System for Prostate Cancer in Practice. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 527-542.	1.1	8
7669	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018, 124, 3677-3683.	4.1	53
7670	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	4.1	15
7671	Semi-automatic RECIST Labeling on CT Scans with Cascaded Convolutional Neural Networks. <i>Lecture Notes in Computer Science</i> , 2018, , 405-413.	1.3	20
7672	Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 1038.	2.6	20
7673	Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?. <i>Radiation Oncology</i> , 2018, 13, 211.	2.7	17
7674	Increased Plasma Circulating Cell-Free DNA Could Be a Potential Marker for Oral Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3303.	4.1	56
7675	Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. <i>European Journal of Cancer</i> , 2018, 104, 182-187.	2.8	58
7676	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <i>Gynecologic Oncology</i> , 2018, 151, 407-413.	1.4	17
7677	Remote measurement of urinary radioactivity in 18 F-FDG PET patients using Compton camera for accuracy evaluation of standardized uptake value. <i>Biomedical Physics and Engineering Express</i> , 2018, 4, 065029.	1.2	0
7678	Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 389-393.	1.0	1
7679	Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6633-6646.	2.0	1
7680	Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats. <i>Cancer</i> , 2018, 124, 4633-4649.	4.1	125
7681	ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2018, 124, 4667-4675.	4.1	12

#	ARTICLE	IF	CITATIONS
7682	The clinical impact of miRNA34a and P53 gene expression in colon cancer. <i>Biochemistry and Biophysics Reports</i> , 2018, 16, 88-95.	1.3	7
7684	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. <i>Theranostics</i> , 2018, 8, 5213-5230.	10.0	115
7685	A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). <i>Cancer</i> , 2018, 124, 4548-4555.	4.1	35
7686	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , 2018, 36, 1110-1115.	2.6	9
7687	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	2.8	97
7688	Automatic liver tumor segmentation in CT with fully convolutional neural networks and object-based postprocessing. <i>Scientific Reports</i> , 2018, 8, 15497.	3.3	155
7689	90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. <i>EJNMMI Research</i> , 2018, 8, 60.	2.5	46
7690	Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7061-7075.	2.0	14
7691	Clinical perspectives of PSMA PET/MRI for prostate cancer. <i>Clinics</i> , 2018, 73, e586s.	1.5	18
7692	Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. <i>Annals of Oncology</i> , 2018, 29, 2092-2097.	1.2	56
7693	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
7694	The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: A case series. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2018, 47, 62.	1.9	2
7695	Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. <i>Cancer Management and Research</i> , 2018, Volume 10, 4333-4347.	1.9	37
7696	Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer. <i>In Vivo</i> , 2018, 32, 1587-1590.	1.3	8
7697	Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 979-986.	2.3	10
7698	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	27.6	304
7699	Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-10.	0.8	3
7700	Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, e250-e258.	1.3	18

#	ARTICLE	IF	CITATIONS
7701	Ultrasound in the Re-Staging of Cervical Metastases after Chemoradiotherapy for Head and Neck Cancer. <i>Ultraschall in Der Medizin</i> , 2018, 39, 659-666.	1.5	12
7702	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
7704	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1200-1207.	6.4	83
7705	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e93.	2.2	37
7706	A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2018, 151, 422-427.	1.4	49
7707	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	6.4	133
7708	The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer. <i>PLoS ONE</i> , 2018, 13, e0205251.	2.5	22
7709	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	1.8	75
7710	Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6333-6338.	2.0	9
7711	Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3303-3310.	2.5	28
7712	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 745-755.	3.6	14
7713	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2018, 126, 41-47.	2.0	39
7714	Assessing Chemotherapeutic Response in Pancreatic Ductal Adenocarcinoma: Histogram Analysis of Iodine Concentration and CT Number in Single-Source Dual-Energy CT. <i>American Journal of Roentgenology</i> , 2018, 211, 1221-1226.	2.2	26
7715	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 39-46.	7.7	14
7716	Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. <i>Annales De Dermatologie Et De Venereologie</i> , 2018, 145, 649-658.	1.0	3
7717	Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. <i>European Journal of Cancer</i> , 2018, 104, 188-194.	2.8	58
7718	Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. <i>Targeted Oncology</i> , 2018, 13, 735-743.	3.6	6
7719	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. <i>Annals of Oncology</i> , 2018, 29, 2247-2253.	1.2	101

#	ARTICLE	IF	CITATIONS
7720	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
7721	Phase 1 study of ARQ 761, a \hat{I}^2 -lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. <i>British Journal of Cancer</i> , 2018, 119, 928-936.	6.4	66
7722	Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 2045-2053.	1.6	32
7723	Prevalence, risk factors, and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis: a study from the Middle East. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 37.	1.5	7
7724	Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. <i>Pleura and Peritoneum</i> , 2018, 3, 20180118.	1.2	24
7726	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1437-1448.	10.7	345
7727	Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 1135-1141.	1.1	20
7728	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDia study. <i>Immunotherapy</i> , 2018, 10, 1229-1239.	2.0	38
7729	Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. <i>BMJ Open</i> , 2018, 8, e020731.	1.9	10
7730	Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 227.	1.6	21
7731	Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880690.	1.9	11
7732	Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. <i>Journal of Translational Medicine</i> , 2018, 16, 287.	4.4	45
7733	Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. <i>Surgical Case Reports</i> , 2018, 4, 71.	0.6	17
7734	Optimising the design of population-based patient-derived tumor xenograft studies to better predict clinical response. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	2.4	3
7735	Proton Beam Therapy in Combination with Intra-Arterial Infusion Chemotherapy for T4 Squamous Cell Carcinoma of the Maxillary Gingiva. <i>Cancers</i> , 2018, 10, 333.	3.7	6
7736	Comparative biodistribution analysis across four different ⁸⁹ Zr-monoclonal antibody tracers – The first step towards an imaging warehouse. <i>Theranostics</i> , 2018, 8, 4295-4304.	10.0	46
7737	Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2018, 103, 88-97.	2.8	22
7738	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 707-712.	6.4	28

#	ARTICLE	IF	CITATIONS
7739	Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 179.	2.4	37
7740	Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. <i>Clinical Sarcoma Research</i> , 2018, 8, 13.	2.3	32
7741	Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5401-5407.	1.1	4
7742	Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study. <i>Journal of Surgical Oncology</i> , 2018, 118, 687-693.	1.7	8
7743	The value of different 18F-FDG PET/CT baseline parameters in risk stratification of stage I surgical NSCLC patients. <i>Annals of Nuclear Medicine</i> , 2018, 32, 687-694.	2.2	10
7744	Distraction-suppression effect on osteosarcoma. <i>Medical Hypotheses</i> , 2018, 121, 4-5.	1.5	2
7745	A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 333-339.	0.6	33
7746	Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. <i>Oncotarget</i> , 2018, 9, 16477-16488.	1.8	23
7747	Advances in oncological treatment: limitations of RECIST 1.1 criteria. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 129-139.	0.7	29
7748	Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. <i>Diagnostic and Interventional Radiology</i> , 2018, 24, 195-202.	1.5	19
7749	Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil and oxaliplatin-based preoperative chemotherapy for liver metastases. <i>Molecular and Clinical Oncology</i> , 2018, 9, 3-10.	1.0	5
7750	Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 437-444.e6.	1.9	7
7751	Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 768-774.	1.8	5
7752	Evaluation of intravenous and subcutaneous administration of a novel, excipient-free, nanoparticulate formulation of paclitaxel in dogs with spontaneously occurring neoplasia. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 650-657.	1.8	6
7753	T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations. <i>In Vivo</i> , 2018, 32, 1199-1204.	1.3	9
7754	An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. <i>European Journal of Cancer</i> , 2018, 103, 17-23.	2.8	8
7755	Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2018, 22, 27.	0.1	20
7756	Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. <i>Medical Journal of Australia</i> , 2018, 209, 354-355.	1.7	35

#	ARTICLE	IF	CITATIONS
7757	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 359-366.	1.6	350
7758	Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 1707.	7.1	86
7759	Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study. <i>Updates in Surgery</i> , 2018, 70, 441-447.	2.0	4
7760	Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?. <i>European Journal of Cancer</i> , 2018, 103, 32-40.	2.8	19
7761	Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. <i>Journal of Medical Economics</i> , 2018, 21, 1191-1205.	2.1	78
7762	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 185-192.	0.5	6
7763	Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 527-535.	0.8	47
7764	Effect of preoperative chemotherapy on distal spread of low rectal cancer located close to the anus. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1685-1693.	2.2	3
7765	The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value. <i>Molecular Biology Reports</i> , 2018, 45, 2025-2035.	2.3	6
7766	Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot. <i>Clinica Chimica Acta</i> , 2018, 487, 6-14.	1.1	17
7767	Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	13
7768	Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. <i>Trials</i> , 2018, 19, 500.	1.6	6
7769	Accurate Weakly-Supervised Deep Lesion Segmentation Using Large-Scale Clinical Annotations: Slice-Propagated 3D Mask Generation from 2D RECIST. <i>Lecture Notes in Computer Science</i> , 2018, , 396-404.	1.3	41
7770	Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancer. <i>Esophagus</i> , 2018, 15, 256-262.	1.9	6
7771	Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. <i>Lung Cancer</i> , 2018, 125, 35-42.	2.0	28
7772	Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes. <i>Annals of Medicine</i> , 2018, 50, 713-720.	3.8	16
7773	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	6.4	66
7774	Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4443-4447.	2.0	0

#	ARTICLE	IF	CITATIONS
7775	miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2018, 10, 321.	3.7	18
7776	The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. <i>Cancer</i> , 2018, 124, 4241-4247.	4.1	100
7777	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 877-885.	2.3	5
7778	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. <i>Investigational New Drugs</i> , 2018, 36, 1072-1084.	2.6	32
7779	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1315-1327.	10.7	469
7780	Radiomic analysis using contrast-enhanced CT: predict treatment response to pulsed low dose rate radiotherapy in gastric carcinoma with abdominal cavity metastasis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2018, 8, 410-420.	2.0	34
7781	Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. <i>Yonsei Medical Journal</i> , 2018, 59, 930.	2.2	6
7782	PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2018, 10, 314.	3.7	32
7783	A method for tumor dosimetry based on hybrid planar ⁶⁷ Ge SPECT/CT images and semiautomatic segmentation. <i>Medical Physics</i> , 2018, 45, 5004-5018.	3.0	16
7784	Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs. <i>Cell Death and Disease</i> , 2018, 9, 930.	6.3	16
7785	Can Adrenal Adenomas Be Differentiated From Adrenal Metastases at Single-Phase Contrast-Enhanced CT?. <i>American Journal of Roentgenology</i> , 2018, 211, 1044-1050.	2.2	16
7786	Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model. <i>Medical Oncology</i> , 2018, 35, 146.	2.5	0
7787	Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. <i>RMD Open</i> , 2018, 4, e000714.	3.8	65
7788	Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. <i>Journal of Translational Medicine</i> , 2018, 16, 251.	4.4	21
7789	Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 382-394.	2.2	2
7790	Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2018, 12, 1105-1114.	1.4	30
7791	Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. <i>Cancers</i> , 2018, 10, 16.	3.7	62
7792	Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the <i>EGFR</i> T790M Mutation After Failure of Initial <i>EGFR</i> -TKI Treatment. <i>Anticancer Research</i> , 2018, 38, 5231-5237.	1.1	20

#	ARTICLE	IF	CITATIONS
7793	Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5387-5392.	1.1	11
7794	Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 839-845.	2.3	9
7795	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1404-1416.	10.7	105
7796	CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin. <i>European Journal of Radiology</i> , 2018, 107, 175-182.	2.6	11
7797	Pleural thymoma: Radiological and histological findings. <i>European Journal of Radiology Open</i> , 2018, 5, 147-152.	1.6	3
7798	Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2018, 151, 208-214.	1.4	24
7799	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. <i>Sarcoma</i> , 2018, 2018, 1-8.	1.3	14
7800	Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin. <i>Anticancer Research</i> , 2018, 38, 5283-5288.	1.1	5
7801	Prediction of Response to Stereotactic Radiosurgery for Brain Metastases Using Convolutional Neural Networks. <i>Anticancer Research</i> , 2018, 38, 5437-5445.	1.1	40
7802	Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer. <i>Molecular and Clinical Oncology</i> , 2018, 8, 791-796.	1.0	9
7803	Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. <i>In Vivo</i> , 2018, 32, 1155-1160.	1.3	5
7804	Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1825-1832.	4.2	86
7805	Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1257-e1265.	1.9	10
7806	Repeatability and Reproducibility of Radiomic Features: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1143-1158.	0.8	527
7807	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2018, 151, 202-207.	1.4	10
7808	Activation of central/effector memory T cells and T _H 1 polarization in malignant melanoma patients treated with anti-CD28 antibody. <i>Cancer Science</i> , 2018, 109, 3032-3042.	3.9	50
7809	Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 139-154.	1.9	13
7810	Resection of Isolated Port Site Metastasis in Gall Bladder Cancers—Careful Selection and Perioperative Systemic Therapy May Improve Outcomes. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 427-431.	0.7	4

#	ARTICLE	IF	CITATIONS
7811	Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma. Cancer Science, 2018, 109, 2873-2880.	3.9	16
7812	Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer – toxicities and response assessment. Cancer Management and Research, 2018, Volume 10, 519-526.	1.9	7
7813	Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Medicine (United States), 2018, 97, e11309.	1.0	5
7814	Ultralow dose CT for follow-up of solid pulmonary nodules. Medicine (United States), 2018, 97, e12019.	1.0	10
7815	Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm. Clinical Nuclear Medicine, 2018, 43, 676-678.	1.3	2
7816	Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE, 2018, 13, e0203058.	2.5	43
7817	SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discovery, 2018, 8, 1250-1257.	9.4	244
7818	Immunotherapy in melanoma. Immunotherapy, 2018, 10, 987-998.	2.0	22
7819	Early Assessment of Tumor Response to Radiation Therapy using High-Resolution Quantitative Microvascular Ultrasound Imaging. Theranostics, 2018, 8, 156-168.	10.0	37
7820	Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. International Journal of Radiation Oncology Biology Physics, 2018, 102, 451-461.	0.8	76
7821	Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer. Lung Cancer, 2018, 125, 22-28.	2.0	16
7822	Comparison between computed tomography-guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non-small cell lung cancer. Thoracic Cancer, 2018, 9, 1376-1382.	1.9	26
7824	[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. PLoS ONE, 2018, 13, e0197754.	2.5	15
7825	Tumor Infiltrating Lymphocytes and Tertiary Lymphoid Structure as Prognostic and Predictive Factor for Neoadjuvant Chemotherapy in Stage II & III Breast Cancer. Annals of Behavioural Science, 2018, 04, .	0.1	1
7826	Screen Printed Phosphorus Dopant Paste Diffusion optimization for Silicon Solar Cell Applications. , 2018, , .		1
7828	ICCEE 2018 Index. , 2018, , .		0
7829	Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 342-350.	2.6	21
7830	The Evolution of Phase I Trials, Past, Present, and Future. , 2018, , 17-32.		1

#	ARTICLE	IF	CITATIONS
7831	Clinical Trial Design in Immuno-Oncology. , 2018, , 151-173.		0
7832	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic Oncology, 2018, 150, 274-281.	1.4	105
7833	A single dose of intravenous combretastatin A4â€phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. Veterinary and Comparative Oncology, 2018, 16, 467-477.	1.8	9
7834	Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Investigational New Drugs, 2018, 36, 1044-1059.	2.6	0
7835	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. European Journal of Cancer, 2018, 98, 10-16.	2.8	57
7836	Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. Lung Cancer, 2018, 121, 5-11.	2.0	37
7837	Computer-Aided Theragnosis Based on Tumor Volumetric Information in Breast Cancer. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2018, 65, 1359-1369.	3.0	4
7838	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research, 2018, 24, 4072-4080.	7.0	25
7839	A phase 1/2 doseâ€finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood and Cancer, 2018, 65, e27217.	1.5	6
7840	Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 131-141.	2.5	12
7841	Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clinical and Translational Oncology, 2018, 20, 1522-1528.	2.4	10
7842	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open, 2018, 8, e022899.	1.9	85
7843	Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer. Cancer Research, 2018, 78, 4036-4044.	0.9	31
7844	Treatment of hepatic metastases with computed tomographyâ€guided interstitial brachytherapy. Oncology Letters, 2018, 15, 8717-8722.	1.8	9
7845	Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2018, 13, 958-967.	1.1	59
7846	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Research, 2018, 78, 4270-4281.	0.9	117
7847	RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. Clinical Chemistry, 2018, 64, 1054-1062.	3.2	55
7848	Gemcitabine/nabâ€paclitaxel for pediatric relapsed/refractory sarcomas. Pediatric Blood and Cancer, 2018, 65, e27246.	1.5	8

#	ARTICLE	IF	CITATIONS
7849	Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 150, 119-126.	1.4	15
7850	Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine. <i>Chinese Journal of Integrative Medicine</i> , 2018, 24, 573-578.	1.6	7
7851	Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). <i>Breast</i> , 2018, 40, 76-81.	2.2	29
7852	Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. <i>Thoracic Cancer</i> , 2018, 9, 847-855.	1.9	103
7853	Diffusion-weighted MRI Is Superior to PET/CT in Predicting Survival of Patients Undergoing ⁹⁰ Y Radioembolization of Hepatic Metastases. <i>Radiology</i> , 2018, 288, 764-773.	7.3	17
7854	Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 379-387.	3.6	4
7855	Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers. <i>Human Pathology</i> , 2018, 79, 127-134.	2.0	11
7856	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	1.2	14
7857	The Role of Angiogenesis Inhibitors in Hypertension: Following “Ariadne’s Thread”. <i>American Journal of Hypertension</i> , 2018, 31, 961-969.	2.0	5
7858	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387.	7.0	49
7859	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 904-915.	10.7	648
7860	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	6.4	39
7861	Advances in the systemic treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2018, 29, 1509-1520.	1.2	31
7862	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	3.9	25
7863	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	4.2	42
7864	CT perfusion in non-small cell lung cancers for assessing treatment response, monitoring treatment and predicting prognosis. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2018, 49, 338-345.	0.6	1
7865	Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 978-986.	1.1	87
7866	Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 987-995.	1.1	67

#	ARTICLE	IF	CITATIONS
7867	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1121-1127.	1.1	59
7868	Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer. <i>Medicine (United States)</i> , 2018, 97, e10745.	1.0	10
7869	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	1.1	29
7870	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	3.7	46
7871	Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1004-e102.	3.7	6
7872	Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1547-1559.	2.5	3
7873	Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 795-802.	1.3	37
7874	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 451-460.	10.7	185
7875	Utility of intravoxel incoherent motion diffusion-weighted imaging in predicting early response to concurrent chemoradiotherapy in oesophageal squamous cell carcinoma. <i>Clinical Radiology</i> , 2018, 73, 756.e17-756.e26.	1.1	11
7876	Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. <i>Oncology Letters</i> , 2018, 15, 8951-8958.	1.8	4
7877	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 211-219.	2.3	4
7878	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. <i>Medical Oncology</i> , 2018, 35, 100.	2.5	13
7879	Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. <i>Hepatology Research</i> , 2018, 48, 956-966.	3.4	39
7880	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , 2018, 24, 4081-4088.	7.0	24
7881	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , 2018, 20, 72.	4.4	0
7882	Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 3976-3980.	1.8	3
7883	Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 9307-9316.	1.8	0
7884	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 4399-4406.	7.0	44

#	ARTICLE	IF	CITATIONS
7885	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 3689-3697.	1.1	32
7886	Clinical outcomes of periophtic tumors treated with hypofractionated stereotactic radiotherapy using CyberKnife® stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2018, 139, 679-688.	2.9	14
7887	Transcatheter arterial chemoembolization (TACE) combined with \hat{I}^3 -knife compared to TACE or \hat{I}^3 -knife alone for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e10890.	1.0	2
7888	Phase III study with FOLFIRI+ cetuximab versus FOLFIRI+ cetuximab followed by cetuximab alone in <i><i>RAS</i></i> and <i><i>BRAF</i></i> WT mCRC. <i>Future Oncology</i> , 2018, 14, 1339-1346.	2.4	5
7889	Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST. <i>Annals of Nuclear Medicine</i> , 2018, 32, 453-462.	2.2	6
7890	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	10.7	1,816
7891	Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results. <i>Clinical Radiology</i> , 2018, 73, 832.e9-832.e16.	1.1	6
7892	Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST “ multicenter study in Japan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1661-1671.	6.4	23
7893	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 426-434.e1.	2.6	102
7894	Clinical Value of 18 F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer. <i>Clinical Oncology</i> , 2018, 30, 507-514.	1.4	10
7895	Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? ~ RESPONDER trial. <i>European Journal of Radiology</i> , 2018, 104, 94-100.	2.6	8
7896	Deep hyperthermia with the HYPERcollar system combined with irradiation for advanced head and neck carcinoma “ a feasibility study. <i>International Journal of Hyperthermia</i> , 2018, 34, 994-1001.	2.5	29
7897	Study design and early result of a phase I study of SABR for early-stage glottic cancer. <i>Laryngoscope</i> , 2018, 128, 2560-2565.	2.0	10
7898	Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. <i>Vaccine</i> , 2018, 36, 3247-3253.	3.8	18
7899	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	7.7	124
7900	Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1012-1021.	1.1	85
7901	Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. <i>Future Oncology</i> , 2018, 14, 2493-2505.	2.4	15
7902	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 429-440.	2.3	35

#	ARTICLE	IF	CITATIONS
7903	Learning curve for the management of tyrosine kinase inhibitors as the first line of treatment for patients with metastatic renal cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 389-395.	0.2	0
7904	Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 473-481.	1.9	6
7905	Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. <i>Clinical Lung Cancer</i> , 2018, 19, e823-e830.	2.6	10
7906	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242.	2.0	22
7907	Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1026-1033.	3.0	6
7908	NACT and laparoscopic-assisted radical vaginal trachelectomy in young patients with large (≥5 cm) high risk cervical cancers: Safety and obstetrical outcome. <i>Surgical Oncology</i> , 2018, 27, 236-244.	1.6	19
7909	The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. <i>Clinical Endocrinology</i> , 2018, 89, 481-488.	2.4	5
7910	Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2018, 38, 4027-4034.	1.1	9
7911	Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. <i>Anticancer Research</i> , 2018, 38, 4367-4373.	1.1	10
7912	Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	2.2	23
7913	Serum 8-Oxo-dG as a Predictor of Sensitivity and Outcome of Radiotherapy and Chemotherapy of Upper Gastrointestinal Tumours. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-8.	4.0	12
7914	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. <i>Oncologist</i> , 2018, 23, 1358-1365.	3.7	196
7915	Basic Statistics and Clinical Studies in Radiation Oncology. , 2018, , 1-30.		0
7916	Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes. <i>Journal of Oncology</i> , 2018, 2018, 1-5.	1.3	4
7917	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1176-1178.	6.4	54
7918	Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. <i>PLoS ONE</i> , 2018, 13, e0195945.	2.5	46
7919	Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis. <i>Tohoku Journal of Experimental Medicine</i> , 2018, 245, 123-129.	1.2	7
7920	Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1062-1068.	1.9	13

#	ARTICLE	IF	CITATIONS
7921	PET imaging for assessing tumor response to therapy. Journal of Surgical Oncology, 2018, 118, 362-373.	1.7	7
7922	Imaging for the diagnosis and response assessment of renal tumours. World Journal of Urology, 2018, 36, 1927-1942.	2.2	59
7923	Issues in Response Assessment of Brain Tumor Chemotherapy. , 2018, , 715-727.		2
7924	Response Assessment in Neuro-oncology (RANO): An Update. , 2018, , 747-759.		1
7925	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. European Urology, 2018, 74, 455-462.	1.9	250
7926	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421.	2.1	17
7927	Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. In Vivo, 2018, 32, 887-891.	1.3	11
7928	Transarterial Embolization with Small-Size Particles Loaded with Irinotecan for the Treatment of Colorectal Liver Metastases: Results of the MIRACLE III Study. CardioVascular and Interventional Radiology, 2018, 41, 1708-1715.	2.0	14
7929	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317.	2.3	12
7930	Real-World Pseudoprogression: an Uncommon Phenomenon. Journal of Thoracic Oncology, 2018, 13, 880-882.	1.1	15
7931	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. British Journal of Cancer, 2018, 119, 339-346.	6.4	83
7932	Adjudication of Clinical Data. , 2018, , 549-573.		0
7933	Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. Journal of Vascular and Interventional Radiology, 2018, 29, 1061-1067.	0.5	11
7934	Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.8	5
7935	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	2.5	40
7936	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	2.8	22
7937	Imaging biomarkers in oncology: Basics and application to MRI. Journal of Magnetic Resonance Imaging, 2018, 48, 13-26.	3.4	39
7938	Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. British Journal of Cancer, 2018, 119, 170-175.	6.4	6

#	ARTICLE	IF	CITATIONS
7939	Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. <i>Cancer Science</i> , 2018, 109, 2549-2557.	3.9	48
7940	Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878387.	1.9	15
7941	Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. <i>Oncology Letters</i> , 2018, 16, 1348-1356.	1.8	9
7942	Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1365-1370.	4.2	26
7943	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	27.0	1,677
7944	Dual-energy CT-based iodine quantification to differentiate abdominal malignant lymphoma from lymph node metastasis. <i>European Journal of Radiology</i> , 2018, 105, 255-260.	2.6	21
7945	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	6.4	13
7946	Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach. <i>BioMed Research International</i> , 2018, 2018, 1-11.	1.9	12
7947	Role of Dual-Energy Computed Tomography in Thoracic Oncology. <i>Radiologic Clinics of North America</i> , 2018, 56, 535-548.	1.8	32
7949	Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-10.	1.5	21
7950	Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix â€” An Italian Multicenter Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 3627-3634.	1.1	9
7951	Exosome-mediated transfer of lncRNA RP11â€™838N2.4 promotes erlotinib resistance in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2018, 53, 527-538.	3.3	74
7952	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	3.6	38
7953	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. <i>BMC Cancer</i> , 2018, 18, 766.	2.6	42
7954	Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). <i>Radiation Oncology</i> , 2018, 13, 138.	2.7	34
7955	Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 641-647.	1.3	47
7956	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1166-1173.	1.9	10
7957	Modulated radiotherapy for head and neck carcinomas: an outcome study. <i>Journal of Radiotherapy in Practice</i> , 2018, 17, 384-389.	0.5	0

#	ARTICLE	IF	CITATIONS
7958	Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating <i>PABPC1</i> expression through H3K27 acetylation. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4935-4947.	3.6	95
7959	Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 375-381.	2.0	11
7960	Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 4723-4729.	1.1	43
7961	Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and <i>KRAS</i> mutation. <i>Journal of Cancer</i> , 2018, 9, 2930-2937.	2.5	17
7962	A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1138-1145.	1.1	426
7963	Combination Ipsilateral Lobar and Segmental Radioembolization Using Glass Yttrium-90 Microspheres for Treatment of Multifocal Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1110-1116.	0.5	4
7964	Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 419-423.	6.4	12
7965	Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis. <i>BMC Cancer</i> , 2018, 18, 776.	2.6	12
7966	Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report. <i>BMC Cancer</i> , 2018, 18, 630.	2.6	13
7967	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0201809.	2.5	20
7968	Immunotherapy treatment: an issue for metabolic response. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 140-151.	0.7	4
7969	Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with <i>ALK</i> / <i>ROS-1</i> mutations. <i>Journal of Cancer</i> , 2018, 9, 1863-1869.	2.5	8
7970	Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?. <i>Cancer Management and Research</i> , 2018, Volume 10, 425-437.	1.9	47
7971	Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. <i>Oncology Letters</i> , 2018, 16, 3674-3680.	1.8	12
7972	Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 148.	1.8	4
7973	Diagnostic Yield and False-Referral Rate of Staging Chest CT in Patients with Colon Cancer. <i>Radiology</i> , 2018, 289, 535-545.	7.3	10
7974	A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 196.	4.4	19
7975	The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 2232-2236.	2.5	17

#	ARTICLE	IF	CITATIONS
7976	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1363-1372.	1.1	140
7977	Evaluation of β -tubulin, detyrosinated β -tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. <i>Breast Cancer Research</i> , 2018, 20, 67.	5.0	25
7978	Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 150.	1.9	12
7979	Stereotactic Volume Modulated Arc Radiotherapy in Canine Meningiomas: Imaging-Based and Clinical Neurological Posttreatment Evaluation. <i>Journal of the American Animal Hospital Association</i> , 2018, 54, 77-84.	1.1	9
7980	Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Journal of Cancer</i> , 2018, 9, 1113-1120.	2.5	18
7981	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. <i>The Cochrane Library</i> , 2018, 7, CD012838.	2.8	11
7982	Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. <i>Annals of Oncology</i> , 2018, 29, 2052-2060.	1.2	387
7983	p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 6571-6577.	1.8	10
7984	LY2495655, an antityrosine kinase antibody, in pancreatic cancer: a randomized, phase 2 trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 871-879.	7.3	80
7985	Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4149-4158.	2.0	8
7986	First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. <i>Annals of Oncology</i> , 2018, 29, 1911-1917.	1.2	103
7987	A Coclinal Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Perostin-Expressing Glioblastoma in Patients and Xenograft Models. <i>Clinical Cancer Research</i> , 2018, 24, 6288-6299.	7.0	74
7988	Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. <i>European Journal of Pharmacology</i> , 2018, 837, 64-71.	3.5	3
7989	The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 625-633.	2.3	11
7990	Locoregional control and survival after lymph node SBRT in oligometastatic disease. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 625-633.	3.3	28
7991	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 2897.	12.8	293
7992	Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients. <i>Oncology</i> , 2018, 94, 19-28.	1.9	22
7993	Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker. <i>Physics in Medicine and Biology</i> , 2018, 63, 155020.	3.0	35

#	ARTICLE	IF	CITATIONS
7994	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281.	7.0	20
7995	Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. <i>Core Evidence</i> , 2018, Volume 13, 1-12.	4.7	10
7996	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. <i>Cell Death and Disease</i> , 2018, 9, 810.	6.3	38
7997	Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. <i>ESMO Open</i> , 2018, 3, e000381.	4.5	10
7998	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. <i>Cancer Discovery</i> , 2018, 8, 1237-1249.	9.4	216
7999	Use of 18Fâ€FDG PET/CT to predict shortâ€term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung. <i>Oncology Letters</i> , 2018, 16, 1067-1072.	1.8	3
8000	Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AERO): a phase 2, single-arm, prospective study. <i>Lancet Oncology</i> , The, 2018, 19, 1239-1246.	10.7	130
8001	Anatomically plausible models and quality assurance criteria for online mono- and multi-modal medical image registration. <i>Physics in Medicine and Biology</i> , 2018, 63, 155016.	3.0	23
8002	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , 2018, 24, 5585-5593.	7.0	113
8003	The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. <i>PLoS ONE</i> , 2018, 13, e0198138.	2.5	28
8004	Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. <i>Anticancer Research</i> , 2018, 38, 4699-4704.	1.1	6
8005	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. <i>Journal of Cancer</i> , 2018, 9, 205-212.	2.5	9
8006	Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. <i>Journal of Cancer</i> , 2018, 9, 250-255.	2.5	39
8007	Non-invasive Early Response Monitoring of Nanoparticle-assisted Photothermal Cancer Therapy Using ¹⁸ F-FDG, ¹⁸ F-FLT, and ¹⁸ F-FET PET/CT Imaging. <i>Nanotheranostics</i> , 2018, 2, 201-210.	5.2	12
8008	Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. <i>Lung Cancer</i> , 2018, 124, 110-116.	2.0	43
8009	High expression of the p53 isoform Î³ is associated with reduced progression-free survival in uterine serous carcinoma. <i>BMC Cancer</i> , 2018, 18, 684.	2.6	15
8010	How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 95.	2.7	13
8011	MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. <i>British Journal of Radiology</i> , 2018, 91, 20170563.	2.2	33

#	ARTICLE	IF	CITATIONS
8012	DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. <i>Theranostics</i> , 2018, 8, 3198-3213.	10.0	18
8013	Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2018, 9, 224.	3.5	24
8014	Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance. <i>Frontiers in Immunology</i> , 2017, 8, 1886.	4.8	14
8015	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intravesical Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 411.	4.8	49
8016	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	4.8	174
8017	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. <i>Frontiers in Oncology</i> , 2018, 8, 18.	2.8	34
8018	Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation. <i>Frontiers in Oncology</i> , 2018, 8, 52.	2.8	13
8019	Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1991-1999.	2.5	13
8020	Single and Multiphoton Responsive Nanomaterials for the Investigation of Cancer Microenvironment. , 2018, , 63-95.		0
8021	Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1027-1039.	10.7	170
8022	Volumetric Modulated Arc (Radio) Therapy in Pets Treatment: The “La Cittadina Fondazione” Experience. <i>Cancers</i> , 2018, 10, 30.	3.7	3
8023	A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 160.	3.7	93
8024	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	2.0	10
8025	Carboplatin and epirubicin combination therapy for advanced malignant epithelial skin tumors: Retrospective study of six patients. <i>Journal of Dermatology</i> , 2018, 45, 874-875.	1.2	6
8026	Electrochemotherapy: a well-accepted palliative treatment by patients with head and neck tumours. <i>Acta Otorhinolaryngologica Italica</i> , 2018, 38, 181-187.	1.5	17
8027	Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel. <i>Anticancer Research</i> , 2018, 38, 4179-4185.	1.1	19
8029	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 691-697.	8.1	50
8030	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1093-1103.	1.9	18

#	ARTICLE	IF	CITATIONS
8031	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1344.	7.1	169
8032	A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 1060-1071.	2.6	27
8033	Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 1881-1889.	1.7	26
8034	Overview and definitions on lung cancer diagnosis. , 2018, , .		2
8035	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell, 2018, 34, 148-162.e7.	16.8	129
8036	Randomised phase II trial to investigate catumaxomab (anti-EpCAM—anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. British Journal of Cancer, 2018, 119, 296-302.	6.4	60
8037	Skin Reaction to Cetuximab as a Criterion for Treatment Selection in Head and Neck Cancer. Anticancer Research, 2018, 38, 4213-4220.	1.1	4
8038	IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies. International Journal of Molecular Sciences, 2018, 19, 1766.	4.1	38
8039	Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. Clinical Case Reports (discontinued), 2018, 6, 1338-1341.	0.5	8
8040	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	30.7	1,071
8041	Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. , 2018, 6, 42.		15
8042	Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab. Immunotherapy, 2018, 10, 743-752.	2.0	2
8043	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy, 2018, 10, 797-805.	2.0	20
8044	Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology, The, 2018, 19, 1126-1134.	10.7	113
8045	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respiratory Medicine, the, 2018, 6, 681-690.	10.7	166
8046	Non-“Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation”-positive Cancer. Radiology, 2018, 289, 227-237.	7.3	19
8047	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clinical Cancer Research, 2018, 24, 3845-3856.	7.0	35
8048	Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. Clinical Cancer Research, 2018, 24, 5261-5271.	7.0	42

#	ARTICLE	IF	CITATIONS
8049	FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST. PLoS ONE, 2018, 13, e0199529.	2.5	15
8050	Development of a Genetic and Clinical Data-Based (GC) Risk Score for Predicting Survival of Hepatocellular Carcinoma Patients After Tumor Resection. Cellular Physiology and Biochemistry, 2018, 48, 491-502.	1.6	9
8051	Impact of relative dose intensity in gemcitabine+cisplatin chemotherapy for metastatic urothelial carcinoma. SAGE Open Medicine, 2018, 6, 205031211878301.	1.8	5
8052	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer, 2018, 18, 702.	2.6	19
8053	Multidisciplinary approach for treatment of primary hepatic choriocarcinoma in adult male patient. Annals of Hepato-biliary-pancreatic Surgery, 2018, 22, 164.	0.1	3
8054	Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone. Cancer Management and Research, 2018, Volume 10, 1901-1906.	1.9	8
8055	Exosome-mediated transfer of lncRNA SNHG14 promotes trastuzumab chemoresistance in breast cancer. International Journal of Oncology, 2018, 53, 1013-1026.	3.3	129
8056	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate, 2018, 78, 1077-1083.	2.3	0
8057	A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clinical and Experimental Medicine, 2018, 18, 555-562.	3.6	25
8058	Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. Tumori, 2018, 104, 388-393.	1.1	2
8059	The impact of postoperative therapy on primary cardiac sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 2194-2203.	0.8	24
8060	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Annals of Oncology, 2018, 29, 1807-1813.	1.2	261
8061	Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China. Journal of Cellular and Molecular Medicine, 2018, 22, 4328-4334.	3.6	18
8062	Canine urinary bladder transitional cell carcinoma tumor volume is dependent on imaging modality and measurement technique. Veterinary Radiology and Ultrasound, 2018, 59, 767-776.	0.9	14
8063	Preoperative evaluation of the efficacy of radio-hyperthermo-chemotherapy for soft tissue sarcoma in a case series. PLoS ONE, 2018, 13, e0195289.	2.5	5
8064	The Predictive Value of SPECT/CT imaging in colorectal liver metastases response after 90Y-radioembolization. PLoS ONE, 2018, 13, e0200488.	2.5	13
8065	c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/ β -Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation. American Journal of Pathology, 2018, 188, 1921-1933.	3.8	25
8066	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	4.4	34

#	ARTICLE	IF	CITATIONS
8067	Discrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors. <i>Scientific Reports</i> , 2018, 8, 10924.	3.3	5
8068	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	4.5	20
8069	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	7.0	116
8070	Cell-free DNA and chemoembolization in patients with liver metastases from colorectal cancer. <i>Oncology Letters</i> , 2018, 16, 2654-2660.	1.8	7
8071	Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma. <i>Oncology Letters</i> , 2018, 16, 2382-2390.	1.8	8
8072	An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 511-519.	2.3	25
8073	The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 230-233.	0.7	2
8074	Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2018, 9, 92-95.	1.0	2
8076	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. <i>Molecular Imaging and Biology</i> , 2018, 20, 696-704.	2.6	30
8077	Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 23-30.	2.0	12
8078	Incorporating drug delivery into an imaging-driven, mechanics-coupled reaction diffusion model for predicting the response of breast cancer to neoadjuvant chemotherapy: theory and preliminary clinical results. <i>Physics in Medicine and Biology</i> , 2018, 63, 105015.	3.0	41
8079	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	3.4	13
8080	The effect of epidural analgesia on cancer progression in patients with stage IV colorectal cancer after primary tumor resection: A retrospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0200893.	2.5	19
8081	Serial Assessment of Growth Factors Associated with Liver Regeneration in Patients Operated with Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. <i>European Surgical Research</i> , 2018, 59, 72-82.	1.3	13
8082	Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. <i>BMC Cancer</i> , 2018, 18, 247.	2.6	10
8083	Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F-FDG-PET/CT. <i>BMC Cancer</i> , 2018, 18, 253.	2.6	2
8084	Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 296.	2.6	4
8085	A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). <i>Pediatric Blood and Cancer</i> , 2018, 65, e27066.	1.5	15

#	ARTICLE	IF	CITATIONS
8086	Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 111-117.	2.3	2
8087	Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 1529-1537.	2.4	0
8088	Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 410-417.e1.	2.6	109
8089	Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. <i>Journal of Surgical Research</i> , 2018, 227, 158-167.	1.6	8
8090	Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 920-926.	0.5	13
8091	Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma. <i>International Journal of Clinical Oncology</i> , 2018, 23, 877-885.	2.2	2
8092	Great veins invasion in follicular thyroid cancer: single-centre study assessing prevalence and clinical outcome. <i>Endocrine</i> , 2018, 62, 71-75.	2.3	12
8093	Prospective Study of Serial ¹⁸ F-FDG PET and ¹⁸ F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1823-1830.	5.0	41
8094	A nomogram for predicting survival in patients with breast cancer brain metastasis. <i>Oncology Letters</i> , 2018, 15, 7090-7096.	1.8	26
8095	Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. <i>European Radiology</i> , 2018, 28, 4839-4848.	4.5	13
8096	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. <i>Clinical Drug Investigation</i> , 2018, 38, 639-648.	2.2	20
8097	SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. <i>Npj Precision Oncology</i> , 2018, 2, 9.	5.4	21
8098	FDA's Approval of the First Biosimilar to Bevacizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4365-4370.	7.0	23
8099	MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. <i>BMC Cancer</i> , 2018, 18, 74.	2.6	48
8100	Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. <i>BMC Cancer</i> , 2018, 18, 101.	2.6	11
8101	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	2.6	17
8102	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.	2.6	9
8103	Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study. <i>BMC Cancer</i> , 2018, 18, 138.	2.6	6

#	ARTICLE	IF	CITATIONS
8104	Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. <i>BMC Cancer</i> , 2018, 18, 515.	2.6	25
8105	Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer. <i>BMC Veterinary Research</i> , 2018, 14, 87.	1.9	19
8106	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. <i>Journal of Hematology and Oncology</i> , 2018, 11, 10.	17.0	181
8107	Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports. , 2018, 6, 2.		11
8108	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
8109	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
8110	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
8111	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153
8112	¹⁸ F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma. <i>Cancer Imaging</i> , 2018, 18, 2.	2.8	7
8113	Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer. <i>BMC Immunology</i> , 2018, 19, 14.	2.2	5
8114	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	2.6	18
8115	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018, 7, CRC01.	0.8	3
8116	Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoteric acid disodium-enhanced magnetic resonance imaging. <i>Abdominal Radiology</i> , 2018, 43, 3301-3306.	2.1	11
8117	Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 607-620.	1.8	3
8118	The Results of the Combine Treatment of Patients with Liver Bilobar Metastases from Colorectal Cancer Using Radiofrequency Ablation. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 175-180.	0.7	2
8119	Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors. <i>Current Radiology Reports</i> , 2018, 6, 1.	1.4	1
8120	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30
8121	Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2018, 34, 341-347.	1.9	16

#	ARTICLE	IF	CITATIONS
8122	A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018, 7, 2442-2451.	2.8	10
8123	Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. <i>International Journal of Clinical Oncology</i> , 2018, 23, 900-907.	2.2	10
8124	Endoscopic criteria to evaluate tumor response of rectal cancer to neoadjuvant chemoradiotherapy using magnifying chromoendoscopy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1247-1253.	1.0	12
8125	Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma. <i>American Journal of Neuroradiology</i> , 2018, 39, 1316-1321.	2.4	10
8126	Role of Fludeoxyglucose in Breast Cancer. <i>PET Clinics</i> , 2018, 13, 395-414.	3.0	21
8127	Gastroenteropancreatic neuroendocrine tumors: impact of consistent contrast agent selection on radiologists' confidence in hepatic lesion assessment on restaging MRIs. <i>Abdominal Radiology</i> , 2018, 43, 1386-1392.	2.1	10
8128	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.9	372
8129	Ultrasound-guided fine needle aspiration of retropharyngeal lymph nodes after radiotherapy for nasopharyngeal carcinoma: a novel technique for accurate diagnosis. <i>Cancer Communications</i> , 2018, 38, 1-8.	9.2	15
8130	Outcome of indeterminate liver lesions on computed tomography in patients with colorectal cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2018, 100, 382-387.	0.6	7
8132	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 119-127.	2.3	5
8133	The application of a three-dimensional visualized seed planning and navigation system in ¹²⁵ I seed implantation for pancreatic cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 619-627.	2.0	5
8134	Rucaparib: a novel PARP inhibitor for BRCA &advanced ovarian cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 605-617.	4.3	26
8135	The mode of progressive disease affects the prognosis of patients with metastatic breast cancer. <i>World Journal of Surgical Oncology</i> , 2018, 16, 169.	1.9	5
8136	Influential factors on radiotherapy efficacy and prognosis in patients with secondary lymph node metastasis after esophagectomy of thoracic esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 217-225.	1.9	6
8137	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018, 124, 3586-3595.	4.1	5
8139	Prophylactic selective arterial embolization for renal angiomyolipomas: efficacy and evaluation of predictive factors of significant shrinkage. <i>International Urology and Nephrology</i> , 2018, 50, 1765-1770.	1.4	10
8140	PET/CT and Bone Scintigraphy: Metabolic Results in Musculoskeletal Lesions. <i>Current Radiology Reports</i> , 2018, 6, 1.	1.4	0
8141	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	30.7	473

#	ARTICLE	IF	CITATIONS
8142	High Platelet Levels Attenuate the Efficacy of Platinum-Based Treatment in Non-Small Cell Lung Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 2456-2469.	1.6	17
8143	Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review. <i>Internal Medicine</i> , 2018, 57, 527-535.	0.7	40
8144	Pilot Dose Comparison of Apatinib in Chinese Patients With Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3640-3646.	3.6	15
8145	Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance. <i>Journal of Cancer</i> , 2018, 9, 2140-2146.	2.5	6
8146	EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. <i>Human Pathology</i> , 2018, 82, 163-171.	2.0	2
8147	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPI). <i>Lung Cancer</i> , 2018, 124, 117-124.	2.0	46
8148	Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-arm phase II study. <i>Cancer Communications</i> , 2018, 38, 1-9.	9.2	25
8149	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	10.9	34
8150	Phase 1B Study of Mometotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. <i>Clinical Lung Cancer</i> , 2018, 19, e853-e859.	2.6	21
8151	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	4.5	55
8152	Prospective comparison of various radiological response criteria and pathological response to preoperative chemotherapy and survival in operable high-grade soft tissue sarcomas in the Japan Clinical Oncology Group study JCOG0304. <i>World Journal of Surgical Oncology</i> , 2018, 16, 162.	1.9	13
8153	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2245-2261.	2.5	28
8154	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	1.1	146
8155	Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 1174-1179.	4.5	20
8156	Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4573-4582.	2.0	15
8157	MRI. , 2018, , 75-89.		1
8158	Estimation of tumour volume at therapy initiation by back-extrapolating the post-therapy regression curve of tumour volume. <i>Applied Cancer Research</i> , 2018, 38, .	1.0	1
8159	From validity to clinical utility: the influence of circulating tumor <sc>DNA</sc> on melanoma patient management in a real-world setting. <i>Molecular Oncology</i> , 2018, 12, 1661-1672.	4.6	32

#	ARTICLE	IF	CITATIONS
8160	Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study. <i>Advances in Radiation Oncology</i> , 2018, 3, 305-313.	1.2	4
8161	Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0202387.	2.5	15
8162	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309.	3.7	46
8163	Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 909-919.	7.3	42
8164	Tumor Response Criteria—Radiological Implications. <i>Academic Radiology</i> , 2018, 25, 1361-1362.	2.5	0
8165	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 102, 95-102.	2.8	50
8166	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018, 125, 273-281.	2.0	69
8167	A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. <i>Neoplasia</i> , 2018, 20, 975-984.	5.3	4
8168	HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis. <i>Diagnostic Pathology</i> , 2018, 13, 57.	2.0	5
8169	Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 353-362.	2.5	20
8170	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	21.4	438
8171	A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA. <i>Oncology Letters</i> , 2018, 16, 4353-4360.	1.8	18
8172	Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. <i>Cancer Medicine</i> , 2018, 7, 4420-4433.	2.8	46
8173	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 513-521.	2.8	12
8175	Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer. <i>Journal of Radiation Research</i> , 2018, 59, 767-773.	1.6	5
8176	Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial. <i>BMJ Open</i> , 2018, 8, e021633.	1.9	6
8177	Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. <i>Chemotherapy</i> , 2018, 63, 181-189.	1.6	4
8178	Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 282.	2.8	14

#	ARTICLE	IF	CITATIONS
8179	Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI. <i>Journal of Cancer</i> , 2018, 9, 528-534.	2.5	9
8180	Efficacy of icotinib in advanced lung squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 4456-4466.	2.8	13
8181	A Bayesian hierarchal modeling approach to shortening phase I/II trials of anticancer drug combinations. <i>Pharmaceutical Statistics</i> , 2018, 17, 750-760.	1.3	2
8182	Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27383.	1.5	30
8183	⁸⁹ Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2300-2306.	6.4	99
8184	Current Chemotherapy Use in Neuroendocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 603-614.	3.2	12
8185	The NETest. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 485-504.	3.2	91
8186	Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). <i>Pancreatology</i> , 2018, 18, 841-845.	1.1	23
8187	Tumor infiltrating CD19 ⁺ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. <i>Oncolmunology</i> , 2018, 7, 1-9.	4.6	93
8188	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. <i>Neuro-Oncology</i> , 2019, 21, 234-241.	1.2	16
8189	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2018, 24, 5543-5551.	7.0	18
8190	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 46-52.	1.4	48
8191	A validated proton beam therapy patch-field protocol for effective treatment of large hepatocellular carcinoma. <i>Journal of Radiation Research</i> , 2018, 59, 632-638.	1.6	11
8192	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2018, 101, 197-200.	1.3	12
8193	Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects. <i>Frontiers in Oncology</i> , 2018, 8, 277.	2.8	21
8194	Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: A case report. <i>Oncology Letters</i> , 2018, 16, 4085-4089.	1.8	2
8195	Preliminary Results about Application of Intensity-Modulated Radiotherapy to Reduce Prophylactic Radiation Dose in Limited-Stage Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 2625-2630.	2.5	9
8196	Improving the analysis of composite endpoints in rare disease trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 81.	2.7	13

#	ARTICLE	IF	CITATIONS
8197	Pre-therapy CT scan showing peritoneal thickening from metastatic renal pelvis carcinoma patients. <i>Medical Oncology</i> , 2018, 35, 128.	2.5	2
8198	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	1.5	15
8199	Prognostic value of selected preoperative inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4551-4558.	2.0	9
8200	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 06784314 rgBT /Over	2.5	14
8201	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 2115-2120.	1.2	131
8202	Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data. <i>BMJ Open</i> , 2018, 8, e021642.	1.9	4
8203	Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators. <i>BMC Cancer</i> , 2018, 18, 671.	2.6	4
8204	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , 2018, 35, 131.	2.5	14
8205	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 413-419.e1.	1.9	21
8206	Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. <i>Oncolmunology</i> , 2018, 7, e1507670.	4.6	116
8207	Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 2401-2407.	1.9	10
8208	Itraconazole inhibits the proliferation of gastric cancer cells in vitro and improves patient survival. <i>Oncology Letters</i> , 2018, 16, 3651-3657.	1.8	8
8209	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 419-430.	3.9	3
8210	Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. <i>Molecular and Clinical Oncology</i> , 2018, 8, 623-627.	1.0	4
8211	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018, 392, 123-133.	13.7	984
8212	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	27.0	997
8213	Analysis of short-term efficacy as defined by RECIST and pathological response of neoadjuvant chemotherapy comprised paclitaxel and cisplatin followed by radical surgery in patients with locally advanced cervical cancer. <i>Medicine (United States)</i> , 2018, 97, e10913.	1.0	8
8214	Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. <i>Acta Oncologica</i> , 2018, 57, 1580-1585.	1.8	8

#	ARTICLE	IF	CITATIONS
8215	New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 2007-2014.	2.8	15
8216	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1207.	7.1	56
8217	Dose-response study for the highly aggressive and metastatic primary F3II mammary carcinoma under direct current. <i>Bioelectromagnetics</i> , 2018, 39, 460-475.	1.6	5
8218	Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 275-283.	2.3	1
8219	CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates. <i>European Radiology</i> , 2018, 28, 5069-5075.	4.5	11
8220	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 243-257.	1.7	52
8221	Encouraging Trends in Modern Phase 1 Oncology Trials. <i>New England Journal of Medicine</i> , 2018, 378, 2242-2243.	27.0	58
8222	SPECT/CT imaging of chemotherapy-induced tumor apoptosis using ^{99m} Tc-labeled dendrimer-entrapped gold nanoparticles. <i>Drug Delivery</i> , 2018, 25, 1384-1393.	5.7	47
8223	Clinical significance of androgen receptor expression in triple negative breast cancer—an immunohistochemistry study. <i>Oncology Letters</i> , 2018, 15, 10008-10016.	1.8	26
8224	CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. <i>European Radiology</i> , 2018, 28, 5284-5292.	4.5	17
8225	Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research. <i>Future Oncology</i> , 2018, 14, 2841-2848.	2.4	17
8226	Metabolic imaging in the response assessment of patients treated with ²²³ Ra. What should be. <i>Clinical and Translational Imaging</i> , 2018, 6, 317-319.	2.1	0
8227	Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e775-e781.	2.6	22
8228	Liver lesion segmentation informed by joint liver segmentation. , 2018, , .		78
8229	Radiomic features analysis in computed tomography images of lung nodule classification. <i>PLoS ONE</i> , 2018, 13, e0192002.	2.5	118
8230	The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. <i>International Journal of Surgery</i> , 2018, 56, 133-140.	2.7	9
8231	Immune checkpoint inhibition in gastric cancer: A systematic review. <i>Journal of Cellular Immunotherapy</i> , 2018, 4, 49-55.	0.6	7
8232	Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. <i>PLoS ONE</i> , 2018, 13, e0192227.	2.5	78

#	ARTICLE	IF	CITATIONS
8233	Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?. PLoS ONE, 2018, 13, e0194270.	2.5	14
8234	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. PLoS ONE, 2018, 13, e0194841.	2.5	7
8235	Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study. Annals of Otology, Rhinology and Laryngology, 2018, 127, 456-462.	1.1	2
8236	Checkpoint blockade in esophagogastric cancer. Journal of Surgical Oncology, 2018, 118, 77-85.	1.7	9
8238	High dose hypofractionated frameless volumetric modulated arc radiotherapy is a feasible method for treating canine trigeminal nerve sheath tumors. Veterinary Radiology and Ultrasound, 2018, 59, 624-631.	0.9	7
8239	Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis. CardioVascular and Interventional Radiology, 2018, 41, 1545-1556.	2.0	31
8240	Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy. Oral Oncology, 2018, 81, 75-80.	1.5	8
8241	Radium-223 in the treatment of bone metastases in patients with castration-resistant prostate cancer. Review and procedure. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 330-337.	0.2	2
8242	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nature Medicine, 2018, 24, 1024-1035.	30.7	285
8243	Cancer symptom response as an oncology clinical trial end point. Expert Review of Quality of Life in Cancer Care, 2018, 3, 35-46.	0.6	10
8244	Neoadjuvant chemotherapy response influences outcomes in non-colorectal, non-neuroendocrine liver metastases. British Journal of Surgery, 2018, 105, 1665-1670.	0.3	4
8245	Clinical Trials in CRS and HIPEC: Ongoing Trials and Future Directives. , 2018, , 433-445.		0
8246	CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?. European Radiology, 2018, 28, 5250-5257.	4.5	3
8247	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 2018, 17, 313-319.	2.3	9
8248	Molecular pathway activation “New type of biomarkers for tumor morphology and personalized selection of target drugs. Seminars in Cancer Biology, 2018, 53, 110-124.	9.6	101
8249	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Review of Gastroenterology and Hepatology, 2018, 12, 723-731.	3.0	37
8250	Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877703.	3.2	60
8251	<i>In Vitro</i> Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. Journal of Clinical Microbiology, 2018, 56, .	3.9	17

#	ARTICLE	IF	CITATIONS
8252	A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 8703-8710.	1.8	19
8253	Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. <i>Medical Oncology</i> , 2018, 35, 108.	2.5	3
8254	Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H ⁺ -ATPase expression and activity. <i>Oncology Letters</i> , 2018, 15, 7279-7290.	1.8	7
8255	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. <i>European Urology</i> , 2018, 1, 71-77.	5.4	24
8256	Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach. <i>Scientific Reports</i> , 2018, 8, 8968.	3.3	13
8257	Quantifying local tumor morphological changes with Jacobian map for prediction of pathologic tumor response to chemo-radiotherapy in locally advanced esophageal cancer. <i>Physics in Medicine and Biology</i> , 2018, 63, 145020.	3.0	30
8258	Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?. <i>Clinical Orthopaedics and Related Research</i> , 2018, 476, 2177-2186.	1.5	22
8259	Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. <i>PLoS ONE</i> , 2018, 13, e0190497.	2.5	13
8260	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0198812.	2.5	51
8261	Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M. <i>Anticancer Research</i> , 2018, 38, 3567-3571.	1.1	11
8262	Simultaneous PET/MRI in assessing the response to chemo/radiotherapy in head and neck carcinoma: initial experience. <i>Medical Oncology</i> , 2018, 35, 112.	2.5	12
8263	Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center. <i>Medical Oncology</i> , 2018, 35, 109.	2.5	10
8264	Sensory acceptable equivalent doses of β -phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer <i>in vitro</i> and <i>in vivo</i> . <i>Food and Function</i> , 2018, 9, 3640-3656.	4.6	16
8265	Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. <i>European Radiology</i> , 2019, 29, 458-467.	4.5	10
8266	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. <i>Investigational New Drugs</i> , 2019, 37, 271-281.	2.6	7
8267	The pleural thickening approximation from thoracic CT scans. <i>Multimedia Tools and Applications</i> , 2019, 78, 13033-13046.	3.9	2
8268	Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 134-144.	8.9	176
8269	High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. <i>European Radiology</i> , 2019, 29, 545-555.	4.5	13

#	ARTICLE	IF	CITATIONS
8270	Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022). <i>TJ</i> 2019, 105, 486-495.	2.0	0
8271	A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 486-495.	4.7	23
8272	First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 147-158.	2.6	5
8273	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 87-97.	2.6	59
8274	Change in microcalcifications on mammography after neoadjuvant chemotherapy in breast cancer patients: correlation with tumor response grade and comparison with lesion extent. <i>Acta Radiologica</i> , 2019, 60, 131-139.	1.1	10
8276	An adjoint-based method for a linear mechanically-coupled tumor model: application to estimate the spatial variation of murine glioma growth based on diffusion weighted magnetic resonance imaging. <i>Computational Mechanics</i> , 2019, 63, 159-180.	4.0	8
8277	Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 147-154.	5.3	16
8278	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. <i>Investigational New Drugs</i> , 2019, 37, 98-108.	2.6	33
8279	Interobserver Variation in Response Evaluation Criteria in Solid Tumors 1.1. <i>Academic Radiology</i> , 2019, 26, 489-501.	2.5	9
8280	PET-based prognostic survival model after radiotherapy for head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 638-649.	6.4	20
8281	Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 813-822.	4.2	51
8282	The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy. <i>Telemedicine Journal and E-Health</i> , 2019, 25, 462-470.	2.8	27
8283	Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer. <i>Current Problems in Cancer</i> , 2019, 43, 5-17.	2.0	24
8284	A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 576-585.	1.4	25
8285	A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. <i>Oncologist</i> , 2019, 24, 14-e10.	3.7	32
8286	Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 78-86.	2.2	3
8287	Toxicity and effectiveness of carboplatin in obese or overweight patients. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1328-1335.	0.9	4
8288	A risk-based approach to identifying oligometastatic disease on imaging. <i>International Journal of Cancer</i> , 2019, 144, 422-430.	5.1	17

#	ARTICLE	IF	CITATIONS
8289	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 1185-1195.	7.0	97
8290	Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. <i>FASEB Journal</i> , 2019, 33, 151-162.	0.5	29
8291	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. <i>Hepatology Research</i> , 2019, 49, 111-117.	3.4	81
8292	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	1.2	114
8293	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	2.6	32
8294	The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. <i>Journal of Geriatric Oncology</i> , 2019, 10, 411-414.	1.0	51
8295	Comparison of <sc>PD</sc>-L1 immunohistochemistry assays and response to <sc>PD</sc>-L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. <i>Histopathology</i> , 2019, 74, 269-275.	2.9	15
8296	Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 377-385.	5.0	81
8297	Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. <i>Clinical and Translational Oncology</i> , 2019, 21, 314-323.	2.4	17
8298	Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. <i>Hpb</i> , 2019, 21, 107-113.	0.3	20
8299	Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. <i>British Journal of Ophthalmology</i> , 2019, 103, 775-780.	3.9	36
8300	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 457-467.	2.2	19
8301	Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 19-27.	3.3	10
8302	Fully Automatic CAD System for Segmentation and Classification of Spinal Metastatic Lesions in CT Data. <i>IFMBE Proceedings</i> , 2019, , 155-158.	0.3	1
8303	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 663-673.	0.9	8
8304	Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. <i>Molecular Imaging and Biology</i> , 2019, 21, 582-590.	2.6	62
8305	Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer. <i>Annals of Surgery</i> , 2019, 270, 1090-1095.	4.2	47
8306	Can unenhanced MRI of the breast replace contrast-enhanced MRI in assessing response to neoadjuvant chemotherapy?. <i>Acta Radiologica</i> , 2019, 60, 35-44.	1.1	12

#	ARTICLE	IF	CITATIONS
8307	Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1251.	2.4	12
8308	Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. <i>Oncology Letters</i> , 2019, 18, 2091-2101.	1.8	16
8309	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. <i>Cancer Letters</i> , 2019, 464, 5-14.	7.2	148
8310	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). <i>Lung Cancer</i> , 2019, 136, 109-114.	2.0	16
8311	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	7.3	45
8312	Intratumoral <i>Fusobacterium Nucleatum</i> Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 6170-6179.	7.0	104
8313	Radiographic Assessment of Objective Responses Using the ITMIG-Modified Criteria in Thymic Carcinoma. <i>Oncology</i> , 2019, 97, 264-269.	1.9	0
8314	Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. <i>Future Oncology</i> , 2019, 15, 2449-2462.	2.4	11
8315	Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients. <i>Lung Cancer</i> , 2019, 136, 23-29.	2.0	15
8316	Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). <i>Journal of Clinical Oncology</i> , 2019, 37, 2682-2688.	1.6	8
8317	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2571-2580.	1.6	49
8318	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. <i>Immunotherapy</i> , 2019, 11, 1005-1013.	2.0	21
8319	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1448.	7.1	94
8320	Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. <i>Cancer Medicine</i> , 2019, 8, 5554-5563.	2.8	3
8321	Imaging Melanoma. , 2019, , 557-581.		0
8322	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). <i>Sarcoma</i> , 2019, 2019, 1-8.	1.3	45
8323	Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study. <i>Clinical Cancer Research</i> , 2019, 25, 6692-6699.	7.0	18
8324	Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data. <i>Journal of Translational Medicine</i> , 2019, 17, 255.	4.4	11

#	ARTICLE	IF	CITATIONS
8325	Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. <i>Cancers</i> , 2019, 11, 1113.	3.7	41
8326	Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6812-6821.	3.6	12
8327	P.R.O.P.S. – A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>World Journal of Surgical Oncology</i> , 2019, 17, 138.	1.9	2
8328	Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). <i>Journal of Neuro-Oncology</i> , 2019, 144, 303-311.	2.9	30
8329	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 11542.	3.3	25
8330	Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1043-1048.	1.3	3
8331	Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy. <i>Molecular and Clinical Oncology</i> , 2019, 11, 289-295.	1.0	3
8332	Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 243-251.	1.0	1
8333	Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27953.	1.5	12
8334	Pretreatment low prognostic nutritional index and low albumin-globulin ratio are predictive for overall survival in nasopharyngeal cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 3221-3230.	1.6	30
8335	Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 473-477.	2.5	4
8336	Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. <i>Cancer Medicine</i> , 2019, 8, 5823-5830.	2.8	9
8337	Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. <i>Prostate</i> , 2019, 79, 1572-1579.	2.3	23
8338	Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. <i>Translational Oncology</i> , 2019, 12, 1425-1431.	3.7	21
8339	Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. <i>BMC Cancer</i> , 2019, 19, 788.	2.6	64
8340	Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1417-1428.	4.2	23
8341	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	2.6	9
8342	Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib. <i>Future Oncology</i> , 2019, 15, 21-25.	2.4	0

#	ARTICLE	IF	CITATIONS
8343	Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy. Trends in Cancer, 2019, 5, 467-474.	7.4	43
8344	Irreversible Electroporation: Expanding the Armamentarium against Pancreatic Cancer. Digestive Disease Interventions, 2019, 03, 138-142.	0.2	0
8345	Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease. Journal of Thoracic Disease, 2019, 11, 514-520.	1.4	1
8346	miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Molecular Oncology, 2019, 13, 2278-2296.	4.6	30
8347	Hybrid Imaging for Tumours of the Chest. , 2019, , 523-542.		0
8348	Different Types of <i>ROS1</i> Fusion Partners Yield Comparable Efficacy to Crizotinib. Oncology Research, 2019, 27, 901-910.	1.5	27
8349	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	7.7	57
8350	Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Nonâ€Small-Cell Lung Cancer Data Set. JCO Clinical Cancer Informatics, 2019, 3, 1-13.	2.1	69
8351	The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma. Tuberculosis and Respiratory Diseases, 2019, 82, 211.	1.8	3
8352	Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANGLE). Japanese Journal of Clinical Oncology, 2019, 49, 1055-1060.	1.3	46
8353	Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. Annals of Surgical Oncology, 2019, 26, 4633-4641.	1.5	24
8354	An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs. Scientific Reports, 2019, 9, 11877.	3.3	4
8355	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS ONE, 2019, 14, e0221301.	2.5	16
8357	Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma. Journal of Neuro-Oncology, 2019, 144, 603-610.	2.9	14
8358	Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer, 2019, 17, e886-e887.	1.9	1
8359	Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer. Scientific Reports, 2019, 9, 11899.	3.3	2
8360	Perioperative Gemcitabine+â€Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology, 2019, 26, 4489-4497.	1.5	19
8361	Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology, 2019, 8, e1629261.	4.6	40

#	ARTICLE	IF	CITATIONS
8362	Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer. <i>Journal of Radiation Research</i> , 2019, 60, 831-836.	1.6	13
8363	Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. <i>Medicine (United States)</i> , 2019, 98, e16249.	1.0	2
8364	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. <i>Drugs in R and D</i> , 2019, 19, 267-275.	2.2	4
8365	Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 781-789.	2.3	3
8366	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1306-1315.	10.7	87
8367	Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. <i>Clinical Lung Cancer</i> , 2019, 20, 442-450.e4.	2.6	83
8368	Evaluation of response to chemotherapy: Work still in progress. <i>Digestive and Liver Disease</i> , 2019, 51, 1192-1193.	0.9	0
8369	Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. <i>Lung Cancer</i> , 2019, 136, 30-36.	2.0	32
8370	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11131.	3.3	21
8371	Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2019, 25, 5752-5758.	7.0	24
8372	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. <i>PLoS ONE</i> , 2019, 14, e0220570.	2.5	20
8373	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 227-234.	2.8	17
8374	Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer. <i>Anticancer Research</i> , 2019, 39, 4337-4342.	1.1	8
8376	Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1844-1851.	4.1	13
8377	Assessment of spatial tumor heterogeneity using CT growth patterns estimated by tumor tracking on 3D CT volumetry of multiple pulmonary metastatic nodules. <i>PLoS ONE</i> , 2019, 14, e0220550.	2.5	3
8378	Overall survival for neuroblastoma in South Africa between 2000 and 2014. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27944.	1.5	20
8379	Bone Target Therapy in Urologic Malignancies. , 2019, , 77-93.		0
8380	Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 4371-4377.	1.1	14

#	ARTICLE	IF	CITATIONS
8381	Challenges of international oncology trial collaboration—a call to action. <i>British Journal of Cancer</i> , 2019, 121, 515-521.	6.4	17
8382	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	17.8	132
8383	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	14.5	217
8384	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. <i>Scientific Reports</i> , 2019, 9, 11153.	3.3	44
8385	Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 2074-2081.	1.3	1
8386	Breast MRI: State of the Art. <i>Radiology</i> , 2019, 292, 520-536.	7.3	442
8387	Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2349-2359.	1.6	56
8388	Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, 2350-2360.	1.4	34
8389	Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2019, 39, 4343-4350.	1.1	21
8390	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. <i>JAMA Network Open</i> , 2019, 2, e198243.	5.9	25
8391	Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. <i>Cancer Medicine</i> , 2019, 8, 5399-5413.	2.8	15
8392	Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 999-1005.	1.6	7
8393	Impact of increased resection rates and a liver parenchyma sparing strategy on long-term survival after surgery for colorectal liver metastases. A population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 890-898.	1.5	7
8394	Primary angiosarcoma of the kidney: case report and comprehensive literature review. <i>Open Medicine (Poland)</i> , 2019, 14, 443-455.	1.3	5
8395	Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer. <i>Future Oncology</i> , 2019, 15, 1617-1627.	2.4	10
8396	Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience. <i>Immunotherapy</i> , 2019, 11, 945-952.	2.0	2
8397	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. <i>Oncology Letters</i> , 2019, 18, 3373-3380.	1.8	4
8398	Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: A multicentre study. <i>EBioMedicine</i> , 2019, 46, 160-169.	6.1	69

#	ARTICLE	IF	CITATIONS
8399	Nonâ€“Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 2019, 94, 1623-1640.	3.0	1,153
8400	Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea. Gynecologic Oncology, 2019, 155, 75-82.	1.4	64
8401	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discovery, 2019, 9, 1372-1387.	9.4	158
8402	Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. Oncology Letters, 2019, 18, 1872-1880.	1.8	12
8403	Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC). European Radiology Experimental, 2019, 3, 23.	3.4	5
8404	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). Oncologist, 2019, 24, 1439-1445.	3.7	40
8405	EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncology, 2019, 15, 3209-3218.	2.4	43
8406	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1464.	7.1	28
8407	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer, 2019, 19, 705.	2.6	27
8408	Retrospective analysis of seven cases of pancreatic mixed adenoneuroendocrine carcinoma from a high-volume center and review of the literature. BMC Surgery, 2019, 19, 89.	1.3	4
8409	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
8410	Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study). Journal of Nippon Medical School, 2019, 86, 165-171.	0.9	1
8411	Serum Paraoxonase-1-Related Variables and Lipoprotein Profile in Patients with Lung or Head and Neck Cancer: Effect of Radiotherapy. Antioxidants, 2019, 8, 213.	5.1	14
8412	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2â€“positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125, 3974-3984.	4.1	67
8413	Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer. International Journal of Clinical Oncology, 2019, 24, 1429-1439.	2.2	6
8414	AÂ€“case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and aÂ€“review of immunotherapy in gastroesophageal tumors. Memo - Magazine of European Medical Oncology, 2019, 12, 51-59.	0.5	0
8415	DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade. Developmental Cell, 2019, 50, 658-671.e7.	7.0	76
8416	Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large Bâ€“cell lymphoma. Cancer Medicine, 2019, 8, 5012-5022.	2.8	24

#	ARTICLE	IF	CITATIONS
8417	Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3ÂGy/fraction). <i>Radiologia Medica</i> , 2019, 124, 1324-1332.	7.7	6
8418	Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. <i>Clinical Cancer Research</i> , 2019, 25, 6052-6060.	7.0	61
8419	Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribiform-Morular Variant of Papillary Thyroid Carcinoma and an <i>APC</i> Gene Mutation: A Case Study. <i>Thyroid</i> , 2019, 29, 1511-1517.	4.5	9
8420	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 277-285.	1.9	66
8421	Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam. <i>Cancer Control</i> , 2019, 26, 107327481986377.	1.8	4
8422	Changes in Volume and Density Parameters Measured on Computed Tomography Images Following Stereotactic Body Radiation Therapy of Nonspine Bone Metastases. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381985353.	1.9	1
8423	Association between EGFR exon 19 or exon 21 mutations and survival rates after firstâ€line EGFRâ€TKI treatment in patients with nonâ€small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 301-308.	1.0	23
8424	Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal ¹⁸F-FES PET/CT. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-8.	0.8	7
8425	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 1919-1928.	1.4	13
8426	Positive PDâ€L1 expression is predictive for patients with advanced EGFR wildâ€type nonâ€small cell lung cancer treated with gemcitabine and cisplatin. <i>Oncology Letters</i> , 2019, 18, 161-168.	1.8	2
8427	Management of recurrent or refractory Ewing sarcoma: A systematic review of phaseï½II clinical trials in the last 15ï½years. <i>Oncology Letters</i> , 2019, 18, 348-358.	1.8	6
8428	Cytoplasmic ERÎ²1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exonï½21 L858R subsequent to treatment with EGFRâ€TKIs. <i>Oncology Letters</i> , 2019, 18, 792-803.	1.8	3
8429	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3140-3144.	2.5	5
8430	Rapid atrophy of cardiac left ventricular mass in patients with nonâ€small cell carcinoma of the lung. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1070-1082.	7.3	21
8431	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
8432	Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 479.	2.8	20
8433	Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI. <i>Cancer Medicine</i> , 2019, 8, 5047-5057.	2.8	19
8434	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 135, 92-96.	2.0	22

#	ARTICLE	IF	CITATIONS
8435	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. , 2019, 7, 180.		137
8436	Intra-individual variation of circulating tumour DNA in lung cancer patients. Molecular Oncology, 2019, 13, 2098-2106.	4.6	14
8437	Optimal mass transport kinetic modeling for head and neck DCE-MRI: Initial analysis. Magnetic Resonance in Medicine, 2019, 82, 2314-2325.	3.0	3
8439	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research, 2019, 21, 78.	5.0	141
8440	Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatric Blood and Cancer, 2019, 66, e27900.	1.5	6
8441	Uveal Melanoma: Metastases. , 2019, , 317-329.		0
8442	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	2.5	9
8443	The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis. Clinical Genitourinary Cancer, 2019, 17, e847-e859.	1.9	8
8444	A Phase 1/2 Study of Carbon Ion Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Uterine Cervical Squamous Cell Carcinoma (Protocol 1302). International Journal of Radiation Oncology Biology Physics, 2019, 104, 631-639.	0.8	8
8445	From Bench to Bedside – The Bad Berka Experience With First-in-Human Studies. Seminars in Nuclear Medicine, 2019, 49, 422-437.	4.6	30
8446	Vollständiges pathologisches Ansprechen auf Pembrolizumab nach Ex-vivo-Leberresektion bei einer Patientin mit Lebermetastasen eines kolorektalen Karzinoms. Karger Kompass Onkologie, 2019, 6, 115-119.	0.0	0
8447	Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. Journal of Clinical Oncology, 2019, 37, 2141-2151.	1.6	175
8448	Using Image-guided Intensity-modulated Radiotherapy on Patients With Head and Neck Soft-tissue Sarcoma. In Vivo, 2019, 33, 1293-1300.	1.3	6
8449	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e196879.	5.9	161
8450	Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small cell lung cancer treated with nivolumab. Journal of Clinical Laboratory Analysis, 2019, 33, e22964.	2.1	171
8451	Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy. Clinical Genitourinary Cancer, 2019, 17, e1036-e1047.	1.9	8
8452	Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecologic Oncology, 2019, 154, 554-557.	1.4	21
8453	Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging. Experimental and Molecular Medicine, 2019, 51, 1-11.	7.7	20

#	ARTICLE	IF	CITATIONS
8454	Tumour response in non-small cell lung cancer patients treated with chemoradiotherapy – Can spectral CT predict recurrence?. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 641-649.	1.8	16
8455	Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience. Radiology, 2019, 292, 628-635.	7.3	24
8456	Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer, 2019, 19, 672.	2.6	144
8457	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. , 2019, 7, 170.		36
8458	Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer. International Journal of Clinical Oncology, 2019, 24, 1406-1411.	2.2	4
8459	Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab. Memo - Magazine of European Medical Oncology, 2019, 12, 149-155.	0.5	1
8460	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
8461	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1239-1251.	10.7	812
8462	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 2974-2986.	1.6	643
8463	Safety and efficacy of transarterial embolization of hepatocellular adenomas. British Journal of Surgery, 2019, 106, 1362-1371.	0.3	12
8464	Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer. Cell Reports, 2019, 28, 938-948.e6.	6.4	29
8465	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 813.e1-813.e9.	1.6	16
8466	Predictive Value of First Posttreatment Imaging Using Standardized Reporting in Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2019, 161, 978-985.	1.9	25
8467	The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer, 2019, 19, 718.	2.6	43
8468	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	3.7	63
8469	Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 932.	4.3	97
8470	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2019, 381, 338-348.	27.0	885
8471	Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncology, 2019, 5, 1421.	7.1	99

#	ARTICLE	IF	CITATIONS
8472	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. <i>BioDrugs</i> , 2019, 33, 555-570.	4.6	36
8473	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProFiLER programme. <i>European Journal of Cancer</i> , 2019, 118, 156-165.	2.8	11
8474	Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study. <i>Cancer Control</i> , 2019, 26, 107327481986377.	1.8	2
8475	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
8476	Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. <i>PLoS ONE</i> , 2019, 14, e0219480.	2.5	26
8477	<i>RAS</i> and <i>BRAF</i> mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested <i>RAS</i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	4.6	32
8478	Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2244-2251.	6.4	43
8479	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 433-440.	3.6	9
8480	68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. <i>Annals of Nuclear Medicine</i> , 2019, 33, 766-775.	2.2	35
8481	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2340-2346.	1.0	14
8482	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2019, 121, 318-324.	6.4	35
8483	Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 10742.	3.3	10
8484	Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2019, 19, 688.	2.6	5
8485	Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study. <i>BMC Cancer</i> , 2019, 19, 725.	2.6	7
8486	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019, 96, 7-14.	1.5	45
8487	Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST). <i>Acta Oncologica</i> , 2019, 58, 1648-1654.	1.8	11
8488	Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. <i>Clinical Trials</i> , 2019, 16, 502-511.	1.6	7
8489	Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. <i>Oncologist</i> , 2019, 24, e542-e550.	3.7	87

#	ARTICLE	IF	CITATIONS
8490	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	2.3	31
8491	Towards quantitative imaging biomarkers of tumor dissemination: A multi-scale parametric modeling of multiple myeloma. <i>Medical Image Analysis</i> , 2019, 57, 214-225.	11.6	6
8492	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. <i>British Journal of Cancer</i> , 2019, 121, 417-420.	6.4	24
8493	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2592-2600.	1.6	404
8494	Regorafenib Prior to Selective Internal Radiation Therapy Using 90Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers. <i>Frontiers in Oncology</i> , 2019, 9, 624.	2.8	6
8495	Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1543-1548.	2.2	16
8496	Clonal replacement of tumor-specific T cells following PD-1 blockade. <i>Nature Medicine</i> , 2019, 25, 1251-1259.	30.7	974
8497	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1. <i>Bladder Cancer</i> , 2019, 5, 131-145.	0.4	11
8498	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019, 41, 3670-3676.	2.0	29
8499	Advanced urothelial cancer: a radiology update. <i>Abdominal Radiology</i> , 2019, 44, 3858-3873.	2.1	5
8500	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2019, 14, 453-463.	3.6	53
8501	Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology. <i>Current Pathobiology Reports</i> , 2019, 7, 97-108.	3.4	15
8502	Medullary Thyroid Carcinoma: An Update on Imaging. <i>Journal of Thyroid Research</i> , 2019, 2019, 1-17.	1.3	36
8503	Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review. <i>BMC Cancer</i> , 2019, 19, 748.	2.6	7
8504	A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. <i>Annals of Oncology</i> , 2019, 30, 1487-1495.	1.2	130
8505	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	7.0	115
8506	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1628-1636.	4.1	18
8507	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	19

#	ARTICLE	IF	CITATIONS
8508	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
8509	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	10.7	169
8510	Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer. <i>BMC Cancer</i> , 2019, 19, 615.	2.6	7
8511	Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis. <i>BMC Cancer</i> , 2019, 19, 625.	2.6	16
8512	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2169-2177.	6.4	30
8513	Basic principles of brain tumor chemotherapy. , 2019, , 309-330.		0
8514	Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e620-e630.	2.6	39
8515	Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy. <i>Journal of Interdisciplinary Nanomedicine</i> , 2019, 4, 54-71.	3.6	26
8516	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
8517	Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028). <i>Gynecologic Oncology</i> , 2019, 154, 547-553.	1.4	68
8518	First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGS 1602. <i>BMC Cancer</i> , 2019, 19, 623.	2.6	0
8519	Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients. <i>PLoS ONE</i> , 2019, 14, e0219080.	2.5	1
8520	Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2019, 9, 470.	2.8	7
8521	Gastrointestinal stromal tumours at Inkosi Albert Luthuli Central Hospital from 2005 to 2015. <i>South African Journal of Oncology</i> , 2019, 3, .	0.1	0
8522	Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. <i>Lancet Oncology</i> , The, 2019, 20, e368-e377.	10.7	206
8523	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. <i>European Journal of Radiology</i> , 2019, 117, 132-139.	2.6	10
8524	Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. <i>Gynecologic Oncology</i> , 2019, 154, 461-466.	1.4	27
8525	GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. <i>Scientific Reports</i> , 2019, 9, 9312.	3.3	12

#	ARTICLE	IF	CITATIONS
8526	Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer. <i>Anticancer Research</i> , 2019, 39, 3871-3878.	1.1	23
8527	Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2019, 39, 3887-3892.	1.1	25
8528	Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?. <i>Anticancer Research</i> , 2019, 39, 3923-3929.	1.1	24
8529	Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 3937-3944.	1.1	0
8530	Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷ Lu-DOTATATE. <i>Cancers</i> , 2019, 11, 909.	3.7	56
8531	Diffusion-Weighted Magnetic Resonance Imaging of the Breast: an Accurate Method for Measuring Early Response to Neoadjuvant Chemotherapy?. <i>Current Breast Cancer Reports</i> , 2019, 11, 74-82.	1.0	1
8532	Outcomes of enhanced one-stage ultrasound-guided hepatectomy for bilobar colorectal liver metastases compared to those of ALPPS: a multicenter case-match analysis. <i>Hpb</i> , 2019, 21, 1411-1418.	0.3	37
8533	Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. <i>International Immunopharmacology</i> , 2019, 74, 105707.	3.8	11
8534	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	2.4	14
8535	A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2019, 9, e028147.	1.9	14
8536	Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 929-934.	2.5	11
8537	Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. <i>Radiographics</i> , 2019, 39, 998-1016.	3.3	14
8538	Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols. <i>Acta Pharmaceutica</i> , 2019, 69, 87-97.	2.0	0
8539	Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 4644-4655.	2.8	55
8540	Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1185-1192.	0.5	45
8541	Durvalumab in cancer medicine: a comprehensive review. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 927-935.	3.1	36
8542	The Onset of Grade 3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. <i>Anticancer Research</i> , 2019, 39, 3967-3969.	1.1	7
8543	Beyond T2 and 3T: New MRI techniques for clinicians. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 87-97.	1.7	10

#	ARTICLE	IF	CITATIONS
8544	Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1004-1012.	0.5	7
8545	Cross-modality (CT-MRI) prior augmented deep learning for robust lung tumor segmentation from small MR datasets. <i>Medical Physics</i> , 2019, 46, 4392-4404.	3.0	42
8546	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	451
8547	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966.	7.0	206
8548	Neutrophil-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2019, 39, 5675-5682.	1.1	30
8549	Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. <i>American Journal of Roentgenology</i> , 2019, 213, 1232-1239.	2.2	9
8550	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	3.7	37
8551	Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study. <i>Radiotherapy and Oncology</i> , 2019, 141, 62-66.	0.6	18
8552	Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. <i>Thyroid</i> , 2019, 29, 1804-1810.	4.5	17
8553	Clinical Evaluation of Dynamic Monitoring of Neutrophil-lymphocyte and Platelet-lymphocyte Ratios in Primary Endocrine Therapy for Advanced Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 5581-5588.	1.1	5
8554	Challenges and Opportunities for Childhood Cancer Drug Development. <i>Pharmacological Reviews</i> , 2019, 71, 671-697.	16.0	13
8555	The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 880.	2.8	9
8556	Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT). <i>International Journal of Surgery</i> , 2019, 72, 34-42.	2.7	24
8557	The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY). <i>BMC Cancer</i> , 2019, 19, 941.	2.6	4
8558	Advanced Deep Learning Embedded Motion Radiomics Pipeline for Predicting Anti-PD-1/PD-L1 Immunotherapy Response in the Treatment of Bladder Cancer: Preliminary Results. <i>Electronics (Switzerland)</i> , 2019, 8, 1134.	3.1	26
8559	Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma. <i>Value in Health</i> , 2019, 22, 1170-1177.	0.3	2
8560	Radiation-related Adverse Effects of CT-guided Implantation of 125I Seeds for Thoracic Recurrent and/or Metastatic Malignancy. <i>Scientific Reports</i> , 2019, 9, 14803.	3.3	5
8561	Fractional exhaled nitric oxide as a potential biomarker for radiation pneumonitis in patients with non-small cell lung cancer: A pilot study. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 103-109.	1.7	5

#	ARTICLE	IF	CITATIONS
8562	Clinical outcome and toxicity after simultaneous integrated boost IMRT in head and neck squamous cell cancer patients. <i>Oral Oncology</i> , 2019, 98, 132-140.	1.5	18
8563	rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 5353-5359.	1.1	7
8564	Standardization and quantification is a key to the future of atherosclerosis FDG PET/CT imaging. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1360-1363.	2.1	3
8565	Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. <i>Journal of Translational Medicine</i> , 2019, 17, 338.	4.4	16
8566	Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. <i>Journal of Translational Medicine</i> , 2019, 17, 339.	4.4	8
8567	Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. <i>Cancers</i> , 2019, 11, 1503.	3.7	35
8568	MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1871-1877.	2.2	7
8569	Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)—A concordance comparison cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0222917.	2.5	6
8570	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1&2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.	10.7	92
8571	Cabozantinib for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 847-855.	2.4	12
8572	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreaticobiliary origin. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 944-956.	1.4	11
8573	KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. <i>Cancers</i> , 2019, 11, 1514.	3.7	19
8574	Intravoxel Incoherent Motion Parameters for Assessing the Efficiency of Locoregional Bridging Treatments before Liver Transplantation. <i>Transplantation Proceedings</i> , 2019, 51, 2391-2396.	0.6	5
8575	First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 910-917.	1.4	15
8576	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , 2019, 29, 1634-1645.	4.5	69
8577	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019, 41, 2517-2528.e28.	2.5	2
8578	Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. <i>Cancer Medicine</i> , 2019, 8, 6853-6859.	2.8	11
8579	Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. <i>Journal of Surgical Oncology</i> , 2019, 120, 1208-1219.	1.7	13

#	ARTICLE	IF	CITATIONS
8580	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1750-1759.	10.7	86
8581	Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. <i>Cytokine and Growth Factor Reviews</i> , 2019, 49, 1-9.	7.2	11
8582	Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. <i>Gastroenterology Report</i> , 2019, 7, 301-311.	1.3	16
8583	Completely Abdominal Approach Laparoscopic Partial Intersphincteric Resection After Neoadjuvant Chemoradiation for Initial cT3 Juxta-Anal Rectal Cancer. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 809-816.	1.0	6
8584	The Mechanisms Underlying the Cytotoxic Effects of Copper Via Differentiated Embryonic Chondrocyte Gene 1. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5225.	4.1	15
8585	The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 577-582.	2.0	52
8586	Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2~ Advanced/Metastatic Breast Cancer. <i>In Vivo</i> , 2019, 33, 2037-2044.	1.3	2
8587	NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1649.	3.7	17
8588	Phase II study of nab~paclitaxel~+~carboplatin for patients with non~small~cell lung cancer and interstitial lung disease. <i>Cancer Science</i> , 2019, 110, 3738-3745.	3.9	49
8589	Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1080.	2.8	20
8590	Real~world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau. <i>Cancer Reports</i> , 2019, 2, e1180.	1.4	4
8591	Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. <i>European Journal of Radiology</i> , 2019, 121, 108688.	2.6	20
8592	Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma. <i>European Journal of Radiology</i> , 2019, 121, 108734.	2.6	9
8593	Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. <i>International Immunopharmacology</i> , 2019, 77, 105942.	3.8	11
8594	Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 712.	3.5	13
8595	Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 15819.	3.3	10
8596	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	7.0	80
8597	Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy. <i>Future Oncology</i> , 2019, 15, 3935-3944.	2.4	11

#	ARTICLE	IF	CITATIONS
8598	Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients. <i>Journal of Cancer</i> , 2019, 10, 5608-5613.	2.5	31
8599	Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease. <i>In Vivo</i> , 2019, 33, 2059-2064.	1.3	13
8600	Day-to-day and within-day biological variation of cell-free DNA. <i>EBioMedicine</i> , 2019, 49, 284-290.	6.1	49
8601	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	7.0	13
8602	Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer. <i>BMC Cancer</i> , 2019, 19, 1029.	2.6	8
8603	Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3. <i>In Vivo</i> , 2019, 33, 2217-2224.	1.3	2
8604	Prognostic Value of Texture Analysis Based on Pretreatment DWI-Weighted MRI for Esophageal Squamous Cell Carcinoma Patients Treated With Concurrent Chemo-Radiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1057.	2.8	8
8605	Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response – A Prospective Study. <i>Scientific Reports</i> , 2019, 9, 16372.	3.3	44
8606	The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2019, 39, 6265-6271.	1.1	33
8607	Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?. <i>Pharmaceutics</i> , 2019, 11, 566.	4.5	14
8608	AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma. <i>Journal of Cancer</i> , 2019, 10, 5212-5222.	2.5	4
8609	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	20
8610	Genetic polymorphism of CYP3A4 is associated with poor response to ifosfamide treatment in children with solid embryonic tumors. <i>Archives of Medical Science</i> , 2019, 17, 1766-1771.	0.9	2
8611	Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 462.	8.6	41
8612	Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. <i>Cancers</i> , 2019, 11, 1769.	3.7	44
8613	Local experience in Saudi Arabia of selective internal radiation therapy with yttrium-90 microspheres for the treatment of unresectable liver tumours. <i>Journal of Radiotherapy in Practice</i> , 2019, 18, 365-368.	0.5	1
8614	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
8615	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019, 5, 1790.	7.1	8

#	ARTICLE	IF	CITATIONS
8616	Immunotherapy for head and neck cancer: Recent advances and future directions. <i>Oral Oncology</i> , 2019, 99, 104460.	1.5	202
8617	A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes. <i>Gynecologic Oncology</i> , 2019, 155, 444-451.	1.4	36
8618	Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 15451.	3.3	8
8619	Progression of deep infiltrating rectosigmoid endometriotic nodules. <i>Human Reproduction</i> , 2019, 34, 2144-2152.	0.9	22
8620	Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. <i>Cancer Medicine</i> , 2019, 8, 7669-7678.	2.8	27
8621	Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease. <i>Lung Cancer</i> , 2019, 138, 116-123.	2.0	14
8622	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K inhibitors. <i>Science</i> , 2019, 366, 714-723.	12.6	185
8624	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	3.7	53
8625	Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. <i>Brachytherapy</i> , 2019, 18, 829-834.	0.5	6
8626	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
8627	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
8628	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2019, , .	2.8	3
8630	Extracellular Vesicle-derived circular RNAs confers chemoresistance in Colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 16497.	3.3	98
8631	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019, 24, e646-e652.	3.7	5
8632	Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer – A Matched-Pair Analysis. <i>Anticancer Research</i> , 2019, 39, 5781-5787.	1.1	5
8633	A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1094.	2.8	3
8634	Genomic stratification beyond Ras/Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	2.8	8
8635	Prognostic impact of a large mesenteric mass >2cm in ileal neuroendocrine tumors. <i>Journal of Surgical Oncology</i> , 2019, 120, 1311-1317.	1.7	18

#	ARTICLE	IF	CITATIONS
8636	Imaging Glioblastoma Posttreatment. Radiologic Clinics of North America, 2019, 57, 1199-1216.	1.8	55
8637	Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. European Journal of Cancer, 2019, 121, 177-183.	2.8	43
8638	Radioembolization in liver tumors. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 370-381.	0.2	1
8639	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecologic Oncology, 2019, 155, 420-428.	1.4	28
8640	Simulation of explosion proof capacity of material partition in micro initiation sequence. Journal of Physics: Conference Series, 2019, 1209, 012014.	0.4	0
8641	Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. Cancer Science, 2019, 110, 2894-2904.	3.9	69
8642	Grey eosinophils in a Miniature Schnauzer with a poorly differentiated mast cell tumor. Veterinary Clinical Pathology, 2019, 48, 406-412.	0.7	3
8643	Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC Cancer, 2019, 19, 1006.	2.6	18
8644	Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer, 2019, 19, 990.	2.6	17
8645	The Role of Post-Neoadjuvant Chemotherapy Tumor Volume for Prognostication and Treatment Guidance in Loco-Regionally Advanced Nasopharyngeal Carcinoma. Cancers, 2019, 11, 1632.	3.7	23
8646	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642.	3.7	47
8647	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. Targeted Oncology, 2019, 14, 707-717.	3.6	15
8648	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Science, 2019, 110, 3049-3060.	3.9	20
8649	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research, 2019, 25, 7331-7339.	7.0	110
8650	Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience. European Thyroid Journal, 2019, 8, 262-267.	2.4	7
8651	Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). Annals of Gastroenterological Surgery, 2019, 3, 523-533.	2.4	13
8652	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Medicine, 2019, 8, 6986-6994.	2.8	37
8653	A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Reports, 2019, 2, e1183.	1.4	7

#	ARTICLE	IF	CITATIONS
8654	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1752-1761.	2.3	1
8655	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	11
8656	PD1 ⁺ tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma. <i>Future Oncology</i> , 2019, 15, 4019-4030.	2.4	12
8657	Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 922.	2.8	32
8658	Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. <i>Cancer Medicine</i> , 2019, 8, 28-39.	2.8	12
8659	A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. <i>Cancer</i> , 2019, 125, 1124-1132.	4.1	41
8660	Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. <i>In Vivo</i> , 2019, 33, 271-276.	1.3	26
8661	Post-progression survival is highly linked to overall survival in patients with non-small cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2019, 10, 2200-2208.	1.9	8
8662	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	1.9	9
8663	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 3244-3254.	3.9	32
8664	Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. <i>Cancer Science</i> , 2019, 110, 3434-3441.	3.9	13
8665	Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2019, 14, 182.	2.7	21
8666	Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). <i>Future Oncology</i> , 2019, 15, 2841-2855.	2.4	9
8667	FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond. <i>Cancers</i> , 2019, 11, 1190.	3.7	12
8668	Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection. <i>Oncology Letters</i> , 2019, 18, 1513-1520.	1.8	6
8669	Carbon Ion Radiotherapy for Patients with Extracranial Chordoma or Chondrosarcoma - Initial Experience from Shanghai Proton and Heavy Ion Center. <i>Journal of Cancer</i> , 2019, 10, 3315-3322.	2.5	11
8670	An analysis of genetic heterogeneity in untreated cancers. <i>Nature Reviews Cancer</i> , 2019, 19, 639-650.	28.4	139
8671	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	4.1	49

#	ARTICLE	IF	CITATIONS
8672	PtCu nanoprobe-initiated cascade reaction modulated iodide-responsive sensing interface for improved electrochemical immunosensor of neuron-specific enolase. <i>Biosensors and Bioelectronics</i> , 2019, 143, 111612.	10.1	33
8673	Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: a retrospective study. <i>International Journal of Hyperthermia</i> , 2019, 36, 826-833.	2.5	21
8674	The Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4145.	4.1	49
8675	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	7.1	62
8676	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. <i>Cancers</i> , 2019, 11, 1203.	3.7	10
8677	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	2.8	103
8678	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	1.9	71
8679	Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update. <i>Future Oncology</i> , 2019, 15, 3149-3157.	2.4	8
8680	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 873-880.	2.3	32
8681	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. <i>European Journal of Cancer</i> , 2019, 119, 77-86.	2.8	23
8682	Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation. <i>PLoS ONE</i> , 2019, 14, e0221718.	2.5	10
8683	Targeted Treatment Options of Recurrent Radioactive Iodine Refractory H ¹²⁵ I-secreting Cell Cancer. <i>Cancers</i> , 2019, 11, 1185.	3.7	7
8684	Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. <i>Medical Oncology</i> , 2019, 36, 83.	2.5	5
8685	SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. <i>European Journal of Cancer</i> , 2019, 119, 158-167.	2.8	19
8686	Radiology workflow for RECIST assessment in clinical trials: Can we reconcile time-efficiency and quality?. <i>European Journal of Radiology</i> , 2019, 118, 257-263.	2.6	9
8687	Intravoxel incoherent motion (IVIM) for response assessment in patients with osteosarcoma undergoing neoadjuvant chemotherapy. <i>European Journal of Radiology</i> , 2019, 119, 108635.	2.6	29
8688	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , 2019, 71, 1175-1183.	3.7	64
8689	Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2019, 136, 45-51.	2.0	84

#	ARTICLE	IF	CITATIONS
8690	Effects of Neoadjuvant FAC Chemotherapy response to CD4 + Serum Levels before and after chemotherapy in breast cancer patients local advanced stage at Dr. Mohammad Hoesin Palembang General Hospital. Journal of Physics: Conference Series, 2019, 1246, 012038.	0.4	0
8691	Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World Journal of Surgical Oncology, 2019, 17, 145.	1.9	16
8692	MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Into Imaging, 2019, 10, 8.	3.4	22
8693	<i>EGFR</i> plasma mutation in prediction models for resistance with EGFR TKI and survival of nonâ€small cell lung cancer. Clinical and Translational Medicine, 2019, 8, 4.	4.0	15
8694	Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyondâ€”Part 2. Journal of Gastrointestinal and Abdominal Radiology, 2019, 02, 107-115.	0.3	1
8695	Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyondâ€”Part 1. Journal of Gastrointestinal and Abdominal Radiology, 2019, 02, 098-106.	0.3	1
8696	Lung and Abdominal Biopsies in the Age of Precision Medicine. Seminars in Interventional Radiology, 2019, 36, 255-263.	0.8	8
8697	Investigation of a Brain Cancer with Interfacing of 3-Dimensional Image Processing. , 2019, , .		10
8698	Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Nonâ€Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	7.0	139
8699	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. Journal of Translational Medicine, 2019, 17, 296.	4.4	13
8700	Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Into Imaging, 2019, 10, 87.	3.4	61
8701	FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. Diagnostics, 2019, 9, 106.	2.6	9
8702	A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2019, 84, 899-907.	2.3	20
8703	Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2019, 17, e1137-e1146.	1.9	3
8704	<p></p>Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years<p></p>. Cancer Management and Research, 2019, Volume 11, 7183-7195.	1.9	2
8705	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1547-1559.	4.2	32
8706	Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review. Cancer Chemotherapy and Pharmacology, 2019, 84, 959-975.	2.3	9
8707	Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab. Cancer Chemotherapy and Pharmacology, 2019, 84, 1039-1049.	2.3	26

#	ARTICLE	IF	CITATIONS
8708	Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. <i>Cancers</i> , 2019, 11, 1282.	3.7	43
8709	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	4.1	17
8710	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1582.	7.1	91
8711	Revised staging system for malignant lymphoma based on the Lugano classification. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 895-900.	1.3	12
8712	Survival of patients with advanced and recurrent ovarian cancer treated using integrative medicine in Malaysia: A case series. <i>Complementary Therapies in Clinical Practice</i> , 2019, 37, 73-85.	1.7	3
8713	Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study. <i>Thyroid</i> , 2019, 29, 1811-1819.	4.5	19
8714	Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1828-1838.	1.1	50
8715	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 122-128.	2.0	38
8716	Early differentiating between the chemotherapy responders and nonresponders: preliminary results with ultrasonic spectrum analysis of the RF time series in preclinical breast cancer models. <i>Cancer Imaging</i> , 2019, 19, 61.	2.8	4
8717	Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 3004-3014.	1.4	22
8718	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. <i>Cancers</i> , 2019, 11, 1271.	3.7	27
8719	Primary peritoneal serous papillary carcinoma: a case series. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1023-1028.	1.7	1
8720	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 74-79.	2.0	14
8721	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
8722	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
8723	A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 52-56.	2.0	5
8724	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). <i>British Journal of Cancer</i> , 2019, 121, 537-544.	6.4	18
8725	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. <i>Annals of Oncology</i> , 2019, 30, 1821-1830.	1.2	99

#	ARTICLE	IF	CITATIONS
8726	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2019, 109, 100-112.	2.5	27
8727	Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. <i>BMC Cancer</i> , 2019, 19, 896.	2.6	33
8728	Cetuximab, irinotecan and fluorouracil in first-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. <i>BMC Cancer</i> , 2019, 19, 899.	2.6	10
8729	Prognostic Value of the Volumetric Parameters of Dual ¹⁸ F-FDG PET/CT in Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy. <i>American Journal of Roentgenology</i> , 2019, 213, 1366-1373.	2.2	14
8730	Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience. <i>BMC Urology</i> , 2019, 19, 84.	1.4	7
8731	Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2866-2874.	1.6	70
8732	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 815.	2.8	53
8733	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. <i>Annals of Surgical Oncology</i> , 2019, 26, 4699-4706.	1.5	36
8734	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	5.9	6
8735	Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1527-1535.	4.2	30
8736	Late Gadolinium Hyperintensity of Suspected Colorectal Liver Metastases on Gadofosveset-Enhanced Magnetic Resonance Imaging: A Predictor of Benignity and a Potential Problem-Solving Tool. <i>Canadian Association of Radiologists Journal</i> , 2019, 70, 239-245.	2.0	2
8737	Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 803-811.	0.8	40
8738	Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1113-1118.	0.8	14
8739	Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma with macrovascular invasion or extrahepatic metastases. <i>Journal of Interventional Medicine</i> , 2019, 2, 55-59.	0.5	1
8740	Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2071-2083.	1.1	33
8741	Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 697.	6.3	18
8742	Percutaneous minimally invasive thermal ablation for management of osseous metastases: recent advances. <i>International Journal of Hyperthermia</i> , 2019, 36, 3-12.	2.5	18
8743	Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response. <i>International Journal of Radiation Biology</i> , 2019, 95, 1640-1647.	1.8	2

#	ARTICLE	IF	CITATIONS
8744	Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3032-3041.	1.6	51
8745	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1181-e1184.	1.9	0
8746	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	2.8	27
8747	Safety of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions: A single-center experience of 214 patients. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 562-568.	1.3	16
8748	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 857.	2.8	12
8749	Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?. <i>Journal of the Endocrine Society</i> , 2019, 3, 1693-1706.	0.2	21
8750	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. <i>PLoS ONE</i> , 2019, 14, e0221994.	2.5	23
8751	Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2353.	4.8	22
8752	Continued Chemotherapy After Concurrent Chemoradiotherapy Improves Treatment Outcomes for Unresectable Cutaneous Squamous Cell Carcinoma: An Analysis of 13 Cases. <i>Frontiers in Medicine</i> , 2019, 6, 207.	2.6	2
8753	Deep Learning and Convolutional Neural Networks for Medical Imaging and Clinical Informatics. <i>Advances in Computer Vision and Pattern Recognition</i> , 2019, , .	1.3	51
8754	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	10.9	10
8755	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. <i>Clinical Colorectal Cancer</i> , 2019, 18, 245-256.e5.	2.3	2
8756	Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 78-83.	0.5	7
8757	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	1.1	69
8758	Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1892-1900.	1.1	16
8759	CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib—a preliminary retrospective cohort study. <i>British Journal of Radiology</i> , 2019, 92, 20190158.	2.2	9
8760	Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI. <i>Journal of Cancer</i> , 2019, 10, 5108-5113.	2.5	2
8761	The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 2091-2098.	1.9	15

#	ARTICLE	IF	CITATIONS
8762	Chemoradiotherapy with Concurrent Regional Arterial Chemotherapy for Locally Bulky Unresectable Rectal Cancer: A Case Series. <i>Oncology Research and Treatment</i> , 2019, 42, 678-683.	1.2	3
8763	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2857-2865.	1.6	132
8764	Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 350.	3.0	13
8765	A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 889.	2.8	12
8766	Prognostic value of EGFR 19â€ˆdel and 21â€ˆL858R mutations in patients with nonâ€ˆsmall cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 3887-3895.	1.8	26
8767	Embedding MRI information into MRSI data source extraction improves brain tumour delineation in animal models. <i>PLoS ONE</i> , 2019, 14, e0220809.	2.5	3
8768	Preoperative chemoradiotherapy using S-1 combined with celecoxib for advanced lower rectal cancer: Phase I/II study. <i>Journal of the Anus, Rectum and Colon</i> , 2019, 3, 43-48.	1.1	0
8769	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600Eâ€ˆMutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	27.0	918
8770	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. <i>Annals of Oncology</i> , 2019, 30, 1959-1968.	1.2	37
8771	68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. <i>Radiotherapy and Oncology</i> , 2019, 141, 108-115.	0.6	62
8772	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	21.4	250
8774	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. <i>Radiology</i> , 2019, 293, 374-383.	7.3	25
8775	<p>Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8285-8294.	1.9	2
8776	Prognostic Factors for Event-Free Survival in Pediatric Patients with Hepatoblastoma Based on the 2017 PRETEXT and CHIC-HS Systems. <i>Cancers</i> , 2019, 11, 1387.	3.7	15
8777	Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1856-1883.	1.2	592
8778	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 835.	2.8	32
8779	A New Therapeutic Strategy for Recurrent Ovarian Cancerâ€ˆBevacizumab beyond Progressive Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 109.	2.0	8
8780	The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience. <i>Oral Oncology</i> , 2019, 97, 115-123.	1.5	10

#	ARTICLE	IF	CITATIONS
8781	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancerâ€”A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	2.8	23
8782	The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2019, 5, 1779.	7.1	26
8783	Incidental pulmonary nodules: Characterization and management. <i>Radiologia</i> , 2019, 61, 357-369.	0.5	2
8784	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	27.0	627
8785	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2391-2402.	27.0	1,337
8786	Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy. <i>Scientific Reports</i> , 2019, 9, 14157.	3.3	10
8787	Pathologic response after modern radiotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S124-S134.	2.8	9
8788	Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. <i>Chemico-Biological Interactions</i> , 2019, 314, 108822.	4.0	19
8789	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	16.8	145
8790	Immune Checkpoint Inhibitor Therapyâ€™related Pneumonitis: Patterns and Management. <i>Radiographics</i> , 2019, 39, 1923-1937.	3.3	109
8791	<p>The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3419-3424.	4.3	12
8792	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). <i>Anticancer Research</i> , 2019, 39, 5123-5133.	1.1	23
8793	Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2019, 39, 5195-5201.	1.1	46
8794	Is progression in the future liver remnant a contraindication for second-stage hepatectomy?. <i>Hpb</i> , 2019, 21, 1478-1484.	0.3	2
8795	Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. <i>Lung Cancer</i> , 2019, 137, 71-75.	2.0	11
8796	18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 13362.	3.3	39
8797	Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. <i>European Urology Oncology</i> , 2021, 4, 651-658.	5.4	25
8798	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	7.0	80

#	ARTICLE	IF	CITATIONS
8799	Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. <i>Laboratory Investigation</i> , 2019, 99, 659-670.	3.7	23
8800	Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. <i>Urologia Internationalis</i> , 2019, 102, 390-398.	1.3	1
8801	Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women. <i>BMC Gastroenterology</i> , 2019, 19, 17.	2.0	4
8802	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
8803	Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 701-710.	2.8	18
8804	Evaluation of Simulated Lesions as Surrogates to Clinical Lesions for Thoracic CT Volumetry: The Results of an International Challenge. <i>Academic Radiology</i> , 2019, 26, e161-e173.	2.5	4
8805	Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol. <i>BMC Pediatrics</i> , 2019, 19, 31.	1.7	9
8806	Gemcitabine Plus Cisplatin Split <i>Versus</i> Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function. <i>In Vivo</i> , 2019, 33, 167-172.	1.3	10
8807	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. <i>Bioengineering</i> , 2019, 6, 11.	3.5	2
8808	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019, 125, 1113-1123.	4.1	45
8809	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. <i>Investigational New Drugs</i> , 2019, 37, 524-530.	2.6	3
8810	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 127-134.	1.4	56
8811	Rectal Paraganglioma. <i>Internal Medicine</i> , 2019, 58, 195-199.	0.7	4
8812	68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1054-1062.	6.4	51
8813	Emerging Functional Imaging Biomarkers of Tumour Responses to Radiotherapy. <i>Cancers</i> , 2019, 11, 131.	3.7	12
8814	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e309-e316.	2.6	11
8816	Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy. <i>European Radiology</i> , 2019, 29, 3696-3704.	4.5	1
8817	The Effectiveness and Prognostic Factors of CT-Guided Radioactive I-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer After External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 638-645.	0.8	37

#	ARTICLE	IF	CITATIONS
8818	Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1077-1084.	0.8	202
8819	<i>ZNF671</i> DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer. <i>Cancer Science</i> , 2019, 110, 1105-1116.	3.9	30
8820	Multiparametric MR for noninvasive evaluation of tumour tissue histological characteristics after radionuclide therapy. <i>NMR in Biomedicine</i> , 2019, 32, e4060.	2.8	12
8821	Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance. <i>Neuroendocrinology</i> , 2019, 108, 308-316.	2.5	10
8822	Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. <i>BMC Cancer</i> , 2019, 19, 92.	2.6	33
8823	Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2019, 67, 537-543.	0.9	0
8825	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. <i>Cancers</i> , 2019, 11, 124.	3.7	36
8826	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 112.	2.4	7
8827	Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 27.	1.6	12
8829	Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver metastases: the LIVER-T(W)O-HEAL study. <i>World Journal of Surgical Oncology</i> , 2019, 17, 11.	1.9	28
8830	Chest radiography or chest CT plus head and neck CT versus 18F-FDG PET/CT for detection of distant metastasis and synchronous cancer in patients with head and neck cancer. <i>Oral Oncology</i> , 2019, 88, 109-114.	1.5	25
8831	Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-5.	1.3	17
8832	A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 743-753.	2.3	15
8833	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019, 20, 215-221.	2.6	16
8834	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	2.8	69
8835	Calcium electroporation for recurrent head and neck cancer: A clinical phase I study. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 49-56.	1.5	39
8836	Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. <i>European Radiology</i> , 2019, 29, 3871-3880.	4.5	11
8837	Immunotherapy for genitourinary tumors. <i>International Journal of Urology</i> , 2019, 26, 326-333.	1.0	8

#	ARTICLE	IF	CITATIONS
8838	Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGS 1202. <i>Anticancer Research</i> , 2019, 39, 1059-1065.	1.1	8
8839	The long-term prognostic difference between gastrectomy with and without preoperative chemotherapy in patients with clinical stage IV gastric cancer. <i>Asian Journal of Surgery</i> , 2019, 42, 922-929.	0.4	4
8840	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	14.3	93
8841	Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility?. <i>Oral Oncology</i> , 2019, 90, 13-16.	1.5	2
8842	Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 379-386.	6.4	16
8843	Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882544.	1.3	17
8844	The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial. <i>Anticancer Research</i> , 2019, 39, 853-861.	1.1	10
8845	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. <i>Cancers</i> , 2019, 11, 93.	3.7	22
8846	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	10.7	1,202
8847	Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. <i>Radiotherapy and Oncology</i> , 2019, 132, 42-47.	0.6	44
8848	Novel patterns of response under immunotherapy. <i>Annals of Oncology</i> , 2019, 30, 385-396.	1.2	343
8849	Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 13.	4.4	13
8850	A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer. <i>In Vivo</i> , 2019, 33, 933-937.	1.3	15
8851	Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. <i>Frontiers in Veterinary Science</i> , 2019, 6, 106.	2.2	28
8852	Experience with Sorafenib in 3 Hospitals in Sao Paulo. <i>Annals of Hepatology</i> , 2019, 18, 172-176.	1.5	0
8853	Developing a Quantitative Ultrasound Image Feature Analysis Scheme to Assess Tumor Treatment Efficacy Using a Mouse Model. <i>Scientific Reports</i> , 2019, 9, 7293.	3.3	9
8854	Cisplatin and Sâ€¢1 for urachal carcinoma: A singleâ€¢institution case series. <i>IJU Case Reports</i> , 2019, 2, 150-154.	0.3	1
8855	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , 2019, 12, 968-972.	3.7	15

#	ARTICLE	IF	CITATIONS
8856	<p>HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 283-300.	1.9	5
8857	<p>Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis</p>. Cancer Management and Research, 2019, Volume 11, 4255-4272.	1.9	11
8858	<p>Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience</p>. OncoTargets and Therapy, 2019, Volume 12, 3077-3085.	2.0	14
8859	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. European Journal of Cancer, 2019, 115, 97-106.	2.8	29
8860	Bayesian uncertaintyâ€directed dose finding designs. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 1393-1410.	1.0	1
8861	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research, 2019, 25, 4624-4633.	7.0	21
8862	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology, 2019, 5, 1-19.	0.5	34
8863	Clinical and Pre-clinical Methods for Quantifying Tumor Hypoxia. Advances in Experimental Medicine and Biology, 2019, 1136, 19-41.	1.6	26
8864	A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Investigational New Drugs, 2019, 37, 755-762.	2.6	18
8865	Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. Cancers, 2019, 11, 826.	3.7	9
8866	Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma. Auris Nasus Larynx, 2019, 46, 882-888.	1.2	6
8867	Predictive factors associated with involved margins in breast cancer treated with neoadjuvant chemotherapy followed by breast-conserving therapy. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, 467-472.	1.3	3
8868	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. Radiation Oncology, 2019, 14, 106.	2.7	22
8869	68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. Cancer Imaging, 2019, 19, 37.	2.8	28
8870	Immune Checkpoint Inhibitor Outcomes for Patients With Nonâ€Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology, 2019, 37, 1927-1934.	1.6	220
8871	The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. Annals of Nuclear Medicine, 2019, 33, 681-688.	2.2	24
8872	Chromosome 12p Amplification in Triple-Negative/<i>BRCA1-</i>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.9	17
8873	Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC) Tj ETQq1 1 0.784314 rgBT /Overlook Medical Oncology, 2019, 11, 175883591984640.	3.2	67

#	ARTICLE	IF	CITATIONS
8874	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984887.	3.2	30
8875	EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer, 2019, 19, 595.	2.6	93
8876	Communicating with the hepatobiliary surgeon through structured report. BJR Open, 2019, 1, 20190012.	0.6	1
8877	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. Journal of Cancer, 2019, 10, 1985-1990.	2.5	11
8878	Mechanisms of immunogenicity in colorectal cancer. British Journal of Surgery, 2019, 106, 1283-1297.	0.3	32
8879	Role of surgical resection in the era of <sc>FOLFIRINOX</sc> for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 416-425.	2.6	33
8880	Use of Precision Imaging in the Evaluation of Pancreas Cancer. Cancer Treatment and Research, 2019, 178, 209-236.	0.5	10
8882	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. British Journal of Cancer, 2019, 121, 131-138.	6.4	16
8883	Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation â€” a retrospective study. Transplant International, 2019, 32, 1144-1150.	1.6	23
8884	CD8⁺ PD-1⁺ T-cells and PD-L1⁺ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	3.2	13
8885	Non-mono-exponential diffusion models for assessing early response of liver metastases to chemotherapy in colorectal Cancer. Cancer Imaging, 2019, 19, 39.	2.8	13
8886	Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. International Journal of Clinical Oncology, 2019, 24, 1089-1098.	2.2	20
8887	Prognostic value of ADC measurements in predicting overall survival in patients undergoing 90Y radioembolization for colorectal cancer liver metastases. Clinical Imaging, 2019, 57, 124-130.	1.5	7
8888	The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer. Future Oncology, 2019, 15, 2561-2569.	2.4	8
8889	Medical Science and Research. Advances in Experimental Medicine and Biology, 2019, , .	1.6	2
8890	Change in Skeletal Muscle Following Resection of Stage Iâ€”III Colorectal Cancer is Predictive of Poor Survival: A Cohort Study. World Journal of Surgery, 2019, 43, 2518-2526.	1.6	20
8891	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 2019, 154, 531-538.	1.4	49
8892	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical Cancer Research, 2019, 25, 5295-5300.	7.0	70

#	ARTICLE	IF	CITATIONS
8893	Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 393-404.	2.3	14
8894	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 167-173.	2.0	9
8895	Comparing the diagnostic value of 18F-FDG-PET/CT versus CT for differentiating benign and malignant solitary pulmonary nodules: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2019, 11, 2082-2098.	1.4	17
8896	Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2019, 48, 461-466.	1.3	4
8897	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , 2019, 25, 5808-5817.	7.0	66
8898	Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 635-646.	2.3	32
8899	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	1.9	67
8900	Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. <i>ESMO Open</i> , 2019, 4, e000488.	4.5	39
8901	Circulating tumor cell-related transcripts in blood as prognostic biomarkers of early recurrence after liver resection for colorectal metastases. <i>International Journal of Biological Markers</i> , 2019, 34, 269-275.	1.8	1
8902	Radiologic Modalities and Response Assessment Schemes for Clinical and Preclinical Oncology Imaging. <i>Frontiers in Oncology</i> , 2019, 9, 471.	2.8	6
8903	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	2.4	27
8904	RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 211-217.	6.4	29
8905	Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 947-955.	1.3	2
8906	Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). <i>Hepatology Research</i> , 2019, 49, 981-989.	3.4	27
8907	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	7.1	50
8908	Treatment of community-onset pneumonia in neutropenic cancer patients: β -lactam monotherapy versus combination antibiotic regimens. <i>Pneumonia (Nathan Qld)</i> , 2019, 11, 2.	6.1	0
8909	The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?. <i>Clinical Oncology</i> , 2019, 31, 824-833.	1.4	66
8910	Functional systemic CD^+ 4 immunity is required for clinical responses to PD^+ L1^+ blockade therapy. <i>EMBO Molecular Medicine</i> , 2019, 11, e10293.	6.9	145

#	ARTICLE	IF	CITATIONS
8911	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1931-1939.	6.4	53
8912	Intra-individual consistency of spectral detector CT-enabled iodine quantification of the vascular and renal blood pool. <i>European Radiology</i> , 2019, 29, 6581-6590.	4.5	15
8913	Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>BioDrugs</i> , 2019, 33, 357-371.	4.6	23
8914	Recent perspective on CAR and FcÎ³-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. <i>Biochemical Pharmacology</i> , 2019, 166, 335-346.	4.4	20
8915	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 291-298.	1.9	30
8916	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	3.7	180
8917	Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 5376-5387.	7.0	145
8918	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	7.1	353
8919	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancerâ€”A Phase 1 Study. <i>JAMA Oncology</i> , 2019, 5, 1332.	7.1	153
8920	Effects of epidural analgesia on cancer recurrence and long-term mortality in patients after non-small-cell lung cancer resection: a propensity score-matched study. <i>BMJ Open</i> , 2019, 9, e027618.	1.9	19
8921	Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 1536-1545.	1.4	20
8922	Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 3089-3094.	1.1	5
8923	Potential of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. <i>International Journal of Oncology</i> , 2019, 54, 2149-2156.	3.3	8
8924	A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 31-49.	0.1	1
8925	Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLCâ€”A retrospective cohort study. <i>Lung Cancer</i> , 2019, 134, 59-65.	2.0	31
8926	Imaging in Lung Cancer. <i>Current Radiology Reports</i> , 2019, 7, 1.	1.4	0
8927	Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study. <i>Current Problems in Cancer</i> , 2019, 43, 495-503.	2.0	3
8928	Altered expression of TIMâ€³, LAGâ€³, IDO, PDâ€¹1, and CTLAâ€²4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 669-676.	2.7	29

#	ARTICLE	IF	CITATIONS
8929	2018 FIGO Staging System for Uterine Cervical Cancer: Enter Cross-sectional Imaging. <i>Radiology</i> , 2019, 292, 15-24.	7.3	96
8930	The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. <i>PLoS ONE</i> , 2019, 14, e0216781.	2.5	14
8931	Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2019, 17, 5292-5300.	1.8	18
8932	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , 2019, 25, 4945-4954.	7.0	82
8933	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5212-5220.	7.0	60
8934	Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2019, 5, 999.	7.1	47
8935	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions—Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 3719-3728.	2.8	131
8936	Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. <i>Advances in Therapy</i> , 2019, 36, 2122-2136.	2.9	111
8937	Can We Omit Radiation Therapy in the Treatment of Brain Metastases from Melanoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 473-477.	0.8	3
8938	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. <i>Cancer</i> , 2019, 125, 3184-3197.	4.1	73
8939	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , 2019, 20, 948-960.	10.7	346
8940	<i>In silico</i> simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. <i>Royal Society Open Science</i> , 2019, 6, 190366.	2.4	54
8941	Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 1561-1566.	1.9	0
8942	The Value of Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in the Evaluation of the Osteosarcoma Response to Preoperative Neoadjuvant Chemotherapy in Teens. <i>Concepts in Magnetic Resonance Part A: Bridging Education and Research</i> , 2019, 2019, 1-8.	0.5	2
8943	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. <i>BMC Cancer</i> , 2019, 19, 517.	2.6	42
8944	Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study. <i>Cancer Imaging</i> , 2019, 19, 27.	2.8	10
8945	Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. <i>Oncologist</i> , 2019, 24, e687-e695.	3.7	19
8946	Utility of Multi-Parametric Quantitative Magnetic Resonance Imaging for Characterization and Radiotherapy Response Assessment in Soft-Tissue Sarcomas and Correlation With Histopathology. <i>Frontiers in Oncology</i> , 2019, 9, 280.	2.8	24

#	ARTICLE	IF	CITATIONS
8947	Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma. <i>Cancers</i> , 2019, 11, 482.	3.7	13
8948	Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 α -type voltage-gated calcium channels and Ca ²⁺ influx. <i>EBioMedicine</i> , 2019, 44, 209-224.	6.1	31
8949	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	3.7	20
8950	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	7.0	26
8951	From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 741.	3.7	17
8953	Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results. <i>Surgical Oncology</i> , 2019, 30, 52-57.	1.6	31
8954	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	27.0	1,521
8955	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	27.0	982
8956	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	1.6	811
8957	Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. <i>Cancer</i> , 2019, 125, 3234-3241.	4.1	73
8958	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1897-1905.	2.5	4
8959	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 961-971.	10.7	126
8960	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. <i>Scientific Reports</i> , 2019, 9, 7754.	3.3	10
8961	The stability of imaging biomarkers in radiomics: a framework for evaluation. <i>Physics in Medicine and Biology</i> , 2019, 64, 165012.	3.0	8
8962	Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. <i>International Journal of Urology</i> , 2019, 26, 820-826.	1.0	0
8963	Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. <i>Cancer Imaging</i> , 2019, 19, 31.	2.8	39
8964	Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	25
8966	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1197-1203.	2.2	5

#	ARTICLE	IF	CITATIONS
8967	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	27.0	656
8968	Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage. <i>Journal of Oncology</i> , 2019, 2019, 1-9.	1.3	9
8969	Quantitative temporal diffusion spectroscopy as an early imaging biomarker of radiation therapeutic response in gliomas: A preclinical proof of concept. <i>Advances in Radiation Oncology</i> , 2019, 4, 367-376.	1.2	14
8970	Circular collimator arc versus dynamic conformal arc treatment planning for linac-based stereotactic radiosurgery of an intracranial small single lesion: a perspective of lesion asymmetry. <i>Radiation Oncology</i> , 2019, 14, 91.	2.7	1
8971	Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2071-2082.	2.5	27
8972	Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 331-342.	3.3	13
8973	Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 109, 333-345.	2.5	52
8974	A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 437.	2.8	23
8975	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	4.1	96
8976	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	1.1	78
8977	Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study. <i>Journal of Medical Economics</i> , 2019, 22, 924-935.	2.1	6
8978	Experiences with Prescribing Large Quantities of Systemic Anticancer Therapy Near Death. <i>Journal of Palliative Medicine</i> , 2019, 22, 1515-1521.	1.1	4
8979	A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 413.	2.8	22
8980	Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1187-1194.	4.2	40
8981	Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 68.	2.5	8
8982	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 cEGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2235-2245.	1.6	193
8983	Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	26
8984	Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients. <i>Cancers</i> , 2019, 11, 803.	3.7	7

#	ARTICLE	IF	CITATIONS
8985	Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1141.	7.1	355
8986	Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. <i>European Journal of Cancer</i> , 2019, 116, 114-115.	2.8	17
8987	A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. <i>International Journal of Radiation Biology</i> , 2019, 95, 1287-1294.	1.8	4
8988	Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models. <i>Cancer Science</i> , 2019, 110, 1921-1930.	3.9	12
8989	A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. <i>BMC Cancer</i> , 2019, 19, 568.	2.6	19
8990	Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. <i>BMC Cancer</i> , 2019, 19, 574.	2.6	12
8991	Prognostic Value of Quality of Life in Endocrine Therapy for Elderly Patients With Breast Cancer: A Retrospective Study. <i>Anticancer Research</i> , 2019, 39, 2941-2950.	1.1	3
8992	Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. <i>BMC Cancer</i> , 2019, 19, 573.	2.6	4
8993	Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung. <i>Lung Cancer</i> , 2019, 135, 116-122.	2.0	10
8994	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. <i>Lung Cancer</i> , 2019, 133, 103-109.	2.0	29
8995	Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. <i>Respiratory Investigation</i> , 2019, 57, 466-471.	1.8	31
8996	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2019, 25, 5049-5060.	7.0	66
8997	Peripheral Inflammation Markers of Chemosensitivity to Induction Chemotherapy in Hypopharyngeal Cancer Patients. <i>Orl</i> , 2019, 81, 82-91.	1.1	10
8998	Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2019, 90, 37-44.	2.0	7
8999	Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 856-861.	1.3	16
9000	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. <i>Cancer Research</i> , 2019, 79, 3776-3788.	0.9	32
9001	New frontiers in the medical management of gastrointestinal stromal tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984194.	3.2	33
9002	Clinical significance of preoperative chemoradiotherapy for advanced esophageal cancer, evaluated by propensity score matching and weighting of inverse probability of treatment. <i>Molecular and Clinical Oncology</i> , 2019, 10, 575-582.	1.0	2

#	ARTICLE	IF	CITATIONS
9003	Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 993.	7.1	209
9004	A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. <i>Scientific Reports</i> , 2019, 9, 7625.	3.3	16
9005	Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. <i>Annals of Oncology</i> , 2019, 30, 1381-1392.	1.2	120
9006	Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 845-855.	1.3	23
9007	Quantitative Multiparametric MRI May Augment the Response to Radiotherapy in Mid-Treatment Assessment of Patients with Esophageal Carcinoma. <i>Oncology Research and Treatment</i> , 2019, 42, 326-333.	1.2	5
9008	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. , 2019, 7, 121.		71
9009	PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?. <i>American Journal of Roentgenology</i> , 2019, 213, 254-265.	2.2	78
9010	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion. <i>JAMA Oncology</i> , 2019, 5, 953.	7.1	292
9011	Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 307-313.	2.3	9
9012	Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 597-605.	2.5	7
9013	Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 495-506.	2.5	7
9014	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019, 120, 1026-1032.	6.4	33
9015	Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2019, 12, 40.	3.0	45
9016	Survival and clinical prognostic factors in metastatic nonâ€clear cell renal cell carcinoma treated with targeted therapy: A multiâ€institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. <i>Cancer Medicine</i> , 2019, 8, 3401-3410.	2.8	13
9017	Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 114, 67-75.	2.8	88
9018	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 339-348.	28.4	35
9019	Treatment outcomes of stereotactic ablative radiation therapy for non-spinal bone metastases: focus on response assessment and treatment indication. <i>British Journal of Radiology</i> , 2019, 92, 20181048.	2.2	14
9020	Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, 1117-1123.	1.4	46

#	ARTICLE	IF	CITATIONS
9021	Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. <i>Radiologia Medica</i> , 2019, 124, 870-876.	7.7	12
9022	Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy. <i>Anticancer Research</i> , 2019, 39, 2501-2508.	1.1	7
9023	Developing Picornaviruses for Cancer Therapy. <i>Cancers</i> , 2019, 11, 685.	3.7	35
9024	Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. <i>Oncology Letters</i> , 2019, 17, 4768-4778.	1.8	16
9025	Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. <i>Medical Oncology</i> , 2019, 36, 59.	2.5	24
9026	Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. <i>Surgical Oncology</i> , 2019, 29, 84-89.	1.6	10
9027	One-lung ventilation to treat hepatic dome lesion “a further step towards minimally invasive surgery: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 83.	0.8	6
9028	Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. <i>PLoS ONE</i> , 2019, 14, e0216954.	2.5	92
9029	Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials. <i>BMC Medical Research Methodology</i> , 2019, 19, 90.	3.1	2
9030	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , 2019, 19, 415.	2.6	49
9031	Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2401-2408.	1.5	6
9032	Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. <i>Cancers</i> , 2019, 11, 608.	3.7	5
9033	Paclitaxel and Alisertib in Recurrent Ovarian Cancer—In Reply. <i>JAMA Oncology</i> , 2019, 5, 910.	7.1	1
9034	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 862-876.	10.7	68
9035	Loss of 1p36.33 Frequent in Low-Grade Serosus Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590.	5.3	24
9036	Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 9, 28-34.	2.9	1
9037	Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	1.3	19
9038	Data-driven identification of tumor subregions based on intravoxel incoherent motion reveals association with proliferative activity. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 1480-1490.	3.0	5

#	ARTICLE	IF	CITATIONS
9039	Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma. American Journal of Ophthalmology, 2019, 207, 62-70.	3.3	29
9040	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	2.8	42
9041	Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol ³ gica, 2019, 58, 953-961.	1.8	35
9042	Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma. Radiology, 2019, 292, 103-109.	7.3	10
9043	RECIST Needs Revision: A Wake-up Call for Radiologists. Radiology, 2019, 292, 110-111.	7.3	9
9044	Peripheral memory and na ⁺ ve T cells in non-small cell lung cancer patients with lung metastases undergoing stereotactic body radiotherapy: predictors of early tumor response. Cancer Cell International, 2019, 19, 121.	4.1	17
9045	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer, 2019, 134, 42-45.	2.0	37
9046	18F-PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography. Nuklearmedizin - NuclearMedicine, 2019, , .	0.7	3
9047	Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. Cancer Medicine, 2019, 8, 3437-3446.	2.8	12
9048	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. British Journal of Cancer, 2019, 120, 1105-1112.	6.4	22
9049	Modified core-shell magnetic mesoporous zirconia nanoparticles formed through a facile outside-to-inside way for CT/MRI dual-modal imaging and magnetic targeting cancer chemotherapy. RSC Advances, 2019, 9, 13220-13233.	3.6	15
9050	The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?. Liver International, 2019, 39, 1307-1314.	3.9	20
9051	First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 5458-5465.	7.0	47
9052	Clinicopathologic Characteristics and Treatment Outcomes of Patients With Up-Front Metastatic Breast Cancer: Single-Center Experience in India. Journal of Global Oncology, 2019, 5, 1-9.	0.5	4
9053	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS ONE, 2019, 14, e0215970.	2.5	3
9054	Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia: 6 years of follow-up. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 519-526.	0.9	7
9055	EVALUATING MMP-2 AND TGF β -RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2019, 32, e1433.	0.5	9
9056	ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology, 2019, 15, 2211-2225.	2.4	16

#	ARTICLE	IF	CITATIONS
9057	Oligometastases in prostate cancer: Ablative treatment. <i>World Journal of Clinical Oncology</i> , 2019, 10, 38-51.	2.3	27
9058	A meta-analysis of clinical benefit rates for fulvestrant 500Âmg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. <i>Breast Cancer</i> , 2019, 26, 703-711.	2.9	5
9059	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	1.1	99
9060	Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. <i>Radiotherapy and Oncology</i> , 2019, 137, 83-94.	0.6	44
9061	Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. <i>Future Oncology</i> , 2019, 15, 1791-1804.	2.4	8
9062	Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. <i>Toxics</i> , 2019, 7, 27.	3.7	7
9063	Modelling bistable tumour population dynamics to design effective treatment strategies. <i>Journal of Theoretical Biology</i> , 2019, 474, 88-102.	1.7	19
9064	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	30.7	589
9065	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	6.3	90
9066	Randomized study of individualized pharmacokineticallyâ€guided dosing of paclitaxel compared with bodyâ€surface area dosing in Chinese patients with advanced nonâ€small cell lung cancer. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2292-2301.	2.4	26
9067	Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol. <i>BMJ Open</i> , 2019, 9, e026732.	1.9	7
9068	Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 768-771.	2.5	16
9069	Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1064-1071.	2.5	2
9070	Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381984258.	1.9	6
9071	Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Deathâ€Dependent Changes in Glycolysis. <i>Cancer Research</i> , 2019, 79, 3557-3569.	0.9	36
9072	Skeletal muscle mass loss and doseâ€limiting toxicities in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 803-813.	7.3	65
9073	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1153-1163.	5.3	19
9074	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	2.6	26

#	ARTICLE	IF	CITATIONS
9075	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 2483-2491.	1.1	3
9076	Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e190103.	5.9	18
9077	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. <i>JAMA Network Open</i> , 2019, 2, e193981.	5.9	7
9078	<p>Weekly alternate intensive regimen FlrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2159-2170.	2.0	8
9079	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. <i>Theranostics</i> , 2019, 9, 2812-2826.	10.0	20
9080	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e772-e778.	1.9	15
9081	Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. <i>Digestive and Liver Disease</i> , 2019, 51, 1130-1134.	0.9	9
9082	Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. <i>Hpb</i> , 2019, 21, 1385-1392.	0.3	16
9083	Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 3266-3275.	7.0	364
9084	Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer. <i>Endocrine Journal</i> , 2019, 66, 597-604.	1.6	18
9085	Serial Texture Analyses on ADC Maps for Evaluation of Antiangiogenic Therapy in Rat Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 1875-1882.	1.1	1
9086	Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. <i>Gynecologic Oncology Reports</i> , 2019, 28, 120-123.	0.6	23
9087	Evaluation of the response of breast cancer patients to neoadjuvant chemotherapy by combined contrast-enhanced ultrasonography and ultrasound elastography. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 3655-3663.	1.8	15
9088	Application of computed tomography-based radiomics signature analysis in the prediction of the response of small cell lung cancer patients to first-line chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 3621-3629.	1.8	19
9089	Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 4701-4709.	1.8	6
9090	A whole-body FDG PET/MR atlas for multiparametric voxel-based analysis. <i>Scientific Reports</i> , 2019, 9, 6158.	3.3	6
9091	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
9092	Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy. <i>Abdominal Radiology</i> , 2019, 44, 3664-3673.	2.1	17

#	ARTICLE	IF	CITATIONS
9093	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	7.1	335
9094	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	3.4	23
9095	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1380-1390.	1.6	178
9096	Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1035-1042.	0.5	51
9097	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. <i>Nature Medicine</i> , 2019, 25, 744-750.	30.7	443
9098	Intra- and interobserver reproducibility of pancreatic perfusion by computed tomography. <i>Scientific Reports</i> , 2019, 9, 6043.	3.3	2
9099	Intrahepatic Oxaliplatin and Systemic 5-FU +/â€“ Cetuximab in Chemo-NaÃ“ve Patients with Liver Metastases from Colorectal Cancer. <i>Oncology</i> , 2019, 96, 299-308.	1.9	2
9100	<p>Long-term response of metastatic renal clear cell carcinoma following a subcutaneous injection of mixed bacterial vaccine: a case report</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2531-2538.	2.0	4
9101	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. <i>Annals of Oncology</i> , 2019, 30, 970-976.	1.2	329
9102	Impact of AferBioÂ® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial. <i>BMC Cancer</i> , 2019, 19, 382.	2.6	1
9103	Relationship of circulating tumor cells and Epsteinâ€“Barr virus DNA to progressionâ€“free survival and overall survival in metastatic nasopharyngeal carcinoma patients. <i>International Journal of Cancer</i> , 2019, 145, 2873-2883.	5.1	38
9104	Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors. <i>Endocrine</i> , 2019, 65, 460-467.	2.3	7
9105	Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2019, 136, 37-43.	0.6	34
9106	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. <i>BMC Cancer</i> , 2019, 19, 413.	2.6	57
9107	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	5.9	8
9108	Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 325-333.	2.5	13
9109	3â€“Deoxy-3â€“TM-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1713-1722.	6.4	8
9110	Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019, 9, 35-43.	7.1	49

#	ARTICLE	IF	CITATIONS
9111	Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, 278-286.e1.	2.6	10
9112	Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy. <i>In Vivo</i> , 2019, 33, 889-895.	1.3	8
9113	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. <i>Clinical Cancer Research</i> , 2019, 25, 5743-5751.	7.0	129
9114	Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. <i>Cancer Biomarkers</i> , 2019, 25, 213-221.	1.7	12
9115	Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 522-530.	3.9	15
9116	Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). <i>BMC Cancer</i> , 2019, 19, 341.	2.6	12
9117	Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias. <i>Molecular and Clinical Oncology</i> , 2019, 10, 541-546.	1.0	9
9118	Neoadjuvant chemotherapy in patients with advanced endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 281-285.	2.3	32
9119	Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. <i>PLoS ONE</i> , 2019, 14, e0215135.	2.5	6
9120	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 810-820.	4.7	27
9121	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 201-208.e1.	1.9	29
9122	Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 199.	2.8	9
9123	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1631.	4.1	59
9124	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1692.	4.1	61
9125	Segmentation of Gliomas and Prediction of Patient Overall Survival: A Simple and Fast Procedure. <i>Lecture Notes in Computer Science</i> , 2019, , 199-209.	1.3	15
9126	Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. <i>European Journal of Cancer</i> , 2019, 113, 78-86.	2.8	98
9127	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 975-981.	6.4	61
9128	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 298.	2.6	24

#	ARTICLE	IF	CITATIONS
9129	Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. , 2019, 7, 102.		87
9130	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology, 2019, 37, 1424-1431.	1.6	172
9131	Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	31
9132	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 2019, 19, 390.	2.6	83
9133	Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics. Cancer Chemotherapy and Pharmacology, 2019, 84, 51-60.	2.3	16
9134	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 806-815.	10.7	154
9135	Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983896.	3.2	10
9136	Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Cancer Genomics and Proteomics, 2019, 16, 207-219.	2.0	13
9137	DNA damage in blood leucocytes of prostate cancer patients during therapy with ¹⁷⁷ Lu-PSMA. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1723-1732.	6.4	13
9138	Application of time-dependent modeling for the exposureâ€“efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 501-511.	2.3	5
9139	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs, 2019, 37, 738-747.	2.6	12
9140	Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. Scientific Reports, 2019, 9, 4721.	3.3	16
9141	Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open, 2019, 4, e000439.	4.5	16
9142	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	9.2	418
9143	Prediction of Treatment Outcome of Chemotherapy Using Perfusion Computed Tomography in Patients with Unresectable Advanced Gastric Cancer. Korean Journal of Radiology, 2019, 20, 589.	3.4	4
9144	Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. Journal of Clinical Medicine, 2019, 8, 380.	2.4	25
9145	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. British Journal of Surgery, 2019, 106, 519-522.	0.3	35
9146	Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Advances in Experimental Medicine and Biology, 2019, 1153, 31-45.	1.6	7

#	ARTICLE	IF	CITATIONS
9147	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349.	2.5	19
9148	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
9149	The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 2200-2209.	1.5	19
9150	Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial. <i>PLoS ONE</i> , 2019, 14, e0213892.	2.5	6
9151	Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer â€” study protocol for a randomized control trial. <i>Pleura and Peritoneum</i> , 2019, 4, 20180111.	1.2	6
9152	Study of diffusionâ€”weighted magnetic resonance imaging in the evaluation of the response to AAV2â€”EGFâ€”Trap neoadjuvant treatment in a tripleâ€”negative breast cancer animal model. <i>Cancer Medicine</i> , 2019, 8, 1594-1603.	2.8	7
9153	Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1037-1046.	2.3	10
9154	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 1464-1471.	2.4	1
9155	Firstâ€”line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced nonâ€”squamous nonâ€”small cell lung cancer with wildâ€”type driver genes: A realâ€”world study in China. <i>Thoracic Cancer</i> , 2019, 10, 1043-1050.	1.9	2
9156	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1095-1101.	1.1	159
9157	Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. <i>Oncology Letters</i> , 2019, 17, 3890-3898.	1.8	13
9158	Predictive and prognostic value of phosphorylated câ€”KIT and PDGFRA in advanced nonâ€”small cell lung cancer harboring ALK fusion. <i>Oncology Letters</i> , 2019, 17, 3071-3076.	1.8	8
9159	Incidentalomas in Spine and Spinal Cord Imaging. <i>Clinical Neuroradiology</i> , 2019, 29, 191-213.	1.9	11
9160	Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Targeted Oncology</i> , 2019, 14, 187-195.	3.6	5
9161	Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. <i>Targeted Oncology</i> , 2019, 14, 169-178.	3.6	17
9162	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 35.	2.5	4
9163	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019, 112, 12-19.	2.8	8
9164	Spatial resolution of CT. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1748.	1.0	2

#	ARTICLE	IF	CITATIONS
9165	Nuclear protein of the testis midline carcinoma in the oral cavity: retrospective review of those initially diagnosed as poorly differentiated squamous cell carcinoma using an anti-C52B1 antibody. International Journal of Oral and Maxillofacial Surgery, 2019, 48, 1265-1272.	1.5	4
9166	Salvage Carbon-Ion Radiation Therapy For Locoregionally Recurrent Head and Neck Malignancies. Scientific Reports, 2019, 9, 4259.	3.3	24
9167	Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China. Scientific Reports, 2019, 9, 4816.	3.3	19
9168	A Progressively-Trained Scale-Invariant and Boundary-Aware Deep Neural Network for the Automatic 3D Segmentation of Lung Lesions. , 2019, , .		5
9169	Deep Learning for Automated Segmentation of Liver Lesions at CT in Patients with Colorectal Cancer Liver Metastases. Radiology: Artificial Intelligence, 2019, 1, 180014.	5.8	74
9170	<p></p>Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study</p>. Cancer Management and Research, 2019, Volume 11, 2007-2013.	1.9	8
9171	Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as firstâ€line therapy for metastatic colorectal cancer: GERCOR VELVET phaseï¼ll study. International Journal of Oncology, 2019, 54, 1433-1445.	3.3	7
9172	Radiotherapy is an independent prognostic marker of favorable prognosis in nonâ€small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thoracic Cancer, 2019, 10, 992-1000.	1.9	44
9173	Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology, 2019, 96, 252-258.	1.9	4
9175	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	3.7	131
9176	Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. Journal of Gynecologic Oncology, 2019, 30, e32.	2.2	44
9177	Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptorâ€positive, human epidermal growth factor receptor 2â€negative breast cancer (CBCSGâ€036): A randomized, controlled, multicenter trial. Cancer, 2019, 125, 2185-2193.	4.1	17
9178	<sc>KEYNOTE</sc>â€025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1â€positive advanced nonâ€smallâ€cell lung cancer. Cancer Science, 2019, 110, 1012-1020.	3.9	40
9179	Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1336-1344.	3.6	95
9180	Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. Cancers, 2019, 11, 267.	3.7	24
9181	Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer. Molecular Biology Reports, 2019, 46, 2809-2818.	2.3	20
9182	Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC). Journal of Medical Economics, 2019, 22, 625-637.	2.1	21
9183	Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. Breast Journal, 2019, 25, 237-242.	1.0	1

#	ARTICLE	IF	CITATIONS
9184	Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. <i>Oncology Research and Treatment</i> , 2019, 42, 182-189.	1.2	22
9185	Prognostic Values of Systemic Inflammation Response (SIR) Parameters in Resectable Cervical Cancer. <i>Dose-Response</i> , 2019, 17, 155932581982954.	1.6	10
9186	Large incidental gastrointestinal stromal tumors in a patient presenting with acutely symptomatic nephrolithiasis: A case report. <i>Radiology Case Reports</i> , 2019, 14, 555-560.	0.6	2
9187	Expected and Unexpected Imaging Findings after ⁹⁰Y Transarterial Radioembolization for Liver Tumors. <i>Radiographics</i> , 2019, 39, 578-595.	3.3	39
9188	GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy. <i>Oncology Letters</i> , 2019, 17, 2897-2904.	1.8	7
9189	Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. <i>Oncolmunology</i> , 2019, 8, e1580128.	4.6	35
9190	First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 151-157.	1.1	2
9191	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). <i>Annals of Surgical Oncology</i> , 2019, 26, 1332-1339.	1.5	12
9192	Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. <i>Investigational New Drugs</i> , 2019, 37, 538-547.	2.6	12
9193	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	10.7	362
9194	The potential of breath analysis to improve outcome for patients with lung cancer. <i>Journal of Breath Research</i> , 2019, 13, 034002.	3.0	31
9195	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 458-464.	1.3	17
9196	Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341982907.	1.1	39
9197	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
9198	MicroRNA in Lung Cancer Metastasis. <i>Cancers</i> , 2019, 11, 265.	3.7	55
9199	Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. <i>Theranostics</i> , 2019, 9, 1417-1425.	10.0	58
9200	Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment. <i>World Journal of Urology</i> , 2019, 37, 2585-2595.	2.2	8
9201	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 33.	2.5	66

#	ARTICLE	IF	CITATIONS
9202	Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-11.	7.7	26
9203	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. <i>Thoracic Cancer</i> , 2019, 10, 880-889.	1.9	14
9204	Eligibility criteria for phase I clinical trials: tight vs loose?. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 999-1002.	2.3	11
9205	Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer. <i>Surgery Today</i> , 2019, 49, 678-685.	1.5	0
9206	Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases. <i>Clinical Lung Cancer</i> , 2019, 20, e274-e283.	2.6	15
9207	Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3486-3494.	7.0	56
9208	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. <i>Cancers</i> , 2019, 11, 278.	3.7	31
9209	Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-BI) among advanced urothelial cancer patients. <i>Supportive Care in Cancer</i> , 2019, 27, 4189-4198.	2.2	26
9210	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	16.8	353
9211	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27
9212	Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017. <i>Lung Cancer</i> , 2019, 131, 122-127.	2.0	22
9213	The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report. <i>Acta Oncologica</i> , 2019, 58, 897-900.	1.8	2
9214	Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 614-619.	1.3	6
9215	Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 153-157.	2.5	1
9216	Isolated adrenocorticotrophic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2019, 13, 88.	0.8	28
9217	Long-term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	1.5	35
9218	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	2.5	7
9219	Very long-term survivors among patients with metastatic soft tissue sarcoma. <i>Cancer Medicine</i> , 2019, 8, 1368-1378.	2.8	16

#	ARTICLE	IF	CITATIONS
9220	Imaging in Pediatric Oncology: New Advances and Techniques. <i>Pediatric Oncology</i> , 2019, , 1-7.	0.5	0
9221	PET/CT in Pediatric Oncology. <i>Pediatric Oncology</i> , 2019, , 29-61.	0.5	3
9223	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1613-1623.	2.5	66
9224	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. <i>European Journal of Cancer</i> , 2019, 112, 57-65.	2.8	56
9225	Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging. <i>Scientific Reports</i> , 2019, 9, 4907.	3.3	30
9226	Circulating CD137 ⁺ CD8 ⁺ T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12765.	2.7	7
9228	Introduction to Multivariate Survival Analysis. <i>SpringerBriefs in Statistics</i> , 2019, , 9-37.	0.4	0
9229	Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet. <i>Bioscience Reports</i> , 2019, 39, .	2.4	2
9230	Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1437-1457.	2.4	16
9231	¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1579-1586.	5.0	34
9232	Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis. <i>Korean Journal of Radiology</i> , 2019, 20, 449.	3.4	8
9233	Multimodality Imaging Assessment of Malignant Pleural Mesothelioma. , 2019, , 19-34.		0
9234	Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 169-176.e1.	1.9	2
9235	Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer. <i>Pathology Research and Practice</i> , 2019, 215, 152369.	2.3	2
9236	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	4.4	103
9237	Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 1391-1396.	1.1	38
9238	Reproducibility and Comparability of Preclinical PET Imaging Data: A Multicenter Small-Animal PET Study. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1483-1491.	5.0	20
9239	Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer. <i>Translational Oncology</i> , 2019, 12, 699-704.	3.7	17

#	ARTICLE	IF	CITATIONS
9240	Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1259-1265.	5.0	27
9241	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. <i>Anticancer Research</i> , 2019, 39, 1309-1316.	1.1	8
9242	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93.	2.2	38
9243	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1008-1015.	2.3	12
9244	Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1573-1577.	2.4	11
9245	The clinical significance of indeterminate pulmonary nodules in melanoma patients at baseline and during follow-up chest CT. <i>European Journal of Radiology Open</i> , 2019, 6, 85-90.	1.6	9
9246	Trimodality therapy for superior sulcus tumour: experience of a single institution over 19 years. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 167-173.	1.4	4
9247	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. , 2019, 7, 23.		20
9248	Randomized Phase 2 Study of Trebananib (AMC 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib â€” Results of NCI/CTEP Protocol 9048. <i>Kidney Cancer</i> , 2019, 3, 51-61.	0.4	8
9249	Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. <i>Journal of Cancer</i> , 2019, 10, 1097-1102.	2.5	12
9250	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	4.2	38
9251	Inflammatory myopathy associated with PD-1 inhibitors. <i>Journal of Autoimmunity</i> , 2019, 100, 105-113.	6.5	73
9252	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. <i>Journal of Autoimmunity</i> , 2019, 100, 17-26.	6.5	33
9253	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019, 567, 521-524.	27.8	222
9254	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. <i>Scientific Reports</i> , 2019, 9, 3668.	3.3	7
9255	Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. <i>Scientific Reports</i> , 2019, 9, 4278.	3.3	26
9256	Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas. <i>Scientific Reports</i> , 2019, 9, 4285.	3.3	23
9257	Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 942-949.	1.9	5

#	ARTICLE	IF	CITATIONS
9258	Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. <i>American Journal of Transplantation</i> , 2019, 19, 2210-2218.	4.7	32
9259	Serum cell-free DNA levels are a useful marker for extramammary Paget disease. <i>British Journal of Dermatology</i> , 2019, 181, 505-511.	1.5	10
9260	Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1317-1328.	1.1	2
9261	Primary Mediastinal HER2-positive Apocrine Carcinoma in Mature Teratoma Treated With Anti-HER2 Therapy and Chemoradiation. <i>In Vivo</i> , 2019, 33, 551-557.	1.3	2
9262	Efficacy of Second-Line Chemotherapy after a First-Line Triplet in Patients with Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2019, 26, 4217.	2.2	4
9263	Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 314-319.	0.5	21
9264	Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 3910-3918.	1.8	2
9265	Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 3466-3474.	1.8	11
9266	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	10.7	137
9267	Rhabdomyosarcoma disease spread evaluation on CT scans: Association with primary tumor size and Ki-67 proliferation marker. <i>Clinical Imaging</i> , 2019, 56, 41-46.	1.5	11
9268	Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter. <i>PLoS ONE</i> , 2019, 14, e0213749.	2.5	21
9269	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>EBioMedicine</i> , 2019, 42, 304-310.	6.1	51
9270	Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 298-304.e2.	0.5	19
9271	Clinical significance of primary prophylactic pegylated granulocyte colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1005-1008.	1.9	9
9272	Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 451-458.	1.9	25
9273	Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?. <i>Clinical and Translational Oncology</i> , 2019, 21, 1532-1537.	2.4	13
9274	A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.3	2
9275	Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis. <i>BMC Cancer</i> , 2019, 19, 306.	2.6	30

#	ARTICLE	IF	CITATIONS
9276	Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. <i>BMC Cancer</i> , 2019, 19, 325.	2.6	38
9277	Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 504-512.	1.6	108
9278	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 1102-1110.	1.6	53
9279	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	1.6	267
9280	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
9281	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 946-953.	1.6	377
9282	Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. <i>Anticancer Research</i> , 2019, 39, 2053-2059.	1.1	10
9283	Atypical Response Patterns in Patients Treated With Nivolumab. <i>American Journal of Roentgenology</i> , 2019, 212, 1177-1181.	2.2	22
9284	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	2.3	12
9285	Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. <i>European Journal of Cancer</i> , 2019, 112, 98-106.	2.8	21
9286	Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2019, 113, 1-9.	2.8	19
9287	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. <i>European Urology Oncology</i> , 2019, 2, 677-684.	5.4	22
9288	Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. <i>Oncology Research and Treatment</i> , 2019, 42, 275-282.	1.2	10
9289	LPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. <i>BMC Cancer</i> , 2019, 19, 293.	2.6	10
9290	<i>MMP-2</i> mRNA Expression in Ovarian Cancer Tissues Predicts Patients' Response to Platinum-Taxane Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 1821-1827.	1.1	18
9291	Lymphocyte-to-Monocyte Ratio and Prognostic Nutritional Index Predict Poor Prognosis in Patients on Chemotherapy for Unresectable Pancreatic Cancer. <i>Anticancer Research</i> , 2019, 39, 2169-2176.	1.1	35
9292	Prediction of Early Response to Chemotherapy in Breast Cancer Liver Metastases by Diffusion-Weighted MR Imaging. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381984294.	1.9	7
9293	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. <i>Angiogenesis</i> , 2019, 22, 433-440.	7.2	28

#	ARTICLE	IF	CITATIONS
9294	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019, 19, 268-277.e1.	2.4	13
9295	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	4.5	151
9296	Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial. <i>Radiology</i> , 2019, 291, 620-629.	7.3	7
9297	Repeatability of texture features derived from magnetic resonance and computed tomography imaging and use in predictive models for non-small cell lung cancer outcome. <i>Physics in Medicine and Biology</i> , 2019, 64, 145007.	3.0	24
9298	Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 120.	4.4	22
9299	Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients. <i>Cancers</i> , 2019, 11, 514.	3.7	21
9300	The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>World Journal of Surgery</i> , 2019, 43, 2006-2015.	1.6	15
9301	Water-soluble pillar[6]arene functionalized PdPt porous core-shell octahedral nanodendrites to construct highly sensitive and robust neuron-specific enolase immunosensor by host-guest chemistry assisted catalytic amplification. <i>Analytica Chimica Acta</i> , 2019, 1068, 18-27.	5.4	23
9302	Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol. <i>Thoracic Cancer</i> , 2019, 10, 1310-1315.	1.9	4
9303	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	3.7	106
9304	Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo-controlled trial involving patients with head and neck cancer. <i>Cancer Medicine</i> , 2019, 8, 2020-2030.	2.8	23
9305	Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 33-39.	2.3	7
9306	A novel biomarker, active whole skeletal total lesion glycolysis (WS-TLG), as a quantitative method to measure bone metastatic activity in breast cancer patients. <i>Annals of Nuclear Medicine</i> , 2019, 33, 502-511.	2.2	6
9307	Are we ready to describe response or progression to immunotherapy in lung cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 112-119.	4.4	10
9308	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. <i>EClinicalMedicine</i> , 2019, 9, 19-25.	7.1	6
9309	Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. <i>Oral Oncology</i> , 2019, 93, 1-7.	1.5	32
9310	Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma. <i>Tumori</i> , 2019, 105, 259-264.	1.1	4
9311	Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. <i>Breast Journal</i> , 2019, 25, 418-424.	1.0	36

#	ARTICLE	IF	CITATIONS
9312	Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100130.	1.7	6
9313	Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 131, 62-68.	2.0	75
9314	TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2020, 112, 38-45.	6.3	15
9315	First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. <i>BMC Cancer</i> , 2019, 19, 279.	2.6	53
9316	Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. <i>BMC Cancer</i> , 2019, 19, 288.	2.6	20
9317	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019, 70, 1262-1277.	3.7	150
9318	Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1670-1683.	2.4	9
9319	Ultra-sensitive <i>EGFR</i> T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i> del19 Mutations and Treated with First-generation TKIs. <i>Clinical Cancer Research</i> , 2019, 25, 4280-4289.	7.0	31
9320	Very Early Response Evaluation by PET/MR in Patients with Lung Cancer—Timing and Feasibility. <i>Diagnostics</i> , 2019, 9, 35.	2.6	5
9321	Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy. <i>Cancer</i> , 2019, 125, 2394-2399.	4.1	8
9322	Radiomics: Principles and radiotherapy applications. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 44-50.	4.4	46
9323	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 355.e21-355.e29.	1.6	64
9324	Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial. <i>BMC Cancer</i> , 2019, 19, 275.	2.6	11
9325	Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013–2017). <i>Journal of the American Veterinary Medical Association</i> , 2019, 254, 960-966.	0.5	16
9326	¹⁸ F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1537-1542.	5.0	19
9327	From waterfall plots to spaghetti plots in early oncology clinical development. <i>Pharmaceutical Statistics</i> , 2019, 18, 526-532.	1.3	8
9328	Re-irradiation in locally recurrent lung cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 725-733.	2.0	17
9329	Late gadolinium MRI enhancement of colorectal liver metastases is associated with overall survival among nonsurgical patients. <i>European Radiology</i> , 2019, 29, 3901-3907.	4.5	6

#	ARTICLE	IF	CITATIONS
9330	Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. <i>Investigational New Drugs</i> , 2019, 37, 1257-1265.	2.6	10
9331	A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome. <i>PLoS ONE</i> , 2019, 14, e0213942.	2.5	10
9332	<p>Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2129-2138.	1.9	29
9333	Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2019, 9, 184.	2.8	15
9334	Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome. <i>Cancers</i> , 2019, 11, 424.	3.7	23
9335	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 506-514.	1.3	41
9336	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 532-542.	1.0	31
9337	Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. <i>BMC Cancer</i> , 2019, 19, 292.	2.6	50
9338	Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2019, 9, 155.	2.8	14
9339	The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis. <i>Cancers</i> , 2019, 11, 451.	3.7	6
9340	Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1153, 47-54.	1.6	2
9341	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1206-1214.	5.3	28
9342	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2019, 153, 555-561.	1.4	19
9343	Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. <i>Journal of Dermatology</i> , 2019, 46, 498-506.	1.2	13
9344	Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 305.	2.6	17
9345	<i>EGFR</i>-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	1.6	286
9346	Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1529-1537.	1.6	138
9347	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	1.6	274

#	ARTICLE	IF	CITATIONS
9348	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Nonâ€‘Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 2019, 37, 537-546.	1.6	1,144
9349	Validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: extra-cranial disease progression is an independent risk factor. Annals of Palliative Medicine, 2019, 8, 390-400.	1.2	6
9350	Efficacy of Combined VEGFR1-3, PDGFR α/β , and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	7.0	10
9351	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€‘Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2019, 37, 1081-1089.	1.6	251
9352	Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. Journal of Clinical Oncology, 2019, 37, 1062-1069.	1.6	212
9353	Bevacizumab as a steroidâ€‘sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports, 2019, 2, e115.	1.5	29
9354	Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Singleâ€‘institution outcomes. Head and Neck, 2019, 41, 2309-2314.	2.0	37
9355	Metabolic Bone Diseases. , 2019, , .		22
9356	Medullary Thyroid Cancer. , 2019, , 673-691.		0
9357	Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma. CardioVascular and Interventional Radiology, 2019, 42, 800-811.	2.0	29
9358	Keys to successful induction chemoradiotherapy followed by surgery for stage III/N2 non-small cell lung cancer. Surgery Today, 2019, 49, 547-555.	1.5	4
9359	Predictors of Nasoseptal Flap Use After Endoscopic Transsphenoidal Pituitary Mass Resection. World Neurosurgery, 2019, 124, e356-e364.	1.3	6
9360	The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study. Liver International, 2019, 39, 905-913.	3.9	34
9361	Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. International Journal of Clinical Oncology, 2019, 24, 836-841.	2.2	3
9362	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
9363	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. Lung Cancer, 2019, 130, 135-142.	2.0	10
9364	Impact of sarcopenia in patients with advanced nonâ€‘small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Scientific Reports, 2019, 9, 2447.	3.3	116
9365	Larger tumors are associated with inferior progressionâ€‘free survival of firstâ€‘line EGFRâ€‘tyrosine kinase inhibitors and a lower abundance of <i>EGFR</i> mutation in patients with advanced nonâ€‘small cell lung cancer. Thoracic Cancer, 2019, 10, 686-694.	1.9	6

#	ARTICLE	IF	CITATIONS
9366	Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue. <i>Immunotherapy</i> , 2019, 11, 365-368.	2.0	0
9367	Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas. <i>Clinical Oncology</i> , 2019, 31, 365-373.	1.4	20
9368	Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1239-1246.	1.7	4
9369	Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 830-838.	1.2	88
9370	A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 2708-2716.	7.0	49
9371	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44
9372	<p>Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 523-538.	4.3	23
9373	A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. <i>Journal of Clinical Medicine</i> , 2019, 8, 263.	2.4	16
9374	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	7.0	43
9375	Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e556-e564.	1.9	17
9376	Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer. <i>JAMA Network Open</i> , 2019, 2, e187754.	5.9	22
9377	<p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 31-39.	3.7	55
9378	The Radiosensitization of Sodium Glycididazole on Nasopharyngeal Carcinoma Cells via Enhancing DNA Damage and Promoting Apoptosis. <i>Journal of Cancer</i> , 2019, 10, 305-312.	2.5	8
9379	Phase I Study of the Focal Adhesion Kinase Inhibitor BIÂ853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. <i>Targeted Oncology</i> , 2019, 14, 57-65.	3.6	20
9380	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1â€“2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 383-393.	10.7	131
9381	Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 408-419.	10.7	276
9382	Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. <i>Neuro-Oncology</i> , 2019, 21, 659-668.	1.2	42
9383	DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models. <i>Journal of Translational Medicine</i> , 2019, 17, 39.	4.4	13

#	ARTICLE	IF	CITATIONS
9384	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , 2019, 109, 154-161.	2.8	64
9385	Prognostic value of quality-of-life scores in patients with breast cancer undergoing preoperative chemotherapy. <i>BJS Open</i> , 2019, 3, 38-47.	1.7	5
9386	Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy. <i>Head and Neck</i> , 2019, 41, 2380-2388.	2.0	2
9387	Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries. <i>Lecture Notes in Computer Science</i> , 2019, , .	1.3	10
9388	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	4.2	21
9389	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	2.8	25
9390	Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882367.	2.0	10
9391	Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. <i>Immunotherapy</i> , 2019, 11, 467-472.	2.0	21
9392	Comparison of Temozolomide-Capecitabine to 5-Fluorouracil-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. <i>Neuroendocrinology</i> , 2019, 108, 343-353.	2.5	34
9393	Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381982948.	1.9	29
9394	Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. <i>Cancers</i> , 2019, 11, 173.	3.7	1
9395	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	4.2	94
9396	Radiology reporting of low-grade glioma growth underestimates tumor expansion. <i>Acta Neurochirurgica</i> , 2019, 161, 569-576.	1.7	22
9397	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 111-121.	0.8	30
9398	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
9399	A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06). <i>Annals of Surgical Oncology</i> , 2019, 26, 1779-1786.	1.5	8
9400	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. <i>Clinical and Translational Oncology</i> , 2019, 21, 1270-1279.	2.4	38
9401	Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. <i>Surgery</i> , 2019, 165, 1151-1160.	1.9	30

#	ARTICLE	IF	CITATIONS
9402	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers, 2019, 11, 223.	3.7	18
9403	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. American Journal of Ophthalmology, 2019, 202, 109-117.	3.3	62
9404	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. Angiogenesis, 2019, 22, 383-395.	7.2	5
9405	Analysis of MRI Volumetric Changes After Hypofractionated Stereotactic Radiation Therapy for Benign Intracranial Neoplasms. Advances in Radiation Oncology, 2019, 4, 43-49.	1.2	6
9406	A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). European Journal of Cancer, 2019, 109, 183-191.	2.8	13
9407	Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. Hpb, 2019, 21, 773-783.	0.3	31
9408	Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdominal Radiology, 2019, 44, 1795-1807.	2.1	25
9409	Multimodality therapy for thymoma patients with pleural dissemination. General Thoracic and Cardiovascular Surgery, 2019, 67, 524-529.	0.9	14
9410	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
9411	Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. European Journal of Cancer, 2019, 109, 196-203.	2.8	9
9412	A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. Hpb, 2019, 21, 1024-1031.	0.3	51
9413	Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. Journal of Orthopaedic Science, 2019, 24, 332-336.	1.1	7
9414	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. Lung Cancer, 2019, 130, 18-24.	2.0	10
9415	Abdominal Manifestations of Neuroendocrine Tumors. Digestive Disease Interventions, 2019, 03, 014-029.	0.2	1
9416	Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?. , 2019, 7, 39.		14
9417	Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, B11361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. , 2019, 7, 38.		121
9418	A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 2019, 120, 579-586.	6.4	2
9419	Electrochemotherapy as treatment for generalised squamous cell carcinoma in a dog. Veterinary Record Case Reports, 2019, 7, e000787.	0.2	1

#	ARTICLE	IF	CITATIONS
9420	Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	1.5	11
9421	Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. <i>In Vivo</i> , 2019, 33, 507-514.	1.3	8
9422	Covalent Inhibition in Drug Discovery. <i>ChemMedChem</i> , 2019, 14, 889-906.	3.2	168
9423	Rogaratinib: A potent and selective pan-EGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. <i>International Journal of Cancer</i> , 2019, 145, 1346-1357.	5.1	65
9424	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	5.1	26
9425	The influence of treatment sequence in the prognostic value of <i>TPR2</i> as biomarker of taxane resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 1970-1981.	5.1	13
9426	Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1063-1073.	2.5	14
9427	Management of Metastatic Colorectal Cancer to the Liver. , 2019, , 2074-2092.		0
9428	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. <i>Current Problems in Cancer</i> , 2019, 43, 487-494.	2.0	9
9429	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 775-781.	1.9	64
9430	Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 856-863.	1.9	1
9431	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019, 291, 5-13.	7.3	209
9432	Don't Throw Away RECIST 1.1 Quite Yet. <i>Radiology</i> , 2019, 291, 268-269.	7.3	2
9433	Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. <i>Future Oncology</i> , 2019, 15, 2933-2942.	2.4	32
9434	Malignancies of the Bone. , 2019, , 245-261.		0
9435	The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. <i>Endocrine</i> , 2019, 64, 632-638.	2.3	15
9436	Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 101-110.	0.8	52
9437	Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2019, 8, e1568812.	4.6	148

#	ARTICLE	IF	CITATIONS
9438	Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review. <i>Frontiers in Oncology</i> , 2019, 9, 30.	2.8	75
9439	Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition. <i>Npj Precision Oncology</i> , 2019, 3, 5.	5.4	8
9440	Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. <i>Annals of Oncology</i> , 2019, 30, 788-795.	1.2	73
9441	Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381882232.	1.9	27
9442	Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. <i>Radiation Oncology</i> , 2019, 14, 34.	2.7	12
9443	Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 681.	7.1	67
9444	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	2.5	31
9445	Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. <i>Targeted Oncology</i> , 2019, 14, 43-55.	3.6	42
9446	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 120, 612-620.	6.4	109
9447	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). <i>Clinical Cancer Research</i> , 2019, 25, 3229-3238.	7.0	61
9448	The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment. <i>Tumori</i> , 2019, 105, NP28-NP31.	1.1	2
9449	Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1402-1411.	0.9	15
9450	Imaging strategies in the management of gastric cancer: current role and future potential of MRI. <i>British Journal of Radiology</i> , 2019, 92, 20181044.	2.2	61
9451	Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. <i>PLoS ONE</i> , 2019, 14, e0211105.	2.5	7
9452	Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 56-61.	0.8	23
9453	Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. <i>Breast Journal</i> , 2019, 25, 219-225.	1.0	7
9454	Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 68.	1.9	7
9455	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 817-825.	2.3	13

#	ARTICLE	IF	CITATIONS
9456	Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases. <i>Journal of Bone Oncology</i> , 2019, 15, 100218.	2.4	24
9457	Current state of clinical trials in breast cancer brain metastases. <i>Neuro-Oncology Practice</i> , 2019, 6, 392-401.	1.6	16
9458	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. <i>ERJ Open Research</i> , 2019, 5, 00179-2019.	2.6	20
9459	Automated quantitative assessment of oncological disease progression using deep learning. <i>Annals of Translational Medicine</i> , 2019, 7, S379-S379.	1.7	13
9460	Fractionated Gamma Knife radiosurgery for skull base meningiomas: a single-institution experience. <i>Neurosurgical Focus</i> , 2019, 46, E8.	2.3	13
9461	A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2019, , 1-15.	1.2	0
9462	Using Technology to Help Humans Perform Difficult Inspections. , 2019, , .		0
9463	High-quality face image super-resolution based on Generative Adversarial Networks. , 2019, , .		2
9464	Fast Serial Approach of Object Distance Measurement based on Deep Learning and Stereo Camera. , 2019, , .		0
9465	Improving the Accuracy and Quality of Wireless Coverage Measurements using Autonomous Drones and Wheeled Robots. , 2019, , .		0
9467	Smart Heat Stress and Toxic Gases Monitoring Instrument with a Developed Graphical User Interface Using IoT. , 2019, , .		4
9468	Major earthquake event prediction using various machine learning algorithms. , 2019, , .		21
9469	On the Electromagnetic Torque Expression of an Induction Machine Asymmetrical Supplied. , 2019, , .		0
9470	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	3.7	81
9471	An Extended Sequence Labeling Approach For Relation Extraction. , 2019, , .		1
9472	Prognostics and health management techniques for integrated avionics systems. , 2019, , .		3
9473	Supplementary Sorafenib Therapies for Hepatocellular Carcinoma—A Systematic Review and Meta-Analysis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 486-494.	2.2	6
9474	A Practical Method for BEP Estimation of Convolutional Coding in Impulse Noise Environments. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
9476	Spatial Distribution of Rural Residential Building Types in Shandong Province Based on Spatial Interpolation. , 2019, , .		0
9477	Attracting Black High School Boys to Computer Science Through Tech Innovation and Entrepreneurship. , 2019, , .		1
9478	Analysis of Fiber Based Emitting Head for Optical Wireless Communication. , 2019, , .		1
9479	Impacts of Plug-in Electric Vehicles on a Distribution Level Microgrid. , 2019, , .		11
9480	Bio-Medical Image Enhancement Using Adaptive Multi-Resolution Technique. , 2019, , .		0
9481	Message from the Chairs IEEE International Workshop on Artificial Intelligence for Mobile. , 2019, , .		0
9482	Comnetsat 2019 Index. , 2019, , .		0
9483	Sun Shadow Localization Problem Based on Genetic Algorithm. , 2019, , .		0
9484	Third-order virtual measurements with signal injection. , 2019, , .		2
9486	Computed Tomographyâ€‘Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	19
9487	Utilization of combined PD-L1 expression and neutrophil-to-lymphocyte ratio prior to surgery as a prognostic factor in non-small cell lung cancer with brain metastasis. Translational Cancer Research, 2019, 8, 2864-2877.	1.0	12
9488	Irreversible Electroporation as a Bridge to Liver Transplantation. American Surgeon, 2019, 85, 103-110.	0.8	5
9489	Testicular Seminoma: Correlation Between Staging and Chemotherapy Response, Two Years Overall Survival Rate. JBN (Jurnal Bedah Nasional), 2019, 3, 24.	0.1	0
9490	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	11
9491	Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review. BMJ Open, 2019, 9, e029475.	1.9	6
9492	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1095-1102.	3.7	37
9493	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs, 2019, 30, 394-401.	1.4	3
9494	Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 820-828.	3.7	87

#	ARTICLE	IF	CITATIONS
9495	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	3.7	127
9496	Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	23
9497	Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 854-861.	2.8	31
9498	Performance Gap Between Valid and Invalid Patents in Six Technology Fields. , 2019, , .		0
9499	Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 1016-1028.	2.8	16
9500	Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. <i>Oncologist</i> , 2019, 24, e662-e670.	3.7	8
9501	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. <i>Oncologist</i> , 2019, 24, e740-e748.	3.7	38
9502	A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors. <i>Oncologist</i> , 2019, 24, e755-e764.	3.7	11
9503	Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Tripleâ€Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival. <i>Oncologist</i> , 2019, 24, 753-761.	3.7	21
9504	Computed Tomographyâ€Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	16
9505	Intratumoral CD3+ and CD8+ T-Cell Densities in Patients With DNA Mismatch Repairâ€Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	3.0	9
9506	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	3.7	26
9507	Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patientsâ€™ Outcome in Neuroendocrine Tumors (NET)â€The GREPONET Study. <i>Oncologist</i> , 2019, 24, e1082-e1090.	3.7	26
9508	Change in PMI During Neoadjuvant Therapy Is a Predictive Prognostic Marker in Rectal Cancer. <i>Anticancer Research</i> , 2019, 39, 5157-5163.	1.1	6
9509	Dilated convolutional recurrent neural network for monaural speech enhancement. , 2019, , .		1
9510	Analysis on Internal Flow Characteristics of Tubular Turbine Draft Tube. , 2019, , .		0
9511	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575.	4.5	5
9512	Second-Order Non-Local Attention Networks for Person Re-Identification. , 2019, , .		56

#	ARTICLE	IF	CITATIONS
9513	Paragangliomas of the Head and Neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 818-823.	1.3	7
9514	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer, 2019, 29, 1396-1404.	2.5	19
9515	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. Clinical Cancer Research, 2019, 25, 7485-7496.	7.0	18
9516	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. Kidney Cancer, 2019, 3, 241-251.	0.4	2
9517	Face Anti-spoofing using Hybrid Residual Learning Framework. , 2019, , .		6
9518	Short-term prognosis of childhood hepatoblastoma in relation to ERCC1 C118T single nucleotide polymorphism and VEGF expression. Polish Journal of Pathology, 2019, 70, 304-310.	0.3	0
9519	RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice. American Journal of Neuroradiology, 2019, 40, 1978-1986.	2.4	7
9520	Performance of Maximum Distance on-demand Routing Protocol based on Random Variable Velocity. , 2019, , .		1
9521	Optimal Power Distribution Algorithm for Energy Efficient IoT-NOMA Enabled Networks. , 2019, , .		6
9522	CU-Net: Cascaded U-Net Model for Automated Liver and Lesion Segmentation and Summarization. , 2019, , .		20
9523	Numerical Simulation of Bonding Spot Welding of Steel and Aluminum Door Cover Parts Considering the Thickness of Hemming Adhesive. , 2019, , .		0
9524	Fog Computing Challenges and Future Directions: A Mirror Review. , 2019, , .		2
9525	Effect of Signal Characteristics on Focusing Property of Time Reversal Electromagnetic Wave. , 2019, , .		3
9526	Continuous Relaxation of Symbolic Planner for One-Shot Imitation Learning. , 2019, , .		15
9527	Memory-Based Multiagent One-Shot Learning: Extended Abstract. , 2019, , .		0
9528	Project Teaching in Computer Subjects. , 2019, , .		0
9529	Crossing iVRoad: A VR application for detecting unilateral visuospatial neglect in poststroke patients. , 2019, , .		2
9530	Horizontally Polarized Array on a Mast-Like Form for Azimuthal Beam Switching. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
9531	Regorafenib in Patients with Antiangiogenic- and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial. <i>Oncologist</i> , 2019, 24, 1180-1187.	3.7	19
9532	Direct Kinematics and Jacobian Analysis of Exoskeleton Robots using Screw Theory and Simscape Multibody. <i>IEEE Transactions on Systems, Man, and Cybernetics: Systems</i> , 2019, 49, 1-12.		8
9533	Smart Parking Area Management System for the Disabled using IoT and Mobile Application. <i>Journal of Intelligent and Fuzzy Systems</i> , 2019, 31, 1-12.		9
9534	A Terahertz Tunable Dual-Band Modulator Based on Graphene Metamaterials. <i>Optics Express</i> , 2019, 27, 1-12.		0
9535	Centralized Caching with Shared Caches in Heterogeneous Cellular Networks. <i>IEEE Transactions on Communications</i> , 2019, 67, 1-12.		7
9536	A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma. <i>BMJ Open</i> , 2019, 9, e030522.	1.9	2
9537	Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1132-1139.	2.4	19
9538	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). <i>Future Oncology</i> , 2019, 15, 4009-4017.	2.4	8
9539	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000532.	4.5	13
9540	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019, 25, 7381-7387.	7.0	13
9541	Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy. <i>BJR Open</i> , 2019, 1, 20190029.	0.6	2
9543	Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen. <i>Oncology</i> , 2019, 97, 341-347.	1.9	0
9544	Rare entities in head-and-neck cancer: salvage re-irradiation with carbon ions. <i>Radiation Oncology</i> , 2019, 14, 202.	2.7	6
9546	The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1100.	2.6	40
9547	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. <i>BMC Medical Imaging</i> , 2019, 19, 90.	2.7	9
9548	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 1102.	2.6	17
9549	Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. <i>Cancer Imaging</i> , 2019, 19, 75.	2.8	29
9550	Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. <i>Future Oncology</i> , 2019, 15, 17-23.	2.4	3

#	ARTICLE	IF	CITATIONS
9551	Histological tumor response assessment in colorectal liver metastases after neoadjuvant chemotherapy: impact of the variation in tumor regression grading and peritumoral lymphocytic infiltration. <i>Journal of Cancer</i> , 2019, 10, 5852-5861.	2.5	7
9552	Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. <i>Annals of Oncology</i> , 2019, 30, viii31-viii35.	1.2	22
9553	Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. <i>Journal of Thoracic Disease</i> , 2019, 11, 4241-4248.	1.4	13
9554	Costâ€effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in theÂUSA. <i>Immunotherapy</i> , 2019, 11, 1463-1478.	2.0	43
9555	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. <i>The Cochrane Library</i> , 2019, 2019, .	2.8	34
9556	Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol. <i>The Cochrane Library</i> , 2019, , .	2.8	2
9557	Therapeutic vaccines for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2019, , .	2.8	6
9558	Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. <i>The Cochrane Library</i> , 0, , .	2.8	1
9559	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	2.8	0
9560	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	2.8	2
9561	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3775-3782.	2.4	10
9562	A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. <i>Seminars in Oncology</i> , 2019, 46, 362-371.	2.2	46
9563	Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 149.	5.0	89
9564	23 Locally Advanced Supraglottic Cancer: Organ-Preservation Protocol. , 2019, , .		0
9565	Scale-Space DCE-MRI Radiomics Analysis Based on Gabor Filters for Predicting Breast Cancer Therapy Response. , 2019, , .		2
9566	Measures of Treatment Workload for Patients With Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	8
9567	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Nonâ€Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	58
9568	Biomarker-guided trials: Challenges in practice. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100493.	1.1	32

#	ARTICLE	IF	CITATIONS
9569	Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. <i>Scientific Reports</i> , 2019, 9, 19501.	3.3	12
9570	Clinical and Prognostic Characteristics of 53 Cases of Extracranial Malignant Rhabdoid Tumor in Children. A Single-Institute Experience from 2007 to 2017. <i>Oncologist</i> , 2019, 24, e551-e558.	3.7	26
9571	mRECIST pour le carcinome h�patocellulaire. <i>Journal D'imagerie Diagnostique Et Interventionnelle</i> , 2019, 2, 121-125.	0.0	0
9572	Clinical Activity of Sunitinib and Regorafenib in Endometriosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2591-2593.	3.0	2
9573	Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 367-371.	2.0	16
9574	Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study. <i>Sarcoma</i> , 2019, 2019, 1-7.	1.3	13
9575	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
9576	Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. <i>PLoS ONE</i> , 2019, 14, e0227366.	2.5	57
9577	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019, 12, 145.	17.0	35
9578	Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. <i>Journal of Immunotherapy</i> , 2019, 42, 89-93.	2.4	21
9579	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. <i>Journal of Immunotherapy</i> , 2019, 42, 208-214.	2.4	12
9580	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 46, 337-346.	1.3	4
9581	Immune checkpoint inhibitors therapy in older patients (��� 70 years) with metastatic melanoma: a multicentre study. <i>Postepy Dermatologii I Alergologii</i> , 2019, 36, 566-571.	0.9	13
9582	One-Pot Radiosynthesis and Biological Evaluation of a Caspase-3 Selective 5-[123,125I]iodo-1,2,3-triazole derived Isatin SPECT Tracer. <i>Scientific Reports</i> , 2019, 9, 19299.	3.3	9
9583	Exceptional Responders in Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 624-635.	1.3	2
9584	Defining, Identifying, and Understanding ���Exceptional Responders���in Oncology Using the Tools of Precision Medicine. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 296-299.	2.0	6
9586	Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. <i>Journal of Oncology</i> , 2019, 2019, 1-9.	1.3	24
9587	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. <i>Radiology Imaging Cancer</i> , 2019, 1, e190031.	1.6	22

#	ARTICLE	IF	CITATIONS
9588	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
9589	Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Cancer, 2019, 10, 6261-6268.	2.5	22
9590	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	13.7	142
9591	Hot and Cold Spine Tumor Ablations. Neuroimaging Clinics of North America, 2019, 29, 529-538.	1.0	8
9592	Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol. BMC Cancer, 2019, 19, 1153.	2.6	8
9593	Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers, 2019, 11, 1856.	3.7	15
9594	Radiographic Features of Metastatic Brain Tumors from ALK-rearranged Non-small Cell Lung Cancer: Implications for Optimal Treatment Modalities. Journal of Cancer, 2019, 10, 6660-6665.	2.5	4
9595	From <i>Scutellaria barbata</i> to BZL101 in Cancer Patients: Phytochemistry, Pharmacology, and Clinical Evidence. Natural Product Communications, 2019, 14, 1934578X1988064.	0.5	5
9596	Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. Scientific Reports, 2019, 9, 18069.	3.3	7
9597	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. Journal of Cancer, 2019, 10, 6185-6190.	2.5	7
9598	Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. BMC Cancer, 2019, 19, 1167.	2.6	20
9599	Reprioritizing Risk and Benefit: The Future of Study Design in Early-Phase Cancer Research. Ethics & Human Research, 2019, 41, 2-11.	0.9	8
9600	Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. Journal of Vascular and Interventional Radiology, 2019, 30, 1893-1894.	0.5	0
9601	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Annals of Oncology, 2019, 30, 1796-1803.	1.2	136
9602	Robustness of radiomic features in magnetic resonance imaging: review and a phantom study. Visual Computing for Industry, Biomedicine, and Art, 2019, 2, 19.	3.7	68
9603	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	2.5	24
9604	Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2. Journal of Cancer, 2019, 10, 6025-6036.	2.5	8
9605	Long-term Results of Conversion Therapy for Initially Unresectable Gastric Cancer: Analysis of 122 Patients at the National Cancer Center in China. Journal of Cancer, 2019, 10, 5975-5985.	2.5	6

#	ARTICLE	IF	CITATIONS
9606	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. JAMA Network Open, 2019, 2, e1916211.	5.9	7
9607	FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. Journal of Molecular Medicine, 2019, 97, 1657-1668.	3.9	7
9608	Quantitative Changes in the Population of Cancer Stem Cells after Radiation Exposure in a Dose of 10 Gy as a Prognostic Marker of Immediate Results of the Treatment of Squamous Cell Cervical Cancer. Bulletin of Experimental Biology and Medicine, 2019, 168, 156-159.	0.8	3
9609	Current management of succinate dehydrogenaseâ€“deficient gastrointestinal stromal tumors. Cancer and Metastasis Reviews, 2019, 38, 525-535.	5.9	23
9610	Clinical Trials and Developmental Therapeutics. , 2019, , 340-351.		0
9611	Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Scientific Reports, 2019, 9, 17808.	3.3	38
9612	<p>Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation</p>. OncoTargets and Therapy, 2019, Volume 12, 8863-8871.	2.0	6
9613	The Evolving Landscape of Cancer Therapeutics. Handbook of Experimental Pharmacology, 2019, 260, 43-79.	1.8	10
9614	Interferon-Î± versus interleukin-2 in Chinese patients with malignant melanoma. Anti-Cancer Drugs, 2019, 30, 402-409.	1.4	7
9615	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenetics and Genomics, 2019, 29, 123-131.	1.5	4
9616	A Repeated Biopsy by EBUS-TBNA Contributed to the Selection of an Appropriate Therapeutic Regimen for a Lung Cancer Patient. Journal of Bronchology and Interventional Pulmonology, 2019, 26, 129-131.	1.4	2
9617	Breast metastasis from colorectal cancer treated by multimodal therapy. Medicine (United States), 2019, 98, e18016.	1.0	14
9618	Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema. Clinical Nuclear Medicine, 2019, 44, 501-503.	1.3	0
9619	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Nonâ€“Small Cell Lung Cancer. Clinical Nuclear Medicine, 2019, 44, 535-543.	1.3	48
9620	Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer. Anti-Cancer Drugs, 2019, 30, 854-858.	1.4	2
9621	Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?. Clinical Orthopaedics and Related Research, 2019, 477, 707-714.	1.5	8
9622	Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatologic Surgery, 2019, 45, 254-267.	0.8	21
9623	Comparing Linear and Volumetric Vestibular Schwannoma Measurements Between T1 and T2 Magnetic Resonance Imaging Sequences. Otology and Neurotology, 2019, 40, S67-S71.	1.3	10

#	ARTICLE	IF	CITATIONS
9624	Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection?. <i>Medicine (United States)</i> , 2019, 98, e15442.	1.0	9
9625	Endoscopy and magnetic resonance imaging-based prediction of ypT stage in patients with rectal cancer who received chemoradiotherapy. <i>Medicine (United States)</i> , 2019, 98, e16614.	1.0	9
9626	The usefulness of stereotactic radiosurgery for recursive partitioning analysis class II/III lung cancer patients with brain metastases in the modern treatment era. <i>Medicine (United States)</i> , 2019, 98, e17390.	1.0	1
9627	Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 461-468.	1.1	12
9628	Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2019, 44, 719-727.	1.3	23
9629	Measurement Variability in Treatment Response Determination for Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2019, 34, 103-115.	1.5	14
9630	Definitive Radiation Therapy Versus Postoperative Radiation Therapy for Patients With Maxillary Sinus Cancer Invading the Upper Jaw. <i>Journal of Craniofacial Surgery</i> , 2019, 30, 1234-1238.	0.7	5
9631	Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. <i>Annals of Palliative Medicine</i> , 2019, 8, 717-727.	1.2	6
9632	Semi-quantitative analysis of 99mTc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1394-1401.	2.0	17
9633	The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer. <i>International Journal of Surgery Protocols</i> , 2019, 18, 5-11.	1.1	6
9634	Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy. <i>BMC Cancer</i> , 2019, 19, 1241.	2.6	12
9635	Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer. <i>Cancer Imaging</i> , 2019, 19, 91.	2.8	16
9636	Feasibility Technique of Low-passage In Vitro Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical Outcome. <i>Anticancer Research</i> , 2019, 39, 6981-6988.	1.1	7
9637	Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 46-55.	1.3	26
9638	Endometrial carcinoma complicated by malignant pericardial effusion. <i>Medicine (United States)</i> , 2019, 98, e17584.	1.0	4
9639	Volume Computed Tomography Perfusion Imaging. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 493-498.	0.9	2
9640	Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	4.1	14
9641	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 188.	4.1	27

#	ARTICLE	IF	CITATIONS
9642	Efficacy and feasibility of stereotactic radiotherapy after folfinirox in patients with locally advanced pancreatic cancer (LAPC-1 trial). <i>EClinicalMedicine</i> , 2019, 17, 100200.	7.1	41
9643	Pancreatic neuroendocrine tumors. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 468-477.	2.3	29
9644	Therapeutic options in lung neuroendocrine tumors. <i>Anti-Cancer Drugs</i> , 2019, 30, 649-654.	1.4	5
9645	Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. <i>Anti-Cancer Drugs</i> , 2019, 30, 745-748.	1.4	2
9646	Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?: Reply. <i>Clinical Nuclear Medicine</i> , 2019, 44, 341-342.	1.3	0
9647	Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988900.	3.2	6
9648	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	1.9	56
9649	Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-12.	0.8	15
9650	Lesion measurement on a combined â€œall-in-oneâ€ window for chest CT: effect on intra- and interobserver variability. <i>Cancer Imaging</i> , 2019, 19, 78.	2.8	2
9651	The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. <i>Nature Genetics</i> , 2019, 51, 1645-1651.	21.4	171
9652	CORR InsightsÂ®: Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?. <i>Clinical Orthopaedics and Related Research</i> , 2019, 477, 715-717.	1.5	1
9653	Multimodality palliative treatment with transarterial chemoembolization and high-intensity focused ultrasound for gastric leiomyosarcoma multiple liver metastasis pain. <i>Medicine (United States)</i> , 2019, 98, e17328.	1.0	6
9654	Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor. <i>Clinical Nuclear Medicine</i> , 2019, 44, e286-e288.	1.3	6
9655	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 432-439.	1.3	21
9656	Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 649-654.	1.3	21
9657	Hormone therapy following surgery in low-grade endometrial stromal sarcoma. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 385-389.	1.4	9
9658	Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. <i>Journal of Pancreatology</i> , 2019, 2, 91-99.	0.9	4
9659	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	1.0	28

#	ARTICLE	IF	CITATIONS
9660	Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2019, 54, 638-644.	6.2	25
9661	A Phase 2 Study of Galunisertib (TGF- β 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00056.	2.5	151
9662	Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). <i>Scientific Reports</i> , 2019, 9, 18135.	3.3	12
9663	A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China. <i>Medicine (United States)</i> , 2019, 98, e15696.	1.0	12
9664	Chordoma: update on disease, epidemiology, biology and medical therapies. <i>Current Opinion in Oncology</i> , 2019, 31, 114-120.	2.4	70
9665	Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 862-869.	1.3	6
9666	A Staged Procedure in the Treatment of Primary Lacrimal Sac Epithelial Malignancy: A Retrospective Cases Analysis. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 187-192.	0.8	8
9667	Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. <i>Medicine (United States)</i> , 2019, 98, e15341.	1.0	13
9668	Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 6851-6857.	1.1	24
9669	Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. <i>Anticancer Research</i> , 2019, 39, 6887-6893.	1.1	27
9670	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	1.3	20
9671	Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer. <i>Medicine (United States)</i> , 2019, 98, e16967.	1.0	7
9672	EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	3.7	57
9673	Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). <i>EBioMedicine</i> , 2019, 50, 433-441.	6.1	32
9674	Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. <i>Medicine (United States)</i> , 2019, 98, e16608.	1.0	10
9675	RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019, 19, 85.	2.8	9
9676	<p>Nomogram-Integrated C-Reactive Protein/Albumin Ratio Predicts Efficacy And Prognosis In Patients With Thoracic Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9459-9468.	1.9	19
9677	<p>Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9707-9713.	2.0	7

#	ARTICLE	IF	CITATIONS
9678	Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. Lung Cancer Management, 2019, 8, LMT15.	1.5	4
9679	Partial response after treatment with Conversion chemotherapy. Medicine (United States), 2019, 98, e15239.	1.0	1
9680	Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial. BMC Cancer, 2019, 19, 1206.	2.6	20
9681	A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer. Journal of Thoracic Disease, 2019, 11, 4529-4537.	1.4	8
9682	The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors. Scientific Reports, 2019, 9, 19917.	3.3	9
9683	18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma. Pancreas, 2019, 48, 996-1002.	1.1	12
9684	Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 Trial. Clinical Nuclear Medicine, 2019, 44, 223-226.	1.3	8
9685	Genes Involved in the Transcriptional Regulation of Pluripotency Are Expressed in Malignant Tumors of the Uterine Cervix and Can Induce Tumorigenic Capacity in a Nontumorigenic Cell Line. Stem Cells International, 2019, 2019, 1-14.	2.5	6
9686	First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. Oncologist, 2019, 24, e930-e942.	3.7	41
9687	High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. Oncology Reports, 2019, 42, 2750-2758.	2.6	7
9688	Behavioural Response Alteration in <i>Caenorhabditis elegans</i> to Urine After Surgical Removal of Cancer: Nematode-NOSE (N-NOSE) for Postoperative Evaluation. Biomarkers in Cancer, 2019, 11, 1179299X1989655.	3.6	10
9689	A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. Oncologist, 2019, 24, e1409-e1416.	3.7	25
9690	Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 4562-4572.	1.4	12
9691	Exosome-Mediated Transfer of lncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells by Regulating HMGA1/miR-218 Axis. OncoTargets and Therapy, 2019, Volume 12, 11325-11338.	2.0	77
9692	Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer. Journal of Cellular Biochemistry, 2019, 120, 507-518.	2.6	25
9693	Direct and indirect assessment of cancer metabolism explored by MRI. NMR in Biomedicine, 2019, 32, e3966.	2.8	6
9694	Predicting marker for early progression in unresectable melanoma treated with nivolumab. International Journal of Clinical Oncology, 2019, 24, 323-327.	2.2	17
9695	Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition. Oncogene, 2019, 38, 549-563.	5.9	56

#	ARTICLE	IF	CITATIONS
9696	Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. <i>Radiotherapy and Oncology</i> , 2019, 130, 104-112.	0.6	189
9697	Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: results of a Delphi survey. <i>Human Pathology</i> , 2019, 84, 26-34.	2.0	22
9698	Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 150-158.	3.9	6
9699	BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. <i>Future Oncology</i> , 2019, 15, 133-139.	2.4	1
9700	Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule. <i>Radiologia Medica</i> , 2019, 124, 58-64.	7.7	2
9701	Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. <i>Pharmacogenomics Journal</i> , 2019, 19, 5-14.	2.0	34
9702	Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 860-866.	1.3	2
9703	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 90-98.	7.0	73
9704	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Nonâ€Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 64-72.	7.0	159
9705	Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2019, 19, 71-77.	2.4	16
9706	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	7.1	557
9707	Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. <i>Endocrine</i> , 2019, 63, 293-300.	2.3	13
9708	Immune Checkpoints. , 2019, , 19-43.		0
9709	Gynecologic Malignancies. , 2019, , 135-155.		0
9710	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. <i>Journal of Nuclear Medicine</i> , 2019, 60, 511-516.	5.0	29
9711	The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 228-241.	2.4	22
9712	Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment. <i>Abdominal Radiology</i> , 2019, 44, 766-774.	2.1	13
9713	Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, e53-e61.	2.6	25

#	ARTICLE	IF	CITATIONS
9714	T ₂ -based MRI Delta-radiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy.. Journal of Magnetic Resonance Imaging, 2019, 50, 497-510.	3.4	74
9715	Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation. Clinical Colorectal Cancer, 2019, 18, e251-e260.	2.3	12
9716	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European Journal of Cancer, 2019, 107, 164-174.	2.8	9
9717	A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer. Gynecologic Oncology, 2019, 152, 574-580.	1.4	23
9718	HEF1 regulates differentiation through the Wnt5a/ β 2-catenin signaling pathway in human gastric cancer. Biochemical and Biophysical Research Communications, 2019, 509, 201-208.	2.1	6
9719	A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. British Journal of Cancer, 2019, 120, 286-293.	6.4	39
9720	Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer, 2019, 130, 59-66.	2.0	65
9721	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Medicine, 2019, 8, 137-146.	2.8	112
9722	Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response?. European Radiology, 2019, 29, 4389-4399.	4.5	8
9723	Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy. Japanese Journal of Clinical Oncology, 2019, 49, 270-275.	1.3	7
9724	Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer. Journal of Radiation Research, 2019, 60, 228-233.	1.6	0
9725	Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 376.	7.1	235
9726	The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma. Cancer Medicine, 2019, 8, 216-226.	2.8	23
9727	Artificial Intelligence and Health Care. Computers in Health Care, 2019, , 29-40.	0.3	7
9728	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clinical Cancer Research, 2019, 25, 1472-1478.	7.0	38
9729	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 107, 186-195.	2.8	11
9730	Isolated thoracic perfusion in lung metastases from breast cancer: a retrospective observational study. Updates in Surgery, 2019, 71, 165-177.	2.0	4
9731	Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy. European Journal of Cardio-thoracic Surgery, 2019, 55, 934-941.	1.4	13

#	ARTICLE	IF	CITATIONS
9732	Accuracy of iodine density thresholds for the separation of vertebral bone metastases from healthy-appearing trabecular bone in spectral detector computed tomography. <i>European Radiology</i> , 2019, 29, 3253-3261.	4.5	11
9733	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	2.4	16
9734	Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 253-268.	3.2	18
9735	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. <i>European Journal of Cancer</i> , 2019, 106, 133-143.	2.8	35
9736	SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). <i>European Journal of Cancer</i> , 2019, 107, 37-45.	2.8	21
9737	A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 722-730.	2.6	53
9738	Huge ameloblastic carcinoma of the mandible with metastases treated in several different ways. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2019, 57, 182-184.	0.8	5
9739	Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. <i>Brachytherapy</i> , 2019, 18, 154-162.	0.5	10
9740	Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis. <i>European Journal of Radiology</i> , 2019, 110, 22-29.	2.6	37
9741	Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. <i>Radiotherapy and Oncology</i> , 2019, 131, 45-51.	0.6	81
9742	Efficient Hydrodesulfurization of 4,6-Dimethyldibenzothiophene via $\text{Ni}_{4\text{Mo}_{12}\text{Al}_2\text{O}_3}$ Catalysts Prepared by a One-Step Hydrothermal Polyoxometalate Dispersion Method. <i>Energy & Fuels</i> , 2019, 33, 135-147.	5.1	17
9743	A Predictive Scoring Model for Short-Term Local Recurrent Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 76-84.	1.0	5
9744	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	1.2	214
9745	Statistical Considerations for Planning Clinical Trials with Quantitative Imaging Biomarkers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 19-26.	6.3	11
9746	A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis. <i>Internal Medicine</i> , 2019, 58, 921-927.	0.7	18
9747	Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel <i>KIF5B-ALK</i> Fusion Oncokinase. <i>Anticancer Research</i> , 2019, 39, 413-420.	1.1	18
9748	Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer. <i>In Vivo</i> , 2019, 33, 163-166.	1.3	1
9749	A Qualitative Analysis of the Impact of Carboplatin AUC 10 on Physical, Work Functioning and Bone Marrow Toxicity Among Seminoma Patients – A Single-centre Experience. <i>In Vivo</i> , 2019, 33, 233-237.	1.3	6

#	ARTICLE	IF	CITATIONS
9750	Artificial Intelligence for Breast MRI in 2008â€“2018: A Systematic Mapping Review. <i>American Journal of Roentgenology</i> , 2019, 212, 280-292.	2.2	43
9751	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	7.1	127
9752	Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 933-938.	2.4	19
9753	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). <i>Annals of Oncology</i> , 2019, 30, 250-258.	1.2	230
9754	A Pilot Trial of the Combination of Transgenic NY-ESO-1â€“reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. <i>Clinical Cancer Research</i> , 2019, 25, 2096-2108.	7.0	69
9755	Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1063-1072.	6.4	100
9756	Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice. <i>Annals of Nuclear Medicine</i> , 2019, 33, 193-200.	2.2	16
9757	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZCOG-1103). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 97-105.	2.3	3
9758	A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. <i>Supportive Care in Cancer</i> , 2019, 27, 1497-1507.	2.2	29
9759	Time to abandon single-site irradiation for inducing abscopal effects. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 123-135.	27.6	233
9760	Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study. <i>Radiology</i> , 2019, 290, 349-356.	7.3	58
9761	Is RECIST Version 1.1 Reliable for Tumor Response Assessment in Metastatic Cancer?. <i>Radiology</i> , 2019, 290, 357-358.	7.3	10
9762	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. <i>Thyroid</i> , 2019, 29, 79-92.	4.5	18
9763	Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27540.	1.5	4
9764	MRI diagnosis and follow-up of chest wall and breast desmoid tumours in patients with a history of oncologic breast surgery and silicone implants: A pictorial report. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 47-53.	1.8	7
9765	Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. <i>International Journal of Cancer</i> , 2019, 144, 2880-2886.	5.1	25
9766	Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1073-1080.	6.4	57
9767	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 241-255.	27.6	56

#	ARTICLE	IF	CITATIONS
9768	Detection of Colorectal Hepatic Metastases Is Superior at Standard Radiation Dose CT versus Reduced Dose CT. <i>Radiology</i> , 2019, 290, 400-409.	7.3	69
9769	Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer. <i>Future Oncology</i> , 2019, 15, 271-280.	2.4	12
9770	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. <i>Lung Cancer</i> , 2019, 127, 153-163.	2.0	77
9771	Modified Quality Threshold Clustering for Temporal Analysis and Classification of Lung Lesions. <i>IEEE Transactions on Image Processing</i> , 2019, 28, 1813-1823.	9.8	9
9772	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	7.0	249
9773	Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27510.	1.5	22
9774	An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy. <i>Annals of Nuclear Medicine</i> , 2019, 33, 128-134.	2.2	2
9775	The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2019, 33, 147-152.	2.2	6
9776	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2019, 20, 82-87.	2.6	19
9777	Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 250-257.	0.4	17
9778	Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 169-178.	2.3	12
9779	A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2019, 37, 338-344.	2.6	6
9780	¹⁸ F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 335-341.	5.0	123
9781	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	6.4	279
9782	From the Double Helix to Oncogenomics and Precision Cancer Medicine. , 2019, , 3-16.		0
9783	Immuno-Oncology in Lung Cancer. , 2019, , 487-497.		1
9784	Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. <i>Oncoimmunology</i> , 2019, 8, e1515611.	4.6	12
9785	Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. <i>JAMA Oncology</i> , 2019, 5, 551.	7.1	178

#	ARTICLE	IF	CITATIONS
9786	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	1.1	241
9787	EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 71-77.	1.6	9
9788	Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. <i>Clinical and Translational Oncology</i> , 2019, 21, 790-795.	2.4	22
9789	Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 317-323.	1.5	7
9790	Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCA-GY-GINECO phase IB-II trial. <i>Gynecologic Oncology</i> , 2019, 152, 68-75.	1.4	4
9791	Diagnostic Accuracy of CT for Prediction of Bladder Cancer Treatment Response with and without Computerized Decision Support. <i>Academic Radiology</i> , 2019, 26, 1137-1145.	2.5	46
9792	Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. <i>Clinical Cancer Research</i> , 2019, 25, 1727-1736.	7.0	39
9793	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 524-532.	4.1	8
9794	Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 743-753.e3.	0.8	30
9795	Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor. <i>Clinical and Translational Science</i> , 2019, 12, 58-65.	3.1	17
9796	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	7.0	40
9797	MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 346-355.	4.1	24
9798	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 445-455.	2.5	6
9799	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 19-24.	2.0	41
9800	Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. <i>Surgery</i> , 2019, 165, 703-711.	1.9	7
9801	Health Outcomes for Definite Concurrent Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Prospective Study. <i>Respiration</i> , 2019, 97, 310-318.	2.6	12
9802	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 120-133.	10.7	222
9803	Exaggeration of PFS by blinded, independent, central review (BICR). <i>Annals of Oncology</i> , 2019, 30, 332-338.	1.2	17

#	ARTICLE	IF	CITATIONS
9804	Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction. <i>Abdominal Radiology</i> , 2019, 44, 836-844.	2.1	8
9805	A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e203-e208.	1.9	6
9806	Prognostic Factors and Appropriate Lymph Node Dissection in Salvage Esophagectomy for Locally Advanced T4 Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 209-216.	1.5	20
9807	Electrochemotherapy – A locoregional therapy with well-established palliative effect in patient with large recurrent lesion of head and neck. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2019, 47, 41-46.	1.7	11
9808	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-“programmed death-1 and anti-“programmed death ligand 1 trials. <i>European Journal of Cancer</i> , 2019, 106, 1-11.	2.8	37
9809	Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy. <i>Lung Cancer</i> , 2019, 127, 53-58.	2.0	14
9810	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	7.3	147
9811	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	7.1	280
9812	Vascular disrupting effect of combretastatin A-4 phosphate with inhibition of vascular endothelial cadherin in canine osteosarcoma-xenografted mice. <i>Research in Veterinary Science</i> , 2019, 122, 1-6.	1.9	6
9813	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 578-584.	1.2	15
9814	E3611 – A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon- γ in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 524-532.	7.0	8
9815	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 722-731.	2.5	22
9816	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 684-692.	2.6	30
9817	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019, 127, 37-43.	2.0	60
9818	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 108-118.e4.	1.3	270
9819	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , 2019, 30, 243-249.	1.2	170
9820	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2072-2079.	7.0	29
9821	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2080-2087.	7.0	93

#	ARTICLE	IF	CITATIONS
9822	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	7.0	106
9823	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , 2019, 19, 55.	2.6	24
9824	Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. <i>BMC Cancer</i> , 2019, 19, 66.	2.6	42
9825	Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy. <i>BMC Cancer</i> , 2019, 19, 51.	2.6	19
9826	Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 313-318.	1.1	6
9827	A <i>UGT1A1</i> genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1629-1636.	4.1	27
9828	Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	2.8	58
9829	CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2019, 152, 568-573.	1.4	7
9830	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019, 5, 5.	30.5	579
9831	Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. <i>Current Medical Research and Opinion</i> , 2019, 35, 1241-1256.	1.9	65
9832	Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. <i>Journal of Medical Economics</i> , 2019, 22, 531-544.	2.1	15
9833	Influence of <i>ABCB1</i> C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 188-196.	1.5	13
9834	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019, 135, 161-168.	2.0	10
9835	FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. <i>Pancreatology</i> , 2019, 19, 296-301.	1.1	24
9836	CONSORT 2010 statement: extension checklist for reporting within person randomised trials. <i>British Journal of Dermatology</i> , 2019, 180, 534-552.	1.5	31
9837	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. <i>Immunotherapy</i> , 2019, 11, 297-309.	2.0	22
9838	Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 707-718.	2.0	10
9839	A successful compartmental approach for the treatment of breast cancer brain metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 573-580.	2.3	1

#	ARTICLE	IF	CITATIONS
9840	Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided?. <i>Surgery Today</i> , 2019, 49, 197-205.	1.5	8
9841	Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 508-515.	2.2	15
9842	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351.	2.6	28
9843	Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e306-e313.	1.9	19
9844	Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. <i>Translational Oncology</i> , 2019, 12, 502-512.	3.7	14
9845	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis" generator preliminary report. <i>Thoracic Cancer</i> , 2019, 10, 347-351.	1.9	54
9846	EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells. <i>EBioMedicine</i> , 2019, 39, 194-206.	6.1	31
9847	Peroxiredoxins in Cancer and Response to Radiation Therapies. <i>Antioxidants</i> , 2019, 8, 11.	5.1	34
9848	Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. <i>International Journal of Cancer</i> , 2019, 145, 295-305.	5.1	168
9849	Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases. <i>Journal of Surgical Oncology</i> , 2019, 119, 532-538.	1.7	3
9850	Impact of Baseline Cholinesterase in Patients with Primary Liver Tumors Undergoing Radioembolization: Impact on Outcome. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 85-92.	0.6	1
9851	KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 62-66.	1.3	2
9852	Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 468-474.	1.1	81
9853	Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. <i>Oral Oncology</i> , 2019, 89, 84-94.	1.5	27
9854	The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 5-9.	2.5	54
9855	Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin. <i>BMC Cancer</i> , 2019, 19, 10.	2.6	19
9857	Dosimetry for Iodine-131 Therapy for Metastatic Differentiated Thyroid Cancer. , 2019, , 633-645.		1
9858	Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). <i>Archives of Pharmacal Research</i> , 2019, 42, 14-24.	6.3	133

#	ARTICLE	IF	CITATIONS
9859	Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. <i>Clinical Biochemistry</i> , 2019, 65, 45-52.	1.9	23
9860	Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-“small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e233-e237.	2.6	11
9861	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019, 141, 392-396.	7.1	47
9862	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. <i>Annals of Oncology</i> , 2019, 30, 281-289.	1.2	88
9863	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
9864	The prognostic value of volumetric reduction of the target lesions after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2019, 41, 1863-1872.	2.0	5
9865	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	5.3	124
9866	Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 871-879.	3.3	12
9867	Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e420-e428.	1.9	6
9868	The diagnostic performance of 18F-fluoride PET/CT in bone metastases detection: a meta-analysis. <i>Clinical Radiology</i> , 2019, 74, 196-206.	1.1	17
9869	Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 564-566.	1.2	83
9870	Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-“IIA2 cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 3-12.	1.4	130
9871	Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. <i>Oncogene</i> , 2019, 38, 3387-3401.	5.9	109
9872	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. <i>Annals of Oncology</i> , 2019, 30, 325-331.	1.2	110
9873	Usefulness of ¹⁸ F-“Labeled Fluorodeoxyglucose-“Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2019, 71, 1147-1157.	5.6	30
9874	Patients with in-“transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-“A propensity score matched, single center study. <i>Journal of Surgical Oncology</i> , 2019, 119, 717-727.	1.7	1
9875	Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. <i>European Radiology</i> , 2019, 29, 2981-2988.	4.5	1
9876	Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab. <i>European Radiology</i> , 2019, 29, 3183-3191.	4.5	36

#	ARTICLE	IF	CITATIONS
9877	Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 82-89.	1.3	8
9878	Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i44-i61.	1.2	100
9879	Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. <i>BMC Cancer</i> , 2019, 19, 28.	2.6	44
9881	Metastasis of lower gingival squamous cell carcinoma to buccinator lymph node: case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2019, 17, 13.	1.9	3
9882	Treatment Response Prediction of Nasopharyngeal Carcinoma Based on Histogram Analysis of Diffusional Kurtosis Imaging. <i>American Journal of Neuroradiology</i> , 2019, 40, 326-333.	2.4	11
9883	Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 50.	3.7	30
9884	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , 2019, 96, 59-69.	1.9	14
9885	Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, e183773.	7.1	60
9886	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	7.1	206
9887	The cancer registry as an ally in monitoring treatment effectiveness. <i>Pulmonology</i> , 2019, 25, 3-8.	2.1	5
9888	Radiomics in RayPlus: a Web-Based Tool for Texture Analysis in Medical Images. <i>Journal of Digital Imaging</i> , 2019, 32, 269-275.	2.9	17
9889	Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. <i>Annals of Oncology</i> , 2019, 30, 13-16.	1.2	8
9890	Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 83.	7.1	63
9891	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
9892	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 718-727.	6.4	17
9893	Repeated SBRT for in- and out-of-field recurrences in the liver. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 246-253.	2.0	17
9894	The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 285-292.	3.6	17
9895	A meta-analysis of the efficacy and safety of iodine [¹³¹ I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 451-459.	1.5	9

#	ARTICLE	IF	CITATIONS
9896	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncolimmunology</i> , 2019, 8, e1537581.	4.6	61
9897	Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 123-129.	2.3	26
9898	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTRIC cancer HER2 reassessment study 3 (GASTHER3). <i>Gastric Cancer</i> , 2019, 22, 527-535.	5.3	88
9899	Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors. <i>Practical Radiation Oncology</i> , 2019, 9, e90-e97.	2.1	24
9900	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>Oncolimmunology</i> , 2019, 8, e1524695.	4.6	44
9901	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF μ mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	4.1	10
9902	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 1-14.		0
9903	Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 669-676.	6.4	44
9904	A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology. <i>Clinical Breast Cancer</i> , 2019, 19, 89-96.	2.4	13
9905	The impact of R1 resection for colorectal liver metastases on local recurrence and overall survival in the era of modern chemotherapy: An analysis of 1,428 resection areas. <i>Surgery</i> , 2019, 165, 712-720.	1.9	27
9906	Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. <i>Oncology</i> , 2019, 96, 1-7.	1.9	9
9907	Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 131-143.	2.3	8
9908	COSMIC: the Catalogue Of Somatic Mutations In Cancer. <i>Nucleic Acids Research</i> , 2019, 47, D941-D947.	14.5	3,196
9909	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	7.0	390
9910	Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 115-122.	2.3	14
9911	Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. <i>Oncology</i> , 2019, 96, 51-58.	1.9	6
9912	A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27524.	1.5	19
9913	Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 196-203.	4.1	61

#	ARTICLE	IF	CITATIONS
9914	Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic <i>PDGFR</i> D846V mutation. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27493.	1.5	7
9915	Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 652-662.	7.0	4
9916	A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. <i>Cancer</i> , 2019, 125, 99-108.	4.1	17
9917	Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 518-525.	5.3	44
9918	Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 455-463.	2.5	127
9919	Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma. <i>Oncotarget</i> , 2019, 8, e1500106.	4.6	18
9920	Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases. <i>European Radiology</i> , 2019, 29, 1939-1949.	4.5	12
9921	SPECT Imaging of Treatment-Related Tumor Necrosis Using Technetium-99m-Labeled Rhein. <i>Molecular Imaging and Biology</i> , 2019, 21, 660-668.	2.6	7
9922	The Response Evaluation Criteria in Solid Tumors (RECIST). , 2019, , 501-511.		6
9923	Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. <i>Breast</i> , 2019, 43, 113-119.	2.2	13
9924	Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 114-124.	1.9	8
9925	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
9926	Prognostic value of functional tumor burden on ⁶⁸ Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. <i>Neoplasia</i> , 2019, 66, 140-148.	1.6	9
9927	Rare Pelvic Malignant Tumors in Adults: Treatment Features and Clinical Outcome in Nonmetastatic Disease (Single Institution Experience). <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 56-66.	1.0	0
9928	Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 297-302.	1.9	44
9929	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.9	226
9930	Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [¹⁸ F] fluorodeoxyglucose and [¹⁸ F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 821-830.	6.4	31
9931	Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2019, 37, 105-116.	3.3	13

#	ARTICLE	IF	CITATIONS
9932	Digital Medicine. Computers in Health Care, 2019, , .	0.3	2
9933	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 501-508.	2.3	6
9934	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-L1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer, 2019, 125, 1038-1049.	4.1	66
9935	Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Molecular Cancer Therapeutics, 2019, 18, 448-458.	4.1	63
9936	Study of Percutaneous Stent Placement with Iodine-125 Seed Strand for Malignant Biliary Obstruction. CardioVascular and Interventional Radiology, 2019, 42, 268-275.	2.0	22
9937	A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 2019, 16, 185-204.	27.6	223
9938	The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. International Journal of Hyperthermia, 2019, 36, 36-43.	2.5	40
9939	OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Annals of Oncology, 2019, 30, 297-302.	1.2	147
9940	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clinical Cancer Research, 2019, 25, 1494-1504.	7.0	45
9941	Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdominal Radiology, 2019, 44, 2040-2047.	2.1	50
9942	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, The, 2019, 393, 156-167.	13.7	1,153
9943	Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis. Annals of Surgical Oncology, 2019, 26, 593-603.	1.5	27
9944	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. International Journal of Cancer, 2019, 144, 2887-2896.	5.1	56
9945	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. Acta Dermato-Venereologica, 2019, 99, 206-210.	1.3	22
9946	Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model. Journal of Immunological Methods, 2019, 465, 1-6.	1.4	6
9947	FOLFOX Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clinical Colorectal Cancer, 2019, 18, e39-e52.	2.3	21
9948	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene, 2019, 38, 1477-1488.	5.9	11
9949	Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-L1 inhibitor. International Journal of Cancer, 2019, 144, 1170-1179.	5.1	29

#	ARTICLE	IF	CITATIONS
9950	Impact of Topoisomerase II \pm , PTEN, ABCC1/MRP1, and Ki67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 275-288.	2.5	27
9951	Sizeâ€dependent Tumor Response to Photodynamic Therapy and Irinotecan Monotherapies Revealed by Longitudinal Ultrasound Monitoring in an Orthotopic Pancreatic Cancer Model. <i>Photochemistry and Photobiology</i> , 2019, 95, 378-386.	2.5	25
9952	Evaluation of Effects of TGF β 21 Inhibition on Gastric Cancer in Nude Mice by Diffusion Kurtosis Imaging and Inâ€line Xâ€ray Phase Contrast Imaging With Sequential Histology. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1553-1564.	3.4	3
9953	Discrimination of Pulmonary Nodule Volume Change for Low- and High-contrast Tasks in a Phantom CT Study with Low-dose Protocols. <i>Academic Radiology</i> , 2019, 26, 937-948.	2.5	5
9954	Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 73-91.	4.5	102
9955	Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for treatment of clear cell sarcoma of the kidney in children. <i>Journal of Pediatric Surgery</i> , 2019, 54, 550-556.	1.6	9
9956	Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. <i>Modern Pathology</i> , 2019, 32, 367-375.	5.5	31
9957	Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of CWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort. <i>Pharmacogenomics Journal</i> , 2019, 19, 25-32.	2.0	12
9958	Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2019, 37, 473-481.	2.6	9
9959	Analysis of a National Programme for Selective Internal Radiation Therapy for Colorectal Cancer Liver Metastases. <i>Clinical Oncology</i> , 2019, 31, 58-66.	1.4	22
9960	Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC. <i>International Journal of Cancer</i> , 2019, 144, 2677-2682.	5.1	34
9961	Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. <i>European Radiology</i> , 2019, 29, 1882-1892.	4.5	31
9962	Preâ€Operative chemotherapy response assessed by contrastâ€enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2019, 37, 258-264.	2.3	10
9963	Usefulness of Stereotactic Radiotherapy Using the CyberKnife for Patients with Inoperable Locoregional Recurrences of Differentiated Thyroid Cancer. <i>World Journal of Surgery</i> , 2019, 43, 513-518.	1.6	8
9964	Conversion Surgery for Gastric Cancer with Peritoneal Metastasis Based on the Diagnosis of Second-Look Staging Laparoscopy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1758-1766.	1.7	29
9965	Identification of a highly lethal V3⁺TP53⁺ subset in ALK⁺ lung adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 144, 190-199.	5.1	67
9966	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16â€Related Cancer. <i>JAMA Oncology</i> , 2019, 5, 67.	7.1	344
9967	Incidence and Patterns of Locoregional Failure After Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. <i>Practical Radiation Oncology</i> , 2019, 9, e29-e37.	2.1	12

#	ARTICLE	IF	CITATIONS
9968	Are volume measurements of non-functioning pituitary adenomas reliable?. <i>Endocrine</i> , 2019, 63, 171-176.	2.3	5
9969	Copenhagen Prospective Personalized Oncology (CoPPO)â€”Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1239-1247.	7.0	59
9970	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 155-165.	2.5	11
9971	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019, 20, 30-36.e3.	2.6	37
9972	Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. <i>British Journal of Radiology</i> , 2019, 92, 20180642.	2.2	111
9973	Gastric cancer and imaging biomarkers: Part 1 â€” a critical review of DW-MRI and CE-MDCT findings. <i>European Radiology</i> , 2019, 29, 1743-1753.	4.5	40
9974	Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. <i>Endocrine</i> , 2019, 64, 384-392.	2.3	12
9975	Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using Hâ€šscan Ultrasound Imaging: Preliminary Preclinical Results. <i>Journal of Ultrasound in Medicine</i> , 2019, 38, 1259-1268.	1.7	44
9976	Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e81-e90.	2.6	40
9977	Long-term outcomes of advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy followed by surgery: a 20-year experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 360-367.	1.1	15
9978	Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18 Fâ€šfluorodeoxyglucoseâ€špositron emission tomography and CT perfusion study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 94-101.	1.8	10
9979	Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. <i>Pathology and Oncology Research</i> , 2019, 25, 45-50.	1.9	9
9980	Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2019, 25, 51-58.	1.9	17
9981	Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. <i>Journal of Pharmacy Practice</i> , 2019, 32, 219-224.	1.0	4
9982	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. <i>Annals of Surgery</i> , 2019, 270, 340-347.	4.2	280
9983	Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 335-346.	12.1	138
9984	Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 298-303.	1.3	18
9985	Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases. <i>Irish Journal of Medical Science</i> , 2019, 188, 43-53.	1.5	2

#	ARTICLE	IF	CITATIONS
9986	Oligometastatic cancer in elderly patients: the "oligometastatic" radiotherapy approach. Aging Clinical and Experimental Research, 2019, 31, 109-114.	2.9	13
9987	Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. Current Problems in Diagnostic Radiology, 2019, 48, 235-240.	1.4	15
9988	Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. Journal of Neurosurgery, 2018, 130, 1-8.	1.6	54
9989	Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics Journal, 2019, 19, 164-177.	2.0	28
9990	Carboplatin plus pemetrexed for the elderly incurable chemo-naïve nonsquamous non-small cell lung cancer: Meta-analysis. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e3-e10.	1.1	3
9991	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 2020, 6, 999-1005.	3.1	5
9992	A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints. Statistical Methods in Medical Research, 2020, 29, 230-242.	1.5	2
9993	Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. Neuroendocrinology, 2020, 110, 83-91.	2.5	44
9994	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut, 2020, 69, 531-539.	12.1	97
9995	Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. Journal of Geriatric Oncology, 2020, 11, 475-481.	1.0	25
9996	Critical Challenges to the Management of Clinical Trial Imaging: Recommendations for the Conduct of Imaging at Investigational Sites. Academic Radiology, 2020, 27, 300-306.	2.5	1
9997	Primary Intra-abdominal Ewing's Sarcoma in Adults: A Multimodality Imaging Spectrum. Current Problems in Diagnostic Radiology, 2020, 49, 133-139.	1.4	3
9998	Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. European Radiology, 2020, 30, 291-300.	4.5	10
9999	Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. Acta Clinica Belgica, 2020, 75, 362-369.	1.2	3
10000	Effect of MRI-based semiautomatic size-assessment in cerebral metastases on the RANO-BM classification. Clinical Neuroradiology, 2020, 30, 263-270.	1.9	3
10001	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. International Journal of Cancer, 2020, 146, 1359-1368.	5.1	55
10002	Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Digestive Endoscopy, 2020, 32, 39-48.	2.3	10
10003	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 561-570.	2.2	43

#	ARTICLE	IF	CITATIONS
10004	Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 33-39.	5.0	17
10005	Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study. <i>Clinical and Translational Oncology</i> , 2020, 22, 151-157.	2.4	6
10006	HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. <i>Cancer Gene Therapy</i> , 2020, 27, 341-355.	4.6	61
10007	Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 21-36.	2.4	39
10008	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. <i>Investigational New Drugs</i> , 2020, 38, 172-180.	2.6	57
10009	A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. <i>Brazilian Journal of Otorhinolaryngology</i> , 2020, 86, 676-686.	1.0	12
10010	Effects of Neoadjuvant Chemotherapy Toxicity and Postoperative Complications on Short-term and Long-term Outcomes After Curative Resection of Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1278-1289.	1.7	9
10011	Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas. <i>British Journal of Radiology</i> , 2020, 93, 20180883.	2.2	11
10012	Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 659-670.	1.7	13
10013	Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 402-409.	2.6	43
10014	Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy. <i>Clinical and Translational Oncology</i> , 2020, 22, 50-59.	2.4	65
10015	A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer. <i>Investigational New Drugs</i> , 2020, 38, 392-401.	2.6	9
10016	Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 410-418.	2.6	0
10017	PET/CT-Based Response Evaluation in Cancer—A Systematic Review of Design Issues. <i>Molecular Imaging and Biology</i> , 2020, 22, 33-46.	2.6	8
10018	First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2020, 22, 158-162.	2.4	15
10019	Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy. <i>Magnetic Resonance in Medical Sciences</i> , 2020, 19, 29-39.	2.0	6
10020	Major Pathologic Response after Induction Therapy Has a Long-Term Impact on Survival and Tumor Recurrence in Stage IIIA/B Locally Advanced NSCLC. <i>Thoracic and Cardiovascular Surgeon</i> , 2020, 68, 639-645.	1.0	5
10021	Advancing Semantic Interoperability of Image Annotations: Automated Conversion of Non-standard Image Annotations in a Commercial PACS to the Annotation and Image Markup. <i>Journal of Digital Imaging</i> , 2020, 33, 49-53.	2.9	5

#	ARTICLE	IF	CITATIONS
10022	Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 311-316.	1.2	55
10023	Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 151-157.	2.2	7
10024	Albuminâ€globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 74-81.	2.2	25
10025	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 440-459.	1.2	37
10026	Temozolomide-Capcitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. <i>Neuroendocrinology</i> , 2020, 110, 155-157.	2.5	8
10027	Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 124-133.	0.8	28
10028	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 854-861.	1.2	64
10029	Withholding the Introduction of Antiâ€Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wildâ€Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <i>Oncologist</i> , 2020, 25, e266-e275.	3.7	3
10030	Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2020, 6, 125.	7.1	53
10031	Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases. <i>International Journal of Clinical Oncology</i> , 2020, 25, 267-273.	2.2	18
10032	Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 62-68.e2.	1.9	15
10033	Response of patients with melanoma to immune checkpoint blockadeâ€ insights gleaned from analysis of a new mathematical mechanistic model. <i>Journal of Theoretical Biology</i> , 2020, 485, 110033.	1.7	17
10034	The McCaVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). <i>Oncologist</i> , 2020, 25, e451-e459.	3.7	30
10035	Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab. <i>Clinical and Translational Oncology</i> , 2020, 22, 928-934.	2.4	9
10036	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptorâ€Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapyâ€MONARCH 2. <i>JAMA Oncology</i> , 2020, 6, 116.	7.1	572
10037	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	5.4	59
10038	Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. <i>Endocrine Reviews</i> , 2020, 41, 371-403.	20.1	116
10039	Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandardâ€TM's Tumor Regression Grade (TRG) in gastric adenocarcinoma. <i>Digestive and Liver Disease</i> , 2020, 52, 107-114.	0.9	24

#	ARTICLE	IF	CITATIONS
10040	Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. <i>Acta Oncologica</i> , 2020, 59, 310-314.	1.8	5
10041	MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer. <i>Digestion</i> , 2020, 101, 794-806.	2.3	16
10042	The Landmark Series: Non-melanoma Skin Cancers. <i>Annals of Surgical Oncology</i> , 2020, 27, 22-27.	1.5	13
10043	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	3.6	32
10045	Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine</i> , 2020, 67, 233-242.	2.3	5
10046	Positron Emission Tomography in T3/T4 Non-Small Cell Lung Cancer After Induction Chemoradiotherapy. <i>Annals of Thoracic Surgery</i> , 2020, 109, 255-261.	1.3	1
10047	Growth of hepatocellular adenoma during pregnancy: A prospective study. <i>Journal of Hepatology</i> , 2020, 72, 119-124.	3.7	23
10048	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 169-185.	3.1	21
10049	Nephron-Sparing Robotic Radiosurgical Therapy for Primary Renal Cell Carcinoma: Single-Institution Experience and Review of the Literature. <i>Advances in Radiation Oncology</i> , 2020, 5, 204-211.	1.2	9
10050	CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 225-231.	2.6	4
10051	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncoimmunology</i> , 2020, 9, 1659093.	4.6	62
10052	Ferumoxitol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. <i>American Journal of Roentgenology</i> , 2020, 214, 105-113.	2.2	17
10053	Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. <i>European Urology Oncology</i> , 2020, 3, 680-686.	5.4	14
10054	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	1.1	181
10055	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	4.1	25
10056	Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1202-1209.	2.4	16
10057	Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of Neuroendocrine Tumor Liver Metastasis to Transcatheter Arterial Bland Embolization. <i>Neuroendocrinology</i> , 2020, 110, 697-704.	2.5	7
10058	PD-1 Blockade in Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 71-80.	1.6	119

#	ARTICLE	IF	CITATIONS
10059	Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial. <i>Acta Oncologica</i> , 2020, 59, 212-218.	1.8	3
10060	Two novel TSC2 mutations in renal epithelioid angiomyolipoma sensitive to everolimus. <i>Cancer Biology and Therapy</i> , 2020, 21, 4-11.	3.4	5
10061	Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 325-333.	2.0	19
10062	Histogram analysis of DCE-MRI for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma. <i>Radiologia Medica</i> , 2020, 125, 165-176.	7.7	19
10064	Clinical Trial Designs in Oncology. , 2020, , 296-307.e2.		3
10065	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2020, 25, 33-45.	3.7	87
10066	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. <i>Clinical and Translational Oncology</i> , 2020, 22, 844-851.	2.4	21
10067	Comparison of Perioperative and Survival Outcomes of Laparoscopic Versus Open Gastrectomy after Preoperative Chemotherapy: a Propensity Score-Matched Analysis. <i>Indian Journal of Surgery</i> , 2020, 82, 42-49.	0.3	6
10068	Volumetric histogram analysis of apparent diffusion coefficient for predicting pathological complete response and survival in esophageal cancer patients treated with chemoradiotherapy. <i>American Journal of Surgery</i> , 2020, 219, 1024-1029.	1.8	12
10069	MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma. <i>European Radiology</i> , 2020, 30, 537-546.	4.5	104
10070	Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 881-894.	6.4	47
10071	The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1228-1238.	6.4	16
10072	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	1.2	94
10073	Heterogeneity of Hepatocellular Carcinoma on Imaging. <i>Seminars in Liver Disease</i> , 2020, 40, 061-069.	3.6	12
10074	Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. <i>Supportive Care in Cancer</i> , 2020, 28, 1639-1647.	2.2	7
10075	Endoscopic Evaluation of Neoadjuvant Chemotherapeutic Efficacy in Gastric Cancer before Gastrectomy Might be as Useful as Histological Assessment after Gastrectomy. <i>Digestion</i> , 2020, 101, 466-472.	2.3	2
10076	A response-adaptive randomization procedure for multi-armed clinical trials with normally distributed outcomes. <i>Biometrics</i> , 2020, 76, 197-209.	1.4	18
10077	Clinical outcomes according to the modified endoscopic criteria for neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma. <i>Digestive Endoscopy</i> , 2020, 32, 337-345.	2.3	3

#	ARTICLE	IF	CITATIONS
10078	Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. <i>Academic Radiology</i> , 2020, 27, e10-e18.	2.5	11
10079	Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. <i>Clinical and Translational Oncology</i> , 2020, 22, 603-611.	2.4	36
10080	Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020, 21, 28-36.	2.6	5
10081	Diffusion gradient nonlinearity bias correction reduces bias of breast cancer bone metastasis ADC values. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 904-911.	3.4	2
10082	Quantitative evaluation of the intratumoral distribution of platinum in oxaliplatin-treated rectal cancer: <i>in situ</i> visualization of platinum <i>via</i> synchrotron radiation X-ray fluorescence spectrometry. <i>International Journal of Cancer</i> , 2020, 146, 2498-2509.	5.1	6
10083	Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. <i>Gastric Cancer</i> , 2020, 23, 319-327.	5.3	40
10084	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. <i>Hepatology Research</i> , 2020, 50, 137-143.	3.4	19
10085	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 831-843.	2.6	71
10086	A Complete Response Achieved in a Patient with Hepatic Metastasis from Sigmoid Colon Cancer by a Regimen Containing Ramucirumab: a Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 624-627.	1.3	0
10087	Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 807-815.	6.4	12
10088	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 1077-1084.	2.6	15
10089	Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2020, 142, 17-26.	0.6	18
10090	Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma. <i>Methods in Molecular Biology</i> , 2020, 2059, 191-205.	0.9	14
10091	Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours. <i>Neuroendocrinology</i> , 2020, 110, 413-421.	2.5	23
10092	Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 110-119.	2.0	19
10093	First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. <i>Journal of Nuclear Medicine</i> , 2020, 61, 350-356.	5.0	19
10094	Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. <i>Neuroendocrinology</i> , 2020, 110, 517-524.	2.5	22
10095	Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma. <i>European Radiology</i> , 2020, 30, 1679-1689.	4.5	19

#	ARTICLE	IF	CITATIONS
10096	PET/Computed Tomography in Treatment Response Assessment in Cancer. PET Clinics, 2020, 15, 101-123.	3.0	8
10097	Surveillance Imaging After Curative Intent Therapy for Lung Cancer. Seminars in Roentgenology, 2020, 55, 60-69.	0.6	1
10098	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. Cancer Chemotherapy and Pharmacology, 2020, 85, 469-472.	2.3	0
10099	REFLECTâ€”a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. Journal of Gastroenterology, 2020, 55, 113-122.	5.1	123
10100	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptorâ€”Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. JAMA Oncology, 2020, 6, 100.	7.1	68
10101	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 493-501.	2.5	7
10102	A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposureâ€”Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). Clinical Colorectal Cancer, 2020, 19, 13-21.e3.	2.3	17
10103	The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy. Clinical Radiology, 2020, 75, 79.e9-79.e18.	1.1	3
10104	Treatment Outcome of metastatic lesions from renal cell carcinoma under Going Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer Treatment and Research Communications, 2020, 22, 100161.	1.7	18
10105	Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. Journal of Vascular Surgery, 2020, 71, 318-327.	1.1	117
10106	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 139, 80-88.	2.0	9
10107	Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 417-428.	2.5	9
10108	Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e180-e189.	1.9	15
10109	Evaluation of 18Fâ€”FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. Head and Neck, 2020, 42, 163-170.	2.0	7
10110	[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 849-859.	6.4	22
10111	Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. CardioVascular and Interventional Radiology, 2020, 43, 402-410.	2.0	11
10112	HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies. Breast Cancer Research and Treatment, 2020, 179, 543-555.	2.5	28
10113	A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational New Drugs, 2020, 38, 1145-1155.	2.6	14

#	ARTICLE	IF	CITATIONS
10114	Olaparib as maintenance therapy in patients with BRCA 1&2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020, 156, 38-44.	1.4	62
10115	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	7.1	112
10116	Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 502-507.	2.2	9
10117	Efficacy and safety of dabrafenib&trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF&V600 mutation: A systematic review and network meta&analysis. <i>Dermatologic Therapy</i> , 2020, 33, e13145.	1.7	8
10118	Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 113-119.	2.3	10
10119	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc&,) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 77-83.	3.3	22
10120	The Value of Contrast-Enhanced CT in the Detection of Residual Disease After Neo-Adjuvant Chemotherapy in Ovarian Cancer. <i>Academic Radiology</i> , 2020, 27, 951-957.	2.5	5
10121	JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8. <i>Gastric Cancer</i> , 2020, 23, 426-436.	5.3	15
10122	Could excision repair cross&complementing group& mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e19-e26.	1.1	1
10123	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 5-18.	1.8	3
10124	Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 19-28.	1.9	7
10125	The prognostic role of soluble TGF&beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. <i>Cancer Medicine</i> , 2020, 9, 43-51.	2.8	14
10127	Beyond Randomized Clinical Trials: Use of External Controls. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 806-816.	4.7	65
10128	Measurement Reliability and Diagnostic Accuracy of Virtual Monoenergetic Dual-Energy CT in Patients with Colorectal Liver Metastases. <i>Academic Radiology</i> , 2020, 27, e168-e175.	2.5	15
10129	Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in&sporadic medullary thyroid carcinoma. <i>Surgery</i> , 2020, 167, 80-86.	1.9	8
10130	The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non&small-cell lung cancer: a real-life retrospective study. <i>Oncolmmunology</i> , 2020, 9, 1682383.	4.6	34
10131	Application of apparent diffusion coefficient values derived from diffusion-weighted imaging for assessing different sized metastatic lymph nodes in cervical cancers. <i>Acta Radiologica</i> , 2020, 61, 848-855.	1.1	13
10132	A pilot study to assess oxidative and inflammatory markers as early indicator for response to chemotherapy in non&small cell lung cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 179-184.	1.5	1

#	ARTICLE	IF	CITATIONS
10133	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 73-83.	7.7	37
10134	Health care utilization and steroidâ€refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	4.1	13
10135	Response assessment using [⁶⁸ Ga]Gaâ€PSMA ligand PET in patients undergoing systemic therapy for metastatic castrationâ€resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	2.3	49
10136	Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 3-11.	3.0	5
10137	Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. <i>Cancer</i> , 2020, 126, 105-111.	4.1	47
10138	Combined ipilimumab and nivolumab firstâ€line and after BRAFâ€targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	3.3	51
10139	Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 205-219.	2.5	16
10140	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	1.1	53
10141	¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 662-670.	2.5	34
10142	Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma. <i>In Vivo</i> , 2020, 34, 247-253.	1.3	6
10143	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i> ¹⁸F-FDG-PET. <i>Theranostics</i> , 2020, 10, 925-937.	10.0	46
10144	Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 265-272.	2.3	47
10145	Comparison of the effects of radiotherapy doses of 50.4ÂGy and 60ÂGy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society. <i>Esophagus</i> , 2020, 17, 122-126.	1.9	12
10146	Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis. <i>Head and Neck</i> , 2020, 42, 955-962.	2.0	3
10147	Antiâ€tumour immune response in GL261 glioblastoma generated by Temozolomide Immuneâ€Enhancing Metronomic Schedule monitored with MRSIâ€based nosological images. <i>NMR in Biomedicine</i> , 2020, 33, e4229.	2.8	15
10148	Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 435-448.	4.2	44
10149	Determining the prevalence and severity of cancer cachexia in advanced non-small cell lung cancer and its relationship with chemotherapy outcomes. <i>Supportive Care in Cancer</i> , 2020, 28, 4373-4380.	2.2	7
10150	Breast and colorectal cancer recurrence and progression captured by five U.S. population-based registries: Findings from National Program of Cancer Registries patient-centered outcome research. <i>Cancer Epidemiology</i> , 2020, 64, 101653.	1.9	10

#	ARTICLE	IF	CITATIONS
10151	The QIBA Profile for FDG PET/CT: Improving the Value of PET. <i>Radiology</i> , 2020, 294, 658-659.	7.3	1
10152	Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. <i>Clinical Sarcoma Research</i> , 2020, 10, 1.	2.3	23
10153	Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 55-63.	3.7	123
10154	Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-small Cell Lung Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 143-152.	2.5	6
10155	Prospective use of the single-mouse experimental design for the evaluation of PLX038A. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 251-263.	2.3	12
10156	Advances in the Diagnosis and Management of Nonfunctional Pancreatic Neuroendocrine Tumors. , 2020, , 221-232.		0
10157	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. <i>Nature Cancer</i> , 2020, 1, 75-85.	13.2	68
10158	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	7.1	64
10160	Measurements of cervical lymph nodes in children on computed tomography. <i>Pediatric Radiology</i> , 2020, 50, 534-542.	2.0	10
10162	Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1175-1185.	2.6	11
10163	Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e277-e283.	1.9	5
10164	Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 18-24.	7.0	10
10165	Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study. <i>Medical Principles and Practice</i> , 2020, 29, 429-435.	2.4	6
10166	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.4	2
10167	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). <i>Annals of Oncology</i> , 2020, 31, 79-87.	1.2	36
10168	Neoadjuvant treatment by ECT in cutaneous malignant neoplastic lesions. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 904-912.	1.0	5
10169	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	6.3	138
10170	iRECIST: how to do it. <i>Cancer Imaging</i> , 2020, 20, 2.	2.8	41

#	ARTICLE	IF	CITATIONS
10171	Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis. <i>Hormones and Cancer</i> , 2020, 11, 42-51.	4.9	10
10172	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <i>Cancer</i> , 2020, 126, 1274-1282.	4.1	37
10173	A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. <i>International Journal of Cancer</i> , 2020, 147, 1143-1151.	5.1	16
10175	Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). <i>Abdominal Radiology</i> , 2020, 45, 1872-1882.	2.1	1
10176	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 457-466.	2.5	21
10177	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
10178	Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei. <i>International Journal of Clinical Oncology</i> , 2020, 25, 774-781.	2.2	15
10179	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 705-712.	2.2	3
10180	Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2020, 33, 469-481.	2.0	1
10181	Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 333-339.	3.3	5
10182	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. <i>Journal of Neuro-Oncology</i> , 2020, 146, 339-346.	2.9	17
10183	Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2020, 37, 12.	2.5	5
10184	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10.	2.8	19
10185	Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2020, 125, 121-129.	2.8	32
10186	Imaging for Response Assessment in Radiation Oncology. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 293-306.	2.2	11
10187	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. <i>Lung Cancer</i> , 2020, 140, 71-79.	2.0	8
10188	The Charge to Liberate Siloed Radiation Oncology Treatment Data Through Uniform and Structured Documentation: A Commentary on American Society for Radiation Oncology and Commission on Cancer Recommendations. <i>Practical Radiation Oncology</i> , 2020, 10, 304-307.	2.1	2
10189	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 526-532.	1.6	18

#	ARTICLE	IF	CITATIONS
10190	Radiographic findings after stereotactic body radiation therapy for stage I non-small cell lung carcinomas: retrospective analysis of 90 patients. <i>Journal of Radiotherapy in Practice</i> , 2020, 19, 333-340.	0.5	0
10191	Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 498-505.	6.4	105
10192	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 1485-1494.	2.8	48
10193	Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. <i>Cancer Medicine</i> , 2020, 9, 1383-1391.	2.8	37
10194	Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?. <i>Thyroid</i> , 2020, 30, 418-424.	4.5	3
10195	Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem. <i>Thyroid</i> , 2020, 30, 229-236.	4.5	14
10196	Imaging of Novel Oncologic Treatments in Lung Cancer Part 1. <i>Journal of Thoracic Imaging</i> , 2020, 35, 26-36.	1.5	4
10197	Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy. <i>Cancer Research</i> , 2020, 80, 868-876.	0.9	10
10198	Clinical outcomes of patients with nasopharyngeal carcinoma treated with antibiotics for radiation-induced mucositis: a retrospective study. <i>Journal of International Medical Research</i> , 2020, 48, 030006051987489.	1.0	2
10199	PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 293-304.	1.6	10
10200	Intensity modulation radiation therapy as alternative primary non-surgical treatment of upper tract urothelial carcinoma. <i>International Journal of Urology</i> , 2020, 27, 266-268.	1.0	2
10201	Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 408-414.	1.9	12
10202	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1009-1016.	7.0	56
10203	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	1.5	39
10204	Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. <i>Thoracic Cancer</i> , 2020, 11, 389-393.	1.9	3
10205	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 101, 104523.	1.5	38
10206	Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences. <i>Thyroid</i> , 2020, 30, 214-221.	4.5	29
10207	A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 8-14.	1.9	13

#	ARTICLE	IF	CITATIONS
10208	Favorable radiological antitumor response at 2Âweeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 374-381.	3.4	25
10209	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28073.	1.5	52
10210	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 165-174.	2.2	27
10211	Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 29-39.	2.5	24
10212	Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: Application of automated measurements on computed tomography scans. <i>JGH Open</i> , 2020, 4, 145-152.	1.6	4
10213	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. <i>International Journal of Cancer</i> , 2020, 146, 3196-3206.	5.1	28
10214	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2020, 156, 13-22.	1.4	9
10215	Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Nonâ€Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 108-119.	3.4	187
10216	Quality of life in patients with liver tumors treated with holmium-166 radioembolization. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 95-105.	3.3	4
10217	Shear Wave Elastography Can Differentiate between Radiation-Responsive and Non-responsive Pancreatic Tumors: An ex Vivo Study with Murine Models. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 393-404.	1.5	4
10218	What is the value of thirdâ€line chemotherapy in advanced gastroesophageal cancer? A 5â€year retrospective analysis at a single center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 23-27.	1.1	1
10219	Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. <i>Acta Radiologica</i> , 2020, 61, 983-991.	1.1	9
10220	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. <i>Theranostics</i> , 2020, 10, 1708-1718.	10.0	68
10221	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	2.9	126
10222	Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapyâ€The Value of Salvage Peptide Receptor Radionuclide Therapy. <i>Clinical Nuclear Medicine</i> , 2020, 45, e198-e200.	1.3	1
10223	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1461-1468.	3.6	39
10224	Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 651-659.	1.5	29
10225	Liver Metastases. , 2020, , 846-862.e4.		2

#	ARTICLE	IF	CITATIONS
10226	Efficacy of cascade-primed cell infusion as an adjuvant immunotherapy with concurrent chemotherapy for patients with non-“small-cell lung cancer: A retrospective observational study with a 5-year follow-up. <i>Cytotherapy</i> , 2020, 22, 35-43.	0.7	3
10227	Diffusion-Weighted MR Imaging of Primary and Secondary Lung Cancer: Predictive Value for Response to Transpulmonary Chemoembolization and Transarterial Chemoperfusion. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 301-310.	0.5	3
10228	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 37-43.	2.0	24
10229	Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. <i>Thrombosis Research</i> , 2020, 187, 9-17.	1.7	21
10230	The expression levels and clinical significance of MFG-E8 and CD133 in epithelial ovarian cancer. <i>Gynecological Endocrinology</i> , 2020, 36, 803-807.	1.7	7
10231	Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea. <i>Thyroid</i> , 2020, 30, 732-738.	4.5	28
10232	The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. <i>Radiology</i> , 2020, 294, 647-657.	7.3	49
10233	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 2908-2920.	7.0	30
10234	GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 565-571.	1.7	15
10235	Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. <i>Medical Oncology</i> , 2020, 37, 13.	2.5	18
10236	Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 220-227.	2.4	10
10237	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100492.	1.1	5
10238	Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion. <i>Neuro-Oncology</i> , 2020, 22, 318-332.	1.2	40
10239	Comparison Between ¹⁸ F-FDG PET-Based and CT-Based Criteria in Non-“Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 990-998.	5.0	44
10240	Definition and diagnosis of aggressive pituitary tumors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 203-208.	5.7	33
10241	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	10.7	204
10242	Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome. <i>Radiotherapy and Oncology</i> , 2020, 144, 121-126.	0.6	11
10243	U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 20-28.	0.5	15

#	ARTICLE	IF	CITATIONS
10244	Poor glycemic control might compromise the efficacy of chemotherapy in non-small cell lung cancer patients with diabetes mellitus. <i>Cancer Medicine</i> , 2020, 9, 902-911.	2.8	8
10245	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e484-e491.	3.7	29
10246	Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. <i>Journal of Nuclear Medicine</i> , 2020, 61, 678-682.	5.0	81
10247	Evolving Practice Patterns Over Two Decades (1993-2013) in the Management of Desmoid-type Fibromatosis in British Columbia. <i>Clinical Oncology</i> , 2020, 32, e102-e110.	1.4	12
10248	Hypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults. <i>Clinical Oncology</i> , 2020, 32, 316-326.	1.4	12
10249	Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 318-324.	1.3	1
10250	First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 272-276.	1.0	1
10251	Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. <i>Cancer Medicine</i> , 2020, 9, 1033-1043.	2.8	23
10252	Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study. <i>JGH Open</i> , 2020, 4, 477-483.	1.6	9
10253	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	2.8	31
10254	MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. <i>Journal of Dermatological Science</i> , 2020, 97, 77-79.	1.9	13
10255	Production of CAR-T Cells for Clinical Applications. , 2020, , 51-62.		0
10256	DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 1449-1459.	7.0	16
10257	Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 1837-1845.	7.0	32
10258	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
10259	Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer. <i>European Radiology</i> , 2020, 30, 1896-1907.	4.5	26
10260	Alterations in plasma concentrations of energy-balance-related metabolites in patients with lung, or head & neck, cancers: Effects of radiotherapy. <i>Journal of Proteomics</i> , 2020, 213, 103605.	2.4	10
10261	Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2020, 9, 920-930.	2.8	4

#	ARTICLE	IF	CITATIONS
10262	A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 720-731.	2.2	7
10263	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. <i>Oral Oncology</i> , 2020, 100, 104477.	1.5	9
10264	Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 723-728.	5.0	13
10265	Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1168-1182.	6.4	115
10266	Prostate MRI with PI-RADS v2.1: initial detection and active surveillance. <i>Abdominal Radiology</i> , 2020, 45, 2133-2142.	2.1	6
10267	CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 558-566.	1.6	23
10268	Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel. <i>Prostate</i> , 2020, 80, 247-255.	2.3	8
10269	The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 777-785.	2.5	40
10270	Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 28-34.	1.3	8
10271	Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. <i>Pain</i> , 2020, 161, 127-134.	4.2	15
10272	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>JAMA Oncology</i> , 2020, 6, 217.	7.1	18
10273	Challenges in assessing solid tumor responses to immunotherapy. <i>Cancer Gene Therapy</i> , 2020, 27, 528-538.	4.6	36
10274	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
10275	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
10276	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 3-11.	1.3	7
10277	Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network. <i>Neuroendocrinology</i> , 2020, 110, 338-350.	2.5	43
10278	Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 168-177.	4.1	19
10279	Augmented Radiologist Workflow Improves Report Value and Saves Time: A Potential Model for Implementation of Artificial Intelligence. <i>Academic Radiology</i> , 2020, 27, 96-105.	2.5	47

#	ARTICLE	IF	CITATIONS
10280	CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage. <i>Cancer Medicine</i> , 2020, 9, 350-360.	2.8	16
10281	Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels. <i>Acta Oncologica</i> , 2020, 59, 257-259.	1.8	7
10282	Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. <i>Oncologist</i> , 2020, 25, e469-e476.	3.7	20
10283	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. <i>JAMA Oncology</i> , 2020, 6, 133.	7.1	11
10284	Clinical utility of ¹⁷⁷ Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. <i>Head and Neck</i> , 2020, 42, 401-416.	2.0	50
10285	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177.	0.8	13
10286	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	1.1	102
10287	Perfusion Quantification of Liver Metastases of Colorectal Cancer Treated with Anti-angiogenic-Based Therapy: Assessment of Intra- and Inter-observer Reproducibility of Parameters in Three Regions of Interest Outlining Lesions. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 286-296.	1.5	2
10288	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. <i>Acta Oncologica</i> , 2020, 59, 284-290.	1.8	11
10289	Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report. <i>Thoracic Cancer</i> , 2020, 11, 447-450.	1.9	6
10290	Sâ€ plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e68-e73.	1.1	1
10291	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	1.6	450
10292	Response evaluation after stereotactic ablative radiotherapy for localised non-small-cell lung cancer: an equipoise of available resource and accuracy. <i>British Journal of Radiology</i> , 2020, 93, 20190647.	2.2	0
10293	Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 711-720.	2.5	15
10295	Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy. <i>Breast</i> , 2020, 49, 115-122.	2.2	52
10296	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. <i>Clinical Lung Cancer</i> , 2020, 21, 255-263.e4.	2.6	28
10297	Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. <i>Investigational New Drugs</i> , 2020, 38, 211-218.	2.6	31
10298	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	10.7	450

#	ARTICLE	IF	CITATIONS
10299	Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2133-2143.	2.4	9
10300	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 214-222.	1.6	106
10301	18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1158-1167.	6.4	72
10302	Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma: Systematic review and meta-analysis. <i>Head and Neck</i> , 2020, 42, 774-786.	2.0	52
10303	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 217-223.	2.3	13
10304	External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 67-73.	2.5	14
10305	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
10306	Early response evaluation during preoperative chemotherapy for colorectal liver metastases: Combined size and morphology-based criteria predict pathological response and survival after resection. <i>Journal of Surgical Oncology</i> , 2020, 121, 382-391.	1.7	8
10308	Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846. <i>Biomedicine and Pharmacotherapy</i> , 2020, 122, 109587.	5.6	12
10309	Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer. <i>Genomics</i> , 2020, 112, 2063-2071.	2.9	55
10310	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1&2 study. <i>Lancet Oncology</i> , The, 2020, 21, 134-144.	10.7	103
10311	The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 695-712.	6.4	37
10312	Nodal metastasis in gynecologic malignancies: Update on imaging and management. <i>Clinical Imaging</i> , 2020, 59, 157-166.	1.5	2
10313	The expression of versican and its role in pancreatic neuroendocrine tumors. <i>Pancreatology</i> , 2020, 20, 142-147.	1.1	5
10314	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 211-221.	1.4	15
10315	99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 105-112.	1.3	8
10316	Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 67-74.	2.4	14
10317	Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy. <i>Clinical Nuclear Medicine</i> , 2020, 45, e48-e50.	1.3	7

#	ARTICLE	IF	CITATIONS
10318	Ectopic Corticotropin-Releasing Hormoneâ€“Secreting Pancreatic Neuroendocrine Tumor. Clinical Nuclear Medicine, 2020, 45, e125-e127.	1.3	1
10319	Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery, 2020, 271, 245-256.	4.2	54
10320	Novel treatment of refractory / recurrent pulmonary hepatoblastoma. Pediatrics International, 2020, 62, 324-329.	0.5	12
10321	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science Translational Medicine, 2020, 12, .	12.4	260
10322	Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies. In Vivo, 2020, 34, 275-282.	1.3	5
10323	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 2020, 16, 4429-4438.	2.4	59
10324	Hyperprogressive Disease in Patients with Nonâ€“Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸ F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 821-826.	5.0	73
10325	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	3.7	22
10326	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 741-749.	2.5	21
10327	Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 365-372.	4.2	18
10328	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer, 2020, 126, 21-32.	2.8	16
10329	Criteria of metabolic response to immunotherapy. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2020, 39, 51-56.	0.2	0
10330	EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecologic Oncology, 2020, 156, 301-307.	1.4	37
10331	Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies. Neuro-Oncology Advances, 2020, 2, vdaa085.	0.7	1
10332	Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR. Neuro-Oncology Advances, 2020, 2, vdaa119.	0.7	14
10333	Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer. , 2020, 8, e000502.		3
10334	A Case of Significant Response to Olaparib in a Patient with Primary Peritoneal Carcinosarcoma Diagnosed by Laparoscopic Surgery. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-6.	0.3	1
10335	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clinical Cancer Research, 2020, 26, 6464-6474.	7.0	16

#	ARTICLE	IF	CITATIONS
10336	Magnetic resonance assessment of sinusoidal obstruction syndrome after neoadjuvant chemotherapy for colorectal liver metastases is not reproducible. <i>Acta Radiologica</i> , 2020, 62, 028418512095798.	1.1	2
10337	Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study. <i>BMC Cancer</i> , 2020, 20, 947.	2.6	12
10338	A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. <i>Breast Cancer Research</i> , 2020, 22, 97.	5.0	27
10339	Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. <i>Journal of Clinical Oncology</i> , 2020, 38, 4076-4085.	1.6	44
10340	Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial. <i>Anticancer Research</i> , 2020, 40, 5765-5776.	1.1	24
10341	Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population. <i>Frontiers in Oncology</i> , 2020, 10, 1752.	2.8	10
10342	Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. <i>Cancers</i> , 2020, 12, 2663.	3.7	3
10343	An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 2843.	3.7	6
10344	Neurofilament Light Chain as A Biomarker for Brain Metastases. <i>Cancers</i> , 2020, 12, 2852.	3.7	20
10345	Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer. <i>Current Oncology</i> , 2020, 27, 155-158.	2.2	9
10346	Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma – a pilot study. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 548-558.	0.9	5
10347	Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, 47, 676-686.	1.2	11
10348	Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. <i>BMC Cancer</i> , 2020, 20, 946.	2.6	10
10349	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. <i>Diagnostics</i> , 2020, 10, 732.	2.6	7
10350	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	2.0	5
10351	Targeted therapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 2020, 2020, CD012796.	2.8	23
10352	Impact of age-related cell dynamics on the identification of biomarkers predictive of immunotherapy discontinuation: A prospective cohort study. <i>Aging and Cancer</i> , 2020, 1, 58-70.	1.6	1
10353	Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer. <i>British Journal of Surgery</i> , 2021, 108, 667-674.	0.3	17

#	ARTICLE	IF	CITATIONS
10354	DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, , .	1.2	1
10355	Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients. <i>Pulmonology</i> , 2022, 28, 368-375.	2.1	4
10356	Endoscopic ultrasound-guided radiofrequency ablation of pancreatic microcystic serous cystic neoplasms: a retrospective study. <i>Endoscopy</i> , 2020, 53, 739-743.	1.8	15
10357	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 559-566.	1.3	3
10358	Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study. <i>Thoracic Cancer</i> , 2020, 11, 3634-3640.	1.9	5
10359	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1657-1664.	2.5	220
10360	Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. , 2020, 8, e001343.		64
10361	Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis. <i>Oncology</i> , 2020, 98, 876-883.	1.9	18
10362	Impact of waiting times on tumour growth and pathologic upstaging in patients with non-small cell lung cancer having lung resection. <i>Tumori</i> , 2021, 107, 329-334.	1.1	0
10363	Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2020, 20, 1006.	2.6	17
10364	<p>Application and Prospects of Molecular Imaging in Immunotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9389-9403.	1.9	8
10365	<p>The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3941-3950.	4.3	6
10366	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. <i>Frontiers in Immunology</i> , 2020, 11, 579894.	4.8	4
10367	Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019). <i>European Journal of Cancer</i> , 2020, 138, 30-40.	2.8	60
10368	Assessment of Systemic Inflammatory Response and Nutritional Markers in Patients With Trastuzumab-treated Unresectable Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 2851-2857.	1.3	3
10369	Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy. <i>Biomedicines</i> , 2020, 8, 371.	3.2	11
10370	Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma. <i>Cancer</i> , 2020, 126, 5173-5183.	4.1	26
10371	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021, 24, 457-466.	5.3	34

#	ARTICLE	IF	CITATIONS
10372	Treatment after progression in the era of immunotherapy. <i>Lancet Oncology</i> , The, 2020, 21, e463-e476.	10.7	115
10373	Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 208-216.e1.	1.9	16
10374	Primary tumour location is an important prognostic factor in colorectal cancer liver metastases following radiofrequency ablation. <i>Clinical Radiology</i> , 2020, 75, 961.e1-961.e9.	1.1	2
10375	Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1425-1433.	1.1	4
10376	Combination of Bronchial Arterial Infusion Chemotherapy plus Drug-Eluting Embolic Transarterial Chemoembolization for Treatment of Advanced Lung Cancer—A Retrospective Analysis of 23 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1645-1653.	0.5	18
10377	FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. <i>Pancreatology</i> , 2020, 20, 1519-1525.	1.1	6
10378	The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population. <i>Surgery</i> , 2020, 168, 1115-1121.	1.9	1
10379	Staging of Locally Advanced Rectal Cancer Beyond TME. <i>Clinics in Colon and Rectal Surgery</i> , 2020, 33, 258-267.	1.1	3
10380	Icaritinâ€induced immunomodulatory efficacy in advanced hepatitis B virusâ€related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. <i>Cancer Science</i> , 2020, 111, 4218-4231.	3.9	40
10381	Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. <i>Medicine (United States)</i> , 2020, 99, e22250.	1.0	14
10382	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy—A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020, 215, 1539-1548.	2.2	21
10383	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. , 2020, 8, e000700.		8
10384	Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. <i>Radiology</i> , 2020, 297, 622-629.	7.3	24
10385	Automatic segmentation and RECIST score evaluation in osteosarcoma using diffusion MRI: A computer aided system process. <i>European Journal of Radiology</i> , 2020, 133, 109359.	2.6	9
10386	Postoperative liver regeneration does not elicit recurrence of colorectal cancer liver metastases after major hepatectomy. <i>Surgical Oncology</i> , 2020, 35, 24-33.	1.6	4
10387	Upregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p. <i>Cell Death and Disease</i> , 2020, 11, 883.	6.3	37
10388	Non-invasive decision support for NSCLC treatment using PET/CT radiomics. <i>Nature Communications</i> , 2020, 11, 5228.	12.8	149
10389	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	3.3	11

#	ARTICLE	IF	CITATIONS
10390	Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. <i>Thoracic Cancer</i> , 2020, 11, 3521-3527.	1.9	1
10391	Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15-year clinical experience in a tertiary referral center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 338-342.	1.1	4
10392	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
10393	<p></p>Predicting Prognosis and Adverse Events by Hematologic Markers in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 8497-8507.	1.9	17
10394	Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 3026.	3.7	11
10395	Platinum-containing regimens for triple-negative metastatic breast cancer. <i>The Cochrane Library</i> , 2020, 2020, CD013750.	2.8	9
10396	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 61-66.	1.7	15
10397	Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020, 133, 109340.	2.6	15
10398	Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study. <i>Acta Oncologica</i> , 2020, 59, 1528-1537.	1.8	11
10399	Real-life effectiveness of first-line anticancer treatments in stage <sc>IIIB</sc>/<sc>IV NSCLC</sc> patients: Data from the <sc>C</sc>zech <sc>TULUNG R</sc>egistry. <i>Thoracic Cancer</i> , 2020, 11, 3346-3356.	1.9	8
10400	Highly Activated Ex Vivo-expanded Natural Killer Cells in Patients With Solid Tumors in a Phase I/IIa Clinical Study. <i>Anticancer Research</i> , 2020, 40, 5687-5700.	1.1	7
10401	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	10.7	466
10402	Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study. <i>Lung Cancer</i> , 2020, 150, 97-106.	2.0	4
10403	Estrogen hormone replacement therapy in incidental intracranial meningioma: a growth-rate analysis. <i>Scientific Reports</i> , 2020, 10, 17960.	3.3	9
10404	99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, e349-e357.	1.3	15
10405	Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-13.	1.2	3
10406	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020, 150, 83-89.	2.0	9
10407	Neuroendocrine Tumors. <i>Radiologic Clinics of North America</i> , 2020, 58, 1161-1171.	1.8	3

#	ARTICLE	IF	CITATIONS
10408	Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study. <i>Anti-Cancer Drugs</i> , 2020, 31, 973-978.	1.4	8
10409	Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalanâ€”Long-Term Overall Survival Negatively Correlates with Tumor Burden. <i>Radiology Research and Practice</i> , 2020, 2020, 1-7.	1.3	9
10410	Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity. <i>Breast Cancer Research</i> , 2020, 22, 105.	5.0	10
10411	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020, 8, 578.	4.4	16
10412	Prognostic value of CEA/CA72-4 immunohistochemistry in combination with cytology for detecting tumor cells in peritoneal lavage in gastric cancer. <i>Journal of Cancer</i> , 2020, 11, 6319-6325.	2.5	1
10413	A gene expression signature of TREM2hi macrophages and $\gamma\delta$ T cells predicts immunotherapy response. <i>Nature Communications</i> , 2020, 11, 5084.	12.8	90
10414	Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1333-1342.	2.8	6
10415	Treatment of Patients With Non-small-cell Lung Cancer With Uncommon <i>EGFR</i> Mutations in Clinical Practice. <i>Anticancer Research</i> , 2020, 40, 5757-5764.	1.1	12
10416	Immunotherapy for Renal Cell Carcinoma. , 0, , .		0
10417	The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy. <i>Journal of Cancer</i> , 2020, 11, 6256-6263.	2.5	8
10418	Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Non-small Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations. <i>Advances in Radiation Oncology</i> , 2020, 5, 984-993.	1.2	9
10419	In advanced pancreatic cancer: The value and significance of interventional therapy. <i>Journal of Interventional Medicine</i> , 2020, 3, 118-121.	0.5	5
10420	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. <i>Lung Cancer</i> , 2020, 150, 90-96.	2.0	18
10421	Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , 2020, 31, 959-965.	1.4	0
10422	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3759-3769.	3.9	29
10423	c-Met expression in renal cell carcinoma with bone metastases. <i>Journal of Bone Oncology</i> , 2020, 25, 100315.	2.4	10
10424	Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study. <i>International Immunopharmacology</i> , 2020, 89, 107033.	3.8	13
10425	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	3.8	76

#	ARTICLE	IF	CITATIONS
10426	Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. <i>Clinical Cancer Research</i> , 2020, 26, 6445-6452.	7.0	30
10427	Week 2020 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2020, 8, 144-887.	3.8	7
10428	Imaging in disappearing colorectal liver metastases and their accuracy: a systematic review. <i>World Journal of Surgical Oncology</i> , 2020, 18, 264.	1.9	26
10429	Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 263.	1.9	6
10430	Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. <i>Journal of Cancer</i> , 2020, 11, 6612-6622.	2.5	11
10431	Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. <i>Lung Cancer</i> , 2020, 149, 53-60.	2.0	8
10432	Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1389-1406.	4.1	4
10433	Undetectable <i>RAS</i> -Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With <i>RAS</i> -Mutant Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1070-1079.	3.0	20
10434	Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 117-131.	3.7	15
10435	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	1.1	1
10436	Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 566297.	2.8	39
10437	Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. <i>Theranostics</i> , 2020, 10, 11127-11143.	10.0	14
10438	Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 937.e19-937.e25.	1.6	2
10439	Development of prediction models for the sensitivity of oral squamous cell carcinomas to preoperative S-1 administration. <i>Heliyon</i> , 2020, 6, e04601.	3.2	0
10440	A novel technique of arterial blood flow modification in intra-arterial chemoradiotherapy of maxillary sinus squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 109, 104873.	1.5	0
10441	Impact of radiation source activity on short- and long-term outcomes of cervical carcinoma patients treated with high-dose-rate brachytherapy: A retrospective cohort study. <i>Gynecologic Oncology</i> , 2020, 159, 365-372.	1.4	2
10442	Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. <i>Scientific Reports</i> , 2020, 10, 16988.	3.3	32
10443	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	7.0	6

#	ARTICLE	IF	CITATIONS
10444	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.	7.1	746
10445	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	28.9	206
10446	Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2a~ Breast Cancer: A Prospective Phase II Study. <i>Clinical Breast Cancer</i> , 2020, 20, 462-468.	2.4	4
10447	Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. <i>Respiratory Medicine</i> , 2020, 172, 106131.	2.9	6
10448	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. <i>Nature Medicine</i> , 2020, 26, 1742-1753.	30.7	185
10449	Statistical and practical considerations in designing of immuno-oncology trials. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1130-1146.	0.8	6
10450	Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study. <i>Cancer Science</i> , 2020, 111, 3303-3312.	3.9	13
10451	Potential Functional Variants in DNA Repair Genes Are Associated with Efficacy and Toxicity of Radiotherapy in Patients with Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	1.3	9
10452	<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5641-5650.	1.9	15
10453	The use of intervalâ€compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28559.	1.5	13
10454	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	3.7	254
10455	Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. <i>Translational Oncology</i> , 2020, 13, 100829.	3.7	6
10456	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. <i>Gynecologic Oncology</i> , 2020, 158, 653-658.	1.4	29
10457	DaPeCa-4: outcome in penile cancer patients with N3 disease due to extra nodal extension treated with surgery and chemo-irradiation. <i>Scandinavian Journal of Urology</i> , 2020, 54, 334-338.	1.0	6
10458	An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. <i>Journal of Oncology</i> , 2020, 2020, 1-6.	1.3	9
10459	Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patientsâ€™ Perspective beyond the Medical Evaluation. <i>European Thyroid Journal</i> , 2021, 10, 1-7.	2.4	7
10460	Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 653.	2.6	9
10461	Real-world osimertinib for <i>EGFR</i> mutation-positive non-small-cell lung cancer with acquired T790M mutation. <i>Future Oncology</i> , 2020, 16, 1537-1547.	2.4	6

#	ARTICLE	IF	CITATIONS
10462	Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis. <i>Cancers</i> , 2020, 12, 1711.	3.7	1
10463	Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeonsâ€™ Perspective. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1494-1502.	1.7	8
10464	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	27.8	96
10465	Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. <i>Science Advances</i> , 2020, 6, eaay5279.	10.3	70
10466	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5092-5101.	7.0	28
10467	Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study. <i>BMC Cancer</i> , 2020, 20, 540.	2.6	15
10468	Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 452-460.	1.9	11
10469	Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103044.	4.4	29
10470	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146.	1.0	8
10471	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100013.	1.1	4
10472	Immune checkpoint inhibitors in multiple myeloma: A review of the literature. <i>Pathology Research and Practice</i> , 2020, 216, 153114.	2.3	17
10474	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18â€“12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	2.5	12
10475	Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trialâ†. <i>Annals of Oncology</i> , 2020, 31, 1350-1358.	1.2	206
10476	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	3.9	6
10477	<p>The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5255-5264.	1.9	9
10478	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 832.	4.3	105
10479	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056.	10.7	39
10480	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	2.8	8

#	ARTICLE	IF	CITATIONS
10481	A Review of T-Cell Related Therapy for Osteosarcoma. International Journal of Molecular Sciences, 2020, 21, 4877.	4.1	10
10482	Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis. Targeted Oncology, 2020, 15, 513-522.	3.6	2
10483	Melanoma brain metastases – Interdisciplinary management recommendations 2020. Cancer Treatment Reviews, 2020, 89, 102083.	7.7	52
10484	Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective. Drug Discovery Today, 2020, 25, 1855-1864.	6.4	0
10485	A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients. World Journal of Surgical Oncology, 2020, 18, 172.	1.9	6
10486	Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy. Immunotherapy, 2020, 12, 785-798.	2.0	21
10487	Carcinoembryonic Antigen-related Tumor Kinetics After Eight Weeks of Chemotherapy is Independently Associated With Overall Survival in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, e200-e207.	2.3	1
10488	A Ki-67 Index to Predict Treatment Response to the Capecitabine Temozolomide (CAPTEM) Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study. Neuroendocrinology, 2020, 111, 752-763.	2.5	16
10489	A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma. Translational Lung Cancer Research, 2020, 9, 833-836.	2.8	0
10490	Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. JAMA Dermatology, 2020, 156, 982.	4.1	14
10491	Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 1110-1122.	10.7	63
10492	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 238-245.	2.4	44
10493	Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Current Problems in Cancer, 2020, 44, 100540.	2.0	39
10494	Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Oncoimmunology, 2020, 9, 1776058.	4.6	19
10495	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). BJU International, 2020, 126, 559-567.	2.5	5
10496	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1944-1956.	2.4	94
10497	The Early Decline of Î±-Fetoprotein and Des-Î³-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients. Gastrointestinal Tumors, 2020, 7, 83-92.	0.7	6
10498	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 382-396.	7.7	54

#	ARTICLE	IF	CITATIONS
10499	Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2706-2712.	1.4	10
10500	<p>Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5439-5450.	1.9	8
10501	Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2020, 55, 1072-1086.	5.1	3
10502	Cetuximab Concurrent with Radiotherapy in Unresectable, Locally Advanced Squamous Cell Carcinoma of Head and Neck: Real-World Evidence from a Tertiary Care Hospital. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2022, 74, 1857-1863.	0.9	1
10503	Enhancing the Critical Role of Core Needle Biopsy in Breast Cancer. <i>Hellenike Cheirourgike Acta Chirurgica Hellenica</i> , 2020, 92, 76-84.	0.1	1
10504	Treatment Outcome and Patterns of Failure in Patients with Maxillary Sinus Cancer: Clinical Experience from a Regional Cancer Centre in North India. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 401-405.	0.7	0
10505	Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1853-1861.	2.8	18
10506	Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data. <i>Neoplasia</i> , 2020, 22, 820-830.	5.3	39
10507	European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000798.	4.5	6
10508	Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. , 2020, 8, e001429.		46
10509	Electrochemotherapy and Simultaneous Photodynamic Bone Stabilization of Upper Limbs in Metastatic Renal Cancer Disease: Case Report and Literature Review. <i>Case Reports in Medicine</i> , 2020, 2020, 1-7.	0.7	2
10510	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	5.0	60
10511	Optimizing the Treatment Pattern for De Novo Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2020, 10, 543646.	2.8	7
10512	Predicting Chemotherapeutic Response for Far-advanced Gastric Cancer by Radiomics with Deep Learning Semi-automatic Segmentation. <i>Journal of Cancer</i> , 2020, 11, 7224-7236.	2.5	20
10513	A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100045.	1.1	8
10514	A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. <i>BMC Cancer</i> , 2020, 20, 1118.	2.6	5
10515	Analysis of Factors Affecting Brain Metastasis in Limited-Stage Small-Cell Lung Cancer Treated With Definitive Thoracic Irradiation. <i>Frontiers in Oncology</i> , 2020, 10, 556634.	2.8	6
10516	Potential and Clinical Significance of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. <i>Oncology</i> , 2021, 99, 169-176.	1.9	6

#	ARTICLE	IF	CITATIONS
10517	Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	8
10518	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. <i>Lung Cancer</i> , 2020, 148, 122-128.	2.0	7
10519	Inappropriate practice in tumor marker requests at a university hospital in Western Saudi Arabia: A 3-year retrospective study. <i>International Journal of Biological Markers</i> , 2020, 35, 35-43.	1.8	3
10520	The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis. <i>BMC Cancer</i> , 2020, 20, 1121.	2.6	11
10521	Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study. <i>Frontiers in Oncology</i> , 2020, 10, 587849.	2.8	2
10522	CT reconstruction with thick slices not only underestimates lymph node size but also reduces data reproducibility in colorectal cancer. <i>Acta Radiologica</i> , 2020, 62, 028418512096856.	1.1	3
10523	Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer. <i>Gland Surgery</i> , 2020, 9, 1415-1427.	1.1	4
10524	Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 590707.	2.8	14
10525	Antitumor activity without on-target off-tumor toxicity of GD2α-chimeric antigen receptor T cells in patients with neuroblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	108
10526	CT-guided percutaneous implantation of 125I particles in treatment of early lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 5996-6009.	1.4	4
10527	Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2020, 9, 2514.	4.1	18
10528	Sintilimab: A Promising Anti-Tumor PD-1 Antibody. <i>Frontiers in Oncology</i> , 2020, 10, 594558.	2.8	76
10529	Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. <i>Cancers</i> , 2020, 12, 3451.	3.7	6
10530	Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00685.	2.4	8
10531	Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1143-1143.	1.7	5
10532	Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer. <i>Anticancer Research</i> , 2020, 40, 5829-5835.	1.1	4
10533	Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer. <i>Anticancer Research</i> , 2020, 40, 6485-6492.	1.1	16
10534	Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. <i>Scientific Reports</i> , 2020, 10, 19699.	3.3	7

#	ARTICLE	IF	CITATIONS
10535	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	4.5	343
10536	<p>Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma</p>. Research and Reports in Urology, 2020, Volume 12, 455-461.	1.0	4
10537	Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes. Frontiers in Pharmacology, 2020, 11, 576955.	3.5	8
10538	Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nature Communications, 2020, 11, 6093.	12.8	60
10539	Can computed tomography-based radiomics potentially discriminate between anterior mediastinal cysts and type B1 and B2 thymomas?. BioMedical Engineering OnLine, 2020, 19, 89.	2.7	9
10540	Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2020, 12, 3493.	3.7	18
10541	Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report. Annals of Medicine and Surgery, 2020, 60, 31-35.	1.1	2
10542	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. Cancer Treatment and Research Communications, 2020, 25, 100249.	1.7	1
10543	Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis. Neuroendocrinology, 2021, 111, 895-906.	2.5	23
10544	Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases. Annals of Translational Medicine, 2020, 8, 1493-1493.	1.7	11
10545	Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Annals of Internal Medicine, 2020, 173, 368-374.	3.9	18
10546	Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatric Investigation, 2020, 4, 157-167.	1.4	14
10547	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 495-505.	1.1	6
10548	Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097084.	3.2	3
10549	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	4.1	88
10550	<p>A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma</p>. Breast Cancer: Targets and Therapy, 2020, Volume 12, 259-266.	1.8	7
10551	Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies. Frontiers in Oncology, 2020, 10, 587692.	2.8	3
10552	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, The, 2020, 396, 1817-1828.	13.7	992

#	ARTICLE	IF	CITATIONS
10553	Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Techniques in Vascular and Interventional Radiology, 2020, 23, 100675.	1.0	31
10554	Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in <i>de novo</i> stage IV breast cancer patients: study protocol of the i-GO study. BMJ Open, 2020, 10, e040162.	1.9	19
10555	The accuracy and safety of CT-guided iodine-125 seed implantation assisted by 3D non-coplanar template for retroperitoneal recurrent carcinoma. World Journal of Surgical Oncology, 2020, 18, 307.	1.9	7
10556	The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1749-1758.	2.8	14
10557	A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Frontiers in Endocrinology, 2020, 11, 594264.	3.5	10
10558	A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 3579.	3.7	2
10559	Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer. Diagnostics, 2020, 10, 1001.	2.6	10
10560	ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Scientific Reports, 2020, 10, 21063.	3.3	21
10561	Paclitaxel Plus Platinum Neoadjuvant Chemotherapy Followed by Surgery Versus Primary Surgery in Locally Advanced Cervical Cancer—A Propensity Score Matching Analysis. Frontiers in Oncology, 2020, 10, 604308.	2.8	1
10562	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. European Journal of Cancer, 2020, 141, 162-170.	2.8	29
10563	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Scientific Reports, 2020, 10, 19281.	3.3	8
10564	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	2.8	28
10565	Pictorial review of the clinical applications of MIBG in neuroblastoma: current practices. Clinical and Translational Imaging, 2020, 8, 483-507.	2.1	2
10566	High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases. Frontiers in Oncology, 2020, 10, 519164.	2.8	30
10567	Radiomics and radiogenomics in ovarian cancer: a literature review. Abdominal Radiology, 2021, 46, 2308-2322.	2.1	41
10568	Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer. Tumori, 2021, 107, 416-423.	1.1	3
10569	Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097004.	3.2	22
10570	Pulmonary benign metastasizing leiomyomas: a case series of 23 patients at a single facility. BMC Pulmonary Medicine, 2020, 20, 292.	2.0	17

#	ARTICLE	IF	CITATIONS
10571	Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report. <i>Annals of Palliative Medicine</i> , 2020, 9, 4339-4345.	1.2	2
10572	Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-7.	1.9	1
10573	Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097005.	3.2	9
10574	Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions. <i>Cancer Management and Research</i> , 2020, Volume 12, 11133-11143.	1.9	22
10575	Whole Brain Radiation Therapy Plus Focal Radiation Boost May Generate Better Survival Benefit for Brain Metastases From Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 576700.	2.8	5
10576	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756.	2.8	36
10577	Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4395-4400.	1.1	3
10578	Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer. <i>Cancer</i> , 2020, 126, 4473-4484.	4.1	14
10579	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	2.8	16
10580	Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 1-11.	2.0	68
10581	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1235-1243.	6.4	12
10582	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	13.2	253
10583	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 743-753.	2.4	1
10584	Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer. <i>Radiographics</i> , 2020, 40, 1412-1430.	3.3	17
10585	Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. <i>Radiation Oncology</i> , 2020, 15, 190.	2.7	10
10586	Efficacy and safety of cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e21539.	1.0	3
10587	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020, 126, 4532-4544.	4.1	14
10588	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 4521-4531.	4.1	10

#	ARTICLE	IF	CITATIONS
10589	An infant with ETV6â€NTRK3 fusionâ€positive congenital infantile fibrosarcoma and delayed response to conventional chemotherapy avoiding the need for TRK inhibition. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28628.	1.5	3
10590	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.1784314238T /Ov	1.1	1
10591	Advanced colonic cancer with clinically suspected bladder invasion: Outcomes and prognosis from a multicentric study of 117 patients from the FRENCH research group. <i>Surgery</i> , 2020, 168, 786-792.	1.9	2
10592	Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy. <i>Translational Oncology</i> , 2020, 13, 100831.	3.7	24
10593	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e17-798.e24.	1.6	6
10594	Somatostatin Receptorâ€Targeted Radioligand Therapy in Head and Neck Paraganglioma. <i>World Neurosurgery</i> , 2020, 143, e391-e399.	1.3	13
10595	Stereotactic Body Radiation Therapy (SBRT) in Pelvic Lymph Node Oligometastases. <i>Cancer Investigation</i> , 2020, 38, 599-607.	1.3	2
10596	Efficacy and safety of dabrafenibâ€trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: A systematic review and network metaâ€analysis. <i>Dermatologic Therapy</i> , 2020, 33, e14135.	1.7	1
10597	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 297, 87-96.	7.3	70
10598	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Nonâ€Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1243-1250.	3.4	154
10599	Atezolizumab in a <u>C</u><u>H</u>ort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyp<u>E</u>s (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	3.2	5
10600	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF^{V600E}</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	1.6	145
10601	Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3259-3267.	1.5	14
10602	The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLCâ€A Matter as Actual Now as in the Past. <i>Processes</i> , 2020, 8, 936.	2.8	0
10603	Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. <i>Lung Cancer</i> , 2020, 148, 149-158.	2.0	16
10604	The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1454-1463.	1.3	2
10605	Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€Naive ALK-Positive Nonâ€Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	1.6	224
10606	Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1161.	2.8	14

#	ARTICLE	IF	CITATIONS
10607	The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2302.	2.4	25
10608	Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 617-627.	2.5	12
10609	Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. <i>Npj Precision Oncology</i> , 2020, 4, 17.	5.4	15
10610	Volumetric tumor response assessment is inefficient without overt clinical benefit compared to conventional, manual veterinary response assessment in canine nasal tumors. <i>Veterinary Radiology and Ultrasound</i> , 2020, 61, 592-603.	0.9	7
10611	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	2.6	53
10612	Randomized Phase III Trial of Pegvorhalyuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	1.6	233
10613	A nomogram for predicting axillary pathologic complete response in hormone receptorâ€“positive breast cancer with cytologically proven axillary lymph node metastases. <i>Cancer</i> , 2020, 126, 3819-3829.	4.1	15
10614	Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index. <i>European Radiology</i> , 2020, 30, 6740-6748.	4.5	9
10615	Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1870-1878.	2.2	7
10616	Agressive pituitary tumours: A diagnostic and therapeutic challenge for multidisciplinary pituitary units. <i>EndocrinologÃa Diabetes Y NutriciÃn (English Ed)</i> , 2020, 67, 75-77.	0.2	0
10617	Update on Quantitative Imaging for Predicting and Assessing Response in Oncology. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 505-517.	4.6	2
10618	Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. <i>Medicine (United States)</i> , 2020, 99, e21329.	1.0	17
10619	A Deep Learning-Facilitated Radiomics Solution for the Prediction of Lung Lesion Shrinkage in Non-Small Cell Lung Cancer Trials. , 2020, , .		5
10620	Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1450-1454.	2.5	33
10621	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	7.0	102
10622	Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. <i>World Journal of Surgical Oncology</i> , 2020, 18, 179.	1.9	21
10623	Effect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis. <i>Thoracic Cancer</i> , 2020, 11, 2698-2703.	1.9	2
10624	Longâ€“term followâ€“up of children with risk organâ€“negative Langerhans cell histiocytosis after 2â€“chlorodeoxyadenosine treatment. <i>British Journal of Haematology</i> , 2020, 191, 825-834.	2.5	14

#	ARTICLE	IF	CITATIONS
10625	S-1 Maintenance Therapy in Extensive Stage Small-Cell Lung Cancer—A Randomized Clinical Study. Cancer Control, 2020, 27, 107327482093200.	1.8	6
10626	Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma. Frontiers in Oncology, 2020, 10, 1198.	2.8	25
10627	Simulation Study of Low-Dose Sparse-Sampling CT with Deep Learning-Based Reconstruction: Usefulness for Evaluation of Ovarian Cancer Metastasis. Applied Sciences (Switzerland), 2020, 10, 4446.	2.5	14
10628	The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast—Long-Term Prognostic Significance. Cells, 2020, 9, 1718.	4.1	10
10629	Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Inpatient Drug Responses. Cell Reports, 2020, 31, 107762.	6.4	155
10630	A Self-Evaluating Photothermal Therapeutic Nanoparticle. ACS Nano, 2020, 14, 9585-9593.	14.6	61
10631	Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. Neuroendocrinology, 2021, 111, 831-839.	2.5	7
10632	Response dataset from canine extramedullary plasmacytoma treated with lipophobic drugs enhanced by electroporation. Data in Brief, 2020, 32, 106085.	1.0	1
10633	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer, 2020, 148, 48-54.	2.0	18
10634	Predictive Value of Early Response to Chemoradiotherapy in Advanced Esophageal Squamous Cell Carcinoma by Diffusion-Weighted MR Imaging. Technology in Cancer Research and Treatment, 2020, 19, 153303382094322.	1.9	0
10635	The efficacy and dosimetry analysis of CT-guided 125I seed implantation assisted with 3D-printing non-co-planar template in locally recurrent rectal cancer. Radiation Oncology, 2020, 15, 179.	2.7	11
10636	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. Frontiers in Oncology, 2020, 10, 1137.	2.8	7
10637	Expression of Concern Issued: Exosome-Mediated Transfer of Long Noncoding RNA HOTAIR Regulates Temozolomide Resistance by miR-519a-3p/RRM1 Axis in Glioblastoma. Cancer Biotherapy and Radiopharmaceuticals, 2020, , .	1.0	22
10638	Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. BMC Cancer, 2020, 20, 707.	2.6	23
10639	Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018. PLoS ONE, 2020, 15, e0236345.	2.5	14
10640	<p>Distinguishing Radiation Pneumonitis from Local Tumour Recurrence Following SBRT for Lung Cancer</p>. Reports in Medical Imaging, 2020, Volume 13, 1-23.	0.8	1
10641	Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. Frontiers in Oncology, 2020, 10, 1259.	2.8	4
10642	Clinical usefulness of saphenous vein graft in major arterial reconstruction during extended pancreatectomy. Langenbeck's Archives of Surgery, 2020, 405, 1051-1059.	1.9	4

#	ARTICLE	IF	CITATIONS
10643	Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094094.	3.2	7
10644	Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. Journal of Clinical Oncology, 2020, 38, 3051-3061.	1.6	106
10645	<p>Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study</p>. Cancer Management and Research, 2020, Volume 12, 5345-5351.	1.9	4
10646	Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. Frontiers in Oncology, 2020, 10, 1090.	2.8	20
10647	m6A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis. Frontiers in Oncology, 2020, 10, 1166.	2.8	50
10648	Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma. Frontiers in Oncology, 2020, 10, 1311.	2.8	2
10649	Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence. Clinical and Translational Radiation Oncology, 2020, 24, 92-98.	1.7	6
10650	Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 1155-1163.	1.1	4
10651	Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Dermatologic Therapy, 2020, 33, e14093.	1.7	3
10652	Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. Medicina (Lithuania), 2020, 56, 373.	2.0	8
10653	Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncology, The, 2020, 21, 1173-1187.	10.7	81
10654	Active surveillance in desmoid-type fibromatosis: A systematic literature review. European Journal of Cancer, 2020, 137, 18-29.	2.8	21
10656	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. ESMO Open, 2020, 5, e000763.	4.5	20
10657	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
10658	<p><p>>Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxaliplatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis<p>>. Cancer Management and Research, 2020, Volume 12, 6641-6653.	1.9	9
10659	Paradoxical Effects of Tumor Shrinkage on Long-Term Survival of Cancer Patients. Frontiers in Applied Mathematics and Statistics, 2020, 6, .	1.3	2
10661	High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Scientific Reports, 2020, 10, 12348.	3.3	48
10662	Metastatic Pancreatic Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 3217-3230.	1.6	151

#	ARTICLE	IF	CITATIONS
10663	<p>A Six-Epithelialâ€“Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 6497-6509.	2.0	7
10664	The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Oral Oncology, 2020, 111, 104924.	1.5	6
10665	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
10666	Role of programmed deathâ€“ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma. Head and Neck, 2020, 42, 3275-3281.	2.0	8
10667	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. Journal of Thoracic Oncology, 2020, 15, 1758-1766.	1.1	60
10668	Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer. Journal of Vascular and Interventional Radiology, 2020, 31, 925-933.	0.5	12
10669	Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology, 2020, 20, 1183-1188.	1.1	6
10670	Differential Change in Size of Human Papillomavirusâ€“Positive Cystic Versus Solid Squamous Cell Carcinoma Lymph Node Metastases in Response to Induction Chemotherapy. Journal of Computer Assisted Tomography, 2020, 44, 389-392.	0.9	1
10671	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. Journal of the Endocrine Society, 2020, 4, bvaa069.	0.2	14
10672	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers, 2020, 12, 1943.	3.7	18
10673	Experience of a tertiary referral center in managing bladder cancer in conjunction with neurogenic bladder. Spinal Cord Series and Cases, 2020, 6, 61.	0.6	4
10674	The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. BMC Urology, 2020, 20, 110.	1.4	13
10675	Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis. Diagnostic Pathology, 2020, 15, 91.	2.0	35
10676	Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 5086-5095.	1.5	18
10677	Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. Cancers, 2020, 12, 2222.	3.7	10
10678	Prognostic value of MRIâ€“determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Medicine, 2020, 9, 7100-7106.	2.8	11
10679	Tumour Biology Characterisation by Imaging in Clinic. Medical Radiology, 2020, , 325-360.	0.1	0
10680	Single administration of avelumab induced a complete response in thyroid transcription factor 1â€“positive combined Merkel cell carcinoma. Journal of Dermatology, 2020, 47, 1317-1321.	1.2	0

#	ARTICLE	IF	CITATIONS
10681	Adverse impact of bone metastases on clinical outcomes of patients with advanced nonâ€‘small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2020, 11, 2812-2819.	1.9	23
10682	Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis. <i>Dose-Response</i> , 2020, 18, 155932582094135.	1.6	8
10683	Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 527-533.	2.6	14
10684	Radiomics and â€‘radiâ€‘omicsâ€‘in cancer immunotherapy: a guide for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103068.	4.4	26
10685	Perioperative considerations for neoadjuvant immunotherapy in nonâ€‘small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1376-1382.	0.8	18
10686	Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. <i>Cancer Imaging</i> , 2020, 20, 57.	2.8	31
10687	A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas. <i>Frontiers in Oncology</i> , 2020, 10, 1228.	2.8	10
10688	Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2913-2935.	2.5	14
10689	Imaging characteristics and prognostic values of hepatic epithelioid hemangioendothelioma on 18F-FDG PET/CT. <i>Clinical and Experimental Medicine</i> , 2020, 20, 557-567.	3.6	6
10690	Interleukin-17â€‘induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	219
10691	Long-term clinical course and outcomes of immunoglobulin G4-related lung disease. <i>Respiratory Research</i> , 2020, 21, 273.	3.6	18
10692	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Childrenâ€™s Oncology Group phase 1 consortium study (ADVL1212). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 829-840.	2.3	22
10693	Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). <i>Lung Cancer</i> , 2020, 150, 70-75.	2.0	26
10694	Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study. <i>ERJ Open Research</i> , 2020, 6, 00189-2019.	2.6	2
10695	<p>The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9013-9021.	1.9	7
10696	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. <i>Cancers</i> , 2020, 12, 3004.	3.7	3
10697	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1682-1688.	1.1	13
10698	Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1943-1950.	2.5	4

#	ARTICLE	IF	CITATIONS
10699	Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020, 123, 1720-1729.	6.4	18
10700	Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. <i>Lancet Oncology</i> , 2020, 21, 1478-1488.	10.7	41
10701	Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent. <i>Pancreas</i> , 2020, 49, 1264-1275.	1.1	5
10702	A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e36-e40.	1.1	4
10703	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. , 2020, 8, e001153.		37
10704	ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study. <i>Neuroendocrinology</i> , 2021, 111, 951-964.	2.5	17
10705	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	1.6	69
10706	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. <i>ESMO Open</i> , 2020, 5, e000926.	4.5	35
10707	Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-12.	1.9	6
10708	Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy. <i>Cancer Research</i> , 2021, 81, 144-157.	0.9	52
10709	Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096386.	2.6	5
10710	Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. <i>Cancer Imaging</i> , 2020, 20, 77.	2.8	11
10711	Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 571304.	2.8	10
10712	Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1928-1934.	2.5	7
10713	Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective. <i>Journal of Clinical Medicine</i> , 2020, 9, 3483.	2.4	26
10714	Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). <i>Lung Cancer</i> , 2020, 150, 114-122.	2.0	38
10715	Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. <i>Scientific Reports</i> , 2020, 10, 15822.	3.3	12
10716	Comparison of two different doses of bleomycin in electrochemotherapy protocols for feline cutaneous squamous cell carcinoma nonsegregated from ultraviolet light exposure. <i>Scientific Reports</i> , 2020, 10, 18362.	3.3	8

#	ARTICLE	IF	CITATIONS
10717	Treatment of intracranial meningioma with single-session and fractionated radiosurgery: a propensity score matching study. <i>Scientific Reports</i> , 2020, 10, 18500.	3.3	9
10718	Knockdown of LINC00473 promotes radiosensitivity of non-small cell lung cancer cells via sponging miR-513a-3p. <i>Free Radical Research</i> , 2020, 54, 756-764.	3.3	14
10719	Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1733-1737.	2.5	4
10720	Machine Learning in Oncology: Methods, Applications, and Challenges. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 885-894.	2.1	42
10721	Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0236503.	2.5	25
10722	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	3.7	21
10723	Effectiveness of bronchial arterial embolization using N-butyl-2-cyanoacrylate for local control of pulmonary hilar or mediastinal tumors that are refractory to chemotherapy. <i>European Journal of Radiology</i> , 2020, 131, 109160.	2.6	1
10724	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	1.1	12
10725	One last round of chemo? Insights from conversations between oncologists and lung cancer patients about prognosis and treatment decisions. <i>Social Science and Medicine</i> , 2020, 266, 113413.	3.8	4
10726	Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 356-361.	1.3	5
10727	Presence of constipation predicts the therapeutic efficacy of pembrolizumab in metastatic urothelial cancer patients. <i>International Journal of Urology</i> , 2020, 27, 1116-1123.	1.0	7
10728	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. <i>ESMO Open</i> , 2020, 5, e000827.	4.5	18
10729	Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. , 2020, 8, e001193.		28
10730	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
10731	Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 2736.	2.4	10
10732	Hedgehog Pathway Inhibitors for Periocular Basal Cell Carcinoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 13-30.	0.7	1
10733	Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1600-1608.	0.5	15
10734	CroSSED sequence, a new tool for 3D processing in geosciences using the free software 3DSlicer. <i>Scientific Data</i> , 2020, 7, 270.	5.3	13

#	ARTICLE	IF	CITATIONS
10735	Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 944-957.	27.0	542
10736	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Translational Lung Cancer Research, 2020, 9, 1258-1267.	2.8	47
10737	Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Research and Treatment, 2020, 184, 469-479.	2.5	15
10738	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Experimental and Molecular Medicine, 2020, 52, 1550-1563.	7.7	99
10739	Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). British Journal of Cancer, 2020, 123, 1535-1542.	6.4	42
10740	Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea. PLoS ONE, 2020, 15, e0238207.	2.5	14
10741	A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. Anticancer Research, 2020, 40, 4875-4883.	1.1	6
10742	From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?. Cancer Medicine, 2020, 9, 7849-7862.	2.8	8
10743	Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Medicine, 2020, 9, 8355-8363.	2.8	15
10744	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Japanese Journal of Clinical Oncology, 2020, 50, 1447-1453.	1.3	14
10745	Radiologic response of chemotherapy alone versus radiation and chemotherapy in the treatment of locally advanced or advanced thymic epithelial tumors. Thoracic Cancer, 2020, 11, 2924-2931.	1.9	7
10746	Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial. Cancer Science, 2020, 111, 4187-4194.	3.9	17
10747	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clinical Cancer Research, 2020, 26, 6158-6167.	7.0	37
10748	Intratreatment Tumor Volume Change During Definitive Chemoradiotherapy is Predictive for Treatment Outcome of Patients with Esophageal Carcinoma. Cancer Management and Research, 2020, Volume 12, 7331-7339.	1.9	5
10749	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer, 2020, 126, 4936-4947.	4.1	31
10750	Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status. Clinical Cancer Research, 2020, 26, 6277-6283.	7.0	18
10751	Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study. Anticancer Research, 2020, 40, 5285-5290.	1.1	3
10752	Prediction of Therapeutic Effects from One Course of TPF Chemotherapy for Advanced Hypopharyngeal Laryngeal Cancer. In Vivo, 2020, 34, 2891-2896.	1.3	1

#	ARTICLE	IF	CITATIONS
10753	Targeting Signaling Pathways in Inflammatory Breast Cancer. <i>Cancers</i> , 2020, 12, 2479.	3.7	25
10754	Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis. <i>Cancer Control</i> , 2020, 27, 107327482093482.	1.8	16
10755	Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1039-1039.	1.7	2
10756	Secondary and tertiary ovarian cancer recurrence: what is the best management?. <i>Gland Surgery</i> , 2020, 9, 1118-1129.	1.1	18
10757	Clinical Significance of Conversion Surgery for Gastric Cancer with Peritoneal Dissemination: A Retrospective Study. <i>Oncology</i> , 2020, 98, 798-806.	1.9	6
10758	Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan. <i>In Vivo</i> , 2020, 34, 2883-2889.	1.3	7
10759	Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 1478.	2.8	7
10760	Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck. <i>Journal of Personalized Medicine</i> , 2020, 10, 131.	2.5	7
10761	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. <i>Lung Cancer</i> , 2020, 149, 46-52.	2.0	28
10762	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020, 50, 1375-1385.	3.4	22
10763	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. <i>Translational Lung Cancer Research</i> , 2020, 9, 1533-1542.	2.8	43
10764	Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. <i>Cells</i> , 2020, 9, 2110.	4.1	17
10765	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma. <i>JAMA Oncology</i> , 2020, 6, 1778.	7.1	66
10766	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. <i>Cancer</i> , 2020, 126, 5303-5310.	4.1	17
10767	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. <i>Tumor Biology</i> , 2020, 42, 101042832095860.	1.8	3
10768	High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. <i>BMC Cancer</i> , 2020, 20, 907.	2.6	16
10769	Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. <i>Cancer Medicine</i> , 2020, 9, 8498-8518.	2.8	24
10770	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	4.1	22

#	ARTICLE	IF	CITATIONS
10771	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1413-1422.	10.7	475
10772	Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 150, 76-82.	2.0	60
10773	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. <i>Nature Communications</i> , 2020, 11, 4858.	12.8	124
10774	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	7.0	9
10775	Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience. <i>Cancer</i> , 2020, 126, 5256-5262.	4.1	28
10776	Deforming to Best Practice: Key considerations for deformable image registration in radiotherapy. <i>Journal of Medical Radiation Sciences</i> , 2020, 67, 318-332.	1.5	15
10777	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 517-525.	2.3	3
10778	Functional Imaging of Immunotherapy: Response Criteria, Imaging Characteristics, and Novel Immunoimaging of Advanced Malignancies. <i>Current Radiology Reports</i> , 2020, 8, 1.	1.4	0
10779	The role of magnetic resonance imaging on evaluating response of neoadjuvant therapy for breast cancer. <i>Chinese Journal of Academic Radiology</i> , 2020, 3, 125-136.	0.6	0
10780	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	1.1	85
10781	Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer. <i>Frontiers in Medicine</i> , 2020, 7, 495.	2.6	7
10782	Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 1455.	2.8	9
10783	Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1495.	2.8	24
10784	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , 2020, 10, 1499.	2.8	9
10785	Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. <i>Carcinogenesis</i> , 2020, 41, 1507-1517.	2.8	11
10786	<p>High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy</p>OncoTargets and Therapy, 2020, Volume 13, 8273-8285.	2.0	19
10787	Response to Electrochemotherapy in a Patient With Advanced Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 1178.	2.2	2
10788	Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report. <i>Anti-Cancer Drugs</i> , 2020, 31, 866-871.	1.4	14

#	ARTICLE	IF	CITATIONS
10789	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage <sc>III</sc> nonâ€small cell lung cancer: Chinese multicenter report and literature review. Thoracic Cancer, 2020, 11, 2916-2923.	1.9	7
10790	Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	27.0	454
10791	Efficacy of Selpercatinib in <i>RET</i> Fusionâ€Positive Nonâ€Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 813-824.	27.0	505
10792	Association of <i>MUC16</i> Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. JAMA Network Open, 2020, 3, e2013201.	5.9	54
10793	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Medicine, 2020, 9, 7453-7459.	2.8	11
10794	Artificial intelligence in radiation oncology. Nature Reviews Clinical Oncology, 2020, 17, 771-781.	27.6	167
10795	Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. , 2020, 8, e000870.		21
10796	Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. Clinical Cancer Research, 2020, 26, 5609-5620.	7.0	32
10797	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094615.	3.2	15
10798	Efficacy and safety of S â€1 monotherapy in previously treated elderly patients (aged â‰¥75â€years) with nonâ€small cell lung cancer: A retrospective analysis. Thoracic Cancer, 2020, 11, 2867-2876.	1.9	4
10799	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
10800	Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians. Cancers, 2020, 12, 2390.	3.7	21
10801	Realâ€world effectiveness of pembrolizumab in previously treated nonâ€small cell lung cancer: A populationâ€based cohort study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1295-1302.	1.9	6
10802	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Current Oncology Reports, 2020, 22, 116.	4.0	9
10803	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nature Communications, 2020, 11, 4333.	12.8	82
10804	The efficacy and safety of osimertinib in treating nonsmall cell lung cancer. Medicine (United States), 2020, 99, e21826.	1.0	12
10805	US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Centerâ€Experience. Ultraschall in Der Medizin, 2022, 43, 380-386.	1.5	6
10806	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	4.5	51

#	ARTICLE	IF	CITATIONS
10807	A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 7558-7571.	2.8	9
10808	Phase II trial of Sâ€1 treatment as palliativeâ€intent chemotherapy for previously treated advanced thymic carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7418-7427.	2.8	13
10809	Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1224-1233.	10.7	80
10810	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced nonâ€small cell lung cancer without tumor PDâ€L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877.	4.1	69
10811	Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1â€%â€¥50%. <i>Scientific Reports</i> , 2020, 10, 14990.	3.3	23
10812	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
10813	Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>Chemotherapy</i> , 2020, 65, 101-109.	1.6	8
10814	Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis. <i>BMC Cancer</i> , 2020, 20, 868.	2.6	3
10815	Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. <i>Anticancer Research</i> , 2020, 40, 5245-5254.	1.1	14
10816	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. <i>Theranostics</i> , 2020, 10, 10838-10848.	10.0	39
10817	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 497-505.	2.3	7
10819	Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2020, 20, 885.	2.6	12
10820	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2591.	3.7	8
10822	Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 52, 947-951.	1.3	10
10823	Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion. <i>Medicine (United States)</i> , 2020, 99, e22115.	1.0	9
10824	<p><Effects of Surgery Combined with Chemoradiotherapy on Short- and Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7813-7826.	1.9	7
10825	Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series. <i>Tumori</i> , 2021, 107, 030089162095284.	1.1	4
10826	Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab. <i>IJU Case Reports</i> , 2020, 3, 252-256.	0.3	5

#	ARTICLE	IF	CITATIONS
10827	Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2020, 34, 2647-2652.	1.3	11
10828	Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy. <i>EBioMedicine</i> , 2020, 59, 102973.	6.1	9
10829	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095135.	1.3	24
10830	A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1503.	2.8	1
10831	Hepatocellular Carcinoma—Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. <i>Hepatology Communications</i> , 2020, 4, 1527-1540.	4.3	60
10832	The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. <i>Oncology</i> , 2020, 98, 807-813.	1.9	4
10833	Prognostic Role of the Platelet-to-Lymphocyte Ratio for Patients With Metastatic Colorectal Cancer Treated With Aflibercept. <i>In Vivo</i> , 2020, 34, 2667-2673.	1.3	9
10834	Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 2997-3003.	1.3	11
10835	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. <i>Frontiers in Oncology</i> , 2020, 10, 1677.	2.8	32
10836	Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 654-659.	1.3	18
10837	A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2270.	3.7	18
10838	Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 613-625.	1.8	7
10839	Initial Approach to the Patient with Multiple Newly Diagnosed Brain Metastases. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 505-513.	1.7	1
10840	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	1.2	14
10841	A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature. <i>Journal of Personalized Medicine</i> , 2020, 10, 113.	2.5	6
10842	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , The, 2020, 21, 1353-1365.	10.7	1,363
10843	Evaluation of the Reproducibility of Bolus Transit Quantification With Contrast-Enhanced Ultrasound Across Multiple Scanners and Analysis Software Packages—A Quantitative Imaging Biomarker Alliance Study. <i>Investigative Radiology</i> , 2020, 55, 643-656.	6.2	12
10844	Effectiveness and Safety of Oral Chinese Patent Medicines Combined with Chemotherapy for Gastric Cancer: A Bayesian Network Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-16.	1.2	8

#	ARTICLE	IF	CITATIONS
10845	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , 2020, 8, 1365-1380.	3.4	37
10846	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	1.6	78
10847	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598.	6.4	57
10848	Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094761.	3.2	21
10849	Retrospective accuracy analysis of MRI based lesion size measurement in neuroblastic tumors: which sequence should we choose?. <i>BMC Medical Imaging</i> , 2020, 20, 105.	2.7	8
10850	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	1.5	8
10851	Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. <i>Molecular Biology Reports</i> , 2020, 47, 7073-7082.	2.3	9
10852	Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. <i>Liver Cancer</i> , 2020, 9, 613-624.	7.7	45
10853	Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary. <i>Clinical Sarcoma Research</i> , 2020, 10, 15.	2.3	2
10854	Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer. <i>British Journal of Radiology</i> , 2020, 93, 20200751.	2.2	2
10855	Potentialities of multi-b-values diffusion-weighted imaging for predicting efficacy of concurrent chemoradiotherapy in cervical cancer patients. <i>BMC Medical Imaging</i> , 2020, 20, 97.	2.7	1
10856	Diagnostic and Predictive Values of ¹⁸ F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 6453-6465.	1.9	12
10857	Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2245.	3.7	2
10858	Genetic variants in the Folic acid Metabolic Pathway Genes predict outcomes of metastatic Colorectal Cancer patients receiving first-line Chemotherapy. <i>Journal of Cancer</i> , 2020, 11, 6507-6515.	2.5	1
10859	Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 407-420.	2.5	11
10860	High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. <i>Chemotherapy</i> , 2020, 65, 2-10.	1.6	17
10861	Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. <i>Cancer Management and Research</i> , 2020, Volume 12, 5365-5372.	1.9	8
10862	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 109.	4.0	10

#	ARTICLE	IF	CITATIONS
10863	YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 919-928.	1.3	3
10864	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 17-26.	0.8	18
10865	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.8	3
10867	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2020, 36, 1667-1675.	1.9	11
10868	Distant Metastasis in Pediatric and Adolescent Differentiated Thyroid Cancer: Clinical Outcomes and Risk Factor Analyses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3981-e3988.	3.6	29
10869	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. <i>Cancers</i> , 2020, 12, 2259.	3.7	6
10870	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	6.3	57
10871	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5869-5878.	7.0	131
10872	Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. <i>BMC Cancer</i> , 2020, 20, 783.	2.6	13
10873	The Real-Life Journey of Elderly Patients in Soft Tissue and Bone Sarcomas: A Retrospective Analysis from a Sarcoma Referral Center. <i>Journal of Clinical Medicine</i> , 2020, 9, 2503.	2.4	0
10874	Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study. <i>Chinese Journal of Integrative Medicine</i> , 2021, 27, 674-679.	1.6	1
10875	Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. <i>Acta Oncologica</i> , 2020, 59, 1382-1387.	1.8	11
10876	Incidental pulmonary embolism in CT scans of oncological patients with metastatic disease undergoing clinical trials: frequency and linkage with onset of disease progression (PE-PD) Tj ETQq0 0 0 rgBT /Overlook 10 Tf50 257 Td		
10877	Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. <i>Cancers</i> , 2020, 12, 2359.	3.7	30
10878	The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA. <i>Journal of Clinical Medicine</i> , 2020, 9, 2642.	2.4	3
10879	Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 1135-1139.	1.6	14
10880	Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. <i>Cancers</i> , 2020, 12, 3698.	3.7	33
10881	Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 272.	2.5	5

#	ARTICLE	IF	CITATIONS
10882	BRCAness as a prognostic indicator in patients with early breast cancer. Scientific Reports, 2020, 10, 21173.	3.3	14
10883	Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Scientific Reports, 2020, 10, 21712.	3.3	12
10884	<p><p>Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2â€“3 After Progression of Second-Line or Later-Line Treatment</p>.</p> Cancer Management and Research, 2020, Volume 12, 12709-12714.	1.9	9
10885	Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). International Journal of Surgical Oncology, 2020, 2020, 1-14.	0.6	2
10887	Primary mediastinal germ cell tumors: Survival outcomes and prognostic factors â€“ 10 years experience from a tertiary care institute. Rare Tumors, 2020, 12, 203636132097222.	0.6	5
10888	Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?. Translational Lung Cancer Research, 2020, 9, 951-955.	2.8	1
10889	Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. Anticancer Research, 2020, 40, 6493-6497.	1.1	5
10890	Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 606133.	2.8	1
10891	Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097119.	3.2	3
10892	Pediatric Rhabdomyosarcomas: Three-Dimensional Radiological Assessments after Induction Chemotherapy Predict Survival Better than One-Dimensional and Two-Dimensional Measurements. Cancers, 2020, 12, 3808.	3.7	9
10893	3D Non-Local Neural Network: A Non-Invasive Biomarker for Immunotherapy Treatment Outcome Prediction. Case-Study: Metastatic Urothelial Carcinoma. Journal of Imaging, 2020, 6, 133.	3.0	11
10894	Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria. International Journal of Endocrinology, 2020, 2020, 1-8.	1.5	19
10895	Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study. World Journal of Surgical Oncology, 2020, 18, 330.	1.9	1
10896	A Potential Biomarker from Diffusion Weighted Imaging and Parametric Response Map Analysis for Treatment Response Prediction in Nasopharyngeal Cancer. Journal of Physics: Conference Series, 2020, 1505, 012032.	0.4	0
10897	Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. Technology in Cancer Research and Treatment, 2020, 19, 153303382097970.	1.9	5
10898	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a â€“Real-Lifeâ€™ Setting. Cancers, 2020, 12, 3707.	3.7	12
10899	Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers, 2020, 12, 3740.	3.7	14
10900	Cytoreductive nephrectomy in metastatic renal cell carcinoma. The Cochrane Library, 2020, , .	2.8	0

#	ARTICLE	IF	CITATIONS
10901	Immunotherapy for advanced or metastatic urothelial carcinoma. The Cochrane Library, 0, , .	2.8	1
10902	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Disease Markers, 2020, 2020, 1-14.	1.3	13
10903	Applications of Quantitative Perfusion and Permeability in the Liver. Advances in Magnetic Resonance Technology and Applications, 2020, , 405-426.	0.1	0
10904	Chinese herbal medicine for small cell lung cancer patients. Medicine (United States), 2020, 99, e23746.	1.0	1
10905	Radiological Assessment and Outcome of Local Disease Progression after Neoadjuvant Chemotherapy in Children and Adolescents with Localized Osteosarcoma. Journal of Clinical Medicine, 2020, 9, 4070.	2.4	7
10906	Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients. Journal of Hematology and Oncology, 2020, 13, 174.	17.0	12
10907	Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Advances in Radiation Oncology, 2020, 5, 1267-1273.	1.2	4
10908	Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials. Cell Systems, 2020, 11, 449-460.e2.	6.2	6
10909	A Comparison Of Stereotactic Body Radiation Therapy For Metastases To The Sacral Spine And Treatment Of The Thoracolumbar Spine. International Journal of Radiation Oncology Biology Physics, 2020, 108, e692.	0.8	0
10910	Integrating Quantitative Assays with Biologically Based Mathematical Modeling for Predictive Oncology. IScience, 2020, 23, 101807.	4.1	22
10911	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. JGH Open, 2020, 4, 1183-1190.	1.6	6
10912	Subjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the <scp>MD</scp> Anderson Symptom Inventory (<scp>MDASI</scp>). Laryngoscope Investigative Otolaryngology, 2020, 5, 1104-1109.	1.5	4
10913	Pathwayâ€extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors. MedComm, 2020, 1, 311-327.	7.2	7
10914	Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 686-694.	2.5	1
10916	On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. Npj Precision Oncology, 2020, 4, 30.	5.4	13
10917	A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations. Medicine (United States), 2020, 99, e23455.	1.0	1
10918	Radiosensitivity-Related Genes and Clinical Characteristics of Nasopharyngeal Carcinoma. BioMed Research International, 2020, 2020, 1-13.	1.9	4
10919	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-5.	1.9	6

#	ARTICLE	IF	CITATIONS
10920	Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles. BMC Cancer, 2020, 20, 1199.	2.6	3
10921	Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. BMC Cancer, 2020, 20, 1184.	2.6	3
10922	Recent advances in the management of anaplastic thyroid cancer. Thyroid Research, 2020, 13, 17.	1.5	39
10923	Clinicopathological significance and prognostic implication of CD44 and its splice variants (v3 and v4) in colorectal cancer. BMC Cancer, 2020, 20, 1184.	1.0	4
10924	Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel: A Final Analysis of the Prostly II Trial. Anticancer Research, 2020, 40, 6915-6921.	1.1	2
10925	Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer. Cancers, 2020, 12, 3614.	3.7	6
10926	Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. Anticancer Research, 2020, 40, 7067-7075.	1.1	25
10927	Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views. Cancers, 2020, 12, 3638.	3.7	25
10928	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. The Cochrane Library, 2020, 12, CD013257.	2.8	30
10929	FASTRACK II magnetic resonance imaging sub-study Diffusion and perfusion biomarkers for renal SABR response. Journal of Physics: Conference Series, 2020, 1662, 012018.	0.4	0
10930	FOLFIRI vs FOLFOX as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancer Management and Research, 2020, Volume 12, 10271-10278.	1.9	7
10931	Pretreatment Apparent Diffusion Coefficient as a Predictor of Response to Transcatheter Arterial Chemoembolization Immediately Combined with Radiofrequency Ablation for Treatment of Solitary Large Hepatocellular Carcinoma. Cancer Management and Research, 2020, Volume 12, 10127-10138.	1.9	6
10932	SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Cancer Management and Research, 2020, 8, e001037.		27
10933	Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bulletin Du Cancer, 2020, 107, 946-958.	1.6	15
10934	Persistent Cancer Cells: The Deadly Survivors. Cell, 2020, 183, 860-874.	28.9	157
10935	Impact of Adjuvant Radiotherapy on Survival Outcomes in Intermediate-Risk, Early-Stage Cervical Cancer: Analyses Regarding Surgical Approach of Radical Hysterectomy. Journal of Clinical Medicine, 2020, 9, 3545.	2.4	5
10936	Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 812-819.	1.4	5
10937	Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis. Hepatology, 2020, 22, 1450-1456.	0.3	12

#	ARTICLE	IF	CITATIONS
10938	Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 4442-4452.	3.9	25
10939	Palliative Hypofractionated Radiotherapy in Advanced Squamous Cell Carcinoma of Head and Neck. <i>Nepalese Journal of Cancer</i> , 2020, 4, 39-44.	0.1	1
10940	Safety, Efficacy and Pharmacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/Ila Study. <i>Cancers</i> , 2020, 12, 3130.	3.7	34
10941	Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis. <i>Journal of Cancer</i> , 2020, 11, 6916-6924.	2.5	8
10942	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2020, 15, 723-732.	3.6	6
10943	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , 2020, 150, 159-163.	2.0	33
10944	FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥ 3 circulating tumour cells: the randomised phase III VISION-1 trial. <i>ESMO Open</i> , 2020, 5, e000944.	4.5	32
10945	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
10946	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
10947	Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1623-1630.	0.9	0
10948	Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin. <i>Journal of Thoracic Disease</i> , 2020, 12, 4825-4832.	1.4	6
10949	Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11089-11095.	2.0	1
10950	Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. <i>ESMO Open</i> , 2020, 5, e000876.	4.5	12
10951	Predictors of survival after surgery with curative intent for perihilar cholangiocarcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 286.	1.9	4
10952	Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. <i>JCO Precision Oncology</i> , 2020, 4, 1302-1306.	3.0	20
10953	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	3.0	42
10954	Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096847.	3.2	9
10955	Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE). <i>BMC Urology</i> , 2020, 20, 181.	1.4	6

#	ARTICLE	IF	CITATIONS
10956	Outcome of lung metastases due to bone giant cell tumor initially managed with observation. Journal of Orthopaedic Surgery and Research, 2020, 15, 510.	2.3	17
10957	¹¹ C-sorafenib and ¹⁵ O-H ₂ O PET for early evaluation of sorafenib therapy. Journal of Nuclear Medicine, 2020, 62, jnumed.120.251611.	5.0	0
10958	Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 61-69.	0.4	1
10959	Pediatric Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2020, 49, 589-611.	3.2	28
10960	¹⁷⁷ Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma. Clinical Nuclear Medicine, 2020, 45, e232-e235.	1.3	10
10961	Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. Annals of Translational Medicine, 2020, 8, 388-388.	1.7	16
10962	Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo, 2020, 34, 1377-1386.	1.3	4
10963	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With <i>MET</i> Exon 14 Skipping. In Vivo, 2020, 34, 1399-1406.	1.3	10
10964	Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. In Vivo, 2020, 34, 1541-1546.	1.3	10
10965	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. Cancers, 2020, 12, 1084.	3.7	17
10966	Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2399-2410.	2.5	10
10967	Understanding the Uptake of Nanomedicines at Different Stages of Brain Cancer Using a Modular Nanocarrier Platform and Precision Bispecific Antibodies. ACS Central Science, 2020, 6, 727-738.	11.3	36
10968	Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 231-235.	1.3	17
10969	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Science Advances, 2020, 6, eaay6298.	10.3	41
10970	A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics, 2020, 10, 5181-5194.	10.0	17
10971	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	5.1	288
10972	Metformin and everolimus in neuroendocrine tumours: A synergic effect?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 954-960.	1.5	5
10973	Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2020, 21, 534-544.	2.6	10

#	ARTICLE	IF	CITATIONS
10974	Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression. <i>Clinical Lung Cancer</i> , 2020, 21, 389-394.e3.	2.6	14
10975	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 920-933.	2.8	15
10976	Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. <i>Lung Cancer</i> , 2020, 144, 40-48.	2.0	9
10977	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	7.0	95
10978	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with ⁹⁰ Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1736-1742.	5.0	27
10979	Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies. <i>American Journal of Neuroradiology</i> , 2020, 41, 866-873.	2.4	7
10980	In vivo Imaging Technologies to Monitor the Immune System. <i>Frontiers in Immunology</i> , 2020, 11, 1067.	4.8	45
10981	Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 679-689.	2.5	30
10982	Cyclin-dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor-positive breast cancer patients: A systematic review and meta-analysis of randomized clinical trials. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100175.	1.7	7
10983	11 β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 61-71.	6.4	6
10984	The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 903-908.	1.3	13
10985	Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e000653.	4.5	5
10986	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 3517-3524.	7.0	11
10987	Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study. <i>Tumor Biology</i> , 2020, 42, 101042832091919.	1.8	8
10988	Anti-Tumor Activity of Intravenously Administered Plumbagin Entrapped in Targeted Nanoparticles. <i>Journal of Biomedical Nanotechnology</i> , 2020, 16, 85-100.	1.1	6
10989	Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 366-375.	1.4	9
10990	Ribcage procedure after neoadjuvant chemoradiotherapy for non-small cell lung cancer involving the chest wall. <i>Surgery Today</i> , 2020, 50, 1262-1271.	1.5	0
10991	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e598-e609.	1.9	11

#	ARTICLE	IF	CITATIONS
10992	Noadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	1.6	145
10994	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. <i>European Radiology</i> , 2020, 30, 5663-5673.	4.5	62
10995	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. <i>British Journal of Cancer</i> , 2020, 123, 392-402.	6.4	28
10996	The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: a single-center experience. <i>Cancer Biology and Therapy</i> , 2020, 21, 675-687.	3.4	2
10997	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMJ Open</i> , 2020, 10, e034527.	1.9	11
10998	Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091529.	3.2	17
10999	The combination of methotrexate and cytosine arabinoside in newly diagnosed adult Langerhans cell histiocytosis: a prospective phase II interventional clinical trial. <i>BMC Cancer</i> , 2020, 20, 433.	2.6	2
11000	Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume. <i>BMC Cancer</i> , 2020, 20, 440.	2.6	13
11001	Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1477.	2.4	8
11002	Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 499-508.	3.3	5
11003	Combined dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging to predict neoadjuvant chemotherapy effect in FIGO stage IB2-â€œIIA2 cervical cancers. <i>Radiologia Medica</i> , 2020, 125, 1233-1242.	7.7	29
11004	Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. <i>Oncology</i> , 2020, 98, 621-629.	1.9	1
11005	Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer. <i>Oncology</i> , 2020, 98, 630-636.	1.9	12
11006	Multi-Habitat Based Radiomics for the Prediction of Treatment Response to Concurrent Chemotherapy and Radiation Therapy in Locally Advanced Cervical Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 563.	2.8	38
11007	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter â€œSLAVEâ€•Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
11008	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. <i>Diagnostics</i> , 2020, 10, 310.	2.6	38
11009	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€œmutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€œPET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	2.8	14
11010	The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively. <i>European Radiology</i> , 2020, 30, 5768-5776.	4.5	4

#	ARTICLE	IF	CITATIONS
11011	Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report. <i>Anticancer Research</i> , 2020, 40, 2265-2269.	1.1	4
11012	Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. <i>Advances in Therapy</i> , 2020, 37, 2829-2840.	2.9	2
11013	Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 831.	7.1	221
11014	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 999-1013.	5.9	38
11015	Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases. <i>BMC Cancer</i> , 2020, 20, 402.	2.6	13
11016	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
11017	Hepatic Arterial Infusion Combined with Systemic Chemotherapy for Patients with Extensive Liver Metastases from Gastric Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 2911-2916.	1.9	2
11018	Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 480.	2.8	28
11019	Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 628.	2.8	34
11020	18F-FDG PET Parameters and Radiomics Features Analysis in Advanced NSCLC Treated with Immunotherapy as Predictors of Therapy Response and Survival. <i>Cancers</i> , 2020, 12, 1163.	3.7	70
11021	Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center. <i>Cancer Communications</i> , 2020, 40, 222-233.	9.2	11
11022	Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28370.	1.5	15
11023	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. <i>Pathology and Oncology Research</i> , 2020, 26, 2225-2235.	1.9	15
11024	Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States. <i>Advances in Therapy</i> , 2020, 37, 2841-2852.	2.9	28
11025	Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized ¹³ C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 887-896.	0.8	18
11026	Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment. <i>Lung Cancer</i> , 2020, 145, 173-180.	2.0	14
11027	Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma. <i>Medicine (United States)</i> , 2020, 99, e20081.	1.0	10
11028	Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Thoracic Cancer</i> , 2020, 11, 1790-1800.	1.9	20

#	ARTICLE	IF	CITATIONS
11029	Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. , 2020, 8, e000146.		49
11030	Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. , 2020, 8, e000798.		80
11031	Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate. Chinese Clinical Oncology, 2020, 9, 15-15.	1.2	9
11032	The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. Journal of Thoracic Disease, 2020, 12, 1520-1528.	1.4	52
11033	Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease. Internal Medicine, 2020, 59, 1939-1945.	0.7	7
11034	A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2020, 40, 2981-2987.	1.1	4
11035	A primary analysis on measuring repeatability of the maximum diameter between CT and MR imaging for lung cancers. Journal of X-Ray Science and Technology, 2020, 28, 333-344.	1.0	0
11036	Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities. Journal of Clinical Medicine, 2020, 9, 1314.	2.4	40
11037	Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma. European Radiology, 2020, 30, 5392-5403.	4.5	42
11038	A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. Advances in Therapy, 2020, 37, 2853-2864.	2.9	6
11039	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs, 2020, 34, 463-476.	4.6	49
11040	Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses. Acta Oncol ³ gica, 2020, 59, 1036-1042.	1.8	2
11041	Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials, 2020, 21, 391.	1.6	8
11043	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	4.2	60
11044	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e317-e329.	10.7	69
11045	Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 553-554.	1.6	1
11046	Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. Journal of Clinical Oncology, 2020, 38, 2427-2437.	1.6	88
11047	A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist, 2020, 25, 652-660.	3.7	11

#	ARTICLE	IF	CITATIONS
11049	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanesâ€”a Hellenic Cooperative Oncology Group (HeCOG) Trial. British Journal of Cancer, 2020, 123, 355-361.	6.4	8
11050	Thermal ablation versus hepatic resection for the treatment of liver metastases from gastrointestinal stromal tumors: a retrospective study. International Journal of Hyperthermia, 2020, 37, 592-599.	2.5	0
11051	Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 422-427.	1.3	12
11052	In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. , 2020, 8, e000204.		35
11053	⁸⁹ Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following ¹²⁵ I- and ¹²⁵ I ² -particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics, 2020, 10, 5802-5814.	10.0	15
11056	Formulation and Delivery Technologies for mRNA Vaccines. Current Topics in Microbiology and Immunology, 2020, , 71-110.	1.1	107
11057	Lipid-weighted intraoperative photoacoustic tomography of breast tumors: Volumetric comparison to preoperative MRI. Photoacoustics, 2020, 18, 100165.	7.8	12
11058	Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer. Medicine (United Tj ETQq1 1 0.784314 rgBT ₆ /Overl	1.0	
11059	Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial. BMC Cancer, 2020, 20, 385.	2.6	4
11060	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer, 2020, 6, 43-52.	0.4	2
11061	Measuring Efficiency of Semi-automated Brain Tumor Segmentation by Simulating User Interaction. Frontiers in Computational Neuroscience, 2020, 14, 32.	2.1	6
11062	Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses. Frontiers in Oncology, 2020, 10, 515.	2.8	20
11063	HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis. Journal of Clinical Medicine, 2020, 9, 1425.	2.4	6
11064	Low-Dose Erlotinib Treatment in Elderly or Frail Patients With <i>EGFR</i> Mutationâ€”Positive Nonâ€”Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e201250.	7.1	36
11065	Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer, 2020, 145, 18-26.	2.0	57
11066	Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. Biostatistics, 2022, 23, 120-135.	1.5	24
11067	Predictive value of integrated ¹⁸ F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer. , 2020, 8, e000349.		19
11068	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19

#	ARTICLE	IF	CITATIONS
11069	Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1486-1496.	4.1	18
11070	Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma. <i>Anticancer Research</i> , 2020, 40, 2911-2916.	1.1	3
11071	Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. <i>Pharmacogenomics</i> , 2020, 21, 393-402.	1.3	0
11072	Duration of nivolumab for pretreated, advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 6923-6932.	2.8	5
11073	Does lymph node ratio have any prognostic significance in maximally cytoreduced node-positive low-grade serous ovarian carcinoma?. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 183-190.	1.7	6
11074	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 796-807.	10.7	620
11075	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020, 132, 150-158.	2.8	28
11076	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	3.2	25
11077	Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. <i>Cancer</i> , 2020, 126, 3516-3525.	4.1	45
11078	Impact of Serum γ -Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2020, 15, 347-356.	3.6	9
11079	Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2020, 31, 291-300.	9.0	34
11080	Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 2303-2311.	2.4	10
11081	Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 940-947.	1.3	3
11082	Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 56.	5.0	25
11083	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2020, 22, 57.	5.0	63
11084	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
11085	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3488-3497.	1.5	24
11086	Therapeutically-induced stable disease in oncology early clinical trials. <i>PLoS ONE</i> , 2020, 15, e0233882.	2.5	1

#	ARTICLE	IF	CITATIONS
11087	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. <i>JAMA Oncology</i> , 2020, 6, 1048.	7.1	96
11088	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. <i>JAMA Oncology</i> , 2020, 6, 1231.	7.1	12
11089	Radiotranscriptomics signature-based predictive nomograms for radiotherapy response in patients with nonsmall cell lung cancer: Combination and association of CT features and serum miRNAs levels. <i>Cancer Medicine</i> , 2020, 9, 5065-5074.	2.8	15
11090	Multi-energy computed tomography and material quantification: Current barriers and opportunities for advancement. <i>Medical Physics</i> , 2020, 47, 3752-3771.	3.0	14
11091	Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2957-2966.	2.5	14
11092	The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1531-1542.	3.3	18
11093	Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study. <i>Journal of Integrative Medicine</i> , 2020, 18, 319-325.	3.1	16
11094	Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 305-310.	1.3	9
11095	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
11096	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	1.6	102
11097	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379.	1.6	410
11098	From CENTRAL to SENTRAL (SErum aNGiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	3.7	7
11099	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092342.	3.2	14
11100	Intestinal microbiota: a new force in cancer immunotherapy. <i>Cell Communication and Signaling</i> , 2020, 18, 90.	6.5	56
11101	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. <i>PLoS ONE</i> , 2020, 15, e0234302.	2.5	13
11102	Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2020, 12, 715-724.	2.0	13
11103	Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. <i>Cancer</i> , 2020, 126, 3689-3697.	4.1	11
11104	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 135, 31-38.	2.8	11

#	ARTICLE	IF	CITATIONS
11105	The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 196-203.	2.4	36
11106	Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. , 2020, 8, e000908.		18
11107	A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor. <i>AAPS Journal</i> , 2020, 22, 85.	4.4	26
11108	Using a doseâ€finding benchmark to quantify the loss incurred by dichotomization in Phase II doseâ€ranging studies. <i>Biometrical Journal</i> , 2020, 62, 1717-1729.	1.0	1
11109	Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a Randomized phaseÂ2 trial (LEOPARD-2). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 795-804.	2.0	9
11110	Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/computed tomography for assessing prostate cancer with bone metastasis: a phantom and clinical study. <i>Radiological Physics and Technology</i> , 2020, 13, 219-229.	1.9	6
11111	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.9	13
11112	Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 631-639.	1.4	16
11113	Relationship Between Progressionâ€Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PDâ€1/PDâ€L1 Immune Checkpoint Blockade: A Metaâ€Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1274-1288.	4.7	27
11114	Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3003-3012.	2.5	18
11115	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 689-697.	2.5	25
11116	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3195-3204.	1.6	152
11117	Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 3345-3354.	1.1	11
11118	Phase I Study of Ficlatazumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 1537.	3.7	19
11119	An Electronic Health Record Text Mining Tool to Collect Realâ€World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 644-652.	4.7	19
11120	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. <i>European Journal of Cancer</i> , 2020, 135, 89-97.	2.8	13
11121	Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO). <i>Gynecologic Oncology Reports</i> , 2020, 33, 100594.	0.6	10
11122	Clinical implications of the serum CA19-9 level in â€biological borderline resectabilityâ€and â€biological downstagingâ€in the setting of preoperative chemoradiation therapy for pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 919-928.	1.1	25

#	ARTICLE	IF	CITATIONS
11123	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. <i>Nature Communications</i> , 2020, 11, 3083.	12.8	173
11124	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. <i>Cancers</i> , 2020, 12, 1619.	3.7	24
11125	Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 653-660.	4.7	25
11126	Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. , 2020, 8, e000367.		72
11127	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3088-3094.	1.6	61
11128	<p>Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 77-85.	1.8	3
11129	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naïve advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. <i>Future Oncology</i> , 2020, 16, 1525-1536.	2.4	50
11130	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 9050.	3.3	43
11131	Primary transitional cell carcinoma of the fallopian tube. <i>Medicine (United States)</i> , 2020, 99, e20499.	1.0	3
11132	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. <i>Science</i> , 2020, 368, 1127-1131.	12.6	83
11133	Evaluation of Parametrial Status in Locally Advanced Cervical Cancer Patients after Neoadjuvant Chemotherapy: A Prospective Study on Diagnostic Accuracy of Three-Dimensional Transvaginal Ultrasound. <i>Oncology</i> , 2020, 98, 603-611.	1.9	4
11134	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020, 20, 492.	2.6	16
11135	<p>Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5017-5032.	2.0	9
11136	A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2020, 12, 1425.	3.7	3
11137	Influence of tube voltage, tube current and newer iterative reconstruction algorithms in CT perfusion imaging in rabbit liver VX2 tumors. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 264-270.	1.5	0
11138	Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e330-e336.	10.7	59
11139	Effectiveness of anti-PD-1 for hepatocellular carcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e294.	10.7	2
11140	Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 563-569.	1.8	2

#	ARTICLE	IF	CITATIONS
11141	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. <i>Thoracic Cancer</i> , 2020, 11, 2188-2195.	1.9	11
11142	Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1195-e1201.	3.7	7
11143	Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. <i>Cancers</i> , 2020, 12, 1395.	3.7	7
11144	Nivolumab in Metastatic Melanoma: Good Efficacy and Tolerability in Elderly Patients. <i>Current Oncology</i> , 2020, 27, 75-80.	2.2	8
11145	Two-staged gamma knife radiosurgery for treatment of numerous (>10) brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105847.	1.4	7
11146	A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 12-18.	2.0	21
11147	Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 309-315.	1.4	4
11148	Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 843-850.	10.7	124
11149	Neck Imaging Reporting and Data System. <i>Neuroimaging Clinics of North America</i> , 2020, 30, 369-377.	1.0	2
11150	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. <i>Gynecologic Oncology</i> , 2020, 158, 303-308.	1.4	4
11151	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , 2020, 31, 632-636.	1.4	4
11152	Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients. <i>Medicine (United States)</i> , 2020, 99, e20545.	1.0	18
11153	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
11154	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	2.6	29
11155	C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 75-85.	2.3	10
11156	Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. , 2020, 8, e000665.		8
11157	³ H-Ki67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment. <i>Tumor Biology</i> , 2020, 42, 101042832092530.	1.8	7
11158	The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial. <i>Journal of Ovarian Research</i> , 2020, 13, 70.	3.0	1

#	ARTICLE	IF	CITATIONS
11159	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2658-2666.	1.6	186
11160	<p><Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4385-4395.	2.0	6
11161	Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch. <i>Frontiers in Immunology</i> , 2020, 11, 1228.	4.8	49
11162	Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1769.	2.4	25
11163	Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 471-486.	4.7	50
11164	Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC. <i>Clinical Lung Cancer</i> , 2020, 21, 562-567.	2.6	5
11165	Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 329-343.	1.8	10
11166	Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers. <i>Journal of Radiation Research</i> , 2020, 61, 554-562.	1.6	1
11167	Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. <i>Journal of Clinical Oncology</i> , 2020, 38, 2667-2676.	1.6	44
11168	Multimodality Imaging of Uterine Cervical Malignancies. <i>American Journal of Roentgenology</i> , 2020, 215, 292-304.	2.2	11
11169	HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 1623.	3.7	7
11170	Tipifarnib in recurrent, metastatic HRASâ€ mutant salivary gland cancer. <i>Cancer</i> , 2020, 126, 3972-3981.	4.1	34
11171	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	2.1	12
11172	Prostateâ€™specific membrane antigen theranostics in advanced prostate cancer: an evolving option. <i>BJU International</i> , 2020, 126, 525-535.	2.5	14
11173	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
11174	Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 487.	1.6	11
11175	Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine. <i>Nuclear Medicine Communications</i> , 2020, 41, 350-355.	1.1	7
11176	Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination. <i>Anticancer Research</i> , 2020, 40, 3459-3468.	1.1	4

#	ARTICLE	IF	CITATIONS
11177	Abdominal lymph node size in children at computed tomography. <i>Pediatric Radiology</i> , 2020, 50, 1263-1270.	2.0	7
11178	DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer. <i>Scientific Reports</i> , 2020, 10, 9239.	3.3	34
11179	Evaluation of liver tumour response by imaging. <i>JHEP Reports</i> , 2020, 2, 100100.	4.9	33
11180	Imaging for Response Assessment in Cancer Clinical Trials. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 488-504.	4.6	22
11181	Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 522-527.	0.7	10
11182	Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 1173.	4.8	26
11183	Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China. <i>Frontiers in Oncology</i> , 2020, 10, 800.	2.8	13
11184	Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 808.	2.8	11
11185	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1835-1844.	13.7	423
11186	A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6+â€‰Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	1
11187	Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. <i>Clinical Colorectal Cancer</i> , 2020, 19, 291-300.e5.	2.3	8
11188	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expressionâ€‰â‰¥ 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
11189	Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1281-1297.	1.1	109
11190	Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged â‰¥75 years with squamous-cell lung cancer: TOR1322. <i>Lung Cancer</i> , 2020, 146, 182-188.	2.0	1
11191	Third-line sunitinib treatment in a <i>VHL</i>-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review. <i>Cancer Biology and Therapy</i> , 2020, 21, 785-789.	3.4	2
11192	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
11193	Treatment of a feline cutaneous mast cell tumour using imatinib mesylate as a neoadjuvant tyrosine kinase inhibitor therapeutic agent. <i>Veterinari Medicina</i> , 2020, 65, 84-88.	0.6	1
11194	Percutaneous microwave ablation therapy of renal cancer local relapse after radical nephrectomy: a feasibility and efficacy study. <i>Medical Oncology</i> , 2020, 37, 27.	2.5	5

#	ARTICLE	IF	CITATIONS
11195	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020, 21, e337-e348.	2.6	6
11196	An Intrusion Detection System Against DDoS Attacks in IoT Networks. , 2020, , .		63
11197	Metabolic activity of primary tumour on PET/CT has a relationship with survival in stages lâ€“II smallâ€“cell lung carcinoma. <i>Clinical Respiratory Journal</i> , 2020, 14, 695-702.	1.6	3
11198	Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma. <i>Future Oncology</i> , 2020, 16, 9-13.	2.4	3
11199	Prognostic Value of ¹⁸ F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1560-1569.	5.0	48
11200	Phase I and pharmacokinetic study of the vascularâ€“disrupting agent CKDâ€“516 (NOV120401) in patients with refractory solid tumors. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00568.	2.4	5
11201	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 893-903.	5.3	20
11202	ILâ€“28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1813-1820.	2.8	2
11203	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. <i>Radiology</i> , 2020, 295, 361-372.	7.3	17
11204	Limited Knee-Joint Range of Motion in Patients With Tophaceous Gout Improved With Medical Treatment: A 18-Months Follow Up. <i>Frontiers in Medicine</i> , 2020, 7, 74.	2.6	5
11205	Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. <i>Cancers</i> , 2020, 12, 659.	3.7	8
11206	A patientâ€“derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 3337-3343.	2.8	1
11207	Â“Authorâ€“s Response to â€“A Letter in Support of Real-World RECISTâ€“. <i>Advances in Therapy</i> , 2020, 37, 1691-1693.	2.9	0
11208	Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.4	20
11209	Singleâ€“center study to determine the safety and efficacy of CTâ€“707 in Chinese patients with advanced anaplastic lymphoma kinaseâ€“rearranged nonâ€“smallâ€“cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1216-1223.	1.9	5
11210	Kidney retransplantation after antiâ€“programmed cell death-1 (PD-1)â€“related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	4.7	20
11211	Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival. <i>AAPS Journal</i> , 2020, 22, 58.	4.4	14
11212	Establishing M1 stage subdivisions by incorporating radiological features and Epstein-Barr virus DNA for metastatic nasopharyngeal carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 83-83.	1.7	13

#	ARTICLE	IF	CITATIONS
11213	Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma. <i>Anticancer Research</i> , 2020, 40, 1613-1618.	1.1	3
11214	Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. <i>Nature Communications</i> , 2020, 11, 1456.	12.8	91
11215	Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2020, 2020, 1-10.	1.3	6
11216	Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. <i>Immunotherapy</i> , 2020, 12, 235-243.	2.0	17
11217	Minimally invasive treatment of tibial plateau depression fractures using balloon tibioplasty: Clinical outcome and absorption of bioabsorbable calcium phosphate cement. <i>Journal of Orthopaedic Surgery</i> , 2020, 28, 230949902090872.	1.0	7
11218	A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 313.	2.8	11
11219	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712.	4.1	26
11220	Locally unresectable differentiated thyroid cancer: outcomes and perspectives. <i>Endocrine</i> , 2020, 69, 133-141.	2.3	10
11221	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429.	1.5	10
11222	Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre. <i>Frontiers in Oncology</i> , 2020, 10, 167.	2.8	22
11223	Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. <i>Frontiers in Oncology</i> , 2020, 10, 193.	2.8	7
11224	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 497-507.	10.7	196
11225	Imaging Cell Death: Focus on Early Evaluation of Tumor Response to Therapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 1025-1051.	3.6	15
11226	Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3616-3628.	7.0	31
11227	Hybrid Minimally-invasive Esophagectomy for Esophageal Cancer: Clinical and Oncological Outcomes. <i>Anticancer Research</i> , 2020, 40, 1753-1758.	1.1	6
11228	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. <i>Thoracic Cancer</i> , 2020, 11, 1280-1287.	1.9	37
11229	Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3220-3229.	7.0	13
11230	Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 3278-3286.	2.8	3

#	ARTICLE	IF	CITATIONS
11231	The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. CardioVascular and Interventional Radiology, 2020, 43, 1165-1172.	2.0	6
11232	JOINUS: A User-Friendly Open-Source Software to Simulate Digital Superconductor Circuits. IEEE Transactions on Applied Superconductivity, 2020, 30, 1-7.	1.7	8
11233	Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy. Chinese Medical Journal, 2020, 133, 552-560.	2.3	11
11234	Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thoracic Cancer, 2020, 11, 1068-1075.	1.9	15
11235	KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 650-e1145.	3.7	11
11236	Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British Journal of Cancer, 2020, 122, 1166-1174.	6.4	30
11237	Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome, 2020, 8, 28.	11.1	102
11238	Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1321-1334.	2.5	6
11239	ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Annals of Oncology, 2020, 31, 609-618.	1.2	100
11240	EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. Clinical Lung Cancer, 2020, 21, 365-377.e5.	2.6	44
11241	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European Journal of Cancer, 2020, 129, 107-116.	2.8	35
11242	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. Journal of Thoracic Oncology, 2020, 15, 1015-1026.	1.1	58
11243	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology, 2020, 15, 1190-1199.	1.1	23
11244	Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma. Journal of Vascular and Interventional Radiology, 2020, 31, 701-709.	0.5	9
11245	The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 602.e1-602.e10.	1.6	37
11246	Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome. Gynecologic Oncology, 2020, 157, 392-397.	1.4	6
11247	Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica, 2020, 59, 713-722.	1.8	5
11248	A patent review of anticancer glucocorticoid receptor modulators (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 313-324.	5.0	3

#	ARTICLE	IF	CITATIONS
11249	Influence of Satellite Observation Angle to Tropical Cyclone Intensity Estimation Using the Deviation Angle Variance Technique. <i>IEEE Transactions on Geoscience and Remote Sensing</i> , 2020, 58, 3703-3710.	6.3	3
11250	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. <i>Theranostics</i> , 2020, 10, 3254-3262.	10.0	15
11251	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in colorectal cancer treatment. , 2020, , 215-226.		1
11252	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 895-904.	10.7	111
11253	Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. <i>International Immunopharmacology</i> , 2020, 82, 106375.	3.8	28
11254	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 761-771.	2.3	32
11255	Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck. <i>Head and Neck</i> , 2020, 42, 2050-2057.	2.0	14
11256	The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. <i>British Journal of Dermatology</i> , 2020, 183, 831-839.	1.5	26
11257	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1148-1156.	4.1	22
11258	Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma. <i>JCO Global Oncology</i> , 2020, 6, 462-470.	1.8	1
11259	The histological replacement growth pattern represents aggressive invasive behavior in liver metastasis from pancreatic cancer. <i>Cancer Medicine</i> , 2020, 9, 3130-3141.	2.8	11
11260	Isolated limb infusion: Institutional protocol and implementation. <i>Journal of Surgical Oncology</i> , 2020, 122, 99-105.	1.7	7
11261	OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. <i>British Journal of Cancer</i> , 2020, 122, 1507-1517.	6.4	48
11262	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. <i>British Journal of Cancer</i> , 2020, 122, 1518-1524.	6.4	31
11263	The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 4940.	3.3	12
11264	Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study. <i>BMC Research Notes</i> , 2020, 13, 176.	1.4	7
11265	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1824-1835.	1.6	102
11266	Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. <i>Frontiers in Oncology</i> , 2020, 10, 254.	2.8	19

#	ARTICLE	IF	CITATIONS
11267	Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. <i>Theranostics</i> , 2020, 10, 3612-3621.	10.0	24
11268	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. <i>Molecular Imaging and Biology</i> , 2020, 22, 1446-1454.	2.6	3
11269	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	10.7	247
11270	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1693-1701.	1.6	86
11271	<p>Evaluation of Contrast-Enhanced Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) in the Detection of Retropharyngeal Lymph Node Metastases in Nasopharyngeal Carcinoma Patients<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1733-1739.	1.9	13
11272	High-dose ¹³¹ I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan. <i>Annals of Nuclear Medicine</i> , 2020, 34, 397-406.	2.2	10
11273	Differential expression of circulating serum miR-1249-3p, miR-3195, and miR-3692-3p in non-small cell lung cancer. <i>Human Cell</i> , 2020, 33, 839-849.	2.7	16
11274	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	1.5	16
11275	Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study. <i>Radiation Oncology</i> , 2020, 15, 70.	2.7	13
11276	Status Update on Data Required to Build a Learning Health System. <i>Journal of Clinical Oncology</i> , 2020, 38, 1602-1607.	1.6	18
11277	Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer. <i>FEBS Journal</i> , 2020, 287, 5236-5248.	4.7	6
11278	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781.	3.7	8
11279	Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 785.	3.7	5
11280	Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 855-862.	2.3	24
11281	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 655-663.	10.7	335
11282	The discovery and development of binimetinib for the treatment of melanoma. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 745-754.	5.0	25
11283	THz Cluster-Based Modeling and Propagation Characterization in a Data Center Environment. <i>IEEE Access</i> , 2020, 8, 56544-56558.	4.2	43
11284	Pattern-Based Knowledge Graph Embedding for Non-functional Requirements. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
11285	Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival. <i>Radiology</i> , 2020, 295, 572-580.	7.3	7
11286	Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 244-257.	3.0	32
11287	Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2341-2347.	1.6	16
11288	Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1883-1890.	2.5	9
11289	Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases. <i>Journal of Neuro-Oncology</i> , 2020, 147, 691-700.	2.9	11
11290	A retrospective cohort study of low-dose intensity-modulated radiotherapy for unresectable liver metastases. <i>Journal of International Medical Research</i> , 2020, 48, 030006051989238.	1.0	2
11291	Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. <i>BMC Cancer</i> , 2020, 20, 207.	2.6	26
11292	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2981-2992.	1.6	364
11293	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 725.	2.4	46
11294	First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 3310-3318.	2.8	24
11295	Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer. <i>Surgery Today</i> , 2020, 50, 1049-1055.	1.5	9
11296	Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients. <i>Esophagus</i> , 2020, 17, 425-432.	1.9	5
11297	A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 715-724.	2.5	2
11298	Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 324-328.	0.5	1
11299	Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories: real-world experience. <i>Current Problems in Cancer</i> , 2020, 44, 100565.	2.0	6
11300	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
11301	Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. <i>European Journal of Cancer</i> , 2020, 130, 12-19.	2.8	39
11302	Predictive role of Apparent Diffusion Coefficient (ADC) from Diffusion Weighted MRI in patients with sacral chordoma treated with carbon ion radiotherapy (CIRT) alone. <i>European Journal of Radiology</i> , 2020, 126, 108933.	2.6	6

#	ARTICLE	IF	CITATIONS
11303	Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 4484.	3.3	14
11304	Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis. <i>Cancer Research</i> , 2020, 80, 2286-2297.	0.9	43
11305	Vorinostat in patients with resistant <i>BRAF</i> ^{V600E} mutated advanced melanoma: a proof of concept study. <i>Future Oncology</i> , 2020, 16, 619-629.	2.4	16
11306	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. <i>Cancers</i> , 2020, 12, 638.	3.7	52
11307	Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1092-1099.	2.8	22
11308	GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	6
11309	Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study. <i>Oncology</i> , 2020, 98, 267-272.	1.9	4
11310	GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2020, 20, 161.	2.6	20
11311	Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. <i>Genome Medicine</i> , 2020, 12, 22.	8.2	98
11312	Magnetic resonance imaging assessment of chemotherapy-related adipocytic maturation in myxoid/round cell liposarcomas: specificity and prognostic value. <i>British Journal of Radiology</i> , 2020, 93, 20190794.	2.2	6
11313	<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1543-1567.	1.9	38
11314	18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. <i>Current Radiopharmaceuticals</i> , 2020, 13, 228-237.	0.8	17
11315	Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 897-902.	1.3	1
11316	Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer. <i>In Vivo</i> , 2020, 34, 903-908.	1.3	4
11317	⁶⁴ Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1491-1497.	5.0	27
11318	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 141.	4.1	35
11319	Prediction of Response to Preoperative Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Using Multicenter CT-Based Radiomic Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 77.	2.8	29
11320	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020, 12, 540.	3.7	55

#	ARTICLE	IF	CITATIONS
11321	Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma. <i>Cancers</i> , 2020, 12, 559.	3.7	28
11322	Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine. <i>Genes</i> , 2020, 11, 263.	2.4	9
11323	Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). <i>International Journal of Radiation Biology</i> , 2020, 96, 759-766.	1.8	12
11324	Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 935-942.	1.9	24
11325	Hypofractionated Robotic Stereotactic Radiosurgery for Vagal Paragangliomas: A Novel Treatment Strategy for Cranial Nerve Preservation. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 897-904.	1.9	1
11326	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989028.	3.2	6
11327	Using salvage Boron Neutron Capture Therapy (BNCT) for recurrent malignant brain tumors in Taiwan. <i>Applied Radiation and Isotopes</i> , 2020, 160, 109105.	1.5	28
11328	Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer. <i>BMC Cancer</i> , 2020, 20, 182.	2.6	14
11329	Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. <i>Anticancer Research</i> , 2020, 40, 1467-1473.	1.1	3
11330	Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2020, 10, 3974.	3.3	83
11331	Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 417-423.	2.0	3
11332	Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer. <i>Clinica Chimica Acta</i> , 2020, 509, 295-303.	1.1	13
11333	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5129-5139.	7.0	67
11334	EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients. <i>Clinical and Translational Medicine</i> , 2020, 9, 17.	4.0	19
11335	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
11336	Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 3928-3935.	7.0	154
11337	The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1247-1253.	1.0	19
11338	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>Onc Immunology</i> , 2020, 9, 1738814.	4.6	13

#	ARTICLE	IF	CITATIONS
11339	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-“PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	28
11340	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	7.0	27
11341	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4767-4776.	7.0	68
11342	Efficient and Accurate Extracting of Unstructured EHRs on Cancer Therapy Responses for the Development of RECIST Natural Language Processing Tools: Part I, the Corpus. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 383-391.	2.1	9
11343	Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population. <i>JCO Global Oncology</i> , 2020, 6, 19-26.	1.8	8
11344	EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 471-483.	2.8	11
11345	Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 997.	2.8	16
11346	The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. <i>European Radiology</i> , 2020, 30, 6593-6602.	4.5	28
11347	Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. <i>Annals of Oncology</i> , 2020, 31, 1160-1168.	1.2	41
11348	Combination Therapy for Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 477-483.	1.3	3
11349	<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2423-2433.	4.3	82
11350	Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. <i>Targeted Oncology</i> , 2020, 15, 485-493.	3.6	6
11351	Tumor texture parameters of invasive ductal breast carcinoma in neoadjuvant chemotherapy: early identification of non-responders on breast MRI. <i>Clinical Imaging</i> , 2020, 65, 119-123.	1.5	4
11352	Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. <i>Clinical Oncology</i> , 2020, 32, 656-664.	1.4	11
11353	Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1317-1327.	1.1	46
11354	Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 2179-2185.	1.3	4
11355	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. <i>Cancers</i> , 2020, 12, 1707.	3.7	18
11357	FAS and FASL variations in outcomes of tobacco- and alcohol-related head and neck squamous cell carcinoma patients. <i>Tumor Biology</i> , 2020, 42, 101042832093849.	1.8	2

#	ARTICLE	IF	CITATIONS
11358	PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093797.	3.2	19
11359	Immunotherapy in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1752.	3.7	58
11360	Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1305-1314.	2.0	41
11361	Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 163.	1.9	3
11362	Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 123-130.	2.9	12
11363	Phase I pharmacological study of continuous chronomodulated capecitabine treatment. <i>Pharmaceutical Research</i> , 2020, 37, 89.	3.5	12
11364	Aggressive Pituitary Adenomas and Carcinomas. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 505-515.	3.2	28
11365	Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1131-1138.	1.1	16
11366	Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 340-347.	1.1	9
11367	Patient-derived tumor-like cell clusters for drug testing in cancer therapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	39
11368	Biocurcumin as Radiosensitiser for Cervical Cancer Study (BRACES): A Double-Blind Randomised Placebo-Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-10.	1.2	4
11369	Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 631-631.	1.7	9
11370	Extended pleurectomy and decortication with resection and reconstruction of pericardium and hemidiaphragm for malignant pleural mesothelioma. <i>Journal of Visualized Surgery</i> , 2020, 6, 20-20.	0.2	1
11371	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. <i>Future Oncology</i> , 2020, 16, 1629-1637.	2.4	5
11372	Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. <i>Investigational New Drugs</i> , 2020, 38, 1836-1845.	2.6	4
11373	Radiological assessment after stereotactic body radiation of lung tumours. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 379-387.	1.4	6
11374	Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1061-1066.	1.0	11
11375	Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e20596.	1.0	1

#	ARTICLE	IF	CITATIONS
11376	MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. , 2020, 8, e000328.		25
11377	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		66
11378	FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-8.	1.9	5
11380	In Vivo Evaluation of Indium-111 ⁶⁶ Labeled 800CW as a Necrosis-Avid Contrast Agent. Molecular Imaging and Biology, 2020, 22, 1333-1341.	2.6	6
11381	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
11382	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. Oncologist, 2020, 25, e1777-e1784.	3.7	27
11383	<p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p>. Cancer Management and Research, 2020, Volume 12, 4161-4168.	1.9	17
11384	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research, 2020, 26, 4531-4541.	7.0	46
11385	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	1.4	30
11386	Early treatment-related neutropenia predicts response to palbociclib. British Journal of Cancer, 2020, 123, 912-918.	6.4	14
11387	Combined PLT and NE to predict the prognosis of patients with locally advanced cervical cancer. Scientific Reports, 2020, 10, 11210.	3.3	5
11388	Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clinical Cancer Research, 2020, 26, 4756-4766.	7.0	7
11389	Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. Anticancer Research, 2020, 40, 4157-4163.	1.1	6
11390	A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. Frontiers in Oncology, 2020, 10, 1056.	2.8	5
11391	A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer. International Journal of Molecular Sciences, 2020, 21, 4813.	4.1	17
11392	Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior. Immunologic Research, 2020, 68, 204-212.	2.9	5
11393	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. European Journal of Cancer, 2020, 136, 76-83.	2.8	19
11394	Desmoid-type fibromatosis: Tumour response assessment using magnetic resonance imaging signal and size criteria. Clinical Imaging, 2020, 68, 111-120.	1.5	4

#	ARTICLE	IF	CITATIONS
11395	A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1657-1669.	1.1	395
11396	Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). <i>Scientific Reports</i> , 2020, 10, 10853.	3.3	10
11397	Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 5534-5538.	7.0	15
11398	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	1.4	12
11399	<p>Antibiotics Modulate Chemotherapy Efficacy in Patients with Esophageal Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4991-4997.	1.9	8
11400	Perioperative systemic chemo-immunotherapy for upper urinary tract urothelial carcinoma. <i>The Cochrane Library</i> , 2020, , .	2.8	0
11401	Successful use of transarterial radioembolization with yttriumâ€90 (TAREâ€90) in two children with hepatoblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28421.	1.5	16
11402	Systemic Therapies for Melanoma Brain Metastases. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 346-355.	0.9	1
11403	Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3313-3322.	2.5	4
11404	Dose and Volume De-Escalation for Human Papillomavirusâ€Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 662-671.	0.8	13
11405	A priori prediction of tumour response to neoadjuvant chemotherapy in breast cancer patients using quantitative CT and machine learning. <i>Scientific Reports</i> , 2020, 10, 10936.	3.3	19
11406	Transgenic T-cell receptor immunotherapy for cancer: building on clinical success. , 2020, 8, 251513552093350.	2.3	10
11407	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020, 16, 2059-2073.	2.4	2
11408	Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. <i>British Journal of Surgery</i> , 2020, 107, 1811-1817.	0.3	39
11409	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. <i>BMC Cancer</i> , 2020, 20, 103.	2.6	14
11410	Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 3.	2.7	14
11411	Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 59.	4.4	27
11412	<p>Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 143-149.	2.0	15

#	ARTICLE	IF	CITATIONS
11413	<p><p>Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma<p>. Cancer Management and Research, 2020, Volume 12, 91-102.	1.9	10
11414	<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism<p>. OncoTargets and Therapy, 2020, Volume 13, 603-613.	2.0	15
11415	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1217-1225.	2.5	42
11416	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. Clinical Pharmacokinetics, 2020, 59, 1013-1026.	3.5	3
11417	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	2.8	112
11418	Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA) Tj ETQq1 1 0.784314rgBT /Overlock 10	1.4	9
11419	Comparison of two-stage Gamma Knife radiosurgery outcomes for large brain metastases among primary cancers. Journal of Neuro-Oncology, 2020, 147, 237-246.	2.9	21
11420	Modified Liujunzi Decoction (å...å±) Alleviates Chemotherapy-Induced Anorexia in Advanced Non-Small Cell Lung Cancer: A Propensity Score Matched Case-Control Study. Chinese Journal of Integrative Medicine, 2020, 26, 256-262.	1.6	7
11421	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. Gynecologic Oncology, 2020, 157, 36-45.	1.4	9
11422	A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020, 122, 963-970.	6.4	17
11423	Rapamycin (sirolimus) in treatment of recurrent intravenous leiomyomatosis: a case report. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 768-771.	2.3	7
11424	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸F) positronâ€emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 150-157.	1.1	2
11425	Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Translational Cancer Research, 2020, 9, 203-209.	1.0	15
11426	Involvement of the TNF-± Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2020, 35, e31.	2.5	12
11427	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 2020, 12, 344.	3.7	60
11428	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	3.7	23
11429	Frequent EGFR expression/ EGFR amplification and lack of activating mutation in testicular choriocarcinoma. Pathology International, 2020, 70, 262-269.	1.3	6
11430	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma, 2020, 2020, 1-8.	1.3	33

#	ARTICLE	IF	CITATIONS
11431	Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, e536-e544.	3.7	39
11432	<p>The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 891-903.	1.9	4
11433	Advanced Cancer Imaging Applied in the Comparative Setting. <i>Frontiers in Oncology</i> , 2020, 10, 84.	2.8	7
11434	The prognostic impact of tumour NSD2 expression in advanced prostate cancer. <i>Biomarkers</i> , 2020, 25, 268-273.	1.9	6
11435	Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-9.	1.5	2
11436	Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. <i>Journal of Clinical Oncology</i> , 2020, 38, 1138-1145.	1.6	32
11437	Renal Mass Biopsy. , 2020, , .		1
11438	Stereotactic body radiotherapy for elderly patients (≥75 years) with early-stage non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1263-1271.	2.5	9
11439	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e405-e414.	2.6	21
11440	Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 487.	3.7	29
11441	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> , 2020, 12, 512.	3.7	15
11442	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2020, 9, 2752-2760.	2.8	13
11443	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	2.0	17
11444	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1052-1060.	1.9	36
11445	Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. <i>Oncology Research and Treatment</i> , 2020, 43, 211-220.	1.2	20
11446	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 295-302.	1.9	24
11447	Prolonged Progression-Free Survival in a Patient With Malignant Pleural Mesothelioma Following Korean Herbal Medicine Treatment Alone: A Case Report. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542090834.	2.0	1
11448	Radiomics: from qualitative to quantitative imaging. <i>British Journal of Radiology</i> , 2020, 93, 20190948.	2.2	164

#	ARTICLE	IF	CITATIONS
11449	<p>The Correlation Between Computed Tomography Volumetry and Prognosis of Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy</p>. Cancer Management and Research, 2020, Volume 12, 759-768.	1.9	2
11450	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652.	2.8	21
11451	Tumor volume and sphericity as predictors of local control after stereotactic radiosurgery for limited number (1â€4) brain metastases from nonsmall cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 165-171.	1.1	7
11452	Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepatic Oncology, 2020, 7, HEP16.	4.2	27
11453	Application of the Z1071 criteria: classification of axillary lymph nodes on ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer. Journal of Medical Ultrasonics (2001), 2020, 47, 299-303.	1.3	1
11454	Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. Journal of Neuro-Oncology, 2020, 147, 459-463.	2.9	35
11455	Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biology and Therapy, 2020, 21, 432-440.	3.4	20
11456	A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Pancreas, 2020, 49, 187-192.	1.1	22
11457	Scalable 3D Silicon Photonic Electronic Integrated Circuits and Their Applications. IEEE Journal of Selected Topics in Quantum Electronics, 2020, 26, 1-10.	2.9	23
11458	Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. Neuro-Oncology, 2020, 22, 1203-1213.	1.2	12
11459	Biosimilar monoclonal antibodies for cancer treatment. The Cochrane Library, 0, , .	2.8	5
11460	The Growing Impact of Micro/Nanomaterialâ€Based Systems in Precision Oncology: Translating â€œMultiomicsâ€Technologies. Advanced Functional Materials, 2020, 30, 1909306.	14.9	25
11461	Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 673-683.	2.3	39
11462	Assessing Treatment Benefit in Immuno-oncology. Statistics in Biosciences, 2020, 12, 83-103.	1.2	10
11463	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 446-455.	10.7	182
11464	Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using 99m Tc-duramycin imaging. Biomedicine and Pharmacotherapy, 2020, 125, 109947.	5.6	4
11465	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (United States), 2020, 99, e19059.	1.0	30
11466	The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy. Medicine (United States), 2020, 99, e19258.	1.0	6

#	ARTICLE	IF	CITATIONS
11467	Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976.	3.9	51
11468	The prognostic importance of VEGF-A, PDGF-BB and c-MET in patients with metastatic colorectal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1878-1885.	0.9	1
11469	Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis. <i>Radiation Oncology</i> , 2020, 15, 37.	2.7	26
11470	The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance. <i>Translational Andrology and Urology</i> , 2020, 9, S3-S13.	1.4	16
11471	Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. <i>Frontiers in Oncology</i> , 2020, 10, 64.	2.8	14
11472	Development and validation of a radiomics signature on differentially expressed features of 18F-FDG PET to predict treatment response of concurrent chemoradiotherapy in thoracic esophagus squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2020, 146, 9-15.	0.6	19
11473	Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to <i>EGFR</i> , <i>ALK</i> and <i>KRAS</i> mutation status. <i>Thoracic Cancer</i> , 2020, 11, 1026-1037.	1.9	11
11474	A correlation between BCL-2 modifying factor, p53 and livin gene expressions in cancer colon patients. <i>Biochemistry and Biophysics Reports</i> , 2020, 22, 100747.	1.3	6
11475	How does contrast-enhanced ultrasonography influence Bosniak classification for complex cystic renal mass compared with conventional ultrasonography?. <i>Medicine (United States)</i> , 2020, 99, e19190.	1.0	8
11476	Indication and Prognostic Significance of Conversion Surgery in Patients with Liver Metastasis from Gastric Cancer. <i>Oncology</i> , 2020, 98, 273-279.	1.9	12
11477	Diagnostic Imaging Modalities to Assess Treatment Response of Bone Metastasis in Patients Receiving Palliative Radiotherapy: A Scoping Review of the Literature. <i>Canadian Association of Radiologists Journal</i> , 2020, 71, 495-504.	2.0	4
11478	Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response. <i>BMC Cancer</i> , 2020, 20, 134.	2.6	27
11479	<p>Peripheral Blood Platelet-Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1303-1311.	1.9	24
11480	Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 848.	7.1	89
11481	Landscape of combination therapy trials in breast cancer brain metastasis. <i>International Journal of Cancer</i> , 2020, 147, 1939-1952.	5.1	31
11482	SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging. <i>European Radiology</i> , 2020, 30, 3125-3136.	4.5	6
11483	Urothelial phase CT for assessment of pathologic complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>European Journal of Radiology</i> , 2020, 126, 108902.	2.6	6
11484	Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 1044-1052.e1.	1.0	43

#	ARTICLE	IF	CITATIONS
11485	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020, 21, 100282.	2.4	59
11486	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 379-385.	1.4	89
11487	Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 525-530.	0.5	10
11488	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	3.3	10
11489	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1 α 'Positive, Advanced Non α 'Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	1.6	189
11490	Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. <i>Future Oncology</i> , 2020, 16, 247-254.	2.4	15
11491	Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 141-149.	2.0	21
11492	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	7.7	61
11493	Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti α 'PD α 1 monotherapy. <i>International Journal of Cancer</i> , 2020, 147, 1707-1714.	5.1	14
11494	Relevance of apparent diffusion coefficient features for a radiomics α -based prediction of response to induction chemotherapy in sinonasal cancer. <i>NMR in Biomedicine</i> , 2020, , e4265.	2.8	15
11495	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1239-1251.	6.4	12
11496	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
11497	Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. <i>Clinical Nutrition</i> , 2020, 39, 3319-3330.	5.0	5
11498	Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 594-601.	1.3	23
11499	Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non α 'small cell lung cancer harboring α 'EGFR α mutation. <i>Thoracic Cancer</i> , 2020, 11, 1045-1051.	1.9	14
11500	Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non α 'small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 210-217.	1.3	16
11501	Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3. <i>Clinical Nuclear Medicine</i> , 2020, 45, e165-e168.	1.3	5
11502	Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated α '2-Emitter Peptide Receptor Radionuclide Therapy. <i>Clinical Nuclear Medicine</i> , 2020, 45, 241-243.	1.3	24

#	ARTICLE	IF	CITATIONS
11503	Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 581-587.	7.0	60
11504	Prognostic Values of LDH and CRP in Cervical Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1255-1263.	2.0	23
11505	Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 965-975.	1.1	12
11506	Risk Factors of Severe Benign Cicatricial Stricture After Definitive Chemoradiation for Localized T3 Esophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 1071-1077.	1.1	2
11507	Nutritional outcomes after radiotherapy target volume reduction for nasopharyngeal cancer: a Phase III trial. <i>Future Oncology</i> , 2020, 16, 427-437.	2.4	1
11508	The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 919-928.	7.3	15
11509	Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation. <i>Pharmaceutical Statistics</i> , 2020, 19, 126-136.	1.3	0
11510	Increased autophagy/mitophagy levels in primary tumours of patients with pancreatic neuroendocrine neoplasms. <i>Endocrine</i> , 2020, 68, 438-447.	2.3	11
11511	Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eribulin-based treatment in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2020, 27, 732-738.	2.9	14
11512	Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina. <i>Clinical Lung Cancer</i> , 2020, 21, e380-e387.	2.6	19
11513	Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression. <i>Clinical Lung Cancer</i> , 2020, 21, e366-e379.	2.6	26
11514	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	2.0	19
11515	A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 177-184.	2.5	5
11516	Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 703-709.	1.9	9
11517	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	4.2	18
11518	Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. <i>International Journal of Colorectal Disease</i> , 2020, 35, 685-694.	2.2	14
11519	Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, e151-e156.	2.3	11
11520	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	5.4	29

#	ARTICLE	IF	CITATIONS
11521	Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. <i>Gynecologic Oncology</i> , 2020, 157, 386-391.	1.4	25
11522	A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial). <i>Neuroendocrinology</i> , 2020, 110, 988-993.	2.5	18
11523	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. <i>Oncologist</i> , 2020, 25, e782-e788.	3.7	7
11524	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	3.7	10
11525	Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. <i>In Vivo</i> , 2020, 34, 239-245.	1.3	28
11526	Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone. <i>Frontiers in Medicine</i> , 2020, 6, 342.	2.6	5
11527	Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. <i>Cancers</i> , 2020, 12, 371.	3.7	49
11528	A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. <i>Journal of Molecular Medicine</i> , 2020, 98, 375-382.	3.9	7
11529	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 605-614.	2.3	3
11530	Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. <i>Clinical Lung Cancer</i> , 2020, 21, e355-e362.	2.6	6
11531	Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2020, 59, 21-27.	1.3	6
11532	Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy. <i>Cancers</i> , 2020, 12, 379.	3.7	12
11533	Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-8.	1.2	2
11534	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020, 38, 1655-1663.	1.6	138
11535	Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants. <i>Oncologist</i> , 2020, 25, 161-169.	3.7	26
11536	Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 18.	3.0	11
11537	Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy. <i>Acta Radiologica</i> , 2020, 61, 1316-1325.	1.1	2
11538	Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition. <i>Clinical Proteomics</i> , 2020, 17, 5.	2.1	3

#	ARTICLE	IF	CITATIONS
11539	Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1131-1140.	4.2	12
11540	Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 741-751.	2.3	19
11541	Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. <i>Targeted Oncology</i> , 2020, 15, 193-201.	3.6	4
11542	Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence. <i>Current Oncology Reports</i> , 2020, 22, 28.	4.0	11
11543	Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1506-1513.	1.7	4
11544	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.9	140
11545	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	4.1	15
11546	Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study. <i>Clinical Breast Cancer</i> , 2020, 20, 228-237.	2.4	6
11547	Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine. <i>Frontiers in Endocrinology</i> , 2019, 10, 884.	3.5	18
11548	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4687-4695.	2.2	16
11550	Current state of the art imaging approaches for colorectal liver metastasis. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 35-48.	1.5	23
11551	Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy. <i>Journal of Cancer</i> , 2020, 11, 1223-1230.	2.5	2
11552	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2020, 1, CD011313.	2.8	8
11553	Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 247.	3.7	22
11554	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 663-675.	4.2	22
11555	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC). <i>Clinical and Translational Imaging</i> , 2020, 8, 29-38.	2.1	0
11556	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 214-221.	1.4	2
11557	Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy. <i>Medicine (United States)</i> , 2020, 99, e18735.	1.0	2

#	ARTICLE	IF	CITATIONS
11558	Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 2.	1.5	9
11559	Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. <i>Oncologist</i> , 2020, 25, e668-e674.	3.7	15
11560	mRECIST for HCC: Performance and novel refinements. <i>Journal of Hepatology</i> , 2020, 72, 288-306.	3.7	292
11561	Criterios de respuesta metabólica a la inmunoterapia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 51-56.	0.0	0
11562	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	1.4	14
11563	Evaluation of Calcium Electroporation for the Treatment of Cutaneous Metastases: A Double Blinded Randomised Controlled Phase II Trial. <i>Cancers</i> , 2020, 12, 179.	3.7	34
11564	Evaluation of the accuracy of deformable image registration on MRI with a physical phantom. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 166-173.	1.9	13
11565	Pattern of loco-regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (<i>Fracture</i>) contribution. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28154.	1.5	11
11566	How to Best Image Colorectal Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 11-17.	0.5	2
11567	Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2020, 10, 227.	3.3	42
11568	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2257-2267.	7.0	39
11569	N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 511.	4.1	5
11570	Role of positron emission tomography-contrast enhanced computed tomography in locally advanced gallbladder cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 164-170.	2.6	11
11571	Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. <i>Journal of Geriatric Oncology</i> , 2020, 11, 802-806.	1.0	14
11572	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 353-363.	3.7	235
11573	Systemic therapy for chromophobe renal cell carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 137-149.	1.6	9
11574	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	4.0	10
11575	18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1116-1126.	6.4	60

#	ARTICLE	IF	CITATIONS
11576	Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. CardioVascular and Interventional Radiology, 2020, 43, 996-1005.	2.0	37
11577	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. Supportive Care in Cancer, 2020, 28, 4825-4831.	2.2	8
11578	Intérêt pronostique et prédictif de la TEP-TDM au 18F-FDG au bilan initial des mélanomes de stade IIIB-C-D et IV avant traitement par anti-PD-1. Medecine Nucleaire, 2020, 44, 65-71.	0.2	0
11579	Radical (chemo)radiotherapy in oropharyngeal squamous cell carcinoma: Comparison of TNM 7th and 8th staging systems. Radiotherapy and Oncology, 2020, 145, 146-153.	0.6	16
11580	Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan. Journal of Dermatology, 2020, 47, 356-362.	1.2	15
11581	Computed tomography of thoracic lymph nodes in 100 dogs with no abnormalities in the dominated area. Journal of Veterinary Medical Science, 2020, 82, 279-285.	0.9	5
11582	Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis. Cancer Medicine, 2020, 9, 2085-2095.	2.8	9
11583	Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma. Medicine (United States), 2020, 99, e18732.	1.0	3
11584	Salvage treatment of NSCLC recurrence after first-line chemotherapy failure: Iodine-125 seed brachytherapy or microwave ablation?. Thoracic Cancer, 2020, 11, 697-703.	1.9	8
11585	FGFR1 is associated with c-MYC and proangiogenic molecules in metastatic renal cell carcinoma under antiangiogenic therapy. Histopathology, 2020, 76, 838-851.	2.9	5
11586	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 364-372.	7.0	29
11587	Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice. Current Problems in Cancer, 2020, 44, 100550.	2.0	7
11588	Prospective evaluation of XRCC1 Arg194Trp polymorphism as a predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head and Neck, 2020, 42, 1045-1056.	2.0	7
11589	Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. Journal of Cellular and Molecular Medicine, 2020, 24, 2993-3021.	3.6	36
11590	Neoadjuvant checkpoint blockade for cancer immunotherapy. Science, 2020, 367, .	12.6	553
11591	Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. European Journal of Cancer, 2020, 127, 108-117.	2.8	14
11592	Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises. Expert Review of Molecular Diagnostics, 2020, 20, 335-344.	3.1	12
11593	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1799-1807.	2.3	10

#	ARTICLE	IF	CITATIONS
11594	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	3.7	74
11595	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020, 26, 2789-2799.	7.0	130
11596	Integrating circulating miRNA analysis in the clinical management of lung cancer: Present or future?. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100844.	6.4	23
11597	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	7.1	125
11598	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 2020, CD009256.	2.8	28
11599	Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice. <i>International Journal of Clinical Oncology</i> , 2020, 25, 899-905.	2.2	34
11600	Clinical research tools in pediatric oncology: challenges and opportunities. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 149-160.	5.9	9
11601	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2020, 21, 294-305.	10.7	304
11602	Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. <i>Lung Cancer</i> , 2020, 141, 64-71.	2.0	14
11603	Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 107-118.	3.8	41
11604	Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection- can local recurrence be radically cured by radiation?. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 425-433.	1.3	8
11605	Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in <i>HER2</i> -Mutant Lung Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e545-e554.	3.7	42
11606	ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy. <i>Cancer Biomarkers</i> , 2020, 27, 251-264.	1.7	9
11607	Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e286-e293.	2.6	22
11608	Frameless radiosurgery for intraocular metastatic tumor: Case report. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 1-5.	0.6	2
11609	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	4.6	9
11610	Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. <i>Cancer Imaging</i> , 2020, 20, 14.	2.8	27
11611	The Homologous Recombination Repair Pathway is Associated with Resistance to Radiotherapy in Nasopharyngeal Carcinoma. <i>International Journal of Biological Sciences</i> , 2020, 16, 408-419.	6.4	12

#	ARTICLE	IF	CITATIONS
11612	Tumor Timeâ€‘Course Predicts Overall Survival in Nonâ€‘Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Followâ€‘Up Time. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 115-123.	2.5	8
11613	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (United States), 2020, 99, e18726.	1.0	23
11614	Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review. Cancers, 2020, 12, 294.	3.7	22
11615	Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial. European Radiology, 2020, 30, 2692-2702.	4.5	31
11616	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. Cancers, 2020, 12, 330.	3.7	11
11617	Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases. Technology in Cancer Research and Treatment, 2020, 19, 153303382090444.	1.9	20
11618	Prognosis of patients receiving induction chemotherapy for locally advanced or lymph node metastatic bladder cancer. Journal of Clinical Urology, 2020, 13, 425-436.	0.1	1
11619	Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Nonâ€‘Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. JCO Precision Oncology, 2020, 4, 393-410.	3.0	32
11620	Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Singleâ€‘Arm , Openâ€‘Label , Phase II Study. Oncologist, 2020, 25, e1464-e1472.	3.7	20
11621	Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. International Journal of Clinical Oncology, 2020, 25, 1223-1232.	2.2	22
11622	An MRI study of immune checkpoint inhibitorâ€‘induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. Rheumatology, 2020, 59, 1041-1050.	1.9	25
11623	Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers, 2020, 12, 1046.	3.7	47
11624	Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). British Journal of Cancer, 2020, 123, 26-32.	6.4	17
11625	Outcomes of patients with spinal metastases from renal cell carcinoma treated with conventionally-fractionated external beam radiation therapy. Medicine (United States), 2020, 99, e19838.	1.0	2
11626	The Application of Radiomics in Breast MRI: A Review. Technology in Cancer Research and Treatment, 2020, 19, 153303382091619.	1.9	46
11627	An Open-Label Study of the Safety and Efficacy of <i>Tag-7</i> Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer. Oncologist, 2020, 25, e1303-e1317.	3.7	1
11628	Response to Preoperative Therapy in Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 516.	2.8	16
11629	Buparlisib in combination with tamoxifen in pretreated patients with hormone receptorâ€‘positive, HER2â€‘negative advanced breast cancer molecularly stratified for <i>PIK3CA</i> mutations and loss of PTEN expression. Cancer Medicine, 2020, 9, 4527-4539.	2.8	7

#	ARTICLE	IF	CITATIONS
11630	Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response. <i>Scientific Reports</i> , 2020, 10, 6996.	3.3	9
11631	The neutrophil/lymphocyte ratio as a predictor of successful conversion surgery for stage IV gastric cancer: a retrospective study. <i>BMC Cancer</i> , 2020, 20, 363.	2.6	8
11632	Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors. <i>Endocrine Journal</i> , 2020, 67, 869-876.	1.6	3
11633	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	2.4	136
11634	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	7.1	293
11635	Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-EPD therapy. <i>International Journal of Cancer</i> , 2020, 147, 2327-2334.	5.1	5
11637	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2351-2358.	2.5	21
11638	Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2411-2417.	2.5	5
11639	Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 561-570.	2.5	8
11640	A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 391-399.	3.3	5
11641	Ablation, consolidation and radiotherapy for the management of metastatic lesions of the spine: impact on the quality of life in a mid-term clinical and diagnostic follow-up in a pilot study. <i>Medical Oncology</i> , 2020, 37, 53.	2.5	9
11642	Systemic Therapy in Lung Cancer. <i>Advances in Clinical Radiology</i> , 2020, 2, 1-15.	0.2	0
11643	Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. <i>JCO Precision Oncology</i> , 2020, 4, 258-271.	3.0	16
11644	S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer. <i>Anticancer Research</i> , 2020, 40, 991-997.	1.1	12
11645	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	3.7	28
11646	Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases. <i>BJS Open</i> , 2020, 4, 456-466.	1.7	9
11647	Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e374-e385.	1.9	12
11648	Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 443-451.	1.1	6

#	ARTICLE	IF	CITATIONS
11649	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
11650	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology, 2020, 38, 1814-1823.	1.6	202
11651	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	1.5	12
11652	Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Oncologist, 2020, 25, 859-866.	3.7	21
11653	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. JAMA - Journal of the American Medical Association, 2020, 323, 1266.	7.4	190
11654	Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease. JAMA Network Open, 2020, 3, e201617.	5.9	28
11655	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	7.1	446
11656	Role of MRI to Assess Response to Neoadjuvant Therapy for Breast Cancer. Journal of Magnetic Resonance Imaging, 2020, 52, .	3.4	29
11658	Optimization of timing of hepatocellular phase imaging after gadoxetate disodium injection for evaluation of patients with neuroendocrine tumor. Abdominal Radiology, 2020, 45, 2358-2369.	2.1	2
11659	Systemic Therapy Plus Thermal Ablation Versus Systemic Therapy Alone for Oligometastatic Liver Metastases from Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2020, 43, 1285-1293.	2.0	6
11660	Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation. Cancer Chemotherapy and Pharmacology, 2020, 85, 817-825.	2.3	2
11661	Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine. Cancer Chemotherapy and Pharmacology, 2020, 85, 941-947.	2.3	5
11662	Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. European Radiology, 2020, 30, 4534-4544.	4.5	34
11663	The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. International Journal of Clinical Oncology, 2020, 25, 1195-1205.	2.2	11
11664	Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. International Journal of Clinical Oncology, 2020, 25, 1270-1277.	2.2	12
11665	Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine, 2020, 69, 142-148.	2.3	19
11666	Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clinical and Translational Oncology, 2020, 22, 2130-2135.	2.4	31
11667	Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clinical Lung Cancer, 2020, 21, e456-e463.	2.6	28

#	ARTICLE	IF	CITATIONS
11668	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 86, 102020.	7.7	9
11669	Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. <i>Current Problems in Cancer</i> , 2020, 44, 100571.	2.0	16
11670	Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD,) <i>Tj ETQq0.0 0 rgBT/O</i>	0.0	0
11671	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. <i>Lung Cancer</i> , 2020, 143, 67-72.	2.0	17
11672	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2020, 105, 104676.	1.5	16
11673	Zebrafish patient avatars in cancer biology and precision cancer therapy. <i>Nature Reviews Cancer</i> , 2020, 20, 263-273.	28.4	137
11674	Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. <i>Scientific Reports</i> , 2020, 10, 6058.	3.3	22
11675	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6083.	3.3	28
11676	Analysis of <i>CYP450</i> gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients. <i>Biomarkers</i> , 2020, 25, 331-340.	1.9	5
11677	Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study. <i>Journal of Dermatology</i> , 2020, 47, 629-635.	1.2	16
11678	Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 865-872.	2.5	15
11679	Dynamic Changes in Cognitive Function in Patients With Radiation-Induced Temporal Lobe Necrosis After IMRT for Nasopharyngeal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 450.	2.8	6
11680	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. <i>Cancers</i> , 2020, 12, 941.	3.7	38
11681	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 947.	3.7	20
11682	Exploring Circulating Tumor Cells in Cholangiocarcinoma Using a Novel Glycosaminoglycan Probe on a Microfluidic Platform. <i>Advanced Healthcare Materials</i> , 2020, 9, e1901875.	7.6	13
11683	Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 859-866.	1.3	23
11684	Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. <i>Journal of Radiation Research</i> , 2020, 61, 494-498.	1.6	11
11685	Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. <i>Cancer Science</i> , 2020, 111, 1899-1909.	3.9	54

#	ARTICLE	IF	CITATIONS
11686	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1025-1033.	7.0	45
11687	Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 3537-3545.	7.0	36
11688	Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2020, 40, 2089-2093.	1.1	33
11689	Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	3.7	17
11690	Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). <i>BJS Open</i> , 2020, 4, 467-477.	1.7	50
11691	Predictive value of 0.35T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. <i>Medical Physics</i> , 2020, 47, 3682-3690.	3.0	35
11692	Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1713-1724.	4.2	22
11693	Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold. <i>Journal of Statistical Planning and Inference</i> , 2020, 208, 119-129.	0.6	3
11694	Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2789-2794.	2.4	9
11695	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	7.0	13
11696	Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. <i>Liver Cancer</i> , 2020, 9, 275-292.	7.7	34
11697	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1427-1440.	2.5	10
11698	Radiological findings of denosumab treatment for giant cell tumours of bone. <i>Skeletal Radiology</i> , 2020, 49, 1345-1358.	2.0	26
11699	Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. <i>Radiotherapy and Oncology</i> , 2020, 148, 82-88.	0.6	20
11700	A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection. <i>Liver International</i> , 2020, 40, 2272-2278.	3.9	7
11701	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
11702	Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1210-1217.	4.1	17
11703	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	2.8	62

#	ARTICLE	IF	CITATIONS
11704	Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer, 2020, 143, 40-46.	2.0	38
11705	Pegylated liposomal doxorubicin as neoadjuvant therapy for stage IIâ€“III locally advanced breast cancer. Journal of Chemotherapy, 2020, 32, 202-207.	1.5	10
11706	The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced nonâ€“small cell lung cancer. Thoracic Cancer, 2020, 11, 1559-1565.	1.9	11
11707	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7.0	67
11708	<i>KLF4</i> p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 956-965.	4.1	5
11709	Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial. BMC Cancer, 2020, 20, 268.	2.6	14
11710	Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatology Research, 2020, 50, 871-884.	3.4	35
11711	Sexâ€“dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. Cancer Medicine, 2020, 9, 4148-4159.	2.8	48
11712	Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma. Cancer, 2020, 126, 2079-2085.	4.1	7
11713	Pembrolizumab for the treatment of programmed deathâ€“ligand 1â€“positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTEâ€“028 study. Cancer, 2020, 126, 3021-3030.	4.1	97
11714	Role of Conversion Surgery for Unresectable Pancreatic Cancer After Longâ€“Term Chemotherapy. World Journal of Surgery, 2020, 44, 2752-2760.	1.6	9
11715	Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology, 2020, 73, 342-348.	3.7	49
11716	Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 657-668.	1.3	5
11717	Imaging response assessment following stereotactic body radiotherapy for solid tumour metastases of the spine: Current challenges and future directions. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 385-397.	1.8	6
11718	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research, 2020, 26, 1812-1819.	7.0	47
11719	Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis: a cohort study. BMC Surgery, 2020, 20, 78.	1.3	8
11720	Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring <i>RET</i> Gene Alterations. JCO Precision Oncology, 2020, 4, 341-347.	3.0	29
11721	Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3163-3170.	1.5	18

#	ARTICLE	IF	CITATIONS
11722	<p><p>Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study</p>. Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 21-33.</p>	1.2	3
11723	<p>How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. Frontiers in Physiology, 2020, 11, 154.</p>	2.8	27
11724	<p>Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. International Journal of Molecular Sciences, 2020, 21, 2814.</p>	4.1	18
11725	<p>Usefulness of ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Cancer Medicine, 2020, 9, 4059-4068.</p>	2.8	23
11727	<p>Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2787-2795.</p>	6.4	21
11728	<p>Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2020, 69, 1565-1576.</p>	4.2	72
11729	<p>Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 979-993.</p>	2.3	13
11730	<p>Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy. Targeted Oncology, 2020, 15, 317-325.</p>	3.6	19
11731	<p>Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis. Advances in Radiation Oncology, 2020, 5, 889-896.</p>	1.2	11
11732	<p>Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Annals of Oncology, 2020, 31, 780-788.</p>	1.2	42
11733	<p>Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 416-422.</p>	1.9	11
11734	<p>Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering. Computers in Biology and Medicine, 2020, 120, 103751.</p>	7.0	27
11735	<p>Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer. Clinical Radiology, 2020, 75, 641.e19-641.e27.</p>	1.1	9
11736	<p>Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis. European Journal of Radiology, 2020, 127, 108978.</p>	2.6	5
11737	<p>Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine, 2020, 70, 153218.</p>	5.3	94
11738	<p>Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy. Radiologia, 2020, 62, 131-138.</p>	0.5	6
11739	<p>Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid, 2020, 30, 1384-1389.</p>	4.5	25
11740	<p>Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer. Chinese Medical Journal, 2020, 133, 786-791.</p>	2.3	13

#	ARTICLE	IF	CITATIONS
11741	High <scp>MAF</scp> of <scp><i>EGFR</i></scp> mutations and high ratio of <scp>T790M sensitizing mutations</scp> in <scp>ctDNA</scp> predict better thirdâ€‘generation <scp>TKI</scp> outcomes. Thoracic Cancer, 2020, 11, 1503-1511.	1.9	9
11742	Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Nonâ€‘Small Cell Lung Cancer Harboring Only EGFR Mutations. Clinical and Translational Science, 2020, 13, 1150-1160.	3.1	2
11743	Predictive value of FDGâ€‘PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2261-2267.	2.4	6
11744	Prognostic significance of neutrophilâ€‘toâ€‘lymphocyte ratio in HPV status era for oropharyngeal cancer. Oral Diseases, 2020, 26, 1384-1392.	3.0	15
11745	Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome. ESMO Open, 2020, 5, e000623.	4.5	4
11746	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
11747	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. Clinical Cancer Research, 2020, 26, 598-607.	7.0	63
11748	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 71-81.	7.0	109
11749	A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma. Clinical Cancer Research, 2020, 26, 2819-2826.	7.0	25
11750	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer, 2020, 20, 326.	2.6	38
11751	Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer. BMC Cancer, 2020, 20, 338.	2.6	6
11752	Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma. BMC Surgery, 2020, 20, 75.	1.3	13
11753	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology, 2020, 38, 2476-2487.	1.6	152
11754	Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE, 2020, 15, e0227256.	2.5	42
11755	Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS ONE, 2020, 15, e0231895.	2.5	15
11756	Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Oncologist, 2020, 25, e1181-e1187.	3.7	14
11757	Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients. Journal of Thoracic Disease, 2020, 12, 782-793.	1.4	12
11758	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. Anticancer Research, 2020, 40, 1571-1578.	1.1	0

#	ARTICLE	IF	CITATIONS
11759	Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. <i>Anticancer Research</i> , 2020, 40, 2239-2246.	1.1	2
11760	Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. <i>Anticancer Research</i> , 2020, 40, 2247-2255.	1.1	16
11761	Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 2379-2386.	1.1	5
11762	Identification of Non-“Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. <i>Clinical Cancer Research</i> , 2020, 26, 2151-2162.	7.0	110
11763	Metastatic Melanoma Patient-“Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 3803-3818.	7.0	21
11764	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. <i>Clinical Cancer Research</i> , 2020, 26, 3211-3219.	7.0	64
11765	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 4414-4425.	7.0	70
11766	On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 468-478.	4.1	29
11767	Stereotactic Radiotherapy in Recurrent Glioblastoma: A Valid Salvage Treatment Option. <i>Stereotactic and Functional Neurosurgery</i> , 2020, 98, 167-175.	1.5	12
11768	Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’™ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 286.	2.6	3
11769	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	3.0	36
11770	Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. <i>PLoS ONE</i> , 2020, 15, e0231413.	2.5	10
11771	A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy. <i>Oncologist</i> , 2020, 25, e833-e842.	3.7	19
11772	Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. <i>Oncologist</i> , 2020, 25, 515-522.	3.7	7
11773	Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world. <i>Journal of Thoracic Disease</i> , 2020, 12, 550-557.	1.4	11
11774	Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1079-1084.	1.4	5
11775	Molecular Imaging of Bone Metastases and Their Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 799-806.	5.0	37
11776	A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 34.	3.5	5

#	ARTICLE	IF	CITATIONS
11777	Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. <i>Cancers</i> , 2020, 12, 873.	3.7	34
11778	Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy. <i>Journal of Cancer</i> , 2020, 11, 3310-3317.	2.5	13
11779	Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects. <i>Journal of Cancer</i> , 2020, 11, 3020-3026.	2.5	0
11780	Spatio-temporal context based recurrent visual attention model for lymph node detection. <i>International Journal of Imaging Systems and Technology</i> , 2020, 30, 1220-1242.	4.1	2
11781	A phase I&II design based on periodic and continuous monitoring of disease status and the times to toxicity and death. <i>Statistics in Medicine</i> , 2020, 39, 2035-2050.	1.6	5
11782	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1588-1595.	1.0	15
11783	Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 188-195.	0.8	131
11784	Head and Neck Tumor Control Probability: Radiation Dose&Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 137-146.	0.8	37
11785	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. <i>British Journal of Dermatology</i> , 2021, 184, 319-327.	1.5	28
11786	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	6.3	17
11787	Preliminary Assessment of an Optical Flow Method (OFM) for Nonrigid Registration and Temporal Subtraction (TS) of Serial CT Examinations to Facilitate Evaluation of Interval Change in Metastatic Lung Nodules. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 344-350.	1.4	3
11788	Short- and long-term outcomes of laparoscopic versus open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1682-1690.	2.4	24
11789	Gefitinib as neoadjuvant therapy for resectable stage II-IIIa non&small cell lung cancer: A phase II study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 434-442.e2.	0.8	58
11790	Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. <i>Acta Radiologica</i> , 2021, 62, 164-171.	1.1	5
11791	Clinical Effects of Neoadjuvant Chemotherapy in Treating Breast Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 174-179.	1.0	4
11792	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	7.3	235
11793	Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. <i>Surgery</i> , 2021, 169, 162-167.	1.9	4
11794	Preoperative CT staging of borderline pancreatic cancer patients after neoadjuvant treatment: accuracy in the prediction of vascular invasion and resectability. <i>Abdominal Radiology</i> , 2021, 46, 280-289.	2.1	10

11796	Volume computed tomography perfusion as a predictive marker for treatment response to concurrent chemoradiotherapy in cervical cancer: a prospective study. <i>Acta Radiologica</i> , 2021, 62, 281-288.	1.1	2
-------	--	-----	---

#	ARTICLE	IF	CITATIONS
11813	Dose-Effect Relationships of ¹⁶⁶ Ho Radioembolization in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 272-279.	5.0	32
11814	Automation of data analysis in molecular cancer imaging and its potential impact on future clinical practice. <i>Methods</i> , 2021, 188, 30-36.	3.8	8
11815	Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e70-e76.	1.1	4
11816	Neoadjuvant chemotherapy and the complexity of operative procedure in advanced epithelial ovarian cancer: a retrospective analysis. <i>International Journal of Surgery Oncology</i> , 2021, 3, 59.	0.2	0
11817	Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. <i>Cancer Medicine</i> , 2021, 10, 109-118.	2.8	12
11818	Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. <i>Hormones</i> , 2021, 20, 73-84.	1.9	4
11819	Monitoring real-life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 342-349.	1.9	2
11820	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.9	12
11821	Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. <i>Translational Oncology</i> , 2021, 14, 100920.	3.7	21
11822	Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 53-64.	2.3	6
11823	Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 551-559.	1.3	2
11824	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 460-472.	7.0	48
11825	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e917-e925.	3.6	37
11826	¹³¹ I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy. <i>Annals of Nuclear Medicine</i> , 2021, 35, 92-101.	2.2	14
11827	FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1836-1841.	7.0	102
11828	Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. <i>Thoracic Cancer</i> , 2021, 12, 145-152.	1.9	12
11829	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 164-183.	1.5	0
11830	Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 507-514.	2.2	1

#	ARTICLE	IF	CITATIONS
11831	Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer. JAMA Oncology, 2021, 7, 61.	7.1	22
11832	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clinical Cancer Research, 2021, 27, 447-459.	7.0	22
11833	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer, 2021, 124, 587-594.	6.4	79
11834	Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clinical and Translational Science, 2021, 14, 277-287.	3.1	5
11835	Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil. Annals of Surgical Oncology, 2021, 28, 712-721.	1.5	18
11836	Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. Annals of Surgical Oncology, 2021, 28, 1130-1141.	1.5	19
11837	PET/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival. Journal of Magnetic Resonance Imaging, 2021, 53, 305-318.	3.4	9
11838	On precision dosing of oral small molecule drugs in oncology. British Journal of Clinical Pharmacology, 2021, 87, 263-270.	2.4	3
11839	Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. Journal of Cancer Research and Clinical Oncology, 2021, 147, 263-273.	2.5	5
11840	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. International Journal of Cancer, 2021, 148, 702-712.	5.1	41
11841	The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. British Journal of Clinical Pharmacology, 2021, 87, 1291-1302.	2.4	3
11842	Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues. Journal of Endocrinological Investigation, 2021, 44, 403-419.	3.3	35
11843	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine, 2021, 72, 268-278.	2.3	10
11844	Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'evaluation de l'interleukine-2 intralésionnelle pour traiter les mélanomes en transit. Plastic Surgery, 2021, 29, 4-9.	1.0	0
11845	A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 337-348.	4.2	18
11846	[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. Journal of Endocrinological Investigation, 2021, 44, 811-818.	3.3	2
11847	A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Investigational New Drugs, 2021, 39, 175-181.	2.6	7
11848	The Delivery Materials with Chemotherapy Drugs for Treatment of the Positive Margin in Solid Tumors. Tissue Engineering - Part A, 2021, 27, 536-548.	3.1	2

#	ARTICLE	IF	CITATIONS
11849	Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3). <i>Gastric Cancer</i> , 2021, 24, 428-434.	5.3	7
11850	First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. <i>International Journal of Cancer</i> , 2021, 148, 950-960.	5.1	5
11851	TGF β biology in cancer progression and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 9-34.	27.6	420
11852	Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101440.	1.5	0
11853	The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies. <i>SLAS Technology</i> , 2021, 26, 42-54.	1.9	16
11854	Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. <i>International Journal of Cancer</i> , 2021, 148, 140-149.	5.1	11
11855	Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report. <i>Familial Cancer</i> , 2021, 20, 75-80.	1.9	17
11856	Deep Reinforcement Learning for Weakly-Supervised Lymph Node Segmentation in CT Images. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021, 25, 774-783.	6.3	21
11857	Association Between the Size and 3D CT-Based Radiomic Features of Breast Cancer Hepatic Metastasis. <i>Academic Radiology</i> , 2021, 28, e93-e100.	2.5	5
11858	Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. <i>BJU International</i> , 2021, 127, 90-95.	2.5	3
11859	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 471-480.	6.3	17
11860	Head-to-Head Evaluation of ¹⁸ F-FES and ¹⁸ F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 326-331.	5.0	69
11861	Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. <i>Clinical Oncology</i> , 2021, 33, e31-e38.	1.4	16
11862	A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 607-621.	1.6	7
11863	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	4.5	10
11864	A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 509-515.	2.6	18
11865	Artificial intelligence in radiology. , 2021, , 265-289.		14
11866	Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 35-44.	3.2	16

#	ARTICLE	IF	CITATIONS
11867	A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 375-382.	6.4	6
11868	A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naïve patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 383-390.	6.4	54
11869	Quantitative distribution of iodinated contrast media in body computed tomography: data from a large reference cohort. <i>European Radiology</i> , 2021, 31, 2340-2348.	4.5	15
11870	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€”2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
11871	Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. <i>Journal of Hepatology</i> , 2021, 74, 603-612.	3.7	118
11872	Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. <i>Clinical Cancer Research</i> , 2021, 27, 141-149.	7.0	17
11873	Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , 2021, 155, 56-64.	0.6	12
11874	Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. <i>Updates in Surgery</i> , 2021, 73, 233-249.	2.0	13
11875	The development of numerous radiation-induced cavernous malformations in a germ cell tumor patient: A case report. <i>Current Problems in Cancer</i> , 2021, 45, 100654.	2.0	1
11876	Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation. <i>Journal of Investigative Dermatology</i> , 2021, 141, 930-933.	0.7	6
11877	PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 78.e9-78.e16.	1.6	4
11878	Lesion-Harvester: Iteratively Mining Unlabeled Lesions and Hard-Negative Examples at Scale. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 59-70.	8.9	18
11879	MRâ€”guided simulation is superior than FDG/PETâ€”guided simulation for local control in nasopharyngeal cancer patients treated with intensityâ€”modulated radiotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 43-51.	1.1	3
11880	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	9.4	148
11881	Preâ€”and Postâ€”Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. <i>Laryngoscope</i> , 2021, 131, E1162-E1171.	2.0	9
11882	Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheres. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1127-1136.	1.7	5
11883	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 391-398.	6.4	10
11884	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	5.5	6

#	ARTICLE	IF	CITATIONS
11885	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	6.4	10
11886	Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 961-965.	4.2	26
11887	Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults. <i>Cancer Reports</i> , 2021, 4, e1306.	1.4	5
11888	Texture analysis for chemotherapy response evaluation in osteosarcoma using MR imaging. <i>NMR in Biomedicine</i> , 2021, 34, e4426.	2.8	19
11889	Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 52-59.	7.0	12
11890	Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study. <i>Journal of Surgical Oncology</i> , 2021, 123, 252-260.	1.7	20
11891	Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. <i>Abdominal Radiology</i> , 2021, 46, 1572-1585.	2.1	5
11892	Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 271-280.	2.0	5
11893	Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis. <i>Surgery Today</i> , 2021, 51, 595-604.	1.5	1
11894	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 156-161.	1.1	22
11895	Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment. <i>Oncology</i> , 2021, 99, 32-40.	1.9	9
11896	¹⁸ F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 808-815.	5.0	53
11897	Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study. <i>Investigational New Drugs</i> , 2021, 39, 516-523.	2.6	9
11898	Aggressive recurrences determine oncologic outcomes after resection of liver metastases from primary right colon cancer: Results of a case-control study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 834-841.	1.0	2
11899	Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 96-106.	7.0	59
11900	Advanced Imaging in Musculoskeletal Oncology: Moving Away From RECIST and Embracing Advanced Bone and Soft Tissue Tumor Imaging (ABASTI) - Part I - Tumor Response Criteria and Established Functional Imaging Techniques. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 201-214.	1.5	4
11901	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 438-446.	7.0	21
11902	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i> -mutant Non-“small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 992-1002.	7.0	36

#	ARTICLE	IF	CITATIONS
11903	Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. <i>Annals of Oncology</i> , 2021, 32, 218-228.	1.2	26
11904	PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 1875-1881.	7.0	40
11905	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1529-1536.	2.5	4
11906	Outcome assessment criteria and terminology should be consistent and reported clearly. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111009.	5.6	0
11907	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 728-735.	6.4	64
11908	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	7.0	58
11909	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy—Reply. <i>JAMA Oncology</i> , 2021, 7, 137.	7.1	2
11910	Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 404-418.	1.1	63
11911	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 646-653.	1.3	22
11912	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 452-463.	1.1	51
11913	Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. <i>Journal of Surgical Research</i> , 2021, 259, 1-7.	1.6	13
11914	Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. <i>Journal of Radiation Research</i> , 2021, 62, 142-148.	1.6	10
11915	A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy. <i>Oncologist</i> , 2021, 26, e742-e748.	3.7	2
11916	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	3.7	4
11917	Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients. <i>International Journal of Clinical Oncology</i> , 2021, 26, 523-531.	2.2	20
11918	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. <i>British Journal of Dermatology</i> , 2021, 184, 1113-1122.	1.5	7
11919	Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. <i>Radiology</i> , 2021, 298, 332-340.	7.3	13
11920	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. <i>Radiographics</i> , 2021, 41, 120-143.	3.3	27

#	ARTICLE	IF	CITATIONS
11921	Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA : Liquidâ€Lungâ€A. Thoracic Cancer, 2021, 12, 444-452.	1.9	2
11922	Phase I, multicenter, doseâ€escalation study of avadomide in adult Japanese patients with advanced malignancies. Cancer Science, 2021, 112, 331-338.	3.9	8
11923	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research, 2021, 27, 1037-1047.	7.0	55
11924	Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1195-1205.	0.8	12
11925	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer, 2021, 151, 30-38.	2.0	30
11927	Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer. Current Opinion in Oncology, 2021, 33, 55-58.	2.4	6
11928	Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2~) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials. Frontiers of Medicine, 2021, 15, 208-220.	3.4	8
11929	Clinical Characteristics, Treatments, and Concurrent Mutations in Nonâ€Small Cell Lung Cancer Patients With NF1 Mutations. Clinical Lung Cancer, 2021, 22, 32-41.e1.	2.6	6
11930	Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 872-882.	3.6	12
11931	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81
11932	Preâ€existing interstitial lung disease does not affect prognosis in nonâ€small cell lung cancer patients with <sc>PDâ€L1</sc> expression â‰¥50% on firstâ€line pembrolizumab. Thoracic Cancer, 2021, 12, 304-313.	1.9	17
11933	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	3.9	13
11934	Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. Hepatology Research, 2021, 51, 190-200.	3.4	9
11935	Eficacia y seguridad de la radioembolizaci3n con 90Y en el tratamiento de met3stasis hep3ticas de tumores neuroendocrinos. Seguimiento a largo plazo y repercusi3n en la supervivencia. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 82-90.	0.0	2
11936	Proposing synchronous oligometastatic nonâ€smallâ€cell lung cancer based on progression after firstâ€line systemic therapy. Cancer Science, 2021, 112, 359-368.	3.9	10
11937	Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. JAMA Oncology, 2021, 7, 78.	7.1	103
11938	Impact of the generation of <sc>EGFRâ€TKIs</sc> administered as prior therapy on the efficacy of osimertinib in patients with nonâ€small cell lung cancer harboring <sc><i>EGFR</i> T790M</sc> mutation. Thoracic Cancer, 2021, 12, 329-338.	1.9	2
11939	Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 1287-1295.	7.0	2

#	ARTICLE	IF	CITATIONS
11940	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	7.0	49
11941	A Phase II Study of Telisotuzumab Vedotin in Patients With "MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021, 22, 170-177.	2.6	41
11942	Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. <i>Cancer Medicine</i> , 2021, 10, 230-236.	2.8	7
11943	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021, 26, e669-e678.	3.7	15
11944	A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 418-426.	1.4	7
11945	Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 494-506.	2.2	40
11946	Randomized phase II trial of carboplatin+ nab-paclitaxel versus cisplatin+ gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302. <i>International Journal of Clinical Oncology</i> , 2021, 26, 515-522.	2.2	3
11947	Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). <i>Clinical Lung Cancer</i> , 2021, 22, 100-109.e3.	2.6	31
11948	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 153-164.	1.9	28
11949	Prediction of mediastinal lymph node metastasis based on 18F-FDG PET/CT imaging using support vector machine in non-small cell lung cancer. <i>European Radiology</i> , 2021, 31, 3983-3992.	4.5	16
11950	Imaging Glioblastoma Posttreatment. <i>Neuroimaging Clinics of North America</i> , 2021, 31, 103-120.	1.0	23
11951	A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. <i>Radiotherapy and Oncology</i> , 2021, 155, 232-236.	0.6	30
11952	Molecular Profiling of Exceptional Responders to Cancer Therapy. <i>Oncologist</i> , 2021, 26, 186-195.	3.7	15
11953	A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 337-347.	2.3	5
11954	Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma. <i>Surgery Today</i> , 2021, 51, 798-806.	1.5	7
11955	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1349-1358.	0.8	35
11956	Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). <i>Clinical Cancer Research</i> , 2021, 27, 704-712.	7.0	20
11957	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	4.1	30

#	ARTICLE	IF	CITATIONS
11958	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	3.9	62
11959	Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 3616-3626.	1.5	17
11960	Pasotuxizumab, a BiTE [®] immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. <i>Immunotherapy</i> , 2021, 13, 125-141.	2.0	72
11961	Efficacy of nivolumab versus molecularly targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. <i>International Journal of Urology</i> , 2021, 28, 99-106.	1.0	4
11962	Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. <i>Clinical Cancer Research</i> , 2021, 27, 1082-1093.	7.0	20
11963	A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer. <i>Oncologist</i> , 2021, 26, e658-e668.	3.7	13
11964	Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. <i>Annals of Oncology</i> , 2021, 32, 384-394.	1.2	70
11965	Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. <i>European Journal of Surgical Oncology</i> , 2021, 47, 699-707.	1.0	18
11966	iRECIST pour les nuls. <i>Journal D'imagerie Diagnostique Et Interventionnelle</i> , 2021, 4, 18-21.	0.0	0
11967	Impact of Body Mass Index on Perioperative Complications and Oncologic Outcomes in Patients Undergoing Thermal Ablation for Renal Cell Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 33-38.	0.5	0
11968	Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. <i>Thyroid</i> , 2021, 31, 1050-1055.	4.5	11
11969	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. <i>Science</i> , 2021, 371, 602-609.	12.6	784
11970	Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases. <i>International Journal of Cancer</i> , 2021, 148, 1717-1730.	5.1	18
11971	Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. <i>British Journal of Cancer</i> , 2021, 124, 176-182.	6.4	17
11972	MR cell size imaging with temporal diffusion spectroscopy. <i>Magnetic Resonance Imaging</i> , 2021, 77, 109-123.	1.8	9
11973	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2021, 124, 744-753.	6.4	65
11974	Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 3243-3253.	1.5	48
11975	Current practice in patients with differentiated thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2021, 17, 176-188.	9.6	161

#	ARTICLE	IF	CITATIONS
11976	Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 600459.	2.8	2
11977	Prognostic and therapeutic factors influencing the clinical outcome of metastatic Ewing sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28844.	1.5	3
11978	Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial. <i>Neuro-Oncology</i> , 2021, 23, 967-978.	1.2	15
11979	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 136-146.	3.4	12
11980	Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). <i>Journal of Clinical Oncology</i> , 2021, 39, 190-201.	1.6	43
11981	Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1396-1405.	0.8	12
11982	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1904-1911.	7.0	28
11984	Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100621.	1.2	10
11985	Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. <i>Breast</i> , 2021, 55, 7-15.	2.2	5
11986	Local regression smoothers with set-valued outcome data. <i>International Journal of Approximate Reasoning</i> , 2021, 128, 129-150.	3.3	1
11987	Imaging Beyond Seeing: Early Prognosis of Cancer Treatment. <i>Small Methods</i> , 2021, 5, e2001025.	8.6	14
11988	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 277-288.	10.7	34
11989	18F-FDG-PET/CT in laryngeal cancer: comparison with conventional imaging and prognostic role. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 229-238.	0.2	1
11990	Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 144, 151-161.	2.8	13
11991	Advantageous factors of R0 curative conversion esophagectomy and the optimal extent of lymphadenectomy after induction therapy for cT4b thoracic esophageal cancer. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 204-214.	2.4	1
11992	Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. <i>Cancer Reports</i> , 2021, 4, e1322.	1.4	4
11993	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 810-819.	2.0	11
11994	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2021, 26, 182-e361.	3.7	24

#	ARTICLE	IF	CITATIONS
11995	Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey. <i>Human Pathology</i> , 2021, 108, 60-67.	2.0	12
11996	Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer. <i>Acta Oncologica</i> , 2021, 60, 157-164.	1.8	7
11997	DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer. <i>BJU International</i> , 2021, 127, 254-262.	2.5	12
11998	Bizarre giant cells in human angiosarcoma exhibit chemoresistance and contribute to poor survival outcomes. <i>Cancer Science</i> , 2021, 112, 397-409.	3.9	7
11999	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. <i>Investigational New Drugs</i> , 2021, 39, 605-613.	2.6	6
12000	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> -mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	4.1	6
12001	A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, e549-e566.	3.7	2
12002	Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 429-437.	2.2	1
12003	Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases. <i>Medical Physics</i> , 2021, 48, 513-522.	3.0	32
12004	Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1203-1211.	4.2	11
12005	Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. <i>European Radiology</i> , 2021, 31, 2737-2746.	4.5	8
12006	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	7.0	5
12007	Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607.	1.6	156
12008	Factors affecting post-treatment radiation-induced lung disease in patients receiving stereotactic body radiotherapy to lung. <i>Radiation and Environmental Biophysics</i> , 2021, 60, 87-92.	1.4	0
12009	Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 764-774.	0.8	11
12010	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e17-77.e25.	1.6	16
12011	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 439-447.	3.9	0
12012	<i>SMARCA4</i> mutations in <i>KRAS</i> -mutant lung adenocarcinoma: a multi-cohort analysis. <i>Molecular Oncology</i> , 2021, 15, 462-472.	4.6	29

#	ARTICLE	IF	CITATIONS
12013	Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts'™ recommendations. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1031-1036.	4.2	3
12014	Arterial Embolization Using Microspheres for Hypervascular Liver Metastases Refractory to Standard Treatments: A Multicenter Prospective Clinical Trial. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 392-400.	2.0	5
12015	Everolimus after failure of one prior VEGF -targeted therapy in metastatic renal cell carcinoma: Final results of the MARC -2 trial. <i>International Journal of Cancer</i> , 2021, 148, 1685-1694.	5.1	7
12016	Dynamic analysis of circulating tumor <scp>DNA</scp> to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. <i>International Journal of Cancer</i> , 2021, 148, 921-931.	5.1	13
12017	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 66-78.	1.9	32
12018	Long-term outcome of indigenous ¹⁷⁷Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. <i>British Journal of Radiology</i> , 2021, 94, 20201041.	2.2	19
12019	Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>International Journal of Clinical Oncology</i> , 2021, 26, 51-58.	2.2	0
12020	Safety and efficacy of S-1 plus oxaliplatin 130Âmg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A). <i>International Journal of Clinical Oncology</i> , 2021, 26, 345-354.	2.2	1
12021	Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate. <i>Molecular Imaging and Biology</i> , 2021, 23, 220-229.	2.6	2
12022	Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS -¥ 50%) NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, 127-133.e3.	2.6	9
12023	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	1.3	21
12024	18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1154-1165.	6.4	10
12025	Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1585-1592.	6.4	6
12026	A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 135-144.	2.5	3
12027	Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 133.e1-133.e8.	1.6	6
12028	Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjvant chemotherapy. <i>Breast Cancer</i> , 2021, 28, 414-423.	2.9	2
12029	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <i>British Journal of Radiology</i> , 2021, 94, 20200663.	2.2	13
12030	Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1550-1559.	6.4	15

#	ARTICLE	IF	CITATIONS
12031	Prediction of response and survival after standardized treatment with 7400ÂMBq 177Lu-PSMA-617 every 4Âweeks in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1650-1657.	6.4	21
12032	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. <i>Gynecologic Oncology</i> , 2021, 160, 71-76.	1.4	9
12033	The impact of BRAF mutation status on clinical outcomes with antiâ€PDâ€1 monotherapy versus combination ipilimumab/nivolumab in treatmentâ€naÃve advanced stage melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 629-640.	3.3	6
12034	Erlotinib and bevacizumab in elderly patients â€¥75Âyears old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. <i>Investigational New Drugs</i> , 2021, 39, 210-216.	2.6	4
12035	Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. <i>European Radiology</i> , 2021, 31, 864-874.	4.5	8
12036	Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. <i>European Radiology</i> , 2021, 31, 1049-1058.	4.5	144
12037	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	1.6	239
12038	An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review. <i>Annals of Palliative Medicine</i> , 2021, 10, 5797-5807.	1.2	3
12040	Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 193-201.	2.6	10
12041	ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/Î2-catenin and FAK/Akt/mTOR. <i>Clinical and Translational Oncology</i> , 2021, 23, 902-910.	2.4	22
12042	Phase II Study: The Outcome of Hypofractionated Involved-Field Radiation Therapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Non-small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 35-43.	2.1	2
12043	Possible role of the receptor of advanced glycation end products (RAGE) in the clinical course of prostate neoplasia in patients with and without type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2021, 75, e13723.	1.7	5
12044	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. <i>Cancer Discovery</i> , 2021, 11, 59-67.	9.4	38
12045	Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A realâ€world evidence. <i>International Journal of Cancer</i> , 2021, 148, 1183-1191.	5.1	1
12046	Long-term outcome of â€œSandwichâ€chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 913-923.	6.4	24
12047	Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 657-665.	4.2	20
12048	High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour. <i>Endocrine</i> , 2021, 71, 494-501.	2.3	8
12049	A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 100-105.	1.3	3

#	ARTICLE	IF	CITATIONS
12050	Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. <i>Endocrine</i> , 2021, 72, 462-469.	2.3	15
12051	The Negative Impact of Preoperative Chemotherapy on Survival After Esophagectomy for Vulnerable Elderly Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1786-1795.	1.5	9
12052	Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 2001-2009.	1.6	18
12053	Effects of pretreatment radiological and pathological lymph node statuses on prognosis in patients with ovarian cancer who underwent interval debulking surgery with lymphadenectomy following neoadjuvant chemotherapy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 152-158.	1.3	4
12054	Circulating T-cell Immunosenescence in Patients with Advanced Nonâ€‘small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
12055	Impact of <scp>DNA</scp> damage repair defects and aggressive variant features on response to carboplatinâ€‘based chemotherapy in metastatic castrationâ€‘resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	5.1	28
12056	Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 571-577.	2.6	20
12057	Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. <i>European Radiology</i> , 2021, 31, 2242-2251.	4.5	11
12058	68Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors. <i>Oncologist</i> , 2021, 26, 21-29.	3.7	15
12059	Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 120-130.	0.8	27
12060	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 224-232.	4.5	30
12061	Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. <i>European Thyroid Journal</i> , 2021, 10, 125-139.	2.4	11
12062	Predictive value of initial imaging and staging with long-term outcomes in young adults diagnosed with colorectal cancer. <i>Abdominal Radiology</i> , 2021, 46, 909-918.	2.1	0
12063	Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1491-1496.	4.2	15
12064	Flow cytometric analysis ofÂ‘circulating endothelial cells and endothelial progenitor cells in pediatric solid tumors: prognostic impact on treatment response and survival. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 755-761.	4.2	3
12065	Yttriumâ€‘90 radiation segmentectomy for hepatic metastases: A multiâ€‘institutional study of safety and efficacy. <i>Journal of Surgical Oncology</i> , 2021, 123, 172-178.	1.7	21
12066	A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 469-476.	2.6	15
12067	Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. <i>Molecular Imaging and Biology</i> , 2021, 23, 139-147.	2.6	12

#	ARTICLE	IF	CITATIONS
12068	Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 533-546.	4.2	16
12069	Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2â€“positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). <i>Investigational New Drugs</i> , 2021, 39, 217-225.	2.6	7
12070	Magnetic resonance imaging for assessing treatment response in bone marrow metastases. <i>Acta Radiologica</i> , 2021, 62, 483-499.	1.1	2
12071	Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2021, 30, 106-114.	1.2	4
12072	A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 115-122.	1.0	30
12073	MOCRPC overview of management options. <i>World Journal of Urology</i> , 2021, 39, 349-356.	2.2	6
12074	Lymph Node Response to Neoadjuvant Chemotherapy as an Independent Prognostic Factor in Metastatic Esophageal Cancer. <i>Annals of Surgery</i> , 2021, 273, 1141-1149.	4.2	45
12075	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 806-813.	4.2	61
12076	Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. <i>International Journal of Surgery Oncology</i> , 2019, 4, e76-e76.	0.2	2
12077	A Phase I/IIa Study of Antidisialoganglioside Antibody Dinutuximab in Japanese Patients With Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e358-e364.	0.6	4
12078	Definitive concurrent chemoradiation versus laryngectomy and postoperative radiation using IMRT in locally advanced laryngeal cancer: experience from a regional cancer centre of Eastern India. <i>Journal of Radiotherapy in Practice</i> , 2021, 20, 71-77.	0.5	2
12079	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.	5.4	26
12080	The importance of weight loss during definitive radiotherapy in patients with laryngeal carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021, .	0.9	0
12081	Methodological studies. , 2021, , 227-237.		0
12082	Gliosarcoma. , 2021, , 149-162.		0
12083	Radiomics in head and neck cancer. , 2021, , 83-105.		0
12084	Preliminary Analysis of CyberKnife Stereotactic Radiotherapy for Primary and Recurrent Head and Neck Cancers: A Delicate Balance. <i>International Journal of Head and Neck Surgery</i> , 2021, 12, 43-47.	0.2	1
12085	Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. <i>Laryngoscope</i> , 2021, 131, E1941-E1949.	2.0	24

#	ARTICLE	IF	CITATIONS
12086	Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1929-1937.	4.2	19
12087	The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition <i>in vivo</i> . <i>International Journal of Biological Sciences</i> , 2021, 17, 728-741.	6.4	2
12088	Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy. <i>Yonsei Medical Journal</i> , 2021, 62, 231.	2.2	10
12089	Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple-negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways. <i>Cancer Cell International</i> , 2021, 21, 42.	4.1	13
12090	Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy. <i>In Vivo</i> , 2021, 35, 563-569.	1.3	13
12091	Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 38-45.	1.0	0
12092	Comparison of Intrafractional Motion in Head and Neck Cancer Between Two Immobilization Methods During Stereotactic Ablative Radiation Therapy by CyberKnife. <i>Cancer Management and Research</i> , 2020, Volume 12, 13599-13606.	1.9	5
12093	Pediatric Thyroid Cancer. , 2021, , 255-263.e3.		0
12094	Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. <i>Cancers</i> , 2021, 13, 443.	3.7	12
12095	Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma. <i>Annals of Palliative Medicine</i> , 2021, 10, 584-589.	1.2	2
12096	Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 107815522098425.	0.9	1
12097	Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. <i>Translational Lung Cancer Research</i> , 2021, 10, 415-429.	2.8	13
12098	The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382199781.	1.9	6
12099	The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	3.2	3
12100	Comparison of CT Volumetry and RECIST to Predict the Treatment Response and Overall Survival in Gastric Cancer Liver Metastases. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 876.	0.2	0
12101	Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study. <i>Journal of Cancer</i> , 2021, 12, 4478-4487.	2.5	0
12102	A combined protocol with piroxicam, chemotherapy, and whole pelvic irradiation with simultaneous boost volumetric modulated arc radiotherapy for muscle-invasive canine urinary transitional cell carcinoma: First clinical experience. <i>Journal of Veterinary Medical Science</i> , 2021, 83, 695-704.	0.9	3
12103	An overview of machine learning methods for monotherapy drug response prediction. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	19

#	ARTICLE	IF	CITATIONS
12104	Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 34-42.	2.5	9
12105	Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. <i>Onc Immunology</i> , 2021, 10, 1862948.	4.6	20
12106	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100393.	1.7	2
12107	Primary cystic and solid neuroendocrine tumor of the retroperitoneum. <i>Medicine (United States)</i> , 2021, 100, e24054.	1.0	1
12108	Prognostic value of metabolic tumor parameters in pretreatment ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography scan in advanced non-small cell lung cancer. <i>Indian Journal of Nuclear Medicine</i> , 2021, 36, 107.	0.3	1
12109	The Prognostic Value of the CA-125 Elimination Rate (KELIM) as an Indicator of Response During Neo-Adjuvant Chemotherapy in Advanced-Stage Ovarian Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
12110	Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2021, 60, 3593-3598.	0.7	8
12111	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. <i>BMC Cancer</i> , 2021, 21, 57.	2.6	3
12112	The Value of Early Tumor Size Response to Chemotherapy in Pediatric Rhabdomyosarcoma. <i>Cancers</i> , 2021, 13, 510.	3.7	15
12113	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110216.	1.3	12
12114	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting. , 2021, , 59-81.		0
12115	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. <i>Cells</i> , 2021, 10, 212.	4.1	24
12116	Hepatic epithelioid hemangioendothelioma (HEHE) – rare vascular malignancy mimicking cholangiocarcinoma: a case report. <i>Translational Gastroenterology and Hepatology</i> , 0, 7, 42-42.	3.0	1
12117	ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 0-0.	1.4	3
12118	Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs). , 2021, , 55-74.		0
12119	Innovating Metabolic Biomarkers for Hyperpolarized NMR. , 2021, , 151-179.		0
12120	Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 347-357.	0.9	7
12121	Treatment Response Evaluation: Science and Practice. , 2021, , 3-9.		0

#	ARTICLE	IF	CITATIONS
12122	Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab. <i>Thoracic Cancer</i> , 2021, 12, 603-612.	1.9	20
12123	Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2021, 12, 2395-2402.	2.5	7
12124	Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110390.	3.2	2
12125	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110229.	3.2	2
12126	A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 339-347.	4.3	14
12127	Prediction of treatment response to transarterial radioembolization of liver metastases: Radiomics analysis of pre-treatment cone-beam CT: A proof of concept study. <i>European Journal of Radiology Open</i> , 2021, 8, 100375.	1.6	11
12128	Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 494-504.	2.0	7
12129	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	7.7	25
12130	Effectiveness of ADC Difference Value on Pre-neoadjuvant Chemotherapy MRI for Response Evaluation of Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110391.	1.9	4
12131	Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy. <i>In Vivo</i> , 2021, 35, 2869-2874.	1.3	1
12132	L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy. <i>Journal of Cancer</i> , 2021, 12, 6401-6410.	2.5	1
12133	Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110426.	3.2	8
12134	Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites. <i>Oncology</i> , 2021, 99, 652-658.	1.9	2
12135	Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. <i>Investigational New Drugs</i> , 2021, 39, 1150-1158.	2.6	14
12136	Liquid biopsy enters the clinic – implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	27.6	609
12137	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2773-2781.	7.0	55
12138	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	7.0	67
12139	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. <i>Clinical Cancer Research</i> , 2021, 27, 1864-1874.	7.0	20

#	ARTICLE	IF	CITATIONS
12140	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. <i>Oncology</i> , 2021, 99, 562-570.	1.9	3
12141	Hepatic and Extrahepatic Colorectal Metastases Have Discordant Responses to Systemic Therapy. Pathology Data from Patients Undergoing Simultaneous Resection of Multiple Tumor Sites. <i>Cancers</i> , 2021, 13, 464.	3.7	5
12142	A feasibility study of circulating melanoma cells in the perioperative context of hyperthermic isolated limb perfusion (HILP) in 20 patients. <i>International Journal of Hyperthermia</i> , 2021, 38, 70-78.	2.5	0
12143	Potential retropharyngeal lymph node metastasis on diagnostic image and changes in retropharyngeal regional dose depending on the irradiation technique in maxillary sinus cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2021, 47, 47-52.	0.1	0
12144	Intra-arterial Radiopeptide Infusions with High Activity of ¹¹¹ In-Octreotide: From the Aretaieion Protocol to the Temporal Intra-arterial Port Installation. , 2021, , 85-105.		0
12145	Evaluation and Assessment of the Radio-Peptide Treatment Efficacy. , 2021, , 163-170.		0
12146	Biomarkers for Hypoxia, HPVness, and Proliferation from Imaging Perspective. , 2021, , 13-20.		0
12147	Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function. <i>In Vivo</i> , 2021, 35, 2821-2829.	1.3	2
12148	Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 2855-2862.	1.3	6
12149	Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.	7.0	54
12150	A Preoperative Nomogram for Predicting Chemoresistance to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Squamous Carcinoma Treated with Radical Hysterectomy. <i>Cancer Research and Treatment</i> , 2021, 53, 233-242.	3.0	3
12151	The Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 173-180.	1.9	8
12152	PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 618341.	3.7	2
12153	Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management. <i>In Vivo</i> , 2021, 35, 385-391.	1.3	3
12154	Aidi Injection as Adjuvant Drug Combined with Chemotherapy in Treatment of Breast Cancer: A Systematic Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-12.	1.2	0
12155	Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?. <i>Medicina (Lithuania)</i> , 2021, 57, 77.	2.0	1
12156	Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 621435.	2.8	9
12157	Management of aggressive pituitary tumors. , 2021, , 485-497.		0

#	ARTICLE	IF	CITATIONS
12158	Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer: a Brazilian private payer perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110005.	3.2	6
12159	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	3.2	15
12160	Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors. <i>In Vivo</i> , 2021, 35, 1277-1283.	1.3	9
12161	18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib. <i>Cancers</i> , 2021, 13, 317.	3.7	15
12162	Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199665.	3.2	18
12163	Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. <i>EClinicalMedicine</i> , 2021, 31, 100673.	7.1	23
12164	Treatment of anaplastic thyroid cancer with tyrosine kinase inhibitors targeted on the tumor vasculature: initial experience in clinical practice. <i>Endocrine Journal</i> , 2021, 68, 63-68.	1.6	6
12165	A CASE OF VAGUS NERVE SCHWANNOMA DIFFICULT TO DISTINGUISH FROM LYMPH NODAL METASTASIS OF ESOPHAGEAL CANCER. <i>Journal of Medical Investigation</i> , 2021, 68, 205-208.	0.5	0
12166	Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125I Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery. <i>Frontiers in Oncology</i> , 2020, 10, 540096.	2.8	7
12167	Olmotinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. <i>Cancer</i> , 2021, 127, 1407-1416.	4.1	17
12168	The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer. <i>Medicine (United States)</i> , 2021, 100, e24110.	1.0	0
12169	Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 1, 177-190.	3.0	16
12170	Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4625-4634.	1.5	9
12172	Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 251-258.	2.3	14
12173	Granulocyte Colony-stimulating Factor Producing Oropharyngeal Squamous Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 1785-1790.	1.3	1
12174	Clearance of circulating tumor DNA in a high-risk stage-IV rectal carcinoma patient with synchronous liver metastases after conversion surgery is correlated with pathologic complete response. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , 2021, 14, 263177452110202.	1.9	0
12176	Multi-threshold Attention U-Net (MTAU) Based Model for Multimodal Brain Tumor Segmentation in MRI Scans. <i>Lecture Notes in Computer Science</i> , 2021, , 168-178.	1.3	8
12177	Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI. <i>European Radiology</i> , 2021, 31, 5640-5649.	4.5	10

#	ARTICLE	IF	CITATIONS
12178	Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. <i>Cancer Reports</i> , 2021, 4, e1329.	1.4	1
12179	Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098406.	3.2	8
12180	Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100449.	1.7	3
12181	Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2021, 14, 2.	3.0	14
12182	Weakly-Supervised Universal Lesion Segmentation with Regional Level Set Loss. <i>Lecture Notes in Computer Science</i> , 2021, , 515-525.	1.3	11
12183	Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a039537.	6.2	46
12184	Trends in Phase II Trials for Cancer Therapies. <i>Cancers</i> , 2021, 13, 178.	3.7	4
12185	Liver Tumor Localization and Characterization from Multi-phase MR Volumes Using Key-Slice Prediction: A Physician-Inspired Approach. <i>Lecture Notes in Computer Science</i> , 2021, , 47-58.	1.3	0
12186	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	7.0	51
12187	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630.	7.0	33
12188	Quantification of thermal dose in moderate clinical hyperthermia with radiotherapy: a relook using temperature-time area under the curve (AUC). <i>International Journal of Hyperthermia</i> , 2021, 38, 296-307.	2.5	9
12189	Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 143-155.	2.8	24
12190	Low value of whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage II nasopharyngeal carcinoma: a nest case-control study. <i>European Radiology</i> , 2021, 31, 5222-5233.	4.5	5
12191	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	1.9	5
12192	The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis. <i>Oncology</i> , 2021, 99, 271-279.	1.9	11
12193	An adaptive multi-scale network with nonorthogonal multi-union input for reducing false positive of lymph nodes. <i>Biocybernetics and Biomedical Engineering</i> , 2021, 41, 265-277.	5.9	4
12194	Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110136.	3.2	18
12195	Dosimetric analysis and acute toxicity comparison of bone marrow sparing intensity-modulated radiation therapy versus three-dimensional conformal therapy with concurrent chemotherapy for the treatment of cervical carcinoma: A prospective single institutional study. <i>Journal of Radiation and Cancer Research</i> , 2021, 12, 70.	0.1	0

#	ARTICLE	IF	CITATIONS
12196	Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. <i>Oncology</i> , 2021, 99, 310-317.	1.9	10
12197	A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. <i>Cancer Research and Treatment</i> , 2021, 53, 93-103.	3.0	2
12198	Evaluation of diagnostic and predictive values of the serum VEGF-A level and systemic immune-inflammation index in small cell lung cancer. <i>Journal of Cancer</i> , 2021, 12, 1356-1364.	2.5	8
12199	Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer. <i>BMC Medical Research Methodology</i> , 2021, 21, 14.	3.1	3
12200	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2023-2031.	1.7	4
12201	Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 526.	3.7	5
12202	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	3.3	17
12203	Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 684-693.	2.2	1
12204	Comparative Survival Outcome of Robot-Assisted Staging Surgery Using Three Robotic Arms versus Open Surgery for Endometrial Cancer. <i>Yonsei Medical Journal</i> , 2021, 62, 68.	2.2	8
12205	Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors. <i>In Vivo</i> , 2021, 35, 467-474.	1.3	7
12206	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. <i>BMC Cancer</i> , 2021, 21, 19.	2.6	24
12207	Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer. <i>Oncology</i> , 2021, 99, 632-640.	1.9	9
12208	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110428.	3.2	6
12209	Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer. <i>Abdominal Radiology</i> , 2021, 46, 2833-2838.	2.1	16
12210	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e16.	2.2	8
12211	Current status and future perspectives on neoadjuvant therapy in gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 181-192.	2.2	8
12212	Image-Guided Brachytherapy: Follow-Up. <i>Imaging and Clinical Management</i> , 2021, , 63-73.		0
12213	The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110258.	3.2	5

#	ARTICLE	IF	CITATIONS
12214	Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China. <i>Frontiers in Oncology</i> , 2020, 10, 567529.	2.8	6
12215	Pre-treatment FLT-PET parameters as a prognostic tool for patients with locally advanced recurrent nasopharyngeal carcinoma salvaged by carbon-ion radiotherapy: a pilot study. <i>Annals of Translational Medicine</i> , 2021, .	1.7	0
12216	The role of carbon-ion radiotherapy in the treatment of adenoid cystic carcinoma of the nasopharynx. <i>Annals of Translational Medicine</i> , 2022, 10, 1198-1198.	1.7	1
12217	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	2.3	16
12218	Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 3.	5.2	25
12219	Chemotherapy-induced early transient increase and surge of CA 19â€“9 level in patients with pancreatic Adenocarcinomaâ€“. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100397.	1.7	1
12220	Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Anticancer Research</i> , 2021, 41, 445-452.	1.1	15
12221	Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2145-2152.	2.5	4
12222	Stereotactic body radiotherapy for pelvic boost in gynecological cancer patients with local recurrence or unsuitable for intracavitary brachytherapy. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 111-118.	1.3	7
12223	Namodenoson in Advanced Hepatocellular Carcinoma and Childâ€“Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. <i>Cancers</i> , 2021, 13, 187.	3.7	25
12224	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	1.7	16
12225	Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1369-1376.	2.2	34
12226	Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1727-1732.	0.9	3
12227	MRI and Diffusion-Weighted MRI in Treatment Response Evaluation Overview. , 2021, , 17-26.		0
12228	Pharmacokinetics and Safety of PTC596, a Novel Tubulinâ€“Binding Agent, in Subjects With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 940-949.	1.6	11
12229	Quantification of Pancreas Surface Lobularity on CT: A Feasibility Study in the Normal Pancreas. <i>Korean Journal of Radiology</i> , 2021, 22, 1300.	3.4	5
12230	Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer. <i>Oncolmmunology</i> , 2021, 10, 1951019.	4.6	33
12231	Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2475-2483.	1.4	10

#	ARTICLE	IF	CITATIONS
12232	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	2.7	13
12233	Comparisons of survival outcomes between bevacizumab and olaparib in <i>BRCA</i> -mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052). <i>Journal of Gynecologic Oncology</i> , 2021, 32, e90.	2.2	2
12234	Detection of Early Progression with ¹⁸ F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1270-1273.	5.0	6
12235	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110027.	3.2	91
12236	Development and Validation of Multivariate Models Integrating Preoperative Clinicopathological Parameters and Radiographic Findings Based on Late Arterial Phase CT Images for Predicting Lymph Node Metastasis in Gastric Cancer. <i>Academic Radiology</i> , 2021, 28, S167-S178.	2.5	7
12237	Predictive effect of DCE-MRI and DWI in brain metastases from NSCLC. <i>Open Medicine (Poland)</i> , 2021, 16, 1265-1275.	1.3	4
12238	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. <i>Oncolmmunology</i> , 2021, 10, 1909296.	4.6	13
12239	Prediction of axillary response after neoadjuvant chemotherapy in clinical node positive breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 2822-2830.	1.0	1
12240	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	7.7	12
12241	Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2035-2044.	1.4	3
12242	Expression Status of Serine Protease 27: A Prognostic Marker for Esophageal Squamous Cell Carcinoma Treated with Preoperative Chemotherapy/Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 5373-5381.	1.5	2
12243	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 53-60.	2.2	8
12244	Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 12.	1.9	8
12245	Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. <i>Endocrine-Related Cancer</i> , 2021, 28, 15-26.	3.1	12
12246	Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 268.	3.7	16
12247	Estimating the False Positive Prediction Rate in Automated Volumetric Measurements of Malignant Pleural Mesothelioma. <i>Communications in Computer and Information Science</i> , 2021, , 116-139.	0.5	1
12248	A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 701-707.	2.2	2
12249	Switching of Hormone Therapies in Breast Cancer Women. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 185-189.	0.8	0

#	ARTICLE	IF	CITATIONS
12250	Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy. <i>In Vivo</i> , 2021, 35, 401-410.	1.3	5
12251	Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 621329.	2.8	11
12253	Circulating tumor cells: A surrogate to predict the effect of treatment and overall survival in gastric adenocarcinoma. <i>International Journal of Biological Markers</i> , 2021, 36, 28-35.	1.8	7
12254	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198899.	3.2	17
12255	Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 43-50.	2.5	7
12256	Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00810.	2.9	0
12257	Impact of Immune-related Adverse Events on Nivolumab Efficacy in Patients With Upper Gastrointestinal Cancer. <i>In Vivo</i> , 2021, 35, 2321-2326.	1.3	5
12258	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. <i>Cancer Medicine</i> , 2021, 10, 843-856.	2.8	3
12259	Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma. <i>Frontiers in Oncology</i> , 2020, 10, 610858.	2.8	5
12260	Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 535.	4.1	17
12261	Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110342.	1.9	20
12262	Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma. <i>Dermatology</i> , 2021, 237, 1023-1028.	2.1	7
12263	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. <i>Thoracic Cancer</i> , 2021, 12, 864-873.	1.9	10
12264	Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non-small cell lung cancer. <i>Aging Medicine (Milton (N S W))</i> , 2021, 4, 42-46.	2.1	4
12265	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
12266	Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration. <i>Transplantation Direct</i> , 2021, 7, e656.	1.6	8
12267	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1755-1769.	4.2	4
12268	Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2127-2135.	2.5	2

#	ARTICLE	IF	CITATIONS
12269	A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. Cancer Treatment and Research Communications, 2021, 27, 100330.	1.7	16
12271	PET and PET-CT in Treatment Response Evaluation: Overview. , 2021, , 27-35.		0
12272	18F-FDG PET-CT in Treatment Response Evaluation in Cutaneous Malignant Melanoma. , 2021, , 377-394.		0
12273	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
12274	The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen. Technology in Cancer Research and Treatment, 2021, 20, 153303382110194.	1.9	9
12275	Development and Application of a Single Cell-Level PK-PD Model for ADCs. Methods in Pharmacology and Toxicology, 2021, , 331-355.	0.2	0
12276	Assessment of prognosis by established prognosis scores and physicians' judgement in mRCC patients: an analysis of the STAR-TOR registry. Translational Andrology and Urology, 2021, 10, 0-0.	1.4	3
12277	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers, 2021, 13, 475.	3.7	20
12278	Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer, 2021, 21, 60.	2.6	19
12279	FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110298.	3.2	4
12280	Safety of biliary stent placement followed by definitive chemoradiotherapy in patients with pancreatic cancer with bile duct obstruction. Journal of Gastrointestinal Oncology, 2021, 12, 2260-2267.	1.4	0
12281	A phase 1b trial of the CXCR4 inhibitor mavoxixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs, 2021, 39, 1019-1027.	2.6	22
12282	Harmonization of radiomic feature distributions: impact on classification of hepatic tissue in CT imaging. European Radiology, 2021, 31, 6059-6068.	4.5	11
12283	The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Therapeutic Advances in Urology, 2021, 13, 175628722110433.	2.0	6
12284	Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110005.	3.2	25
12285	Predicting the efficacy of chemoradiotherapy for locally advanced human papilloma virus-related oropharyngeal squamous cell carcinoma using one course of TPF chemotherapy. European Archives of Oto-Rhino-Laryngology, 2021, 278, 3497-3506.	1.6	1
12286	Post-Neoadjuvant Surveillance and Surgery as Needed Compared with Post-Neoadjuvant Surgery on Principle in Multimodal Treatment for Esophageal Cancer: A Scoping Review. Cancers, 2021, 13, 429.	3.7	13
12287	Systematic review of phase I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research. Cancer Medicine, 2021, 10, 1589-1604.	2.8	8

#	ARTICLE	IF	CITATIONS
12288	Oncology treatment outcome in human immunodeficiency virus-positive cancer cervix patients: Where we are and what we achieved?. Journal of Cancer Research and Therapeutics, 2021, .	0.9	1
12289	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 563-580.	2.8	14
12290	Quantitative imaging decision support (QIDS TM) tool consistency evaluation and radiomic analysis by means of 594 metrics in lung carcinoma on chest CT scan. Cancer Control, 2021, 28, 107327482098578.	1.8	45
12291	Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma. Anticancer Research, 2021, 41, 527-532.	1.1	6
12292	Stem-Cell Therapy Following High-Dose Chemotherapy in Advanced Retinoblastoma: A Systematic Review. Asia-Pacific Journal of Ophthalmology, 2021, 10, 397-407.	2.5	8
12293	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸ F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 2021, 62, 1050-1056.	5.0	19
12294	Phenocopying Glioblastoma: A Review. IEEE Reviews in Biomedical Engineering, 2023, 16, 456-471.	18.0	3
12295	Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study. BMC Cancer, 2021, 21, 77.	2.6	31
12296	Cancer Detection and Quantification of Treatment Response Using Diffusion-Weighted MRI. , 2021, , 1091-1116.		1
12297	Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Clinical Cancer Research, 2021, 27, 2139-2147.	7.0	77
12298	A Segmentation-Assisted Model for Universal Lesion Detection with Partial Labels. Lecture Notes in Computer Science, 2021, , 117-127.	1.3	6
12299	Lesion Segmentation and RECIST Diameter Prediction via Click-Driven Attention and Dual-Path Connection. Lecture Notes in Computer Science, 2021, , 341-351.	1.3	6
12300	Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110473.	2.5	1
12301	Checkpoint-Inhibitoren. Springer Reference Medizin, 2021, , 1-11.	0.0	0
12302	Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring <i>STK11</i> or <i>KEAP1</i> mutation. Oncoimmunology, 2021, 10, 1865670.	4.6	9
12303	Radio-Chemotherapy in Pre-Operative Rectal Adenocarcinoma at Dalal Jamm Hospital, Senegal. Journal of Cancer Therapy, 2021, 12, 221-231.	0.4	0
12304	Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer, 2021, 21, 52.	2.6	9
12305	Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110381.	1.9	2

#	ARTICLE	IF	CITATIONS
12306	Metformin plus Irinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial. British Journal of Cancer, 2021, 124, 1072-1078.	6.4	17
12307	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biology and Medicine, 2021, 18, 562-568.	3.0	7
12308	Methylation of <i>PAX1</i> gene promoter in the prediction of concurrent chemo-radiotherapy efficacy in cervical cancer. Journal of Cancer, 2021, 12, 5136-5143.	2.5	4
12309	Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Theranostics, 2021, 11, 8143-8151.	10.0	14
12310	Negative impact of antibiotic administration on the clinical activity in patients with advanced gastric cancer. Biotechnology and Biotechnological Equipment, 2021, 35, 1052-1057.	1.3	0
12312	CT in Treatment Response Assessment in Oncology. , 2021, , 11-16.		0
12313	DeepRecS: From RECIST Diameters to Precise Liver Tumor Segmentation. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 614-625.	6.3	10
12314	Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer. Asian Journal of Andrology, 2022, 24, 50.	1.6	2
12315	Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. Oncology Letters, 2021, 21, 212.	1.8	3
12316	The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer, 2021, 21, 20.	2.6	21
12317	A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms. International Journal of Medical Sciences, 2021, 18, 2166-2175.	2.5	7
12318	Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2021, 47, 1527-1535.	1.3	10
12319	Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. British Journal of Cancer, 2021, 124, 1130-1137.	6.4	11
12320	Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-resistant extensive-stage SCLC: a real-world retrospective study. International Journal of Clinical Oncology, 2021, 26, 670-683.	2.2	4
12321	Circular RNA circ_0081001 knockdown enhances methotrexate sensitivity in osteosarcoma cells by regulating miR-494-3p/TGM2 axis. Journal of Orthopaedic Surgery and Research, 2021, 16, 50.	2.3	16
12322	Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood. Technology in Cancer Research and Treatment, 2021, 20, 153303382199781.	1.9	7
12323	Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. Cancers, 2021, 13, 773.	3.7	13
12324	Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. Internal Medicine, 2021, 60, 345-351.	0.7	14

#	ARTICLE	IF	CITATIONS
12325	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. The Cochrane Library, 2021, 2, CD005343.	2.8	29
12326	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers, 2021, 13, 635.	3.7	10
12327	Effect of <i>TOP2A</i> and <i>ERCC1</i> gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients. Archives of Medical Science, 2021, 17, 474-480.	0.9	4
12328	The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Japanese Journal of Clinical Oncology, 2021, 51, 693-699.	1.3	4
12329	Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer. Cancer Research, 2021, 81, 2522-2533.	0.9	13
12330	Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Frontiers in Pharmacology, 2021, 12, 636324.	3.5	2
12331	Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist, 2021, 26, e632-e638.	3.7	9
12332	Are radiologists ready to evaluate true response to immunotherapy?. Insights Into Imaging, 2021, 12, 29.	3.4	5
12333	Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. Frontiers in Oncology, 2021, 11, 626275.	2.8	4
12334	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. Clinical and Experimental Nephrology, 2021, 25, 674-682.	1.6	2
12335	KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 737-752.	2.8	28
12336	Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS ONE, 2021, 16, e0247645.	2.5	15
12337	Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	1.1	2
12338	Intratumoral CXCL13 ⁺ CD8 ⁺ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
12339	The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 855-865.	2.8	7
12340	Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study. Cancer Management and Research, 2021, Volume 13, 1491-1503.	1.9	1
12341	Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (â€‘Pro-PETâ€™ score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nuclear Medicine Communications, 2021, 42, 566-574.	1.1	7
12342	Assessment of Tumor Volume Dynamics and Outcome After Radiosurgery for the Treatment of Vestibular Schwannoma: A Single-Center Experience. Otology and Neurotology, 2021, 42, e750-e757.	1.3	2

#	ARTICLE	IF	CITATIONS
12343	Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer. Thoracic Cancer, 2021, 12, 949-957.	1.9	8
12344	Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy. Cancer Research, 2021, 81, 2545-2555.	0.9	18
12345	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
12346	Nivolumab plus ipilimumab, with or without enzalutamide, in AR α -expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	2.3	35
12347	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. Seminars in Cancer Biology, 2021, 77, 67-82.	9.6	12
12348	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84
12349	CT-based whole-body tumor volumetry versus RECIST 1.1: Feasibility and implications for inter-reader variability. European Journal of Radiology, 2021, 135, 109514.	2.6	3
12350	The characteristic computed tomography findings of pulmonary B-cell non-Hodgkin's lymphoma and their role in predicting patient survival. Quantitative Imaging in Medicine and Surgery, 2021, 11, 772-783.	2.0	0
12351	Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 230-240.	2.5	3
12352	Development and Validation of a Nomogram for the Estimation of Response to Platinum-Based Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer. Cancer Management and Research, 2021, Volume 13, 1279-1289.	1.9	1
12353	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 776-789.	2.8	6
12354	Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. Lung Cancer, 2021, 152, 149-156.	2.0	11
12355	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2459-2469.	2.5	3
12356	Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2385-2396.	2.5	6
12357	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
12358	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212
12359	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. Genes, 2021, 12, 285.	2.4	18
12360	Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine. Medicine (United States), 2021, 100, e24292.	1.0	3

#	ARTICLE	IF	CITATIONS
12361	Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. <i>Medicine (United States)</i> , 2021, 100, e24640.	1.0	11
12362	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021, 13, 25.	4.1	11
12363	Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. <i>Endocrine</i> , 2021, 73, 232-239.	2.3	4
12364	Quantitative ⁶⁸ Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1406-1414.	5.0	40
12365	PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. <i>European Journal of Cancer</i> , 2021, 144, 317-325.	2.8	13
12366	Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. <i>Cancer</i> , 2021, 127, 1984-1992.	4.1	3
12367	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2470-2480.	7.0	51
12368	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284.	5.0	25
12369	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. <i>Lancet</i> , The, 2021, 397, 592-604.	13.7	441
12370	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	1.6	254
12371	Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. <i>Oncologist</i> , 2021, 26, 383-388.	3.7	21
12372	Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 962.	3.7	25
12373	A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. <i>Translational Cancer Research</i> , 2021, 10, 1119-1130.	1.0	5
12374	NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 3258.	3.3	19
12375	Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. <i>ESMO Open</i> , 2021, 6, 100020.	4.5	19
12376	Positron Emission Tomography-Based Short-Term Efficacy Evaluation and Prediction in Patients With Non-Small Cell Lung Cancer Treated With Hypo-Fractionated Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 590836.	2.8	3
12377	Evaluation of Definitive Chemoradiotherapy Versus Radical Esophagectomy in Clinical T1bNOMO Esophageal Squamous Cell Carcinoma. <i>World Journal of Surgery</i> , 2021, 45, 1835-1844.	1.6	9
12378	Stereotactic Body Radiotherapy for Lymph Node Oligometastases: Real-World Evidence From 90 Consecutive Patients. <i>Frontiers in Oncology</i> , 2020, 10, 616494.	2.8	6

#	ARTICLE	IF	CITATIONS
12379	Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 665-672.	2.3	1
12380	Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 701-710.	2.3	1
12381	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185.	1.2	14
12382	Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2021, 50, 138-146.	1.1	8
12383	Randomized <scp>Phase II</scp> trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without <scp>KRAS</scp> exon 2 mutations. <i>International Journal of Cancer</i> , 2021, 149, 119-126.	5.1	8
12384	Intravoxel Incoherent Motion Magnetic Resonance Imaging for Prediction of Induction Chemotherapy Response in Locally Advanced Hypopharyngeal Carcinoma: Comparison With Modelâ€Free Dynamic Contrastâ€Enhanced Magnetic Resonance Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 91-100.	3.4	6
12385	Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. <i>Cancers</i> , 2021, 13, 823.	3.7	44
12386	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
12387	Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma. <i>Frontiers in Surgery</i> , 2021, 8, 594570.	1.4	1
12388	Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data. <i>BMJ Open</i> , 2021, 11, e044420.	1.9	8
12389	Quantitative FDG PET Assessment for Oncology Therapy. <i>Cancers</i> , 2021, 13, 869.	3.7	20
12390	Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. <i>Transplantation</i> , 2021, 105, 602-607.	1.0	24
12391	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
12392	Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC). <i>Annals of Surgical Oncology</i> , 2021, 28, 5311-5326.	1.5	31
12393	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Nonâ€Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	9.4	154
12394	Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	7.1	49
12395	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	4.9	356
12396	The effect of Gamma Knife radiosurgery on large posterior fossa metastases and the associated mass effect from peritumoral edema. <i>Journal of Neurosurgery</i> , 2021, 134, 466-474.	1.6	2

#	ARTICLE	IF	CITATIONS
12397	Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma. <i>Immunotherapy</i> , 2021, 13, 217-225.	2.0	6
12398	Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-Cell mediated anti-tumor immunity in an esophageal adenocarcinoma model. <i>Oncotarget</i> , 2021, 12, 292-303.	1.8	20
12399	Non-contrast and portal venous phase computed tomography in breast cancer hepatic metastases: comparison of tumor measurements and impact on response assessment. <i>Acta Radiologica Open</i> , 2021, 10, 205846012199801.	0.6	1
12400	Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). <i>Thoracic Cancer</i> , 2021, 12, 1264-1268.	1.9	1
12401	Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2036741.	5.9	12
12402	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. <i>Nature Communications</i> , 2021, 12, 733.	12.8	33
12403	Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes. <i>International Journal of Clinical Oncology</i> , 2021, 26, 913-921.	2.2	4
12404	Management for Residual Ground-Glass Opacity Lesions After Resection of Main Tumor in Multifocal Lung Cancer: A Case Report and Literature Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 977-985.	1.9	8
12405	Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. <i>JGH Open</i> , 2021, 5, 356-363.	1.6	0
12406	Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. <i>Scientific Reports</i> , 2021, 11, 2741.	3.3	16
12407	Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III-IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study. <i>Frontiers in Oncology</i> , 2021, 11, 578865.	2.8	1
12408	Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. <i>Annals of Palliative Medicine</i> , 2021, 10, 1589-1598.	1.2	5
12409	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 155-165.	2.5	18
12410	Early response by <sc>MR</sc> imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the <sc>WSG ADAPT</sc> subtrials. <i>International Journal of Cancer</i> , 2021, 148, 2614-2627.	5.1	5
12411	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2+ positive breast cancer: An open-label, dose-escalation, phase I study. <i>Cancer Communications</i> , 2021, 41, 171-182.	9.2	15
12412	A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. <i>Cancers</i> , 2021, 13, 792.	3.7	7
12413	A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 39-44.	1.4	2
12414	Images Are Data: A Breast Imaging Perspective on a Contemporary Paradigm. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 898-908.	1.3	7

#	ARTICLE	IF	CITATIONS
12415	Trastuzumab±Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. Journal of Gastrointestinal Cancer, 2022, 53, 282-288.	1.3	2
12416	Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precision Oncology, 2021, 5, 418-431.	3.0	9
12417	Dissociated response and clinical benefit in patients treated with nivolumab monotherapy. Investigational New Drugs, 2021, 39, 1170-1178.	2.6	11
12418	First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs, 2021, 39, 1047-1056.	2.6	20
12419	The Impact of Early Referrals to Dietitians for Patients With Esophagogastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 235-238.	4.9	2
12420	Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatric Blood and Cancer, 2021, 68, e28964.	1.5	6
12421	Treatment response correlation between primary tumor and axillary lymph nodes after neoadjuvant therapy in breast cancer: a retrospective study based on real-world data. Gland Surgery, 2021, 10, 656-669.	1.1	7
12422	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484.	2.6	20
12423	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. ESMO Open, 2021, 6, 100013.	4.5	2
12424	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
12425	Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma. Journal of Immunotherapy, 2021, 44, 167-174.	2.4	12
12426	Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. Oncotarget, 2021, 12, 268-277.	1.8	6
12427	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
12428	The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 1-10.	1.4	65
12429	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. JAMA Oncology, 2021, 7, 255.	7.1	17
12430	A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. BMC Cancer, 2021, 21, 165.	2.6	2
12431	Molecular Aspects of the Isolated Limb Infusion Procedure. Biomedicines, 2021, 9, 163.	3.2	3
12432	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. Thoracic Cancer, 2021, 12, 1171-1179.	1.9	1

#	ARTICLE	IF	CITATIONS
12433	Considering the potential for gene-based therapy in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 170-184.	3.8	13
12434	The efficacy and safety of endostar combined gemcitabine and cisplatin in the treatment of non-small cell lung cancer: a meta-analysis. <i>Food Science and Technology</i> , 0, 42, .	1.7	0
12435	Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors. , 2021, 9, e001177.		0
12436	A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. <i>International Journal of Cancer</i> , 2021, 148, 3041-3050.	5.1	5
12437	What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 60.	8.6	22
12438	LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. <i>Investigational New Drugs</i> , 2021, 39, 1057-1071.	2.6	26
12439	Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. <i>Cancer</i> , 2021, 127, 1788-1795.	4.1	42
12440	Reliability of NI-RADS criteria in the interpretation of contrast-enhanced magnetic resonance imaging considering the potential role of diffusion-weighted imaging. <i>European Radiology</i> , 2021, 31, 6295-6304.	4.5	5
12441	Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an <i>ETV6-NTRK3</i> gene fusion. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1905-1912.	0.5	9
12442	Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 72.	0.8	1
12443	Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. <i>Endocrine</i> , 2021, 73, 358-366.	2.3	14
12444	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. <i>Targeted Oncology</i> , 2021, 16, 197-205.	3.6	12
12445	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 3360-3369.	7.0	47
12446	HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 638.	3.7	6
12448	Locally advanced pancreatic carcinoma with jaundice: the benefit of a sequential treatment with stenting followed by CT-guided 125I seeds implantation. <i>European Radiology</i> , 2021, 31, 6500-6510.	4.5	9
12449	Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer. <i>Abdominal Radiology</i> , 2021, 46, 2712-2721.	2.1	21
12450	Selection of Treatment Regimens for Recurrent Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 618485.	2.8	22
12451	A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1036-1046.	2.6	11

#	ARTICLE	IF	CITATIONS
12452	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. , 2021, 9, e002100.		29
12453	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 267-276.	10.7	79
12454	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2021, 11, e041345.	1.9	3
12455	Fecal microbiota transplant overcomes resistance to anti-“PD-1 therapy in melanoma patients. <i>Science</i> , 2021, 371, 595-602.	12.6	746
12456	Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 789-797.	2.3	6
12457	Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. <i>European Radiology</i> , 2021, 31, 6116-6124.	4.5	44
12458	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	7.0	23
12459	The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 1261-1272.	1.2	28
12460	Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer. <i>Experimental and Molecular Medicine</i> , 2021, 53, 223-234.	7.7	12
12461	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With <i>Kras</i> Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	1.1	11
12462	The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized controlled study. <i>Medical Oncology</i> , 2021, 38, 23.	2.5	11
12463	Short diameter may be a useful simple indicator of the tumor response in skull base meningiomas after conventionally fractionated stereotactic radiotherapy. <i>European Radiology</i> , 2021, 31, 6367-6373.	4.5	0
12464	Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis. <i>Cancers</i> , 2021, 13, 811.	3.7	4
12465	Semiautomatic Tumor Delineation for Evaluation of ⁶⁴ Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1564-1570.	5.0	20
12466	PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistant prostate cancer patients treated with docetaxel. <i>Andrologia</i> , 2021, 53, e13916.	2.1	2
12467	The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 73.	17.1	15
12468	Psoas muscle depletion during preoperative chemotherapy for advanced gastric cancer has a negative impact on long-term outcomes after gastrectomy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 61-69.	1.1	4
12469	Transsacrococcygeal approach in rectal gastrointestinal stromal tumour resection: 10-year experience at a single centre. <i>Annals of Translational Medicine</i> , 2021, 9, 341-341.	1.7	3

#	ARTICLE	IF	CITATIONS
12470	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open, 2021, 6, 100019.	4.5	12
12471	Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma. Internal Medicine, 2021, 60, 545-552.	0.7	2
12472	Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature. Journal of Medical Case Reports, 2021, 15, 32.	0.8	3
12473	Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer. Acta Radiologica, 2021, , 028418512199429.	1.1	18
12474	<scp>ALK</scp>-rearranged squamous cell carcinoma of the lung. Thoracic Cancer, 2021, 12, 1106-1114.	1.9	12
12475	Nationwide survey of neuroendocrine carcinoma of the esophagus: a multicenter study conducted among institutions accredited by the Japan Esophageal Society. Journal of Gastroenterology, 2021, 56, 350-359.	5.1	6
12476	â€œ3Gâ€•Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Cancer Research, 2021, 81, 2788-2798.	0.9	9
12477	Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. Cancer Research and Treatment, 2021, 53, 1195-1203.	3.0	4
12478	Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 2805-2817.	4.2	13
12479	Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. Cancers, 2021, 13, 586.	3.7	10
12480	Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. , 2021, 9, e001564.		34
12481	Radiation Response of Cervical Cancer Stem Cells Is Associated with Pretreatment Proportion of These Cells and Physical Status of HPV DNA. International Journal of Molecular Sciences, 2021, 22, 1445.	4.1	6
12482	Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. Journal of Endocrinological Investigation, 2021, 44, 2139-2151.	3.3	17
12483	Clinical implications of systemic and local immune responses in human angiosarcoma. Npj Precision Oncology, 2021, 5, 11.	5.4	6
12484	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2021, 152, 27-33.	2.0	35
12485	Revision Surgery for Incidental Gallbladder Cancerâ€”Challenging the Dogma: Ideal Timing and Real-World Applicability. Annals of Surgical Oncology, 2021, 28, 6758-6766.	1.5	14
12486	First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II). BMJ Open, 2021, 11, e044811.	1.9	7
12488	Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Hormone and Metabolic Research, 2021, 53, 149-160.	1.5	7

#	ARTICLE	IF	CITATIONS
12489	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	3.7	15
12490	Predicting treatment response from longitudinal images using multi-task deep learning. <i>Nature Communications</i> , 2021, 12, 1851.	12.8	87
12491	Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data. <i>BMC Cancer</i> , 2021, 21, 325.	2.6	6
12492	Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). <i>BMC Cancer</i> , 2021, 21, 303.	2.6	13
12493	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	3.0	4
12494	Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT. <i>Case Reports in Oncology</i> , 2021, 14, 520-524.	0.7	1
12495	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021, 21, 323.	2.6	22
12496	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. <i>Lung Cancer</i> , 2021, 153, 108-116.	2.0	28
12497	Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer—the Experience of a Tertiary Cancer Center. <i>Frontiers in Pharmacology</i> , 2021, 12, 487316.	3.5	2
12498	Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 1196.	3.7	0
12499	Is major pathologic response sufficient to predict survival in resectable non-small cell lung cancer patients receiving neoadjuvant chemotherapy?. <i>Thoracic Cancer</i> , 2021, 12, 1336-1346.	1.9	3
12500	Inmunoterapia, cáncer y PET. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.0	0
12501	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 337-386.	4.5	297
12502	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	3.7	18
12503	Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. <i>Cancer Research</i> , 2021, 81, 3402-3414.	0.9	21
12504	A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). <i>Frontiers in Pharmacology</i> , 2021, 12, 599598.	3.5	10
12505	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021, 26, e847-e858.	3.7	31
12506	Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements. <i>Diagnostics</i> , 2021, 11, 499.	2.6	6

#	ARTICLE	IF	CITATIONS
12507	Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma. <i>Pathology Research and Practice</i> , 2021, 219, 153364.	2.3	11
12508	Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy. <i>Thoracic Cancer</i> , 2021, 12, 1366-1372.	1.9	19
12509	Understanding Sources of Variation to Improve the Reproducibility of Radiomics. <i>Frontiers in Oncology</i> , 2021, 11, 633176.	2.8	58
12510	Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3027-e3036.	3.6	15
12511	Regional Control and Chemoradiotherapy Dose Response for Clinically Involved Lymph Nodes in Patients with Locally Advanced Endometrial Cancers Who are Not Candidates for Upfront Surgical Staging Extrafascial Hysterectomy. <i>Clinical Oncology</i> , 2021, 33, e110-e117.	1.4	1
12512	Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	48
12513	Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. <i>Nature Communications</i> , 2021, 12, 1613.	12.8	114
12514	Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 562-568.	2.5	4
12515	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	6.4	25
12516	Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. <i>Cancers</i> , 2021, 13, 1586.	3.7	9
12517	To study the role of pre-treatment microRNA (micro ribonucleic acid) expression as a predictor of response to chemoradiation in locally advanced carcinoma cervix. <i>Cancer Reports</i> , 2021, 4, e1348.	1.4	2
12518	Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. <i>British Journal of Cancer</i> , 2021, 124, 1661-1669.	6.4	20
12519	Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 656741.	3.7	39
12520	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 987.	2.4	7
12521	Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. <i>Life</i> , 2021, 11, 198.	2.4	4
12522	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3028-3038.	7.0	4
12523	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. <i>Lung Cancer</i> , 2021, 153, 150-157.	2.0	45
12524	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. <i>Liver Cancer</i> , 2021, 10, 320-329.	7.7	108

#	ARTICLE	IF	CITATIONS
12525	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. <i>Cancers</i> , 2021, 13, 1019.	3.7	12
12526	Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. <i>Investigational New Drugs</i> , 2021, 39, 1275-1283.	2.6	9
12527	A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 836-841.	1.3	2
12528	The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine. <i>Translational Cancer Research</i> , 2021, 10, 1193-1203.	1.0	1
12529	Calcium Electroporation for Keloids: A First-in-Man Phase I Study. <i>Dermatology</i> , 2021, 237, 961-969.	2.1	8
12531	Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 654020.	2.8	6
12532	Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 145, 245-254.	2.8	52
12533	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. <i>European Journal of Cancer</i> , 2021, 145, 158-167.	2.8	26
12534	PRISM: recovering cell-type-specific expression profiles from individual composite RNA-seq samples. <i>Bioinformatics</i> , 2021, 37, 2882-2888.	4.1	17
12535	Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-oesophageal junction from a tertiary cancer care center in India. <i>Journal of Surgical Oncology</i> , 2021, 123, 1547-1557.	1.7	3
12536	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 649496.	3.5	27
12537	Outcome of testicular non-seminomatous germ cell tumours: report from a tertiary cancer centre in eastern India. <i>Ecancermedicalscience</i> , 2021, 15, 1204.	1.1	1
12538	Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 622142.	2.8	5
12539	A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. <i>Supportive Care in Cancer</i> , 2021, 29, 5237-5244.	2.2	0
12540	Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1255.	3.7	3
12541	Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 596-604.	5.0	79
12542	MRI Posttreatment Surveillance for Head and Neck Squamous Cell Carcinoma: Proposed MR NI-RADS Criteria. <i>American Journal of Neuroradiology</i> , 2021, 42, 1123-1129.	2.4	11
12543	Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2139-2148.	2.0	7

#	ARTICLE	IF	CITATIONS
12544	Radial Scars and Complex Sclerosing Lesions of the Breast: Prevalence of Malignancy and Natural History Under Active Surveillance. <i>Annals of Surgical Oncology</i> , 2021, 28, 5149-5155.	1.5	13
12545	Early response assessment after CyberKnife stereotactic radiosurgery for symptomatic vertebral hemangioma by quantitative parameters from dynamic contrast-enhanced MRI. <i>European Spine Journal</i> , 2021, 30, 2867-2873.	2.2	2
12546	Treatment outcomes and prognostic factor analyses in pulmonary or hepatic metastatic patients treated with stereotactic body radiation therapy—a single institution experience. <i>Therapeutic Radiology and Oncology</i> , 0, 5, 2-2.	0.2	0
12547	What Effect Do Pulmonary Micronodules Detected at Presentation in Patients with Osteosarcoma Have on 5-Year Overall Survival?. <i>Journal of Clinical Medicine</i> , 2021, 10, 1213.	2.4	7
12548	Prognostic factors of survival in stageÂIV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation. <i>Molecular and Clinical Oncology</i> , 2021, 14, 93.	1.0	4
12549	MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis. <i>Frontiers in Oncology</i> , 2021, 11, 615986.	2.8	2
12550	RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?. <i>Insights Into Imaging</i> , 2021, 12, 36.	3.4	9
12551	Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1054-1064.	27.0	2
12552	Standard-Dose Osimertinib in EGFR-Mutated Nonâ€Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. <i>JCO Precision Oncology</i> , 2021, 5, 561-568.	3.0	1
12553	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. <i>Cancers</i> , 2021, 13, 1370.	3.7	9
12554	Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy. <i>Diagnostics</i> , 2021, 11, 428.	2.6	10
12555	Shear-wave velocity for colorectal cancer liver metastases as a potential prognostic factor after chemotherapy: a preliminary study. <i>Clinical Radiology</i> , 2021, 76, 224-232.	1.1	1
12556	Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations. <i>Radiation Oncology</i> , 2021, 16, 47.	2.7	11
12557	Feasibility of quantitative and volumetric enhancement measurement to assess tumor response in patients with breast cancer after early neoadjuvant chemotherapy. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199101.	1.0	3
12558	The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2020, 11, 630825.	3.5	20
12559	Baseline and Kinetic Circulating Tumor Cell Counts Are Prognostic Factors in a Prospective Study of Metastatic Colorectal Cancer. <i>Diagnostics</i> , 2021, 11, 502.	2.6	6
12560	Chances, challenges and outcomes of patients with complex bilobar colorectal liver metastases approached by a combined multimodal therapy with liver resection and local ablative therapy. <i>Journal of Surgical Oncology</i> , 2021, 123, 1578-1591.	1.7	2
12561	Assessing Response to ¹⁷⁷ Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1741-1746.	5.0	21

#	ARTICLE	IF	CITATIONS
12562	Assessing Toxicity in Drug Trials in Liver Disease. <i>Seminars in Liver Disease</i> , 2021, 41, 277-284.	3.6	2
12563	Thoroscopic Ablation of Critically Located Liver Tumors: A Safety and Efficacy Cohort Study. <i>Frontiers in Surgery</i> , 2021, 8, 626297.	1.4	5
12564	A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 817-828.	3.5	10
12565	BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients. <i>Melanoma Research</i> , 2021, 31, 218-223.	1.2	4
12566	The Prognostic Significance of Anisomycin-Activated Phospho-c-Jun NH2-Terminal Kinase (p-JNK) in Predicting Breast Cancer Patients' Survival Time. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 656693.	3.7	3
12567	The Accuracy of Individualized 3D-Printing Template-Assisted I125 Radioactive Seed Implantation for Recurrent/Metastatic Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 664996.	2.8	8
12568	Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clínico fase II. <i>Revista Colombiana De Cancerología</i> , 2021, 25, .	0.2	2
12569	Human CD141 ⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. , 2021, 9, e001963.		25
12570	Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 35.	3.0	25
12571	PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 410-410.	1.7	37
12572	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 Cancers, 2021, 13, 1223.	3.7	15
12573	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	7.0	25
12574	Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT. <i>Cancers</i> , 2021, 13, 1098.	3.7	7
12576	KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 632962.	2.8	9
12577	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	6.8	43
12578	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	2.0	6
12579	Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1041-1055.	1.8	10
12580	Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1305.	2.4	28

#	ARTICLE	IF	CITATIONS
12581	Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. <i>Nature Nanotechnology</i> , 2021, 16, 734-742.	31.5	51
12582	Diagnostic accuracy of Liver Imaging Reporting and Data System locoregional treatment response criteria: a systematic review and meta-analysis. <i>European Radiology</i> , 2021, 31, 7725-7733.	4.5	10
12583	Cumulative effective dose from recurrent CT examinations in Europe: proposal for clinical guidance based on an ESR EuroSafe Imaging survey. <i>European Radiology</i> , 2021, 31, 5514-5523.	4.5	30
12584	A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. <i>Mammalian Genome</i> , 2021, 32, 223-231.	2.2	17
12585	Rational nanocarrier design towards clinical translation of cancer nanotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 032005.	3.3	14
12586	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	1.6	329
12587	Metastatic Acinar Cell Carcinoma of the Pancreas. <i>Pancreas</i> , 2021, 50, 300-305.	1.1	8
12588	Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-choleangiocarcinoma. <i>Liver International</i> , 2021, 41, 1398-1408.	3.9	22
12590	Site-specific Response to Nivolumab in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 1539-1545.	1.1	14
12591	Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies. <i>Anticancer Research</i> , 2021, 41, 1587-1592.	1.1	2
12592	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1251.	2.4	21
12593	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. <i>Investigational New Drugs</i> , 2021, 39, 1324-1334.	2.6	2
12594	Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 646328.	2.8	1
12595	Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial. <i>Trials</i> , 2021, 22, 214.	1.6	1
12596	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. <i>Cancers</i> , 2021, 13, 1562.	3.7	10
12597	Carcinoma intraductal de pr ³ stata concomitante y respuesta al tratamiento hormonal en el carcinoma de pr ³ stata metastásico. <i>Actas Urológicas Españolas</i> , 2021, 45, 455-460.	0.7	4
12598	Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors. <i>MedComm</i> , 2021, 2, 60-68.	7.2	16
12599	Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography. <i>Journal of Clinical Medicine</i> , 2021, 10, 1151.	2.4	8

#	ARTICLE	IF	CITATIONS
12600	Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 592215.	2.8	5
12601	Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 82-90.	0.2	0
12602	The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy. <i>Bladder Cancer</i> , 2021, 7, 13-21.	0.4	2
12603	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	2.8	16
12604	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021, 11, 607531.	2.8	18
12605	Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond. <i>International Journal of Urology</i> , 2021, 28, 502-513.	1.0	7
12606	The relationship between NFKB, HER2, ER expression and anthracycline -based neoadjuvant chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia. <i>Annals of Medicine and Surgery</i> , 2021, 63, 102164.	1.1	11
12607	Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1361.	2.4	16
12608	Radiomics for the Prediction of Treatment Outcome and Survival in Patients With Colorectal Cancer: A Systematic Review. <i>Clinical Colorectal Cancer</i> , 2021, 20, 52-71.	2.3	66
12609	A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1387-1397.	1.9	6
12610	Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. <i>Endocrine</i> , 2021, 72, 798-808.	2.3	7
12611	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. <i>Clinical Cancer Research</i> , 2021, 27, 3061-3068.	7.0	66
12612	Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis. <i>Journal of Immunotherapy</i> , 2021, 44, 224-233.	2.4	3
12613	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. <i>Nutrients</i> , 2021, 13, 960.	4.1	16
12614	Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 107-115.	2.5	13
12615	Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer – PanHER. <i>Cancers</i> , 2021, 13, 1225.	3.7	8
12616	Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 1760-1768.	1.4	36
12617	Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1057-1064.	2.2	2

#	ARTICLE	IF	CITATIONS
12618	Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer. <i>Journal of Leukocyte Biology</i> , 2021, 110, 327-334.	3.3	10
12619	[18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3386-3399.	6.4	13
12620	Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1021-1032.	1.7	5
12621	Structural and functional radiomics for lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3961-3974.	6.4	48
12622	CT-guided iodine-125 brachytherapy as salvage therapy for recurrent mediastinal lymph node metastasis. <i>Thoracic Cancer</i> , 2021, 12, 1517-1524.	1.9	2
12623	Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 325-340.	0.6	3
12624	Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model. <i>Journal of Clinical Imaging Science</i> , 2021, 11, 15.	1.1	1
12625	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021, 11, 610952.	2.8	10
12626	Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2021, 9, 235.	4.4	3
12627	A phase II study of first-line afatinib for patients aged ≥ 75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i> , 2021, 21, 208.	2.6	13
12628	Development and validation of an in-silico tool for the study of therapeutic agents in 3D cell cultures. <i>Computers in Biology and Medicine</i> , 2021, 130, 104211.	7.0	7
12629	Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. <i>Lung Cancer</i> , 2021, 153, 25-34.	2.0	17
12630	Assessment of Tumor Response in Mice with Ovarian Peritoneal Carcinomatosis using Doppler Ultrasound of the Superior Mesenteric Artery and Celiac Trunk. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 759-768.	1.5	1
12631	Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. <i>Gut and Liver</i> , 2021, 15, 315-323.	2.9	8
12632	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	2.6	17
12633	Immunotherapy, cancer and PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.2	1
12634	A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2021, 146, 87-94.	2.8	12
12635	Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. <i>Pharmaceutical Statistics</i> , 2021, 20, 990-1001.	1.3	2

#	ARTICLE	IF	CITATIONS
12636	A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report. Cancer Management and Research, 2021, Volume 13, 2849-2867.	1.9	10
12637	Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer, 2021, 21, 291.	2.6	12
12638	Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers. Scientific Reports, 2021, 11, 6255.	3.3	2
12639	Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?. Radiation Oncology, 2021, 16, 62.	2.7	13
12640	Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting. Current Oncology, 2021, 28, 1143-1152.	2.2	2
12641	Extramedullary type of solitary nasopharyngeal plasmacytoma: case report and short review of the literature. Otorhinolaryngology(Italy), 2021, 71, .	0.1	0
12642	Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. BMC Cancer, 2021, 21, 294.	2.6	2
12643	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Medicine, 2021, 10, 2645-2659.	2.8	23
12644	Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. Frontiers in Oncology, 2021, 11, 609054.	2.8	23
12645	Discrepancies in metabolomic biomarker identification from patient-derived lung cancer revealed by combined variation in data pre-treatment and imputation methods. Metabolomics, 2021, 17, 37.	3.0	3
12646	Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. , 2021, 9, e002262.		5
12647	Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancerâ€”a two center experience. Strahlentherapie Und Onkologie, 2021, 197, 405-415.	2.0	2
12648	Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha-fetoprotein score: a new prognostic risk factor. Transplant International, 2021, 34, 954-963.	1.6	8
12649	Radiomics in immuno-oncology. Immuno-Oncology Technology, 2021, 9, 100028.	0.3	2
12651	Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Medicine, 2021, 10, 2341-2349.	2.8	15
12652	Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Anticancer Research, 2021, 41, 1683-1691.	1.1	7
12653	NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis. Anticancer Research, 2021, 41, 1563-1570.	1.1	5
12654	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). Journal of Clinical Oncology, 2021, 39, 990-1000.	1.6	30

#	ARTICLE	IF	CITATIONS
12655	Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. <i>International Journal of Cancer</i> , 2021, 149, 473-482.	5.1	35
12656	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. <i>Radiotherapy and Oncology</i> , 2021, 156, 120-126.	0.6	19
12657	PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2301-2309.	2.0	6
12658	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2021, 56, 456-469.	5.1	11
12659	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
12660	Monitoring tumor cell death in murine tumor models using deuterium magnetic resonance spectroscopy and spectroscopic imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	33
12661	First-in-Humans Study of the SSTR Antagonist ¹⁷⁷ Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1571-1581.	5.0	44
12662	Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2991-3000.	4.2	18
12663	Photodynamic Therapy as an Alternative Therapeutic Tool in Functionally Inoperable Oral and Oropharyngeal Carcinoma: A Single Tertiary Center Retrospective Cohort Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 626394.	2.8	14
12664	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	2.8	120
12665	The Prognostic Significance of c-Met and p53 Immunohistochemical Expression in Gastric and Colorectal Carcinomas. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 134-142.	0.2	0
12666	Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance. <i>Translational Lung Cancer Research</i> , 2021, 10, 1277-1291.	2.8	15
12667	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 379-387.	2.5	3
12668	Retrospective research of neoadjuvant therapy on tumor-downstaging, post-operative complications, and prognosis in locally advanced rectal cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 267-278.	1.5	0
12669	Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 642511.	3.5	11
12670	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	3.7	12
12671	Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2021, 4, e212274.	5.9	13
12672	Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC. <i>Advances in Therapy</i> , 2021, 38, 1843-1859.	2.9	24

#	ARTICLE	IF	CITATIONS
12673	Outcomes of Patients With Spinal Metastases From Prostate Cancer Treated With Conventionally-Fractionated External Beam Radiation Therapy. <i>Global Spine Journal</i> , 2021, , 219256822199479.	2.3	1
12675	Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?. <i>Clinical and Translational Oncology</i> , 2021, 23, 1717-1726.	2.4	15
12676	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 5303.	3.3	20
12677	Implementing Historical Controls in Oncology Trials. <i>Oncologist</i> , 2021, 26, e859-e862.	3.7	12
12678	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657615.	2.8	29
12679	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	2.8	15
12680	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2021, 13, 1489.	3.7	7
12681	Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma. <i>Anticancer Research</i> , 2021, 41, 1647-1654.	1.1	9
12682	Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 232-238.	1.3	4
12683	Comparison of local therapy in patients with lung oligo-recurrence of non-small-cell lung cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1828-1835.	1.7	4
12684	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
12685	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191.	3.7	9
12686	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	5.4	12
12687	Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. <i>Anti-Cancer Drugs</i> , 2021, 32, 567-574.	1.4	3
12688	The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 109-113.	1.7	7
12689	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48
12690	Upfront pembrolizumab as an effective treatment start in patients with PD-L1<math>\geq 50\% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1818-1826.	2.4	11
12691	Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. <i>Cancers</i> , 2021, 13, 1057.	3.7	8

#	ARTICLE	IF	CITATIONS
12692	Children's Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) System for Pediatric Patients with Hepatoblastoma: A Retrospective, Hospital-Based Cohort Study in South Korea. Cancer Research and Treatment, 2021, , .	3.0	1
12693	Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma. Molecular and Clinical Oncology, 2021, 14, 91.	1.0	4
12694	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	7.0	45
12695	Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC: A Retrospective Study. Annals of Thoracic Surgery, 2022, 113, 993-999.	1.3	20
12696	Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network. ESMO Open, 2021, 6, 100083.	4.5	11
12697	Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and 18F-FDG-PET/CT. Contrast Media and Molecular Imaging, 2021, 2021, 1-11.	0.8	3
12698	Radiotherapy with Intensity-Modulated (IMRT) Techniques in the Treatment of Anal Carcinoma (RAINSTORM): A Multicenter Study on Behalf of AIRO (Italian Association of Radiotherapy and Clinical) Tj ETQq0 0 0.7 BT / Overlock 10 T	0.7	0
12699	Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 350-361.	2.5	3
12700	Modeling Dendritic Cell Pulsed Immunotherapy for Mice with Melanoma-Protocols for Success and Recurrence. Applied Sciences (Switzerland), 2021, 11, 3199.	2.5	0
12701	Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri. Cancers, 2021, 13, 1689.	3.7	7
12702	Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. OncoTargets and Therapy, 2021, Volume 14, 2815-2819.	2.0	2
12703	Efficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma. Advances in Urology, 2021, 2021, 1-7.	1.3	2
12704	Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy. Gut and Liver, 2022, 16, 129-137.	2.9	2
12706	Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma. Cancers, 2021, 13, 1875.	3.7	16
12707	Tamoxifen and aromatase inhibitors for relapse of tubo-ovarian high-grade serous cancer. The Cochrane Library, 0, , .	2.8	0
12709	Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients. Annals of Surgical Oncology, 2021, 28, 7983-7989.	1.5	7
12710	Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. Frontiers in Oncology, 2021, 11, 652560.	2.8	8
12711	The value of dynamic contrast enhanced ultrasound (DCE-US) in monitoring treatment effect of high-intensity focused ultrasound (HIFU) in locally advanced pancreatic cancer (LAPC). Clinical Hemorheology and Microcirculation, 2021, 77, 323-333.	1.7	6

#	ARTICLE	IF	CITATIONS
12712	Modified Glasgow Prognostic Score as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated With Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e78-e83.	1.9	8
12713	Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer. <i>Oncologist</i> , 2021, 26, e1018-e1035.	3.7	21
12714	Comparison of Measurement Techniques and Response Criteria for MR Imaging Follow-up in Adult Primary Central Nervous System Lymphoma. <i>American Journal of Neuroradiology</i> , 2021, 42, 1415-1420.	2.4	4
12715	[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2355-2366.	3.6	10
12716	Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). <i>BioDrugs</i> , 2021, 35, 429-444.	4.6	15
12717	Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. <i>European Journal of Dermatology</i> , 2021, 31, 205-212.	0.6	3
12718	A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. <i>ESMO Open</i> , 2021, 6, 100082.	4.5	2
12719	Personalising sarcoma care using quantitative multimodality imaging for response assessment. <i>Clinical Radiology</i> , 2021, 76, 313.e1-313.e13.	1.1	7
12720	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3556-3566.	7.0	21
12721	A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1284-1297.	2.6	28
12722	Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancers</i> , 2021, 13, 1806.	3.7	7
12723	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	7.3	54
12724	Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics. <i>Indian Journal of Radiology and Imaging</i> , 2021, 31, 345-349.	0.8	2
12725	Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy. <i>Anticancer Research</i> , 2021, 41, 2053-2058.	1.1	4
12726	Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib. <i>Anticancer Research</i> , 2021, 41, 2025-2032.	1.1	6
12727	Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 2157-2163.	1.1	4
12728	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. <i>Breast Cancer</i> , 2021, 28, 1038-1050.	2.9	10
12729	Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. <i>ESMO Open</i> , 2021, 6, 100064.	4.5	21

#	ARTICLE	IF	CITATIONS
12730	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	10.7	260
12731	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	27.0	601
12733	Colorectal liver metastases: ADC as an imaging biomarker of tumor behavior and therapeutic response. <i>European Journal of Radiology</i> , 2021, 137, 109609.	2.6	18
12734	Neoadjuvant Cyto-reductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	4.2	28
12735	Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors. <i>Circulation Reports</i> , 2021, 3, 234-240.	1.0	5
12736	Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma. <i>Oncologist</i> , 2021, 26, 364.	3.7	6
12737	Impact of COVID-19 On Breast Cancer Management: A Radiological Perspective from A Tertiary Centre. <i>The Journal of Breast Health</i> , 2021, 17, 180-187.	1.0	2
12738	Radiological and Clinical Efficacy of Intra-Arterial 90Y-DOTATATE in Patients with Unresectable, Progressive, Liver Dominant Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 1794.	2.4	4
12739	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. <i>Cancer Management and Research</i> , 2021, Volume 13, 3303-3316.	1.9	5
12740	Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. <i>Endocrine Connections</i> , 2021, 10, 422-431.	1.9	5
12741	Prediction of Microscopic Metastases in Patients with Metachronous Oligo-Metastases after Curative Treatment of Non-Small Cell Lung Cancer: A Microsimulation Study. <i>Cancers</i> , 2021, 13, 1884.	3.7	0
12742	Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 464-473.	1.4	16
12743	PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 9013.	3.3	6
12744	A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients. <i>Annals of Translational Medicine</i> , 2021, 9, 703-703.	1.7	7
12745	Association of albuminâ€“bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1257-1263.	2.2	13
12746	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , 2021, 14, 954-963.	3.1	5
12747	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multiâ€“arm phase Ib study. <i>Investigational New Drugs</i> , 2021, 39, 1357-1365.	2.6	5
12748	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	7.0	53

#	ARTICLE	IF	CITATIONS
12749	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open, 2021, 6, 100079.	4.5	7
12750	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3834-3844.	7.0	36
12751	A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2021, 157, 203-209.	0.6	12
12752	Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Annals of Surgery Open, 2021, 2, e057.	1.4	18
12753	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. Annals of Oncology, 2021, 32, 542-551.	1.2	13
12754	Safety and efficacy of sorafenib in patients with advanced thyroid carcinoma: a phase II study (NCT02084732). Archives of Endocrinology and Metabolism, 2021, , .	0.6	1
12755	Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 1893.	3.7	10
12756	First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. International Journal of Clinical Oncology, 2021, 26, 1073-1082.	2.2	9
12757	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 531-540.	2.6	15
12758	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nature Cancer, 2021, 2, 498-502.	13.2	26
12759	Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13, 371-385.	2.0	16
12760	Theranostics in Boron Neutron Capture Therapy. Life, 2021, 11, 330.	2.4	32
12761	Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3606-3617.	6.4	50
12762	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3620-3629.	7.0	151
12763	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Journal of Clinical Oncology, 2021, 39, 1349-1359.	1.6	147
12764	Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4016-4027.	6.4	14
12765	Contribution of XPD and XPF Polymorphisms to Susceptibility of Non-Small Cell Lung Cancer in High-Altitude Areas. Public Health Genomics, 2021, 24, 189-198.	1.0	2
12766	The need for immunotherapy when neoadjuvant chemoradiotherapy achieves pathologic complete response in stage IIIB non-small cell lung cancer: a case report. Annals of Palliative Medicine, 2021, 10, 4965-4969.	1.2	0

#	ARTICLE	IF	CITATIONS
12767	Hedgehog inhibitor in the treatment of basal cell skin cancer: case report. <i>Opuholi Golovy I Sei</i> , 2021, 11, 109-114.	0.4	1
12768	Efficacy of modified bevacizumab-XELOX therapy in Japanese patients with stage IV recurrent or non-resectable colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 527-534.	1.4	3
12769	Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 595-601.	1.1	7
12770	MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 625593.	3.5	7
12771	Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. <i>Cancers</i> , 2021, 13, 1857.	3.7	5
12772	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 656611.	2.8	4
12773	Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 824-828.	2.5	6
12774	Prognostic Impact of AHNK2 Expression in Patients Treated with Radical Cystectomy. <i>Cancers</i> , 2021, 13, 1748.	3.7	6
12775	Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid-Polymer Hybrid Nanoparticles. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2615-2631.	6.7	15
12776	Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Current Oncology</i> , 2021, 28, 1402-1411.	2.2	11
12777	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105173.	1.5	15
12778	Modified TPEX as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 2045-2051.	1.1	3
12779	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	4.5	35
12780	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 540-546.	1.9	10
12781	Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 858-865.	0.8	6
12782	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 255-262.	0.6	4
12783	Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 637804.	2.8	10
12784	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639.	2.8	18

#	ARTICLE	IF	CITATIONS
12785	Imaging response evaluation after neoadjuvant treatment in soft tissue sarcomas: Where do we stand?. Critical Reviews in Oncology/Hematology, 2021, 160, 103309.	4.4	14
12786	Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trialâ€”PEARL. Annals of Oncology, 2021, 32, 488-499.	1.2	69
12787	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell, 2021, 39, 566-579.e7.	16.8	107
12788	Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 635-635.	1.7	7
12789	Inflammatory factorâ€”based prognostic risk stratification for patients with metastatic castrationâ€”resistant prostate cancer treated with docetaxel. Andrologia, 2021, 53, e14064.	2.1	0
12790	Are recist criteria adequate in assessing the response to therapy in metastatic NEN?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 637-645.	5.7	3
12791	A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatric Blood and Cancer, 2021, 68, e29065.	1.5	16
12792	Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method. Journal of Gastrointestinal Oncology, 2021, 12, 237-248.	1.4	9
12793	Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. Journal of Clinical Medicine, 2021, 10, 1504.	2.4	3
12794	Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncology Letters, 2021, 21, 448.	1.8	5
12795	Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunology, Immunotherapy, 2021, 70, 3513-3524.	4.2	26
12796	Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection. American Surgeon, 2022, 88, 2899-2906.	0.8	1
12797	Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center. Medical Science Monitor, 2021, 27, e930738.	1.1	5
12798	Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Medicine, 2021, 10, 3059-3067.	2.8	19
12799	Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma. Frontiers in Oncology, 2021, 11, 626566.	2.8	14
12800	Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 621422.	2.8	8
12801	Genomic landscape of extraordinary responses in metastatic breast cancer. Communications Biology, 2021, 4, 449.	4.4	3
12802	Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. Cancers, 2021, 13, 2148.	3.7	8

#	ARTICLE	IF	CITATIONS
12803	Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000–2019): A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 624534.	3.5	24
12804	Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy. <i>Surgery Today</i> , 2021, 51, 1496-1505.	1.5	3
12805	The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 257.	2.5	4
12806	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. <i>Lung Cancer</i> , 2021, 154, 92-98.	2.0	3
12808	Omental hemangiosarcoma in five dogs. <i>Veterinary Record Case Reports</i> , 2021, 9, e60.	0.2	1
12809	lncRNA <i>HAR1B</i> has potential to be a predictive marker for pazopanib therapy in patients with sarcoma. <i>Oncology Letters</i> , 2021, 21, 455.	1.8	7
12810	A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers. <i>Medicine (United States)</i> , 2021, 100, e25494.	1.0	1
12811	Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer. <i>Clinical Therapeutics</i> , 2021, 43, 747-759.	2.5	6
12813	Role of induction chemotherapy for oral cavity squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 3107-3112.	4.1	9
12814	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619.	7.0	17
12815	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. <i>Cancers</i> , 2021, 13, 1740.	3.7	17
12816	Real-life Effectiveness of Afatinib <i>Versus</i> Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. <i>Anticancer Research</i> , 2021, 41, 2059-2065.	1.1	1
12817	Complete fully automatic segmentation and 3-dimensional measurement of mediastinal lymph nodes for a new response evaluation criteria for solid tumors. <i>Biocybernetics and Biomedical Engineering</i> , 2021, 41, 617-635.	5.9	2
12818	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	2.8	35
12819	Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 645170.	4.8	22
12820	Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. <i>Medicine (United States)</i> , 2021, 100, e25402.	1.0	2
12821	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
12822	First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. <i>EClinicalMedicine</i> , 2021, 34, 100797.	7.1	115

#	ARTICLE	IF	CITATIONS
12823	Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. <i>Cells</i> , 2021, 10, 977.	4.1	25
12824	Depletion of hsa_circ_0000144 Suppresses Oxaliplatin Resistance of Gastric Cancer Cells by Regulating miR-502-5p/ADAM9 Axis. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2773-2787.	2.0	13
12825	Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1055-1063.	1.7	5
12826	177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3582-3594.	6.4	7
12827	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
12828	Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. <i>Current Oncology</i> , 2021, 28, 1652-1662.	2.2	4
12829	Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1642-1652.	2.8	11
12830	Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy. <i>European Radiology</i> , 2021, 31, 8765-8774.	4.5	36
12831	Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study. <i>Annals of Translational Medicine</i> , 2021, 9, 685-685.	1.7	10
12832	Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction. <i>Frontiers in Oncology</i> , 2021, 11, 591106.	2.8	11
12833	Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. <i>Journal of Clinical Medicine</i> , 2021, 10, 1846.	2.4	4
12834	APOBEC3B deletion polymorphism and lung cancer risk in the southern Chinese population. <i>Annals of Translational Medicine</i> , 2021, 9, 656-656.	1.7	6
12835	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 662205.	2.8	7
12836	Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. <i>Journal of Clinical Medicine</i> , 2021, 10, 1777.	2.4	8
12837	Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms. <i>Pancreas</i> , 2021, 50, 500-505.	1.1	9
12838	A Multicenter, 10-Year Experience With Hepatocellular Adenoma: Risk Factors and Disease Course. <i>American Surgeon</i> , 2022, 88, 2345-2350.	0.8	2
12839	Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. <i>Thoracic Cancer</i> , 2021, 12, 1598-1604.	1.9	2
12840	A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). <i>Cancers</i> , 2021, 13, 2010.	3.7	7

#	ARTICLE	IF	CITATIONS
12841	Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. <i>Gland Surgery</i> , 2021, 10, 1300-1314.	1.1	4
12843	T2-weighted, apparent diffusion coefficient and 18F-FDG PET histogram analysis of rectal cancer after preoperative chemoradiotherapy. <i>Techniques in Coloproctology</i> , 2021, 25, 569-577.	1.8	2
12844	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). <i>Breast Cancer</i> , 2021, 28, 1023-1037.	2.9	5
12845	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2021, 141, 761-769.e2.	0.7	7
12846	FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST. <i>Diagnostics</i> , 2021, 11, 723.	2.6	10
12847	Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice. <i>Gynecologic Oncology</i> , 2021, 161, 202-210.	1.4	8
12848	Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. <i>Cancers</i> , 2021, 13, 1683.	3.7	11
12849	Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 313.	1.6	11
12850	A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. <i>Biomarker Research</i> , 2021, 9, 24.	6.8	14
12851	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. <i>Current Opinion in Oncology</i> , 2021, 33, 386-394.	2.4	13
12852	Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1049-1056.	2.2	4
12853	Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. <i>British Journal of Cancer</i> , 2021, 125, 155-163.	6.4	27
12854	Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3723-3731.	6.4	10
12855	Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 659135.	2.8	16
12856	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	4.1	41
12857	A multi-institutional analysis of fractionated versus single-fraction stereotactic body radiotherapy (SBRT) in the treatment of primary lung tumors: a comparison between two antipodal fractionations. <i>Clinical and Translational Oncology</i> , 2021, 23, 2133-2140.	2.4	2
12858	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. <i>Cancers</i> , 2021, 13, 2170.	3.7	15
12859	Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2041.	3.7	9

#	ARTICLE	IF	CITATIONS
12860	Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma. <i>Cancers</i> , 2021, 13, 1983.	3.7	5
12861	The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study. <i>Cancers</i> , 2021, 13, 2002.	3.7	8
12862	Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7663-7672.	1.5	48
12864	Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers. <i>Frontiers in Pharmacology</i> , 2021, 12, 631135.	3.5	2
12865	Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	1.3	0
12866	A review of response in neoadjuvant therapy for exocrine pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1449-1459.	1.7	0
12867	The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy. <i>Oncology Letters</i> , 2021, 21, 489.	1.8	5
12868	Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes. <i>Frontiers in Immunology</i> , 2021, 12, 623762.	4.8	15
12869	Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. <i>BMC Cancer</i> , 2021, 21, 354.	2.6	1
12870	Neoadjuvant chemoradiotherapy followed by laparoscopic distal gastrectomy in advanced gastric cancer: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 2542-2554.	0.8	0
12871	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). <i>Melanoma Research</i> , 2021, 31, 162-172.	1.2	6
12872	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degradar, in ER-Positive, HER2-Negative Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1360-1370.	1.6	69
12873	Injectables in Head and Neck Cutaneous Melanoma Treatment. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 425-438.	1.1	1
12874	Definitive chemoradiotherapy for clinical T4b esophageal cancer — Treatment outcomes, failure patterns, and prognostic factors. <i>Radiotherapy and Oncology</i> , 2021, 157, 56-62.	0.6	12
12875	Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. , 2021, 9, e002193.		27
12876	Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 646883.	2.8	7
12877	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride. <i>Scientific Reports</i> , 2021, 11, 7389.	3.3	7
12878	Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 295-304.	2.0	1

#	ARTICLE	IF	CITATIONS
12879	Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). <i>Diagnostics</i> , 2021, 11, 742.	2.6	11
12880	Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. <i>Frontiers in Endocrinology</i> , 2021, 12, 667784.	3.5	13
12881	FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4680-4684.	7.0	84
12882	Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 1871-1882.	1.1	3
12883	Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI. <i>Journal of Personalized Medicine</i> , 2021, 11, 256.	2.5	18
12884	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 601-609.	1.1	40
12885	Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e25992.	1.0	5
12886	Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e25690.	1.0	8
12887	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. <i>BMC Cancer</i> , 2021, 21, 514.	2.6	10
12888	Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma. <i>Archivos De Bronconeumologia</i> , 2021, 57, 323-329.	0.8	2
12889	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 154.	8.6	19
12890	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3037-3049.	2.0	2
12891	Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2193-2204.	2.8	16
12892	Comparison of surgical and oncologic outcomes in patients with clear cell ovarian carcinoma associated with and without endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1569-1576.	1.7	1
12893	Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers. <i>Cancer Reports</i> , 2021, 4, e1412.	1.4	4
12894	Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 787.	1.8	1
12895	Transformational Role of Medical Imaging in (Radiation) Oncology. <i>Cancers</i> , 2021, 13, 2557.	3.7	4
12896	Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. <i>Hepatology Research</i> , 2021, 51, 813-822.	3.4	13

#	ARTICLE	IF	CITATIONS
12897	Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 511-521.	2.5	8
12899	The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development. Pharmaceutics, 2021, 13, 704.	4.5	11
12900	An excellent nomogram predicts microvascular invasion that cannot independently stratify outcomes of small hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 757-757.	1.7	4
12902	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of Oncology, 2021, 32, 600-608.	1.2	69
12903	DNA-based functionalization of two-dimensional MoS ₂ FET biosensor for ultrasensitive detection of PSA. Applied Surface Science, 2021, 548, 149169.	6.1	46
12904	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. The Cochrane Library, 0, , .	2.8	0
12905	Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer, 2021, 127, 2279-2293.	4.1	9
12906	Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US). Journal of Cancer Research and Clinical Oncology, 2022, 148, 955-965.	2.5	2
12907	Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 683289.	2.8	4
12908	Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science, 2021, 112, 2361-2370.	3.9	33
12909	The role of MRI in cervical cancer – (FIGO stage IB2-IIA1) conservatively treated with neoadjuvant chemotherapy followed by conization: a pilot study. Radiologia Medica, 2021, 126, 1055-1063.	7.7	12
12910	Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy. World Journal of Clinical Oncology, 2021, 12, 323-334.	2.3	8
12911	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine & cisplatin in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 510-519.	6.4	59
12912	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Modern Pathology, 2021, 34, 1719-1727.	5.5	48
12913	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 520-527.	6.4	37
12914	Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. BMC Gastroenterology, 2021, 21, 231.	2.0	16
12915	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2021, 22, 690-701.	10.7	396
12916	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 609-619.	10.7	186

#	ARTICLE	IF	CITATIONS
12917	Ultrathin bronchoscope combined with virtual bronchoscopic navigation and endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions with or without fluoroscopy: A randomized trial. <i>Thoracic Cancer</i> , 2021, 12, 1864-1872.	1.9	18
12918	Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. , 2021, 9, e002088.		59
12919	11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after castration. <i>JCI Insight</i> , 2021, 6, .	5.0	5
12920	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. <i>Lung Cancer</i> , 2021, 155, 114-119.	2.0	12
12921	Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial. <i>Oncologist</i> , 2021, 26, e1240-e1249.	3.7	17
12922	Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial. <i>Journal of Veterinary Internal Medicine</i> , 2021, 35, 1487-1495.	1.6	12
12923	Outcome of staging chest CT and identification of factors associated with lung metastasis in children with hepatoblastoma. <i>European Radiology</i> , 2021, 31, 8850-8857.	4.5	4
12924	Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI: A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. <i>Cancers</i> , 2021, 13, 2726.	3.7	9
12925	Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?. <i>Radiotherapy and Oncology</i> , 2021, 158, 118-124.	0.6	13
12926	Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD011220.	2.8	8
12927	R��sultats et perspectives des traitements par Lutathera des tumeurs neuroendocrines �� l'h��pital de Beaujon, centre RENATEN. <i>Medecine Nucleaire</i> , 2021, 45, 119-126.	0.2	0
12928	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 71-78.	1.7	6
12929	Impact of ALK Inhibitors in Patients With <i>ALK</i> -Rearranged Nonlung Solid Tumors. <i>JCO Precision Oncology</i> , 2021, 5, 756-766.	3.0	16
12930	Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2021, 14, 445.	3.8	9
12931	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247.	3.7	8
12932	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. <i>European Journal of Cancer</i> , 2021, 148, 440-450.	2.8	13
12933	Treosulfan in platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002395.	2.5	1
12934	Role of PET/CT in post-therapeutic assessment of bronchogenic carcinoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2021, 52, .	0.6	1

#	ARTICLE	IF	CITATIONS
12935	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	27.8	64
12936	Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 361-371.	3.8	5
12937	Pre-operative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer (PREVADER): Clinical Feasibility Trial. <i>Frontiers in Medicine</i> , 2021, 8, 588375.	2.6	2
12938	Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. <i>Npj Precision Oncology</i> , 2021, 5, 45.	5.4	11
12939	Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer. <i>Abdominal Radiology</i> , 2021, 46, 4401-4409.	2.1	5
12940	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	2.2	5
12941	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
12943	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
12944	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	7.0	54
12945	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1531-1539.	1.6	88
12946	Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative <i>EGFR</i> profiling in vesicular RNA. <i>Molecular Oncology</i> , 2021, 15, 2423-2438.	4.6	10
12947	Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 2536.	12.8	147
12948	Immunotherapy for pancreatic cancer. <i>World Journal of Clinical Cases</i> , 2021, 9, 2969-2982.	0.8	16
12949	Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib. <i>Cancer Reports</i> , 2021, , e1414.	1.4	4
12950	Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Cancers</i> , 2021, 13, 2279.	3.7	10
12951	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021, 155, 127-135.	2.0	6
12952	Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294. <i>Medical Physics</i> , 2021, 48, e697-e732.	3.0	16
12953	Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 217-226.	0.8	7

#	ARTICLE	IF	CITATIONS
12954	Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 90-96.	1.7	14
12955	Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2021, 21, 519.	2.6	7
12956	Drug development in the era of precision medicine in oncology—Clues beyond randomization. <i>Chinese Clinical Oncology</i> , 2021, 10, 23-23.	1.2	2
12957	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 28-37.	6.4	62
12958	Molecular markers of systemic therapy response in urothelial carcinoma. <i>Asian Journal of Urology</i> , 2021, 8, 376-390.	1.2	22
12959	Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). <i>EClinicalMedicine</i> , 2021, 35, 100844.	7.1	31
12960	Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. <i>Oncogene</i> , 2021, 40, 3899-3913.	5.9	13
12961	Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). <i>Current Oncology</i> , 2021, 28, 1761-1772.	2.2	5
12962	A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials. <i>Radiology Imaging Cancer</i> , 2021, 3, e210008.	1.6	7
12963	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	1.7	5
12964	Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e218175.	5.9	13
12965	Distribution of Peripheral Blood Cells in Esophageal Cancer Patients During Concurrent Chemoradiotherapy Predicts Long-Term Locoregional Progression Hazard After Treatment (GASTO1072). <i>Cancer Management and Research</i> , 2021, Volume 13, 4203-4215.	1.9	0
12966	ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies. <i>BMC Cancer</i> , 2021, 21, 584.	2.6	6
12967	Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. <i>Nature Communications</i> , 2021, 12, 2581.	12.8	103
12968	Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study. <i>Cancer</i> , 2021, 127, 3163-3171.	4.1	23
12969	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. <i>Lung Cancer</i> , 2021, 155, 151-155.	2.0	9
12970	BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β -catenin acetylation. <i>Journal of Pathology</i> , 2021, 254, 265-278.	4.5	15
12971	Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. <i>JGH Open</i> , 2021, 5, 679-685.	1.6	11

#	ARTICLE	IF	CITATIONS
12972	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations. <i>Medicina</i> (Lithuania), 2021, 57, 508.	2.0	2
12973	Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. , 2021, 9, e002171.		12
12974	Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 507-522.	0.8	0
12975	Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas. <i>Radiotherapy and Oncology</i> , 2021, 158, 33-39.	0.6	4
12976	Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 22, 554.	1.8	29
12977	Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 619461.	2.8	14
12978	A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. <i>Medicine (United States)</i> , 2021, 100, e26052.	1.0	5
12979	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 407.e1-407.e16.	1.3	11
12980	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (â€œMETRICâ€): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021, 7, 57.	5.2	26
12981	External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancerâ€”Setting a New Threshold Value. <i>Life</i> , 2021, 11, 479.	2.4	5
12982	Firstâ€line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice. <i>International Journal of Urology</i> , 2021, 28, 920-926.	1.0	6
12983	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy â€” A multicentre study of 90 patients from the German Dermat oncology Group. <i>European Journal of Cancer</i> , 2021, 149, 1-10.	2.8	10
12984	Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2707.	3.7	8
12985	Imaging of Malignant Pleural Mesothelioma: Pearls and Pitfalls. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 542-551.	1.5	4
12986	Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study. <i>Onkourologiya</i> , 2021, 17, 31-44.	0.3	1
12987	A firstâ€inâ€class, firstâ€inâ€human, phase I trial of CIGB â€52, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NFâ€B in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 1313-1321.	5.1	0
12988	Analysis of factors affecting progression-free survival of first-line chemotherapy in older patients with advanced gastrointestinal cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1200-1207.	1.0	2
12989	Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	5

#	ARTICLE	IF	CITATIONS
12990	Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). <i>BMC Cancer</i> , 2021, 21, 593.	2.6	34
12991	A Model Combining Skeletal Muscle Mass and a Hematological Biomarker to Predict Survival in Patients With Nasopharyngeal Carcinoma Undergoing Concurrent Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 644676.	2.8	1
12992	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 667658.	2.8	6
12993	Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 1983-1994.	1.9	26
12994	Prognostic Significance of Tumor-Associated Macrophages in Chondroblastoma and Their Association with Response to Adjuvant Radiotherapy. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1991-2005.	3.5	6
12995	Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2103-2117.	2.8	12
12996	Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 705-711.	1.6	2
12997	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of the Italian Peritoneal Surface Malignancies Oncoteam's S.I.C.O.™. <i>Annals of Surgical Oncology</i> , 2021, 28, 9060-9070.	1.5	24
12998	Intracerebral Administration of Autologous Mesenchymal Stem Cells as HSV-TK Gene Vehicle for Treatment of Glioblastoma Multiform: Safety and Feasibility Assessment. <i>Molecular Neurobiology</i> , 2021, 58, 4425-4436.	4.0	11
12999	A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters. <i>Cancers</i> , 2021, 13, 2587.	3.7	16
13000	Initial Data Pooling for Radiation Dose-Volume Tolerance for Carotid Artery Blowout and Other Bleeding Events in Hypofractionated Head and Neck Retreatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 147-159.	0.8	12
13001	Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3584-3594.	7.0	26
13002	Successful eight-year survival of unresectable lung adenocarcinoma with bronchial artery infusion chemotherapy: A case report. <i>Journal of Interventional Medicine</i> , 2021, 4, 101-104.	0.5	0
13003	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
13004	First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. <i>Clinical Cancer Research</i> , 2021, 27, 4168-4176.	7.0	9
13005	Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 833-850.	1.3	32
13006	Lung Nodules in Melanoma Patients: Morphologic Criteria to Differentiate Non-Metastatic and Metastatic Lesions. <i>Diagnostics</i> , 2021, 11, 837.	2.6	2
13007	Breast MRI for Evaluation of Response to Neoadjuvant Therapy. <i>Radiographics</i> , 2021, 41, 665-679.	3.3	33

#	ARTICLE	IF	CITATIONS
13008	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. <i>Frontiers in Immunology</i> , 2021, 12, 663865.	4.8	17
13009	Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials. <i>Translational Lung Cancer Research</i> , 2021, 10, 2278-2289.	2.8	1
13010	Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk-adapted adjuvant therapy: A phase II trial. <i>Cancer Reports</i> , 2022, 5, e1456.	1.4	3
13011	ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , 2021, 17, 1709-1719.	2.4	10
13012	Efficacy and Safety of ¹⁷⁷ Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 218-225.	5.0	22
13013	Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma. <i>Archivos De Bronconeumologia</i> , 2021, 57, 323-329.	0.8	1
13014	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	3.4	15
13015	Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 403-414.	2.3	3
13016	Comparative Study of Two Thoracic Radiotherapy Schedules for Palliation of Symptom, Radiological Response and Acute Toxicities in Advanced Non-small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Care</i> , 2021, 6, 159-165.	0.1	0
13017	Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. <i>International Journal of Urology</i> , 2021, 28, 899-905.	1.0	15
13018	Dose fusion and efficacy evaluation of different radical radiotherapy doses for cervical cancer. <i>Brachytherapy</i> , 2021, 20, 519-526.	0.5	1
13019	Clinical significance of the cachexia index in patients with small cell lung cancer. <i>BMC Cancer</i> , 2021, 21, 563.	2.6	19
13020	Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 550-560.	2.1	4
13021	Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging. <i>Lung Cancer</i> , 2021, 155, 156-162.	2.0	11
13022	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e859-e869.	2.6	23
13023	Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models. <i>Clinical Cancer Research</i> , 2021, 27, 4367-4378.	7.0	11
13024	Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3905-3918.	2.8	11
13025	Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres. <i>Oncology Letters</i> , 2021, 22, 552.	1.8	8

#	ARTICLE	IF	CITATIONS
13026	SDF-1 β predicts poor prognosis in patients with locally advanced esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy. Biomedical Journal, 2021, , .	3.1	1
13027	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	3.7	13
13028	Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. International Journal of Urology, 2021, 28, 765-773.	1.0	10
13029	A Phase I Study of Alpelisib in Combination with Trastuzumab and UJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3867-3875.	7.0	15
13030	Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab. Annals of Nuclear Medicine, 2021, 35, 871-880.	2.2	5
13031	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 493-499.	3.3	13
13032	Interventional Radiology Approaches for Liver Metastases from Thyroid Cancer: A Case Series and Overview of the Literature. Journal of Gastrointestinal Cancer, 2021, 52, 823-832.	1.3	6
13033	On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biology, 2021, 41, 101926.	9.0	20
13034	Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy. Cancers, 2021, 13, 2549.	3.7	3
13035	Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Annals of Oncology, 2021, 32, 631-641.	1.2	150
13036	Staged radiosurgery in the management of patients with brain metastases. Russian Journal of Neurosurgery, 2021, 23, 26-37.	0.2	0
13037	A Cancer-Specific Qualitative Method for Estimating the Proportion of Tumor-Infiltrating Immune Cells. Frontiers in Immunology, 2021, 12, 672031.	4.8	1
13038	Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study. Scientific Reports, 2021, 11, 10112.	3.3	3
13039	Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncology, 2021, 7, 739.	7.1	125
13040	Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer after definitive chemoradiotherapy. Thoracic Cancer, 2021, 12, 2024-2030.	1.9	3
13041	Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan. Cancer Reports, 2021, 4, e1398.	1.4	12
13042	Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older. Cancer Reports, 2021, 4, e1405.	1.4	8
13043	uPAR extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23

#	ARTICLE	IF	CITATIONS
13044	An institutional audit of the use of novel drugs in pediatric oncology. <i>Cancer Reports</i> , 2021, , e1404.	1.4	1
13045	Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial. <i>Hepatology International</i> , 2021, 15, 685-694.	4.2	6
13046	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021, 26, e1226-e1239.	3.7	17
13047	A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study. <i>Diagnostics</i> , 2021, 11, 979.	2.6	5
13048	Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1581-1590.	1.2	4
13049	Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses. <i>Cancers</i> , 2021, 13, 2663.	3.7	7
13050	Favorable Outcomes of Neoadjuvant Chemotherapy and Limited Para-aortic Lymph Node Dissection for Advanced Gastric Cancer with Para-aortic Lymph Node Metastasis. <i>World Journal of Surgery</i> , 2021, 45, 2849-2859.	1.6	1
13051	Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix. <i>Cancers</i> , 2021, 13, 2713.	3.7	9
13052	Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 206-216.	0.8	27
13053	Machine Learning and Radiomics Applications in Esophageal Cancers Using Non-Invasive Imaging Methods—A Critical Review of Literature. <i>Cancers</i> , 2021, 13, 2469.	3.7	16
13054	Association between time to stent dysfunction and the anti-tumour effect of systemic chemotherapy following stent placement in patients with pancreaticobiliary cancers and malignant gastric outlet obstruction: a retrospective cohort study. <i>BMC Cancer</i> , 2021, 21, 576.	2.6	5
13055	Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3665-e3672.	3.6	23
13056	Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience. <i>Annals of Surgical Oncology</i> , 2021, 28, 7383-7394.	1.5	3
13057	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. <i>Frontiers in Oncology</i> , 2021, 11, 635096.	2.8	3
13058	Laterally Extended Endopelvic Resection Versus Chemo or Targeted Therapy Alone for Pelvic Sidewall Recurrence of Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 683441.	2.8	2
13059	Radiosensitization using hydrogen peroxide in patients with cervical cancer. <i>Molecular and Clinical Oncology</i> , 2021, 15, 142.	1.0	2
13060	A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5592.	2.6	19
13061	Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors. <i>Breast Care</i> , 2022, 17, 1-8.	1.4	2

#	ARTICLE	IF	CITATIONS
13062	Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2514.	3.7	19
13063	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. <i>Clinical Lung Cancer</i> , 2021, 22, e870-e877.	2.6	6
13064	A Model-Strengthened Imaging Biomarker for Survival Prediction in EGFR-Mutated Non-small-cell Lung Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. <i>Bulletin of Mathematical Biology</i> , 2021, 83, 68.	1.9	0
13065	Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2021, 13, 2824-2832.	1.4	9
13066	HPV Status and Individual Characteristics of Human Papillomavirus Infection as Predictors for Clinical Outcome of Locally Advanced Cervical Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 479.	2.5	3
13067	Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. <i>Cancer Medicine</i> , 2021, 10, 3886-3895.	2.8	5
13068	CDISC-compliant clinical trial imaging management system with automatic verification and data Transformation: Focusing on tumor response assessment data in clinical trials. <i>Journal of Biomedical Informatics</i> , 2021, 117, 103782.	4.3	1
13069	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases. <i>JAMA Surgery</i> , 2021, 156, 710-720.	4.3	34
13070	Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). <i>JTO Clinical and Research Reports</i> , 2021, 2, 100166.	1.1	1
13071	Metronomic oral cyclophosphamide in relapsed ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1037-1044.	2.5	8
13072	CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1. <i>Radiology Imaging Cancer</i> , 2021, 3, e200090.	1.6	8
13073	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021, 22, 187-194.e1.	2.6	18
13074	Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2~ metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2021, 37, 1179-1187.	1.9	20
13075	Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review. <i>Investigational New Drugs</i> , 2021, 39, 1702-1706.	2.6	4
13076	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 89.	8.2	10
13077	Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study. <i>Future Oncology</i> , 2021, 17, 1777-1791.	2.4	8
13078	Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3666-3682.	6.4	4
13079	Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 24-31.	1.7	4

#	ARTICLE	IF	CITATIONS
13080	A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. <i>Oncologist</i> , 2021, 26, e1499-e1507.	3.7	9
13081	Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. <i>Nuclear Medicine Communications</i> , 2021, 42, 1217-1226.	1.1	7
13082	Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 3981-3990.	1.9	4
13083	Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 131-144.	2.5	13
13084	Usefulness of albumin/globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1015-1021.	2.2	5
13085	Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252665.	2.5	13
13086	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
13087	Association of tumor downstaging after neoadjuvant chemotherapy with survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2913-2922.	2.5	1
13088	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 613-621.	10.7	44
13089	Volumetric modulated arc radiosurgery for brain metastases from breast cancer: A single-center study. <i>Colombia Medica</i> , 2021, 52, e2004567.	0.2	4
13090	Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. <i>BMC Cancer</i> , 2021, 21, 743.	2.6	3
13091	Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: A Phase II Trial. <i>Clinical Oncology</i> , 2021, 33, 788-794.	1.4	9
13092	Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 505-516.	3.0	17
13093	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
13094	Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer. <i>BMC Cancer</i> , 2021, 21, 663.	2.6	1
13095	Bone Density Changes Following Radiotherapy to Vertebral Metastases. <i>Cureus</i> , 2021, 13, e15417.	0.5	2
13096	A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4186-4194.	7.0	15
13097	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 97, 102187.	7.7	31

#	ARTICLE	IF	CITATIONS
13098	Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 387-398.	4.2	16
13099	Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors. <i>Acta Radiologica</i> , 2022, 63, 995-1004.	1.1	4
13100	Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo. <i>Cancer Biomarkers</i> , 2021, 32, 221-230.	1.7	8
13101	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. <i>Cancer Medicine</i> , 2021, 10, 4356-4365.	2.8	6
13102	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data. <i>JAMA Oncology</i> , 2021, 7, 940.	7.1	1
13103	Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load. <i>Frontiers in Oncology</i> , 2021, 11, 683475.	2.8	11
13104	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. , 2021, 9, e002349.		16
13105	Methylation Status of Corticotropin-Releasing Factor (CRF) Receptor Genes in Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2680.	2.4	9
13106	Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2703-2714.	1.8	7
13107	Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. <i>Nature Communications</i> , 2021, 12, 3807.	12.8	12
13108	Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. <i>European Journal of Endocrinology</i> , 2021, 184, 837-845.	3.7	16
13109	The effect of VEGF rs35569394 in esophageal cancer and response to chemotherapy. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	1.0	1
13110	Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. , 2021, 9, e002118.		75
13111	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. <i>Cancers</i> , 2021, 13, 3083.	3.7	9
13112	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. , 2021, 9, e002344.		12
13113	Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin. <i>Cancers</i> , 2021, 13, 3206.	3.7	6
13114	Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 2509-2522.	2.8	13
13115	Drug Development in Tissue-Agnostic Indications. <i>Cancers</i> , 2021, 13, 2758.	3.7	8

#	ARTICLE	IF	CITATIONS
13116	Avidity and Outcomes of Radioiodine Therapy for Distant Metastasis of Distinct Types of Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3911-e3922.	3.6	15
13117	The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study. <i>NIHR Open Research</i> , 2021, 1, 1.	0.0	2
13118	Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 643-654.	2.3	1
13119	European guideline for imaging in paediatric and adolescent rhabdomyosarcoma “joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology. <i>Pediatric Radiology</i> , 2021, 51, 1940-1951.	2.0	27
13120	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4511-4520.	7.0	39
13121	A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1977-1985.	2.2	3
13122	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	7.0	18
13123	5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235.	7.0	82
13124	Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. <i>Lung Cancer Management</i> , 2021, 10, LMT44.	1.5	3
13125	Bevacizumab in advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 720-726.	1.4	11
13126	CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. <i>Cancer Letters</i> , 2021, 507, 70-79.	7.2	7
13127	Imaging Assessment of Tumor Response in the Era of Immunotherapy. <i>Diagnostics</i> , 2021, 11, 1041.	2.6	3
13128	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. <i>Annals of Lymphoma</i> , 2021, 5, 15-15.	4.5	13
13129	Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 4796-4804.	2.8	13
13130	M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021, 161, 681-686.	1.4	5
13131	High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	1.3	2
13132	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	8.6	23
13133	Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2021, 15, 162.	1.0	1

#	ARTICLE	IF	CITATIONS
13135	Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?. <i>Surgery</i> , 2021, 170, 1481-1486.	1.9	1
13136	A Comparative Study between 18F-FDG PET/CT and Conventional Imaging in the Evaluation of Progressive Disease and Recurrence in Ovarian Carcinoma. <i>Healthcare (Switzerland)</i> , 2021, 9, 666.	2.0	9
13137	Exploratory Analysis of 18F-3â€™-deoxy-3â€™-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 601053.	2.8	11
13138	Deep learning for semi-automated unidirectional measurement of lung tumor size in CT. <i>Cancer Imaging</i> , 2021, 21, 43.	2.8	4
13139	Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. <i>PLoS ONE</i> , 2021, 16, e0252574.	2.5	5
13140	Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 649766.	2.8	6
13141	Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 703318.	2.8	2
13142	Programmed Deathâ€™Ligand 1 Expression and Tumorâ€™Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2021, 131, 2674-2683.	2.0	4
13143	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
13144	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 883-892.	10.7	116
13145	Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data. <i>Lung Cancer</i> , 2021, 156, 20-30.	2.0	25
13146	Neoadjuvant radiation therapy versus resection alone in the management of non-metastatic retroperitoneal soft tissue sarcoma: A review of the literature. <i>Surgery Open Digestive Advance</i> , 2021, 2, 100008.	0.1	0
13147	CAR T-Cell Therapy: An Update for Radiologists. <i>American Journal of Roentgenology</i> , 2021, 217, 1461-1474.	2.2	20
13148	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	3.7	31
13149	The Importance of Accurate Tumor Measurements and Staging in Oncologic Imaging: Impact on Patientsâ€™ Health. <i>Academic Radiology</i> , 2021, 28, 767-768.	2.5	5
13150	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 77.	5.2	16
13151	Long-term outcome of Stereotactic Body Radiation Therapy for patient with unresectable liver metastases from colorectal cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 350-357.	1.4	5
13152	Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis. <i>Anticancer Research</i> , 2021, 41, 3099-3107.	1.1	0

#	ARTICLE	IF	CITATIONS
13153	Chest radiographs and machine learning – Past, present and future. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 538-544.	1.8	10
13154	Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1232-1241.	1.3	9
13155	On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1500-1505.	2.2	2
13156	Enrolment of older adults with cancer in early phase clinical trials – an observational study on the experience in the north west of England. <i>Age and Ageing</i> , 2021, 50, 1736-1743.	1.6	2
13157	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	3.7	19
13158	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2021, 27, 4557-4565.	7.0	61
13159	SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner. <i>Translational Oncology</i> , 2021, 14, 101075.	3.7	6
13160	Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. <i>Clinical Therapeutics</i> , 2021, 43, 1092-1111.	2.5	5
13161	<sc>FDA</sc> Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Oncologist</i> , 2021, 26, 797-806.	3.7	61
13162	Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 1521-1532.	2.7	3
13163	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 679-686.	6.4	31
13164	Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 566-573.	1.5	2
13165	A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment. <i>European Journal of Cancer</i> , 2021, 150, 42-52.	2.8	2
13166	Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 697572.	2.8	0
13167	Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. <i>Frontiers in Oncology</i> , 2021, 11, 686776.	2.8	13
13168	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. <i>Scientific Reports</i> , 2021, 11, 12084.	3.3	7
13169	Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence. <i>Cancers</i> , 2021, 13, 2835.	3.7	23
13170	Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. <i>BMC Cancer</i> , 2021, 21, 655.	2.6	14

#	ARTICLE	IF	CITATIONS
13171	Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 834-837.	1.0	1
13172	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. <i>PLoS ONE</i> , 2021, 16, e0252537.	2.5	20
13173	Everolimus for the treatment of epithelioid hemangioma: a case report. <i>Medical Journal of Indonesia</i> , 2021, 50, 1-5.	0.5	0
13174	Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 622-630.	2.1	3
13175	Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer—Results from a Prospective Cohort. <i>Cancers</i> , 2021, 13, 2862.	3.7	2
13176	Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience. <i>Cancers</i> , 2021, 13, 3129.	3.7	12
13177	Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Stent Placement. <i>Digestive Diseases and Sciences</i> , 2021, 36, 1-8.	2.3	1
13178	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 672521.	4.8	13
13179	Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 671629.	2.8	3
13180	Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer. <i>Tumor Biology</i> , 2021, 43, 115-127.	1.8	11
13181	Prognostic significance of extracellular volume fraction with equilibrium contrast-enhanced computed tomography for pancreatic neuroendocrine neoplasms. <i>Pancreatology</i> , 2021, 21, 779-786.	1.1	4
13182	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	3.9	17
13183	Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. <i>Annals of Translational Medicine</i> , 2021, 9, 937-937.	1.7	9
13184	Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. <i>BJU International</i> , 2022, 130, 226-234.	2.5	15
13185	Long-Term Results of Dose-Intensified Fractionated Stereotactic Body Radiation Therapy (SBRT) for Painful Spinal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 348-357.	0.8	15
13186	Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, e002057.		39
13187	Review of Palliative Radiation Therapy Patterns of Practice for Adrenal Metastases in British Columbia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 438-443.	0.8	1
13188	Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study. <i>Cancers</i> , 2021, 13, 3101.	3.7	5

#	ARTICLE	IF	CITATIONS
13189	Association of T2285C polymorphism in <i>PARP1</i> gene coding region with its expression, activity and NSCLC risk along with prognosis. <i>Mutagenesis</i> , 2021, 36, 281-293.	2.6	0
13190	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	4.5	37
13191	Efficacy of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: A real life experience and outcome from a tertiary referral centre.. <i>Journal of Cancer & Allied Specialties</i> , 2021, 7, .	0.3	1
13192	Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 403-411.	0.8	5
13193	Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4205-4220.	7.0	29
13194	Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from <i>REGARD</i> , <i>RAINBOW</i> , and <i>RAINFALL</i> Phase III Studies. <i>Oncologist</i> , 2021, 26, e1538-e1547.	3.7	19
13195	Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. <i>Nature Communications</i> , 2021, 12, 4014.	12.8	19
13196	Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. <i>British Journal of Surgery</i> , 2021, 108, 976-982.	0.3	8
13197	Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. <i>Journal of Hepatology</i> , 2021, 74, 1483-1488.	3.7	23
13198	Prognostic impact of surgery after chemotherapy for type 4 gastric cancer. <i>Surgery Today</i> , 2021, 51, 1851-1859.	1.5	1
13199	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021, 11, 682449.	2.8	16
13200	Association of patient-reported outcomes and ovarian cancer recurrence. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1248-1259.	2.5	1
13201	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.7	104
13202	Characterization of response to atezolizumab+Âbevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. <i>Cancer Medicine</i> , 2021, 10, 5437-5447.	2.8	29
13203	Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. <i>Current Problems in Cancer</i> , 2021, 45, 100685.	2.0	5
13204	The Pan-Immune-Inflammation Value in microsatellite instability“high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	2.8	45
13205	Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 669-677.	2.0	10
13206	The utility of Multi-Detector Computed Tomography criteria after neoadjuvant therapy in Borderline Resectable Pancreatic cancer: Prospective, bi-institutional study. <i>European Journal of Radiology</i> , 2021, 139, 109685.	2.6	4

#	ARTICLE	IF	CITATIONS
13207	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
13208	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/â~ Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	3.7	11
13209	C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 191-199.	1.5	5
13210	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2022, 5, e1464.	1.4	43
13211	Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit. <i>Anticancer Research</i> , 2021, 41, 3109-3119.	1.1	11
13212	Current Guidelines for Management of Medullary Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2021, 36, 514-524.	3.0	29
13213	The role of unenhanced phase of the liver in the scanning protocol of metastatic breast cancer: implications for sensitivity, response evaluation and size measurement. <i>Radiology and Oncology</i> , 2021, 55, 418-425.	1.7	0
13214	Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29025.	1.5	16
13215	Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2021, 16, 493-502.	3.6	6
13216	GLIM vs ESPEN criteria for the diagnosis of early malnutrition in oncological outpatients. <i>Clinical Nutrition</i> , 2021, 40, 3741-3747.	5.0	25
13217	Effects of different soil compost and aphid (Hemiptera: Aphididae) density on the growth and development of <i>Cedrus libani</i> a. rich. <i>International Journal of Tropical Insect Science</i> , 0, , 1.	1.0	1
13218	Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin: a non-randomised phase II clinical trial. <i>BMJ Open</i> , 2021, 11, e046779.	1.9	13
13219	Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery. <i>Journal of Neuro-Oncology</i> , 2021, 153, 527-536.	2.9	3
13220	Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 156, 50-58.	2.0	5
13221	Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1416-1422.	1.3	11
13222	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Nonâ€“Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
13223	Multimodal treatment involving molecular targeted agents and onâ€“demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 154.	1.0	3
13224	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4746-4756.	7.0	22

#	ARTICLE	IF	CITATIONS
13225	The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. <i>British Journal of Cancer</i> , 2021, 125, 816-825.	6.4	7
13226	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1459-1463.	0.8	4
13227	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	7.0	112
13228	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. , 2021, 9, e002568.		87
13229	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 848-857.	10.7	150
13230	Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data. <i>Clinical Cancer Research</i> , 2021, 27, 4634-4641.	7.0	32
13231	Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. <i>Targeted Oncology</i> , 2021, 16, 485-492.	3.6	3
13232	Evolving Role of MRI in Assessment of Response of Hepatocellular Carcinoma Patients Post Trans-Arterial Chemoembolization: What Does the Physician Want to Know?. <i>Medical Journal of the University of Cairo Faculty of Medicine</i> , 2021, 89, 1017-1024.	0.0	0
13233	Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer. <i>Surgery Today</i> , 2022, 52, 198-206.	1.5	3
13234	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	4.2	16
13235	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	1.4	28
13236	Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes. <i>Frontiers in Oncology</i> , 2021, 11, 683605.	2.8	6
13237	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 11427.	3.3	3
13238	Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. <i>Journal of Surgical Oncology</i> , 2021, 124, 589-597.	1.7	6
13239	Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Cancer Science</i> , 2021, 112, 3005-3017.	3.9	31
13240	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	27.6	148
13241	Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 700806.	3.5	2
13242	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , 2021, 17, 1977-1985.	2.4	24

#	ARTICLE	IF	CITATIONS
13243	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR-Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 570921.	2.6	2
13244	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , 2021, 13, 2931.	3.7	19
13245	Clinical Observation of Prophylactic Extended-Field Intensity-Modulated Radiation Therapy with Synchronous Chemotherapy in Locally Advanced Cervical Cancer. <i>Medical Science Monitor</i> , 2021, 27, e930457.	1.1	1
13246	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2950.	3.7	12
13247	Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1735-1742.	4.1	8
13248	Molecular Markers that Matter in Salivary Malignancy. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 613-627.	1.1	2
13249	Interrelations between Patientsâ€™ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. <i>Cancers</i> , 2021, 13, 3249.	3.7	9
13250	Avoiding breast cancer surgery in a select cohort of complete responders to neoadjuvant chemotherapy: The long-term outcomes. <i>Annals of Medicine and Surgery</i> , 2021, 66, 102380.	1.1	6
13251	CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). <i>British Journal of Cancer</i> , 2021, 125, 725-733.	6.4	13
13252	Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105781.	4.0	0
13253	High-Density of FcÎ³RIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis. <i>Frontiers in Oncology</i> , 2021, 11, 684478.	2.8	1
13254	Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007â€“2018. <i>Melanoma Research</i> , 2021, 31, 456-463.	1.2	1
13255	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. <i>Cancers</i> , 2021, 13, 2797.	3.7	11
13256	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 377-389.	3.1	16
13257	Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Oncology and Therapy</i> , 2021, 9, 505-524.	2.6	6
13258	Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4710-4716.	7.0	51
13259	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) â€“ an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.	1.0	10
13260	Association of Inflammation-Related Gene Polymorphisms With Susceptibility and Radiotherapy Sensitivity in Head and Neck Squamous Cell Carcinoma Patients in Northeast China. <i>Frontiers in Oncology</i> , 2021, 11, 651632.	2.8	4

#	ARTICLE	IF	CITATIONS
13263	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. <i>Cancers</i> , 2021, 13, 2789.	3.7	1
13264	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 8903-8912.	4.5	3
13265	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	1.6	10
13266	Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. <i>Annals of Translational Medicine</i> , 2021, 9, 1014-1014.	1.7	4
13267	Role of PSA Kinetics in Hormone-refractory Prostate Cancer. <i>Journal of the College of Physicians and Surgeons--Pakistan: JCPSP</i> , 2021, 31, 673-678.	0.4	0
13268	Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers. <i>International Journal of Biostatistics</i> , 2021, .	0.7	0
13269	Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). <i>Oncologist</i> , 2021, 26, e1693-e1703.	3.7	35
13270	A Machine Learning Model for Predicting a Major Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 675458.	2.8	18
13271	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 32-38.	1.0	4
13272	Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT. <i>Medicine (United States)</i> , 2021, 100, e26206.	1.0	3
13273	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3020.	3.7	11
13274	Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy. <i>Academic Radiology</i> , 2021, .	2.5	2
13275	Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases. <i>Hpb</i> , 2022, 24, 40-46.	0.3	0
13276	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 177-185.	2.5	15
13277	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	2.0	4
13278	Reliability and validity of D-dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab. <i>Molecular and Clinical Oncology</i> , 2021, 15, 165.	1.0	1
13279	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4369-4376.	6.4	23
13280	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4566-4573.	7.0	13

#	ARTICLE	IF	CITATIONS
13281	Neoadjuvant chemotherapy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial). International Journal of Gynecological Cancer, 2021, 31, 1175-1178.	2.5	5
13282	Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). Journal of Geriatric Oncology, 2022, 13, 82-87.	1.0	13
13283	Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review. Cancers, 2021, 13, 3212.	3.7	3
13284	Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2021, 13, 3518-3528.	1.4	49
13285	Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients. Journal of Dermatological Science, 2021, 102, 158-166.	1.9	8
13286	Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis. Journal of Neuro-Oncology, 2021, 153, 455-465.	2.9	1
13287	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	1.2	22
13288	Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdominal Radiology, 2021, 46, 4765-4778.	2.1	2
13289	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology, 2021, 32, 757-765.	1.2	105
13290	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	7.0	23
13291	Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open, 2021, 6, 100103.	4.5	62
13292	Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer—a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quantitative Imaging in Medicine and Surgery, 2021, 11, 2376-2387.	2.0	26
13293	Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. European Journal of Cancer, 2021, 150, 99-107.	2.8	36
13294	Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clinical Cancer Research, 2021, 27, 5188-5194.	7.0	9
13295	Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers, 2021, 13, 3702.	3.7	4
13296	Study of ⁸⁹ Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2022, 63, 362-367.	5.0	44
13297	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precision Oncology, 2021, 5, 1166-1177.	3.0	55
13298	Inmunoterapia en oncología de las vías aerodigestivas superiores. EMC - Otorrinolaringología, 2021, 50, 1-20.	0.0	0

#	ARTICLE	IF	CITATIONS
13299	Differential frequency in <scp>imaging–based</scp> outcome measurement: Bias in <scp>real–world</scp> oncology <scp>comparative–effectiveness</scp> studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 46-54.	1.9	9
13301	Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC. <i>Scientific Reports</i> , 2021, 11, 15305.	3.3	4
13302	Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence. <i>Frontiers in Oncology</i> , 2021, 11, 709779.	2.8	1
13303	Frequency and clinical course of residual orbital masses after treatment of orbital rhabdomyosarcoma. <i>American Journal of Ophthalmology</i> , 2021, 234, 28-36.	3.3	3
13304	ASO Author Reflections: Establishment of an Ideal Criterion for Evaluating the Therapeutic Effect on Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 8483-8484.	1.5	0
13305	Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1258-1264.	1.6	1
13306	Novel Criterion Using Esophageal Major and Minor Axes is Useful to Evaluate the Therapeutic Effect and Prognosis After Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 8474-8482.	1.5	3
13307	Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis. <i>Translational Cancer Research</i> , 2021, 10, 3206-3217.	1.0	1
13308	Electrochemotherapy with bleomycin for basal cell carcinomas: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2208-2215.	2.4	11
13309	Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD–1 or PD–1 inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	1.1	2
13310	Molecular and Pathological Profiling of Corresponding Treatment-Na–ve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISC-04/NOPASS Study. <i>Biology</i> , 2021, 10, 639.	2.8	1
13311	18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 199-204.	5.0	3
13312	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 537-546.	2.5	12
13313	Intrapulmonic Cavity or Necrosis on Baseline CT Scan Serves as an Efficacy Predictor of Anti-PD-(L)1 Inhibitor in Advanced Lung Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 5931-5939.	1.9	2
13314	Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial. , 2021, 9, e003119.		10
13315	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 21-29.	2.0	8
13316	Spinal cord compression due to a solitary, bulky plasmacytoma of posterior mediastinum.. <i>Radiology Case Reports</i> , 2021, 16, 1622-1627.	0.6	1
13317	Taxane–based versus platinum–based chemotherapy in early recurrent gastric cancer after radical surgery with S–1 adjuvant chemotherapy: A multi–institutional retrospective analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	1.1	0

#	ARTICLE	IF	CITATIONS
13318	Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomarker Research, 2021, 9, 52.	6.8	55
13319	Quantitative Assessment of the Echogenicity of a Breast Tumor Predicts the Response to Neoadjuvant Chemotherapy. Cancers, 2021, 13, 3546.	3.7	1
13320	The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study. Annals of Gastroenterological Surgery, 2021, 5, 794-803.	2.4	15
13321	A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Investigational New Drugs, 2021, 39, 1613-1623.	2.6	8
13322	Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer – A Phase II trial. Clinical Oncology, 2021, 33, e553-e560.	1.4	2
13323	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer, 2021, 22, 301-312.e8.	2.6	10
13324	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
13325	Long-Term Safety and Efficacy of CT-Guided I125 Radioactive Seed Implantation as a Salvage Therapy for Recurrent Head and Neck Squamous Carcinoma: A Multicenter Retrospective Study. Frontiers in Oncology, 2021, 11, 645077.	2.8	4
13326	[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 70.	2.5	11
13327	Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World Journal of Clinical Cases, 2021, 9, 5754-5768.	0.8	9
13328	Characterizing intra-tumor regions on quantitative ultrasound parametric images to predict breast cancer response to chemotherapy at pre-treatment. Scientific Reports, 2021, 11, 14865.	3.3	9
13329	Prediction of Inflammatory Breast Cancer Survival Outcomes Using Computed Tomography-Based Texture Analysis. Frontiers in Bioengineering and Biotechnology, 2021, 9, 695305.	4.1	3
13330	Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer. Anticancer Research, 2021, 41, 3535-3542.	1.1	1
13331	Therapeutic Strategy of Colorectal Liver Metastasis Using Modified-JHBPS Nomogram. Anticancer Research, 2021, 41, 3657-3665.	1.1	1
13332	EarlyÂdiarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. United European Gastroenterology Journal, 2021, 9, 655-661.	3.8	2
13333	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology, 2021, 39, 2327-2338.	1.6	146
13334	Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 437.e1-437.e9.	1.6	7
13335	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216

#	ARTICLE	IF	CITATIONS
13336	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5272-5279.	7.0	26
13337	Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). <i>Radiotherapy and Oncology</i> , 2021, 160, 159-165.	0.6	67
13338	Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy. <i>Anticancer Research</i> , 2021, 41, 3673-3682.	1.1	16
13339	False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (TÂ€VEC). <i>Journal of Surgical Oncology</i> , 2021, 124, 1161-1165.	1.7	1
13340	Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. <i>Scientific Reports</i> , 2021, 11, 14426.	3.3	17
13341	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	17.1	19
13342	Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours. <i>Reproductive BioMedicine Online</i> , 2021, 43, 637-644.	2.4	1
13343	Window mean survival time. <i>Statistics in Medicine</i> , 2021, 40, 5521-5533.	1.6	7
13344	<sc>HO</sc>â€1 in lymph node metastasis predicted overall survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation therapy. <i>Cancer Reports</i> , 2022, 5, e1477.	1.4	5
13345	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 411-423.	2.5	3
13346	Cliniciansâ€™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, â€œReal-Lifeâ€ Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021,, .	2.3	8
13347	Concomitant intraductal carcinoma of the prostate and response to hormonal therapy in metastatic prostate carcinoma. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2021, 45, 455-460.	0.2	1
13348	Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1003-1012.	0.8	21
13349	Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. <i>Cells</i> , 2021, 10, 1912.	4.1	13
13350	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021, 10, 3093-3105.	2.8	23
13351	Hyperprogression under immunotherapy: a new form of immunotherapy response?â€a narrative literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3276-3291.	2.8	15
13352	Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence. <i>Frontiers in Oncology</i> , 2021, 11, 697952.	2.8	2
13353	A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 1151-1151.	1.7	1

#	ARTICLE	IF	CITATIONS
13354	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 834.e21-834.e28.	1.6	14
13355	A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4994-5003.	7.0	24
13356	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	6.4	9
13357	Interferon- β 1b for the treatment of metastatic melanoma: results of a retrospective study. <i>Anti-Cancer Drugs</i> , 2021, 32, 1105-1110.	1.4	6
13358	Advanced Densely Connected System with Embedded Spatio-Temporal Features Augmentation for Immunotherapy Assessment. , 2021, , .		0
13359	Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique. <i>Gynecologic Oncology</i> , 2021, 162, 72-79.	1.4	10
13360	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 131-142.	13.7	167
13361	Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY- α CRADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. <i>Cancer Medicine</i> , 2021, 10, 5859-5865.	2.8	22
13362	An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer. <i>Anticancer Research</i> , 2021, 41, 3925-3931.	1.1	13
13363	La PET/TC con 18F-FDG en el c�ncer de laringe: comparaci�n con t�cnicas de imagen convencional y valor pron�stico. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 229-238.	0.0	0
13364	Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis. <i>Gynecologic Oncology</i> , 2021, 163, 29-35.	1.4	16
13365	Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638123.	2.8	3
13366	3D Deep Learning Model for the Pretreatment Evaluation of Treatment Response in Esophageal Carcinoma: A Prospective Study (ChiCTR2000039279). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 926-935.	0.8	19
13367	Clinical Outcomes and Prognostic Factors of Salvage Treatment for Local Lymph Node Recurrence After Radical Resection of Oesophageal Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 5845-5853.	1.9	0
13368	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. <i>European Journal of Cancer</i> , 2021, 151, 14-24.	2.8	18
13369	Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. <i>BMC Cancer</i> , 2021, 21, 777.	2.6	3
13370	Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non�small cell lung cancer patients. <i>Anti-Cancer Drugs</i> , 2021, 32, 1099-1104.	1.4	8
13371	Head-to-Head Comparison of Neck 18F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment. <i>Cancers</i> , 2021, 13, 3436.	3.7	6

#	ARTICLE	IF	CITATIONS
13372	Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. Cancer Management and Research, 2021, Volume 13, 5699-5709.	1.9	6
13373	Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer. JAMA Network Open, 2021, 4, e2116240.	5.9	25
13374	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid, 2021, 31, 1009-1019.	4.5	54
13375	Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	3.1	20
13376	Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 727-739.	2.6	5
13377	Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy. European Journal of Surgical Oncology, 2021, , .	1.0	0
13378	Comparative pharmacoeconomic analysis of biologicals used for metastatic urothelial carcinoma. Onkourologiya, 2021, 17, 112-127.	0.3	0
13379	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1340.	2.6	6
13380	Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1255-1266.	2.5	13
13381	Safe pneumonectomy for locally advanced lung cancer after induction therapy. Surgery Today, 2022, 52, 316-323.	1.5	2
13382	Assessing prognostic value of early tumor shrinkage and depth of response in first-line therapy for patients with advanced unresectable pancreatic cancer. BMC Gastroenterology, 2021, 21, 294.	2.0	0
13383	Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab-paclitaxel as a first-line therapy: A retrospective analysis. Medicine International, 2021, 1, .	0.6	0
13384	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. Clinical Pharmacology and Therapeutics, 2022, 111, 168-178.	4.7	14
13385	Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. Journal of the Formosan Medical Association, 2021, , .	1.7	4
13386	Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study. F1000Research, 0, 10, 673.	1.6	0
13387	First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2022, 63, 536-542.	5.0	56
13388	Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. Molecular Imaging and Biology, 2021, 23, 914-928.	2.6	3
13389	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of Thoracic Oncology, 2021, 16, 1883-1892.	1.1	93

#	ARTICLE	IF	CITATIONS
13390	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only. <i>Annals of Surgery</i> , 2021, 274, 729-735.	4.2	13
13391	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021, 274, 894-901.	4.2	15
13392	Effects of Exercise on Cancer Treatment Efficacy: A Systematic Review of Preclinical and Clinical Studies. <i>Cancer Research</i> , 2021, 81, 4889-4895.	0.9	34
13393	Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1745-1751.	2.2	6
13394	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. <i>Cancers</i> , 2021, 13, 3492.	3.7	3
13395	Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial. <i>Annals of Surgery Open</i> , 2021, 2, e081.	1.4	4
13396	A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients. <i>Journal of Surgical Research</i> , 2021, 268, 737-747.	1.6	1
13397	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
13398	Proton Beam Therapy for Local Recurrence of Rectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3589-3595.	1.1	11
13399	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). <i>BioDrugs</i> , 2021, 35, 417-428.	4.6	13
13400	Predictive value of ^{18}F -fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. , 2021, 9, e003079.		5
13401	MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. <i>Radiology Imaging Cancer</i> , 2021, 3, e210016.	1.6	7
13402	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.	1.6	24
13403	HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. <i>BMC Surgery</i> , 2021, 21, 308.	1.3	9
13404	Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. <i>Cancers</i> , 2021, 13, 3863.	3.7	6
13405	Development and validation of a longitudinal soft-tissue metastatic lesion matching algorithm. <i>Physics in Medicine and Biology</i> , 2021, 66, 155017.	3.0	3
13406	Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. <i>Acta Oncol</i> , 2021, 60, 1114-1121.	1.8	6
13407	Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. <i>Immunotherapy</i> , 2021, 13, 799-806.	2.0	29

#	ARTICLE	IF	CITATIONS
13408	Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 2560-2567.	2.4	7
13409	Efficacy of Sâ€1 after pemetrexed in patients with nonâ€small cell lung cancer: A retrospective multiâ€institutional analysis. <i>Thoracic Cancer</i> , 2021, 12, 2300-2306.	1.9	1
13410	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. <i>Clinical Cancer Research</i> , 2021, 27, 4794-4806.	7.0	17
13411	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	9.2	323
13412	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5â€13/TESARO PR-30â€50â€10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	7.0	25
13413	Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases. <i>Journal of Neurology</i> , 2022, 269, 815-823.	3.6	6
13414	First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Antiâ€PD-L1 Probody. <i>Clinical Cancer Research</i> , 2021, 27, 5325-5333.	7.0	19
13415	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>. <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	7.0	74
13416	Selective internal radiation therapy in older patients with hepatocellular carcinoma: a retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 417-421.	1.6	4
13417	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062.	1.4	9
13418	Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. <i>Acta Radiologica</i> , 2022, 63, 877-888.	1.1	5
13419	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	4.2	6
13420	Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies. <i>Investigational New Drugs</i> , 2021, 39, 1694-1701.	2.6	0
13421	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. <i>BMC Cancer</i> , 2021, 21, 761.	2.6	12
13422	Radiologists and Clinical Trials: Part 1 The Truth About Reader Disagreements. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1111-1121.	1.6	12
13423	Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. <i>Translational Lung Cancer Research</i> , 2021, 10, 3191-3202.	2.8	10
13424	A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Nonâ€small-cell Lung Cancer: SWOG 1206 (8811). <i>Clinical Lung Cancer</i> , 2021, 22, 313-323.e1.	2.6	11
13425	Colletâ€Picard syndrome due to concurrent extramedullary intracranial plasmacytoma and jugular venous sinus thrombosis in multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04457.	0.5	3

#	ARTICLE	IF	CITATIONS
13426	MRI and CT bladder segmentation from classical to deep learning based approaches: Current limitations and lessons. <i>Computers in Biology and Medicine</i> , 2021, 134, 104472.	7.0	22
13427	12â€–6â€–Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma?. <i>Strahlentherapie Und Onkologie</i> , 2021, , 1.	2.0	1
13428	The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 212.	1.9	13
13429	Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1137-1146.	2.5	12
13430	MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach. <i>Tumori</i> , 2022, 108, 376-385.	1.1	8
13431	Plasma Levels of Heat Shock Protein 90 Alpha Associated With Colorectal Cancer Development. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 684836.	3.5	5
13432	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase III Trial. <i>Advances in Therapy</i> , 2021, 38, 4581-4591.	2.9	7
13433	Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. <i>European Journal of Cancer</i> , 2021, 151, 201-210.	2.8	5
13434	Can 3D pseudo-continuous arterial spin labeling perfusion imaging be applied to predict early response to chemoradiotherapy in patients with advanced nasopharyngeal carcinoma?. <i>Radiotherapy and Oncology</i> , 2021, 160, 97-106.	0.6	7
13435	A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. <i>Oncologist</i> , 2021, 26, e1844-e1853.	3.7	18
13436	Semi-Automatic Volumetric and Standard Three-Dimensional Measurements for Primary Tumor Evaluation and Response to Treatment Assessment in Pediatric Rhabdomyosarcoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 717.	2.5	3
13437	Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. <i>Frontiers in Oncology</i> , 2021, 11, 695038.	2.8	3
13438	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2022, 129, 610-620.	2.5	22
13439	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€–Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547.	5.9	20
13440	Application Research of Individualized Conditional Reprogramming System to Guide Treatment of Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 709511.	2.8	4
13441	Biomarcadores asociados con la supervivencia y la respuesta terapéutica a la radioembolización con esferas cargadas de itrio-90 en las metástasis hepáticas del carcinoma colorrectal: nuestra experiencia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 231-238.	0.0	1
13442	Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs. <i>Scientific Reports</i> , 2021, 11, 14123.	3.3	34
13443	Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. <i>British Journal of Cancer</i> , 2021, 125, 948-954.	6.4	11

#	ARTICLE	IF	CITATIONS
13444	Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. The Cochrane Library, 2021, 2021, CD005343.	2.8	25
13445	Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemotherapy and Pharmacology, 2021, 88, 825-836.	2.3	8
13446	Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 2021, 11, 1302.	2.6	3
13447	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. Applied Sciences (Switzerland), 2021, 11, 6930.	2.5	4
13448	Long-term clinical outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy using the CyberKnife [®] robotic radiosurgery system for vestibular schwannoma. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	1.1	4
13449	Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis. Cancer Management and Research, 2021, Volume 13, 5889-5898.	1.9	6
13450	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer, 2021, 21, 775.	2.6	28
13451	PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma. Modern Pathology, 2021, 34, 1966-1978.	5.5	17
13452	Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer. Thyroid, 2021, 31, 1514-1522.	4.5	3
13453	Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 424-433.	3.0	11
13454	Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROC 19-02). Cancer Research and Treatment, 2022, 54, 478-487.	3.0	4
13455	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death Ligand 1 Blockade Responses. Hepatology, 2021, 74, 1914-1931.	7.3	48
13456	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. Clinical Cancer Research, 2021, 27, 5536-5545.	7.0	15
13457	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 2021, 151, 115-125.	2.8	22
13458	Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer. British Journal of Radiology, 2021, 94, 20201125.	2.2	0
13459	A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. BMC Cancer, 2021, 21, 851.	2.6	2
13460	Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma. Frontiers in Oncology, 2021, 11, 653050.	2.8	7
13461	Machine Learning Models to Predict Survival Outcomes According to the Surgical Approach of Primary Radical Hysterectomy in Patients with Early Cervical Cancer. Cancers, 2021, 13, 3709.	3.7	8

#	ARTICLE	IF	CITATIONS
13462	Monoclonal Antibodies for Cancer Treatment. , 0, , .		0
13463	Contrast-enhanced spectral mammography: successful initial clinical institute experience. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.6	1
13464	Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. Clinical Lung Cancer, 2022, 23, e104-e115.	2.6	13
13465	Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. Frontiers in Oncology, 2021, 11, 716467.	2.8	8
13466	Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases. Clinical Colorectal Cancer, 2021, 20, e263-e272.	2.3	5
13467	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. Journal of Translational Medicine, 2021, 19, 324.	4.4	13
13468	Evaluation of Early Response to Preoperative Accelerated Partial Breast Irradiation (PAPBI) by Histopathology, Magnetic Resonance Imaging, and 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT). International Journal of Radiation Oncology Biology Physics, 2021, 110, 1151-1158.	0.8	5
13469	Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. European Journal of Cancer. 2021, 152, 100-115.	2.8	9
13470	Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan. Cancers, 2021, 13, 3554.	3.7	10
13471	High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis. Radiation Oncology, 2021, 16, 131.	2.7	4
13472	Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474.	3.3	13
13473	Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Anticancer Research, 2021, 41, 3573-3582.	1.1	6
13474	Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study. Respiratory Investigation, 2021, 59, 545-549.	1.8	1
13475	Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. Clinical Lung Cancer, 2021, 22, 282-291.e6.	2.6	12
13476	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. JCO Precision Oncology, 2021, 5, 1151-1159.	3.0	16
13477	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study. European Journal of Cancer, 2021, 151, 84-93.	2.8	21
13478	Phase I study of napabucasin in combination with FOLFIRI+bevacizumab in Japanese patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 2017-2024.	2.2	8
13479	Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course. Liver International, 2021, 41, 2474-2484.	3.9	15

#	ARTICLE	IF	CITATIONS
13480	¹⁷⁷ Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO Global Oncology, 2021, 7, 1167-1175.	1.8	10
13481	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3K ^{Î²} Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 5248-5257.	7.0	15
13482	Root-cause Analysis of Mortality After Pancreatic Resection (CARE Study). Annals of Surgery, 2021, 274, 789-796.	4.2	9
13483	Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients. BMC Cancer, 2021, 21, 894.	2.6	9
13484	Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vsÂHistological Specimens. Chest, 2021, 160, 743-753.	0.8	10
13485	Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). BMC Cancer, 2021, 21, 947.	2.6	4
13486	Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. Cancers, 2021, 13, 4232.	3.7	3
13487	Molecularly Targeted Therapies for Gastric Cancer. State of the Art. Cancers, 2021, 13, 4094.	3.7	10
13488	Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of Clinical Oncology, 2021, 39, 3273-3282.	1.6	48
13489	Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti“PD-1/PD-L1”Based Therapy. Frontiers in Molecular Biosciences, 2021, 8, 621883.	3.5	2
13490	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	3.7	1
13491	Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities. Cancer Research and Treatment, 2021, , .	3.0	1
13492	Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer. BMC Cancer, 2021, 21, 908.	2.6	6
13493	Radiomics Analysis in Ovarian Cancer: A Narrative Review. Applied Sciences (Switzerland), 2021, 11, 7833.	2.5	14
13494	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	1.6	66
13495	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). , 2021, 9, e002990.		58
13496	Treatment of Advanced Pancreatic Body and Tail Cancer by En Bloc Distal Pancreatectomy with Transverse Mesocolon Resection Using a Mesenteric Approach. Journal of Nippon Medical School, 2021, 88, 301-310.	0.9	2
13497	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast, 2021, 58, 18-26.	2.2	3

#	ARTICLE	IF	CITATIONS
13498	The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis. <i>Breast</i> , 2021, 58, 50-56.	2.2	4
13499	A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. <i>Annals of Oncology</i> , 2021, 32, 1034-1044.	1.2	24
13500	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	2.6	21
13501	Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma. <i>BMC Cancer</i> , 2021, 21, 978.	2.6	5
13502	Para-aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F-Fluorodeoxyglucose PET (Positron Emission Tomography) in Advanced Cervical Cancer: Final Results of a Prospective Observational Cohort Study. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 1.	0.3	0
13503	Blood Flow and Shear Stress Allow Monitoring of Progression and Prognosis of Tumor Diseases. <i>Frontiers in Physiology</i> , 2021, 12, 693052.	2.8	5
13504	Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly. <i>Molecular Oncology</i> , 2021, 15, 2565-2579.	4.6	5
13505	Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study. <i>Clinical Nutrition</i> , 2021, 40, 4980-4987.	5.0	7
13506	MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). <i>BMC Cancer</i> , 2021, 21, 932.	2.6	3
13507	A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. <i>Annals of Oncology</i> , 2021, 32, 1425-1433.	1.2	24
13508	Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 772-784.	3.4	17
13509	Role of the CXCR3-mediated TLRs/MyD88 signaling pathway in promoting the development of hepatitis B into cirrhosis and liver cancer. <i>Molecular Medicine Reports</i> , 2021, 24, .	2.4	5
13510	Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis. <i>Thoracic Cancer</i> , 2021, 12, 2749-2757.	1.9	12
13511	Use of diffusion-weighted magnetic resonance imaging (DW-MRI) to predict early response to anti-tumor therapy in advanced non-small cell lung cancer (NSCLC): a comparison of intravoxel incoherent motion-derived parameters and apparent diffusion coefficient. <i>Translational Lung Cancer Research</i> , 2021, 10, 3671-3681.	2.8	4
13513	Deuterium MRS of early treatment-induced changes in tumour lactate in vitro. <i>NMR in Biomedicine</i> , 2021, 34, e4599.	2.8	1
13514	Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 202, 114147.	2.8	2
13515	Postoperative changes in plasma miR21 as a novel biomarker for colorectal cancer recurrence: A prospective study. <i>Cancer Science</i> , 2021, 112, 4270-4280.	3.9	12
13516	Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1584-1595.	2.7	4

#	ARTICLE	IF	CITATIONS
13517	Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>European Journal of Cancer Care</i> , 2021, 30, e13504.	1.5	6
13518	Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus. <i>Radiation Oncology</i> , 2021, 16, 149.	2.7	4
13519	Safety and Efficacy of Laparoscopic Versus Open Gastrectomy in Patients With Advanced Gastric Cancer Following Neoadjuvant Chemotherapy: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 704244.	2.8	11
13520	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
13521	A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer. <i>Journal of Theoretical Biology</i> , 2021, 522, 110697.	1.7	1
13522	Effect of Neoadjuvant Therapies on Soft Tissue Sarcomas with Tail-like Lesions: A Multicenter Retrospective Study. <i>Cancers</i> , 2021, 13, 3901.	3.7	0
13523	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021, 162, 375-381.	1.4	7
13525	Rectal Cancer in Patients Younger than 40: Tumor Characteristics and Comparative Survival Based on a Single Institution. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 244-250.	0.3	0
13526	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcS@-ESMART Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3546-3560.	1.6	17
13527	Perillyl alcohol as a treatment for cancer: A systematic review. <i>Phytomedicine Plus</i> , 2021, 1, 100090.	2.0	3
13528	Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3463-3473.	4.3	2
13529	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center. <i>Oncologist</i> , 2021, 26, e2143-e2150.	3.7	12
13530	New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor. <i>Gastric Cancer</i> , 2021, , 1.	5.3	3
13531	An Overview of Phase 2 Clinical Trial Designs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 22-29.	0.8	11
13532	Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate. <i>Frontiers in Veterinary Science</i> , 2021, 8, 675804.	2.2	4
13533	Survey of chemotherapy-induced nausea and vomiting in patients with urothelial carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 15, 219.	1.0	0
13534	Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5546-5556.	7.0	22
13535	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2667-2675.	1.6	58

#	ARTICLE	IF	CITATIONS
13536	Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT. <i>Diagnostics</i> , 2021, 11, 1417.	2.6	1
13537	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2021, 163, 274-280.	1.4	59
13538	Clinical, neuroradiological and genetic findings in a cohort of patients with multiple Cerebral Cavernous Malformations. <i>Metabolic Brain Disease</i> , 2021, 36, 1871-1878.	2.9	5
13539	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
13540	Increase of Ki67 index and influence on mortality in patients with neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2021, 33, e13018.	2.6	6
13541	Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i> -mutated Urothelial Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2177-2188.	4.1	13
13542	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
13543	Volumetric growth rates of untreated cavernous sinus meningiomas. <i>Journal of Neurosurgery</i> , 2022, 136, 749-756.	1.6	4
13544	Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. <i>ESMO Open</i> , 2021, 6, 100233.	4.5	4
13545	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3829-3838.	1.6	44
13546	Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1743-1752.	1.4	6
13547	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3538-3549.	2.8	21
13548	The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis. <i>Indian Journal of Surgical Oncology</i> , 2021, , 1-9.	0.7	5
13549	Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 498-506.	1.5	10
13550	Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: in patients with different clinicopathologic characteristics. <i>World Journal of Surgical Oncology</i> , 2021, 19, 228.	1.9	3
13551	Molecular magnetic resonance imaging of Alpha-v-Beta-3 integrin expression in tumors with ultrasound microbubbles. <i>Biomaterials</i> , 2021, 275, 120896.	11.4	17
13552	A simple preoperative stratification tool predicting the risk of postoperative pancreatic fistula after pancreatoduodenectomy. <i>Pancreatology</i> , 2021, 21, 957-964.	1.1	17
13553	Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching. <i>Gastric Cancer</i> , 2021, 24, 1355-1364.	5.3	25

#	ARTICLE	IF	CITATIONS
13554	Exceptional Responders in Gynecologic Oncology: A case series and review of literature. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.3	0
13555	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology, 2021, 5, 1432-1442.	3.0	29
13557	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. Cancers, 2021, 13, 4152.	3.7	4
13559	Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Surgery, 2021, 8, 715318.	1.4	7
13560	Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.3	1
13561	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	2.6	12
13562	Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. Biomedicines, 2021, 9, 1021.	3.2	13
13563	Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study. British Journal of Radiology, 2021, 94, 20201088.	2.2	6
13564	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. Clinical Drug Investigation, 2021, 41, 795-808.	2.2	4
13565	Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori, 2022, 108, 19-25.	1.1	2
13566	Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study. Frontiers in Medicine, 2021, 8, 669587.	2.6	8
13567	Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports, 2021, 4, 25.	0.5	0
13568	Enzalutamide+androgen deprivation therapy (ADT) versus flutamide+ADT in Japanese men with castration-resistant prostate cancer: ATERCAB study. BJUI Compass, 2022, 3, 26-36.	1.3	9
13569	Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. European Urology Focus, 2022, 8, 1256-1269.	3.1	4
13570	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research and Treatment, 2021, 189, 641-651.	2.5	16
13571	Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. Npj Breast Cancer, 2021, 7, 108.	5.2	30
13572	The Role of Ultra-Radical Surgery in the Management of Advanced Ovarian Cancer: State of Art. , 0, , .		0
13573	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	5.2	20

#	ARTICLE	IF	CITATIONS
13574	The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion. <i>Cancer Investigation</i> , 2022, 40, 81-89.	1.3	3
13575	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. <i>Nature Communications</i> , 2021, 12, 5155.	12.8	85
13576	The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1721-1735.	2.5	3
13577	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. <i>Gynecologic Oncology</i> , 2021, 163, 93-99.	1.4	14
13578	Drug-Eluting Beads Bronchial Arterial Chemoembolization in Treating Relapsed/Refractory Small Cell Lung Cancer Patients: Results from a Pilot Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 6239-6248.	1.9	10
13579	Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4717-4725.	7.0	9
13580	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. <i>Nature Medicine</i> , 2021, 27, 1553-1563.	30.7	41
13581	Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report. <i>Annals of Oncology</i> , 2021, 32, 1447-1449.	1.2	13
13582	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
13583	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162.	2.4	14
13584	A Single-arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 325-332.	1.9	3
13585	Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. <i>Cancers</i> , 2021, 13, 4399.	3.7	1
13586	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	3.4	71
13587	Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report. <i>Anti-Cancer Drugs</i> , 2022, 33, e784-e788.	1.4	2
13588	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
13589	Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. <i>PLoS Medicine</i> , 2021, 18, e1003734.	8.4	35
13590	Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 368-375.	1.3	6
13591	A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 887-897.	2.3	6

#	ARTICLE	IF	CITATIONS
13592	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	2.6	19
13593	Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab. <i>Molecular and Clinical Oncology</i> , 2021, 15, 214.	1.0	1
13594	Tumor Blood Flow Is a Predictor of Radiotherapy Response in Patients With Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 567954.	2.8	3
13595	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study. <i>Scientific Reports</i> , 2021, 11, 15623.	3.3	16
13596	The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma: A Randomized Controlled Trial. <i>Frontiers in Oncology</i> , 2021, 11, 723193.	2.8	7
13597	Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3599.	2.4	4
13598	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6971-6984.	2.8	21
13599	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	12.8	42
13600	Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting—initial results. <i>Acta Radiologica Open</i> , 2021, 10, 205846012110306.	0.6	1
13601	Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4224.	3.7	9
13602	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. <i>Journal of Clinical Medicine</i> , 2021, 10, 3744.	2.4	11
13603	A survival mediation model with Bayesian model averaging. <i>Statistical Methods in Medical Research</i> , 2021, 30, 2413-2427.	1.5	4
13604	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	2.4	10
13605	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	1.1	0
13606	Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	5
13607	Bleomycin Concentration in Patients' Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group. <i>Pharmaceutics</i> , 2021, 13, 1324.	4.5	5
13608	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	1.5	3
13609	RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody. <i>European Journal of Radiology</i> , 2021, 141, 109823.	2.6	4

#	ARTICLE	IF	CITATIONS
13610	Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition. <i>Thrombosis Update</i> , 2021, 4, 100056.	0.9	4
13611	Understanding the Lymphatics: An Updated Review of the N Category of the AJCC 8th Edition for Urogenital Cancers. <i>American Journal of Roentgenology</i> , 2021, 217, 368-377.	2.2	2
13612	White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome. <i>Pathology Research and Practice</i> , 2021, 224, 153543.	2.3	0
13613	Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study. <i>Cancers</i> , 2021, 13, 3991.	3.7	6
13614	Development of a model to predict pathologic response to chemotherapy in patients with colorectal liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1498-1508.	1.4	4
13615	Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 6755-6766.	1.9	2
13616	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
13617	Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2069-2077.	2.5	13
13618	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , 2021, 127, 4585-4593.	4.1	7
13619	Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer. <i>Radiation Oncology</i> , 2021, 16, 161.	2.7	14
13621	Neoadjuvant Chemotherapy Versus Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 718556.	2.8	5
13622	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	1.5	8
13623	Optical “Magnetic probe for evaluating cancer therapy. <i>Coordination Chemistry Reviews</i> , 2021, 441, 213978.	18.8	15
13624	Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial. <i>Radiology</i> , 2021, 301, 474-484.	7.3	20
13625	Estimation of delivered dose to lung tumours considering setup uncertainties and breathing motion in a cohort of patients treated with stereotactic body radiation therapy. <i>Physica Medica</i> , 2021, 88, 53-64.	0.7	5
13626	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	2
13627	Ultrasound-guided fine needle aspiration cytology of Para-aortic lymph node metastasis in uterine cervical cancer: diagnostic accuracy and impact on clinical decision making. <i>BMC Cancer</i> , 2021, 21, 964.	2.6	1
13628	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 401-414.	1.5	11

#	ARTICLE	IF	CITATIONS
13629	Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC). <i>Diagnostics</i> , 2021, 11, 1430.	2.6	7
13630	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 775-791.	2.2	8
13631	Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. <i>Pharmacological Research</i> , 2021, 170, 105734.	7.1	7
13632	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-“PD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	2.8	7
13633	Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. <i>Current Problems in Cancer</i> , 2022, 46, 100787.	2.0	5
13634	Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 659113.	2.8	4
13635	Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles. <i>BMC Cancer</i> , 2021, 21, 939.	2.6	7
13636	¹⁷⁷ Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Biomedicines</i> , 2021, 9, 1042.	3.2	10
13637	A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 16829.	3.3	12
13638	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. <i>Annals of Oncology</i> , 2021, 32, 1381-1390.	1.2	33
13639	Overview of serum and tissue markers in colorectal cancer: a primer for radiologists. <i>Abdominal Radiology</i> , 2021, 46, 5521-5535.	2.1	2
13640	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. <i>Scientific Reports</i> , 2021, 11, 16992.	3.3	13
13641	PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 719192.	3.7	5
13642	Efficacy of Sirolimus Treatment in PEComa—10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 3705.	2.4	12
13643	Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. <i>Gynecologic Oncology</i> , 2021, 163, 162-170.	1.4	6
13644	Stent with radioactive strand insertion for inoperable hilar cholangiocarcinoma: comparison of unilateral and bilateral insertion. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1473-1479.	1.5	2
13645	Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis. <i>Cancer Research and Treatment</i> , 2022, 54, 383-395.	3.0	4
13646	A phase I/II study of rovalpituzumab tesirine in delta-like “3” expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	5.4	27

#	ARTICLE	IF	CITATIONS
13647	FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma. <i>Cancers</i> , 2021, 13, 3952.	3.7	4
13648	A nonrandom association of breast implants and the formation of desmoid tumors. <i>Breast Journal</i> , 2021, 27, 768-775.	1.0	4
13649	Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptorâ€mutant nonâ€small cell lung cancer: A prospective, multicenter, doseâ€modification study. <i>Geriatrics and Gerontology International</i> , 2021, 21, 881-886.	1.5	3
13650	Multiâ€parametric MRI (mpMRI) for treatment response assessment of radiation therapy. <i>Medical Physics</i> , 2022, 49, 2794-2819.	3.0	3
13651	Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1254-1254.	1.7	35
13652	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	3.7	5
13653	Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study. <i>Disease Markers</i> , 2021, 2021, 1-11.	1.3	0
13654	Factors That Drive Heterogeneity of Response-to-Treatment of Different Metastatic Deposits Within the Same Patients as Measured by RECIST 1.1 Analyses. <i>Academic Radiology</i> , 2021, 28, e235-e239.	2.5	5
13655	A retrospective study of the epidemiology and histological subtypes of ovarian epithelial neoplasms at Charlotte Maxeke Johannesburg Academic Hospital. <i>Southern African Journal of Gynaecological Oncology</i> , 2021, 13, 26-35.	0.3	3
13656	Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM). <i>European Radiology</i> , 2022, 32, 938-949.	4.5	4
13657	The Association between Tumour Markers and Meta-iodobenzylguanidine Scans in South African Children with High-risk Neuroblastoma. <i>Clinical Oncology</i> , 2021, 33, 517-526.	1.4	2
13658	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1â€Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	1.1	32
13659	Behavior and complications of hepatocellular adenoma during pregnancy and puerperium: a retrospective study and systematic review. <i>Hpb</i> , 2021, 23, 1152-1163.	0.3	10
13660	Malignant transformation of metastatic giant cell tumor of bone in a patient undergoing denosumab treatment: A case report. <i>Journal of Orthopaedic Science</i> , 2023, 28, 1492-1496.	1.1	2
13661	Serum levels of VCAMâ€1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	3.4	5
13662	Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 4080.	3.7	8
13663	Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 107.e1-107.e9.	1.6	1
13664	Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, , .	0.2	0

#	ARTICLE	IF	CITATIONS
13665	The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutationsâ€”The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. <i>Frontiers in Oncology</i> , 2021, 11, 646577.	2.8	12
13666	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939.	2.4	9
13667	Surgical perspective in neoadjuvant chemoimmunotherapy for stage <sc>II</sc>â€”<sc>III</sc> nonâ€”small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2796-2802.	1.9	11
13668	Treatment of refractory mycetoma by radiotherapy: a case study and review. <i>Precision Radiation Oncology</i> , 0, , .	1.1	1
13669	A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. <i>Targeted Oncology</i> , 2021, 16, 633-642.	3.6	8
13670	Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, , 1.	2.0	5
13671	Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	1
13672	The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. <i>Anti-Cancer Drugs</i> , 2022, 33, e635-e643.	1.4	4
13673	Use of dynamic contrast-enhanced MRI for the early assessment of outcome of CyberKnife stereotactic radiosurgery for patients with spinal metastases. <i>Clinical Radiology</i> , 2021, 76, 864.e1-864.e6.	1.1	3
13674	The Initial Step Towards Establishing a Quantitative, Magnetic Resonance Imaging-Based Framework for Response Assessment of Spinal Metastases After Stereotactic Body Radiation Therapy. <i>Neurosurgery</i> , 2021, 89, 884-891.	1.1	6
13675	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 689-699.	2.5	21
13676	Perfusion imaging of neuroblastoma and nephroblastoma in a paediatric population using pseudo-continuous arterial spin-labelling magnetic resonance imaging. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, , 1.	2.0	0
13677	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression â‰¥50%. <i>Future Oncology</i> , 2021, 17, 3007-3016.	2.4	6
13678	Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. <i>Oncologist</i> , 2021, 26, 854-864.	3.7	16
13679	Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. <i>European Journal of Cancer</i> , 2021, 153, 142-152.	2.8	12
13680	High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy. <i>Current Cancer Therapy Reviews</i> , 2022, 18, 14-40.	0.3	1
13681	A phase I study of the <sc>anaplastic lymphoma kinase</sc> inhibitor ceritinib in combination with <sc>gemcitabineâ€”based</sc> chemotherapy in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 2063-2074.	5.1	8
13682	Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. <i>Transplant International</i> , 2021, 34, 1722-1732.	1.6	27

#	ARTICLE	IF	CITATIONS
13683	The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score ≥49%: a network meta-analysis. Translational Lung Cancer Research, 2021, 10, 3550-3566.	2.8	4
13684	Proton stereotactic body radiation therapy for liver metastases—results of 5-year experience for 81 hepatic lesions. Journal of Gastrointestinal Oncology, 2021, 12, 1753-1760.	1.4	6
13685	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 103.	5.2	17
13686	The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy. Cancer Management and Research, 2021, Volume 13, 6065-6078.	1.9	5
13687	Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer. Bioscience Reports, 2021, 41, .	2.4	7
13688	Initial clinical experience with ⁹⁰ Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. Journal of Nuclear Medicine, 2021, , jnumed.121.262468.	5.0	64
13689	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. Scientific Reports, 2021, 11, 16333.	3.3	14
13690	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. Scientific Reports, 2021, 11, 16457.	3.3	1
13691	Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer. Pancreas, 2021, 50, 957-964.	1.1	5
13692	NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer. Oncogene, 2021, 40, 5993-6006.	5.9	21
13693	A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncology, 2021, 119, 105366.	1.5	31
13694	Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients. Reports of Practical Oncology and Radiotherapy, 2021, 26, 747-755.	0.6	0
13695	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Scientific Reports, 2021, 11, 16663.	3.3	30
13696	Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical Cancer Research, 2022, 28, 187-200.	7.0	19
13697	Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. JAMA Oncology, 2021, 7, e213428.	7.1	18
13698	Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial). ESMO Open, 2021, 6, 100208.	4.5	7
13699	Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	4.5	6
13700	Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1122-1135.	7.3	47

#	ARTICLE	IF	CITATIONS
13701	ONCOGRAM: study protocol for the evaluation of therapeutic response and survival of metastatic colorectal cancer patients treated according to the guidelines of a chemosensitivity assay, the Oncogramme®. Trials, 2021, 22, 556.	1.6	0
13702	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5760-5770.	7.0	25
13703	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 2078-2090.	1.1	29
13704	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clinical Cancer Research, 2021, 27, 5781-5792.	7.0	30
13705	Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. Cancer Management and Research, 2021, Volume 13, 6833-6845.	1.9	4
13706	Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer. , 2021, 9, e002752.		2
13707	Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer. Journal of Nippon Medical School, 2021, 88, 354-360.	0.9	1
13708	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. European Urology, 2021, 80, 693-700.	1.9	65
13709	Long-term effect of everolimus in recurrent thymic neuroendocrine neoplasia. Clinical Endocrinology, 2021, 95, 744-751.	2.4	5
13710	A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Investigational New Drugs, 2021, , 1.	2.6	0
13711	Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience. International Journal of Clinical Oncology, 2021, 26, 2275-2281.	2.2	9
13712	Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncology, 2021, 17, 3445-3456.	2.4	7
13713	Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage SCLC: Results From the Phase 3 MERU Study. Journal of Thoracic Oncology, 2021, 16, 1570-1581.	1.1	65
13714	A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology. Pharmacology Research and Perspectives, 2021, 9, e00862.	2.4	2
13715	Liquid biopsy: the current state of the issue. Innovative Medicine of Kuban, 2021, , 57-63.	0.2	1
13716	Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Investigational New Drugs, 2022, 40, 290-299.	2.6	3
13717	Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer. Experimental Cell Research, 2021, 406, 112742.	2.6	5
13718	A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1129-1145.	3.7	5

#	ARTICLE	IF	CITATIONS
13719	Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma. American Journal of Roentgenology, 2021, , .	2.2	4
13720	Clinical analysis of systemic chemotherapy combined with microwave ablation in the treatment of lung cancer. Asian Journal of Surgery, 2022, 45, 1107-1112.	0.4	5
13721	Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials. Cancers, 2021, 13, 4533.	3.7	5
13722	Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis. EClinicalMedicine, 2021, 40, 101130.	7.1	16
13723	Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers, 2021, 13, 4462.	3.7	2
13724	Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. Cancers, 2021, 13, 4564.	3.7	6
13725	Non-Invasive Ultrasonic Description of Tumor Evolution. Cancers, 2021, 13, 4560.	3.7	0
13726	Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecologic Oncology, 2021, 163, 237-245.	1.4	30
13727	Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience. Oncology Research and Treatment, 2021, 44, 590-601.	1.2	3
13728	Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial. Journal of Clinical Oncology, 2021, 39, 2979-2990.	1.6	38
13729	Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report. Frontiers in Immunology, 2021, 12, 744571.	4.8	8
13730	Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World Journal of Clinical Oncology, 2021, 12, 725-745.	2.3	9
13731	Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. BMC Cancer, 2021, 21, 1033.	2.6	9
13732	Sintilimab, stereotactic body radiotherapy and granulocyte macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiation Oncology, 2021, 16, 177.	2.7	14
13733	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research, 2021, 27, 6314-6322.	7.0	22
13734	Differences between lung adenocarcinoma and squamous cell carcinoma in histological distribution of residual tumor after induction chemoradiotherapy. Discover Oncology, 2021, 12, 36.	2.1	3
13735	Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. Scientific Reports, 2021, 11, 19154.	3.3	17
13736	Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Anticancer Research, 2021, 41, 5137-5145.	1.1	6

#	ARTICLE	IF	CITATIONS
13737	Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	2
13738	Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results. <i>Surgical Oncology</i> , 2021, 38, 101636.	1.6	4
13739	¹⁷⁷ Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1075-1085.	6.4	37
13740	First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	2.8	2
13741	Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 95-99.	1.7	5
13742	Necroptosis in Esophageal Squamous Cell Carcinoma: An Independent Prognostic Factor and Its Correlation with Tumor-Infiltrating Lymphocytes. <i>Cancers</i> , 2021, 13, 4473.	3.7	11
13743	A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 728155.	2.8	9
13744	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. <i>Science Translational Medicine</i> , 2021, 13, eabd4811.	12.4	48
13745	Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study. <i>BMC Cancer</i> , 2021, 21, 1008.	2.6	7
13746	Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location. <i>American Journal of Roentgenology</i> , 2021, 217, 1141-1152.	2.2	3
13747	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro). <i>Journal of Urology</i> , 2021, 194, 1000-1007.	1.9	3
13748	Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 1489-1489.	1.7	5
13749	Design of InnoPrimers-Duplex Real-Time PCR for Detection and Treatment Response Prediction of EBV-Associated Nasopharyngeal Carcinoma Circulating Genetic Biomarker. <i>Diagnostics</i> , 2021, 11, 1761.	2.6	4
13750	Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review. <i>Precision Cancer Medicine</i> , 0, 4, 30-30.	1.8	2
13751	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. <i>Cancer Treatment Reviews</i> , 2021, 99, 102239.	7.7	13
13752	Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2429-2435.	1.0	9
13753	Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1332-1341.	2.2	8
13754	Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , 2021, 39, 3705-3715.	1.6	51

#	ARTICLE	IF	CITATIONS
13755	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3619-3625.	2.5	5
13756	Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1856-1867.	27.0	440
13757	Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. <i>Biomarker Research</i> , 2021, 9, 69.	6.8	4
13758	Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5363-5373.	1.8	1
13759	EUS-guided fiducial marker insertion for radiotherapy in advanced esophageal carcinoma: submucosal insertion may lead to less migration when compared to intratumoral insertion. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 1666-1674.	2.4	2
13760	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7012-7020.	2.8	8
13761	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e401-e408.	1.9	14
13762	Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. <i>BMC Cancer</i> , 2021, 21, 1021.	2.6	7
13763	Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors. <i>Medicine (United States)</i> , 2021, 100, e27029.	1.0	4
13764	Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e27161.	1.0	14
13765	Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. <i>Thrombosis Research</i> , 2021, 205, 29-39.	1.7	35
13766	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3693-3704.	1.6	19
13767	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	2.5	5
13768	FOXC1 modulates stem-like cell properties and chemoresistance through Hedgehog and EMT signaling in gastric adenocarcinoma. <i>Molecular Therapy</i> , 2021, , .	8.2	4
13769	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1617.	7.1	105
13770	Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. <i>Cancers</i> , 2021, 13, 4726.	3.7	13
13771	Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 526-532.	1.3	3
13772	Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. <i>Medicina (Lithuania)</i> , 2021, 57, 929.	2.0	3

#	ARTICLE	IF	CITATIONS
13773	Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 702-709.	1.6	53
13774	Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. <i>BJU International</i> , 2022, 130, 244-253.	2.5	5
13775	Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. <i>Scientific Reports</i> , 2021, 11, 18762.	3.3	13
13776	Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI. <i>Frontiers in Oncology</i> , 2021, 11, 700023.	2.8	4
13777	Combined ¹⁷⁷ Lu-PSMA-617 PRLT and abiraterone acetate versus ¹⁷⁷ Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability. <i>Prostate</i> , 2021, 81, 1225-1234.	2.3	11
13778	Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). <i>Journal of Clinical Medicine</i> , 2021, 10, 4315.	2.4	5
13779	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1063-1074.	4.2	26
13780	Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. <i>Gastroenterology</i> , 2021, 161, 814-826.e7.	1.3	36
13781	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	10.7	178
13782	Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?. <i>Annals of Medicine and Surgery</i> , 2021, 70, 102793.	1.1	29
13783	Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas. <i>Bone and Joint Research</i> , 2021, 10, 602-610.	3.6	2
13784	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. <i>Targeted Oncology</i> , 2021, 16, 569-589.	3.6	10
13785	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 1541-1559.	10.7	60
13786	Challenges in ensuring the generalizability of image quantitation methods for MRI. <i>Medical Physics</i> , 2022, 49, 2820-2835.	3.0	16
13787	An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer. <i>Anticancer Research</i> , 2021, 41, 5007-5014.	1.1	1
13788	DCE-MRI for early evaluation of therapeutic response in esophageal cancer after concurrent chemoradiotherapy and its values in predicting HIF-1 α expression. <i>Precision Medical Sciences</i> , 2021, 10, 118-126.	0.5	0
13789	Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. <i>Gynecologic Oncology</i> , 2021, 163, 392-397.	1.4	0
13790	Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1148-1156.	1.2	146

#	ARTICLE	IF	CITATIONS
13791	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. <i>Acta Oncologica</i> , 2021, 60, 1565-1571.	1.8	2
13792	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	6.4	14
13793	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	1.8	2
13794	Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3897-3907.	1.6	59
13795	Post-chemotherapy and targeted therapy imaging of the chest in lung cancer. <i>Clinical Radiology</i> , 2022, 77, e1-e10.	1.1	5
13796	Clinical Outcome of CT-Guided Stereotactic Ablative Brachytherapy for Unresectable Early Non-Small Cell Lung Cancer: A Retrospective, Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 706242.	2.8	4
13797	¹⁸ F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 899-905.	5.0	36
13798	Neo-adjuvant chemotherapy in fertility-sparing cervical cancer treatment. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 75, 82-100.	2.8	6
13799	Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor. <i>Gastric Cancer</i> , 2021, 24, 1374-1375.	5.3	0
13800	Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 709617.	2.8	3
13801	Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 78, 365-377.	1.7	4
13802	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	27.0	376
13803	LGR5, HES1 and ATOH1 in Young Rectal Cancer Patients in Egyptian. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2819-2830.	1.2	1
13804	Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. <i>Hepatology</i> , 2022, 75, 1386-1401.	7.3	27
13805	Pazopanib in rare histologies of metastatic soft tissue sarcoma. <i>Ecancermedicalscience</i> , 2021, 15, 1281.	1.1	5
13806	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021, 155, 56-63.	2.8	8
13807	Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2837-2847.	2.4	17
13808	Successful Endoscopic Sclerotherapy Using Lauromacrogol Injection for Laryngopharyngeal Hemangioma. <i>Ear, Nose and Throat Journal</i> , 2021, 100, 662-666.	0.8	6

#	ARTICLE	IF	CITATIONS
13809	Contrast-enhanced spectral mammography in the radiological assessment of response to neoadjuvant chemotherapy in breast cancer. Journal of Medical Science, 0, , e521.	0.7	0
13810	Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma. Updates in Surgery, 2021, , 1.	2.0	0
13812	Temporal subtraction CT with nonrigid image registration improves detection of bone metastases by radiologists: results of a large-scale observer study. Scientific Reports, 2021, 11, 18422.	3.3	3
13813	Learning from the past to advance tomorrow's real-world evidence: what demonstration projects have to teach us. Journal of Comparative Effectiveness Research, 2021, 10, 1169-1173.	1.4	3
13814	BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC). Anticancer Research, 2021, 41, 4463-4470.	1.1	0
13815	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer, 2021, 154, 253-268.	2.8	8
13816	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Investigational New Drugs, 2022, 40, 392-402.	2.6	36
13818	The Prognostic Significance of a Histological Response to Preoperative Chemotherapy in Patients With Synchronous Colorectal Liver Metastases. International Surgery, 2022, 106, 5-17.	0.1	0
13819	RBMX Protein Expression in T-Cell Lymphomas Predicts Chemotherapy Response and Prognosis. Cancers, 2021, 13, 4788.	3.7	6
13820	A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer. Journal of Clinical Medicine, 2021, 10, 4011.	2.4	12
13821	Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer, 2021, 10, 561-571.	7.7	11
13822	Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment. Surgical Oncology, 2021, 38, 101629.	1.6	4
13823	Precision Nuclear Medicine. Radiologic Clinics of North America, 2021, 59, 755-772.	1.8	3
13824	Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. Scientific Reports, 2021, 11, 17947.	3.3	9
13825	Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers. Frontiers in Molecular Medicine, 2021, 1, .	1.9	1
13826	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	12.8	19
13827	Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational New Drugs, 2022, 40, 106-114.	2.6	0
13828	Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis. Frontiers in Genetics, 2021, 12, 608324.	2.3	1

#	ARTICLE	IF	CITATIONS
13829	Successful En Bloc Resection of Locally Advanced Pancreatic Tail Cancer with Colonic Perforation Following Neoadjuvant Chemotherapy: A Case Report. American Journal of Case Reports, 2021, 22, e933226.	0.8	2
13830	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Seminars in Liver Disease, 2022, 42, 087-103.	3.6	10
13831	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 837.e9-837.e17.	1.6	3
13832	Predictive value of red blood cell distribution width level on histological response and prognosis in colorectal liver metastases. Annals of Palliative Medicine, 2021, 10, 9383-9397.	1.2	0
13833	Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China. Annals of Translational Medicine, 2021, 9, 1480-1480.	1.7	7
13834	Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 111-121.	2.6	7
13835	Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization. Abdominal Radiology, 2021, , 1.	2.1	2
13836	Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. Cancers, 2021, 13, 4742.	3.7	5
13837	Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. Anticancer Research, 2021, 41, 4555-4562.	1.1	7
13838	Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. Carcinogenesis, 2021, 42, 1239-1249.	2.8	13
13839	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. JTO Clinical and Research Reports, 2021, 2, 100231.	1.1	16
13840	Analysis of Hepatocellular Carcinoma Stereotactic Body Radiation Therapy Dose Prescription Method Using Uncomplicated Tumor Control Probability Model. Advances in Radiation Oncology, 2021, 6, 100739.	1.2	6
13841	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
13842	A Clinical-Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Gallbladder Cancer. Frontiers in Oncology, 2021, 11, 633852.	2.8	6
13843	Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, 1064-1070.	1.1	3
13844	Intracranial meningioma surveillance using volumetrics from T2-weighted MRI. Journal of Neuroimaging, 2021, , .	2.0	3
13845	Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 641044.	2.8	2
13846	White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung, 2021, 199, 549-557.	3.3	6

#	ARTICLE	IF	CITATIONS
13847	Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification. <i>Medicine (United States)</i> , 2021, 100, e27017.	1.0	1
13848	Brigatinib Versus Crizotinib in ALK Inhibitor-“Naïve Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	1.1	156
13849	Neoadjuvant Chemotherapy Followed by Surgery Versus Abdominal Radical Hysterectomy Alone for Oncological Outcomes of Stage IB3 Cervical Cancer-“A Propensity Score Matching Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 730753.	2.8	6
13850	Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series. <i>Oncologist</i> , 2021, 26, e2247-e2253.	3.7	11
13851	DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 708294.	2.8	15
13852	Predicting Response to Systemic Chemotherapy for Advanced Gastric Cancer Using Pre-Treatment Dual-Energy CT Radiomics: A Pilot Study. <i>Frontiers in Oncology</i> , 2021, 11, 740732.	2.8	7
13853	Circulating Tumor Cells and TWIST Expression in Patients with Metastatic Gastric Cancer: A Preliminary Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4481.	2.4	9
13854	“Neuroendocrine Tumor Grade 3 (NET G3)” of the Uterine Cervix. <i>International Journal of Gynecological Pathology</i> , 2021, Publish Ahead of Print, .	1.4	4
13855	Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2021, 32, 1618-1625.	1.2	15
13856	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. <i>Cancer Medicine</i> , 2021, 10, 7503-7513.	2.8	4
13857	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. , 2021, 9, e003122.		9
13858	Case Report:clinical experience of bilateral giant pediatric Testicular adrenal rest tumors with 3 Beta-Hydroxysteroid Dehydrogenase-2 family history. <i>BMC Pediatrics</i> , 2021, 21, 405.	1.7	2
13859	Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. <i>Cancers</i> , 2021, 13, 4514.	3.7	6
13860	Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. <i>British Journal of Radiology</i> , 2022, 95, 20210842.	2.2	10
13862	Soft Tissue Sarcomas: The Role of Quantitative MRI in Treatment Response Evaluation. <i>Academic Radiology</i> , 2022, 29, 1065-1084.	2.5	10
13863	TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. <i>Translational Oncology</i> , 2021, 14, 101163.	3.7	11
13864	Utilization of Mutational Analysis (MA) in Gastrointestinal Stromal Tumor (GIST) Management in British Columbia (BC) Between January 2008 to December 2017: a Retrospective Population-Based Study. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	1.3	2
13865	Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 1137-1147.	1.2	94

#	ARTICLE	IF	CITATIONS
13866	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 1751-1756.	1.3	7
13867	Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival. Thoracic Cancer, 2021, 12, 2740-2748.	1.9	7
13868	Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs. Medicina (Lithuania), 2021, 57, 967.	2.0	1
13869	Ovarian cancer staging: What the surgeon needs to know. British Journal of Radiology, 2021, 94, 20210091.	2.2	4
13870	Efficacy and Safety of Chinese Herbal Medicine on Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials. The American Journal of Chinese Medicine, 2021, 49, 1557-1575.	3.8	10
13871	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. Practical Radiation Oncology, 2022, 12, e34-e39.	2.1	3
13872	Repurposing Routine Imaging for Cancer Biomarker Discovery Using Machine Learning. Intelligent Systems Reference Library, 2022, , 153-176.	1.2	2
13873	Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell International, 2021, 21, 503.	4.1	14
13874	Quantitative dual-energy CT techniques in the abdomen. Abdominal Radiology, 2022, 47, 3003-3018.	2.1	12
13875	Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. Contemporary Clinical Trials Communications, 2021, 23, 100827.	1.1	0
13876	Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy. European Journal of Radiology, 2021, 142, 109863.	2.6	16
13877	PET Imaging for Breast Cancer. Radiologic Clinics of North America, 2021, 59, 725-735.	1.8	15
13878	Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respiratory Medicine, the, 2021, 9, 969-976.	10.7	29
13879	Efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real-world study. Hepatology Research, 2021, 51, 1153-1163.	3.4	4
13880	The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. Clinical Lung Cancer, 2021, 22, 432-440.	2.6	16
13881	Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Investigational New Drugs, 2021, , 1.	2.6	0
13882	Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. International Journal of Cancer, 2022, 150, 100-111.	5.1	11
13883	Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines. BMC Cancer, 2021, 21, 1049.	2.6	1

#	ARTICLE	IF	CITATIONS
13884	<scp>First-In-Human</scp>, <scp>First-In-Class</scp>, Phase I Trial of the Fucosylation Inhibitor <scp>SGN-2FF</scp> in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, 925-e1918.	3.7	15
13885	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. <i>Gynecologic Oncology</i> , 2021, 162, 652-660.	1.4	17
13886	Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma. , 2021, 9, e003125.		13
13887	Radiologic criteria of retropharyngeal lymph node metastasis in maxillary sinus cancer. <i>Radiation Oncology</i> , 2021, 16, 190.	2.7	5
13888	Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2240-2249.	4.1	20
13889	The Impact of Tumor-associated Macrophages on Chemoresistance <i>via</i> Angiogenesis in Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 4447-4453.	1.1	4
13890	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stageÂsmall-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1093-1101.	4.2	23
13891	Computed tomography-derived biomarker for predicting the treatment response to neoadjuvant chemoradiotherapy of rectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2246-2254.	2.2	1
13892	Short-Term Clinical Efficacy of Neoadjuvant Chemotherapy Combined With Laparoscopic Gastrectomy for Locally Advanced Siewert Type II and III Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Propensity Score-Matched Study. <i>Frontiers in Oncology</i> , 2021, 11, 690662.	2.8	1
13893	Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 1633-1641.	2.2	6
13894	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. <i>Molecular Oncology</i> , 2021, 15, 2910-2922.	4.6	23
13895	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. <i>Journal of Thoracic Oncology</i> , 2021, , .	1.1	21
13896	Lutetium-177â€PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	27.0	1,042
13898	Theranostics in oncology: What radiologists want to know. <i>European Journal of Radiology</i> , 2021, 142, 109875.	2.6	2
13899	Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	1.9	3
13900	The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-7.	1.3	6
13901	Surgical Approaches and Oncological Outcomes in the Management of Duodenal Gastrointestinal Stromal Tumors (GIST). <i>Journal of Clinical Medicine</i> , 2021, 10, 4459.	2.4	6
13902	Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. <i>European Journal of Cancer</i> , 2021, 154, 102-110.	2.8	6

#	ARTICLE	IF	CITATIONS
13903	Less-invasive fascia-preserving surgery for abdominal wall desmoid. Scientific Reports, 2021, 11, 19379.	3.3	3
13904	Advanced Deep Network with Attention and Genetic-Driven Reinforcement Learning Layer for an Efficient Cancer Treatment Outcome Prediction. , 2021, , .		0
13905	MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiotherapy and Oncology, 2021, 164, 73-82.	0.6	35
13906	Objective criteria for MRI evaluation of the effectiveness of treatment of bone metastases in patients with prostate cancer and breast cancer: systematic review and meta-analysis. Digital Diagnostics, 0, , .	0.6	1
13907	The Wessex Fit-4-Cancer Surgery Trial (WesFit): a protocol for a factorial-design, pragmatic randomised-controlled trial investigating the effects of a multi-modal prehabilitation programme in patients undergoing elective major intraabdominal cavity cancer surgery. F1000Research, 0, 10, 952.	1.6	4
13908	Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. JTO Clinical and Research Reports, 2021, 2, 100234.	1.1	10
13909	Comparison between RECIST 1.1, Choi and PERCIST 1.0 criteria to evaluate response to SBRT of liver metastasis. AME Medical Journal, 0, 6, 26-26.	0.4	0
13910	Features of pain syndrome in patients with bone metastasis. Voprosy Onkologii, 2021, 67, 569-578.	0.2	0
13911	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13044.	2.6	14
13912	Carcinosarcoma of the Thoracic Esophagus That Presented as Focal Ulcerative Lesion. Case Reports in Gastroenterology, 2022, 15, 795-800.	0.6	1
13913	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine, 2021, 19, 384.	4.4	6
13914	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nature Communications, 2021, 12, 5262.	12.8	40
13915	Aggressive pituitary tumours and pituitary carcinomas. Nature Reviews Endocrinology, 2021, 17, 671-684.	9.6	60
13916	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. JAMA Oncology, 2021, 7, 1669.	7.1	194
13917	Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report. Molecular and Clinical Oncology, 2021, 15, 243.	1.0	4
13918	Impact of Computed Tomography-Based, Artificial Intelligence-Driven Volumetric Sarcopenia on Survival Outcomes in Early Cervical Cancer. Frontiers in Oncology, 2021, 11, 741071.	2.8	11
13919	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study. PLoS ONE, 2021, 16, e0257551.	2.5	0
13920	Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. International Journal of Cancer, 2022, 150, 317-326.	5.1	12

#	ARTICLE	IF	CITATIONS
13921	MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 711642.	2.8	2
13922	Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 5025-5031.	1.1	2
13924	Prediction of chemotherapy response in breast cancer patients at pre-treatment using second derivative texture of CT images and machine learning. <i>Translational Oncology</i> , 2021, 14, 101183.	3.7	13
13925	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103460.	4.4	3
13926	Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptorâ€“positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. <i>European Journal of Cancer</i> , 2021, 156, 70-82.	2.8	14
13927	Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2021, 31, 371-388.	2.2	16
13928	Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?. <i>Radiotherapy and Oncology</i> , 2021, 163, 185-191.	0.6	3
13929	Rim enhancement on hepatobiliary phase of pre-treatment 3.0Â T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX. <i>European Journal of Radiology</i> , 2021, 143, 109887.	2.6	2
13930	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	3.7	217
13931	Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapyÂ or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option. <i>European Journal of Cancer</i> , 2021, 156, 175-186.	2.8	3
13932	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2022, 81, 274-282.	1.9	55
13933	Learning From Multiple Datasets With Heterogeneous and Partial Labels for Universal Lesion Detection in CT. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 2759-2770.	8.9	35
13934	eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 36-43.	2.0	11
13935	Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2595-2601.	1.0	3
13936	Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 75, 879-887.	3.7	12
13937	Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. <i>Journal of Geriatric Oncology</i> , 2022, 13, 207-213.	1.0	7
13938	Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway. <i>Lung Cancer</i> , 2021, 160, 28-31.	2.0	7
13939	Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 121, 105480.	1.5	6

#	ARTICLE	IF	CITATIONS
13940	Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 479-490.	0.8	3
13941	The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. <i>Breast</i> , 2021, 59, 58-66.	2.2	4
13942	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	1.6	34
13943	Late phase 1 studies: concepts and outcomes. <i>Lancet Oncology</i> , The, 2021, 22, e446-e455.	10.7	2
13944	Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report. <i>Surgical Case Reports</i> , 2021, 7, 221.	0.6	2
13945	The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4157-4166.	4.3	1
13946	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 4061-4068.	1.6	24
13947	Whole-body MRI: a practical guide for imaging patients with malignant bone disease. <i>Clinical Radiology</i> , 2021, 76, 715-727.	1.1	11
13948	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021, 156, 149-163.	2.8	11
13949	Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1291-1302.	0.7	0
13950	Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 396-404.	1.9	13
13951	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e9-735.e16.	1.6	15
13952	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1438-1447.	10.7	45
13953	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021, 156, 1-11.	2.8	24
13954	Descriptive analysis of MRI functional changes occurring during reduced dose radiotherapy for myxoid liposarcomas. <i>British Journal of Radiology</i> , 2021, 94, 20210310.	2.2	1
13955	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. <i>ESMO Open</i> , 2021, 6, 100230.	4.5	15
13956	Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. <i>Lung Cancer</i> , 2021, 160, 44-49.	2.0	1
13957	A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 722039.	2.8	12

#	ARTICLE	IF	CITATIONS
13958	PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. , 2021, 9, e002955.		8
13959	PET/MRI Improves Management of Children with Cancer. Journal of Nuclear Medicine, 2021, 62, 1334-1340.	5.0	12
13960	Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study. Translational Oncology, 2021, 14, 101187.	3.7	4
13961	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	2.8	42
13962	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02â€“15 study). Lung Cancer, 2021, 161, 122-127.	2.0	2
13963	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. European Journal of Cancer, 2021, 157, 40-49.	2.8	3
13964	Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer. Cancer Genetics, 2021, 258-259, 27-36.	0.4	2
13965	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung Cancer, 2021, 161, 60-67.	2.0	2
13966	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. European Journal of Cancer, 2021, 157, 428-440.	2.8	26
13967	Carbon Ion Radiation Therapy for Postoperative Pelvic Recurrence of Rectal Cancer With a Large Tumor Infiltrating and Compressing the Rectum: A Case Report. Advances in Radiation Oncology, 2021, 6, 100774.	1.2	1
13968	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. Cancer Treatment Reviews, 2021, 100, 102293.	7.7	3
13969	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500) Tj ETQq1 1 0.784314 rgBT /Overlock 373-382.	2.8	9
13970	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer, 2021, 157, 21-30.	2.8	18
13971	Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Oral Oncology, 2021, 122, 105520.	1.5	4
13972	A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung Cancer, 2021, 161, 49-54.	2.0	9
13973	Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. European Journal of Cancer, 2021, 157, 153-164.	2.8	10
13974	Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptorâ€“Mutant Non-Small Cell Lung Cancer With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 111, 804-815.	0.8	22
13975	Progress and challenges of immunotherapy in triple-negative breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188593.	7.4	106

#	ARTICLE	IF	CITATIONS
13976	Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2021, 522, 198-210.	7.2	20
13977	On optimal subset designs for phase II clinical trials with both total response and disease control. <i>Journal of Statistical Planning and Inference</i> , 2021, 215, 85-94.	0.6	0
13978	Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids. <i>Journal of Ethnopharmacology</i> , 2022, 283, 114676.	4.1	5
13979	Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 21-32.	1.2	5
13980	A Bayesian adaptive design for biosimilar trials with time-to-event endpoint. <i>Pharmaceutical Statistics</i> , 2021, 20, 597-609.	1.3	1
13981	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). <i>Breast Care</i> , 2021, 16, 1-9.	1.4	3
13982	Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. <i>Radiation Oncology</i> , 2021, 16, 18.	2.7	14
13983	Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome. <i>Scientific Reports</i> , 2021, 11, 1794.	3.3	3
13984	Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 384.	2.4	4
13985	A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers. <i>Targeted Oncology</i> , 2021, 16, 177-187.	3.6	3
13986	Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy. <i>Korean Journal of Radiology</i> , 2021, 22, 366.	3.4	9
13987	Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e73.	2.2	4
13988	Thymic epithelial tumors: Do we know all the prognostic factors?. <i>Thoracic Cancer</i> , 2021, 12, 339-348.	1.9	8
13989	Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 120.	3.7	18
13990	A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e64.	2.2	2
13991	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. <i>Oncolimmunology</i> , 2021, 10, 1863631.	4.6	16
13992	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
13993	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	27

#	ARTICLE	IF	CITATIONS
13994	Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110228.	3.2	5
13995	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	7.0	38
13996	A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study. <i>Gut and Liver</i> , 2021, 15, 135-141.	2.9	15
13997	Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study. <i>Cancer Science</i> , 2021, 112, 1114-1122.	3.9	13
13998	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021, 10, 314-325.	2.8	13
13999	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e21.	2.2	7
14000	Diagnostic and prognostic value of heat shock protein 90 α in malignant melanoma. <i>Melanoma Research</i> , 2021, 31, 152-161.	1.2	5
14001	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1745-1753.	4.2	1
14002	Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110337.	3.2	8
14003	Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response. <i>Anticancer Research</i> , 2021, 41, 497-502.	1.1	5
14004	The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	2
14005	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 343-352.	1.4	13
14006	Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma. <i>4open</i> , 2021, 4, 3.	0.4	2
14007	Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. <i>Korean Journal of Radiology</i> , 2021, 22, 1310.	3.4	4
14008	Lung Nodule Malignancy Prediction in Sequential CT Scans: Summary of ISBI 2018 Challenge. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 3748-3761.	8.9	13
14009	Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab. <i>In Vivo</i> , 2021, 35, 1743-1747.	1.3	5
14010	Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110363.	1.9	6
14011	Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2021, 10, 399-407.	2.4	19

#	ARTICLE	IF	CITATIONS
14012	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. <i>Chemotherapy</i> , 2021, 66, 65-71.	1.6	4
14013	<i>Bifidobacterium bifidum</i> strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. <i>Nature Microbiology</i> , 2021, 6, 277-288.	13.3	130
14014	AIM and Brain Tumors. , 2021, , 1-16.		0
14015	The Role of Serum 5-HIAA as a Predictor of Progression and an Alternative to 24-h Urine 5-HIAA in Well-Differentiated Neuroendocrine Neoplasms. <i>Biology</i> , 2021, 10, 76.	2.8	12
14016	Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 2975-2985.	1.5	19
14017	Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. <i>Endocrine Journal</i> , 2021, 68, 671-681.	1.6	2
14018	PET Diagnosis and Response Monitoring in Oncology. , 2021, , 1049-1076.		0
14019	Molecular and Functional Imaging in Central Nervous System Drug Development. , 2021, , 1489-1502.		0
14020	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 175-181.	1.7	13
14021	Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 26.	17.1	112
14022	Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer. <i>Journal of Medical Economics</i> , 2021, 24, 1124-1133.	2.1	2
14023	Immune Therapy: What Can We Learn From Acquired Resistance?. <i>Current Cancer Research</i> , 2021, , 75-114.	0.2	0
14024	Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study. <i>BMC Cancer</i> , 2021, 21, 16.	2.6	5
14025	Predictive value of microvessel features for the clinical response to neoadjuvant chemotherapy in cervical squamous carcinoma and the associations with prognosis. <i>Translational Cancer Research</i> , 2021, 10, 162-173.	1.0	3
14026	Efficacy and safety of Chinese patent medicine (Kang-ai injection) as an adjuvant in the treatment of patients with hepatocellular carcinoma: a meta-analysis. <i>Pharmaceutical Biology</i> , 2021, 59, 470-481.	2.9	7
14027	Predicting the Local Response of Metastatic Brain Tumor to Gamma Knife Radiosurgery by Radiomics With a Machine Learning Method. <i>Frontiers in Oncology</i> , 2020, 10, 569461.	2.8	20
14028	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021, 13, 11.	8.2	17
14029	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. <i>Liver Cancer</i> , 2021, 10, 380-393.	7.7	51

#	ARTICLE	IF	CITATIONS
14030	Radiopeptide Infusions of Hepatic Metastases After Temporal Implementation of an Intra-arterial Port System. , 2021, , 107-117.		0
14031	Preoperative Therapy in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. , 2021, , 729-741.		0
14033	A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 2021, 5, 297-308.	22.5	28
14034	Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers, 2021, 13, 420.	3.7	3
14035	A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Translational Lung Cancer Research, 2021, 10, 252-260.	2.8	5
14036	Roles of the SNHG7/microRNA-95p/DPP4 ceRNA network in the growth and ¹³¹ I resistance of thyroid carcinoma cells through PI3K/Akt activation. Oncology Reports, 2021, 45, .	2.6	10
14037	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer. Cancer Research and Treatment, 2021, 53, 87-92.	3.0	0
14038	Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemotherapy and Pharmacology, 2021, 87, 543-553.	2.3	14
14039	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemotherapy and Pharmacology, 2021, 87, 397-404.	2.3	5
14040	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. Cancers, 2021, 13, 358.	3.7	11
14041	Treatment of Unresectable Differentiated Thyroid Carcinoma With Upfront External Radiotherapy and Salvage Surgery: A STROBE-Compliant Retrospective Cohort Study. Frontiers in Oncology, 2020, 10, 572958.	2.8	4
14042	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy. Scientific Reports, 2021, 11, 296.	3.3	6
14043	Cabozantinib real-world effectiveness in the first- through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221.	2.8	22
14044	Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100115.	1.1	3
14045	CASE REPORT: TREATMENT OF PLEOMORPHIC RHABDOMYOSARCOMA IN ADULT. , 2021, , 1-3.		0
14046	Advanced Non-linear Generative Model with a Deep Classifier for Immunotherapy Outcome Prediction: A Bladder Cancer Case Study. Lecture Notes in Computer Science, 2021, , 227-242.	1.3	3
14047	Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma. In Vivo, 2021, 35, 1253-1259.	1.3	5
14048	The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. Journal of Cancer, 2021, 12, 379-386.	2.5	8

#	ARTICLE	IF	CITATIONS
14049	The efficacy and safety of the combination of axitinib and pembrolizumabâ€activated autologous DCâ€CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. Clinical and Translational Immunology, 2021, 10, e1257.	3.8	4
14050	Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. Frontiers in Oncology, 2020, 10, 613089.	2.8	4
14051	MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 368-380.	2.8	18
14052	Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setting. , 2021, , 49-57.		0
14053	Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients. Cancer Treatment and Research Communications, 2021, 28, 100410.	1.7	17
14054	Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis. Chemotherapy, 2021, 66, 58-64.	1.6	3
14055	Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study. Cancer Treatment and Research Communications, 2021, 27, 100368.	1.7	3
14056	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. Neuroendocrinology, 2022, 112, 88-100.	2.5	6
14057	Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 137-142.	1.3	3
14058	Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. Journal of Cancer, 2021, 12, 5753-5759.	2.5	3
14059	The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Surgery Today, 2021, 51, 1099-1107.	1.5	5
14060	Response Evaluation After Radiotherapy. , 2021, , 285-294.		0
14061	Survival Impact of Surgical Resection in Locally Advanced T4b Oral Squamous Cell Carcinoma. Laryngoscope, 2021, 131, E2266-E2274.	2.0	13
14062	Combining regulatory and exploratory trials. , 2021, , 251-255.		0
14063	The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. International Journal of Clinical Oncology, 2021, 26, 954-961.	2.2	9
14064	NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study. Current Therapeutic Research, 2021, 94, 100631.	1.2	2
14065	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110384.	3.2	10
14066	A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International Journal of Clinical Oncology, 2021, 26, 941-950.	2.2	15

#	ARTICLE	IF	CITATIONS
14067	Prognostic significance of 8 weeksâ€™ relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. <i>Endocrine Journal</i> , 2021, 68, 639-647.	1.6	9
14068	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. <i>JCO Precision Oncology</i> , 2021, 5, 133-144.	3.0	22
14069	Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
14070	Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
14071	A Machine Learning Tool to Predict the Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 823.	2.5	18
14072	Changes in the diversity of local cervical bacteria in women with cervical cancer receiving antineoplastic treatment. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 56.	0.9	1
14073	Hepatic metastases in gastrointestinal stromal tumors: oncologic outcomes with curative-intent hepatectomy, resection of treatment-resistant disease, and tyrosine kinase inhibitor therapy alone. <i>Hpb</i> , 2021, 23, S465-S466.	0.3	0
14074	First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma. <i>Oncology</i> , 2021, 99, 622-631.	1.9	4
14075	Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 659-669.	2.2	1
14076	The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. <i>Frontiers in Oncology</i> , 2020, 10, 570465.	2.8	60
14077	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110365.	3.2	24
14078	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	7.7	20
14079	Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept. <i>Anticancer Research</i> , 2021, 41, 533-541.	1.1	3
14080	A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110Î± in cell lines and tumor tissues. <i>Analyst</i> , The, 2021, 146, 6566-6575.	3.5	1
14081	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. <i>Nature Communications</i> , 2021, 12, 574.	12.8	39
14082	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€™urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	2.8	10
14083	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	4.0	22
14084	A lowâ€™grade malignant soft tissue tumor with <sc>S100</sc> and <sc>CD34</sc> coâ€™expression showing novel <sc><i>CDC42SE2â€™BRAF</i></sc> fusion with distinct features. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 595-600.	2.8	14

#	ARTICLE	IF	CITATIONS
14085	<scp>Whole-body magnetic resonance imaging</scp> for prostate cancer assessment: Current status and future directions. Journal of Magnetic Resonance Imaging, 2022, 55, 653-680.	3.4	22
14086	Primary mesenteric sarcomas: Collaborative experience from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Journal of Surgical Oncology, 2021, 123, 1057-1066.	1.7	3
14087	Modeling Tumor Growth in Oncology. , 2011, , 1-19.		12
14088	Electrochemotherapy for Larger Malignant Tumors. , 2011, , 103-113.		1
14089	Considerations for Clinical Translation of MG1 Maraba Virus. Methods in Molecular Biology, 2020, 2058, 285-293.	0.9	8
14090	Sarcoma. Methods in Molecular Biology, 2011, 727, 191-203.	0.9	11
14092	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
14093	Infusion Technique. , 2020, , 357-366.		1
14094	Radiomics and Imaging Genomics for Evaluation of Tumor Response. Medical Radiology, 2020, , 221-238.	0.1	5
14095	Molecular and Functional Imaging in Oncology Therapy Response. Medical Radiology, 2020, , 255-272.	0.1	2
14096	MULAN: Multitask Universal Lesion Analysis Network for Joint Lesion Detection, Tagging, and Segmentation. Lecture Notes in Computer Science, 2019, , 194-202.	1.3	49
14097	Improving RetinaNet for CT Lesion Detection with Dense Masks from Weak RECIST Labels. Lecture Notes in Computer Science, 2019, , 402-410.	1.3	62
14098	Cancer Imaging in Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1244, 309-324.	1.6	4
14099	One Click Lesion RECIST Measurement and Segmentation on CT Scans. Lecture Notes in Computer Science, 2020, , 573-583.	1.3	14
14100	Lymph Node Gross Tumor Volume Detection in Oncology Imaging via Relationship Learning Using Graph Neural Network. Lecture Notes in Computer Science, 2020, , 772-782.	1.3	14
14101	2D View Aggregation for Lymph Node Detection Using a Shallow Hierarchy of Linear Classifiers. Lecture Notes in Computer Science, 2014, 17, 544-552.	1.3	38
14102	Metastatic Liver Tumor Segmentation Using Texture-Based Omni-Directional Deformable Surface Models. Lecture Notes in Computer Science, 2014, , 74-83.	1.3	15
14103	Detection of Bone Metastases and Evaluation of Therapy Response in Prostate Cancer Patients by Radiolabelled Choline PET/CT. , 2017, , 75-85.		1

#	ARTICLE	IF	CITATIONS
14104	Challenges of Immunotherapy. , 2016, , 419-434.		1
14105	Hybrid Imaging for Breast Malignancies. , 2019, , 543-570.		1
14106	Evaluation of Malignant Bone Disease Using DW-MRI. Medical Radiology, 2010, , 207-226.	0.1	3
14107	Biometrie. , 2013, , 353-370.		1
14108	Chemotherapie. , 2010, , 249-264.		2
14109	Targeted Agents and Systemic Therapy in Hepatocellular Carcinoma. Recent Results in Cancer Research, 2013, 190, 225-246.	1.8	21
14110	Radiological Response Criteria. , 2011, , 3150-3153.		1
14111	Relating Fisher Information to Detectability of Changes in Nodule Characteristics with CT. Lecture Notes in Computer Science, 2013, 23, 584-593.	1.3	2
14112	Overview of Functional Imaging Techniques for Liver Malignancies in Current Clinical Practice or in a Very Near Future. , 2014, , 951-985.		1
14113	Multi-state Models Used in Oncology Trials. , 2014, , 283-304.		1
14114	Imaging Features of Renal Cell Carcinoma Differential Diagnosis, Staging, and Posttreatment Evaluation. , 2017, , 139-176.		4
14115	Imaging of Hepatic Metastases. Cancer Metastasis - Biology and Treatment, 2011, , 307-351.	0.1	3
14116	Assessment of Therapeutic Response Through Clinical Assessment Measures. Cancer Metastasis - Biology and Treatment, 2014, , 407-417.	0.1	1
14117	Hybrid imaging of the abdomen and pelvis. Der Radiologe, 2020, 60, 80-89.	1.7	5
14118	18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2031-2037.	6.4	27
14119	Study of self-expandable metallic stent placement intraluminal 125I seed strands brachytherapy of malignant biliary obstruction. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 4996-5005.	2.4	41
14120	Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. Wiener Klinische Wochenschrift, 2020, 132, 467-474.	1.9	8
14121	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Investigational New Drugs, 2020, 38, 1421-1429.	2.6	33

#	ARTICLE	IF	CITATIONS
14122	A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates in Surgery, 2020, 72, 39-45.	2.0	17
14123	Multiple Endocrine Neoplasia. , 2016, , 1723-1761.e3.		2
14124	Brain Tumor Outcome Studies. , 2011, , 1243-1253.		1
14125	Multiple Endocrine Neoplasia. , 2011, , 1728-1767.		6
14127	The importance of optimal ROIs delineation for FBPA-PET before BNCT. Applied Radiation and Isotopes, 2020, 163, 109219.	1.5	6
14128	Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres. Bulletin Du Cancer, 2020, 107, 1274-1283.	1.6	6
14129	Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome. Clinical Gastroenterology and Hepatology, 2020, , .	4.4	5
14130	Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2â€“negative Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 160-167.	2.4	4
14131	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. Clinical Genitourinary Cancer, 2019, 17, e505-e512.	1.9	24
14132	The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial. Clinical Nutrition, 2020, 39, 3005-3013.	5.0	31
14133	Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in nonâ€“small-cell lung cancer. European Journal of Cancer, 2020, 133, 74-85.	2.8	38
14134	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
14135	Tumour subregion analysis of colorectal liver metastases using semi-automated clustering based on DCE-MRI: Comparison with histological subregions and impact on pharmacokinetic parameter analysis. European Journal of Radiology, 2020, 126, 108934.	2.6	5
14136	Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases. European Journal of Surgical Oncology, 2018, 44, 139-147.	1.0	6
14137	CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. Hpb, 2019, 21, 582-588.	0.3	13
14138	Imaging response evaluation after local ablative treatments in locally advanced pancreatic cancer: an expedited systematic review. Hpb, 2020, 22, 1083-1091.	0.3	1
14139	Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 99, 22-30.	0.8	103
14140	Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2020, 144, 57-63.	2.0	17

#	ARTICLE	IF	CITATIONS
14141	Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 145, 1-9.	2.0	18
14142	Clinical outcomes and the role of bronchoscopic intervention in patients with primary pulmonary salivary gland-type tumors. <i>Lung Cancer</i> , 2020, 146, 58-65.	2.0	19
14143	Reacciones adversas inmunomediadas como predictoras de respuesta en pacientes oncológicos en tratamiento con inmunoterapia. <i>Radiología</i> , 2020, 62, 131-138.	0.5	5
14144	Papillary and Follicular Thyroid Cancer in children and adolescents: Current approach and future directions. <i>Seminars in Pediatric Surgery</i> , 2020, 29, 150920.	1.1	5
14145	Hypoxia and renal cell carcinoma: The influence of HIF1A + 1772C/T functional genetic polymorphism on prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e25-532.e30.	1.6	2
14146	Modulation of Immune Checkpoints by Chemotherapy in Human Colorectal Liver Metastases. <i>Cell Reports Medicine</i> , 2020, 1, 100160.	6.5	18
14148	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1730-1736.	6.4	63
14149	The beginning of the end for conventional RECIST – novel therapies require novel imaging approaches. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 442-458.	27.6	97
14150	A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. <i>Lab on A Chip</i> , 2018, 18, 179-189.	6.0	55
14151	Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 443-450.	0.7	13
14152	Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. <i>Endoscopy International Open</i> , 2020, 08, E1511-E1519.	1.8	6
14153	Anatomically-adaptive multi-modal image registration for image-guided external-beam radiotherapy. <i>Physics in Medicine and Biology</i> , 2020, 65, 215028.	3.0	12
14154	Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 915-922.	4.5	7
14155	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery – the BUMPER study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa140.	0.7	6
14156	Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. <i>Anti-Cancer Drugs</i> , 2021, 32, 95-101.	1.4	16
14157	Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia. <i>Journal of Immunotherapy</i> , 2021, 44, 9-15.	2.4	10
14158	The Prognostic Role of Pretreatment Neutrophil to Lymphocyte Ratio (NLR) in Malignant Adrenal Lesions Treated With Stereotactic Body Radiation Therapy (SBRT). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 945-950.	1.3	4
14159	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 261-268.	1.6	9

#	ARTICLE	IF	CITATIONS
14160	Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. Nuclear Medicine Communications, 2010, 31, 1008-1015.	1.1	5
14161	Two Tumors in 1: What Should be the Therapeutic Target? Pediatric Germ Cell Tumor With Somatic Malignant Transformation. Journal of Pediatric Hematology/Oncology, 2017, 39, 388-394.	0.6	13
14162	Checkpoint Inhibitor-Associated Arthritis. Journal of Clinical Rheumatology, 2021, 27, e317-e322.	0.9	39
14163	A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer. Annals of Surgery, 2022, 276, 140-145.	4.2	13
14164	Novel imaging in advanced prostate cancer. Current Opinion in Supportive and Palliative Care, 2017, 11, 238-246.	1.3	1
14177	Simple MyUnet3D for BraTS Segmentation. , 2020, , .		3
14178	Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Thoracic Cancer, 2020, 11, 3317-3325.	1.9	20
14179	Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer Science, 2019, 110, 3754-3760.	3.9	14
14180	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. Cancer Science, 2020, 111, 561-570.	3.9	31
14181	Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy. Cancer Science, 2020, 111, 253-265.	3.9	6
14182	First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Science, 2020, 111, 571-579.	3.9	16
14183	Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Cancer Science, 2020, 111, 2460-2471.	3.9	7
14184	Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. Cancer Science, 2021, 112, 287-295.	3.9	11
14185	Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group. Oral Diseases, 2022, 28, 345-351.	3.0	7
14186	The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 123.	1.0	11
14187	Oral and IV Contrast Enhanced Ultrasonography of the digestive tract - a useful completion of the B-mode examination: a literature review and an exhaustive illustration through images. Medical Ultrasonography, 2015, 17, 62.	0.8	6
14188	Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. Journal of Medical Imaging, 2017, 5, 1.	1.5	18
14189	DeepLesion: automated mining of large-scale lesion annotations and universal lesion detection with deep learning. Journal of Medical Imaging, 2018, 5, 1.	1.5	288

#	ARTICLE	IF	CITATIONS
14190	Radiomic biomarkers from PET/CT multi-modality fusion images for the prediction of immunotherapy response in advanced non-small cell lung cancer patients. , 2018, , .		16
14191	Reader Disagreement Index: a better measure of overall review quality monitoring in an oncology trial compared to adjudication rate. , 2019, , .		2
14192	A combination of intra- and peritumoral features on baseline CT scans is associated with overall survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a multi-agent multi-site study. , 2019, , .		4
14193	Uncertainties in RECIST as a measure of volume for lung nodules and liver tumors. Medical Physics, 2012, 39, 2628-2637.	3.0	3
14194	Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Reports, 2012, 2012, bcr2012007576-bcr2012007576.	0.5	11
14195	Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation. BMJ Case Reports, 2014, 2014, bcr2014204809-bcr2014204809.	0.5	2
14196	Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. European Journal of Hospital Pharmacy, 2022, 29, 139-144.	1.1	17
14197	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. ESMO Open, 2020, 5, e000689.	4.5	11
14198	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.	12.1	188
14199	Palliative treatment with electrochemotherapy in recurrent or metastatic vaginal cancer. International Journal of Gynecological Cancer, 2020, 30, 939-946.	2.5	7
14200	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
14201	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
14202	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
14203	277...Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. , 2020, , .		2
14204	Clinical Impact of PET/MR Imaging in Patients with Cancer Undergoing Same-Day PET/CT: Initial Experience in 134 Patients—A Hypothesis-generating Exploratory Study. Radiology, 0, , 131306.	7.3	2
14205	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics, 2017, 37, 2132-2144.	3.3	87
14206	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer. Clinical Cancer Research, 2020, 26, 6417-6428.	7.0	11
14207	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 1256-1266.	7.0	20

#	ARTICLE	IF	CITATIONS
14208	Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2549-2559.	7.0	34
14209	Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903). <i>Clinical Cancer Research</i> , 2021, 27, 1604-1611.	7.0	18
14210	Local experience with radiosurgery for vestibular schwannomas and recommendations for management. <i>Singapore Medical Journal</i> , 2018, 59, 590-596.	0.6	8
14211	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. <i>JCI Insight</i> , 2019, 4, .	5.0	36
14212	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. <i>JCI Insight</i> , 2019, 4, .	5.0	113
14213	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	5.0	11
14214	Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. <i>JCI Insight</i> , 2020, 5, .	5.0	74
14215	Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. <i>JCI Insight</i> , 2020, 5, .	5.0	85
14216	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. <i>JCI Insight</i> , 2017, 2, e89760.	5.0	55
14217	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017, 2, e90449.	5.0	45
14218	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. <i>JCI Insight</i> , 2017, 2, .	5.0	62
14219	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4276-4289.	8.2	134
14220	IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. <i>Journal of Clinical Investigation</i> , 2014, 124, 99-110.	8.2	183
14221	New cast for a new era: preclinical cancer drug development revisited. <i>Journal of Clinical Investigation</i> , 2013, 123, 3639-3645.	8.2	72
14222	Development and translational imaging of a TP53 porcine tumorigenesis model. <i>Journal of Clinical Investigation</i> , 2014, 124, 4052-4066.	8.2	92
14223	Radiotherapy Timing in the Treatment of Limited-stage Small Cell Lung Cancer: The Impact of Thoracic and Brain Irradiation on Survival. <i>Tumori</i> , 2014, 100, 289-295.	1.1	5
14224	Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097419.	3.2	15
14225	Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097715.	3.2	14

#	ARTICLE	IF	CITATIONS
14226	Long-term follow-up of mTOR inhibition for Erdheim-Chester disease. <i>Blood</i> , 2020, 135, 1994-1997.	1.4	14
14227	Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial. <i>Trials</i> , 2020, 21, 420.	1.6	6
14228	Colorectal liver metastases: radiopathological correlation. <i>Insights Into Imaging</i> , 2020, 11, 99.	3.4	18
14229	Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients. <i>Insights Into Imaging</i> , 2020, 11, 106.	3.4	11
14230	[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?. <i>EJNMMI Research</i> , 2019, 9, 84.	2.5	21
14231	Texture analysis of pretreatment [18F]FDG PET/CT for the prognostic prediction of locally advanced salivary gland carcinoma treated with interstitial brachytherapy. <i>EJNMMI Research</i> , 2019, 9, 89.	2.5	10
14232	Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. <i>EJNMMI Research</i> , 2020, 10, 63.	2.5	22
14233	Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response. <i>Cancer Imaging</i> , 2020, 20, 11.	2.8	9
14234	Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB [®] . <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 27.	3.9	9
14235	Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 61.	1.9	6
14236	Image-guided laser ablation in the treatment of recurrence of renal tumours: technique and preliminary results. <i>European Radiology Experimental</i> , 2020, 4, 1.	3.4	57
14237	Imaging of tumour response to immunotherapy. <i>European Radiology Experimental</i> , 2020, 4, 2.	3.4	65
14238	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	3.4	38
14239	Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center. <i>Journal of the Egyptian National Cancer Institute</i> , 2020, 32, 20.	1.5	7
14240	Localized Wilms's [™] tumor in low-middle-income countries (LMIC): how can we get better?. <i>Journal of the Egyptian National Cancer Institute</i> , 2020, 32, 32.	1.5	4
14241	Predicting response to neo-adjuvant chemotherapy and assessment of residual disease in breast cancer using contrast-enhanced spectral mammography: a combined qualitative and quantitative approach. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2020, 51, .	0.6	6
14242	PET/CT implication on bronchogenic carcinoma TNM staging and follow-up using RECIST/PERCIST criteria: a comparative study with CT. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2020, 51, .	0.6	2
14243	Pharmacokinetics (PK) of eribulin mesylate in cancer patients (pts) with normal and impaired renal function.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2595-2595.	1.6	59

#	ARTICLE	IF	CITATIONS
14244	Measuring Tumor Epichaperome Expression Using [¹²⁴ I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1414-1424.	3.0	13
14245	Comparison of Combination Stereotactic Body Radiotherapy Plus High-Intensity Focused Ultrasound Ablation Versus Stereotactic Body Radiotherapy Alone for Massive Hepatocellular Carcinoma. Medical Science Monitor, 2018, 24, 8298-8305.	1.1	6
14246	Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations. Medical Science Monitor, 2019, 25, 8430-8437.	1.1	20
14247	Influence of Hypertension on the Survival of Non-Small Cell Lung Cancer Patients with Type 2 Diabetes Mellitus. Medical Science Monitor, 2020, 26, e921676.	1.1	7
14248	Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy. Medical Science Monitor, 2020, 26, e922576.	1.1	17
14249	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000Research, 2020, 9, 337.	1.6	6
14250	Treatment of distant metastases from follicular cell-derived thyroid cancer. F1000prime Reports, 2015, 7, 22.	5.9	12
14251	Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance. Hong Kong Medical Journal, 2018, 24, 252-260.	0.1	7
14252	HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World Journal of Clinical Cases, 2019, 7, 1964-1977.	0.8	39
14253	Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report. World Journal of Clinical Cases, 2019, 7, 2065-2074.	0.8	17
14254	<i>In-vitro</i> proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report. World Journal of Clinical Cases, 2019, 7, 4036-4043.	0.8	2
14255	Irreversible electroporation for liver metastasis from pancreatic cancer: A case report. World Journal of Clinical Cases, 2020, 8, 390-397.	0.8	4
14256	Comparison of Radiological Criteria (RECIST - MASS - SACT -Choi) in Antiangiogenic Therapy of Renal Cell Carcinoma. Universal Journal of Public Health, 2016, 4, 239-243.	0.1	2
14257	In vivo assessment of functional and morphological alterations in tumors under treatment using OCT-angiography combined with OCT-elastography. Biomedical Optics Express, 2020, 11, 1365.	2.9	31
14258	A micro CT based tumor volume reference standard for phantom experiments. , 2013, , .		3
14259	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. PLoS Genetics, 2016, 12, e1006225.	3.5	64
14260	Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Medicine, 2016, 13, e1002198.	8.4	219
14261	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). PLoS ONE, 2012, 7, e26331.	2.5	39

#	ARTICLE	IF	CITATIONS
14262	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS ONE, 2012, 7, e45127.	2.5	15
14263	Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients. PLoS ONE, 2012, 7, e48372.	2.5	40
14264	Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials. PLoS ONE, 2012, 7, e52638.	2.5	4
14265	Evaluation of Chemotherapy Response with Serum Squamous Cell Carcinoma Antigen Level in Cervical Cancer Patients: A Prospective Cohort Study. PLoS ONE, 2013, 8, e54969.	2.5	18
14266	Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients. PLoS ONE, 2013, 8, e59941.	2.5	88
14267	Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors. PLoS ONE, 2013, 8, e61538.	2.5	26
14268	Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3-Deoxy-3-[18F]fluorothymidine Positron Emission Tomography. PLoS ONE, 2013, 8, e63705.	2.5	19
14269	The Impact of Polymorphic Variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the Risk and Prognosis of Portuguese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e72373.	2.5	26
14270	Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data. PLoS ONE, 2013, 8, e81468.	2.5	61
14271	A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization. PLoS ONE, 2013, 8, e82225.	2.5	19
14272	Growth Pattern Analysis of Murine Lung Neoplasms by Advanced Semi-Automated Quantification of Micro-CT Images. PLoS ONE, 2013, 8, e83806.	2.5	15
14273	[18F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients. PLoS ONE, 2014, 9, e87629.	2.5	24
14274	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	2.5	50
14275	Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography. PLoS ONE, 2014, 9, e91694.	2.5	29
14276	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/ β -Catenin Signaling. PLoS ONE, 2014, 9, e94748.	2.5	35
14277	Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: A Randomized, Controlled, Biomarker Study. PLoS ONE, 2014, 9, e95310.	2.5	4
14278	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. PLoS ONE, 2015, 10, e0103258.	2.5	21
14279	Can We Negotiate with a Tumor?. PLoS ONE, 2014, 9, e103834.	2.5	2

#	ARTICLE	IF	CITATIONS
14280	Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients. PLoS ONE, 2014, 9, e104004.	2.5	35
14281	Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS ONE, 2014, 9, e107160.	2.5	11
14282	Long Noncoding RNAs Expression Patterns Associated with Chemo Response to Cisplatin Based Chemotherapy in Lung Squamous Cell Carcinoma Patients. PLoS ONE, 2014, 9, e108133.	2.5	32
14283	Is Non-Contrast CT Adequate for the Evaluation of Hepatic Metastasis in Patients Who Cannot Receive Iodinated Contrast Media?. PLoS ONE, 2015, 10, e0134133.	2.5	15
14284	Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS ONE, 2015, 10, e0135165.	2.5	5
14285	Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS ONE, 2015, 10, e0136252.	2.5	44
14286	Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0143132.	2.5	13
14287	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0145004.	2.5	20
14288	The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0146456.	2.5	12
14289	Adjuvant Therapy for Thymic Carcinoma – A Decade of Experience in a Taiwan National Teaching Hospital. PLoS ONE, 2016, 11, e0146609.	2.5	7
14290	Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS ONE, 2016, 11, e0149722.	2.5	23
14291	Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0153018.	2.5	38
14292	Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer. PLoS ONE, 2016, 11, e0153459.	2.5	49
14293	Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. PLoS ONE, 2016, 11, e0154133.	2.5	12
14294	Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0155178.	2.5	4
14295	Monitoring the Growth of an Orthotopic Tumour Xenograft Model: Multi-Modal Imaging Assessment with Benchtop MRI (1T), High-Field MRI (9.4T), Ultrasound and Bioluminescence. PLoS ONE, 2016, 11, e0156162.	2.5	17
14296	Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series. PLoS ONE, 2016, 11, e0156985.	2.5	5
14297	Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0157836.	2.5	53

#	ARTICLE	IF	CITATIONS
14298	Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. PLoS ONE, 2016, 11, e0158125.	2.5	18
14299	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0161303.	2.5	7
14300	Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate. PLoS ONE, 2016, 11, e0161959.	2.5	15
14301	Glioblastoma Segmentation: Comparison of Three Different Software Packages. PLoS ONE, 2016, 11, e0164891.	2.5	35
14302	A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. PLoS ONE, 2016, 11, e0167923.	2.5	7
14303	Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS ONE, 2016, 11, e0168215.	2.5	17
14304	Assessment of Volumetric versus Manual Measurement in Disseminated Testicular Cancer; No Difference in Assessment between Non-Radiologists and Genitourinary Radiologist. PLoS ONE, 2017, 12, e0168977.	2.5	5
14305	A concept for holistic whole body MRI data analysis, Imiomics. PLoS ONE, 2017, 12, e0169966.	2.5	29
14306	Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS ONE, 2017, 12, e0174308.	2.5	40
14307	Study of metastatic kinetics in metastatic melanoma treated with B-Raf inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision. PLoS ONE, 2017, 12, e0176080.	2.5	8
14308	The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS ONE, 2017, 12, e0178676.	2.5	20
14309	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE, 2017, 12, e0180628.	2.5	4
14310	Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. PLoS ONE, 2017, 12, e0181867.	2.5	9
14311	Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images. PLoS ONE, 2017, 12, e0182596.	2.5	12
14312	Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PLoS ONE, 2017, 12, e0182885.	2.5	21
14313	Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. PLoS ONE, 2017, 12, e0183754.	2.5	10
14314	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS ONE, 2017, 12, e0183841.	2.5	22
14315	Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)? PLoS ONE, 2017, 12, e0185350.	2.5	5

#	ARTICLE	IF	CITATIONS
14316	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0189766.	2.5	46
14317	Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters. PLoS ONE, 2018, 13, e0192706.	2.5	3
14318	Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer. PLoS ONE, 2018, 13, e0193814.	2.5	5
14319	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology, 2017, XX, 1-14.	1.4	16
14320	Development of Clinical Programs for Carbon Ion Beam Therapy at MedAustron. International Journal of Particle Therapy, 2015, 2, 474-477.	1.8	9
14321	Long-Term Outcomes of Fractionated Stereotactic Proton Therapy for Vestibular Schwannoma: A Case Series. International Journal of Particle Therapy, 2018, 4, 37-46.	1.8	7
14322	Body Mass Index and Response to Neoadjuvant Chemotherapy in Korean Breast Cancer. Journal of Breast Disease, 2014, 2, 1-7.	0.2	1
14323	Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice. Journal of Clinical Medicine Research, 2020, 12, 300-306.	1.2	12
14324	Evaluation of Acute Toxicity and Early Clinical Outcome in Head and Neck Cancers Treated With Conventional Radiotherapy and Simultaneous Integrated Boost Arc Radiotherapy. World Journal of Oncology, 2017, 8, 117-121.	1.5	14
14325	Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. World Journal of Oncology, 2019, 10, 35-45.	1.5	29
14326	Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. World Journal of Oncology, 2019, 10, 187-198.	1.5	20
14327	The prognostic value of whole blood <i>SOX2</i> , <i>NANOG</i> and <i>OCT4</i> mRNA expression in advanced small-cell lung cancer. Radiology and Oncology, 2016, 50, 188-196.	1.7	36
14328	Treatment of nasopharyngeal carcinoma using simultaneous modulated accelerated radiation therapy via helical tomotherapy: a phase II study. Radiology and Oncology, 2016, 50, 218-225.	1.7	7
14329	Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocrine Connections, 2019, 8, 641-653.	1.9	11
14330	Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma. Endocrine Connections, 2020, 9, 498-505.	1.9	5
14331	¹⁷⁷ Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma. Endocrine Connections, 2020, 9, 864-873.	1.9	35
14332	Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using ¹⁷⁷ Lu-DOTATATE. European Journal of Endocrinology, 2019, 181, 45-53.	3.7	63
14333	No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH. European Journal of Endocrinology, 2020, 183, 411-417.	3.7	8

#	ARTICLE	IF	CITATIONS
14334	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	3.1	114
14335	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020, 27, 97-110.	3.1	28
14336	Sonodynamic and Photodynamic Therapy in Breast Cancer - A Pilot Study. <i>International Journal of Complementary & Alternative Medicine</i> , 2017, 9, .	0.1	4
14337	Recommendations of Polish Gynecological Oncology Society concerning epithelial tumors of the ovary: ovarian cancer and borderline tumors. <i>Current Gynecologic Oncology</i> , 2013, 11, 9-23.	0.1	2
14338	Perihepatic lymphadenectomy in children with chronic viral hepatitis. , 2015, 61, 137-150.		10
14339	The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. <i>Journal of Kidney Cancer and VHL</i> , 2017, 4, 10-18.	1.0	3
14340	Image guided robotic interstitial brachytherapy, a new innovative treatment for malignancies. <i>Hematology & Medical Oncology</i> , 2018, 3, .	0.1	1
14341	TACE in colorectal liver metastases “different outcomes in right-sided and left-sided primary tumour location. <i>Integrative Cancer Science and Therapeutics</i> , 2020, 7, .	0.1	2
14342	Gliosarcomas: magnetic resonance imaging findings. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 112-120.	0.8	8
14343	Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2013, 46, 1074-1081.	1.5	5
14344	Tratamento paliativo do adenocarcinoma gástrico. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2011, 24, 74-80.	0.5	1
14345	Expression of Hypoxia-inducible factor 1- α and vascular endothelial growth factor-C in locally advanced breast cancer patients. <i>Clinics</i> , 2011, 66, 1313-20.	1.5	11
14346	Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study. <i>Oncologist</i> , 2020, 25, e668-e678.	3.7	19
14347	Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, 438-446.	3.7	56
14348	The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma. <i>Radiation Research</i> , 2020, 194, 124.	1.5	11
14349	Spatially Fractionated Radiation Therapy Using Lattice Radiation in Far-advanced Bulky Cervical Cancer: A Clinical and Molecular Imaging and Outcome Study. <i>Radiation Research</i> , 2020, 194, 724-736.	1.5	20
14350	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. <i>European Journal of Dermatology</i> , 2018, 28, 736-749.	0.6	6
14351	Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. <i>Tumori</i> , 2012, 98, 308-13.	1.1	23

#	ARTICLE	IF	CITATIONS
14352	Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. Tumori, 2013, 99, 611-6.	1.1	10
14353	Radiotherapy timing in the treatment of limited-stage small cell lung cancer: the impact of thoracic and brain irradiation on survival. Tumori, 2014, 100, 289-95.	1.1	3
14356	Automatic liver tumor segmentation on computed tomography for patient treatment planning and monitoring. EXCLI Journal, 2016, 15, 406-23.	0.7	27
14357	Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. Journal of Patient-centered Research and Reviews, 2014, 1, 85-92.	0.9	18
14358	5 fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Bosnian Journal of Basic Medical Sciences, 2018, 18, 170-177.	1.0	10
14359	Therapeutic options for advanced thyroid cancer. International Journal of Clinical Endocrinology and Metabolism, 2019, 5, 026-034.	1.2	30
14360	Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM. Onkourologiya, 2019, 15, 56-69.	0.3	2
14361	The General Rules for the Study of Primary Liver Cancer. Journal of Liver Cancer, 2017, 17, 19-44.	1.1	28
14362	A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology. Tomography, 2016, 2, 406-410.	1.8	19
14363	QIN Benchmarks for Clinical Translation of Quantitative Imaging Tools. Tomography, 2019, 5, 1-6.	1.8	14
14364	Comparison of Voxel-Wise and Histogram Analyses of Glioma ADC Maps for Prediction of Early Therapeutic Change. Tomography, 2019, 5, 7-14.	1.8	25
14365	ePAD: An Image Annotation and Analysis Platform for Quantitative Imaging. Tomography, 2019, 5, 170-183.	1.8	30
14366	A Web-Based Response-Assessment System for Development and Validation of Imaging Biomarkers in Oncology. Tomography, 2019, 5, 220-225.	1.8	3
14367	Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study. Tomography, 2020, 6, 86-92.	1.8	8
14368	Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. Tomography, 2020, 6, 129-138.	1.8	14
14369	Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial. Tomography, 2020, 6, 177-185.	1.8	10
14370	Intrasession Reliability of Arterial Spin-Labeled MRI—Measured Noncontrast Perfusion in Glioblastoma at 3 T. Tomography, 2020, 6, 139-147.	1.8	6
14371	Intraobserver Variability in Bladder Cancer Treatment Response Assessment With and Without Computerized Decision Support. Tomography, 2020, 6, 194-202.	1.8	13

#	ARTICLE	IF	CITATIONS
14372	Combined test of third lumbar skeletal muscle index and prognostic nutrition index improve prognosis prediction power in resected colorectal cancer liver metastasis. <i>Aging</i> , 2019, 11, 10301-10315.	3.1	12
14373	Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. <i>Genes and Cancer</i> , 2017, 8, 559-565.	1.9	7
14374	Increased <i>FGF19</i> copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. <i>Oncotarget</i> , 2016, 7, 49091-49098.	1.8	35
14375	Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide. <i>Oncotarget</i> , 2016, 7, 54723-54732.	1.8	32
14376	Germline <i>PTPRD</i> Mutations in Ewing Sarcoma: Biologic and Clinical Implications. <i>Oncotarget</i> , 2013, 4, 884-889.	1.8	24
14377	The emergence of T790M mutation in <i>EGFR</i> -mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M. <i>Oncotarget</i> , 2016, 7, 48059-48069.	1.8	24
14378	Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. <i>Oncotarget</i> , 2016, 7, 64400-64409.	1.8	3
14379	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016, 7, 64421-64430.	1.8	17
14380	Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 74303-74313.	1.8	19
14381	Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review. <i>Oncotarget</i> , 2016, 7, 58105-58110.	1.8	28
14382	Clinical outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> mutation, <i>ALK</i> rearrangement and <i>EGFR</i> / <i>ALK</i> co-alterations. <i>Oncotarget</i> , 2016, 7, 65185-65195.	1.8	31
14383	Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects. <i>Oncotarget</i> , 2016, 7, 62619-62626.	1.8	14
14384	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	1.8	44
14385	Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). <i>Oncotarget</i> , 2016, 7, 76298-76307.	1.8	8
14386	Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. <i>Oncotarget</i> , 2016, 7, 71211-71222.	1.8	20
14387	A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. <i>Oncotarget</i> , 2016, 7, 84736-84747.	1.8	22
14388	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2016, 7, 78433-78447.	1.8	45
14389	Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model. <i>Oncotarget</i> , 2016, 7, 77348-77357.	1.8	21

#	ARTICLE	IF	CITATIONS
14390	Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma. <i>Oncotarget</i> , 2017, 8, 15934-15942.	1.8	5
14391	Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 25650-25659.	1.8	6
14392	Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. <i>Oncotarget</i> , 2017, 8, 23851-23861.	1.8	15
14393	Dynamic contrast-enhanced magnetic resonance imaging for pretreatment prediction of early chemo-radiotherapy response in larynx and hypopharynx carcinoma. <i>Oncotarget</i> , 2017, 8, 33836-33843.	1.8	8
14394	Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 30477-30494.	1.8	17
14395	Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 83735-83743.	1.8	18
14396	The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 7666-7677.	1.8	18
14397	A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. <i>Oncotarget</i> , 2017, 8, 56199-56209.	1.8	8
14398	Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy. <i>Oncotarget</i> , 2017, 8, 39703-39710.	1.8	6
14399	Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 13304-13311.	1.8	40
14400	SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic. <i>Oncotarget</i> , 2017, 8, 20476-20495.	1.8	37
14401	Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 14995-15003.	1.8	4
14402	Effect of chromatin structure on quantitative ultrasound parameters. <i>Oncotarget</i> , 2017, 8, 19631-19644.	1.8	4
14403	Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 46937-46945.	1.8	4
14404	Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy. <i>Oncotarget</i> , 2017, 8, 43427-43438.	1.8	31
14405	Reduced NOV expression correlates with disease progression in colorectal cancer and is associated with survival, invasion and chemoresistance of cancer cells. <i>Oncotarget</i> , 2017, 8, 26231-26244.	1.8	7
14406	Aurora-A affects radiosensitivity in cervical squamous cell carcinoma and predicts poor prognosis. <i>Oncotarget</i> , 2017, 8, 31509-31520.	1.8	11
14407	Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 28796-28804.	1.8	39

#	ARTICLE	IF	CITATIONS
14408	Clinical significance of cripto-1 expression in lung adenocarcinoma. Oncotarget, 2017, 8, 79087-79098.	1.8	16
14409	Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer. Oncotarget, 2017, 8, 41631-41640.	1.8	10
14410	High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 25384-25394.	1.8	5
14411	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget, 2017, 8, 32626-32638.	1.8	14
14412	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget, 2017, 8, 31169-31179.	1.8	13
14413	GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 29151-29160.	1.8	20
14414	Application of embolization microspheres in interventional therapy of malignant non-hypervascular tumor of liver. Oncotarget, 2017, 8, 55593-55599.	1.8	4
14415	Efficacy and safety of T-DM1 in the "common-practice" of HER2+ advanced breast cancer setting: a multicenter study. Oncotarget, 2017, 8, 64481-64489.	1.8	22
14416	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget, 2017, 8, 38389-38398.	1.8	8
14417	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget, 2017, 8, 32918-32929.	1.8	46
14418	In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. Oncotarget, 2017, 8, 43458-43469.	1.8	15
14419	Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2017, 8, 30410-30421.	1.8	19
14420	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	1.8	5
14421	IER5 as a promising predictive marker promotes irradiation-induced apoptosis in cervical cancer tissues from patients undergoing chemoradiotherapy. Oncotarget, 2017, 8, 36438-36448.	1.8	8
14422	Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in <i>in vitro</i> and <i>in vivo</i> models of renal cell carcinoma. Oncotarget, 2017, 8, 56311-56326.	1.8	44
14423	Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget, 2014, 5, 4071-4086.	1.8	24
14424	Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. Oncotarget, 2017, 8, 49084-49092.	1.8	9
14425	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 2017, 8, 44073-44081.	1.8	63

#	ARTICLE	IF	CITATIONS
14426	Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , 2017, 8, 45898-45917.	1.8	12
14427	Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. <i>Oncotarget</i> , 2014, 5, 1475-1490.	1.8	51
14428	Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. <i>Oncotarget</i> , 2017, 8, 49839-49850.	1.8	24
14429	The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2017, 8, 44312-44325.	1.8	76
14430	Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 71805-71816.	1.8	13
14431	Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. <i>Oncotarget</i> , 2017, 8, 46337-46347.	1.8	35
14432	Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations. <i>Oncotarget</i> , 2017, 8, 56714-56725.	1.8	6
14433	<i>MET</i> aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. <i>Oncotarget</i> , 2014, 5, 1837-1845.	1.8	27
14434	Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients. <i>Oncotarget</i> , 2017, 8, 75914-75923.	1.8	5
14435	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014, 5, 1846-1855.	1.8	28
14436	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. <i>Oncotarget</i> , 2017, 8, 57882-57888.	1.8	10
14437	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. <i>Oncotarget</i> , 2017, 8, 81329-81342.	1.8	6
14438	Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. <i>Oncotarget</i> , 2017, 8, 61901-61916.	1.8	10
14439	Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. <i>Oncotarget</i> , 2017, 8, 79662-79669.	1.8	13
14440	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741.	1.8	77
14441	Peripheral CD4+ na ^{ve} /memory ratio is an independent predictor of survival in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 83650-83659.	1.8	16
14442	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	1.8	12
14443	Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. <i>Oncotarget</i> , 2014, 5, 4050-4059.	1.8	23

#	ARTICLE	IF	CITATIONS
14444	Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014, 5, 3871-3879.	1.8	11
14445	Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 70865-70873.	1.8	7
14446	The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. <i>Oncotarget</i> , 2014, 5, 3895-3906.	1.8	16
14447	The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 78633-78641.	1.8	18
14448	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	1.8	7
14449	Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture. <i>Oncotarget</i> , 2017, 8, 72860-72871.	1.8	17
14450	The prognostic role of nutrition risk score (NRS) in patients with metastatic or recurrent esophageal squamous cell carcinoma (ESCC). <i>Oncotarget</i> , 2017, 8, 77465-77473.	1.8	9
14451	A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. <i>Oncotarget</i> , 2017, 8, 93633-93643.	1.8	13
14452	Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatment. <i>Oncotarget</i> , 2017, 8, 86056-86065.	1.8	13
14453	Combined neutrophil-platelet score and hemoglobin level predict survival in esophageal squamous cell carcinoma patients treated with chemoradiotherapy. <i>Oncotarget</i> , 2017, 8, 87971-87979.	1.8	10
14454	Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. <i>Oncotarget</i> , 2017, 8, 92401-92410.	1.8	20
14455	Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103117-103128.	1.8	84
14456	Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison. <i>Oncotarget</i> , 2017, 8, 100056-100065.	1.8	5
14457	An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 101795-101807.	1.8	31
14458	Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 97769-97786.	1.8	28
14459	Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer. <i>Oncotarget</i> , 2017, 8, 107844-107858.	1.8	20
14460	Role of <i>VEGFA</i> gene polymorphisms in colorectal cancer patients who treated with bevacizumab. <i>Oncotarget</i> , 2017, 8, 105472-105478.	1.8	15
14461	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 104430-104443.	1.8	5

#	ARTICLE	IF	CITATIONS
14462	Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 107630-107639.	1.8	16
14463	New role of ID3 in melanoma adaptive drug-resistance. <i>Oncotarget</i> , 2017, 8, 110166-110175.	1.8	20
14464	Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. <i>Oncotarget</i> , 2017, 8, 113472-113493.	1.8	15
14465	Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 114268-114280.	1.8	169
14466	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014, 5, 8937-8946.	1.8	6
14467	Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review. <i>Oncotarget</i> , 2018, 9, 7148-7161.	1.8	21
14468	Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. <i>Oncotarget</i> , 2018, 9, 3875-3886.	1.8	9
14469	Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 5811-5822.	1.8	11
14470	Who will benefit more from maintenance therapy of metastatic colorectal cancer?. <i>Oncotarget</i> , 2018, 9, 12479-12486.	1.8	5
14471	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). <i>Oncotarget</i> , 2018, 9, 8253-8262.	1.8	25
14472	S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of <i>RELB</i> . <i>Oncotarget</i> , 2018, 9, 7631-7643.	1.8	32
14473	An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 10714-10722.	1.8	20
14474	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , 2018, 9, 8155-8164.	1.8	18
14475	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	1.8	29
14476	Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 19817-19825.	1.8	54
14477	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , 2018, 9, 22332-22339.	1.8	12
14478	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 19283-19293.	1.8	54
14479	Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. <i>Oncotarget</i> , 2018, 9, 20747-20760.	1.8	17

#	ARTICLE	IF	CITATIONS
14480	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. <i>Oncotarget</i> , 2018, 9, 21569-21579.	1.8	20
14481	Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. <i>Oncotarget</i> , 2018, 9, 22038-22046.	1.8	14
14482	Carbon ion radiotherapy for inoperable pediatric osteosarcoma. <i>Oncotarget</i> , 2018, 9, 22976-22985.	1.8	39
14483	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study. <i>Oncotarget</i> , 2018, 9, 23749-23760.	1.8	18
14484	Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review. <i>Oncotarget</i> , 2018, 9, 24000-24013.	1.8	17
14485	Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients. <i>Oncotarget</i> , 2018, 9, 29538-29547.	1.8	25
14486	Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. <i>Oncotarget</i> , 2018, 9, 25617-25629.	1.8	10
14487	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. <i>Oncotarget</i> , 2018, 9, 28842-28848.	1.8	4
14488	² -deoxy- ² -[¹⁸ F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 2018, 9, 28572-28585.	1.8	6
14489	miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2. <i>Oncotarget</i> , 2018, 9, 30053-30065.	1.8	23
14490	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014, 5, 11168-11179.	1.8	53
14491	Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.	1.8	9
14492	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	1.8	15
14493	Genomic mutations and histopathologic biomarkers in Y90 radioembolization for chemorefractory colorectal liver metastases. <i>Oncotarget</i> , 2018, 9, 32523-32533.	1.8	7
14494	Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles. <i>Oncotarget</i> , 2018, 9, 34229-34239.	1.8	2
14495	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	1.8	26
14496	Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. <i>Oncotarget</i> , 2018, 9, 33702-33709.	1.8	6
14497	Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. <i>Oncotarget</i> , 2018, 9, 34103-34121.	1.8	38

#	ARTICLE	IF	CITATIONS
14498	The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. <i>Oncotarget</i> , 2018, 9, 34336-34346.	1.8	31
14499	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. <i>Oncotarget</i> , 2018, 9, 36894-36905.	1.8	9
14500	CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. <i>Oncotarget</i> , 2018, 9, 37352-37366.	1.8	33
14501	Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma. <i>Oncotarget</i> , 2019, 10, 76-81.	1.8	13
14502	Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results. <i>Oncotarget</i> , 2019, 10, 847-855.	1.8	8
14503	Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2019, 10, 1775-1784.	1.8	8
14504	Application of cell-free DNA for genomic tumor profiling: a feasibility study. <i>Oncotarget</i> , 2019, 10, 1388-1398.	1.8	13
14505	Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry. <i>Oncotarget</i> , 2019, 10, 1688-1703.	1.8	37
14506	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. <i>Oncotarget</i> , 2019, 10, 1669-1687.	1.8	12
14507	Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study. <i>Oncotarget</i> , 2019, 10, 3840-3851.	1.8	8
14508	<i>A priori</i> prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks. <i>Oncotarget</i> , 2019, 10, 3910-3923.	1.8	16
14509	Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. <i>Oncotarget</i> , 2019, 10, 5605-5621.	1.8	15
14510	A close relationship between HIF-1 α expression and bone metastases in advanced NSCLC, a retrospective analysis. <i>Oncotarget</i> , 2019, 10, 7071-7079.	1.8	21
14511	Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. <i>Oncotarget</i> , 2020, 11, 378-385.	1.8	28
14512	Prognostic value of a three-scale grading system based on combining molecular imaging with ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias. <i>Oncotarget</i> , 2020, 11, 589-599.	1.8	23
14513	A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. <i>Oncotarget</i> , 2020, 11, 1235-1243.	1.8	3
14514	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , 2020, 11, 1334-1343.	1.8	18
14515	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2020, 11, 1929-1941.	1.8	7

#	ARTICLE	IF	CITATIONS
14516	Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget, 2020, 11, 4401-4410.	1.8	5
14517	Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget, 2020, 11, 4570-4581.	1.8	7
14518	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget, 2015, 6, 6029-6039.	1.8	29
14519	<i>MLH1</i> V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with <i>EGFR</i> L858R-positive lung adenocarcinoma. Oncotarget, 2015, 6, 8407-8417.	1.8	17
14520	Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget, 2015, 6, 15690-15703.	1.8	27
14521	Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. Oncotarget, 2015, 6, 16735-16745.	1.8	31
14522	Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget, 2015, 6, 18174-18182.	1.8	21
14523	Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget, 2015, 6, 28502-28512.	1.8	19
14524	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget, 2015, 6, 26388-26399.	1.8	9
14525	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6, 32228-32243.	1.8	58
14526	Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget, 2015, 6, 32212-32219.	1.8	23
14527	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 30929-30938.	1.8	10
14528	Allele frequencies of BRAF V600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget, 2015, 6, 37895-37905.	1.8	26
14529	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget, 2015, 6, 34561-34572.	1.8	10
14530	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 44971-44984.	1.8	13
14531	In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography. Oncotarget, 2015, 6, 37486-37499.	1.8	15
14532	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget, 2016, 7, 12404-12413.	1.8	209
14533	Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget, 2016, 7, 11380-11396.	1.8	12

#	ARTICLE	IF	CITATIONS
14534	The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. <i>Oncotarget</i> , 2016, 7, 15566-15576.	1.8	21
14535	Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. <i>Oncotarget</i> , 2016, 7, 13680-13687.	1.8	16
14536	A genetic variation in microRNA target site of <i>ETS2</i> is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 15948-15958.	1.8	11
14537	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016, 7, 23227-23238.	1.8	23
14538	Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. <i>Oncotarget</i> , 2016, 7, 18135-18145.	1.8	21
14539	<i>XPD</i> c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. <i>Oncotarget</i> , 2017, 8, 16190-16201.	1.8	21
14540	Parotid area lymph node metastases from preliminarily diagnosed patients with nasopharyngeal carcinoma: report on tumor characteristics and oncologic outcomes. <i>Oncotarget</i> , 2016, 7, 19654-19665.	1.8	6
14541	Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. <i>Oncotarget</i> , 2016, 7, 20033-20040.	1.8	41
14542	Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy. <i>Oncotarget</i> , 2016, 7, 21591-21600.	1.8	21
14543	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. <i>Oncotarget</i> , 2016, 7, 24172-24178.	1.8	41
14544	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25632-25639.	1.8	9
14545	Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. <i>Oncotarget</i> , 2016, 7, 33391-33407.	1.8	17
14546	Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach. <i>Oncotarget</i> , 2016, 7, 45094-45111.	1.8	38
14547	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016, 7, 36311-36320.	1.8	44
14548	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.	1.8	9
14549	ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. <i>Oncotarget</i> , 2016, 7, 35159-35168.	1.8	14
14550	Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX. <i>Oncotarget</i> , 2016, 7, 31204-31214.	1.8	10
14551	Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 48586-48599.	1.8	14

#	ARTICLE	IF	CITATIONS
14552	Are TKIs favourable for the elderly with non-small-cell lung cancer?. Oncotarget, 2016, 7, 46871-46877.	1.8	7
14553	Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget, 0, 7, 42625-42638.	1.8	7
14554	Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis. Oncotarget, 2016, 7, 38513-38522.	1.8	9
14555	Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget, 2016, 7, 35655-35669.	1.8	11
14556	A novel approach to inoperable or recurrent rectal cancer by chemoembolization. A new arrow in our quiver?. Oncotarget, 2016, 7, 45275-45282.	1.8	5
14557	Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0. Nagoya Journal of Medical Science, 2018, 80, 183-197.	0.3	15
14558	Retrospective analysis of hypofractionated stereotactic radiotherapy for tumors larger than 2 cm. Nagoya Journal of Medical Science, 2019, 81, 397-406.	0.3	3
14559	Targeting the JAK/STAT pathway in solid tumors. Journal of Cancer Metastasis and Treatment, 0, 2020, .	0.8	46
14560	Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Research, 2020, 2020, .	1.5	19
14561	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	3.0	95
14562	Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy. Cancer Biology and Medicine, 2020, 17, 501-512.	3.0	11
14563	Thyroid dysfunctions and autoimmunity in breast cancer patients: a prospective case-control study. Archives of Endocrinology and Metabolism, 2020, 64, 743-750.	0.6	3
14564	Scientific rationale for immunotherapy in lymphoma and predictors of response. Annals of Lymphoma, 0, 1, 1-1.	4.5	2
14565	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267.	1.7	17
14566	The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. Annals of Translational Medicine, 2016, 4, S68-S68.	1.7	8
14567	Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?. Annals of Translational Medicine, 2018, 6, 222-222.	1.7	19
14568	Surrogate study endpoints in the era of cancer immunotherapy. Annals of Translational Medicine, 2018, 6, S27-S27.	1.7	18
14569	Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer. Annals of Translational Medicine, 2018, 6, 401-401.	1.7	17

#	ARTICLE	IF	CITATIONS
14570	Clinical and prognostic significance of combined plasma fibrinogen concentrations and the monocyte-to-lymphocyte ratio in patients with ovarian cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 242-242.	1.7	9
14571	Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy. <i>Annals of Translational Medicine</i> , 2019, 7, 331-331.	1.7	8
14572	Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. <i>Annals of Translational Medicine</i> , 2019, 7, 467-467.	1.7	24
14573	Application of apatinib after multifaceted therapies for metastatic breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 4488-4497.	1.0	6
14574	Application of next-generation sequencing in resistance genes of neoadjuvant chemotherapy for esophageal cancer. <i>Translational Cancer Research</i> , 2020, 9, 4847-4856.	1.0	1
14575	Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report. <i>Translational Cancer Research</i> , 2019, 8, 693-698.	1.0	3
14576	Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR- mutant Non-small cell lung cancer. <i>Translational Cancer Research</i> , 2020, 9, 2875-2883.	1.0	5
14577	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2391-2400.	2.8	19
14578	A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 135-143.	2.8	12
14579	Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 161-167.	2.2	2
14580	Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 478-485.	2.2	25
14581	Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 579-588.	2.2	22
14582	Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 281-293.	2.2	117
14583	Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 543-552.	2.2	27
14584	Effectiveness and safety of different amifostine regimens: Preliminary results of a phase II multicenter randomized controlled trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 307-314.	2.2	7
14585	Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase IIa~III randomized trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 516-525.	2.2	30
14586	Risk-stratification model to select conversion surgery for advanced gastric cancer patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2019, 31, 178-187.	2.2	4
14587	Quantitative ultrasound delta-radiomics during radiotherapy for monitoring treatment responses in head and neck malignancies. <i>Future Science OA</i> , 2020, 6, FSO624.	1.9	14

#	ARTICLE	IF	CITATIONS
14588	<p><p>Synthetic and External Controls in Clinical Trials – A Primer for Researchers</p></p>. Clinical Epidemiology, 2020, Volume 12, 457-467.	3.0	141
14589	The Efficacy and Response Predictors of Platinum-Based Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. Cancer Management and Research, 2020, Volume 12, 10469-10477.	1.9	10
14590	<p><p>Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study</p></p>. International Journal of COPD, 2020, Volume 15, 3323-3334.	2.3	3
14591	<p><p>Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study</p></p>. Lung Cancer: Targets and Therapy, 2020, Volume 11, 113-121.	2.7	7
14592	<p><p>Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population</p></p>. OncoTargets and Therapy, 2020, Volume 13, 867-876.	2.0	8
14593	Pseudoprogression in patients on immunotherapy. Meditsinskiy Sovet, 2019, , 10-14.	0.5	3
14594	Liver Radioembolization: An Analysis of Parameters that Influence the Catheter-Based Particle-Delivery via CFD. Current Medicinal Chemistry, 2020, 27, 1600-1615.	2.4	15
14595	Clinical and Translational Research Challenges in Biliary Tract Cancers. Current Medicinal Chemistry, 2020, 27, 4756-4777.	2.4	21
14596	Clinical and Translational Research Challenges in Neuroendocrine Tumours. Current Medicinal Chemistry, 2020, 27, 4823-4839.	2.4	5
14597	Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluoro Uracil (5FU) in Breast Adenocarcinoma. Current Pharmaceutical Design, 2019, 25, 1643-1652.	1.9	8
14598	Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy. Current Pharmaceutical Biotechnology, 2014, 14, 693-707.	1.6	17
14599	Treatment of Pancreatic Cancer with Pharmacological Ascorbate. Current Pharmaceutical Biotechnology, 2015, 16, 759-770.	1.6	41
14600	Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. Current Cancer Drug Targets, 2020, 20, 811-817.	1.6	8
14601	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Current Cancer Drug Targets, 2020, 20, 887-895.	1.6	8
14602	2,4,5-Trisubstituted Thiazole: A Privileged Scaffold in Drug Design and Activity Improvement. Current Topics in Medicinal Chemistry, 2020, 20, 2535-2577.	2.1	9
14603	“Impact of Smoking Cessation Treatment” on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study. Recent Patents on Anti-Cancer Drug Discovery, 2015, 10, 342-351.	1.6	8
14604	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Current Radiopharmaceuticals, 2020, 13, 24-31.	0.8	6
14605	Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in “Real-world” Patients. Anticancer Research, 2016, 36, 4947-4950.	1.1	5

#	ARTICLE	IF	CITATIONS
14606	Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer Research, 2016, 36, 4951-4954.	1.1	4
14607	Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions. Anticancer Research, 2016, 36, 5163-5170.	1.1	3
14608	Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases. Anticancer Research, 2016, 36, 5333-5338.	1.1	13
14609	Efficacy of PET-CT in the Diagnosis and Treatment of Recurrence After Esophageal Cancer Surgery. Anticancer Research, 2016, 36, 5473-5480.	1.1	7
14610	Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma. Anticancer Research, 2016, 36, 5543-5550.	1.1	20
14611	Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Research, 2016, 36, 5719-5730.	1.1	10
14612	Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. Anticancer Research, 2016, 36, 6431-6438.	1.1	21
14613	Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer. Anticancer Research, 2016, 36, 6515-6520.	1.1	6
14614	Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers. Anticancer Research, 2017, 37, 233-238.	1.1	1
14615	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. Anticancer Research, 2017, 37, 315-320.	1.1	21
14616	Immune-based Therapies for Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 377-388.	1.1	66
14617	Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 923-928.	1.1	7
14618	CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. Anticancer Research, 2017, 37, 935-940.	1.1	20
14619	Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemoradiotherapy in Cervical Cancer: a Preliminary Analysis. Anticancer Research, 2017, 37, 1249-1256.	1.1	18
14620	Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer. Anticancer Research, 2017, 37, 1297-1304.	1.1	4
14621	Multicenter Phase II Clinical Trial of Genexol-PM [®] with Gemcitabine in Advanced Biliary Tract Cancer. Anticancer Research, 2017, 37, 1467-1474.	1.1	22
14622	The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. Anticancer Research, 2017, 37, 1475-1480.	1.1	9
14623	EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 2457-2464.	1.1	3

#	ARTICLE	IF	CITATIONS
14624	Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. Anticancer Research, 2017, 37, 2465-2476.	1.1	8
14625	Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer. Anticancer Research, 2017, 37, 2663-2671.	1.1	14
14626	Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy. Anticancer Research, 2017, 37, 2715-2720.	1.1	7
14627	Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC. Anticancer Research, 2017, 37, 3189-3194.	1.1	20
14628	Antibiotic Use Does Not Appear to Influence Response to Nivolumab. Anticancer Research, 2017, 37, 3195-3200.	1.1	83
14629	Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin+Paclitaxel: A Prospective Study. Anticancer Research, 2017, 37, 3505-3512.	1.1	3
14630	Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study). Anticancer Research, 2017, 37, 3941-3946.	1.1	18
14631	Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study. Anticancer Research, 2017, 37, 4177-4182.	1.1	58
14632	Neoadjuvant Imatinib Therapy Followed by Intersphincteric Resection for Low Rectal Gastrointestinal Stromal Tumors. Anticancer Research, 2017, 37, 5155-5160.	1.1	8
14633	Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 5199-5205.	1.1	32
14634	Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 5285-5291.	1.1	19
14635	Impact of Nab+Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. , 2017, 37, 5533-5539.		13
14636	Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer. , 2017, 37, 5623-5630.		5
14637	A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer. , 2017, 37, 5851-5855.		3
14638	Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab. , 2017, 37, 5857-5862.		53
14639	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. Anticancer Research, 2017, 37, 5955-5965.	1.1	45
14640	Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab. Anticancer Research, 2017, 37, 6429-6436.	1.1	10
14641	Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer. Anticancer Research, 2017, 37, 6459-6468.	1.1	8

#	ARTICLE	IF	CITATIONS
14642	Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. <i>Anticancer Research</i> , 2017, 37, 6469-6476.	1.1	11
14643	Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 379-383.	1.1	8
14644	Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. <i>Anticancer Research</i> , 2018, 38, 449-456.	1.1	5
14645	Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-“small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 559-563.	1.1	24
14646	Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. <i>Anticancer Research</i> , 2018, 38, 1643-1649.	1.1	22
14647	Tumor Hypoxia Detected by 18F-fluoromisonidazole Positron Emission Tomography (FMISO PET) as a Prognostic Indicator of Radiotherapy (RT). <i>Anticancer Research</i> , 2018, 38, 1775-1781.	1.1	10
14648	WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. <i>Anticancer Research</i> , 2018, 38, 2217-2225.	1.1	36
14649	Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes. <i>Anticancer Research</i> , 2018, 38, 2311-2321.	1.1	37
14650	Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 2929-2938.	1.1	39
14651	Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response. <i>Anticancer Research</i> , 2018, 38, 2961-2965.	1.1	11
14652	Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 1051-1057.	1.1	18
14653	Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects. <i>In Vivo</i> , 2017, 31, 773-777.	1.3	8
14654	Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control. <i>In Vivo</i> , 2018, 32, 121-124.	1.3	4
14655	Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. <i>In Vivo</i> , 2018, 32, 637-642.	1.3	5
14656	Clinical Significance of the Neutrophil-“Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. <i>In Vivo</i> , 2018, 32, 669-675.	1.3	19
14657	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial. <i>JMIR Research Protocols</i> , 2018, 7, e10487.	1.0	18
14658	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11234.	1.0	31
14659	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	1.0	27

#	ARTICLE	IF	CITATIONS
14660	Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. JMIR MHealth and UHealth, 2020, 8, e12306.	3.7	27
14662	Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol. JMIR Research Protocols, 2017, 6, e195.	1.0	5
14663	Effects of ABCC2 and SLC01B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2757-2764.	1.2	7
14664	Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2018, 19, 435-441.	1.2	6
14665	A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1761-1766.	1.2	5
14666	The Efficiency of Respiratory-gated F-FDG PET/CT in Lung Adenocarcinoma: Amplitude-gating Versus Phase-gating Methods. Asia Oceania Journal of Nuclear Medicine and Biology, 2017, 5, 30-36.	0.1	2
14667	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 2020, 16, 1069-1081.	2.4	15
14668	A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib. The Journal of Internal Korean Medicine, 2017, 38, 72-80.	0.3	5
14669	COLORECTAL LIVER METASTASES AFTER CHEMOEMBOLIZATION WITH MICROSPHERES: PROGNOSTIC VALUE OF LESION FEATURES AND CHOICE OF THE OBJECTIVE RESPONSE CRITERIA. Diagnostic Radiology and Radiotherapy, 2018, , 75-84.	0.2	2
14670	Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 59-65.	0.1	3
14671	Quality of life in patients with non-small cell lung cancer. Vojnosanitetski Pregled, 2017, 74, 625-632.	0.2	3
14672	Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 150-158.	0.7	7
14673	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.7	8
14674	Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 265-277.	0.7	7
14675	Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab. Acta Biomedica, 2019, 90, 468-474.	0.3	3
14676	Phase I Clinical Study of Survivin-Derived Peptide Vaccine for Patients with Advanced Gastrointestinal Cancers. International Journal of Cancer and Clinical Research, 2015, 2, .	0.1	2
14677	Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. International Journal of Cancer and Clinical Research, 2015, 2, .	0.1	22
14678	Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients. Radiology and Oncology, 2019, 53, 85-95.	1.7	6

#	ARTICLE	IF	CITATIONS
14679	The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. <i>Radiology and Oncology</i> , 2019, 53, 373-387.	1.7	36
14680	Retrospective analysis of treatment-naïve Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience. <i>Radiology and Oncology</i> , 2020, 54, 119-127.	1.7	8
14681	Long term response of electrochemotherapy with reduced dose of bleomycin in elderly patients with head and neck non-melanoma skin cancer. <i>Radiology and Oncology</i> , 2020, 54, 79-85.	1.7	19
14682	ARTERIAL CHEMOINFUSION IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREAS CANCER. <i>Vestnik Khirurgii Imeni I I Grekova</i> , 2016, 175, 36-40.	0.2	1
14683	Appropriateness and limitations of modified Response Evaluation Criteria in Solid Tumors (mRECIST) in evaluating the efficacy of molecular-targeted therapy for patients with hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2012, 53, 147-154.	0.1	2
14684	A case of hepatocellular carcinoma obtained marked anti-tumor effect by low dose sorafenib after the progression of the disease during high-dose of sorafenib. <i>Acta Hepatologica Japonica</i> , 2012, 53, 564-569.	0.1	3
14685	Response Evaluation Criteria in Cancer of the Liver (RECICL 2019 revised version). <i>Acta Hepatologica Japonica</i> , 2019, 60, 55-62.	0.1	10
14686	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 943-950.	5.0	39
14687	Preliminary assessment of electrochemotherapy feasibility in dogs with vesical transitional cell carcinoma. <i>Veterinary Research Forum</i> , 2020, 11, 289-293.	0.3	3
14688	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 239.	0.8	2
14689	Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2995-3000.	1.2	6
14690	Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2955-2960.	1.2	3
14691	Predicting Lung Cancer Patients' Survival Time via Logistic Regression-based Models in a Quantitative Radiomic Framework. <i>Journal of Biomedical Physics and Engineering</i> , 2020, 10, 479-492.	0.9	4
14692	Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis. <i>Neurosurgical Focus</i> , 2019, 46, E2.	2.3	29
14693	Volumetric growth rates of untreated vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2020, 133, 742-748.	1.6	33
14694	Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. <i>Disease Markers</i> , 2013, 34, 105-11.	1.3	20
14695	Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 326-31.	3.3	44
14696	The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 692-7.	3.3	11

#	ARTICLE	IF	CITATIONS
14697	Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. <i>Health Technology Assessment</i> , 2013, 17, 1-99.	2.8	43
14698	The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-294.	2.8	24
14699	Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2018, 22, 1-276.	2.8	69
14700	Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. <i>Health Technology Assessment</i> , 2019, 23, 1-144.	2.8	25
14701	Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis. <i>Ecancermedalscience</i> , 2020, 14, 1069.	1.1	15
14702	Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis. <i>Ecancermedalscience</i> , 2020, 14, 1113.	1.1	5
14703	Diagnostic and Therapeutic Approaches to Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2012, 55, 403.	0.2	2
14704	Response Evaluation to Neoadjuvant Chemotherapy in Advanced Breast Cancer: Comparison of MRI and Positron Emission Tomography/CT (RECIST 1.1 versus PERCIST 1.0). <i>Journal of the Korean Society of Radiology</i> , 2014, 71, 89.	0.2	2
14705	2018 Korean Liver Cancer Association National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2019, 20, 1042.	3.4	189
14706	Stereotactic body radiation therapy for small (≤ 5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 506-515.	8.9	52
14708	The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care. <i>The Korean Journal of Hepatology</i> , 2011, 17, 189.	1.5	7
14709	Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 614785.	2.8	10
14710	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. <i>Cancers</i> , 2020, 12, 1282.	3.7	17
14711	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	3.7	6
14712	Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients The Importance of Tissue/Plasma Discordant Cases. <i>Journal of Clinical Medicine</i> , 2021, 10, 87.	2.4	10
14713	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 3157.	2.4	9
14714	Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer. <i>Nutrients</i> , 2020, 12, 1473.	4.1	33
14715	An Update on Preoperative Radiotherapy for Locally Advanced Rectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2012, 28, 179.	0.9	6

#	ARTICLE	IF	CITATIONS
14716	18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2015, 54, 163-172.	0.7	18
14717	The Usefulness of Pretreatment MR-Based Radiomics on Early Response of Neoadjuvant Chemotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma. <i>Oncology Research</i> , 2020, 28, 605-613.	1.5	22
14718	Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 1104.	3.3	6
14719	Predictive value of ^{18}F -fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 3215-22.	3.3	37
14720	Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: A pilot study. <i>World Journal of Gastroenterology</i> , 2012, 18, 5753.	3.3	25
14721	<i>UGT1A1</i> predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. <i>World Journal of Gastroenterology</i> , 2012, 18, 6635.	3.3	50
14722	Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. <i>World Journal of Gastroenterology</i> , 2012, 18, 7026.	3.3	29
14723	Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. <i>World Journal of Gastroenterology</i> , 2012, 18, 7056.	3.3	17
14724	Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. <i>World Journal of Gastroenterology</i> , 2012, 18, 541.	3.3	29
14725	Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 3473.	3.3	51
14726	Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. <i>World Journal of Gastroenterology</i> , 2013, 19, 4552.	3.3	10
14727	New approaches for precise response evaluation in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 3059.	3.3	11
14728	hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. <i>World Journal of Gastroenterology</i> , 2014, 20, 8482.	3.3	67
14729	Towards personalized perioperative treatment for advanced gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 11586.	3.3	25
14730	Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. <i>World Journal of Gastroenterology</i> , 2015, 21, 3441-3446.	3.3	3
14731	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 4268.	3.3	8
14732	Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. <i>World Journal of Gastroenterology</i> , 2015, 21, 4911.	3.3	9
14733	Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. <i>World Journal of Gastroenterology</i> , 2015, 21, 7281-7288.	3.3	10

#	ARTICLE	IF	CITATIONS
14734	Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 9966.	3.3	90
14735	Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11185.	3.3	135
14736	Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 13500.	3.3	15
14737	FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 2096-2101.	3.3	60
14738	Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies. <i>World Journal of Gastroenterology</i> , 2016, 22, 3006.	3.3	5
14739	Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 4250.	3.3	8
14740	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 6065.	3.3	23
14741	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6287.	3.3	8
14742	Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. <i>World Journal of Gastroenterology</i> , 2017, 23, 4767.	3.3	53
14743	Safety and efficacy of metallic stent for unresectable distal malignant biliary obstruction in elderly patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 69-75.	3.3	2
14744	Role of D2 gastrectomy in gastric cancer with clinical para-aortic lymph node metastasis. <i>World Journal of Gastroenterology</i> , 2019, 25, 2338-2353.	3.3	9
14745	Neoadjuvant radiotherapy for rectal cancer management. <i>World Journal of Gastroenterology</i> , 2019, 25, 4850-4869.	3.3	128
14746	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. <i>World Journal of Gastroenterology</i> , 2019, 25, 5991-6005.	3.3	43
14747	Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 2427-2439.	3.3	13
14748	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. <i>World Journal of Gastroenterology</i> , 2020, 26, 2792-2809.	3.3	23
14749	Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2020, 26, 4639-4655.	3.3	33
14750	Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. <i>Chinese Medical Journal</i> , 2013, 126, 1464-1468.	2.3	1
14752	Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 86.	2.2	5

#	ARTICLE	IF	CITATIONS
14753	Involved-field radiation therapy for selected cases of recurrent ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e67.	2.2	10
14754	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e86.	2.2	18
14755	Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e15.	2.2	5
14756	Radiation Therapy for Bone Metastases from Hepatocellular Carcinoma: Effect of Radiation Dose Escalation. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2011, 29, 63.	0.1	7
14757	Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer. <i>Radiation Oncology Journal</i> , 2013, 31, 18.	1.5	9
14758	Role of radiotherapy for pancreatobiliary neuroendocrine tumors. <i>Radiation Oncology Journal</i> , 2013, 31, 125.	1.5	11
14759	Treatment results of breast cancer patients with locoregional recurrence after mastectomy. <i>Radiation Oncology Journal</i> , 2013, 31, 138.	1.5	11
14760	PET/CT planning during chemoradiotherapy for esophageal cancer. <i>Radiation Oncology Journal</i> , 2014, 32, 31.	1.5	11
14761	Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer. <i>Radiation Oncology Journal</i> , 2014, 32, 49.	1.5	3
14762	Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. <i>Radiation Oncology Journal</i> , 2015, 33, 12.	1.5	5
14763	Early treatment volume reduction rate as a prognostic factor in patients treated with chemoradiotherapy for limited stage small cell lung cancer. <i>Radiation Oncology Journal</i> , 2015, 33, 117.	1.5	12
14764	Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. <i>Radiation Oncology Journal</i> , 2015, 33, 294.	1.5	16
14765	Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. <i>Radiation Oncology Journal</i> , 2015, 33, 301.	1.5	44
14766	Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer. <i>Radiation Oncology Journal</i> , 2015, 33, 320.	1.5	3
14767	Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. <i>Radiation Oncology Journal</i> , 2016, 34, 59-63.	1.5	17
14768	Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment. <i>Radiation Oncology Journal</i> , 2017, 35, 144-152.	1.5	18
14769	Characterization and predictive value of volume changes of extremity and pelvis soft tissue sarcomas during radiation therapy prior to definitive wide excision. <i>Radiation Oncology Journal</i> , 2019, 37, 117-126.	1.5	6
14770	Prognostic factors in hepatocellular carcinoma patients with bone metastases. <i>Radiation Oncology Journal</i> , 2019, 37, 207-214.	1.5	8

#	ARTICLE	IF	CITATIONS
14771	Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer. Radiation Oncology Journal, 2019, 37, 185-192.	1.5	9
14772	Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases. Radiation Oncology Journal, 2019, 37, 265-270.	1.5	12
14773	Evaluation of Paclitaxel, Ifosfamide, and Cisplatin (TIP) Regimen on Penile Cancer in Adam Malik Medan: A Single Center 2 Years of Experience. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1148-1152.	0.2	7
14774	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. Biomedical Reports, 2020, 12, 59-67.	2.0	9
14775	Circulating non-coding RNA-biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?. International Journal of Oncology, 2020, 56, 47-68.	3.3	20
14776	Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer. International Journal of Oncology, 2020, 56, 932-944.	3.3	14
14777	Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series. Molecular and Clinical Oncology, 2017, 7, 51-55.	1.0	1
14778	Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. Molecular and Clinical Oncology, 2020, 12, 23-30.	1.0	5
14779	Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response. Molecular and Clinical Oncology, 2020, 12, 3-8.	1.0	9
14780	Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis. Molecular and Clinical Oncology, 2020, 12, 374-383.	1.0	2
14781	Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. Molecular and Clinical Oncology, 2020, 12, 456-460.	1.0	1
14782	Predicting therapeutic efficacy of endocrine therapy for stage-IV breast cancer by tumor-infiltrating lymphocytes. Molecular and Clinical Oncology, 2020, 13, 195-202.	1.0	3
14783	Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	3
14785	Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer. Molecular Medicine Reports, 2019, 19, 2330-2340.	2.4	11
14786	Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis. Oncology Letters, 2019, 18, 5437-5447.	1.8	6
14787	Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report. Oncology Letters, 2019, 18, 5085-5090.	1.8	4
14788	Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report. Oncology Letters, 2019, 18, 6469-6474.	1.8	3
14789	Comparison of pre-implant treatment planning and post-implant dosimetry in L125 spinal metastases brachytherapy. Oncology Letters, 2020, 19, 309-316.	1.8	5

#	ARTICLE	IF	CITATIONS
14790	Overexpression of miRâ€106a enhances oxaliplatin sensitivity of colorectal cancer through regulation of FOXQ1. <i>Oncology Letters</i> , 2020, 19, 663-670.	1.8	8
14791	Association of serum levels of deoxyribose 1â€phosphate and Sâ€lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study. <i>Oncology Letters</i> , 2020, 19, 2231-2242.	1.8	4
14792	Predictive value of tumor genetic alteration profiling for chemotherapy and EGFRâ€TKI treatment in advanced NSCLC. <i>Oncology Letters</i> , 2020, 19, 3859-3870.	1.8	1
14793	Open vs. laparoscopic surgery for locally advanced gastric cancer after neoadjuvant therapy: Shortâ€term and longâ€term survival outcomes. <i>Oncology Letters</i> , 2020, 20, 861-867.	1.8	13
14794	Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with nonâ€small cell lung cancer treated with erlotinib. <i>Oncology Letters</i> , 2020, 20, 1376-1382.	1.8	3
14795	Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, nonâ€randomized, singleâ€center study. <i>Oncology Letters</i> , 2020, 20, 2131-2142.	1.8	8
14796	Patients with advanced nonâ€small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A realâ€world data analysis. <i>Oncology Letters</i> , 2020, 20, 2266-2272.	1.8	7
14797	Early response of bone metastases can predict tumor response in patients with nonâ€smallâ€cell lung cancer with bone metastases in the treatment with nivolumab. <i>Oncology Letters</i> , 2020, 20, 2977-2986.	1.8	11
14798	Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. <i>Oncology Letters</i> , 2020, 20, 3035-3045.	1.8	7
14799	ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOXâ€based neoadjuvant concurrent chemoradiation. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	7
14800	Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	6
14801	Decline in serum progastrinâ€releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	4
14802	Efficacy and safety of nanosomal docetaxel lipid suspensionâ€based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	1
14803	Plasma platinâ€3: A tumor marker in patients with nonâ€smallâ€cell lung cancer treated with nivolumab. <i>Oncology Letters</i> , 2020, 21, 1-1.	1.8	4
14804	<i>KRAS</i> and <i>NRAS</i> mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation. <i>Oncology Letters</i> , 2020, 21, 15.	1.8	8
14805	Splice variants of lysosomeâ€associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells. <i>Oncology Reports</i> , 2020, 44, 1810-1820.	2.6	5
14806	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
14807	Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 608-617.	1.7	13

#	ARTICLE	IF	CITATIONS
14808	Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy. Korean Journal of Internal Medicine, 2019, 34, 1100-1106.	1.7	3
14809	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. Korean Journal of Internal Medicine, 2019, 34, 1313-1323.	1.7	12
14810	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 1116-1124.	1.7	6
14811	Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean Journal of Internal Medicine, 2020, 35, 171-184.	1.7	10
14812	Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment. Discrete and Continuous Dynamical Systems - Series B, 2013, 18, 915-943.	0.9	23
14813	Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 689-94.	2.2	23
14814	Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 404-9.	2.2	17
14815	New techniques for assessing response after hypofractionated radiotherapy for lung cancer. Journal of Thoracic Disease, 2014, 6, 375-86.	1.4	18
14816	Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. Journal of Thoracic Disease, 2013, 5, 783-9.	1.4	73
14817	Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?. Journal of Thoracic Disease, 2014, 6, 785-94.	1.4	8
14818	PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). Journal of Thoracic Disease, 2014, 6, 677-83.	1.4	48
14819	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. Journal of Thoracic Disease, 2014, 6, 958-64.	1.4	9
14820	Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. Journal of Thoracic Disease, 2014, 6, 1239-50.	1.4	10
14821	Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. Journal of Thoracic Disease, 2015, 7, 1181-8.	1.4	17
14822	The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2015, 7, 1749-55.	1.4	20
14823	KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. Journal of Gastrointestinal Oncology, 2010, 1, 90-6.	1.4	8
14824	Gastrointestinal stromal tumor. Journal of Gastrointestinal Oncology, 2012, 3, 189-208.	1.4	95
14825	Stereotactic body radiation therapy for liver metastases. Journal of Gastrointestinal Oncology, 2014, 5, 190-7.	1.4	66

#	ARTICLE	IF	CITATIONS
14826	Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. Journal of Gastrointestinal Oncology, 2015, 6, 594-604.	1.4	14
14827	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. Translational Lung Cancer Research, 2013, 2, 251-5.	2.8	8
14828	Immunotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 2-14.	2.8	53
14829	Individual profiling of circulating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment. Translational Lung Cancer Research, 2014, 3, 100-6.	2.8	48
14830	The use of isodose levels to interpret radiation induced lung injury: a quantitative analysis of computed tomography changes. Quantitative Imaging in Medicine and Surgery, 2016, 6, 35-41.	2.0	8
14831	Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Translational Andrology and Urology, 2015, 4, 310-25.	1.4	16
14832	Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Annals of Translational Medicine, 2015, 3, 118.	1.7	14
14833	Assessment of the Predictive Role of Serum Lipid Profiles in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Journal of Breast Cancer, 2020, 23, 246.	1.9	7
14834	Is neo-adjuvant chemotherapy a better option for management of cervical cancer patients of rural India?. Indian Journal of Cancer, 2016, 53, 56.	0.2	6
14835	Paratesticular rhabdomyosarcoma in young adults: A tertiary care institute experience. Indian Journal of Urology, 2013, 29, 110.	0.6	13
14836	Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?. Indian Journal of Urology, 2015, 31, 22.	0.6	3
14837	Impact of chemotherapy on symptom profile, oxidant-antioxidant balance and nutritional status in non-small cell Lung Cancer. Lung India, 2017, 34, 336.	0.7	8
14838	Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian Journal of Radiology and Imaging, 2015, 25, 121-128.	0.8	16
14839	Nonrhabdomyosarcomatous abdominopelvic sarcomas: Analysis of prognostic factors. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 100-105.	0.2	2
14840	Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. Indian Journal of Nuclear Medicine, 2015, 30, 227.	0.3	3
14841	Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy. Journal of Cancer Research and Therapeutics, 2018, 14, 1049.	0.9	7
14842	Interventional bronchoscopy in the initial management of benign and malignant tracheal stenoses. Egyptian Journal of Bronchology, 2015, 9, 146-153.	0.8	1
14843	Sequential use of cryoextraction postelectrocautery for airway recanalization using fiberoptic bronchoscopy. Egyptian Journal of Bronchology, 2015, 9, 269-275.	0.8	3

#	ARTICLE	IF	CITATIONS
14844	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , 2015, 10, 61-6.	1.8	30
14845	Systematic analysis of measurement variability in lung cancer with multidetector computed tomography. <i>Annals of Thoracic Medicine</i> , 2017, 12, 95.	1.8	9
14846	Dedicated Breast CT: Feasibility for Monitoring Neoadjuvant Chemotherapy Treatment. <i>Journal of Clinical Imaging Science</i> , 2014, 4, 64.	1.1	18
14847	Long term outcome analysis of role of radiotherapy in Grade I meningiomas: A single centre experience from North India. <i>International Journal of Applied & Basic Medical Research</i> , 2015, 5, 128.	0.5	3
14848	Different fractionation schedules of radiotherapy in locally advanced head and neck malignancy: A prospective randomized study to compare the results of treatment and toxicities of different protocols. <i>South Asian Journal of Cancer</i> , 2013, 02, 031-035.	0.6	11
14849	Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population. <i>South Asian Journal of Cancer</i> , 2016, 05, 196-203.	0.6	3
14850	Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. <i>Indian Journal of Cancer</i> , 2017, 54, 652.	0.2	12
14851	Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. <i>Indian Journal of Cancer</i> , 2018, 55, 88.	0.2	3
14852	Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma. <i>Indian Journal of Cancer</i> , 2019, 56, 4.	0.2	3
14853	Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. <i>Indian Journal of Cancer</i> , 2018, 55, 125.	0.2	6
14854	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. <i>Indian Journal of Cancer</i> , 2018, 55, 138.	0.2	5
14855	Analytical study on the efficacy of neoadjuvant chemotherapy using a combination of methotrexate, bleomycin, and cisplatin in the management of advanced squamous cell carcinoma of the buccal mucosa. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 345.	0.2	1
14856	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. <i>Indian Journal of Medical Research</i> , 2018, 148, 284.	1.0	5
14857	Effect of hypofractionated, palliative radiotherapy on quality of life in late-stage oral cavity cancer: A prospective clinical trial. <i>Indian Journal of Palliative Care</i> , 2019, 25, 383.	1.0	20
14858	Role of hypofractionated palliative radiotherapy in patients with stage four head-and-neck squamous cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 528-532.	0.9	5
14859	Efficacy and safety of computed tomography-guided 125I brachytherapy for lymph node metastatic from hepatocellular carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 754-759.	0.9	12
14860	Single institution experience treating adrenal metastases with stereotactic body radiation therapy. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 27.	0.9	11
14861	Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 222.	0.9	2

#	ARTICLE	IF	CITATIONS
14862	Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 2019, 15, 1629.	0.9	23
14863	Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital. Lung India, 2018, 35, 390.	0.7	9
14864	Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian Journal of Cancer, 2019, 08, 092-097.	0.6	2
14865	Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: A prospective randomized study. South Asian Journal of Cancer, 2018, 07, 27-30.	0.6	14
14866	Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. South Asian Journal of Cancer, 2018, 07, 219-222.	0.6	2
14867	Metastatic anorectal melanomas – An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India. South Asian Journal of Cancer, 2017, 06, 147-150.	0.6	2
14868	Metastatic Gastric cancer: Real world scenario from a developing country. South Asian Journal of Cancer, 2018, 07, 171-174.	0.6	9
14869	Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. South Asian Journal of Cancer, 2017, 06, 110-112.	0.6	5
14870	Validity and clinical impact of glucose transporter 1 expression in colorectal cancer. Saudi Journal of Gastroenterology, 2017, 23, 348.	1.1	4
14871	Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. Indian Journal of Cancer, 2018, 55, 123-128.	0.6	12
14872	Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies. Cancer Research and Treatment, 2012, 44, 235-241.	3.0	23
14873	Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2014, 46, 339-347.	3.0	5
14874	Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2013, 45, 79-85.	3.0	21
14875	A Rare Presentation of Follicular Lymphoma: Cerebellar Involvement, Successfully Treated with a Combination of Radiotherapy and Chemotherapy. Cancer Research and Treatment, 2013, 45, 234-238.	3.0	6
14876	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. Cancer Research and Treatment, 2015, 47, 630-637.	3.0	21
14877	Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 661-669.	3.0	23
14878	Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment. Cancer Research and Treatment, 2014, 46, 172-177.	3.0	7
14879	Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis. Cancer Research and Treatment, 2016, 48, 1110-1119.	3.0	11

#	ARTICLE	IF	CITATIONS
14880	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. <i>Cancer Research and Treatment</i> , 2016, 48, 1210-1221.	3.0	11
14881	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 416-422.	3.0	27
14882	Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. <i>Cancer Research and Treatment</i> , 2017, 49, 141-149.	3.0	12
14883	Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective. <i>Cancer Research and Treatment</i> , 2017, 49, 168-177.	3.0	14
14884	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. <i>Cancer Research and Treatment</i> , 2017, 49, 423-429.	3.0	7
14885	Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. <i>Cancer Research and Treatment</i> , 2017, 49, 759-765.	3.0	31
14886	Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 283-292.	3.0	4
14887	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1001-1011.	3.0	43
14888	Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. <i>Cancer Research and Treatment</i> , 2018, 50, 1164-1174.	3.0	5
14889	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1294-1303.	3.0	49
14890	Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1324-1330.	3.0	21
14891	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312.	3.0	48
14892	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	3.0	13
14893	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	3.0	30
14894	Verification of Low Risk for Perihippocampal Recurrence in Patients with Brain Metastases Who Received Whole-Brain Radiotherapy with Hippocampal Avoidance. <i>Cancer Research and Treatment</i> , 2019, 51, 568-575.	3.0	4
14895	A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. <i>Cancer Research and Treatment</i> , 2019, 51, 777-787.	3.0	46
14896	Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. <i>Cancer Research and Treatment</i> , 2019, 51, 758-768.	3.0	9
14897	Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1144-1155.	3.0	17

#	ARTICLE	IF	CITATIONS
14898	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1086-1097.	3.0	59
14899	Early Assessment of Response to Neoadjuvant Chemotherapy with 18 F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1211-1218.	3.0	4
14900	Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases. <i>Cancer Research and Treatment</i> , 2020, 52, 855-866.	3.0	3
14901	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1112-1119.	3.0	10
14902	Diagnosis and treatment of prostate cancer-related bone disease. <i>Clinical Investigation</i> , 2011, 1, 265-283.	0.0	2
14903	Tumor Increase on MRI after Neoadjuvant Treatment is Associated with Greater Pathologic Necrosis and Poor Survival in Patients with Soft Tissue Sarcoma. <i>Journal of Integrative Oncology</i> , 2013, 02, .	0.3	1
14904	Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer. <i>Annals of Surgical Treatment and Research</i> , 2020, 98, 291.	1.0	8
14905	Body Mass Index as a Prognostic Factor for Disease Progression in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab Based Systematic Therapy. <i>Acta Endocrinologica</i> , 2017, 13, 425-430.	0.3	3
14906	Link Availability Prediction for Cognitive Radio Ad Hoc Networks. <i>Journal of Computer and Communications</i> , 2014, 02, 18-24.	0.9	3
14907	Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies. <i>Journal of Cancer Therapy</i> , 2014, 05, 60-66.	0.4	1
14908	A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with Nab-Paclitaxel at a Single Institution. <i>Journal of Cancer Therapy</i> , 2014, 05, 605-610.	0.4	2
14909	Hepatoblastoma in Developing Countries; Eight Years of Single Centre Experience. <i>Journal of Cancer Therapy</i> , 2018, 09, 793-806.	0.4	3
14910	Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer. <i>Journal of Cancer Therapy</i> , 2019, 10, 146-156.	0.4	4
14911	Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer. <i>Genetics and Molecular Research</i> , 2014, 13, 8997-9004.	0.2	21
14912	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 788-803.	2.0	8
14913	Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 295-309.	2.0	8
14914	FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 182-194.	2.0	40
14915	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 332-346.	2.0	7

#	ARTICLE	IF	CITATIONS
14916	Complete clinical response of liver metastasis after chemotherapy: To resect or not?. World Journal of Gastrointestinal Oncology, 2011, 3, 107.	2.0	4
14917	Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. World Journal of Hepatology, 2013, 5, 696.	2.0	9
14918	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World Journal of Hepatology, 2015, 7, 1866.	2.0	24
14919	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World Journal of Hepatology, 2015, 7, 2245.	2.0	8
14920	How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World Journal of Hepatology, 2016, 8, 1541.	2.0	10
14921	YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer. Tâşârk Jinekoloji Ve Obstetrik Dernei Dergisi, 2018, 15, 177-181.	0.8	5
14922	Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. World Journal of Radiology, 2011, 3, 70.	1.1	36
14923	Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonography. World Journal of Radiology, 2012, 4, 291.	1.1	10
14924	Evaluation of cancer treatment in the abdomen: Trends and advances. World Journal of Radiology, 2013, 5, 126.	1.1	2
14925	Can imaging patterns of neuroendocrine hepatic metastases predict response yttrium-90 radioembolotherapy?. World Journal of Radiology, 2013, 5, 241.	1.1	13
14926	Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?. World Journal of Radiology, 2017, 9, 27.	1.1	17
14927	Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma. Gut and Liver, 2013, 7, 343-351.	2.9	17
14928	Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Gut and Liver, 2018, 12, 728-735.	2.9	8
14929	2018 Korean Liver Cancer Associationâ€National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut and Liver, 2019, 13, 227-299.	2.9	255
14930	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut and Liver, 2020, 14, 765-774.	2.9	20
14931	Contrast-enhanced CT- and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. Diagnostic and Interventional Radiology, 2016, 22, 407-421.	1.5	29
14932	Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer. Journal of Gastric Cancer, 2020, 20, 408.	2.5	14
14933	Objective response rate assessment in oncology: Current situation and future expectations. World Journal of Clinical Oncology, 2020, 11, 53-73.	2.3	49

#	ARTICLE	IF	CITATIONS
14934	Positron emission tomography to assess hypoxia and perfusion in lung cancer. World Journal of Clinical Oncology, 2014, 5, 824.	2.3	10
14935	Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World Journal of Clinical Oncology, 2015, 6, 64.	2.3	9
14936	Past, present and future of primary systemic treatment in breast cancer. World Journal of Obstetrics and Gynecology, 2013, 2, 21.	0.5	1
14937	RECIST and beyond. Journal of the Belgian Society of Radiology, 2015, 96, 167.	0.2	6
14938	Integrating Imaging Data into Predictive Biomathematical and Biophysical Models of Cancer. , 2012, 2012, 1-12.		8
14939	Glasgow Prognostic Score in Patients Receiving Chemotherapy for Non-small-cell Lung Cancer in Stages IIb and IV. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2014, 68, 83.	0.9	17
14940	Eribulin for heavily pre-treated metastatic breast cancer patients. World Journal of Experimental Medicine, 2015, 5, 194.	1.7	6
14941	The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chinese Journal of Cancer, 2012, 31, 399-408.	4.9	11
14942	Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience. Hepato-Gastroenterology, 2013, 60, 647-52.	0.5	3
14943	Three Cases Showing Discrepancy between Preoperative Imaging and Postoperative Histopathological Findings after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2013, 46, 106-113.	0.1	3
14944	Efficacy and Safety of Neoadjuvant Chemoradiotherapy with Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Advanced Esophageal Cancer. Japanese Journal of Gastroenterological Surgery, 2019, 52, 753-763.	0.1	1
14946	Clinical analysis for head and neck cancer cases treated with nivolumab in Osaka International Cancer Institute. Japanese Journal of Head and Neck Cancer, 2019, 45, 46-50.	0.1	1
14947	Pseudoprogression and Immunotherapy Phenomena. Journal of the Advanced Practitioner in Oncology, 2020, 11, 723-731.	0.4	2
14948	Metastatic Breast Cancer, Version 1.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 821-829.	4.9	94
14949	A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 432-440.	4.9	4
14950	Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 302-310.	4.9	214
14951	Quantitative Imaging Assessment for Clinical Trials in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1505-1511.	4.9	4
14952	Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics, 2012, 67, 125-129.	1.5	16

#	ARTICLE	IF	CITATIONS
14953	Serum alkaline phosphatase predicts survival outcomes in patients with skeletal metastatic nasopharyngeal carcinoma. <i>Clinics</i> , 2015, 70, 264-272.	1.5	29
14954	Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?. <i>Clinics</i> , 2017, 72, 588-594.	1.5	3
14955	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. <i>JOP: Journal of the Pancreas</i> , 2013, 14, 515-20.	1.5	3
14956	Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. <i>Journal of Cancer</i> , 2010, 1, 80-92.	2.5	205
14957	Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 4959-4962.	1.2	26
14958	Genetic Variants of NBS1 Predict Clinical Outcome of Platinum-based Chemotherapy in Advanced Non-small Cell Lung Cancer in Chinese. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 851-856.	1.2	17
14959	Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Platinum-based Chemotherapy Response of Advanced Non-small Cell Lung Cancers in a Chinese Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 2157-2162.	1.2	36
14960	Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 2771-2774.	1.2	6
14961	Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3213-3218.	1.2	35
14962	Whole Brain Radiotherapy Plus Chemotherapy in the Treatment of Brain Metastases from Lung Cancer: A Meta-analysis of 19 Randomized Controlled Trails. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3253-3258.	1.2	20
14963	Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 489-494.	1.2	78
14964	Overexpression of Semaphorin4D Indicates Poor Prognosis and Prompts Monocyte Differentiation toward M2 Macrophages in Epithelial Ovarian Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5883-5890.	1.2	35
14965	Nausea and Vomiting after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5995-6000.	1.2	17
14966	Comparison of Efficacy and Toxicity of First Line Chemotherapy with or without Epirubicin for Patients with Advanced Stage Soft Tissue Sarcoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 7171-7177.	1.2	6
14967	Efficiency and Side Effects of Sorafenib Therapy for Advanced Hepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of Medical Oncology. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 7367-7369.	1.2	27
14968	Detection of Circulating Tumor Cells in Breast Cancer Patients: Prognostic Predictive Role. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 1601-1607.	1.2	9
14969	Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 2101-2105.	1.2	27
14970	Manual Contouring Based Volumetric Evaluation for Colorectal Cancer with Liver Limited Metastases: A Comparison with RECIST. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 4151-4155.	1.2	3

#	ARTICLE	IF	CITATIONS
14971	Intensity-modulated Radiotherapy Combined with Endocrine Therapy for Intermediate and Advanced Prostate Cancer: Long-term Outcome of Chinese Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4711-4715.	1.2	9
14972	Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4751-4758.	1.2	19
14973	Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases. Asian Pacific Journal of Cancer Prevention, 2014, 15, 61-67.	1.2	16
14974	Clinical Characteristics of Gynecologic Cancer Patients who Respond to Salvage Treatment with Lingzhi. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4193-4196.	1.2	17
14975	Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4781-4786.	1.2	23
14976	Lobaplatin-TACE Combined with Radioactive ¹²⁵ I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5155-5160.	1.2	22
14977	Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5195-5200.	1.2	7
14978	Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5945-5950.	1.2	3
14979	Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6559-6564.	1.2	5
14980	Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7119-7123.	1.2	15
14981	Pre-Treatment Performance Status and Stage at Diagnosis in Patients with Head and Neck Cancers. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8479-8482.	1.2	13
14982	Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8661-8666.	1.2	8
14983	Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1581-1584.	1.2	9
14984	in vitro Assessment of Antineoplastic Effects of Deuterium Depleted Water. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2179-2183.	1.2	17
14985	Importance of Volumetric Measurement Processes in Oncology Imaging Trials for Screening and Evaluation of Tumors as Per Response Evaluation Criteria in Solid Tumors. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2375-2378.	1.2	3
14986	Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3151-3156.	1.2	5
14987	Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 321-326.	1.2	12
14988	Comparison of Three Different Induction Regimens for Nasopharyngeal Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 59-63.	1.2	2

#	ARTICLE	IF	CITATIONS
14989	Radiotherapy and Concurrent Chemo-Radiotherapy in Locally Advanced Hypopharyngeal Cancers - A Hospital Registry Based Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4723-4726.	1.2	3
14990	Efficacy and Tolerability of Weekly Docetaxel, Cisplatin, and 5-Fluorouracil for Locally Advanced or Metastatic Gastric Cancer Patients with ECOG Performance Scores of 1 and 2. Asian Pacific Journal of Cancer Prevention, 2015, 16, 985-989.	1.2	2
14991	Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2355-2359.	1.2	5
14992	Changing patterns of Serum CEA and CA199 for Evaluating the Response to First-line Chemotherapy in Patients with Advanced Gastric Adenocarcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3111-3116.	1.2	13
14993	TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study. Drugs in Context, 2020, 9, 1-8.	2.2	6
14994	Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies. Drugs in Context, 2017, 6, 1-8.	2.2	8
14995	On the relationship between tumour growth rate and survival in non-small cell lung cancer. PeerJ, 2017, 5, e4111.	2.0	3
14996	Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer. PeerJ, 2019, 7, e7767.	2.0	1
14997	Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension. PeerJ, 2019, 7, e8188.	2.0	12
14998	Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases. Cureus, 2017, 9, e1926.	0.5	4
14999	Abscopal Resolution of a Hepatic Metastasis in a Patient with Metastatic Cholangiocarcinoma Following Radical Stereotactic Body Radiotherapy to a Synchronous Early Stage Non-small Cell Lung Cancer. Cureus, 2019, 11, e4082.	0.5	6
15000	Safety and Efficacy of Lattice Radiotherapy in Voluminous Non-small Cell Lung Cancer. Cureus, 2019, 11, e4263.	0.5	30
15001	Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Cureus, 2020, 12, e7107.	0.5	9
15002	Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer. Cureus, 2020, 12, e7147.	0.5	9
15003	Postoperative Long-term Outcomes of Patient with Craniopharyngioma Based on CyberKnife Treatment. Cureus, 2020, 12, e7207.	0.5	3
15004	Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation. Cureus, 2020, 12, e9988.	0.5	3
15005	A Comparative Analysis of Two Different Dose Fractionation Regimens of High Dose Rate Intracavitary Brachytherapy in Treatment of Carcinoma of Uterine Cervix: A Prospective Randomized Study. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, XC06-XC10.	0.8	11
15006	Prognostic Significance of Epidermal Growth Factor Receptor in Patients of Glioblastoma Multiforme. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, EC05-EC08.	0.8	11

#	ARTICLE	IF	CITATIONS
15007	Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments. British Journal of Medicine and Medical Research, 2014, 4, 3101-3131.	0.2	23
15009	A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. Journal of Cancer, 2021, 12, 7018-7025.	2.5	3
15010	The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study. Cancer Biology and Medicine, 2021, 19, 755-767.	3.0	4
15011	Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept. Theranostics, 2021, 11, 9538-9556.	10.0	10
15012	Response Assessment to Cancer Therapy. UNIPA Springer Series, 2021, , 249-257.	0.1	0
15013	Efficacy and safety of bevacizumab-containing therapy for refractory advanced breast cancer: a retrospective study. Annals of Palliative Medicine, 2021, 10, 10997-11005.	1.2	1
15014	Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis. Interactive Cardiovascular and Thoracic Surgery, 2021, , .	1.1	0
15015	Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial. British Journal of Surgery, 2021, 109, 121-128.	0.3	8
15016	Central Nervous System Malignancies. UNIPA Springer Series, 2021, , 731-754.	0.1	0
15017	Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience. Technology in Cancer Research and Treatment, 2021, 20, 153303382110507.	1.9	3
15018	Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors. Annals of Palliative Medicine, 2021, 10, 11244-11254.	1.2	7
15019	Remissionsparameter. Springer Reference Medizin, 2021, , 1-22.	0.0	0
15020	Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Translational Andrology and Urology, 2021, 10, 0-0.	1.4	1
15021	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. Translational Lung Cancer Research, 2021, 10, 3929-3942.	2.8	6
15022	The influence of 18F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 684-695.	1.5	1
15023	Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning. Cancer Control, 2021, 28, 107327482110446.	1.8	18
15024	Hypofractionated radiation therapy as palliative management for symptomatic and local control of advanced thoracic malignancies. Annals of Palliative Medicine, 2021, 10, 10360-10368.	1.2	2
15025	Characterization of Anti-Angiogenic Chemo-Sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts. IEEE Transactions on Biomedical Engineering, 2022, 69, 1449-1460.	4.2	8

#	ARTICLE	IF	CITATIONS
15026	Role of pre-operative percutaneous embolization in orbital alveolar soft part sarcoma – An experience from a tertiary eye-care center. Indian Journal of Ophthalmology, 2021, 69, 2796.	1.1	1
15027	Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.. Cancer Treatment and Research Communications, 2021, 29, 100481.	1.7	1
15028	Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. Cancer Medicine, 2021, 10, 1745-1758.	2.8	1
15029	JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer, 2022, 128, 65-74.	4.1	36
15030	Epstein-Barr DNA in advanced pediatric nasopharyngeal cancer. Paediatrica Indonesiana, 2021, 61, 261-70.	0.1	0
15031	Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma. Chinese Medical Journal, 2021, 134, 2430-2437.	2.3	1
15032	Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy. Medicina (Lithuania), 2021, 57, 1044.	2.0	7
15033	The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Medicine, 2021, 10, 7977-7987.	2.8	16
15034	Metabolic PET/CT response after induction chemotherapy and chemo(re)irradiation is associated with higher negative resection margins rate in patients with locally recurrent rectal cancer. Colorectal Disease, 2021, , .	1.4	3
15035	Clinical Outcomes of Intra-arterial Chemoradiotherapy and Neoadjuvant Chemoradiotherapy Followed by Surgery for Maxillary Sinus Squamous Cell Carcinoma. Iranian Journal of Radiology, 2021, 18, .	0.2	0
15036	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 2021, 39, 1531-1547.e10.	16.8	106
15037	Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.8	1
15038	VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. British Journal of Cancer, 2021, , .	6.4	3
15039	Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status after Neoadjuvant Chemotherapy in Chinese Women with Breast Cancer. Diagnostics, 2021, 11, 1846.	2.6	2
15040	SEOR-SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. Clinical and Translational Oncology, 2022, 24, 215-226.	2.4	5
15041	CT-Based Sarcopenic Nomogram for Predicting Progressive Disease in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 643941.	2.8	8
15042	18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12). Oncology and Therapy, 2021, 9, 635-645.	2.6	2
15043	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34

#	ARTICLE	IF	CITATIONS
15044	Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise during intravenous chemotherapy versus usual care. <i>BMC Cancer</i> , 2021, 21, 1093.	2.6	19
15045	Detailed Analysis and Radiomic Prediction of First Progression Sites of First-Line Targeted Therapy for EGFR-Mutant Lung Adenocarcinoma Patients With Systemic Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 757892.	2.8	0
15046	Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 742971.	2.8	3
15047	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
15048	Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy±immune checkpoint inhibition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1407-1416.	6.4	5
15049	Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5168.	3.7	1
15050	Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event. <i>Thyroid</i> , 2021, , .	4.5	8
15051	Neoadjuvant and Adjuvant Nivolumab and Liriumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	7.0	45
15052	Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. <i>BMC Cancer</i> , 2021, 21, 1113.	2.6	10
15053	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. <i>Cancer Cell</i> , 2021, 39, 1578-1593.e8.	16.8	275
15054	The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 139-157.	3.3	23
15055	Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?. <i>Npj Breast Cancer</i> , 2021, 7, 139.	5.2	3
15056	Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. <i>Cancer Communications</i> , 2022, 42, 3-16.	9.2	22
15057	Evolving Patterns of Metastasis in Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2021, 8, 13-19.	1.0	1
15058	Case Report: Two Cases of Salivary Duct Carcinoma in Workers With a History of Chromate Exposure. <i>Frontiers in Medicine</i> , 2021, 8, 730403.	2.6	0
15059	Imaging of Colorectal Liver Metastasis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 245-257.	1.7	10
15060	Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation. <i>Nutrients</i> , 2021, 13, 3761.	4.1	10
15062	Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 736940.	3.5	4

#	ARTICLE	IF	CITATIONS
15063	Clinical and metabolic parameters for predicting disease progression of gallbladder adenocarcinoma. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 42-48.	1.1	0
15064	The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 73-77.	1.1	3
15065	Results of the observational prospective RealFLOT study. BMC Cancer, 2021, 21, 1086.	2.6	17
15066	Correlation Between Thymoma and Soluble Interleukin-2 Receptor Expression in a Patient with Good Syndrome. OncoTargets and Therapy, 2021, Volume 14, 5045-5049.	2.0	0
15067	Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. Journal of Clinical Oncology, 2022, 40, 262-271.	1.6	59
15068	Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nature Reviews Clinical Oncology, 2022, 19, 132-146.	27.6	221
15069	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulmonary Medicine, 2021, 21, 309.	2.0	2
15070	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
15071	Practical and robust test for comparing binomial proportions in the randomized phase <scp>II</scp> setting. Pharmaceutical Statistics, 2022, 21, 361-371.	1.3	2
15072	Impact of synbiotics treatment on bacteremia induced during neoadjuvant chemotherapy for esophageal cancer: A randomised controlled trial. Clinical Nutrition, 2021, 40, 5781-5791.	5.0	11
15073	Role of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Predicting the Response to First Line Chemotherapy in Colorectal Cancer Patients with Synchronous Liver Metastases: A Retrospective Study. International Journal of Cancer Management, 2021, 14, .	0.4	0
15074	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 2021, 163, 246-253.	1.4	62
15075	Patientâ€Derived Organoids Can Guide Personalizedâ€Therapies for Patients with Advanced Breast Cancer. Advanced Science, 2021, 8, e2101176.	11.2	42
15076	Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases. American Journal of Surgery, 2022, 223, 1151-1156.	1.8	4
15077	Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clinical Cancer Research, 2022, 28, 36-44.	7.0	32
15078	The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer. Cancers, 2021, 13, 5100.	3.7	5
15079	Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid, 2021, , .	4.5	31
15080	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Nonâ€Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 72-81.	2.6	17

#	ARTICLE	IF	CITATIONS
15081	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. <i>Cancers</i> , 2021, 13, 5142.	3.7	2
15082	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 150-160.	1.6	137
15083	FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2022, 33, 99-106.	1.2	15
15084	The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine. <i>Clinical Colorectal Cancer</i> , 2022, 21, e87-e97.	2.3	6
15085	Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis. <i>Targeted Oncology</i> , 2021, 16, 743-752.	3.6	3
15086	Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas. <i>Neurosurgical Review</i> , 2022, 45, 1401-1411.	2.4	6
15087	State of the art and future directions in the systemic treatment of medullary thyroid cancer. <i>Current Opinion in Oncology</i> , 2022, 34, 1-8.	2.4	3
15089	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , 2022, 54, 47-54.	1.4	3
15091	Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Cancer Research</i> , 2021, 81, 6004-6017.	0.9	25
15092	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	1.1	114
15093	Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. <i>Esophagus</i> , 2021, , 1.	1.9	0
15094	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021, 13, 155.	8.2	44
15096	Prognostic significance of the number of removed lymph nodes according to FIGO stage in ovarian clear cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 15, 263.	1.0	2
15097	MRI in the Setting of Neoadjuvant Treatment of Breast Cancer. <i>Journal of Breast Imaging</i> , 2022, 4, 320-330.	1.3	4
15098	Inter- and intraobserver agreement for CT measurement of mandibular and medial retropharyngeal lymph nodes is excellent in dogs with histologically confirmed oral melanoma. <i>Veterinary Radiology and Ultrasound</i> , 2021, , .	0.9	1
15099	Prognostic factors for refractory pheochromocytoma and paraganglioma after ¹³¹ I-metaiodobenzylguanidine therapy. <i>Annals of Nuclear Medicine</i> , 2022, 36, 61-69.	2.2	3
15100	Magnetic resonance imaging-radiomics evaluation of response to chemotherapy for synchronous liver metastasis of colorectal cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 6465-6475.	3.3	8
15101	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2021, 5, 1603-1610.	3.0	4

#	ARTICLE	IF	CITATIONS
15102	Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1051-1062.	2.0	2
15103	RECIST criteria and clinical practice. <i>Nowotwory</i> , 2021, 71, 319-320.	0.3	0
15104	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2022, 20, 45-55.	3.4	13
15105	Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Breast Cancer</i> , 2022, 29, 174-184.	2.9	10
15107	Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. <i>Targeted Oncology</i> , 2021, 16, 773-787.	3.6	2
15108	Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. <i>Journal of Geriatric Oncology</i> , 2022, 13, 302-307.	1.0	4
15109	International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC1). <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 227-240.	2.4	39
15110	Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer. <i>Colorectal Disease</i> , 2021, , .	1.4	4
15111	Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, , .	1.9	2
15112	In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator. <i>Pathology and Oncology Research</i> , 2021, 27, 1609811.	1.9	11
15113	FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. <i>Cancer Imaging</i> , 2021, 21, 57.	2.8	11
15114	Comparison of different malnutrition screening tools according to GLIM criteria in cancer outpatients. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 698-702.	2.9	6
15116	Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110429.	1.0	3
15117	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 19659.	3.3	0
15118	A Narrative Review of Ultrasound Technologies for the Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7885-7895.	1.9	13
15119	Analysis of mammograms using artificial intelligence to predict response to neoadjuvant chemotherapy in breast cancer patients: proof of concept. <i>European Radiology</i> , 2022, 32, 3131-3141.	4.5	10
15120	Technical Feasibility and Safety of Repeated CT-guided Trans-thoracic Intratumoral Injection of Gene Modified Cellular Immunotherapy in Metastatic Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100242.	1.1	0
15121	Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 778459.	4.8	6

#	ARTICLE	IF	CITATIONS
15122	Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	1.4	12
15123	FAN score comprising fibrosis-4 index, albuminâ€“bilirubin score and neutrophilâ€“lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab. Scientific Reports, 2021, 11, 21199.	3.3	11
15124	Immunotherapy after liver transplantation: Where are we now?. World Journal of Gastrointestinal Surgery, 2021, 13, 1267-1278.	1.5	20
15125	Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110512.	1.2	2
15126	Disease-free time stratification in locally recurrent head and neck carcinoma after definitive radiotherapy or chemoradiotherapy. European Archives of Oto-Rhino-Laryngology, 2022, 279, 3063-3069.	1.6	3
15127	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 2021, , .	1.9	6
15128	Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 734323.	2.8	7
15129	Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study. Cancers, 2021, 13, 5267.	3.7	10
15130	Immunotherapy after liver transplantation: Where are we now?. World Journal of Gastrointestinal Surgery, 2021, 13, 1266-1277.	1.5	0
15131	The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab. Cancer Management and Research, 2021, Volume 13, 8049-8056.	1.9	11
15132	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertionâ€“Positive Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, e214761.	7.1	160
15133	Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Frontiers in Immunology, 2021, 12, 721830.	4.8	50
15134	Three-Dimensional H-Scan Ultrasound Imaging of Early Breast Cancer Response to Neoadjuvant Therapy in a Murine Model. Investigative Radiology, 2022, 57, 222-232.	6.2	19
15135	Draft of the clinical practice guidelines â€œAdrenal incidentalomaâ€œ. Endocrine Surgery, 2021, 15, 4-26.	0.2	5
15136	Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer. Biomedical Journal, 2022, 45, 821-827.	3.1	9
15137	Long-Term Follow-Up of Patients Receiving Neoadjuvant Treatment Modalities for Soft Tissue Sarcomas of the Extremities. Cancers, 2021, 13, 5244.	3.7	1
15138	Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia. Advances in Therapy, 2021, 38, 5684-5699.	2.9	2
15139	Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. Frontiers in Oncology, 2021, 11, 712053.	2.8	5

#	ARTICLE	IF	CITATIONS
15140	Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 13.e19-13.e27.	1.6	4
15141	Added Value of Tomoelastography for Characterization of Pancreatic Neuroendocrine Tumor Aggressiveness Based on Stiffness. <i>Cancers</i> , 2021, 13, 5185.	3.7	8
15142	Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). <i>Gynecologic Oncology</i> , 2022, 164, 18-26.	1.4	4
15143	Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1479.	1.8	7
15144	CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1851-1867.	2.0	46
15145	Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2021, 10, 8272-8287.	2.8	5
15146	Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib: Real-world AXILONG study. <i>Clinical Genitourinary Cancer</i> , 2021, , .	1.9	2
15147	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	1.6	283
15148	Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. <i>Cancer</i> , 2022, 128, 509-518.	4.1	10
15149	A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690336.	2.8	4
15150	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	3.3	53
15151	Computed tomography-based radiomic analysis for prediction of treatment response to salvage chemoradiotherapy for locoregional lymph node recurrence after curative esophagectomy. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 71-79.	1.9	5
15152	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. <i>JGH Open</i> , 2021, 5, 1266-1274.	1.6	9
15153	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 49-58.	2.3	2
15154	The liver-first approach for synchronous colorectal liver metastases: A systematic review and meta-analysis of completion rates and effects on survival. <i>Scandinavian Journal of Surgery</i> , 2021, , 145749692110301.	2.6	4
15155	Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1493-1493.	1.7	1
15156	Î”CT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 684661.	3.5	1
15157	A Practical Predictive Model Based on Ultrasound Imaging and Clinical Indices for Estimation of Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7783-7793.	1.9	3

#	ARTICLE	IF	CITATIONS
15158	Stereotactic body radiotherapy for head and neck skin cancer. <i>Radiotherapy and Oncology</i> , 2021, 165, 1-7.	0.6	9
15159	Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6609-6620.	1.8	9
15160	Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases. <i>Radiation Oncology Journal</i> , 2021, 39, 254-264.	1.5	2
15161	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Étude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , 2021, 158, 1-11.	2.8	4
15162	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , 2021, 157, 474-484.	2.8	45
15163	Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100883.	0.6	11
15164	Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. <i>European Journal of Cancer</i> , 2021, 158, 72-84.	2.8	14
15165	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	2.8	33
15166	Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials. <i>Contemporary Clinical Trials</i> , 2021, 110, 106589.	1.8	0
15167	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. <i>Oral Oncology</i> , 2021, 122, 105566.	1.5	10
15168	Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-CTLA-4 programmed cell death-1 therapies for melanoma: A cross-sectional study. <i>JAAD International</i> , 2021, 5, 112-120.	2.2	10
15169	All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. <i>Journal of Bone Oncology</i> , 2021, 31, 100399.	2.4	12
15170	The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. <i>Lung Cancer</i> , 2021, 162, 36-41.	2.0	5
15171	eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer. <i>Pharmacological Research</i> , 2021, 174, 105934.	7.1	11
15172	Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients. <i>Breast</i> , 2021, 60, 131-137.	2.2	9
15173	Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib. <i>IFMBE Proceedings</i> , 2009, , 327-330.	0.3	0
15174	Analysis of antitumor immunity of HVJ-E (hemagglutinating virus of Japan envelope) and development in its clinical application for advanced malignant melanoma patients. <i>Skin Cancer</i> , 2009, 24, 181-191.	0.0	0
15177	Critères d'efficacité des traitements de première ligne métastatique du cancer du sein. , 2010, , 345-354.		0

#	ARTICLE	IF	CITATIONS
15178	MÃ©thodes radiologiques d'Ã©valuation de la rÃ©ponse thÃ©rapeutique en cancérologie. , 2010, , 41-52.		0
15179	Onkologie: Ã—sophagus/Magen/DÃ¼nn darm. , 2010, , 37-74.		0
15180	Prinzipien der Statistik und Studienbiometrie. , 2010, , 409-422.		0
15181	A patient with advanced hepatocellular carcinoma in whom changes in tumor vascularization under Sorafenib treatment could be evaluated in a short period by parametric imaging using Sonazoid -case study-. Acta Hepatologica Japonica, 2010, 51, 56-58.	0.1	0
15182	Result of Neoadjuvant Chemotherapy, Surgery and Radiation Therapy in Locally Advanced Breast Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2010, 28, 71.	0.1	0
15184	Phase III studies. , 2010, , 211-266.		0
15185	Targeted Therapies for Hepatocellular Carcinoma. , 2011, , 355-368.		0
15188	Molecular Imaging of Cancer and the Implications for Pre-invasive Disease. , 2011, , 167-207.		1
15189	Evaluation of Response After Radiotherapy for Hodgkin Lymphoma. , 2011, , 161-166.		0
15190	Imaging in Gastrointestinal Cancer. , 2011, , 1-20.		0
15191	Phase II Trials with Anticancer Agents. , 2011, , 141-161.		0
15192	Bildgebende Diagnostik und Therapiekontrolle mit PET-CT und MRT. , 2011, , 53-63.		0
15193	Selecting Patients for Hyperthermia Treatment Based on Patient Backgrounds. Thermal Medicine, 2011, 27, 51-60.	0.1	0
15194	Modeling the Progression of Disease. , 2011, , 57-90.		0
15195	Medical Management of Islet Cell Carcinoma. , 2011, , 137-155.		0
15196	Comparison of Sorafenib response evaluation with RECIST, mRECIST and RECICL for hepatocellular carcinoma. Acta Hepatologica Japonica, 2011, 52, 322-324.	0.1	5
15198	Biostatistique : plans expÃ©rimentaux. , 2011, , 957-972.		0
15199	How to measure the size of tumors: the RECIST standard vs. volumetrics. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
15200	Evidence-Based Head and Neck Oncology: Principles and Pitfalls. , 2011, , 317-325.		0
15201	Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. , 2011, , 329-366.		0
15202	Analysis of the results of multidisciplinary treatments based on the tumor response to 40Gy chemoradiotherapy for hypopharyngeal carcinomas. Japanese Journal of Head and Neck Cancer, 2011, 37, 417-423.	0.1	1
15203	A Case of Neuroendocrine Tumor of the Ileum with Liver Metastases Treated with Transcatheter Arterial Chemoembolization with Degradable Starch Microspheres and Biotherapy with Octreotide. Yamaguchi Medical Journal, 2011, 60, 255-261.	0.1	1
15204	Principes van de medicamenteuze antikankerbehandeling. , 2011, , 175-195.		0
15206	Principles of systemic therapy. , 2011, , 30-44.		0
15207	RECIST Applied to Realistic Tumor Models. Journal of Research of the National Institute of Standards and Technology, 2011, 116, 685.	1.2	2
15208	CHEMOTHERAPY IN GYNECOLOGIC MALIGNANCIES. , 2011, , 1-36.		0
15210	Targeted Therapy of Thyroid Cancer. Growth Hormone, 2012, , 301-315.	0.2	0
15211	Principles of Medical Oncology and Chemotherapy. , 2012, , 3-13.		0
15212	A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer. Journal of Cancer Therapy, 2012, 03, 948-955.	0.4	1
15213	Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 661-689.		0
15214	Targeted Therapies and Vaccination. , 2012, , 261-275.		0
15215	Power Technology: How to Safely Use Ports and Central Catheters to Deliver Contrast Medium in Radiology Procedures. , 2012, , 239-246.		0
15216	An Empirical Bayes Approach to Robust Variance Estimation: A Statistical Proposal for Quantitative Medical Image Testing. Open Journal of Statistics, 2012, 02, 260-268.	0.7	0
15217	Survival and Treatment Responses of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Journal of Cancer Science & Therapy, 2012, 04, .	1.7	0
15218	Long-term survivor of stage IVb pancreatic cancer with peritoneal dissemination treated with neoadjuvant chemoradiotherapy followed by pancreaticoduodenectomy. Suizo, 2012, 27, 62-68.	0.1	0
15219	Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma. , 0, , .		0

#	ARTICLE	IF	CITATIONS
15220	Immunotherapy of Renal Cell Carcinoma “ From Antigen Identification to Patient Treatment. , 0, , .		0
15221	Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15080-e15080.	1.6	0
15222	Prognostic, Predictive, and Surrogate Factors for Individualizing Treatment for Men with Castration-Resistant Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 292-297.	3.8	0
15223	A Case Series of Survival Outcomes in Patients with Advanced-stage IIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus. Journal of Pharmacopuncture, 2012, 15, 31-35.	1.1	3
15225	Tumors of the Liver and Biliary Tract. , 2013, , 451-472.		1
15226	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
15227	Aggressive Fibromatosis Treatment - Imatinib Challenges. Macedonian Journal of Medical Sciences, 2012, 5, .	0.0	1
15229	Predictive value of clinicopathologic parameters in locally advanced breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy. Korean Journal of Clinical Oncology, 2012, 8, 98-104.	0.1	0
15230	Klinisch wetenschappelijk onderzoek. , 2013, , 43-52.		0
15231	New PET/CT Features for the Evaluation of Tumor Response. Journal of Nuclear Medicine & Radiation Therapy, 2013, 04, .	0.2	1
15232	Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. World Journal of Obstetrics and Gynecology, 2013, 2, 167.	0.5	0
15234	Therapy Monitoring and Assessment Using Quantitative Ultrasound. , 2013, , 193-216.		4
15235	A Case of Pathological Complete Response after Combination Chemotherapy by Sorafenib and Cisplatin Hepatic Arterial Infusion for an Advanced Hepatocellular Carcinoma. Japanese Journal of Gastroenterological Surgery, 2013, 46, 915-923.	0.1	0
15236	Study of Appropriate Surgical Timing for Liver Metastasis of Colon Cancer“From Tumor Shrinkage Speed by Chemotherapy”. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2013, 38, 746-752.	0.0	0
15237	Molecular Imaging for Renal Cell Carcinoma. , 2013, , 93-111.		0
15238	CT Tumor Sizing as a Quantitative Imaging Biomarker: When is Bias Relevant?. , 2013, , .		0
15239	OPRT Is a Potential Predictive Factor for the Response to S-1 in Gastric Cancer. Journal of Cancer Therapy, 2013, 04, 104-111.	0.4	0
15240	Efficacy and optimal treatment sequence of Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Acta Hepatologica Japonica, 2013, 54, 233-248.	0.1	2

#	ARTICLE	IF	CITATIONS
15241	Extramammary Paget's disease : a report of 69 cases with literature review. Skin Cancer, 2013, 28, 63-67.	0.0	2
15243	Intussusception Induced by Cecal Metastasis of Primary Small Cell Lung Cancer. Korean Journal of Medicine, 2013, 85, 218.	0.3	0
15244	Diagnosis of Metastasis. , 2013, , 251-273.		0
15245	Curative Radiotherapy in Patients Inoperable for Medical Reasons. , 2013, , 151-162.		0
15246	Palliation and Quality of Life. , 2013, , 161-173.		0
15247	Imaging Following Treatment of Lung Cancer. , 2013, , 169-179.		0
15248	Dynamic Contrast-Enhanced CT in Advanced Lung Cancer after Chemotherapy with/without Radiation Therapy: Can It Predict Treatment Responsiveness of the Tumor?. Journal of the Korean Society of Radiology, 2013, 69, 131.	0.2	0
15249	Analysis of prognostic factors for overall survival in patients with advanced non-small cell lung cancer treated with second line chemotherapy. Advances in Lung Cancer (Irvine), 2013, 02, 55-61.	0.2	0
15250	PATHOLOGIE TUMORALE DU PARENCHYME PULMONAIRE. , 2013, , 277-451.		0
15251	Short-term Outcome of Hypofractionated Three-dimensional Conformal Radiation Therapy for Pituitary Tumors in Dogs. Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 2013, 66, 709-712.	0.1	0
15252	âĖĖâĖ,“âĖĖ-âĖĖ ħ™,æ³•âĖâĖ...“âĖĖĖœæ¹-âĖâĖ½µĖ”“âĖâĖ,âĖĖ. Kampo Medicine, 2013, 64, 119-122.	0.1	0
15253	Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2013, 3, 17-26.	0.1	3
15254	RANO, mÃĖs que ficciÃĖn.. Revista Colombiana De HematologĖa Y OncologĖa, 2013, 2, 34-44.	0.0	0
15257	Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?.. , 2014, , 91-100.		0
15259	Imaging Criteria for Tumor Treatment Response Evaluation. , 2014, , 13-25.		0
15265	Role of Functional MRI in the Management of Liver Metastases. , 2014, , 1003-1023.		0
15266	Zastosowanie doÃĖylnych ultrasonograficznych ÅĖrodkÃĖw kontrastujÃĖcych w porÃĖwnaniu z innymi metodami obrazowymi u dzieci leczonych z powodu choroby nowotworowej. , 2013, 13, 438-445.		2
15269	Monitoring Responses to Therapy in Oncology. , 2014, , 155-171.		1

#	ARTICLE	IF	CITATIONS
15270	Functional Imaging of Ovarian Cancer and Peritoneal Carcinomatosis. , 2014, , 877-900.		0
15271	Imaging Review Charters and Operational Considerations. , 2014, , 65-82.		1
15272	Neuroimaging in Clinical Trials. , 2014, , 197-235.		0
15273	Bone Metastasis. , 2014, , 1389-1410.		0
15274	Revisiting epidermal growth factor receptor in glioblastoma multiforme: Does it play a role in response to therapy?. Indian Journal of Pathology and Microbiology, 2014, 57, 390.	0.2	3
15275	Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.. Journal of Clinical Oncology, 2014, 32, 174-174.	1.6	1
15276	Aspects post-thérapeutiques des carcinomes hépatocellulaires. , 2014, , 137-166.		0
15277	Imagerie post-thérapeutique des cancers de l'ovaire. , 2014, , 219-225.		0
15278	Bildgebende Diagnostik von ossären Metastasen. , 2014, , 33-47.		0
15279	Metastatic Uveal Melanoma. , 2014, , 275-285.		0
15280	Defining Clinical Endpoints in Castration-Resistant Prostate Cancer. Current Clinical Urology, 2014, , 187-199.	0.0	0
15281	Therapiesteuerung in der medikamentösen Tumorthérapie. , 2014, , 1-9.		0
15283	Clinical Trial Endpoints in Breast Cancer. , 2014, , 535-545.		0
15284	Knochenmetastasen bei urologischen Malignomen. , 2014, , 177-192.		0
15287	Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies. , 2014, , 155-165.		0
15288	Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress. , 2014, , 53-62.		0
15289	Low-Dose Involved-Field Radiotherapy in Relapsed Low-Grade Non-Hodgkin's Lymphoma in Elderly Patients (Mansoura University Experience). Journal of Cancer Therapy, 2014, 05, 500-505.	0.4	0
15290	Weekly irinotecan and carboplatin for patients with small cell lung cancer. Yeungnam University Journal of Medicine, 2014, 31, 82.	0.1	0

#	ARTICLE	IF	CITATIONS
15291	Advanced thyroid cancer patients in Phase I clinical trials: Outcome assessment and literature review. World Journal of Oncology, 2014, 5, 24-32.	1.5	0
15292	Nuclear Oncology. , 2014, , 223-252.		0
15293	UGT1A1*28 Polymorphism in Advanced Colorectal Cancer: The Story Is Not Yet Ended. Journal of Cancer Therapy, 2014, 05, 53-59.	0.4	0
15294	New Imaging Modalities. Current Clinical Urology, 2014, , 43-63.	0.0	0
15295	Chemotherapy and Targeted Molecular Therapy in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2014, 67, 897-905.	0.0	0
15296	Comparison of tumor response in patients treated with sorafenib for hepatocellular carcinoma. Acta Hepatologica Japonica, 2012, 53, 344-347.	0.1	0
15297	First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3157-3161.	1.2	2
15299	Effect of chronic liver disease using a multivariate analysis of associated risk factors in patients with hepatocellular carcinoma treated with transarterial chemoembolization. Journal of Cancer Research & Therapy, 2014, 2, 74-81.	0.1	0
15300	Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature. F1000Research, 0, 3, 255.	1.6	3
15303	MRI of Bone Marrow Posttreatment Changes. , 2015, , 143-163.		1
15305	Cyberknife fractionated radiotherapy for adrenal metastases: Preliminary report from a multispecialty Indian cancer care center. International Journal of Cancer Therapy and Oncology, 2014, 3, 03012.	0.2	1
15306	Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature. F1000Research, 2014, 3, 255.	1.6	4
15307	A Case Report of Complete Response of Advanced Gastric Carcinoma Patient Treated with Korean Medicine Treatment in Conjunction with Chemoradiation Therapy. Journal of Korean Traditional Oncology, 2014, 19, 25-32.	0.0	2
15308	Renal Salt Wasting Syndrome due to Carboplatin in a Patient with Lung Cancer. Pulmonary Research and Respiratory Medicine: Open Journal, 2014, 1, 9-12.	1.0	1
15309	Isolated limb infusion: efficacy, toxicity and an evolution in the management of in-transit melanoma. Plastic Surgery, 2015, 23, 25-30.	1.0	5
15310	Effectiveness of Positron Emission Tomography-Computed Tomography in Evaluation of Superselective Intra-arterial Chemoradiotherapy in Patients with Advanced Maxillary and Upper Gingival Carcinomas. Practica Otologica, 2015, 108, 39-44.	0.0	0
15311	Designs for Evaluating Precision Medicine Trials. , 2015, , 113-131.		0
15312	Pre-radiotherapy Haemoglobin Level is A Prognosticator in Locally Advanced Head and Neck Cancers Treated with Concurrent Chemoradiation. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, XC14-XC18.	0.8	6

#	ARTICLE	IF	CITATIONS
15313	The Role of FDG-PET in the Treatment of Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer. Radioisotopes, 2015, 64, 145-167.	0.2	0
15314	Pharmacokineticâ€“Pharmacodynamic Modeling in Drug Development with Special Reference to Oncology. RSC Drug Discovery Series, 2015, , 391-413.	0.3	0
15315	Recurrence of liver metastases from colorectal cancer and repeat liver resection. Revista Espanola De Enfermedades Digestivas, 2015, 107, 732-9.	0.3	1
15316	Phase I Trials Today. , 2015, , 661-676.e2.		0
15317	Radiological Response Criteria. , 2015, , 1-5.		0
15318	Stadieneinteilung endokriner Tumore. , 2015, , 255-266.		0
15319	Post-therapy Surveillance of Bone Tumors. Pediatric Oncology, 2015, , 211-219.	0.5	0
15320	Is there a Need to Identify Novel Tumour Antigens as Targets for Immunotherapy Clinical Trials for The Removal of Minimal Residual Disease in Haematological Malignancies?. International Journal of Hematology Research, 2015, 1, 40-42.	0.2	0
15321	A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First-Line Treatment in Elderly Patients with Unresectable Colorectal Cancer. Journal of Cancer Therapy, 2015, 06, 153-162.	0.4	0
15322	Evaluation of Response in Malignant Tumors Treated with Targeted Agents. Current Clinical Pathology, 2015, , 43-55.	0.0	0
15323	Bone Scan Index Is a Prognostic Factor for Breast Cancer Patients with Bone Metastasis Being Treated with Zoledronic Acid. Open Journal of Radiology, 2015, 05, 149-158.	0.2	1
15324	Recurrent ovarian cancer. , 2015, , 303-318.		0
15325	BP-C2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment: A Case of Advanced Inoperable Pancreatic Cancer. Journal of Clinical Case Reports, 2015, 05, .	0.0	1
15326	The causes, diagnosis, and treatment of recurrent ovarian cancer. A literature review and analysis of the authorsâ€™ data. Onkologiya Zhurnal Imeni P A Gertsena, 2015, 4, 59.	0.2	2
15327	Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis. Advances in Lung Cancer (Irvine), 2015, 04, 8-15.	0.2	0
15328	Gastrointestinal Stromal Tumors (GIST)â€“Paving the Way for Modern Oncologyâ€“Epidemiology, Diagnosis, Treatment. European Oncology and Haematology, 2015, 11, 57.	0.0	0
15329	Onkologische Bildgebung zur Beurteilung des Therapieansprechens. , 2015, , 91-100.		0
15330	A case of long term survival of pancreatic cancer with paraaortic nodal metastasis. Suizo, 2015, 30, 137-143.	0.1	0

#	ARTICLE	IF	CITATIONS
15332	Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2879-2881.	1.2	3
15333	MULTIDISCIPLINARY APPROACH IN THE TREATMENT OF PATIENTS WITH RECTAL CANCER. Malignant Tumours, 2015, , 64.	0.5	1
15334	Low-dose chemotherapy with methotrexate and vinblastine for Japanese patients with desmoid tumors: Relationship to CTNNB1 mutational status.. Journal of Clinical Oncology, 2015, 33, e21524-e21524.	1.6	1
15335	Hormonal Receptor Positivity and Clinical Multifocality Are Independent Predisposing Factors for Positive Margin Events in Breast-Conserving Surgery after Neoadjuvant Chemotherapy. Journal of Breast Disease, 2015, 3, 8-15.	0.2	0
15336	Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. Journal of Analytical Oncology, 2015, 4, 94-101.	0.1	0
15337	Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study. International Journal of Cancer Therapy and Oncology, 2015, 3, 3313.	0.2	1
15338	Elastic Net Constrained Stereotype Logit Model for Ordered Categorical Data. Biometrics & Biostatistics International Journal, 2015, 2, .	0.2	2
15339	Colon Adenocarcinoma Associated with Synchronous Extramural Gastrointestinal Stromal Tumor (GIST) of the Ileum. American Journal of Case Reports, 2015, 16, 837-839.	0.8	5
15340	The Efficacy and Safety of Gemcitabine Plus Paclitaxel Compared to Doxorubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Journal of Cancer Prevention & Current Research, 2015, 3, .	0.1	0
15341	The correlation between aldehyde dehydrogenase-1A1 level and tumor shrinkage after preoperative chemoradiation in locally advanced rectal cancer. Advances in Modern Oncology Research, 2015, 1, .	0.1	0
15342	Clinical correlation between <i>in vitro&/i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients. Korean Journal of Clinical Oncology, 2015, 11, 51-58.	0.1	1
15343	RECIST 1.1. , 2016, , 576-581.		0
15344	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2016, , 1-12.		0
15345	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2016, , 1-25.		0
15346	Locally Advanced Gallbladder Cancer Treated with Chemotherapy and Subsequent Curative Resection. Japanese Journal of Gastroenterological Surgery, 2016, 49, 1214-1221.	0.1	0
15347	Quantum Magnetic Resonance Therapy: Targeting Biophysical Cancer Vulnerabilities to Effectively Treat and Palliate. Journal of Clinical & Experimental Oncology, 2016, 05, .	0.1	5
15348	The Existence of Symptomatic Localized Lesion(s) and 4 Lesions Are Indications for Radiotherapy: Screening Computed Tomography Images of Patients with Metastatic/Recurrent/Inoperable Cancer in a Single Japanese Institution Observational Study. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2016, 05, 110-119.	0.1	0
15349	Staging of Lung Cancer. Medical Radiology, 2016, , 195-211.	0.1	0

#	ARTICLE	IF	CITATIONS
15350	Sorafenib Acts through VEGFR-2 Inhibition in a Metastatic Clear-Cell Sarcoma of the Kidney. Journal of Cancer Therapy, 2016, 07, 487-493.	0.4	0
15351	Radiation Therapy in Paediatric Orbital Granulocytic Sarcomas: Experience from a Tertiary Cancer Center. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, XC01-XC05.	0.8	2
15352	An imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials. Translational and Clinical Pharmacology, 2016, 24, 189.	0.9	0
15354	A Prospective Study of the Effect of Different Palliative Radiotherapy Fractionation Schedules on Tumor Response and Toxicity in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Cancer Therapy, 2016, 07, 924-938.	0.4	1
15355	The Role of Radiology in Personalized Medicine. Europeanization and Globalization, 2016, , 219-230.	0.1	0
15356	â€œMagicâ€•of our gastric cancer results on perioperative chemotherapy. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 283.	1.0	0
15357	Relation between the Half-life of Serum CEA during First-line Chemotherapy and the Overall Survival in Patients with Metastatic Colorectal Carcinoma. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq0 0 00gBT/Overclock 10 Tf	0.0	0
15358	Electrochemotherapy of Locally Advanced Pancreatic Cancer. , 2016, , 1-16.		0
15359	International Network for Sharing Practices on Electrochemotherapy (InspECT): An Integrative Patients Treatment Consortium. , 2016, , 1-18.		0
15360	Radiological Response Criteria. , 2016, , 3880-3883.		0
15361	Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer. , 2016, , 337-348.		0
15362	Management of Patients with Metastatic Medullary Thyroid Carcinoma: The Role for Systemic Therapy. , 2016, , 157-164.		0
15363	Imaging of Tumor Response by Preoperative Systemic Treatment. , 2016, , 295-308.		0
15364	Neuroendocrine and Small Cell Carcinoma of the Urinary Tract. , 2016, , 121-138.		0
15365	Therapiesteuerung in der medikamentÃ¶sen Tumorthherapie. , 2016, , 1039-1045.		0
15366	Lung and Mediastinal Tumors. , 2016, , 1-46.		0
15367	HEPATOCELLULAR CARCINOMA; CORRELATION OF SERUM ALPHA FETOPROTEIN AND TUMOR SIZE. The Professional Medical Journal, 2016, 23, 209-212.	0.0	0
15368	RE: Ultrasonic Measurement of Testicular Tumors and the Correlation with Pathologic Specimen Sizes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 172-173.	1.5	1

#	ARTICLE	IF	CITATIONS
15369	Adenocarcinoma of Ceruminous Glands: Role of the VMAT. , 0, , 009-012.		0
15370	Abstract 1903: A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. , 2016, , .		0
15371	Data and Analysis Considerations in Oncology Clinical Trials. Biometrics & Biostatistics International Journal, 2016, 4, .	0.2	0
15373	Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 242-250.	0.2	3
15374	Response Evaluation of Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma with Respect to Tumour Size, Number of Lesion, and Alpha-Fetoprotein (AFP) Level. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2016, 17, 3.	0.0	0
15375	Imaging Biomarker Structural Analysis. , 2017, , 65-69.		0
15376	Liver Tumors. Pediatric Oncology, 2017, , 453-476.	0.5	0
15377	Imaging Biomarker Measurements. , 2017, , 87-99.		1
15378	Three general concepts to improve risk prediction: good data, wisdom of the crowd, recalibration. F1000Research, 0, 5, 2671.	1.6	2
15379	The Influence of Neoadjuvant Chemotherapy with Docetaxel, Nedaplatin and 5-Fluorouracil After Esophagectomy. Anticancer Research, 2016, 36, 6165-6172.	1.1	0
15380	Basics and Advances of Quantitative PET Imaging. , 2017, , 303-322.		3
15381	Imaging Biomarkers in Clinical Trials. , 2017, , 295-306.		0
15383	Lung Adenocarcinomas: A Novel KRAS/EGFR Exon 21 Double Mutation with Limited Response to TKI Treatment and Two Rare EGFR Exon 19 Deletions with Variable Response. International Clinical Pathology Journal, 2016, 3, .	0.1	0
15384	Evaluation of Prognostic Factors and Validation of Tumor Response Ratios after Neoadjuvant Chemotherapy in Patients with Breast Cancer. Journal of Breast Disease, 2016, 4, 108-115.	0.2	2
15385	Radiologische Primär- und Ausbreitungsdiagnostik des Magen- und Kardiakarzinoms. , 2017, , 37-47.		0
15386	Malignant Pleural Mesothelioma in Young People. Journal of Cancer Therapy, 2017, 08, 443-451.	0.4	0
15387	Prognostic Factors for Overall and Disease-specific Survival of Stage I Non-Small-Cell Lung Cancer after Stereotactic Body Radiotherapy: A Retrospective Analysis. Journal of St Marianna University, 2017, 8, 55-64.	0.1	0
15388	Therapeutische Grundlagen in der gynäkologischen Onkologie. , 2017, , 183-253.		0

#	ARTICLE	IF	CITATIONS
15389	International Network for Sharing Practices on Electrochemotherapy (InspECT): An Integrative Patients Treatment Consortium. , 2017, , 1799-1816.		1
15391	Bone Target Therapy in Urologic Malignancies. , 2017, , 1-16.		0
15392	Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET). , 2017, , 247-264.		0
15393	Klinische onderzoeksmethodologie in de oncologie. , 2017, , 107-114.		0
15394	Once Daily High-dose Radiation (â‰¥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer. Journal of Oncology Translational Research, 2017, 02, .	0.2	0
15395	METASTAZAVUSIO KRÄTIES VÄ–Å½IO GYDYMAS TIK GERIAMAISIAIS CHEMOTERAPIJOS IR HORMONÅ² TERAPIJOS PREPARATAIS. Medicinos Teorija Ir Praktika, 2017, 22, 464-471.	0.0	0
15396	Neuron Specific Enolase, a Biomarker of Breast Cancer Cerebral Metastasis. Open Access Library Journal (oalib), 2017, 04, 1-11.	0.2	0
15397	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2017, , 613-637.		0
15398	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2017, , 697-708.		0
15399	Cisplatin, Methotrexate and Bleomycin for Advanced Recurrent or Metastatic Penile Squamous Cell Carcinoma. , 2017, 06, .		0
15400	Diagnostic Applications of Nuclear Medicine: Esophageal Cancers. , 2017, , 685-696.		0
15401	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.2	0
15403	PET and PET-CT in Soft Tissue Sarcoma. , 2017, , 59-69.		0
15404	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 117-131.	0.1	0
15405	Radiological Imaging in Melanoma. , 2017, , 25-35.		1
15406	Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 369-373.	2.2	2
15407	Cardiac Tumors: Multimodality Approach, Follow-Up, and Prognosis. , 2017, , 417-422.		1
15408	Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study. Journal of Cancer Therapy, 2017, 08, 827-837.	0.4	0

#	ARTICLE	IF	CITATIONS
15409	Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 105-116.	0.1	0
15410	Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. , 2017, , 639-684.		0
15411	Klinische Krebsforschung. , 2017, , 663-673.		0
15412	Principes van de medicamenteuze antikankerbehandeling. , 2017, , 137-159.		0
15413	Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. , 2017, , 1-46.		0
15414	Clinical applications of PET/CT and SPECT/CT imaging. Imaging in Medical Diagnosis and Therapy, 2017, , 439-472.	0.0	0
15415	Improving efficacy of metastatic tumor segmentation to facilitate early prediction of ovarian cancer patients' response to chemotherapy. , 2017, , .		0
15416	Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. Anticancer Research, 2017, 37, 1523-1528.	1.1	2
15417	Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology. Korean Journal of Medicine, 2017, 92, 124-141.	0.3	2
15418	Advances in the Use of Immunotherapy in Oncology. Journal of the Advanced Practitioner in Oncology, 2017, 8, 221-225.	0.4	0
15419	Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma. PLoS ONE, 2017, 12, e0177975.	2.5	2
15421	The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients â€” single centre experience. OnCOReview, 2017, 7, 92-97.	0.2	0
15422	The Management of Locally Advanced Nonmetastatic Pancreas Cancer. , 2018, , 183-204.		0
15423	Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated IL-2 T Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. Anticancer Research, 2017, 37, 3921-3932.	1.1	1
15424	Male Breast Cancer : A Retrospective Study. The Egyptian Journal of Hospital Medicine, 2017, 68, 1308-1315.	0.1	0
15425	Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 3723-3728.	1.1	3
15426	Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated IL-2 T-cells. Anticancer Research, 2017, 37, 3933-3939.	1.1	2
15427	Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations. Anticancer Research, 2017, 37, 3781-3786.	1.1	19

#	ARTICLE	IF	CITATIONS
15428	Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent. <i>Anticancer Research</i> , 2017, 37, 3741-3749.	1.1	5
15429	Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Journal of Cancer Prevention & Current Research</i> , 2017, 8, .	0.1	0
15430	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	1.8	0
15431	Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms. , 2017, 77, .		0
15432	Squamous Cell Carcinoma of Lung Associated with Rare Cutaneousparaneoplastic Syndrome-Systemic Lupus Erythromatosus (SLE). <i>MOJ Clinical & Medical Case Reports</i> , 2017, 7, .	0.0	0
15433	Treatment response assessment and response guided adaptive treatment. <i>Imaging in Medical Diagnosis and Therapy</i> , 2017, , 337-350.	0.0	0
15434	Can MRI Replace Biopsy in Men on Surveillance?. <i>Current Clinical Urology</i> , 2018, , 111-119.	0.0	0
15435	Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure. <i>Anticancer Research</i> , 2017, 37, 6477-6480.	1.1	7
15436	A Case Study of a Patient with Breast Cancer Treated with a Combination of Traditional Korean Medicine and Chemotherapy. <i>The Journal of Internal Korean Medicine</i> , 2017, 38, 820-827.	0.3	3
15437	Imaging Melanoma. , 2018, , 1-25.		0
15438	Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 6443-6451.	1.1	4
15439	The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter. , 2017, 37, 5885-5891.		9
15440	Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab. , 2017, 37, 5565-5571.		4
15441	Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 6481-6488.	1.1	3
15444	Can Nigella Sativa and Pure Honey Improved Chemoradiotherapy Effects in Advanced Pancreatic Cancer. <i>Journal of Nutritional Health & Food Engineering</i> , 2017, 7, .	0.5	0
15445	Tumor Vascularity Does Not Predict Response to Yttrium-90 Radioembolization for Hepatic Metastases from Colorectal Cancer. <i>Journal of Clinical Interventional Radiology ISVIR</i> , 2018, 02, 003-012.	0.2	1
15446	Treatment Response Evaluation in Hepatic Tumors using CT and MRI: Road Map for Radiologist. <i>Medical Visualization</i> , 2017, , 49-62.	0.4	0
15447	Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer. <i>Journal of Breast Disease</i> , 2017, 5, 39-45.	0.2	0

#	ARTICLE	IF	CITATIONS
15448	Prognostic and Predictive Value of Pretreatment Derived Neutrophil-to-Lymphocyte Ratio in Non-Small-Cell Lung Cancer Patients Treated with an Immune Checkpoint Inhibitor. Journal of Cancer Therapy, 2018, 09, 23-34.	0.4	0
15449	Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom. Journal of Cancer Therapy, 2018, 09, 545-558.	0.4	1
15450	Clinical Profile and Results in Cancers Treated with Nivolumab: A Single Centre Study. Open Journal of Immunology, 2018, 08, 107-111.	0.2	0
15451	The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. Journal of Cancer Research and Therapeutics, 2018, 14, 587.	0.9	0
15452	Durable complete response with a short course of streptozotocin plus doxorubicin combination in malignant metastatic insulinoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1149-1151.	0.9	2
15453	Die frÃ¼he Nutzenbewertung von Arzneimitteln gemÃÃ Â§35a SGB V. , 2018, , 113-141.		3
15454	Outcomes and Prognostic Factors of Small Cell Lung Cancer: A Retrospective Study. Advances in Lung Cancer (Irvine), 2018, 07, 21-31.	0.2	2
15455	Intravascular Contrast Agents. , 2018, , 39-89.		0
15456	Investigation of the effect of low-molecular-weight heparins on the hemostatic system and the immediate results of chemoradiotherapy in patients with locally advanced cervical cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 12.	0.2	0
15457	Extravascular Contrast Agents. , 2018, , 91-130.		0
15458	Effects of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Using a Combination of Platinum Agents (Cisplatin plus Miriplatin): A Retrospective Comparison with Cisplatin Monotherapy. Open Journal of Radiology, 2018, 08, 260-273.	0.2	0
15459	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2018, , 1-14.		0
15460	Surgical Treatment for Cardiac Sarcomas. , 2018, , 167-174.		0
15461	Primary Vulvar Ewing Sarcoma in a 30-Year-Old Woman: A Case Report. Case Reports in Clinical Medicine, 2018, 07, 241-248.	0.2	0
15463	Stadieneinteilung endokriner Tumore. , 2018, , 289-300.		0
15464	The Many Different Designs of Phase II Trials in Oncology. , 2018, , 189-202.		1
15465	Superiority and Non-inferiority Phase III Oncology Trials. , 2018, , 203-216.		0
15466	Laparoscopy-assisted Ileocecal Resection for Cecal Cancer with Invasion of the Abdominal Wall: A Case Report. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2018, 43, 102-108.	0.0	0

#	ARTICLE	IF	CITATIONS
15467	Radiological Signs of Tumor Dissemination. Cancer Dissemination Pathways, 2018, , 13-25.	0.0	0
15468	A Case Report of Successful Conversion Therapy with XELOX + Bevacizumab in a Patient with AFP-producing Colon Cancer and Synchronous Liver Metastases. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2018, 43, 845-854.	0.0	0
15469	Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. Anticancer Research, 2018, 38, 491-499.	1.1	8
15470	Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma. In Vivo, 2018, 32, 203-209.	1.3	1
15471	Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer. Anticancer Research, 2018, 38, 547-552.	1.1	5
15473	Treatment Outcome of Pharmacokinetics-Based Dosing of Docetaxel and Fluorouracil in Advanced Head and Neck Cancer Patients. Journal of Cancer Therapy, 2018, 09, 998-1010.	0.4	1
15474	Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer, 2018, 55, 144.	0.2	2
15475	Cyclophosphamide and Etoposide as a Salvage Treatment in Metastatic Osteosarcoma Patients. Journal of Cancer Therapy, 2018, 09, 529-537.	0.4	2
15476	Konzepte klinischer Studien. , 2018, , 257-263.		0
15477	Efficacy Study of Metronomic Chemotherapy in Metastatic Triple Negative Breast Cancer and Correlation with VEGF, TSP Levels. Advances in Breast Cancer Research, 2018, 07, 107-119.	0.1	0
15478	Therapy Monitoring of Oncologic Disease in the Abdomen (Including PET/CT). IDKD Springer Series, 2018, , 35-47.	0.8	0
15479	Impact of Pre-Radiotherapy and/or Chemoradiotherapy Hemoglobin Level on Response to Treatment in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. Journal of Cancer Therapy, 2018, 09, 362-381.	0.4	0
15480	Chemotherapy for Temporal Bone Cancer. , 2018, , 403-410.		0
15481	Relative Chemo-, Hormonal, and Immunosensitivity. , 2018, , 29-40.		0
15482	Assessing the performance of quantitative image features on early stage prediction of treatment effectiveness for ovary cancer patients: a preliminary investigation. , 2018, , .		0
15483	Development of a computer aided diagnosis model for prostate cancer classification on multi-parametric MRI. , 2018, , .		1
15484	Combination Therapies â€”in Advanced, Hormone â€”Receptorâ€”Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.4	3
15486	Definitive Treatment for Locally Advanced Cervical Cancer: A Retrospective Analysis from A Singe Institution. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2018, 28, 19-29.	0.1	1

#	ARTICLE	IF	CITATIONS
15487	Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 2285-2294.	1.1	7
15488	Skin Rash Can Be a Useful Marker for Afatinib Efficacy. <i>Anticancer Research</i> , 2018, 38, 1783-1788.	1.1	5
15489	A Case Study of an Advanced Breast Cancer Patient Treated with a Combination of Traditional Korean Medicine and Chemotherapy. <i>The Journal of Internal Korean Medicine</i> , 2018, 39, 268-276.	0.3	0
15490	Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases. <i>Anticancer Research</i> , 2018, 38, 3069-3077.	1.1	3
15492	Neoadjuvant Chemotherapy in Cervical Cancer: A Review Article. <i>Journal of Obstetrics, Gynecology and Cancer Research</i> , 2018, 3, 87-91.	0.1	3
15494	The Potential Use of 11C-Choline Positron Emission Tomography/Computed Tomography to Monitor the Treatment Effects of Radium-223 in a Patient with Prostate Cancer. <i>Cureus</i> , 2018, 10, e2948.	0.5	0
15495	Pazopanib as first-line therapy for patients with metastatic kidney cancer. <i>Meditinskiy Sovet</i> , 2018, , 70-76.	0.5	0
15496	Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial. <i>Opuholi Golovy I Sei</i> , 2018, 8, 39-52.	0.4	1
15497	Preliminary experiences of DBT (digital breast tomosynthesis) and hybrid 18F-FDG-PET/MR (PETMR) for neoadjuvant chemotherapy (NAC) cases in breast cancer. , 2018, , .		0
15498	A Case of Aggressive Squamous Cell Carcinoma of the Breast with a Poor Prognosis. <i>Journal of the Nihon University Medical Association</i> , 2018, 77, 271-275.	0.0	0
15499	The role of immunotherapy in the treatment of non-small cell lung cancer. <i>Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 342</i>	0.1	0
15501	Rosiglitazone Effect on Radioiodine Uptake in a Case of Dedifferentiated Thyroid Carcinoma. , 2019, , 297-303.		0
15502	Two Cases of Adjuvant Immunotherapy with Cytokine-Induced Killer Cells for Relapsed or Refractory Neuroblastoma. <i>Clinical Pediatric Hematology-Oncology</i> , 2018, 25, 202-207.	0.2	0
15503	Preliminary Study of Computed Tomography Texture Analysis in Pancreatic Cystadenoma. <i>Journal of Medical Imaging and Health Informatics</i> , 2018, 8, 1573-1577.	0.3	0
15504	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
15505	NEW THERAPIES IN UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS. <i>Journal of Surgical Sciences</i> , 2019, 1, 135-138.	0.0	0
15507	Statystyka w praktyce hematologicznej. <i>Acta Haematologica Polonica</i> , 2018, 49, 121-127.	0.3	1
15508	NTENSITY-MODULATED RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY FOR NASOPHARYNGEAL CARCINOMA. <i>Journal of Medicine and Pharmacy</i> , 2018, 8, 105-113.	0.0	0

#	ARTICLE	IF	CITATIONS
15509	Rectal Carcinoma: Imaging for Staging. , 2019, , 359-389.		1
15510	Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors. Journal of Cancer Research and Therapeutics, 2019, 15, 1574.	0.9	0
15511	A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates. Springer Proceedings in Mathematics and Statistics, 2019, , 125-133.	0.2	0
15513	COX-2/C-MET/KRAS status-based prognostic nomogram for colorectal cancer: A multicenter cohort study. Saudi Journal of Gastroenterology, 2019, 25, 293.	1.1	1
15515	Functional Activity of Circulating Phagocytes as Potential Pretreatment Marker of Tumor Drug Resistance. Journal of Biosciences and Medicines, 2019, 07, 1-15.	0.2	2
15516	Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic. Oncology & Hematology Review, 2019, 15, 33.	0.2	1
15517	A durable complete response to pembrolizumab therapy in a female patient with metastatic melanoma involving the bones. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 221.	0.2	0
15518	A comparative study of nab-paclitaxel versus cisplatin concurrent chemoradiotherapy in locally advanced cervical cancer. Clinical Cancer Investigation Journal, 2019, 8, 198.	0.9	0
15519	Beyond Synthetic Lethality: Charting the Landscape of Clinically Relevant Genetic Interactions in Cancer. SSRN Electronic Journal, 0, , .	0.4	0
15520	A Case of Effective Multidisciplinary Therapy for Gastric Endocrine Carcinoma with Bulky Metastatic Lymph Nodes. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 320-325.	0.0	1
15521	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. JMA Journal, 2019, 3, 58-66.	0.8	13
15522	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1
15523	Comparison of Paclitaxel Liposome Combined with Cisplatin and Docetaxel Combined with Cisplatin in the Treatment of Advanced Lung Squamous Cell Carcinoma. World Journal of Cancer Research, 2019, 09, 32-38.	0.1	1
15524	Comparison of the Response Evaluation Criteria in Solid Tumors with Volumetric Measurement for Evaluation of Response and Overall Survival with Liver Metastases from Colorectal Cancer. Journal of the Korean Society of Radiology, 2019, 80, 906.	0.2	2
15525	Impact of early enteral nutrition on intestinal mucosal barrier and nutrition status in advanced esophageal cancer patients undergoing synchronous chemoradiotherapy. World Chinese Journal of Digestology, 2019, 27, 101-106.	0.1	0
15526	Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study. Breast Cancer: Targets and Therapy, 2019, Volume 11, 43-51.	1.8	4
15528	¹²⁵ I implantation under computed tomography guidance to treat patients with recurrent pelvic tumors: Retrospective analysis of clinical results. Journal of Cancer Research and Therapeutics, 2019, 15, 1496.	0.9	2
15530	Resectable and Borderline Resectable Pancreatic Cancer. , 2019, , 235-254.		0

#	ARTICLE	IF	CITATIONS
15531	IMPACT OF HOMOGENEITY INDEX ON RESPONSE RATE AND SURVIVAL IN HEAD AND NECK CANCER PATIENTS TREATED WITH IMRT. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 62-66.	0.1	0
15532	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2019, , 463-494.		0
15534	Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer. Cancer Research Statistics and Treatment, 2019, 2, 21.	0.6	0
15536	Primary Bladder Adenocarcinoma: A Five-Year Retrospective Clinicopathologic Study of 42 Cases in Egyptian NCI (2010-14). Journal of Cancer Therapy, 2019, 10, 97-116.	0.4	0
15537	Maintenance Treatment for Recurrent Ovarian Carcinoma â€“ Evidence Supporting the Efficacy and Safety of PARP Inhibitors. European Oncology and Haematology, 2019, 15, 29.	0.0	1
15538	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
15539	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 241-253.		0
15540	Survival of Patients with Small-Cell Lung Cancer Treated at Tertiary Hospitals in the East of Thailand, 2007-2016: A Retrospective Study. Advances in Lung Cancer (Irvine), 2019, 08, 1-14.	0.2	0
15542	Comparison of breast tumor diameter by intraoperative photoacoustic screening, magnetic resonance imaging and pathology. , 2019, , .		0
15543	Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study. Research in Oncology, 2019, .	0.2	1
15544	Developing a new quantitative imaging marker to predict pathological complete response to neoadjuvant chemotherapy. , 2019, , .		0
15545	Texture-based prostate cancer classification on MRI: how does inter-class size mismatch affect measured system performance?. , 2019, , .		1
15546	Stereotaktik radyocerrahi uygulanan vertebra metastazlarÄ±nda yanÄ±t deÄŸerlendirmesinde PET-BTâ€™nin yeri. Cukurova Medical Journal, 0, 44, 1-10.	0.2	0
15550	The role of ARTAs in treating metastatic castration-resistant prostate cancer. Urologie Pro Praxi, 2019, 20, 62-65.	0.1	0
15551	Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. Minerva Ginecologica, 2019, 71, 182-190.	0.8	4
15553	THE RESULTS OF MODULAR ENDOPROTHESIS OF PERIACETABULAR REGION IN TUMOR LESIONS OF THE ACETABULUM AND HIP JOINT. IssledovaniÄƒ I Praktika V Medicine, 2019, 6, 20-31.	0.5	0
15554	Nab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice. Meditsinskiy Sovet, 2019, , 81-86.	0.5	0
15555	Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. Annals of Translational Medicine, 2019, 7, 253-253.	1.7	1

15557	Metastatic Synovial Sarcoma: Experience from a Tertiary Care Center from India. Indian Journal of Medical and Paediatric Oncology, 2019, 40, S95-S98.	0.2	1
15561	Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2415-2420.	1.2	1
15562	Diffusion-Weighted Magnetic Resonance Imaging for Early Detection of Chemotherapy Resistance in Non-Small Cell Lung Cancer. Medical Science Monitor, 2019, 25, 6264-6270.	1.1	4
15563	Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience. Annals of Clinical Oncology, 2019, , 1-7.	0.0	1
15564	Surgical Strategies for High Risk Neuroblastoma. , 2020, , 327-336.		0
15565	Prognostic values of platelet-associated indicators in advanced breast cancer. Translational Cancer Research, 2019, 8, 1326-1335.	1.0	2
15566	Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy. The Korean Journal of Urological Oncology, 2019, 17, 96-102.	0.1	0
15569	Å...ç-«äfä,šäffä,äfä,äfäfä^ë»ä®³ë-ñäŒä~tä,šæ«äâ†ç™äf»è»ççš»éé,éf¨ç™Œæ²»ç™,. Journal of Otolaryngology of Japan, 2019, 127, 107-112.		0
15570	Serviks Kanserinde Prognostik Kriterlerin Tedavi Sonrası Erken Radyolojik Cevaba Etkisi. Celal Bayar Âeniversitesi SaÄYlÄ±k Bilimleri EnstitÄ¼sÄ¼ Dergisi, 0, , .	0.3	0
15571	Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy. World Journal of Gastroenterology, 2019, 25, 5334-5343.	3.3	1
15572	Comparison of Different Radiotherapy Techniques for Locally Advanced Pancreatic Tumors. IFMBE Proceedings, 2020, , 1283-1290.	0.3	2
15573	Characteristics of Patients with Large-Cell Neuroendocrine Carcinoma of the Lung. Turkish Thoracic Journal, 2020, 21, 150-155.	0.6	1
15574	Magnetic-resonance imaging as a basis for a modern approach in diagnostics and treatment evaluation of cervical cancer (literature review). Medical Visualization, 2019, , 82-106.	0.4	0
15575	The Management of Hepatocellular Carcinoma. , 2020, , 237-271.		1
15576	NÃ³dulo pulmonar incidental: caracterizaciÃ³n y manejo. Radiologia, 2019, 61, 357-369.	0.5	1
15577	An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era. Journal of Liver Cancer, 2019, 19, 117-127.	1.1	0
15578	Outcome of thirdâ€line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. Molecular and Clinical Oncology, 2019, 11, 505-510.	1.0	0

#	ARTICLE	IF	CITATIONS
15579	Características clínicas y patológicas de cáncer de pulmón. Revista Colombiana De Hematología Y Oncología, 2019, 6, 23-27.	0.0	0
15580	An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness. Translational Cancer Research, 2019, 8, 2357-2370.	1.0	1
15581	The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-line Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2891-2896.	1.2	0
15582	Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma-like carcinoma. Oncology Letters, 2019, 18, 6143-6149.	1.8	2
15583	Cytostatic, cytotoxic, and antioxidant effects of an antitumor compound - maleimide derivative. Reports National Academy of Science of Ukraine, 2019, 10, 89-96.	0.1	0
15584	Prognostic and predictive roles of microRNA-411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer. Molecular Medicine Reports, 2020, 21, 267-281.	2.4	10
15585	Malignant Pleural Mesothelioma: 18F-FDG PET/CT for Response Assessment of Malignant Pleural Mesothelioma Following Immunotherapy. , 2020, , 43-53.		0
15586	Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?. Ecancermedicalscience, 2019, 13, 973.	1.1	1
15587	Treatment time to the end of thoracic radiotherapy has more predictive power for survival than radiation dose intensity in patients with limited-stage small-cell lung cancer receiving concurrent chemoradiation of more than 45 Gy. Oncology Letters, 2020, 19, 239-246.	1.8	3
15588	Evaluation of the Feasibility of Transfusing Leucocyte Depletion Filter (LDF) Processed Intra-Operative Cell Salvage (IOCS) Blood in Metastatic Spine Tumour Surgery (MSTS): Protocol for a Non Randomised study (Preprint). JMIR Research Protocols, 0, , .	1.0	0
15589	Developing global image feature analysis models to predict cancer risk and prognosis. Visual Computing for Industry, Biomedicine, and Art, 2019, 2, 17.	3.7	2
15590	Radioembolización en tumores hepáticos. Revista Española De Medicina Nuclear E Imagen Molecular, 2019, 38, 370-381.	0.0	0
15593	CT-Based Quantification. , 2020, , 289-304.		0
15594	Evolution of Response Criteria in Immunotherapy. , 2020, , 7-11.		0
15595	Clinical Trials: Endpoints and Outcome Assessment. , 2020, , 407-421.		0
15596	Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice. , 2020, , 379-394.		0
15597	Hedgehog Signaling Pathway Inhibitors for Basal Cell Carcinoma. , 2020, , 233-249.		0
15598	Opportunities and limitations of CT - assessment of neoadjuvant chemoradiation therapy of gastric cancer. Issledovaniya I Praktika V Medicine, 2019, 6, 92-101.	0.5	1

#	ARTICLE	IF	CITATIONS
15599	Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2019, 62, 712-719.	0.2	0
15600	Clinical Scoring Systems for Colorectal Cancer Liver Metastases. , 2020, , 95-111.		0
15601	A case of Advanced Gastric cancer patient treated by Korean Medicine monotherapy. Journal of Korean Medicine, 2019, 40, 91-100.	0.4	2
15603	Three-Dimensional Conformal Radiotherapy with Concomitant Boost and Weekly Cisplatin in Muscle-Invasive Transitional Cell Bladder Carcinoma. Medical Journal of the University of Cairo Faculty of Medicine, 2019, 87, 4867-4875.	0.0	0
15604	Computed Tomography and Magnetic Resonance Imaging. Recent Results in Cancer Research, 2020, 216, 31-110.	1.8	1
15605	Evaluation of Roles of MicroRNA-21 and MicroRNA-18a in Esophageal Squamous Cell Carcinoma and Comparison of Their Changes in Expression Post-Chemoradiotherapy. Gastroenterology Research, 2020, 13, 107-113.	1.3	2
15606	T-Staging and Target Volume Definition by Imaging in GI Tumors. Medical Radiology, 2020, , 203-220.	0.1	0
15607	Computed Tomography of Lymph Node Metastasis Before and After Radiation Therapy: Correlations With Residual Tumour. In Vivo, 2020, 34, 2721-2725.	1.3	1
15608	Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, e131-e137.	0.8	6
15609	Drug Toxicity, Approach to Cancer as a Systemic Disease, and Imaging Modality-Specific Considerations. Medical Radiology, 2020, , 31-43.	0.1	0
15610	Therapy Response Imaging in Gastrointestinal Malignancy. Medical Radiology, 2020, , 99-115.	0.1	0
15612	Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma. Oncology Letters, 2020, 19, 2943-2949.	1.8	4
15613	Upfront radiosurgery plus targeted agents followed by active brain control using radiosurgery delays neurological death in non-small cell lung cancer with brain metastasis. Clinical and Experimental Metastasis, 2020, 37, 353-363.	3.3	3
15615	Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World Journal of Gastroenterology, 2020, 26, 2426-2438.	3.3	0
15618	MICA enhances sensitivity to cisplatin in patients with extensive small cell lung cancer via downregulation of ABCG2. Oncology Letters, 2020, 20, 1143-1152.	1.8	1
15619	A Case Report of Partial Remission of End-stage Pancreatic Cancer Patient with Liver Metastasis Treated with Chemotherapy and Integrated Medicine Therapy. The Journal of Internal Korean Medicine, 2020, 41, 166-176.	0.3	1
15620	Impact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer. Klinichna Khirurgiia, 2020, 87, 53-59.	0.2	0
15622	Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy. Clinical and Translational Oncology, 2020, 22, 2333-2340.	2.4	7

#	ARTICLE	IF	CITATIONS
15623	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 76-82.	1.7	10
15630	Linear acceleratorâ€‘based stereotactic body radiation therapy in the treatment of oligometastatic disease. <i>Molecular and Clinical Oncology</i> , 2020, 13, 109-114.	1.0	4
15631	Efficacy of abiraterone combined with flutamide on prostate cancer patients and its effect on serum miR-493-5p and miR-195-5p. <i>Oncology Letters</i> , 2020, 20, 1922-1930.	1.8	4
15632	Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 249, 64-69.	1.1	4
15633	Oral intake of royal jelly improves antiâ€‘cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNFâ€‘ α ; and TGFâ€‘ β ; in renal cell carcinoma: A preliminary study based on a randomized doubleâ€‘blind clinical trial. <i>Molecular and Clinical Oncology</i> , 2020, 13, 29.	1.0	9
15634	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	2.4	2
15635	Clinical decision making in small non-functioning VHL-related incidentalomas. <i>Endocrine Connections</i> , 2020, 9, 834-844.	1.9	1
15636	Outcome Following Curative-Intent Electrochemotherapy for Extramedullary Plasmocytoma in Dogs â€‘ Case Reports. <i>Topics in Companion Animal Medicine</i> , 2020, 40, 100441.	0.9	2
15637	Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 975-984.	1.7	5
15638	Significance of ageâ€‘associated quality of life in patients with stage IV breast cancer who underwent endocrine therapy in Japan. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	3
15639	Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients Who Cannot Receive Cytotoxic Chemotherapy. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 140-146.	0.1	0
15641	Quantitative Musculoskeletal Tumor Imaging. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 428-440.	0.7	5
15642	Using miR-125b in the Prediction of Aromatase Inhibitors Resistance in Metastatic Breast Cancer. <i>Journal of Cancer and Tumor International</i> , 0, , 1-9.	0.1	1
15643	Possible local treatment for liver metastases of adenoid cystic carcinoma (ACC): single-centre experience and literature review. <i>Translational Cancer Research</i> , 2020, 9, 4573-4582.	1.0	0
15644	Downregulation of exosomal miRâ€‘1273a increases cisplatin resistance of nonâ€‘small cell lung cancer by upregulating the expression of syndecan binding protein. <i>Oncology Reports</i> , 2020, 44, 2165-2173.	2.6	8
15645	Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies. <i>Anticancer Research</i> , 2020, 40, 5901-5907.	1.1	2
15646	Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries. <i>Pancreas</i> , 2021, 50, 1230-1235.	1.1	0
15647	The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment. <i>Annals of Surgery Open</i> , 2021, 2, e103.	1.4	3

#	ARTICLE	IF	CITATIONS
15648	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.	1.5	4
15649	Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma. <i>JCO Precision Oncology</i> , 2021, 5, 1659-1665.	3.0	3
15650	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) Tj ETQq2000rgBT45Overlock	2.0	0
15651	Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. <i>Cancer Science</i> , 2022, 113, 240-250.	3.9	17
15652	Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors. <i>Cancers</i> , 2021, 13, 5399.	3.7	17
15653	Clinical analysis of multimodal treatment for localized synovial sarcoma: A multicenter retrospective study. <i>Journal of Orthopaedic Science</i> , 2023, 28, 261-266.	1.1	3
15654	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4994.	2.4	4
15655	Uveitis associated with cancer immunotherapy: long-term outcomes. <i>Immunotherapy</i> , 2021, 13, 1465-1481.	2.0	3
15656	Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. <i>Cancers</i> , 2021, 13, 5466.	3.7	6
15657	Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. <i>PLoS ONE</i> , 2021, 16, e0258988.	2.5	4
15658	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. <i>Patterns</i> , 2021, 2, 100372.	5.9	22
15659	Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYC trial. <i>BMC Cancer</i> , 2021, 21, 1161.	2.6	6
15660	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer. <i>Cancers</i> , 2021, 13, 5442.	3.7	1
15661	Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period. <i>Breast Care</i> , 2022, 17, 264-271.	1.4	4
15662	Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. <i>Advances in Radiation Oncology</i> , 2022, 7, 100838.	1.2	2
15663	Therapy response assessment of non-small cell lung cancer using dual-energy computed tomography iodine map. <i>Journal of X-Ray Science and Technology</i> , 2022, 30, 111-122.	1.0	0
15664	Preclinical Application of Conditional Reprogramming Culture System for Laryngeal and Hypopharyngeal Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 744969.	3.7	4
15665	Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2022, 28, 279-288.	7.0	10

#	ARTICLE	IF	CITATIONS
15666	Attempt at Outpatient Chemotherapy with Nivolumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Utilizing the Services of a Part-time Surgeon. Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho, 2021, 124, 1406-1412.	0.1	0
15667	Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2&B3) and thymic carcinoma previously treated with chemotherapy. Cancer, 2022, 128, 719-726.	4.1	12
15668	A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer, 2022, 22, 269-278.	2.4	6
15669	Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC). Annals of Surgical Oncology, 2022, 29, 1939-1951.	1.5	10
15670	Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers. BMC Cancer, 2021, 21, 1167.	2.6	12
15671	Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 2013-2021.	1.4	23
15672	Prevalence of <i>BRAF</i>V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with <i>BRAF</i>V600 mutation-positive glioma: systematic review. Neuro-Oncology, 2022, 24, 528-540.	1.2	26
15673	Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease. Clinical Oncology, 2021, , .	1.4	7
15674	Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas. Cancer Management and Research, 2021, Volume 13, 8169-8178.	1.9	1
15675	Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Current Oncology, 2021, 28, 4357-4366.	2.2	2
15676	Application Value of Magnetic Resonance Radiomics and Clinical Nomograms in Evaluating the Sensitivity of Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma. Frontiers in Oncology, 2021, 11, 740776.	2.8	8
15677	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer: Targets and Therapy, 2021, Volume 12, 123-131.	2.7	4
15678	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	17.5	110
15679	Identification of modes of tumour regression in NSCLC patients during radiotherapy. Medical Physics, 2021, , .	3.0	4
15680	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase <sc>I</sc>/<sc>II</sc> open&Elabel, dose escalation study. International Journal of Cancer, 2022, 150, 993-1006.	5.1	28
15682	Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer. Journal of Cancer Research and Therapeutics, 2020, 16, 559-564.	0.9	4
15683	Clinicopathological characteristics and treatment outcome in small cell lung cancer: A single institutional experience from India. Lung India, 2020, 37, 134.	0.7	3
15685	Therapy Response Imaging in Genitourinary Malignancies. Medical Radiology, 2020, , 139-157.	0.1	0

#	ARTICLE	IF	CITATIONS
15686	Capecitabine plus bevacizumab as first-line therapy for metastatic colorectal cancer patients with poor performance status. Journal of Nippon Medical School, 2020, 88, 496-499.	0.9	2
15687	Salvage Irradiation for Patients with Recurrent Brain Metastases. , 2020, , 371-378.		0
15688	Response Assessment and Follow-Up by Imaging in GYN Tumours. Medical Radiology, 2020, , 517-530.	0.1	0
15689	Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis. Molecular and Clinical Oncology, 2020, 14, 28.	1.0	10
15690	Clinicopathologic Characteristics and Chemotherapy Response of Classic Hodgkin Lymphoma: A Study in Tertiary Teaching Hospital. Journal of Drug Delivery and Therapeutics, 2020, 10, 95-98.	0.5	0
15691	A confidence function-based posterior probability design for phase II cancer trials. Pharmaceutical Statistics, 2021, 20, 485-498.	1.3	1
15692	Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study. Journal of Neuroimaging, 2021, 31, 317-323.	2.0	14
15693	Functional Assessment of Lung Cancer and Nodules. Medical Radiology, 2021, , 259-297.	0.1	1
15695	F-18 FDG PET Tests in Head and Neck Cancer. , 2021, , 51-69.		0
15696	F-18 FDG PET Tests in Skin Cancer Including Malignant Melanoma. , 2021, , 119-134.		0
15697	Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers, 2021, 13, 8.	3.7	2
15698	Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma. PLoS ONE, 2020, 15, e0240736.	2.5	1
15699	Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma. Head and Neck, 2021, 43, 1184-1193.	2.0	4
15700	Association between SOX2 and OCT4 expression and the chemoradiation therapeutic response in undifferentiated non-keratinizing nasopharyngeal carcinoma. Medical Journal of Indonesia, 2021, 29, 354-8.	0.5	0
15702	Important Points to Consider When Evaluating the Response to Drug Therapy for Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 942-950.	0.1	0
15703	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. Protein and Peptide Letters, 2020, 27, 1276-1287.	0.9	2
15704	R��sultats pr��liminaires oncologiques des ex��r��ses trans-anal TME dans les cancers du bas rectum��: ��tude comparative. Journal De Chirurgie Visc��rale, 2020, 159, 12-12.	0.0	0
15705	Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01). Japanese Journal of Lung Cancer, 2020, 60, 966-971.	0.1	0

#	ARTICLE	IF	CITATIONS
15706	Toward radiomics for assessment of response to systemic therapies in lung cancer. <i>Oncotarget</i> , 2020, 11, 4677-4680.	1.8	1
15707	Overview of FDG PET in Oncology in Japan. , 2021, , 1-21.		0
15708	Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases. , 2021, , 327-335.		0
15709	A phaseÂ study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nabâ€paclitaxel for resectable pancreatic cancer. <i>Molecular and Clinical Oncology</i> , 2020, 14, 26.	1.0	2
15711	Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2890-2907.	1.4	13
15712	Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 7135-7140.	1.1	1
15713	Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. <i>European Journal of Dermatology</i> , 2020, 30, 699-709.	0.6	1
15714	A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 1421-1430.	1.4	2
15715	Synthesis and Clinical Development of Palbociclib: An Overview. <i>Medicinal Chemistry</i> , 2022, 18, 2-25.	1.5	8
15716	Trans-anal total mesorectal excision in low rectal cancers: Preliminary oncological results of a comparative study. <i>Journal of Visceral Surgery</i> , 2022, 159, 13-20.	0.8	0
15717	Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 68-73.	1.3	5
15718	Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13087-13096.	2.0	6
15719	Successful Pre-Operative Local Control of Skin Invasion of Breast Cancer Using a Combination of Systemic Chemotherapy and Mohs Paste. <i>Journal of Breast Cancer</i> , 2021, 24, 481.	1.9	2
15720	Imaging in drug development. , 2022, , 343-358.		0
15721	Biomarkers in drug development. , 2022, , 323-342.		3
15722	A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma. <i>Internal Medicine</i> , 2022, , .	0.7	2
15723	Applications of [18F] FDG PET and PET/CT in colorectal carcinoma. , 2022, , 119-129.		0
15724	Lower pretreatment hemoglobin status and treatment breaks in locally advanced head and neck squamous cell carcinoma during concurrent chemoradiation. <i>Indian Journal of Cancer</i> , 2020, 58, 62-68.	0.2	1

#	ARTICLE	IF	CITATIONS
15725	Incorporating Circulating Biomarkers into Clinical Trials. , 2020, , 233-247.		0
15726	Response Evaluations for Precision Cancer Therapy and Immunotherapy. Medical Radiology, 2020, , 15-27.	0.1	0
15727	Molecular Imaging for Renal Cell Carcinoma. , 2020, , 99-118.		0
15728	Medullary Thyroid Cancer “ Feature Review and Update on Systemic Treatment. Acta Clinica Croatica, 2020, 59, 50-59.	0.2	5
15729	T Cell Receptor Engineered T Cell Therapy in Oncology. , 2020, , 377-408.		0
15730	Renal Mass Biopsy: Simple Techniques and Optimizing Navigational/Targeting Tools. , 2020, , 71-102.		0
15731	Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series. Neoplasma, 2020, 67, 684-691.	1.6	1
15732	In Frail Elderly Patients, Low-Dose Gemcitabine over 6-Hour Infusion Is Equally Effective and Less Toxic Than the Standard Gemcitabine Protocol for Advanced Pancreatic Adenocarcinoma: A Randomized Phase II Trial. Journal of Cancer Therapy, 2020, 11, 124-141.	0.4	2
15733	Radiation therapy for advanced canine nasal planum squamous cell carcinoma: case report. Arquivo Brasileiro De Medicina Veterinaria E Zootecnia, 2020, 72, 119-124.	0.4	0
15734	When and How to Use Imaging in Brain Tumors, Protocols. , 2020, , 15-28.		0
15735	Chemotherapy: Knowing When to Start, Evaluate for Response, and Stop. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 40-45.	0.1	0
15736	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
15737	Evolution of Clinical Trial Imaging and Co-clinical Imaging. Medical Radiology, 2020, , 239-253.	0.1	1
15738	Klinische onderzoeksmethodologie in de oncologie. , 2020, , 113-120.		0
15739	Efficacy Considerations in Phase I Trials. , 2020, , 159-183.		0
15740	Correlation of CTR1, ERCC-1, and HSP70 expressions with cisplatin response in cervical cancer stage IIB. Majalah Obstetri Dan Ginekologi, 2020, 27, 119.	0.1	0
15741	Factors associated with disease progression among hormone receptor-positive breast cancer patients treated with endocrine therapy: A 5-year cross-sectional, retrospective follow-up study. Journal of Applied Pharmaceutical Science, 0, , .	1.0	0
15742	Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. Medical Radiology, 2020, , 475-494.	0.1	0

#	ARTICLE	IF	CITATIONS
15743	Correlation Analysis of ctDNA in the Prognosis Evaluation of Advanced SCLC. <i>Advances in Clinical Medicine</i> , 2020, 10, 1932-1941.	0.0	0
15744	Quality of Life During Chemotherapy in Japanese Patients with Unresectable Advanced Pancreatic Cancer. <i>Asian Journal of Human Services</i> , 2020, 19, 42-54.	0.2	1
15745	Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers. <i>Journal of Gastric Cancer</i> , 2020, 20, 233.	2.5	1
15746	Diagnostic Imaging of Oral Squamous Cell Carcinoma. <i>Textbooks in Contemporary Dentistry</i> , 2020, , 127-140.	0.4	0
15749	Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study. <i>Investigative and Clinical Urology</i> , 2020, 61, 146.	2.0	0
15750	18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 2.	1.5	2
15752	Therapy Response Imaging in Hepatobiliary and Pancreatic Malignancies. <i>Medical Radiology</i> , 2020, , 117-137.	0.1	0
15754	Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 185-193.	1.7	1
15755	Segmenting Hepatocellular Carcinoma in Multi-phase CT. <i>Communications in Computer and Information Science</i> , 2020, , 82-92.	0.5	0
15756	MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response. <i>Lecture Notes in Computer Science</i> , 2020, , 211-220.	1.3	3
15757	Response Assessment and Follow-Up by Imaging in Breast Tumors. <i>Medical Radiology</i> , 2020, , 451-474.	0.1	0
15758	Machine Learning Applications in Cancer Therapy Assessment and Implications on Clinical Practice. , 2020, , 1794-1823.		0
15759	Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer. <i>Indian Journal of Medical Research</i> , 2020, 152, 475.	1.0	4
15760	Gastric Cancer Showing Partial Response 10 Months after Administration of Nivolumab. <i>Japanese Journal of Gastroenterological Surgery</i> , 2020, 53, 1-7.	0.1	0
15761	Quantitative analysis of proteins related to chemoresistance to paclitaxel and carboplatin in human SiHa cervical cancer cells via iTRAQ. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e28.	2.2	2
15763	Treatment of relapse/progression of the disease in patients with neuroblastoma in the Republic of Belarus over a 20-year period: a cohort study. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2020, 6, 40-47.	0.3	0
15764	Surgery Following Primary Systemic Therapy: How to Increase Breast Conservation Rate. , 2020, , 533-546.		0
15765	Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer. <i>World Journal of Oncology</i> , 2020, 11, 98-105.	1.5	9

#	ARTICLE	IF	CITATIONS
15766	Therapy Response Imaging in Breast Cancer. Medical Radiology, 2020, , 65-78.	0.1	0
15768	Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study. World Journal of Oncology, 2020, 11, 139-149.	1.5	9
15769	Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study. Wspolczesna Onkologia, 2020, 24, 221-228.	1.4	1
15770	Response Assessment and Follow-Up by Imaging in Lung Tumours. Medical Radiology, 2020, , 417-449.	0.1	0
15771	Surgical and Survival Outcomes with Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Longitudinal Study in a Tertiary Cancer Center. Journal of SAFOG, 2020, 12, 27-30.	0.2	0
15772	Tumores adenohipofisarios agresivos: Reto diagnóstico y terapéutico para las Unidades Multidisciplinares de Excelencia en Patología Hipofisaria. Endocrinología, Diabetes Y Nutrición, 2020, 67, 75-77.	0.3	0
15773	The Role of Radiological Parameters in Assessing Response to Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer. Research in Oncology, 2020, .	0.2	1
15775	Serum C-Reactive Protein Level Predicts Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. Cancer Investigation, 2020, 38, 122-129.	1.3	0
15777	Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer. Medical Science Monitor, 2020, 26, e921933.	1.1	1
15778	Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non-radical resection: A real-world study. Oncology Reports, 2020, 43, 1089-1102.	2.6	1
15779	Highlights on the Management of Oligometastatic Disease. Journal of Immunotherapy and Precision Oncology, 2020, 3, 34-44.	1.4	3
15780	A clinical study of Cyberknife treatment for oral squamous cell carcinoma. Nihon Koku Geka Gakkai Zasshi, 2020, 66, 124-130.	0.0	0
15781	Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer. Oncology Letters, 2020, 19, 3229-3238.	1.8	5
15782	Deep Lesion Tracker: Monitoring Lesions in 4D Longitudinal Imaging Studies. , 2021, , .		19
15783	A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6 Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated Meta-analysis. Korean Journal of Clinical Pharmacy, 2020, 30, 1-10.	0.3	0
15784	EVALUATION OF THE EFFECTIVENESS OF MODERN IMMUNOTHERAPY. Voprosy Onkologii, 2020, 66, 211-217.	0.2	0
15785	Analysis of <i>EGFR</i> mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1547-1555.	2.3	5
15786	Radiology in pleural disease: what is the role of chest radiographs, CT and PET in modern management?. , 2020, , 48-72.		1

#	ARTICLE	IF	CITATIONS
15787	Diagnostic ability of multi-detector spiral computed tomography for pathological lymph node metastasis of advanced gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 435-446.	2.0	3
15790	Princípios básicos e aplicações oncológicas da PET-CT/18F-FDG. , 2020, 99, 156-163.	0.1	1
15791	Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases. <i>Nuclear Medicine Communications</i> , 2020, 41, 327-335.	1.1	0
15792	Deep Random Forests for Small Sample Size Prediction with Medical Imaging Data. , 2020, , .		3
15794	Harmonized Outcome Measures for Use in Non-Small Cell Lung Cancer Patient Registries and Clinical Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , .	4.9	0
15795	Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. <i>Molecular Oncology</i> , 2022, 16, 319-332.	4.6	13
15796	Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy. <i>BMC Cancer</i> , 2021, 21, 1129.	2.6	6
15797	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 744724.	2.8	15
15798	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100426.	6.5	28
15799	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	15
15800	A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC. <i>Cancers</i> , 2021, 13, 5566.	3.7	2
15801	Impact of Serum γ -Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. <i>Cancers</i> , 2021, 13, 5587.	3.7	1
15802	Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 5469-5475.	1.1	4
15803	Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma. <i>British Journal of Dermatology</i> , 2022, 186, 587-588.	1.5	3
15804	Efficacy of Combination Chemotherapy With Docetaxel, Estramustine and Carboplatin in Men With Castration-resistant Prostate Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 451-457.	0.7	3
15805	Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma. <i>Anticancer Research</i> , 2021, 41, 5767-5773.	1.1	7
15806	Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour. <i>Case Reports in Oncology</i> , 2022, 14, 1567-1573.	0.7	5
15807	The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 471-478.	0.7	1

#	ARTICLE	IF	CITATIONS
15808	Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated PI3K in early and advanced HER2-positive breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e589.	4.0	6
15809	Contribution of complete response to treatment to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis. <i>PLoS ONE</i> , 2021, 16, e0259622.	2.5	0
15810	Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 5739-5747.	1.1	4
15811	Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer. <i>Oncology Reports</i> , 2021, 47, .	2.6	9
15812	The Clinical Significance of CA19-9 and Tumor Size Ratios for Predicting Prognosis After Conversion Surgery in Patients With Stage IV Gastric Cancer. <i>Anticancer Research</i> , 2021, 41, 5643-5649.	1.1	0
15813	Utility of diffusion-weighted magnetic resonance imaging in predicting the treatment response of nasopharyngeal carcinoma. <i>Neuroradiology Journal</i> , 2022, 35, 477-485.	1.2	3
15814	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. <i>Genome Medicine</i> , 2021, 13, 175.	8.2	12
15815	Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a non-endemic region. <i>Journal of Medical Virology</i> , 2022, 94, 720-728.	5.0	5
15816	A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 8307-8316.	1.9	6
15817	Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2022, 100, 12-21.	1.9	19
15818	A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. <i>Statistics in Medicine</i> , 2022, 41, 374-389.	1.6	2
15819	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series. <i>Case Reports in Oncology</i> , 2022, 14, 1561-1566.	0.7	5
15820	Surgical technique for the successful curative resection of locally advanced caecal cancer invading the external iliac artery: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 88, 106550.	0.6	1
15821	Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. <i>Future Oncology</i> , 2021, 17, 4861-4869.	2.4	2
15822	Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 399-409.	0.7	2
15823	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5160.	2.4	20
15824	Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 783327.	2.8	7
15825	Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 491-498.	0.7	1

#	ARTICLE	IF	CITATIONS
15826	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	12.8	22
15827	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. <i>Scientific Reports</i> , 2021, 11, 21454.	3.3	1
15828	Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 585-594.	2.3	6
15829	Lung Cancer Versus “Young Cancer”: Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 451-458.	1.3	4
15830	A Case of Muscle-Invasive Bladder Cancer With Pelvic Lymph Node Involvement Treated With Pembrolizumab and Subsequent Radical Cystectomy and Maintained No Evidence of Disease After Surgery. <i>Cureus</i> , 2021, 13, e19375.	0.5	1
15831	Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from ⁶⁸ Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1014-1020.	5.0	11
15832	Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 770268.	2.8	2
15833	Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1625-1631.	4.2	9
15834	Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world. <i>Thoracic Cancer</i> , 2021, 12, 3416-3425.	1.9	2
15835	In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines. <i>Cells</i> , 2021, 10, 3048.	4.1	4
15836	Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. <i>ELife</i> , 2021, 10, .	6.0	8
15837	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2022, 61, 52-57.	1.8	0
15838	Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. <i>Frontiers in Oncology</i> , 2021, 11, 686308.	2.8	21
15839	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 80.	6.8	16
15840	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021, 21, 1180.	2.6	9
15841	Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 5785-5791.	1.1	6
15842	Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, .	1.2	1
15843	Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 81.	2.5	5

#	ARTICLE	IF	CITATIONS
15844	Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC). <i>Anticancer Research</i> , 2021, 41, 5749-5759.	1.1	3
15845	Polydatin protects neuronal cells from hydrogen peroxide damage by activating CREB/Ngb signaling. <i>Molecular Medicine Reports</i> , 2021, 25, .	2.4	4
15846	Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020. <i>ESMO Open</i> , 2021, 6, 100301.	4.5	4
15847	Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2020, 13, 13.	1.0	5
15848	Prognostic value of fibrinogen-to-albumin ratio in patients with gastric cancer receiving first-line chemotherapy. <i>Oncology Letters</i> , 2020, 20, 10.	1.8	12
15849	Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma. <i>Oncology Reports</i> , 2020, 44, 909-926.	2.6	3
15851	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 250-264.	0.7	4
15852	Squamous Cell Carcinoma of Head and Neck in Vajira Hospital: The Outcomes in a Real-World Practice. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2020, 103, .	0.1	1
15853	Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2020, 13, 14.	1.0	0
15855	Germline and Somatic <i>BRCA1/2</i> Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1229-1241.	3.0	8
15856	A Multicenter Retrospective Study to Evaluate Safety and Efficacy of Tocopheryl Polyethylene Glycol Succinate Docetaxel in Various Cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 543-546.	0.2	0
15857	Machine Learning Applications in Cancer Therapy Assessment and Implications on Clinical Practice. <i>Advances in Healthcare Information Systems and Administration Book Series</i> , 0, , 227-256.	0.2	0
15858	Response Assessment in Pediatric Rhabdomyosarcoma: Can Response Evaluation Criteria in Solid Tumors Replace Three-dimensional Volume Assessments?. <i>Radiology</i> , 0, , 122607.	7.3	0
15859	Intra- and Interobserver Variability in CT Measurements in Oncology. <i>Radiology</i> , 2013, 269, 451-459.	7.3	50
15860	Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab. <i>Radiology</i> , 0, , 130776.	7.3	0
15861	The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care. <i>The Korean Journal of Hepatology</i> , 2011, 17, 189.	1.5	0
15862	Pleural empyema due to Salmonella in a patient with bronchogenic carcinoma: the first case report from a cancer hospital in Egypt. <i>Access Microbiology</i> , 2020, 2, acmi000151.	0.5	1
15863	Mode of progression after radioembolization in patients with colorectal cancer liver metastases. <i>EJNMMI Research</i> , 2020, 10, 107.	2.5	3

#	ARTICLE	IF	CITATIONS
15864	Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?. Cancer Imaging, 2020, 20, 69.	2.8	5
15868	Comparing the Responses of Osseous Versus Soft-Tissue Metastases of Renal Cell Carcinoma to Receptor Tyrosine Kinase Inhibitors and Immunotherapy. Kidney Cancer, 2020, 4, 151-158.	0.4	2
15870	Liver Metastases. Medical Radiology, 2021, , 141-174.	0.1	0
15871	MRI Morphometry in Brain Tumors: Challenges and Opportunities in Expert, Radiomic, and Deep-Learning-Based Analyses. Neuromethods, 2021, , 323-368.	0.3	3
15872	Pseudoprogression in lung cancer: a case report. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.8	0
15873	Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer. Korean Journal of Internal Medicine, 2020, 35, 1468-1476.	1.7	3
15874	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technology Assessment, 2020, 24, 1-264.	2.8	4
15877	Immunotherapy for regional, recurrent and metastatic head and neck cancer: recent advances and future directions. Medical Alphabet, 2020, , 60-69.	0.2	0
15878	Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience. Cureus, 2020, 12, e10618.	0.5	1
15879	Real world efficacy of immunotherapy in nonsmall cell lung cancer. Malignant Tumours, 2020, 10, 5-20.	0.5	1
15880	Simultaneous triple cancer of the esophagus, pancreas and rectum treated with multimodal strategies: a case report. Surgical Case Reports, 2020, 6, 259.	0.6	2
15881	Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report. Surgical Case Reports, 2020, 6, 271.	0.6	1
15882	A feasibility study to evaluate early treatment response of brain metastases one week after stereotactic radiosurgery using perfusion weighted imaging. PLoS ONE, 2020, 15, e0241835.	2.5	3
15883	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. Digestive Disease Interventions, 2020, 04, 373-381.	0.2	0
15884	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerita"™ study. Japanese Journal of Clinical Oncology, 2021, 51, 484-491.	1.3	1
15885	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. Melanoma Research, 2021, 31, 49-57.	1.2	4
15886	Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China. International Journal of Surgery Oncology, 2021, 5, 97.	0.2	2
15887	Analysis of disease progression and prognosis in differentiated thyroid cancer with pulmonary metastases: a retrospective study. International Journal of Surgery Oncology, 2021, 5, 104.	0.2	1

#	ARTICLE	IF	CITATIONS
15891	Prospective evaluation of patients with small cell lung cancer: A single center study. <i>Journal of Surgery and Medicine</i> , 2020, 4, 1008-1012.	0.1	0
15892	Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 864-869.	1.2	1
15893	A Phase I Study of OMN54 (Aneustatâ,,ç) in Patients with Advanced Malignancies. <i>Clinical Cancer Drugs</i> , 2020, 7, 125-132.	0.3	0
15894	A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial. <i>Acta Medica Okayama</i> , 2018, 72, 431-436.	0.2	8
15896	Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. <i>Annals of Translational Medicine</i> , 2016, 4, 74.	1.7	6
15897	Vinorelbine-based chemo-radiotherapy in non-small cell lung cancer. <i>Tumori</i> , 2012, 98, 464-70.	1.1	3
15898	Semantic reasoning with image annotations for tumor assessment. <i>AMIA ... Annual Symposium proceedings</i> , 2009, 2009, 359-63.	0.2	7
15899	Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastoma. <i>Indian Journal of Nuclear Medicine</i> , 2010, 25, 147-55.	0.3	6
15900	Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. <i>Current Oncology</i> , 2011, 18 Suppl 2, S5-S10.	2.2	11
15901	Endpoints in advanced breast cancer: methodological aspects & clinical implications. <i>Indian Journal of Medical Research</i> , 2011, 134, 413-8.	1.0	5
15902	Factors influencing progression-free survival in gastrointestinal stromal tumors with special reference to pathologic features, cytogenetics, and radiologic response. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 173-7.	0.7	6
15903	(18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 1, 63-4.	1.0	23
15904	How to study optimal timing of PET/CT for monitoring of cancer treatment. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 1, 54-62.	1.0	30
15905	Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 110-21.	1.0	16
15906	Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy. <i>International Journal of Biomedical Science</i> , 2012, 8, 28-35.	0.1	7
15907	ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. <i>American Journal of Cancer Research</i> , 2013, 3, 221-9.	1.4	11
15908	Invasive catheterization of the hepatic artery for preclinical investigation of liver-directed therapies in rodent models of liver cancer. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 269-78.	0.0	9
15909	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 393-403.	0.0	21

#	ARTICLE	IF	CITATIONS
15911	Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. <i>Minerva Endocrinologica</i> , 2012, 37, 335-56.	1.8	32
15912	A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 55-8.	0.7	1
15914	Stability of preclinical models of aggressive renal cell carcinomas. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 2950-62.	0.5	6
15915	Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer. <i>Iranian Journal of Cancer Prevention</i> , 2013, 6, 195-200.	0.7	3
15916	High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy. <i>American Journal of Cancer Research</i> , 2014, 4, 528-36.	1.4	15
15917	Semi-automated volumetric quantification of tumor necrosis in soft tissue sarcoma using contrast-enhanced MRI. <i>Anticancer Research</i> , 2012, 32, 4951-61.	1.1	16
15918	Plasma tumor DNA: on your markers, get set, go!. <i>Annals of Translational Medicine</i> , 2014, 2, 2.	1.7	8
15919	Neoadjuvant chemotherapy in Albinos with locally advanced skin cancer at a Blantyre Hospital: - Case Series. <i>Malawi Medical Journal</i> , 2014, 26, 97-9.	0.6	1
15920	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 72-82.	1.0	16
15922	Initial hepatic artery infusion and systemic chemotherapy for asymptomatic colorectal cancer with un-resectable liver metastasis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1000-8.	1.3	8
15924	Recent developments in imaging of pancreatic neuroendocrine tumors. <i>Annals of Gastroenterology</i> , 2015, 28, 193-202.	0.6	38
15925	Functional CT imaging techniques for the assessment of angiogenesis in lung cancer. <i>Translational Lung Cancer Research</i> , 2012, 1, 78-83.	2.8	9
15926	Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 18-26.	2.8	7
15927	Variability in the anti-tumor effect of tegafur-uracil depending on histologic types of lung cancer. <i>Journal of Thoracic Disease</i> , 2015, 7, 433-8.	1.4	2
15928	Feasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary report. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 172-80.	2.2	1
15929	The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 220-32.	1.0	4
15930	Significance of local treatment in patients with metastatic soft tissue sarcoma. <i>American Journal of Cancer Research</i> , 2015, 5, 2075-82.	1.4	6
15931	Microcalcification of Tumor is a Predictor of Response to Neoadjuvant Chemotherapy for Invasive Breast Carcinoma. <i>Yonago Acta Medica</i> , 2015, 58, 85-8.	0.7	3

#	ARTICLE	IF	CITATIONS
15932	High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer. American Journal of Cancer Research, 2015, 5, 2409-21.	1.4	9
15933	Retrospective comparison of abdominal ultrasonography and radiography in the investigation of feline abdominal disease. Canadian Veterinary Journal, 2015, 56, 1065-8.	0.0	1
15934	Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy?. Nagoya Journal of Medical Science, 2015, 77, 475-80.	0.3	2
15935	Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 431-56.	1.0	24
15936	Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients. International Journal of Clinical and Experimental Medicine, 2015, 8, 16064-70.	1.3	2
15937	Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer. American Health and Drug Benefits, 2015, 8, 176-9.	0.5	13
15938	Radiofrequency ablation of advanced lung tumors: imaging features, local control, and follow-up protocol. International Journal of Clinical and Experimental Medicine, 2015, 8, 18137-43.	1.3	10
15939	Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy. International Journal of Clinical and Experimental Medicine, 2015, 8, 18375-82.	1.3	2
15940	A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 19030-6.	1.3	3
15941	Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 611-26.	2.2	0
15943	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biology and Medicine, 2015, 12, 316-27.	3.0	5
15944	Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 21303-10.	1.3	5
15945	Image-guided stereotactic radiotherapy in 4 dogs with intracranial neoplasia. Canadian Veterinary Journal, 2016, 57, 519-22.	0.0	2
15947	Optimal MRI interval for detection of asymptomatic recurrence in surgically treated early cervical cancer by use of a mathematical model. Hippokratia, 2016, 20, 4-8.	0.3	10
15948	A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Research, 2016, 36, 713-9.	1.1	66
15949	Once Daily High-dose Radiation (â‰¥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer. , 2016, 2, .		0
15950	Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer. American Journal of Cancer Research, 2016, 6, 2890-2900.	1.4	3
15951	Contrast-Enhanced Ultrasonography in Evaluation of the Therapeutic Effect of Chemotherapy for Patients with Liver Metastases. Yonago Acta Medica, 2016, 59, 255-261.	0.7	8

#	ARTICLE	IF	CITATIONS
15953	Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma. Canadian Veterinary Journal, 2017, 58, 1059-1064.	0.0	14
15954	Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer. American Journal of Cancer Research, 2017, 7, 1971-1977.	1.4	3
15955	Gamma knife stereotactic radiosurgery for renal cell carcinoma and melanoma brain metastases-comparison of dose response. Journal of Radiosurgery and SBRT, 2013, 2, 193-207.	0.2	5
15956	Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases. Journal of Radiosurgery and SBRT, 2012, 2, 63-72.	0.2	0
15957	Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases. Journal of Radiosurgery and SBRT, 2012, 1, 317-325.	0.2	0
15958	Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience. Ochsner Journal, 2017, 17, 331-334.	1.1	5
15959	Compliance with National Guidelines on the Treatment of Stage IIa-IVB Nasopharyngeal Carcinoma in a Regional Cancer Center of Southern China. Asian Pacific Journal of Cancer Prevention, 2018, 19, 115-120.	1.2	0
15960	A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second-Line Therapy in Patients with Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2018, 19, 283-290.	1.2	0
15961	Stereotactic radiosurgery for primary tumors of the spine and spinal cord. Journal of Radiosurgery and SBRT, 2018, 5, 107-113.	0.2	3
15962	Long-term survival following neoadjuvant chemotherapy and concomitant radiochemotherapy in locally advanced cervical cancer: results of the Oncology Institute "Prof. Dr. Ion Chiricuta" experience. Journal of Medicine and Life, 2018, 11, 42-50.	1.3	9
15983	Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. JOP: Journal of the Pancreas, 2018, 19, 75-85.	1.5	16
15984	Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer. American Journal of Cancer Research, 2018, 8, 1074-1082.	1.4	3
15985	Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 189-199.	1.0	2
15986	Non Size Based Morphology Criteria for Assessment of Response in Patients with Liver Metastases of Gastrointestinal Origin Receiving Systemic Treatment. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1655-1660.	1.2	0
15987	Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review. P and T, 2018, 43, 549-556.	0.9	9
15990	Development of metastatic brain disease involves progression through lung metastases in mutated non-small cell lung cancer. Convergent Science Physical Oncology, 2017, 3, .	2.6	3
15991	Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2043-2055.	1.2	3
15992	Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2177-2181.	1.2	1

#	ARTICLE	IF	CITATIONS
15993	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American Journal of Cancer Research, 2018, 8, 1873-1886.	1.4	5
15994	Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer. American Journal of Cancer Research, 2018, 8, 2096-2105.	1.4	5
15995	Stereotactic body radiotherapy used as a bridge to liver transplant in patients with hepatocellular carcinoma and Child-Pugh score ≥ 8 cirrhosis. Journal of Radiosurgery and SBRT, 2018, 5, 261-267.	0.2	5
15997	Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, 43-54.	0.4	5
15998	Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models. American Journal of Cancer Research, 2019, 9, 562-573.	1.4	6
15999	Cancer cell-derived exosomes promote cell proliferation and inhibit cell apoptosis of both normal lung fibroblasts and non-small cell lung cancer cell through delivering alpha-smooth muscle actin. American Journal of Translational Research (discontinued), 2019, 11, 1711-1723.	0.0	15
16001	Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya Journal of Medical Science, 2019, 81, 233-239.	0.3	3
16003	Diagnostic value/performance of radiological liver imaging during chemotherapy for gastrointestinal malignancy: a critical review. Acta Biomedica, 2019, 90, 51-61.	0.3	3
16004	[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population]. Chinese Journal of Lung Cancer, 2019, 22, 562-567.	0.7	1
16006	CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer. American Journal of Cancer Research, 2019, 9, 2531-2543.	1.4	9
16007	Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma. American Journal of Cancer Research, 2019, 9, 2456-2468.	1.4	5
16008	Smurf1-positive expression indicates favorable survival for resected non-small cell lung cancer patients. International Journal of Clinical and Experimental Pathology, 2018, 11, 399-405.	0.5	3
16009	Role of CA19-9 in the prognostic evaluation of SOX neoadjuvant chemotherapy for gastric cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 5387-5393.	0.5	1
16011	Aberrant miR-1246 expression promotes radioresistance in non-small cell lung cancer: a potential prognostic biomarker and radiotherapy sensitization target. American Journal of Cancer Research, 2020, 10, 314-335.	1.4	7
16012	TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma. American Journal of Cancer Research, 2020, 10, 454-472.	1.4	10
16013	Cell-Free Circulating Tumour DNA Blood Testing to Detect T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-176.	1.8	7
16017	The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population. International Journal of Clinical and Experimental Pathology, 2020, 13, 2130-2136.	0.5	2
16018	Natural Products That Target Cancer Stem Cells. Anticancer Research, 2015, 35, 5773-88.	1.1	33

#	ARTICLE	IF	CITATIONS
16019	Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. American Journal of Cancer Research, 2020, 10, 3037-3046.	1.4	0
16020	Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study. Nagoya Journal of Medical Science, 2020, 82, 457-467.	0.3	1
16022	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncology Letters, 2020, 20, 378.	1.8	1
16023	Effect of rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer. American Journal of Translational Research (discontinued), 2020, 12, 6941-6953.	0.0	3
16024	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. Medical Science Monitor, 2020, 26, e927187.	1.1	4
16025	Strong Long-Term Survival with Targeted Therapy in Inoperable/Metastatic Gastrointestinal Stromal Tumors. Current Health Sciences Journal, 2020, 46, 315-318.	0.2	0
16026	A comparison of stereotactic body radiation therapy for metastases to the sacral spine and treatment of the thoracolumbar spine. Journal of Radiosurgery and SBRT, 2020, 7, 95-103.	0.2	0
16027	Two-staged stereotactic radiosurgery for the treatment of large brain metastases: Single institution experience and review of literature. Journal of Radiosurgery and SBRT, 2020, 7, 105-114.	0.2	0
16028	Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. BMJ Case Reports, 2020, 13, .	0.5	2
16029	Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. American Journal of Cancer Research, 2020, 10, 4547-4560.	1.4	3
16030	Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Journal of Clinical and Translational Research, 2020, 6, 155-167.	0.3	3
16031	Targeting the JAK/STAT pathway in solid tumors. Journal of Cancer Metastasis and Treatment, 2020, 6, .	0.8	21
16032	A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. American Journal of Translational Research (discontinued), 2021, 13, 743-756.	0.0	11
16034	Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. American Journal of Translational Research (discontinued), 2021, 13, 1568-1579.	0.0	0
16035	Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3153-3163.	1.2	2
16036	Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 143-153.	1.0	3
16037	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2319-2330.	1.4	3
16039	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 218-229.	1.0	1

#	ARTICLE	IF	CITATIONS
16040	Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Medicine, 2021, 19, 193.	5.5	1
16041	Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 724389.	3.7	0
16043	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Frontiers in Oncology, 2021, 11, 683502.	2.8	2
16044	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211042301.	3.2	1
16045	Omental Macrophagic "Crown-like Structures" Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer. Current Oncology, 2021, 28, 4234-4246.	2.2	1
16046	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110396.	1.9	4
16047	Quantitative Imaging and Bladder Cancer. , 2021, , 1-32.		0
16048	Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors. Cancer Diagnosis & Prognosis, 2021, 1, 13-17.	0.7	0
16049	Grundprinzipien der Tumorthherapie. , 2022, , 2-7.		0
16050	Breast imaging: Beyond the detection. European Journal of Radiology, 2022, 146, 110051.	2.6	16
16051	Natural speed of growth of untreated soft-tissue sarcomas: A dimension-based imaging analysis. European Journal of Radiology, 2022, 146, 110082.	2.6	3
16052	Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice. Cancer Diagnosis & Prognosis, 2021, 1, 83-88.	0.7	12
16053	Stereotactic Body Radiation Therapy Boost in Patients With Cervical Cancer Ineligible for Brachytherapy. Cancer Diagnosis & Prognosis, 2021, 1, 53-60.	0.7	4
16054	Automated Lymph Nodes Classification using Factorized Convolution-based CNN. , 2021, , .		1
16055	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 6716-6725.	7.0	12
16056	End-to-End Non-“Small-Cell Lung Cancer Prognostication Using Deep Learning Applied to Pretreatment Computed Tomography. JCO Clinical Cancer Informatics, 2021, 5, 1141-1150.	2.1	2
16057	Omental Macrophagic “Crown-like Structures” Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer. Current Oncology, 2021, 28, 4234-4246.	2.2	4
16058	Borderline Resectable and Locally Advanced Pancreatic Cancers. Pancreas, 2021, 50, 1243-1249.	1.1	3

#	ARTICLE	IF	CITATIONS
16059	Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review. Ecological Management and Restoration, 2021, , .	0.4	2
16060	Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC). Surgical Endoscopy and Other Interventional Techniques, 2021, , 1.	2.4	6
16061	Response evaluation of locoregional therapies in combined hepatocellularâ€“cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study. Clinical Radiology, 2022, 77, 121-129.	1.1	3
16062	⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy. Journal of Nuclear Medicine, 2022, 63, 1191-1198.	5.0	22
16063	Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Annals of Oncology, 2022, 33, 216-226.	1.2	31
16064	Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study. Cancer Cell International, 2021, 21, 604.	4.1	7
16065	Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy. Frontiers in Oncology, 2021, 11, 736769.	2.8	17
16066	Comparison of safety and efficacy of fluorouracil+â€“oxaliplatin+â€“irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. International Journal of Colorectal Disease, 2022, 37, 337-348.	2.2	4
16067	High Levels of Expression of Cartilage Oligomeric Matrix Protein in Lymph Node Metastases in Breast Cancer Are Associated with Reduced Survival. Cancers, 2021, 13, 5876.	3.7	6
16068	Comparison of response assessment in veterinary neuroâ€“oncology and two volumetric neuroimaging methods to assess therapeutic brain tumour responses in veterinary patients. Veterinary and Comparative Oncology, 2021, , .	1.8	2
16069	Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group. European Radiology, 2021, , 1.	4.5	19
16070	Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study). Asia-Pacific Journal of Clinical Oncology, 2021, , .	1.1	1
16071	Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced computed tomography. International Journal of Clinical Oncology, 2022, 27, 373-382.	2.2	0
16072	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival. BMC Cancer, 2021, 21, 1246.	2.6	0
16073	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. Lung Cancer, 2022, 163, 14-18.	2.0	2
16074	Computed tomography-based deep-learning prediction of induction chemotherapy treatment response in locally advanced nasopharyngeal carcinoma. Strahlentherapie Und Onkologie, 2022, 198, 183-193.	2.0	15
16075	Phase 1 trial of ADIâ€“PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Medicine, 2022, 11, 340-347.	2.8	13
16076	Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13â€“Targeted Tissue Factor tTF-NCR in Advanced Malignant Disease. Cancers, 2021, 13, 5880.	3.7	4

#	ARTICLE	IF	CITATIONS
16077	Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. EPMA Journal, 2021, 12, 629-645.	6.1	0
16078	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	2.8	14
16079	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 369-402.	0.3	5
16080	Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia-Pacific Journal of Clinical Oncology, 2021, , .	1.1	3
16081	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for secondâ€line clinical trials. Liver International, 2022, 42, 458-467.	3.9	6
16082	Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 53-59.	1.9	4
16083	Assessment of Early Therapy Response of Nonâ€Hodgkin's and Hodgkin's Lymphoma Using Bâ€Mode Ultrasound and Dynamic Contrastâ€Enhanced Ultrasound. Journal of Ultrasound in Medicine, 2022, 41, 2033-2040.	1.7	2
16084	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. Lung Cancer, 2021, 164, 84-90.	2.0	0
16086	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer, 2021, 21, 1247.	2.6	3
16087	Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. Frontiers in Immunology, 2021, 12, 697298.	4.8	13
16088	Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging. Nature Communications, 2021, 12, 6654.	12.8	29
16089	A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. Journal of Experimental Medicine, 2022, 219, .	8.5	37
16090	Valor pronÃstico de los criterios PERCIST y los parÃmetros metabÃlicos de la PET/TC en pacientes con cÃncer de esÃfago tras tratamiento neoadyuvante. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, , .	0.0	0
16091	Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis. Acta Clinica Belgica, 2022, 77, 897-905.	1.2	2
16092	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer â€ a study protocol. BMC Cancer, 2021, 21, 1238.	2.6	4
16093	A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2022, 28, 882-892.	7.0	29
16094	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 2022, 24, 997-1007.	1.2	72
16095	Impact of Dose Reduction of Afatinib Used in Patients With Nonâ€Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 781084.	3.5	3

#	ARTICLE	IF	CITATIONS
16096	Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Supportive Care in Cancer, 2022, 30, 2803-2810.	2.2	3
16097	A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 194.e7-194.e14.	1.6	5
16098	Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 \geq 50% non-small cell lung cancer patients treated with first-line pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 1747-1756.	4.2	5
16099	Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting. Breast Cancer Research, 2021, 23, 110.	5.0	5
16100	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naïve metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 105-115.	2.3	10
16101	HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy. OncoTargets and Therapy, 2021, Volume 14, 5297-5307.	2.0	10
16102	Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review. Head and Neck, 2022, 44, 562-571.	2.0	12
16103	Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatology International, 2021, 15, 1402-1412.	4.2	33
16104	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
16105	Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review. British Journal of Radiology, 2022, 95, 20210200.	2.2	4
16106	Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Annals of Translational Medicine, 2021, 9, 1623-1623.	1.7	39
16107	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 729764.	2.8	28
16108	177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1754-1764.	6.4	25
16109	Pseudoprogression in lung cancer patients treated with immunotherapy. Critical Reviews in Oncology/Hematology, 2022, 169, 103531.	4.4	11
16110	Fracture Risk Evaluation of Bone Metastases: A Burning Issue. Cancers, 2021, 13, 5711.	3.7	10
16111	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. Journal of Clinical Medicine, 2021, 10, 5325.	2.4	25
16112	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Lithuania), 2021, 57, 1252.	2.0	5
16113	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2022, 28, 479-488.	7.0	16

#	ARTICLE	IF	CITATIONS
16114	Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer. <i>Investigational New Drugs</i> , 2022, 40, 420-429.	2.6	0
16115	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. <i>Cancer Cell</i> , 2021, 39, 1594-1609.e12.	16.8	151
16116	Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 7340-7349.	3.3	32
16117	Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non-Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8903-8918.	1.8	3
16118	Paradigm shift for defining the resectability of pancreatic cancer. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2021, 25, 451-455.	0.1	4
16119	The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology. , 2022, , 471-493.		0
16120	A tumor microenvironment responsive nanoplatform with oxidative stress amplification for effective MRI-based visual tumor ferroptosis. <i>Acta Biomaterialia</i> , 2022, 138, 518-527.	8.3	34
16121	Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 42-50.	1.4	6
16122	VEGF Expression, Cellular Infiltration, and Intratumoral Collagen Levels after Electroporation-Based Treatment of Dogs with Cutaneous Squamous Cell Carcinoma. <i>Life</i> , 2021, 11, 1321.	2.4	2
16123	Hepatic metastases in gastrointestinal stromal tumors: oncologic outcomes with curative-intent hepatectomy, resection of treatment-resistant disease, and tyrosine kinase inhibitor therapy alone. <i>Hpb</i> , 2022, 24, 986-993.	0.3	4
16124	Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 6287-6292.	1.1	2
16125	Experience of using 1 st line combination immunotherapy in patients with metastatic renal cell carcinoma. <i>Onkourologiya</i> , 2021, 17, 47-63.	0.3	1
16126	A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. , 2021, 9, e003261.		20
16127	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. <i>BMC Cancer</i> , 2021, 21, 1244.	2.6	7
16128	Machine Learning-Based Radiomics Nomogram With Dynamic Contrast-Enhanced MRI of the Osteosarcoma for Evaluation of Efficacy of Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 758921.	2.8	13
16130	Effect of Traditional Chinese Medicine Combined with Bladder Perfusion with Hydroxycamptothecin on Color Ultrasound and Clinical Efficacy in Patients with Bladder Cancer Surgery. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-8.	1.2	3
16131	Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11334.	2.5	0
16132	Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram. <i>Frontiers in Oncology</i> , 2021, 11, 718531.	2.8	7

#	ARTICLE	IF	CITATIONS
16133	Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	1.3	4
16134	Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy. <i>Cancer Research and Treatment</i> , 2022, 54, 1219-1229.	3.0	1
16135	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 434-445.	1.1	21
16136	Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types. <i>World Journal of Surgical Oncology</i> , 2021, 19, 324.	1.9	4
16137	Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. <i>BMC Cancer</i> , 2021, 21, 1269.	2.6	10
16138	Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. <i>Lung Cancer</i> , 2022, 164, 46-51.	2.0	3
16139	Phase I/II clinical trial of high-dose [¹³¹ I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1574-1583.	6.4	3
16140	Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. <i>Oncology Reports</i> , 2021, 47, .	2.6	3
16141	Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review. <i>Cancers</i> , 2021, 13, 5961.	3.7	6
16142	The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting. <i>Anticancer Research</i> , 2021, 41, 6211-6216.	1.1	2
16143	Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. <i>British Journal of Cancer</i> , 2022, 126, 628-639.	6.4	11
16144	Investigation of EGFR mutations in non-small cell lung cancer usually undetectable by PCR methods. <i>Molecular and Clinical Oncology</i> , 2021, 16, 15.	1.0	1
16145	Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage III&IV ovarian cancer and poor general condition. <i>Molecular and Clinical Oncology</i> , 2021, 16, 14.	1.0	1
16146	Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study. <i>Molecular and Clinical Oncology</i> , 2021, 16, 17.	1.0	2
16147	Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 160, 227-234.	2.8	5
16148	Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 732525.	2.8	2
16149	Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients. <i>Human Cell</i> , 2021, , 1.	2.7	0
16150	Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. <i>International Journal of Clinical Oncology</i> , 2021, 27, 95.	2.2	7

#	ARTICLE	IF	CITATIONS
16151	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 126-141.	3.4	9
16152	Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. <i>Cancers</i> , 2021, 13, 5835.	3.7	6
16153	Testicular metastasis from urothelial carcinoma of the bladder. <i>IJU Case Reports</i> , 2022, 5, 79-83.	0.3	3
16154	Survival impact of additional chemotherapy after adjuvant concurrent chemoradiation in patients with early cervical cancer who underwent radical hysterectomy. <i>BMC Cancer</i> , 2021, 21, 1260.	2.6	6
16155	First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. <i>Future Oncology</i> , 2022, 18, 291-300.	2.4	4
16156	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
16157	Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India. <i>Clinical Breast Cancer</i> , 2022, 22, 300-307.	2.4	7
16158	Best regimens for treating chemoâ€naÃ~ve incurable squamous nonâ€small cell lung cancer with a programmed deathâ€ligand 1 tumor proportion score of 1%â€49%: A network metaâ€analysis. <i>Thoracic Cancer</i> , 2021, , .	1.9	2
16159	Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations. , 2022, , 61-101.		0
16160	Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4686-4701.	2.2	13
16161	Late Toxicities, Failure Patterns, Local Tumor Control, and Survival of Esophageal Squamous Cell Carcinoma Patients After Chemoradiotherapy With a Simultaneous Integrated Boost: A 5-Year Phase II Study. <i>Frontiers in Oncology</i> , 2021, 11, 738936.	2.8	2
16162	Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 749064.	2.8	17
16163	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
16164	Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 401-408.	2.5	4
16165	Machine Learning Models That Integrate Tumor Texture and Perfusion Characteristics Using Low-Dose Breast Computed Tomography Are Promising for Predicting Histological Biomarkers and Treatment Failure in Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 6013.	3.7	11
16166	Recent Advances in Functional MRI to Predict Treatment Response for Locally Advanced Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 0, , 1.	0.5	0
16167	Circulating cytokines associated with clinical outcomes in advanced nonâ€small cell lung cancer patients who received chemoimmunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 219-227.	1.9	19
16168	Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery. <i>International Journal of Dermatology</i> , 2022, 61, 911-915.	1.0	6

#	ARTICLE	IF	CITATIONS
16169	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
16170	Imaging of Gastric Carcinomatosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5294.	2.4	9
16171	Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 653-661.	7.0	10
16172	Application of Gross Tissue Response System in Gastric Cancer After Neoadjuvant Chemotherapy: A Primary Report of a Prospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 585006.	2.8	3
16173	Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 613-618.	1.3	2
16174	Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study. <i>Anticancer Research</i> , 2021, 41, 6279-6285.	1.1	1
16175	A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 6199-6209.	1.1	7
16176	Immuno-Oncology æ™, ä»Šä«Šäšä, ä†ç™ªäƒ»è»¢ç\$»éé, éƒ™ç™CEä®æ²»ç™, æ~ ç•¥. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaishi</i> , 2021, 116, 100-104.		
16177	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 4106-4119.	2.8	4
16178	EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 4084-4094.	2.8	5
16179	Radiotherapy and immunotherapy in melanoma brain metastases. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	7
16180	18F FDG IMAGING â€“ RESPONSE CRITERIA IN TUMORS. <i>European Journal of Radiology</i> , 2021, 147, 110054.	2.6	3
16181	Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1046-1053.	1.0	7
16182	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100497.	1.7	4
16184	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 7005.	12.8	66
16185	Radiomics signature based on computed tomography images for the preoperative prediction of lymph node metastasis at individual stations in gastric cancer: A multicenter study. <i>Radiotherapy and Oncology</i> , 2021, 165, 179-190.	0.6	9
16186	Paired 18F-Fluorodeoxyglucose (18F-FDG), and 64Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (64Cu-ATSM) PET Scans in Dogs with Spontaneous Tumors and Evaluation for Hypoxia-Directed Therapy. <i>Radiation Research</i> , 2021, 197, .	1.5	1
16187	Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2995-3005.	2.5	5

#	ARTICLE	IF	CITATIONS
16188	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	7.7	20
16189	Bone metastases with post-treatment intralesional fatty content of the spine: imaging features from T1-weighted imaging with CT finding correlations. <i>Acta Radiologica</i> , 2023, 64, 153-163.	1.1	3
16190	Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	1.3	16
16191	Studying the association between breast cancer and renal cell carcinoma. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 643-652.	2.5	0
16192	Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal adenocarcinoma. <i>European Journal of Radiology</i> , 2021, 145, 110036.	2.6	11
16193	Assessment of Response to Chemotherapy in Pancreatic Cancer with Liver Metastasis: CT Texture as a Predictive Biomarker. <i>Diagnostics</i> , 2021, 11, 2252.	2.6	1
16194	Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. <i>The Lancet Healthy Longevity</i> , 2021, 2, e791-e800.	4.6	10
16195	Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). <i>ESMO Open</i> , 2021, 6, 100325.	4.5	24
16196	A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 163, 19-26.	2.0	19
16197	Machine Learning-Based Radiomics in Neuro-Oncology. <i>Acta Neurochirurgica Supplementum</i> , 2022, 134, 139-151.	1.0	5
16198	Comparison of amide proton transfer imaging with perfusion imaging of using arterial spin-labeling for evidence of tumor invasion in glioblastoma. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2022, 28, 101461.	0.3	1
16199	Adaptive Designs. <i>Springer Series in Pharmaceutical Statistics</i> , 2021, , 225-251.	0.0	0
16200	Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110638.	1.9	10
16201	Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100496.	1.7	9
16202	Clinical Translation and Adaption. , 2021, , 1-16.		0
16203	Real-World Effectiveness and Prognostic Factors Analysis of Stages Iâ€“III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, 111-120.	0.8	9
16204	Volumetric measurements of target lesions: does it improve inter-reader variability for oncological response assessment according to RECIST 1.1 guidelines compared to standard unidimensional measurements?. <i>Polish Journal of Radiology</i> , 2021, 86, 594-600.	0.9	3
16206	Manufacturersâ€™ views on outcome-based agreements. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1993593.	1.5	2

#	ARTICLE	IF	CITATIONS
16207	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110423.	3.2	3
16208	Meta-Analysis of Combined Treatment of Integrated Traditional Chinese Medicine and Western Medicine in Treatment of Top 10 Cancers in the World. <i>Traditional Chinese Medicine</i> , 2021, 10, 807-822.	0.2	0
16209	Defining primary anal cancer tumour volume on FDG- ¹⁸ F PET: an initial assessment of semi-automated methods. <i>International Journal of Radiology & Radiation Therapy</i> , 2021, 8, 1-7.	0.1	1
16210	Clinical Study of 2 Radiotherapy Techniques for Semi-Hepatic Alternating Radiotherapy on Diffuse Liver Metastasis in Patients with Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110518.	1.9	0
16211	Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110591.	1.3	0
16212	Computed Tomography Evaluation of Tumor Response in Oncology in Togo. <i>Journal of Cancer Therapy</i> , 2021, 12, 695-707.	0.4	0
16213	Longitudinal Dynamics of Coagulation and Angiogenesis Markers in Cancer Patients During and After Chemotherapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110566.	1.7	3
16214	C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1358.	3.8	15
16215	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 431-447.	1.6	2
16216	Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110561.	3.2	7
16217	Quantitative Imaging in Lung Cancer. , 2021, , 1-24.		0
16218	Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 975-983.	1.9	4
16219	Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 61-65.	1.3	4
16220	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e15-166.e25.	1.6	6
16221	The validity of progression-free survival 2 as a surrogate trial end point for overall survival. <i>Cancer</i> , 2022, 128, 1449-1457.	4.1	15
16222	Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA. <i>Lung Cancer</i> , 2022, 165, 43-48.	2.0	2
16223	Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort. <i>Oncologist</i> , 2022, 27, e142-e150.	3.7	2
16224	Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. <i>Oncologist</i> , 2022, 27, e18-e28.	3.7	41

#	ARTICLE	IF	CITATIONS
16225	Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1969-e1975.	3.6	11
16226	Upfront brain radiotherapy improves intracranial progression-free survival but not overall survival in lung adenocarcinoma patients with brain metastases: a retrospective, single-institutional analysis from China. <i>Journal of Cancer</i> , 2022, 13, 602-609.	2.5	2
16227	Global-Local attention network with multi-task uncertainty loss for abnormal lymph node detection in MR images. <i>Medical Image Analysis</i> , 2022, 77, 102345.	11.6	13
16228	A computational modeling approach for dosing endoscopic intratumoral chemotherapy for advanced non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, 44.	3.3	5
16229	A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 688679.	2.8	13
16230	Ninety-day mortality and clinical outcomes of patients with solid tumours and COVID-19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study. <i>International Journal of Cancer</i> , 2021, , .	5.1	0
16231	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
16232	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. <i>Cancers</i> , 2022, 14, 241.	3.7	14
16233	LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways. <i>Journal of Cancer</i> , 2022, 13, 253-267.	2.5	9
16234	Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response”<i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 218, 767-780.	2.2	15
16235	Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 790-801.	2.2	4
16236	Efficacy prediction based on attribute and multi-source data collaborative for auxiliary medical system in developing countries. <i>Neural Computing and Applications</i> , 2022, 34, 5497-5512.	5.6	16
16237	Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer. <i>Cancer Control</i> , 2022, 29, 107327482110531.	1.8	9
16238	Reevaluation of statistically significant meta-analyses in advanced cancer patients using the <scp>Hartung"Knapp</scp> method and prediction intervals"A methodological study. <i>Research Synthesis Methods</i> , 2022, 13, 330-341.	8.7	9
16239	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 55-63.	0.7	2
16240	Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. <i>Discover Oncology</i> , 2022, 13, 2.	2.1	2
16241	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group " ESOI Joint Paper. <i>Frontiers in Oncology</i> , 2021, 11, 800547.	2.8	10
16242	Prognosis in primary mucinous ovarian carcinoma: focusing on the five pathological findings indicating metastatic mucinous carcinoma to the ovary. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	4

#	ARTICLE	IF	CITATIONS
16243	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. <i>Cancers</i> , 2022, 14, 343.	3.7	19
16244	Regorafenib+avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. <i>European Journal of Cancer</i> , 2022, 162, 161-169.	2.8	22
16245	Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. <i>ESMO Open</i> , 2022, 7, 100348.	4.5	16
16246	Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients. <i>ESMO Open</i> , 2022, 7, 100366.	4.5	6
16247	Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer. <i>Lung Cancer</i> , 2022, 164, 39-45.	2.0	4
16248	Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. <i>Translational Oncology</i> , 2022, 16, 101321.	3.7	5
16249	Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2022, 47, 108-116.	1.3	4
16250	Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy. <i>ESMO Open</i> , 2022, 7, 100346.	4.5	5
16251	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
16252	Extraction parameter optimized radiomics for neoadjuvant chemotherapy response prognosis in advanced nasopharyngeal carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 37-44.	1.7	2
16253	Complete radiographic response of a rectal gastrointestinal stromal tumor to imatinib mesylate. <i>Journal of Cancer Research and Practice</i> , 2019, 6, 37.	0.2	0
16255	Role of Metformin in Combination with Neoadjuvant Chemotherapy in Treatment of Breast Cancer. <i>The Egyptian Journal of Hospital Medicine</i> , 2020, 81, 1379-1388.	0.1	0
16256	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	6
16257	Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study. <i>Translational Cancer Research</i> , 2020, 9, 6039-6049.	1.0	1
16259	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	8
16261	Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non-Small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3153-3163.	1.2	2
16262	Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC. , 2020, , .		0
16263	Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment. <i>Breast Care</i> , 2021, 16, 468-474.	1.4	4

#	ARTICLE	IF	CITATIONS
16264	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	3.2	4
16266	ALDH1B1 predicts poor survival for locally advanced nasopharyngeal carcinoma patients. Translational Cancer Research, 2022, 11, 382-391.	1.0	3
16267	Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis. Journal of Thoracic Disease, 2022, 14, 333-342.	1.4	8
16268	Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Medicine, 2021, 19, 193.	5.5	8
16269	Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 724389.	3.7	8
16270	Advanced 3D Deep Non-Local Embedded System for Self-Augmented X-Ray-based COVID-19 Assessment. , 2021, , .		5
16271	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Frontiers in Oncology, 2021, 11, 683502.	2.8	21
16272	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. JCO Precision Oncology, 2021, 5, 1821-1829.	3.0	17
16273	Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. Scientific Reports, 2021, 11, 23803.	3.3	4
16275	Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. BMC Medicine, 2021, 19, 322.	5.5	0
16276	Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma. Kidney Cancer, 2021, 5, 181-187.	0.4	1
16277	Percent change in apparent diffusion coefficient and plasma EBV DNA after induction chemotherapy identifies distinct prognostic response phenotypes in advanced nasopharyngeal carcinoma. BMC Cancer, 2021, 21, 1320.	2.6	4
16278	Signal pathways of melanoma and targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 424.	17.1	115
16279	A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an α 3 β 3 Binder for the Treatment of Multiple Cancer Types. Cancers, 2022, 14, 391.	3.7	12
16280	Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study). International Journal of Clinical Oncology, 2022, 27, 684.	2.2	2
16281	Clinicopathological characteristics and treatment of patients with high-grade endometrial stromal sarcoma. Medicine (United States), 2022, 101, e28490.	1.0	0
16282	A Novel Technique of 4K Laparoscopic Suprapancreatic Lymph Node Dissection After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer With Right Lateral Approach. SSRN Electronic Journal, 0, , .	0.4	0
16283	A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients. Endocrine, 2022, 76, 70-77.	2.3	2

#	ARTICLE	IF	CITATIONS
16284	Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-002908.	2.5	1
16285	Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study. <i>BMC Cancer</i> , 2022, 22, 56.	2.6	9
16286	PET metabolic tumor volume as a new prognostic factor in childhood rhabdomyosarcoma. <i>PLoS ONE</i> , 2022, 17, e0261565.	2.5	3
16287	Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901). <i>Future Oncology</i> , 2022, 18, 523-531.	2.4	7
16288	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	4.1	5
16289	Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 1016-1021.	0.8	8
16290	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
16291	Risk of recurrence and long-term mortality following radical cystectomy for bladder cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 149-154.	1.0	3
16292	Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. <i>Clinical Cancer Research</i> , 2022, 28, 2038-2049.	7.0	16
16293	Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma. <i>Anticancer Research</i> , 2022, 42, 981-989.	1.1	6
16294	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	4.1	9
16295	Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492110671.	1.3	4
16296	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 2022, 2022, CD013453.	2.8	18
16297	Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. , 2022, 10, e003198.		21
16298	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. <i>Future Oncology</i> , 2022, 18, 771-779.	2.4	3
16299	Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas. <i>Cancers</i> , 2022, 14, 324.	3.7	5
16300	Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 25-30.	0.7	0
16301	Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 101.	2.6	11

#	ARTICLE	IF	CITATIONS
16302	Modeling of Tumor Growth with Input from Patient-Specific Metabolomic Data. <i>Annals of Biomedical Engineering</i> , 2022, 50, 314-329.	2.5	7
16303	Early detection of treatment futility in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2022, 13, 61-72.	1.8	7
16304	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
16305	Locally advanced breast cancer involving the skin surface treated with radiotherapy using a hydrogen peroxide solution-soaked gauze bolus: a case report. <i>Advances in Radiation Oncology</i> , 2022, 7, 100894.	1.2	1
16306	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 1353-1362.	7.0	10
16307	Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type,) Tj ETQq1 1 0.7843 14 rgBZ /Overlock		
16308	Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis. <i>Brain Tumor Pathology</i> , 2022, 39, 99-110.	1.7	5
16309	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	6.4	40
16310	A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	4.2	1
16311	Carbon ion radiotherapy with complete tumor regression for primary malignant melanoma of female urethra orifice: a case report. <i>Journal of International Medical Research</i> , 2022, 50, 030006052110727.	1.0	2
16312	Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence. <i>Asian Journal of Andrology</i> , 2022, 24, 180.	1.6	3
16313	Metastatic uveal melanoma: The final frontier. <i>Progress in Retinal and Eye Research</i> , 2022, 90, 101041.	15.5	36
16314	Nutritional Risk Index Predicts Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>Frontiers in Nutrition</i> , 2021, 8, 786742.	3.7	8
16315	Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 730646.	2.8	1
16316	Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 37-44.	1.1	6
16317	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	1.6	13
16318	Changes in apparent diffusion coefficient and pathological response in colorectal liver metastases after preoperative chemotherapy. <i>Acta Radiologica</i> , 2023, 64, 51-57.	1.1	2
16319	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. , 2022, 10, e004008.		28

#	ARTICLE	IF	CITATIONS
16320	A prospective study on the efficacy of oral estrogen in female patients with acromegaly. Pituitary, 2022, 25, 433-443.	2.9	5
16321	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clinical and Research Reports, 2022, 3, 100262.	1.1	7
16322	Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas. Journal of Gastrointestinal Surgery, 2022, 26, 869-886.	1.7	5
16323	Non-Epithelial Ovarian Cancers: How Much Do We Really Know?. International Journal of Environmental Research and Public Health, 2022, 19, 1106.	2.6	46
16324	Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer. Journal of Cancer, 2022, 13, 987-997.	2.5	5
16325	Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response. Frontiers in Oncology, 2021, 11, 691638.	2.8	0
16326	Serum Metabolic Fingerprints on Bowl-Shaped Submicroreactor Chip for Chemotherapy Monitoring. ACS Nano, 2022, 16, 2852-2865.	14.6	47
16327	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022, 386, 24-34.	27.0	766
16328	Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome. Cancer Treatment and Research Communications, 2022, 31, 100524.	1.7	5
16329	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer. , 2022, 10, e003581.		19
16330	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	2.6	2
16331	High-risk HPV-related Squamous Cell Carcinoma in the Conjunctiva and Lacrimal sac. American Journal of Surgical Pathology, 2022, 46, 977-987.	3.7	8
16332	PET imaging in breast cancer. , 2022, , .		0
16333	An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer. Current Oncology, 2022, 29, 544-550.	2.2	2
16334	Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer, 2022, 22, 22.	2.6	6
16335	Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study. BMC Cancer, 2022, 22, 31.	2.6	2
16336	Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. Future Oncology, 2022, 18, 139-148.	2.4	1
16337	Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5Âyears: a case report. Surgical Case Reports, 2022, 8, 21.	0.6	0

#	ARTICLE	IF	CITATIONS
16338	Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). <i>European Journal of Cancer</i> , 2022, 161, 26-37.	2.8	11
16339	Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4939-4949.	2.3	8
16340	Prospective Phase II Trial of Prognostication by ⁶⁸ Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1371-1377.	5.0	13
16341	Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. <i>Radiotherapy and Oncology</i> , 2022, 168, 95-103.	0.6	3
16342	Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103569.	4.4	13
16343	The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 796317.	2.8	4
16344	Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?. <i>Abdominal Radiology</i> , 2022, 47, 1071-1081.	2.1	2
16345	Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements. <i>European Radiology</i> , 2022, 32, 4067-4078.	4.5	7
16346	Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT. <i>British Journal of Cancer</i> , 2022, 126, 1271-1279.	6.4	15
16347	A prognostic nomogram for intrahepatic progression-free survival in patients with colorectal liver metastases after ultrasound-guided percutaneous microwave ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 144-154.	2.5	5
16348	Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. <i>Cancers</i> , 2022, 14, 331.	3.7	3
16349	Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 3938-3949.	1.5	2
16350	Influence Factors of Gefitinib Concentration in Patients with Non-Small Cell Lung Cancer in Clinical Treatment. <i>Advances in Clinical Medicine</i> , 2022, 12, 196-205.	0.0	1
16351	From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). <i>Cancers</i> , 2022, 14, 694.	3.7	9
16352	Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy. <i>World Journal of Clinical Cases</i> , 2022, 10, 899-918.	0.8	1
16353	Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 481.	3.7	13
16354	Can the computed tomography texture analysis of colorectal liver metastases predict the response to first-line cytotoxic chemotherapy?. <i>World Journal of Hepatology</i> , 2022, 14, 244-259.	2.0	6
16355	Can the computed tomography texture analysis of colorectal liver metastases predict the response to first-line cytotoxic chemotherapy?. <i>World Journal of Hepatology</i> , 2022, 14, 224-233.	2.0	3

#	ARTICLE	IF	CITATIONS
16356	Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 752.	3.7	0
16357	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 255-265.	2.3	1
16358	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600 <i>i</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1098-1106.	7.0	32
16359	Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy. <i>Cancers</i> , 2022, 14, 540.	3.7	2
16360	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	16.8	64
16361	Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC. <i>Cancers</i> , 2022, 14, 741.	3.7	10
16362	Regression Analysis of Rectal Cancer and Possible Application of Artificial Intelligence (AI) Utilization in Radiotherapy. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 725.	2.5	2
16363	Molecular response assessment with immune adaptive positron emission tomography response criteria in solid tumors in lung cancer patients treated with nivolumab: Is it better than immune response evaluation criteria in solid tumors?. <i>World Journal of Nuclear Medicine</i> , 2022, .	0.5	0
16364	The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3103-3108.	2.5	24
16365	Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, 29.	1.6	3
16366	Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. <i>BMC Cancer</i> , 2022, 22, 51.	2.6	3
16367	Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis. <i>International Journal of Cancer</i> , 2022, 150, 1318-1328.	5.1	21
16368	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	3.7	2
16369	Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 779700.	2.8	3
16370	Longitudinal Analysis of 1,25-dihydroxyvitamin D3 and Homocysteine Changes in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 658.	3.7	0
16371	Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer) Tj ETQq1 1 0.784314 rgBT /Overlo 3.4 12	3.4	12
16373	Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 2882-2894.	1.5	20
16374	The Predictive Role of Serum Levels of Soluble Cell Adhesion Molecules (sCAMs) in the Therapy of Advanced Breast Cancer—A Single-Centre Study. <i>Medicina (Lithuania)</i> , 2022, 58, 153.	2.0	4

#	ARTICLE	IF	CITATIONS
16375	Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. <i>Clinical Cancer Research</i> , 2022, 28, 1773-1782.	7.0	11
16376	Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 3322-3334.	1.5	3
16377	Impact of preoperative endoscopy for predicting treatment response and prognosis in patients with gastric cancer after neoadjuvant chemotherapy. <i>Endoscopy International Open</i> , 2022, 10, E62-E73.	1.8	1
16378	Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 753-760.	2.5	3
16379	Prognostic value of complete metabolic response on 18F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	3
16380	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1949-1958.	4.2	7
16381	Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Childrenâ€™s Oncology Group Study AREN0534. <i>Annals of Surgical Oncology</i> , 2022, 29, 3252-3261.	1.5	8
16382	VERDICT MRI for radiation treatment response assessment in neuroendocrine tumors. <i>NMR in Biomedicine</i> , 2021, , e4680.	2.8	0
16383	Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial. <i>Journal of Cancer</i> , 2022, 13, 1097-1102.	2.5	2
16384	A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 761428.	2.8	4
16385	CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer. <i>Anticancer Research</i> , 2022, 42, 697-707.	1.1	2
16386	Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer. <i>Anticancer Research</i> , 2022, 42, 1099-1106.	1.1	4
16387	Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 973-979.	1.1	5
16388	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	10.7	526
16389	Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. <i>British Journal of Surgery</i> , 2022, 109, 489-492.	0.3	17
16390	Small-size (40Âµm) Beads Loaded with Irinotecan in the Treatment of Patients with Colorectal Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 770-779.	2.0	6
16391	Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. <i>Investigational New Drugs</i> , 2022, 40, 634-642.	2.6	8
16392	Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0261939.	2.5	2

#	ARTICLE	IF	CITATIONS
16393	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	3.2	7
16394	Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance. <i>Frontiers in Pharmacology</i> , 2021, 12, 746707.	3.5	9
16395	Imaging Evaluation of Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 810419.	2.8	17
16396	Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. <i>Cancer Research and Treatment</i> , 2022, 54, 1240-1255.	3.0	4
16397	Deep Learning for the Automatic Diagnosis and Analysis of Bone Metastasis on Bone Scintigrams. <i>Cancer Management and Research</i> , 2022, Volume 14, 51-65.	1.9	15
16398	Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts. <i>Communications Biology</i> , 2022, 5, 59.	4.4	3
16399	Neutrophil-to-lymphocyte ratio change predicts histological response to and oncological outcome of neoadjuvant chemotherapy for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2022, 19, 426-435.	1.9	8
16400	Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 599-610.	1.8	5
16401	Clinical impact of a deep learning system for automated detection of missed pulmonary nodules on routine body computed tomography including the chest region. <i>European Radiology</i> , 2022, 32, 2891-2900.	4.5	4
16402	Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 965-974.	1.9	3
16403	Effectiveness of early exercise on reducing skeletal muscle loss during preoperative neoadjuvant chemotherapy for esophageal cancer. <i>Surgery Today</i> , 2022, 52, 1143-1152.	1.5	8
16404	Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab. <i>Thoracic Cancer</i> , 2022, , .	1.9	4
16405	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Oncology</i> , 2022, 100, 131-139.	1.9	5
16406	Prognostic factors in patients who received paraaortic lymph node dissection for locally advanced gastric cancer with extensive lymph node metastasis. <i>Langenbeck's Archives of Surgery</i> , 2022, , 1.	1.9	0
16407	Analysis of Routine Computed Tomographic Scans With Radiomics and Machine Learning. <i>JAMA Oncology</i> , 2022, , .	7.1	5
16408	Image-Guided Robotic Radiosurgery for the Treatment of Lung Metastases of Renal Cell Carcinoma—A Retrospective, Single Center Analysis. <i>Cancers</i> , 2022, 14, 356.	3.7	1
16409	Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer. <i>World Journal of Clinical Cases</i> , 2022, 10, 1164-1171.	0.8	3
16410	Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. <i>Anticancer Research</i> , 2022, 42, 1131-1136.	1.1	9

#	ARTICLE	IF	CITATIONS
16411	Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer. <i>Anticancer Research</i> , 2022, 42, 939-946.	1.1	5
16412	Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion. <i>Frontiers in Immunology</i> , 2021, 12, 783243.	4.8	9
16413	PET imaging of Gastrointestinal Stromal Tumors (GIST). , 2022, , .		0
16414	Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study. <i>World Journal of Surgical Oncology</i> , 2022, 20, 27.	1.9	8
16415	PD-L1 in circulating exosomes of Merkel cell carcinoma. <i>Experimental Dermatology</i> , 2022, 31, 869-877.	2.9	6
16416	Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 101-113.	0.8	17
16417	Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study. <i>Translational Lung Cancer Research</i> , 2022, 11, 87-99.	2.8	11
16418	Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. <i>Oncologist</i> , 2022, 27, 432-e452.	3.7	2
16419	Intensified Total Neoadjuvant Therapy <i>Versus</i> Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis. <i>Anticancer Research</i> , 2022, 42, 991-1000.	1.1	2
16420	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. <i>Clinical Cancer Research</i> , 2022, 28, 1285-1293.	7.0	16
16421	Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. <i>Esophagus</i> , 2022, 19, 444-451.	1.9	3
16422	Benchmarking Eliminative Radiomic Feature Selection for Head and Neck Lymph Node Classification. <i>Cancers</i> , 2022, 14, 477.	3.7	4
16423	Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma. <i>European Thyroid Journal</i> , 2022, , .	2.4	0
16424	A stochastically curtailed single-arm phase II trial design for binary outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 671-691.	0.8	2
16425	Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study. <i>Supportive Care in Cancer</i> , 2022, 30, 3829-3838.	2.2	2
16426	Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 479-485.	1.3	8
16427	Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 499-506.	2.1	12
16428	Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. , 2022, 10, e003868.		7

#	ARTICLE	IF	CITATIONS
16429	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	3.7	3
16430	Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancer Management and Research</i> , 2022, Volume 14, 427-435.	1.9	6
16431	The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 779882.	2.8	7
16432	Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1549-1559.	7.0	24
16433	Metastatic Neoplasm Volume Kinetics Following 2-Stage Stereotactic Radiosurgery. <i>World Neurosurgery</i> , 2022, 161, e210-e219.	1.3	5
16434	Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. <i>BMC Cancer</i> , 2022, 22, 129.	2.6	5
16435	First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. <i>Investigational New Drugs</i> , 2022, , 1.	2.6	5
16436	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. <i>Lancet Oncology</i> , The, 2022, 23, 220-233.	10.7	106
16437	Prospective Evaluation of Response Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. <i>Cureus</i> , 2022, 14, e21831.	0.5	2
16438	Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study. <i>Future Oncology</i> , 2022, 18, 1461-1471.	2.4	2
16439	Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results. <i>Supportive Care in Cancer</i> , 2022, 30, 4447-4455.	2.2	4
16440	Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>South Asian Journal of Cancer</i> , 2022, 11, 084-094.	0.6	2
16441	Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. <i>BMC Medicine</i> , 2022, 20, 42.	5.5	26
16442	MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. <i>Diagnostics</i> , 2022, 12, 374.	2.6	9
16443	Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 203-212.	1.4	4
16444	Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study. <i>Cancer Research and Treatment</i> , 2022, 54, 1038-1052.	3.0	1
16445	T1 mapping as a surrogate marker of chemotherapy response evaluation in patients with osteosarcoma. <i>European Journal of Radiology</i> , 2022, 148, 110170.	2.6	4
16446	Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy. <i>Lung Cancer</i> , 2022, 165, 10-17.	2.0	1

#	ARTICLE	IF	CITATIONS
16447	Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102338.	7.7	4
16448	Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-1.	3.0	1
16449	Prospective validation and extension of the Multimodality Prognostic Score for the treatment allocation of pleural mesothelioma patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	1.4	3
16450	Evaluation of doseâ€“Volume-based image-guided high-dose-rate brachytherapy in carcinoma uterine cervix: A prospective study. <i>Journal of Radiation and Cancer Research</i> , 2022, 13, 12.	0.1	0
16451	Total cellâ€“free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay. <i>Molecular and Clinical Oncology</i> , 2022, 16, 64.	1.0	2
16452	Evaluation of histopathological heterogeneity of colorectal cancer liver metastasis sites after preoperative chemotherapy. <i>Molecular and Clinical Oncology</i> , 2022, 16, 61.	1.0	0
16453	Monitoring tumor growth rate to predict immune checkpoint inhibitorsâ€™ treatment outcome in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	3.2	2
16454	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	2
16455	Actual practice of Kochi oxydol radiation therapy for unresectable carcinomas by intraâ€“tumoral administration of hydrogen peroxide as a radiosensitizer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 68.	1.0	3
16456	The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. <i>PLoS ONE</i> , 2022, 17, e0263247.	2.5	8
16457	Evaluating the Role of Hepatobiliary Phase of Gadoteric Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 827.	3.7	18
16458	Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review. <i>Musculoskeletal Surgery</i> , 2023, 107, 7-18.	1.5	11
16459	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
16460	Efficacy and safety exposureâ€“response analyses of entrectinib in patients with advanced or metastatic solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 363-372.	2.3	4
16461	The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. <i>Clinical and Translational Oncology</i> , 2022, 24, 1533-1541.	2.4	5
16462	Palbociclib plus endocrine therapy significantly enhances overall survival of ^{HR}+/^{HER2}- metastatic breast cancer patients compared to endocrine therapy alone in the secondâ€“line setting: A large institutional study. <i>International Journal of Cancer</i> , 2022, 150, 2025-2037.	5.1	16
16463	CD8⁺PD-1⁺ to CD4⁺PD-1⁺ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. , 2022, 10, e004012.		16
16464	Deep learning of quantitative ultrasound multi-parametric images at pre-treatment to predict breast cancer response to chemotherapy. <i>Scientific Reports</i> , 2022, 12, 2244.	3.3	16

#	ARTICLE	IF	CITATIONS
16465	A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial. Hpb, 2022, 24, 1245-1251.	0.3	1
16466	Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. Scientific Reports, 2022, 12, 2025.	3.3	5
16467	Efficacy and Safety of Super-Selective Bronchial Arterial Infusion Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Chemotherapy, 2022, 67, 123-131.	1.6	3
16468	Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecologic Oncology, 2022, 165, 97-104.	1.4	8
16469	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell, 2022, 40, 318-334.e9.	16.8	97
16470	Multimodal treatment in oligometastatic gastric cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 434-449.	2.0	8
16471	Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas. Advances in Therapy, 2022, 39, 1596-1610.	2.9	4
16472	[177Lu]Lu-DOTA-TATE and [131I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center. Frontiers in Endocrinology, 2022, 13, 778322.	3.5	9
16473	Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutationâ€“positive melanoma. Annals of Oncology, 2022, 33, 544-555.	1.2	12
16474	Artificial Intelligence Comes of Age in the Fight Against Cancer. Oncology Times, 2022, 44, 1,15-16.	0.1	0
16475	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 541-553.	13.7	75
16476	Data of â€“Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stageâ€“TM. Data in Brief, 2022, 41, 107944.	1.0	0
16477	Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 794.	3.7	6
16478	Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine, 2022, 76, 484-490.	2.3	8
16480	Baseline Amide Proton Transfer Imaging at 3T Fails to Predict Early Response to Induction Chemotherapy in Nasopharyngeal Carcinoma. Frontiers in Oncology, 2022, 12, 822756.	2.8	2
16481	Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinumâ€“based chemotherapy. Journal of Obstetrics and Gynaecology Research, 2022, , .	1.3	4
16482	Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy. Urologia Internationalis, 2022, , 1-5.	1.3	1
16483	<scp>Realâ€“world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022, 150, 2012-2024.	5.1	8

#	ARTICLE	IF	CITATIONS
16484	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by <i>NRG1</i> Gene Rearrangements. <i>Cancer Discovery</i> , 2022, 12, 1233-1247.	9.4	60
16485	Attenuation of obesity-induced hyperlipidemia reduces tumor growth. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159124.	2.4	1
16487	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	1.6	26
16488	Clinical significance of CD8 ⁺ positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high-grade serous carcinoma. <i>Cancer Medicine</i> , 2022, 11, 2085-2095.	2.8	3
16489	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 51.	8.6	9
16490	Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer. <i>Cancer Medicine</i> , 2022, , .	2.8	5
16491	Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 1290-1310.	2.4	17
16492	Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors. <i>Endocrine Connections</i> , 2022, , .	1.9	0
16493	Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 757-764.	2.5	4
16494	Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 573-582.	2.5	1
16495	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	10.7	97
16496	Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2022, 13, 846235.	4.8	5
16497	Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib. <i>Medicine (United States)</i> , 2022, 101, e28680.	1.0	12
16498	Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. <i>ESMO Open</i> , 2022, 7, 100391.	4.5	6
16499	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	1.6	43
16500	I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response. <i>Annals of Nuclear Medicine</i> , 2022, 36, 213-223.	2.2	4
16501	Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain. <i>Cancers</i> , 2022, 14, 861.	3.7	0
16502	Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer. <i>Medicine (United States)</i> , 2022, 101, e28863.	1.0	3

#	ARTICLE	IF	CITATIONS
16503	Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial. <i>Radiotherapy and Oncology</i> , 2022, 169, 64-70.	0.6	3
16505	Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	3.0	9
16506	Assessing Post-Treatment Pathologic Tumor Response in Female Genital Tract Carcinomas: An Update. <i>Frontiers in Oncology</i> , 2022, 12, 814989.	2.8	2
16507	A New Preoperative Scoring System for Predicting Aggressiveness of Non-Functioning Pancreatic Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2022, 12, 397.	2.6	4
16508	Implementing Real-World RECIST-based Tumor Response Assessment in Patients with Metastatic Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	5
16509	A review on advances in 18F-FDG PET/CT radiomics standardisation and application in lung disease management. <i>Insights Into Imaging</i> , 2022, 13, 22.	3.4	9
16510	Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703.	6.4	5
16511	Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 889-898.	2.2	1
16512	Head-to-head evaluation of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2889-2901.	6.4	27
16513	Treatment Response Prediction Using Ultrasound-Based Pre-, Post-Early, and Delta Radiomics in Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 748008.	2.8	13
16514	Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). <i>Trials</i> , 2022, 23, 119.	1.6	6
16515	Classical mathematical models for prediction of response to chemotherapy and immunotherapy. <i>PLoS Computational Biology</i> , 2022, 18, e1009822.	3.2	36
16516	Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 39.	2.7	1
16517	Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 593-602.	2.5	5
16518	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548.	7.0	21
16519	Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 816.	12.8	192
16520	Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 596-605.	2.6	18
16521	Definitive radiation therapy and liver local therapy in de novo liver metastatic nasopharyngeal carcinoma: Large cohort study. <i>Head and Neck</i> , 2022, , .	2.0	1

#	ARTICLE	IF	CITATIONS
16522	Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 603-610.	2.5	4
16523	Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 261.	2.5	4
16524	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. <i>Annals of Oncology</i> , 2022, 33, 321-329.	1.2	97
16525	The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. <i>European Journal of Radiology</i> , 2022, 149, 110200.	2.6	5
16526	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6267.	3.7	7
16527	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	1.1	43
16528	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	4.1	28
16529	Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 196.e1-196.e9.	1.9	9
16530	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. <i>European Urology</i> , 2022, 81, 364-372.	1.9	70
16531	Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 661-671.e4.	0.8	6
16532	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 7348.	12.8	96
16533	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730.	27.8	335
16534	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. <i>Npj Precision Oncology</i> , 2021, 5, 100.	5.4	21
16535	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	13.2	112
16536	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. <i>Nature Cancer</i> , 2022, 3, 108-121.	13.2	150
16537	Long-term Oncological Outcome of Segmental Versus Extended Colectomy for Colorectal Cancer in Crohn's Disease: Results from an International Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 954-962.	1.3	4
16538	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
16539	Diagnostic performance of digital breast tomosynthesis for predicting response to neoadjuvant systemic therapy in breast cancer patients: A comparison with magnetic resonance imaging, ultrasound, and full-field digital mammography. <i>Acta Radiologica Open</i> , 2021, 10, 205846012110637.	0.6	2

#	ARTICLE	IF	CITATIONS
16540	Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 604.	0.8	6
16541	Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series. <i>Frontiers in Immunology</i> , 2021, 12, 784336.	4.8	12
16542	Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events. <i>Frontiers in Oncology</i> , 2021, 11, 757069.	2.8	9
16545	Improvement in the condition of patients with primary liver cancer with transcatheter arterial chemoembolization before and after microwave ablation interventional therapy. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 11908-11916.	0.0	0
16546	Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 411-411.	1.7	5
16547	Therapeutische Grundlagen in der gynÄkologischen Onkologie. , 2021, , 179-254.		0
16548	Survival analysis of patients with recurrent or metastatic soft tissue sarcoma who were treated by cryoablation: A real-world retrospective study. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1736.	0.9	2
16549	Clinical outcomes of definitive radiotherapy for patients with cT1aN0M0 esophageal cancer unsuitable for endoscopic resection and surgery. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 454-461.	1.4	2
16551	The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkinâ€™s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2022, 15, 42-53.	0.4	0
16553	A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab. <i>In Vivo</i> , 2022, 36, 1047-1051.	1.3	1
16554	A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542210839.	2.0	8
16555	Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
16556	A case of synchronous triple autoimmune disorders secondary to thymoma: Pure red cell aplasia, Good's syndrome, and thymoma-associated multi-organ autoimmunity. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101619.	0.4	3
16557	Prognostic Implication of Preoperative Serum Albumin to Carcinoembryonic Antigen Ratio in Colorectal Cancer Patients. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210786.	1.9	2
16558	Re-irradiation with interstitial brachytherapy in uterine cancer patients with vaginal recurrence after post-operative pelvic irradiation. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 60-65.	0.9	0
16559	Deep Supervoxel Segmentation forÂSurvival Analysis inÂHead andÂNeck Cancer Patients. <i>Lecture Notes in Computer Science</i> , 2022, , 257-265.	1.3	3
16560	Pre-treatment hematological parameters as a cost effective predictive marker for response to concurrent chemo radiation in locally advanced cervical cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100539.	1.7	3
16561	Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer. <i>In Vivo</i> , 2022, 36, 979-984.	1.3	4

#	ARTICLE	IF	CITATIONS
16562	Thoracic Imaging Manifestations of Treated Lymphomas. <i>Journal of Thoracic Imaging</i> , 2022, 37, 67-79.	1.5	0
16563	Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210865.	1.3	1
16564	Combination of Circulating Tumour DNA and ¹⁸ F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 270-281.	2.0	4
16565	AIM and Brain Tumors. , 2022, , 1717-1732.		0
16566	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210839.	3.2	16
16567	Short-term effectiveness and safety of CT-guided radioactive iodine-125 seed implantation for treatment of adrenal metastases. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 148-156.	0.9	1
16568	PET imaging of lung and pleural cancer. , 2022, , .		0
16569	Nuclear Medicine Therapy in primary liver cancers. , 2022, , .		0
16570	Olaparib as Maintenance Treatment in Patients with Chemosensitive Small Cell Lung Cancer (STOMP): A Randomised, Double-Blind, Placebo-Controlled Phase II Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
16572	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. <i>Scripta Medica</i> , 2022, 53, 29-35.	0.1	0
16574	Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210860.	1.9	0
16575	Prognostic factors for treatment response and survival outcomes after first-line management of Stage 4 non-small cell lung cancer: A real-world Indian perspective. <i>Lung India</i> , 2022, 39, 102.	0.7	6
16576	Analysis of miR-375-3p, miR-197-3p, and miR-15a-5p Expression and Their Clinical Relevance as Biomarkers in Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210809.	1.9	9
16577	Teaching cancer imaging in the era of precision medicine: Looking at the big picture. <i>European Journal of Radiology Open</i> , 2022, 9, 100414.	1.6	3
16578	A single-nucleotide-polymorphism in the 5'-flanking region of <i>MSX1</i> gene as a predictive marker candidate for platinum-based therapy of esophageal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210805.	3.2	0
16579	Fractal analysis improves tumour size measurement on computed tomography in pancreatic ductal adenocarcinoma: comparison with gross pathology and multi-parametric MRI. <i>European Radiology</i> , 2022, 32, 5053-5063.	4.5	5
16580	PD-1/PD-L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials. <i>Oncology Letters</i> , 2022, 23, 134.	1.8	1
16581	A nomogram based on tumor response to induction chemotherapy may predict survival in locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2022, 44, 1301-1312.	2.0	8

#	ARTICLE	IF	CITATIONS
16582	Imaging of Bone Metastases in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 531-541.	4.6	3
16583	HOXB9 Overexpression Promotes Colorectal Cancer Progression and Is Associated with Worse Survival in Liver Resection Patients for Colorectal Liver Metastases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2281.	4.1	8
16584	DKK3, Downregulated in Invasive Epithelial Ovarian Cancer, Is Associated with Chemoresistance and Enhanced Paclitaxel Susceptibility via Inhibition of the β^2 -Catenin-P-Glycoprotein Signaling Pathway. <i>Cancers</i> , 2022, 14, 924.	3.7	2
16585	Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 732-739.	2.5	7
16586	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
16587	Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period. <i>Radiotherapy and Oncology</i> , 2022, 170, 165-168.	0.6	9
16588	Refining Tumor Treatment in Sinonasal Cancer Using Delta Radiomics of Multi-Parametric MRI after the First Cycle of Induction Chemotherapy. <i>Journal of Imaging</i> , 2022, 8, 46.	3.0	6
16589	Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 462-469.	1.0	6
16590	Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. <i>Cancers</i> , 2022, 14, 1244.	3.7	0
16591	Optimised point estimators for multi-stage single-arm phase II oncology trials. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 817-831.	0.8	1
16592	Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 263-276.	2.8	40
16593	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. <i>BMC Cancer</i> , 2022, 22, 177.	2.6	2
16594	Correlation of histopathology and multi-modal magnetic resonance imaging in childhood osteosarcoma: Predicting tumor response to chemotherapy. <i>PLoS ONE</i> , 2022, 17, e0259564.	2.5	12
16595	The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 751106.	2.8	7
16596	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168.	3.7	0
16597	PET/MR Imaging in Evaluating Treatment Failure of Head and Neck Malignancies: A Neck Imaging Reporting and Data System-Based Study. <i>American Journal of Neuroradiology</i> , 2022, 43, 435-441.	2.4	9
16598	FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. <i>Annals of Oncology</i> , 2022, 33, 522-533.	1.2	93
16599	In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy. <i>Journal of Translational Medicine</i> , 2022, 20, 92.	4.4	7

#	ARTICLE	IF	CITATIONS
16600	A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis. <i>Annals of Surgery</i> , 2023, 277, 689-696.	4.2	16
16601	Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. <i>World Journal of Surgical Oncology</i> , 2022, 20, 38.	1.9	5
16602	Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer. <i>Pharmaceutics</i> , 2022, 14, 440.	4.5	9
16603	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.7	1
16604	Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs). <i>Anticancer Research</i> , 2022, 42, 1421-1431.	1.1	0
16605	Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 91.	1.0	7
16606	First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. <i>Liver Cancer</i> , 2022, 11, 268-277.	7.7	7
16607	Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 384-394.	2.5	5
16608	Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2022, 22, 176.	2.6	2
16609	Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 600-608.	2.8	24
16610	Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib. <i>IJU Case Reports</i> , 2022, 5, 149-152.	0.3	1
16611	Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China. <i>BMJ Open</i> , 2022, 12, e047611.	1.9	3
16612	A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4027-4032.	7.0	21
16613	Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	2.2	0
16614	Feasibility of cabazitaxel in octogenarian prostate cancer patients. <i>Current Urology</i> , 2022, Publish Ahead of Print, .	0.6	0
16615	Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. <i>Current Oncology</i> , 2022, 29, 1237-1251.	2.2	1
16616	Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2022, 42, 1403-1412.	1.1	7
16617	CLINICAL OUTCOME USING WEEKLY PACLITAXEL WITH RADIATION IN LOCALLY ADVANCED LUNG CANCER. , 2022, , 23-25.		0

#	ARTICLE	IF	CITATIONS
16618	Radiology of Castleman disease: the pivotal role of imaging in diagnosis, staging, and response assessment of this rare entity. <i>Clinical Radiology</i> , 2022, , .	1.1	2
16619	Association of ALDH1 with Response to Radiotherapy and Its Impact on Survival in Patients with Advanced Stage of Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 419-427.	1.2	2
16620	The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, e727.	4.0	17
16621	High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1^{low/negative} non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	2
16622	Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab. <i>Anticancer Research</i> , 2022, 42, 1599-1605.	1.1	0
16623	miR-148a promotes cell sensitivity through downregulating SOS2 in radiation-resistant non-small cell lung cancer cells. <i>Oncology Letters</i> , 2022, 23, 135.	1.8	2
16624	Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-10.	1.5	0
16625	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100448.	3.0	5
16626	The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group –CNAPS/CTC for early detection of cancer–. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 821-829.	2.3	6
16627	PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. <i>Anticancer Research</i> , 2022, 42, 1547-1554.	1.1	13
16628	Safety of peptide receptor radionuclide therapy with ¹⁷⁷Lutetium DOTATATE in neuroendocrine tumour patients with chronic kidney disease. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263056.	5.0	2
16629	Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma. <i>Molecular and Clinical Oncology</i> , 2022, 16, 87.	1.0	3
16630	Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients. <i>Biochemical Genetics</i> , 2022, 60, 1963-1985.	1.7	3
16631	Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 553.	7.1	21
16632	Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e220165.	5.9	7
16633	Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting. <i>Molecular and Clinical Oncology</i> , 2022, 16, 88.	1.0	1
16634	Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	0
16635	CT-Based Radiomics Showing Generalization to Predict Tumor Regression Grade for Advanced Gastric Cancer Treated With Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 758863.	2.8	7

#	ARTICLE	IF	CITATIONS
16636	A Review of Clinical Applications for Super-resolution Ultrasound Localization Microscopy. <i>Current Medical Science</i> , 2022, 42, 1-16.	1.8	12
16637	Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management. <i>Diagnostics</i> , 2022, 12, 581.	2.6	4
16638	Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 820302.	2.8	12
16639	Evaluation of Monoexponential, Stretched-Exponential and Intravoxel Incoherent Motion <scp>MRI</scp> Diffusion Models in Early Response Monitoring to Neoadjuvant Chemotherapy in Patients With Breast Cancer—A Preliminary Study. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1079-1088.	3.4	8
16640	Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1144.	2.4	3
16641	Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. <i>Annals of HPB Surgery</i> , 2022, 27, 33-39.	0.5	0
16642	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	4.1	3
16643	Effect of chemotherapy on tumour-vessel relationship in colorectal liver metastases. <i>British Journal of Surgery</i> , 2022, 109, 401-404.	0.3	4
16644	The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis. <i>BMC Cancer</i> , 2022, 22, 216.	2.6	5
16645	MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, , 101888.	1.5	1
16646	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	5.9	48
16647	Robotic total gastrectomy with thrombectomy and portal vein reconstruction for gastric cancer and portal vein tumor thrombus. <i>World Journal of Surgical Oncology</i> , 2022, 20, 36.	1.9	4
16648	Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy. <i>Radiology and Oncology</i> , 2022, 56, 228-237.	1.7	0
16649	Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy. <i>Liver Cancer</i> , 2022, 11, 383-396.	7.7	19
16650	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100525.	6.5	22
16651	Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study. <i>Annals of Translational Medicine</i> , 2022, 10, 205-205.	1.7	4
16652	Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes. <i>Current Oncology</i> , 2022, 29, 1080-1092.	2.2	4
16653	Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 188-200.	2.8	6

#	ARTICLE	IF	CITATIONS
16654	Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab. <i>Anticancer Research</i> , 2022, 42, 1535-1540.	1.1	3
16655	Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2371-2379.	4.2	4
16656	A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment. <i>International Cancer Conference Journal</i> , 2022, 11, 134-137.	0.5	3
16657	Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 157-170.	3.7	23
16658	Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac032.	0.2	9
16659	Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1. <i>Frontiers in Oncology</i> , 2022, 12, 834761.	2.8	12
16660	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	2.6	2
16661	Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 529-537.	2.3	1
16662	Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. <i>Cancers</i> , 2022, 14, 1410.	3.7	0
16663	Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2631-2643.	4.2	23
16664	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	1.6	72
16665	Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA. <i>Frontiers in Oncology</i> , 2022, 12, 843561.	2.8	3
16666	Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2022, , 1.	2.6	15
16667	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29644.	1.5	18
16668	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. <i>Clinical Lung Cancer</i> , 2022, 23, 300-310.	2.6	12
16669	Human Observer Net: A Platform Tool for Human Observer Studies of Image Data. <i>Radiology</i> , 2022, 303, 524-530.	7.3	6
16670	Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pancreatic cancer. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 635-641.	0.8	3
16671	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. <i>BMC Cancer</i> , 2022, 22, 293.	2.6	18

#	ARTICLE	IF	CITATIONS
16672	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	2.3	7
16673	Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2022, 42, 1905-1910.	1.1	7
16674	Comparison of Diagnostic Accuracies of USG, MG and MRI Modalities Defined with BI-RADS Classification System. <i>Current Medical Imaging</i> , 2022, 18, 986-995.	0.8	1
16675	The combination of radiotherapy and immunotherapy is effective and well tolerated for unresectable biliary tract cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	2
16676	Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. <i>Annals of Medicine</i> , 2022, 54, 803-811.	3.8	9
16677	Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 333-338.	1.4	3
16678	Locoregional progression-free survival of bone metastases from differentiated thyroid cancer. <i>Endocrine Connections</i> , 2022, 11, .	1.9	1
16679	A <sc>WIN</sc> Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced nonâ€small cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 2790-2800.	2.8	7
16680	Role of 18F-FDGâPET/CT in management of adrenocortical carcinoma: a comprehensive review of the literature. <i>Clinical and Translational Imaging</i> , 0, , 1.	2.1	1
16681	Neoâ€adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	1
16682	PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. <i>Cancers</i> , 2022, 14, 1770.	3.7	21
16683	Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different frontâ€line chemotherapy regimens. <i>Cancer Medicine</i> , 2022, , .	2.8	3
16684	The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005). <i>BMC Cancer</i> , 2022, 22, 271.	2.6	0
16685	Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-5.	1.3	0
16686	Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017. <i>Cancers</i> , 2022, 14, 1477.	3.7	6
16687	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022, 12, e055821.	1.9	23
16688	Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1103-1113.	2.5	1
16689	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2597-2608.	4.2	25

#	ARTICLE	IF	CITATIONS
16690	Neoadjuvant tyrosine kinase inhibitor therapy for patients with gastrointestinal stromal tumor: A propensity-matched analysis. American Journal of Surgery, 2022, , .	1.8	1
16691	PSMA-targeting TGF β 2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine, 2022, 28, 724-734.	30.7	171
16692	Encorafenib plus binimetinib in patients with <i>BRAF</i> ^{V600} -mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncology, 2022, 18, 781-791.	2.4	9
16693	Oncolytic viral therapy engenders a clinical response in a recurrent ovarian cancer patient. Anti-Cancer Drugs, 2022, Publish Ahead of Print, .	1.4	2
16694	Machine Learning-Assisted Ensemble Analysis for the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. Frontiers in Oncology, 2022, 12, 817250.	2.8	1
16695	A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of ¹⁷⁷ Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma—LuDO-N. Frontiers in Pediatrics, 2022, 10, 836230.	1.9	5
16696	Clinical Outcomes of MRI-Guided Adaptive Brachytherapy for Each Fraction in Locally Advanced Cervical Cancer: A Single Institution Experience. Frontiers in Oncology, 2022, 12, 841980.	2.8	0
16697	Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. Radiation Oncology, 2022, 17, 45.	2.7	7
16698	Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis. JCO Precision Oncology, 2022, 6, e2100362.	3.0	1
16699	Prognostic role of infracentimetric colorectal liver metastases. Langenbeck's Archives of Surgery, 2022, , 1.	1.9	0
16700	Reflectance confocal microscopy â€“ a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
16701	Percutaneous Thermal Segmentectomy: Proof of Concept. CardioVascular and Interventional Radiology, 2022, 45, 665-676.	2.0	13
16702	Prognostic significance of platelet-to-albumin ratio in patients with esophageal squamous cell carcinoma receiving definitive radiotherapy. Scientific Reports, 2022, 12, 3535.	3.3	17
16703	Gross Tumor Volume Definition and Comparative Assessment for Esophageal Squamous Cell Carcinoma From 3D 18F-FDG PET/CT by Deep Learning-Based Method. Frontiers in Oncology, 2022, 12, 799207.	2.8	7
16704	Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population. Medicine (United States), 2022, 101, e28970.	1.0	3
16705	Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer. Annals of Translational Medicine, 2022, 10, 253-253.	1.7	2
16706	Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers. Thyroid, 2022, 32, 657-666.	4.5	16
16707	The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. Current Oncology, 2022, 29, 1761-1772.	2.2	1

#	ARTICLE	IF	CITATIONS
16708	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 818679.	2.8	8
16709	The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. <i>Cancer Medicine</i> , 2022, 11, 2079-2084.	2.8	8
16710	Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 255-266.	2.0	2
16711	Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1157-1166.	7.0	16
16712	Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. , 2022, 10, e003883.		13
16713	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 1735.	3.7	6
16714	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. <i>Cancers</i> , 2022, 14, 1682.	3.7	2
16715	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. <i>Frontiers in Endocrinology</i> , 2022, 13, 864253.	3.5	17
16716	Profile and Clinical Outcome of Children with Wilms' Tumor treated at a Tertiary Care Centre, India. <i>South Asian Journal of Cancer</i> , 0, , .	0.6	1
16717	A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 808808.	2.8	5
16718	Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 390.e1-390.e8.	1.9	3
16719	A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202). <i>Anticancer Research</i> , 2022, 42, 1859-1865.	1.1	0
16720	Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy. <i>World Journal of Clinical Cases</i> , 2022, 10, 2429-2438.	0.8	0
16721	Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 706.	7.1	22
16722	Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. <i>Journal of Surgical Oncology</i> , 2022, 126, 292-301.	1.7	5
16723	Mechanical stress shapes the cancer cell response to neddylation inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 115.	8.6	6
16724	Pretreatment Positron Emission Tomography with ^{18}F -Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2022, 100, 320-330.	1.9	5
16725	Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy. <i>JAMA Network Open</i> , 2022, 5, e220587.	5.9	23

#	ARTICLE	IF	CITATIONS
16726	Multimodal treatment of radiation-induced esophageal cancer: Results of a case-matched comparative study from a single center. <i>International Journal of Surgery</i> , 2022, 99, 106268.	2.7	2
16727	Higher Pathological Complete Response Rate of Less than 10 Total Axillary Lymph Nodes After Axillary Lymph Node Dissection Following Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Surgery</i> , 2022, 9, 678169.	1.4	0
16728	The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. <i>Abdominal Radiology</i> , 2022, 47, 1725-1740.	2.1	4
16729	The Potential of Photoacoustic Imaging in Radiation Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 803777.	2.8	11
16730	Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in Primary and Secondary Liver Malignancies. <i>Journal of Personalized Medicine</i> , 2022, 12, 430.	2.5	7
16731	Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumors. <i>Immunotherapy</i> , 2022, , .	2.0	4
16732	Predictive molecular pathology in metastatic thyroid cancer: the role of <i>RET</i> fusions. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 167-178.	2.4	1
16733	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	2.8	5
16734	Efficacy and Adverse Events of Carboplatin Desensitisation Therapy for Gynaecological Cancer: A Retrospective Study. <i>Medicines (Basel, Switzerland)</i> , 2022, 9, 26.	1.4	3
16735	Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study. <i>Tomography</i> , 2022, 8, 644-656.	1.8	5
16736	Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 1788-1791.	1.6	1
16737	The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. <i>Cancer Discovery</i> , 2022, 12, 1266-1281.	9.4	67
16738	Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 344.e11-344.e17.	1.6	7
16739	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 289-300.e4.	16.8	148
16740	Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2022, 42, 2045-2051.	1.1	5
16741	Editorial to the Special Issue Entitled "Imaging in Immuno-oncology". <i>Molecular Imaging and Biology</i> , 2022, 24, 177-180.	2.6	1
16742	The Potential Prognostic Value of Dual-Imaging PET Parameters Based on ¹⁸ F-FDG and ¹⁸ F-OC for Neuroendocrine Neoplasms. <i>Molecular Imaging</i> , 2022, 2022, 6511179.	1.4	2
16743	Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 536-545.	1.8	5

#	ARTICLE	IF	CITATIONS
16744	Establishment of prognostic nomograms for predicting the progression free survival of <sc>EGFR</sc>-sensitizing mutation, advanced lung cancer patients treated with <sc>EGFR-TKIs</sc>. Thoracic Cancer, 2022, 13, 1289-1298.	1.9	1
16745	The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics, 2022, 12, 715.	2.6	4
16746	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 762-769.	3.9	13
16747	Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers, 2022, 14, 1354.	3.7	6
16748	Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy. European Radiology, 2022, 32, 5086-5096.	4.5	7
16749	Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan. Frontiers in Oncology, 2022, 12, 822375.	2.8	2
16750	Outcomes of Irreversible Electroporation for Perihilar Cholangiocarcinoma: A Prospective Pilot Study. Journal of Vascular and Interventional Radiology, 2022, 33, 805-813.e1.	0.5	7
16751	Preoperative immunotherapy for head and neck cancers: state of art. Current Opinion in Oncology, 2022, 34, 185-195.	2.4	10
16752	Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharmaceutical Research, 2022, 39, 511-528.	3.5	12
16753	Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma. Digestive Diseases, 2023, 41, 138-147.	1.9	4
16754	Contrast-free MRI quantitative parameters for early prediction of pathological response to neoadjuvant chemotherapy in breast cancer. European Radiology, 2022, 32, 5759-5772.	4.5	14
16755	Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. European Radiology, 2022, 32, 5156-5165.	4.5	4
16756	Response Prediction to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Delta-Radiomics Based on Sequential Whole-Tumor ADC Map. Frontiers in Oncology, 2022, 12, 787489.	2.8	3
16757	Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 487-497.	2.3	3
16758	Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors. Targeted Oncology, 2022, 17, 125-138.	3.6	4
16759	Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2022, 29, 5528-5538.	1.5	14
16760	Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Science, 2022, 113, 1808-1820.	3.9	10
16761	Evaluation of correlation between CD44, radiotherapy response, and survival rate in patients with advanced stage of head and neck squamous cell carcinoma (HNSCC). Cancer Medicine, 2022, 11, 1937-1947.	2.8	11

#	ARTICLE	IF	CITATIONS
16762	Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 782730.	2.8	4
16763	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. <i>Clinical and Experimental Immunology</i> , 2022, , .	2.6	1
16764	Clinical Impact of Pathologic Residual Tumor in Locally Advanced Cervical Cancer Patients Managed by Chemoradiotherapy Followed by Radical Surgery: A Large, Multicenter, Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4806-4814.	1.5	3
16765	Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100311.	1.1	2
16766	Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study. , 2022, 10, e004157.		19
16767	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	9.4	34
16768	Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1511.	3.7	5
16769	Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1059-1078.	2.0	0
16770	Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	2.5	6
16772	Single agent VS-6766 or VS-6766 plus defactinib in <i>KRAS</i> -mutant non-small-cell lung cancer: the RAMP-202 phase II trial. <i>Future Oncology</i> , 2022, 18, 1907-1915.	2.4	11
16773	Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. <i>Cancers</i> , 2022, 14, 1793.	3.7	3
16774	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. <i>Cancers</i> , 2022, 14, 1722.	3.7	26
16775	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.	5.4	18
16776	Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2 ⁺ advanced breast cancer in real-world clinical practice. <i>Annals of Translational Medicine</i> , 2022, 10, 362-362.	1.7	5
16777	Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 65-81.	2.5	22
16778	Pretreatment <i>HDL</i> and <i>ApoA1</i> are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with <i>TKI</i> . <i>Thoracic Cancer</i> , 2022, 13, 1126-1135.	1.9	4
16779	Clinical and analytical validation of FoundationOne [®] CDx, a comprehensive genomic profiling assay for solid tumors. <i>PLoS ONE</i> , 2022, 17, e0264138.	2.5	100
16780	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643.	3.7	55

#	ARTICLE	IF	CITATIONS
16781	Exploratory study of microparticle transcatheter arterial chemoembolization combined with resection for huge hepatocellular carcinoma. , 2022, 1, 35-42.		3
16782	Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. Frontiers in Molecular Biosciences, 2022, 9, 753318.	3.5	7
16783	Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase <scp>II</scp> study. Thoracic Cancer, 2022, , .	1.9	2
16784	Mediastinal lymph nodes segmentation using 3D convolutional neural network ensembles and anatomical priors guiding. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2023, 11, 44-58.	1.9	5
16785	METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedalscience, 0, 16, .	1.1	1
16786	Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2022, 71, 2511-2522.	4.2	43
16787	Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential. Cancers, 2022, 14, 1754.	3.7	7
16788	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nature Communications, 2022, 13, 1325.	12.8	31
16789	Prolonged progression-free survival achieved by octreotide <scp>LAR</scp> plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden. Cancer Medicine, 2022, 11, 2588-2600.	2.8	4
16790	FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation. Clinical Cancer Research, 2022, 28, 2733-2737.	7.0	20
16791	The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective. Nature Communications, 2022, 13, 1613.	12.8	12
16792	Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma. Future Oncology, 2022, , .	2.4	0
16793	Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers. Insights Into Imaging, 2022, 13, 46.	3.4	1
16794	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i>-mutant Melanoma. Clinical Cancer Research, 2022, 28, 3002-3010.	7.0	18
16795	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
16796	Phase IIÂclinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncology, 2022, 18, 2173-2191.	2.4	1
16797	18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers, 2022, 14, 1507.	3.7	3
16798	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918.	2.2	5

#	ARTICLE	IF	CITATIONS
16799	Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?. World Journal of Nuclear Medicine, 2022, 21, 34-43.	0.5	0
16800	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. Gynecologic Oncology, 2022, , .	1.4	2
16801	Transcriptional suppression of Dicer by HOXBâ€œAS3/EZH2 complex dictates sorafenib resistance and cancer stemness. Cancer Science, 2022, 113, 1601-1612.	3.9	8
16802	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma. JAMA Oncology, 2022, 8, 740.	7.1	12
16803	Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer. Archives of Gynecology and Obstetrics, 2022, 306, 875-885.	1.7	9
16804	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792.	1.1	50
16805	Artificial Intelligenceâ€œPowered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Nonâ€œSmall-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1916-1928.	1.6	94
16806	Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. Cancer Management and Research, 2022, Volume 14, 1179-1194.	1.9	8
16807	Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Langenbeck's Archives of Surgery, 2022, 407, 1911-1921.	1.9	2
16808	Selective Targeting of Protein Kinase C (PKC)-Î, Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers, 2022, 14, 1596.	3.7	3
16809	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. Radiology, 2022, 303, 664-672.	7.3	28
16810	Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. Cancers, 2022, 14, 1766.	3.7	6
16811	Progression-free survival: it is time for a new name. Lancet Oncology, The, 2022, 23, 328-330.	10.7	24
16812	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in Peopleâ€œs Republic of China. Journal of Thoracic Oncology, 2022, 17, 816-826.	1.1	15
16813	Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. Cancers, 2022, 14, 1465.	3.7	0
16814	Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene, 2022, 41, 2372-2389.	5.9	21
16815	Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer. JAMA Surgery, 2022, 157, 374.	4.3	88
16816	Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach. Gynecologic Oncology, 2022, 164, 535-542.	1.4	19

#	ARTICLE	IF	CITATIONS
16818	Population pharmacokinetics and exposureâ€“response of antiâ€“programmed cell death proteinâ€“1 monoclonal antibody dostarlimab in advanced solid tumours. British Journal of Clinical Pharmacology, 2022, 88, 4142-4154.	2.4	11
16819	Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3+ T regulatory cells in colorectal cancer. BMC Gastroenterology, 2022, 22, 122.	2.0	3
16820	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. PLoS ONE, 2022, 17, e0265235.	2.5	4
16821	The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer. Archives of Gynecology and Obstetrics, 2022, 306, 1665-1672.	1.7	6
16822	Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial. BMC Cancer, 2022, 22, 277.	2.6	1
16823	Prognostic impact of inter-metastatic heterogeneity of viable tumour cells in colorectal liver metastases. European Journal of Surgical Oncology, 2022, , .	1.0	0
16824	A global perspective in <scp>secondâ€“line</scp> treatment patterns for patients with advanced esophageal squamous cell carcinoma. Thoracic Cancer, 2022, 13, 1240-1257.	1.9	4
16825	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. European Journal of Cancer, 2022, 167, 142-148.	2.8	32
16826	Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Radiology, 2022, 303, 548-556.	7.3	10
16827	Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma. American Journal of Roentgenology, 2022, 218, 867-876.	2.2	6
16828	Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patientsâ€™ Survival: A Randomized Controlled Trial. Medicina (Lithuania), 2022, 58, 394.	2.0	0
16829	Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatinâ€“ineligible renal dysfunction: A retrospective study. Oncology Letters, 2022, 23, .	1.8	2
16830	Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas. Cancers, 2022, 14, 1482.	3.7	5
16831	Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea. Gynecologic Oncology, 2022, 165, 369-375.	1.4	6
16832	Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma. Current Oncology, 2022, 29, 2240-2251.	2.2	12
16833	Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3203-3214.	6.4	8
16834	Predicting pathological response of locally advanced breast cancer to neoadjuvant chemotherapy: comparing the performance of whole body 18F-FDG PETCT versus DCE-MRI of the breast. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.6	1
16835	eEF2K promotes PD-L1 stabilization through inactivating GSK3Î² in melanoma. , 2022, 10, e004026.		11

#	ARTICLE	IF	CITATIONS
16836	Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 838870.	2.8	4
16837	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. <i>Frontiers in Pharmacology</i> , 2022, 13, 803935.	3.5	8
16838	Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?. <i>Anticancer Research</i> , 2022, 42, 1987-1995.	1.1	2
16839	Impact of Modern Management Strategies on the Clinical Outcome of Patients With Low Rectal Cancer – A Retrospective, Monocentric Cohort Study. <i>Anticancer Research</i> , 2022, 42, 1949-1963.	1.1	1
16840	Challenges of Systemic Therapy Investigations for Bone Sarcomas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3540.	4.1	11
16841	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 762-771.	1.6	71
16842	Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients. <i>World Journal of Clinical Cases</i> , 2022, 10, 3389-3400.	0.8	1
16843	Successful treatment of immune-related cystitis by Chai-Ling-Tang (Sairei-To) in a gastric carcinoma patient: Case report and literature review. <i>Explore: the Journal of Science and Healing</i> , 2023, 19, 458-462.	1.0	6
16844	Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. <i>Oral Oncology</i> , 2022, 127, 105787.	1.5	10
16845	An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up. <i>Annals of Nuclear Medicine</i> , 2022, , 1.	2.2	1
16846	A review on the added value of whole-body MRI in metastatic lobular breast cancer. <i>European Radiology</i> , 2022, 32, 6514-6525.	4.5	8
16847	Percutaneous Radiofrequency Ablation Is an Effective Method for Local Control of Liver Metastases From Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 877273.	2.8	2
16848	Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption. <i>Biomaterials</i> , 2022, 283, 121416.	11.4	13
16849	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	4.4	12
16850	Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. , 2022, 10, e004656.		59
16851	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSC) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
16852	Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+ HER2+ Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy. <i>Journal of Breast Imaging</i> , 2022, 4, 273-284.	1.3	4
16853	A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers. <i>Oral Oncology</i> , 2022, 127, 105798.	1.5	8

#	ARTICLE	IF	CITATIONS
16854	The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13112.	2.6	1
16855	Impact of HPV status on immune responses in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 127, 105774.	1.5	11
16856	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.	1.4	14
16857	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
16858	Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spatalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2313-2320.	7.0	28
16859	Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: Radiomics analysis of pretreatment computed tomography. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 56-64.	2.5	15
16860	Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. <i>Dermatologic Therapy</i> , 2022, , e15472.	1.7	1
16861	The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 871675.	2.8	9
16862	Acquisition repeatability of MRI radiomics features in the head and neck: a dual-3D-sequence multi-scan study. <i>Visual Computing for Industry, Biomedicine, and Art</i> , 2022, 5, 10.	3.7	6
16863	Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103650.	4.4	4
16864	Fully automated longitudinal tracking and in-depth analysis of the entire tumor burden: unlocking the complexity. , 2022, , .		0
16865	Effects of feature type and multiple scanners on brain metastasis stereotactic radiosurgery outcome prediction. , 2022, , .		0
16866	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	6.4	48
16867	Satisfaction of search (SOS) error and new lesions identification on imaging in central review for clinical trials. , 2022, , .		0
16868	Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1783-1791.	7.0	3
16869	Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non-small cell lung cancer: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
16870	Visual Symptoms Outcomes in Cavernous Sinus Radiosurgery and a Systematic Review. <i>Cureus</i> , 2022, 14, e23928.	0.5	0
16871	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2022, 6, 23.	5.4	17

#	ARTICLE	IF	CITATIONS
16872	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
16873	Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, , .	1.5	0
16874	Long-term survival of two patients with inoperable post-irradiation osteosarcoma treated with carbon-ion radiotherapy: a case report. <i>Radiation Oncology</i> , 2022, 17, 68.	2.7	0
16875	DICE: Dual mTORC Inhibition in advanced/recurrent Epithelial ovarian cancer resistant to standard treatment—a study protocol for a randomised trial investigating a novel therapy called TAK228. <i>Trials</i> , 2022, 23, 261.	1.6	3
16876	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2235-2245.	1.6	21
16877	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	1.3	0
16878	Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. <i>Clinical Nuclear Medicine</i> , 2022, 47, e437-e443.	1.3	2
16879	Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer. <i>Cancers</i> , 2022, 14, 1837.	3.7	17
16880	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1479-1489.	1.9	6
16881	A phase I study of talazoparib (<sc>BMN</sc> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<sc>NCI9782</sc>). <i>Cancer Medicine</i> , 2022, 11, 3969-3981.	2.8	11
16882	Identifying Biomarkers of Cisplatin Sensitivity in Non-Small Cell Lung Cancer <i>via</i> Comprehensive Integrative Analysis. <i>Current Bioinformatics</i> , 2022, 17, 498-509.	1.5	1
16883	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2237-2247.	7.0	16
16884	Interobserver and intraobserver variability of RECIST assessment in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 656-661.	2.5	2
16885	Current status of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression. <i>Cancer Science</i> , 2022, , .	3.9	1
16886	Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. <i>Molecular Oncology</i> , 2022, 16, 2575-2584.	4.6	8
16887	Clinical Biology of the Pituitary Adenoma. <i>Endocrine Reviews</i> , 2022, 43, 1003-1037.	20.1	81
16888	A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece. <i>Cancers</i> , 2022, 14, 1879.	3.7	3
16889	Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis: A Case Report. <i>Case Reports in Oncology</i> , 0, , 388-393.	0.7	1

#	ARTICLE	IF	CITATIONS
16890	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	12.8	3
16891	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	5.4	13
16892	The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery. Gynecologic Oncology, 2022, 165, 453-458.	1.4	6
16893	Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center. Gynecologic Oncology, 2022, 165, 478-485.	1.4	3
16894	Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer. Current Issues in Molecular Biology, 2022, 44, 1552-1563.	2.4	3
16895	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Npj Breast Cancer, 2022, 8, 45.	5.2	16
16896	Clinical outcomes after positron emission tomography/computed tomography-based image-guided brachytherapy for cervical cancer. Asia-Pacific Journal of Clinical Oncology, 2022, , .	1.1	2
16897	Modern Linear Accelerator-Based Radiotherapy Is Safe and Effective in the Treatment of Secretory and Nonsecretory Pituitary Adenomas. World Neurosurgery, 2022, 160, e33-e39.	1.3	1
16898	Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation. Molecular Cancer, 2022, 21, 91.	19.2	6
16899	Stem cell transplant for mantle cell lymphoma in Taiwan. Scientific Reports, 2022, 12, 5662.	3.3	3
16900	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
16901	Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clinical Cancer Research, 2022, , .	7.0	0
16902	Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors. Dermato, 2022, 2, 14-20.	0.9	3
16903	Dual energy CT applications in oncological imaging. Seminars in Ultrasound, CT and MRI, 2022, 43, 344-351.	1.5	2
16904	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NG). Neuro-Oncology, 2022, 24, 1776-1789.	1.2	37
16905	Recent advances and clinical applications of deep learning in medical image analysis. Medical Image Analysis, 2022, 79, 102444.	11.6	215
16906	Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Lung Cancer, 2022, 167, 49-57.	2.0	7
16907	MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG. European Journal of Cancer, 2022, 167, 32-41.	2.8	9

#	ARTICLE	IF	CITATIONS
16908	Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2022, 166, 208-218.	2.8	16
16909	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80.	2.8	19
16910	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. <i>Current Problems in Cancer</i> , 2022, 46, 100848.	2.0	5
16911	Prognostic value of pre-operative systemic immune-inflammation index and platelet to lymphocyte ratio in peritoneal carcinomatosis of ovarian origin. <i>Surgical Oncology</i> , 2022, 42, 101750.	1.6	8
16912	Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 219, 106785.	4.7	6
16913	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. <i>Breast</i> , 2022, 63, 85-100.	2.2	5
16914	Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. <i>JCO Precision Oncology</i> , 2021, 5, 1813-1820.	3.0	5
16915	ANALYSIS OF TREATMENT OUTCOMES IN LOCALLY ADVANCED CERVICAL CARCINOMA - AN INSTITUTIONAL STUDY. , 2021, , 55-57.		0
16916	Deformable Dilated Faster R-CNN for Universal Lesion Detection in CT Images. , 2021, 2021, 2896-2902.		2
16917	Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e346-e352.	1.9	5
16918	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. <i>Hepatology Research</i> , 2022, 52, 298-307.	3.4	31
16919	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	7.7	25
16920	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	2.8	14
16921	An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. <i>Annals of Nuclear Medicine</i> , 2022, 36, 267-278.	2.2	5
16922	A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 40-59.	0.8	14
16923	Discovering novel mechanisms of taxane resistance in human breast cancer by whole-exome sequencing. <i>Oncology Letters</i> , 2021, 23, 60.	1.8	1
16924	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205.	4.1	26
16925	Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers. <i>Molecular and Clinical Oncology</i> , 2021, 16, 52.	1.0	3

#	ARTICLE	IF	CITATIONS
16926	Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3123-3132.	1.4	1
16927	Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 647-656.	2.5	6
16928	Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer. Respiratory Research, 2021, 22, 322.	3.6	26
16930	Automatic Segmentation of Metastatic Breast Cancer Lesions on 18F-FDG PET/CT Longitudinal Acquisitions for Treatment Response Assessment. Cancers, 2022, 14, 101.	3.7	14
16931	A Clinicalâ€“Radiomics Model for Predicting Axillary Pathologic Complete Response in Breast Cancer With Axillary Lymph Node Metastases. Frontiers in Oncology, 2021, 11, 786346.	2.8	10
16932	PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110642.	1.2	2
16933	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdominal Radiology, 2022, 47, 969-980.	2.1	11
16934	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neuro-Oncology Advances, 2022, 4, vdab188.	0.7	9
16935	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. British Journal of Cancer, 2022, 126, 1018-1026.	6.4	11
16936	Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer. Cancer Management and Research, 2021, Volume 13, 9297-9304.	1.9	4
16937	Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies. Biomedicines, 2021, 9, 1929.	3.2	17
16938	Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer. In Vivo, 2022, 36, 409-415.	1.3	3
16939	Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. Statistics in Medicine, 2022, 41, 751-768.	1.6	3
16940	Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. , 2021, 9, e003645.		23
16941	Contact X-ray Brachytherapy for Older or Inoperable Rectal Cancer Patients: Short-Term Oncological and Functional Follow-Up. Cancers, 2021, 13, 6333.	3.7	8
16942	First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. British Journal of Cancer, 2022, 126, 1010-1017.	6.4	8
16943	Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer. Anticancer Research, 2022, 42, 349-353.	1.1	2
16944	Natural Changes in Radiological and Radiomics Features on <scp>MRIs</scp> of <scp>Softâ€“Tissue</scp> Sarcomas Naïve of Treatment: Correlations With Histology and Patients' Outcomes. Journal of Magnetic Resonance Imaging, 2022, 56, 77-96.	3.4	10

#	ARTICLE	IF	CITATIONS
16945	Outcomes of Gamma Knife Radiosurgery for Brain Metastases From Anaplastic Lymphoma Kinase Rearrangement-Positive and EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e20398.	0.5	3
16946	Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria. <i>Frontiers in Oncology</i> , 2021, 11, 764189.	2.8	12
16947	Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report. <i>Meditinskiy Sovet</i> , 2021, , 124-128.	0.5	1
16948	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2046-2049.e3.	0.7	8
16949	Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis. <i>Cancer Medicine</i> , 2022, 11, 1088-1098.	2.8	4
16950	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. <i>Molecular Oncology</i> , 2022, 16, 2042-2056.	4.6	8
16951	Cyberknife Radiosurgery for the Treatment of Head and Neck Cancer: A Systematic Review. <i>European Journal of Dentistry</i> , 2022, 16, 266-273.	1.7	2
16952	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. <i>Cancer Cell International</i> , 2021, 21, 675.	4.1	9
16953	<scp>MRI-Based</scp> Back Propagation Neural Network Model as a Powerful Tool for Predicting the Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 547-559.	3.4	14
16954	Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2022, 6, 29-35.	1.6	6
16955	Clinical and prognostic significance of CD14 (+) HLA-DR (high/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13132.	2.7	4
16956	ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. <i>Journal of the ICRU</i> , 2021, 21, 1-212.	15.5	52
16957	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. <i>Cancers</i> , 2021, 13, 6210.	3.7	19
16958	Brain Metastases from Adult Sarcomas: A Retrospective Cohort Study from the Hellenic Group of Sarcomas and Rare Cancers (HGSRC). <i>Journal of Clinical Medicine</i> , 2021, 10, 5978.	2.4	4
16959	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. <i>Cancers</i> , 2021, 13, 6096.	3.7	14
16960	NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	3.4	26
16961	Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 6266.	3.7	9
16962	Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review. <i>Anticancer Research</i> , 2022, 42, 13-24.	1.1	4

#	ARTICLE	IF	CITATIONS
16963	Imaging evaluation of the liver in oncology patients: A comparison of techniques. World Journal of Hepatology, 2021, 13, 1936-1955.	2.0	6
16964	Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1348-e1355.	3.6	5
16965	Neoadjuvant <scp>PD</scp>-inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung. Thoracic Cancer, 2022, 13, 442-452.	1.9	4
16966	Multivariable Models Based on Baseline Imaging Features and Clinicopathological Characteristics to Predict Breast Pathologic Response after Neoadjuvant Chemotherapy in Patients with Breast Cancer. Breast Care, 0, , 1-10.	1.4	0
16967	Is Long-Term Survival in Metastases from Neuroendocrine Neoplasms Improved by Liver Resection?. Medicina (Lithuania), 2022, 58, 22.	2.0	2
16968	Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy. Frontiers in Oncology, 2021, 11, 770230.	2.8	2
16969	Clinical Significance of Expression of Immunoadojuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer. Anticancer Research, 2022, 42, 125-136.	1.1	6
16970	CircRNA_0044556 diminishes the sensitivity of triple-negative breast cancer cells to adriamycin by sponging miR-145 and regulating NRAS. Molecular Medicine Reports, 2021, 25, .	2.4	9
16971	The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance. International Journal of Molecular Sciences, 2022, 23, 392.	4.1	15
16972	Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma. South Asian Journal of Cancer, 0, , .	0.6	0
16973	Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1). Frontiers in Oncology, 2021, 11, 769037.	2.8	1
16974	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 2022, 28, 851-859.	7.0	90
16975	Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.2	0
16976	Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions?. Molecular and Clinical Oncology, 2021, 16, 29.	1.0	2
16977	Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1700-1710.	6.4	10
16979	Not so "rare" - an example of malignant melanoma in India: report from a tertiary cancer centre. Ecancermedicalscience, 2021, 15, 1335.	1.1	1
16980	Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy. Chinese Medical Journal, 2022, 135, 333-340.	2.3	4
16981	Pitfalls in the diagnosis of yolk sac tumor: Lessons from a clinical trial. Pediatric Blood and Cancer, 2022, 69, e29451.	1.5	1

#	ARTICLE	IF	CITATIONS
16982	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , 2021, 13, 6141.	3.7	11
16983	Effect of Xiaoyutang Combined with Intraperitoneal Heat Perfusion Chemotherapy on Immune Function, Circulating mir, Prognosis, and Survival of Postoperative Patients with Colorectal Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-7.	1.3	4
16984	Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis. <i>Cancers</i> , 2022, 14, 57.	3.7	23
16985	Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung). <i>Journal of Immunotherapy</i> , 2022, 45, 89-99.	2.4	2
16986	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	6.4	5
16987	[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2010-2022.	6.4	11
16988	The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 315-323.	1.2	4
16989	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria – Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	3.4	25
16990	Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version). <i>Acta Hepatologica Japonica</i> , 2021, 62, 823-829.	0.1	2
16991	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	3.7	5
16992	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in <scp>China</scp>. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	1.9	19
16993	Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis. <i>Future Science OA</i> , 2021, 7, FSO750.	1.9	5
16994	Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice. <i>Frontiers in Oncology</i> , 2021, 11, 791946.	2.8	1
16995	Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10483-10493.	1.8	9
16996	A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 752504.	2.8	10
16997	Prognostic role of computed tomography-based, artificial intelligence-driven waist skeletal muscle volume in uterine endometrial carcinoma. <i>Insights Into Imaging</i> , 2021, 12, 192.	3.4	7
16998	Serial CT changes in different components of lung cancer associated with cystic airspace in patients treated with neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2021, 11, 23544.	3.3	1
16999	Comprehensive Imaging Characterization of Colorectal Liver Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 730854.	2.8	7

#	ARTICLE	IF	CITATIONS
17000	Clinical Significance of Sarcopenia in Patients with Advanced Hepatocellular Carcinoma Undergoing Sorafenib Treatment. , 2021, 13, 62-67.		1
17001	Association between Foxp3 Tumor Infiltrating Lymphocyte Expression and Response After Chemoradiation in Nasopharyngeal Carcinoma. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 1285-1291.	0.2	0
17003	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical Cancer Research, 2022, 28, 1363-1371.	7.0	2
17006	Analysis of the efficacy and safety of paclitaxel (albumin-bound) combined with S-1 and oxaliplatin combined with S-1 in the first-line treatment of advanced gastric cancer: a cohort study. Journal of Gastrointestinal Oncology, 2022, 13, 630-636.	1.4	1
17007	Real-World Outcomes with Ipilimumab and Nivolumab in Advanced Melanoma: A Multicentre Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
17008	Virtual Populations for Quantitative Systems Pharmacology Models. Methods in Molecular Biology, 2022, 2486, 129-179.	0.9	13
17009	Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy. Wspolczesna Onkologia, 2022, 26, 69-77.	1.4	2
17010	A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210875.	3.2	4
17011	Implication of <i>VEGFR2</i> Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study. Technology in Cancer Research and Treatment, 2022, 21, 153303382210809.	1.9	0
17012	OUP accepted manuscript. Gastroenterology Report, 2022, 10, goac016.	1.3	2
17013	Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nature Medicine, 2022, 28, 545-556.	30.7	167
17014	Sarcopenia. Pancreas, 2022, 51, 148-152.	1.1	10
17015	Clinical characteristics and treatment outcomes of primary malignant melanoma of esophagus: a single center experience. BMC Gastroenterology, 2022, 22, 157.	2.0	6
17016	Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab. Frontiers in Oncology, 2022, 12, 848129.	2.8	3
17017	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). Oncoimmunology, 2022, 11, 2066609.	4.6	13
17018	A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Frontiers in Immunology, 2022, 13, 845417.	4.8	3
17019	Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study. International Journal of General Medicine, 2022, Volume 15, 3977-3989.	1.8	4
17020	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine, 2022, 14, eabm6420.	12.4	29

#	ARTICLE	IF	CITATIONS
17021	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	7.0	31
17022	The Need for Medical Artificial Intelligence That Incorporates Prior Images. <i>Radiology</i> , 2022, 304, 283-288.	7.3	17
17023	Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol. <i>BMJ Open</i> , 2022, 12, e060900.	1.9	0
17024	Progress in neoadjuvant therapy for gastric cancer (Review). <i>Oncology Letters</i> , 2022, 23, 172.	1.8	2
17025	Application of SPECT and PET / CT with computer-aided diagnosis in bone metastasis of prostate cancer: a review. <i>Cancer Imaging</i> , 2022, 22, 18.	2.8	4
17026	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	7.0	32
17027	A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptorâ€‘targeting Agent. <i>Clinical Cancer Research</i> , 2022, 28, 2789-2795.	7.0	17
17028	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. <i>Advances in Therapy</i> , 2022, 39, 2831-2849.	2.9	5
17029	Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 751-759.	2.3	5
17030	Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2022, 52, 630-640.	3.4	25
17031	Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant nonâ€‘small cell lung cancer: A multicenter retrospective analysis (<scp>TOPGAN2020</scp>â€‘02). <i>Thoracic Cancer</i> , 2022, 13, 1471-1478.	1.9	5
17032	Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China. <i>Pediatric Surgery International</i> , 2022, , 1.	1.4	0
17033	Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1241-1247.	2.5	1
17034	<scp>Realâ€‘world</scp> efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	4
17035	Real-world comparison of healthcare resource utilization and costs of [¹⁷⁷ Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the Hospital Episode Statistics dataset. <i>Current Medical Research and Opinion</i> , 2022, , 1-33.	1.9	0
17036	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. <i>Cancer Discovery</i> , 2022, 12, 1248-1265.	9.4	36
17037	[Translated article] Vismodegib y sonidegib en el carcinoma de c�lulas basales localmente avanzado y metast�sico: actualizaci�n acerca de los inhibidores de la v�a de Hedgehog. <i>Actas Dermo-sifiliogr�ficas</i> , 2022, , .	0.4	0
17038	iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	1

#	ARTICLE	IF	CITATIONS
17039	Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2436-2446.	1.6	24
17040	Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary Study on Assessment of Tumor Aggressiveness and Response to Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 638.	2.5	6
17041	A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. <i>Investigational New Drugs</i> , 2022, 40, 747-755.	2.6	10
17042	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	4.1	12
17043	Predictors of maximum efficacy of lenvatinib for real-world patients with differentiated thyroid carcinoma. <i>Surgery Today</i> , 2022, 52, 1660-1669.	1.5	2
17044	Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. <i>Acta Oncologica</i> , 2022, 61, 705-713.	1.8	2
17045	Locally advanced cervical carcinoma patients treated with chemoradiation followed by radical surgery: clinical response and oncological outcomes according to histotype after propensity score analysis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 2045-2052.	1.0	2
17047	Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1164-1172.	2.2	5
17048	Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 485-491.	1.3	3
17049	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 830627.	2.8	2
17050	Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands. <i>World Journal of Urology</i> , 2022, , 1.	2.2	0
17051	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 780186.	2.8	8
17053	Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. <i>JGH Open</i> , 2022, 6, 301-308.	1.6	7
17054	Palliative radiotherapy: a one-week course in advanced head and neck cancer – quality of life outcomes. <i>BMJ Supportive and Palliative Care</i> , 2022, , bmjspcare-2021-002908.	1.6	1
17055	Surgery in platinum-resistant recurrent epithelial ovarian carcinoma. <i>World Journal of Clinical Cases</i> , 2022, 10, 3739-3753.	0.8	0
17056	Treatment efficacy and prognosis analysis in locally advanced or metastatic colorectal cancer patients with hydronephrosis. <i>Molecular and Clinical Oncology</i> , 2022, 16, .	1.0	2
17057	Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T. <i>Biomedicines</i> , 2022, 10, 946.	3.2	6
17058	Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 716-724.	1.3	6

#	ARTICLE	IF	CITATIONS
17059	AKT mutant allele-specific activation dictates pharmacologic sensitivities. <i>Nature Communications</i> , 2022, 13, 2111.	12.8	10
17060	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. <i>Investigational New Drugs</i> , 2022, 40, 782-788.	2.6	5
17061	PET-CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients. <i>Advanced Materials</i> , 2022, 34, e2201043.	21.0	19
17062	Curative remnant total pancreatectomy for recurrent pancreatic acinar cell carcinoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2022, 94, 107091.	0.6	2
17063	Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial. <i>European Journal of Cancer</i> , 2022, 167, 112-122.	2.8	35
17064	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24.	2.8	9
17149	Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study. <i>Cancer Medicine</i> , 2022, , .	2.8	3
17150	Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29739.	1.5	4
17151	The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. <i>Targeted Oncology</i> , 2022, 17, 295-306.	3.6	7
17152	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. <i>Targeted Oncology</i> , 2022, 17, 307-319.	3.6	4
17153	Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer. <i>Pharmacological Research</i> , 2022, 179, 106232.	7.1	8
17154	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	30.7	38
17155	Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2022, , 1-5.	0.9	1
17156	Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1642-1650.	1.9	1
17157	Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. <i>BMJ Case Reports</i> , 2020, 13, e236242.	0.5	5
17158	Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e055273.	1.9	0
17159	Space-Making Particle Therapy for Unresectable Hilar Cholangiocarcinoma. <i>Digestive Surgery</i> , 2022, 39, 99-108.	1.2	5
17161	Simultaneous or staged resection for synchronous liver metastasis and primary rectal cancer: a propensity score matching analysis. <i>BMC Gastroenterology</i> , 2022, 22, 201.	2.0	2

#	ARTICLE	IF	CITATIONS
17165	The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer. Tumori, 2011, 97, 704-10.	1.1	2
17166	Response to concurrent chemoradiotherapy as a prognostic marker in elderly patients with locally advanced esophageal cancer. Tumori, 2012, 98, 225-32.	1.1	5
17167	Curative radiotherapy using different radiation techniques for isolated lung metastasis from colorectal cancer. Tumori, 2013, 99, 68-75.	1.1	2
17168	Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature. Tumori, 2013, 99, e172-6.	1.1	6
17169	Salvage stereotactic re-irradiation with CyberKnife for locally recurrent head and neck cancer: a single center experience. Tumori, 2014, 100, 278-83.	1.1	6
17170	From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. Tumori, 2011, 97, 160-5.	1.1	8
17171	The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation. Acta Medica Okayama, 2013, 67, 105-12.	0.2	6
17172	Aggressive multimodality treatment for advanced rectal cancer. Acta Medica Okayama, 2015, 69, 113-8.	0.2	0
17173	Evaluation of Treatment Response in Prostate Cancer and Renal Cell Carcinoma Patients Using 11C-choline PET/CT Findings. Acta Medica Okayama, 2019, 73, 341-347.	0.2	1
17176	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. Nagoya Journal of Medical Science, 2021, 83, 827-840.	0.3	6
17183	Using ⁶⁸ Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice. Journal of Nuclear Medicine, 2022, 63, 1815-1821.	5.0	8
17211	On independent data monitoring committees in oncology clinical trials. Chinese Clinical Oncology, 2014, 3, 40.	1.2	7
17212	Phase III design: principles. Chinese Clinical Oncology, 2016, 5, 10.	1.2	3
17213	Design and statistical principles of the SHIVA trial. Chinese Clinical Oncology, 2015, 4, 32.	1.2	1
17214	Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study. Chinese Clinical Oncology, 2015, 4, 39.	1.2	5
17216	Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastoma. Indian Journal of Nuclear Medicine, 2010, 25, 147.	0.3	6
17217	Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment). Nuclear Medicine Review, 2012, 15, 52-60.	0.5	14
17220	dNLR and TILS can be used as indicators for prognosis and efficacy evaluation of neo-adjuvant chemotherapy in breast cancer.. American Journal of Translational Research (discontinued), 2021, 13, 13093-13098.	0.0	0

#	ARTICLE	IF	CITATIONS
17221	Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.. American Journal of Cancer Research, 2021, 11, 6173-6187.	1.4	0
17222	Efficacy of ifosfamide combined with liposome doxorubicin on osteosarcoma and its effects on serum IL-10, TNF- α , and IFN- γ in patients with osteosarcoma.. American Journal of Translational Research (discontinued), 2022, 14, 1288-1296.	0.0	0
17223	Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes.. AMIA ... Annual Symposium proceedings, 2021, 2021, 716-725.	0.2	0
17225	Melanoma: An immunotherapyÂjourney from bench to bedside. Cancer Treatment and Research, 2022, 183, 49-89.	0.5	0
17226	Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis. SSRN Electronic Journal, 0, , .	0.4	0
17227	Subjective and perceptive assessment of speech/voice and swallowing function before and after radiation therapy in patients of head-and-neck squamous cell cancer. Journal of Cancer Research and Therapeutics, 2022, .	0.9	0
17228	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210948.	3.2	2
17230	Soluble Periostin is a Potential Biomarker for Chemotherapy Efficacy Monitoring in Advanced Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	0
17231	Natural Products That Target Cancer Stem Cells. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 169-186.	0.1	0
17232	Improved overall survival in dual compared to single immune checkpoint inhibitors in <i>BRAF</i> ^{V600} -negative advanced melanoma. Melanoma Management, 2022, 9, MMT60.	0.5	1
17233	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics. Cancers, 2022, 14, 2080.	3.7	6
17234	Immortal Time Bias-Corrected Effectiveness of Traditional Chinese Medicine in Non-Small Cell Lung Cancer (C-EVID): A Prospective Cohort Study. Frontiers in Oncology, 2022, 12, 845613.	2.8	3
17235	Phase 2 study of firstâ€line pembrolizumab monotherapy in elderly patients with nonâ€smallâ€cell lung cancer expressing high ^{PD-L1}. Thoracic Cancer, 2022, 13, 1611-1618.	1.9	4
17236	Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. Translational Lung Cancer Research, 2022, 11, 670-685.	2.8	13
17237	Novel Carbon Ion and Proton Partial Irradiation of Recurrent Unresectable Bulky Tumors (Particle-PATHY): Early Indication of Effectiveness and Safety. Cancers, 2022, 14, 2232.	3.7	7
17238	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Pharmaceuticals, 2022, 15, 533.	3.8	5
17239	Tumour burden score and immuneâ€related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	1.3	0
17240	Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial. Anticancer Research, 2022, 42, 2683-2687.	1.1	3

#	ARTICLE	IF	CITATIONS
17241	Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study. <i>Anticancer Research</i> , 2022, 42, 2783-2790.	1.1	2
17242	Impact of Cyto-reductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 2727-2735.	1.1	14
17243	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. <i>Genome Medicine</i> , 2022, 14, 45.	8.2	73
17244	Activity of Pemigatinib in Pilocytic Astrocytoma and <i>FGFR1</i> N546K Mutation. <i>JCO Precision Oncology</i> , 2022, 6, e2100371.	3.0	4
17245	CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, 428-437.	2.6	3
17246	Prognosis for Metastatic Colorectal Cancer Patients Achieving Complete Response After Systemic Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2022, , .	1.3	0
17247	Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort. <i>Medicina (Lithuania)</i> , 2022, 58, 607.	2.0	0
17248	Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report. <i>Translational Cancer Research</i> , 2022, 11, 973-979.	1.0	3
17249	Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. <i>Clinical Lung Cancer</i> , 2022, 23, 386-392.	2.6	15
17250	Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. <i>Communications Medicine</i> , 2022, 2, .	4.2	26
17251	Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, 6906.	3.3	4
17252	Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy10 for Non-bone Oligometastases. <i>Advances in Radiation Oncology</i> , 2022, 7, 100978.	1.2	5
17253	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ~CaboGIST™. <i>Acta Oncol</i> gica, 2022, 61, 663-668.	1.8	1
17254	Protective Effect of Alkaline Phosphatase Supplementation on Infant Health. <i>Foods</i> , 2022, 11, 1212.	4.3	7
17255	Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 617-631.	2.8	12
17256	Lymph Node Diameter as a Predictor of Lymph Node Metastasis in Patients with Colorectal Neuroendocrine Neoplasms. <i>Journal of the Anus, Rectum and Colon</i> , 2022, 6, 129-133.	1.1	2
17257	Concurrent Weekly Cisplatin and Simultaneous Integrated Boost-IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma~An Institutional Experience. <i>South Asian Journal of Cancer</i> , 0, , .	0.6	0
17258	Interleukin-15 augments NK cell~mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies. <i>Blood Advances</i> , 2023, 7, 384-394.	5.2	8

#	ARTICLE	IF	CITATIONS
17259	A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. <i>Frontiers in Oncology</i> , 2022, 12, 842281.	2.8	1
17260	Quantitative ultrasonography as a tool for the evaluation of breast tumor response to neoadjuvant chemotherapy. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ-SzopiÅska</i> , 2022, 22, 86-92.	1.2	0
17261	Sequential treatment of severe airway stenosis caused by esophageal cancer by using airway stent implantation and arterial infusion chemotherapy. <i>Scientific Reports</i> , 2022, 12, 6918.	3.3	0
17262	Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma. <i>Frontiers in Urology</i> , 2022, 2, .	0.5	1
17263	Apparent Diffusion Coefficient <scp>MRI</scp> Shows Association With Early Progression of Unresectable Intrahepatic Cholangiocarcinoma With Combined Targetedâ€œImmuno-therapy. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 275-284.	3.4	5
17264	Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100461.	3.0	2
17265	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 3180-3189.	1.6	29
17267	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	7.0	10
17268	Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival. <i>Cancers</i> , 2022, 14, 2225.	3.7	1
17269	A case of melanoma of the mandibular gingiva with long-term survival: Effect of nivolumab therapy and immuno-radiotherapy for cervical recurrence and nasal metastasis. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2022, , .	0.3	0
17270	Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals. <i>Cancers</i> , 2022, 14, 2114.	3.7	2
17271	Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series. <i>Frontiers in Pharmacology</i> , 2022, 13, 912153.	3.5	4
17272	Prognostic implication of serum Alpha-fetoprotein response to neoadjuvant chemotherapy in Hepatoblastoma patients. <i>International Journal of Health Sciences</i> , 0, , 5464-5471.	0.1	0
17273	Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach. <i>Biology</i> , 2022, 11, 660.	2.8	3
17274	Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. <i>Clinical Lung Cancer</i> , 2022, 23, 477-486.	2.6	10
17275	Chemotherapy-induced Reversion of Mutant <i>RAS</i> to Wild-type <i>RAS</i> in Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2022, 42, 2625-2635.	1.1	2
17276	Effectiveness of Pembrolizumab in Patients with HNSCC in Japanese Real-World Clinical Practice. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 78-79.	0.0	0
17277	Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. <i>Disease Markers</i> , 2022, 2022, 1-10.	1.3	2

#	ARTICLE	IF	CITATIONS
17278	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. <i>Journal of Personalized Medicine</i> , 2022, 12, 726.	2.5	2
17279	Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, Publish Ahead of Print, .	0.6	0
17280	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100332.	1.1	15
17281	Rectal adenocarcinoma with synchronous liver metastasis: robotic liver and rectal resection with partial mesorectal excision. A video correspondence.. <i>Colorectal Disease</i> , 2022, , .	1.4	0
17282	Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2354.	3.7	4
17283	Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, 160.	5.5	10
17284	Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. <i>Cancer Management and Research</i> , 2022, Volume 14, 1641-1651.	1.9	6
17285	MRI as a biomarker for breast cancer diagnosis and prognosis. <i>BJR Open</i> , 2022, 4, .	0.6	4
17286	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	7.0	15
17287	Deciphering radiological stable disease to immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2022, 33, 824-835.	1.2	21
17288	Neoadjuvant therapy in pancreatic ductal adenocarcinoma: a competing risk analysis. <i>Surgical Practice</i> , 0, , .	0.2	0
17289	A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints. <i>Biometrics</i> , 2023, 79, 1459-1471.	1.4	1
17290	Association between epidermal growth factor receptor gene mutation status and short-term efficacy of first-line platinum-containing chemotherapy in advanced non-small cell lung cancer. <i>Biomedical Reports</i> , 2022, 17, .	2.0	0
17291	Can RECIST 1.1 Criteria Provide a Solution to the Achilles' Heel in the Management of Medication-Related Osteonecrosis of Jaws?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2022, , .	1.2	0
17292	Survival Outcomes and Treatment Patterns in Patients with NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	2
17293	A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer. <i>Surgery Today</i> , 2022, , 1.	1.5	1
17294	Toripalimab in advanced biliary tract cancer. <i>Innovation(China)</i> , 2022, 3, 100255.	9.1	4
17295	A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 415-422.	1.9	1

#	ARTICLE	IF	CITATIONS
17296	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396.	3.7	8
17297	Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
17298	The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 2133-2142.	1.7	4
17299	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 523-545.	6.7	2
17300	Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	0
17301	In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3841-3851.	6.4	6
17302	Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 293-299.	0.7	1
17303	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 219, 533-546.	2.2	6
17304	Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study. <i>Journal of Pancreatology</i> , 0, Publish Ahead of Print, .	0.9	1
17305	The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis. <i>Tumori</i> , 2022, , 030089162210827.	1.1	1
17306	Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Radiology</i> , 2022, 304, 310-319.	7.3	15
17307	Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials. <i>Lancet Oncology</i> , The, 2022, 23, e229-e234.	10.7	6
17308	68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. <i>Annals of Nuclear Medicine</i> , 2022, 36, 610-622.	2.2	16
17309	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3032-3041.	7.0	7
17310	Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma. <i>World Journal of Surgery</i> , 2022, 46, 1934-1943.	1.6	6
17311	Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2022, 38, 496-502.	0.8	6
17312	Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	7
17313	Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program. <i>Journal of Surgical Oncology</i> , 2022, 126, 513-522.	1.7	3

#	ARTICLE	IF	CITATIONS
17314	Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients. <i>European Journal of Endocrinology</i> , 2022, , .	3.7	1
17315	A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, 517.	2.6	7
17316	TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response. <i>Nucleic Acids Research</i> , 2022, 50, W761-W767.	14.5	2
17317	Radiomics for Predicting Response of Neoadjuvant Chemotherapy in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	8
17318	Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma. <i>Journal of the National Cancer Center</i> , 2022, 2, 98-105.	7.4	3
17319	Volumetric reduction of brain metastases after stereotactic radiotherapy: Prognostic factors and effect on local control. <i>Cancer Medicine</i> , 2022, 11, 4806-4815.	2.8	5
17320	Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Nonâ€“Small Cell Lung Cancer Treated With First-Line Therapy. <i>JAMA Network Open</i> , 2022, 5, e229655.	5.9	6
17321	Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 499.e1-499.e8.	1.9	6
17322	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The â€œretryâ€“ study from the Italian Group of Onco-Nephrology (G.I.O.N.). <i>Journal of Onco-Nephrology</i> , 2022, 6, 107-114.	0.6	1
17323	Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases. <i>Radiology Imaging Cancer</i> , 2022, 4, e210105.	1.6	3
17324	Evaluation of Safety of Treatment With Antiâ€“Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2022, 8, 1042.	7.1	15
17325	Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. <i>Clinical and Experimental Immunology</i> , 2022, 208, 316-322.	2.6	13
17326	The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery Open</i> , 2022, 3, e163.	1.4	5
17327	The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results. <i>Life</i> , 2022, 12, 706.	2.4	2
17328	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	3.7	4
17329	Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1074.	3.2	3
17330	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	0
17331	gBOINâ€“ET: The generalized Bayesian optimal interval design for optimal doseâ€“finding accounting for ordinal graded efficacy and toxicity in early clinical trials. <i>Biometrical Journal</i> , 2022, 64, 1178-1191.	1.0	11

#	ARTICLE	IF	CITATIONS
17332	A randomized phase <scp>II</scp> study of <scp>SM</scp>â€88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer Medicine, 2022, 11, 4169-4181.	2.8	4
17333	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	9.4	48
17334	Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Medicine, 2022, 20, 155.	5.5	9
17335	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. European Radiology, 2022, 32, 7323-7334.	4.5	5
17336	⁸⁹Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer. Journal of Nuclear Medicine, 2022, 63, 1523-1530.	5.0	15
17337	Neutrophil infiltration combined with necrosis in the primary tumor is a useful prognostic indicator for threeâ€year diseaseâ€free survival time in patients with colorectal cancer. Oncology Letters, 2022, 23, 199.	1.8	6
17338	Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research, 2022, 8, 00115-2022.	2.6	13
17339	Histologic characterization of paediatric mesenchymal neoplasms treated with kinaseâ€targeted therapy. Histopathology, 2022, 81, 215-227.	2.9	11
17340	The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Scientific Reports, 2022, 12, 7656.	3.3	13
17341	Cutaneous and subcutaneous Kaposi's sarcoma lesions treated with electrochemotherapy. International Journal of Dermatology, 2023, 62, 115-119.	1.0	3
17342	Electrochemical immunosensor for point-of-care quantitative detection of tumor markers based on personal glucometer. Journal of Electroanalytical Chemistry, 2022, 915, 116333.	3.8	1
17343	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. European Urology Open Science, 2022, 40, 117-124.	0.4	1
17344	Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer. ESMO Open, 2022, 7, 100430.	4.5	2
17345	Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science, 2022, 40, 38-45.	0.4	5
17346	CT-based radiomics analysis in the prediction of response to neoadjuvant chemotherapy in locally advanced gastric cancer: A dual-center study. Radiotherapy and Oncology, 2022, 171, 155-163.	0.6	15
17347	Avelumab in unresectable/metastatic, progressive, grade 2â€3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. European Journal of Cancer, 2022, 169, 74-81.	2.8	15
17348	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. International Immunopharmacology, 2022, 108, 108803.	3.8	5
17349	First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. European Journal of Cancer, 2022, 169, 135-145.	2.8	13

#	ARTICLE	IF	CITATIONS
17350	Clinical implications of lipid peroxides levels in plasma and tumor tissue in breast cancer patients. Prostaglandins and Other Lipid Mediators, 2022, 161, 106639.	1.9	4
17351	Early assessment of chemotherapeutic response in hepatocellular carcinoma based on serum surface-enhanced Raman spectroscopy. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 278, 121314.	3.9	5
17352	Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer. Journal of Thoracic Disease, 2022, 14, 1544-1555.	1.4	9
17353	Sources of bias for single-arm phase II cancer clinical trials. Annals of Translational Medicine, 2021, .	1.7	0
17354	Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study. AAPS Journal, 2022, 24, 58.	4.4	2
17355	Current and future imaging modalities in gastric cancer. Journal of Surgical Oncology, 2022, 125, 1123-1134.	1.7	1
17356	Value of Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prediction of Treatment Outcomes in Nasopharyngeal Carcinoma. Journal of Computer Assisted Tomography, 2022, Publish Ahead of Print, .	0.9	0
17357	Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 540.	2.2	2
17358	S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Frontiers in Oncology, 2022, 12, .	2.8	3
17359	Feasibility of drug-eluting embolics chemoembolization for the management of recurrent/advanced head and neck cancer. Journal of Vascular and Interventional Radiology, 2022, , .	0.5	6
17360	Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 175, 103705.	4.4	3
17361	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. International Journal of Environmental Research and Public Health, 2022, 19, 5999.	2.6	3
17362	A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. British Journal of Cancer, 2022, 127, 92-101.	6.4	4
17363	Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine, 2022, 20, 225.	4.4	7
17364	First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Cancer, 2022, 128, 2932-2938.	4.1	3
17365	Artificial intelligence-powered programmed death ligand-1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. European Journal of Cancer, 2022, 170, 17-26.	2.8	21
17367	Survival Outcome of Rhabdomyosarcoma (RMS) in Egyptian Children: Experience of the National Cancer Institute-Egypt. Cancer and Oncology Research, 2014, 2, 21-27.	0.2	1
17368	Positron Emission Tomography and Computed Tomography of the Hollow Viscera. , 2015, , 96-111.		0

#	ARTICLE	IF	CITATIONS
17370	OXALIPLATIN RE-INTRODUCTION THERAPY AMONG PATIENTS WITH ADVANCE STAGE COLORECTAL CANCER. , 2019, 3, 40-44.		0
17371	Segmentation of Brain Tumor from Medical Images with Novel U-Shaped Encoder Decoder Architecture. , 2022, , .		0
17372	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	15
17373	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies. Frontiers in Immunology, 2022, 13, .	4.8	5
17374	Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data. Biomedicines, 2022, 10, 1144.	3.2	7
17375	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. Frontiers in Pharmacology, 2022, 13, .	3.5	1
17376	Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer. Oncology Letters, 2022, 24, .	1.8	4
17377	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. BMJ Open, 2022, 12, e048833.	1.9	1
17379	First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. Cancer, 2022, , .	4.1	6
17380	Role of radiomics in predicting immunotherapy response. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 575-591.	1.8	10
17381	Maintenance therapy for long-term control of high-grade endometrial stromal sarcoma. BMJ Case Reports, 2022, 15, e248971.	0.5	1
17382	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
17383	Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clinical Cancer Research, 2022, 28, 3214-3224.	7.0	10
17384	Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRIT): A Single-Center Prospective Two-Arm Study. Clinical Cancer Research, 2022, 28, 4194-4202.	7.0	28
17385	Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. Clinical Cancer Research, 2022, 28, 3225-3234.	7.0	5
17386	Can artificial intelligence improve cancer treatments?. Health Informatics Journal, 2022, 28, 146045822211023.	2.1	7
17387	B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors. World Journal of Surgical Oncology, 2022, 20, 159.	1.9	8
17388	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Oncology, 2022, 40, 3246-3256.	1.6	190

#	ARTICLE	IF	CITATIONS
17389	Angiogenesis versus metabolic imaging in locally advanced breast cancer patients â€” A comparative study. Indian Journal of Nuclear Medicine, 2022, 37, 54.	0.3	1
17390	Combination of CRAFTY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1899-1911.	1.4	0
17391	Efficacy and safety of raltitrexed plus S-1 <i>versus</i> regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210982.	3.2	0
17394	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 311-326.	3.8	3
17395	The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research. Frontiers in Oncology, 2022, 12, .	2.8	5
17396	Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Nonâ€”small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clinical Lung Cancer, 2022, 23, e415-e427.	2.6	7
17397	A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy â€” including photon and proton therapy â€” for the treatment of radioresistant tumors: the ETOILE trial. BMC Cancer, 2022, 22, .	2.6	9
17398	Anlotinib in recurrent or metastatic endometrial cancer. International Journal of Gynecological Cancer, 2022, 32, 1147-1152.	2.5	1
17399	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. Cancers, 2022, 14, 2479.	3.7	3
17400	Short and long-term outcomes between laparoscopic and open total gastrectomy for advanced gastric cancer after neoadjuvant chemotherapy. World Journal of Gastrointestinal Surgery, 2022, 14, 452-469.	1.5	7
17401	Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. British Journal of Radiology, 2022, 95, .	2.2	1
17402	Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. , 2022, 10, e003890.		37
17403	PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy. Frontiers in Immunology, 2022, 13, .	4.8	5
17404	Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China. Drug Design, Development and Therapy, 0, Volume 16, 1483-1493.	4.3	5
17405	Non-Invasive Characterization of Experimental Bone Metastasis in Obesity Using Multiparametric MRI and PET/CT. Cancers, 2022, 14, 2482.	3.7	2
17406	Significance of postâ€”progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open, 0, , .	1.6	3
17407	Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Scientific Reports, 2022, 12, .	3.3	7
17408	Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer. Lung Cancer, 2022, 170, 52-57.	2.0	3

#	ARTICLE	IF	CITATIONS
17409	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK3</i> Oncogenic Fusion. <i>JCO Precision Oncology</i> , 2022, , .	3.0	4
17410	Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Tomography</i> , 2022, 8, 1363-1373.	1.8	1
17411	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	13
17412	Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2985-2998.	4.2	5
17413	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	30.7	88
17414	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	2.8	12
17415	Flow-compensated diffusion encoding in MRI for improved liver metastasis detection. <i>PLoS ONE</i> , 2022, 17, e0268843.	2.5	5
17416	Quantitative Synthetic Magnetic Resonance Imaging for Brain Metastases: A Feasibility Study. <i>Cancers</i> , 2022, 14, 2651.	3.7	3
17417	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. <i>World Journal of Urology</i> , 0, , .	2.2	3
17418	Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 37-42.	1.4	3
17419	Developing dietary interventions as therapy for cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 452-466.	28.4	52
17420	Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology. <i>Biophysics Reviews</i> , 2022, 3, .	2.7	21
17421	Characteristics of Patients in SPCG-15 – A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. <i>European Urology Open Science</i> , 2022, 41, 63-73.	0.4	3
17422	Prognostic value of CT characteristics in GEP-NET: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103713.	4.4	3
17423	MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy. <i>Cancer Letters</i> , 2022, 541, 215750.	7.2	11
17424	Tensor Radiomics: Paradigm for Systematic Incorporation of Multi-Flavoured Radiomics Features. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
17425	Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent <i>EGFR</i> ; <i>T790M</i> Mutated NSCLC: A Phase IIb Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
17426	Epigenetic Genes Alterations in Metastatic Solid Tumors: Results from the Prospective Precision Medicine MOSCATO and MATCH-R Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
17427	Improving the tolerability of osimertinib by identifying its toxic limit. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211032.	3.2	16
17428	Zebrafish as a Xenotransplantation Model for Studying Cancer Biology and Cancer Drug Discovery. , 2022, , 43-59.		1
17429	Double Trouble: Immunotherapy Doublets in Melanomaâ€”Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 745-766.	3.8	6
17430	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2022, 23, 876-887.	10.7	83
17431	Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101962.	1.5	4
17432	Outcome of dogs treated with chemotherapy for mesothelioma: A retrospective clinical study on 40 cases and a literature review. Veterinary and Comparative Oncology, 2022, 20, 825-835.	1.8	4
17433	Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment. Anticancer Research, 2022, 42, 3151-3158.	1.1	4
17434	Assessment of antitumor activity of BP-C1, a platinum-based anticancer agent with a lignin-derived polymeric ligand, in autochthonous induced and spontaneous carcinogenesis rodent models. Journal of Trace Elements in Medicine and Biology, 2022, , 127013.	3.0	1
17435	Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial. Translational Lung Cancer Research, 2022, 11, 832-844.	2.8	6
17436	Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity. Frontiers in Oncology, 0, 12, .	2.8	6
17437	Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta OncolÃ³gica, 2022, 61, 869-873.	1.8	1
17438	Comparing dosimetric and cancer control outcomes after intensityâ€modulated radiation therapy and tomotherapy for advanced cervical cancer. Oncology Letters, 2022, 24, .	1.8	1
17439	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
17440	Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma. Cancers, 2022, 14, 2730.	3.7	5
17441	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. BMC Cancer, 2022, 22, .	2.6	2
17442	Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade. European Thyroid Journal, 2022, 11, .	2.4	2
17443	Combining Clinicopathology, IVIM-DWI and Texture Parameters for a Nomogram to Predict Treatment Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. Frontiers in Oncology, 0, 12, .	2.8	1
17444	Stereotactic Ablative Radiotherapy Using CALYPSOÂ® Extracranial Tracking for Intrafractional Tumor Motion Managementâ€”A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study. Cancers, 2022, 14, 2688.	3.7	2

#	ARTICLE	IF	CITATIONS
17445	Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	6
17446	Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2022, 29, 7104-7113.	1.5	2
17447	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2022, 187, 381-391.	1.5	14
17448	The Î±-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
17449	Reattachable fiducial skin marker for automatic multimodality registration. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2022, 17, 2141-2150.	2.8	3
17450	Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer. <i>Anticancer Research</i> , 2022, 42, 2977-2987.	1.1	15
17451	Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2022, 29, 3996-4011.	2.2	3
17452	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 816-823.	4.6	5
17453	Predictive value of <scp>post-treatment C-reactive protein/albumin</scp> ratio in locally advanced <scp>non-small</scp> cell lung cancer patients receiving durvalumab after chemoradiotherapy. <i>Thoracic Cancer</i> , 2022, 13, 2031-2040.	1.9	8
17454	Somatic <i>RET</i> Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2195-2202.	3.6	14
17455	Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC. <i>Healthcare (Switzerland)</i> , 2022, 10, 922.	2.0	2
17456	Relative tumor volume has prognostic relevance in canine sinonasal tumors treated with radiation therapy: A retrospective study. <i>PLoS ONE</i> , 2022, 17, e0269083.	2.5	0
17457	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 707-719.	4.6	10
17458	New Therapy Options for Neuroendocrine Carcinoma of the Pancreasâ€”The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. <i>Cancers</i> , 2022, 14, 2685.	3.7	3
17459	Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
17460	Systemic Chemotherapy for High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread After Unsuccessful CRS/HIPEC. <i>Annals of Surgical Oncology</i> , 2022, 29, 6581-6589.	1.5	3
17461	The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. <i>International Journal of Clinical Oncology</i> , 0, , .	2.2	1
17462	Review of functional magnetic resonance imaging in the assessment of nasopharyngeal carcinoma treatment response. <i>Precision Radiation Oncology</i> , 2022, 6, 177-185.	1.1	1

#	ARTICLE	IF	CITATIONS
17463	The efficacy of Endostar combined with platinum pleural infusion for malignant pleural effusion in tumor patients is significantly better than that of monotherapy, but the economy is lower: a systematic review, network meta-analysis and cost-effectiveness analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 604-604.	1.7	2
17464	Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101955.	1.5	1
17465	18F-FDG PET/CT for Response Assessment in Lung Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 662-672.	4.6	5
17466	Association of CT-Based Delta Radiomics Biomarker With Progression-Free Survival in Patients With Colorectal Liver Metastases Undergo Chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
17467	T Stage and Pretreatment SUV Predict for Tumor Recurrence with 5 Fraction SABR in Early-Stage Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2022, , 100995.	1.2	0
17468	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. <i>Hepatology Research</i> , 2022, 52, 773-783.	3.4	34
17469	Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment. <i>British Journal of Cancer</i> , 2022, 127, 898-907.	6.4	13
17470	Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. <i>Annals of Oncology</i> , 2022, 33, 909-915.	1.2	21
17471	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281.	3.6	3
17472	ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach. <i>Cancers</i> , 2022, 14, 2592.	3.7	8
17473	Effectiveness of photodynamic therapy with 5-aminolevulinic acid for Bowenoid papulosis: A retrospective study with long-term follow-up. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 39, 102918.	2.6	1
17474	Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2476.	3.7	3
17475	Development of Two Diagnostic Prediction Models for Leptomeningeal Metastasis in Patients With Solid Tumors. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	0
17476	Tumor Diagnosis and Treatment: Imaging Assessment. <i>Tomography</i> , 2022, 8, 1463-1465.	1.8	1
17477	High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia. <i>JHEP Reports</i> , 2022, 4, 100512.	4.9	7
17478	Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC). <i>Pleura and Peritoneum</i> , 2022, 7, 143-148.	1.2	2
17479	Could Concurrent Capecitabine with Hypofractionated Radiotherapy in Elderly Patients with Muscle-Invasive Bladder Cancer be an Option?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1733-1740.	1.2	2
17480	Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System. <i>Anticancer Research</i> , 2022, 42, 2989-2995.	1.1	4

#	ARTICLE	IF	CITATIONS
17481	The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	2
17482	Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	1.0	0
17483	Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	25
17484	Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. <i>Thyroid</i> , 0, .	4.5	19
17485	Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors. <i>Biomarker Research</i> , 2022, 10, .	6.8	0
17486	CircSCAF8 promotes growth and metastasis of prostate cancer through the circSCAF8-miR-140-3p/miR-335-LIF pathway. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	12
17487	Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. <i>Annals of Surgical Oncology</i> , 2022, 29, 5462-5473.	1.5	16
17488	Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. <i>Science Advances</i> , 2022, 8, .	10.3	31
17489	Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients. <i>EJHaem</i> , 0, .	1.0	0
17490	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	39
17491	Prognostic value of tumor-infiltrating CD163+macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
17492	RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e052294.	1.9	5
17493	Stereotactic radiofrequency ablation as a valid first-line treatment option for hepatocellular adenomas. <i>International Journal of Hyperthermia</i> , 2022, 39, 780-787.	2.5	5
17494	Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 23-37.	4.2	4
17495	Long-term results of liver-first approach strategy in patients with advanced synchronous liver metastases from colorectal cancer. <i>Cirug�a Espa�ola (English Edition)</i> , 2022, .	0.1	0
17496	Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
17497	DNA Damage Repair Proteins, HSP27, and Phosphorylated-HSP90� as Predictive/Prognostic Biomarkers of Platinum-based Cancer Chemotherapy: An Exploratory Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 425-434.	1.2	1
17498	Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. <i>BMC Cancer</i> , 2022, 22, .	2.6	1

#	ARTICLE	IF	CITATIONS
17499	Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
17500	Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2830.	1.6	23
17501	Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	1
17502	Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
17503	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
17504	Stereotactic body radiotherapy boost in patients with cervical cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2022, 42, 3033-3040.	0.9	2
17505	Standardized Reporting of Oncologic Response: Making Every Report Count. <i>Radiology Imaging Cancer</i> , 2022, 4, .	1.6	5
17506	A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
17507	Does Reorganization of Clinicopathological Information Improve Prognostic Stratification and Prediction of Chemoradiosensitivity in Sinonasal Carcinomas? A Retrospective Study on 145 Patients. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	2
17508	Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4228-4240.	6.4	15
17509	Does firstâ€‘line treatment have prognostic impact for unresectable <scp>HCC</scp>?â€‘Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	2.8	25
17510	Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	1
17511	Isolated Limb Perfusion of Upper Limb: How I Do It. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.7	0
17512	Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0269115.	2.5	2
17513	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100355.	1.1	5
17514	Single material beam hardening correction via an analytical energy response model for diagnostic CT. <i>Medical Physics</i> , 0, , .	3.0	1
17515	Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma. <i>JAAD Case Reports</i> , 2022, 26, 53-56.	0.8	2
17516	Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study. <i>Oral Oncology</i> , 2022, 130, 105932.	1.5	4

#	ARTICLE	IF	CITATIONS
17517	Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. <i>EClinicalMedicine</i> , 2022, 49, 101430.	7.1	16
17518	Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study. <i>Gynecologic Oncology Reports</i> , 2022, 42, 101013.	0.6	2
17519	ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100934.	1.1	5
17520	Evaluation of pathological complete response after neoadjuvant systemic treatment of invasive breast cancer using diffusion-weighted imaging compared with dynamic contrast-enhanced based kinetic analysis. <i>European Journal of Radiology</i> , 2022, 154, 110372.	2.6	1
17525	The predictive value of tumor volume reduction ratio on three-dimensional endorectal ultrasound for tumor response to chemoradiotherapy for locally advanced rectal cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 666-666.	1.7	5
17526	A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world. <i>Translational Lung Cancer Research</i> , 2022, 11, 1051-1068.	2.8	10
17527	Mamoplastia de reducci3n oncopl3stica en paciente con cancer de seno y macromastia: reporte de caso. <i>Medicas UIS</i> , 2021, 34, .	0.0	0
17528	Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211054.	2.0	6
17529	Circulating Low Density Neutrophils are Associated with Resistance to First-Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
17530	Comparison of Survival Outcomes According to<i>BRCA1/2</i> Variant Type in High-grade Serous Ovarian Cancer. <i>In Vivo</i> , 2022, 36, 1903-1910.	1.3	0
17531	Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211032.	3.2	13
17532	Oligometastatic breast cancer: An institutional analysis. <i>Indian Journal of Cancer</i> , 2022, , .	0.2	0
17533	Radioiodine Refractory Differentiated Thyroid Cancer. <i>Methods in Molecular Biology</i> , 2022, , 243-257.	0.9	2
17534	A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2022, , .	1.2	1
17535	Imaging response assessment for oncology: An algorithmic approach. <i>European Journal of Radiology Open</i> , 2022, 9, 100426.	1.6	2
17536	Tumor Glycolytic Profiling Through 18F-FDG PET/CT Predicts Immune Checkpoint Inhibitor Efficacy in Advanced NSCLC. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
17537	Primary pulmonary leiomyosarcoma with coexistent pulmonary aspergillosis: a case report. <i>Pan African Medical Journal</i> , 0, 42, .	0.8	3
17538	A Meta-Analysis of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 4692-4699.	0.0	0

#	ARTICLE	IF	CITATIONS
17539	Electrochemotherapy using thin-needle electrode improves recovery in feline nasal planum squamous cell carcinoma - a translational model. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 595-611.	2.1	4
17540	Novel Imaging Biomarkers to Assess Oncologic Treatmentâ€‘Related Changes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 687-699.	3.8	1
17541	Programmed death 1 (PDâ€‘1) and ligand (PDâ€‘L1) inhibitors in head and neck squamous cell carcinoma: A metaâ€‘analysis. World Journal of Otorhinolaryngology - Head and Neck Surgery, 0, , .	1.6	0
17542	O6-Methylguanine-DNA Methyltransferase and ATP-Binding Cassette Membrane Transporter G2 Promotor Methylation: Can Predict the Response to Chemotherapy in Advanced Breast Cancer?. Reports of Biochemistry and Molecular Biology, 2022, 11, 20-29.	1.4	2
17543	A Transcriptomic Liquid Biopsy Assay for Predicting Resistance to Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma. Annals of Surgery, 2022, 276, 101-110.	4.2	6
17544	Neoadjuvant immunotherapy followed by surgery with curative intent in 35 patients with advanced NSCLC: the retrospective experiences of a multidisciplinary team. Annals of Translational Medicine, 2022, 10, 609-609.	1.7	4
17545	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
17546	Is it possible to achieve longâ€‘term survival in relapsed intracranial nonâ€‘germinomatous germ cell tumours?. Pediatric Blood and Cancer, 2023, 70, .	1.5	0
17547	Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force. European Radiology, 2022, 32, 8617-8628.	4.5	4
17548	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	5.9	10
17549	<i>InÂ‘vivo</i> visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model. MedComm, 2022, 3, .	7.2	1
17550	Carbonâ€‘ion radiotherapy for urological cancers. International Journal of Urology, 2022, 29, 1109-1119.	1.0	6
17551	Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (<sc>FGF401</sc>) drug treatment. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1122-1134.	2.5	4
17552	Efficacy evaluation of different measurement methods for target lesions after neoadjuvant chemotherapy and radical radiotherapy in locally advanced hypopharyngeal carcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 187-195.	1.1	1
17553	Realâ€‘world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensiveâ€‘disease smallâ€‘cell lung cancer. Cancer Medicine, 2023, 12, 73-83.	2.8	13
17554	Evaluation of cancer outcome assessment using MRI: A review of deep-learning methods. BJR Open, 2022, 4, .	0.6	0
17555	Plasma Circulating Tumor Epsteinâ€‘Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma. Frontiers in Oncology, 0, 12, .	2.8	1
17556	Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study. Targeted Oncology, 0, , .	3.6	14

#	ARTICLE	IF	CITATIONS
17557	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2975.	3.7	5
17558	The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	1.3	1
17559	Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. <i>Nature Communications</i> , 2022, 13, .	12.8	43
17560	Successful dose escalation of lenvatinib for thyroid cancer after disease progression. <i>Endocrine</i> , 2022, 78, 77-84.	2.3	1
17561	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	27.8	54
17562	The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	3
17563	A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 7-17.	2.3	5
17564	A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 338-345.	0.9	2
17565	Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3353-3356.	1.6	2
17566	Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. <i>Cancers</i> , 2022, 14, 2998.	3.7	11
17567	Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients. <i>Biomedicines</i> , 2022, 10, 1474.	3.2	7
17568	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, , .	1.4	1
17569	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). <i>Lancet Oncology</i> , The, 2022, 23, 899-909.	10.7	26
17570	Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?. <i>Cancer Imaging</i> , 2022, 22, .	2.8	5
17571	Special issue â€œThe advance of solid tumor research in Chinaâ€• Presurgical therapy in the management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. <i>International Journal of Cancer</i> , 0, , .	5.1	0
17572	Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. <i>Pharmaceutics</i> , 2022, 14, 1278.	4.5	7
17573	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 621-632.	0.9	2
17574	Role of diffusion-weighted MRI in recurrent rectal cancer treated with carbon ion radiotherapy. <i>Future Oncology</i> , 0, , .	2.4	1

#	ARTICLE	IF	CITATIONS
17575	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	1.2	22
17576	Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. , 2022, 10, e004797.		7
17577	T Cell Therapies for Cancer. , 2022, 1, 262-270.		0
17578	Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy. <i>Cancer Investigation</i> , 2022, 40, 710-721.	1.3	1
17579	Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. <i>Nature Medicine</i> , 2022, 28, 1581-1589.	30.7	16
17580	High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial. <i>Lung Cancer</i> , 2022, 170, 133-140.	2.0	20
17581	An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 286-293.	1.3	0
17582	Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 1066-1079.	2.6	9
17583	Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
17584	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. <i>Scientific Reports</i> , 2022, 12, .	3.3	13
17585	Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). <i>British Journal of Cancer</i> , 2022, 127, 1153-1161.	6.4	7
17586	Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. <i>Journal of Bone Oncology</i> , 2022, 35, 100441.	2.4	9
17587	Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1835-1847.	2.5	2
17588	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€‘Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. <i>JAMA Network Open</i> , 2022, 5, e2215589.	5.9	15
17589	The Role of Imaging in Soft Tissue Sarcoma Diagnosis and Management. <i>Surgical Clinics of North America</i> , 2022, 102, 539-550.	1.5	2
17590	Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	12
17591	Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in nonâ€‘small cell lung cancer. <i>Cancer Science</i> , 0, , .	3.9	1
17592	A Comprehensive Prognostic Model for Colorectal Cancer Liver Metastasis Recurrence After Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
17593	A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. Clinical Genitourinary Cancer, 2022, 20, 473-481.	1.9	2
17594	Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. Meditsinskiy Sovet, 2022, , 157-162.	0.5	0
17595	Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. Clinical Cancer Research, 2022, 28, 4410-4424.	7.0	6
17596	Whole exome analysis reveals the genomic profiling related to chemoâ€resistance in Chinese population with limitedâ€disease small cell lung cancer. Cancer Medicine, 0, , .	2.8	2
17597	Potential for cure and predictors of long-term survival after radiofrequency ablation for colorectal liver metastases: A 20-years single-center experience. European Journal of Surgical Oncology, 2022, 48, 2487-2494.	1.0	2
17598	Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases. BMC Cancer, 2022, 22, .	2.6	1
17599	CT-based radiomics to distinguish progressive from stable neuroendocrine liver metastases treated with somatostatin analogues: an explorative study. Acta Radiologica, 2023, 64, 1062-1070.	1.1	2
17600	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. Journal of Clinical Medicine, 2022, 11, 3364.	2.4	20
17601	Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. Cancers, 2022, 14, 2914.	3.7	3
17602	Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer, 2022, 22, .	2.6	17
17603	Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nature Communications, 2022, 13, .	12.8	17
17604	Absolute lymphocyte count and Câ€™reactive proteinâ€™albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy. Oncology Letters, 2022, 24, .	1.8	9
17605	Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers, 2022, 14, 2872.	3.7	1
17606	Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. , 2022, 10, e004509.		8
17607	Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax, 2022, 77, 1163-1174.	5.6	5
17608	The Prognostic Value of Posttreatment⁶⁸Ga-PSMA-11 PET/CT and¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). Journal of Nuclear Medicine, 2023, 64, 69-74.	5.0	12
17609	New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. Seminars in Nuclear Medicine, 2022, 52, 781-796.	4.6	7
17610	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2022, 40, 2957-2995.	1.6	97

#	ARTICLE	IF	CITATIONS
17612	Postchemotherapy gross residual tumor in nonâ€highâ€risk neuroblastoma: Clinical significance and the role of adjuvant therapy. <i>Pediatric Blood and Cancer</i> , 0, .	1.5	0
17613	Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitorâ€treated unresectable hepatocellular carcinoma. , 2022, 10, e004779.		47
17614	The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	1.4	7
17615	Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. <i>Cancers</i> , 2022, 14, 2985.	3.7	3
17616	Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 0, .	1.0	0
17617	Microsatellite instability in patients with hepato-biliary-pancreatic malignancies in clinical practice (KHBO 1903). <i>International Journal of Clinical Oncology</i> , 2022, 27, 1340-1347.	2.2	3
17618	iRECIST and atypical patterns of response to immuno-oncology drugs. , 2022, 10, e004849.		12
17619	Secondâ€line lurbinectedin as a new treatment option for smallâ€cell lung cancer: Preliminary results in realâ€clinical practice. <i>Thoracic Cancer</i> , 2022, 13, 2248-2252.	1.9	7
17620	Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 785-794.	2.4	3
17621	MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. <i>Immuno-Oncology Technology</i> , 2022, 15, 100089.	0.3	9
17623	Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. <i>Journal of Personalized Medicine</i> , 2022, 12, 958.	2.5	0
17624	Clinical activity of <sc>CCâ€90011</sc>, an oral, potent, and reversible <sc>LSD1</sc> inhibitor, in advanced malignancies. <i>Cancer</i> , 2022, 128, 3185-3195.	4.1	10
17625	The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis. <i>Medicina (Lithuania)</i> , 2022, 58, 768.	2.0	1
17626	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	1.6	24
17627	Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study. <i>American Journal of Roentgenology</i> , 2022, 219, 884-894.	2.2	10
17628	Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. <i>Pancreatology</i> , 2022, 22, 789-796.	1.1	10
17629	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	19
17630	Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children. <i>World Journal of Clinical Cases</i> , 2022, 10, 6437-6445.	0.8	2

#	ARTICLE	IF	CITATION
17631	Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clinica Chimica Acta, 2022, 533, 71-78.	1.1	4
17632	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. European Journal of Cancer, 2022, 171, 114-123.	2.8	5
17633	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Critical Reviews in Oncology/Hematology, 2022, 176, 103746.	4.4	1
17634	The MUSESâ—: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment. European Journal of Cancer, 2022, 171, 161-182.	2.8	18
17635	Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study. Cancer Control, 2022, 29, 107327482211152.	1.8	0
17636	An analysis of clinical effectiveness of electrochemotherapy in the treatment of advanced metastatic malignant melanoma performed in the eastern part of Central Europe: a single-centre experience. Postepy Dermatologii i Alergologii, 2022, 39, 559-564.	0.9	0
17637	Intravoxel incoherent motion diffusion-weighted imaging for early assessment of combined anti-angiogenic/chemotherapy for colorectal cancer liver metastases. Quantitative Imaging in Medicine and Surgery, 2022, 12, 4587-4600.	2.0	2
17638	The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial. Technology in Cancer Research and Treatment, 2022, 21, 153303382211099.	1.9	1
17639	Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211101.	3.2	1
17640	Tumor Volume Reduction Rate to Induction Chemotherapy is a Prognostic Factor for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Cohort Study. Technology in Cancer Research and Treatment, 2022, 21, 153303382211077.	1.9	3
17642	Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2022, .	1.4	0
17643	Magnetic resonance imaging in cervical cancer interventional radiotherapy (brachytherapy): a pictorial essay focused on radiologist management. Journal of Contemporary Brachytherapy, 2022, 14, 287-298.	0.9	5
17645	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. Advances in Clinical Medicine, 2022, 12, 5913-5936.	0.0	0
17646	Transarterial chemoembolization and isolated liver chemoperfusion in the treatment of uveal melanoma in patients with liver metastases (a systematic review). Medical Technologies Assessment and Choice (ÐœÐµÐ´Ð¸Ñ†Ð¸Ð½Ð° Ð¸ Ð¢ÐµÑ…Ð½Ð¸ÐºÐ¸ ÐœÐµÐ´Ð¸Ñ†Ð¸Ð½ÑÐºÐ¸Ð¼ Ð¸ Ð¢ÐµÑ…Ð½Ð¸ÐºÐ¸Ð¼ Ð¸Ð½ÑÑ‚Ñ€ÑÐ¼ÐµÐ½ÑÐ°Ð¼), 2022, 44, 72.	0.4	0
17647	A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211091.	3.2	3
17648	Assessment of Neoadjuvant Treatment Response Using Automated Breast Ultrasound in Breast Cancer. Journal of Breast Cancer, 0, 25, .	1.9	1
17649	Factors Influencing the Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer. International Journal of Pharmacology, 2022, 18, 1071-1078.	0.3	0
17650	A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. Investigational New Drugs, 2022, 40, 1087-1094.	2.6	7

#	ARTICLE	IF	CITATIONS
17651	Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis. Pathology and Oncology Research, 0, 28, .	1.9	0
17652	Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	12
17653	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	3.0	4
17654	Prediction of Incomplete Response of Primary Tumour Based on Clinical and Radiomics Features in Inoperable Head and Neck Cancers after Definitive Treatment. Journal of Personalized Medicine, 2022, 12, 1092.	2.5	3
17655	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10, e003811.		26
17656	Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. Journal of Hematology (Brossard, Quebec), 2022, 11, 113-120.	1.0	3
17657	Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers, 2022, 14, 3193.	3.7	9
17658	Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study. BMJ Open, 2022, 12, e061674.	1.9	4
17659	Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma. Frontiers in Oncology, 0, 12, .	2.8	0
17660	Microwave Ablation Combined with Lipiodol-microsphere Mixed or Conventional Transarterial Chemoembolization for the Treatment of Colorectal Liver metastases: A Retrospective Study. Clinics and Research in Hepatology and Gastroenterology, 2022, , 101986.	1.5	4
17661	Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. International Journal of Radiation Oncology Biology Physics, 2022, 114, 910-918.	0.8	11
17662	Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers, 2022, 14, 3231.	3.7	5
17663	Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series. Translational Cancer Research, 2022, 11, 1697-1704.	1.0	1
17664	Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. Translational Lung Cancer Research, 2022, 11, 1038-1050.	2.8	4
17665	Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. Radiation Oncology, 2022, 17, .	2.7	5
17666	Giant hepatic adenoma managed with anatomical right hepatectomy: A case report. Pyramid Journal of Medicine, 2022, 5, .	0.1	0
17667	Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE in Neuroendocrine Tumor Patients. Journal of Nuclear Medicine, 2023, 64, 40-46.	5.0	5
17668	A Novel Electromagnetic Navigation Bronchoscopy System for the Diagnosis of Peripheral Pulmonary Nodules: A Randomized Clinical Trial. Annals of the American Thoracic Society, 2022, 19, 1730-1739.	3.2	8

#	ARTICLE	IF	CITATIONS
17670	Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor–induced bullous pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 670-671.	1.2	6
17671	Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC). <i>Endocrine</i> , 2022, 78, 68-76.	2.3	2
17672	Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study. <i>Endocrine-Related Cancer</i> , 2022, 29, 569-580.	3.1	6
17673	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	7.3	14
17674	Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2543-2550.	2.5	1
17675	Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
17676	Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 704-716.	1.6	10
17677	Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4212-4221.	7.0	19
17678	Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations. <i>Cancer Science</i> , 0, , .	3.9	1
17679	Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world. <i>Annals of Translational Medicine</i> , 2022, 10, 708-708.	1.7	1
17680	A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
17681	The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies. <i>Journal of Thoracic Disease</i> , 2022, 14, 2201-2212.	1.4	1
17682	Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
17683	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria. <i>Targeted Oncology</i> , 2022, 17, 475-482.	3.6	4
17684	Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 777-787.	2.0	1
17685	Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4705-4715.	6.4	2
17686	Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-8.	1.9	1
17687	Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4

#	ARTICLE	IF	CITATIONS
17688	Pretreatment Modified Albuminâ€“Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 4799-4810.	2.2	8
17689	Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1044-1054.	10.7	35
17690	Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study. <i>Irish Journal of Medical Science</i> , 2023, 192, 1033-1040.	1.5	2
17691	Radiomic Features From Diffusion-Weighted MRI of Retroperitoneal Soft-Tissue Sarcomas Are Repeatable and Exhibit Change After Radiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
17692	Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea. <i>Gynecologic Oncology</i> , 2022, 166, 444-452.	1.4	2
17693	Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer. <i>Radiation Oncology</i> , 2022, 17, .	2.7	1
17694	The role of selenoprotein P in the determining the sensitivity of cervical cancer patients to concurrent chemoradiotherapy: A metabonomics-based analysis. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 73, 127041.	3.0	4
17695	The efficacy, toxicity and survival of salvage retreatment PRRT with ¹⁷⁷ Lu-DOTATATE in patients with progressive NET following initial course of PRRT. <i>British Journal of Radiology</i> , 2022, 95, .	2.2	6
17696	Intraarterial Therapies for the Management of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 3351.	3.7	10
17697	Criteria for assessing the response to treatments in solid tumor in the era of new oncology: what radiologists should know. <i>Journal of Radiological Review</i> , 2022, 9, .	0.1	0
17698	CpG ODN (K3)â€“toll-like receptor 9 agonistâ€“induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	2.6	7
17699	First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 1001-1010.	2.6	14
17700	Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 4098.	2.4	4
17701	Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study. <i>Investigational New Drugs</i> , 2022, 40, 1095-1105.	2.6	6
17702	Dynamic characterization of breast cancer response to neoadjuvant therapy using biophysical metrics of spatial proliferation. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
17703	Pozotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. <i>Cancer Cell</i> , 2022, 40, 754-767.e6.	16.8	34
17704	Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas. <i>JAMA Oncology</i> , 2022, 8, 1263.	7.1	107
17705	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	3.0	15

#	ARTICLE	IF	CITATIONS
17706	Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression. <i>Cancer Imaging</i> , 2022, 22, .	2.8	2
17707	Dual α -V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 943-951.	8.1	25
17708	Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial. <i>BioMed Research International</i> , 2022, 2022, 1-9.	1.9	2
17709	Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 444-453.	0.8	4
17710	Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study. , 2022, 39, .		2
17711	Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	9
17712	Arterial spin labeling of nasopharyngeal carcinoma shows early therapy response. <i>Insights Into Imaging</i> , 2022, 13, .	3.4	1
17713	Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. <i>JAMA Oncology</i> , 2022, 8, 1352.	7.1	8
17714	Non-small cell lung cancer with tumor proportion score $\geq 90\%$ could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. <i>Thoracic Cancer</i> , 2022, 13, 2450-2458.	1.9	4
17715	Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer. <i>BMC Cancer</i> , 2022, 22, .	2.6	4
17716	Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. <i>Cancer Science</i> , 2022, 113, 4059-4069.	3.9	7
17717	Clinical impact of tumour burden on the efficacy of $PD-1/PD-L1$ inhibitors plus chemotherapy in non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	2.8	1
17718	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , .	3.0	11
17719	The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 475-493.	3.8	12
17720	Comparison of the somatic mutations between circulating tumor DNA and tissue DNA in Chinese patients with non-small cell lung cancer. <i>International Journal of Biological Markers</i> , 0, , 039361552210990.	1.8	1
17721	Inflammatory and autoimmune predictive markers of response to anti- $PD-1/PD-L1$ therapy in NSCLC and melanoma. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	1.8	5
17722	The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. <i>Biomedicines</i> , 2022, 10, 1609.	3.2	6
17723	Gastrointestinal stromal tumors: a comprehensive radiological review. <i>Japanese Journal of Radiology</i> , 2022, 40, 1105-1120.	2.4	17

#	ARTICLE	IF	CITATIONS
17724	PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 3307-3320.	0.9	3
17725	Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2022, 42, 3627-3636.	1.1	2
17726	Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
17727	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
17728	<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. <i>OncolImmunology</i> , 2022, 11, .	4.6	11
17729	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
17730	Indian Data on the Response of Positive Pelvic Lymph Nodes in Carcinoma Cervix Patients Treated with Simultaneous Integrated Boost Using Volumetric Modulated Arc Radiation Therapy. <i>Asian Journal of Oncology</i> , 0, , .	0.2	0
17731	Statistical handling of death events in the analysis of time to progression: A review of oncology journals. <i>Contemporary Clinical Trials</i> , 2022, 119, 106858.	1.8	1
17732	Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
17733	Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 524-534.	3.2	4
17734	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
17735	Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
17736	Management of cutaneous melanoma: radiologists challenging and risk assessment. <i>Radiologia Medica</i> , 2022, 127, 899-911.	7.7	20
17737	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	7.0	45
17738	Association of thyroid transcription factor-1 with the efficacy of immune checkpoint inhibitors in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2309-2317.	1.9	7
17739	A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical. <i>Trials</i> , 2022, 23, .	1.6	4
17740	Recurrent of ovarian cancer with lymph node involvement: surgery or chemotherapy? Retrospective cohort study. <i>Journal of Modern Oncology</i> , 2022, 24, 170-176.	0.3	0
17741	Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA. <i>Seminars in Oncology</i> , 2022, 49, 298-305.	2.2	2

#	ARTICLE	IF	CITATIONS
17742	Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 577-584.	5.4	19
17743	The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7878.	4.1	4
17744	Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3476.	3.7	9
17745	Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review. <i>PLoS ONE</i> , 2022, 17, e0271506.	2.5	1
17746	Camrelizumab plus chemotherapy in advanced nonâ€squamous nonâ€small cell lung cancer: Treatment response, survival pattern, and safety. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1775-1782.	1.5	2
17747	Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation. <i>Anticancer Research</i> , 2022, 42, 3523-3527.	1.1	0
17748	Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study. <i>Anticancer Research</i> , 2022, 42, 3653-3664.	1.1	5
17749	Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100606.	1.7	4
17750	The Potential and Emerging Role of Quantitative Imaging Biomarkers for Cancer Characterization. <i>Cancers</i> , 2022, 14, 3349.	3.7	2
17751	Tumor Growth Inhibition Modeling to Support the Starting Dose for Dacomitinib. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 0, , .	2.5	3
17752	Percutaneous cryoablation for desmoid fibromatosis: initial experience at a UK centre. <i>Clinical Radiology</i> , 2022, , .	1.1	1
17753	Evaluation of outcomes in the management of primary sporadic desmoid-type fibromatosis at a specialist soft tissue sarcoma unit. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	0
17754	Association of Apatinib and Breast Cancer: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2022, , 101818.	1.6	2
17755	The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. <i>Gastric Cancer</i> , 2022, 25, 943-955.	5.3	5
17756	Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	15
17757	Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 183-191.	4.2	4
17758	Prognostic value of the ratio of maximum to minimum diameter of primary tumor in metastatic clear cell renal cell carcinoma. <i>BMC Urology</i> , 2022, 22, .	1.4	2
17759	Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 443-451.	0.7	0

#	ARTICLE	IF	CITATIONS
17760	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 919-930.	10.7	11
17761	Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment. <i>Thoracic Cancer</i> , 2022, 13, 2170-2179.	1.9	4
17762	Status of liquid profiling in precision oncology— the need for integrative diagnostics for successful implementation into standard care. <i>Laboratoriums Medizin</i> , 2022, 46, 237-245.	0.6	1
17763	Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro). <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
17764	Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Using Optical Surface Management System — AlignRT as an Optical Body Surface Motion Management in Deep Breath Hold Patients: Results from a Single-Arm Retrospective Study. <i>Cancer Management and Research</i> , 0, Volume 14, 2161-2172.	1.9	0
17765	Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1281-1294.	2.0	4
17766	Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma. <i>Medicina (Lithuania)</i> , 2022, 58, 908.	2.0	3
17767	Radiomics to the Rescue. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
17768	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches. <i>Cancer Treatment Reviews</i> , 2022, 109, 102437.	7.7	3
17769	Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. <i>Communications Medicine</i> , 2022, 2, .	4.2	5
17770	In Patients with Melanoma Brain Metastases is Combination Immune Checkpoint Inhibition a Safe and Effective First-line Treatment? A Critically Appraised Topic. <i>Neurologist</i> , 0, Publish Ahead of Print, .	0.7	1
17771	Safety and feasibility of laterally extended endopelvic resection for sarcoma in the female genital tract: a prospective cohort study. <i>Obstetrics and Gynecology Science</i> , 2022, 65, 355-367.	1.6	2
17772	Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response. <i>Cancer Research</i> , 2022, 82, 3275-3290.	0.9	17
17773	Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. <i>Immunotherapy</i> , 2022, 14, 1027-1041.	2.0	4
17774	Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
17775	The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, , 100373.	1.1	1
17776	Comparison of Recurrence Patterns and Salvage Treatments After Definitive Radiotherapy for cT1a and cT1bN0M0 Esophageal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
17777	Gastric Metastasis of Primary Lung Cancer: Case Report and Systematic Review With Pooled Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2

#	ARTICLE	IF	CITATIONS
17778	Key factors for effective mitotane therapy in children with adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2022, 29, 545-555.	3.1	5
17779	Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 814-823.	1.4	2
17780	Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. <i>Lung Cancer</i> , 2022, 171, 26-33.	2.0	16
17781	Synchronous breast cancer and non-Hodgkin lymphoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2022, 97, 107398.	0.6	1
17782	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. <i>IScience</i> , 2022, 25, 104702.	4.1	15
17783	Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study. <i>Oral Oncology</i> , 2022, 132, 106018.	1.5	6
17784	Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. <i>European Journal of Cancer</i> , 2022, 172, 340-348.	2.8	12
17785	Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. <i>European Journal of Cancer</i> , 2022, 172, 264-275.	2.8	12
17786	Alveolar soft part sarcoma of the superior rectus muscle: Case report and review of literature. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 27, 101645.	0.7	2
17787	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. <i>International Immunopharmacology</i> , 2022, 110, 108985.	3.8	14
17788	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. <i>European Journal of Cancer</i> , 2022, 172, 199-208.	2.8	9
17789	A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study. <i>EClinicalMedicine</i> , 2022, 51, 101541.	7.1	12
17790	Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2022, 172, 387-399.	2.8	4
17791	Bone Metastases. , 2023, , 587-605.		0
17792	Pancreatic Neuroendocrine Tumors. , 2023, , 197-217.		26
17793	Cancer and Heart Disease. , 2023, , 70-82.		0
17794	Assessing Response to Therapy. , 2023, , 28-38.		0
17796	A Multidisciplinary Approach to Cancer: A Radiologist's View. , 2023, , 1-6.		0

#	ARTICLE	IF	CITATIONS
17797	Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 474-483.	0.4	0
17798	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 347-366.	5.9	11
17799	Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 1029-1040.	1.2	28
17800	Effect of <i>BRCA1/2</i> Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study. <i>Cancer Research and Treatment</i> , 0, , .	3.0	0
17801	Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score matching cohort study. <i>Journal of Surgical Oncology</i> , 2022, 126, 1205-1214.	1.7	1
17802	A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	2
17803	Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	4
17804	A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 709-719.	2.6	8
17805	Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases. <i>Diseases of the Colon and Rectum</i> , 0, Publish Ahead of Print, .	1.3	1
17806	Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
17807	Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
17808	Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. <i>Journal of Clinical Oncology</i> , 2023, 41, 75-85.	1.6	42
17809	Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C. <i>Annals of Surgical Oncology</i> , 2022, 29, 7568-7576.	1.5	5
17810	Microsatellite Instability-High Endometrial Cancers with <i>MLH1</i> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles. <i>Clinical Cancer Research</i> , 2022, 28, 4302-4311.	7.0	14
17811	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
17812	Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
17813	Transcatheter arterial chemoembolization is safe and effective for patients with late-stage or recurrent oral carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
17814	Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	2

#	ARTICLE	IF	CITATIONS
17815	CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). <i>Clinical Genitourinary Cancer</i> , 2023, 21, 106.e1-106.e8.	1.9	7
17816	Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK+ Inhibitor-Naïve ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. <i>Clinical Lung Cancer</i> , 2022, 23, 720-730.	2.6	5
17817	Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?. , 2022, 10, e004848.		14
17818	Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2022, 127, 1473-1478.	6.4	2
17819	A flexible three-dimensional heterophase computed tomography hepatocellular carcinoma detection algorithm for generalizable and practical screening. <i>Hepatology Communications</i> , 2022, 6, 2901-2913.	4.3	5
17820	Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3065-3073.	2.5	6
17821	Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 217-226.	27.0	266
17822	Deep Learning-based Assessment of Oncologic Outcomes from Natural Language Processing of Structured Radiology Reports. <i>Radiology: Artificial Intelligence</i> , 2022, 4, .	5.8	16
17823	Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring <i>POLE</i> exonuclease domain mutation. , 2022, 10, e004487.		5
17824	Editorial: Response assessment of radioligand therapies. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
17825	RPP30 is a novel diagnostic and prognostic biomarker for gastric cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
17826	Polymorphisms in solute carrier genes (<i>SLC19A1</i> , <i>SLCO1B1</i> , and) Tj ETQq1 1 0.784314 rgST undergoing platinum-based doublet chemotherapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2049-2067.	1.5	1
17827	5-Fluorouracil combined with cisplatin via arterial induction for advanced T-stage nasopharyngeal carcinoma: A 10-year outcome of a phase I/II study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
17828	Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100382.	1.1	2
17829	Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. <i>British Journal of Cancer</i> , 2022, 127, 1487-1496.	6.4	5
17830	PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4893-4906.	7.0	18
17831	Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3109-3119.	2.5	1
17832	Short bevacizumab infusion as an effective and safe treatment for colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	1.0	3

#	ARTICLE	IF	CITATIONS
17833	Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. <i>Lancet Oncology</i> , The, 2022, 23, e374-e384.	10.7	45
17834	Clinical performance evaluation of O-Ring Halcyon Linac: A real-world study. <i>World Journal of Clinical Cases</i> , 2022, 10, 7728-7737.	0.8	1
17835	Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. <i>European Journal of Cancer</i> , 2022, 173, 133-145.	2.8	1
17836	Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials. <i>European Journal of Cancer</i> , 2022, 173, 167-177.	2.8	6
17837	Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients. <i>Contemporary Clinical Trials</i> , 2022, 120, 106849.	1.8	0
17838	Mek Inhibition Causes BIM Stabilization and Increased Sensitivity to BCL-2 Family Member Inhibitors in RAS-MAPK-Mutated Neuroblastoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
17839	Efficacy and safety of selpercatinib in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211050.	3.2	14
17840	MiR-21/Sonic Hedgehog (SHH)/PI3K/AKT Pathway is Associated with NSCLC of Primary EGFR-TKI Resistance. <i>Oncologie</i> , 2022, 24, 579-590.	0.7	3
17841	Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202). <i>Journal of Gastrointestinal Oncology</i> , 2022, .	1.4	2
17842	Performance of NI-RADS on CECT Alone to Predict Recurrent Head and Neck Squamous Cell Carcinoma after Chemoradiotherapy: Added Value of RECIST 1.1.. <i>Indian Journal of Radiology and Imaging</i> , 2022, 32, 151-158.	0.8	2
17843	Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2022, 67, 1-10.	7.2	4
17844	The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors. <i>Paediatric Drugs</i> , 0, , .	3.1	1
17845	Prediction of 5-year progression-free survival in advanced nasopharyngeal carcinoma with pretreatment PET/CT using multi-modality deep learning-based radiomics. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
17846	Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study. <i>Translational Cancer Research</i> , 2022, 11, 2310-2320.	1.0	0
17847	18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?. <i>Clinical and Translational Imaging</i> , 2022, 10, 687-695.	2.1	8
17848	A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients. <i>BMC Pharmacology & Toxicology</i> , 2022, 23, .	2.4	3
17849	Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-â€Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. <i>JCO Precision Oncology</i> , 2022, , .	3.0	7
17850	Comparison Between FOLFIRINOX and na-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. <i>Anticancer Research</i> , 2022, 42, 3889-3894.	1.1	3

#	ARTICLE	IF	CITATIONS
17851	Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB. <i>Disease Markers</i> , 2022, 2022, 1-25.	1.3	7
17852	Correlation of treatment outcome in sanger/RT-qPCR <i>KIT/PDGFR</i> wild-type metastatic gastrointestinal stromal tumors with next-generation sequencing results: A single-center report. <i>Oncology Reports</i> , 2022, 48, .	2.6	4
17853	A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 175-187.	2.3	1
17854	Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
17855	Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study. <i>BMC Cancer</i> , 2022, 22, .	2.6	2
17856	Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. <i>Cancers</i> , 2022, 14, 3695.	3.7	1
17857	The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer. <i>Anticancer Research</i> , 2022, 42, 3937-3946.	1.1	0
17858	Prognosis Associated with Glycolytic Activity in Regional Lymph Nodes of Patients with Previously Untreated Metastatic Breast Cancer: A Preliminary Study. <i>Diagnostics</i> , 2022, 12, 1809.	2.6	0
17859	Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
17860	Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. <i>Esophagus</i> , 2022, 19, 645-652.	1.9	3
17861	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
17862	New endpoints in adrenocortical carcinoma studies: a mini review. <i>Endocrine</i> , 2022, 77, 419-424.	2.3	2
17863	Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2023, 12, 1102-1113.	2.8	3
17864	Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 792-802.	0.8	9
17865	Evaluation of ¹¹ C-choline positron emission tomography/computed tomography for determining treatment response in castration-resistant prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 1072-1078.	1.0	3
17866	Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
17867	Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI-H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	12
17868	The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	3

#	ARTICLE	IF	CITATIONS
17869	Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases. <i>Radiation Oncology</i> , 2022, 17, .	2.7	0
17870	Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer. <i>Cancer Medicine</i> , 2023, 12, 2417-2426.	2.8	4
17871	Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy. <i>Cancers</i> , 2022, 14, 3706.	3.7	4
17872	The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. <i>F1000Research</i> , 0, 11, 853.	1.6	0
17873	Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100385.	1.1	3
17874	Softgan: Towards Accurate Lung Nodule Segmentation via Soft Mask Supervision. , 2022, , .		4
17876	Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
17877	The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-14.	0.8	5
17878	Peptide Receptor Radionuclide Therapy Using ¹⁷⁷ Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment. <i>World Journal of Nuclear Medicine</i> , 0, , .	0.5	0
17879	Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
17880	Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 395-403.	1.5	4
17881	A phase <sc>II</sc> trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: <sc>SARCO24</sc> trial results. <i>Cancer Medicine</i> , 2023, 12, 1532-1539.	2.8	9
17882	Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Nonâ€“Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2022, , .	3.0	26
17883	Comparing the associations between host and tumor factors with survival outcomes with <sc>antiâ€“PD</sc>â€“1 immunotherapy in metastatic melanoma. <i>Cancer Medicine</i> , 2023, 12, 2427-2439.	2.8	3
17884	Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2292-2300.	1.7	5
17885	Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
17886	Does protracted chemotherapy have an influence on the clinical outcomes in advanced epithelial ovarian cancer?. <i>Medicine (United States)</i> , 2022, 101, e29967.	1.0	0
17887	Bintrafusp Alfa, an Anti-PD-L1:TGFÎ² Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 979-986.	1.7	9

#	ARTICLE	IF	CITATIONS
17888	Itâ€™s time to propose a uniform criteria for determining â€œclinical complete responseâ€œ in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 620-622.	1.5	1
17889	First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Annals of Oncology, 2022, 33, 1179-1185.	1.2	4
17890	Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	4.8	14
17891	Quantitative CT evaluation after two cycles of induction chemotherapy to predict prognosis of patients with locally advanced oesophageal squamous cell carcinoma before undergoing definitive chemoradiotherapy/radiotherapy. European Radiology, 2023, 33, 380-390.	4.5	1
17892	Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy. Frontiers in Oncology, 0, 12, .	2.8	2
17893	Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma. JAMA Oncology, 2022, 8, 1420.	7.1	3
17894	Outcomes after partially covered self-expandable metal stent placement for recurrent duodenal obstruction. Surgical Endoscopy and Other Interventional Techniques, 2023, 37, 319-328.	2.4	3
17895	Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors. ERJ Open Research, 0, , 00684-2021.	2.6	0
17897	Neoadjuvant therapy for resectable pancreatic cancer: a narrative review. Journal of Pancreatology, 2022, 5, 69-77.	0.9	2
17898	18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer. Clinical Lung Cancer, 2022, 23, 608-619.	2.6	5
17899	Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study. Anticancer Research, 2022, 42, 4603-4610.	1.1	5
17900	Limited predictive impact of tumor size dynamics on further tumor shrinkage after 4 cycles of first-line chemotherapy in patients with advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
17901	Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of Clinical Oncology, 2023, 41, 528-540.	1.6	62
17902	Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer. Journal of Computer Assisted Tomography, 2022, 46, 707-715.	0.9	3
17903	Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of Nuclear Medicine, 2023, 64, 221-226.	5.0	14
17904	Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	1.4	2
17905	The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls. Cancers, 2022, 14, 3965.	3.7	5
17906	Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. Npj Precision Oncology, 2022, 6, .	5.4	5

#	ARTICLE	IF	CITATIONS
17907	Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study. <i>Insights Into Imaging</i> , 2022, 13, .	3.4	6
17908	Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting. <i>Cancers</i> , 2022, 14, 3968.	3.7	2
17909	Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	1.2	1
17910	Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge. <i>Cancer Research Communications</i> , 2022, 2, 814-826.	1.7	1
17911	Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
17912	A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study. <i>Clinical Breast Cancer</i> , 2022, 22, e881-e891.	2.4	1
17913	Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
17914	Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 1263-1273.	2.6	6
17915	The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX). <i>Clinical Lung Cancer</i> , 2022, 23, e501-e509.	2.6	0
17916	Bayesian sample size determination in basket trials borrowing information between subsets. <i>Biostatistics</i> , 0, , .	1.5	2
17917	Coexisting Alterations of MHC Class I Antigen Presentation and IFN γ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 1254-1262.	3.4	5
17918	Liver directed stereotactic body radiotherapy can be reliably delivered to selected patients without internal fiducial markers- a case series. <i>Journal of the Chinese Medical Association</i> , 0, Publish Ahead of Print, .	1.4	0
17919	Prediction of response to neoadjuvant chemotherapy in breast cancer with recurrent neural networks and raw ultrasound signals. <i>Physics in Medicine and Biology</i> , 2022, 67, 185007.	3.0	3
17920	A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	0
17921	Optimized scaling of translational factors in oncology: from xenografts to RECIST. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 239-250.	2.3	1
17922	The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	3
17923	Primary adenoid cystic carcinoma of the trachea: an elusive diagnosis of chronic dyspnoea. <i>BMJ Case Reports</i> , 2022, 15, e250227.	0.5	1
17924	Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1840-1847.	30.7	152

#	ARTICLE	IF	CITATIONS
17925	Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 620-629.	2.6	6
17926	Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study. <i>Cancer Medicine</i> , 2023, 12, 2658-2665.	2.8	5
17927	Sensitivity analyses for the principal ignorability assumption using multiple imputation. <i>Pharmaceutical Statistics</i> , 2023, 22, 64-78.	1.3	0
17928	Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. <i>Cancer Medicine</i> , 2023, 12, 2731-2738.	2.8	15
17929	Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 475-491.	4.2	15
17930	Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer. <i>World Journal of Oncology</i> , 2022, 13, 195-204.	1.5	2
17931	Efficacy of <i>Lentinula edodes</i> Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients. <i>Nutrition and Cancer</i> , 2023, 75, 236-246.	2.0	1
17932	Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre. <i>Ecancermedicalscience</i> , 0, 16, .	1.1	0
17933	Retrospective analysis of independent predictors of progression-free survival in patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. <i>Thoracic Cancer</i> , 2022, 13, 2741-2750.	1.9	5
17934	Prospective Phase II Trial of [⁶⁸ Ga]Ga-NODAGA-E[c(RGDyK)] ₂ PET/CT Imaging of Integrin $\alpha_5\beta_1$ for Prognostication in Patients with Neuroendocrine Neoplasms. <i>Journal of Nuclear Medicine</i> , 2023, 64, 252-259.	5.0	2
17935	Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. <i>Journal of Immunotherapy</i> , 2022, 45, 349-357.	2.4	4
17936	Lung tumor segmentation using dual-coupling net with shape prior based on lung and mediastinal window images from chest CT images. <i>Journal of X-Ray Science and Technology</i> , 2022, 30, 1067-1083.	1.0	1
17937	Various impacts of driver mutations on the PD-L1 expression of NSCLC. <i>PLoS ONE</i> , 2022, 17, e0273207.	2.5	2
17938	Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. <i>Oncologist</i> , 2022, 27, 971-981.	3.7	9
17939	The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3830.	3.7	5
17940	Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-9.	1.9	2
17941	Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
17942	Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
17943	Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study. <i>Head and Neck</i> , 2022, 44, 2040-2045.	2.0	3
17944	Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3846.	3.7	15
17946	Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment. <i>Clinical Lung Cancer</i> , 2022, 23, e473-e477.	2.6	1
17947	Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. <i>Anti-Cancer Drugs</i> , 2022, 33, 752-757.	1.4	0
17948	Predictive role of diffusion-weighted MRI in the assessment of response to total neoadjuvant therapy in locally advanced rectal cancer. <i>European Radiology</i> , 2023, 33, 854-862.	4.5	7
17949	Clinical Outcomes of Patients with Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience. <i>Journal of Pediatric Hematology/Oncology</i> , 0, Publish Ahead of Print, .	0.6	0
17950	Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3549-3562.	2.5	5
17952	Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 925-951.	4.9	122
17953	An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
17954	A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High-Grade Bone Sarcomas: A Multicenter Study. <i>Orthopaedic Surgery</i> , 0, , .	1.8	0
17955	Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 136-145.	1.9	2
17956	Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. <i>Scientific Reports</i> , 2022, 12, .	3.3	9
17957	Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
17958	The Wessex Fit-4-Cancer Surgery Trial (WesFit): a protocol for a factorial-design, pragmatic randomised-controlled trial investigating the effects of a multi-modal prehabilitation programme in patients undergoing elective major intra-cavity cancer surgery. <i>F1000Research</i> , 0, 10, 952.	1.6	1
17959	Artificial intelligence in radiotherapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 160-171.	9.6	14
17960	Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. , 2022, 10, e004904.		12
17961	Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2538-2547.	3.9	15
17962	Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study. <i>International Journal of Hyperthermia</i> , 2022, 39, 1078-1087.	2.5	1

#	ARTICLE	IF	CITATIONS
17963	Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. <i>Cell Reports Medicine</i> , 2022, 3, 100711.	6.5	17
17964	Functional tumor diameter measurement with molecular breast imaging: development and clinical application. <i>Biomedical Physics and Engineering Express</i> , 2022, 8, 055026.	1.2	1
17965	L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. <i>Discover Oncology</i> , 2022, 13, .	2.1	3
17966	Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	13
17967	Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. <i>Current Oncology</i> , 2022, 29, 6154-6166.	2.2	7
17968	Efficacy and safety of EGFRâ€˜TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	2
17969	A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions. <i>Radiology</i> , 2022, 305, 721-728.	7.3	10
17970	Prospective of ³¹P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	4
17971	STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4737-4746.	7.0	7
17972	Healthâ€related quality of life trajectories in melanoma patients after electrochemotherapy: realâ€world insights from the ^{InspECT} register. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2352-2363.	2.4	3
17973	Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
17974	Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Acta Radiologica</i> , 2023, 64, 1194-1204.	1.1	0
17975	Special issue â€The advance of solid tumor research in Chinaâ€: ^{FGFR4} alterations predict efficacy of immune checkpoint inhibitors in nonâ€small cell lung cancer. <i>International Journal of Cancer</i> , 0, , .	5.1	2
17976	Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. <i>Discover Oncology</i> , 2022, 13, .	2.1	5
17977	Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 887-897.e3.	4.9	3
17978	FDG PET/CT for Staging and Restaging Malignant Mesothelioma. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 806-815.	4.6	5
17979	Synchronous pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4â€ALK fusion: A case report. <i>Oncology Letters</i> , 2022, 24, .	1.8	3
17980	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3469-3483.	2.5	9

#	ARTICLE	IF	CITATIONS
17981	Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. , 2022, 10, e005147.		24
17982	Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy. Annals of Surgery, 2023, 278, 118-126.	4.2	12
17983	A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. Frontiers in Genetics, 0, 13, .	2.3	6
17984	Carbonâ€ion radiotherapy versus radiofrequency ablation as initial treatment for earlyâ€stage hepatocellular carcinoma. Hepatology Research, 0, , .	3.4	3
17985	Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). Japanese Journal of Clinical Oncology, 0, , .	1.3	1
17986	PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. Frontiers in Immunology, 0, 13, .	4.8	3
17987	Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer?. Journal of Clinical Medicine, 2022, 11, 4815.	2.4	1
17988	The value of the SUV ratio between lymph node and bone marrow in predicting pelvic lymphatic metastasis of patients with locally advanced cervical cancer: an integrated PET/CT study. Nuclear Medicine Communications, 0, Publish Ahead of Print, .	1.1	0
17989	Clinical Validation of Companion Diagnostics for the Selection of Patients with Nonâ€Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. Journal of Molecular Diagnostics, 2022, 24, 1181-1188.	2.8	2
17990	Interventional radiology meets immuno-oncology for hepatocellular carcinoma. Journal of Hepatology, 2022, , .	3.7	5
17991	First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer. International Journal of Clinical Oncology, 2022, 27, 1733-1741.	2.2	4
17992	Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkinâ€s Lymphoma in Children. Children, 2022, 9, 1279.	1.5	0
17993	Sacituzumab Govitecan in Hormone Receptorâ€Positive/Human Epidermal Growth Factor Receptor 2â€Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3365-3376.	1.6	90
17994	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. Journal of Oncology, 2022, 2022, 1-15.	1.3	1
17995	Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	2.8	5
17998	Sarcoid-like reaction in patients with malignant tumors: Long-term clinical course and outcomes. Frontiers in Medicine, 0, 9, .	2.6	7
17999	EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. Journal of Clinical Oncology, 2023, 41, 640-650.	1.6	9
18000	Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Medicine, 2022, 20, .	5.5	3

#	ARTICLE	IF	CITATIONS
18001	Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. <i>Cancers</i> , 2022, 14, 3971.	3.7	5
18002	Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients. <i>Cancers</i> , 2022, 14, 4069.	3.7	4
18003	Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9527.	4.1	4
18004	Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 762-770.	0.8	13
18005	Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. , 2022, 10, e005226.		17
18006	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 1045-1053.	1.4	2
18007	Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. <i>Nature Medicine</i> , 2022, 28, 1612-1618.	30.7	80
18008	HERIZON-GEA-01: Zanidatamab + chemo± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. <i>Future Oncology</i> , 2022, 18, 3255-3266.	2.4	13
18009	Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. <i>Hepatology International</i> , 2022, 16, 1179-1187.	4.2	6
18010	Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer. <i>Anticancer Research</i> , 2022, 42, 4581-4588.	1.1	0
18011	Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	5
18012	PD1 blockade alters cell-cycle distribution and affects 3â€²-deoxy-3â€²-[18F]fluorothymidine uptake in a mouse CT26 tumor model. <i>Annals of Nuclear Medicine</i> , 2022, 36, 931-940.	2.2	1
18013	Predicting chemotherapy response in non-small-cell lung cancer via computed tomography radiomic features: Peritumoral, intratumoral, or combined?. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	9
18014	Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma. <i>Gynecologic Oncology</i> , 2022, 167, 28-36.	1.4	2
18015	Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study. <i>Cancer Medicine</i> , 2023, 12, 3160-3166.	2.8	4
18016	Progress in gallbladder cancer with lymph node metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18017	Survival analysis of patients with advanced metastatic differentiated thyroid cancer. <i>Opuholi Golovy I Sei</i> , 2022, 12, 63-70.	0.4	1
18018	PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with<1% PD-L1 expression: a meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	3

#	ARTICLE	IF	CITATIONS
18019	Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer. The Application of Clinical Genetics, 0, Volume 15, 97-109.	3.0	4
18020	Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. BMC Cancer, 2022, 22, .	2.6	12
18021	Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. PLoS ONE, 2022, 17, e0272367.	2.5	3
18022	Preoperative neoadjuvant targeted therapy with lenvatinib for inoperable thyroid cancer. Medicine, Case Reports and Study Protocols, 2022, 3, e0240.	0.1	1
18023	Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<sc>KHBO1401</sc>â€•<sc>MITSUBA</sc>). Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 102-110.	2.6	65
18024	A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. BMC Cancer, 2022, 22, .	2.6	3
18025	Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Oncologist, 2022, 27, e774-e782.	3.7	3
18026	Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN. Clinical Orthopaedics and Related Research, 2023, 481, 107-116.	1.5	6
18027	Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation. Anticancer Research, 2022, 42, 4589-4595.	1.1	1
18028	POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatinâ€“paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Frontiers in Oncology, 0, 12, .	2.8	3
18029	Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. International Journal of Molecular Sciences, 2022, 23, 9535.	4.1	6
18030	Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S-1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma. Experimental and Therapeutic Medicine, 2022, 24, .	1.8	1
18031	Comparison of progressed and unresponsive patients with responsive patients at Â±nterim assessment during breast cancer neoadjuvant chemotherapy. Ege Tıp Dergisi, 0, , 313-318.	0.2	0
18032	Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation. Molecular Therapy - Oncolytics, 2022, 26, 330-346.	4.4	1
18033	Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer, 2022, 174, 68-77.	2.8	45
18034	The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA. Breast, 2022, 65, 116-123.	2.2	8
18035	EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients. ESMO Open, 2022, 7, 100550.	4.5	1
18036	Ranking the most influential predictors of CT-based radiomics feature values in metastatic lung adenocarcinoma. European Journal of Radiology, 2022, 155, 110472.	2.6	0

#	ARTICLE	IF	CITATIONS
18037	Clinical considerations of bleomycin based electrochemotherapy with variable electrode geometry electrodes for inoperable, deep-seated soft tissue sarcomas. <i>Bioelectrochemistry</i> , 2022, 148, 108220.	4.6	2
18038	Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. <i>European Journal of Endocrinology</i> , 2022, 187, 685-696.	3.7	20
18039	The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study. <i>Cancers</i> , 2022, 14, 4333.	3.7	7
18040	A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4291.	3.7	2
18042	Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy. <i>International Journal of Clinical Oncology</i> , 0, , .	2.2	0
18043	IgG+ Extracellular Vesicles Measure Therapeutic Response in Advanced Pancreatic Cancer. <i>Cells</i> , 2022, 11, 2800.	4.1	1
18044	Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. , 2022, 10, e005328.		6
18046	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	13
18047	Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 4284.	3.7	9
18048	ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy in metastatic colorectal cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1671-1683.	2.0	1
18049	Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
18050	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1011-1027.	3.7	3
18051	The efficacy and safety of 125I brachytherapy combined with pre-operative transarterial chemoembolization in patients with locally advanced head and neck cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18052	Earlyâ€phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. <i>Cancer</i> , 2022, 128, 3775-3783.	4.1	2
18053	Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study. <i>Journal of Liver Cancer</i> , 2022, 22, 136-145.	1.1	5
18055	Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy. <i>Acta OncolÃ³gica</i> , 2022, 61, 1116-1120.	1.8	2
18056	Imaging of pediatric cardiac tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	1
18057	Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	0

#	ARTICLE	IF	CITATIONS
18058	Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. <i>Cancers</i> , 2022, 14, 4413.	3.7	7
18059	Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?. <i>Cancer Medicine</i> , 0, .	2.8	2
18060	Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. <i>ESMO Open</i> , 2022, 7, 100571.	4.5	6
18061	Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1274-1286.	10.7	202
18062	Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. <i>European Journal of Cancer</i> , 2022, 174, 221-231.	2.8	22
18063	Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. <i>ESMO Open</i> , 2022, 7, 100573.	4.5	16
18064	Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1287-1296.	10.7	18
18065	Head-to-head assessment of [68Ga]Ga-DOTA-FAPI-04 PET/CT vs [18F]FDG PET/CT in fibroblastic tumors. <i>European Journal of Radiology</i> , 2022, 155, 110507.	2.6	1
18066	Machine learning on the road to unlocking microbiota's potential for boosting immune checkpoint therapy. <i>International Journal of Medical Microbiology</i> , 2022, 312, 151560.	3.6	1
18067	A rare HIV-associated hyaline vascular multicentric castleman disease with good early response to single-agent rituximab: A case from Tanzania. <i>Human Pathology Reports</i> , 2022, 30, 300677.	0.3	0
18068	Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients. <i>Lung Cancer</i> , 2022, 173, 35-42.	2.0	4
18069	Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2022, 175, 43-53.	2.8	4
18070	A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases. <i>Radiotherapy and Oncology</i> , 2022, 176, 9-16.	0.6	3
18071	Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2022, 173, 101-106.	2.0	6
18072	Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. <i>European Journal of Cancer</i> , 2022, 175, 60-76.	2.8	12
18073	A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. <i>European Journal of Cancer</i> , 2022, 175, 125-135.	2.8	6
18074	Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2022, 112, 109223.	3.8	7
18075	S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial. <i>EClinicalMedicine</i> , 2022, 54, 101667.	7.1	2

#	ARTICLE	IF	CITATIONS
18076	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2022, , 1-18.		0
18077	The Value of Magnetic Resonance Diffusion-Weighted Imaging in Evaluating the Efficacy of Concurrent Chemoradiotherapy in Patients with Hypopharyngeal Carcinoma. Journal of Biosciences and Medicines, 2022, 10, 132-142.	0.2	0
18078	Pretreatment hematological parameters as predictors of tumor granulocyte-colony-stimulating factor expression in patients of head-and-neck squamous cell carcinoma. Journal of Cancer Research and Therapeutics, 2022, .	0.9	0
18079	Diagnostic Applications of Nuclear Medicine: Esophageal Cancers. , 2022, , 1-18.		0
18080	Class Imbalance Correction forÂImproved Universal Lesion Detection andÂTagging inÂCT. Lecture Notes in Computer Science, 2022, , 177-186.	1.3	0
18081	Universal Lesion Detection andÂClassification Using Limited Data andÂWeakly-Supervised Self-training. Lecture Notes in Computer Science, 2022, , 55-64.	1.3	0
18082	Magnetotherapy in patients with malignant tumors receiving immunotherapy. Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury, 2022, 99, 51.	0.5	0
18083	Diagnostic Applications of Nuclear Medicine: Esophageal Cancers. , 2022, , 811-828.		0
18084	Statistical considerations for repeatability and reproducibility of quantitative imaging biomarkers. BJR Open, 2022, 4, .	0.6	0
18085	Lung Nodules Segmentation withÂDeepHealth Toolkit. Lecture Notes in Computer Science, 2022, , 487-497.	1.3	1
18086	Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery. Neuro-Oncology Advances, 2022, 4, .	0.7	3
18087	Accurate andÂRobust Lesion RECIST Diameter Prediction andÂSegmentation withÂTransformers. Lecture Notes in Computer Science, 2022, , 535-544.	1.3	4
18088	Deep Treatment Response Assessment andÂPrediction ofÂColorectal Cancer Liver Metastases. Lecture Notes in Computer Science, 2022, , 482-491.	1.3	3
18089	Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211195.	3.2	12
18090	EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A caseâ€“control study. Endoscopic Ultrasound, 2022, .	1.5	0
18091	Assessment of Tumour Response to Neoadjuvant Therapy for the Treatment of Oesophageal Cancer. GI Surgery Annual, 2022, , 147-162.	0.0	0
18092	First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for <i>de novo</i> Metastatic Nasopharyngeal Carcinoma: A Matched Cohort Study. Cancer Control, 2022, 29, 107327482211248.	1.8	0
18093	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
18094	Predictive Value of Radiological Response, Pathological Response and Relapse-Free Survival for Overall Survival in Neoadjuvant Immunotherapy Trials: Meta-Analyses of Individual Patient Data. SSRN Electronic Journal, 0, , .	0.4	0
18095	Diagnostic Applications of Nuclear Medicine: Gastrointestinal Stromal Tumors. , 2022, , 847-864.		0
18096	M1 stage subdivisions based on ¹⁸ F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211187.	3.2	0
18097	Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 365-382.	2.2	11
18098	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2022, , 431-474.		0
18099	Chirurgische Grundlagen. , 2022, , 1-73.		0
18100	Effects of Nivolumab for the Head and Neck Carcinoma Patients. Practica Otologica, 2022, 115, 875-881.	0.0	0
18101	The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211126.	3.2	15
18102	Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study. Cancer Control, 2022, 29, 107327482211305.	1.8	2
18103	Diagnostic Applications of Nuclear Medicine: Gastric Cancers. , 2022, , 829-846.		0
18104	Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211236.	1.3	2
18105	Joint Analysis of Longitudinal and Time-to-Event Data. , 2022, , 1919-1935.		0
18106	Quantitative DCE-MRI of the Breast. Advances in Magnetic Resonance Technology and Applications, 2022, , 425-458.	0.1	0
18107	Breast Magnetic Resonance Imaging for Patients With Newly Diagnosed Breast Cancer: A Review. Journal of Breast Cancer, 2022, 25, 263.	1.9	1
18108	Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan. Journal of Cancer, 2022, 13, 2922-2932.	2.5	0
18109	Diagnostic Applications of Nuclear Medicine: Gastrointestinal Stromal Tumors. , 2022, , 1-19.		0
18110	Neuroimaging issues in assessing glioma response to brain tumour therapy. , 2022, , 809-819.		0
18111	Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival. In Vivo, 2022, 36, 2332-2341.	1.3	1

#	ARTICLE	IF	CITATIONS
18112	Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence. Korean Journal of Radiology, 2022, 23, 1089.	3.4	9
18114	Primary huge gastric leiomyosarcoma with multiple metastases in a 60-year-old female: a case report. Pan African Medical Journal, 0, 42, .	0.8	0
18115	Assessment of response of neoadjuvant chemotherapy in carcinoma breast patients by high-frequency ultrasound. Journal of Family Medicine and Primary Care, 2022, 11, 4717.	0.9	0
18116	Pseudo-progression in neuro-oncology. , 2022, , 821-839.		0
18117	â€”FLAREâ€” of tumor marker in advanced gastric cancer treated with first-line systemic therapy. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211240.	3.2	0
18118	Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer. Cancer Treatment and Research Communications, 2022, 33, 100637.	1.7	3
18119	The clinical effect of conversion surgery for advanced gastric cancer patients with peritoneal metastasis. Journal of Gastrointestinal Oncology, 2022, .	1.4	0
18120	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2022, , 715-741.		0
18121	Understanding Uncertainty Maps in Vision with Statistical Testing. , 2022, , .		2
18122	Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 4091-4099.	2.5	8
18123	Electrochemotherapy with intravenous bleomycin for patients with cutaneous malignancies, across tumour histology: a systematic review. Acta OncolÃ³gica, 2022, 61, 1093-1104.	1.8	6
18124	Brigatinib in Japanese patients with tyrosine kinase inhibitor-naïve ALK-positive non-small cell lung cancer: first results from the phase 2 AJ-ALTA study. International Journal of Clinical Oncology, 2022, 27, 1828-1838.	2.2	4
18125	Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients. Journal of Gastrointestinal Oncology, 2022, 13, 1898-1906.	1.4	3
18127	Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncology, 2022, 18, 3267-3276.	2.4	2
18128	Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy. Cancers, 2022, 14, 4167.	3.7	6
18129	High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. Biomedicines, 2022, 10, 2109.	3.2	0
18130	Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2023, 41, 22-31.	1.6	91
18131	Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. Neuroendocrinology, 2023, 113, 332-342.	2.5	5

#	ARTICLE	IF	CITATIONS
18132	A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1989-1996.	1.4	1
18133	The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 913-927.	3.7	3
18134	Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	27
18136	A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). <i>Clinical Lung Cancer</i> , 2022, 23, e536-e539.	2.6	7
18137	Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	1.3	1
18138	Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
18139	Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	1
18140	Cambios histopatológicos secundarios a terapia diana en melanoma. <i>Actas Dermo-sifiliográficas</i> , 2022, 114, 75-75.	0.4	0
18141	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 1151-1164.	13.2	79
18142	Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9394.	4.1	3
18143	A comparative study of functional MRI in predicting response of regional nodes to induction chemotherapy in patients with nasopharyngeal carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18144	A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report. <i>Medicine (United States)</i> , 2022, 101, e30269.	1.0	0
18145	Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
18146	A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
18147	Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. <i>Molecular Therapy</i> , 2023, 31, 78-89.	8.2	2
18148	Is there a potential biomarker in distinguishing invasive breast carcinomas with elevated Ki67 levels among <sc>2Dâ€SWE</sc> , <sc>SMI</sc> , and <sc>18Fâ€FDG PETâ€CT</sc> / <sc>MRI</sc> â€derived parameters?: A singleâ€center data. <i>Journal of Clinical Ultrasound</i> , 0, , .	1.8	0
18149	Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18150	Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	4

#	ARTICLE	IF	CITATIONS
18151	Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy. <i>Oncologist</i> , 2022, 27, 1048-1057.	3.7	4
18152	Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer. <i>Endocrine</i> , 2022, 78, 543-551.	2.3	2
18153	Inferring FDG-PET-positivity of lymph node metastases in proven lung cancer from contrast-enhanced CT using radiomics and machine learning. <i>European Radiology Experimental</i> , 2022, 6, .	3.4	0
18154	A novel case of malignant ossifying fibromyxoid tumor with a <i>BCOR</i> internal tandem duplication in a child. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	0
18155	<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. <i>JCO Precision Oncology</i> , 2022, , .	3.0	5
18156	Microballoon Interventions for Liver Tumors: Review of Literature and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 5334.	2.4	3
18157	The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients. <i>Pathology and Oncology Research</i> , 0, 28, .	1.9	0
18158	¹⁷⁷ Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷ Lu-PSMA- <i>i&T</i> Therapy. <i>Journal of Nuclear Medicine</i> , 2023, 64, 410-415.	5.0	13
18159	Assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor α ⁶ observational single center study. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	1.0	1
18160	First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18162	NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 4459.	3.7	5
18163	Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/ <i>DICER1</i> Registry. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	6
18164	The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. <i>Cancers</i> , 2022, 14, 4598.	3.7	3
18165	Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	1
18166	Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18167	Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
18168	Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
18169	Dual-energy CT with virtual monoenergetic images and iodine maps improves tumor conspicuity in patients with pancreatic ductal adenocarcinoma. <i>Insights Into Imaging</i> , 2022, 13, .	3.4	12

#	ARTICLE	IF	CITATIONS
18170	Echocardiography-Assessed Changes of Left and Right Ventricular Cardiac Function May Correlate with Progression of Advanced Lung Cancer—A Generating Hypothesis Study. <i>Cancers</i> , 2022, 14, 4770.	3.7	4
18171	Postâ€progression survival after atezolizumab plus carboplatin and etoposide as firstâ€line chemotherapy in small cell lung cancer has a significant impact on overall survival. <i>Thoracic Cancer</i> , 2022, 13, 2776-2785.	1.9	3
18172	Overall Survival in Patients with Stage IV Panâ€NET Eligible for Liver Transplantation. <i>World Journal of Surgery</i> , 2023, 47, 340-347.	1.6	5
18173	Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4807-4819.	7.0	6
18174	Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProFiLER-01 Trial. <i>Journal of Personalized Medicine</i> , 2022, 12, 1595.	2.5	3
18175	Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival. <i>HemaSphere</i> , 2022, 6, e781.	2.7	4
18176	Immune Effect of T Lymphocytes Infiltrated by Tumors on Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	1.3	0
18177	Preclinical Characterization and Phase I Study of an Antiâ€HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. <i>Cancer Immunology Research</i> , 2022, 10, 1441-1461.	3.4	18
18178	Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
18179	Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2022, 387, 1557-1568.	27.0	101
18180	Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
18181	Diagnosis of Malnutrition According to GLIM Criteria Predicts Complications and 6-Month Survival in Cancer Outpatients. <i>Biomedicines</i> , 2022, 10, 2201.	3.2	3
18182	Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. <i>Annals of Surgical Oncology</i> , 2023, 30, 2401-2408.	1.5	4
18183	IL-6, TNF-Î± and IL-12p70 levels in patients with colorectal cancer and their predictive value in anti-vascular therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
18184	KEYNOTE â€ D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. <i>Future Oncology</i> , 0, , .	2.4	7
18185	Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. <i>BMC Cancer</i> , 2022, 22, .	2.6	6
18186	Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response. <i>Cancer Medicine</i> , 2023, 12, 4010-4022.	2.8	4
18187	Chemotherapy response evaluation using diffusion weighted MRI in Ewing Sarcoma: A single center experience. <i>Acta Radiologica</i> , 2023, 64, 1508-1517.	1.1	1

#	ARTICLE	IF	CITATIONS
18188	Effect of Pre-Existent Sarcopenia on Oncological Outcome of Advanced Thyroid Cancer Patients Treated with Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 4569.	3.7	1
18190	Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
18191	Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
18192	Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	3
18193	Endothelial activation and stress index (EASIX) as a predictive biomarker in small cell lung cancer. <i>Cancer Biomarkers</i> , 2022, 35, 217-225.	1.7	2
18194	Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 5505.	2.4	4
18195	Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade. <i>Cancers</i> , 2022, 14, 4445.	3.7	7
18196	Doseâ€ effect relationship between doseâ€volume parameters of residual gross tumor volume and clinical prognosis in MRI-guided adaptive brachytherapy for locally advanced cervical cancer: a single-center retrospective study. <i>Strahlentherapie Und Onkologie</i> , 0, , .	2.0	2
18197	The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 924-924.	1.7	0
18198	P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	9
18199	Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 1858-1864.	6.4	4
18200	The utility of low-iodine diet in preparation for thyroid cancer therapy with radioactive iodineâ€A cohort study. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	0
18201	Effect of Covid-19 pandemic on patients undergoing definitive chemoradiotherapy. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	0
18202	Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
18203	The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review. <i>Cureus</i> , 2022, , .	0.5	0
18204	Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	5
18205	Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. <i>Annals of Surgical Oncology</i> , 2023, 30, 35-45.	1.5	2
18206	Advances in the management of peritoneal malignancies. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 698-718.	27.6	20

#	ARTICLE	IF	CITATIONS
18207	Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function <i>NOTCH1</i> -Mutant Head and Neck Cancer. <i>Oncologist</i> , 2022, 27, 1004-e926.	3.7	6
18208	Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 477-485.	3.3	1
18209	A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. <i>Cancer Medicine</i> , 2023, 12, 4270-4281.	2.8	4
18210	Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	10
18211	Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18212	Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. <i>Liver International</i> , 2023, 43, 8-17.	3.9	6
18213	Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation. <i>European Journal of Cancer</i> , 2022, 176, 193-206.	2.8	1
18214	Collaborative multi-feature extraction and scale-aware semantic information mining for medical image segmentation. <i>Physics in Medicine and Biology</i> , 2022, 67, 205008.	3.0	1
18215	Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naïve and Castration-Resistant Prostate Cancer Patients. <i>Cancers</i> , 2022, 14, 4404.	3.7	1
18216	<i>MRI</i> -Based Metastatic Nodal Number and Associated Nomogram Improve Stratification of Nasopharyngeal Carcinoma Patients: Potential Indications for Individual Induction Chemotherapy. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 1790-1802.	3.4	6
18217	ICBAtlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles. <i>Cancer Immunology Research</i> , 2022, 10, 1398-1406.	3.4	12
18218	Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	1.3	0
18219	Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. <i>Clinical Cancer Research</i> , 2023, 29, 379-388.	7.0	10
18221	Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i> -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 212-221.	1.6	76
18222	Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 991-991.	1.7	5
18224	Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1049-1059.	2.4	5
18225	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
18226	The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, Tj ETQq1 1 0.784314 rgBT /Over Chemotherapy”The Randomized NORDIC9-Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5603.	2.4	7

#	ARTICLE	IF	CITATIONS
18227	Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 841-849.	4.2	2
18228	CD133 is an independent predictive and prognostic marker in metastatic breast cancer. <i>Cancer Biomarkers</i> , 2022, 35, 207-215.	1.7	2
18229	A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 167, 213-225.	1.4	12
18230	Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer. <i>European Thyroid Journal</i> , 2022, , .	2.4	2
18232	TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
18233	The study of predictive factors for the evolution of vestibular schwannomas. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 1661-1670.	1.6	2
18234	No Impact of PolySia-NCAM Expression on Treatment Response in Neuroendocrine Neoplasms of the Lung. <i>Cancers</i> , 2022, 14, 4376.	3.7	1
18235	Efficacy and potential resistance mechanisms of afatinib in advanced non-“small cell lung cancer patients with <sc>EGFR G719X</sc>/<sc>L861Q</sc>/<sc>S768I</sc>. <i>Cancer</i> , 2022, 128, 3804-3814.	4.1	6
18236	Comparable Outcomes in Early Hepatocellular Carcinomas Treated with Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Biomedicines</i> , 2022, 10, 2361.	3.2	6
18237	Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer. <i>Cureus</i> , 2022, , .	0.5	0
18238	Utility of Integrated PET/MRI for the Primary Diagnostic Work-Up of Patients with Ewing Sarcoma: Preliminary Results. <i>Diagnostics</i> , 2022, 12, 2278.	2.6	2
18239	Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study. <i>Cancers</i> , 2022, 14, 4576.	3.7	5
18240	Association between tumor response to systemic therapy and patient-reported disease symptoms. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	0
18241	Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 4579.	3.7	1
18242	Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy. <i>Advanced Science</i> , 2022, 9, .	11.2	41
18243	Peritoneal regression grading score (PRGS) in peritoneal metastasis: how many biopsies should be examined?. <i>Pleura and Peritoneum</i> , 2022, 7, 179-185.	1.2	1
18244	Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group. <i>Leukemia and Lymphoma</i> , 0, , 1-8.	1.3	0
18245	Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy. <i>European Radiology</i> , 2022, 32, 7295-7306.	4.5	7

#	ARTICLE	IF	CITATIONS
18246	S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
18247	Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer. <i>Cancers</i> , 2022, 14, 4417.	3.7	7
18248	Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). , 2022, 10, e005424.		7
18250	Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
18251	Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study. <i>Thoracic Cancer</i> , 2022, 13, 2829-2833.	1.9	2
18252	Distal pancreatectomy with en bloc celiac axis resection (DP-CAR) using retroperitoneal-first laparoscopic approach (Retlap): A novel minimally invasive approach for determining resectability and achieving tumor-free resection margins of locally advanced pancreatic body cancer. <i>Surgical Oncology</i> , 2022, 45, 101857.	1.6	1
18253	Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. <i>Nature Cancer</i> , 2022, 3, 1123-1136.	13.2	71
18254	Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic. <i>Cureus</i> , 2022, , .	0.5	0
18255	Photoimmunotherapy with surgical navigation and computed tomography guidance for recurrent maxillary sinus carcinoma. <i>Auris Nasus Larynx</i> , 2022, , .	1.2	3
18256	Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11529.	4.1	11
18257	Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. <i>Nature Communications</i> , 2022, 13, .	12.8	18
18258	Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. <i>Oncology and Therapy</i> , 2022, 10, 463-479.	2.6	2
18259	The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?. <i>Gynecologic Oncology</i> , 2022, 167, 174-180.	1.4	2
18260	Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma. <i>Cancer Medicine</i> , 2023, 12, 3027-3035.	2.8	1
18261	Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
18262	Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	2.0	1
18263	Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	1
18264	PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2023, 64, 372-378.	5.0	3

#	ARTICLE	IF	CITATIONS
18265	Gene expression based inference of cancer drug sensitivity. <i>Nature Communications</i> , 2022, 13, .	12.8	34
18266	Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature. <i>European Radiology</i> , 2023, 33, 825-835.	4.5	10
18267	The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The I ¹ -Meet-URO analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
18268	Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	1.3	7
18269	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. <i>Nature Medicine</i> , 2022, 28, 2155-2161.	30.7	93
18270	Reâ€challenging chemotherapy after pembrolizumab in platinumâ€refractory urothelial carcinoma. <i>BJU International</i> , 2023, 131, 477-485.	2.5	6
18271	Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients. <i>Cancers</i> , 2022, 14, 4410.	3.7	4
18274	ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. <i>BMJ Open</i> , 2022, 12, e060782.	1.9	3
18276	Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. <i>Gut Microbes</i> , 2022, 14, .	9.8	20
18277	Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	0
18278	Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 1061-1065.	0.5	5
18279	Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
18280	Protocol of a randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer: JCOG1611 (GENERATE). <i>Japanese Journal of Clinical Oncology</i> , 0, .	1.3	1
18281	Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. <i>Esophagus</i> , 2023, 20, 109-115.	1.9	4
18282	Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands: the BELIVER study. <i>BMJ Open</i> , 2022, 12, e055104.	1.9	2
18283	Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18284	Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
18285	Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer. <i>Oncology Letters</i> , 2022, 24, .	1.8	3

#	ARTICLE	IF	CITATIONS
18286	HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	2
18287	CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	1.2	2
18288	Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy. <i>Anti-Cancer Drugs</i> , 2022, 33, e842-e849.	1.4	5
18289	Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18290	A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 575-580.	1.9	2
18291	Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. <i>Translational Lung Cancer Research</i> , 2022, 11, 1866-1876.	2.8	1
18292	Disappearing Colorectal Liver Metastases: Do We Really Need a Ghostbuster?. <i>Healthcare (Switzerland)</i> , 2022, 10, 1898.	2.0	1
18293	Predictors of survival outcomes among patients with gastric cancer in a leading tertiary, teaching and referral hospital in Kenya. <i>Cancer Medicine</i> , 2023, 12, 4147-4160.	2.8	2
18294	Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	1
18295	Intra- and Inter-Reader Variations in Lung Nodule Measurements: Influences of Nodule Size, Location, and Observers. <i>Diagnostics</i> , 2022, 12, 2319.	2.6	0
18296	Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 7581-7591.	1.8	3
18297	Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11353.	4.1	6
18298	Alteration of Clinical Tumor Characteristics Is Associated with Pathological Regression in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2600-2605.	1.7	0
18299	The Management of Oligometastases in Non-small Cell Lung Cancer “is Stereotactic Ablative Radiotherapy now Standard of Care?”. <i>Clinical Oncology</i> , 2022, , .	1.4	2
18300	Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti- PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. <i>Journal of Digestive Diseases</i> , 2022, 23, 535-545.	1.5	5
18301	Molecular and Anatomic Imaging of Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2022, , .	1.5	0
18302	The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator. <i>Pathology and Oncology Research</i> , 0, 28, .	1.9	1
18303	Treatment planning computed tomography radiomics for predicting treatment outcomes and haematological toxicities in locally advanced cervical cancer treated with radiotherapy: A retrospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2023, 130, 222-230.	2.3	5

#	ARTICLE	IF	CITATIONS
18304	Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study. World Journal of Gastrointestinal Oncology, 2022, 14, 1785-1797.	2.0	1
18305	First-in-human study of ²ONO-4578, an antagonist of prostaglandin ² receptor 4, alone and with nivolumab in solid tumors. Cancer Science, 2023, 114, 211-220.	3.9	4
18306	Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors. Cancer Medicine, 2023, 12, 3046-3053.	2.8	2
18307	High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. European Journal of Cancer, 2022, 177, 80-93.	2.8	12
18308	Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical Cancer Research, 2022, 28, 5180-5189.	7.0	9
18309	Bayesian forecasting of tumor size metrics and overall survival. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1604-1613.	2.5	3
18310	Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. Heliyon, 2022, 8, e10932.	3.2	7
18311	Imaging of pediatric adrenal tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatric Blood and Cancer, 2023, 70, .	1.5	0
18312	Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing ¹⁸F-FDG PET/CT with Conventional CT. Journal of Nuclear Medicine, 2023, 64, 355-361.	5.0	13
18313	Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist, 2022, 27, e938-e948.	3.7	8
18314	Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research, 2022, 28, 4871-4884.	7.0	27
18315	Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. Journal of Biological Chemistry, 2022, 298, 102442.	3.4	2
18316	Proton Radiotherapy Following Chemotherapy in the Management of Aggressive Mediastinal non-Hodgkin Lymphomas: A PTCOG Lymphoma Subcommittee Collaboration. Advances in Radiation Oncology, 2022, , 101090.	1.2	1
18317	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. Frontiers in Oncology, 0, 12, .	2.8	9
18318	Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. Frontiers in Oncology, 0, 12, .	2.8	1
18319	The Effect and Tolerability of Second-line Chemotherapy Are Associated With Disease Control by Nivolumab Chemotherapy in Patients With Gastric Cancer. Anticancer Research, 2022, 42, 4973-4980.	1.1	0
18320	Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. European Urology, 2023, 83, 82-89.	1.9	5
18321	CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy. Frontiers in Oncology, 0, 12, .	2.8	8

#	ARTICLE	IF	CITATIONS
18322	Special issue “The advance of solid tumor research in China” Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors. International Journal of Cancer, 2023, 152, 90-99.	5.1	3
18323	Cost and effectiveness of microwave ablation versus video-assisted thoracoscopic surgical resection for ground-glass nodule lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	2.8	5
18324	Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations. JTO Clinical and Research Reports, 2022, 3, 100407.	1.1	2
18326	Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. European Journal of Cancer, 2022, 177, 45-52.	2.8	3
18327	Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy. Anticancer Research, 2022, 42, 4805-4812.	1.1	2
18328	Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Anticancer Research, 2022, 42, 4907-4912.	1.1	2
18329	Long-term result of ¹²⁵ I seed brachytherapy for pediatric desmoid tumor in the head and neck. Pediatric Blood and Cancer, 0, , .	1.5	3
18330	Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists. Radiographics, 2022, 42, 1670-1689.	3.3	4
18331	Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	1
18332	Persistent lymph nodes after curative chemoradiotherapy for head and neck cancer: imaging predictors of response for decision-making. European Archives of Oto-Rhino-Laryngology, 0, , .	1.6	0
18333	Current issues in medical epistemology and statistics: a view from the frontline of medicine. Synthese, 2022, 200, .	1.1	1
18335	Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1. AAPS Journal, 2022, 24, .	4.4	1
18336	A case of pathological complete response with liposomal irinotecan+5-FU/LV for unresectable locally advanced pancreatic cancer. Surgical Case Reports, 2022, 8, .	0.6	0
18337	Comparison of Survival Outcomes Based on Pre-treatment Pleural Effusion in Advanced Epithelial Ovarian Cancer. Anticancer Research, 2022, 42, 4937-4943.	1.1	0
18338	Clinical analysis of prophylactic para-aortic intensity-modulated radiation in cervical cancer. Clinical Radiology, 2022, , .	1.1	0
18339	Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. Hpb, 2023, 25, 100-108.	0.3	4
18340	Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer, 2023, 12, 72-84.	7.7	16
18341	Prophylactic cranial irradiation (PCI) versus active surveillance in patients with limited-stage small cell lung cancer: a retrospective, multicentre study. Respiratory Research, 2022, 23, .	3.6	0

#	ARTICLE	IF	CITATIONS
18342	Artificial Intelligence for Image Registration in Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2022, 32, 330-342.	2.2	6
18343	Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
18344	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
18345	A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement. <i>Annals of Surgical Oncology</i> , 2023, 30, 193-202.	1.5	6
18346	Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. <i>BMC Cancer</i> , 2022, 22, .	2.6	3
18347	Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. <i>European Journal of Cancer</i> , 2022, 176, 121-132.	2.8	8
18348	The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases. <i>Surgery</i> , 2022, 172, 1434-1441.	1.9	0
18349	Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. <i>Drug Resistance Updates</i> , 2022, 65, 100883.	14.4	10
18350	Bronchial Artery Chemoembolization With Radiopaque Doxorubicin Eluting Beads in Patients With Malignant Hemoptysis from Metastatic Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211311.	1.9	3
18351	Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma. <i>Theranostics</i> , 2022, 12, 7420-7430.	10.0	10
18352	Breast Cancer: PET/CT Imaging. , 2022, , 45-49.		0
18353	Breast MRI: Techniques and Indications. <i>Medical Radiology</i> , 2022, , 165-214.	0.1	0
18354	Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211331.	3.2	7
18355	Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. <i>Cancer Control</i> , 2022, 29, 107327482211344.	1.8	1
18356	Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study. <i>Journal of Gastric Cancer</i> , 2022, 22, 408.	2.5	1
18357	Prediction of Ablation Volume in Percutaneous Lung Microwave Ablation: A Single Centre Retrospective Study. <i>Tomography</i> , 2022, 8, 2475-2485.	1.8	1
18358	Impact of skeletal muscle loss during conversion therapy on clinical outcomes in lavage cytology positive patients with gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
18359	Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 4796.	3.7	4

#	ARTICLE	IF	CITATIONS
18360	Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report. <i>Veterinary Sciences</i> , 2022, 9, 541.	1.7	1
18361	Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	23
18363	Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
18364	Reexposición de la terapia con Anti-EGFR en pacientes con cáncer colorrectal metastásico RAS/BRAF tipo salvaje. , 2022, 26, .		0
18365	Measurement Accuracy and Repeatability of RECIST-Defined Pulmonary Lesions and Lymph Nodes in Ultra-Low-Dose CT Based on Deep Learning Image Reconstruction. <i>Cancers</i> , 2022, 14, 5016.	3.7	3
18366	An exploration of <sc>LAF&TMB</sc> as a predictor for the efficacy of immunotherapy combined with chemotherapy in <sc>non&small cell lung cancer</sc>. <i>Thoracic Cancer</i> , 0, , .	1.9	1
18367	Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18368	Gradual Self&Training via Confidence and Volume Based Domain Adaptation for Multi Dataset Deep Learning&Based Brain Metastases Detection Using Nonlocal Networks on MRI Images. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 1728-1740.	3.4	4
18369	Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. <i>Cancer Discovery</i> , 2022, 12, 2754-2762.	9.4	30
18370	Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. <i>Pharmaceutics</i> , 2022, 14, 2263.	4.5	3
18371	Tumor response assessment on imaging following immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	12
18372	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial. <i>Cancers</i> , 2022, 14, 5234.	3.7	4
18373	CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2023, 30, 207-219.	1.5	11
18374	Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 306-314.	3.6	4
18375	A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2022, 14, 4996.	3.7	0
18376	Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18377	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100427.	1.1	3
18378	One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. <i>BMC Medicine</i> , 2022, 20, .	5.5	4

#	ARTICLE	IF	CITATIONS
18379	Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. <i>Acta Oncologica</i> , 2022, 61, 1339-1346.	1.8	1
18380	Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 805-814.	4.2	6
18381	Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
18382	Survival outcomes among colorectal cancer patients at Kenyatta National Hospital: A retrospective cohort study. <i>Cancer Reports</i> , 2023, 6, .	1.4	2
18383	Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study. <i>Cancer Medicine</i> , 0, , .	2.8	1
18384	Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 938-939.	1.6	2
18386	Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer. <i>Cancers</i> , 2022, 14, 5245.	3.7	1
18387	A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 341-348.	7.0	2
18388	MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
18389	Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis. <i>Kidney International</i> , 2022, , .	5.2	5
18390	Meta-Analysis of the Testâ€Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. <i>Clinical Cancer Research</i> , 2023, 29, 143-153.	7.0	1
18391	Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 443-449.	1.3	0
18393	Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study. <i>BMJ Open</i> , 2022, 12, e055718.	1.9	12
18394	A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.8	1
18395	Eldest gastric cancer patient with high microsatellite instability responding to pembrolizumab. <i>International Cancer Conference Journal</i> , 0, , .	0.5	0
18396	PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
18397	Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer. <i>Breast</i> , 2022, 66, 262-271.	2.2	2
18398	Realâ€world outcomes among patients with advanced or metastatic biliary tract cancers initiating secondâ€line treatment. <i>Cancer Medicine</i> , 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
18399	Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR Study. <i>JCO Precision Oncology</i> , 2022, , .	3.0	15
18400	Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2022, 160, 233-240.	2.9	3
18401	Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. <i>Clinical Radiology</i> , 2023, 78, e37-e44.	1.1	1
18402	Comparative analysis of QS3D versus droplet digital PCR for quantitative measures of EGFR T790M mutation from identical plasma. <i>Heliyon</i> , 2022, 8, e11339.	3.2	1
18403	A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). <i>Trials</i> , 2022, 23, .	1.6	4
18405	Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. <i>JCO Precision Oncology</i> , 2022, , .	3.0	7
18407	Characteristics and response to next-generation sequencing-guided therapy in locally advanced or metastatic esophageal cancer. <i>International Journal of Cancer</i> , 0, , .	5.1	2
18408	Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. <i>Cell Research</i> , 2022, 32, 1086-1104.	12.0	31
18409	Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy. <i>Drugs</i> , 0, , .	10.9	0
18410	A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [18F]FDG PET/CT metabolic parameters, inflammatory markers, and clinical variables. <i>European Radiology</i> , 0, , .	4.5	1
18411	Brachytherapy via a depot of biopolymer-bound ¹³¹ I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. <i>Nature Biomedical Engineering</i> , 2022, 6, 1148-1166.	22.5	10
18412	Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. <i>Journal of Clinical Oncology</i> , 2023, 41, 871-880.	1.6	15
18414	Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage <i>III</i> gastric or esophagogastric junction adenocarcinoma. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 247-254.	2.4	9
18415	Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy. <i>Cancers</i> , 2022, 14, 4970.	3.7	5
18416	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 583-705.	8.9	102
18417	Evolution and modulation of antigen-specific T cell responses in melanoma patients. <i>Nature Communications</i> , 2022, 13, .	12.8	10
18418	Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. <i>British Journal of Cancer</i> , 0, , .	6.4	1
18419	Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. <i>European Urology</i> , 2023, 83, 200-209.	1.9	14

#	ARTICLE	IF	CITATIONS
18420	Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review. <i>Cancers</i> , 2022, 14, 5076.	3.7	5
18421	Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.8	1
18422	Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 593-601.	6.4	7
18423	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. <i>Nature Cancer</i> , 2022, 3, 1181-1191.	13.2	42
18424	Practical Implications of KRAS Mutation Status and Sidedness of Primary Tumour in Patients with Colorectal Cancer and Synchronous Liver Metastases: A Subset Analysis of the CoSMIC Study. <i>Cancers</i> , 2022, 14, 4833.	3.7	1
18426	Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface. <i>Radiologia Medica</i> , 2022, 127, 1342-1354.	7.7	13
18427	Deep learning in bladder cancer imaging: A review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
18428	Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial. <i>Hepatology International</i> , 2022, 16, 1368-1378.	4.2	7
18429	LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	3
18430	Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5895.	2.4	0
18431	Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited-stage small-cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 3208-3216.	1.9	4
18432	Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab. <i>Current Oncology</i> , 2022, 29, 7695-7704.	2.2	0
18433	The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 5158.	3.7	3
18435	Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis. <i>Medicina (Lithuania)</i> , 2022, 58, 1505.	2.0	3
18436	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. , 2022, 10, e005119.		8
18437	Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit): Tj ETQq1 1 0z284314 rgBT /Overdo		
18438	Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study. <i>JCO Precision Oncology</i> , 2022, , .	3.0	8
18439	Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer. <i>Medicine (United States)</i> , 2022, 101, e30892.	1.0	1

#	ARTICLE	IF	CITATIONS
18440	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 2364-2373.	30.7	45
18441	Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis. <i>Cancer Medicine</i> , 0, , .	2.8	3
18442	Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience. <i>Prostate</i> , 0, , .	2.3	5
18443	Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. <i>Oncotarget</i> , 2022, 11, .	4.6	17
18444	Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	8
18446	Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4125-4135.	1.4	3
18447	Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1029-1045.	4.2	2
18448	Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): prospective pilot study. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 3487-3499.	1.9	5
18449	Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 511-521.	2.3	2
18450	Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. <i>JAMA Oncology</i> , 2022, 8, 1794.	7.1	33
18451	Management and outcomes after neoadjuvant treatment for locally advanced breast cancer in older <i>versus</i> younger women. <i>Acta Oncologica</i> , 2022, 61, 1362-1368.	1.8	1
18452	Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. <i>Cancer Discovery</i> , 2023, 13, 312-331.	9.4	20
18453	First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. , 2022, 10, e005471.		16
18454	Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152110.	3.4	6
18455	Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100424.	1.1	1
18456	Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26). <i>Gynecologic Oncology</i> , 2022, 167, 436-443.	1.4	3
18457	Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 2227-2233.	6.4	1
18458	Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 1045-1057.	3.1	5

#	ARTICLE	IF	CITATIONS
18459	Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. <i>Current Oncology</i> , 2022, 29, 7953-7963.	2.2	10
18460	Assessment of Treatment Response after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Appendiceal Peritoneal Metastases. <i>Cancers</i> , 2022, 14, 4998.	3.7	5
18461	Prognostic value of PERCIST and PET/CT metabolic parameters after neoadjuvant treatment in patients with esophageal cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, , .	0.2	0
18462	Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. <i>BMC Medical Imaging</i> , 2022, 22, .	2.7	4
18463	Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 4933.	3.7	5
18464	Microwave versus cryoablation and radiofrequency ablation for small renal mass: a multicenter comparative analysis. <i>Minerva Urology and Nephrology</i> , 2023, 75, .	2.5	17
18465	Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spatalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2023, 29, 110-121.	7.0	37
18466	A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10â€“2 trial). <i>Journal of Radiation Research</i> , 0, , .	1.6	1
18468	Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications. <i>Radiology</i> , 2022, 305, 512-525.	7.3	6
18469	Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma. <i>Oncology</i> , 2023, 101, 96-104.	1.9	0
18470	Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate. <i>Frontiers in Veterinary Science</i> , 0, 9, .	2.2	1
18471	Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study. <i>Cancers</i> , 2022, 14, 5045.	3.7	5
18472	Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. <i>Cancer Research Communications</i> , 2022, 2, 1426-1435.	1.7	4
18473	Prognostic Value of Tumor Volume Assessment on PSMA PET After ¹⁷⁷ Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0. <i>Journal of Nuclear Medicine</i> , 2023, 64, 605-610.	5.0	8
18474	Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	15
18475	The long-term outcomes of clinical responders to neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
18476	Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
18477	A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. <i>Investigational New Drugs</i> , 2022, 40, 1306-1314.	2.6	7

#	ARTICLE	IF	CITATIONS
18478	Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC. <i>Oncology Reports</i> , 2022, 48, .	2.6	4
18479	Localized malignant peritoneal mesothelioma presenting hepatohilar giant mass. <i>Oxford Medical Case Reports</i> , 2022, 2022, .	0.4	0
18480	Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5173.	3.7	6
18481	A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma. <i>Nature Communications</i> , 2022, 13, .	12.8	5
18482	Integrated proteomics and phosphoproteomics revealed druggable kinases in neoadjuvant chemotherapy resistant tongue cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	2
18483	First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations. <i>Journal of Thoracic Oncology</i> , 2023, 18, 204-222.	1.1	29
18484	Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide+platinum+atezolizumab treatment. <i>Thoracic Cancer</i> , 2022, 13, 3384-3392.	1.9	6
18485	Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. <i>Nature Cancer</i> , 2022, 3, 1192-1210.	13.2	15
18486	Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
18487	T Mapping From MPRAGE Acquisitions: Application to the Measurement of the Concentration of Nanoparticles in Tumors for Theranostic Use. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	1
18488	Chylous effusions in advanced medullary thyroid cancer patients treated with selipratinib. <i>European Journal of Endocrinology</i> , 2022, 187, 905-915.	3.7	9
18489	Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data. <i>Hepatology Research</i> , 2023, 53, 116-126.	3.4	6
18490	Characterization of Cutaneous Adverse Events to Enfortumab Vedotin: A Retrospective Case-Control Study. <i>JAAD International</i> , 2022, , .	2.2	1
18491	Case report: Individualized treatment of advanced breast cancer with the use of the patient-derived tumor-like cell cluster model. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18492	Prediction of response to neoadjuvant chemotherapy in advanced gastric cancer: A radiomics nomogram analysis based on CT images and clinicopathological features. <i>Journal of X-Ray Science and Technology</i> , 2022, , 1-13.	1.0	0
18493	A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma. <i>Cancer</i> , 2022, 128, 4223-4231.	4.1	13
18494	Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 93-101.	2.5	5
18495	Clinical and prognostic analysis of 42 children with malignant rhabdoid tumor of the kidney: a 7-year retrospective multi-center study. <i>BMC Pediatrics</i> , 2022, 22, .	1.7	1

#	ARTICLE	IF	CITATIONS
18496	Eficácia e Segurança de Regorafenibe em Pacientes com Características de Bom Prognóstico no Tratamento do Câncer Colorretal Metastático: Análise de Subgrupo do Estudo CORRECT. Revista Brasileira De Cancerologia, 2022, 68, .	0.3	0
18497	Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients'™ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study. Frontiers in Oncology, 0, 12, .	2.8	9
18498	Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. Frontiers in Molecular Biosciences, 0, 9, .	3.5	9
18499	Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India. Cureus, 2022, , .	0.5	0
18500	Association of metastatic nodal size with survival in non-surgical non-small cell lung cancer patients: Recommendations for clinical N staging. Frontiers in Oncology, 0, 12, .	2.8	0
18501	Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score. Cancers, 2022, 14, 5324.	3.7	1
18502	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. British Journal of Cancer, 2022, 127, 2241-2248.	6.4	9
18503	Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature, 2022, 611, 155-160.	27.8	114
18504	Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease—Results of a Prospective Trial. Cancers, 2022, 14, 5069.	3.7	7
18505	Rectal gastrointestinal stromal tumor with metachronous liver metastasis demonstrated no relapse after multidisciplinary team discussion and comprehensive treatment: a case report. Journal of Gastrointestinal Oncology, 2022, 13, 2679-2688.	1.4	1
18506	Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. , 2022, 10, e005248.		8
18507	A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms. Clinical Cancer Research, 2023, 29, 731-741.	7.0	11
18508	Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Frontiers in Oncology, 0, 12, .	2.8	4
18509	Ga-68 Prostate-Specific Membrane Antigen PET/CT: Imaging and Clinical Perspective in Prostate Cancer. PET Clinics, 2022, 17, 595-606.	3.0	0
18510	The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy. Cancer Communications, 2022, 42, 1288-1313.	9.2	13
18511	Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective. Cancer Management and Research, 0, Volume 14, 3047-3062.	1.9	8
18512	Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 5347.	3.7	8
18514	Post-Intervention Plasma IL-10 Level Predicts Early Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Hepatitis Monthly, 2022, 22, .	0.2	0

#	ARTICLE	IF	CITATIONS
18515	Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 50-59.	7.0	8
18516	MRI-based delta-radiomic features for prediction of local control in liver lesions treated with stereotactic body radiation therapy. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
18517	Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. <i>Gastric Cancer</i> , 2023, 26, 132-144.	5.3	2
18518	Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 886-896.	1.5	5
18519	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
18520	Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	3
18521	Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
18522	Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis. <i>Cancers</i> , 2022, 14, 5405.	3.7	15
18523	PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1389-1397.	10.7	77
18524	Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18525	Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
18526	Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. <i>IScience</i> , 2022, 25, 105382.	4.1	0
18527	Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5066-5078.	7.0	5
18528	Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.8	1
18529	Editorial. Assessing treatment response following stereotactic body radiotherapy for spinal metastases. <i>Neurosurgical Focus</i> , 2022, 53, E11.	2.3	0
18530	Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2239778.	5.9	28
18531	Adult-Type Ovarian Granulosa Cell Tumour: Treatment Outcomes From a Single-Institution Experience. <i>Cureus</i> , 2022, , .	0.5	0
18532	Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by⁹⁰Y Radioembolization: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2023, 64, 529-535.	5.0	7

#	ARTICLE	IF	CITATIONS
18533	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 1213-1227.	1.6	107
18534	¹⁸ F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer. <i>Radiology Imaging Cancer</i> , 2022, 4, .	1.6	9
18535	Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
18536	Mediating effect assessment of ifosfamide on limb salvage rate in osteosarcoma: A study from a single center in China. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18537	Interventions for treatment of cutaneous melanoma in horses: a structured literature review. <i>Veterinary Research Communications</i> , 2023, 47, 347-360.	1.6	4
18538	Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2022, 160, 591-599.	2.9	1
18539	Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics. <i>Life</i> , 2022, 12, 1753.	2.4	3
18540	The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. <i>Cancers</i> , 2022, 14, 5391.	3.7	1
18541	A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology. <i>Neurosurgical Focus</i> , 2022, 53, E10.	2.3	0
18542	Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. <i>Lancet Oncology</i> , The, 2022, 23, 1398-1408.	10.7	12
18543	Long-Term Outcome of Sustained Endocrine Monotherapy for Elderly Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2023, 30, 1671-1677.	1.5	1
18544	Current Applications of Artificial Intelligence to Classify Cervical Lymph Nodes in Patients with Head and Neck Squamous Cell Carcinoma: A Systematic Review. <i>Cancers</i> , 2022, 14, 5397.	3.7	13
18545	Qualitative and quantitative parameters on hepatobiliary phase of gadoxetic acid-enhanced MR imaging for predicting pathological response to preoperative systemic therapy in colorectal liver metastases. <i>European Journal of Radiology</i> , 2022, 157, 110572.	2.6	1
18546	A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 135, 106219.	1.5	5
18547	Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?. <i>Journal of Clinical Neuroscience</i> , 2022, 106, 110-116.	1.5	0
18548	Optimizing Imaging of Pediatric Liver Lesions: Guidelines from the Pediatric LI-RADS Working Group. <i>Radiographics</i> , 2023, 43, .	3.3	3
18549	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
18550	Liver lesion changes analysis in longitudinal CECT scans by simultaneous deep learning voxel classification with SimU-Net. <i>Medical Image Analysis</i> , 2023, 83, 102675.	11.6	6

#	ARTICLE	IF	CITATIONS
18551	Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study. <i>Cancer Management and Research</i> , 0, Volume 14, 2625-2638.	1.9	2
18552	ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. <i>Translational Lung Cancer Research</i> , 2022, 11, 2216-2229.	2.8	3
18553	Bilateral breast desmoid-type fibromatosis, case report and literature review. <i>Gland Surgery</i> , 2022, 11, 1832-1841.	1.1	2
18554	Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2769-2778.	1.4	1
18555	Delving into Universal Lesion Segmentation: Method, Dataset, and Benchmark. <i>Lecture Notes in Computer Science</i> , 2022, , 485-503.	1.3	1
18556	The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2022, 76, 333.	0.9	1
18557	Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211367.	3.2	4
18558	Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIa small-cell lung cancer: a retrospective single-arm clinical trial. <i>Journal of Thoracic Disease</i> , 2022, 14, 4405-4415.	1.4	1
18559	Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2023, 168, 17-22.	1.4	0
18560	Active breathing control guided stereotactic body ablative radiotherapy for management of liver metastases from colorectal cancer. <i>Acta Gastro-Enterologica Belgica</i> , 2022, 85, 469-475.	1.0	0
18561	Evaluating Neoadjuvant Chemotherapy for Lower Esophageal Squamous Cell Carcinoma by Measuring Esophageal Wall Thickness. <i>Anticancer Research</i> , 2022, 42, 5655-5662.	1.1	1
18562	Bone metastases in prostate cancer â€“ Gallium-68â€“labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography â€“ the better tracer?. <i>Nuclear Medicine Communications</i> , 2022, 43, 1225-1232.	1.1	3
18563	Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2022, 42, 5479-5486.	1.1	2
18564	Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study. <i>Anticancer Research</i> , 2022, 42, 5465-5473.	1.1	2
18565	Neoadjuvant Therapy for Patients With Non-small Cell Lung Cancer Complicated With Chest Wall Invasion. <i>Anticancer Research</i> , 2022, 42, 5539-5546.	1.1	0
18566	Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. <i>BMJ Open</i> , 2022, 12, e065109.	1.9	3
18567	Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE). <i>Investigational New Drugs</i> , 2023, 41, 44-52.	2.6	1
18568	The heterogeneity effect of surveillance intervals on progression free survival. <i>Journal of Applied Statistics</i> , 2024, 51, 646-663.	1.3	1

#	ARTICLE	IF	CITATIONS
18569	Machine learning applied to MRI evaluation for the detection of lymph node metastasis in patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy. Archives of Gynecology and Obstetrics, 2023, 307, 1911-1919.	1.7	7
18570	Efficacy of Everolimus Combined with ¹⁷⁷ Lu-Dotatate in the Treatment of Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	1.0	1
18571	Clinicopathologic features, prognostic factors, and outcomes of visceral sarcomas: A retrospective 12-year single-center study. Frontiers in Oncology, 0, 12, .	2.8	0
18572	Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies. Clinical and Translational Science, 2023, 16, 383-397.	3.1	4
18573	Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treatment and Research Communications, 2022, 33, 100659.	1.7	2
18574	The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastroenteropancreatic (GEP-NEN) System. Cancers, 2022, 14, 5465.	3.7	1
18575	Prognostic Impact of Gastroduodenal Artery Involvement in Cancer of the Pancreatic Head. Annals of Surgical Oncology, 0, , .	1.5	1
18576	Integrated molecular characterization of esophageal basaloid squamous cell carcinoma: a subtype with distinct RNA expression pattern and immune characteristics, but no specific genetic mutations. Journal of Pathology, 2023, 259, 136-148.	4.5	1
18577	Complete pathological response following chemotherapy and radiotherapy in two cases of advanced anaplastic thyroid carcinoma. European Thyroid Journal, 2023, 12, .	2.4	3
18579	A Framework for Harmonization of Radiomics Data for Multicenter Studies and Clinical Trials. JCO Clinical Cancer Informatics, 2022, , .	2.1	7
18580	Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase I, dose-escalation and expansion study. Lancet Oncology, The, 2022, 23, 1558-1570.	10.7	45
18581	Quality of life, out-of-pocket expenditures, and indirect costs among patients with the central nervous system tumors in Thailand. Journal of Neurosciences in Rural Practice, 0, .	0.8	1
18582	A dynamic nomogram combining tumor stage and magnetic resonance imaging features to predict the response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. European Radiology, 2023, 33, 2171-2184.	4.5	3
18583	Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma. Cancers, 2022, 14, 5561.	3.7	1
18584	Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study. International Journal of Clinical Oncology, 2022, 27, 1795-1804.	2.2	6
18585	Virtual bronchoscopic navigation and endobronchial ultrasound with a guide sheath without fluoroscopy for diagnosing peripheral pulmonary lesions with a bronchus leading to or adjacent to the lesion: A randomized noninferiority trial. Respiriology, 2023, 28, 389-398.	2.3	3
18586	Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Molecular Therapy, 2023, 31, 503-516.	8.2	6
18587	Nomogram-Based Survival Predictions and Treatment Recommendations for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Upfront Surgery. Cancers, 2022, 14, 5567.	3.7	2

#	ARTICLE	IF	CITATIONS
18588	Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18589	Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 1682-1693.e3.	0.8	2
18590	Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2023, 41, 25-34.	2.6	1
18591	Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1761-1774.	3.0	1
18592	Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. <i>Investigational New Drugs</i> , 0, .	2.6	0
18593	Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5181-5192.	2.5	5
18594	The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1321-1330.	2.0	0
18595	Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. <i>Cancer Medicine</i> , 0, .	2.8	1
18596	Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 755-766.	3.6	6
18597	Anlotinib plus chemotherapy for <i>T790M</i> -negative <i>EGFR</i> -mutant <i>non-sqNSCLC</i> resistant to <i>TKIs</i> : A multicenter phase 1b/2 trial. <i>Thoracic Cancer</i> , 2022, 13, 3496-3503.	1.9	1
18598	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. <i>Progres En Urologie</i> , 2022, 32, 1373-1419.	0.8	5
18599	Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study. <i>European Journal of Cancer</i> , 2023, 179, 15-24.	2.8	5
18600	Image Guidance Volume-Modulated Arc Radiation Therapy Concurrently With Nab-Paclitaxel Plus Cisplatin for Patients With Locally Advanced Cervical Cancer: A Single-Arm Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1197-1204.	0.8	2
18601	Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and <i>ctDNA</i> responses—the <i>ComIT</i> trial. <i>Molecular Oncology</i> , 2023, 17, 487-498.	4.6	2
18602	Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 460-471.	1.6	16
18603	Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. <i>European Urology</i> , 2023, 83, 195-199.	1.9	5
18604	Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation. <i>Pharmaceuticals</i> , 2022, 15, 1388.	3.8	2
18605	Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4

#	ARTICLE	IF	CITATIONS
18606	Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2022, 22, .	2.6	5
18607	Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies. Frontiers in Oncology, 0, 12, .	2.8	1
18608	Novel Discrete Component Wavelet Transform for detection of cerebrovascular diseases. Sadhana - Academy Proceedings in Engineering Sciences, 2022, 47, .	1.3	2
18609	Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. Clinical Colorectal Cancer, 2023, 22, 100-110.	2.3	3
18610	Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction. Medicina (Lithuania), 2022, 58, 1611.	2.0	4
18611	A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research, 2023, 29, 331-340.	7.0	8
18612	Quantitative Relaxometry Metrics for Brain Metastases Compared to Normal Tissues: A Pilot MR Fingerprinting Study. Cancers, 2022, 14, 5606.	3.7	2
18613	Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. Thrombosis Research, 2023, 221, 164-172.	1.7	4
18615	Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. Cancers, 2022, 14, 5605.	3.7	4
18616	Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade. Cancer Immunology, Immunotherapy, 2023, 72, 1225-1232.	4.2	2
18617	The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. Biomedicines, 2022, 10, 2827.	3.2	4
18618	Gold nanoparticles as antiangiogenic and antimetastatic agents. Drug Discovery Today, 2023, 28, 103438.	6.4	4
18619	Abemaciclib in combination with pembrolizumab for HR+, HER2 ⁺ metastatic breast cancer: Phase 1b study. Npj Breast Cancer, 2022, 8, .	5.2	14
18622	Circulating miR-326 could serve as a predictive biomarker for response to neoadjuvant chemotherapy in locally advanced cervical cancer. Frontiers in Oncology, 0, 12, .	2.8	2
18623	CACA guidelines for holistic integrative management of thyroid cancer. , 2022, 1, .		0
18624	Pregnancy-associated desmoid fibromatosis: A Dutch multi-centre retrospective study. European Journal of Surgical Oncology, 2022, , .	1.0	1
18625	A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). ESMO Open, 2022, 7, 100601.	4.5	3
18626	The Liver Tumor Segmentation Benchmark (LITS). Medical Image Analysis, 2023, 84, 102680.	11.6	175

#	ARTICLE	IF	CITATIONS
18627	Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma. Advances in Anatomic Pathology, 0, Publish Ahead of Print, .	4.3	0
18628	The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR ⁺ /HER2 ⁻) advanced/metastatic breast cancer. Breast Cancer Research and Treatment, 2023, 197, 319-331.	2.5	9
18629	Direct Evaluation of Treatment Response in Brain Metastatic Disease with Deep Neuroevolution. Journal of Digital Imaging, 2023, 36, 536-546.	2.9	2
18630	Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers, 2022, 14, 5659.	3.7	4
18631	Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 2023, 21, 69-75.	1.9	3
18632	Deep multiple instance learning for predicting chemotherapy response in non-small cell lung cancer using pretreatment CT images. Scientific Reports, 2022, 12, .	3.3	3
18633	[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma. Clinical Cancer Research, 2023, 29, 592-601.	7.0	7
18634	Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. European Urology Open Science, 2023, 47, 58-64.	0.4	2
18635	Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecologic Oncology, 2023, 168, 76-82.	1.4	3
18636	A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer. Translational Cancer Research, 2022, 11, 4326-4337.	1.0	1
18637	SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3. Translational Lung Cancer Research, 2022, 11, 2438-2451.	2.8	1
18638	Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay. Journal of Breast Cancer, 2022, 25, 473.	1.9	1
18639	Yttrium-90 Radioembolization for Metastatic Colorectal Cancer. , 2022, , 397-406.		0
18640	Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer. Biomarker Insights, 2022, 17, 117727192211415.	2.5	1
18641	Artificial Intelligence in the Era of Precision Oncological Imaging. Technology in Cancer Research and Treatment, 2022, 21, 153303382211417.	1.9	5
18642	Non-Rhabdomyosarcoma Soft-Tissue Sarcoma. , 2022, , 1055-1060.		0
18643	<i>Exonuclease 1</i> genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma. Journal of Cancer, 2022, 13, 3701-3709.	2.5	1
18644	Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211417.	3.2	1

#	ARTICLE	IF	CITATIONS
18645	CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. <i>In Vivo</i> , 2022, 36, 2844-2851.	1.3	2
18646	Objective response rate of placebo in randomized controlled trials of anticancer medicines. <i>EClinicalMedicine</i> , 2023, 55, 101753.	7.1	4
18647	The use of imaging and interventional radiology in modern oncology. <i>Medicine</i> , 2023, 51, 7-10.	0.4	0
18648	Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. <i>Radiology</i> , 2023, 306, 32-46.	7.3	10
18649	Prediction of short-term treatment outcome of nasopharyngeal carcinoma based on voxel incoherent motion imaging and arterial spin labeling quantitative parameters. <i>European Journal of Radiology Open</i> , 2023, 10, 100466.	1.6	0
18650	Imaging biomarkers to stratify lymph node metastases in abdominal CT – Is radiomics superior to dual-energy material decomposition?. <i>European Journal of Radiology Open</i> , 2023, 10, 100459.	1.6	0
18651	High-resolution anoscopy predictive modeling of anal canal cancer response after definitive chemoradiotherapy in COVID19 era. <i>Translational Oncology</i> , 2023, 27, 101590.	3.7	0
18652	Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103886.	4.4	3
18653	Multi-Scale Temporal Imaging: From Micro- and Meso- to Macro-scale-time Nuclear Medicine. <i>PET Clinics</i> , 2023, 18, 135-148.	3.0	2
18654	Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. <i>Gynecologic Oncology</i> , 2023, 169, 64-69.	1.4	4
18655	Impact of sex and age on adherence to guidelines in non-small cell lung cancer management. <i>Cancer Treatment and Research Communications</i> , 2023, 34, 100675.	1.7	1
18656	Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100558.	1.7	1
18657	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211173.	1.9	2
18658	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2022, 23, 1126.	3.4	44
18659	Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. <i>In Vivo</i> , 2022, 36, 2852-2860.	1.3	3
18660	Combined Radiomics – Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211424.	1.9	1
18661	A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. <i>Cancer Informatics</i> , 2022, 21, 117693512211360.	1.9	1
18662	First-line chemotherapy analysis on survival in carcinoma ovary patients: Data from a Northern Indian cancer center. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 1589.	0.9	1

#	ARTICLE	IF	CITATIONS
18664	Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2779-2788.	1.4	2
18665	Regorafenib and trifluridine/tipiracil in real clinical practice. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 367.	0.9	2
18666	Tumor glycolytic profiling through ¹⁸ F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211383.	3.2	2
18667	Imaging Response Evaluation. , 2022, , 417-439.		0
18668	Optimal Diagnostic Imaging of CLM for Surgical Candidates. , 2022, , 355-361.		0
18669	Effect of Tranilast on the Frequency of Invasive Treatment for Extra-Abdominal Desmoid Fibromatosis. <i>Journal of Nippon Medical School</i> , 2023, 90, 79-88.	0.9	1
18670	An End-to-End Framework For Universal Lesion Detection With Missing Annotations. , 2022, , .		1
18671	Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015). <i>Chinese Medical Journal</i> , 2022, 135, 2311-2318.	2.3	0
18672	Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma. <i>Cureus</i> , 2022, , .	0.5	1
18674	Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinationsâ€”CONCORDE. <i>JCO Precision Oncology</i> , 2022, , .	3.0	0
18675	Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2022, 11, 2192-2207.	2.8	1
18676	Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53â€”Mutated Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 5921.	3.7	1
18677	Single-cell analyses reveal the therapeutic effects of ATHENA and its mechanism in a rhabdomyosarcoma patient. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18678	Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04). <i>Cancers</i> , 2022, 14, 5848.	3.7	3
18679	MicroRNA-3692-3p is overexpressed in lung tumors but may not serve as a prognostic biomarker in lung cancer patients. <i>Molecular Biology Reports</i> , 0, , .	2.3	1
18680	Tumor Growth Rate in Spinal Giant Cell Tumors of Bone and Association With the Immune Microenvironment and Denosumab Treatment Responsiveness: A Multicenter Study. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, .	1.1	2
18681	Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. <i>Surgery</i> , 2023, 173, 280-288.	1.9	0
18682	Acute and long-term toxicity in patients undergoing induction chemotherapy followed by thermoradiotherapy for advanced cervical cancer. <i>International Journal of Hyperthermia</i> , 2022, 39, 1440-1448.	2.5	4

#	ARTICLE	IF	CITATIONS
18683	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5931.	3.7	6
18684	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. <i>Cancers</i> , 2022, 14, 5676.	3.7	3
18685	The clinical experience of the prognosis in opposite CEA and image change after therapy in stage IV colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
18686	Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
18687	Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop”. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1409-1415.	2.0	2
18688	The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
18690	Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. <i>Strahlentherapie Und Onkologie</i> , 0, , .	2.0	1
18691	Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. <i>Gut</i> , 2023, 72, 1568-1580.	12.1	6
18692	LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
18693	Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. , 2022, 10, e005930.		10
18694	Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. , 2022, 10, e005457.		19
18695	Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case “Control Study and Literature Review. <i>Cancers</i> , 2022, 14, 5914.	3.7	2
18696	Role of Post-Treatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients Receiving Definitive Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinomas. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2022, 65, 697-704.	0.2	0
18697	Locoregional Approaches in Cholangiocarcinoma Treatment. <i>Cancers</i> , 2022, 14, 5853.	3.7	5
18698	ATR Inhibitors in Platinum-Resistant Ovarian Cancer. <i>Cancers</i> , 2022, 14, 5902.	3.7	5
18699	Immune combinations and complete response: a new hope for metastatic renal cell carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.6	0
18700	Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis. <i>Respirology</i> , 2023, 28, 380-388.	2.3	0
18701	Radiomics-based prediction of response to immune checkpoint inhibitor treatment for solid cancers using computed tomography: a real-world study of two centers. <i>BMC Cancer</i> , 2022, 22, .	2.6	2

#	ARTICLE	IF	CITATIONS
18702	[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. <i>Clinical Cancer Research</i> , 2023, 29, 1515-1527.	7.0	6
18704	Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune checkpoint inhibitors in Australian tertiary oncology centres. <i>Cancer Medicine</i> , 2023, 12, 6788-6801.	2.8	2
18705	Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis. <i>Cancer Medicine</i> , 2023, 12, 6477-6487.	2.8	2
18706	The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor. <i>Cancers</i> , 2022, 14, 5753.	3.7	1
18707	USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination. <i>Clinical Breast Cancer</i> , 2023, 23, 162-175.	2.4	2
18708	Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 5789.	3.7	3
18709	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.3	2
18710	Staging Breast Cancer with MRI, the T. A Key Role in the Neoadjuvant Setting. <i>Cancers</i> , 2022, 14, 5786.	3.7	8
18711	Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. <i>Respiratory Investigation</i> , 2023, 61, 74-81.	1.8	2
18712	A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). <i>Tumori</i> , 2023, 109, 129-137.	1.1	16
18713	Serum LAPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-9.	1.9	0
18714	Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. <i>Cancer</i> , 2023, 129, 590-599.	4.1	8
18715	The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
18716	Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18717	An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study. <i>Breast Cancer Research</i> , 2022, 24, .	5.0	9
18718	Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
18719	Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation. <i>Cancers</i> , 2022, 14, 5730.	3.7	5
18720	Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1

#	ARTICLE	IF	CITATIONS
18721	18F-FDG PET/CT parameters for prediction of response to neoadjuvant therapy and prognosis in rectal cancer. <i>Nuclear Medicine Communications</i> , 2023, 44, 81-90.	1.1	1
18722	Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1240-1251.	6.4	2
18723	PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18724	The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. <i>Cancers</i> , 2022, 14, 5700.	3.7	6
18725	Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>JCO Precision Oncology</i> , 2022, , .	3.0	7
18726	Middle East and North Africa Registry to Characterize Rate of RAS Testing Status in Newly Diagnosed Patients with Metastatic Colorectal Cancer. <i>Turkish Journal of Gastroenterology</i> , 2023, 34, 118-127.	1.1	0
18727	Imaging endpoints for clinical trial use: a RECIST perspective. , 2022, 10, e005092.		2
18728	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , 0, , .	1.0	0
18729	Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. <i>Nutrition and Cancer</i> , 2023, 75, 670-677.	2.0	3
18731	A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	1
18732	Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
18733	Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with firstâ€line tyrosine kinase inhibitors. <i>International Journal of Urology</i> , 0, , .	1.0	1
18734	Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. <i>Nature Cancer</i> , 2022, 3, 1498-1512.	13.2	27
18735	Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18736	Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after firstâ€line treatment including immune checkpoint inhibitors: A retrospective multicenter study (<sc>TOPGAN</sc>) Tj ETQq0 0 0 rgBT9/Overlook 10 Tf 50		
18737	Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases. <i>Melanoma Research</i> , 2023, 33, 58-65.	1.2	0
18738	Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1406-1413.	6.4	7
18739	Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma. <i>Cancers</i> , 2022, 14, 6235.	3.7	2

#	ARTICLE	IF	CITATIONS
18740	Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	1
18742	¹⁷⁷ Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. <i>Cancers</i> , 2022, 14, 6022.	3.7	1
18743	Evaluation of the nutritional index and immunological function of a fermented vegetable for esophageal cancer patients undergoing immunotherapy plus chemotherapy: A randomized controlled trial. <i>Journal of Functional Foods</i> , 2022, 99, 105350.	3.4	0
18744	Controlling Nutritional Status (CONUT) as a Novel Postoperative Prognostic Marker in Breast Cancer Patients: A Retrospective Study. <i>BioMed Research International</i> , 2022, 2022, 1-23.	1.9	5
18745	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 1-120.	1.1	24
18746	Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18747	Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 850-866.	6.9	25
18748	Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 1463-1473.	1.5	6
18749	Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report. <i>Thoracic Cancer</i> , 2023, 14, 214-217.	1.9	3
18750	Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
18751	Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 46.	4.1	3
18752	Tailoring the clinical management of colorectal cancer by 18F-FDG PET/CT. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18753	Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 6207.	3.7	1
18754	Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. <i>Clinical Cancer Research</i> , 2023, 29, 899-909.	7.0	14
18755	Oncolytic viral kinetics mechanistic modeling of Talimogene Laherpaprepvec (TVEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 250-260.	2.5	4
18756	IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. <i>Cancer Cell</i> , 2023, 41, 106-123.e10.	16.8	52
18757	Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients. <i>Experimental Biology and Medicine</i> , 2023, 248, 361-369.	2.4	3
18758	Imaging of pediatric extragonadal pelvic soft tissue tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	0

#	ARTICLE	IF	CITATIONS
18759	Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. <i>Cancers</i> , 2022, 14, 6257.	3.7	5
18760	Detection of Cerebrovascular diseases using Novel Discrete Component Wavelet Cosine Transform. <i>Current Computer-Aided Drug Design</i> , 2022, 19, .	1.2	0
18761	Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. <i>Immunogenetics</i> , 0, , .	2.4	1
18762	Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study. <i>Cancers</i> , 2022, 14, 6075.	3.7	2
18763	Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. <i>PLoS ONE</i> , 2022, 17, e0278460.	2.5	1
18764	First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia. <i>Meditinskiy Sovet</i> , 2022, , 12-20.	0.5	1
18765	The value of magnetic resonance blood oxygen level-dependent imaging in evaluating the efficacy of advanced cervical cancer combined with radiotherapy and chemotherapy. <i>Acta Radiologica</i> , 2023, 64, 1668-1675.	1.1	0
18766	Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts. <i>Endoscopy International Open</i> , 2022, 10, E1517-E1525.	1.8	8
18767	Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 387, 2113-2125.	27.0	120
18768	Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib. <i>Pulmonology</i> , 2023, 29, 478-485.	2.1	4
18769	Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs. <i>Human Cell</i> , 2023, 36, 752-761.	2.7	3
18770	Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	3
18771	Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. <i>Nature Medicine</i> , 2022, 28, 2573-2583.	30.7	25
18772	Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group. <i>Journal of Thoracic Oncology</i> , 2023, 18, 278-298.	1.1	6
18773	The Prognostic Value of Plasma Small Extracellular Vesiclesâ€™ Phenotype in Patients With Gastrointestinal Stromal Tumor. <i>Anticancer Research</i> , 2022, 42, 5699-5717.	1.1	1
18774	Immune Checkpoint Inhibitor Therapy inÂOncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	4.0	25
18776	Disease Segmentation Using a Robust Method for Unclear Boundaries in Training with Annotations Including Boundary Errors. <i>Journal of the Japan Society for Precision Engineering</i> , 2022, 88, 919-925.	0.1	0
18779	Diagnostic and prognostic role of circulating neutrophil extracellular trap markers and prekallikrein in patients with high-grade serous ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
18780	Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China. <i>Investigational New Drugs</i> , 2023, 41, 86-92.	2.6	3
18781	Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy. <i>British Journal of Cancer</i> , 2023, 128, 857-876.	6.4	2
18782	GLIM diagnosed malnutrition predicts clinical outcomes and quality of life in patients with non-small cell lung cancer. <i>Clinical Nutrition</i> , 2023, 42, 190-198.	5.0	6
18783	Biology, vulnerabilities and clinical applications of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2023, 23, 95-111.	28.4	58
18784	Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study. <i>Medicine (United Tj ETQq0 0 0 rgt /Overdock 10 Tf</i>		
18785	Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma. , 2022, 1, 328-343.		0
18787	Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2023, 34, 362-368.	0.5	3
18788	Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
18789	Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> Amplification. <i>Journal of Clinical Oncology</i> , 2023, 41, 1725-1734.	1.6	13
18790	Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 157-168.	8.1	73
18791	Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial. <i>Cancers</i> , 2022, 14, 6074.	3.7	1
18792	Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. <i>NamÄ±k Kemal TÄ±p Dergisi</i> , 2022, 10, 350-356.	0.0	0
18793	Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial. <i>PLoS ONE</i> , 2022, 17, e0275058.	2.5	5
18794	A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes. <i>Clinical Cancer Research</i> , 2023, 29, 541-547.	7.0	1
18795	Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic nonâ€clear cell renal cell carcinoma: Realâ€world data from a Japanese multicenter retrospective study. <i>International Journal of Urology</i> , 2023, 30, 714-721.	1.0	3
18796	Intra- and inter-operator variability in MRI-based manual segmentation of HCC lesions and its impact on dosimetry. <i>EJNMMI Physics</i> , 2022, 9, .	2.7	7
18797	FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1651-1657.	7.0	35
18798	Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2

#	ARTICLE	IF	CITATIONS
18799	Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18800	The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients. <i>Cancer Medicine</i> , 2023, 12, 7699-7712.	2.8	7
18801	Does 18F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis?. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1
18802	Is ¹⁸ F-FDG PET Needed to Assess ¹⁷⁷ Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis. <i>Journal of Nuclear Medicine</i> , 2023, 64, 731-737.	5.0	10
18803	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden. <i>JAMA Oncology</i> , 2023, 9, 344.	7.1	13
18804	Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 95-106.	2.4	1
18805	Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma. <i>Oncology Letters</i> , 2022, 25, .	1.8	2
18806	WVVOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
18807	Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 31.	3.7	1
18808	Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 194-200.	3.9	8
18809	Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer. <i>ESMO Open</i> , 2022, 7, 100651.	4.5	4
18810	Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. <i>ESMO Open</i> , 2022, 7, 100630.	4.5	1
18811	A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Prostate</i> , 2023, 83, 376-384.	2.3	3
18812	AAPM task group report 273: Recommendations on best practices for AI and machine learning for computer-aided diagnosis in medical imaging. <i>Medical Physics</i> , 2023, 50, .	3.0	16
18813	Patient-reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG study. <i>Trials</i> , 2022, 23, .	1.6	1
18814	Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. <i>Annals of Oncology</i> , 2023, 34, 251-261.	1.2	23
18815	lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis. <i>Pharmacogenomics</i> , 2022, 23, 973-985.	1.3	8
18816	Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). <i>European Journal of Cancer</i> , 2023, 180, 125-133.	2.8	7

#	ARTICLE	IF	CITATIONS
18817	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. BMC Cancer, 2022, 22, .	2.6	4
18818	Imaging of pediatric head and neck tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper. Pediatric Blood and Cancer, 2023, 70, .	1.5	1
18819	Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study. Japanese Journal of Clinical Oncology, 2023, 53, 253-262.	1.3	4
18820	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Biomedicines, 2022, 10, 3172.	3.2	2
18821	Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. JAMA Network Open, 2022, 5, e2245596.	5.9	15
18822	Baseline extracellular vesicle TGF β ² is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. Cancer, 2023, 129, 521-530.	4.1	11
18823	Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid, 2023, 33, 129-132.	4.5	13
18824	Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma. Oncology Letters, 2022, 25, .	1.8	3
18825	Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer. Bladder Cancer, 2022, , 1-9.	0.4	0
18826	Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study. Frontiers in Urology, 0, 2, .	0.5	2
18827	Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma: A Cohort Study. Annals of Surgical Oncology, 2023, 30, 3084-3094.	1.5	2
18829	Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer. Clinical Neurology and Neurosurgery, 2023, 225, 107572.	1.4	3
18830	CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer. Journal of Oncology, 2022, 2022, 1-11.	1.3	1
18831	Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease. Frontiers in Surgery, 0, 9, .	1.4	0
18832	Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. British Journal of Cancer, 2023, 128, 783-792.	6.4	7
18833	Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1. Clinical Cancer Research, 2023, 29, 858-865.	7.0	4
18834	Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. Nature Medicine, 2022, 28, 2601-2610.	30.7	34
18835	Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis. International Journal of Gynecological Cancer, 0, , ijgc-2022-003920.	2.5	0

#	ARTICLE	IF	CITATIONS
18836	Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
18837	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. <i>Targeted Oncology</i> , 2023, 18, 147-158.	3.6	2
18838	A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer. <i>Investigational New Drugs</i> , 2023, 41, 76-85.	2.6	2
18839	Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma. <i>Oral Diseases</i> , 0, , .	3.0	2
18841	FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2023, 29, 2020-2024.	7.0	0
18842	Rhâ€ndostatin plus camrelizumab and chemotherapy in firstâ€line treatment of advanced nonâ€small cell lung cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2023, 12, 7724-7733.	2.8	7
18843	Safety and preliminary activity of pembrolizumabâ€carboplatinâ€paclitaxel in heavily pretreated and/or fragile patients with PDL1â€positive recurrent/metastatic head and neck cancer. <i>Oncology Letters</i> , 2022, 25, .	1.8	0
18844	Pattern of failure and clinical value of local therapy for oligoâ€recurrence in locally advanced nonâ€small cell lung cancer after definitive chemoradiation: Impact of driver mutation status. <i>Cancer Medicine</i> , 0, , .	2.8	0
18845	A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma. <i>BMC Medicine</i> , 2022, 20, .	5.5	4
18846	Multidisciplinary management of pediatric malignant rhabdoid tumor based on 5 years of experience at a tertiary care center. <i>Pediatric Surgery International</i> , 2023, 39, .	1.4	0
18847	Decomposition-based framework for tumor classification and prediction of treatment response from longitudinal MRI. <i>Physics in Medicine and Biology</i> , 0, , .	3.0	1
18848	Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. <i>British Journal of Cancer</i> , 0, , .	6.4	2
18849	Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	1
18850	A Multicenter Retrospective Cohort Study on Superior Vena Cava Resection in Non-Small-Cell Lung Cancer Surgery. <i>Cancers</i> , 2022, 14, 6138.	3.7	1
18851	Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
18853	Muscle mass loss in breast cancer patients of reproductive age (â‰¥45Âyears) undergoing neoadjuvant chemotherapy. <i>Radiologia Medica</i> , 0, , .	7.7	4
18854	Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirusâ€Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 560-570.	7.0	11
18855	Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	21

#	ARTICLE	IF	CITATIONS
18856	Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. <i>Journal of Clinical Oncology</i> , 2023, 41, 2166-2180.	1.6	32
18857	Translational analysis and final efficacy of the AVETUX trial “Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
18858	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-92.	0.7	1
18859	27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. <i>Clinical Lung Cancer</i> , 2023, 24, 137-144.	2.6	3
18860	Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. , 2022, 10, e005670.		5
18861	Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study. <i>Ecological Management and Restoration</i> , 2023, 36, .	0.4	2
18862	Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	2
18863	Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 0, , .	3.6	1
18864	Study protocol of an open-label prospective phase II umbrella study of precise neoadjuvant therapy for patients with stage II-IIIb resectable non-small cell lung cancer (PURPOSE). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
18865	Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease. <i>Blood Advances</i> , 0, , .	5.2	0
18866	Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity. <i>BMJ Case Reports</i> , 2022, 15, e252590.	0.5	1
18867	A case of thoracic <sc><i>SMARCA4</i></sc> deficient</sc> undifferentiated tumor successfully treated with combination <sc>Ipilimumab&Nivolumab</sc>. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.5	2
18868	Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for relapsed or refractory neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	0
18869	Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population&based analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
18870	Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3. <i>Esophagus</i> , 2023, 20, 302-308.	1.9	1
18871	Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. <i>Annals of Oncology</i> , 2023, 34, 262-274.	1.2	32
18872	Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
18873	Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer. <i>Radiation Oncology</i> , 2022, 17, .	2.7	1

#	ARTICLE	IF	CITATIONS
18874	Anlotinib plus etoposide increases survival in patients with small-cell lung cancer after chemoradiotherapy. <i>Journal of Radiation Research and Applied Sciences</i> , 2022, 15, 100482.	1.2	0
18875	Developing Artificial Intelligence Models for Extracting Oncologic Outcomes from Japanese Electronic Health Records. <i>Advances in Therapy</i> , 2023, 40, 934-950.	2.9	6
18876	United Kingdom criteria for liver transplantation in the setting of isolated unresectable colorectal liver metastases. <i>Colorectal Disease</i> , 0, , .	1.4	3
18877	Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e2244619.	5.9	7
18878	Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 354-366.	10.7	43
18879	Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
18880	Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study. <i>Translational Lung Cancer Research</i> , 2023, 12, 96-108.	2.8	1
18881	Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. <i>Oncogene</i> , 2023, 42, 1951-1956.	5.9	4
18882	Treatment of Peritoneal Metastasis with Pressurized Intraperitoneal Aerosol Chemotherapy: Results from the Prospective PIPAC-OPC2 Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 2634-2644.	1.5	12
18883	The Impact of COVID-19 Pandemic on Surgical Treatment of Resectable Non-Small Cell Lung Cancer in Greece. <i>Life</i> , 2023, 13, 218.	2.4	4
18884	Could conventionally fractionated radiation therapy coupled with stereotactic body radiation therapy improve local control in bone oligometastases?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2023, 27, 1-10.	1.4	1
18885	Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 1290-1302.	3.4	0
18886	Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. <i>Oncologist</i> , 2023, 28, 440-448.	3.7	8
18887	Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study. <i>Journal of Nuclear Medicine</i> , 0, , jnumed.122.264964.	5.0	4
18888	Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. <i>Immunotherapy Advances</i> , 2023, 3, .	3.0	3
18889	Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib. <i>Journal of Cancer Research and Therapeutics</i> , 2022, .	0.9	0
18890	Breast Cancer Workup and Surgical Planning. , 2022, , 341-383.		0
18891	A retrospective study on unresectable or inoperable head and neck cancers treated with stereotactic ablative brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 519-526.	0.9	0

#	ARTICLE	IF	CITATIONS
18893	Immunotherapy Assessment: A New Paradigm for Radiologists. <i>Diagnostics</i> , 2023, 13, 302.	2.6	1
18894	Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation. <i>Nature Communications</i> , 2023, 14, .	12.8	17
18896	Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. <i>Cancers</i> , 2023, 15, 358.	3.7	1
18897	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. <i>IScience</i> , 2023, 26, 105799.	4.1	12
18898	Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy. <i>Asian Journal of Andrology</i> , 2023, .	1.6	0
18899	Microstructural parameters from DWâ€MRI for tumour characterization and local recurrence prediction in particle therapy of skullâ€base chordoma. <i>Medical Physics</i> , 2023, 50, 2900-2913.	3.0	1
18900	The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
18902	Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	5
18903	Developments in the Surgical Approach to Staging and Resection of Rhabdomyosarcoma. <i>Cancers</i> , 2023, 15, 449.	3.7	3
18904	Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. <i>Current Oncology</i> , 2023, 30, 875-896.	2.2	8
18905	The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 45-45.	1.7	2
18906	Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. <i>Journal of the National Cancer Institute</i> , 2023, 115, 437-446.	6.3	3
18907	Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2023, 57, 603-610.	1.6	1
18908	The Significance of the D-Dimer Level as a Prognostic Marker for Survival and Treatment Outcomes in Patients With Stage IV Colorectal Cancer. <i>In Vivo</i> , 2023, 37, 440-444.	1.3	3
18909	Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. <i>Liver International</i> , 2023, 43, 695-707.	3.9	11
18910	Endobronchial ultrasound-guided transbronchial needle injection of cisplatin results in dynamic changes in the tumor immune microenvironment. <i>Respiratory Medicine and Research</i> , 2023, 84, 100994.	0.6	0
18911	Lung cancer in Asian Indian females: Identification of disease-specific characteristics and outcome measures over a 12-year period. <i>Lung India</i> , 2023, 40, 4.	0.7	1
18912	Correlation analysis of HIF-1Î± and Ca15-3 in response to neoadjuvant chemotherapy in locally advanced breast cancer: A cohort study in Indonesia. <i>Breast Disease</i> , 2023, 41, 481-487.	0.8	0

#	ARTICLE	IF	CITATIONS
18913	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <i>Cureus</i> , 2023, , .	0.5	1
18914	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2023, 15, 329.	3.7	8
18915	Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repairâ€“Deficient Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 60-66.e5.	4.9	16
18916	Microwave ablation using two simultaneous antennas for the treatment of liver malignant lesions: a 3 year single-Centre experience. <i>International Journal of Hyperthermia</i> , 2023, 40, .	2.5	1
18917	Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211491.	1.9	0
18918	Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 856.	4.1	2
18919	Treating mast cell tumours in first opinion practice: is it time to put down the knife?. <i>Companion Animal</i> , 2023, 28, 2-7.	0.2	0
18920	Lateâ€“onset immune checkpoint inhibitorâ€“related pneumonitis after cessation of sintilimab: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	1.8	1
18923	Tumor Hyperprogression and Pseudoprogression After Immunotherapy. , 2023, , 1-24.		0
18924	Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment. <i>Radiology Imaging Cancer</i> , 2023, 5, .	1.6	2
18925	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase 2 study. <i>Hepatology Research</i> , 0, , .	3.4	2
18926	<scp>FOLFOX</scp>â€“bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	2.6	5
18927	Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. <i>Biomedicines</i> , 2023, 11, 119.	3.2	2
18928	Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas:<i>Post Hoc</i>Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). <i>Clinical Cancer Research</i> , 2023, 29, 1068-1076.	7.0	2
18929	Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor. <i>Journal of Gastrointestinal Oncology</i> , 2023, .	1.4	0
18930	The IASLC grading system for invasive pulmonary adenocarcinoma: a potential prognosticator for patients receiving neoadjuvant therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211480.	3.2	0
18931	Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. <i>JAMA Network Open</i> , 2023, 6, e2249720.	5.9	5
18932	Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. <i>Cancer Cell</i> , 2023, 41, 304-322.e7.	16.8	34

#	ARTICLE	IF	CITATIONS
18933	Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC. JTO Clinical and Research Reports, 2023, 4, 100460.	1.1	1
18934	Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma. Acta Oncol ³ gica, 2023, 62, 25-32.	1.8	1
18935	A case of pancreatic head cancer with Trousseau [™] s syndrome treated with radical resection and anticoagulant therapy. Surgical Case Reports, 2023, 9, .	0.6	2
18936	Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases. Cancers, 2023, 15, 472.	3.7	3
18937	Landmark mediation survival analysis using longitudinal surrogate. Frontiers in Oncology, 0, 12, .	2.8	0
18938	Differential prognostic significance of sarcopenia in metastatic esophageal squamous and adenocarcinoma. Esophagus, 2023, 20, 557-566.	1.9	1
18939	Radiological response criteria in non-small cell lung cancer treated with immunotherapy: RECIST1.1 vs. iRECIST. Journal of Radiological Review, 2023, 9, .	0.1	0
18940	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	4.8	2
18942	Quantitative analysis of superb microvascular imaging for monitoring tumor response to chemoradiotherapy in locally advanced cervical cancer. Frontiers in Oncology, 0, 12, .	2.8	1
18943	Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC Medicine, 2023, 21, .	5.5	2
18944	Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases. World Journal of Gastroenterology, 0, 29, 521-535.	3.3	4
18945	Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. Biomarker Research, 2023, 11, .	6.8	8
18946	Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. BMJ Open, 2023, 13, e067691.	1.9	2
18947	Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma. Kreativna [®] Hirurgi [®] I Onkologi [®] , 2023, 12, 309-319.	0.3	0
18948	Real-world treatment patterns and outcomes in patients with metastatic melanoma. Srpski Arhiv Za Celokupno Lekarstvo, 2023, , 6-6.	0.2	0
18949	Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small-cell lung cancer patients. Translational Lung Cancer Research, 2023, 12, 14-26.	2.8	1
18950	Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. Journal of Translational Medicine, 2023, 21, .	4.4	8
18951	The maximum tumor growth rate predicts clinical outcomes of patients with small [™] cell lung cancer undergoing first [™] line chemotherapy plus immune [™] checkpoint inhibitor therapy. Cancer Medicine, 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
18952	Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology, 2023, 46, 350-359.	2.0	4
18953	Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer. In Vivo, 2023, 37, 143-148.	1.3	0
18954	Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study. Cancer Immunology, Immunotherapy, 2023, 72, 1709-1723.	4.2	4
18955	Disparity in the era of personalized medicine for epithelial ovarian cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211480.	3.2	1
18956	Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma. Molecular and Cellular Proteomics, 2023, 22, 100502.	3.8	5
18957	Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients. Scientific Reports, 2023, 13, .	3.3	1
18958	A cross-sectional study evaluating health-related quality of life of Chinese pediatric patients with hematological malignancies using EQ-5D-Y. Frontiers in Public Health, 0, 10, .	2.7	1
18959	Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 358-376.	1.2	94
18960	Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current Oncology, 2023, 30, 1381-1394.	2.2	3
18961	Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma. Thyroid Research, 2023, 16, .	1.5	1
18962	Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2023, 27, 337-346.	1.7	2
18963	Phase 1 study of DSâ€¹205c combined with gefitinib for EGFR mutationâ€¹positive nonâ€¹small cell lung cancer. Cancer Medicine, 0, , .	2.8	1
18964	Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. Biotechnology and Genetic Engineering Reviews, 0, , 1-14.	6.2	0
18965	Exploration of immunotherapy in advanced pulmonary lymphoepitheliomaâ€¹like carcinoma. International Journal of Cancer, 2023, 152, 2338-2350.	5.1	5
18966	Clinical impact of MRI-detected additional lesions in breast cancer patients with neoadjuvant systemic therapy at the Netherlands cancer institute. Breast Cancer Research and Treatment, 2023, 198, 131-141.	2.5	1
18967	Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions. Cancers, 2023, 15, 473.	3.7	2
18968	Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	2.8	0
18969	Breast-Conserving Surgery in Triple-Negative Breast Cancer: A Retrospective Cohort Study. Evidence-based Complementary and Alternative Medicine, 2023, 2023, 1-8.	1.2	0

#	ARTICLE	IF	CITATIONS
18970	Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial. <i>Oncologist</i> , 2023, 28, e254-e262.	3.7	3
18971	WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. <i>Cancers</i> , 2023, 15, 393.	3.7	3
18972	Semiautomated pelvic lymph node treatment response evaluation for patients with advanced prostate cancer: based on MET-RADS-P guidelines. <i>Cancer Imaging</i> , 2023, 23, .	2.8	0
18973	The development of a t<scp>umor-associated</scp> autoantibodies panel to predict clinical outcomes for immune checkpoint i<scp>nhibitor-based</scp> treatment in patients with advanced n<scp>onâ€small</scp>â€cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 497-505.	1.9	1
18974	Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	2
18975	Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. <i>Current Oncology</i> , 2023, 30, 575-585.	2.2	1
18976	Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	1
18977	Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). <i>Breast Cancer</i> , 0, , .	2.9	0
18978	High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study. <i>Lung Cancer</i> , 2023, 176, 98-102.	2.0	0
18979	Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors. <i>Oral Oncology</i> , 2023, 137, 106297.	1.5	2
18980	CGBO-Net: Cruciform structure guided and boundary-optimized lymphoma segmentation network. <i>Computers in Biology and Medicine</i> , 2023, 153, 106534.	7.0	0
18981	Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. <i>Radiographics</i> , 2023, 43, .	3.3	3
18982	Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients. <i>International Immunopharmacology</i> , 2023, 115, 109651.	3.8	1
18983	A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2023, 181, 119-134.	2.8	8
18984	Combination of endoscopic ultrasound-guided radiofrequency ablation and adaptive radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: A case report. <i>Current Problems in Cancer Case Reports</i> , 2023, 9, 100216.	0.1	0
18985	Correlation between late gadolinium enhancement sequences in MRI and pathologic response after neoadjuvant chemotherapy in breast cancer. <i>Revista De Senologia Y Patologia Mamaria</i> , 2023, 36, 100438.	0.1	0
18986	Covariate-adjusted response-adaptive designs for censored survival responses. <i>Journal of Statistical Planning and Inference</i> , 2023, 225, 219-242.	0.6	1
18987	Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. <i>Cancer Medicine</i> , 2023, 12, 7932-7940.	2.8	2

#	ARTICLE	IF	CITATIONS
18988	Factor Analysis of Intraoperative Bleeding Loss and its Impact on Prognosis in Breast Cancer. <i>Anticancer Research</i> , 2023, 43, 191-200.	1.1	0
18989	Colorectal Liver Metastases: A Literature Review of Viable Surgical Options with a Special Focus on Microwave Liver Thermal Ablation and Mini-Invasive Approach. <i>Journal of Personalized Medicine</i> , 2023, 13, 33.	2.5	1
18990	Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. <i>Cancers</i> , 2023, 15, 185.	3.7	0
18991	The Applications of Artificial Intelligence in Digestive System Neoplasms: A Review. <i>Health Data Science</i> , 2023, 3, .	2.3	3
18992	Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Nonâ€“Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 197.	3.7	1
18993	Diagnostic Value of Contrast-Enhanced Digital Mammography Versus Contrast-Enhanced MRI for Detecting Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Breast Disease</i> , 2022, 10, 69-76.	0.2	0
18995	DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2539-2566.	2.8	0
18996	Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	1
18997	Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2023, 43, 85-95.	1.1	0
18998	Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2023, 46, 50-57.	1.3	0
18999	Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
19000	Roadmap for precision preclinical x-ray radiation studies. <i>Physics in Medicine and Biology</i> , 2023, 68, 06RM01.	3.0	4
19001	Old Discovery Leading to New Era: Metabolic Imaging of Cancer with Deuterium MRI. <i>Magnetochemistry</i> , 2023, 9, 6.	2.4	1
19002	Transarterial chemoembolization versus surgical resection for giant hepatocellular carcinoma under the different status of capsule: a retrospective study. <i>Translational Cancer Research</i> , 2022, 11, 4359-4372.	1.0	0
19003	Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	1
19004	Significance of second progressionâ€“free survival in patients with advanced urothelial cancer who received platinumâ€“based combination chemotherapy followed by pembrolizumab. <i>International Journal of Urology</i> , 2023, 30, 730-736.	1.0	1
19005	Prognostic Role of ⁶⁸ Ga-PSMA11 PETâ€“Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2023, 64, 896-901.	5.0	2
19006	Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy. <i>Histopathology</i> , 2023, 82, 691-703.	2.9	1

#	ARTICLE	IF	CITATIONS
19007	Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism. <i>Annals of Translational Medicine</i> , 2022, 10, 1337-1337.	1.7	2
19008	Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker. <i>Cancers</i> , 2023, 15, 290.	3.7	2
19009	Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. <i>Breast</i> , 2023, 67, 102-109.	2.2	7
19010	Clinical efficacy and safety analysis of CT-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor. <i>Brachytherapy</i> , 2022, , .	0.5	0
19011	PET-CT in the Evaluation of Neoadjuvant/Adjuvant Treatment Response of Soft-tissue Sarcomas. <i>JBJS Reviews</i> , 2022, 10, .	2.0	2
19012	Tumoral reduction in patients with intra-abdominal tumors treated with CyberKnife: a single center's experience. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.2	0
19013	The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy. <i>Journal of Clinical Medicine</i> , 2023, 12, 325.	2.4	1
19015	Grundlagen der medikamentÄŕsen Tumorthherapie. , 2022, , 1-23.		0
19017	Radiologic assessment of tumor response to immunotherapy and its complications. , 2023, , 239-261.		0
19018	A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1429-1439.	7.0	27
19019	Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	0
19020	Nephron-sparing surgery for Wilms tumor. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	5
19021	Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars DyrskjÄŕt, JÄŕrgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. <i>J Clin Oncol</i> . In press. https://doi.org/10.1200/JCO.22.00470 . <i>European Urology</i> , 2023, , .	1.9	0
19022	Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. <i>OncoTargets and Therapy</i> , 0, Volume 16, 71-86.	2.0	6
19024	Predicting Soft Tissue Sarcoma Response to Neoadjuvant Chemotherapy Using an MRI-Based Delta-Radiomics Approach. <i>Molecular Imaging and Biology</i> , 2023, 25, 776-787.	2.6	7
19025	A Case of Bilateral Internal Mammary Arterial Infusion Chemotherapy Using Implantable Port-catheter Systems for Anterior Chest Wall Metastasis of Breast Cancer. <i>Interventional Radiology</i> , 2023, , .	0.4	0
19026	Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy. <i>Keio Journal of Medicine</i> , 2023, 72, 60-64.	1.1	1
19027	Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. <i>Annals of Oncology</i> , 2023, 34, 420-430.	1.2	25

#	ARTICLE	IF	CITATIONS
19029	Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). <i>Breast Cancer</i> , 2023, 30, 412-423.	2.9	2
19030	Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	3
19031	Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	0
19032	AI-Enhanced Digital Pathology and Radiogenomics in Precision Oncology. , 2023, , 93-113.		1
19033	Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
19034	Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 215.	2.0	2
19035	Survival benefits of para-aortic lymphadenectomy in colorectal cancer with clinically suspected para-aortic lymph node metastasis: a meta-analysis and systematic review. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	2
19036	Resistance of neuroendocrine tumours to somatostatin analogs. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 33-52.	2.4	1
19037	Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. <i>European Journal of Cancer</i> , 2023, 183, 109-118.	2.8	10
19038	Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib. <i>Anticancer Research</i> , 2023, 43, 911-918.	1.1	0
19039	Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 2893-2903.	1.6	48
19041	Single-center analysis of percutaneous ablation in the treatment of hepatocellular carcinoma: long-term outcomes of a 7-year experience. <i>Abdominal Radiology</i> , 0, , .	2.1	1
19042	In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2239.	4.1	1
19043	Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study. <i>Radiation Oncology</i> , 2023, 18, .	2.7	0
19044	National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). <i>Clinical Cancer Research</i> , 2023, 29, 1412-1422.	7.0	14
19045	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Cocksackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. , 2023, 11, e005007.		3
19046	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. <i>Npj Genomic Medicine</i> , 2023, 8, .	3.8	15
19047	Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2023, 128, 1320-1332.	6.4	4

#	ARTICLE	IF	CITATIONS
19048	Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
19049	Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer. <i>Journal of Investigative Medicine</i> , 0, , 108155892311512.	1.6	0
19050	Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. <i>Prostate</i> , 2023, 83, 563-571.	2.3	1
19051	Efficacy and safety of carboplatin and etoposide in older <scp>extensive-stage smallâ€cell</scp> lung cancer patients with a poor performance status. <i>Thoracic Cancer</i> , 0, , .	1.9	2
19052	Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 593.	3.7	4
19053	Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study. <i>Anticancer Research</i> , 2023, 43, 927-934.	1.1	0
19054	Charachterization of spatially mapped volumetric molecular ultrasound signals for predicting response to anti-vascular therapy. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
19056	Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. <i>Discover Oncology</i> , 2023, 14, .	2.1	7
19057	Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience. <i>European Journal of Cancer</i> , 2023, 183, 79-89.	2.8	2
19058	Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1267-1278.	7.0	7
19059	Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211489.	3.2	3
19060	Scoring System to Predict Survival After Resection of Locally Advanced Pancreas Cancer: What is Achieved?. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
19061	Ferroptosis-Related Prognostic Gene LAMP2 Is a Potential Biomarker Differential Expressed in Castration Resistant Prostate Cancer. <i>Disease Markers</i> , 2023, 2023, 1-14.	1.3	0
19062	Photodynamic therapy in combination with immune checkpoint inhibitors plus chemotherapy for first-line treatment in advanced or metastatic gastric or gastroesophageal junction cancer: A phase 2â€3 clinical trial protocol. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3
19064	Hyperthermic Extracorporeal Applied Tumor Therapy for Six Cycles for Recurrent Metastatic Peritoneal Serous Papillary Carcinoma. <i>Cureus</i> , 2023, , .	0.5	1
19065	Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. <i>Nature Communications</i> , 2023, 14, .	12.8	1
19066	A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311523.	1.9	4
19067	Imaging Recommendations for Diagnosis, Staging, and Management of Lung Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.2	1

#	ARTICLE	IF	CITATIONS
19068	Canadian Urological Association guideline: Diagnosis, management, and followup of the incidentally discovered adrenal mass. Canadian Urological Association Journal, 2022, 17, 12-24.	0.6	2
19069	Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel. Pulmonology, 2024, 30, 159-169.	2.1	0
19070	Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Nonâ€“Small-Cell Lung Cancer Reveals <i>EGFR</i> Mutations to Be Associated With Longer Overall Survival. JCO Precision Oncology, 2023, , .	3.0	1
19071	Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. European Journal of Surgical Oncology, 2023, 49, 1283-1290.	1.0	2
19072	Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2023, 41, 2098-2107.	1.6	13
19073	Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Nonâ€“small Cell Lung Cancer Harboring Activating EGFR Mutations. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	2
19074	A phase 1 doseâ€“escalation study of the poly(ADPâ€“ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer, 0, , .	4.1	1
19075	Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery. International Journal of Gynecological Cancer, 2023, 33, 489-497.	2.5	5
19076	Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. Cancers, 2023, 15, 700.	3.7	2
19077	Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. , 2023, 11, e005809.		4
19079	Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxelâ€“based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	2.8	2
19080	Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer. Cancer Medicine, 2023, 12, 9175-9185.	2.8	3
19081	WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2023, 115, 1095-1101.	0.8	4
19082	High-risk HPV-related squamous cell carcinoma in the temporal bone: a rare but noteworthy subtype. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	2.8	1
19083	Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study. Asian Pacific Journal of Cancer Prevention, 2023, 24, 61-67.	1.2	2
19084	Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6181-6190.	2.5	4
19085	Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers. Journal of Personalized Medicine, 2023, 13, 229.	2.5	0
19086	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 339-357.	1.2	118

#	ARTICLE	IF	CITATIONS
19087	Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patientsâ€™ survival. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
19088	The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer. <i>Cancers</i> , 2023, 15, 805.	3.7	5
19089	Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 2436-2445.	1.6	83
19090	<i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1741-1750.	7.0	2
19091	The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria. <i>Journal of Clinical Medicine</i> , 2023, 12, 879.	2.4	1
19092	Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
19093	Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. <i>Annals of Oncology</i> , 2023, 34, 377-388.	1.2	18
19094	A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, 117955492311520.	1.3	0
19095	Futibatinib for<i>FGFR2</i>-Rearranged Intrahepatic Cholangiocarcinoma. <i>New England Journal of Medicine</i> , 2023, 388, 228-239.	27.0	120
19096	A radiomic biomarker for prognosis of resected colorectal cancer liver metastases generalizes across MRI contrast agents. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19097	Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer. <i>Bulletin Du Cancer</i> , 2023, 110, 285-292.	1.6	1
19098	A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 217-229.	2.5	1
19099	Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study. <i>JCO Precision Oncology</i> , 2023, , .	3.0	4
19100	Association between <sc>PD</sc> â€1 inhibitorâ€™related adverse events and frailty assessed by frailty index in lung cancer patients. <i>Cancer Medicine</i> , 0, , .	2.8	1
19101	A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal) Tj ETQq0 0 0 rgBT /Overlock 10 Medical Oncology, 2023, 15, 175883592311659.	3.2	0
19102	Carbon-ion Radiotherapy for Inoperable Solitary Fibrous Tumor of the Skull Base: A Case Report. <i>In Vivo</i> , 2023, 37, 908-911.	1.3	1
19103	Albuminâ€™derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study. <i>In Vivo</i> , 2023, 37, 818-824.	1.3	0
19104	Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy. <i>Journal of Cancer</i> , 2023, 14, 519-531.	2.5	0

#	ARTICLE	IF	CITATIONS
19105	Recent Advances in Fibrinogen Research in Colorectal Cancer. Journal of Biosciences and Medicines, 2023, 11, 28-38.	0.2	0
19106	Cone Beam Computed Tomography Image Fusion with Cross Sectional Images for Percutaneous Renal Tumor Ablation: Preliminary Data. Technology in Cancer Research and Treatment, 2023, 22, 153303382311549.	1.9	2
19107	Neoadjuvant Chemotherapy Compared with Surgery for Oesophageal Carcinoma: A Retrospective Study and Missing Evidence. Journal of Cancer, 2023, 14, 434-445.	2.5	0
19108	Efficacy of lymph node dissection on stage IIICr of cervical cancer before CCRT: study protocol for a phase III, randomized controlled clinical trial (CQGOG0103). Journal of Gynecologic Oncology, 2023, 34, .	2.2	2
19109	Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311563.	3.2	1
19110	Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. Oncologist, 0, , .	3.7	0
19111	Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report. , 2023, 11, e006467.		1
19112	Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncology, 2023, 19, 217-228.	2.4	7
19113	Safety and efficacy of stereotactic ablative brachytherapy as a salvage therapy for recurrent chest wall cancer: A retrospective, multicenter study. Frontiers in Oncology, 0, 12, .	2.8	1
19114	Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017â€“2019. Cancer Medicine, 0, , .	2.8	2
19115	Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. Cancer Discovery, 2023, 13, 1364-1385.	9.4	10
19116	TGF-Î² in the microenvironment induces a physiologically occurring immune-suppressive senescent state. Cell Reports, 2023, 42, 112129.	6.4	9
19117	Impact of skeletal muscle volume on patients with <scp>BCLC stageâ€B</scp> hepatocellular carcinoma undergoing sorafenib therapy. Cancer Medicine, 0, , .	2.8	1
19118	Longâ€term survivors with desmoplastic small round cell tumor (<scp>DSRCT</scp>): Results from a retrospective singleâ€institution case series analysis. Cancer Medicine, 2023, 12, 10694-10703.	2.8	3
19119	Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2023, 41, 3339-3351.	1.6	60
19120	Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. Investigational New Drugs, 2023, 41, 306-316.	2.6	3
19121	Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and tripleâ€negative breast cancer. Cancer, 0, , .	4.1	0
19122	Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Pancreatology, 2023, 23, 367-376.	1.1	2

#	ARTICLE	IF	CITATIONS
19123	Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A <scp>meta-analysis</scp>. Cancer Medicine, 2023, 12, 10222-10229.	2.8	5
19124	mlf-core: a framework for deterministic machine learning. Bioinformatics, 2023, 39, .	4.1	0
19125	Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer. OncoTargets and Therapy, 0, Volume 16, 215-225.	2.0	1
19126	The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE. Nuclear Medicine Communications, 2023, 44, 509-517.	1.1	1
19127	Use of Pretreatment Multiparametric MRI to Predict Tumor Regression Pattern to Neoadjuvant Chemotherapy in Breast Cancer. Academic Radiology, 2023, 30, S62-S70.	2.5	0
19128	Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small cell lung cancer. Thoracic Cancer, 0, , .	1.9	1
19129	Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer. Frontiers in Oncology, 0, 13, .	2.8	0
19130	Predictive power of deep-learning segmentation based prognostication model in non-small cell lung cancer. Frontiers in Oncology, 0, 13, .	2.8	1
19131	Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. EClinicalMedicine, 2023, 58, 101897.	7.1	3
19132	Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression. Cancer Research and Treatment, 0, , .	3.0	0
19133	Efficacy and dose-response relationship of stereotactic body radiotherapy for abdominal lymph node metastases from hepatocellular carcinoma. Oncologist, 0, , .	3.7	0
19134	Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2023, 49, 102666.	3.3	3
19135	Predicting lung cancer treatment response from <scp>CT</scp> images using deep learning. International Journal of Imaging Systems and Technology, 0, , .	4.1	0
19136	Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial. BMC Cancer, 2023, 23, .	2.6	0
19137	2-[18F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer. Scientific Reports, 2023, 13, .	3.3	5
19138	FDG PET/CT-based Response Assessment in Malignancies. Radiographics, 2023, 43, .	3.3	8
19139	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). European Journal of Cancer, 2023, 184, 62-72.	2.8	9
19141	Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. Cytotherapy, 2023, 25, 986-992.	0.7	3

#	ARTICLE	IF	CITATIONS
19142	A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. <i>Oncotarget</i> , 2023, 14, 302-315.	1.8	1
19143	Intravoxel incoherent motion radiomics nomogram for predicting tumor treatment responses in nasopharyngeal carcinoma. <i>Translational Oncology</i> , 2023, 31, 101648.	3.7	2
19144	Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study. <i>Translational Oncology</i> , 2023, 31, 101657.	3.7	2
19145	Instant Oncology: OlympiAD. <i>Clinical Oncology</i> , 2023, 35, 329-330.	1.4	0
19146	Patterns of Failure After Stereotactic Body Radiotherapy to Sacral Metastases. <i>Clinical Oncology</i> , 2023, 35, 339-346.	1.4	1
19147	CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2023, 185, 167-177.	2.8	1
19148	Neoadjuvant chemotherapy combined with transoral robotic surgery for stage III and IV laryngeal and hypopharyngeal carcinomas. <i>Oral Oncology</i> , 2023, 140, 106371.	1.5	2
19149	Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2023, 183, 109635.	0.6	0
19150	Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. <i>European Journal of Cancer</i> , 2023, 186, 27-37.	2.8	1
19151	Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX â€” The LAPC-2 trial. <i>Radiotherapy and Oncology</i> , 2023, 183, 109541.	0.6	0
19152	Gastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer. <i>Cellular Signalling</i> , 2023, 106, 110639.	3.6	6
19153	Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer. <i>Cancers</i> , 2023, 15, 2318.	3.7	2
19154	Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. <i>Gynecologic Oncology</i> , 2023, 171, 23-30.	1.4	1
19155	Toxicity and therapy outcome associations in <i>LIG3</i> , <i>SLCO1B3</i> , <i>ABCB1</i> , <i>OPRM1</i> and <i>GSTP1</i> in high-grade serous ovarian cancer. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2023, 132, 517-527.	2.5	2
19156	Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). <i>European Journal of Radiology</i> , 2023, 163, 110834.	2.6	1
19160	Aggressive Pituitary Adenomas. , 2022, , 637-648.		0
19161	Recent Developments in the Management of Orbital and Periocular Neoplasms. , 2022, , 311-325.		0
19162	Validation of the North America expert consensus statement on reporting CT findings for COVID-19 in individuals with lung cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 0, 55, .	1.5	0

#	ARTICLE	IF	CITATIONS
19163	Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study. Journal of Contemporary Brachytherapy, 2022, 14, 536-541.	0.9	1
19164	Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy. Cancers, 2023, 15, 613.	3.7	5
19165	Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients â€” Knowledge from two independent international studies. Neoplasia, 2023, 37, 100877.	5.3	3
19166	Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital. International Journal of Gynecology and Obstetrics, 2023, 162, 317-324.	2.3	0
19167	Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncology, 2023, 138, 106311.	1.5	1
19168	Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. Anticancer Research, 2023, 43, 841-847.	1.1	1
19169	First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. JCO Precision Oncology, 2023, , .	3.0	1
19170	The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center. Frontiers in Oncology, 0, 13, .	2.8	1
19171	Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology, 2023, 84, 109-116.	1.9	15
19172	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
19173	Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations. Journal of Pediatric Hematology/Oncology, 2023, 45, 315-321.	0.6	1
19174	Could nucleolin and nucleophosmin levels be prognostic indicators in non-small cell lung cancer?. Acta Facultatis Medicae Naissensis, 2022, 39, 433-442.	0.4	0
19175	Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative Cancer Therapies, 2023, 22, 153473542211511.	2.0	1
19176	Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma. Endocrine-Related Cancer, 2023, 30, .	3.1	2
19177	The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial. European Journal of Cancer, 2023, 183, 49-59.	2.8	1
19178	Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRÎ±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology, 2023, 170, 241-247.	1.4	26
19179	Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community. Clinical and Translational Oncology, 2023, 25, 1455-1462.	2.4	1
19180	Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Cancer, 2023, 54, 1240-1251.	1.3	1

#	ARTICLE	IF	CITATIONS
19181	Management of Recurrent Well-Differentiated Thyroid Carcinoma in the Neck: A Comprehensive Review. <i>Cancers</i> , 2023, 15, 923.	3.7	6
19183	Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers. <i>Journal of Clinical Medicine</i> , 2023, 12, 1119.	2.4	2
19185	Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. <i>Surgical Oncology</i> , 2023, 47, 101909.	1.6	2
19186	The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis. <i>Hepatology Research</i> , 2023, 53, 511-521.	3.4	4
19187	Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. <i>Journal of the American College of Surgeons</i> , 2023, 236, 1126-1136.	0.5	4
19188	SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. <i>Cancers</i> , 2023, 15, 906.	3.7	7
19189	Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. <i>Oncologist</i> , 2023, 28, 453-459.	3.7	1
19190	A phase 1 trial of NY-ESO-1-specific TCR-engineered T cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. <i>International Journal of Cancer</i> , 2023, 152, 2554-2566.	5.1	7
19191	Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNI-P-RCC trial. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1903-1915.	4.2	4
19192	Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 3304-3315.	1.5	2
19193	Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	1
19194	Immunotherapy combined with chemotherapy in the treatment for rare primary mucoepidermoid carcinoma of the liver: a case report. <i>Anti-Cancer Drugs</i> , 2023, 34, 582-588.	1.4	1
19195	Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive-disease small cell lung cancer. <i>Oncology Letters</i> , 2023, 25, .	1.8	0
19196	Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature. <i>Case Reports in Oncology</i> , 0, , 30-35.	0.7	0
19197	JGOG2046: a feasibility study of neoadjuvant chemotherapy followed by debulking surgery for clinically diagnosed FIGO stage IVb endometrial cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 436-444.	2.2	3
19198	The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. <i>Cancers</i> , 2023, 15, 947.	3.7	3
19199	Salvage Surgery for Advanced Lung Adenocarcinoma After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. <i>Annals of Thoracic Surgery</i> , 2023, 116, 111-119.	1.3	7
19200	Posttransplant sequential adrenal and spine metastasis of hepatocellular carcinoma responsive to combined regorafenib and radiotherapy: a case report. <i>Korean Journal of Transplantation</i> , 2023, 37, 69-75.	0.1	1

#	ARTICLE	IF	CITATIONS
19202	Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review. <i>Diagnostics</i> , 2023, 13, 564.	2.6	9
19203	Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomizedâ€“controlled open-label Phase II study. <i>Gastroenterology Report</i> , 2022, 11, .	1.3	0
19204	Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. <i>Radiology Imaging Cancer</i> , 2023, 5, .	1.6	3
19205	Integration of artificial intelligence in lung cancer: Rise of the machine. <i>Cell Reports Medicine</i> , 2023, 4, 100933.	6.5	9
19206	The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity scoreâ€“matched analyses. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 1036-1045.	2.6	2
19207	MiR-7-5p/KLF4 signaling inhibits stemness and radioresistance in colorectal cancer. <i>Cell Death Discovery</i> , 2023, 9, .	4.7	5
19208	Combined Resection Approaches: Decision Making for Synchronous Resection, Timing of Staged Intervention to Optimize Outcome. <i>Clinics in Colon and Rectal Surgery</i> , 2024, 37, 096-101.	1.1	0
19209	A case of hepatocellular carcinoma with â€œpseudoprogressionâ€“followed by complete response to atezolizumab plus bevacizumab. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 392-396.	0.8	1
19210	Phase 1 first-in-human study of dalutrafusp alfa, an antiâ€“CD73-TGF-Î²-trap bifunctional antibody, in patients with advanced solid tumors. , 2023, 11, e005267.		7
19211	Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19213	Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. <i>BMC Cancer</i> , 2023, 23, .	2.6	3
19214	Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3151.	4.1	5
19216	Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. <i>Proteomes</i> , 2023, 11, 6.	3.5	1
19217	Canine squamous cell carcinoma: Electrochemotherapy association with surgery and correlation with overall survival. <i>Veterinary and Comparative Oncology</i> , 0, , .	1.8	0
19218	Transplant for colorectal cancer liver metastases. <i>Surgery</i> , 2023, 174, 106-107.	1.9	2
19221	Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2023, 18, e0281459.	2.5	6
19222	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. <i>Lung Cancer</i> , 2023, 178, 96-102.	2.0	1
19223	Response Evaluation in Patients with Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). <i>Journal of Clinical Medicine</i> , 2023, 12, 1289.	2.4	1

#	ARTICLE	IF	CITATIONS
19224	Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 170, 300-308.	1.4	4
19225	Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. <i>Nature Communications</i> , 2023, 14, .	12.8	15
19226	Relevance of Volumetric Parameters Applied to [68Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT. <i>Diagnostics</i> , 2023, 13, 606.	2.6	0
19227	Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases. <i>JAMA Network Open</i> , 2023, 6, e2255050.	5.9	8
19228	Establishing a Prediction Model for the Efficacy of Platinum-Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1318.	2.4	0
19229	Effects of Fractionated Radiation Exposure on Vimentin Expression in Cervical Cancers: Analysis of Association with Cancer Stem Cell Response and Short-Term Prognosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3271.	4.1	1
19230	Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2023, 221, 289-301.	2.2	4
19231	MRI of cervical cancer. , 2023, , 319-344.		0
19232	Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
19233	Pediatric Rhabdomyosarcoma Protocols Should Include More Detailed Imaging Guidelines to Ensure Homogeneous Response Assessment. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
19234	A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	5
19235	Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2023, 149, 300.	2.2	6
19236	Deformable registration with intensity correction for CESM monitoring response to Neoadjuvant Chemotherapy. <i>Biomedical Physics and Engineering Express</i> , 2023, 9, 035003.	1.2	1
19237	Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>PLoS ONE</i> , 2023, 18, e0277708.	2.5	3
19238	The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer. <i>Nutrients</i> , 2023, 15, 880.	4.1	8
19239	Dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors using a gimbal-mounted linac: A multi-institutional phase II study. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100591.	1.7	2
19240	Variation in the management of benign liver tumors: A European survey and case vignette study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102094.	1.5	0
19241	Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF ^{V600E} Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. <i>Thyroid</i> , 2023, 33, 484-491.	4.5	23

#	ARTICLE	IF	CITATIONS
19242	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. JTO Clinical and Research Reports, 2023, 4, 100474.	1.1	0
19243	Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study. European Journal of Clinical Pharmacology, 2023, 79, 503-511.	1.9	2
19244	Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity. Cancers, 2023, 15, 1180.	3.7	3
19245	Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clinical Cancer Research, 2023, 29, 1689-1697.	7.0	1
19246	Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. Cancers, 2023, 15, 1170.	3.7	0
19247	Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer. Future Oncology, 2023, 19, 147-158.	2.4	0
19248	Automatic Classification of Tumor Response From Radiology Reports With Rule-Based Natural Language Processing Integrated Into the Clinical Oncology Workflow. JCO Clinical Cancer Informatics, 2023, , .	2.1	1
19249	Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer. Cancers, 2023, 15, 1151.	3.7	3
19250	A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Molecular Cancer Therapeutics, 2023, 22, 511-518.	4.1	11
19251	Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. Internal Medicine, 2023, 62, 2783-2793.	0.7	2
19252	Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program. JCO Precision Oncology, 2023, , .	3.0	3
19253	A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1714-1725.	2.5	3
19254	The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. Radiologia Medica, 2023, 128, 316-329.	7.7	5
19255	Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2023, 30, 3747-3756.	1.5	4
19256	Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study. Cancer Medicine, 2023, 12, 9202-9212.	2.8	3
19257	Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy. Clinical Cancer Research, 2023, 29, 2513-2524.	7.0	7
19258	Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 133-142.e3.	4.9	5
19259	Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. Cancer Medicine, 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
19260	Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
19261	Clinical Experience of Intra-tumoral Central-Dose Escalated Volumetric Modulated Arc Therapy for Lymph Node Metastases in Patients With Advanced Cancer. <i>Cureus</i> , 2023, , .	0.5	0
19262	Treatment of vulvar cancer recurrences with electrochemotherapy â€” a detailed analysis of possible causes for unsuccessful treatment. <i>Radiology and Oncology</i> , 2023, 57, 121-126.	1.7	6
19263	Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7
19264	The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients. <i>Healthcare (Switzerland)</i> , 2023, 11, 591.	2.0	1
19265	Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2â€”cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 356-367.	8.1	35
19266	Real-world treatment response in Japanese patients with cancer using unstructured data from electronic health records. <i>Health and Technology</i> , 2023, 13, 253-262.	3.6	0
19267	Rucaparib or Physicianâ€™s Choice in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 719-732.	27.0	104
19268	Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3994.	4.1	0
19269	A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2023, 128, 1418-1428.	6.4	2
19270	First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2023, 18, 181-193.	3.6	1
19271	Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial. <i>Clinical Cancer Research</i> , 2023, 29, 2602-2611.	7.0	4
19272	USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. <i>Journal of Zhejiang University: Science B</i> , 2023, 24, 143-156.	2.8	3
19273	Downsizing of rectal cancer following neoadjuvant radiotherapy (5â€”5 Gy) and long interval surgery evaluated using MRI semiautomated volumetric measurements, a retrospective study. <i>Frontiers in Surgery</i> , 0, 10, .	1.4	0
19274	DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer. <i>International Immunopharmacology</i> , 2023, 117, 109886.	3.8	4
19275	Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7
19276	Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity scoreâ€”Matched case-control analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102097.	1.5	0
19277	Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer. <i>Cadernos Saude Coletiva</i> , 2023, 31, .	0.6	0

#	ARTICLE	IF	CITATIONS
19278	Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes. <i>Clinical Cancer Research</i> , 2023, 29, 3110-3123.	7.0	6
19279	Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment. <i>Diagnostics</i> , 2023, 13, 793.	2.6	1
19280	Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients. <i>International Journal of Surgical Pathology</i> , 0, , 106689692311525.	0.8	0
19281	Liver transplantation for isolated unresectable colorectal liver metastases - Protocol for a service evaluation in the United Kingdom - UKCoMET study. <i>Hpb</i> , 2023, 25, 684-692.	0.3	1
19282	MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
19284	Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors. <i>British Journal of Radiology</i> , 2023, 96, .	2.2	0
19285	FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
19286	Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2023, 29, 1906-1915.	7.0	3
19287	Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 103-110.	1.2	1
19288	Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19289	A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (â‰¥2 lines) anti-programmed death-1 monotherapy. <i>Oral Oncology</i> , 2023, 139, 106336.	1.5	0
19290	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
19291	ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling â€” a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. <i>BMC Cancer</i> , 2023, 23, .	2.6	5
19292	Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	4
19293	Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. <i>EClinicalMedicine</i> , 2023, 57, 101873.	7.1	7
19294	Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19295	The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. <i>Neuro-Oncology</i> , 2023, 25, 1605-1616.	1.2	2
19296	PET-MRI for evaluation of response to radiochemotherapy in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 676-682.	2.5	2

#	ARTICLE	IF	CITATIONS
19297	Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Advances in Therapy</i> , 2023, 40, 1686-1704.	2.9	3
19298	Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. <i>Cancer Discovery</i> , 2023, 13, 1100-1115.	9.4	40
19299	The performance of 68Ga-FAPI-04 PET/CT in head and neck squamous cell carcinoma: a prospective comparison with 18F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2114-2126.	6.4	6
19300	Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study. <i>Radiation Oncology</i> , 2023, 18, .	2.7	1
19301	PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. <i>Life</i> , 2023, 13, 611.	2.4	4
19302	A COMPARATIVE PROSPECTIVE STUDY BETWEEN STANDARD AND ALTERED FRACTIONATED RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA. , 2023, , 11-14.		0
19303	The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin. <i>Cancer Research Communications</i> , 2023, 3, 489-500.	1.7	1
19304	Changes in the urine proteome in patients with advanced lung cancer after different drug treatments. <i>Urine</i> , 2023, 5, 1-12.	4.0	1
19305	Magnetic resonance imaging presentation of diffuse and focal adenomyosis before and after pregnancy. <i>Reproductive BioMedicine Online</i> , 2023, 47, 121-128.	2.4	0
19306	Immune checkpoint inhibitors for advanced pancreatic cancer. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	0
19307	Multicenter real-world experience of the clinical efficacy and tolerance of pazopanib in high-risk pediatric solid tumors (PazoPed). <i>Pediatric Hematology and Oncology</i> , 2023, 40, 643-658.	0.8	1
19308	The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2127-2135.	4.2	1
19309	Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100475.	1.1	1
19310	Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer. <i>European Urology Focus</i> , 2023, , .	3.1	2
19311	Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels. <i>Journal of Oncology</i> , 2023, 2023, 1-10.	1.3	0
19312	Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). <i>JTO Clinical and Research Reports</i> , 2023, 4, 100484.	1.1	1
19313	LORELAUS: Lorlatinib REAL-World AUSTRalian Experience in Advanced ALK-Rearranged NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100490.	1.1	0
19314	Thyroid Transcription Factor-1, Tumor Proportion Score and Treatment Effect in Combination Therapy with Carboplatin, Pemetrexed, and Pembrolizumab as a First-line Therapy. <i>Japanese Journal of Lung Cancer</i> , 2023, 63, 15-21.	0.1	0

#	ARTICLE	IF	CITATIONS
19315	Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. International Journal of Molecular Sciences, 2023, 24, 4601.	4.1	2
19316	Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study. Journal of Gastrointestinal Oncology, 2023, 14, 54-63.	1.4	1
19317	Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?. JCO Precision Oncology, 2023, , .	3.0	2
19318	Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). Translational Lung Cancer Research, 2023, 12, 266-276.	2.8	2
19319	Intratumoral and Microenvironmental Heterogeneity in Patient Outcome Prediction. JCO Precision Oncology, 2023, , .	3.0	2
19320	CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation. Journal of the Society for Clinical Data Management, 2023, 3, .	0.2	0
19321	Mapping Tumor Heterogeneity via Local Entropy Assessment: Making Biomarkers Visible. Journal of Digital Imaging, 2023, 36, 1038-1048.	2.9	3
19322	PERCIST and Hopkins criteria and PET/CT metabolic parameters as prognostic factors in squamous head and neck cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2023, 42, 163-170.	0.2	0
19323	Imaging in rhabdomyosarcoma: a patient journey. Pediatric Radiology, 2023, 53, 788-812.	2.0	3
19324	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	25
19325	Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study. Translational Lung Cancer Research, 2023, 12, 312-321.	2.8	1
19326	Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. , 2023, 11, e006234.		10
19327	Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer Research, 2023, 43, 1265-1272.	1.1	0
19328	Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. Anticancer Research, 2023, 43, 1377-1384.	1.1	1
19329	Is High Score of Preoperative Lactate Dehydrogenase to Albumin Ratio Predicting Poor Survivals in Esophageal Carcinoma Patients?. Annals of Thoracic and Cardiovascular Surgery, 2023, 29, 215-222.	0.8	1
19330	Neuroendocrine Tumor Therapy Response Assessment. PET Clinics, 2023, 18, 267-286.	3.0	0
19331	Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma. Anticancer Research, 2023, 43, 1361-1371.	1.1	0
19332	Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers, 2023, 15, 1523.	3.7	2

#	ARTICLE	IF	CITATIONS
19333	Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer. <i>Cancer Imaging</i> , 2023, 23, .	2.8	0
19334	The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2023, 128, 1888-1896.	6.4	3
19335	Neoadjuvant vs Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2023, 388, 813-823.	27.0	184
19336	Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Origin. <i>Annals of Surgery Open</i> , 2022, 3, e203.	1.4	4
19337	Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy. <i>Radiation Oncology</i> , 2023, 18, .	2.7	1
19338	Impact of Clinical Factors and Treatments on SMARCB1 (INI1) Deficient Sinonasal Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2023, 169, 435-440.	1.9	3
19339	Neoplastic Diseases of the Respiratory System in Geriatric Patients. <i>Practical Issues in Geriatrics</i> , 2023, , 171-216.	0.8	0
19340	PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review). <i>International Journal of Oncology</i> , 2023, 62, .	3.3	4
19341	Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. <i>Clinical and Translational Medicine</i> , 2023, 13, .	4.0	2
19342	Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study. <i>Medicine (United States)</i> , 2023, 102, e33157.	1.0	1
19343	Clinical Relevance of Uterine Manipulation on Oncologic Outcome in Robot-Assisted versus Open Surgery in the Management of Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1950.	2.4	2
19344	Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2023, 30, 4444-4454.	1.5	4
19345	Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	1.0	1
19347	Patient outcomes following a response biomarker-guided approach to treatment using ¹⁷⁷ Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311563.	3.2	8
19348	⁸⁹ Zr-immuno-PET using the anti-LAG-3 tracer [⁸⁹ Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2068-2080.	6.4	11
19349	Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORP Palliative Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 1033-1042.	0.8	1
19350	Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer. <i>Oncology Letters</i> , 2023, 25, .	1.8	1
19351	SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post ¹⁷⁷ Lu-DOTATATE and ¹⁷⁷ Lu-PSMA617 setting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2250-2257.	6.4	5

#	ARTICLE	IF	CITATIONS
19352	Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am. <i>Cancers</i> , 2023, 15, 1564.	3.7	1
19353	A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 147-172.	1.8	5
19354	Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. <i>BMC Cancer</i> , 2023, 23, .	2.6	3
19355	ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. <i>NAR Cancer</i> , 2023, 5, .	3.1	0
19356	Clinical outcomes of volume of disease on patients receiving enzalutamide <i>versus</i> abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	1
19357	Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study. <i>International Journal of Hematology</i> , 2023, 118, 107-118.	1.6	1
19358	Imaging recommendations for the management of pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Consensus statement of the International Soft Tissue Sarcoma Consortium (INSTRuCT). , 2023, 1, 100008.		1
19359	Dynamic changes in circulating tumor <scp>DNA</scp> assessed by shallow wholeâ€šgenome sequencing associate with clinical efficacy of checkpoint inhibitors in <scp>NSCLC</scp>. <i>Molecular Oncology</i> , 2023, 17, 779-791.	4.6	0
19360	A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1606.	3.7	3
19361	Advances in Boron Neutron Capture Therapy (BNCT) for Recurrent Intracranial Meningioma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4978.	4.1	2
19362	Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	6
19363	Comparison of radiomics models and dual-energy material decomposition to decipher abdominal lymphoma in contrast-enhanced CT. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 0, , .	2.8	0
19364	Eosinophil and IFN- γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7
19365	Role of GSDMD and VEGF in differentiating between malignant and non-malignant pleural effusions. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2023, 12, .	2.0	0
19366	Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study. <i>OncoTargets and Therapy</i> , 0, Volume 16, 157-163.	2.0	2
19367	How Do Cancer-Specific Computed Tomography Protocols Compare With the American College of Radiology Dose Index Registry? An Analysis of Computed Tomography Dose at 2 Cancer Centers. <i>Journal of Computer Assisted Tomography</i> , 0, Publish Ahead of Print, .	0.9	2
19368	Pegylated liposomal doxorubicin (DuomeisuÂ®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 67-79.	2.5	2
19370	Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4545.	2.6	1

#	ARTICLE	IF	CITATIONS
19371	Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 688-697.	2.2	2
19372	DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer. <i>Cancers</i> , 2023, 15, 1630.	3.7	2
19374	Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan. <i>In Vivo</i> , 2023, 37, 747-755.	1.3	1
19375	Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
19376	A Japanese registry study and systematic review of particle therapy for renal cell carcinoma. <i>Journal of Radiation Research</i> , 0, , .	1.6	0
19377	Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2477-2485.	6.4	7
19378	Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy. <i>In Vivo</i> , 2023, 37, 794-800.	1.3	2
19379	PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial. <i>Cell Reports Medicine</i> , 2023, 4, 100972.	6.5	4
19380	Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	1.1	1
19381	Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 230-235.	0.7	3
19382	Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	2
19383	Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity. , 2023, 11, e006462.		3
19384	Clinical Outcomes and Toxicity of CT-guided High Dose-rate Brachytherapy in Women With Locally-advanced Cervical Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 194-200.	0.7	1
19385	Refusal of Subsequent Treatment in Patients With EGFR-mutant Non-small-cell Lung Cancer After Response to EGFR-TKIs. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 251-256.	0.7	0
19386	A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FFâ€10502â€01 for the treatment of advanced solid tumors. <i>Cancer</i> , 0, , .	4.1	0
19387	NSCLC Patients Achieving Long-term Progression-free Survival With Docetaxel Plus Ramucirumab: A Retrospective Study. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 215-220.	0.7	0
19388	Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 244-250.	0.7	1
19389	Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2023, 178, 247-253.	2.0	1

#	ARTICLE	IF	CITATIONS
19390	Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab+Bevacizumab in Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1661.	3.7	4
19391	Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma. <i>European Thyroid Journal</i> , 2023, 12, .	2.4	2
19392	Therapiesteuerung in der medikamentÄrsen Tumorthherapie. <i>Springer Reference Medizin</i> , 2022, , 1-7.	0.0	0
19393	A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. <i>ESMO Open</i> , 2023, 8, 101183.	4.5	7
19394	Tumor Volume Nadir in Patients With <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib. <i>JCO Precision Oncology</i> , 2023, , .	3.0	0
19396	Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 2843-2851.	1.6	10
19397	Combined CT-guided high-dose-rate brachytherapy (CT-HDRBT) and transarterial chemoembolization with irinotecan-loaded microspheres improve local tumor control and progression-free survival in patients with unresectable colorectal liver metastases compared with mono-CT-HDRBT. <i>Journal of Contemporary Brachytherapy</i> , 2023, 15, 15-26.	0.9	0
19398	Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery. <i>Diseases of the Colon and Rectum</i> , 2023, 66, 733-743.	1.3	3
19399	Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. <i>JAMA Network Open</i> , 2023, 6, e232526.	5.9	2
19402	M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19403	Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e33204.	1.0	1
19404	Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
19406	Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR. <i>Oncologist</i> , 0, , .	3.7	3
19407	Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). <i>European Journal of Cancer</i> , 2023, 189, 112847.	2.8	1
19408	LncRNA CACCLnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51. <i>Oncogene</i> , 2023, 42, 1374-1391.	5.9	6
19409	Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib+â€‰Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma. <i>Targeted Oncology</i> , 2023, 18, 235-245.	3.6	1
19410	Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 251-265.	1.8	1
19411	Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. <i>Metabolites</i> , 2023, 13, 417.	2.9	1

#	ARTICLE	IF	CITATIONS
19412	Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer. <i>Journal of Palliative Medicine</i> , 2023, 26, 831-836.	1.1	4
19413	Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?. <i>Medicina (Lithuania)</i> , 2023, 59, 557.	2.0	1
19414	Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2023, 23, .	2.6	5
19415	Real-world clinical outcomes of the combination of anti-EPD antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer. <i>Cancer Medicine</i> , 2023, 12, 9517-9526.	2.8	2
19416	Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 2211.	2.4	0
19417	BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2023, 14, .	12.8	3
19418	A Deep Learning Radiomics Nomogram to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer: A Two-Center Study. <i>Diagnostics</i> , 2023, 13, 1073.	2.6	4
19419	Different treatment efficacies and T790M acquisition of EGFR TKIs on NSCLC patients with variable Del19 subtypes of EGFR. <i>International Journal of Cancer</i> , 2023, 153, 352-363.	5.1	2
19420	Evaluation of entropy and fractal dimension as biomarkers for tumor growth and treatment response using cellular automata. <i>Journal of Theoretical Biology</i> , 2023, 564, 111462.	1.7	0
19421	Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1-pRB-E2F1 pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 991-1005.	3.6	2
19422	Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5496.	4.1	2
19423	Comparing the effectiveness of 2D and 3D features on predicting the response to chemotherapy for ovarian cancer patients. , 2023, , .		1
19424	Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma. <i>Clinical Immunology</i> , 2023, 249, 109290.	3.2	0
19426	Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 212-212.	1.7	0
19427	Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitors' Effects on Metastatic Renal Cell Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 3779.	2.5	1
19428	A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. <i>Nature Medicine</i> , 2023, 29, 859-868.	30.7	30
19429	Outcomes and endpoints of relevance in gynecologic cancer clinical trials. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 323-332.	2.5	3
19430	Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. <i>Nature Medicine</i> , 2023, 29, 593-604.	30.7	46

#	ARTICLE	IF	CITATIONS
19431	Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19432	Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2023, 128, 1916-1921.	6.4	5
19433	On the correction of respiratory motion-induced image reconstruction errors in positron-emission tomography-guided radiation therapy. <i>Physics and Imaging in Radiation Oncology</i> , 2023, 26, 100430.	2.9	0
19435	Direct GDP-KRAS^{G12C} inhibitors and mechanisms of resistance: the tip of the iceberg. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311601.	3.2	1
19436	Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. <i>Liver Cancer</i> , 2023, 12, 198-208.	7.7	2
19437	Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging. <i>IDKD Springer Series</i> , 2023, , 31-45.	0.8	0
19438	Imaging Features of Immunotherapy. <i>IDKD Springer Series</i> , 2023, , 169-176.	0.8	0
19439	Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. <i>European Journal of Cancer</i> , 2023, 186, 211-221.	2.8	5
19440	Identification of LSM family members as potential chemoresistance predictive and therapeutic biomarkers for gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19441	Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	2.6	1
19443	Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report. <i>Translational Cancer Research</i> , 2023, .	1.0	1
19444	Update of the Bologna Experience in Radioembolization of Intrahepatic cholangiocarcinoma. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311556.	1.9	1
19445	Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). <i>Journal of Clinical Oncology</i> , 2023, 41, 3042-3050.	1.6	12
19446	Case Studies of Basket Trials and Umbrella Trials. , 2023, , 127-139.		0
19447	The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5767.	4.1	4
19448	Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer. <i>Radiologia Medica</i> , 2023, 128, 402-414.	7.7	2
19449	Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study. <i>Targeted Oncology</i> , 2023, 18, 209-220.	3.6	4
19451	Interactive process mining of cancer treatment sequences with melanoma real-world data. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
19452	Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 869-881.	1.1	14
19453	Can Ki-67 predict radiotherapy response in neuroendocrine tumors? Retrospective analysis of a monocentric series of patients. <i>Tumori</i> , 0, , 030089162311605.	1.1	0
19454	Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311601.	3.2	9
19455	CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. <i>Academic Radiology</i> , 2023, 30, 2574-2587.	2.5	3
19456	Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes -AA single centre experience from India. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19457	DeepGeni: deep generalized interpretable autoencoder elucidates gut microbiota for better cancer immunotherapy. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
19458	Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i> -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 2651-2660.	1.6	18
19459	Whole exon capture sequencing for identifying mutations associated with pulmonary benign metastasising leiomyoma. <i>BMJ Case Reports</i> , 2023, 16, e251072.	0.5	1
19460	The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101474.	1.0	3
19461	Predicting pathological complete response after neoadjuvant chemotherapy: A nomogram combining clinical features and ultrasound semantics in patients with invasive breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19462	Case report: Stem cell-based suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene reduces tumor progression in multifocal glioblastoma. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	1
19463	Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies. <i>Cancer</i> , 2023, 129, 2004-2012.	4.1	2
19464	Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
19465	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. <i>Oncologist</i> , 2023, 28, 714-721.	3.7	2
19466	Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study. <i>Cancer Medicine</i> , 0, , .	2.8	1
19467	Backfilling cohorts in phase I dose-escalation studies. <i>Clinical Trials</i> , 2023, 20, 261-268.	1.6	4
19468	Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy. <i>Cancer Medicine</i> , 2023, 12, 11334-11343.	2.8	1
19470	Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy and durvalumab maintenance treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0

#	ARTICLE	IF	CITATIONS
19471	MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics. Scientific Reports, 2023, 13, .	3.3	0
19472	Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis. Frontiers in Immunology, 0, 14, .	4.8	2
19473	Difference after radiotherapy observed in patients with nasopharyngeal carcinoma. Bulletin Du Cancer, 2023, , .	1.6	0
19474	Contribution of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) measurements in determining response to treatment in lung cancer. Cukurova Medical Journal, 2023, 48, 187-193.	0.2	0
19475	Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced nonâ€‘small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2023, 166, 1234-1244.e13.	0.8	3
19476	Multidisciplinary nutritional management improves nutritional and hospitalized outcomes of patients with esophageal cancer undergoing chemoradiotherapy: A randomized control trial. Medicine (United Tj ETQq1 1 0.784314 2gBT /Overl	0.784314	2
19477	Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab. Cancer Imaging, 2023, 23, .	2.8	3
19478	A novel method to identify and characterize personalized functional driver lncRNAs in cancer samples. Computational and Structural Biotechnology Journal, 2023, 21, 2471-2482.	4.1	1
19479	New frontiers in oncological imaging with Computed Tomography: from morphology to function. Seminars in Ultrasound, CT and MRI, 2023, , .	1.5	0
19481	Are more courses of immunochemotherapy beneficial for the shortâ€‘term outcome of locally advanced esophageal squamous cell carcinoma?. Thoracic Cancer, 0, , .	1.9	1
19482	Quantitative Diffusion-Weighted MRI of Neuroblastoma. Cancers, 2023, 15, 1940.	3.7	0
19483	Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma. World Journal of Surgical Oncology, 2023, 21, .	1.9	2
19484	Real-world data of combined immuno-chemotherapy in patients with non-squamous advanced non-small cell lung cancer. A single center retrospective study.. JTO Clinical and Research Reports, 2023, , 100509.	1.1	0
19485	Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. Journal of Gastroenterology, 2023, 58, 413-424.	5.1	10
19486	Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. BMC Gastroenterology, 2023, 23, .	2.0	0
19487	MRI fat fraction imaging of nodal and bone metastases in prostate cancer. European Radiology, 2023, 33, 5851-5855.	4.5	3
19488	Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10Â‘years. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
19489	Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study. International Journal of Clinical Oncology, 2023, 28, 756-763.	2.2	1

#	ARTICLE	IF	CITATIONS
19490	Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2023, 24, 323-334.	10.7	29
19491	Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 2159-2170.	27.0	118
19492	Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular"cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
19493	Chemical Exchange Saturation Transfer <scp>MRI</scp> : Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non"Small Cell Lung Cancer Patients. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	3
19494	A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2023, 29, 2043-2051.	7.0	4
19495	A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2357-2373.	4.2	3
19496	Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST. <i>International Journal of Clinical Oncology</i> , 2023, 28, 680-687.	2.2	3
19497	Molecular imaging for cancer immunotherapy. , 2023, 1, 3-17.		4
19498	Response to induction chemotherapy in sinonasal malignancies: A single"institutional experience. <i>Head and Neck</i> , 2023, 45, 1445-1454.	2.0	2
19499	Prediction of response to preoperative neoadjuvant chemotherapy in extremity high-grade osteosarcoma using X-ray and multiparametric MRI radiomics. <i>Journal of X-Ray Science and Technology</i> , 2023, , 1-16.	1.0	0
19500	Response Evaluation of Neoadjuvant Therapies in Sarcoma. <i>Current Treatment Options in Oncology</i> , 0, , .	3.0	0
19501	Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC). <i>Future Oncology</i> , 2023, 19, 193-203.	2.4	8
19502	Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311637.	3.2	1
19503	Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study. <i>Journal of Breast Cancer</i> , 0, 26, .	1.9	0
19504	Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. <i>Archives of Dermatological Research</i> , 2023, 315, 2295-2302.	1.9	2
19505	Liquid biopsy using cfDNA to predict radiation therapy response in solid tumors. <i>Radiation Oncology Journal</i> , 2023, 41, 32-39.	1.5	2
19506	A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study. <i>Journal of Investigative Dermatology</i> , 2023, 143, 2007-2018.e6.	0.7	2
19507	High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. <i>European Radiology</i> , 0, , .	4.5	0

#	ARTICLE	IF	CITATIONS
19508	A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. Journal of Gastric Cancer, 0, 23, .	2.5	0
19509	Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma. JAMA Oncology, 2023, 9, 656.	7.1	9
19510	PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. JCO Precision Oncology, 2023, , .	3.0	0
19511	Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Current Medical Science, 0, , .	1.8	0
19512	Radiomics and Radiogenomics of Ovarian Cancer. Radiologic Clinics of North America, 2023, , .	1.8	3
19513	Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2023, 29, 2835-2844.	7.0	6
19514	Tumor Immunophenotypingâ€œDerived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. Advanced Science, 2023, 10, .	11.2	3
19515	Testâ€œretest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma. British Journal of Radiology, 2023, 96, .	2.2	1
19516	Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. European Journal of Cancer, 2023, 187, 15-24.	2.8	5
19517	Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience. Cancers, 2023, 15, 2093.	3.7	1
19518	ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. , 2023, 11, e006345.		4
19519	<sc>FIGHT</sc> â€œ102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer Medicine, 0, , .	2.8	3
19520	Eganelisib, a First-in-Class PI3KÎ³ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical Cancer Research, 2023, 29, 2210-2219.	7.0	6
19521	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
19522	Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas. Frontiers in Immunology, 0, 14, .	4.8	2
19523	Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC. Frontiers of Medicine, 2023, 17, 493-502.	3.4	2
19524	Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatology International, 2023, 17, 904-914.	4.2	10
19525	Predictive adjudication rate modeling for prioritizing case distribution in BICR for oncology clinical trials. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
19526	Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Therapeutics and Clinical Risk Management, 0, Volume 19, 329-339.	2.0	2
19527	Safety and efficacy of self-expandable metallic stent combined with 125I brachytherapy for the treatment of malignant obstructive jaundice. Cancer Imaging, 2023, 23, .	2.8	2
19528	Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Research Communications, 2023, 3, 821-829.	1.7	9
19529	German specialists treating testicular cancer follow different guidelines with resulting inconsistency in assessment of retroperitoneal lymph-node metastasis: clinical implications and possible corrective measures. World Journal of Urology, 2023, 41, 1353-1358.	2.2	1
19530	Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. British Journal of Cancer, 2023, 128, 2175-2185.	6.4	9
19531	Plasma extracellular vesicle transcriptomics identifies <scp>CD160</scp> for predicting immunochemotherapy efficacy in lung cancer. Cancer Science, 2023, 114, 2774-2786.	3.9	4
19532	Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Research, 2023, 33, 208-217.	1.2	2
19533	First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 2023, 72, 2443-2458.	4.2	14
19534	The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours. European Journal of Cancer, 2023, 187, 185-194.	2.8	7
19535	Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations. Thoracic Cancer, 2023, 14, 1355-1361.	1.9	4
19536	Prognostic significance of mucinous histology in left-sided metastatic colorectal cancers with wild-type RAS and evaluation of backbone chemotherapy regimens. Oncology Letters, 2023, 25, .	1.8	1
19537	Evaluating the intracranial activity of adagrasib. Translational Lung Cancer Research, 2023, 12, 669-675.	2.8	1
19538	The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. Scientific Reports, 2023, 13, .	3.3	0
19539	Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Oncologist, 2023, 28, e526-e533.	3.7	6
19540	Abdominal Emergencies in Cancer and Immunocompromised Patients. , 2023, , 81-99.		0
19541	Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer. JAMA Oncology, 2023, 9, 825.	7.1	28
19543	Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer. Cancer, 2023, 129, 2297-2307.	4.1	1
19544	A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA). ESMO Open, 2023, 8, 101207.	4.5	0

#	ARTICLE	IF	CITATIONS
19545	TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. International Journal of Surgery, 2023, 109, 1222-1230.	2.7	6
19546	Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. , 2023, 11, e005828.		3
19547	Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer. Clinical and Experimental Medicine, 2023, 23, 3919-3933.	3.6	1
19548	Observational study of HR+/HER2âˆ’ metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS). Clinical and Translational Oncology, 0, , .	2.4	0
19549	The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours. European Journal of Cancer, 2023, 187, 134-143.	2.8	10
19550	Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precision Oncology, 2023, , .	3.0	3
19551	<scp>HMOX1</scp> pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. Cancer Medicine, 2023, 12, 10512-10525.	2.8	3
19552	Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan. Journal of Gastrointestinal Oncology, 2023, 14, 849-862.	1.4	2
19553	Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma. OncoTargets and Therapy, 0, Volume 16, 263-273.	2.0	5
19554	PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nature Cancer, 2023, 4, 535-549.	13.2	9
19556	Efficacy and safety of low concentration hydrogen peroxide as nasopharyngeal lavage fluid in the treatment for nasopharyngeal carcinoma radiotherapy: a pilot cohort study. Journal of Cancer, 2023, 14, 927-934.	2.5	0
19557	Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events. Frontiers in Oncology, 0, 13, .	2.8	3
19558	Prognostic effect of cachexia in patients with nonâ€small cell lung cancer receiving immune checkpoint inhibitors. Thoracic Cancer, 2023, 14, 1362-1367.	1.9	6
19559	PET/CT in Synovial Tumors and Tumor-Like Conditions. Medical Radiology, 2023, , .	0.1	0
19560	Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC Cancer, 2023, 23, .	2.6	0
19561	Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study. , 2023, 40, .		1
19562	Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials. Tomography, 2023, 9, 810-828.	1.8	1
19563	Prognostic assessment in patients operated for brain metastasis from systemic tumors. Cancer Medicine, 2023, 12, 12316-12324.	2.8	1

#	ARTICLE	IF	CITATIONS
19564	Treatment of melanoma with dendritic cell vaccines and immune checkpoint inhibitors: A mathematical modeling study. <i>Journal of Theoretical Biology</i> , 2023, , 111489.	1.7	0
19566	Fast, light, and scalable: harnessing data-mined line annotations for automated tumor segmentation on brain MRI. <i>European Radiology</i> , 0, , .	4.5	0
19567	Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with <i>BRAF</i> -mutant solid tumors. <i>Cancer</i> , 0, , .	4.1	0
19568	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. <i>EClinicalMedicine</i> , 2023, 59, 101955.	7.1	1
19569	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	1
19570	Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients. <i>BMC Women's Health</i> , 2023, 23, .	2.0	0
19571	Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
19572	Exercise during Chemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. <i>BMJ Open</i> , 2023, 13, e067925.	1.9	1
19573	Trametinib in Patients With <i>NF1</i> -, <i>GNAQ</i> -, or <i>GNA11</i> -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. <i>JCO Precision Oncology</i> , 2023, , .	3.0	5
19574	Bayesian network enables interpretable and state-of-the-art prediction of immunotherapy responses in cancer patients. , 0, , .		0
19575	The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311659.	3.2	7
19576	Validation of an orthotopic non-small cell lung cancer mouse model, with left or right tumor growths, to use in conformal radiotherapy studies. <i>PLoS ONE</i> , 2023, 18, e0284282.	2.5	0
19577	Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein. <i>Cancers</i> , 2023, 15, 2304.	3.7	4
19578	Combined CT and serum CA19-9 for stratifying risk for progression in patients with locally advanced pancreatic cancer receiving intraoperative radiotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19579	Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2297.	3.7	3
19580	Therapeutic mastoplasty: a "wise oncoplastic choice" lessons from the largest single-center cohort from Asia. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19581	Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. <i>Nature Medicine</i> , 2023, 29, 1103-1112.	30.7	47
19583	Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients. <i>Cancer Medicine</i> , 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
19584	The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. <i>Cancer Medicine</i> , 2023, 12, 12325-12335.	2.8	6
19585	Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real-world retrospective study. <i>Cancer Medicine</i> , 0, , .	2.8	0
19586	Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. <i>General Thoracic and Cardiovascular Surgery</i> , 0, , .	0.9	1
19587	Draft of clinical guidelines for the diagnosis and treatment of medullary thyroid cancer in adult patients. <i>Endocrine Surgery</i> , 2023, 16, 5-23.	0.2	1
19589	CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1247-1252.	2.5	2
19590	Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies. <i>Lung Cancer</i> , 2023, 180, 107194.	2.0	0
19591	Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer. <i>Molecular Carcinogenesis</i> , 0, , .	2.7	0
19592	Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group. <i>Cancers</i> , 2023, 15, 2314.	3.7	2
19593	Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	1
19594	Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	1
19595	FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data. <i>Clinical Cancer Research</i> , 2023, 29, 2964-2972.	7.0	0
19596	Single Arm Phase II Clinical Trial. , 2023, , 91-118.		0
19597	Outcome of Children and Adolescents With Primary Intracranial Germinoma Treated With Chemotherapy and Reduced Dose-Field Irradiation: A Prospective Brazilian Experience. <i>JCO Global Oncology</i> , 2023, , .	1.8	2
19599	Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. <i>European Journal of Cancer</i> , 2023, 188, 8-19.	2.8	0
19600	Is CT or FDG-PET more useful for evaluation of the treatment response in metastatic HER2-positive breast cancer? a case report and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19601	Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC. <i>Life</i> , 2023, 13, 1051.	2.4	1
19602	Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2023, 401, 1773-1785.	13.7	58
19603	Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. <i>European Journal of Cancer</i> , 2023, 188, 29-38.	2.8	5

#	ARTICLE	IF	CITATIONS
19604	Efficacy and predictive factors of endoscopic ultrasound-guided ethanol ablation in benign solid pancreatic tumors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 5960-5968.	2.4	4
19605	Preliminary report on the short-term efficacy and safety of SAPO-S1 therapy for locally advanced gastric cancer with a deep learning perspective. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-16.	6.2	0
19606	Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor $\hat{\pm}2$ Shows a Poor Response to Gemcitabine-Based Chemotherapy. <i>Pancreas</i> , 2022, 51, 1133-1139.	1.1	0
19607	Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer. <i>European Journal of Cancer</i> , 2023, 188, 81-89.	2.8	3
19608	Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR. <i>Journal of Thoracic Oncology</i> , 2023, 18, 1042-1054.	1.1	3
19609	Clinicopathological Characteristics, Treatment Patterns, and Outcomes in Patients with Laryngeal Cancer. <i>Current Oncology</i> , 2023, 30, 4289-4300.	2.2	1
19610	Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience. <i>Radiologia Medica</i> , 2023, 128, 619-627.	7.7	1
19611	Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment. <i>Asian Journal of Surgery</i> , 2023, 46, 3542-3548.	0.4	0
19613	Understanding the activity of antibodyâ€“drug conjugates in primary and secondary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 372-389.	27.6	18
19614	Prognostic Value of Somatostatin Receptor-Derived Volumetric Parameters from a Hybrid Standardized Uptake Value Thresholding Method in Patients with 68Ga-DOTATATE-Avid Stage IV Neuroendocrine Neoplasms: A Preliminary Study. <i>Neuroendocrinology</i> , 0, , 1-11.	2.5	0
19615	Nomogram Based on Preoperative Absolute Lymphocyte Count to Predict Local Recurrence in Patients with Non-Small Cell Lung Cancer After Microwave Ablation. <i>Journal of Inflammation Research</i> , 0, Volume 16, 1761-1770.	3.5	0
19616	Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 2165-2173.	3.3	3
19617	Efficacy and safety of nanoparticle albuminâ€“bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced nonâ€“small cell lung cancer: A multicenter <scp>Phase 2</scp> clinical trial. <i>Cancer Medicine</i> , 2023, 12, 13041-13053.	2.8	2
19619	Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. , 2023, 11, e006633.		8
19620	A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. <i>PLoS Computational Biology</i> , 2023, 19, e1010976.	3.2	0
19621	Realâ€“world comprehensive diagnosis and â€œSurgery + Xâ€“treatment strategy of earlyâ€“stage synchronous multiple primary lung cancer. <i>Cancer Medicine</i> , 2023, 12, 12996-13006.	2.8	0
19623	Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. <i>Cancer</i> , 2023, 129, 2245-2255.	4.1	6
19624	Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, metaâ€“analysis, and metaâ€“regression analysis. <i>Cancer Medicine</i> , 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
19625	The efficacy of neoadjuvant chemotherapy as compared to upfront surgery for the management of oral squamous cell carcinoma: a systematic review and meta-analysis. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2024, 53, 1-10.	1.5	0
19626	Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study. <i>Lung Cancer</i> , 2023, 180, 107213.	2.0	1
19627	A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 673-686.	3.7	4
19628	Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311678.	3.2	3
19629	Effects of Deep Hyperthermia Combined with Intraperitoneal Chemotherapy on Liver-Kidney Function, Immune Function, and Long-Term Survival in Patients with Abdominal Metastases. <i>Emergency Medicine International</i> , 2023, 2023, 1-7.	0.8	1
19630	Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 621-633.	1.5	1
19631	Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. <i>British Journal of Cancer</i> , 2023, 128, 2227-2235.	6.4	0
19632	Early and Persistent Dysphagia Relief Predicts Tumor Response in Esophageal Squamous Cell Carcinoma Patients Treated with Immunochemotherapy. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	1
19633	Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial. <i>Cells</i> , 2023, 12, 1246.	4.1	3
19634	Pituitary adenoma consistency affects postoperative hormone function: a retrospective study. <i>BMC Endocrine Disorders</i> , 2023, 23, .	2.2	3
19635	Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy. <i>Molecular Diagnosis and Therapy</i> , 0, , .	3.8	1
19636	TheÂprognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index. <i>Future Oncology</i> , 2023, 19, 517-529.	2.4	0
19637	Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7824.	4.1	1
19638	Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. <i>European Radiology</i> , 2023, 33, 7284-7293.	4.5	1
19639	Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
19640	Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4817-4824.	3.6	1
19641	A phase <scp>II</scp> study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 13100-13110.	2.8	0
19642	Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 117, 321-332.	0.8	2

#	ARTICLE	IF	CITATIONS
19643	Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International Journal of Urology, 2023, 30, 754-761.	1.0	1
19644	Pegylated liposomal doxorubicin (<scp>PLD</scp>) in daily practice—A single center experience of treatment with <scp>PLD</scp> in patients with comorbidities and older patients with metastatic breast cancer. Cancer Medicine, 2023, 12, 13388-13396.	2.8	0
19645	Liver Transplantation for Colorectal Liver Metastases. Advances in Surgery, 2023, 57, 171-185.	1.3	2
19646	Postchemoradiotherapy systemic inflammation response index predicts treatment response and overall survival for patients with locally advanced nasopharyngeal cancer. Journal of the Formosan Medical Association, 2023, , .	1.7	1
19647	Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment. Cancer Letters, 2023, 562, 216187.	7.2	3
19648	MUCE: Bayesian hierarchical modelling for the design and analysis of phase 1b multiple expansion cohort trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2023, 72, 649-669.	1.0	6
19649	Is response evaluation criteria in solid tumors (<scp>RECIST</scp>) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced <scp>NSCLC</scp> ?. Thoracic Cancer, 0, , .	1.9	0
19650	Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma. , 2023, 11, e006195.		5
19651	Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer. World Journal of Urology, 2023, 41, 1551-1562.	2.2	1
19652	BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge. Cancers, 2023, 15, 2607.	3.7	5
19653	The Endpoints Dataset: A Quality Control Method for Review and Analysis of Critical Efficacy Endpoints Data. Journal of the Society for Clinical Data Management, 2023, .	0.2	0
19654	Prediction of clinical response to neoadjuvant therapy in advanced breast cancer by baseline B-mode ultrasound, shear-wave elastography, and pathological information. Frontiers in Oncology, 0, 13, .	2.8	2
19655	Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases. Frontiers in Oncology, 0, 13, .	2.8	1
19656	Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience. Journal of the Egyptian National Cancer Institute, 2023, 35, .	1.5	0
19657	Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients. Radiotherapy and Oncology, 2023, 184, 109699.	0.6	1
19658	Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report. Molecular and Clinical Oncology, 2023, 18, .	1.0	1
19659	Liquid Biopsy in Gastrointestinal Cancers: How Close Are We to Reaching the Clinic?. Cancers, 2023, 15, 2831.	3.7	0
19661	Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy. Frontiers in Oncology, 0, 13, .	2.8	1

#	ARTICLE	IF	CITATIONS
19662	Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	3
19663	Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. <i>British Journal of Cancer</i> , 0, , .	6.4	2
19664	Nomograms incorporating primary tumor response at midâ€radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 0, , .	2.0	0
19665	Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 5252-5263.	1.5	6
19666	Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. <i>Annals of Oncology</i> , 2023, 34, 681-692.	1.2	41
19667	Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	4.1	4
19668	Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 187, 104032.	4.4	2
19669	Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 10109-10117.	2.5	1
19670	Impact of induction therapy in locally advanced intrahepatic cholangiocarcinoma. <i>European Journal of Surgical Oncology</i> , 2023, 49, 106939.	1.0	0
19671	HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial. <i>Investigational New Drugs</i> , 2023, 41, 473-482.	2.6	0
19673	Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 803-812.	1.1	1
19674	Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311606.	1.9	0
19675	Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck. <i>Cancers</i> , 2023, 15, 2431.	3.7	0
19676	Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE). , 2023, 11, e006561.		7
19677	Clinical and Demographic Characteristics, Mechanisms, and Outcomes in Patients With Acute Ischemic Stroke and Newly Diagnosed or Known Active Cancer. <i>Neurology</i> , 2023, 100, .	1.1	4
19678	Phase I study of neoadjuvant Sâ€1 plus cisplatin with concurrent radiation for biliary tract cancer (Tokyo Study Group for Biliary Cancer: TOSBIC02). <i>Annals of Gastroenterological Surgery</i> , 0, , .	2.4	0
19679	Optimal timing of hypofractionated stereotactic radiotherapy for epidermal growth factor receptorâ€mutated nonâ€smallâ€cell lung cancer patients with brain metastases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	1.1	0
19680	Early Prediction of Response to Neoadjuvant Chemotherapy Using Quantitative Parameters on Automated Breast Ultrasound Combined with Contrast-Enhanced Ultrasound in Breast Cancer. <i>Ultrasound in Medicine and Biology</i> , 2023, 49, 1638-1646.	1.5	1

#	ARTICLE	IF	CITATIONS
19681	The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer. <i>International Immunopharmacology</i> , 2023, 119, 110200.	3.8	4
19682	Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma. <i>Japanese Journal of Clinical Oncology</i> , 2023, 53, 604-610.	1.3	0
19683	Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma. <i>Hepatology International</i> , 2023, 17, 1289-1299.	4.2	3
19684	The Safety and Effectiveness of Hepatic Transarterial Embolic Locoregional Therapy in Patients with Contraindications to Hepatectomy after Portal Vein Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2023, , .	0.5	0
19685	A phase 2 study of stereotactic body radiation therapy for squamous cell carcinoma of the head and neck (SHINE): a single arm clinical trial protocol. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
19687	The lung cancers: staging and response, CT, ¹⁸ F-FDG PET/CT, MRI, DWI: review and new perspectives. <i>British Journal of Radiology</i> , 2023, 96, .	2.2	2
19688	Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R). <i>Gynecologic Oncology</i> , 2023, 173, 88-97.	1.4	2
19689	Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
19690	Analysis of the efficacy and influencing factors of preoperative P ₅₃ neoadjuvant chemotherapy regimen for progressive gastric cancer—construction of a clinical prediction model. <i>Cancer Medicine</i> , 2023, 12, 13031-13040.	2.8	1
19691	Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting. <i>Cancers</i> , 2023, 15, 2450.	3.7	0
19692	PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma. <i>Future Oncology</i> , 2023, 19, 499-507.	2.4	3
19693	Particle beam therapy for pelvic recurrence of colorectal cancer: a registry data analysis in Japan and a systematic review. <i>Journal of Radiation Research</i> , 2023, 64, i25-i33.	1.6	1
19694	Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors “can we RECIST? Focus on colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311715.	3.2	1
19695	Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 8769-8778.	2.5	0
19696	Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2023, 12, 12861-12873.	2.8	1
19698	Phase II study (KAMELEON) of single-agent T _{DM1} in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. <i>Cancer Medicine</i> , 2023, 12, 12071-12083.	2.8	9
19699	Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	2.2	1
19700	Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). <i>Diagnostics</i> , 2023, 13, 1595.	2.6	0

#	ARTICLE	IF	CITATIONS
19701	Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis. <i>Clinical Cancer Research</i> , 2023, 29, 2612-2620.	7.0	3
19702	Advancement in oral pharmacokinetics of an antibiotic Cefixime using amphiphilic 4-armed macrocyclic surfactant based niosomes. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104958.	4.9	0
19703	The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2023, 14, 1500-1511.	1.9	1
19704	Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's Perspective. <i>Current Oncology</i> , 2023, 30, 4688-4699.	2.2	0
19705	Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2023, 12, 12986-12995.	2.8	0
19706	Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. <i>Cancer</i> , 2023, 129, 2685-2693.	4.1	1
19707	Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
19708	Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCaVE trial. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19709	Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. <i>Journal of Thoracic Oncology</i> , 2023, 18, 1055-1069.	1.1	10
19710	Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	3
19711	Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review. <i>Current Urology</i> , 2023, 17, 271-279.	0.6	1
19712	Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. <i>Nature</i> , 2023, 617, 377-385.	27.8	33
19713	Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. <i>American Journal of Clinical Dermatology</i> , 2023, 24, 453-467.	6.7	2
19714	KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. <i>International Journal of Cancer</i> , 2023, 153, 623-634.	5.1	6
19715	Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. <i>Annals of Surgical Oncology</i> , 2023, 30, 5093-5102.	1.5	1
19716	Evaluation and modification of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy. <i>Siberian Journal of Oncology</i> , 2023, 22, 56-64.	0.3	0
19717	Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 669-678.	2.0	2
19718	Predictive value of serum SCCA and CYFRA21-1 levels on radiotherapy efficacy and prognosis in patients with non-small cell lung cancer. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-10.	6.2	0

#	ARTICLE	IF	CITATIONS
19719	Imaging Assessment of the Efficacy of Chemotherapy in Primary Malignant Bone Tumors: Recent Advances in Qualitative and Quantitative Magnetic Resonance Imaging and Radiomics. Journal of Magnetic Resonance Imaging, 0, , .	3.4	0
19720	Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer. Journal of Clinical Medicine, 2023, 12, 3334.	2.4	1
19721	Panâ€cancer efficacy and safety of anlotinib plus <scp>PD</scp>â€i>1 inhibitor in refractory solid tumor: A singleâ€arm, openâ€label, phase <scp>II</scp> trial. International Journal of Cancer, 2023, 153, 815-825.	5.1	1
19722	Breast cancer epigenetics. , 2023, , 275-299.		0
19723	Current Updates in Bleomycin-Based Electrochemotherapy for Deep-Seated Soft-Tissue Tumors. Electrochem, 2023, 4, 282-290.	3.3	0
19724	A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Radiotherapy and Oncology, 2023, 185, 109697.	0.6	2
19725	Uterine serous carcinoma: assessing association between genomics and patterns of metastasis. Frontiers in Oncology, 0, 13, .	2.8	0
19726	Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Annals of Oncology, 2023, 34, 605-614.	1.2	3
19727	A first-in-human study of the fibroblast activation proteinâ€targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science Translational Medicine, 2023, 15, .	12.4	12
19728	Exposureâ€response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (<scp>CheckMate</scp> 040). Clinical and Translational Science, 2023, 16, 1445-1457.	3.1	1
19729	TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits. Frontiers in Immunology, 0, 14, .	4.8	6
19730	Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine. Journal of Chemotherapy, 2023, 35, 753-759.	1.5	0
19731	A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer. Nanomedicine, 2023, 18, 511-524.	3.3	1
19732	Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Frontiers in Oncology, 0, 13, .	2.8	2
19733	Phase I Study of SYN1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical Cancer Research, 2023, 29, 2435-2444.	7.0	16
19734	Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer, 2023, 23, .	2.6	6
19735	A multistate modeling and simulation framework to learn doseâ€response of oncology drugs: Application to bintrafusp alfa in nonâ€small cell lung cancer. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1738-1750.	2.5	1
19736	Assessing the Feasibility of Laparoscopic Interval Cytoreduction in Advanced Epithelial Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2023, 21, .	0.3	0

#	ARTICLE	IF	CITATIONS
19737	Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19738	Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 29, 473-482.	4.1	2
19739	MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus. <i>Oncology Letters</i> , 2023, 26, .	1.8	0
19740	A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2023, 41, 493-502.	2.6	2
19741	Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial). <i>PLoS ONE</i> , 2023, 18, e0285850.	2.5	1
19742	Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy: a study of real-world data. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 0, , .	2.4	1
19743	Integrated use of ⁹⁰ Y-labeled microspheres and immune checkpoint inhibitors in hepatic tumors: current status and future directions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 531-538.	3.0	1
19744	The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib. <i>OncoTargets and Therapy</i> , 0, Volume 16, 317-326.	2.0	0
19746	Stereotactic Radiotherapy for Critically Located Pancreatic and Biliary Targets: A Review on Simultaneous Integrated Protection and Other Dose-Painting Strategies to Minimize Dose to Critical Organs at Risk. <i>Radiation</i> , 2023, 3, 98-109.	1.4	1
19747	RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France. <i>Pharmaceuticals</i> , 2023, 16, 754.	3.8	1
19748	Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT. <i>Journal of Clinical Medicine</i> , 2023, 12, 3498.	2.4	0
19749	Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis. <i>Indian Journal of Medical Research</i> , 2023, 157, 57-65.	1.0	1
19750	Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer: MAINTAIN Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 4004-4013.	1.6	21
19751	The Ethics of Palliative Surgery for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.9	0
19752	Effective dose window for containing tumor burden under tolerable level. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	3.0	2
19753	Safety and efficacy of robotic-assisted versus laparoscopic distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 6761-6770.	2.4	0
19754	Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry. <i>Kidney Cancer</i> , 2023, 7, 37-48.	0.4	0
19755	Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 92, 15-28.	2.3	6

#	ARTICLE	IF	CITATIONS
19756	A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations. <i>Cancers</i> , 2023, 15, 2869.	3.7	1
19758	Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients. <i>Cells</i> , 2023, 12, 1458.	4.1	0
19759	A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. <i>Cancer Research Communications</i> , 2023, 3, 1004-1012.	1.7	0
19760	Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial. <i>Oncologist</i> , 2023, 28, e1259-e1267.	3.7	0
19761	Intratumoral injection therapies for locally advanced pancreatic cancer: systematic review. <i>BJS Open</i> , 2023, 7, .	1.7	3
19763	High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 1760-1767.	2.8	1
19764	Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311733.	1.0	0
19766	Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C. <i>Journal of the National Cancer Institute</i> , 0, .	6.3	7
19767	The Effect of Induction Chemotherapy with VEGF Inhibition on Tumor Response in Synchronously Metastasized Potentially Resectable Colorectal Cancer. <i>Cancers</i> , 2023, 15, 2900.	3.7	1
19768	Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage IIIa-IV Canine Oral Malignant Melanoma. <i>Vaccines</i> , 2023, 11, 1033.	4.4	2
19770	Can Definitive Radiation Therapy Substitute Surgical Resection in Locally Advanced T3 or T4 Sinonasal Squamous Cell Carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 117, 893-902.	0.8	3
19771	Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma-Importance of Good Liver Function and Good Performance Status. <i>Cancers</i> , 2023, 15, 2952.	3.7	2
19772	An artificial neural network-based radiomics model for predicting the radiotherapy response of advanced esophageal squamous cell carcinoma patients: a multicenter study. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
19773	Longitudinal change of circulating tumor cell level and its relationship with immune checkpoint inhibitor-based treatment benefits in unresectable, metastatic colorectal cancer patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 227-233.	1.2	0
19774	Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 92, 29-37.	2.3	0
19775	Preoperative MRI-based multiparametric model for survival prediction in hepatocellular carcinoma patients with portal vein tumor thrombus following hepatectomy. <i>European Journal of Radiology</i> , 2023, 165, 110895.	2.6	1
19777	Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer. <i>Tumor Biology</i> , 2023, , 1-14.	1.8	1
19778	Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China. <i>Infectious Agents and Cancer</i> , 2023, 18, .	2.6	0

#	ARTICLE	IF	CITATIONS
19779	Prediction of Residual Axillary Nodal Metastasis Following Neoadjuvant Chemotherapy for Breast Cancer: Radiomics Analysis Based on Chest Computed Tomography. Korean Journal of Radiology, 2023, 24, 498.	3.4	2
19780	Standardization of Body Composition Status in Patients with Advanced Urothelial Tumors: The Role of a CT-Based AI-Powered Software for the Assessment of Sarcopenia and Patient Outcome Correlation. Cancers, 2023, 15, 2968.	3.7	0
19781	Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers, 2023, 15, 2978.	3.7	0
19782	Proposal of early <scp>CT</scp> morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to <scp>RECIST</scp>. Journal of Neuroendocrinology, 2023, 35, .	2.6	1
19783	The association between the interval of radioiodine treatment and treatment response, and side effects in patients with lung metastases from differentiated thyroid cancer. Frontiers in Endocrinology, 0, 14, .	3.5	0
19784	Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. European Journal of Endocrinology, 2023, 188, 485-493.	3.7	2
19785	Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule. Frontiers in Oncology, 0, 13, .	2.8	0
19786	The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms. Frontiers in Immunology, 0, 14, .	4.8	1
19787	Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in <i>ALK</i>-positive non-small-cell lung cancer. Immunotherapy, 2023, 15, 809-817.	2.0	2
19788	Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil. Journal of Personalized Medicine, 2023, 13, 923.	2.5	0
19789	Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy -A single center prospective cohort. Frontiers in Oncology, 0, 13, .	2.8	1
19790	Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	0
19792	Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nature Medicine, 2023, 29, 1728-1737.	30.7	6
19793	Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncology, The, 2023, 24, 772-782.	10.7	35
19794	A U.S. Food and Drug Administrationâ€‘pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology, 2023, 84, 373-378.	1.9	2
19795	NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. EClinicalMedicine, 2023, 60, 102015.	7.1	3
19796	S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinomaâ€‘final results of the randomized AIO MATEO phase II trial. ESMO Open, 2023, 8, 101572.	4.5	2
19798	A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India. Cancer Informatics, 2023, 22, 117693512311772.	1.9	0

#	ARTICLE	IF	CITATIONS
19799	Imaging of lung cancer. Current Problems in Cancer, 2023, , 100966.	2.0	0
19800	Evaluation of the capability and reproducibility of RECIST 1.1. measurements by technologists in breast cancer follow-up: a pilot study. Scientific Reports, 2023, 13, .	3.3	1
19801	FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study. Acta Oncol ³ gica, 2023, 62, 579-586.	1.8	0
19802	Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	4.8	2
19803	Quantification of intratumoural heterogeneity in mice and patients via machine-learning models trained on PETâ€“MRI data. Nature Biomedical Engineering, 2023, 7, 1014-1027.	22.5	1
19804	Moderate hypofractionated radiation therapy and pathologic response for soft tissue sarcomas (STS) of limbs and trunk: experience from a tertiary cancer center. Clinical and Translational Oncology, 2024, 26, 204-213.	2.4	0
19805	Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes. Cancers, 2023, 15, 3047.	3.7	0
19806	SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients. Discover Oncology, 2023, 14, .	2.1	0
19807	Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. , 2023, 11, e007104.		1
19808	The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 0, , 1-13.	2.4	0
19811	Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive. Journal of the Chinese Medical Association, 2023, 86, 717-724.	1.4	4
19812	Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus. Journal of Hepatocellular Carcinoma, 0, Volume 10, 847-861.	3.7	0
19813	Efficacy, toxicity and prognostic factors of pyrotinibâ€“involved neoadjuvant therapy in HER2â€“positive breast cancer: A retrospective study. Oncology Letters, 2023, 26, .	1.8	0
19814	Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review. Pharmaceutics, 2023, 15, 1664.	4.5	2
19815	Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2023, 29, 3074-3080.	7.0	3
19817	â€“Efficacy and safety of pyrotinib in combination with albuminâ€“bound paclitaxel for the treatment of HER2â€“positive advanced breast cancer: A realâ€“world study. Oncology Letters, 2023, 26, .	1.8	0
19818	The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nature Medicine, 2023, 29, 1424-1436.	30.7	8
19819	Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precision Oncology, 2023, , .	3.0	1

#	ARTICLE	IF	CITATIONS
19820	The Role of Multimodal Imaging in Pathological Response Prediction of Locally Advanced Cervical Cancer Patients Treated by Chemoradiation Therapy Followed by Radical Surgery. <i>Cancers</i> , 2023, 15, 3071.	3.7	0
19821	Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer. <i>Radiation Oncology</i> , 2023, 18, .	2.7	0
19822	A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19823	Radiomic analysis of MRI for prediction of response to induction chemotherapy in nasopharyngeal carcinoma patients. <i>Clinical Radiology</i> , 2023, 78, e644-e653.	1.1	1
19824	Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. , 2023, 11, e006802.		2
19825	Evaluation of Treatment Response in Patients with Breast Cancer. <i>PET Clinics</i> , 2023, 18, 517-530.	3.0	3
19826	Incorporating lesion-to-lesion heterogeneity into early oncology decision making. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
19827	A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer. <i>ESMO Open</i> , 2023, 8, 101563.	4.5	0
19828	NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. <i>Cancer Research Communications</i> , 2023, 3, 1113-1117.	1.7	0
19829	Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases. <i>Thoracic Cancer</i> , 0, , .	1.9	1
19830	Deep Ensembles Are Robust to Occasional Catastrophic Failures of Individual DNNs for Organs Segmentations in CT Images. <i>Journal of Digital Imaging</i> , 0, , .	2.9	0
19831	Distant antimetastatic effect of enterotropic colon cancer-derived $\pm 4 \times 10^7$ CD8 ⁺ T cells. <i>Science Immunology</i> , 2023, 8, .	11.9	5
19832	Ribociclib in newly diagnosed hepatitis B infection: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19833	Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	2
19834	Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. <i>EBioMedicine</i> , 2023, 93, 104644.	6.1	9
19835	Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	4
19836	Endometrial carcinoma: association between mutational status, sites of metastasis, recurrence, and correlation with overall survival. <i>Abdominal Radiology</i> , 0, , .	2.1	0
19837	Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer. <i>Case Reports in Oncological Medicine</i> , 2023, 2023, 1-5.	0.3	0

#	ARTICLE	IF	CITATIONS
19838	Imaging of colon and rectal cancer. Current Problems in Cancer, 2023, , 100970.	2.0	0
19839	Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. International Journal of Urology, 2023, 30, 866-874.	1.0	2
19840	Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study. Clinical Imaging, 2023, 101, 105-112.	1.5	0
19841	FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements. Clinical Cancer Research, 0, , OF1-OF5.	7.0	1
19842	Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study. Radiologia Medica, 2023, 128, 877-885.	7.7	2
19843	Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current Oncology, 2023, 30, 5546-5559.	2.2	0
19845	Long-term prognostic factors for PRRT in neuroendocrine tumors. Frontiers in Medicine, 0, 10, .	2.6	0
19846	Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status: The INSPECT Experience. Cancers, 2023, 15, 3116.	3.7	1
19847	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. , 2023, 11, e006624.		6
19848	A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer. Oncologist, 2024, 29, e15-e24.	3.7	1
19850	The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition. Scandinavian Journal of Immunology, 0, , .	2.7	0
19851	Model-based prediction of progression-free survival for combination therapies in oncology. CPT: Pharmacometrics and Systems Pharmacology, 0, , .	2.5	0
19852	Driving the Immune Response Through Image-Guided Cancer Therapies. Advances in Clinical Radiology, 2023, 5, 91-98.	0.2	0
19854	Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Medicine, 2023, 12, 15207-15216.	2.8	2
19855	Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatology Research, 2023, 53, 1031-1042.	3.4	5
19856	Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nature Communications, 2023, 14, .	12.8	3
19857	Impact of Circulating Cell-Free DNA (cfDNA) as a Biomarker of the Development and Evolution of Periodontitis. International Journal of Molecular Sciences, 2023, 24, 9981.	4.1	2
19858	Predicting the chemotherapeutic response of colorectal cancer liver metastasis using shear-wave elastography. Ultrasonography, 2023, 42, 457-465.	2.3	0

#	ARTICLE	IF	CITATIONS
19859	An experience with simultaneous integrated boost-volumetric-modulated arc therapy in the definitive treatment of head and neck cancer: An Indian data. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 283.	0.9	0
19860	A Phase I Trial of Bevacizumab and Temozolomide in Combination With Valproic Acid in Advanced Solid Tumors. <i>Oncologist</i> , 2023, 28, 1100-e1292.	3.7	0
19861	Improving segmentation and detection of lesions in CT scans using intensity distribution supervision. <i>Computerized Medical Imaging and Graphics</i> , 2023, 108, 102259.	5.8	0
19862	Low-dose anlotinib combined with EGFR-TKI can be used as an alternative for EGFR-TKI-resistant non-small cell lung cancer in elderly patients. <i>Oncology Letters</i> , 2023, 26, .	1.8	1
19863	Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 3400-3413.	6.4	3
19864	The BEETS (JACCRO CC-18) trial: an observational and translational study of <i>BRAF</i> -mutated metastatic colorectal cancer. <i>Future Oncology</i> , 2023, 19, 1165-1174.	2.4	1
19865	Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis. <i>BMJ Open</i> , 2023, 13, e069047.	1.9	1
19866	Cancer mamar apărut în timpul tratamentului cu inhibitori PARP pentru un cancer ovarian cu mutație BRCA somatică – prezentare de caz. <i>Oncolog-Hematolog Ro</i> , 2023, 2, 27.	0.0	0
19867	The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
19868	Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation. <i>Journal of International Medical Research</i> , 2023, 51, .	1.0	2
19869	Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2023, , .	3.0	2
19870	The Pleura. , 2023, , 3-99.		0
19871	Multilingual RECIST classification of radiology reports using supervised learning. <i>Frontiers in Digital Health</i> , 0, 5, .	2.8	1
19872	Isolated Limb Infusion for Limb-Threatening, Unresectable Sarcoma: Past Progress, Current Applications, and Future Directions. <i>Journal of Clinical Medicine</i> , 2023, 12, 4036.	2.4	0
19873	Safety and utility of Endoscopic Ultrasound with Bronchoscope-guided Fine Needle Aspiration (EUS-B-FNA) in suspected lung cancer patients with poor respiratory or general conditions: a prospective three-center observational study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	1
19874	First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. <i>Lancet Oncology</i> , The, 2023, 24, 757-771.	10.7	14
19875	Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. <i>Nature Cancer</i> , 2023, 4, 860-871.	13.2	4
19876	Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 3180.	3.7	1

#	ARTICLE	IF	CITATIONS
19877	The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study. <i>Breast</i> , 2023, 70, 56-62.	2.2	3
19878	Does the number of cycles of neoadjuvant therapy affect the efficacy of neoadjuvant chemoimmunotherapy for non-small cell lung cancer in locally advanced stage? Retrospective experience based on a single center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	1.1	0
19879	The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. <i>F1000Research</i> , 0, 11, 853.	1.6	0
19880	Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor. <i>Clinical and Translational Science</i> , 2023, 16, 1396-1407.	3.1	0
19881	European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2023, 189, G1-G42.	3.7	53
19882	The NCI-MATCH trial: lessons for precision oncology. <i>Nature Medicine</i> , 2023, 29, 1349-1357.	30.7	20
19883	Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis. <i>Cancer Research Communications</i> , 2023, 3, 1212-1223.	1.7	0
19884	Superiority of [68Ga]Ga-DOTA-FAPI-04 PET/CT to [18F]FDG PET/CT in the evaluation of thymic epithelial tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0
19885	EDGE non-invasive radiosurgery for gastric neuroendocrine hepatic portal lymph node metastases: a case report. , 2018, 4, 215-218.		0
19886	Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study. <i>International Journal of Surgery</i> , 2023, 109, 2168-2178.	2.7	1
19887	Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. , 2023, 11, e007162.		3
19888	Continuous versus fixed 2-year duration immune checkpoint inhibitor treatment of patients with non-small cell lung cancer: a single institution database analysis. <i>Clinical Lung Cancer</i> , 2023, , .	2.6	0
19889	Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	4
19890	The application of 3D printing in the development of RECIST standard for evaluating tumor efficacy. , 2020, , 39-42.		1
19891	Prognostic value of neutrophil-to-lymphocyte ratio in metastatic colorectal cancer âž. , 2016, 2, 75-79.		1
19892	High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer. <i>Biomolecules</i> , 2023, 13, 991.	4.0	1
19893	KIF15 expression characteristics: Relevance toneo-adjuvant chemotherapy efficacy in breast cancer*. , 2021, 7, 69-75.		0
19894	Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study. <i>Cancer Imaging</i> , 2023, 23, .	2.8	1

#	ARTICLE	IF	CITATIONS
19895	The efficacy of capecitabine and temozolomide against neuroendocrine carcinomas. , 2018, 4, 176-178.		0
19896	Analysis of long-term outcomes and application of the tumor regression grading system in the therapeutic assessment of resectable limited-disease small cell lung cancer. , 2016, 2, 227-233.		0
19897	Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	5
19898	Whole Abdominal Radiation Therapy for Chemo- Refractory Adult Granulosa Cell Tumor of the Ovary: A Case Report. <i>Applied Radiation Oncology</i> , 0, , .	0.5	0
19899	Activin Aâ€‘Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 3498-3513.	7.0	1
19900	Dynamics: A Novel and Promising Approach for Improved Breast Cancer Prognosis Prediction. <i>Journal of Personalized Medicine</i> , 2023, 13, 1004.	2.5	0
19901	Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102157.	1.5	1
19902	High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response. <i>Cancers</i> , 2023, 15, 3212.	3.7	1
19903	A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01). <i>BMC Cancer</i> , 2023, 23, .	2.6	1
19904	Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. <i>Lancet, The</i> , 2023, 402, 41-53.	13.7	26
19905	Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy. <i>Acta Biomaterialia</i> , 2023, 167, 121-134.	8.3	6
19906	Diffusion-weighted imaging of the brain for glioblastoma: Implications for radiation oncology. <i>Applied Radiation Oncology</i> , 0, , 5-13.	0.5	6
19908	Deep radiomic model based on the sphereâ€‘shell partition for predicting treatment response to chemotherapy in lung cancer. <i>Translational Oncology</i> , 2023, 35, 101719.	3.7	1
19909	Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i><i>KRAS<sup>G12C</sup></i>-Mutated Nonâ€‘Small-Cell Lung Cancer Who Have Untreated CNS Metastases. <i>Journal of Clinical Oncology</i>, 2023, 41, 4472-4477.</i>	1.6	8
19910	Interdisciplinary management of acoustic neuromas. <i>Applied Radiation Oncology</i> , 0, , 5-16.	0.5	1
19912	Subcutaneous Fat Abundance and Density Are Associated with an Enhanced Response to Immunotherapy in Metastatic Melanoma: A Retrospective Cohort Study. <i>Academic Radiology</i> , 2023, 30, S257-S267.	2.5	1
19913	Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study. <i>Academic Radiology</i> , 2023, 30, S192-S201.	2.5	1
19914	Plasma Dâ€‘dimer and interleukinâ€‘6 are associated with treatment response and progressionâ€‘free survival in advanced <i><sc>NSCLC</sc></i> patients on antiâ€‘ <i><sc>PD</sc></i> â€‘1 therapy. <i>Cancer Medicine</i> , 2023, 12, 15831-15840.	2.8	0

#	ARTICLE	IF	CITATIONS
19915	Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1170-1181.	2.5	4
19916	Treatment of Liver Metastases With Focused Ultrasound and Microbubbles in Patients With Colorectal Cancer Receiving Chemotherapy. Ultrasound in Medicine and Biology, 2023, 49, 2081-2088.	1.5	2
19917	Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer. Cellular Signalling, 2023, 109, 110774.	3.6	2
19918	Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study. Discover Oncology, 2023, 14, .	2.1	0
19919	Enhanced full-inversion-based ultrasound elastography for evaluating tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Physica Medica, 2023, 112, 102619.	0.7	0
19920	ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future Oncology, 2023, 19, 1577-1591.	2.4	1
19921	Prognostic factors and clinical outcomes of breast cancer patients with disease progression during neoadjuvant systemic therapy. Breast, 2023, 70, 63-69.	2.2	0
19922	Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer, 2023, 23, .	2.6	0
19923	Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer. Frontiers in Oncology, 0, 13, .	2.8	1
19924	VARIATION IN RESPONSE RATES TO ISOLATED LIMB PERFUSION IN DIFFERENT SOFT TISSUE TUMOR SUBTYPES – AN INTERNATIONAL MULTI-CENTER STUDY. European Journal of Cancer, 2023, , 112949.	2.8	1
19925	Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager. Frontiers in Pharmacology, 0, 14, .	3.5	2
19927	E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis. BMC Cancer, 2023, 23, .	2.6	1
19928	Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis. Chemotherapy, 2024, 69, 11-22.	1.6	0
19929	Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study. International Journal of Colorectal Disease, 2023, 38, .	2.2	0
19930	Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. International Journal of Clinical Oncology, 0, , .	2.2	0
19931	Tumor dosimetry using ¹⁷⁷ Lu: influence of background activity, measurement method and reconstruction algorithm. EJNMMI Physics, 2023, 10, .	2.7	5
19932	Monitoring of circulating tumour <sc>DNA</sc> in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging. Molecular Oncology, 2023, 17, 1857-1870.	4.6	2
19933	Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer. Korean Journal of Radiology, 2023, 24, 626.	3.4	1

#	ARTICLE	IF	CITATIONS
19934	A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	5.2	0
19935	CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors. <i>Journal of Nuclear Medicine</i> , 2023, 64, 1424-1430.	5.0	2
19936	Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function. <i>Oncology</i> , 2023, 101, 624-633.	1.9	3
19937	Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage Iâ€“III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol. <i>BMJ Open</i> , 2023, 13, e073372.	1.9	1
19938	Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab. <i>International Journal of Clinical Oncology</i> , 0, , .	2.2	0
19939	Efficacy and safety of pembrolizumab and axitinib as firstâ€“line treatment for patients with advanced renal cell carcinoma: Realâ€“world experience in Japan. <i>International Journal of Urology</i> , 2023, 30, 772-777.	1.0	2
19940	Colorectal liver metastases that survive radioembolization display features of aggressive tumor behavior. <i>Hpb</i> , 2023, 25, 1345-1353.	0.3	0
19941	Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 117, 914-924.	0.8	3
19942	Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	2.8	1
19943	Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy. <i>Future Science OA</i> , 2023, 9, .	1.9	1
19944	Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
19945	Whatâ€™s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-17.	2.4	0
19946	Prediction of regional lymph node metastasis in intrahepatic cholangiocarcinoma: itâ€™s not all about size. <i>Abdominal Radiology</i> , 0, , .	2.1	0
19947	Expanded indication for EUS-guided radiofrequency ablation: management of adrenal tumors. <i>Gastrointestinal Endoscopy</i> , 2023, 98, 790-796.	1.0	0
19948	Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
19949	PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy. <i>Seminars in Nuclear Medicine</i> , 2023, , .	4.6	1
19950	ROM-based patient-specific structural analysis of vertebrae affected by metastasis. , 2023, , 309-326.		0
19951	Clinical Efficacy of Photodynamic Therapy in Management of Oral Potentially Malignant Disorders: A Systematic Review and Meta-Analysis. <i>Journal of Evidence-based Dental Practice</i> , 2023, , 101899.	1.5	0

#	ARTICLE	IF	CITATIONS
19952	Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	1
19953	Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment. <i>European Journal of Radiology</i> , 2023, 165, 110950.	2.6	0
19954	Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study. <i>Investigational New Drugs</i> , 2023, 41, 579-586.	2.6	1
19955	Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer. <i>Cancer Medicine</i> , 2023, 12, 15955-15969.	2.8	1
19956	Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study. <i>Cancer Discovery</i> , 2023, 13, 1814-1825.	9.4	4
19957	Role of tumor volume in endometrial cancer: An imaging analysis and prognosis significance. <i>International Journal of Gynecology and Obstetrics</i> , 0, , .	2.3	3
19958	HER2 Expression in Circulating Tumor Cells as Prognostic and Predictive Biomarkers for Anti-HER2 Therapy in Previously Treated Metastatic Colorectal Cancer. <i>Advanced Therapeutics</i> , 0, , .	3.2	0
19959	Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment. <i>Journal of Visceral Surgery</i> , 2023, , .	0.8	0
19960	Outcomes and toxicity of concurrent <i>CDK4</i> /6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer. <i>International Journal of Cancer</i> , 2023, 153, 1386-1396.	5.1	1
19962	Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 396-405.	0.8	0
19963	Prognostic value of primary tumor and lymph node volumetric metabolic parameters at pre-treatment F-18 FDG PET/CT in nasopharyngeal carcinoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2023, , .	0.2	0
19964	Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2023, 29, 3320-3328.	7.0	1
19965	The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer. <i>Clinical and Translational Medicine</i> , 2023, 13, .	4.0	3
19966	Safety, Tolerability, and Antitumor Activity of Ziplertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. <i>Journal of Clinical Oncology</i> , 2023, 41, 4218-4225.	1.6	3
19967	MRI for detection, staging, and follow-up of prostate cancer: Synthesis of the PI-RADS v2.1, MET-RADS, PRECISE, and PI-RR guidelines. <i>Radiologia</i> , 2023, , .	0.5	0
19968	Association between Computed Tomography-Determined Loss of Muscle Mass and Impaired Three-Month Survival in Frail Older Adults with Cancer. <i>Cancers</i> , 2023, 15, 3398.	3.7	0
19969	A nomogram to predict the cumulative risk for brain metastases in patients with limited-stage small cell lung cancer without prophylactic cranial irradiation. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 727-738.	2.0	0
19970	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. <i>International Journal of Clinical Oncology</i> , 2023, 28, 913-921.	2.2	4

#	ARTICLE	IF	CITATIONS
19971	Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study. <i>BMJ Open</i> , 2023, 13, e069090.	1.9	2
19973	Pathogenic variant profile in DNA damage response genes correlates with metastatic breast cancer progression-free survival in a Mexican-mestizo population. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
19975	An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers. <i>Breast Cancer</i> , 2023, 30, 703-713.	2.9	2
19977	Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 8673-8680.	2.5	0
19978	Sinonasal Malignancies Involving the Frontal Sinus: A Mono-Institutional Experience of 84 Cases and Systematic Literature Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 3186.	2.4	0
19979	Oral vinorelbine in young patients with desmoid-type fibromatosis. <i>Tumori</i> , 0, , 030089162311698.	1.1	0
19980	The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2023, 64, 1125-1130.	5.0	4
19981	Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2714-2724.	7.0	11
19982	Toronto Management of Initially Unresectable Liver Metastasis from Colorectal Cancer in a Living Donor Liver Transplant Program. <i>Journal of the American College of Surgeons</i> , 2023, 237, 231-242.	0.5	12
19983	Trifluridine+Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 1657-1667.	27.0	59
19984	NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>British Journal of Cancer</i> , 2023, 129, 135-142.	6.4	1
19985	Multiparametric MRI radiomics fusion for predicting the response and shrinkage pattern to neoadjuvant chemotherapy in breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
19986	Safety and efficacy of CT-guided radioactive iodine-125 seed implantation as a salvage treatment for recurrent head and neck cancer after two or more courses of radiotherapy. <i>Radiation Oncology</i> , 2023, 18, .	2.7	0
19987	Factors affecting outcomes of Yttrium-90 radioembolization in heavily pretreated patients with intrahepatic cholangiocarcinoma. <i>Abdominal Radiology</i> , 2023, 48, 2434-2442.	2.1	1
19988	The role of 18FâˆFDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
19989	The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. <i>PLoS ONE</i> , 2023, 18, e0285365.	2.5	1
19990	Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data. <i>Clinical Epidemiology</i> , 0, Volume 15, 559-568.	3.0	2
19991	Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research. <i>Annals of Medicine and Surgery</i> , 2023, 85, 2640-2646.	1.1	2

#	ARTICLE	IF	CITATIONS
19992	Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC. <i>European Radiology</i> , 2023, 33, 7902-7912.	4.5	3
19993	Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	1
19995	Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	2.1	2
19996	Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349G>A (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	5.2	2
19997	A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	2
19998	CircRNA CircABCB1 Diminishes the Sensitivity of Breast Cancer Cells to Docetaxel by Sponging MiR-153-3p. <i>Tohoku Journal of Experimental Medicine</i> , 2023, , .	1.2	0
19999	Visualization of Phototherapy Evolution by Optical Imaging. <i>Molecules</i> , 2023, 28, 3992.	3.8	1
20000	Safety and Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease. <i>Clinical Nuclear Medicine</i> , 2023, 48, 667-672.	1.3	1
20001	RECISTv1.1 progression in oncology: Shades of gray. <i>Cancer Cell</i> , 2023, 41, 1003-1005.	16.8	5
20003	Efficacy of chemotherapies for unresectable extramammary Paget disease: a single-centre retrospective study. <i>Clinical and Experimental Dermatology</i> , 0, , .	1.3	0
20004	Calcium electroporation in cutaneous metastases – A non-randomised phase II multicentre clinical trial. <i>European Journal of Surgical Oncology</i> , 2023, 49, 106925.	1.0	2
20005	Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2023, 22, 291-297.	2.3	1
20006	Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. <i>Cancer</i> , 2023, 129, 2817-2827.	4.1	2
20007	Radiofrequency and microwave ablation controls hepatic oligoprogression of advanced gastroenteropancreatic neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	2.6	1
20008	Transvenous Pulmonary Chemoembolization and Optional Microwave Ablation for Colorectal Lung Metastases. <i>Journal of Clinical Medicine</i> , 2023, 12, 3394.	2.4	1
20009	Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors. <i>British Journal of Cancer</i> , 2023, 129, 266-274.	6.4	0
20010	Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2023, 28, 872-879.	2.2	0
20011	Efficacy and safety of cabozantinib in metastatic renal cell carcinoma patients: Russian multicenter observational study. <i>Onkourologiya</i> , 2023, 19, 46-60.	0.3	0

#	ARTICLE	IF	CITATIONS
20012	Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study. <i>Journal of Immunotherapy</i> , 2023, 46, 236-243.	2.4	2
20013	Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria. <i>Cancer Imaging</i> , 2023, 23, .	2.8	0
20014	Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous nonâ€small<sc>â€/sc> cell lung cancer in KEYNOTEâ€407. <i>Cancer Science</i> , 2023, 114, 3330-3341.	3.9	0
20015	Pulmonary benign metastasizing leiomyoma in patients aged 45 years and younger: clinical features and novelty in treatment. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	0
20016	MRI-based clinical radiomics nomogram may predict the early response after concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
20017	The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2997-3010.	6.4	7
20018	Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinumâ€refractory/resistant ovarian cancer. <i>Cancer Medicine</i> , 2023, 12, 14196-14206.	2.8	0
20019	Alternating 17Î²-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2767-2773.	7.0	3
20020	Hepatocellular Carcinoma Showing Tumor Shrinkage Due to an Abscopal Effect. <i>Internal Medicine</i> , 2024, 63, 241-246.	0.7	1
20021	Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. <i>Journal of Liver Cancer</i> , 0, , .	1.1	1
20022	Lowâ€energy amplitudeâ€modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma. <i>Cancer Medicine</i> , 2023, 12, 12402-12412.	2.8	0
20023	A Nomogram for Predicting Progression-free Survival in Patients with Endometrial Cancer. <i>Clinical Oncology</i> , 2023, , .	1.4	0
20024	Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. <i>Immunotherapy</i> , 2023, 15, 827-837.	2.0	3
20025	Intraoperative cell-salvaged autologous blood transfusion is safe in metastatic spine tumour surgery: early outcomes of prospective clinical study. <i>European Spine Journal</i> , 2023, 32, 2493-2502.	2.2	1
20026	Molecular imaging as biomarker for treatment response and outcome in breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311707.	3.2	3
20027	Longitudinal change of circulating tumour cell count and its relation to prognosis in advanced intrahepatic cholangiocarcinoma patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 234-240.	1.2	1
20028	Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapyâ€Retrospective Study from a Tertiary-Level Hospital in Romania. <i>Diagnostics</i> , 2023, 13, 1788.	2.6	5
20029	AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2023, 78, 1922-1965.	7.3	144

#	ARTICLE	IF	CITATIONS
20030	Levels of oxidative stress in patients with neoadjuvant chemotherapy for gastric cancer: correlation with treatment response. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
20031	Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study. <i>Current Oncology</i> , 2023, 30, 5103-5115.	2.2	3
20032	Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 9243-9252.	2.5	0
20033	Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2023, 15, 2814.	3.7	4
20034	Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e449-e460.	1.9	0
20035	Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2023, , .	1.9	3
20036	Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 2853.	3.7	0
20038	Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	3
20039	Impact of the pretreatment prognostic nutritional index on the survival after firstâ€line immunotherapy in nonâ€smallâ€cell lung cancer patients. <i>Cancer Medicine</i> , 2023, 12, 14327-14336.	2.8	1
20040	Transfer-Learning Deep Radiomics and Hand-Crafted Radiomics for Classifying Lymph Nodes from Contrast-Enhanced Computed Tomography in Lung Cancer. <i>Cancers</i> , 2023, 15, 2850.	3.7	3
20041	Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis. <i>Radiation Oncology</i> , 2023, 18, .	2.7	1
20042	Neoadjuvant Therapy in Nonmetastatic Breast Cancer in Kurdistan, Iraq. <i>JCO Global Oncology</i> , 2023, , .	1.8	0
20043	Immunotherapy or antiangiogenic therapy plus chemotherapy as <sc>firstâ€line</sc> treatment of patients with <sc>PDâ€L1</sc> (â€) advanced nonâ€squamous nonâ€small cell lung cancer in a Chinese cohort. <i>Cancer Medicine</i> , 2023, 12, 14282-14292.	2.8	1
20044	Real-world treatment patterns and outcomes of abemaciclib for the treatment of HRâ€+â€, HER2-metastatic breast cancer patients in Japan. <i>Breast Cancer</i> , 2023, 30, 657-665.	2.9	0
20045	Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). <i>BMC Cancer</i> , 2023, 23, .	2.6	1
20046	Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study. , 2023, 11, e006514.		1
20047	Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors. <i>Gynecologic Oncology</i> , 2023, 174, 224-230.	1.4	0
20048	Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0

#	ARTICLE	IF	CITATIONS
20049	Towards evidence-based response criteria for cancer immunotherapy. Nature Communications, 2023, 14, .	12.8	5
20050	Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast. Clinical Cancer Research, 2023, 29, 2885-2893.	7.0	1
20051	WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study. Gynecologic Oncology, 2023, 174, 239-246.	1.4	5
20052	Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome. Diagnostics, 2023, 13, 1833.	2.6	2
20053	Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies. Journal of Medical Internet Research, 0, 25, e45662.	4.3	0
20054	TIGIT-based immunotherapeutics in lung cancer. Immunotherapy Advances, 2023, 3, .	3.0	1
20056	Prognostic Factors Analysis of Metastatic Recurrence in Cervical Carcinoma Patients Treated with Definitive Radiotherapy: A Retrospective Study Using Mixture Cure Model. Cancers, 2023, 15, 2913.	3.7	0
20058	Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania. Diagnostics, 2023, 13, 1938.	2.6	3
20059	Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. British Journal of Surgery, 2023, 110, 973-982.	0.3	1
20060	Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma. JAMA Network Open, 2023, 6, e2316161.	5.9	5
20061	Metastatic Disease. , 2023, , 1-31.		0
20062	Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma. JAMA Oncology, 2023, 9, 1099.	7.1	3
20063	Preoperative chemoradiotherapy for locally advanced oral squamous cell carcinoma: A multicenter retrospective study. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2024, 36, 11-20.	0.3	1
20064	Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 447-453.	2.1	1
20065	Evaluation of RANO Criteria for the Assessment of Tumor Progression for Lower-Grade Gliomas. Cancers, 2023, 15, 3274.	3.7	1
20066	AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Monotherapy in Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. Journal of Clinical Oncology, 2023, 41, 4014-4024.	1.6	11
20067	A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. British Journal of Cancer, 2023, 129, 475-485.	6.4	1
20068	Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. Clinical Cancer Research, 2023, 29, 5021-5030.	7.0	2

#	ARTICLE	IF	CITATIONS
20069	Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial. BMC Medicine, 2023, 21, .	5.5	0
20070	A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results. International Journal of Molecular Sciences, 2023, 24, 10565.	4.1	0
20071	Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	8
20072	Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naïve patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial. Thoracic Cancer, 2023, 14, 2233-2237.	1.9	0
20073	Respuesta tumoral a la quimioterapia neoadyuvante en subtipos moleculares de Cáncer de mama en Medellín, Colombia. Estudio de cohorte retrospectivo. Revista Colombiana De Obstetricia Y Ginecología, 2023, 74, .	0.3	0
20074	Plasma fractalkine contributes to systemic myeloid diversity and PD-L1 blockade in lung cancer. EMBO Reports, 2023, 24, .	4.5	3
20075	Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study. Frontiers in Immunology, 0, 14, .	4.8	4
20076	NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2023, 30, 6558-6566.	1.5	8
20077	A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies. Molecular Cancer Therapeutics, 2023, 22, 1073-1086.	4.1	0
20078	Gadoxetic acid in hepatocellular carcinoma and liver metastases: pearls and pitfalls. Clinical Radiology, 2023, 78, 715-723.	1.1	0
20079	Role of computed tomography in sarcopenia detection. Siberian Journal of Oncology, 2023, 22, 125-133.	0.3	0
20080	Efficacy and safety analysis of stereotactic body radiotherapy for brain multi-metastases in non-small cell lung cancer patients. Technology and Health Care, 2024, 32, 293-301.	1.2	0
20082	Traits of Patients With Pituitary Tumors in Multiple Endocrine Neoplasia Type 1 and Comparing Different Mutation Status. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0
20083	A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition. Science Advances, 2023, 9, .	10.3	5
20084	Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study. Nutrients, 2023, 15, 2971.	4.1	0
20085	The Significance of Skin Oedema in Locally Advanced Breast Cancer and Its Response to Neoadjuvant Chemotherapy. Indian Journal of Surgery, 0, , .	0.3	0
20086	Dynamics of the prognostic nutritional index in preoperative chemotherapy in patients with colorectal liver metastases. Surgical Oncology, 2023, 49, 101966.	1.6	1
20087	Desmoid tumours (extra-abdominal), a surgeon's nightmare. Bone and Joint Journal, 2023, 105-B, 729-734.	4.4	0

#	ARTICLE	IF	CITATIONS
20088	The role of clinical imaging in oncology drug development: progress and new challenges. British Journal of Radiology, 2023, 96, .	2.2	0
20089	The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies. Scientific Reports, 2023, 13, .	3.3	1
20090	Patient centered radiology: investigating 3 Tesla whole body MRI acceptance in cancer patients. Radiologia Medica, 2023, 128, 960-969.	7.7	0
20091	Firstâ€line immunotherapy with <scp>antiâ€PD</scp>â€1 antibody for extranodal <scp>NK/T</scp>â€cell lymphoma: A retrospective study. British Journal of Haematology, 2023, 202, 812-824.	2.5	0
20092	Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study. Cancers, 2023, 15, 3465.	3.7	2
20093	Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. Cancers, 2023, 15, 3441.	3.7	0
20094	Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study. , 2023, 1, 100003.		2
20096	Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx. Frontiers in Immunology, 0, 14, .	4.8	1
20097	Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy. Scientific Reports, 2023, 13, .	3.3	2
20098	Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy. Journal of Dermatology, 0, , .	1.2	1
20099	Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms. Cancers, 2023, 15, 3483.	3.7	5
20100	A systematic review and meta-analysis of CT and MRI radiomics in ovarian cancer: methodological issues and clinical utility. Insights Into Imaging, 2023, 14, .	3.4	5
20101	Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer, 2023, 182, 107291.	2.0	3
20102	Atezolizumab and Bevacizumab in Therapy for Patients withÂHepatocellular Carcinoma in Real Clinical Practice. KreativnaÂ HirurgiÂ I OnkologiÂ, 2023, 13, 131-142.	0.3	0
20103	Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy. Gynecologic Oncology, 2023, 176, 10-15.	1.4	1
20104	Pretreatment dual-energy CT for predicting early response to induction chemotherapy and survival in nasopharyngeal carcinoma. European Radiology, 2023, 33, 9052-9062.	4.5	1
20106	Long-term Follow-up of 84 Patients With Giant Prolactinomasâ€A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e1506-e1514.	3.6	1
20108	Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development. Pharmaceutical Statistics, 2023, 22, 921-937.	1.3	2

#	ARTICLE	IF	CITATIONS
20109	Effectiveness, safety, and impact on quality of life of eribulinâ€based therapy in heavily pretreated patients with metastatic breast cancer: A realâ€world analysis. Cancer Medicine, 2023, 12, 16793-16804.	2.8	1
20110	The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallengeâ€A Systematic Review. Cancers, 2023, 15, 3490.	3.7	4
20111	A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecologic Oncology, 2023, 176, 16-24.	1.4	0
20112	Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 2023, 34, 796-805.	1.2	1
20113	Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study. European Journal of Cancer, 2023, 191, 112967.	2.8	2
20114	Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease. Journal of Surgical Oncology, 0, , .	1.7	0
20116	Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	2
20118	Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial. Lancet Oncology, The, 2023, 24, 868-880.	10.7	19
20119	China special issue on gastrointestinal tumorâ€radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant <scp>PD</scp>â€1 blockade: A post hoc analysis of the <scp>PICC</scp> phase <scp>II</scp> trial. International Journal of Cancer, 0, , .	5.1	0
20120	Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 11857-11871.	2.5	0
20121	Navigating the global IV contrast shortage: The experience of a comprehensive cancer center. Clinical Imaging, 2023, 102, 9-13.	1.5	0
20123	Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis. The Lancet Regional Health - Western Pacific, 2023, 38, 100841.	2.9	2
20124	Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. The Cochrane Library, 2023, 2023, .	2.8	0
20125	Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma. Radiotherapy and Oncology, 2023, 186, 109802.	0.6	0
20126	Stereotactic radiosurgery for tumors of the pineal region: A single-center experience. Medicine (United States), 2023, 102, e34005.	1.0	0
20127	Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSÃ© Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncology, The, 2023, 24, 892-902.	10.7	11
20128	Intrathoracic synovial sarcoma with BRAF V600E mutation. Oncotarget, 2023, 14, 703-708.	1.8	1
20130	A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma. BMC Cancer, 2023, 23, .	2.6	1

#	ARTICLE	IF	CITATIONS
20131	Neutrophil-to-lymphocyte ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy. Pigment Cell and Melanoma Research, 0, , .	3.3	0
20132	Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NACCA) Tj ETQ 1 1 0.784314 rgB	2.1	1
20133	The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials. BJU International, 2024, 133, 158-168.	2.5	1
20134	Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma. Cancers, 2023, 15, 3527.	3.7	1
20135	Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2023, 72, 3217-3228.	4.2	1
20136	CD47 polymorphism for predicting nivolumab benefit in patients with advanced non-small cell lung cancer. Oncology Letters, 2023, 26, .	1.8	1
20137	Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: a retrospective analysis from two institutions in India. F1000Research, 0, 12, 802.	1.6	0
20138	Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D4 pathway alterations in the Dutch DRUP and Australian MoST trials. International Journal of Cancer, 0, , .	5.1	1
20139	Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2023, 29, 4408-4418.	7.0	3
20140	A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer. Frontiers in Immunology, 0, 14, .	4.8	1
20141	Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma. Oncology Letters, 2023, 26, .	1.8	1
20142	Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis. International Journal of Clinical Oncology, 2023, 28, 1371-1377.	2.2	1
20143	Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib. Journal of the Endocrine Society, 2023, 7, .	0.2	0
20144	Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study. Respiratory Investigation, 2023, 61, 625-631.	1.8	0
20146	Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. JAMA Network Open, 2023, 6, e2322915.	5.9	5
20147	The Selection for Cytoablative Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. European Urology Oncology, 2023, , .	5.4	5
20148	Phase Ib/II trial of tipapkinogene sovavicev, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. European Journal of Cancer, 2023, 191, 112981.	2.8	0
20149	Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Communications, 2023, 43, 909-937.	9.2	3

#	ARTICLE	IF	CITATIONS
20150	Brigatinib in Japanese patients with <i>ALK</i> -positive non-small-cell lung cancer: Final results of the phase 2 J-ACTA trial. <i>Cancer Science</i> , 2023, 114, 3698-3707.	3.9	0
20151	Efficacy of chemotherapy versus surgery as initial treatment for gastric cancer with positive peritoneal cytology. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	2
20153	Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	1
20154	Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0
20155	Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer. <i>JAMA Oncology</i> , 2023, 9, 1230.	7.1	16
20156	In vivo-Stoffwechselbildung mit [^{13}C]Pyruvat $^{\text{d}}$ $^{\text{3}}$, hyperpolarisiert durch reversiblen Austausch mit Parawasserstoff**. <i>Angewandte Chemie</i> , 0, , .	2.0	0
20157	Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia. <i>Cancers</i> , 2023, 15, 3592.	3.7	4
20158	Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
20159	Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, <i>ERBB2</i> -Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2023, 9, 1267.	7.1	3
20160	Surgery-eligible elderly patients with cutaneous squamous cell carcinoma of the head and neck region gain clinical benefit from definitive weekly hypofractionated radiotherapy. <i>Head and Neck</i> , 0, , .	2.0	0
20161	In Vivo Metabolic Imaging of [^{13}C]Pyruvate $^{\text{d}}$ $^{\text{3}}$ Hyperpolarized By Reversible Exchange With Parahydrogen**. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	13.8	13
20163	Efficacy of intra-abdominal cytoreductive surgery in advanced endometrial cancer with distant metastasis. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	2.2	1
20164	Intact glycopeptides identified by LC-MS/MS as biomarkers for response to chemotherapy of locally advanced cervical cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
20166	Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study. <i>Oncologist</i> , 2023, 28, 1005-e1104.	3.7	1
20167	Bilateral video-assisted thoracic surgery for esophageal cancer with left inferior pulmonary vein invasion following chemoradiation therapy. <i>Surgical Case Reports</i> , 2023, 9, .	0.6	0
20168	The REWRITE Study – REal-World effectiveness of Trifluridine/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. <i>Clinical Oncology</i> , 2023, , .	1.4	0
20169	Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience. <i>Journal of Neuro-Oncology</i> , 2023, 164, 239-247.	2.9	1
20170	Prognostic value of [^{18}F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
20171	Molecular imaging of biomarkers in breast cancer. , 2022, , 1-23.		0
20173	Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall. Cancer, 0, , .	4.1	0
20174	Immunotherapy in combination with neoadjuvant anthracycline-free chemotherapy for triple-negative early breast cancer: A case report. Oncology Letters, 2023, 26, .	1.8	0
20175	Immune-related interaction perturbation networks unravel biological peculiarities and clinical significance of glioblastoma. , 2023, 2, .		2
20176	The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib. Frontiers in Endocrinology, 0, 14, .	3.5	1
20177	The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. Journal of Cancer Survivorship, 0, , .	2.9	1
20178	Genome-scale CRISPR-Cas9 screening stratifies pancreatic cancer with distinct outcomes and immunotherapeutic efficacy. Cellular Signalling, 2023, , 110811.	3.6	0
20179	Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective. Journal of Gastrointestinal Surgery, 2023, 27, 2245-2259.	1.7	0
20180	Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease. Oncology Letters, 2023, 26, .	1.8	1
20181	Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	1
20183	Interpretation of Tumor Response Grade following Preoperative Therapy for Gastric Cancer: An Overview. Cancers, 2023, 15, 3662.	3.7	1
20184	High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival. Translational Oncology, 2023, 36, 101736.	3.7	0
20185	Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. Annals of Gastroenterological Surgery, 2023, 7, 1009-1020.	2.4	0
20186	Post-therapeutic microRNA-146a in liquid biopsies may determine prognosis in metastatic gastrointestinal cancer patients receiving 90Y-radioembolization. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
20187	Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto. Pancreatology, 2023, 23, 682-688.	1.1	1
20188	Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma. BMC Cancer, 2023, 23, .	2.6	1
20189	Monocyte subsets associated with the efficacy of anti-PD-1 antibody monotherapy. Oncology Letters, 2023, 26, .	1.8	2
20190	Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed. Thoracic Cancer, 2023, 14, 2567-2578.	1.9	2

#	ARTICLE	IF	CITATIONS
20191	Case Report on the Five-year Survival and Complete Response of a Patient with Pancreatic Cancer Treated with Integrative Medicine. <i>The Journal of Internal Korean Medicine</i> , 2023, 44, 562-577.	0.3	0
20192	Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	2
20194	Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cellâ€derived organoids. <i>Thoracic Cancer</i> , 0, , .	1.9	0
20195	IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation. , 2023, 11, e006821.		2
20196	Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
20197	Clinical Outcomes of Radiation Therapy for Angiosarcoma of the Scalp and Face: A Multi-Institutional Observational Study. <i>Cancers</i> , 2023, 15, 3696.	3.7	0
20198	Follow-up of liver metastases: a comparison of deep learning and RECIST 1.1. <i>European Radiology</i> , 0, , .	4.5	0
20199	REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon [®]) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2023, 14, .	2.5	0
20200	A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. <i>Lung Cancer</i> , 2023, 183, 107313.	2.0	0
20201	The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, AccessÂto Imaging and Treatment of Metastatic Prostate Cancer. <i>Clinical Oncology</i> , 2023, 35, e628-e635.	1.4	1
20202	Prognostic value of translationally controlled tumor protein in colon cancer. <i>Molecular and Clinical Oncology</i> , 2023, 19, .	1.0	0
20203	Recent advances in the management of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2023, 30, 1-15.	8.9	2
20205	Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. <i>Nature Communications</i> , 2023, 14, .	12.8	5
20206	Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
20207	Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma. <i>Oncology Letters</i> , 2023, 26, .	1.8	1
20208	First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 1154-1165.	4.1	1
20209	A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine â€Flareâ€on Positron Emission Tomography. <i>Cancers</i> , 2023, 15, 3718.	3.7	0
20210	Computational reactiveâ€diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib. <i>Scientific Reports</i> , 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
20211	Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events. Cancer Immunology, Immunotherapy, 0, , .	4.2	0
20212	Significance of Lipopolysaccharides in Gastric Cancer and Their Potential as a Biomarker for Nivolumab Sensitivity. International Journal of Molecular Sciences, 2023, 24, 11790.	4.1	0
20213	The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clinical Trials, 0, , .	1.6	0
20214	Measurement of mouse head and neck tumors by automated analysis of CBCT images. Scientific Reports, 2023, 13, .	3.3	0
20215	Childhood-onset Erdheim-Chester Disease in the molecular era: clinical phenotype and long-term outcome of 21 patients. Blood, 0, , .	1.4	0
20216	Can STereotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study). Current Oncology, 2023, 30, 7073-7088.	2.2	2
20218	INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) Consensus Statement: Imaging Recommendations for the Management of Rhabdomyosarcoma. European Journal of Radiology, 2023, , 111012.	2.6	0
20219	Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors. Computational and Structural Biotechnology Journal, 2023, 21, 3912-3919.	4.1	1
20220	Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. European Journal of Cancer, 2023, 192, 113253.	2.8	2
20221	Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1195-1206.	3.7	0
20223	Therapiesteuerung in der medikamentÄrsen Tumorthherapie. Springer Reference Medizin, 2023, , 1225-1231.	0.0	0
20224	Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer. , 2024, 2, 38-49.		0
20225	Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nature Communications, 2023, 14, .	12.8	4
20226	Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). BMJ Open, 2023, 13, e070275.	1.9	0
20227	Management of Breast Cancer. , 2023, , 17-31.		0
20229	MEDICAL AND RADIOBIOLOGICAL ASPECTS OF RADIATION COMDPLICATIONS IN PATIENTS WITH ONCOGINECOLOGICAL PROFILE. Oncology, 2023, 25, 9-15.	0.1	2
20230	Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastasesâ€”A Repeatability Study. Cancers, 2023, 15, 3757.	3.7	0
20231	Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors. Clinical Cancer Research, 2023, 29, 3592-3602.	7.0	6

#	ARTICLE	IF	CITATIONS
20232	A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. <i>Nature Communications</i> , 2023, 14, .	12.8	2
20233	Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 3789.	3.7	2
20234	Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. <i>Nature Medicine</i> , 2023, 29, 2099-2109.	30.7	8
20235	Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors. <i>Future Oncology</i> , 0, , .	2.4	1
20236	Breast cancer: treatment response assessment with FDG-PET/CT in the neoadjuvant and in the metastatic setting. <i>Clinical and Translational Imaging</i> , 0, , .	2.1	0
20237	TO MARKET, TO MARKETâ€“2021: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 733-805.	0.1	0
20238	Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma and Sinonasal Undifferentiated Carcinoma: A Comprehensive Review. <i>Cancers</i> , 2023, 15, 3798.	3.7	2
20239	Multi-scale 2.5D Integrated Model for False Positive Reduction in Abdominal Lymph Node Detection. , 2023, , .		0
20240	Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intraâ€“individual heterogeneity in patients with advanced cancer. <i>Biometrics</i> , 0, , .	1.4	0
20241	Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	0
20242	The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors. <i>Future Oncology</i> , 0, , .	2.4	2
20243	Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin. <i>European Journal of Cancer</i> , 2023, 192, 113261.	2.8	0
20245	Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents. <i>Oncologist</i> , 0, , .	3.7	0
20246	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	0
20247	Indian data on response of positive pelvic lymph nodes in carcinoma cervix patients treated with simultaneous integrated boost using volumetric modulated arc radiation therapy. <i>Asian Journal of Oncology</i> , 0, 9, 9.	0.2	0
20248	Poly(adenosine diphosphateâ€“ribose) polymerase inhibitor combinations in firstâ€“line metastatic castrateâ€“resistant prostate cancer setting: a systematic review and m<scp>etaâ€“analysis</scp>. <i>BJU International</i> , 0, , .	2.5	4
20249	Delta-radiomics in cancer immunotherapy response prediction: A systematic review. <i>European Journal of Radiology Open</i> , 2023, 11, 100511.	1.6	2
20250	Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients. <i>Current Oncology</i> , 2023, 30, 7229-7240.	2.2	0

#	ARTICLE	IF	CITATIONS
20251	A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer, 2023, 23, .	2.6	3
20252	Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma. Tumori, 0, , .	1.1	1
20253	Regression of colorectal adenoma. International Journal of Gastrointestinal Intervention, 2023, 12, 159-161.	0.3	0
20254	18F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy. Nuclear Medicine Communications, 0, , .	1.1	0
20255	Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors. ESMO Open, 2023, 8, 101575.	4.5	0
20256	Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO Open, 2023, 8, 101594.	4.5	1
20257	HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	0
20258	Stereotactic Body Reirradiation in Gynaecological Cancer: Outcomes and Toxicities from a Single Institution Experience. Clinical Oncology, 2023, , .	1.4	0
20259	Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9. European Radiology, 0, , .	4.5	0
20260	Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology, 2023, 41, 4621-4631.	1.6	3
20261	Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients. Neoplasia, 2023, 43, 100919.	5.3	0
20262	Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series. Frontiers in Oncology, 0, 13, .	2.8	1
20263	Novel Imaging Techniques for Childhood Cancer Management. , 2023, , 1-16.		0
20264	Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology. European Radiology, 0, , .	4.5	2
20265	Efficacy of palliative surgery for gastric cancer patients with peritoneal metastasis who still have residual peritoneal dissemination after chemotherapy. Langenbeck's Archives of Surgery, 2023, 408, .	1.9	0
20266	MRI features for prediction of the intravenous chemotherapy effect in patients with retinoblastoma. Clinical Radiology, 2023, , .	1.1	0
20267	Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 0, , .	1.5	0
20268	Serum microRNA-210 as a predictor of neoadjuvant chemotherapy resistance in breast cancer. Asian Journal of Oncology, 0, 9, 10.	0.2	0

#	ARTICLE	IF	CITATIONS
20269	D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms. JCO Precision Oncology, 2023, , .	3.0	0
20270	Early Increase in Circulating PD-1+CD8+ T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy. Cancers, 2023, 15, 3955.	3.7	1
20271	[Translated article] Treatment strategies in vertebral metastasis. Need for multidisciplinary committees from the perspective of the surgeon. Narration of literature. Revista Española De Cirug�a Ortop�dica Y Traumatolog�a, 2023, 67, S532-S541.	0.1	0
20272	Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nature Communications, 2023, 14, .	12.8	3
20273	⁶⁸Ga-PSMA PET/CT for Response Evaluation of²²³Ra Treatment in Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2023, 64, 1556-1562.	5.0	4
20274	Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survival. PLoS ONE, 2023, 18, e0279235.	2.5	0
20275	Salvage Hepatectomy for Giant GIST Liver Metastases Unresponsive to Systemic Therapy��Case Report. Life, 2023, 13, 1681.	2.4	0
20276	Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non��Small Cell Lung Cancer. JAMA Oncology, 2023, 9, 1348.	7.1	11
20277	Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy. Frontiers in Endocrinology, 0, 14, .	3.5	0
20278	Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors. Frontiers in Nuclear Medicine, 0, 3, .	1.2	0
20279	Graph-based automatic detection and classification of lesion changes in pairs of CT studies for oncology follow-up. International Journal of Computer Assisted Radiology and Surgery, 2024, 19, 241-251.	2.8	1
20280	Objective Definition and Optimized Strategy for ��Biologically Borderline Resectable��Colorectal Liver Metastases. World Journal of Surgery, 2023, 47, 2834-2845.	1.6	1
20281	Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations. Radiology Imaging Cancer, 2023, 5, .	1.6	3
20282	Do Imaging Core Laboratories Better Predict Progression Over Clinical Interpretations?. Radiology Imaging Cancer, 2023, 5, .	1.6	0
20283	Comparison of Staged Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy in Patients with Brain Metastases > 2��cm without Prior Whole Brain Radiotherapy: A Systematic Review and Meta-Analysis. World Neurosurgery, 2023, 178, 213-232.e6.	1.3	1
20284	The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. Cancer Medicine, 2023, 12, 17559-17568.	2.8	1
20285	<scp>IMMUNOREACT</scp> 0: Biopsy��based immune biomarkers as predictors of response to neoadjuvant therapy for rectal cancer��A systematic review and meta��analysis. Cancer Medicine, 2023, 12, 17878-17890.	2.8	1
20286	Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer. Tumor Biology, 2023, , 1-13.	1.8	3

#	ARTICLE	IF	CITATIONS
20287	The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials – Results From the OPTIPAL II Study. <i>Clinical Colorectal Cancer</i> , 2023, 22, 421-430.e1.	2.3	1
20290	Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis. <i>Lung Cancer</i> , 2023, 184, 107321.	2.0	2
20291	Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3543-3558.	4.2	1
20292	A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data. <i>Engineering With Computers</i> , 0, , .	6.1	1
20293	Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1. <i>Acta Radiologica</i> , 0, , .	1.1	0
20294	HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. <i>Modern Pathology</i> , 2023, 36, 100299.	5.5	1
20295	MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer. <i>Cancer Discovery</i> , 2023, 13, 2412-2431.	9.4	5
20296	Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 14125-14136.	2.5	2
20297	Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy. <i>Cancers</i> , 2023, 15, 4018.	3.7	1
20298	Apparent Variation in Measurement Size of Colorectal Cancer Metastases to the Liver on Dual Contrast MRI. <i>Journal of Computer Assisted Tomography</i> , 0, , .	0.9	0
20299	Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD. <i>Liver Cancer</i> , 2024, 13, 193-202.	7.7	2
20300	Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings. <i>Oncology</i> , 2023, 101, 542-552.	1.9	1
20301	Adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma. <i>Cancer Medicine</i> , 0, , .	2.8	1
20302	Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. <i>Oral Oncology</i> , 2023, 145, 106536.	1.5	0
20303	Machine learning for predicting breast-conserving surgery candidates after neoadjuvant chemotherapy based on DCE-MRI. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20304	Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study. <i>Investigational New Drugs</i> , 2023, 41, 677-687.	2.6	3
20305	Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial. <i>BMC Medicine</i> , 2023, 21, .	5.5	2
20306	TotalSegmentator: A Gift to the Biomedical Imaging Community. <i>Radiology: Artificial Intelligence</i> , 2023, 5, .	5.8	1

#	ARTICLE	IF	CITATIONS
20307	Survival Outcomes of Patients with Esophageal Cancer Who Did Not Proceed to Surgery after Neoadjuvant Treatment. <i>Cancers</i> , 2023, 15, 4049.	3.7	1
20308	Pediatric Oncology Surgery: Research Methodology. , 2023, , 1-29.		0
20309	Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	3
20310	A nomogram based on CT texture features to predict the response of patients with advanced pancreatic cancer treated with chemotherapy. <i>BMC Gastroenterology</i> , 2023, 23, .	2.0	0
20311	Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 5140-5150.	1.6	6
20312	Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.. <i>Clinical Cancer Research</i> , 2023, 29, 4128-4138.	7.0	1
20314	ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers. <i>Cancer Immunology Research</i> , 2023, 11, 1367-1383.	3.4	2
20315	Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy. <i>Thyroid</i> , 0, , .	4.5	0
20316	Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1595-1601.	2.5	2
20317	Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 591-604.	1.8	0
20319	Imaging of cell death in malignancy: Targeting pathways or phenotypes?. <i>Nuclear Medicine and Biology</i> , 2023, 124-125, 108380.	0.6	0
20320	PMSG-Net: A priori-guided multilevel graph transformer fusion network for immunotherapy efficacy prediction. <i>Computers in Biology and Medicine</i> , 2023, 164, 107371.	7.0	0
20322	Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study). <i>BMC Cancer</i> , 2023, 23, .	2.6	1
20323	Effect of whole-brain radiotherapy with platinum-based chemotherapy in non-small cell lung cancer patients with multiple metastases including brain metastases. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
20324	Continuation of Aösimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study). <i>Future Oncology</i> , 2023, 19, 1515-1521.	2.4	0
20325	ABVS-Based Radiomics for Early Predicting the Efficacy of Neoadjuvant Chemotherapy in Patients with Breast Cancers. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 625-636.	1.8	0
20326	Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes. <i>Cells</i> , 2023, 12, 2068.	4.1	4
20327	Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. <i>Cancers</i> , 2023, 15, 4117.	3.7	0

#	ARTICLE	IF	CITATIONS
20328	Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2024, 9, 101353.	1.2	0
20329	CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2-Advanced breast cancer with impending or established visceral crisis. <i>Breast Cancer Research and Treatment</i> , 0, , .	2.5	0
20330	KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells. , 2023, 11, e007286.		0
20331	Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study. <i>BMJ Evidence-Based Medicine</i> , 2023, 28, 372-382.	3.5	0
20332	Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 14761-14774.	2.5	1
20333	Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer. <i>Future Oncology</i> , 2023, 19, 1593-1600.	2.4	2
20334	Treatment of Stage IV Non-Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 133-140.	1.4	0
20335	Case Report: Unresectable pulmonary metastases of a giant cell tumor of bone treated with denosumab: a case report and review of literature. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20336	Phase II trial of daily Sunitinib combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. <i>Thoracic Cancer</i> , 2023, 14, 2804-2810.	1.9	0
20337	Conversion surgery for advanced jejunal adenocarcinoma with multiple peritoneal metastases: a case report. <i>Surgical Case Reports</i> , 2023, 9, .	0.6	0
20338	Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20339	Analysis of correlation of pre-therapeutic assessment and the final diagnosis in endometrial cancer: role of tumor volume in the magnetic resonance imaging. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20340	Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. <i>BMC Gastroenterology</i> , 2023, 23, .	2.0	0
20341	Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer?. <i>Seminars in Nuclear Medicine</i> , 2023, , .	4.6	1
20342	A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
20343	Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
20344	Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA". <i>Journal of Thoracic Oncology</i> , 2023, 18, e102-e103.	1.1	0
20345	A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2023, 184, 107349.	2.0	1

#	ARTICLE	IF	CITATIONS
20346	Integrated longitudinal circulating tumor <scp>DNA</scp> profiling predicts immunotherapy response of metastatic urothelial carcinoma in the <scp>POLARIS</scp>â€³ trial. Journal of Pathology, 2023, 261, 198-209.	4.5	2
20347	Checkpoint inhibitor responses can be regulated by the gut microbiota â€ A systematic review. Neoplasia, 2023, 43, 100923.	5.3	0
20348	Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-intent Surgery after Neoadjuvant Therapy. Cancer Research and Treatment, 0, , .	3.0	0
20349	Predicting resectable disease in relapsed epithelial ovarian cancer by using whole-body diffusion-weighted MRI. International Journal of Gynecological Cancer, 2023, 33, 1890-1897.	2.5	0
20350	Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study. Gastric Cancer, 2023, 26, 1020-1029.	5.3	0
20352	Baseline and Post-NACT Imaging in Retinoblastoma With Optic Nerve Involvement: Can MRI Predict Prognosis?. Journal of Pediatric Ophthalmology and Strabismus, 0, , 1-8.	0.7	0
20353	MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients. European Radiology, 2024, 34, 1137-1145.	4.5	1
20354	The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases. European Radiology, 2024, 34, 1146-1154.	4.5	0
20355	Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma. ESMO Open, 2023, 8, 101619.	4.5	1
20356	Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nature Medicine, 2023, 29, 3077-3089.	30.7	9
20357	Adding fastingâ€mimicking diet to firstâ€line carboplatinâ€based chemotherapy is associated with better overall survival in advanced tripleâ€negative breast cancer patients: A subanalysis of the <scp>NCT03340935</scp> trial. International Journal of Cancer, 2024, 154, 114-123.	5.1	1
20358	Effectiveness and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	1
20360	Imaging Assessment of Tumoral Response After Immunotherapy. , 2023, , 1-19.		0
20361	Factores quirÃrgicos pronÃsticos del neuroblastoma en el Centro Regional Oriental de OncologÃa PediÃtrica de HolguÃn, Cuba. , 2023, 3, e232.		0
20362	Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients. Frontiers in Oncology, 0, 13, .	2.8	1
20363	Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls. Current Opinion in Oncology, 0, , .	2.4	0
20364	Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy. Yonsei Medical Journal, 2023, 64, 531.	2.2	0
20366	Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases. Annals of Surgical Oncology, 0, , .	1.5	2

#	ARTICLE	IF	CITATIONS
20367	Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer—long-term data from the prospective PLATIN-2 trial. <i>Strahlentherapie Und Onkologie</i> , 2024, 200, 202-207.	2.0	1
20368	The impact of chemotherapy on quality of life in advanced-stage lung cancer patients. <i>Indian Journal of Cancer</i> , 0, , .	0.2	0
20369	Assessing the Clinical Utility of Liquid Biopsies Across 5 Potential Indications From Therapy Selection to Population Screening. <i>JAMA Internal Medicine</i> , 2023, 183, 1144.	5.1	4
20370	Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/±PD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING. , 2023, 11, e006235.		0
20371	Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. <i>Gut Microbes</i> , 2023, 15, .	9.8	6
20372	Hsa_circ_0041150 serves as a novel biomarker for monitoring chemotherapy resistance in small cell lung cancer patients treated with a first-line chemotherapy regimen. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
20373	Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study. <i>Cancer Treatment and Research Communications</i> , 2023, 37, 100755.	1.7	1
20374	Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system. <i>European Journal of Cancer</i> , 2023, 193, 113310.	2.8	0
20375	Locally Advanced oral Squamous cell Carcinomas: Auditing and Outcome Appraisal. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2024, 76, 380-391.	0.9	0
20376	Comparison of first-line immunotherapy efficacy between advanced lung squamous cell carcinoma and pulmonary lymphoepithelioma-like carcinoma: A propensity score matching multicenter study. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 1011-1018.	0.9	0
20377	A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13). <i>European Journal of Cancer</i> , 2023, 193, 113312.	2.8	0
20378	Progression before local control in osteosarcoma: Outcome and prognosis—predictive factors. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	1
20379	The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience. <i>Genes</i> , 2023, 14, 1708.	2.4	0
20380	Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. <i>Lancet Oncology</i> , The, 2023, 24, 1002-1017.	10.7	11
20381	Osteopontin secreted from obese adipocytes enhances angiogenesis and promotes progression of pancreatic ductal adenocarcinoma in obesity. <i>Cellular Oncology (Dordrecht)</i> , 2024, 47, 229-244.	4.4	0
20382	A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 4555-4563.	7.0	0
20383	First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the <sc>ONO</sc>â€4538â€52/<sc>TASUKI</sc>â€52 randomized controlled trial. <i>Cancer Medicine</i> , 0, , .	2.8	0
20384	The molecular perspective on the melanoma and genome engineering of T-cells in targeting therapy. <i>Environmental Research</i> , 2023, 237, 116980.	7.5	3

#	ARTICLE	IF	CITATIONS
20385	Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2023, 23, .	2.6	4
20386	Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2023, , .	0.8	0
20387	Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets. Clinical Cancer Research, 2023, 29, 4660-4668.	7.0	0
20388	Role of plasma angiogenesis factors in the efficacy of firstâ€line chemotherapy combined with biologics in <scp><i>RAS</i></scp> wildâ€type metastatic colorectal cancer: Results from the <scp>Glâ€SCREEN CRCâ€Ukit</scp> study. Cancer Medicine, 2023, 12, 18702-18716.	2.8	1
20389	Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study. Acta OncolÃ³gica, 2023, 62, 1066-1075.	1.8	1
20390	Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2023, 41, 5163-5173.	1.6	1
20391	Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study. BMC Cancer, 2023, 23, .	2.6	1
20392	Accuracy of Breast Ultrasonography and Mammography in Comparison with Postoperative Histopathology in Breast Cancer Patients after Neoadjuvant Chemotherapy. Diagnostics, 2023, 13, 2811.	2.6	3
20393	Prognostic analysis of stereotactic radiosurgery for brain metastases: a single-center retrospective study. Radiología Medica, 0, , .	7.7	0
20394	Ten-year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?. Clinical Oncology, 2023, , .	1.4	0
20395	Transarterial infusion chemotherapy for advanced esophageal cancer with airway stenosis. Frontiers in Oncology, 0, 13, .	2.8	1
20396	Bepegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. Journal of Clinical Oncology, 2023, 41, 4756-4767.	1.6	10
20398	Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Journal of Clinical Oncology, 2023, 41, 5536-5549.	1.6	4
20399	Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. Frontiers in Endocrinology, 0, 14, .	3.5	3
20400	RECIST Weakly Supervised Lesion Segmentation via Label-Space Co-Training. , 2023, , .		0
20401	Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001). Frontiers in Oncology, 0, 13, .	2.8	0
20402	Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience. Cancers, 2023, 15, 4353.	3.7	1
20403	Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis. Current Oncology, 2023, 30, 8117-8133.	2.2	1

#	ARTICLE	IF	CITATIONS
20404	Lesion Size Assessment on Multi-Frequency Single Transducer-Harmonic Motion Imaging Using Convolutional Neural Network. , 2023, , .		0
20405	Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review. International Journal of Urology, 2023, 30, 1068-1077.	1.0	0
20406	Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. Npj Breast Cancer, 2023, 9, .	5.2	0
20407	Trial Design for Cancer Immunotherapy: A Methodological Toolkit. Cancers, 2023, 15, 4669.	3.7	0
20408	Clinical impact of very early recurrence after conversion surgery for stage ^{IV} gastric cancer. Annals of Gastroenterological Surgery, 2024, 8, 214-220.	2.4	0
20409	Neoadjuvant Sâ€1 and oxaliplatin plus bevacizumab therapy for highâ€risk locally advanced rectal cancer: A prospective multicenter phase ^{II} study. Annals of Gastroenterological Surgery, 0, , .	2.4	0
20410	Intratumoral CD103⁺CD8⁺ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma. Cancer Communications, 2023, 43, 1143-1163.	9.2	0
20411	NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. BMC Cancer, 2023, 23, .	2.6	0
20412	Integration of peripheral bloodâ€and tissueâ€based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. Journal of Pathology, 2023, 261, 349-360.	4.5	2
20413	Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients. Frontiers in Medicine, 0, 10, .	2.6	1
20414	Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study. BMC Cancer, 2023, 23, .	2.6	1
20415	Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. Radiology and Oncology, 2023, 57, 397-404.	1.7	0
20416	Safety and efficacy of tislelizumab plus chemotherapy as preoperative treatment in potentially resectable locally advanced non-small cell lung cancer patients. , 0, , .		0
20417	Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 1261-1272.	2.6	0
20418	Novel electromagnetic navigation bronchoscopy system for the diagnosis of peripheral pulmonary nodules: a prospective, multicentre study. Thorax, 2023, 78, 1197-1205.	5.6	0
20419	Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study. Cancers, 2023, 15, 4452.	3.7	1
20420	A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Cancers, 2023, 15, 4423.	3.7	1
20421	Quality of Life, Clinical, and Patient-Reported Outcomes after Pencil Beam Scanning Proton Therapy Delivered for Intracranial Grade WHO 1â€2 Meningioma in Children and Adolescents. Cancers, 2023, 15, 4447.	3.7	0

#	ARTICLE	IF	CITATIONS
20422	Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. International Journal of Molecular Sciences, 2023, 24, 12192.	4.1	2
20423	Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre's Real-World Experience. Current Oncology, 2023, 30, 8928-8935.	2.2	1
20424	Clinical Possibility of Caenorhabditis elegans as a Novel Evaluation Tool for Esophageal Cancer Patients Receiving Chemotherapy: A Prospective Study. Cancers, 2023, 15, 3870.	3.7	0
20425	MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy. Cancers, 2023, 15, 4697.	3.7	0
20426	Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?. International Journal of Gynecological Cancer, 2024, 34, 99-105.	2.5	0
20427	Prostate-Specific Membrane Antigen-Ligand Therapy. Radiologic Clinics of North America, 2024, 62, 177-187.	1.8	0
20428	Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nature Communications, 2023, 14, .	12.8	2
20429	Exploratory study of an anti-PD-L1/TGF- β 2 antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02). BMC Cancer, 2023, 23, .	2.6	1
20430	Efficacy and safety of reduced-dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real-world observational study. Cancer Medicine, 2023, 12, 18679-18690.	2.8	1
20431	A 3-month survival model after Gamma Knife surgery in patients with brain metastasis from lung cancer with Karnofsky performance status ≥ 70 . Scientific Reports, 2023, 13, .	3.3	1
20432	Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review. Clinical and Translational Oncology, 0, , .	2.4	1
20433	Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPICS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2023, 402, 1423-1433.	13.7	31
20434	Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNIPO-RCC study. International Journal of Urology, 2023, 30, 788-796.	1.0	1
20435	OCT4-positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration-resistant prostate cancer treated with abiraterone plus prednisone therapy. Oncology Letters, 2023, 26, .	1.8	0
20436	CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner. Journal of Chemotherapy, 0, , 1-14.	1.5	0
20437	A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial. Heliyon, 2023, 9, e18680.	3.2	1
20438	Pretreatment total lymphocyte count as a prognostic factor of survival in patients with recurrent cervical cancer after definitive radiation-based therapy: a retrospective study. Obstetrics and Gynecology Science, 2023, 66, 407-416.	1.6	0
20439	Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature. Diagnostic Pathology, 2023, 18, .	2.0	1

#	ARTICLE	IF	CITATIONS
20440	Assessment of the level III of Inoue by preoperative endoscopic ultrasound and elastography: a novel approach to predict a periarterial divestment technique in borderline resectable (BR) or locally advanced (LA) pancreatic adenocarcinoma—How I do it. Langenbeck's Archives of Surgery, 2023, 408, .	1.9	0
20441	Supervised discovery of interpretable gene programs from single-cell data. Nature Biotechnology, 0, , .	17.5	8
20442	Cutaneous and Non-Cutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy. JID Innovations, 2023, , 100232.	2.4	0
20443	The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer. Cell Death and Disease, 2023, 14, .	6.3	0
20444	Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer. Journal of Cellular and Molecular Medicine, 2024, 28, .	3.6	1
20445	Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nature Communications, 2023, 14, .	12.8	7
20446	Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Frontiers in Oncology, 0, 13, .	2.8	2
20447	Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. BMC Cancer, 2023, 23, .	2.6	1
20448	Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression. Clinical Lung Cancer, 2024, 25, 50-60.e6.	2.6	0
20449	Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
20450	C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer. , 2023, 1, .		0
20451	Real-World Outcomes of Nivolumab, Pembrolizumab, and Atezolizumab Treatment Efficacy in Korean Veterans with Stage IV Non-Small-Cell Lung Cancer. Cancers, 2023, 15, 4198.	3.7	2
20452	Predictive Factors Associated with Long-Term Response to Combination Immunotherapy in Patients with Untreated Advanced Non-Small-Cell Lung Cancer: A Multicenter Retrospective Study. Oncology, 2023, 101, 425-434.	1.9	1
20453	Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal Metastasis. Annals of Surgical Oncology, 0, , .	1.5	4
20454	COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers, 2023, 15, 4436.	3.7	0
20455	HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecán (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology, 2023, 41, 5363-5375.	1.6	12
20458	Clinical characterization of patients with g <i>BRCA1/2</i> mutation-positive unresectable pancreatic cancer: a multicenter prospective study. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
20459	A systematic review of radiomics for predicting treatment response and survival in locally advanced cervical cancer: positive results or optimistic illusions?. Clinical and Translational Imaging, 0, , .	2.1	0

#	ARTICLE	IF	CITATIONS
20460	Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors. <i>Endocrine Practice</i> , 2023, , .	2.1	0
20461	ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. <i>Nature Medicine</i> , 2023, 29, 2559-2569.	30.7	12
20462	A Self-Assembled Organic Probe with Activatable Near-Infrared Fluoro-Photoacoustic Signals for In Vivo Evaluation of the Radiotherapy Effect. <i>Analytical Chemistry</i> , 2023, 95, 13984-13991.	6.5	0
20463	Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab. <i>International Immunopharmacology</i> , 2023, 123, 110799.	3.8	0
20464	PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer. <i>Clinical Epigenetics</i> , 2023, 15, .	4.1	0
20465	Volumetric Modulated Arc Therapy for Radiosurgery of Brain Metastases: A Single-Center Study. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 10097.	2.5	0
20466	Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition. <i>Discover Oncology</i> , 2023, 14, .	2.1	0
20467	Indoleamine 2,3-dioxygenase. , 2024, , 485-519.		0
20468	Overview of approaches to estimate real-world disease progression in lung cancer. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	2.9	0
20469	Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	2
20470	Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	1
20471	Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20472	An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2023, 13, 1280.	2.5	0
20473	Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal“gastric varices. <i>Journal of Gastroenterology</i> , 2023, 58, 1134-1143.	5.1	0
20474	The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer. <i>Abdominal Radiology</i> , 0, , .	2.1	0
20475	Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20476	SpaRx: elucidate single-cell spatial heterogeneity of drug responses for personalized treatment. <i>Briefings in Bioinformatics</i> , 2023, 24, .	6.5	4
20477	Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STs): an open-label, multicentre, phase II trial in four histological strata. <i>British Journal of Cancer</i> , 0, , .	6.4	0

#	ARTICLE	IF	CITATIONS
20478	Prognostic significance of serum fucosylated pro-haptoglobin in advanced renal cell carcinoma patients treated with immune checkpoint inhibitors. Scientific Reports, 2023, 13, .	3.3	0
20479	Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nature Reviews Clinical Oncology, 2023, 20, 885-895.	27.6	2
20480	PET/MRI in Endometrial Cancer: Imaging Biomarkers are Associated with Disease Progression and Overall Survival. Academic Radiology, 2024, 31, 939-950.	2.5	0
20481	Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4. Nature Communications, 2023, 14, .	12.8	7
20482	The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma. Melanoma Research, 0, , .	1.2	0
20483	Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy. Frontiers in Oncology, 0, 13, .	2.8	0
20484	A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma. BMC Cancer, 2023, 23, .	2.6	1
20485	TCL1A+ B cells predict prognosis in triple-negative breast cancer through integrative analysis of single-cell and bulk transcriptomic data. Open Life Sciences, 2023, 18, .	1.4	1
20486	Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer, 2023, 194, 113354.	2.8	0
20487	Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
20488	Time-to-event overall survival prediction in glioblastoma multiforme patients using magnetic resonance imaging radiomics. Radiologia Medica, 2023, 128, 1521-1534.	7.7	4
20489	Significance of CD103+ tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer. BMC Cancer, 2023, 23, .	2.6	0
20490	Diagnostic Performance of Preoperative Imaging in Endometrial Cancer. Current Oncology, 2023, 30, 8233-8244.	2.2	1
20491	Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer. Frontiers in Oncology, 0, 13, .	2.8	0
20492	Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century. Current Oncology, 2023, 30, 9230-9243.	2.2	0
20493	Free automatic software for quality assurance of computed tomography calibration, edges and radiomics metrics reproducibility. Physica Medica, 2023, 114, 103153.	0.7	0
20494	Exploring the impact of patientâ€specific clinical features on osimertinib effectiveness in a realâ€world cohort of patients with <i>EGFR</i> mutated nonâ€small cell lung cancer. International Journal of Cancer, 2024, 154, 332-342.	5.1	0
20495	Efficacy and safety of cyclinâ€dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A realâ€world experience. Thoracic Cancer, 2023, 14, 3012-3019.	1.9	0

#	ARTICLE	IF	CITATIONS
20496	Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?. BMC Surgery, 2023, 23, .	1.3	0
20497	KORTUC, a novel hydrogen peroxide-based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer. Oncology Letters, 2023, 26, .	1.8	1
20498	Paclitaxel-carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series. Journal of Obstetrics and Gynaecology Research, 0, , .	1.3	0
20499	Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art. Cancers, 2023, 15, 4065.	3.7	0
20500	Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. International Journal of Urology, 2023, 30, 1180-1186.	1.0	6
20501	Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy. International Journal of Molecular Sciences, 2023, 24, 14679.	4.1	1
20502	Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer. Annals of Surgical Oncology, 0, , .	1.5	1
20503	Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge. Thoracic Cancer, 0, , .	1.9	0
20504	Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis. Oral Oncology, 2023, 145, 106479.	1.5	2
20505	Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial). BMJ Open, 2023, 13, e069499.	1.9	0
20506	Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond. Cancers, 2023, 15, 4905.	3.7	1
20507	Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis. Drugs - Real World Outcomes, 0, , .	1.6	1
20508	Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. Clinical Genitourinary Cancer, 2023, , .	1.9	0
20509	Combination of CT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study. BMC Medicine, 2023, 21, .	5.5	1
20511	Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors' response in non-small cell lung cancer: a multicenter cohort study. Frontiers in Oncology, 0, 13, .	2.8	1
20513	Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clinical Cancer Research, 2023, 29, 5038-5046.	7.0	1
20515	A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors. Cancer Research Communications, 2023, 3, 1638-1647.	1.7	4
20516	Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. The Lancet Child and Adolescent Health, 2023, 7, 613-620.	5.6	4

#	ARTICLE	IF	CITATIONS
20517	[68Ga]Ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: comparison with [18F]F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 4064-4076.	6.4	3
20518	Prognostic significance of the cachexia index in patients with unresectable advanced gastric cancer receiving palliative chemotherapy: a retrospective single-center study. Surgery Today, 2024, 54, 231-239.	1.5	0
20519	Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	1
20520	Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	2
20521	Can a propensity score matching method be applied to assessing efficacy from <scp>singleâ€arm proofâ€ofâ€concept</scp> trials in oncology?. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1347-1357.	2.5	1
20522	Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI. Diagnostic and Interventional Imaging, 2023, 104, 605-614.	3.2	4
20524	Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150. Tumor Biology, 2023, , 1-14.	1.8	1
20526	Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study. Journal of Modern Oncology, 2023, 25, 221-228.	0.3	0
20528	Standardized PSMA-PET Imaging of Advanced Prostate Cancer. Seminars in Nuclear Medicine, 2023, , .	4.6	1
20529	Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies. Oncotarget, 2023, 14, 758-774.	1.8	0
20530	Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry. Frontiers in Immunology, 0, 14, .	4.8	1
20531	Performance of an automated registration-based method for longitudinal lesion matching and comparison to inter-reader variability. Physics in Medicine and Biology, 2023, 68, 175031.	3.0	0
20534	Effect of butyrateâ€producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab. Cancer Medicine, 2023, 12, 17849-17855.	2.8	0
20535	99mTc-macroaggregated albumin SPECT/CT predictive dosimetry and dose-response relationship in uveal melanoma liver metastases treated with first-line selective internal radiation therapy. Scientific Reports, 2023, 13, .	3.3	0
20536	First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2023, 24, 989-1001.	10.7	6
20537	Diagnostic and Prognostic Significance of Serum Biomarkers â€“ Serum Amyloid A and CYFRA 21-1 in Lung Cancer. International Journal of Applied & Basic Medical Research, 2023, 13, 89-94.	0.5	0
20538	The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis. Investigational New Drugs, 2023, 41, 768-776.	2.6	1
20539	Protein kinase D activity is a risk biomarker in prostate cancer that drives cell invasion by a Snail/ERK dependent mechanism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2024, 1870, 166851.	3.8	1

#	ARTICLE	IF	CITATIONS
20540	Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab. Investigational New Drugs, 2023, 41, 727-736.	2.6	3
20541	Assessing the role of positron emission tomography and bone scintigraphy in imaging of pleuropulmonary blastoma (PPB): A report from the International PPB/DICER1 Registry. Pediatric Blood and Cancer, 2023, 70, .	1.5	1
20542	Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2023, , .	2.6	0
20543	Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2023, 92, 381-390.	2.3	2
20544	Applications of quantitative perfusion MRI in the liver. Advances in Magnetic Resonance Technology and Applications, 2023, , 431-454.	0.1	0
20545	Impact of retention index on the neoadjuvant chemotherapy effect and the prognosis in oesophageal cancer. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
20546	Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study. Clinical Cancer Research, 2023, 29, 4341-4351.	7.0	1
20547	Clinicopathological impact of VEGFR2 and VEGFA in patients with EGFR major mutant NSCLC receiving osimertinib. Thoracic Cancer, 2023, 14, 2950-2961.	1.9	0
20548	Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045. International Journal of Cancer, 2023, 153, 2032-2044.	5.1	1
20549	Virtual Treatment Zone From Cone Beam CT Commonly Alters Treatment Plan and Identifies Tumor at Risk for Under-Treatment in US or US Fusion-Guided Microwave Ablation of Liver Tumors. Technology in Cancer Research and Treatment, 2023, 22, .	1.9	0
20551	Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients. Critical Reviews in Oncology/Hematology, 2023, 190, 104113.	4.4	1
20552	Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology. Exploration of Targeted Anti-tumor Therapy, 0, , 569-582.	0.8	3
20553	Predictive Partition Dosimetry and Outcomes after Yttrium-90 Resin Microsphere Radioembolization of Colorectal Cancer Metastatic to the Liver: A Retrospective Analysis. Journal of Vascular and Interventional Radiology, 2023, , .	0.5	0
20554	Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction (CODE-AAMI): Protocol for a Randomized Placebo-Controlled Trial. Chinese Journal of Integrative Medicine, 2023, 29, 1059-1065.	1.6	1
20555	Durable tumor regression and restoration of neurologic function after treatment with anti-PD-1 in patients with functionally unresectable cutaneous squamous cell carcinoma with perineural spread into the cavernous sinus. Journal of Neuro-Oncology, 2023, 164, 431-436.	2.9	0
20556	Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China. Cancers, 2023, 15, 4360.	3.7	0
20557	Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CEST) MRI. Cancer Imaging, 2023, 23, .	2.8	0
20558	Multi-dimension unified Swin Transformer for 3D Lesion Segmentation in Multiple Anatomical Locations. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
20559	Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. <i>Cancers</i> , 2023, 15, 4358.	3.7	2
20560	Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	0
20561	Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy. <i>ESMO Open</i> , 2023, 8, 101629.	4.5	3
20562	Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. <i>International Journal of Clinical Oncology</i> , 2023, 28, 1651-1658.	2.2	3
20563	Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases. <i>British Journal of Radiology</i> , 2023, 96, .	2.2	0
20564	Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling. <i>Cancers</i> , 2023, 15, 4416.	3.7	0
20565	Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies. <i>Discover Oncology</i> , 2023, 14, .	2.1	0
20566	Azurocidin 1 inhibits the aberrant proliferation of triple-negative breast cancer through the regulation of pyroptosis. <i>Oncology Reports</i> , 2023, 50, .	2.6	0
20567	Head to head comparison of 68Ga-DOTA-FAPI-04 vs 18F-FDG PET/CT in the evaluation of primary extrapulmonary tumors in the chest. <i>European Radiology</i> , 2024, 34, 1960-1970.	4.5	0
20568	Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study. <i>Targeted Oncology</i> , 2023, 18, 707-715.	3.6	0
20569	Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 5400-5410.	1.6	6
20570	Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20571	Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
20572	Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials. <i>Oncology Research and Treatment</i> , 2023, 46, 348-361.	1.2	0
20573	Management of Small Bowel Neuroendocrine Tumours: 10 Years' Experience at a Tertiary Referral Centre. <i>Cancers</i> , 2023, 15, 4438.	3.7	0
20575	The Effectiveness of Radiological Methods in Predicting Pathological Complete Response After Neoadjuvant Therapy in Locally Advanced Breast Cancer Patients. <i>Cukurova Anestezi Ve Cerrahi Bilimler Dergisi</i> , 2023, 6, 235-240.	0.0	0
20576	Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
20577	Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2023, 158, 1133.	4.3	4

#	ARTICLE	IF	CITATIONS
20578	Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials. <i>Seminars in Radiation Oncology</i> , 2023, 33, 429-437.	2.2	0
20579	Atezolizumab for Advanced Alveolar Soft Part Sarcoma. <i>New England Journal of Medicine</i> , 2023, 389, 911-921.	27.0	12
20580	Artificial intelligenceâ€powered spatial analysis of tumorâ€infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A singleâ€center, retrospective, longitudinal cohort study. <i>Thoracic Cancer</i> , 2023, 14, 3001-3011.	1.9	0
20581	Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. <i>International Journal of Surgery</i> , 2023, 109, 4000-4008.	2.7	0
20582	Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. <i>Clinical Cancer Research</i> , 2023, 29, 4586-4595.	7.0	3
20583	Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. <i>European Journal of Cancer</i> , 2023, 194, 113336.	2.8	1
20584	Response to programmed cell death protein 1 antibody in patients with Epsteinâ€Barr virus-associated intrahepatic cholangiocarcinoma. <i>European Journal of Cancer</i> , 2023, 194, 113337.	2.8	1
20585	Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Nonâ€Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 4852-4863.	1.6	18
20586	Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. <i>Cancer Cell</i> , 2023, 41, 1680-1688.e2.	16.8	4
20587	Comparative Study of CT and MR Guided Microwave Ablation in the Treatment of Para-vascular VX2 Liver Tumor Model in Rabbits. <i>Current Medical Imaging</i> , 2023, 20, .	0.8	0
20588	Predicting the Prognosis of Lung Cancer Patients Treated with Intensitymodulated Radiotherapy based on Radiomic Features. <i>Current Medical Imaging</i> , 2023, 20, .	0.8	0
20590	NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2023, 402, 1272-1281.	13.7	18
20591	Usefulness of tumor perfusion on cone-beam CT after hepatic arterial infusion port implantation for evaluating tumor response to hepatic arterial infusion chemotherapy in hepatocellular carcinoma treatment. <i>Diagnostic and Interventional Radiology</i> , 2023, .	1.5	0
20592	The Role of Additional Staining in the Assessment of the Peritoneal Regression Grading Score (PRGS) in Peritoneal Metastasis of Gastric Origin. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 583-589.	1.2	0
20593	SNMMI Clinical Trials Network Research Series for Technologists: Imaging Contract Research Organizations, Nuclear Medicine Technologists, and the Role they Play in Medical Imaging Research. <i>Journal of Nuclear Medicine Technology</i> , 0, , jnmt.123.266111.	0.8	0
20594	Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	2.2	1
20595	Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients. <i>Journal of Neuro-Oncology</i> , 2023, 164, 587-595.	2.9	0
20598	Efficacy and safety of drug therapy for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2023, 13, e070645.	1.9	0

#	ARTICLE	IF	CITATIONS
20600	Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma. Liver Cancer International, 2023, 4, 101-108.	1.3	0
20601	Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Nonâ€‘Small Cell Lung Cancer. Clinical Cancer Research, 2023, 29, 4596-4605.	7.0	7
20602	Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway. Cellular Oncology (Dordrecht), 2024, 47, 303-319.	4.4	1
20603	Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discovery, 2023, 13, 2394-2411.	9.4	8
20604	Clinical outcomes of advanced <scp>NSCLC</scp> patients with different <scp>EGFR</scp> exon 19 deletion subtypes treated with firstâ€‘line tyrosine kinase inhibitors: A singleâ€‘center ambispective cohort study. Thoracic Cancer, 2023, 14, 3147-3160.	1.9	1
20605	Outcomes of Metaplastic Breast Cancer Versus Tripleâ€‘Negative Breast Cancer: A Propensity Score Matching Analysis. World Journal of Surgery, 2023, 47, 3192-3202.	1.6	2
20606	Evaluation of post-chemotherapy residual seminomatous masses by 18F-fluorodeoxyglucose PET/CT using tumor-to-liver ratio â€‘ conundrum or solution?. Nuclear Medicine Communications, 0, , .	1.1	0
20607	Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediateâ€‘stage hepatocellular carcinoma: A pilot study. Oncology Letters, 2023, 26, .	1.8	0
20608	<scp>Realâ€‘world</scp> survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for <scp>nonmetastatic castrationâ€‘resistant</scp> prostate cancer. Cancer Medicine, 2023, 12, 19414-19422.	2.8	0
20609	Clinical features and outcomes of patients with pancreatic cancer requiring unplanned medical ICU admission: A retrospective multicenter study. Digestive and Liver Disease, 2024, 56, 514-521.	0.9	0
20612	Imaging of Lung Cancer. , 2023, , 1-39.		0
20613	Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer. JCO Clinical Cancer Informatics, 2023, , .	2.1	0
20614	Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal. Cureus, 2023, , .	0.5	0
20615	Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. JAMA Network Open, 2023, 6, e2333533.	5.9	3
20616	Revalidation of the ATTRACTION-4 study in a real-world setting: a multicenter, retrospective propensity score matching study in China. Frontiers in Immunology, 0, 14, .	4.8	0
20617	Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression. Frontiers in Immunology, 0, 14, .	4.8	0
20618	OLIGOMETASTASIS IN GASTRIC CANCER TREATMENT: IS THERE A PLACE FOR THE SURGEON?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 0, 36, .	0.5	1
20619	A retrospective analysis of concurrent chemoradiation for squamous cell carcinoma of the anus in Johannesburg. South African Journal of Oncology, 0, 7, .	0.1	0

#	ARTICLE	IF	CITATIONS
20620	Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
20622	Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
20623	The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20624	Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors. <i>PLoS ONE</i> , 2023, 18, e0291772.	2.5	0
20625	Undifferentiated pleomorphic sarcoma of the spleen: a case report and literature review. <i>Surgical Case Reports</i> , 2023, 9, .	0.6	0
20626	Value of spectral CT parameters in predicting the efficacy of neoadjuvant chemotherapy for gastric cancer. <i>Clinical Radiology</i> , 2024, 79, 51-59.	1.1	0
20627	The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinoma. <i>Oncology Letters</i> , 2023, 26, .	1.8	0
20628	Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. <i>British Journal of Cancer</i> , 0, , .	6.4	1
20629	Treatment response prediction of neoadjuvant chemotherapy for rectal cancer by deep learning of colonoscopy images. <i>Oncology Letters</i> , 2023, 26, .	1.8	0
20630	Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy. <i>Cancer Science</i> , 2023, 114, 4484-4498.	3.9	4
20631	Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers. <i>JAMA Oncology</i> , 2023, 9, 1536.	7.1	3
20632	Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset. <i>Journal of Cancer Research and Practice</i> , 2023, 10, 94.	0.2	0
20633	Accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID 19 pandemic: A tertiary care experience. <i>Journal of Cancer Research and Therapeutics</i> , 0, , .	0.9	0
20634	Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
20636	HIV and Early Treatment Outcomes Among Women With Cervical Cancer Treated With Concurrent Chemoradiation in Tanzania. <i>JCO Global Oncology</i> , 2023, , .	1.8	0
20637	Impact of PD-1/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: A systematic review. , 2023, , .		0
20638	Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100578.	1.1	0
20639	ALPPS technique for two-stage liver resections: immediate and long-term results. <i>Annals of HPB Surgery</i> , 2023, 28, 39-47.	0.5	0

#	ARTICLE	IF	CITATIONS
20641	Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma. <i>Hepatology Research</i> , 2024, 54, 162-173.	3.4	1
20642	Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST. <i>European Radiology</i> , 0, , .	4.5	0
20643	Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2023, 178, 27-35.	1.4	1
20644	The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14454.	4.1	0
20646	Levels of PIVKA-II and alpha-fetoprotein in unresectable hepatocellular carcinoma compared to healthy controls and predictive values of both markers with radiological responses after loco-regional interventions. <i>PeerJ</i> , 0, 11, e15988.	2.0	0
20647	Induction Chemotherapy for Sinonasal Tumors in Patients Presenting with Brain Invasion and/or Neurological Deficits. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 0, , .	0.8	0
20648	The efficacy and feasibility of neoadjuvant immunotherapy plus chemotherapy followed by McKeown minimally invasive oesophagectomy for locally advanced oesophageal squamous cell carcinoma. <i>Journal of Minimal Access Surgery</i> , 0, , .	0.7	0
20649	Early changes of platelet-lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer. <i>Molecular and Clinical Oncology</i> , 2023, 19, .	1.0	0
20650	Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases. <i>American Journal of Surgery</i> , 2024, 229, 17-23.	1.8	3
20651	Myoepithelial carcinoma of soft tissues and bone. <i>European Journal of Cancer</i> , 2023, 194, 113353.	2.8	0
20653	Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
20654	A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006. <i>Future Oncology</i> , 2023, 19, 1897-1904.	2.4	0
20655	MISTLETOE IN TUMOUR THERAPY Basic Research and Clinical Practice th Mistletoe Symposium 9â€“11 November 2023 Nonnweiler-Otzenhausen, Germany. , 2023, 29, A-1-A-24.		0
20656	Adaptive radiotherapy of locally advanced sigmoid colon cancer with intra-fractional motion using the MRIdian system: A case report. <i>Oncology Letters</i> , 2023, 26, .	1.8	1
20657	A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. <i>Future Oncology</i> , 2023, 19, 1841-1851.	2.4	0
20658	Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. <i>ESMO Open</i> , 2023, 8, 101824.	4.5	2
20660	Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab. <i>Cancer Science</i> , 2023, 114, 4622-4631.	3.9	0
20661	10 Tips for Using RECIST 1.1 in the Community Setting. <i>Oncology Issues</i> , 2023, 38, 82-83.	0.1	0

#	ARTICLE	IF	CITATIONS
20662	Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy. <i>Onc Immunology</i> , 2023, 12, .	4.6	2
20663	SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis. <i>Gastric Cancer</i> , 0, , .	5.3	0
20664	Cost-effectiveness of 2-[18F]FDG-PET/CT versus CE-CT for response monitoring in patients with metastatic breast cancer: a register-based comparative study. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
20666	Correlation between synthetic MRI relaxometry and apparent diffusion coefficient in breast cancer subtypes with different neoadjuvant therapy response. <i>Insights Into Imaging</i> , 2023, 14, .	3.4	0
20667	A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
20668	Multi-scale Self-Supervised Learning for Longitudinal Lesion Tracking with Optional Supervision. <i>Lecture Notes in Computer Science</i> , 2023, , 573-582.	1.3	0
20669	Graph-Theoretic Automatic Lesion Tracking and Detection of Patterns of Lesion Changes in Longitudinal CT Studies. <i>Lecture Notes in Computer Science</i> , 2023, , 106-115.	1.3	0
20670	Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients. <i>Npj Breast Cancer</i> , 2023, 9, .	5.2	0
20671	Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy. <i>Cancer Letters</i> , 2023, 576, 216405.	7.2	1
20672	Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	1
20673	Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 76-83.	1.9	1
20674	Gastrointestinal Kanserlerden Gelişen Beyin Metastazı Olan Hastalarda Stereotaktik Radyocerrahiye Yanıt ve Sağkalım Sonuçları Değerlendirilmesi. <i>Journal of Contemporary Medicine</i> , 2023, 13, 939-948.	0.3	0
20675	Biphasic pleural mesothelioma treated successfully with multimodal therapy: a case report. , 2023, 2, .		0
20676	Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1689-1708.	3.7	1
20677	Clinical Outcomes of Radiation Therapy for Choroidal Metastases and A Literature Review. <i>Kurume Medical Journal</i> , 2023, , .	0.1	0
20678	Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20679	Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy. <i>Abdominal Radiology</i> , 2023, 48, 3661-3676.	2.1	1
20680	Predicting head and neck cancer treatment outcomes with pre-treatment quantitative ultrasound texture features and optimising machine learning classifiers with texture-of-texture features. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2

#	ARTICLE	IF	CITATIONS
20681	Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2024, 15, 101640.	1.0	0
20682	Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 458.e9-458.e19.	1.6	0
20683	Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse. <i>Cold Spring Harbor Perspectives in Medicine</i> , 0, , a041385.	6.2	0
20685	Duration of and time to response in oncology clinical trials from the perspective of the estimand framework. <i>Pharmaceutical Statistics</i> , 2024, 23, 91-106.	1.3	0
20687	Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs). <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 0, , .	1.8	1
20688	Radiomics and artificial intelligence for soft-tissue sarcomas: Current status and perspectives. <i>Diagnostic and Interventional Imaging</i> , 2023, 104, 567-583.	3.2	2
20689	A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors. <i>International Journal of General Medicine</i> , 0, Volume 16, 4485-4498.	1.8	1
20691	Circulating low density neutrophils are associated with resistance to anti-EPD1 immunotherapy in squamous head and neck cancer. <i>Head and Neck</i> , 0, , .	2.0	0
20692	Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. <i>Oncolmunology</i> , 2023, 12, .	4.6	4
20693	Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1709-1721.	3.7	1
20694	Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 4049-4064.	4.2	2
20695	[18F]NaF PET/CT imaging of response to single fraction SABR to bone metastases from breast cancer. <i>Frontiers in Nuclear Medicine</i> , 0, 3, .	1.2	1
20696	Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
20697	European Neuroendocrine Tumour Society (<scp>ENETS</scp>) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	2.6	6
20698	Perioperative outcome and long-term survival for intrahepatic cholangiocarcinoma after portal vein embolization and subsequent resection: A propensity-matched study. <i>European Journal of Surgical Oncology</i> , 2023, , 107100.	1.0	0
20699	Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20700	Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study. <i>Journal of Cancer Prevention</i> , 2023, 28, 106-114.	2.0	0
20701	Induction of Kallikrein-Related Peptidase 13 and TET2/3 by Anticancer Drugs and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Preoperative Treatment. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
20702	Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
20703	Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2023, 9, 1651.	7.1	15
20704	A New Treatment Strategy for Spinal Metastasis: The “Systemic Conditions, Effectiveness of Systemic Treatment, Neurology, and Oncology” Decision Framework System. <i>Neurosurgery</i> , 2024, 94, 584-596.	1.1	1
20705	Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1735-1748.	3.7	0
20706	Long-term survival with a combination of immunotherapy, anti-angiogenesis, and traditional radiotherapy in brain metastatic small cell lung cancer: a case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20707	Castleman disease: Experience from a single institution. <i>Medicine International</i> , 2023, 3, .	0.6	0
20709	Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. <i>Clinical Cancer Research</i> , 2024, 30, 824-835.	7.0	2
20710	Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score-matched analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 0, , .	2.6	0
20711	Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 115-125.e3.	1.9	0
20712	Impact of Trans-Arterial Chemo-Embolization on Tumor Response in Hepatocellular Carcinoma Patients: A Retrospective Study. <i>Pakistan Biomedical Journal</i> , 0, , 29-33.	0.1	0
20713	Tumor Response Metrics in Neuro-Oncology: A Review. <i>Neurographics</i> , 2023, 13, 142-165.	0.1	0
20714	ClinicalOmicsDB: exploring molecular associations of oncology drug responses in clinical trials. <i>Nucleic Acids Research</i> , 0, , .	14.5	1
20715	A phase-field model for non-small cell lung cancer under the effects of immunotherapy. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 18670-18694.	1.9	1
20716	Follow-Up (Response to Treatment, Clinical Management). , 2023, , 131-141.		0
20717	Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review. <i>Oral Oncology</i> , 2023, 146, 106585.	1.5	1
20718	Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
20720	MRI feature-based radiomics models to predict treatment outcome after stereotactic body radiotherapy for spinal metastases. <i>Insights Into Imaging</i> , 2023, 14, .	3.4	0
20721	Capecitabine maintenance therapy in metastatic colorectal cancer patients with no evidence of disease: CAMCO trial. <i>Future Oncology</i> , 2023, 19, 2045-2054.	2.4	0

#	ARTICLE	IF	CITATIONS
20722	Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clinical Cancer Research, 2023, 29, 5104-5115.	7.0	3
20723	Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis. Oncology, 2024, 102, 228-238.	1.9	0
20724	Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas. Neuroendocrinology, 0, , 1-11.	2.5	0
20725	Clinicopathological Characteristics of Breast Cancer Patients with HER-2 Low Expression Receiving Neoadjuvant Therapy. Oncology, 2024, 102, 122-130.	1.9	0
20726	Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer. Oncology, 2024, 102, 271-282.	1.9	0
20727	Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. Cancers, 2023, 15, 4942.	3.7	0
20728	Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel. Oncology, 2024, 102, 30-42.	1.9	0
20729	Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil. Chemotherapy, 2024, 69, 27-34.	1.6	1
20730	PointRendUNet: a model for fine boundary segmentation. , 2023, , .		0
20731	A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research, 2023, 29, 5047-5056.	7.0	0
20732	The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [18F]FDG-PET/CT and CE-CT. Journal of Imaging, 2023, 9, 222.	3.0	0
20733	Immunotherapy for advanced or metastatic urothelial carcinoma. The Cochrane Library, 2023, 2023, .	2.8	0
20734	A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. EJHaem, 2023, 4, 1042-1051.	1.0	0
20735	Assessing Metastasis through Positron Emission Tomography (PET): An In-depth Analysis and Mapping of Thematic Clusters and Prevailing Topics in Nuclear Medicine Research. Medical Science and Discovery, 2023, 10, 803-817.	0.1	1
20736	Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Lung Cancer, 2023, 186, 107401.	2.0	1
20737	Metabolic predictors of response to immune checkpoint blockade therapy. IScience, 2023, 26, 108188.	4.1	2
20738	Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands. , 2023, 1, 100007.		1
20739	Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxaneâ€“PLD versus PLDâ€“Taxane in Patients with Metastatic Breast Cancer. Cancers, 2023, 15, 4953.	3.7	0

#	ARTICLE	IF	CITATIONS
20740	Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study. <i>EClinicalMedicine</i> , 2023, 65, 102271.	7.1	2
20741	Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single institution experience and review of the literature. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	2.6	0
20742	Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. <i>Tumor Biology</i> , 2023, , 1-14.	1.8	1
20743	CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. <i>Tumor Biology</i> , 2023, , 1-13.	1.8	1
20744	89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study. <i>Cancers</i> , 2023, 15, 4980.	3.7	0
20745	Correlation between serum lipid levels and endocrine resistance in patients with ER-positive breast cancer. <i>Medicine (United States)</i> , 2023, 102, e35048.	1.0	0
20746	CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 5227-5243.	7.0	0
20747	Analysis of the clinical factors affecting excellent response of Iodine-131 treatment for pulmonary metastases from differentiated thyroid cancer. <i>Heliyon</i> , 2023, 9, e20853.	3.2	0
20749	Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, , 101827.	4.7	0
20750	Immunotherapy in renal cell carcinoma. <i>Lancet Oncology</i> , The, 2023, , .	10.7	0
20751	First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≥49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. <i>Cancers</i> , 2023, 15, 4988.	3.7	0
20752	Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study. <i>Diagnostics</i> , 2023, 13, 3210.	2.6	0
20753	Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16). <i>European Journal of Cancer</i> , 2023, 195, 113386.	2.8	3
20754	Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the <sc>PanaMa</sc> trial (<sc>AIO KRK</sc> 0212). <i>International Journal of Cancer</i> , 0, , .	5.1	0
20755	Genetic Factors Associated with Response to Breast Cancer Chemotherapy in Burkina Faso: Case of the CHEK2 1100delC Mutation. <i>American Journal of Biochemistry and Molecular Biology</i> , 2023, 13, 42-48.	0.6	0
20756	Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study. <i>BMC Cancer</i> , 2023, 23, .	2.6	2
20757	Efficacy and safety of abemaciclib alone and with<sc>PI3K</sc>/<sc>mTOR</sc>inhibitor<sc>LY3023414</sc>or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. <i>Cancer Medicine</i> , 2023, 12, 20353-20364.	2.8	1
20758	Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. <i>Kaohsiung Journal of Medical Sciences</i> , 2023, 39, 1233-1242.	1.9	0

#	ARTICLE	IF	CITATIONS
20759	Improving the efficacy and safety of concurrent chemoradiotherapy by neoadjuvant chemotherapy: a randomized controlled study of locally advanced cervical cancer with a large tumor. Journal of Gynecologic Oncology, 0, 35, .	2.2	0
20760	Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma. International Journal of Clinical Oncology, 2024, 29, 20-26.	2.2	0
20761	Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer, 0, , 1-11.	7.7	2
20762	Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy. Ultrasound in Medicine and Biology, 2024, 50, 142-149.	1.5	0
20764	Indeterminate pulmonary nodules in non-€rhabdomyosarcoma soft tissue sarcoma: A study of the European paediatric Soft Tissue Sarcoma Study Group. Cancer, 2024, 130, 597-608.	4.1	0
20765	High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell Reports Medicine, 2023, 4, 101244.	6.5	3
20766	Quantitative analysis of pre-treatment dynamic contrast-enhanced ultrasound for assessing the response of colorectal liver metastases to chemotherapy plus targeted therapy: a dual-institutional study. Abdominal Radiology, 0, , .	2.1	0
20767	Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study. BMC Cancer, 2023, 23, .	2.6	0
20768	Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature. Endocrine, 0, , .	2.3	0
20769	Radiation for inflammatory breast cancer: Updates. International Review of Cell and Molecular Biology, 2023, , .	3.2	0
20770	Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment. Clinical Pharmacokinetics, 0, , .	3.5	0
20772	Uncover This Tech Term: Independent Central Image Reading. Korean Journal of Radiology, 2023, 24, 1164.	3.4	1
20773	Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. Cancers, 2023, 15, 5047.	3.7	5
20774	Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentifiCaTion of cliNical and molecular drivers: the PREDICTION study. BMC Cancer, 2023, 23, .	2.6	0
20775	Pelvic Irradiation for Node-Positive Prostate Cancer After Prostatectomy: Long-Term Results of the Prospective PLATIN-4 and PLATIN-5 Trials. International Journal of Radiation Oncology Biology Physics, 2024, 118, 1011-1017.	0.8	1
20776	Unexpected Durable Complete Response With Anti-€PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis. JCO Precision Oncology, 2023, , .	3.0	0
20777	Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet, The, 2023, 402, 2197-2208.	13.7	22
20778	Initial Findings on the Use of [€sup>225Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors. Molecular Imaging and Radionuclide Therapy, 2023, 32, 226-232.	0.7	2

#	ARTICLE	IF	CITATIONS
20779	Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2023, 402, 1835-1847.	13.7	30
20780	Tissue Circular RNA_0004018 and 0003570 as Novel Prognostic Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma. <i>Genes</i> , 2023, 14, 1963.	2.4	1
20781	Dual-energy CT improves differentiation of non-hypervascular pancreatic neuroendocrine neoplasms from CA 19-9-negative pancreatic ductal adenocarcinomas. <i>Radiologia Medica</i> , 0, , .	7.7	1
20782	Using Compression Therapy to Treat Bilateral Lower Limb Edema in Patients with Lung Cancer: A Case Series. <i>Advances in Skin and Wound Care</i> , 2023, 36, 1-6.	1.0	0
20783	Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i> - or <i>ALK</i> -Mutated Non-Small-Cell Lung Cancer (ATLAS, KCSG-LU19-04). <i>Journal of Clinical Oncology</i> , 0, , .	1.6	4
20784	A multistate platform model for time-to-event endpoints in oncology clinical trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2024, 13, 154-167.	2.5	0
20785	Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions. <i>New England Journal of Medicine</i> , 2023, 389, 2039-2051.	27.0	19
20786	Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. , 2023, 11, e007144.		3
20787	Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2023, 389, 2256-2266.	27.0	11
20788	Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors Following Yttrium-90 Resin Microsphere Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2023, , .	0.5	1
20789	Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. <i>Cancer</i> , 0, , .	4.1	0
20790	The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. <i>Annals of Oncology</i> , 2024, 35, 91-97.	1.2	3
20791	First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC. <i>New England Journal of Medicine</i> , 2023, 389, 1839-1850.	27.0	20
20792	Phase 3 Trial of Selpercatinib in Advanced <i>RET</i> -Mutant Medullary Thyroid Cancer. <i>New England Journal of Medicine</i> , 2023, 389, 1851-1861.	27.0	16
20793	Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy. <i>Cancer Imaging</i> , 2023, 23, .	2.8	1
20794	Infusion Product TNF α , Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy. <i>Cancer Immunology Research</i> , 2023, 11, 1589-1597.	3.4	0
20795	Spectrum of Imaging Patterns of Lung Cancer following Radiation Therapy. <i>Diagnostics</i> , 2023, 13, 3283.	2.6	0
20796	Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. <i>ESMO Open</i> , 2023, 8, 101609.	4.5	0

#	ARTICLE	IF	CITATIONS
20797	Early thrombocytopenia predicts longer time to treatment discontinuation in trastuzumab emtansine treatment. <i>Oncology Letters</i> , 2023, 26, .	1.8	0
20798	Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab. <i>Hepatology</i> , 2024, 79, 49-60.	7.3	0
20799	Individualized treatment decision model for inoperable elderly esophageal squamous cell carcinoma based on multi-modal data fusion. <i>BMC Medical Informatics and Decision Making</i> , 2023, 23, .	3.0	0
20800	Systematic review: predictive value of organoids in colorectal cancer. <i>Scientific Reports</i> , 2023, 13, .	3.3	4
20801	Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. <i>Annals of Oncology</i> , 2024, 35, 77-90.	1.2	18
20802	Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	1
20804	Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria. <i>Cancer Imaging</i> , 2023, 23, .	2.8	0
20805	Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 3475-3482.	1.9	0
20806	Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. <i>Nature Communications</i> , 2023, 14, .	12.8	0
20807	Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). <i>Gynecologic Oncology</i> , 2023, 178, 161-169.	1.4	1
20808	Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer. <i>Nature Communications</i> , 2023, 14, .	12.8	2
20809	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
20810	The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer. <i>American Journal of Surgery</i> , 2024, 228, 273-278.	1.8	0
20811	Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. <i>Respiratory Investigation</i> , 2023, 61, 643-650.	1.8	2
20812	Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2023, 101, 609-623.	1.9	1
20813	The neutrophil to lymphocyte ratio in salivary gland cancers treated with pembrolizumab. <i>Head and Neck</i> , 2024, 46, 129-137.	2.0	0
20814	Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles. <i>PLoS Biology</i> , 2023, 21, e3002339.	5.6	2
20815	Association between pathologic response and survival after neoadjuvant therapy in lung cancer. <i>Nature Medicine</i> , 2024, 30, 218-228.	30.7	3

#	ARTICLE	IF	CITATIONS
20816	Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions. <i>Clinical and Translational Immunology</i> , 2023, 12, .	3.8	0
20817	Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma. <i>ESMO Open</i> , 2023, 8, 102038.	4.5	0
20818	Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review. <i>Cancers</i> , 2023, 15, 5216.	3.7	3
20819	Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1923-1933.	3.7	0
20820	Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
20821	Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report. <i>Journal of Surgical Case Reports</i> , 2023, 2023, .	0.4	0
20822	Radium-223 and bone metastatic disease: still more to learn. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	2.9	0
20823	Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
20824	Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
20825	Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023, 14, 2898-2907.	7.3	0
20826	Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20827	PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	0
20828	Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer. <i>Breast Cancer Research</i> , 2023, 25, .	5.0	0
20829	Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer. <i>Breast Cancer Research</i> , 2023, 25, .	5.0	2
20830	Anaesthesia in Veterinary Oncology: The Effects of Surgery, Volatile and Intravenous Anaesthetics on the Immune System and Tumour Spread. <i>Animals</i> , 2023, 13, 3392.	2.3	0
20831	Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 0, , .	3.6	0
20832	Protocol of the <sc>IntenSify</sc> Trial: An open-label phase I trial of the <sc>CYP3A</sc> inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy. <i>Clinical and Translational Science</i> , 2023, 16, 2483-2493.	3.1	0
20833	The Diagnostic and Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Laryngeal Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 5461.	3.7	0

#	ARTICLE	IF	CITATIONS
20834	C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. <i>Cancers</i> , 2023, 15, 5429.	3.7	1
20835	Treatment Outcomes and Risk Factors for Incomplete Treatment after Definitive Chemoradiotherapy for Non-Resectable or Metastatic Esophageal Cancer. <i>Cancers</i> , 2023, 15, 5421.	3.7	0
20836	The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
20837	Diagnostic potential of serum HSP90 beta for HNSCC and its therapeutic prognosis after local hyperthermia therapy. <i>PLoS ONE</i> , 2023, 18, e0281919.	2.5	0
20838	The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Nonâ€“Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, .	1.3	0
20839	The value of MRI in quantification of parametrial invasion and association with prognosis in locally advanced cervical cancer: the â€œPLACEâ€“study. <i>European Radiology</i> , 0, , .	4.5	1
20840	Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 5253.	3.7	1
20841	A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study). <i>Cancers</i> , 2023, 15, 5201.	3.7	0
20842	Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer. <i>Cancers</i> , 2023, 15, 5197.	3.7	0
20843	The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease. <i>Annals of Hematology</i> , 2023, 102, 3335-3343.	1.8	0
20844	Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). <i>Lung Cancer</i> , 2023, 186, 107422.	2.0	0
20845	Pilot study of treatment of patients with deep infiltrative endometriosis with methotrexate carried in lipid nanoparticles. <i>Archives of Gynecology and Obstetrics</i> , 0, , .	1.7	0
20846	Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC). <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	2
20847	Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma. <i>Cells</i> , 2023, 12, 2534.	4.1	1
20848	Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma. <i>Diagnostics</i> , 2023, 13, 3483.	2.6	0
20849	Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
20850	A phase 2 trial combining afatinib with cetuximab in patients with <i>EGFR</i> exon 20 insertionâ€“positive nonâ€“small cell lung cancer. <i>Cancer</i> , 2024, 130, 683-691.	4.1	1
20851	Successful Treatment of Concurrent Follicular Lymphoma and Triple-Negative Breast Cancer Using Rituximab Plus Nab-Paclitaxel and Cisplatin: A Case Report and Literature Review. <i>OncoTargets and Therapy</i> , 0, Volume 16, 905-911.	2.0	0

#	ARTICLE	IF	CITATIONS
20852	Results of salvage neck dissection after chemoradiation in locally advanced head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 0, , .	1.6	0
20853	Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability. <i>Acta Oncol</i> 62, 1921-1930.	1.8	0
20854	AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1966-1969.	2.5	1
20855	Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies. <i>British Journal of Cancer</i> , 2024, 130, 135-142.	6.4	1
20856	First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2024, 30, 506-521.	7.0	1
20857	The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2024, 196, 113441.	2.8	1
20858	Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20859	Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study). <i>Cancers</i> , 2023, 15, 5568.	3.7	0
20860	Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
20861	Impact of <i>Helicobacter pylori</i> infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. , 2023, 11, e007699.		3
20862	Evaluating the Effectiveness of 2D and 3D CT Image Features for Predicting Tumor Response to Chemotherapy. <i>Bioengineering</i> , 2023, 10, 1334.	3.5	0
20863	Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor. <i>Japanese Journal of Clinical Oncology</i> , 2024, 54, 201-205.	1.3	0
20864	Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study. <i>International Immunopharmacology</i> , 2023, 125, 111147.	3.8	0
20865	Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008â€“2022 update. <i>Tumor Biology</i> , 2023, , 1-51.	1.8	1
20866	Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
20867	Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	0
20868	Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. , 2023, 11, e007784.		0
20869	Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population. <i>Biomedicines</i> , 2023, 11, 2933.	3.2	0

#	ARTICLE	IF	CITATIONS
20870	TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
20871	Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells. <i>Clinical Cancer Research</i> , 0, , .	7.0	0
20873	Pancreatic cancer outcomeâ€”local treatment with radiation using MRI-LINAC. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
20874	Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study). <i>Cancer Treatment and Research Communications</i> , 2023, 37, 100772.	1.7	0
20875	CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors. <i>European Radiology</i> , 0, , .	4.5	1
20876	TO MARKET, TO MARKETâ€”2022: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 713-798.	0.1	0
20877	Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience. <i>Journal of Cardiothoracic Surgery</i> , 2023, 18, .	1.1	0
20878	Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
20879	Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1733-1742.	2.5	0
20880	Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. <i>Clinical Trials</i> , 2024, 21, 40-50.	1.6	1
20881	The Efficacy of Immunotherapy and Clinical Utility of Comprehensive Genomic Profiling in Adenoid Cystic Carcinoma of Head and Neck. <i>Medicina (Lithuania)</i> , 2023, 59, 2111.	2.0	0
20882	Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation. <i>Current Oncology</i> , 2023, 30, 10019-10032.	2.2	0
20883	Falseâ€”positive supraclavicular lymph node detected on chest computed tomography in oncology patients: Clinical implication based on subsequent neck ultrasonography and ultrasonographyâ€”guided tissue sampling. <i>Journal of Clinical Ultrasound</i> , 2023, 51, 1589-1595.	0.8	1
20884	Imaging of cervical cancer. Consensus of experts. <i>Medical Visualization</i> , 0, , .	0.4	0
20885	Colorectal liver metastases: Correlations of contrast-enhanced ultrasound features with tumor clinicopathological factors and clinical outcomes following conversion therapy. <i>Clinical Hemorheology and Microcirculation</i> , 2023, , 1-18.	1.7	0
20886	Metastases and treatment-resistant lineages in patient-derived cancer cells of colorectal cancer. <i>Communications Biology</i> , 2023, 6, .	4.4	0
20887	Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	0
20888	HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
20889	Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Japanese Journal of Clinical Oncology, 2024, 54, 206-211.	1.3	1
20890	Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51, 1121-1132.	6.4	1
20892	Chinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis. Integrative Medicine Research, 2023, 12, 101004.	1.8	0
20893	Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801). , 2023, , .		0
20894	Sample size determination and evaluation for two-stage adaptive designs of single arm clinical trials based on median event time test. Contemporary Clinical Trials Communications, 2023, 36, 101225.	1.1	0
20895	Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with nonâ€squamous nonâ€small cell lung cancer after bevacizumab treatment. Asia-Pacific Journal of Clinical Oncology, 0, , .	1.1	0
20896	Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status. Targeted Oncology, 2023, 18, 915-925.	3.6	0
20897	Efficacy of high-dose-rate brachytherapy with different radiation source activities among cervical cancer patients and risk factors for long-term outcomes: A 6-year retrospective study. Brachytherapy, 2023, , .	0.5	0
20898	Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study. Surgery Open Science, 2023, 16, 171-183.	1.2	0
20899	What is the predictive value of RECIST criteria following stereotactic lung radiation?. Radiotherapy and Oncology, 2024, 190, 109976.	0.6	0
20900	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2023, , 233-250.		0
20901	Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody. Breast, 2023, 72, 103597.	2.2	0
20902	Clinical implications of PNAâ€sequencing as a complementary test for EGFR mutation analysis in human lung cancer. Oncology Letters, 2023, 26, .	1.8	0
20903	PADRES (NCT03438708): Phase 2 Clinical Trial of Neoadjuvant Axitinib for Complex Partial Nephrectomy. BJU International, 0, , .	2.5	0
20904	Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers. Thyroid, 2024, 34, 70-81.	4.5	2
20905	Intratumoral and Peritumoral Radiomics Based on Preoperative <sc>MRI</sc> for Evaluation of Programmed Cell Death Ligandâ€1 Expression in Breast Cancer. Journal of Magnetic Resonance Imaging, 0, , .	3.4	0
20906	Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma. Clinical Lung Cancer, 2023, , .	2.6	0
20907	How Does Target Lesion Selection Affect RECIST? A Computer Simulation Study. Investigative Radiology, 0, , .	6.2	0

#	ARTICLE	IF	CITATIONS
20908	Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncology, 2023, 147, 106587.	1.5	1
20909	Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet, The, 2023, 402, 2295-2306.	13.7	4
20910	Yttrium-90 Transarterial Radioembolization of Primary Lung Cancer Metastases to the Liver. Journal of Vascular and Interventional Radiology, 2024, 35, 214-225.e2.	0.5	1
20911	Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series. Biomedicines, 2023, 11, 2974.	3.2	1
20912	An integrated model combined intra- and peritumoral regions for predicting chemoradiation response of non small cell lung cancers based on radiomics and deep learning. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2023, 27, 705-711.	1.4	1
20913	Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients. Heliyon, 2023, 9, e21853.	3.2	1
20914	Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2024, 93, 151-159.	2.3	0
20915	Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study. ELife, 0, 12, .	6.0	0
20916	Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy. Cancer Management and Research, 0, Volume 15, 1251-1262.	1.9	0
20917	Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations. , 2023, 84, 1244.		0
20918	Efficacy of neoadjuvant therapy for lung squamous cell carcinoma and lung adenocarcinoma: A retrospective comparative study. Oncology Letters, 2023, 26, .	1.8	0
20919	Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy. Cancer Imaging, 2023, 23, .	2.8	0
20921	Borderline Resectable and Locally Advanced Pancreatic Cancer. , 2023, , 19-35.		0
20922	A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology, 2023, , .	5.4	0
20923	Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. Journal of Clinical Investigation, 2024, 134, .	8.2	4
20924	ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial. , 2023, 1, 3-8.		1
20927	Effect of denosumab in treatment of unresectable spine and sacrum giant cell tumor of bone. Musculoskeletal Surgery, 2024, 108, 93-98.	1.5	1
20929	Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial. CardioVascular and Interventional Radiology, 2024, 47, 253-262.	2.0	0

#	ARTICLE	IF	CITATIONS
20930	An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors. <i>Journal of Cutaneous Medicine and Surgery</i> , 2023, 27, 614-620.	1.2	0
20932	The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. <i>Medicine (United States)</i> , 2023, 102, e35950.	1.0	1
20933	The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0
20935	Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0
20936	Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. <i>European Journal of Cancer</i> , 2024, 196, 113437.	2.8	0
20937	Impact of anticancer drugs on the therapeutic efficacy and side effects of hepatic arterial embolization for hepatocellular carcinoma. <i>JGH Open</i> , 2023, 7, 884-888.	1.6	0
20938	Maintenance avelumab therapy for urothelial carcinoma in a hemodialysis patient: a case report. <i>International Cancer Conference Journal</i> , 0, , .	0.5	0
20939	Brain metastasis tumor segmentation and detection using deep learning algorithms: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2024, 190, 110007.	0.6	0
20940	Oligo- like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 0, , .	2.4	0
20941	Resection of anorectal fistula cancer associated with Crohn's disease after preoperative chemoradiotherapy: a case report. <i>Surgical Case Reports</i> , 2023, 9, .	0.6	0
20942	Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. <i>Cancer</i> , 2024, 130, 985-994.	4.1	0
20944	Methodology for Good Machine Learning with Multi-Omics Data. <i>Clinical Pharmacology and Therapeutics</i> , 2024, 115, 745-757.	4.7	1
20945	Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. <i>Journal of Hepatology</i> , 2024, 80, 431-442.	3.7	1
20946	Whole tumor based texture analysis of magnetic resonance diffusion imaging for colorectal liver metastases: A prospective study for diffusion model comparison and early response biomarker. <i>European Journal of Radiology</i> , 2024, 170, 111203.	2.6	0
20947	Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1784-1794.	2.5	1
20948	Factors of oncological failure in two stage hepatectomy for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2024, 50, 107267.	1.0	0
20949	Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. <i>Npj Breast Cancer</i> , 2023, 9, .	5.2	0
20950	Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer. <i>JAMA Network Open</i> , 2023, 6, e2343512.	5.9	0

#	ARTICLE	IF	CITATIONS
20951	Small Molecules as Vectors for Radiopharmaceutical Therapy. , 2023, , 349-367.		0
20952	Machine Learning-Based MRI Radiogenomics for Evaluation of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. Academic Radiology, 2023, , .	2.5	1
20953	BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial. EClinicalMedicine, 2023, 66, 102318.	7.1	0
20954	BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy. Journal of Pathology and Translational Medicine, 2023, 57, 323-331.	1.1	0
20955	A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Poncegromab in Participants with Cancer and Cachexia. Clinical Cancer Research, 2024, 30, 489-497.	7.0	0
20956	Selective Personalized Radioimmunotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer Trial (SPRINT). Journal of Clinical Oncology, 2024, 42, 562-570.	1.6	1
20957	Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. European Journal of Cancer, 2024, 196, 113425.	2.8	0
20958	Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group. Advances in Therapy, 0, , .	2.9	0
20960	Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas. Annals of Diagnostic Pathology, 2024, 68, 152239.	1.3	1
20961	Eosinophil may be a predictor of immuneâ€“related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer Medicine, 0, , .	2.8	0
20963	Novel ensemble feature selection techniques applied to high-grade gastroenteropancreatic neuroendocrine neoplasms for the prediction of survival. Computer Methods and Programs in Biomedicine, 2024, 244, 107934.	4.7	0
20964	In Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Ductal Adenocarcinoma, Which Response is the More Reliable Indicator for Prognosis, Radiologic or Biochemical?. Annals of Surgical Oncology, 0, , .	1.5	1
20965	Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer. International Journal of Molecular Sciences, 2023, 24, 16602.	4.1	0
20966	Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Nonâ€“Smallâ€“Cell Lung Cancer. Clinical Lung Cancer, 2023, , .	2.6	0
20967	First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations. JAMA Oncology, 2024, 10, 43.	7.1	3
20968	Pre- and Post-treatment Double-Sequential-Point Dynamic Radiomic Model in the Response Prediction of Gastric Cancer to Neoadjuvant Chemotherapy: 3-Year Survival Analysis. Annals of Surgical Oncology, 0, , .	1.5	0
20969	Cytoreduction Plus Hyperthermic Intraperitoneal Chemotherapy in Primary and Recurrent Ovarian Cancer: A Single-Center Cohort Study. Surgeries, 2023, 4, 590-599.	0.6	0
20970	Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. International Journal of Clinical Oncology, 2024, 29, 188-194.	2.2	0

#	ARTICLE	IF	CITATIONS
20971	Efficacy and quality of life for FOLFOX/bevacizumab +/â” irinotecan in first-line metastatic colorectal cancerâ” final results of the AIO CHARTA trial. British Journal of Cancer, 0, , .	6.4	0
20972	Surgery versus radiotherapy for limited-stage small cell esophageal carcinoma: a multicenter, retrospective, cohort study in China (ChiSCEC). International Journal of Surgery, 2024, 110, 956-964.	2.7	1
20973	Clinicopathologic Features and Prognosis of Female Early Breast Cancer With HER2 Low Expression: A Propensity Score Matched Analysis. Clinical Medicine Insights: Oncology, 2023, 17, .	1.3	0
20974	Carboplatin and paclitaxel after <scp>antiâ”PD</scp>â”1 or <scp>antiâ”PDâ”L1</scp> antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck. Head and Neck, 0, , .	2.0	0
20975	Analysis of treatment response based on 1.5T magnetic resonance imaging texture analysis in stereotactic body radiotherapy of hepatocellular carcinoma. Journal of Radiation Research and Applied Sciences, 2024, 17, 100759.	1.2	0
20976	Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging. Abdominal Radiology, 2024, 49, 801-813.	2.1	0
20977	Clinical outcomes of Epsteinâ”Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy. Gastric Cancer, 0, , .	5.3	1
20978	Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Scientific Reports, 2023, 13, .	3.3	0
20979	Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation. Life, 2023, 13, 2267.	2.4	0
20980	Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. JTO Clinical and Research Reports, 2024, 5, 100613.	1.1	0
20981	Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART). Radiotherapy and Oncology, 2024, 190, 110034.	0.6	0
20982	Tumor endothelial cell autophagy is a key vascularâ”immune checkpoint in melanoma. EMBO Molecular Medicine, 2023, 15, .	6.9	1
20983	Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinumâ”resistant ovarian cancer. Cancer, 2024, 130, 1061-1071.	4.1	0
20984	Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry. ESMO Open, 2023, 8, 102045.	4.5	1
20985	Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemotherapy and Pharmacology, 0, , .	2.3	0
20986	Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. JAMA Network Open, 2023, 6, e2345185.	5.9	1
20987	The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer. BMC Cancer, 2023, 23, .	2.6	0
20988	Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): aâ”prospective observational study. ESMO Open, 2023, 8, 102071.	4.5	0

#	ARTICLE	IF	CITATIONS
20989	Extended <sc>ICI</sc> treatment after firstâ€line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced nonâ€small lung cancer: Post hoc analysis from <sc>NEJ051</sc> (<sc>REACTIVE</sc> study). Thoracic Cancer, 0, , .	1.9	0
20990	Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer. Scientific Reports, 2023, 13, .	3.3	0
20992	Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2023, 24, 1334-1348.	10.7	13
20993	Application and development of Deuterium Metabolic Imaging in tumor glucose metabolism: visualization of different metabolic pathways. Frontiers in Oncology, 0, 13, .	2.8	0
20995	Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study. RMD Open, 2023, 9, e003795.	3.8	0
20996	Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs. Scientific Reports, 2023, 13, .	3.3	1
20998	A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Research and Treatment, 0, , .	2.5	0
20999	PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. BMC Cancer, 2023, 23, .	2.6	0
21000	Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open, 2023, 13, e077427.	1.9	0
21001	Inflammation and Immunity Gene Expression Patterns and Machine Learning Approaches in Association with Response to Immune-Checkpoint Inhibitors-Based Treatments in Clear-Cell Renal Carcinoma. Cancers, 2023, 15, 5637.	3.7	0
21002	Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinoma. Cancer Medicine, 0, , .	2.8	0
21003	Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology, 2023, , .	3.0	0
21004	A study on short-term efficacy and safety of Iodine-125 brachytherapy coupled with preoperative arterial chemoembolization for hypervascular spinal metastasis. Brachytherapy, 2023, , .	0.5	0
21005	A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). European Journal of Cancer, 2024, 197, 113469.	2.8	1
21006	Impact of telephone follow-up on hepatocellular carcinoma patients receiving oral chemotherapy from an ambulatory-care setting. Journal of Oncology Pharmacy Practice, 0, , .	0.9	0
21007	TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Nonâ€Small Cell Lung Cancer. Clinical Cancer Research, 2024, 30, 779-785.	7.0	0
21008	Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer. JAMA - Journal of the American Medical Association, 2023, 330, 2064.	7.4	5
21009	Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI. Future Oncology, 0, , .	2.4	0

#	ARTICLE	IF	CITATIONS
21010	Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSÅ©-ESMART Trial. <i>Clinical Cancer Research</i> , 2024, 30, 741-753.	7.0	0
21011	Promising Therapeutic Activity of 177Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2024, 49, 131-137.	1.3	1
21012	Efficacy and safety of iruplinalkib (WXâ€™0593) on nonâ€™small cell lung cancer with <i>SPECC1Lâ€™ALK</i> fusion: A case report. <i>Experimental and Therapeutic Medicine</i> , 2023, 27, .	1.8	0
21013	Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
21014	Delta Radiomics Based on Longitudinal Dual-modal Ultrasound Can Early Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Academic Radiology</i> , 2023, , .	2.5	0
21016	Clinical significance of baseline Epsteinâ€™Barr virus DNAâ€™for recurrent or metastatic primary pulmonary lymphoepithelioma-like carcinoma. <i>Future Oncology</i> , 0, , .	2.4	0
21017	Towards detection of early response in neoadjuvant chemotherapy of breast cancer using Bayesian intravoxel incoherent motion. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
21018	Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	3.9	0
21019	Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. <i>Cancers</i> , 2023, 15, 5717.	3.7	0
21021	The surgical and clinicopathological characteristics of primary mucinous ovarian cancer: a single institution 30-year retrospective analysis. <i>Journal of the Turkish German Gynecology Association</i> , 2023, 24, 252-260.	0.6	0
21022	Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response. <i>Cancer Biomarkers</i> , 2024, 39, 137-153.	1.7	0
21023	An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. <i>Nature</i> , 2024, 625, 166-174.	27.8	6
21024	HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2024, 180, 91-98.	1.4	0
21025	Deep learning-based segmentation of multisite disease in ovarian cancer. <i>European Radiology Experimental</i> , 2023, 7, .	3.4	0
21026	ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3Î² and integrin Î²1-mediated phosphorylation of FAK. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	0
21027	Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials. <i>Radiotherapy and Oncology</i> , 2024, 190, 110048.	0.6	0
21028	Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. <i>Acta Oto-Laryngologica</i> , 2023, 143, 925-930.	0.9	0
21029	Treatment strategy for successful conversion surgery in clinical stage IVB gastric cancer. <i>European Journal of Surgical Oncology</i> , 2024, 50, 107314.	1.0	0

#	ARTICLE	IF	CITATIONS
21030	CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. Journal of Thoracic Oncology, 2023, , .	1.1	1
21031	Essentials of Theranostics: A Guide for Physicians and Medical Physicists. Radiographics, 2024, 44, .	3.3	0
21032	Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. JCO Precision Oncology, 2023, , .	3.0	0
21033	Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis. Clinical and Translational Radiation Oncology, 2024, 45, 100708.	1.7	0
21034	Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58	7.4	0
21035	Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase Ib Trial. International Journal of Radiation Oncology Biology Physics, 2023, , .	0.8	0
21037	Volumetric Analysis: Rethinking Brain Metastases Response Assessment. Neuro-Oncology Advances, 0, , .	0.7	0
21038	Atezolizumab and bevacizumab for nonâ€resectable or metastatic combined hepatocellularâ€cholangiocarcinoma: AÂmulticentric retrospective study. United European Gastroenterology Journal, 0, , .	3.8	0
21039	Treatmentâ€related neuroendocrine prostate cancer with <i>BRCA2</i> germline mutation treated with olaparib. IJU Case Reports, 2024, 7, 115-119.	0.3	0
21040	A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma. Phenomics, 2023, 3, 549-564.	2.9	2
21041	Eliciting the antitumor immune response with a conditionally activated PDâ€1 targeting antibody analyzed with a quantitative systems pharmacology model. CPT: Pharmacometrics and Systems Pharmacology, 0, , .	2.5	0
21042	Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors. Targeted Oncology, 0, , .	3.6	0
21043	LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma. OncoImmunology, 2024, 13, .	4.6	2
21044	Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Annals of Oncology, 2024, 35, 221-228.	1.2	0
21045	Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy. Clinical and Translational Oncology, 0, , .	2.4	0
21046	Clinicopathological Evaluation of Patients with Hormone Receptorâ€Positive HER2-Negative Metastatic Breast Cancer Progressing on Endocrine Treatment: A Real-World Retrospective Study from a Regional Cancer Center. South Asian Journal of Cancer, 0, , .	0.6	0
21047	Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer. Clinical and Translational Oncology, 0, , .	2.4	0
21048	Comparison of clinical value and diagnostic rate between barium meal radiography and spectral CT scan in the diagnosis and treatment of gastric cancer and benign gastric tumor. , 2023, 21, 639-645.		0

#	ARTICLE	IF	CITATIONS
21050	Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2023, , .	1.5	0
21051	ASO Author Reflections: What is the Optimal Method for Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Cancer?. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
21053	Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	2
21054	Correlation of Radiomics with Treatment Response in Liver Metastases. <i>Academic Radiology</i> , 2023, , .	2.5	0
21055	The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma. <i>Surgical Oncology</i> , 2024, 52, 102027.	1.6	0
21056	Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies. <i>Cancers</i> , 2023, 15, 5778.	3.7	0
21057	Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab. <i>Cancers</i> , 2023, 15, 5780.	3.7	0
21058	Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2024, 197, 113478.	2.8	0
21060	EVALUATION OF VOLUMETRIC RESPONSE ASSESSMENT FROM STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR RENAL CELL CARCINOMA (RCC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, , .	0.8	0
21062	Postoperative recurrence detection using individualized circulating tumor <scp>DNA</scp> in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2024, 115, 529-539.	3.9	1
21064	Successful liver transplantation with ctDNA clearance after PD-1 inhibitor plus FOLFOX+HAIC treatment in HCC: A case report. <i>Oncology Letters</i> , 2023, 27, .	1.8	0
21065	Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2024, 21, 101-124.	17.8	6
21066	The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
21067	Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer. <i>Future Oncology</i> , 2023, 19, 2147-2155.	2.4	0
21068	A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 18215-18240.	2.5	1
21069	Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies. <i>Cell Reports Medicine</i> , 2023, 4, 101311.	6.5	0
21070	Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. <i>European Journal of Cancer</i> , 2024, 198, 113480.	2.8	0
21071	Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study. <i>Clinical and Experimental Medicine</i> , 2023, 23, 5129-5138.	3.6	0

#	ARTICLE	IF	CITATIONS
21072	Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer. World Journal of Surgical Oncology, 2023, 21, .	1.9	0
21073	Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer?. European Journal of Radiology, 2024, 170, 111270.	2.6	0
21074	Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases. European Radiology Experimental, 2023, 7, .	3.4	0
21075	Biomarkers in Cancer Detection, Diagnosis, and Prognosis. Sensors, 2024, 24, 37.	3.8	0
21076	Role of morphofunctional imaging in assessing residual disease after neoadjuvant chemotherapy. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2023, 182, .	0.1	0
21077	Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer. JAMA Oncology, 0, , .	7.1	0
21078	<scp>HS</scp>â€10352 in hormone receptorâ€positive, <scp>HER2</scp>â€negative advanced breast cancer: A phase 1 doseâ€escalation trial. Cancer Medicine, 2023, 12, 21849-21860.	2.8	0
21079	ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	0
21080	Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 0, , .	7.0	0
21081	Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2023, 9, 1629.	7.1	2
21082	A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Nonâ€Small-Cell Lung Cancer. Clinical Lung Cancer, 2024, 25, 128-134.	2.6	0
21083	A Phase II Basket Trial of Dual Antiâ€CTLA-4 and Antiâ€PD-1 Blockade in Rare Tumors (DART SWOG 1609) Tj ETQq1 1 0.784314 rgBT OF1-OF6.	7.0	0
21084	Differential expression of KIF18B in gastric cancer and its role in chemotherapy sensitivity. Critical Reviews in Eukaryotic Gene Expression, 2023, , .	0.9	0
21085	PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study. Frontiers in Oncology, 0, 13, .	2.8	0
21087	Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2023, , .	5.4	1
21088	Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Japanese Journal of Clinical Oncology, 0, , .	1.3	3
21090	Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy. International Journal of Clinical Oncology, 0, , .	2.2	0
21092	Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. , 2023, 11, e007586.		2

#	ARTICLE	IF	CITATIONS
21093	Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer. Radiotherapy and Oncology, 2024, 190, 110022.	0.6	0
21094	Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol. Heliyon, 2024, 10, e23170.	3.2	0
21095	Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer. Cureus, 2023, , .	0.5	0
21096	Siamese Delta Network with Multimodality Fusion for Systemic Treatment Response Prediction in Pancreatic Cancer*. , 2023, , .		0
21097	Bench to Bedside Development of [18F]Fluoromethyl-(1,2-2H4)choline ([18F]D4-FCH). Molecules, 2023, 28, 8018.	3.8	0
21098	An increased relative eosinophil count as a predictive dynamic biomarker in nonâ€small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer, 0, , .	1.9	0
21099	Resolution of the expert council on the question of strategy of tyrosine kinase inhibitor therapy initiation in differentiated thyroid cancer. Opuholi Golovy I Sei, 2023, 13, 106-110.	0.4	0
21100	Precision therapy for intrahepatic cholangiocarcinoma: A case report on adjuvant treatment in a recurrent patient after surgery and literature review. Oncology Letters, 2023, 27, .	1.8	1
21102	Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1â€High (â‰¥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. Journal of Thoracic Oncology, 2023, , .	1.1	2
21103	The Multipurpose Usage of Diffusion-Weighted MRI in Rectal Cancer. Medicina (Lithuania), 2023, 59, 2162.	2.0	0
21104	Cardiophrenic lymph nodes in advanced ovarian cancer. International Journal of Gynecological Cancer, 2024, 34, 150-158.	2.5	1
21105	Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific. Oral Oncology, 2024, 148, 106657.	1.5	0
21106	Management of pheochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nature Reviews Endocrinology, 2024, 20, 168-184.	9.6	1
21107	Dabrafenib plus trametinib in unselected advanced BRAF V600â€mut melanoma: a non-interventional, multicenter, prospective trial. Melanoma Research, 2024, 34, 142-151.	1.2	0
21108	Oxidative Stress Induced by Chemotherapy: Evaluation of Glutathione and Its Related Antioxidant Enzyme Dynamics in Patients with Colorectal Cancer. Nutrients, 2023, 15, 5104.	4.1	2
21109	Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2023, , .	3.0	0
21110	Solid tumours showing oligoprogression to immune checkpoint inhibitors have the potential for abscopal effects. Japanese Journal of Radiology, 0, , .	2.4	0
21111	Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery. Frontiers in Oncology, 0, 13, .	2.8	2

#	ARTICLE	IF	CITATIONS
21112	Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer, 2024, 188, 107442.	2.0	0
21113	Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma. Medicina (Lithuania), 2023, 59, 2174.	2.0	0
21114	Clinical features and prognosis of cardiac metastatic tumors. BMC Cancer, 2023, 23, .	2.6	0
21115	Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer. Cancers, 2023, 15, 5862.	3.7	0
21116	Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision. Computerized Medical Imaging and Graphics, 2024, 111, 102312.	5.8	0
21117	Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 2024, 130, 425-433.	6.4	0
21118	Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial). Annals of Surgical Oncology, 0, , .	1.5	1
21120	Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events. Clinical Genitourinary Cancer, 2024, 22, 368-379.	1.9	0
21121	Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study. BMC Cancer, 2023, 23, .	2.6	0
21122	Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes. Endocrine, 0, , .	2.3	1
21123	Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States. Endocrine, 0, , .	2.3	0
21124	Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Annals of Surgical Oncology, 2024, 31, 2640-2653.	1.5	1
21125	Successful treatment with trastuzumab plus chemotherapy as the first-line regimen in advanced small bowel adenocarcinoma harboring HER2 amplification: A report of two cases. Oncology Letters, 2023, 27, .	1.8	0
21126	Practice and principles of stereotactic body radiation therapy for spine and non-spine bone metastases. Clinical and Translational Radiation Oncology, 2024, 45, 100716.	1.7	0
21127	Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncology, 2024, 149, 106664.	1.5	0
21128	Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea. Targeted Oncology, 0, , .	3.6	0
21129	Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice. International Journal of Molecular Sciences, 2023, 24, 17628.	4.1	0
21130	Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
21131	Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 7761.	2.4	0
21132	Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene <i>KDM6A</i> mutation. , 2023, 2, e000199.		0
21133	Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies. <i>European Journal of Cancer</i> , 2024, 198, 113503.	2.8	0
21135	The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III&IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy"What Can Be Learned From Progression?. <i>Clinical Nuclear Medicine</i> , 0, , .	1.3	0
21136	Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study. <i>Prostate International</i> , 2023, , .	2.3	0
21137	Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)&supcirc;. <i>Journal of the National Cancer Center</i> , 2023, , .	7.4	0
21138	Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2024, 194, 104230.	4.4	0
21139	Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
21140	A Novel Method for Evaluating Early Tumor Response Based on Daily CBCT Images for Lung SBRT. <i>Cancers</i> , 2024, 16, 20.	3.7	0
21141	A comparative study of elective nodal irradiation and involved field irradiation in elderly patients with advanced esophageal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
21142	A European Society of Oncologic Imaging (ESOI) survey on the radiological assessment of response to oncologic treatments in clinical practice. <i>Insights Into Imaging</i> , 2023, 14, .	3.4	1
21143	PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. <i>Oral Oncology</i> , 2024, 149, 106634.	1.5	0
21144	Increase in creatinine levels associated with niraparib maintenance therapy in ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2024, 50, 501-507.	1.3	0
21145	Effectiveness of Head-and-Neck Molecular Imaging Reporting and Data System Criterion in Head-and-Neck Squamous Cell Carcinoma PostConcurrent Chemoradiotherapy. <i>Indian Journal of Nuclear Medicine</i> , 2023, 38, 334-339.	0.3	0
21146	Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2024, 34, 166-174.	1.2	0
21147	Rapid transformation of branched pancreatic duct-derived intraductal tubulopapillary neoplasm into an invasive carcinoma: A case report. <i>World Journal of Clinical Oncology</i> , 0, 14, 620-627.	2.3	0
21148	Prediction of¹⁷⁷Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. <i>Journal of Nuclear Medicine</i> , 2024, 65, 236-244.	5.0	1
21149	FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2024, 42, 605-613.	1.6	0

#	ARTICLE	IF	CITATIONS
21150	Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2024, 170, 828-836.	1.9	0
21151	Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2024, 10, 315.	7.1	0
21152	<i>BLM</i> mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21153	NRGâ€“GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. <i>Cancer</i> , 0, , .	4.1	0
21154	A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials. <i>Clinical Cancer Research</i> , 2024, 30, 877-882.	7.0	0
21155	Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
21156	Serum <i>CXCL10</i> levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced <i>BCLC</i> stage C hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21157	NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. <i>British Journal of Cancer</i> , 2024, 130, 476-482.	6.4	0
21158	S-1 maintenance therapy in advanced gastric cancer without disease progression after first-line chemotherapy: A retrospective analysis. <i>Science Progress</i> , 2023, 106, .	1.9	0
21159	Prognostic Significance of Câ€“Reactive Protein in Unresectable Hepatocellular Carcinoma treated with Atezolizumab and Bevacizumab. <i>Hepatology Research</i> , 0, , .	3.4	0
21160	Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>International Journal of Gynecological Cancer</i> , 0, , <i>ijgc-2023-004995</i> .	2.5	0
21161	The Association Between an Electronic Health Record (EHR)â€“Embedded Frailty Index and Patient-Reported Outcomes Among Patients with Metastatic Nonâ€“Small-Cell Lung Cancer on Immunotherapy: A Brief Report. <i>American Journal of Hospice and Palliative Medicine</i> , 0, , .	1.4	0
21162	Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
21163	Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid <i>NGS</i> after firstâ€“line <i>EGFR</i> inhibitor resistance in lung cancer. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21164	Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study. <i>Swiss Medical Weekly</i> , 2023, 153, 3504.	1.6	0
21165	The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (<i>TOG</i>) study. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21166	Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). <i>Annals of Oncology</i> , 2024, 35, 267-275.	1.2	0
21168	Nivolumab in sorafenib-naïve and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. <i>Annals of Oncology</i> , 2023, , .	1.2	0

#	ARTICLE	IF	CITATIONS
21169	Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0
21170	The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers. <i>Genes</i> , 2024, 15, 27.	2.4	0
21171	Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma. <i>Pharmaceuticals</i> , 2024, 17, 25.	3.8	0
21172	NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08). , 2023, 2, e000065.		1
21173	Hematologic Cancers. , 2023, , 441-511.		0
21174	CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	1
21175	Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. , 2024, 3, .		2
21176	Locoregional Ablative Radiation Therapy for Patients With Breast Cancer Unsuitable for Surgical Resection. <i>Practical Radiation Oncology</i> , 2023, , .	2.1	0
21177	Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
21178	Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience. <i>Thoracic Cancer</i> , 2024, 15, 339-346.	1.9	0
21179	LATTE: Label-efficient incident phenotyping from longitudinal electronic health records. <i>Patterns</i> , 2023, , 100906.	5.9	0
21180	Treatment of non-small cell lung cancer with Yiqi Buxue prescriptions combined with adjuvant chemotherapy on the cancer therapy-related cardiovascular toxicity: A systematic review and meta-analysis. <i>Journal of Ethnopharmacology</i> , 2023, , 117665.	4.1	1
21181	Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A multi-center, real-world study. <i>Hepatology Research</i> , 0, , .	3.4	0
21182	The Role of PET/CT in Lung Cancer Radiotherapy. , 2023, 9, 161-170.		0
21183	Value of CT-based radiomics in evaluating the response of bone metastases to systemic drug therapy in breast cancer patients. <i>Thoracic Cancer</i> , 2024, 15, 361-368.	1.9	0
21184	Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2024, 16, 175.	3.7	0
21186	Spleen dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 680-691.	3.7	0
21187	Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2023, , .	1.1	1

#	ARTICLE	IF	CITATIONS
21188	Prevalence of germline <i>BRCA1/2</i> pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice. Japanese Journal of Clinical Oncology, 2024, 54, 489-497.	1.3	1
21189	Ct-based subregional radiomics using hand-crafted and deep learning features for prediction of therapeutic response to anti-PD1 therapy in NSCLC. Physica Medica, 2024, 117, 103200.	0.7	0
21190	Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy. European Urology Focus, 2023, , .	3.1	0
21191	Functional information guided adaptive radiation therapy. Frontiers in Oncology, 0, 13, .	2.8	0
21192	Quarter-Century Transformation of Oncology. PET Clinics, 2024, 19, 147-162.	3.0	0
21193	Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives. Cancer Treatment and Research, 2023, , 105-147.	0.5	0
21194	RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma. BMC Urology, 2024, 24, .	1.4	0
21195	Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Frontiers in Endocrinology, 0, 14, .	3.5	1
21196	Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature Communications, 2024, 15, .	12.8	3
21197	Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy. PLoS ONE, 2024, 19, e0296253.	2.5	0
21199	ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Research, 2024, 34, 58-75.	12.0	0
21200	Theoretical understanding of evolutionary dosing following tumor dynamics. Chaos, Solitons and Fractals, 2024, 179, 114451.	5.1	0
21201	Anemia in patients 5-75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model. BMC Urology, 2024, 24, .	1.4	0
21202	Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final) Tj ETQq1 1 0.784314 rgBT /Overlock	5.2	0
21203	A protocol for a randomized trial evaluating the role of ¹² C-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer Medicine, 2024, 13, .	2.8	0
21204	Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). Lung Cancer, 2024, 188, 107455.	2.0	0
21205	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Communications, 2024, 44, 127-172.	9.2	2
21206	Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI. British Journal of Radiology, 2024, 97, 228-236.	2.2	0

#	ARTICLE	IF	CITATIONS
21207	Bayesian Methods for Information Borrowing in Basket Trials: An Overview. <i>Cancers</i> , 2024, 16, 251.	3.7	0
21208	Assessing the effect of scanning parameter on the size and density of pulmonary nodules: a phantom study. <i>BMC Medical Imaging</i> , 2024, 24, .	2.7	0
21209	Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). <i>Journal of Clinical Oncology</i> , 2024, 42, 898-906.	1.6	1
21210	Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. <i>Medical Journal of Australia</i> , 2024, 220, 80-90.	1.7	0
21211	Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. <i>Clinical Colorectal Cancer</i> , 2024, 23, 104-110.	2.3	0
21212	Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2024, 204, 617-629.	2.5	0
21213	The outcomes of different regimens depend on the molecular subtypes of pulmonary largeâ€œcell neuroendocrine carcinoma: A retrospective study in China. <i>Cancer Medicine</i> , 2024, 13, .	2.8	1
21214	Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer. <i>Npj Breast Cancer</i> , 2024, 10, .	5.2	1
21215	Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome. <i>Breast Cancer Research and Treatment</i> , 2024, 204, 497-507.	2.5	0
21216	Gut microbiome for predicting immune checkpoint blockade-associated adverse events. <i>Genome Medicine</i> , 2024, 16, .	8.2	0
21217	Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression â‰¥49%: a multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21218	Impact of Dysregulated LINC01559 and LINC01410 Expression on the Diagnosis and Survival of Non-Small Cell Lung Cancer. <i>Biochemical Genetics</i> , 0, , .	1.7	0
21219	Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2024, 29, 124-133.	2.2	0
21220	Applicability of the CT Radiomics of Skeletal Muscle and Machine Learning for the Detection of Sarcopenia and Prognostic Assessment of Disease Progression in Patients with Gastric and Esophageal Tumors. <i>Diagnostics</i> , 2024, 14, 198.	2.6	0
21221	New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders. <i>Clinical Breast Cancer</i> , 2024, , .	2.4	0
21222	Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck. <i>Oncology</i> , 2023, 101, 502-511.	1.9	0
21223	COSMIC:Âa curated database of somatic variants and clinical data for cancer. <i>Nucleic Acids Research</i> , 2024, 52, D1210-D1217.	14.5	10
21224	Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). <i>BJS Open</i> , 2023, 7, .	1.7	1

#	ARTICLE	IF	CITATIONS
21225	Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT. <i>Cancers</i> , 2024, 16, 200.	3.7	0
21226	Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial. <i>Nature Communications</i> , 2024, 15, .	12.8	0
21227	Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study. <i>PLoS ONE</i> , 2024, 19, e0294590.	2.5	1
21228	Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B. <i>Cancer</i> , 2024, 130, 1693-1701.	4.1	0
21229	Evaluation of Three Imaging Methods to Quantify Key Events in Pelvic Bone Metastasis. <i>Cancers</i> , 2024, 16, 214.	3.7	0
21230	The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on 1 line of endocrine therapy: systematic review and meta-analysis. <i>BMC Cancer</i> , 2024, 24, .	2.6	1
21231	Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study. <i>World Journal of Surgical Oncology</i> , 2024, 22, .	1.9	3
21232	Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. <i>Annals of Surgical Oncology</i> , 2024, 31, 1919-1932.	1.5	3
21233	Ninetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis. <i>Lung Cancer</i> , 2024, 188, 107468.	2.0	0
21234	Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. <i>EClinicalMedicine</i> , 2024, 67, 102403.	7.1	0
21235	Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
21236	Transcriptomic and metabolomic analysis of peri-tumoral hepatic tissue in hepatocellular carcinoma: unveiling the molecular landscape of immune checkpoint therapy resistance. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
21237	Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib. <i>Therapeutic Advances in Medical Oncology</i> , 2024, 16, .	3.2	0
21238	Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2024, 24, 17-25.	4.2	0
21239	Leveraging technology-driven strategies to untangle omics big data: circumventing roadblocks in clinical facets of oral cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
21240	Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study. <i>EClinicalMedicine</i> , 2024, 67, 102336.	7.1	0
21241	A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2024, 26, .	5.0	1
21242	Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study. <i>Cancer Immunology, Immunotherapy</i> , 2024, 73, .	4.2	0

#	ARTICLE	IF	CITATIONS
21243	PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2024, 73, .	4.2	0
21244	Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?. <i>Cancers</i> , 2024, 16, 230.	3.7	0
21245	Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea. <i>Thoracic Cancer</i> , 2024, 15, 448-457.	1.9	0
21246	A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. <i>Cell</i> , 2024, 187, 166-183.e25.	28.9	4
21247	ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. <i>Cancer Cell International</i> , 2024, 24, .	4.1	0
21248	Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases. <i>Clinical and Translational Radiation Oncology</i> , 2024, 45, 100719.	1.7	0
21249	Correlation of lung immune prognostic index with the efficacy of immune checkpoint inhibitors in Chinese patients with advanced non-small cell lung cancer. , 2024, 3, .		0
21250	Nomograms combining computed tomography-based body composition changes with clinical prognostic factors to predict survival in locally advanced cervical cancer patients. <i>Journal of X-Ray Science and Technology</i> , 2024, 32, 427-441.	1.0	0
21251	Modelling adaptive therapy for tumor using reaction-diffusion equation. <i>AIP Conference Proceedings</i> , 2024,, .	0.4	0
21252	Outcome of Hypofractionated Palliative Radiotherapy Regimens for Patients With Advanced Head and Neck Cancer in Tikur Anbessa Hospital, Ethiopia: A Prospective Cohort Study. <i>JCO Global Oncology</i> , 2024,, .	1.8	0
21253	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study. <i>Journal of Clinical Oncology</i> , 2024, 42, 1278-1287.	1.6	1
21254	Hippocampal region avoidance in whole brain radiotherapy in brain metastases: For all or for some? A real-world feasibility report. <i>Tumori</i> , 2024, 110, 34-43.	1.1	0
21255	Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2024, 18, .	1.3	0
21256	Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2024, 16, .	3.2	0
21257	Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. <i>Journal of Clinical Oncology</i> , 2024, 42, 1135-1145.	1.6	1
21258	Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2024, 24, .	2.6	1
21259	Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data. <i>Cancers</i> , 2024, 16, 267.	3.7	0
21260	Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0

#	ARTICLE	IF	CITATIONS
21261	A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
21262	PET/Computed Tomography Transformation of Oncology. <i>PET Clinics</i> , 2024, 19, 291-306.	3.0	0
21263	Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study. <i>BioDrugs</i> , 2024, 38, 287-299.	4.6	0
21264	The Predictive Value of 8-Hydroxy-Deoxyguanosine (8-OHdG) Serum Concentrations in Irradiated Non-Small Cell Lung Carcinoma (NSCLC) Patients. <i>Biomedicines</i> , 2024, 12, 134.	3.2	0
21265	Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2024, 118, 1519-1530.	0.8	0
21267	Immunotherapy for lung cancer. <i>Pathology Research and Practice</i> , 2024, 254, 155104.	2.3	0
21268	First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain I±C-helix: Two case reports and a literature review. <i>Medicine (United States)</i> , 2023, 102, e36667.	1.0	1
21269	Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction. <i>Journal of Cancer Research and Clinical Oncology</i> , 2024, 150, .	2.5	0
21270	Can conventional magnetic resonance imaging at presentation predict chemoresistance in osteosarcoma?. <i>British Journal of Radiology</i> , 2024, 97, 451-461.	2.2	0
21271	Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
21272	BRAF/MEK inhibitor rechallenge in advanced melanoma patients. <i>Cancer</i> , 2024, 130, 1673-1683.	4.1	0
21273	Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial. , 2024, 12, e008229.		0
21274	Imaging of Pheochromocytomas and Paragangliomas. <i>Endocrine Reviews</i> , 2024, 45, 414-434.	20.1	0
21275	A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. <i>Immunotherapy</i> , 2024, 16, 319-329.	2.0	0
21276	2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma â€œ An Indian experience. <i>Indian Journal of Cancer</i> , 2023, 60, 493-500.	0.2	0
21277	PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2024, 34, 239-243.	2.5	0
21278	Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma. <i>Immunotherapy</i> , 2024, 16, 305-317.	2.0	0
21279	Fibroblast Activation Protein Î±â€œDirected Imaging and Therapy of Solitary Fibrous Tumor. <i>Journal of Nuclear Medicine</i> , 2024, 65, 252-257.	5.0	0

#	ARTICLE	IF	CITATIONS
21280	Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma. <i>Journal of Nuclear Medicine</i> , 2024, 65, 272-278.	5.0	0
21283	The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. <i>Nature Communications</i> , 2024, 15, .	12.8	2
21284	Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". <i>Journal of Gynecologic Oncology</i> , 0, 35, .	2.2	1
21285	Initial Experience with ⁶⁸ Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. <i>Journal of Nuclear Medicine</i> , 2024, 65, 199-205.	5.0	1
21286	Stem Cell Growth Factor- β 2 as a Predictive Biomarker of Response to Chemotherapy and Prognosis in Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Study. <i>Cancers</i> , 2024, 16, 320.	3.7	0
21287	The Correlation Between Low-Dose Radiotherapy Area of the Mediastinum and CD8+T Cells and the Efficacy of Radiotherapy for Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 0, Volume 16, 23-35.	1.9	0
21288	Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. <i>Gynecologic Oncology</i> , 2024, 181, 162-169.	1.4	0
21289	Comparing deep learning and handcrafted radiomics to predict chemoradiotherapy response for locally advanced cervical cancer using pretreatment MRI. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21290	Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2024, 118, 1497-1506.	0.8	1
21291	Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma. <i>Hepatology International</i> , 0, , .	4.2	0
21292	Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. <i>Journal of Clinical Oncology</i> , 2024, 42, 1301-1310.	1.6	0
21293	Metastatic malignant glomus tumor resistant to pazopanib, a multikinase inhibitor: A case report and review of literature. , 2024, , .		0
21294	Predicting Pathological Response to Preoperative Chemotherapy in Pancreatic Ductal Adenocarcinoma Using Post-Chemotherapy Computed Tomography Radiomics. <i>Cureus</i> , 2024, , .	0.5	0
21295	Prognostic value of immunological components of tumor microenvironment of oncurological tumors. <i>Urologicheskie Vedomosti</i> , 2024, 13, 323-337.	0.3	0
21296	A pilot study on the safety and efficacy of neoadjuvant chemo"adoptive immunotherapy for locally advanced rectal cancer. <i>Oncology Letters</i> , 2024, 27, .	1.8	0
21297	Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2024, 9, 205-217.	8.1	3
21298	Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902). <i>International Journal of Clinical Oncology</i> , 2024, 29, 134-141.	2.2	0
21299	Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. <i>Trials</i> , 2024, 25, .	1.6	0

#	ARTICLE	IF	CITATIONS
21300	Evaluation of Optimal Number of Neoadjuvant Chemotherapy Cycles and Cytoreductive Surgery in Women with Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2024, 22, .	0.3	0
21301	Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis. Frontiers in Oncology, 0, 14, .	2.8	0
21302	Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF ^{V600E} -Mutated Anaplastic Thyroid Carcinoma. Thyroid, 2024, 34, 336-346.	4.5	1
21304	Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy. Cancers, 2024, 16, 385.	3.7	0
21305	Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center. Chinese Medical Journal, 2013, 126, 4477-4482.	2.3	0
21306	Construction of brain metastasis prediction model in limited stage small cell lung cancer patients without prophylactic cranial irradiation. Clinical Respiratory Journal, 2024, 18, .	1.6	0
21307	Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib. ERJ Open Research, 2024, 10, 00676-2023.	2.6	0
21308	Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial-level analysis. Cancer, 2024, 130, 1773-1783.	4.1	0
21309	Evaluating the Efficacy of Carmustine Combined with Temozolomide in the Treatment of Glioma Following Minimally Invasive Surgery. International Journal of Pharmacology, 2023, 19, 915-924.	0.3	0
21310	Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Japanese Journal of Clinical Oncology, 2024, 54, 434-443.	1.3	0
21311	Multi-layer network modelling of genomic and transcriptomic data to investigate the response to checkpoint inhibitors in NSCLC. , 2023, , .		0
21312	Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open, 2024, 7, e2352302.	5.9	2
21313	c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer. Breast Cancer Research, 2024, 26, .	5.0	1
21315	Differences and Common Ground in ¹⁷⁷ Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. Journal of Nuclear Medicine, 2024, 65, 438-445.	5.0	0
21317	Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress. Cell Death Discovery, 2024, 10, .	4.7	0
21318	Tumor-associated microbiome features of metastatic colorectal cancer and clinical implications. Frontiers in Oncology, 0, 13, .	2.8	0
21319	Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. Clinical Colorectal Cancer, 2024, , .	2.3	0
21321	Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non-small cell lung cancer treated with immunotherapy. Oncology Letters, 2024, 27, .	1.8	0

#	ARTICLE	IF	CITATIONS
21322	Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: A Randomized Controlled Trial. JCO Global Oncology, 2024, , .	1.8	0
21323	The Bar Is High: Evaluating Fit-for-Use Oncology Real-World Data for Regulatory Decision Making. JCO Clinical Cancer Informatics, 2024, , .	2.1	1
21324	Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature Medicine, 2024, 30, 708-715.	30.7	3
21325	Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model. JID Innovations, 2024, 4, 100262.	2.4	0
21326	Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy. Current Oncology, 2024, 31, 547-557.	2.2	1
21327	Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors. International Journal of Gynecological Cancer, 0, , ijgc-2023-004953.	2.5	0
21328	Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. Journal of the National Cancer Institute, 2024, 116, 673-680.	6.3	0
21329	Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma. Nature Communications, 2024, 15, .	12.8	0
21330	Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. , 2024, 12, e007990.		0
21331	Development and validation of a nomogram model based on pretreatment ultrasound and contrast-enhanced ultrasound to predict the efficacy of neoadjuvant chemotherapy in patients with borderline resectable or locally advanced pancreatic cancer. Cancer Imaging, 2024, 24, .	2.8	0
21332	Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0
21333	Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2024, 22, 549-557.e5.	1.9	0
21334	The Radiosurgery Society Case-Based Discussion of the Management of Head and Neck or Skull Base Paragangliomas with Stereotactic Radiosurgery and Radiotherapy. Practical Radiation Oncology, 2024, 14, 225-233.	2.1	0
21335	Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes. Gynecologic Oncology, 2024, 182, 32-38.	1.4	0
21336	Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations. JTO Clinical and Research Reports, 2024, 5, 100636.	1.1	0
21337	Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial. European Journal of Cancer, 2024, 199, 113539.	2.8	0
21338	Prospective Analysis of Radiation-Induced Contrast Enhancement and Health-Related Quality of Life After Proton Therapy for Central Nervous System and Skull Base Tumors. International Journal of Radiation Oncology Biology Physics, 2024, 118, 1206-1216.	0.8	0
21339	Phase II Trial of FOLFIRINOX in Advanced Biliary Tract Cancer. Cureus, 2024, , .	0.5	0

#	ARTICLE	IF	CITATIONS
21340	Segment anything in medical images. Nature Communications, 2024, 15, .	12.8	22
21341	A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). Gynecologic Oncology, 2024, 182, 75-81.	1.4	0
21342	Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis. Frontiers in Immunology, 0, 15, .	4.8	0
21343	The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials. Frontiers in Pharmacology, 0, 15, .	3.5	0
21344	Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptorâ€“Mutated Metastatic Nonâ€“Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of Clinical Oncology, 2024, 42, 1252-1264.	1.6	1
21345	A PET/CT radiomics model for predicting distant metastasis in early-stage nonâ€“small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study. Radiation Oncology, 2024, 19, .	2.7	0
21346	Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade. Cancers, 2024, 16, 453.	3.7	0
21347	A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Japanese Journal of Clinical Oncology, 2024, 54, 424-433.	1.3	0
21348	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3Âyears of follow-up. Japanese Journal of Clinical Oncology, 2024, 54, 577-583.	1.3	0
21350	The use of BRAF-inhibitors as monotherapy and in combination with cytosine arabinoside and 2-chloro-2â€“deoxyadenosine in pediatric patients with different forms of Langerhans cell histiocytosis. Russian Journal of Pediatric Hematology and Oncology, 2024, 10, 13-24.	0.3	0
21351	Tumoral melanosis: A case series of patients with metastatic melanoma after systemic immunotherapy. JAAD Case Reports, 2024, 45, 82-87.	0.8	0
21352	MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clinical Radiology, 2024, 79, e582-e591.	1.1	0
21353	Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial. Nature Communications, 2024, 15, .	12.8	0
21354	Dose Optimization for Novel Oncology Agents: Design Options and Strategies. Statistics in Biopharmaceutical Research, 0, , 1-12.	0.8	0
21355	Outcomes of 3-year follow up with induction vs first line chemotherapy in oral cancer patients: An observational hospital-based study. Journal of Cancer Research and Therapeutics, 0, , .	0.9	0
21356	Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens. Breast Cancer Research and Treatment, 2024, 205, 29-37.	2.5	0
21357	NKG2A⁺CD8⁺T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma. , 2024, 12, e008368.		0
21358	Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report. OncoTargets and Therapy, 0, Volume 17, 27-31.	2.0	0

#	ARTICLE	IF	CITATIONS
21359	The prognostic value of radiological and pathological lymph node status in patients with cervical cancer who underwent neoadjuvant chemotherapy and followed hysterectomy. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21360	Monitoring response to neoadjuvant therapy for breast cancer in all treatment phases using an ultrasound deep learning model. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21361	Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer. <i>Gynecologic Oncology</i> , 2024, 184, 16-23.	1.4	0
21362	Systemic therapies in hepatocellular carcinoma: AÂrevolution?. <i>United European Gastroenterology Journal</i> , 2024, 12, 252-260.	3.8	0
21364	Three-Dimensional Ultrasound Imaging of Retinoblastoma and Its Correlation With Pathology. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2024, 55, 136-140.	0.7	0
21365	Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumoursâ€”results from a Turkish multi-centre study. <i>Japanese Journal of Clinical Oncology</i> , 2024, 54, 562-568.	1.3	0
21366	Imaging of Tumor Stroma Using ⁶⁸ Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial. <i>Journal of Nuclear Medicine</i> , 2024, 65, 365-371.	5.0	0
21367	Generation of tissues outside the field of view (FOV) of radiation therapy simulation imaging based on machine learning and patient body outline (PBO). <i>Radiation Oncology</i> , 2024, 19, .	2.7	0
21368	Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2024, 45, 100732.	1.7	0
21369	Comparison of Lugano Criteria Versus RECIL and PERCIST as Prognostic Factors in Diffuse Large B-Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2024, 49, 308-311.	1.3	0
21370	Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
21371	First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study. <i>Japanese Journal of Clinical Oncology</i> , 2024, 54, 452-462.	1.3	0
21373	Selpercatinib Is Effective in Treating Advanced <i>RET</i> -Mutant Medullary Thyroid Cancer. <i>Clinical Thyroidology</i> , 2024, 36, 29-31.	0.1	0
21374	Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. <i>Investigational New Drugs</i> , 2024, 42, 127-135.	2.6	0
21375	Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2024, 31, 3803-3812.	1.5	2
21376	Beta-HCG Secretion by a Pulmonary Choriocarcinoma in a Male Patient. <i>Case Reports in Oncological Medicine</i> , 2024, 2024, 1-5.	0.3	0
21377	Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study. <i>Cancer Chemotherapy and Pharmacology</i> , 2024, 93, 471-479.	2.3	0
21378	Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial. <i>Gastric Cancer</i> , 2024, 27, 375-386.	5.3	0

#	ARTICLE	IF	CITATIONS
21379	A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma. JHEP Reports, 2024, 6, 101021.	4.9	0
21380	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. European Journal of Cancer, 2024, 200, 113580.	2.8	0
21381	Patient-derived organoids for prediction of treatment response in oesophageal adenocarcinoma. British Journal of Surgery, 2024, 111, .	0.3	0
21382	Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives. International Journal of Molecular Sciences, 2024, 25, 1575.	4.1	0
21383	Infection-related Hospitalizations During Immune Checkpoint Inhibitor Treatment Without Immunosuppressants. Journal of Immunotherapy, 2024, 47, 139-147.	2.4	0
21384	Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy. Current Cancer Reports, 0, 5, 168-180.	1.2	0
21385	CT-based peritumoral radiomics nomogram on prediction of response and survival to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	2.5	0
21386	Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy. Frontiers in Immunology, 0, 15, .	4.8	0
21387	Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma. Clinical Lung Cancer, 2024, , .	2.6	0
21388	The impact of pulmonary artery to ascending aorta diameter ratio progression on the prognosis of NSCLC patients treated with immune checkpoint inhibitors. Frontiers in Immunology, 0, 15, .	4.8	0
21390	Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy. , 2024, 12, e008191.		0
21391	Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13). Cancers, 2024, 16, 558.	3.7	0
21392	PITPNC1 Suppress CD8+ T cell immune function and promote radioresistance in rectal cancer by modulating FASN/CD155. Journal of Translational Medicine, 2024, 22, .	4.4	1
21393	Prediction model of radiotherapy outcome for Ocular Adnexal Lymphoma using informative features selected by chemometric algorithms. Computers in Biology and Medicine, 2024, 170, 108067.	7.0	0
21394	The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma. Cancers, 2024, 16, 594.	3.7	0
21395	Dynamic Contrast-Enhanced Ultrasound in the Prediction of Advanced Hepatocellular Carcinoma Response to Systemic and Locoregional Therapies. Cancers, 2024, 16, 551.	3.7	0
21396	Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study. BMC Cancer, 2024, 24, .	2.6	0
21397	PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults. Frontiers in Oncology, 0, 14, .	2.8	0

#	ARTICLE	IF	CITATIONS
21398	Effectiveness of Chemotherapy on Long-Term Survival in a Case of Advanced Juvenile Hepatocellular Carcinoma Without Viral Hepatitis Infection. Cureus, 2024, , .	0.5	0
21399	Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. Journal of Medical Economics, 2024, 27, 279-291.	2.1	0
21401	Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study. Thoracic Cancer, 2024, 15, 559-569.	1.9	0
21402	Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single-institution experience. Oncology Letters, 2024, 27, .	1.8	0
21404	Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with <scp>HCC</scp>. Liver International, 2024, 44, 907-919.	3.9	0
21405	Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer. Radiology: Artificial Intelligence, 2024, 6, .	5.8	1
21406	Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study. Cancer Management and Research, 0, Volume 16, 73-86.	1.9	0
21407	A prediction model for response to immune checkpoint inhibition in advanced melanoma. International Journal of Cancer, 2024, 154, 1760-1771.	5.1	0
21408	Hepatic cytoreduction for lung and renal neuroendocrine tumor metastases. American Journal of Surgery, 2024, 231, 41-45.	1.8	0
21409	Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer. Journal of Gynecologic Oncology, 0, 35, .	2.2	0
21410	CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Surgery, 2024, 175, 1264-1275.	1.9	1
21411	Efficacy and Toxicity of Palliative Chemotherapy in Elderly Patients With Advanced Pancreatic Cancer. Pancreas, 2024, 53, e268-e273.	1.1	0
21412	Stereotactic body radiation therapy (SBRT) for the treatment of primary breast cancer in patients not undergoing surgery. Advances in Medical Sciences, 2024, 69, 29-35.	2.1	0
21413	Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis. European Journal of Clinical Pharmacology, 2024, 80, 505-517.	1.9	0
21415	A statistical framework for planning and analysing test-retest studies of repeatability. Statistical Methods in Medical Research, 2024, 33, 295-308.	1.5	0
21416	Laennec's approach for central liver resection of colorectal cancer liver metastasis adjacent to the hepatic hilum that occurred 10Âyears after colectomy: A case report. International Journal of Surgery Case Reports, 2024, 116, 109327.	0.6	0
21417	Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature Communications, 2024, 15, .	12.8	0
21418	Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review. Urologia Internationalis, 0, , 1-13.	1.3	0

#	ARTICLE	IF	CITATIONS
21419	The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients. <i>Cancers</i> , 2024, 16, 641.	3.7	0
21420	Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment. <i>Translational Oncology</i> , 2024, 42, 101883.	3.7	0
21421	Efficient Registration ofÂLongitudinal Studies forÂFollow-Up Lesion Assessment byÂExploiting Redundancy andÂComposition ofÂDeformations. <i>Lecture Notes in Computer Science</i> , 2023, , 91-99.	1.3	0
21422	PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21423	Anatomy-Aware Lymph Node Detection inÂChest CT Using Implicit Station Stratification. <i>Lecture Notes in Computer Science</i> , 2023, , 299-310.	1.3	0
21424	Case report: From palliative to potentially curative â€“ the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
21425	Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 102047.	1.9	0
21426	External comparators and estimands. <i>Frontiers in Drug Safety and Regulation</i> , 0, 3, .	1.8	0
21427	The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21428	Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. , 2024, 12, e007340.		1
21429	The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. <i>Nature Communications</i> , 2024, 15, .	12.8	1
21430	Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2024, 205, 201-210.	2.5	0
21431	Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis. <i>Cells</i> , 2024, 13, 298.	4.1	0
21432	Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour. <i>EJNMMI Physics</i> , 2024, 11, .	2.7	0
21433	Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2024, 42, 1488-1498.	1.6	0
21434	Development and Validation of Deep Learning-Based Automated Detection of Cervical Lymphadenopathy in Patients with Lymphoma for Treatment Response Assessment: A Bi-institutional Feasibility Study. , 2024, 37, 734-743.		0
21435	Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). , 2024, 12, e007883.		0
21436	Overexpression of FERM Domain Containing Kindlin 2 (FERMT2) in Fibroblasts Correlates with EMT and Immunosuppression in Gastric Cancer. <i>International Journal of Genomics</i> , 2024, 2024, 1-30.	1.6	0

#	ARTICLE	IF	CITATIONS
21437	Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. <i>Journal of Immunotherapy</i> , 2024, 47, 190-194.	2.4	0
21438	MYC targeting by OMO-103 in solid tumors: a phase 1 trial. <i>Nature Medicine</i> , 2024, 30, 762-771.	30.7	3
21439	Skeletal muscle status and survival among patients with advanced biliary tract cancer. <i>International Journal of Clinical Oncology</i> , 2024, 29, 297-308.	2.2	0
21440	Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. <i>International Immunopharmacology</i> , 2024, 129, 111642.	3.8	0
21441	Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC). <i>Journal of Geriatric Oncology</i> , 2024, 15, 101713.	1.0	0
21442	CD47â€”a novel prognostic predictor in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features. <i>World Journal of Surgical Oncology</i> , 2024, 22, .	1.9	0
21444	Concurrent targeting of <sc>GSK3</sc> and <sc>MEK</sc> as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , 2024, 115, 1333-1345.	3.9	0
21446	Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study. <i>Cancers</i> , 2024, 16, 709.	3.7	0
21447	Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
21448	A retrospective analysis of optimal timing of thoracic radiotherapy for driver geneâ€”negative metastatic nonâ€”small cell lung cancer. <i>Thoracic Cancer</i> , 2024, 15, 642-653.	1.9	0
21449	Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21450	Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?. <i>Biomedicines</i> , 2024, 12, 388.	3.2	0
21451	Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 0, , .	2.0	0
21452	Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study. <i>International Immunopharmacology</i> , 2024, 129, 111578.	3.8	0
21453	Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study. <i>Current Oncology</i> , 2024, 31, 862-871.	2.2	0
21454	Diagnostic Accuracy of⁶⁸Ga-FAPI Versus¹⁸F-FDG PET in Patients with Various Malignancies. <i>Journal of Nuclear Medicine</i> , 2024, 65, 372-378.	5.0	0
21455	Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
21456	Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas. <i>Molecular Imaging and Biology</i> , 2024, 26, 344-350.	2.6	0

#	ARTICLE	IF	CITATIONS
21457	Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer. JCO Precision Oncology, 2024, , .	3.0	0
21458	Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice. Melanoma Research, 2024, 34, 182-185.	1.2	0
21459	Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer. International Journal of Molecular Sciences, 2024, 25, 2048.	4.1	0
21460	Radiomics in Musculoskeletal Tumors. Seminars in Musculoskeletal Radiology, 2024, 28, 049-061.	0.7	0
21461	Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas. Clinical Lung Cancer, 2024, , .	2.6	0
21462	Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis. Hpb, 2024, 26, 618-629.	0.3	0
21463	PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer. IScience, 2024, 27, 109160.	4.1	0
21464	Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study) Tj ETQq1 1 0.784314 rgBT ₁ /Overlook Oncology, The, 2024, 25, 317-325.	10.7	0
21465	HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer. Medicine (United States), 2024, 103, e37170.	1.0	0
21466	Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study. Oncology, 0, , 1-12.	1.9	0
21467	Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology, 0, , .	1.9	0
21468	Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy. British Journal of Cancer, 2024, 130, 1109-1118.	6.4	0
21469	Near complete remission of an inoperable pancreatic acinar cell carcinoma after BRAF^{V600E}/MEK^{Q1}-inhibitor treatment – A case report and review of the literature. Genes Chromosomes and Cancer, 2024, 63, .	2.8	0
21470	Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. Cell Reports Medicine, 2024, 5, 101412.	6.5	0
21471	Real-world Prognostic Data on Unresectable Stage III Non-small-cell Lung Cancer Treated with Concurrent Chemoradiation Therapy by Histological Type. Internal Medicine, 2024, , .	0.7	0
21472	Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers, 2024, 16, 744.	3.7	0
21473	Fractal calculus in tumor growth simulations: The proof is in the pudding. BioSystems, 2024, 237, 105141.	2.0	0
21474	Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. Frontiers in Oncology, 0, 14, .	2.8	0

#	ARTICLE	IF	CITATIONS
21475	Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. <i>Genome Medicine</i> , 2024, 16, .	8.2	0
21476	Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer. <i>Pharmaceuticals</i> , 2024, 17, 238.	3.8	0
21478	First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. <i>International Journal of Clinical Oncology</i> , 2024, 29, 473-480.	2.2	0
21479	Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial. <i>ESMO Open</i> , 2024, 9, 102237.	4.5	0
21480	Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21481	MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy. <i>Breast Cancer Research</i> , 2024, 26, .	5.0	0
21482	Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors. <i>Japanese Journal of Radiology</i> , 2024, 42, 519-535.	2.4	0
21484	Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21485	A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. <i>Nature Cancer</i> , 2024, 5, 625-641.	13.2	0
21486	Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. <i>Nature Medicine</i> , 2024, 30, 716-729.	30.7	1
21487	The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21489	INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2024, 73, .	4.2	0
21490	Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 14, .	3.9	0
21491	Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21492	Methodology for the assessment of the risk of failure of metastatic vertebrae through ROM-based patient-specific simulations. <i>Computers and Structures</i> , 2024, 296, 107298.	4.4	0
21493	NeoSCORE II: three vs four cycles of neoadjuvant sintilimab+chemotherapy for squamous non-small-cell lung cancer. <i>Future Oncology</i> , 2024, 20, 121-129.	2.4	0
21494	Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy. <i>Cancers</i> , 2024, 16, 778.	3.7	0
21495	Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2024, , .	3.0	0

#	ARTICLE	IF	CITATIONS
21496	Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma. Hepatology Research, 0, , .	3.4	0
21497	Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated <i>BRAF</i> ^{V600} / <i>NRAS</i> ^{Q61} Wild-Type Melanoma (TraMel-WT). JCO Precision Oncology, 2024, , .	3.0	0
21498	Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study. Frontiers in Oncology, 0, 14, .	2.8	0
21499	Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. , 2024, 12, e008339.		1
21500	Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer. Esophagus, 2024, 21, 85-94.	1.9	0
21501	Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma. Cancer Treatment and Research Communications, 2024, 39, 100796.	1.7	0
21502	Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nature Cancer, 0, , .	13.2	0
21503	Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2024, , .	3.0	0
21504	Phase I trial of apatinib and paclitaxel+oxaliplatin+5-FU/levoleucovorin for treatment-naïve advanced gastric cancer. Cancer Science, 0, , .	3.9	0
21505	Iodine-125 seeds combined with carboplatin in the treatment of retroperitoneal metastatic seminoma: A case report and literature review. Oncology Letters, 2024, 27, .	1.8	0
21506	EfficientNet-Based System for Detecting EGFR-Mutant Status and Predicting Prognosis of Tyrosine Kinase Inhibitors in Patients with NSCLC. , 0, , .		0
21507	Cabozantinib Increases Progression-free Survival in Radioiodine-Refractory Differentiated Thyroid Cancer across Tumor Histologies and after Previous Anti-VEGF Therapy. Clinical Thyroidology, 2024, 36, 71-73.	0.1	0
21508	Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051. Scientific Reports, 2024, 14, .	3.3	0
21509	The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease. Journal of Nuclear Medicine, 2024, 65, 502-509.	5.0	0
21510	Stereotactic body radiotherapy for inoperable patients with renal carcinoma. , 2024, 34, 102575.		0
21512	SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer. Cancer, 0, , .	4.1	0
21513	Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial. Nature Communications, 2024, 15, .	12.8	1
21514	Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma. International Immunopharmacology, 2024, 129, 111684.	3.8	0

#	ARTICLE	IF	CITATIONS
21515	The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer. <i>Colorectal Disease</i> , 2024, 26, 745-753.	1.4	0
21516	Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods. , 2024, 2, 14-26.		0
21517	An Evaluation of Treatment Outcomes and Associated Factors in Nasopharyngeal Cancer Patients at a Tertiary Cancer Center in the United Arab Emirates. <i>Cureus</i> , 2024, , .	0.5	0
21518	Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. <i>Clinical Lung Cancer</i> , 2024, , .	2.6	0
21519	Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade. <i>Journal of Experimental and Clinical Cancer Research</i> , 2024, 43, .	8.6	0
21520	Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study. <i>Molecular Cancer</i> , 2024, 23, .	19.2	0
21521	Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis. <i>BioScience Trends</i> , 2024, 18, 21-41.	3.4	0
21522	Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme. <i>Internal Medicine Journal</i> , 0, , .	0.8	0
21523	Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET- mutant thyroid cancer. <i>Npj Precision Oncology</i> , 2024, 8, .	5.4	0
21524	Is cryoablation still suitable for advanced non-small cell lung cancer after failure of first-line chemotherapy? A multicenter, prospective, randomized-controlled trial of eighty-seven patients. <i>Cryobiology</i> , 2024, 115, 104864.	0.7	0
21525	Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2024, 16, 838.	3.7	0
21526	FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature. <i>Cancers</i> , 2024, 16, 839.	3.7	0
21527	The Liver Frailty Index predicts survival in systemic therapy for hepatocellular carcinoma: a multicentre prospective cohort study. , 2024, 3, 100043.		0
21528	High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study. <i>Journal of Translational Medicine</i> , 2024, 22, .	4.4	0
21529	Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2024, 13, 612-623.	2.5	0
21530	BRAF V600E Mutation in Malignant Melanoma- A Romanian Research Experience. <i>Medicina (Lithuania)</i> , 2024, 60, 351.	2.0	0
21531	Role of diffusion-weighted imaging in response prediction and evaluation after high dose rate brachytherapy in patients with colorectal liver metastases. <i>Radiology and Oncology</i> , 2024, 58, 33-42.	1.7	0
21532	Dual-Energy CT Material Decomposition: The Value in the Detection of Lymph Node Metastasis from Breast Cancer. <i>Diagnostics</i> , 2024, 14, 466.	2.6	0

#	ARTICLE	IF	CITATIONS
21533	Multiple malignant primary tumors (non-head and neck): Contemplation needed. Journal of Cancer Research and Therapeutics, 2023, 19, S752-S757.	0.9	0
21534	The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial. Clinical Breast Cancer, 2024, , .	2.4	0
21535	Multiple primary head and neck squamous cell cancer: Lessons learnt. Journal of Cancer Research and Therapeutics, 2023, 19, S658-S663.	0.9	0
21536	Gene expression in metastatic breast cancerâ€”patterns in primary tumors and metastatic tissue with prognostic potential. Frontiers in Molecular Biosciences, 0, 10, .	3.5	0
21537	Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. Medicine (United States), 2023, 102, e36232.	1.0	0
21538	Intratumoral Heterogeneity, Chemoresistance and Lymph Node Landing Zone Prognosis in Testicular Tumors Based on Histopathological Characteristics. Annals of Surgical Oncology, 2024, 31, 3544-3553.	1.5	0
21539	Evaluation of treatment responses among subgroups of breast cancer patients receiving neoadjuvant chemotherapy. Journal of Cancer Research and Therapeutics, 2023, 19, S821-S826.	0.9	0
21540	Suppression of hypoxia-induced CAV1 autophagic degradation enhances nanoalbumin-paclitaxel transcytosis and improves therapeutic activity in pancreatic cancer. European Journal of Pharmacology, 2024, 969, 176431.	3.5	0
21541	Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer, 2024, 24, .	2.6	0
21542	Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery, 2024, 14, 406-423.	9.4	0
21543	Development and Preliminary Validation of a Novel Convolutional Neural Network Model for Predicting Treatment Response in Patients with Unresectable Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. , 0, , .		0
21544	Case report: Pathological complete response of pregnancy associated pulmonary enteric adenocarcinoma to chemoradiotherapy. Frontiers in Oncology, 0, 14, .	2.8	0
21545	Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. Journal of Thermal Biology, 2024, 120, 103804.	2.5	0
21546	Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study. Digestive and Liver Disease, 2024, , .	0.9	0
21547	Implantable theranostic device for in vivo real-time NMR evaluation of drug impact in brain tumors. Scientific Reports, 2024, 14, .	3.3	0
21548	A multicenter, realâ€‘world study on effectiveness and safety of firstâ€‘line modified <sc>PD</sc>â€‘1 inhibitors with chemotherapy in advanced nonâ€‘small cell lung cancer (<sc>aNSCLC</sc>) with drive geneâ€‘negative. Cancer Medicine, 2024, 13, .	2.8	0
21549	Phase I study of sapanisertib (CBâ€‘228/TAKâ€‘228/MLN0128) in combination with zivâ€‘flibercept in patients with advanced solid tumors. Cancer Medicine, 2024, 13, .	2.8	0
21550	ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach. Cancer Treatment and Research Communications, 2024, 39, 100802.	1.7	0

#	ARTICLE	IF	CITATIONS
21551	Contemporary Surgical Management of Colorectal Liver Metastases. <i>Cancers</i> , 2024, 16, 941.	3.7	0
21552	Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patientsâ€”Real-World Experience in a Single-Center Retrospective Study and Narrative Review. <i>Medicina (Lithuania)</i> , 2024, 60, 398.	2.0	0
21553	A phase 1b study of zilovetamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2024, 26, .	5.0	0
21554	Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21555	Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy. <i>Cancers</i> , 2024, 16, 920.	3.7	0
21556	Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTER II): a non-randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2024, 25, 308-316.	10.7	0
21557	Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients. <i>Computers in Biology and Medicine</i> , 2024, 172, 108240.	7.0	0
21558	Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell deathâ€”immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105â€”204). <i>Cancer</i> , 0, , .	4.1	0
21559	Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MILD-SOC trial. <i>Gynecologic Oncology</i> , 2024, 185, 143-147.	1.4	0
21560	Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21561	Factors related to tumor response rate from TCGA three omics dataâ€”variants, expression, methylation. <i>Journal of Environmental Science and Health, Part C: Toxicology and Carcinogenesis</i> , 0, , 1-16.	0.7	0
21562	Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis. <i>Radiation Oncology</i> , 2024, 19, .	2.7	0
21563	Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. <i>Cell Reports Medicine</i> , 2024, 5, 101435.	6.5	0
21564	Active surveillance for clinical complete responders after chemoradiotherapy for oesophageal squamous cell carcinoma. <i>British Journal of Surgery</i> , 2024, 111, .	0.3	0
21565	Deep learning model based on multi-lesion and time series CT images for predicting the benefits from anti-HER2 targeted therapy in stage IV gastric cancer. <i>Insights Into Imaging</i> , 2024, 15, .	3.4	0
21567	Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. <i>Nature Communications</i> , 2024, 15, .	12.8	0
21569	A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2024, 16, .	3.2	0
21570	Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. <i>JAMA Network Open</i> , 2024, 7, e240260.	5.9	0

#	ARTICLE	IF	CITATIONS
21571	Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression. Cancers, 2024, 16, 964.	3.7	0
21573	Photoacoustic/ultrasound dual-modality imaging for marker clip localization in neoadjuvant chemotherapy of breast cancer. Journal of Biomedical Optics, 2024, 29, .	2.6	0
21574	Deep Texture Analysis—Enhancing CT Radiomics Features for Prediction of Head and Neck Cancer Treatment Outcomes: A Machine Learning Approach. Radiation, 2024, 4, 50-68.	1.4	0
21575	Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study. ClinicoEconomics and Outcomes Research, 0, Volume 16, 97-109.	1.9	0
21576	Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial. The Lancet Healthy Longevity, 2024, 5, e182-e193.	4.6	0
21577	The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of ²²³ Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Journal of Nuclear Medicine, 2024, 65, 541-547.	5.0	0
21578	PET/CT and PET/MR in Soft Tissue Sarcoma: An Update. Seminars in Nuclear Medicine, 2024, , .	4.6	0
21579	Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors. Annals of Surgical Oncology, 2024, 31, 3839-3849.	1.5	0
21580	Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases. Clinical and Translational Radiation Oncology, 2024, 46, 100756.	1.7	0
21581	Impact of time from diagnosis to chemotherapy on prognosis in advanced pancreatic cancer. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
21582	Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments. Cancers, 2024, 16, 993.	3.7	0
21583	Exploring the Efficacy of Pembrolizumab in Combination with Carboplatin and Weekly Paclitaxel for Frail Patients with Advanced Non-Small-Cell Lung Cancer: A Key Investigative Study. Cancers, 2024, 16, 992.	3.7	0
21584	A gut microbial signature for combination immune checkpoint blockade across cancer types. Nature Medicine, 2024, 30, 797-809.	30.7	0
21585	An integrative morpho-molecular approach in malignant ectomesenchymoma diagnosis: report of a new paediatric case and a review of the literature. Frontiers in Oncology, 0, 14, .	2.8	0
21586	First-line systemic treatment for people with extensive-stage small cell lung cancer: a systematic review and network meta-analysis. The Cochrane Library, 2024, 2024, .	2.8	0
21587	Bronchial arterial chemoembolization with Drug-Eluting beads plus sequential chemotherapy for the treatment of stage III and IV lung squamous cell carcinoma. European Journal of Radiology, 2024, 175, 111398.	2.6	0
21588	Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes?. Annals of Surgical Oncology, 2024, 31, 3186-3193.	1.5	0
21589	First experience of using Pembrolizumab® medication in patients with disseminated renal cell carcinoma. Onkourologiya, 2024, 19, 44-51.	0.3	0

#	ARTICLE	IF	CITATIONS
21590	Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy. <i>Nature Cancer</i> , 2024, 5, 642-658.	13.2	0
21592	Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy. <i>Oral Oncology</i> , 2024, 151, 106683.	1.5	0
21594	First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. <i>BMC Endocrine Disorders</i> , 2024, 24, .	2.2	0
21595	Development and validation of an ultrasound-based radiomics nomogram to predict lymph node status in patients with high-grade serous ovarian cancer: a retrospective analysis. <i>Journal of Ovarian Research</i> , 2024, 17, .	3.0	0
21596	Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. <i>Lung Cancer</i> , 2024, 190, 107512.	2.0	0
21597	Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0
21598	The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21599	Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer. <i>Anti-Cancer Drugs</i> , 2024, 35, 426-432.	1.4	0
21600	SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0
21601	Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio). <i>European Journal of Cancer</i> , 2024, 202, 113974.	2.8	0
21602	Yaru3DFPN: a lightweight modified 3D UNet with feature pyramid network and combine thresholding for brain tumor segmentation. <i>Neural Computing and Applications</i> , 2024, 36, 7529-7544.	5.6	0
21603	Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy. <i>Cancer Immunology, Immunotherapy</i> , 2024, 73, .	4.2	0
21604	Effects of intensity-modulated radiotherapy combined with chemotherapy and prognostic factors in patients with locally advanced oesophageal cancer. <i>Advances in Medical Sciences</i> , 2024, 69, 125-131.	2.1	0
21605	Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2024, 30, 456-464.	2.1	0
21606	Reply to comment on “An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers”™ by Fukui et al.. <i>Breast Cancer</i> , 2024, 31, 536-538.	2.9	0
21607	Review of recent advances in managing periocular skin malignancies. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21608	Staging by imaging in gynecologic cancer and the role of ultrasound: an update of European joint consensus statements. <i>International Journal of Gynecological Cancer</i> , 2024, 34, 363-378.	2.5	0
21609	Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance. <i>Journal of Dermatology</i> , 2024, 51, 475-483.	1.2	0

#	ARTICLE	IF	CITATIONS
21610	Intracranial non-germinomatous germ cell tumors in children and adolescents: how can the experience from an uppermiddle-income country contribute to the worldwide effort to improve outcomes?. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21612	HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma. <i>Aging</i> , 0, , .	3.1	0
21613	Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer. <i>Cancers</i> , 2024, 16, 1049.	3.7	0
21614	Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2024, 16, .	3.2	0
21615	Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis. <i>Lancet Oncology</i> , The, 2024, 25, 455-462.	10.7	0
21616	Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer. <i>Heliyon</i> , 2024, 10, e27633.	3.2	0
21617	Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2024, 185, 186-193.	1.4	0
21618	Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol. <i>Lancet Regional Health - Europe</i> , The, 2024, 39, 100875.	5.6	0
21619	Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB α -IIIB lung squamous cell carcinoma. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21620	Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma. <i>Drugs and Aging</i> , 2024, 41, 271-281.	2.7	0
21621	Response to first-line pembrolizumab in metastatic <i>KRAS</i> -mutated non-small-cell lung cancer. <i>Future Oncology</i> , 2024, 20, 373-380.	2.4	0
21622	Olaparib in Patients With Pancreatic Cancer With <i>BRCA1/2</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2024, , .	3.0	0
21623	Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. <i>JCO Precision Oncology</i> , 2024, , .	3.0	0
21624	The Convergence of Radiology and Genomics: Advancing Breast Cancer Diagnosis with Radiogenomics. <i>Cancers</i> , 2024, 16, 1076.	3.7	0
21625	Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21626	External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long-term local disease control?. <i>Head and Neck</i> , 0, , .	2.0	0
21627	PD α 1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD α 1-low and α -negative patients with non-small cell lung cancer. <i>Journal of Extracellular Vesicles</i> , 2024, 13, .	12.2	0
21628	A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2024, 35, 450-458.	1.4	0

#	ARTICLE	IF	CITATIONS
21629	US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
21630	Resected <i>EGFR</i> -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). <i>Therapeutic Advances in Medical Oncology</i> , 2024, 16, .	3.2	0
21631	Prognostic Performance of RECIP 1.0 Based on [¹⁸ F]PSMA-1007 PET in Prostate Cancer Patients Treated with [¹⁷⁷ Lu]Lu-PSMA I&T. <i>Journal of Nuclear Medicine</i> , 2024, 65, 560-565.	5.0	0
21632	Surgery combined with anlotinib for local control of patients with resectable extremity desmoid fibromatosis: a retrospective study. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0
21633	Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP). <i>European Journal of Cancer</i> , 2024, 202, 113988.	2.8	0
21635	Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21636	Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, <i>HER2</i> -negative metastatic breast cancer: A real-world multicenter study. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21637	Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis. , 2024, 12, e008806.		0
21638	NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 102072.	1.9	0
21639	Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
21640	Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol. <i>BMJ Open</i> , 2024, 14, e075696.	1.9	0
21641	Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. <i>Annals of Oncology</i> , 2024, 35, 458-472.	1.2	0
21642	Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway. <i>Cancer Gene Therapy</i> , 0, , .	4.6	0
21643	Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. <i>Pathology International</i> , 0, , .	1.3	0
21644	Multi-scale geometric network analysis identifies melanoma immunotherapy response gene modules. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
21645	Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment. <i>Cancer Management and Research</i> , 0, Volume 16, 151-161.	1.9	0
21646	Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. , 2024, 12, e008409.		0
21647	Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. <i>JCO Global Oncology</i> , 2024, , .	1.8	0

#	ARTICLE	IF	CITATIONS
21648	Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2024, 42, 1687-1698.	1.6	0
21649	Informing immunotherapy with multi-omics driven machine learning. <i>Npj Digital Medicine</i> , 2024, 7, .	10.9	0
21650	Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer. <i>Cancer Science</i> , 0, , .	3.9	0
21652	Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
21653	Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
21654	Artificial intelligence in cancer research and precision medicine. , 2024, , 1-23.		0
21655	High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2024, 16, 1152.	3.7	0
21656	Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	0
21657	Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2024, 150, .	2.5	0
21658	Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity. <i>Heliyon</i> , 2024, 10, e28285.	3.2	0
21659	Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real-world experience. <i>Head and Neck</i> , 0, , .	2.0	0
21660	Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 0, , .	1.8	0
21661	Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Inflammation Research</i> , 0, Volume 17, 1777-1788.	3.5	0
21662	Achievement of textbook outcome after hepatectomy combined with thermal ablation for colorectal liver metastases. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2024, 38, 2611-2621.	2.4	0
21663	Arterial spin labeled perfusion MRI for the assessment of radiation-treated meningiomas. <i>Frontiers in Radiology</i> , 0, 4, .	2.0	0
21664	Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. <i>Nature Communications</i> , 2024, 15, .	12.8	0
21665	Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. <i>Nature Medicine</i> , 2024, 30, 1023-1034.	30.7	0
21666	Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. <i>Oral Oncology</i> , 2024, 151, 106759.	1.5	0

#	ARTICLE	IF	CITATIONS
21667	Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resistance Updates, 2024, 74, 101080.	14.4	0
21668	A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. Cancer Medicine, 2024, 13, .	2.8	0
21669	Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer. Cancer Cell International, 2024, 24, .	4.1	0
21670	Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nature Immunology, 2024, 25, 644-658.	14.5	0
21671	Reporting on invasive lobular breast cancer in clinical trials: a systematic review. Npj Breast Cancer, 2024, 10, .	5.2	0
21673	Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study. European Urology, 2024, , .	1.9	0
21674	A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood and Cancer, 2024, 71, .	1.5	0
21675	Local and Systemic Management Options for Melanoma Brain Metastases. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overdo	2.0	0
21676	Extracellular volume fraction can predict the treatment response and survival outcome of colorectal cancer liver metastases. European Journal of Radiology, 2024, 175, 111444.	2.6	0
21677	Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study. Lung Cancer: Targets and Therapy, 0, Volume 15, 29-40.	2.7	0
21678	Are biomarkers expression and clinical-pathological factors predictive markers of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer?. European Journal of Surgical Oncology, 2024, 50, 108311.	1.0	0
21679	Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report. Journal of Medical Case Reports, 2024, 18, .	0.8	0
21680	Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET. Annals of Oncology, 2024, , .	1.2	0
21681	Baseline and early response 2-[18F]FDG-PET/MRI for prediction of radiotherapy outcome in uterine cervical squamous cell carcinoma: a prospective single-center observational cohort study. , 2024, 8, .		0
21682	A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score. MedComm, 2024, 5, .	7.2	0
21683	Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer. , 2024, 3, 100046.		0
21684	Stereotactic radiotherapy for brain metastases in patients with non-small cell lung cancer: CyberKnife-M6 experience. , 2024, 22, 117-124.		0
21685	Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review. Cancer Imaging, 2024, 24, .	2.8	0

#	ARTICLE	IF	CITATIONS
21686	Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. <i>Nature Communications</i> , 2024, 15, .	12.8	0
21687	Construction and validation of classification models for predicting the response to concurrent chemo-radiotherapy of patients with esophageal squamous cell carcinoma based on multi-omics data. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2024, 48, 102318.	1.5	0
21688	Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. <i>European Journal of Cancer</i> , 2024, 202, 114006.	2.8	0
21689	Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. <i>Med</i> , 2024, 5, 311-320.e3.	4.4	0
21690	Incidence of skeletal-related events in patients with Ewing sarcoma: An observational retrospective study in Japan. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
21691	Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study. <i>Journal of Hepatology</i> , 2024, , .	3.7	0
21692	Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2024, 194, 110223.	0.6	0
21693	Survival time prediction in patients with high-grade serous ovarian cancer based on 18F-FDG PET/CT-derived inter-tumor heterogeneity metrics. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21694	Promising Objective Response Rates and Progression-Free Survival but Modest Overall Survival in the TAB Study. <i>Journal of Clinical Oncology</i> , 2024, 42, 1726-1727.	1.6	0
21695	Nomogram Based on US and Clinicopathologic Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2024, , .	2.4	0
21696	Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability. <i>Cancers</i> , 2024, 16, 1144.	3.7	0
21697	Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review. <i>Frontiers in Endocrinology</i> , 0, 15, .	3.5	0
21698	Diagnostic validity and reliability of BT-RADS in the management of recurrent high-grade glioma. <i>Journal of Neuroradiology</i> , 2024, , 101190.	1.1	0
21699	Successful multidisciplinary treatment for synchronous advanced esophageal and cecal cancers after total gastrectomy with reconstruction by jejunal interposition. <i>World Journal of Surgical Oncology</i> , 2024, 22, .	1.9	0
21700	Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging. <i>Pharmaceuticals</i> , 2024, 17, 373.	3.8	0
21701	Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy. <i>Cancer Imaging</i> , 2024, 24, .	2.8	0
21702	Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2024, 31, 1543-1555.	2.2	0
21703	Immunotherapy efficacy prediction through a feature re-calibrated 2.5D neural network. <i>Computer Methods and Programs in Biomedicine</i> , 2024, 249, 108135.	4.7	0

#	ARTICLE	IF	CITATIONS
21704	Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. <i>European Radiology</i> , 0, , .	4.5	0
21705	A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX. <i>Drug Design, Development and Therapy</i> , 0, Volume 18, 859-870.	4.3	0
21706	Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2024, 23, .	1.9	0
21707	Phase 2 study of the efficacy and safety of ponesegromab in patients with cancer cachexia: PROACCâ€¹ study design. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 0, , .	7.3	0
21708	Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	1.1	0
21709	CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib. <i>Molecular Cancer</i> , 2024, 23, .	19.2	0
21710	Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21711	Long-term outcomes after percutaneous cryoablation of abdominal wall endometriosis. <i>European Radiology</i> , 0, , .	4.5	0
21712	Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drugâ€¹Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma. <i>Biomedicines</i> , 2024, 12, 704.	3.2	0
21713	Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. <i>Current Oncology</i> , 2024, 31, 1656-1666.	2.2	0
21714	PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptorâ€¹Positive/Human Epidermal Growth Factor Receptorâ€¹Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
21715	Japanese Classification of Esophageal Cancer, 12th Edition: Part II. <i>Esophagus</i> , 0, , .	1.9	0
21716	Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors. <i>Clinical and Translational Science</i> , 2024, 17, .	3.1	0
21717	Persistence of peripheral CD8â€¹+â€¹CD28â€¹+ T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 0, , .	6.4	0
21718	Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma. <i>Discover Oncology</i> , 2024, 15, .	2.1	0
21719	MedikamentÃ¶se Tumorthherapie. , 2024, , 625-638.		0
21720	Prognostic Role of Preoperative Chemotherapy in Liver-Limited Metastasis from Gastric Cancer. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
21721	First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer. <i>Med</i> , 2024, , .	4.4	0

#	ARTICLE	IF	CITATIONS
21722	Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. <i>Npj Precision Oncology</i> , 2024, 8, .	5.4	0
21723	Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy. <i>European Radiology</i> , 0, , .	4.5	0
21724	rs822336 binding to C/EBP β and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC. <i>Molecular Cancer</i> , 2024, 23, .	19.2	0
21725	[¹⁷⁷ Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0
21726	Therapeutic vaccines for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2024, 2024, .	2.8	0
21727	Adenoid Cystic Carcinoma of the Vulva: A Case Report. <i>Cureus</i> , 2024, , .	0.5	0
21728	A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
21729	High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. , 2024, 12, e008325.		0
21730	The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial). <i>European Journal of Surgical Oncology</i> , 2024, 50, 108265.	1.0	0
21731	A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2024, 16, 1137.	3.7	0
21732	Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologicâ€“pathologic correlation of response assessment and predictors of progression. <i>Abdominal Radiology</i> , 0, , .	2.1	0
21733	Lung Cancer Diagnoses and Outcomes During the Syrian War, 2011-2018. <i>JAMA Network Open</i> , 2024, 7, e242091.	5.9	0
21735	Thermophoretic glycan profiling of extracellular vesicles for triple-negative breast cancer management. <i>Nature Communications</i> , 2024, 15, .	12.8	0
21737	Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. <i>Nature Communications</i> , 2024, 15, .	12.8	0
21738	Impact of residual microcalcifications on prognosis after neoadjuvant chemotherapy in breast cancer patients. <i>BMC Women's Health</i> , 2024, 24, .	2.0	0
21739	Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 102075.	1.9	0